PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sallee, JL; Wittchen, ES; Burridge, K				Sallee, Jennifer L.; Wittchen, Erika S.; Burridge, Keith			Regulation of cell adhesion by protein-tyrosine phosphatases - II. Cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ADHERENS JUNCTION COMPONENTS; HUMAN ENDOTHELIAL-CELLS; BETA-CATENIN; VE-CADHERIN; PTP-MU; N-CADHERIN; IN-VIVO; PARACELLULAR PATHWAY; CYTOPLASMIC DOMAIN; HOMOPHILIC BINDING	Cell-cell adhesion is critical to the development and maintenance of multicellular organisms. The stability of many adhesions is regulated by protein tyrosine phosphorylation of cell adhesion molecules and their associated components, with high levels of phosphorylation promoting disassembly. The level of tyrosine phosphorylation reflects the balance between protein-tyrosine kinase and protein-tyrosine phosphatase activity. Many protein-tyrosine phosphatases associate with the cadherin-catenin complex, directly regulating the phosphorylation of these proteins, thereby affecting their interactions and the integrity of cell-cell junctions. Tyrosine phosphatases can also affect cell-cell adhesions indirectly by regulating the signaling pathways that control the activities of Rho family G proteins. In addition, receptor-type tyrosine phosphatases can mediate outside-in signaling through both ligand binding and dimerization of their extracellular domains. This review will discuss the role of protein-tyrosine phosphatases in cell-cell interactions, with an emphasis on cadherin-mediated adhesions.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Burridge, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	keith_burridge@med.unc.edu			NHLBI NIH HHS [HL 45100] Funding Source: Medline; NIGMS NIH HHS [GM 29860] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Burridge K, 2006, J BIOL CHEM, V281, P15593, DOI 10.1074/jbc.R500030200; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; KAM Z, 1995, J CELL SCI, V108, P1051; Kellie S, 2004, J CELL SCI, V117, P609, DOI 10.1242/jcs.00879; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; KYPTA RM, 1996, J CELL BIOL, V130, P67; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meng TC, 2005, METHODS, V35, P28, DOI 10.1016/j.ymeth.2004.07.005; MICHALIDES R, 1994, CELL ADHES COMMUN, V2, P481, DOI 10.3109/15419069409014212; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; SAP J, 1994, MOL CELL BIOL, V14, P1; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Sui XF, 2005, AM J PATHOL, V166, P1247, DOI 10.1016/S0002-9440(10)62343-7; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; van Buul JD, 2005, J BIOL CHEM, V280, P21129, DOI 10.1074/jbc.M500898200; van Wetering S, 2003, AM J PHYSIOL-CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003; van Wetering S, 2002, J CELL SCI, V115, P1837; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Wang Q, 2003, J BIOL CHEM, V278, P47731, DOI 10.1074/jbc.M308466200; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Xu G, 2002, J BIOL CHEM, V277, P49989, DOI 10.1074/jbc.M206454200; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Young BA, 2003, AM J PHYSIOL-LUNG C, V285, pL63, DOI 10.1152/ajplung.00423.2002; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	72	71	75	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16189	16192		10.1074/jbc.R600003200	http://dx.doi.org/10.1074/jbc.R600003200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16497667	hybrid			2022-12-27	WOS:000238165700002
J	Keiser, M; Alfalah, M; Propsting, MJ; Castelletti, D; Naim, HY				Keiser, Markus; Alfalah, Marwan; Proepsting, Marcus J.; Castelletti, Deborah; Naim, Hassan Y.			Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; INTESTINAL EPITHELIAL-CELLS; GPI-ANCHORED PROTEINS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; APICAL MEMBRANE; ENZYME; BIOSYNTHESIS; EXPRESSION	Naturally occurring mutants of membrane and secretory proteins are often associated with the pathogenesis of human diseases. Here, we describe the molecular basis of a novel phenotype of congenital sucrase-isomaltase deficiency (CSID), a disaccharide malabsorption disorder of the human intestine in which several structural features and functional capacities of the brush-border enzyme complex sucrase-isomaltase (SI) are affected. The cDNA encoding SI from a patient with CSID reveals a mutation in the isomaltase subunit of SI that results in the substitution of a cysteine by an arginine at amino acid residue 635 (C635R). When this mutation is introduced into the wild type cDNA of SI a mutant enzyme, SIC635R, is generated that shows a predominant localization in the endoplasmic reticulum. Nevertheless, a definite localization of SIC635R in the Golgi apparatus and at the cell surface could be also observed. Epitope mapping with conformation-specific mAbs protease sensitivity assays, and enzymatic activity measurements demonstrate an altered folding pattern of SIC635R that is responsible for a substantially increased turnover rate and an aberrant sorting profile. Thus, SIC635R becomes distributed also at the basolateral membrane in contrast to wild type SI. Concomitant with the altered sorting pattern, the partial detergent extractability of wild type SI shifts to a complete detergent solubility with Triton X-100. The mutation has therefore affected an epitope responsible for the apical targeting fidelity of SI. Altogether, the combined effects of the C635R mutation on the turnover rate, function, polarized sorting, and detergent solubility of SI constitute a unique and novel pathomechanism of CSID.	Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany.	hassan.naim@tiho-hannover.de	Al Falah, Dr. Marwan/C-6281-2011	Keiser, Markus/0000-0003-4842-6273				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alfalah M, 2002, J BIOL CHEM, V277, P10683, DOI 10.1074/jbc.M109357200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2000, J CLIN INVEST, V106, P281, DOI 10.1172/JCI9677; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; KERRY K. R., 1965, Australian Paediatric Journal, V1, P223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LLOYD ML, 1987, NEW ENGL J MED, V316, P438, DOI 10.1056/NEJM198702193160804; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; Ritz V, 2003, GASTROENTEROLOGY, V125, P1678, DOI 10.1053/j.gastro.2003.09.022; SEMENZA G, 1983, CIBA F SYMP, V95, P92; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001	28	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14393	14399		10.1074/jbc.M513631200	http://dx.doi.org/10.1074/jbc.M513631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543230	hybrid			2022-12-27	WOS:000237512300066
J	Kijas, AW; Harris, JL; Harris, JM; Lavin, MF				Kijas, Amanda W.; Harris, Janelle L.; Harris, Jonathan M.; Lavin, Martin F.			Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-LYSINE HYDROLASE; DNA-DAMAGE; ATAXIA; RNA; HINT; PURIFICATION; NUCLEOLUS; MUTATIONS; MECHANISM; INTERACTS	Ataxia with oculomotor apraxia type 1 (AOA1) is an early onset autosomal recessive spinocerebellar ataxia with a defect in the protein Aprataxin, implicated in the response of cells to DNA damage. We describe here the expression of a recombinant form of Aprataxin and show that it has dual DNA binding and nucleotide hydrolase activities. This protein binds to double-stranded DNA with high affinity but is also capable of binding double-stranded RNA and single-strand DNA, with increased affinity for hairpin structures. No increased binding was observed with a variety of DNA structures mimicking intermediates in DNA repair. The DNA binding observed here was not dependent on zinc, and the addition of exogenous zinc abolished DNA binding. We also demonstrate that Aprataxin hydrolyzes with similar efficiency the model histidine triad nucleotide-binding protein substrate, AMPNH(2), and the Fragile histidine triad protein substrate, Ap(4)A. These activities were significantly reduced in the presence of duplex DNA and to a lesser extent in the presence of single-strand DNA, and removal of the N-terminal Forkhead associated domain did not alter activity. Finally, comparison of sequence relationships between the histidine triad superfamily members shows that Aprataxin forms a distinct branch in this superfamily. In addition to its capacity for nucleotide binding and hydrolysis, the observation that it also binds DNA and RNA adds a new dimension to this superfamily of proteins and provides further support for a role for Aprataxin in the cellular response to DNA damage.	Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Queensland Univ Technol, Sch Life Sci, Brisbane, Qld 4000, Australia; Univ Queensland, Cent Clin Sch, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Queensland University of Technology (QUT); University of Queensland	Lavin, MF (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	Martin.Lavin@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Harris, Jonathan/0000-0003-4209-2380; Kijas, Amanda/0000-0001-8538-7766; Hancock, Janelle/0000-0001-6703-7228				Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; CHI NW, 1994, J BIOL CHEM, V269, P29984; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2004, BIOCHEM BIOPH RES CO, V325, P1279, DOI 10.1016/j.bbrc.2004.10.162; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Hirano M, 2004, BIOCHEM BIOPH RES CO, V322, P380, DOI 10.1016/j.bbrc.2004.07.135; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Le Ber I, 2004, BRAIN, V127, P759, DOI 10.1093/brain/awh080; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Matt T, 2004, BIOCHEM J, V381, P685, DOI 10.1042/BJ20040564; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Mosesso P, 2005, CELL MOL LIFE SCI, V62, P485, DOI 10.1007/s00018-004-4441-0; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Seidle HF, 2005, J BIOL CHEM, V280, P20927, DOI 10.1074/jbc.M502889200; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Shaw P, 2005, CELL CYCLE, V4, P102, DOI 10.4161/cc.4.1.1467; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; Tranchant C, 2003, NEUROLOGY, V60, P868, DOI 10.1212/01.WNL.0000048562.88536.A4; Weinberg RL, 2004, J MOL BIOL, V342, P801, DOI 10.1016/j.jmb.2004.07.042; Wesierska-Gadek J, 2003, ANN NY ACAD SCI, V1010, P266, DOI 10.1196/annals.1299.046; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200	32	60	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13939	13948		10.1074/jbc.M507946200	http://dx.doi.org/10.1074/jbc.M507946200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547001	hybrid, Green Published			2022-12-27	WOS:000237512300015
J	Muresanu, L; Pristovsek, P; Lohr, F; Maneg, O; Mukrasch, MD; Rurterjans, H; Ludwig, B; Lucke, C				Muresanu, Lucia; Pristovsek, Primoz; Loehr, Frank; Maneg, Oliver; Mukrasch, Marco D.; Ruerterjans, Heinz; Ludwig, Bernd; Luecke, Christian			The Electron Transfer Complex between Cytochrome c(552) and the Cu-A Domain of the Thermus thermophilus ba(3) Oxidase A COMBINED NMR AND COMPUTATIONAL APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The structural analysis of the redox complex between the soluble cytochrome c(552) and the membrane-integral cytochrome ba(3) oxidase of Thermus thermophilus is complicated by the transient nature of this protein-protein interaction. Using NMR-based chemical shift perturbation mapping, however, we identified the contact regions between cytochrome c(552) and the Cu-A domain, the fully functional water-soluble fragment of subunit II of the ba(3) oxidase. First we determined the complete backbone resonance assignments of both proteins for each redox state. Subsequently, two-dimensional [N-15, H-1]TROSY spectra recorded for each redox partner both in free and complexed state indicated those surface residues affected by complex formation between the two proteins. This chemical shift analysis performed for both redox states provided a topological description of the contact surface on each partner molecule. Remarkably, very pronounced indirect effects, which were observed on the back side of the heme cleft only in the reduced state, suggested that alterations of the electron distribution in the porphyrin ring due to formation of the protein-protein complex are apparently sensed even beyond the heme propionate groups. The contact residues of each redox partner, as derived from the chemical shift perturbation mapping, were employed for a protein-protein docking calculation that provided a structure ensemble of 10 closely related conformers representing the complex between cytochrome c(552) and the Cu-A domain. Based on these structures, the electron transfer pathway from the heme of cytochrome c(552) to the Cu-A center of the ba(3) oxidase has been predicted.	[Muresanu, Lucia; Loehr, Frank; Mukrasch, Marco D.; Ruerterjans, Heinz; Luecke, Christian] Univ Frankfurt, Ctr Biomol Magnet Resonance, Inst Biophys Chem, D-60439 Frankfurt, Germany; [Pristovsek, Primoz] Natl Inst Chem, SI-1000 Ljubljana, Slovenia; [Maneg, Oliver; Ludwig, Bernd] Univ Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt; National Institute of Chemistry - Slovenia; Goethe University Frankfurt	Lucke, C (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Saale, Germany.	luecke@enzyme-halle.mpg.de		Pristovsek, Primoz/0000-0002-2304-1791	Deutsche Forschungsgemeinschaft [SFB 472]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by the Deutsche Forschungsgemeinschaft (SFB 472). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bertini I, 1996, J AM CHEM SOC, V118, P11658, DOI 10.1021/ja9621410; Bertini I., 2001, SOLUTION NMR PARAMAG; Bresser A., 1993, Biological Chemistry Hoppe-Seyler, V374, P736; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cunha CA, 1999, J BIOL INORG CHEM, V4, P360, DOI 10.1007/s007750050323; Diaz-Moreno I, 2005, J BIOL CHEM, V280, P18908, DOI 10.1074/jbc.M413298200; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Drosou V, 2002, EUR J BIOCHEM, V269, P2980, DOI 10.1046/j.1432-1033.2002.02979.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; Fee JA, 2000, PROTEIN SCI, V9, P2074, DOI 10.1110/ps.9.11.2074; Gray HB, 2005, P NATL ACAD SCI USA, V102, P3534, DOI 10.1073/pnas.0408029102; Harrenga A, 2000, J MOL BIOL, V295, P667, DOI 10.1006/jmbi.1999.3382; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Johansson MP, 2002, J AM CHEM SOC, V124, P11771, DOI 10.1021/ja026523j; Johansson MP, 2002, BBA-BIOENERGETICS, V1553, P183, DOI 10.1016/S0005-2728(02)00182-2; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kannt A, 1998, FEBS LETT, V434, P17, DOI 10.1016/S0014-5793(98)00942-9; KELLY M, 1993, J BIOL CHEM, V268, P16781; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Maneg O, 2004, BBA-BIOENERGETICS, V1655, P274, DOI 10.1016/j.bbabio.2003.10.010; Maneg O, 2003, J BIOL CHEM, V278, P46734, DOI 10.1074/jbc.M307594200; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mooser D, 2005, BBA-BIOENERGETICS, V1708, P262, DOI 10.1016/j.bbabio.2005.03.008; Morelli X, 2000, J BIOL CHEM, V275, P23204, DOI 10.1074/jbc.M909835199; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Mukrasch MD, 2004, J BIOMOL NMR, V28, P297, DOI 10.1023/B:JNMR.0000013687.83263.b5; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pristovsek P, 2000, EUR J BIOCHEM, V267, P4205, DOI 10.1046/j.1432-1327.2000.01456.x; REGAN JJ, 1993, J PHYS CHEM-US, V97, P13083, DOI 10.1021/j100152a009; Reincke B, 2001, BIOCHEMISTRY-US, V40, P12312, DOI 10.1021/bi010615o; SCOTT RA, 1996, CYTOCHROME C MULTIDI; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; SOULIMANE T, 1995, FEBS LETT, V368, P132, DOI 10.1016/0014-5793(95)00623-H; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; Ubbink M, 1997, BIOCHEMISTRY-US, V36, P6326, DOI 10.1021/bi963199u; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Williams PA, 1999, NAT STRUCT BIOL, V6, P509; WILLIAMS RAD, 1989, FEMS SYMP, V49, P82; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Worrall JAR, 2001, BIOCHEMISTRY-US, V40, P7069, DOI 10.1021/bi0025823; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	54	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14503	14513		10.1074/jbc.M601108200	http://dx.doi.org/10.1074/jbc.M601108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16554303	hybrid			2022-12-27	WOS:000207179300009
J	Parker, ET; Doering, CB; Lollar, P				Parker, Ernest T.; Doering, Christopher B.; Lollar, Pete			A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; HIGH-LEVEL EXPRESSION; PROCOAGULANT ACTIVITY; VONWILLEBRAND FACTOR; INHIBITORY EPITOPE; MAJOR DETERMINANT; LIGHT-CHAIN; FACTOR-X; INACTIVATION	Factor VIII (fVIII) is the plasma protein that is missing or deficient in hemophilia A. In contrast, elevated levels of fVIII are associated with an increased risk of arterial and venous thrombosis. fVIII is activated by thrombin to form a non-covalently linked A1/A2/A3-C1-C2 heterotrimer. At physiological concentrations, fVIIIa decays as a result of A2 subunit dissociation, which may help regulate the balance between hemostasis and thrombosis. A2 subunit dissociation is faster in human fVIIIa than in porcine fVIIIa, which may represent an evolutionary adaptation associated with the development of the upright posture and venous stasis in the lower extremities. To investigate the basis for the different decay kinetics of human and porcine fVIIIa, hybrid fVIII molecules representing all possible combinations of human and porcine A domains were isolated. The kinetics of fVIIIa decay were measured and fit to a model describing a reversible bimolecular reaction in which the dissociation rate constant, k, and dissociation constant, K-d, were the fitted parameters. Substitution of the porcine A1 domain into human fVIIIa produced a dissociation rate constant indistinguishable from porcine fVIIIa. Subsequently, substitution of the second cupredoxin-like A1 subdomain resulted in a dissociation rate constant similar to porcine fVIIIa, whereas substitution of the first cupredoxin-like A1 subdomain resulted in a dissociation rate constant intermediate between human and porcine fVIIIa. We propose that cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant.	Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Childrens Healthcare Atlanta, Aflac Canc Ctr & Blood Disorders Serv, Atlanta, GA 30322 USA	Emory University; Children's Healthcare of Atlanta (CHOA)	Lollar, P (corresponding author), Emory Childrens Ctr, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		NHLBI NIH HHS [R01-HL40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; BARROW RT, 1994, J BIOL CHEM, V269, P26796; Bevington P.R., 1969, DATA REDUCTION ERROR; Doering CB, 2004, J BIOL CHEM, V279, P6546, DOI 10.1074/jbc.M312451200; Doering CB, 2002, J BIOL CHEM, V277, P38345, DOI 10.1074/jbc.M206959200; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Hakeos WH, 2002, THROMB HAEMOSTASIS, V88, P781, DOI 10.1055/s-0037-1613302; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HULTIN MB, 1981, BLOOD, V57, P476; Kamphuisen PW, 2001, ARTERIOSCL THROM VAS, V21, P731, DOI 10.1161/01.ATV.21.5.731; Keeling DM, 1999, BRIT J HAEMATOL, V105, P1123, DOI 10.1046/j.1365-2141.1999.01460.x; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; Moore J.W., 1981, KINETICS MECH, V3rd, P284; Moore W. J., 1972, PHYSICAL CHEM, P324; OBRIEN DP, 1990, BLOOD, V75, P1664; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARQUETGERNEZ A, 1988, THROMB HAEMOSTASIS, V59, P202; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rudzki Z, 1996, BRIT J HAEMATOL, V94, P400, DOI 10.1046/j.1365-2141.1996.d01-1792.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHIMA M, 1989, BLOOD, V74, P1612; SHOEMAKER DP, 1989, EXPT PHYS CHEM, P801; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	51	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13922	13930		10.1074/jbc.M513124200	http://dx.doi.org/10.1074/jbc.M513124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16513639	hybrid			2022-12-27	WOS:000237512300013
J	Shabalina, IG; Petrovic, N; Kramarova, TV; Hoeks, J; Cannon, B; Nedergaard, J				Shabalina, Irina G.; Petrovic, Natasa; Kramarova, Tatiana V.; Hoeks, Joris; Cannon, Barbara; Nedergaard, Jan			UCP1 and defense against oxidative stress - 4-hydroxy-2-nonenal effects on brown fat mitochondria are uncoupling protein 1-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTIVE NONSHIVERING THERMOGENESIS; ADIPOSE-TISSUE; LIPID-PEROXIDATION; SUPEROXIDE ANION; SIMPLE ASSAY; RAT; NUCLEOTIDES; TARGET; MUSCLE; MICE	Uncoupling proteins have been ascribed a role in defense against oxidative stress, particularly by being activated by products of oxidative stress such as 4-hydroxy-2-nonenal (HNE). We have investigated here the ability of HNE to activate UCP1. Using brown fat mitochondria from UCP1(+/+) and UCP1(+/+) mice to allow for identification of UCP1-dependent effects, we found that HNE could neither ( re) activate purine nucleotide-inhibited UCP1, nor induce additional activation of innately active UCP1. The aldehyde nonenal had a ( re) activating effect only if converted to the corresponding fatty acid by aldehyde dehydrogenase; the presence of a carboxyl group was thus an absolute requirement for (re)activation. The UCP1-dependent proton leak was not increased by HNE but HNE changed basal proton leak characteristics in a UCP1-independent manner. In agreement with the in vitro results, we found, as compared with UCP1(+/+) mice, no increase in HNE/protein adducts in brown fat mitochondria isolated from UCP1(-/-) mice, irrespective of whether they were adapted to thermoneutral temperature (30 degrees C) or to the cold (4 degrees C). The absence of oxidative damage in UCP1(-/-) mitochondria was not due to enhanced activity of antioxidant enzymes. Thus, HNE did not affect UCP1 activity, and UCP1 would appear not to be physiologically involved in defense against oxidative stress. Additionally, it was concluded that at least in brown adipose tissue, conditions of high mitochondrial membrane potential, high oxygen tension, and high substrate supply do not necessarily lead to increased oxidative damage.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Shabalina, Irina/AAC-3720-2019; Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Shabalina, Irina G/A-4225-2011; Cannon, Barbara/B-3089-2016	Shabalina, Irina/0000-0002-2915-6450; Shabalina, Irina G/0000-0002-2915-6450; Hoeks, Joris/0000-0002-0265-0870; Nedergaard, Jan/0000-0003-2070-1587; Cannon, Barbara/0000-0001-6594-2363				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bernal-Mizrachi C, 2005, NATURE, V435, P502, DOI 10.1038/nature03527; Beutler E., 1982, RED CELL METABOLISM, P105; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Cadenas S, 2000, BIOCHEM J, V348, P209, DOI 10.1042/0264-6021:3480209; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Choksi KB, 2004, BBA-MOL BASIS DIS, V1688, P95, DOI 10.1016/j.bbadis.2003.11.007; Cohn JA, 1996, ARCH BIOCHEM BIOPHYS, V328, P158, DOI 10.1006/abbi.1996.0156; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; DEQUIROGA GB, 1991, BIOCHEM J, V277, P289, DOI 10.1042/bj2770289; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; FOSTER DO, 1978, CAN J PHYSIOL PHARM, V56, P110, DOI 10.1139/y78-015; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Meyer MJ, 2004, CHEM RES TOXICOL, V17, P1272, DOI 10.1021/tx049843k; MISRA HP, 1972, J BIOL CHEM, V247, P3170; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Murphy TC, 2003, J NEUROCHEM, V84, P1313, DOI 10.1046/j.1471-4159.2003.01628.x; Nedergaard J, 2005, EMBO REP, V6, P917, DOI 10.1038/sj.embor.7400532; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; NEDERGAARD J, 1983, EUR J BIOCHEM, V133, P185, DOI 10.1111/j.1432-1033.1983.tb07446.x; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Ohta S, 2004, ANN NY ACAD SCI, V1011, P36, DOI 10.1196/annals.1293.004; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Reinheckel T, 1998, FREE RADICAL RES, V29, P297, DOI 10.1080/10715769800300331; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1978, J PHYSIOL-PARIS, V74, P695; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; Siems Werner, 2003, Molecular Aspects of Medicine, V24, P167, DOI 10.1016/S0098-2997(03)00011-6; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; ULLRICH O, 1994, FEBS LETT, V352, P84, DOI 10.1016/0014-5793(94)00922-8; Unami A, 2004, BIOCHEM PHARMACOL, V67, P555, DOI 10.1016/j.bcp.2003.09.010; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Yagi K, 1998, Methods Mol Biol, V108, P101	55	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13882	13893		10.1074/jbc.M601387200	http://dx.doi.org/10.1074/jbc.M601387200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543238	hybrid			2022-12-27	WOS:000237512300008
J	Boix-Chornet, M; Fraga, MF; Villar-Garea, A; Caballero, R; Espada, J; Nunez, A; Casado, J; Largo, C; Casal, JI; Cigudosa, JC; Franco, L; Esteller, M; Ballestar, E				Boix-Chornet, M; Fraga, MF; Villar-Garea, A; Caballero, R; Espada, J; Nunez, A; Casado, J; Largo, C; Casal, JI; Cigudosa, JC; Franco, L; Esteller, M; Ballestar, E			Release of hypoacetylated and trimethylated histone H4 is an epigenetic marker of early apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; CHROMATIN CONDENSATION; NUCLEAR EVENTS; PHOSPHORYLATION; CANCER; H3; HETEROCHROMATIN; FRAGMENTATION; NUCLEOSOME; LYSINE-20	Nuclear events such as chromatin condensation, DNAcleavage at internucleosomal sites, and histone release from chromatin are recognized as hallmarks of apoptosis. However, there is no complete understanding of the molecular events underlying these changes. It is likely that epigenetic changes such as DNA methylation and histone modifications that are involved in chromatin dynamics and structure are also involved in the nuclear events described. In this report we have shown that apoptosis is associated with global DNA hypomethylation and histone deacetylation events in leukemia cells. Most importantly, we have observed a particular epigenetic signature for early apoptosis defined by a release of hypoacetylated and trimethylated histone H4 and internucleosomal fragmented DNA that is hypermethylated and originates from perinuclear heterochromatin. These findings provide one of the first links between apoptotic nuclear events and epigenetic markers.	Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Madrid 28029, Spain; Spanish Natl Canc Ctr, Prot Technol Unit, Biotechnol Programme, Madrid 28029, Spain; Spanish Natl Canc Ctr, Human Canc Genet Programme, Mol Cytogenet Grp, Madrid 28029, Spain; Univ Salamanca, Canc Res Ctr, Lab 14, Salamanca 37007, Spain; Univ Valencia, Dept Biochem & Mol Biol, Valencia 46100, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); University of Salamanca; University of Valencia	Esteller, M (corresponding author), Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Melchor Fernandez Almgro 3, Madrid 28029, Spain.	mesteller@cnio.es; eballestar@cnio.es	Ballestar, Esteban/ABG-8561-2020; Espada, Jesús/AAA-3198-2019; Casal, Ignacio/M-2312-2014; Cigudosa, Juan C/E-4105-2016; Esteller, Manel/L-5956-2014; Fraga, Mario F/H-7824-2017; Casado-Vela, Juan/C-5086-2013	Espada, Jesús/0000-0002-4202-4938; Casal, Ignacio/0000-0003-1085-2840; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Casado-Vela, Juan/0000-0001-5924-6601; Villar Garea, Ana/0000-0001-8960-1635; Franco, Luis/0000-0001-9610-6448; Ballestar, Esteban/0000-0002-1400-2440				Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Allera C, 1997, J BIOL CHEM, V272, P10817; ARENDS MJ, 1990, AM J PATHOL, V136, P593; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Bonaldi T, 2004, METHOD ENZYMOL, V377, P111; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gilchrist Susan, 2004, Chromosome Res, V12, P505; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; Johnson CA, 2001, J BIOL CHEM, V276, P4539, DOI 10.1074/jbc.C000824200; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Krystosek A, 1999, HISTOCHEM CELL BIOL, V111, P265, DOI 10.1007/s004180050357; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Lee E, 1999, IUBMB LIFE, V48, P79, DOI 10.1080/152165499307459; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200; Makatsori D, 2004, J BIOL CHEM, V279, P25567, DOI 10.1074/jbc.M313606200; Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Paz MF, 2003, CANCER RES, V63, P1114; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; SHELTON ER, 1980, J BIOL CHEM, V255, P771; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; van Holde K.E., 1988, CHROMATIN; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Weaver VM, 1996, J CELL SCI, V109, P45; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wojciechowski J, 2003, INT J CANCER, V106, P486, DOI 10.1002/ijc.11290; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200	56	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13540	13547		10.1074/jbc.M601136200	http://dx.doi.org/10.1074/jbc.M601136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531610	Green Published, hybrid			2022-12-27	WOS:000237336600062
J	Iwakura, M; Maki, K; Takahashi, H; Takenawa, T; Yokota, A; Katayanagi, K; Kamiyama, T; Gekko, K				Iwakura, M; Maki, K; Takahashi, H; Takenawa, T; Yokota, A; Katayanagi, K; Kamiyama, T; Gekko, K			Evolutional design of a hyperactive cysteine- and methionine-free mutant of Escherichia coli dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LOCAL FITNESS LANDSCAPE; AMINO-ACID; OXIDATIVE RESISTANCE; CIRCULAR PERMUTATION; MOLECULAR DISSECTION; CRYSTAL-STRUCTURES; FOLDING ELEMENTS; PROTEIN; BINDING	We developed a strategy for finding out the adapted variants of enzymes, and we applied it to an enzyme, dihydrofolate reductase ( DHFR), in terms of its catalytic activity so that we successfully obtained several hyperactive cysteine- and methionine-free variants of DHFR in which all five methionyl and two cysteinyl residues were replaced by other amino acid residues. Among them, a variant ( M1A/M16N/M20L/M42Y/C85A/M92F/C152S), named as ANLYF, has an approximately seven times higher k(cat) value than wild type DHFR. Enzyme kinetics and crystal structures of the variant were investigated for elucidating the mechanism of the hyperactivity. Steady-state and transient binding kinetics of the variant indicated that the kinetic scheme of the catalytic cycle of ANLYF was essentially the same as that of wild type, showing that the hyperactivity was brought about by an increase of the dissociation rate constants of tetrahydrofolate from the enzyme-NADPH-tetrahydrofolate ternary complex. The crystal structure of the variant, solved and refined to an R factor of 0.205 at 1.9-A resolution, indicated that an increased structural flexibility of the variant and an increased size of the N-( p-aminobenzoyl)-L-glutamate binding cleft induced the increase of the dissociation constant. This was consistent with a large compressibility ( volume fluctuation) of the variant. A comparison of folding kinetics between wild type and the variant showed that the folding of these two enzymes was similar to each other, suggesting that the activity enhancement of the enzyme can be attained without drastic changes of the folding mechanism.	Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan; Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Hiroshima University	Iwakura, M (corresponding author), Natl Inst Adv Ind Sci & Technol, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	masa-iwakura@aist.go.jp	Takenawa, Tatsuyuki/M-5439-2018; Yokota, Akiko/M-1807-2018	Takenawa, Tatsuyuki/0000-0001-5642-0117; Yokota, Akiko/0000-0002-5896-9899				ADAMS J, 1989, BIOCHEMISTRY-US, V28, P6611, DOI 10.1021/bi00442a012; ADAMS JA, 1991, BIOCHEMISTRY-US, V30, P11046, DOI 10.1021/bi00110a006; Aita T, 1996, J THEOR BIOL, V182, P469, DOI 10.1006/jtbi.1996.0189; Aita T, 1998, J THEOR BIOL, V193, P383, DOI 10.1006/jtbi.1998.0709; Aita T, 2000, BIOPOLYMERS, V54, P64, DOI 10.1002/(SICI)1097-0282(200007)54:1<64::AID-BIP70>3.0.CO;2-R; Aita T, 2002, BIOPOLYMERS, V64, P95, DOI 10.1002/bip.10126; Aita T, 2001, PROTEIN ENG, V14, P633, DOI 10.1093/protein/14.9.633; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Arai M, 2005, J MOL BIOL, V347, P337, DOI 10.1016/j.jmb.2005.01.033; Arai M, 2003, J MOL BIOL, V329, P779, DOI 10.1016/S0022-2836(03)00511-4; Arai M, 2003, J MOL BIOL, V328, P273, DOI 10.1016/S0022-2836(03)00212-2; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BOLES JO, 1992, J BIOL CHEM, V267, P22217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CAYLEY PJ, 1981, BIOCHEMISTRY-US, V20, P874, DOI 10.1021/bi00507a034; Chelius D, 2000, BIOCHEMISTRY-US, V39, P9687, DOI 10.1021/bi000274z; CHEN JT, 1987, BIOCHEMISTRY-US, V26, P4093, DOI 10.1021/bi00387a053; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; Chien HCR, 2002, BIOCHEM BIOPH RES CO, V297, P282, DOI 10.1016/S0006-291X(02)02184-8; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Gegg CV, 1997, PROTEIN SCI, V6, P1885, DOI 10.1002/pro.5560060909; GEKKO K, 1986, BIOCHEMISTRY-US, V25, P6563, DOI 10.1021/bi00369a034; Gekko K, 2000, J BIOCHEM, V128, P21, DOI 10.1093/oxfordjournals.jbchem.a022726; GREEN SM, 1993, BIOCHEMISTRY-US, V32, P10131, DOI 10.1021/bi00089a032; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUANG Z, 1994, BIOCHEMISTRY-US, V33, P11576, DOI 10.1021/bi00204a020; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P31, DOI 10.1093/oxfordjournals.jbchem.a123714; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Iwakura M, 2001, PROTEIN ENG, V14, P583, DOI 10.1093/protein/14.8.583; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kamiyama T, 2000, BBA-PROTEIN STRUCT M, V1478, P257, DOI 10.1016/S0167-4838(00)00019-4; Kim YH, 2001, PROTEIN ENG, V14, P343, DOI 10.1093/protein/14.5.343; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; Miller GP, 1998, CHEM BIOL, V5, pR105, DOI 10.1016/S1074-5521(98)90616-0; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; MURPHY DJ, 1989, BIOCHEMISTRY-US, V28, P3025, DOI 10.1021/bi00433a043; Nakamura T, 1999, J BIOL CHEM, V274, P19041, DOI 10.1074/jbc.274.27.19041; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohmae E, 1998, J BIOCHEM, V123, P839; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; PENNER MH, 1985, J BIOL CHEM, V260, P5366; PERRY KM, 1989, BIOCHEMISTRY-US, V28, P7961, DOI 10.1021/bi00445a061; REYES VM, 1995, BIOCHEMISTRY-US, V34, P2710, DOI 10.1021/bi00008a039; RICHARDS FM, 1985, METHOD ENZYMOL, V115, P440; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; SCHUSTER P, 1994, COMPUT CHEM, V18, P295, DOI 10.1016/0097-8485(94)85025-9; Slusarczyk H, 2000, EUR J BIOCHEM, V267, P1280, DOI 10.1046/j.1432-1327.2000.01123.x; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Takenawa T, 1998, J BIOCHEM-TOKYO, V123, P1137; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; UWAJIMA T, 1990, BIOCHEM BIOPH RES CO, V171, P684, DOI 10.1016/0006-291X(90)91200-C; WAGNER CR, 1995, BIOCHEMISTRY-US, V34, P15671, DOI 10.1021/bi00048a011; WAGNER CR, 1992, BIOCHEMISTRY-US, V31, P7834, DOI 10.1021/bi00149a013; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511	68	29	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13234	13246		10.1074/jbc.M508823200	http://dx.doi.org/10.1074/jbc.M508823200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16510443	hybrid			2022-12-27	WOS:000237336600029
J	Weider, M; Machnik, A; Klebl, F; Sauer, N				Weider, M; Machnik, A; Klebl, F; Sauer, N			Vhr1p, a new transcription factor from budding yeast, regulates biotin-dependent expression of VHT1 and BIO5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; GENE FAMILY; ARABIDOPSIS-THALIANA; FACTOR IIH; CLUSTER; IDENTIFICATION; REPRESSOR; SYSTEM	Transcription of the Saccharomyces cerevisiae vitamin H transporter gene VHT1 is enhanced by low extracellular biotin. Here we present the identification and characterization of Vhr1p as a transcriptional regulator of VHT1 ( VHR1 ( YIL056w); VHT1 regulator 1) and the identification of the cis- regulatory target sequences for Vhr1p in two yeast promoters. VHR1 was identified in a complementation screening of mutagenized yeast cells that had lost the capacity to express the gene of the green fluorescent protein ( GFP) from the VHT1 promoter. Delta vhr1 deletion mutants fail to induce VHT1 on low biotin concentrations. In yeast one- hybrid analyses performed with fusions of Vhr1p N- terminal and C- terminal fragments to the Gal4p activation domain or to the Gal4p DNA- binding domain, the Vhr1p N terminus mediated biotin- dependent DNA binding, and the Vhr1p C terminus triggered biotin- dependent transcriptional activation. The analyzed Vhr1p N- terminal fragment has previously been described as a domain of unknown function ( DUF352). Deletion and linker scanning analyses of the VHT1 promoter revealed the palindromic 18- nucleotide sequence AATCA-N-8-TGAYT as the vitamin H- responsive element. This sequence was identified also in the BIO5 promoter that is also transcriptionally activated on low biotin concentrations. Bio5p mediates the transport of 7- keto- 8- aminopelargonic acid across the yeast plasma membrane, a compound that is used as a precursor in biotin biosynthesis. Delta vhr1 deletion mutants fail to induce BIO5 on low biotin concentrations. The presented data characterize Vhr1p as an essential component of the biotin- dependent signal transduction cascade in yeast.	Univ Erlangen Nurnberg, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Staudtstr 5, D-91058 Erlangen, Germany.	nsauer@biologie.uni-erlangen.de	Weider, Matthias/AAV-9240-2021					ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; Belli G, 2004, J BIOL CHEM, V279, P12386, DOI 10.1074/jbc.M311879200; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Brachmann CB, 1998, YEAST, V14, P115; BROWN T, 1994, CURRENT PROTOCOLS MO; BURKE D, 2000, METHODS YEAST GENETI, P159; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; Eisenstein E, 1999, BIOCHEMISTRY-US, V38, P13077, DOI 10.1021/bi991241q; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Grunewald S, 2004, NEUROPEDIATRICS, V35, P211, DOI 10.1055/s-2004-821080; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; Jona G, 2002, J BIOL CHEM, V277, P39409, DOI 10.1074/jbc.M202733200; Jorgensen MU, 1997, CURR GENET, V31, P241, DOI 10.1007/s002940050201; Klebl F, 2000, FEBS LETT, V481, P86, DOI 10.1016/S0014-5793(00)01959-1; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Llorente B, 2000, FEBS LETT, V475, P237, DOI 10.1016/S0014-5793(00)01698-7; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; McMahon RJ, 2002, ANNU REV NUTR, V22, P221, DOI 10.1146/annurev.nutr.22.121101.112819; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MINET M, 1992, PLANT J, V2, P417; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Nikolau BJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P211, DOI 10.1016/S0003-9861(03)00156-5; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Said HM, 2004, ANNU REV PHYSIOL, V66, P419, DOI 10.1146/annurev.physiol.66.032102.144611; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; Stephan J, 2004, GENE, V343, P181, DOI 10.1016/j.gene.2004.08.028; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Stolz J, 2004, EUKARYOT CELL, V3, P406, DOI 10.1128/EC.3.2.406-412.2004; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Weaver LH, 2001, P NATL ACAD SCI USA, V98, P6045, DOI 10.1073/pnas.111128198	67	20	21	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13513	13524		10.1074/jbc.M512158200	http://dx.doi.org/10.1074/jbc.M512158200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533810	hybrid			2022-12-27	WOS:000237336600059
J	Zhao, G; Zhou, XK; Wang, LQ; Li, GT; Kisker, C; Lennarz, WJ; Schindelin, H				Zhao, G; Zhou, XK; Wang, LQ; Li, GT; Kisker, C; Lennarz, WJ; Schindelin, H			Structure of the mouse peptide N-glycanase-HR23 complex suggests co-evolution of the endoplasmic reticulum-associated degradation and DNA repair pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; XPC-BINDING DOMAIN; GROUP-C PROTEIN; ER-ASSOCIATED DEGRADATION; N-GLYCANASE; DAMAGE RECOGNITION; QUALITY-CONTROL; YEAST PEPTIDE; MECHANISM; IDENTIFICATION	Peptide N- glycanase removes N- linked oligosaccharides from mis-folded glycoproteins as part of the endoplasmic reticulum- associated degradation pathway. This process involves the formation of a tight complex of peptide N- glycanase with Rad23 in yeast and the orthologous HR23 proteins in mammals. In addition to its function in endoplasmic reticulum- associated degradation, HR23 is also involved in DNA repair, where it plays an important role in damage recognition in complex with the xeroderma pigmentosum group C protein. To characterize the dual role of HR23, we have determined the high resolution crystal structure of the mouse peptide N- glycanase catalytic core in complex with the xeroderma pigmentosum group C binding domain from HR23B. Peptide N- glycanase features a large cleft between its catalytic cysteine protease core and zinc binding domain. Opposite the zinc binding domain is the HR23B- interacting region, and surprisingly, the complex interface is fundamentally different from the orthologous yeast peptide N- glycanase- Rad23 complex. Different regions on both proteins are involved in complex formation, revealing an amazing degree of divergence in the interaction between two highly homologous proteins. Furthermore, the mouse peptide N- glycanase- HR23B complex mimics the interaction between xeroderma pigmentosum group C and HR23B, thereby providing a first structural model of how the two proteins interact within the nucleotide excision repair cascade in higher eukaryotes. The different interaction interfaces of the xeroderma pigmentosum group C binding domains in yeast and mammals suggest a co- evolution of the endoplasmic reticulum- associated degradation and DNA repair pathways.	SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Biol Struct, D-97078 Wurzburg, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wurzburg; University of Wurzburg	Schindelin, H (corresponding author), SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM70783, GM33814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aloy P, 2004, NAT BIOTECHNOL, V22, P1317, DOI 10.1038/nbt1018; Aloy P, 2003, J MOL BIOL, V332, P989, DOI 10.1016/j.jmb.2003.07.006; Anantharaman V, 2001, HUM MOL GENET, V10, P1627, DOI 10.1093/hmg/10.16.1627; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biswas S, 2004, BIOCHEM BIOPH RES CO, V323, P149, DOI 10.1016/j.bbrc.2004.08.061; Brinda KV, 2005, BIOCHEM J, V391, P1, DOI 10.1042/BJ20050434; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fu LW, 2003, J CELL BIOL, V160, P157, DOI 10.1083/jcb.200210086; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamionka M, 2004, PROTEIN SCI, V13, P2370, DOI 10.1110/ps.04824304; Katiyar S, 2002, J BIOL CHEM, V277, P12953, DOI 10.1074/jbc.M111383200; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kim B, 2005, FEBS J, V272, P2467, DOI 10.1111/j.1742-4658.2005.04667.x; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; Makarova KS, 1999, PROTEIN SCI, V8, P1714, DOI 10.1110/ps.8.8.1714; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; McCracken AA, 1996, GENETICS, V144, P1355; Misaghi S, 2004, CHEM BIOL, V11, P1677, DOI 10.1016/j.chembiol.2004.11.010; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Ortolan TG, 2004, NUCLEIC ACIDS RES, V32, P6490, DOI 10.1093/nar/gkh987; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Park SY, 2004, P NATL ACAD SCI USA, V101, P11646, DOI 10.1073/pnas.0401038101; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Royer WE, 2001, TRENDS BIOCHEM SCI, V26, P297, DOI 10.1016/S0968-0004(01)01811-4; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sugasawa K, 2002, DNA REPAIR, V1, P95, DOI 10.1016/S1568-7864(01)00008-8; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Suzuki T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0889rev; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9; Xie ZW, 2004, NUCLEIC ACIDS RES, V32, P5981, DOI 10.1093/nar/gkh934; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870	57	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13751	13761		10.1074/jbc.M600137200	http://dx.doi.org/10.1074/jbc.M600137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16500903	hybrid			2022-12-27	WOS:000237336600086
J	Ferrer, T; Rupp, J; Piper, DR; Tristani-Firouzi, M				Ferrer, T; Rupp, J; Piper, DR; Tristani-Firouzi, M			The S4-S5 linker directly couples voltage sensor movement to the activation gate in the human ether-a '-go-go-related gene (hERG) K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; ION CHANNELS; CHARGE DISPLACEMENT; CRYSTAL-STRUCTURE; INACTIVATION; PORE; CONDUCTION; MUTATIONS; SEGMENT; FAMILY	A key unresolved question regarding the basic function of voltage-gated ion channels is how movement of the voltage sensor is coupled to channel opening. We previously proposed that the S4-S5 linker couples voltage sensor movement to the S6 domain in the human ether-a'-go-go- related gene (hERG) K+ channel. The recently solved crystal structure of the voltage-gated Kv1.2 channel reveals that the S4-S5 linker is the structural link between the voltage sensing and pore domains. In this study, we used chimeras constructed from hERG and ether-a'-go-go (EAG) channels to identify interactions between residues in the S4-S5 linker and S6 domain that were critical for stabilizing the channel in a closed state. To verify the spatial proximity of these regions, we introduced cysteines in the S4-S5 linker and at the C-terminal end of the S6 domain and then probed for the effect of oxidation. The D540C-L666C channel current decreased in an oxidizing environment in a state-dependent manner consistent with formation of a disulfide bond that locked the channel in a closed state. Disulfide bond formation also restricted movement of the voltage sensor, as measured by gating currents. Taken together, these data confirm that the S4-S5 linker directly couples voltage sensor movement to the activation gate. Moreover, rather than functioning simply as a mechanical lever, these findings imply that specific interactions between the S4-S5 linker and the activation gate stabilize the closed channel conformation.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84113 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84113 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84113 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Tristani-Firouzi, M (corresponding author), Univ Utah, Sch Med, Dept Pediat, Suite 1500 PCMC, Salt Lake City, UT 84113 USA.	mfirouzi@cvrti.utah.edu			NHLBI NIH HHS [HL03816] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Chanda B, 2005, NATURE, V436, P852, DOI 10.1038/nature03888; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; CREIGHTON TE, 1997, PROTEINS STRUCTURES, P18; Ding SH, 2003, BIOPHYS J, V84, P295, DOI 10.1016/S0006-3495(03)74850-4; Ding SH, 2002, J GEN PHYSIOL, V120, P87, DOI 10.1085/jgp.20028611; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Horn R, 2000, BIOCHEMISTRY-US, V39, P15653, DOI 10.1021/bi0020473; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Piper DR, 2005, J BIOL CHEM, V280, P7206, DOI 10.1074/jbc.M411042200; Piper DR, 2003, P NATL ACAD SCI USA, V100, P10534, DOI 10.1073/pnas.1832721100; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Stefani E, 1998, METHOD ENZYMOL, V293, P300; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438	31	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12858	12864		10.1074/jbc.M513518200	http://dx.doi.org/10.1074/jbc.M513518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524878	hybrid			2022-12-27	WOS:000237134700081
J	Kanjilal-Kolar, S; Raetz, CRH				Kanjilal-Kolar, S; Raetz, CRH			Dodecaprenyl phosphate-galacturonic acid as a donor substrate for lipopolysaccharide core glycosylation in Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; LIPID-A BIOSYNTHESIS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; EXPRESSION CLONING; O-ANTIGEN; SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; SHIGELLA-FLEXNERI; MASS-SPECTROMETRY; MEMBRANE ENZYME	The lipid A and inner core regions of Rhizobium leguminosarum lipopolysaccharide contain four galacturonic acid ( GalA) residues. Two are attached to the outer unit of the 3-deoxy-D-manno-octulosonic acid (Kdo) disaccharide, one to the mannose residue, and one to the 4'-position of lipid A. The enzymes RgtA and RgtB, described in the accompanying article, catalyze GalA transfer to the Kdo residue, whereas RgtC is responsible for modification of the core mannose unit. Heterologous expression of RgtA in Sinorhizhobium meliloti 1021, a strain that normally lacks GalA modifications on its Kdo disaccharide, resulted in detectable GalA transferase activity in isolated membrane preparations, suggesting that the appropriate GalA donor substrate is available in S. meliloti membranes. In contrast, heterologous expression of RgtA in Escherichia coli yielded inactive membranes. However, RgtA activity was detectable in the E. coli system when total lipids from R. leguminosarum 3841 or S. meliloti 1021 were added. We have now purified and characterized dodecaprenyl (C60) phosphate-GalA as a minor novel lipid of R. leguminosarum 3841 and S. meliloti. This substance is stable to mild base hydrolysis and was purified by DEAE-cellulose column chromatography. Its structure was established by a combination of electrospray ionization mass spectrometry and gas-liquid chromatography. Purified dodecaprenyl phosphate-GalA supports the efficient transfer of GalA to Kdo(2)-1-dephospho-lipid IVA by membranes of E. coli cells expressing RgtA, RgtB, and RgtC. The identification of a polyisoprene phosphate-GalA donor substrate suggests that the active site of RgtA faces the periplasmic side of the inner membrane. This work represents the first definitive characterization of a lipid-linked GalA derivative with the proposed structure dodecaprenyl phosphate-beta-D-GalA.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, R37GM051796, U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069338, R37 GM051796, GM-51796, R37 GM051796-10, R01 GM051796, U54 GM069338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allison GE, 2000, TRENDS MICROBIOL, V8, P17, DOI 10.1016/S0966-842X(99)01646-7; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; Choma A, 2004, EUR J BIOCHEM, V271, P1310, DOI 10.1111/j.1432-1033.2004.04038.x; DO UH, 1980, J LIPID RES, V21, P888; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DOTSON SB, 1995, ARCH BIOCHEM BIOPHYS, V316, P773, DOI 10.1006/abbi.1995.1103; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Guan ZQ, 2005, ANAL BIOCHEM, V345, P336, DOI 10.1016/j.ab.2005.07.002; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; Kanjilal S, 2005, GLYCOBIOLOGY, V15, P1194; Kanjilal-Kolar S, 2006, J BIOL CHEM, V281, P12865, DOI 10.1074/jbc.M513864200; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; Keating DH, 2002, J BACTERIOL, V184, P6681, DOI 10.1128/JB.184.23.6681-6689.2002; Kelleher DJ, 2001, GLYCOBIOLOGY, V11, P321, DOI 10.1093/glycob/11.4.321; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Mavris M, 1997, MOL MICROBIOL, V26, P939, DOI 10.1046/j.1365-2958.1997.6301997.x; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; RUSSOMANDO G, 1992, AN ASOC QUIM ARGENT, V80, P175; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wang XY, 2006, J BIOL CHEM, V281, P9321, DOI 10.1074/jbc.M600435200; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J BIOL CHEM, V270, P20151, DOI 10.1074/jbc.270.34.20151; YOKOYAMA K, 1988, EUR J BIOCHEM, V173, P453, DOI 10.1111/j.1432-1033.1988.tb14020.x	57	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12879	12887		10.1074/jbc.M513865200	http://dx.doi.org/10.1074/jbc.M513865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497671	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000237134700083
J	Dutt, S; Kleber, M; Matasci, M; Sommer, L; Zimmermann, DR				Dutt, S; Kleber, M; Matasci, M; Sommer, L; Zimmermann, DR			Versican V0 and V1 guide migratory neural crest cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HYALURONAN-BINDING PROTEOGLYCANS; AVIAN EMBRYO; NERVOUS-SYSTEM; PG-M; COMMISSURAL AXONS; DEVELOPING BRAIN; AGGRECAN GENE; CHICK-EMBRYO; EXPRESSION	We previously showed the selective expression of the chondroitin sulfate proteoglycans versican V0 and V1 in barrier tissues that impede the migration of neural crest cells during embryonic trunk development (Landolt, R. M., Vaughan, L., Winterhalter, K. H., and Zimmermann, D. R. ( 1995) Development 212, 2303 - 2312). To test for an active involvement of these isoforms in the guidance process, we have now established protocols to isolate intact versican V0 and V1 in quantities sufficient for functional experiments. Using stripe choice assays, we demonstrate that pure preparations of either a mixture of versican V0/V1 or V1 alone strongly inhibit the migration of multipotent Sox10/p75NTR double-positive early neural crest stem cells on fibronectin by interfering with cell-substrate adhesion. We show that this inhibition is largely core glycoprotein-dependent, as the complete removal of the glycosaminoglycan chains has only a minor effect on the inhibitory capacity. Our findings support the notion that versican variants V0 and V1 act, possibly in concert with other inhibitory molecules such as aggrecan and ephrins, in directing the migratory streams of neural crest cells to their appropriate target tissues.	Univ Zurich Hosp, Dept Pathol, Mol Biol Lab, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zimmermann, DR (corresponding author), Univ Zurich Hosp, Dept Pathol, Mol Biol Lab, CH-8091 Zurich, Switzerland.	maurice.kleber@gmx.ch; dieterzi@patho.unizh.ch		Sommer, Lukas/0000-0002-1143-7908				Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Bronner-Fraser Marianne, 1993, Trends in Cell Biology, V3, P392, DOI 10.1016/0962-8924(93)90089-J; BRONNERFRASER M, 1991, DEV BIOL, V143, P213, DOI 10.1016/0012-1606(91)90071-A; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; Debby-Brafman A, 1999, NEURON, V22, P475, DOI 10.1016/S0896-6273(00)80703-5; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Kasemeier-Kulesa JC, 2005, DEVELOPMENT, V132, P235, DOI 10.1242/dev.01553; Kawasaki T, 2002, DEVELOPMENT, V129, P671; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; KIMATA K, 1986, J BIOL CHEM, V261, P3517; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; KLEBER M, 2006, CELL BIOL LAB HDB, P69; Krull CE, 2001, MECH DEVELOP, V105, P37, DOI 10.1016/S0925-4773(01)00395-1; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kubota Y, 1999, DEV DYNAM, V214, P55, DOI 10.1002/(SICI)1097-0177(199901)214:1<55::AID-DVDY6>3.0.CO;2-E; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; Le Douarin NM, 2004, MECH DEVELOP, V121, P1089, DOI 10.1016/j.mod.2004.06.003; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Li S, 2005, ANNU REV BIOMED ENG, V7, P105, DOI 10.1146/annurev.bioeng.7.060804.100340; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; NEWGREEN DF, 1990, DEV BIOL, V139, P100, DOI 10.1016/0012-1606(90)90282-N; OAKLEY RA, 1994, DEVELOPMENT, V120, P103; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Paratore C, 2001, DEVELOPMENT, V128, P3949; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; Perris R, 1996, FASEB J, V10, P293, DOI 10.1096/fasebj.10.2.8641562; PERRIS R, 1991, DEVELOPMENT, V111, P583; Pettway Z, 1996, EXP CELL RES, V225, P195, DOI 10.1006/excr.1996.0170; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RICKMANN M, 1985, J EMBRYOL EXP MORPH, V90, P437; Ring C, 1996, DEV BIOL, V180, P41, DOI 10.1006/dbio.1996.0283; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Santiago A, 2002, DEVELOPMENT, V129, P3621; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Talts JF, 1999, METH MOL B, V129, P153; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; Testaz S, 1999, J CELL SCI, V112, P4715; Tosney KW, 2004, DEV DYNAM, V229, P99, DOI 10.1002/dvdy.10492; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	68	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12123	12131		10.1074/jbc.M510834200	http://dx.doi.org/10.1074/jbc.M510834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510447	hybrid			2022-12-27	WOS:000236988100082
J	Maki, N; Moitra, K; Ghosh, P; Dey, S				Maki, N; Moitra, K; Ghosh, P; Dey, S			Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MULTIDRUG TRANSPORTER; NUCLEOTIDE-BINDING SITES; CATALYTIC CYCLE; ABC TRANSPORTERS; RESISTANCE; INHIBITION; CELLS; PROTEINS; CLEAVAGE; MUTANTS	ATP-dependent drug transport by human P-glycoprotein (Pgp, ABCB1) involves a coordinated communication between its drug-binding site ( substrate site) and the nucleotide binding/hydrolysis domain (ATP sites). It has been demonstrated that the two ATP sites of Pgp play distinct roles within a single catalytic turnover; whereas ATP binding or/and hydrolysis by one drives substrate translocation and dissociation, the hydrolytic activity of the other resets the transporter for the subsequent cycle (Sauna, Z. E., and Ambudkar, S. V. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2515-2520; Sauna, Z. E., and Ambudkar, S. V. (2001) J. Biol. Chem. 276, 11653-11661). Trapping of ADP (or 8-azido-ADP) and vanadate (ADP center dot Vi or 8-azido-ADP center dot Vi) at the catalytic site, following nucleotide hydrolysis, markedly reduces the affinity of Pgp for its transport substrate [I-125]iodoarylazidoprazosin ([I-125]IAAP), resulting in dissociation of the latter. Regeneration of the [I-125] IAAP site requires an additional round of nucleotide hydrolysis. In this study, we demonstrate that certain thioxanthene-based allosteric modulators, such as cis-(Z)-flupentixol and its closely related analogs, induce regeneration of [I-125]IAAP binding to vanadate-trapped (or fluoroaluminate-trapped) Pgp without any further nucleotide hydrolysis. Regeneration was facilitated by dissociation of the trapped nucleotide and vanadate. Once regenerated, the substrate site remains accessible to [I-125] IAAP even after removal of the modulator from the medium, suggesting amodulator-induced relaxation of a constrained transition state conformation. Consistent with this, limited trypsin digestion of vanadate-trapped Pgp shows protection by cis-(Z)-flupentixol of two Pgp fragments (similar to 60 kDa) recognizable by a polyclonal antiserum specific for the NH2-terminal half. No regeneration was observed in the Pgp mutant F983A that is impaired in modulation by flupentixols, indicating involvement of the allosteric modulator site in the phenomenon. In summary, the data demonstrate that in the nucleotide-trapped low affinity state of Pgp, the allosteric site remains accessible and responsive to modulation by flupentixol (and its closely related analogs), which can reset the high affinity state for [I-125]IAAP binding without any further nucleotide hydrolysis.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Dey, S (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	sdey@usuhs.mil			NIGMS NIH HHS [GM067926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FORD JM, 1990, CANCER RES, V50, P1748; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Loo TW, 2005, BIOCHEMISTRY-US, V44, P10250, DOI 10.1021/bi050705j; Loo TW, 2004, BIOCHEMISTRY-US, V43, P12081, DOI 10.1021/bi049045t; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Maki N, 2003, J BIOL CHEM, V278, P18132, DOI 10.1074/jbc.M210413200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Nuti SL, 2002, J BIOL CHEM, V277, P29417, DOI 10.1074/jbc.M204054200; Omote H, 2004, BIOCHEMISTRY-US, V43, P3917, DOI 10.1021/bi035365l; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x	41	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10769	10777		10.1074/jbc.M512579200	http://dx.doi.org/10.1074/jbc.M512579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505485	hybrid			2022-12-27	WOS:000236822200016
J	Tao, Z; Zhang, Z; Grewer, C				Tao, Z; Zhang, Z; Grewer, C			Neutralization of the aspartic acid residue Asp-367, but not Asp-454, inhibits binding of Na+ to the glutamate-free form and cycling of the glutamate transporter EAAC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FUNCTIONAL-CHARACTERIZATION; ANION CONDUCTANCE; CHLORIDE CHANNEL; GLT-1; CARRIER; EXPRESSION; EXCHANGE; CURRENTS; CLONING	Substrate transport by the plasma membrane glutamate transporter EAAC1 is coupled to cotransport of three sodium ions. One of these Na+ ions binds to the transporter already in the absence of glutamate. Here, we have investigated the possible involvement of two conserved aspartic acid residues in transmembrane segments 7 and 8 of EAAC1, Asp-367 and Asp-454, in Na+ cotransport. To test the effect of charge neutralization mutations in these positions on Na+ binding to the glutamate-free transporter, we recorded the Na+-induced anion leak current to determine the K-m of EAAC1 for Na+. For EAAC1WT, this K-m was determined as 120 mM. When the negative charge of Asp-367 was neutralized by mutagenesis to asparagine, Na+ activated the anion leak current with a K-m of about 2 M, indicating dramatically impaired Na+ binding to the mutant transporter. In contrast, the Na+ affinity of EAAC1(D454N) was virtually unchanged compared with the wild type transporter (K-m = 90 mM). The reduced occupancy of the Na+ binding site of EAAC1(D367N) resulted in a dramatic reduction in glutamate affinity (K-m = 3.6 mM, 140 mM [Na+]), which could be partially overcome by increasing extracellular [Na+]. In addition to impairing Na+ binding, the D367N mutation slowed glutamate transport, as shown by pre-steady-state kinetic analysis of transport currents, by strongly decreasing the rate of a reaction step associated with glutamate translocation. Our data are consistent with a model in which Asp-367, but not Asp-454, is involved in coordinating the bound Na+ in the glutamate-free transporter form.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	University of Miami	Grewer, C (corresponding author), 1600 NW 10th Ave, Miami, FL 33136 USA.	cgrewer@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049335] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS049335-02, R01 NS 049335-02, R01 NS049335] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bergles DE, 2002, J NEUROSCI, V22, P10153; Billups B, 1996, J NEUROSCI, V16, P6722; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Canepari M, 2001, J NEUROSCI METH, V112, P29, DOI 10.1016/S0165-0270(01)00451-4; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grewer C, 2004, J PHYSIOL-LONDON, V557, P747, DOI 10.1113/jphysiol.2004.062521; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KLUGE C, 1993, J BIOL CHEM, V268, P14557; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Otis TS, 2000, J NEUROSCI, V20, P2749; Otis TS, 1998, J NEUROSCI, V18, P7099; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tao Z, 2005, BIOCHEMISTRY-US, V44, P3466, DOI 10.1021/bi047812i; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	40	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10263	10272		10.1074/jbc.M510739200	http://dx.doi.org/10.1074/jbc.M510739200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478724	Green Accepted, hybrid			2022-12-27	WOS:000236594300054
J	Rose, IA				Rose, IA			Mechanistic inferences from stereochemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							PHOSPHOGLUCOSE ISOMERASE; EXCHANGE; ALDOLASE		Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92717 USA	University of California System; University of California Irvine	Rose, IA (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92717 USA.	aagsalog@uci.edu						BENDER ML, 1967, J AM CHEM SOC, V89, P1211, DOI 10.1021/ja00981a030; BENDER ML, 1951, J AM CHEM SOC, V73, P1626, DOI 10.1021/ja01148a063; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; Mason S.F., 1991, CHEM EVOLUTION, P260; MIDDLEFORT CF, 1976, J BIOL CHEM, V251, P5881; O'Connell E L, 1977, Methods Enzymol, V46, P381; OGSTON AG, 1948, NATURE, V162, P963, DOI 10.1038/162963b0; ROSE I A, 1962, Brookhaven Symp Biol, V15, P293; ROSE IA, 1961, J BIOL CHEM, V236, P3086; ROSE IA, 1958, J AM CHEM SOC, V80, P5835, DOI 10.1021/ja01554a063; Rose IA, 2002, J AM CHEM SOC, V124, P13047, DOI 10.1021/ja027065h; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; ROSE IA, 1960, BIOCHIM BIOPHYS ACTA, V42, P159, DOI 10.1016/0006-3002(60)90765-4; ROSE IA, 1955, J AM CHEM SOC, V77, P5764, DOI 10.1021/ja01626a107; ROSE IA, 1978, FED PROC, V37, P2775; SCHRAY KJ, 1973, J BIOL CHEM, V248, P2219; SUMMERS MC, 1977, J AM CHEM SOC, V99, P4475, DOI 10.1021/ja00455a044; TOPPER YJ, 1957, J BIOL CHEM, V225, P419; 2006, IN PRESS JBC PA 0201	19	0	0	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6117	6119		10.1074/JBC.X600001200	http://dx.doi.org/10.1074/JBC.X600001200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16517612	hybrid			2022-12-27	WOS:000236030800001
J	Slepenkov, SV; Darzynkiewicz, E; Rhoads, RE				Slepenkov, Sergey V.; Darzynkiewicz, Edward; Rhoads, Robert E.			Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides - Evidence for a one-step binding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MESSENGER-RNA-CAP; ACTIVATED PROTEIN-KINASE; TRANSLATION FACTOR EIF4E; EUKARYOTIC TRANSLATION; FACTOR EIF-4E; SECONDARY STRUCTURE; 4E-BINDING PROTEIN; CIRCULAR-DICHROISM; HYPERTONIC STRESS	Recruitment of eukaryotic mRNA to the 48 S initiation complex is rate-limiting for protein synthesis under normal conditions. Binding of the 5'-terminal cap structure of mRNA to eIF4E is a critical event during this process. Mammalian eIF4E is phosphorylated at Ser-209 by Mnk1 and Mnk2 kinases. We investigated the interaction of both eIF4E and phosphorylated eIF4E(eIF4E(P)) with cap analogs and capped oligoribonucleotides by stopped-flow kinetics. For m7GpppG, the rate constant of association, k(on), was dependent on ionic strength, decreasing progressively up to 350 mM KCl, but the rate constant of dissociation, k(off), was independent of ionic strength. Phosphorylation of eIF4E decreased k(on) by 2.1-2.3fold at 50 - 100 mM KCl but had progressively less effect at higher ionic strengths, being negligible at 350 mM. Contrary to published evidence, eIF4E phosphorylation had no effect on k(off). Several observations supported a simple one-step binding mechanism, in contrast to published reports of a two-step mechanism. The kinetic function that best fit the data changed from single- to double-exponential as the eIF4E concentration was increased. However, measuring koff for dissociation of a pre-formed eIF4E(.)m7GpppG complex suggested that the double-exponential kinetics were caused by dissociation of eIF4E dimers, not a two-step mechanism. Addition of a 12-nucleotide chain to the cap structure increased affinity at high ionic strength for both eIF4E (24-fold) and eIF4E(P) (7-fold), primarily due to a decrease in k(off). This suggests that additional stabilizing interactions between capped oligoribonucleotides and eIF4E, which do not occur with cap analogs alone, act to slow dissociation.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Warsaw, Dept Biophys, PL-02089 Warsaw, Poland	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Warsaw	Rhoads, RE (corresponding author), 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu	Slepenkov, Sergey/D-4039-2016		FOGARTY INTERNATIONAL CENTER [R03TW006446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020818] Funding Source: NIH RePORTER; FIC NIH HHS [1R03 TW 006446] Funding Source: Medline; NIGMS NIH HHS [2R01 GM 20818] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arquier N, 2005, CURR BIOL, V15, P19, DOI 10.1016/j.cub.2004.12.037; Bevington P. R, 1969, DATA REDUCTION ERROR; Blachut-Okrasinska E, 2000, EUR BIOPHYS J BIOPHY, V29, P487, DOI 10.1007/s002490000096; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P6977, DOI 10.1021/bi00242a024; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; DARNBROUGH C, 1973, J MOL BIOL, V76, P379; Dlugosz M, 2003, EUR BIOPHYS J BIOPHY, V31, P608, DOI 10.1007/s00249-002-0258-7; Dyer JR, 1998, J BIOL CHEM, V273, P29469, DOI 10.1074/jbc.273.45.29469; Fechter P, 2005, J GEN VIROL, V86, P1239, DOI 10.1099/vir.0.80755-0; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GOSS DJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P163, DOI 10.1016/0167-4781(90)90160-4; Grudzien E, 2004, RNA, V10, P1479, DOI 10.1261/rna.7380904; Grudzien E, 2006, J BIOL CHEM, V281, P1857, DOI 10.1074/jbc.M509121200; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; Hong-Brown LQ, 2004, AM J PHYSIOL-CELL PH, V287, pC1482, DOI 10.1152/ajpcell.00038.2004; Hu GH, 2003, J BIOL CHEM, V278, P51515, DOI 10.1074/jbc.M307654200; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; Khan MA, 2004, BIOCHEMISTRY-US, V43, P9092, DOI 10.1021/bi049602b; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MCCUBBIN WD, 1988, J BIOL CHEM, V263, P17663; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Niedzwiecka A, 2002, BIOCHEMISTRY-US, V41, P12140, DOI 10.1021/bi0258142; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Orton KC, 2004, J BIOL CHEM, V279, P38649, DOI 10.1074/jbc.M407337200; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Reiling JH, 2005, CURR BIOL, V15, P24, DOI 10.1016/j.cub.2004.12.034; Ren JH, 1996, NUCLEIC ACIDS RES, V24, P3629, DOI 10.1093/nar/24.18.3629; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Righetti P.G., 1983, ISOELECTRIC FOCUSING; Robalino J, 2004, J BIOL CHEM, V279, P10532, DOI 10.1074/jbc.M313688200; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SAFER B, 1978, J BIOL CHEM, V253, P3384; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; SHA M, 1995, J BIOL CHEM, V270, P29904; Stepinski J, 2001, RNA, V7, P1486; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Tomoo K, 2005, BBA-PROTEINS PROTEOM, V1753, P191, DOI 10.1016/j.bbapap.2005.07.023; Tomoo K, 2003, J MOL BIOL, V328, P365, DOI 10.1016/S0022-2836(03)00314-0; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; von der Haar T, 2000, J BIOL CHEM, V275, P30551, DOI 10.1074/jbc.M004565200; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang YH, 1996, BBA-PROTEIN STRUCT M, V1297, P207, DOI 10.1016/S0167-4838(96)00119-7; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; Wieczorek Z, 1999, Z NATURFORSCH C, V54, P278; Wieczorek Z, 1997, BBA-GENE STRUCT EXPR, V1354, P145, DOI 10.1016/S0167-4781(97)00116-4; Wieczorek Z, 1998, J PHOTOCH PHOTOBIO B, V43, P158, DOI 10.1016/S1011-1344(98)00100-6; Worch J, 2004, ONCOGENE, V23, P9162, DOI 10.1038/sj.onc.1208164; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948; Zuberek J, 2004, BIOCHEMISTRY-US, V43, P5370, DOI 10.1021/bi030266t; Zuberek J, 2003, NUCLEOS NUCLEOT NUCL, V22, P1703, DOI 10.1081/NCN-120023118; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403; 1994, BIAPPLICATIONS HDB	87	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14927	14938		10.1074/jbc.M601653200	http://dx.doi.org/10.1074/jbc.M601653200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540463	hybrid			2022-12-27	WOS:000237671300046
J	Sunesen, M; De Carvalho, LP; Dufresne, V; Grailhe, R; Savatier-Duclert, N; Gibor, G; Peretz, A; Attali, B; Changeux, JP; Paas, Y				Sunesen, Morten; De Carvalho, Lia Prado; Dufresne, Virginie; Grailhe, Regis; Savatier-Duclert, Nathalie; Gibor, Gilad; Peretz, Asher; Attali, Bernard; Changeux, Jean-Pierre; Paas, Yoav			Mechanism of Cl- selection by a glutamate-gated chloride (GluCl) receptor revealed through mutations in the selectivity filter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; ACETYLCHOLINE-RECEPTOR; ION SELECTIVITY; NICOTINIC RECEPTOR; GATING MECHANISM; ANION PERMEATION; CHANNEL; GLYCINE; PORE; CONDUCTANCE	To learn about the mechanism of ion charge selectivity by invertebrate glutamate-gated chloride ( GluCl) channels, we swapped segments between the GluCl beta receptor of Caenorhabditis elegans and the vertebrate cationic alpha 7-acetylcholine receptor and monitored anionic/cationic permeability ratios. Complete conversion of the ion charge selectivity in a set of receptor microchimeras indicates that the selectivity filter of the GluCl beta receptor is created by a sequence connecting the first with the second transmembrane segments. A single substitution of a negatively charged residue within this sequence converted the selectivity of the GluCl beta receptor's pore from anionic to cationic. Unexpectedly, elimination of the charge of each basic residue of the selectivity filter, one at a time or concomitantly, moderately reduced the P-Cl/P-Na ratios, but the GluCl beta receptor's mutants retained high capacity to select Cl- over Na+. These results indicate that, unlike the proposed case of anionic Gly- and gamma-aminobutyric acid-gated ion channels, positively charged residues do not play the key role in the selection of ionic charge by the GluCl beta receptor. Taken together with measurements of the effective open pore diameter and with structural modeling, the study presented here collectively indicates that in the most constricted part of the open GluCl beta receptor's channel, Cl- interacts with backbone amides, where it undergoes partial dehydration necessary for traversing the pore.	Inst Pasteur, CNRS, UMR 2182, Unit Receptors & Cognit, F-75724 Paris 15, France; Sophion Biosci AS, DK-2750 Ballerup, Denmark; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tel Aviv University; Sackler Faculty of Medicine	Paas, Y (corresponding author), Inst Pasteur, CNRS, UMR 2182, Unit Receptors & Cognit, 25 Rue Dr Roux, F-75724 Paris 15, France.	yopaas@netvision.net.il						Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Carland JE, 2004, J BIOL CHEM, V279, P54153, DOI 10.1074/jbc.M410625200; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; FATIMASHAD K, 1993, P ROY SOC B-BIOL SCI, V253, P69, DOI 10.1098/rspb.1993.0083; Fuchs S, 2003, ANN NY ACAD SCI, V998, P93, DOI 10.1196/annals.1254.011; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2005, J NEUROCHEM, V92, P962, DOI 10.1111/j.1471-4159.2004.02970.x; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lee DJS, 2003, NEUROSCI LETT, V351, P196, DOI 10.1016/j.neulet.2003.08.005; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; MacInnes D.A., 1961, PRINCIPLES ELECTROCH; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Menard C, 2005, J BIOL CHEM, V280, P27502, DOI 10.1074/jbc.M501624200; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 2002, J GEN PHYSIOL, V119, P411, DOI 10.1085/jgp.20028553; Paas Y, 2005, P NATL ACAD SCI USA, V102, P15877, DOI 10.1073/pnas.0507599102; Pitzer K.S, 1991, ION INTERACTION APPR, Vsecond; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; Wilson GG, 2000, J GEN PHYSIOL, V115, P93, DOI 10.1085/jgp.115.2.93; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; [No title captured]	41	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14875	14881		10.1074/jbc.M511657200	http://dx.doi.org/10.1074/jbc.M511657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16527818	hybrid			2022-12-27	WOS:000237671300041
J	Ulvila, J; Parikka, M; Kleino, A; Sormunen, R; Ezekowitz, RA; Kocks, C; Ramet, M				Ulvila, Johanna; Parikka, Mataleena; Kleino, Anni; Sormunen, Raija; Ezekowitz, R. Alan; Kocks, Christine; Ramet, Mika			Double-stranded RNA is internalized by scavenger receptor-mediated endocytosis in Drosophila S2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN; PROTEASOME; COMPONENTS; INITIATION; CLEAVAGE; IDENTIFICATION; INTERFERENCE; PHAGOCYTOSIS; ARGONAUTE2	Double-stranded RNA ( dsRNA) fragments are readily internalized and processed by Drosophila S2 cells, making these cells a widely used tool for the analysis of gene function by gene silencing through RNA interference (RNAi). The underlying mechanisms are insufficiently understood. To identify components of the RNAi pathway in S2 cells, we developed a screen based on rescue from RNAi-induced lethality. We identified Argonaute 2, a core component of the RNAi machinery, and three gene products previously unknown to be involved in RNAi in Drosophila: DEAD-box RNA helicase Belle, 26 S proteasome regulatory subunit 8 (Pros45), and clathrin heavy chain, a component of the endocytic machinery. Blocking endocytosis in S2 cells impaired RNAi, suggesting that dsRNA fragments are internalized by receptor-mediated endocytosis. Indeed, using a candidate gene approach, we identified two Drosophila scavenger receptors, SR-CI and Eater, which together accounted for more than 90% of the dsRNA uptake into S2 cells. When expressed in mammalian cells, SR-CI was sufficient to mediate internalization of dsRNA fragments. Our data provide insight into the mechanism of dsRNA internalization by Drosophila cells. These results have implications for dsRNA delivery into mammalian cells.	Tampere Univ, Inst Med Technol, FIN-30014 Tampere, Finland; Oulu Univ, Dept Pediat, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Lab Dev Immunol, Boston, MA 02115 USA; Tampere Univ Hosp, Dept Pediat, FIN-33521 Tampere, Finland	Tampere University; University of Oulu; University of Oulu; University of Oulu; Harvard University; Harvard Medical School; Massachusetts General Hospital; Tampere University; Tampere University Hospital	Ramet, M (corresponding author), Tampere Univ, Inst Med Technol, FIN-30014 Tampere, Finland.	Mika.Ramet@uta.fi	Parikka, Mataleena/D-4364-2014	Parikka, Mataleena/0000-0001-5555-3815	NIAID NIH HHS [P01 AI 44220] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker SP, 2005, CELL, V123, P361, DOI 10.1016/j.cell.2005.10.013; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Goto A, 2003, NUCLEIC ACIDS RES, V31, P6619, DOI 10.1093/nar/gkg852; Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Johnson ME, 2004, J SOUND VIB, V277, P101, DOI 10.1016/j.jsv.2003.08.031; Kallio J, 2005, MICROBES INFECT, V7, P811, DOI 10.1016/j.micinf.2005.03.014; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Preall JB, 2005, CELL, V123, P543, DOI 10.1016/j.cell.2005.11.006; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	42	208	215	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14370	14375		10.1074/jbc.M513868200	http://dx.doi.org/10.1074/jbc.M513868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16531407	hybrid			2022-12-27	WOS:000237512300063
J	Kalamvoki, M; Georgopoulou, U; Mavromara, P				Kalamvoki, M; Georgopoulou, U; Mavromara, P			The NS5A protein of the hepatitis C virus genotype 1a is cleaved by caspases to produce C-terminal-truncated forms of the protein that reside mainly in the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NONSTRUCTURAL 5A PROTEIN; NF-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATOR; HEPATOCELLULAR-CARCINOMA; PROTEOLYTIC CLEAVAGE; NUCLEAR-LOCALIZATION; DEPENDENT ACTIVATION; MEDIATED CLEAVAGE; CALPAIN PROTEASES	The nonstructural 5A ( NS5A) protein of the hepatitis C virus ( HCV) is a multifunctional protein that is implicated in viral replication and pathogenesis. We report here that NS5A of HCV- 1a is cleaved at multiple sites by caspase proteases in transfected cells. Two cleavage sites at positions Asp(154) and (DXXD251)-D-248 were mapped. Cleavage at Asp(154) has been previously recognized as one of the caspase cleavage sites for the NS5A protein of HCV genotype 1b ( 1, 2) and results in the production of a 17- kDa fragment. The sequence (DXXD251)-D-248 is a novel caspase recognition motif for NS5A and is responsible for the production of a 31- kDa fragment. Furthermore, we show that Arg(217) is implicated in the production of the previously described 24- kDa product, whose accumulation is affected by both calpain and caspase inhibitors. We also showed that caspase- mediated cleavage occurs in the absence of exogenous proapoptotic stimuli and is not related to the accumulation of the protein in the endoplasmic reticulum. Interestingly, our data indicate that NS5A is targeted by at least two different caspases and suggest that caspase 6 is implicated in the production of the 17- kDa fragment. Most importantly, we report that, all the detectable NS5A fragments following caspase- mediated cleavage are C- terminal-truncated forms of NS5A and are mainly localized in the cytosol. Thus, in sharp contrast to the current view we found no evidence supporting a role for caspase- mediated cleavage in the transport of the NS5A protein to the nucleus, which could lead to transcriptional activation.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Mavromara, P (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127,Vas Sofias Ave, Athens 11521, Greece.	penelopm@hol.gr	Georgopoulou, Urania/AAQ-3831-2020					Al-Molawi N, 2003, J GEN VIROL, V84, P1237, DOI 10.1099/vir.0.18840-0; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Algeciras-Schimnich A, 2002, CURR OPIN CELL BIOL, V14, P721, DOI 10.1016/S0955-0674(02)00384-8; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Best SM, 2004, VIROLOGY, V320, P191, DOI 10.1016/j.virol.2003.11.025; Best SM, 2003, J VIROL, V77, P5305, DOI 10.1128/JVI.77.9.5305-5312.2003; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOI YW, 2004, BIOCHEM BIOPH RES CO, V38, P514; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chung KM, 1997, MOL CELLS, V7, P661; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Chung YL, 2003, INT J CANCER, V107, P65, DOI 10.1002/ijc.11303; Cicala C, 2000, P NATL ACAD SCI USA, V97, P1178, DOI 10.1073/pnas.97.3.1178; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Di Bisceglie AM, 2000, HEPATOLOGY, V31, P1014, DOI 10.1053/he.2000.5762; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckhart L, 2001, BIOCHEM BIOPH RES CO, V289, P777, DOI 10.1006/bbrc.2001.6055; Eleouet JF, 2000, J VIROL, V74, P3975, DOI 10.1128/JVI.74.9.3975-3983.2000; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Francois F, 2000, FEBS LETT, V486, P281, DOI 10.1016/S0014-5793(00)02316-4; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 2003, VIROLOGY, V306, P51, DOI 10.1016/S0042-6822(02)00029-6; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goh PY, 2001, VIROLOGY, V290, P224, DOI 10.1006/viro.2001.1195; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Grand RJA, 2002, VIROLOGY, V301, P255, DOI 10.1006/viro.2002.1586; Hasnain SE, 2003, J BIOSCIENCES, V28, P349, DOI 10.1007/BF02970153; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Hidajat Rachmat, 2004, Kobe Journal of Medical Sciences, V50, P153; Hirota M, 1999, VIROLOGY, V257, P130, DOI 10.1006/viro.1999.9658; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Houshmand H, 2003, BIOCHEM BIOPH RES CO, V309, P695, DOI 10.1016/j.bbrc.2003.08.054; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Irusta PM, 2003, CURR OPIN CELL BIOL, V15, P700, DOI 10.1016/j.ceb.2003.10.007; Kalamvoki M, 2004, J VIROL, V78, P11865, DOI 10.1128/JVI.78.21.11865-11878.2004; Kalamvoki M, 2002, ARCH VIROL, V147, P1733, DOI 10.1007/s00705-002-0836-0; Kalliampakou KI, 2005, J GEN VIROL, V86, P1015, DOI 10.1099/vir.0.80728-0; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; LeBlanc AC, 2003, PROG NEURO-PSYCHOPH, V27, P215, DOI 10.1016/S0278-5846(03)00017-4; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mendez E, 2004, J VIROL, V78, P8601, DOI 10.1128/JVI.78.16.8601-8608.2004; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Munger J, 2003, VIROLOGY, V305, P364, DOI 10.1006/viro.2002.1728; MURPHY FA, 1995, VIRUS TAXONOMY, P424; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; PANARETAKIS T, 2005, MOL BIOL CELL; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Ravi R, 1998, CANCER RES, V58, P882; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Reyes GR, 2002, J BIOMED SCI, V9, P187, DOI 10.1007/BF02256065; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Shisler JL, 1998, TRENDS MICROBIOL, V6, P337, DOI 10.1016/S0966-842X(98)01342-0; Song J, 2000, VIRUS RES, V69, P109, DOI 10.1016/S0168-1702(00)00206-9; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yeh CT, 2005, BIOCHEM BIOPH RES CO, V327, P516, DOI 10.1016/j.bbrc.2004.11.165; Zech B, 2003, J GEN VIROL, V84, P555, DOI 10.1099/vir.0.18801-0; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	117	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13449	13462		10.1074/jbc.M601124200	http://dx.doi.org/10.1074/jbc.M601124200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517592	hybrid			2022-12-27	WOS:000237336600052
J	Duncan, EA; Anest, V; Cogswell, P; Baldwin, AS				Duncan, EA; Anest, V; Cogswell, P; Baldwin, AS			The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser(10) phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; C-FOS; ACTIVATION; ALPHA	Phosphorylation of histone H3 protein at serine 10 is an important step in chromatin remodeling during transcriptional transactivation. IkB kinase-alpha (IKK-alpha) and Mitogen- and Stress- activated protein Kinases 1 and 2 (MSK1/2) have been shown to play key roles in the transcriptional regulation of immediate early genes such as c-fos. Interestingly, IKK-alpha and MSK1/2 have also been implicated as histone H3-Ser(10) kinases. In this work, we have shown that MSK1/2 are required for epidermal growth factor (EGF)-induced, but not tumor necrosis factor-induced, histone H3-Ser(10) phosphorylation, both globally and at specific promoters. Consistent with this, MSK1/2 are required for optimal immediate early c-fos transcription in response to EGF potentially through control of both H3-Ser(10) and promoter-associated cAMP-response element-binding protein phosphorylation. Furthermore, MSK1/2 control EGF-induced IKB alpha promoter H3-Ser(10) phosphorylation in the absence of elevated transcription. These studies demonstrate the existence of pathway-specific mechanisms to control histone H3-Ser(10) phosphorylation and gene expression.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Canc Ctr 22 000, CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			NCI NIH HHS [R01 CA73756] Funding Source: Medline; NIAID NIH HHS [R01 AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	18	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12521	12525		10.1074/jbc.M513333200	http://dx.doi.org/10.1074/jbc.M513333200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517600	hybrid, Green Published			2022-12-27	WOS:000237134700040
J	Delatte, T; Umhang, M; Trevisan, M; Eicke, S; Thorneycroft, D; Smith, SM; Zeeman, SC				Delatte, T; Umhang, M; Trevisan, M; Eicke, S; Thorneycroft, D; Smith, SM; Zeeman, SC			Evidence for distinct mechanisms of starch granule breakdown in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; DEBRANCHING ENZYME; TRANSITORY STARCH; WATER DIKINASE; ALPHA-AMYLASE; POTATO-TUBERS; R1 PROTEIN; ISOAMYLASE; DEGRADATION; LEAVES	The aim of this work was to understand the initial steps of starch breakdown inside chloroplasts. In the non-living endosperm of germinating cereal grains, starch breakdown is initiated by alpha-amylase secreted from surrounding cells. However, loss of alpha-amylase from Arabidopsis does not prevent chloroplastic starch breakdown (Yu, T.-S., Zeeman, S. C., Thorneycroft, D., Fulton, D. C., Dunstan, H., Lue, W.- L., Hegemann, B., Tung, S.- Y., Umemoto, T., Chapple, A., Tsai, D.-L., Wang, S.- M, Smith, A. M., Chen, J., and Smith, S. M. ( 2005) J. Biol. Chem. 280, 9773 - 9779), implying that other enzymes must attack the starch granule. Here, we present evidence that the debranching enzyme isoamylase 3 (ISA3) acts at the surface of the starch granule. Atisa3 mutants have more leaf starch and a slower rate of starch breakdown than wild-type plants. The amylopectin of Atisa3 contains many very short branches and ISA3-GFP localizes to granule-like structures inside chloroplasts. We suggest that ISA3 removes short branches from the granule surface. To understand how some starch is still degraded in Atisa3 mutants we eliminated a second debranching enzyme, limit dextrinase (pullulanase-type). Atlda mutants are indistinguishable from the wild type. However, the Atisa3/Atlda double mutant has a more severe starch-excess phenotype and a slower rate of starch breakdown than Atisa3 single mutants. The double mutant accumulates soluble branched oligosaccharides ( limit dextrins) that are undetectable in the wild-type and the single mutants. Together these results suggest that glucan debranching occurs primarily at the granule surface via ISA3, but in its absence soluble branched glucans are debranched in the stroma via limit dextrinase. Consistent with this model, chloroplastic alpha-amylase AtAMY3, which could release soluble branched glucans, is induced in Atisa3 and in the Atisa3/Atlda double mutant.	ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; University of Edinburgh	Zeeman, SC (corresponding author), ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland.	szeeman@ethz.ch	Smith, Steven M/G-7183-2015; Smith, Steven/HDM-9496-2022	Smith, Steven M/0000-0001-5661-9994; Zeeman, Samuel/0000-0002-2791-0915	Biotechnology and Biological Sciences Research Council [D20100] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Asatsuma S, 2005, PLANT CELL PHYSIOL, V46, P858, DOI 10.1093/pcp/pci091; Bierhals JD, 2004, J AGR FOOD CHEM, V52, P7412, DOI 10.1021/jf049300g; Buleon A, 1998, INT J BIOL MACROMOL, V23, P85, DOI 10.1016/S0141-8130(98)00040-3; Bustos R, 2004, P NATL ACAD SCI USA, V101, P2215, DOI 10.1073/pnas.0305920101; CASPAR T, 1985, PLANT PHYSIOL, V79, P11, DOI 10.1104/pp.79.1.11; Critchley JH, 2001, PLANT J, V26, P89, DOI 10.1046/j.1365-313x.2001.01012.x; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; Delatte T, 2005, PLANT J, V41, P815, DOI 10.1111/j.1365-313X.2005.02348.x; Dinges JR, 2003, PLANT CELL, V15, P666, DOI 10.1105/tpc.007575; EDWARDS A, 1995, PLANT J, V8, P283, DOI 10.1046/j.1365-313X.1995.08020283.x; FINCHER GB, 1989, ANNU REV PLANT PHYS, V40, P305, DOI 10.1146/annurev.pp.40.060189.001513; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; French, 1984, STARCH CHEM TECHNOLO; HARGREAVES JA, 1988, PHYTOCHEMISTRY, V27, P1627, DOI 10.1016/0031-9422(88)80416-3; HARLEY JL, 1963, PLANT PHYSIOL, V38, P117, DOI 10.1104/pp.38.1.117; Hussain H, 2003, PLANT CELL, V15, P133, DOI 10.1105/tpc.006635; HUSSAIN MH, 2002, THESIS U E ANGLIA UK; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Kaplan F, 2005, PLANT J, V44, P730, DOI 10.1111/j.1365-313X.2005.02565.x; Kotting O, 2005, PLANT PHYSIOL, V137, P242, DOI 10.1104/pp.104.055954; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Myers AM, 2000, PLANT PHYSIOL, V122, P989, DOI 10.1104/pp.122.4.989; Nielsen TH, 2002, J BIOL CHEM, V277, P20249, DOI 10.1074/jbc.M201866200; Niittyla T, 2004, SCIENCE, V303, P87, DOI 10.1126/science.1091811; Ritte G, 2004, PLANT PHYSIOL, V135, P2068, DOI 10.1104/pp.104.041301; Ritte G, 2002, P NATL ACAD SCI USA, V99, P7166, DOI 10.1073/pnas.062053099; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Scheidig A, 2002, PLANT J, V30, P581, DOI 10.1046/j.1365-313X.2002.01317.x; Smith AM, 2005, ANNU REV PLANT BIOL, V56, P73, DOI 10.1146/annurev.arplant.56.032604.144257; Smith SM, 2004, PLANT PHYSIOL, V136, P2687, DOI 10.1104/pp.104.044347; Steup M., 1990, METHODS PLANT BIOCH, P103; Till BJ, 2003, GENOME RES, V13, P524, DOI 10.1101/gr.977903; Wattebled F, 2005, PLANT PHYSIOL, V138, P184, DOI 10.1104/pp.105.059295; Weise SE, 2004, PLANTA, V218, P474, DOI 10.1007/s00425-003-1128-y; YAMANOUCHI H, 1992, PLANT CELL PHYSIOL, V33, P985; Yu TS, 2005, J BIOL CHEM, V280, P9773, DOI 10.1074/jbc.M413638200; Yu TS, 2001, PLANT CELL, V13, P1907, DOI 10.1105/tpc.13.8.1907; Zeeman SC, 1998, PLANT J, V15, P357, DOI 10.1046/j.1365-313X.1998.00213.x; Zeeman SC, 1998, PLANT CELL, V10, P1699, DOI 10.1105/tpc.10.10.1699	40	113	120	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12050	12059		10.1074/jbc.M513661200	http://dx.doi.org/10.1074/jbc.M513661200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495218	hybrid			2022-12-27	WOS:000236988100075
J	Nemoda, Z; Sahin-Toth, M				Nemoda, Z; Sahin-Toth, M			Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECREASING FACTOR CALDECRIN; CLEAVAGE SITE MUTATION; HEREDITARY PANCREATITIS; BOVINE PROCARBOXYPEPTIDASE; ENZYMATIC SPECIFICITY; ANIONIC TRYPSINOGEN; MOLECULAR-CLONING; TERNARY COMPLEX; ACTIVATION; PEPTIDE	Trypsin-mediated trypsinogen activation (autoactivation) facilitates digestive zymogen activation in the duodenum but may precipitate pancreatitis if it occurs prematurely in the pancreas. Auto-activation of human cationic trypsinogen is inhibited by a repulsive electrostatic interaction between the unique Asp(218) on the surface of cationic trypsin and the conserved tetra-aspartate (Asp(19-22)) motif in the trypsinogen activation peptide (Nemoda, Z., and Sahin-Toth, M. (2005) J. Biol. Chem. 280, 29645-29652). Here we describe that this interaction is regulated by chymotrypsin C (caldecrin), which can specifically cleave the Phe(18)-Asp(19) peptide bond in the trypsinogen activation peptide and remove the N-terminal tripeptide. In contrast, chymotrypsin B, elastase 2A, or elastase 3A (proteinase E) are ineffective. Autoactivation of N-terminally truncated cationic trypsinogen is stimulated similar to 3-fold, and this effect is dependent on the presence of Asp(218). Because chymotrypsinogen C is activated by trypsin, and chymotrypsin C stimulates trypsinogen activation, these reactions establish a positive feedback mechanism in the digestive enzyme cascade of humans. Furthermore, inappropriate activation of chymotrypsinogen C in the pancreas may contribute to the development of pancreatitis. Consistent with this notion, the pancreatitis-associated mutation A16V in cationic trypsinogen increases the rate of chymotrypsin C-mediated processing of the activation peptide 4-fold and causes accelerated trypsinogen activation in vitro.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Sahin-Toth, M (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA.	miklos@bu.edu		Sahin-Toth, Miklos/0000-0003-4513-9922; Nemoda, Zsofia/0000-0002-9550-7730	NIDDK NIH HHS [R01 DK058088, DK058088] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Applebaum-Shapiro SE, 2001, PANCREATOLOGY, V1, P439, DOI 10.1159/000055844; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Chen JM, 2003, MOL BIOL EVOL, V20, P1767, DOI 10.1093/molbev/msg183; Chen JM, 1999, SCAND J GASTROENTERO, V34, P831; Chen JM, 1999, GASTROENTEROLOGY, V117, P1508, DOI 10.1016/S0016-5085(99)70313-6; CHEN JM, 2003, NATURE ENCY HUMAN GE, P645; FOLK JE, 1965, J BIOL CHEM, V240, P193; FOLK JE, 1965, J BIOL CHEM, V240, P181; GomisRuth FX, 1997, J MOL BIOL, V269, P861, DOI 10.1006/jmbi.1997.1040; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; GUY O, 1978, BIOCHEMISTRY-US, V17, P1669, DOI 10.1021/bi00602a014; Howes N, 2004, CLIN GASTROENTEROL H, V2, P252, DOI 10.1016/S1542-3565(04)00013-8; KEILDLOUHA V, 1972, BIOCHIM BIOPHYS ACTA, V276, P531, DOI 10.1016/0005-2744(72)91013-3; KEIM V, 1992, GASTROENTEROLOGY, V103, P248, DOI 10.1016/0016-5085(92)91120-S; Keim Volker, 2003, JOP, V4, P146; KIRALY O, 2006, PROTEIN EXPR PURIF; Kukor Z, 2003, EUR J BIOCHEM, V270, P2047, DOI 10.1046/j.1432-1033.2003.03581.x; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; Nemoda Z, 2005, J BIOL CHEM, V280, P29645, DOI 10.1074/jbc.M505661200; Otsuki M, 2004, PANCREAS, V28, P200, DOI 10.1097/00006676-200403000-00012; Pasternak A, 1998, BIOCHEMISTRY-US, V37, P16201, DOI 10.1021/bi980951d; PEANASKY RJ, 1969, BIOCHIM BIOPHYS ACTA, V181, P82, DOI 10.1016/0005-2795(69)90229-3; Pfutzer RH, 1999, GASTROENTEROLOGY, V117, P1507, DOI 10.1016/S0016-5085(99)70312-4; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; Szepessy E, 2006, PANCREATOLOGY, V6, P117, DOI 10.1159/000090031; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Teich N, 2002, AM J GASTROENTEROL, V97, P341; TOMOMURA A, 1993, FEBS LETT, V335, P213, DOI 10.1016/0014-5793(93)80732-A; Tomomura A, 2001, FEBS LETT, V508, P454, DOI 10.1016/S0014-5793(01)03107-6; Tomomura A, 1996, FEBS LETT, V386, P26, DOI 10.1016/0014-5793(96)00377-8; Tomomura A, 1995, J BIOL CHEM, V270, P30315, DOI 10.1074/jbc.270.51.30315; TOMOMURA A, 1992, FEBS LETT, V301, P277, DOI 10.1016/0014-5793(92)80256-G; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	38	76	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11879	11886		10.1074/jbc.M600124200	http://dx.doi.org/10.1074/jbc.M600124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505482	Green Accepted, hybrid			2022-12-27	WOS:000236988100055
J	Niittyla, T; Comparot-Moss, S; Lue, WL; Messerli, G; Trevisan, M; Seymour, MDJ; Gatehouse, JA; Villadsen, D; Smith, SM; Chen, JC; Zeeman, SC; Alison, MS				Niittyla, T; Comparot-Moss, S; Lue, WL; Messerli, G; Trevisan, M; Seymour, MDJ; Gatehouse, JA; Villadsen, D; Smith, SM; Chen, JC; Zeeman, SC; Alison, MS			Similar protein phosphatases control starch metabolism in plants and glycogen metabolism in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING DOMAIN; ARABIDOPSIS LEAVES; R1 PROTEIN; DEGRADATION; DISEASE; MALTOSE; ENZYME; FORM; CHLOROPLAST; BREAKDOWN	We report that protein phosphorylation is involved in the control of starch metabolism in Arabidopsis leaves at night. sex4 ( starch excess 4) mutants, which have strongly reduced rates of starch metabolism, lack a protein predicted to be a dual specificity protein phosphatase. We have shown that this protein is chloroplastic and can bind to glucans and have presented evidence that it acts to regulate the initial steps of starch degradation at the granule surface. Remarkably, the most closely related protein to SEX4 outside the plant kingdom is laforin, a glucan-binding protein phosphatase required for the metabolism of the mammalian storage carbohydrate glycogen and implicated in a severe form of epilepsy ( Lafora disease) in humans.	ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland; John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Edinburgh, Inst Mol Plant Sci, Edinburgh EH9 3JH, Midlothian, Scotland; Univ Western Australia, Australian Res Council Ctr Excellence Plant Energ, Crawley, WA 6009, Australia	Swiss Federal Institutes of Technology Domain; ETH Zurich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Academia Sinica - Taiwan; University of Bern; Durham University; University of Edinburgh; University of Western Australia	Zeeman, SC (corresponding author), ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland.	szeeman@ethz.ch	Smith, Steven M/G-7183-2015; Chen, Jychian/ABE-8205-2021; Smith, Steven/HDM-9496-2022	Smith, Steven M/0000-0001-5661-9994; Niittyla, Totte/0000-0001-8029-1503; Gatehouse, John/0000-0002-7192-568X; Seymour, Michael/0000-0002-3030-2398; Villadsen, Dorthe/0000-0002-8384-158X; Zeeman, Samuel/0000-0002-2791-0915	Biotechnology and Biological Sciences Research Council [BBS/B/11923, BB/C512253/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Baunsgaard L, 2005, PLANT J, V41, P595, DOI 10.1111/j.1365-313X.2004.02322.x; BELSHAW NJ, 1991, BIOCHIM BIOPHYS ACTA, V1078, P117, DOI 10.1016/0167-4838(91)90100-E; Chan EM, 2004, HUM MOL GENET, V13, P1117, DOI 10.1093/hmg/ddh130; Chia T, 2004, PLANT J, V37, P853, DOI 10.1111/j.1365-313X.2003.02012.x; Coutinho PM, 1999, ROY SOC CH, P3; Critchley JH, 2001, PLANT J, V26, P89, DOI 10.1046/j.1365-313x.2001.01012.x; Delatte T, 2006, J BIOL CHEM, V281, P12050, DOI 10.1074/jbc.M513661200; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Fordham-Skelton AP, 2002, PLANT J, V29, P705, DOI 10.1046/j.1365-313X.2002.01250.x; Ganesh S, 2004, BIOCHEM BIOPH RES CO, V313, P1101, DOI 10.1016/j.bbrc.2003.12.043; Ganesh S, 2002, HUM MOL GENET, V11, P1251, DOI 10.1093/hmg/11.11.1251; Jonak C, 2002, TRENDS PLANT SCI, V7, P457, DOI 10.1016/S1360-1385(02)02331-2; Kaplan F, 2005, PLANT J, V44, P730, DOI 10.1111/j.1365-313X.2005.02565.x; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; Kotting O, 2005, PLANT PHYSIOL, V137, P242, DOI 10.1104/pp.104.055954; Lohi H, 2005, HUM MOL GENET, V14, P2727, DOI 10.1093/hmg/ddi306; Lu Y, 2004, PLANTA, V218, P466, DOI 10.1007/s00425-003-1127-z; Luan S, 2003, ANNU REV PLANT BIOL, V54, P63, DOI 10.1146/annurev.arplant.54.031902.134743; Machovic M, 2005, FEBS J, V272, P5497, DOI 10.1111/j.1742-4658.2005.04942.x; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Minassian BA, 2001, PEDIATR NEUROL, V25, P21, DOI 10.1016/S0887-8994(00)00276-9; Niittyla T, 2004, SCIENCE, V303, P87, DOI 10.1126/science.1091811; Ritte G, 2002, P NATL ACAD SCI USA, V99, P7166, DOI 10.1073/pnas.062053099; Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11; Serratosa JM, 1999, HUM MOL GENET, V8, P345, DOI 10.1093/hmg/8.2.345; Smith AM, 2005, ANNU REV PLANT BIOL, V56, P73, DOI 10.1146/annurev.arplant.56.032604.144257; Smith SM, 2004, PLANT PHYSIOL, V136, P2687, DOI 10.1104/pp.104.044347; Tetlow IJ, 2004, PLANT CELL, V16, P694, DOI 10.1105/tpc.017400; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Wang W, 2004, BIOCHEM BIOPH RES CO, V325, P726, DOI 10.1016/j.bbrc.2004.10.083; Wattebled F, 2005, PLANT PHYSIOL, V138, P184, DOI 10.1104/pp.105.059295; Weise SE, 2004, PLANTA, V218, P474, DOI 10.1007/s00425-003-1128-y; Yu TS, 2005, J BIOL CHEM, V280, P9773, DOI 10.1074/jbc.M413638200; Yu TS, 2001, PLANT CELL, V13, P1907, DOI 10.1105/tpc.13.8.1907; Zeeman SC, 1998, PLANT J, V15, P357, DOI 10.1046/j.1365-313X.1998.00213.x; Zeeman SC, 2002, PLANT PHYSIOL, V129, P516, DOI 10.1104/pp.003756; Zeeman SC, 1999, PLANT CELL ENVIRON, V22, P1445, DOI 10.1046/j.1365-3040.1999.00503.x	37	117	121	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11815	11818		10.1074/jbc.M600519200	http://dx.doi.org/10.1074/jbc.M600519200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513634	hybrid			2022-12-27	WOS:000236988100047
J	Hata, S; Koyama, S; Kawahara, H; Doi, N; Maeda, T; Toyama-Sorimachi, N; Abe, K; Suzuki, K; Sorimachi, H				Hata, S; Koyama, S; Kawahara, H; Doi, N; Maeda, T; Toyama-Sorimachi, N; Abe, K; Suzuki, K; Sorimachi, H			Stomach-specific calpain, nCL-2, localizes in mucus cells and proteolyzes the beta-subunit of coatomer complex, beta-COP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC CALPAIN; MUSCLE-SPECIFIC CALPAIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; PROTEASE ACTIVITY; ACTIVE-SITE; DOMAIN; GENE; EXPRESSION; APPENDAGE	Calpain is a Ca2+-regulated cytosolic protease. Mammals have 14 calpain genes, half of which are predominantly expressed in specific organ(s); the rest are expressed ubiquitously. A defect in calpains causes lethality/pathogenicity, indicating their physiological indispensability. nCL-2/calpain-8a was identified as a stomach-specific calpain, whose physiological functions are unclear. To elucidate these, we characterized nCL-2 in detail. Unexpectedly, nCL-2 was localized strictly to the surface mucus cells in the gastric epithelium and the mucus-secreting goblet cells in the duodenum. Yeast two-hybrid screening identified several nCL-2-intracting molecules. Of these, the beta-subunit of coatomer complex (beta-COP) occurs in the stomach pit cells and is proteolyzed by nCL-2 in vitro. Furthermore, beta-COP and nCL-2 co-expressed in COS7 cells co-localized in the Golgi, and Ca2+-ionophore stimulation caused the proteolysis of beta-COP near the linker region, resulting in the dissociation of beta-COP from the Golgi. These results strongly suggest novel functions for nCL-2 that involve the membrane trafficking of mucus cells via interactions with coat protein.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol, CREST, Saitama 3320012, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Int Med Ctr Japan, Res Inst, Dept Gastroenterol, Tokyo 1628655, Japan; Toray Industries Ltd, New Frontiers Res Labs, Kanagawa 2488555, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Hokkaido University; Japan Science & Technology Agency (JST); University of Tokyo; National Center for Global Health & Medicine - Japan; Toray Industries, Inc.	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/C-6448-2009; Maeda, Tatsuya/L-5540-2019	Sorimachi, Hiroyuki/0000-0001-9509-6727; 				Amerongen AVN, 1998, BIOL CHEM, V379, P1; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bordone L, 2002, J BIOL CHEM, V277, P26673, DOI 10.1074/jbc.M112037200; Cao Y, 2001, DEV GROWTH DIFFER, V43, P563; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; Duan WR, 2002, BIOCHEM BIOPH RES CO, V295, P261, DOI 10.1016/S0006-291X(02)00655-1; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gotthardt M, 2003, J BIOL CHEM, V278, P6059, DOI 10.1074/jbc.M211723200; Han DS, 2004, NUCLEIC ACIDS RES, V32, P6312, DOI 10.1093/nar/gkh972; Hata S, 2001, J MOL EVOL, V53, P191, DOI 10.1007/s002390010209; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HATTORI T, 1976, CELL TISSUE RES, V175, P49; Hoffman GR, 2003, MOL CELL, V12, P615, DOI 10.1016/j.molcel.2003.08.002; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Karam SM, 2003, STEM CELLS, V21, P322, DOI 10.1634/stemcells.21-3-322; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Kimura E, 2003, BIOSCI BIOTECH BIOCH, V67, P1786, DOI 10.1271/bbb.67.1786; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lid SE, 2005, PLANTA, V221, P339, DOI 10.1007/s00425-004-1448-6; Liu KY, 2000, J BIOL CHEM, V275, P31093, DOI 10.1074/jbc.M005451200; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Morford LA, 2002, BIOCHEM BIOPH RES CO, V295, P540, DOI 10.1016/S0006-291X(02)00676-9; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Ohkawa K, 2000, NEUROREPORT, V11, P4007, DOI 10.1097/00001756-200012180-00021; OLIVER MG, 1991, ANAT REC, V230, P513, DOI 10.1002/ar.1092300410; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Shinozaki K, 1998, INT J MOL MED, V1, P797; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; Watson PJ, 2004, TRAFFIC, V5, P79, DOI 10.1111/j.1600-0854.2004.00158.x; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Xu WJ, 2004, MOL BIOL CELL, V15, P5528, DOI 10.1091/mbc.E04-08-0666; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x	58	24	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11214	11224		10.1074/jbc.M509244200	http://dx.doi.org/10.1074/jbc.M509244200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476741	Green Published, hybrid			2022-12-27	WOS:000236822200065
J	Sun, JC; Duffy, KE; Ranjith-Kumar, CT; Xiong, J; Lamb, RJ; Santos, J; Masarapu, H; Cunningham, M; Holzenburg, A; Sarisky, RT; Mbow, ML; Kao, C				Sun, JC; Duffy, KE; Ranjith-Kumar, CT; Xiong, J; Lamb, RJ; Santos, J; Masarapu, H; Cunningham, M; Holzenburg, A; Sarisky, RT; Mbow, ML; Kao, C			Structural and functional analyses of the human Toll-like receptor 3 - Role of glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUBCELLULAR-LOCALIZATION; BIOSYNTHESIS; ACTIVATION; IMMUNITY; LIGAND; RNA; RECOGNITION; SUPPRESSION; EXPRESSION	Toll-like receptors (TLRs) play critical roles in bridging the innate and adaptive immune responses. The human TLR3 recognizes foreign-derived double-stranded RNA and endogenous necrotic cell RNA as ligands. Herein we characterized the contribution of glycosylation to TLR3 structure and function. Exogenous addition of purified extracellular domain of TLR3 (hTLR3 ECD) expressed in human embryonic kidney cells was found to inhibit TLR3-dependent signaling, thus providing a reagent for structural and functional characterization. Approximately 35% of the mass of the hTLR3 ECD was due to posttranslational modification, with N-linked glycosyl groups contributing substantially to the additional mass. Cells treated with tunicamycin, an inhibitor of glycosylation, prevented TLR3-induced NF-kappa B activation, confirming that N-linked glycosylation is required for bioactivity of this receptor. Further, mutations in two of these predicted glycosylation sites impaired TLR3 signaling without obviously affecting the expression of the protein. Single-particle structures reconstructed from electron microscopy images and two-dimensional crystallization revealed that hTLR3 ECD forms a horseshoe structure similar to the recently elucidated x-ray structure of the protein expressed in insect cells using baculovirus vectors (Choe, J., Kelker, M. S., and Wilson, I. A. ( 2005) Science 309, 581 - 585 and Bell, J. K., Botos, I., Hall, P. R., Askins, J., Shiloach, J., Segal, D. M., and Davies, D. R. ( 2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10976 - 10980). There are, however, notable differences between the human cell-derived and insect cell-derived structures, including features attributable to glycosylation.	Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA	Johnson & Johnson; Johnson & Johnson USA; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Mbow, ML (corresponding author), Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA.	Lmbow@cntus.jnj.com; ckao@tamu.edu	Masarapu, Hema/AAV-9120-2021; Kumar CT, Ranjith/J-5701-2016	Masarapu, Hema/0000-0002-1262-5978				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DEBOUTEILLER O, 2005, J BIOL CHEM; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; Harris JR, 2002, MICRON, V33, P461, DOI 10.1016/S0968-4328(01)00039-7; Hoppert M., 2003, MICROSCOPIC TECHNIQU; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; JANS DA, 1992, ARCH BIOCHEM BIOPHYS, V294, P64, DOI 10.1016/0003-9861(92)90137-L; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Lemaitre B, 2004, NAT REV IMMUNOL, V4, P521, DOI 10.1038/nri1390; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Mbow ML, 2005, DRUG NEWS PERSPECT, V18, P179, DOI 10.1358/dnp.2005.18.3.892763; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Patel RN, 1999, J IMMUNOL, V163, P3459; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Underhill DM, 2004, MICROBES INFECT, V6, P1368, DOI 10.1016/j.micinf.2004.08.016; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102	32	97	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11144	11151		10.1074/jbc.M510442200	http://dx.doi.org/10.1074/jbc.M510442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16533755	hybrid			2022-12-27	WOS:000236822200057
J	Zhao, TJ; Sun, S; Liu, Y; Liu, JM; Liu, Q; Yan, YB; Zhou, HM				Zhao, TJ; Sun, S; Liu, Y; Liu, JM; Liu, Q; Yan, YB; Zhou, HM			Regulating the drought-responsive element (DRE)-mediated signaling pathway by synergic functions of trans-active and trans-inactive DRE binding factors in Brassica napus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; FREEZING TOLERANCE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; COLD-ACCLIMATION; STRESS TOLERANCE; ABSCISIC-ACID; ARABIDOPSIS; PROTEIN	DREB1/C-repeat binding factor (CBF) is a plant-specific family of transcription factors and plays a crucial role in freeze tolerance. In the present work, two groups of drought-responsive element binding factor (DREB)-like genes were isolated from Brassica napus, named Group I and Group II. The two groups of genes were both induced by low temperature, but the expression of Group I preceded that of Group II. The Group I DREBs could specifically bind with the DRE cis-acting element and activate the expression of downstream genes, but Group II factors were trans-inactive although they still had the ability to bind with DRE, which was confirmed by electrophoretic mobility shift assay. Fluorescence quenching assays indicated that the DRE binding ability of the two groups was similar. Co-expression of Group II could depress the trans-activation activity of Group I DREB in a concentration-dependent manner. These results strongly suggested that the trans-active Group I DREBs were expressed at the early stage of cold stress to open the DRE-mediated signaling pathway in cold stress, whereas the trans-inactive Group II DREBs were expressed at the later stage to close the signal pathway in a competitive manner. The results herein provide a new insight into the regulation mechanisms of the DRE-mediated signaling pathway in response to cold stress.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China; Tsing Hua Univ, Yangtze Delta Reg Inst, Jiaxing 314050, Zhejiang, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Zhao, Tong-Jin/AFH-2915-2022; Yan, Yong-Bin/A-4282-2008	Yan, Yong-Bin/0000-0002-8565-3558				ABELES FB, 1992, ETHYLENE PLANT BIOL, P196; BAKER SS, 1994, PLANT MOL BIOL, V24, P710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chinnusamy V, 2003, GENE DEV, V17, P1043, DOI 10.1101/gad.1077503; *CLONT, 2001, YEAST PROT HDB; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; Gao MJ, 2002, PLANT MOL BIOL, V49, P459, DOI 10.1023/A:1015570308704; Gilmour SJ, 1998, PLANT J, V16, P433, DOI 10.1046/j.1365-313x.1998.00310.x; Gong ZZ, 2002, P NATL ACAD SCI USA, V99, P11507, DOI 10.1073/pnas.172399299; Guo Y, 2002, P NATL ACAD SCI USA, V99, P7786, DOI 10.1073/pnas.112040099; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; Jaglo KR, 2001, PLANT PHYSIOL, V127, P910, DOI 10.1104/pp.010548; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Janssen BJ, 1998, PLANT MOL BIOL, V36, P417, DOI 10.1023/A:1005925508579; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; KELLY RC, 1976, J BIOL CHEM, V251, P7240; Lee H, 2002, EMBO J, V21, P2692, DOI 10.1093/emboj/21.11.2692; Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801; Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.1105/tpc.10.8.1391; Liu Y, 2005, PROTEIN EXPRES PURIF, V44, P155, DOI 10.1016/j.pep.2005.03.030; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medina J, 1999, PLANT PHYSIOL, V119, P463, DOI 10.1104/pp.119.2.463; Novillo F, 2004, P NATL ACAD SCI USA, V101, P3985, DOI 10.1073/pnas.0303029101; Ouellet F, 1998, FEBS LETT, V423, P324, DOI 10.1016/S0014-5793(98)00116-1; Pearce RS, 1999, PLANT GROWTH REGUL, V29, P47, DOI 10.1023/A:1006291330661; Sakuma Y, 2002, BIOCHEM BIOPH RES CO, V290, P998, DOI 10.1006/bbrc.2001.6299; Steponkus PL, 1993, CUR TOP PL, V10, P37; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; Thomashow MF, 1998, PLANT PHYSIOL, V118, P1, DOI 10.1104/pp.118.1.1; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; UEMURA M, 1997, MOL BIOL BIOCH PHYSL, P171; Vazquez-Tello A, 1998, MOL GEN GENET, V257, P157, DOI 10.1007/s004380050635; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	36	84	116	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10752	10759		10.1074/jbc.M510535200	http://dx.doi.org/10.1074/jbc.M510535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497677	hybrid			2022-12-27	WOS:000236822200014
J	Okuda, T; Tokuda, N; Numata, S; Ito, M; Ohta, M; Kawamura, K; Wiels, J; Urano, T; Tajima, O; Furukawa, K; Furukawa, K				Okuda, T; Tokuda, N; Numata, S; Ito, M; Ohta, M; Kawamura, K; Wiels, J; Urano, T; Tajima, O; Furukawa, K; Furukawa, K			Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to vVerotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC UREMIC SYNDROME; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; VEROTOXIN RECEPTORS; TOXIN-II; BINDING; CELLS; PATHOGENESIS; GLOBOTRIAOSYLCERAMIDE; APOPTOSIS	To examine whether globotriaosylceramide (Gb3/CD77) is a receptor for verotoxins (VTs) in vivo, sensitivity of Gb3/CD77 synthase null mutant mice to VT-2 and VT-1 was analyzed. Although wild-type mice died after administration of 0.02 mu g of VT-2 or 1.0 mu g of VT-1, the mutant mice showed no reaction to doses as much as 100 times that administered to wild types. Expression analysis of Gb3/CD77 in mouse tissues with antibody revealed that low, but definite, levels of Gb3/CD77 were expressed in the microvascular endothelial cells of the brain cortex and pia mater and in renal tubular capillaries. Corresponding to the Gb3/CD77 expression, tissue damage with edema, congestion, and cytopathic changes was observed, indicating that Gb3/CD77 ( and its derivatives) exclusively function as a receptor for VTs in vivo. The lethal kinetics were similar regardless of lipopolysaccharide elimination in VT preparation, suggesting that basal Gb3/CD77 levels are sufficient for lethal effects of VTs.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Microbiol, Showa Ku, Nagoya, Aichi 4660065, Japan; Inst Gustave Roussy, CNRS, Unite Mixte Rech, F-94805 Villejuif, France	Nagoya University; Nagoya University; Nagoya University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okuda, Tetsuya/K-5305-2018; Wiels, Joëlle/AGL-2319-2022	Okuda, Tetsuya/0000-0002-5262-8057; Wiels, Joëlle/0000-0002-3313-2937; Urano, Takeshi/0000-0003-3383-3554				BARRETT TJ, 1989, INFECT IMMUN, V57, P3434, DOI 10.1128/IAI.57.11.3434-3437.1989; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; Devenish J, 1998, CAN J MICROBIOL, V44, P28, DOI 10.1139/cjm-44-1-28; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Iwamura K, 2003, J BIOL CHEM, V278, P44429, DOI 10.1074/jbc.M301609200; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KASAI K, 1985, J IMMUNOGENET, V12, P213; Kitamura M, 1999, BBA-MOL CELL BIOL L, V1441, P1, DOI 10.1016/S1388-1981(99)00140-7; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; Lalli G, 2003, TRENDS MICROBIOL, V11, P431, DOI 10.1016/S0966-842X(03)00210-5; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; OOSTERWIJK E, 1991, INT J CANCER, V48, P848, DOI 10.1002/ijc.2910480610; Ren J, 1999, BRAIN RES, V825, P183, DOI 10.1016/S0006-8993(99)01196-8; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rutjes NWP, 2002, KIDNEY INT, V62, P832, DOI 10.1046/j.1523-1755.2002.00502.x; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; Tetaud C, 2003, J BIOL CHEM, V278, P45200, DOI 10.1074/jbc.M303868200; TZIPORI S, 1988, J CLIN PATHOL, V41, P1099, DOI 10.1136/jcp.41.10.1099; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; Wandall HH, 2005, J BIOL CHEM, V280, P4858, DOI 10.1074/jbc.C400571200; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; Zhao YL, 2002, ANTIMICROB AGENTS CH, V46, P1522, DOI 10.1128/AAC.46.5.1522-1528.2002; ZOJA C, 1992, J LAB CLIN MED, V120, P229	32	138	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10230	10235		10.1074/jbc.M600057200	http://dx.doi.org/10.1074/jbc.M600057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476743	hybrid			2022-12-27	WOS:000236594300050
J	Su, M; Lee, D; Ganss, B; Sodek, J				Su, M; Lee, D; Ganss, B; Sodek, J			Stereochemical analysis of the functional significance of the conserved inverted CCAAT and TATA elements in the rat bone sialoprotein gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BOX-BINDING-PROTEIN; FACTOR NF-Y; DNA-BINDING; CRYSTAL-STRUCTURE; MINOR-GROOVE; CBF/NF-Y; TRANSCRIPTION INITIATION; QUATERNARY COMPLEX; IN-VIVO	Basal transcription of the bone sialoprotein gene is mediated by highly conserved inverted CCAAT( ICE; ATTGG) and TATA elements (TTTATA) separated by precisely 21 nucleotides. Here we studied the importance of the relative position and orientation of the CCAAT and TATA elements in the proximal promoter by measuring the transcriptional activity of a series of mutated reporter constructs in transient transfection assays. Whereas inverting the TTTATA( wild type) to a TATAAA ( consensus TATA) sequence increased transcription slightly, transcription was reduced when the flanking dinucleotides were also inverted. In contrast, reversing the ATTGG ( wild type; ICE) to a CCAAT ( RICE) sequence caused a marked reduction in transcription, whereas both transcription and NF-Y binding were progressively increased with the simultaneous inversion of flanking nucleotides (f-RICE-f). Reducing the distance between the ICE and TATA elements produced cyclical changes in transcriptional activity that correlated with progressive alterations in the relative positions of the CCAAT and TATA elements on the face of the DNA helix. Minimal transcription was observed after 5 nucleotides were deleted ( equivalent to approximately one half turn of the helix), whereas transcription was fully restored after deleting 10 nucleotides ( approximately one full turn of the DNA helix), transcriptional activity being progressively lost with deletions beyond 10 nucleotides. In comparison, when deletions were made with the ICE in the reversed (f-RICE-f) orientation transcriptional activity was progressively lost with no recovery. These results show that, although transcription can still occur when the CCAAT box is reversed and/or displaced relative to the TATA box, the activity is dependent upon the flexibility of the intervening DNA helix needed to align the NF-Y complex on the CCAAT box with preinitiation complex proteins that bind to the TATA box. Thus, the precise location and orientation of the CCAAT element is necessary for optimizing basal transcription of the bone sialoprotein gene.	Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	Su, M (corresponding author), Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, 234 FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.su@utoronto.ca						Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 2002, CURR OPIN STRUC BIOL, V12, P225, DOI 10.1016/S0959-440X(02)00314-7; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; Cox JM, 1997, P NATL ACAD SCI USA, V94, P13475, DOI 10.1073/pnas.94.25.13475; Dion V, 2003, J BIOL CHEM, V278, P11495, DOI 10.1074/jbc.M211938200; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kabe Y, 2005, MOL CELL BIOL, V25, P512, DOI 10.1128/MCB.25.1.512-522.2005; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kays AR, 2000, CHEM BIOL, V7, P601, DOI 10.1016/S1074-5521(00)00009-0; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim RH, 1999, CANCER RES, V59, P565; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Lewis DEA, 2002, J BIOL CHEM, V277, P2498, DOI 10.1074/jbc.M108456200; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Liberati C, 1998, FEBS LETT, V433, P174, DOI 10.1016/S0014-5793(98)00905-3; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Miaskiewicz K, 1996, J BIOMOL STRUCT DYN, V13, P593, DOI 10.1080/07391102.1996.10508872; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P6450; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SILVIO A, 1999, NUCLEIC ACIDS RES, V27, P2578; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; Spencer JV, 2002, MOL CELL BIOL, V22, P8744, DOI 10.1128/MCB.22.24.8744-8755.2002; Su M, 2005, J BIOL CHEM, V280, P38365, DOI 10.1074/jbc.M501609200; Suzuki M, 1996, NUCLEIC ACIDS RES, V24, P2767, DOI 10.1093/nar/24.14.2767; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; Tan S, 1998, CURR OPIN STRUC BIOL, V8, P41, DOI 10.1016/S0959-440X(98)80008-0; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	53	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9882	9890		10.1074/jbc.M508364200	http://dx.doi.org/10.1074/jbc.M508364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16495225	hybrid			2022-12-27	WOS:000236594300009
J	Zhang, WW; Patil, S; Chauhan, B; Guo, SD; Powell, DR; Le, J; Klotsas, A; Matika, R; Xiao, XS; Franks, R; Heidenreich, KA; Sajan, MP; Farese, RV; Stolz, DB; Tso, P; Koo, SH; Montminy, M; Unterman, TG				Zhang, WW; Patil, S; Chauhan, B; Guo, SD; Powell, DR; Le, J; Klotsas, A; Matika, R; Xiao, XS; Franks, R; Heidenreich, KA; Sajan, MP; Farese, RV; Stolz, DB; Tso, P; Koo, SH; Montminy, M; Unterman, TG			FoxO1 regulates multiple metabolic pathways in the liver - Effects on gluconeogenic, glycolytic, and lipogenic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; TRANSCRIPTION FACTOR FKHR; GLUCOSE-INDUCED LIPOGENESIS; INSULIN-RESPONSE-SEQUENCE; FATTY-ACID SYNTHESIS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; KINASE-B; PEROXISOME PROLIFERATOR; AQUAPORIN ADIPOSE; SKELETAL-MUSCLE	FoxO transcription factors are important targets of insulin action. To better understand the role of FoxO proteins in the liver, we created transgenic mice expressing constitutively active FoxO1 in the liver using the alpha 1-antitrypsin promoter. Fasting glucose levels are increased, and glucose tolerance is impaired in transgenic (TGN) versus wild type (WT) mice. Interestingly, fasting triglyceride and cholesterol levels are reduced despite hyperinsulinemia, and post-prandial changes in triglyceride levels are markedly suppressed in TGN versus WT mice. Activation of pro-lipogenic signaling pathways (atypical protein kinase C and protein kinase B) and the ability to suppress beta-hydroxybutyrate levels are not impaired in TGN. In contrast, de novo lipogenesis measured with (H2O)-H-3 is suppressed by similar to 70% in the liver of TGN versus WT mice after refeeding. Gene-array studies reveal that the expression of genes involved in gluconeogenesis, glycerol transport, and amino acid catabolism is increased, whereas genes involved in glucose utilization by glycolysis, the pentose phosphate shunt, lipogenesis, and sterol synthesis pathways are suppressed in TGN versus WT. Studies with adenoviral vectors in isolated hepatocytes confirm that FoxO1 stimulates expression of gluconeogenic genes and suppresses expression of genes involved in glycolysis, the shunt pathway, and lipogenesis, including glucokinase and SREBP-1c. Together, these results indicate that FoxO proteins promote hepatic glucose production through multiple mechanisms and contribute to the regulation of other metabolic pathways important in the adaptation to fasting and feeding in the liver, including glycolysis, the pentose phosphate shunt, and lipogenic and sterol synthetic pathways.	Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, James A Haley Vet Med Ctr, Res Serv, Tampa, FL 33612 USA; Univ Pittsburgh, Ctr Biol Imaging Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA; Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 440746, South Korea	US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati; Salk Institute; Sungkyunkwan University (SKKU)	Unterman, TG (corresponding author), Jesse Brown Vet Affairs Med Ctr, Room 6229,Med Res Unit MP 151,820 S Damen Ave, Chicago, IL 60612 USA.	Unterman@uic.edu	Farese, Robert/B-3605-2015; Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879	NCI NIH HHS [CA 76541] Funding Source: Medline; NIDDK NIH HHS [DK 41430, R01 DK065969, DK 59630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076541, R01CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041430, R01DK065969, U2CDK059630, U24DK059630, R01DK041430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Churukian CJ, 1999, J HISTOTECHNOL, V22, P309; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Du H, 2001, J LIPID RES, V42, P489; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gan LX, 2005, ENDOCRINOLOGY, V146, P4274, DOI 10.1210/en.2005-0224; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kim S, 2004, DIABETES, V53, pS66, DOI 10.2337/diabetes.53.2007.S66; Kondo H, 2002, EUR J BIOCHEM, V269, P1814, DOI 10.1046/j.1432-1033.2002.02821.x; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Kuriyama H, 2002, DIABETES, V51, P2915, DOI 10.2337/diabetes.51.10.2915; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIANG Y, 1991, J BIOL CHEM, V266, P6999; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Matsumoto M, 2005, CELL METAB, V1, P215, DOI 10.1016/j.cmet.2005.03.008; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Roth U, 2004, J BIOL CHEM, V279, P2623, DOI 10.1074/jbc.M308391200; Rozen S, 2000, BIOINFORMATICS METHO; Sandberg MB, 2005, MOL CELL ENDOCRINOL, V240, P94, DOI 10.1016/j.mce.2005.05.005; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scheimann AO, 2001, HORM METAB RES, V33, P631, DOI 10.1055/s-2001-18687; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Silha JV, 2001, ENDOCRINOLOGY, V142, P4305, DOI 10.1210/en.142.10.4305; Standaert ML, 2004, J BIOL CHEM, V279, P24929, DOI 10.1074/jbc.M402440200; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Towle HC, 2005, TRENDS ENDOCRIN MET, V16, P489, DOI 10.1016/j.tem.2005.10.003; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Valverde AM, 2003, DIABETES, V52, P2239, DOI 10.2337/diabetes.52.9.2239; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; ZHAO X, 2003, BIOCHEM J, V378, P839	78	386	412	0	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10105	10117		10.1074/jbc.M600272200	http://dx.doi.org/10.1074/jbc.M600272200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492665	hybrid			2022-12-27	WOS:000236594300036
J	Nicholls, DG				Nicholls, David G.			Simultaneous monitoring of ionophore- and inhibitor-mediated plasma and mitochondrial membrane potential changes in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FLUORESCENT DYE; GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; HIPPOCAMPAL-NEURONS; INTACT SYNAPTOSOMES; CYTOCHROME-C; NITRIC-OXIDE; CALCIUM; DEPOLARIZATION; RESPIRATION	Although natural and synthetic ionophores are widely exploited in cellstudies, for example, to influence cytoplasmic free calcium concentrations and to depolarize in situ mitochondria, their inherent lack of membrane selectivity means that they affect the ion permeability of both plasma and mitochondrial membranes. A similar ambiguity affects the interpretation of signals from fluorescent membrane-permeant cations (usually termed "mitochondrial membrane potential indicators"), because the accumulation of these probes is influenced by both plasma and mitochondrial membrane potentials. To resolve some of these problems a technique is developed to allow simultaneous monitoring of plasma and mitochondrial membrane potentials at single-cell resolution using a cationic and anionic fluorescent probe. A computer program is described that transforms the fluorescence changes into dynamic estimates of changes in plasma and mitochondrial potentials. Exploiting this technique, primary cultures of rat cerebellar granule neurons display a concentration-dependent response to ionomycin: low concentrations mimic nigericin by hyperpolarizing the mitochondria while slowly depolarizing the plasma membrane and maintaining a stable elevated cytoplasmic calcium. Higher ionomycin concentrations induce a stochastic failure of calcium homeostasis that precedes both mitochondrial depolarization and an enhanced rate of plasma membrane depolarization. In addition, the protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone only selectively depolarizes mitochondria at submicromolar concentrations. ATP synthase reversal following respiratory chain inhibition depolarizes the mitochondria by 26 mV.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), 8001 Redwood Blvd, Novato, CA 94945 USA.	dnicholls@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041908] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 41908] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; AKERMAN KEO, 1981, EUR J BIOCHEM, V115, P67; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; Baxter DF, 2002, J BIOMOL SCREEN, V7, P79, DOI 10.1177/108705710200700110; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CIVITELLI R, 1987, J CELL PHYSIOL, V131, P434, DOI 10.1002/jcp.1041310316; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; Fink C, 1998, BIOPHYS J, V75, P1648, DOI 10.1016/S0006-3495(98)77607-6; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Kiedrowski L, 2001, NEUROREPORT, V12, P3579, DOI 10.1097/00001756-200111160-00041; Kiedrowski L, 2001, NEUROREPORT, V12, P59, DOI 10.1097/00001756-200101220-00020; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; MALOFF BL, 1978, J CELL BIOL, V78, P214, DOI 10.1083/jcb.78.1.214; Marks JD, 2005, J NEUROSCI, V25, P6561, DOI 10.1523/JNEUROSCI.1450-05.2005; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Rego AC, 2001, J NEUROSCI, V21, P1893, DOI 10.1523/JNEUROSCI.21-06-01893.2001; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Safiulina D, 2006, J CELL PHYSIOL, V206, P347, DOI 10.1002/jcp.20476; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Toescu EC, 2000, PFLUG ARCH EUR J PHY, V440, P941, DOI 10.1007/s004240000390; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Ward MW, 2000, J NEUROSCI, V20, P7208; Whiteaker KL, 2001, J BIOMOL SCREEN, V6, P305, DOI 10.1177/108705710100600504; Yamada A, 2001, JPN J PHARMACOL, V86, P342, DOI 10.1254/jjp.86.342	43	144	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14864	14874		10.1074/jbc.M510916200	http://dx.doi.org/10.1074/jbc.M510916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551630	hybrid			2022-12-27	WOS:000237671300040
J	Zhu, H; Shuman, S				Zhu, Hui; Shuman, Stewart			Substrate specificity and structure-function analysis of the 3 '-phosphoesterase component of the bacterial NHEJ protein, DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDE KINASE; 3'-PHOSPHATASE; MYCOBACTERIA; ARCHITECTURE; PHOSPHATASE; ENZYME; KU	DNA ligase D (LigD) performs end remodeling and end sealing reactions during nonhomologous end joining in bacteria. Pseudomonas aeruginosa LigD consists of a central ATP-dependent ligase domain fused to a C-terminal polymerase domain and an N-terminal phosphoesterase (PE) module. The PE domain catalyzes manganese-dependent phosphodiesterase and phosphomonoesterase reactions at the 3' end of the primer strand of a primer-template. The phosphodiesterase cleaves a 3'-terminal diribonucleotide to yield a primer strand with a ribonucleoside 3'-PO4 terminus. The phosphomonoesterase converts a terminal ribonucleoside 3'-PO4 or deoxyribonucleoside 3'-PO4 of a primer-template to a 3'-OH. Here we report that the phosphodiesterase and phosphomonoesterase activities are both dependent on the presence and length of the 5' single-strand tail of the primer-template substrate. Although the phosphodiesterase activity is strictly dependent on the 2'-OH of the penultimate ribose, it is indifferent to a 2'-OH versus a 2'-H on the terminal nucleoside. Incision at the ribonucleotide linkage is suppressed when the 2'-OH is moved by 1 nucleotide in the 5' direction, suggesting that LigD is an exoribonuclease that cleaves the 3'-terminal phosphodiester. We report the effects of conservative amino acid substitutions at residues: (i) His(42), His(48), Asp(50), Arg(52), His(84), and Tyr(88), which are essential for both the ribonuclease and 3'-phosphatase activities; (ii) Arg(14), Asp(15), Glu(21), and Glu(82), which are critical for 3'-phosphatase activity but not 3'-ribonucleoside removal; and (iii) at Lys(66) and Arg(76), which participate selectively in the 3'-ribonuclease reaction. The results suggest roles for individual functional groups in metal binding and/or phosphoesterase chemistry.	Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; Vance JR, 2001, J BIOL CHEM, V276, P15073, DOI 10.1074/jbc.M011075200; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200; Zhu H, 2004, J BIOL CHEM, V279, P26358, DOI 10.1074/jbc.M403200200	15	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13873	13881		10.1074/jbc.M600055200	http://dx.doi.org/10.1074/jbc.M600055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540477	hybrid			2022-12-27	WOS:000237512300007
J	Izaguirre, G; Olson, ST				Izaguirre, G; Olson, ST			Residues Tyr(253) and Glu(255) in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEINASE COMPLEX; BLOOD-COAGULATION; TERNARY COMPLEX; BASIC RESIDUES; AUTOLYSIS LOOP; HIGH-AFFINITY; MECHANISM; THROMBIN; BINDING	We previously showed that conformational activation of the anticoagulant serpin, antithrombin, by heparin generates new exosites in strand 3 of beta- sheet C, which promote the reaction of the inhibitor with the target proteases, factor Xa and factor IXa. To determine which residues comprise the exosites, we mutated strand 3C residues that are conserved in all vertebrate antithrombins. Combined mutations of the three conserved surface- accessible residues, Tyr(253), Glu(255), and Lys(257), or of just Tyr(253) and Glu(255), but not any of these residues alone, was sufficient to reproduce the exosite defects of a strand 3C antithrombin- alpha(1)- proteinase inhibitor chimera in reactions of the heparin- activated variants with both factor Xa and factor IXa. Importantly, the exosite- defective antithrombins bound heparin with nearly wild- type affinities, and the heparin- activated mutants showed near normal reactivities with thrombin, a protease that does not utilize the exosite. Mutation of the conserved but partially buried strand 3C residue, Gln(254), the reactive loop P6 ' residue, Arg(399), which interacts with Glu(255), or a residue proposed to constitute the exosite from modeling studies, Glu(237), all produced minimal effects on antithrombin reactivity with thrombin, factor Xa, and factor IXa in the absence or presence of heparin. Together, these results indicate that Tyr(253) and Glu(255) are key exosite determinants responsible for promoting the reactions of conformationally activated antithrombin with both factor Xa and factor IXa.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Rm 530E,Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	stolson@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Izaguirre G, 2003, J BIOL CHEM, V278, P51433, DOI 10.1074/jbc.M309266200; IZAGUIRRE G, 2005, 4 INT C SERP STRUCT, P45; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langdown J, 2004, J BIOL CHEM, V279, P47288, DOI 10.1074/jbc.M408961200; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Olson ST, 2004, THROMB HAEMOSTASIS, V92, P929, DOI 10.1160/TH04-06-0384; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P2898, DOI 10.1021/bi036145a; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Yang LK, 2003, J BIOL CHEM, V278, P25032, DOI 10.1074/jbc.M302174200; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	43	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13424	13432		10.1074/jbc.M600415200	http://dx.doi.org/10.1074/jbc.M600415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517611	hybrid			2022-12-27	WOS:000237336600049
J	Kawaguchi, M; Minami, K; Nagashima, K; Seino, S				Kawaguchi, M; Minami, K; Nagashima, K; Seino, S			Essential role of ubiquitin-proteasome system in normal regulation of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SENSITIVE POTASSIUM CHANNELS; UNRESPONSIVE MIN6 SUBLINES; CYCLIN-DEPENDENT KINASE-5; CALCIUM-CHANNELS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; QUALITY-CONTROL; GLUCOSE	Insulin secretion from pancreatic beta-cells occurs by sequential cellular processes, including glucose metabolism, electrical activity, Ca2+ entry, and regulated exocytosis. Abnormalities in any of these functions can impair insulin secretion. In the present study, we demonstrate that inhibition of proteasome activity severely reduces insulin secretion in the mouse pancreatic beta-cell line MIN6-m9. Although no significant effects on glucose metabolism including ATP production were found in the presence of proteasome inhibitors, both glucose- and KCl-induced Ca2+ entry were drastically reduced. As Ca2+-ionophore-induced insulin secretion was unaffected by proteasome inhibition, a defect in Ca2+ entry through voltage-dependent calcium channels (VDCCs) is the likely cause of the impaired insulin secretion. We found that the pore-forming alpha-subunit of VDCCs undergoes ubiquitination, which does not decrease but slightly increases expression of the alpha-subunit protein at the plasma membrane. However, electrophysiological analysis revealed that treatment with proteasome inhibitors results in a severe reduction in VDCC activity in MIN6-m9 cells, indicating that VDCC function is suppressed by proteasome inhibition. Furthermore, insulin secretion in isolated mouse pancreatic islets was also decreased by proteasome inhibition. These results demonstrate that the ubiquitin-proteasome system plays a critical role in insulin secretion by maintaining normal function of VDCCs.	Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan; Kyoto Univ Hosp, Dept Expt Therapeut Translat Res Ctr, Kyoto 6068507, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto 6068507, Japan	Kobe University; Kyoto University; Chiba University; Kyoto University	Seino, S (corresponding author), Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan.	seino@med.kobe-u.ac.jp		Minami, Kohtaro/0000-0003-4698-6250				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Cornet V, 2002, EUR J NEUROSCI, V16, P883, DOI 10.1046/j.1460-9568.2002.02168.x; Cuesta-Munoz AL, 2004, DIABETES, V53, P2164, DOI 10.2337/diabetes.53.8.2164; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Kitiphongspattana K, 2005, J BIOL CHEM, V280, P15727, DOI 10.1074/jbc.M410876200; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Minami K, 2002, J BIOL CHEM, V277, P25277, DOI 10.1074/jbc.M203988200; Minami K, 2001, DIABETES, V50, pA336; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; REED PW, 1972, J BIOL CHEM, V247, P6970; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Rougier JS, 2005, AM J PHYSIOL-CELL PH, V288, pC692, DOI 10.1152/ajpcell.00460.2004; SAITO Y, 1990, NEUROSCI LETT, V120, P1, DOI 10.1016/0304-3940(90)90153-Z; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Yada T, 1996, ANN NY ACAD SCI, V805, P329; Yan FF, 2005, AM J PHYSIOL-CELL PH, V289, pC1351, DOI 10.1152/ajpcell.00240.2005; ZAWALICH WS, 1993, REGUL PEPTIDES, V44, P277, DOI 10.1016/0167-0115(93)90137-W; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	45	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13015	13020		10.1074/jbc.M601228200	http://dx.doi.org/10.1074/jbc.M601228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543239	hybrid			2022-12-27	WOS:000237336600004
J	Nam, JS; Turcotte, TJ; Smith, PF; Choi, S; Yoon, JK				Nam, JS; Turcotte, TJ; Smith, PF; Choi, S; Yoon, JK			Mouse cristin/R-spondin family proteins are novel ligands for the frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; WNT SIGNALING PATHWAY; PARAXIAL MESODERM; NORRIE DISEASE; CANDIDATE GENE; GROWTH-FACTOR; DROSOPHILA; SUPERFAMILY; PMESOGENIN1; DICKKOPF-1	Wnt signaling plays critical biological roles during normal embryonic development and homeostasis in adults. In the canonical pathway, binding of Wnt ligands to the Frizzled ( Fzd) receptor and the low density lipoprotein-related receptor ( LRP) 5 or LRP6 coreceptor initiates downstream signaling events leading to gene activation by beta-catenin and the T-cell factor ( TCF)-lymphoid enhancer factor ( LEF) family transcription factor complex. In this study, we provide several lines of evidence that the mouse Cristin/R-spondin family proteins function as Fzd8 and LRP6 receptor ligands and induce the canonical Wnt/beta-catenin signaling pathway, leading to TCF-dependent gene activation. First, conditioned medium containing Cristin/R-spondin proteins effectively induced reporter activity in a TCF-binding site-dependent manner. Second, stimulation of cells with Cristin/R-spondin was accompanied by stabilization of endogenous beta-catenin proteins and induction of canonical Wnt target genes. Third, Cristin/R-spondin proteins physically interacted with the extracellular domains of the LRP6 and Fzd8 receptors in vivo and in vitro. Interestingly, unlike canonical Wnt ligands, Cristin/R-spondin failed to form a ternary complex with both LRP6 and Fzd8 receptors, suggesting that R-spondin may activate the canonical Wnt signaling pathway by different mechanisms. Furthermore, Cristin/R-spondin proteins possess an intriguing positive modulatory activity on Wnt ligands, possibly through a direct interaction. Our findings expand the repertoire of ligands that induce beta-catenin/TCF-dependent gene activation and implicate the presence of active beta-catenin-dependent gene activation in a Wnt-free biological context.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Maine Medical Center; California Institute of Technology	Yoon, JK (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	yoonje@mmc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018789] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR018789] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams JC, 2000, DEV DYNAM, V218, P280; Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kuhl M, 2004, FRONT BIOSCI-LANDMRK, V9, P967; Latinkic BV, 2003, DEVELOPMENT, V130, P2429, DOI 10.1242/dev.00449; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Polakis P, 2000, GENE DEV, V14, P1837; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wang HY, 2004, FRONT BIOSCI-LANDMRK, V9, P1043, DOI 10.2741/1310; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Yoon JK, 2000, DEV BIOL, V222, P376, DOI 10.1006/dbio.2000.9717; Yoon JK, 2000, GENE DEV, V14, P3204, DOI 10.1101/gad.850000; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522	44	219	250	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13247	13257		10.1074/jbc.M508324200	http://dx.doi.org/10.1074/jbc.M508324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543246	hybrid, Green Accepted			2022-12-27	WOS:000237336600030
J	Qiu, LY; Swarts, HGP; Tonk, ECM; Willems, PHGM; Koenderink, JB; De Pont, JJHHM				Qiu, LY; Swarts, HGP; Tonk, ECM; Willems, PHGM; Koenderink, JB; De Pont, JJHHM			Conversion of the low affinity ouabain-binding site of non-gastric H,K-ATPase into a high affinity binding site by substitution of only five amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; H-K-ATPASE; FUNCTIONAL EXPRESSION; DISTAL COLON; BETA-SUBUNITS; H+,K+-ATPASE; TRANSMEMBRANE; NA+,K+-ATPASE; KIDNEY; DETERMINANT	P- type ATPases of the IIC subfamily exhibit large differences in sensitivity toward ouabain. This allows a strategy in which ouabaininsensitive members of this subfamily are used as template for mutational elucidation of the ouabain-binding site. With this strategy, we recently identified seven amino acids in Na, K-ATPase that conferred high affinity ouabain binding to gastric H, K-ATPase (Qiu, L. Y., Krieger, E., Schaftenaar, G., Swarts, H. G. P., Willems, P. H. G. M., De Pont, J. J. H. H. M., and Koenderink, J. B. (2005) J. Biol. Chem. 280, 32349 - 32355). Because important, but identical, amino acids were not recognized in that study, here we used the non-gastric H, K-ATPase, which is rather ouabain-insensitive, as template. The catalytic subunit of this enzyme, in which several amino acids from Na, K-ATPase were incorporated, was expressed with the Na, K-ATPase beta 1 subunit in Xenopus laevis oocytes. A chimera containing 14 amino acids, located in M4, M5, and M6, which are unique to Na, K-ATPase, displayed high affinity ouabain binding. Four of these residues, all located in M5, appeared dispensable for high affinity binding. Individual mutation of the remaining 10 residues to their non-gastric H, K-ATPase counterparts yielded five amino acids (Glu(312), Gly(319), Pro(778), Leu(795), and Cys(802)) whose mutation resulted in a loss of ouabain binding. In a final gain-of-function experiment, we introduced these five amino acids in different combinations in non-gastric H, K-ATPase and demonstrated that all five were essential for high affinity ouabain binding. The non-gastric H, K-ATPase with these five mutations had a similar apparent affinity for ouabain as the wild type Na, K-ATPase and showed a 2000 times increased affinity for ouabain in theNH(4)(+)-stimulated ATPase activity in membranes of transfected Sf9 cells.	Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Biochem 286, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pharmacol Toxicol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Biochem 286, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.ru.nl	Koenderink, Jan/N-3578-2014; Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				Asano S, 1998, AM J PHYSIOL-CELL PH, V275, pC669, DOI 10.1152/ajpcell.1998.275.3.C669; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; Campbell WG, 1999, AM J PHYSIOL-RENAL, V276, pF237, DOI 10.1152/ajprenal.1999.276.2.F237; Codina J, 1998, J BIOL CHEM, V273, P7894, DOI 10.1074/jbc.273.14.7894; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Jaisser F, 1999, AM J PHYSIOL-RENAL, V276, pF812, DOI 10.1152/ajprenal.1999.276.6.F812; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 2003, J BIOL CHEM, V278, P51213, DOI 10.1074/jbc.M306384200; Kraut JA, 1998, KIDNEY INT, V53, P958, DOI 10.1111/j.1523-1755.1998.00841.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MATSUI H, 1968, BIOCHIM BIOPHYS ACTA, V151, P655, DOI 10.1016/0005-2744(68)90013-2; MODYANOV NN, 1995, AM J PHYSIOL, V269, pC922; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Qiu LY, 2005, J BIOL CHEM, V280, P32349, DOI 10.1074/jbc.M505168200; Qiu LY, 2003, J BIOL CHEM, V278, P47240, DOI 10.1074/jbc.M308833200; Sangan P, 2000, AM J PHYSIOL-CELL PH, V278, pC182, DOI 10.1152/ajpcell.2000.278.1.C182; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 2005, J BIOL CHEM, V280, P33115, DOI 10.1074/jbc.M504535200; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B	33	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13533	13539		10.1074/jbc.M600551200	http://dx.doi.org/10.1074/jbc.M600551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531406	hybrid, Green Published			2022-12-27	WOS:000237336600061
J	Sanematsu, F; Takami, Y; Barman, HK; Fukagawa, T; Ono, T; Shibahara, KI; Nakayama, T				Sanematsu, F; Takami, Y; Barman, HK; Fukagawa, T; Ono, T; Shibahara, KI; Nakayama, T			Asf1 is required for viability and chromatin assembly during DNA replication in vertebrate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD DIPEPTIDE MOTIFS; HISTONE CHAPERONES; DAMAGE CHECKPOINT; CHICKEN HIRA; LXXLL MOTIF; FACTOR-I; PROTEIN; GENE; TRANSCRIPTION; PHASE	Asf1 ( anti- silencing function 1), a well conserved protein from yeast to humans, acts as a histone chaperone and is predicted to participate in a variety of chromatin- mediated cellular processes. To investigate the physiological role of vertebrate Asf1 in vivo, we generated a conditional Asf1- deficient mutant from chicken DT40 cells. Induction of Asf1 depletion resulted in the accumulation of cells in S phase with decreased DNA replication and increased mitotic aberrancy forming multipolar spindles, leading to cell death. In addition, nascent chromatin in Asf1- depleted cells showed increased nuclease sensitivity, indicating impaired nucleosome assembly during DNA replication. Complementation analyses revealed that the functional domain of Asf1 for cell viability was confined to the N- terminal core domain ( amino acids 1 - 155) that is a binding platform for histones H3/ H4, CAF- 1p60, and HIRA, whereas Asf1 mutant proteins, abolishing binding abilities with both p60 and HIRA, exhibit no effect on viability. These results together indicate that the vertebrate Asf1 plays a crucial role in replication- coupled chromatin assembly, cell cycle progression, and cellular viability and provide a clue of a possible role in a CAF- 1- and HIRA- independent chromatin- modulating process for cell proliferation.	Miyazaki Univ, Coll Med, Dept Med Sci, Sect Biochem & Mol Biol, Kiyotake, Miyazaki 8891692, Japan; Natl Inst Genet, Dept Integrated Genet, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Miyazaki Univ, Dept Life Sci, Frontier Sci Res Ctr, Miyazaki 8891692, Japan	University of Miyazaki; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Univ, Coll Med, Dept Med Sci, Sect Biochem & Mol Biol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	tnakayam@med.miyazaki-u.ac.jp	Fukagawa, Tatsuo/AAK-3922-2021					Adkins MW, 2004, J BIOL CHEM, V279, P52069, DOI 10.1074/jbc.M406113200; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Ahmad A, 2005, J BIOL CHEM, V280, P32090, DOI 10.1074/jbc.M501426200; Ahmad A, 2004, GENE, V342, P125, DOI 10.1016/j.gene.2004.07.031; Ahmad A, 2003, BIOCHEM BIOPH RES CO, V312, P1266, DOI 10.1016/j.bbrc.2003.11.073; Ahmad K, 2002, P NATL ACAD SCI USA, V99, P16477, DOI 10.1073/pnas.172403699; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; Daganzo SM, 2003, CURR BIOL, V13, P2148, DOI 10.1016/S0960-9822(03)00869-8; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Fukagawa T, 1999, NUCLEIC ACIDS RES, V27, P1966, DOI 10.1093/nar/27.9.1966; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Groth A, 2003, EMBO J, V22, P1676, DOI 10.1093/emboj/cdg151; Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Hu FH, 2001, GENE DEV, V15, P1061, DOI 10.1101/gad.873201; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Mousson F, 2005, P NATL ACAD SCI USA, V102, P5975, DOI 10.1073/pnas.0500149102; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Polo SE, 2005, CANCER LETT, V220, P1, DOI 10.1016/j.canlet.2004.08.024; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schulz LL, 2006, FASEB J, V20, P488, DOI 10.1096/fj.05-5020fje; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Sutton A, 2001, GENETICS, V158, P587; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1999, J BIOL CHEM, V274, P23977, DOI 10.1074/jbc.274.34.23977; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zabaronick SR, 2005, MOL CELL BIOL, V25, P652, DOI 10.1128/MCB.25.2.652-660.2005; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	49	73	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13817	13827		10.1074/jbc.M511590200	http://dx.doi.org/10.1074/jbc.M511590200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537536	hybrid			2022-12-27	WOS:000237336600092
J	Joselin, AP; Schulze-Osthoff, K; Schwerk, C				Joselin, AP; Schulze-Osthoff, K; Schwerk, C			Loss of acinus inhibits oligonucleosomal DNA fragmentation but not chromatin condensation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; PROTEOMIC ANALYSIS; CELL-DEATH; ENDONUCLEASE-G; PROTEIN; NUCLEASE; CLEAVAGE; REVEALS; HISTONE; DIFFERENTIATION	Chromatin condensation and oligonucleosomal DNA fragmentation are the nuclear hallmarks of apoptosis. A proteolytic fragment of the apoptotic chromatin condensation inducer in the nucleus ( Acinus), which is generated by caspase cleavage, has been implicated in mediating apoptotic chromatin condensation prior to DNA fragmentation. Acinus is also involved in mRNA splicing and a component of the apoptosis and splicing-associated protein ( ASAP) complex. To study the role of Acinus for apoptotic nuclear alterations, we generated stable cell lines in which Acinus isoforms were knocked down by inducible and reversible RNA interference. We show that Acinus is not required for nuclear localization and interaction of the other ASAP subunits SAP18 and RNPS1; however, knockdown of Acinus leads to a reduction in cell growth. Most strikingly, down-regulation of Acinus did not inhibit apoptotic chromatin condensation either in intact cells or in a cell-free system. In contrast, although apoptosis proceeds rapidly, analysis of nuclear DNA from apoptotic Acinus knockdown cells shows inhibition of oligonucleosomal DNA fragmentation. Our results therefore suggest that Acinus is not involved in DNA condensation but rather point to a contribution of Acinus in internucleosomal DNA cleavage during programmed cell death.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schwerk, C (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Christian.Schwerk@uni-duesseldorf.de	Schwerk, Christian/GNP-5375-2022; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Joselin, Alvin/0000-0002-9010-0421				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Korn C, 2005, J BIOL CHEM, V280, P6005, DOI 10.1074/jbc.M413035200; Lechardeur D, 2004, J CELL BIOL, V167, P851, DOI 10.1083/jcb.200404105; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	48	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12475	12484		10.1074/jbc.M509859200	http://dx.doi.org/10.1074/jbc.M509859200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537548	hybrid			2022-12-27	WOS:000237134700035
J	Li, KY; Tong, WH; Hughes, RM; Rouault, TA				Li, KY; Tong, WH; Hughes, RM; Rouault, TA			Roles of the mammalian cytosolic cysteine desulfurase, ISCS, and scaffold protein, ISCU, in iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST NFS1P; MITOCHONDRIAL; BIOGENESIS; IDENTIFICATION; PURIFICATION; HOMEOSTASIS; FRATAXIN; ABILITY	Iron-sulfur clusters are prosthetic groups composed of sulfur and iron that are found in respiratory chain complexes and numerous enzymes. Iron-sulfur clusters are synthesized in a multistep process that utilizes cysteine desulfurases, scaffold proteins, chaperones, and iron donors. Assembly of iron-sulfur clusters occurs in the mitochondrial matrix of mammalian cells, but cytosolic isoforms of three major mammalian iron-sulfur cluster (ISC) assembly components have been found, raising the possibility that de novo iron-sulfur cluster biogenesis also occurs in cytosol. The human cysteine desulfurase, ISCS, has two isoforms, one of which targets to the mitochondria, whereas the other less abundant form is cytosolic and nuclear. The open-reading frame of cytosolic mammalian ISCS begins at the second AUG of the transcript and lacks mitochondrial targeting information. Yeast complementation experiments have suggested that the human cytosolic ISCS isoform (c-ISCS) cannot be functional. To evaluate function of c-ISCS, we overexpressed the human cytosolic ISCS in yeast Pichia pastoris and showed that the cytosolic form of ISCS is an active cysteine desulfurase that covalently binds S-35 acquired from desulfuration of radiolabeled cysteine. Human cytosolic ISCS dimerized as efficiently as bacterial ISCS and formed a complex in vitro with overexpressed cytosolic human ISCU. When incubated with iron regulatory protein 1, cysteine, and iron, the cytosolic forms of ISCS and ISCU facilitated efficient formation of a [4Fe-4S] cluster on IRP1. Thus, the cytosolic form of ISCS is a functional cysteine desulfurase that can collaborate with cytosolic ISCU to promote de novo iron-sulfur cluster formation.	NICHD, Cell Biol & Metab Branch, NIH, Intramural Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rouault, TA (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Intramural Program, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	Rouault@mail.nih.gov	Li, Kuanyu/AAL-2051-2020	Hughes, Robert M./0000-0002-4182-9136	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008814] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008814] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allerson CR, 2003, RNA, V9, P364, DOI 10.1261/rna.2143303; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Dos Santos PC, 2004, J BIOL CHEM, V279, P19705, DOI 10.1074/jbc.M400278200; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Sun GF, 2003, J HUM GENET, V48, P415, DOI 10.1007/s10038-003-0048-9; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	24	76	83	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12344	12351		10.1074/jbc.M600582200	http://dx.doi.org/10.1074/jbc.M600582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527810	hybrid			2022-12-27	WOS:000237134700019
J	DAs, TK; Dewilde, S; Friedman, JM; Moens, L; Rousseau, DL				DAs, TK; Dewilde, S; Friedman, JM; Moens, L; Rousseau, DL			Multiple active site conformers in the carbon monoxide complexes of trematode hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; RESONANCE RAMAN-SPECTRA; DISTAL POCKET POLARITY; SPERM-WHALE MYOGLOBIN; LIGAND-BINDING; HORSERADISH-PEROXIDASE; HEME POCKET; TRUNCATED HEMOGLOBINS; ASCARIS HEMOGLOBIN; 2 CONFORMATIONS	Sequence alignment of hemoglobins of the trematodes Paramphistomum epiclitum and Gastrothylax crumenifer with myoglobin suggests the presence of an unusual active site structure in which two tyrosine residues occupy the E7 and B10 helical positions. In the crystal structure of P. epiclitum hemoglobin, such an E7-B10 tyrosine pair at the putative helical positions has been observed, although the E7 Tyr is displaced toward CD region of the polypeptide. Resonance Raman data on both P. epiclitum and G. crumenifer hemoglobins show that interactions of heme-bound ligands with neighboring amino acid residues are unusual. Multiple conformers in the CO complex, termed the C, O, and N conformers, are observed. The conformers are separated by a large difference ( similar to 60 cm(-1)) in the frequencies of their Fe-CO stretching modes. In the C conformer the Fe-CO stretching frequency is very high, 539 and 535 cm(-1), for the P. epiclitum and G. crumenifer hemoglobins, respectively. The Fe-CO stretching of the N conformer appears at an unusually low frequency, 479 and 476 cm(-1), respectively, for the two globins. A population of an O conformer is seen in both hemoglobins, at 496 and 492 cm(-1), respectively. The C conformer is stabilized by a strong polar interaction of the CO with the distal B10 tyrosine residue. The O conformer is similar to the ones typically seen in mutant myoglobins in which there are no strong interactions between the CO and residues in the distal pocket. The N conformer possesses an unusual configuration in which a negatively charged group, assigned as the oxygen atom of the B10 Tyr side chain, interacts with the CO. In this conformer, the B10 Tyr assumes an alternative conformation consistent with one of the conformers seen the crystal structure. Implications of the multiple configurations on the ligand kinetics are discussed.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Pfizer Global Biol, Chesterfield, MO 63017 USA; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	Yeshiva University; Albert Einstein College of Medicine; Pfizer; University of Antwerp	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu		Das, Tapan/0000-0002-3641-3988	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890, R01GM054806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54806, GM58890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderton CL, 1997, BBA-PROTEIN STRUCT M, V1338, P107, DOI 10.1016/S0167-4838(96)00194-X; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CHAMPION PM, 1988, BIOL APPLICATIONS RA, V3, P249; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Das TK, 2002, INDIAN J CHEM A, V41, P32; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Deng TJ, 2001, J AM CHEM SOC, V123, P269, DOI 10.1021/ja001517d; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Dewilde S, 1998, J BIOL CHEM, V273, P32467, DOI 10.1074/jbc.273.49.32467; Egawa T, 2005, J INORG BIOCHEM, V99, P72, DOI 10.1016/j.jinorgbio.2004.10.017; EVANGELISTAKIRKUP R, 1986, BIOCHEMISTRY-US, V25, P4420, DOI 10.1021/bi00363a037; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Guarrera L, 1998, BIOCHEMISTRY-US, V37, P5608, DOI 10.1021/bi972380f; Hardison R, 1998, J EXP BIOL, V201, P1099; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; Kim SY, 1996, J AM CHEM SOC, V118, P8769, DOI 10.1021/ja961411b; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Matsu-ura M, 2002, J AM CHEM SOC, V124, P1941, DOI 10.1021/ja011963g; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Milani M, 2002, ACTA CRYSTALLOGR D, V58, P719, DOI 10.1107/S0907444902001865; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Nakashima S, 1998, CHEM PHYS, V228, P323, DOI 10.1016/S0301-0104(97)00353-4; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pesce A, 2001, J MOL BIOL, V309, P1153, DOI 10.1006/jmbi.2001.4731; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; Samuni U, 2004, J AM CHEM SOC, V126, P2682, DOI 10.1021/ja038093i; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SMULEVICH G, 1986, BIOCHEMISTRY-US, V25, P4426, DOI 10.1021/bi00363a038; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TSUNASAWA S, 1982, J BIOCHEM-TOKYO, V92, P607, DOI 10.1093/oxfordjournals.jbchem.a133971; Unno M, 1998, J AM CHEM SOC, V120, P2670, DOI 10.1021/ja973293d; UNO T, 1987, J BIOL CHEM, V262, P4549; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Yeh SR, 2004, J PHYS CHEM B, V108, P1478, DOI 10.1021/jp037054q; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028; Zhang W, 1997, J BIOL CHEM, V272, P3000, DOI 10.1074/jbc.272.5.3000; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	75	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11471	11479		10.1074/jbc.M512054200	http://dx.doi.org/10.1074/jbc.M512054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16481317	hybrid			2022-12-27	WOS:000236988100008
J	Ducrot, C; Lefebvre, O; Landrieux, E; Guirouilh-Barbat, J; Sentenac, A; Acker, J				Ducrot, C; Lefebvre, O; Landrieux, E; Guirouilh-Barbat, J; Sentenac, A; Acker, J			Reconstitution of the yeast RNA polymerase III transcription system with all recombinant factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; FACTOR-TAU; SUBUNIT; GENE; TFIIIB; PURIFICATION; COMPONENTS; EXPRESSION	Transcription factor TFIIIC is a multisubunit complex required for promoter recognition and transcriptional activation of class III genes. We describe here the reconstitution of complete recombinant yeast TFIIIC and the molecular characterization of its two DNA-binding domains, tau A and tau B, using the baculovirus expression system. The B block-binding module, r tau B, was reconstituted with r tau 138, r tau 91, and r tau 60 subunits. r tau 131, r tau 95, and r tau 55 formed also a stable complex, r tau A, that displayed nonspecific DNA binding activity. Recombinant rTFIIIC was functionally equivalent to purified yeast TFIIIC, suggesting that the six recombinant subunits are necessary and sufficient to reconstitute a transcriptionally active TFIIIC complex. The formation and the properties of rTFIIIC-DNA complexes were affected by dephosphorylation treatments. The combination of complete recombinant rTFIIIC and rTFIIIB directed a low level of basal transcription, much weaker than with the crude B" fraction, suggesting the existence of auxiliary factors that could modulate the yeast RNA polymerase III transcription system.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Acker, J (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 144, F-91191 Gif Sur Yvette, France.	joel.acker@cea.fr	LEFEBVRE, Olivier/C-3847-2014; Acker, Joël/F-5138-2010; guirouilh-barbat, josee/O-7286-2017	LEFEBVRE, Olivier/0000-0002-3903-9450; Acker, Joël/0000-0002-0855-875X; guirouilh-barbat, josee/0000-0002-8845-7333				Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; Arrebola R, 1998, MOL CELL BIOL, V18, P1; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; Brown TRP, 2000, GENE EXPRESSION, V9, P15; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; CONESA C, 1993, J BIOL CHEM, V268, P18047; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; DIECI G, 1993, J BIOL CHEM, V268, P11199; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3432, DOI 10.1093/nar/22.16.3432; Jourdain S, 2003, J BIOL CHEM, V278, P10450, DOI 10.1074/jbc.M213310200; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P11938, DOI 10.1073/pnas.91.25.11938; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; Mylona A, 2006, PROTEIN EXPRES PURIF, V45, P255, DOI 10.1016/j.pep.2005.06.013; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Ptacek J, 2005, NATURE, V438, P679, DOI 10.1038/nature04187; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	57	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11685	11692		10.1074/jbc.M600101200	http://dx.doi.org/10.1074/jbc.M600101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517597	hybrid			2022-12-27	WOS:000236988100032
J	Fugier, C; Tousaint, JJ; Prieur, X; Plateroti, M; Samarut, J; Delerive, P				Fugier, C; Tousaint, JJ; Prieur, X; Plateroti, M; Samarut, J; Delerive, P			The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-3; RECEPTOR-BETA; CHOLESTEROL-METABOLISM; LIPID-METABOLISM; GENE; ALPHA; LIVER; MICE; IDENTIFICATION; OVEREXPRESSION	Whereas the role of thyroid hormone is clearly established in the regulation of cholesterol homeostasis, its involvement in the control of serum triglyceride ( TG) levels remains largely debated. Angiopoietin-like proteins 3 and 4 have recently been characterized as potent lipoprotein lipase inhibitors and therefore as important components of plasma triglyceride homeostasis. In the present study, the role of thyroid hormone in the regulation of both ANGPTL4 and ANGPTL3 gene expression was investigated. In vivo studies revealed that thyroid hormone down-regulates ANGPTL3 but not ANGPTL4 gene expression in hypothyroid rats. Using thyroid hormone receptor ( TR)-deficient mice, we show that thyroid hormone regulates ANGPTL3 gene expression in a TR beta-dependent manner. Transfection studies revealed that this inhibition occurs at the transcriptional level in a DNA binding-independent fashion and requires the proximal ( -171 to +66) region of the ANGPTL3 gene promoter. Moreover, site-directed mutagenesis experiments indicate that the HNF1 site within this proximal region mediates this TR beta-dependent repression. Finally, co-transfection studies and electrophoretic mobility shift assays suggest that TR beta antagonizes the HNF1 alpha signaling pathway by inhibiting its transcriptional activity without interfering with its DNA-binding capacity. Taken together, our results lead to the identification of ANGPTL3 as a novel TR beta target gene and provide a new potential mechanism to explain the hypotriglyceridemic properties of TR beta agonists in vivo.	GlaxoSmithKline R&D, CVU CEDD, F-91951 Les Ulis, France; Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule,IFR 128, UMR 5161,INRA,UMR 1237, F-69364 Lyon, France	GlaxoSmithKline; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Delerive, P (corresponding author), GlaxoSmithKline R&D, CVU CEDD, 25 Ave Quebec, F-91951 Les Ulis, France.	pxd14884@gsk.com	Samarut, Jacques/AAD-2587-2019; Plateroti, Michelina/F-2928-2017; Prieur, Xavier/D-4760-2015	Prieur, Xavier/0000-0003-0215-5447				ABRAMS JJ, 1981, J LIPID RES, V22, P307; AVIRAM M, 1982, CLIN BIOCHEM, V15, P62, DOI 10.1016/S0009-9120(82)90529-X; Caturla M, 1997, MOL CELL ENDOCRINOL, V135, P139, DOI 10.1016/S0303-7207(97)00196-2; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Dignam D R, 1983, Healthc Financ Manage, V37, P38; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Duntas LH, 2002, THYROID, V12, P287, DOI 10.1089/10507250252949405; ENGELKEN SF, 1981, ATHEROSCLEROSIS, V38, P177, DOI 10.1016/0021-9150(81)90114-3; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Flores-Morales A, 2002, MOL ENDOCRINOL, V16, P1257, DOI 10.1210/me.16.6.1257; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Gauthier K, 2001, MOL CELL BIOL, V21, P4748, DOI 10.1128/MCB.21.14.4748-4760.2001; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Gullberg H, 2002, MOL ENDOCRINOL, V16, P1767, DOI 10.1210/me.2002-0009; HANSSON P, 1983, HORM METAB RES, V15, P449, DOI 10.1055/s-2007-1018751; Hashimoto K, 2006, J BIOL CHEM, V281, P295, DOI 10.1074/jbc.M507877200; Ito M, 2003, CLIN ENDOCRINOL, V58, P621, DOI 10.1046/j.1365-2265.2003.01762.x; Johansson L, 2005, P NATL ACAD SCI USA, V102, P10297, DOI 10.1073/pnas.0504379102; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Kawai K, 2004, ENDOCRINOLOGY, V145, P5515, DOI 10.1210/en.2004-0382; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Korstanje R, 2004, ATHEROSCLEROSIS, V177, P443, DOI 10.1016/j.atherosclerosis.2004.08.006; Koster A, 2005, ENDOCRINOLOGY, V146, P4943, DOI 10.1210/en.2005-0476; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; Moore JMR, 2005, MOL CELL PROTEOMICS, V4, P475, DOI 10.1074/mcp.R500001-MCP200; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; NIKKILA EA, 1972, J CLIN INVEST, V51, P2103, DOI 10.1172/JCI107017; OIKE Y, 2005, TRENDS MOL MED; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Prieur X, 2005, J BIOL CHEM, V280, P27533, DOI 10.1074/jbc.M503139200; Roberts CGP, 2004, LANCET, V363, P793, DOI 10.1016/S0140-6736(04)15696-1; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; Staton JM, 1998, ENDOCRINOLOGY, V139, P1093, DOI 10.1210/en.139.3.1093; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Taylor AH, 1997, MOL PHARMACOL, V52, P542, DOI 10.1124/mol.52.3.542; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Wu YF, 2000, TRENDS ENDOCRIN MET, V11, P207, DOI 10.1016/S1043-2760(00)00263-0; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200; Yu XX, 2005, P NATL ACAD SCI USA, V102, P1767, DOI 10.1073/pnas.0409564102	53	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11553	11559		10.1074/jbc.M512554200	http://dx.doi.org/10.1074/jbc.M512554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505486	hybrid, Green Published			2022-12-27	WOS:000236988100017
J	Birmingham, CL; Smith, AC; Bakowski, MA; Yoshimori, T; Brumell, JH				Birmingham, CL; Smith, AC; Bakowski, MA; Yoshimori, T; Brumell, JH			Autophagy controls Salmonella infection in response to damage to the Salmonella-containing vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; LATE ENDOCYTIC COMPARTMENTS; PROTEIN SECRETION SYSTEM; EPITHELIAL-CELLS; MAMMALIAN-CELLS; HOST-CELL; INTRACELLULAR SALMONELLA; LEGIONELLA-PNEUMOPHILA; FILAMENTOUS STRUCTURES	Salmonella enterica serovar Typhimurium ( S. Typhimurium) is a facultative intracellular pathogen that causes disease in a variety of hosts. S. Typhimurium actively invade host cells and typically reside within a membrane-bound compartment called the Salmonella-containing vacuole (SCV). The bacteria modify the fate of the SCV using two independent type III secretion systems(TTSS). TTSS are known to damage eukaryotic cell membranes and S. Typhimurium has been suggested to damage the SCV using its Salmonella pathogenicity island (SPI)-1 encoded TTSS. Here we show that this damage gives rise to an intracellular bacterial population targeted by the autophagy system during in vitro infection. Approximately 20% of intracellular S. Typhimurium colocalized with the autophagy marker GFP-LC3 at 1 h postinfection. Autophagy of S. Typhimurium was dependent upon the SPI-1 TTSS and bacterial protein synthesis. Bacteria targeted by the autophagy system were often associated with ubiquitinated proteins, indicating their exposure to the cytosol. Surprisingly, these bacteria also colocalized with SCV markers. Autophagy-deficient (atg5(-/-)) cells were more permissive for intracellular growth by S. Typhimurium than normal cells, allowing increased bacterial growth in the cytosol. We propose a model in which the host autophagy system targets bacteria in SCVs damaged by the SPI-1 TTSS. This serves to retain intracellular S. Typhimurium within vacuoles early after infection to protect the cytosol from bacterial colonization. Our findings support a role for autophagy in innate immunity and demonstrate that Salmonella infection is a powerful model to study the autophagy process.	Hosp Sick Children, Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Natl Inst Genet, Dept Cell Genet, Shizuoka 4118540, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Brumell, JH (corresponding author), Hosp Sick Children, Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	john.brumell@sickkids.ca	Birmingham, Cheryl/AAF-6649-2020					Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Birmingham CL, 2005, INFECT IMMUN, V73, P1204, DOI 10.1128/IAI.73.2.1204-1208.2005; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Brumell JH, 2003, TRAFFIC, V4, P36, DOI 10.1034/j.1600-0854.2003.40106.x; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Brumell JH, 2002, INFECT IMMUN, V70, P3264, DOI 10.1128/IAI.70.6.3264-3270.2002; Brumell JH, 2004, CURR OPIN MICROBIOL, V7, P78, DOI 10.1016/j.mib.2003.12.005; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chakravortty D, 2002, J EXP MED, V195, P1155, DOI 10.1084/jem.20011547; CIECHANOVER A, 1991, BIOMED BIOCHIM ACTA, V50, P321; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; Dorn BR, 2001, INFECT IMMUN, V69, P5698, DOI 10.1128/IAI.69.9.5698-5708.2001; Drecktrah D, 2005, CELL MICROBIOL, V7, P105, DOI 10.1111/j.1462-5822.2004.00436.x; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Gallois A, 2001, J IMMUNOL, V166, P5741, DOI 10.4049/jimmunol.166.9.5741; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Holden DW, 2002, TRAFFIC, V3, P161, DOI 10.1034/j.1600-0854.2002.030301.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Martens S, 2005, PLOS PATHOG, V1, P187, DOI 10.1371/journal.ppat.0010024; Mastroeni P, 2004, MICROBES INFECT, V6, P398, DOI 10.1016/j.micinf.2003.12.009; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P5711; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; RIKIHISA Y, 1984, ANAT REC, V208, P319, DOI 10.1002/ar.1092080302; Roy D, 2004, SCIENCE, V304, P1515, DOI 10.1126/science.1098371; Salcedo SP, 2001, CELL MICROBIOL, V3, P587, DOI 10.1046/j.1462-5822.2001.00137.x; Smith AC, 2005, J BIOL CHEM, V280, P24634, DOI 10.1074/jbc.M500358200; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tsolis RM, 1999, ADV EXP MED BIOL, V473, P261; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Walker DH, 1997, LAB INVEST, V76, P129; Wood MW, 1998, MOL MICROBIOL, V29, P883, DOI 10.1046/j.1365-2958.1998.00984.x; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	73	505	517	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11374	11383		10.1074/jbc.M509157200	http://dx.doi.org/10.1074/jbc.M509157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495224	hybrid			2022-12-27	WOS:000236822200080
J	Salas, A; Shimaoka, M; Phan, U; Kim, M; Springer, TA				Salas, A; Shimaoka, M; Phan, U; Kim, M; Springer, TA			Transition from rolling to firm adhesion can be mimicked by extension of integrin alpha(L)beta(2) in an intermediate affinity state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; I-LIKE DOMAIN; DISULFIDE BOND; CONFORMATION; REVEALS; LFA-1; FLOW; ALPHA-L-BETA-2; ADHESIVENESS; ANTAGONISTS	alpha(L)beta(2) affinity for intercellular adhesion molecule-1 (ICAM-1) is regulated by the conformation of the alpha(L) I domain, which is in turn controlled by the conformation and orientation of other adjacent domains. Additionally, overall integrin conformation (bent versus straightened) influences the orientation of the I domain and access to its ligands, influencing adhesive efficiency. The open or high affinity I domain conformation supports strong adhesion, whereas the closed, low affinity conformation mediates weak interactions or rolling. We have previously suggested that alpha(L)beta(2) can also exist on the cell surface in an intermediate affinity state. Here we have studied the adhesive properties of integrin alpha(L)beta(2) containing mutant I domains with intermediate affinities for ICAM-1. In an overall bent conformation, the intermediate affinity state of alpha(L)beta(2) is hardly detected by conventional adhesion assays, but robust adhesion is seen when an extended conformation is induced by a small molecule alpha/beta I allo-steric antagonist. Intermediate affinity alpha(L)beta(2) supports more stable rolling than wild-type alpha(L)beta(2) under shear conditions. Moreover, antagonist-induced extension transforms rolling adhesion into firm adhesion in a manner reminiscent of chemokine activation of integrin alpha(L)beta(2). These findings suggest the relevance of intermediate affinity states of alpha(L)beta(2) to the transition between inactive and active states and demonstrate the importance of both I domain affinity and overall integrin conformation for cell adhesion.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Salas, Azucena/AAN-7035-2020	Salas, Azucena/0000-0003-4572-2907	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798, R01 CA031798, R37 CA031798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	25	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10876	10882		10.1074/jbc.M512472200	http://dx.doi.org/10.1074/jbc.M512472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505487	Green Accepted, hybrid			2022-12-27	WOS:000236822200027
J	Jiang, N; Wang, XX; Jhanwar-Uniyal, M; Darzynkiewicz, Z; Dai, W				Jiang, N; Wang, XX; Jhanwar-Uniyal, M; Darzynkiewicz, Z; Dai, W			Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC5; CELL-CYCLE ARREST; SERINE/THREONINE KINASE; PHOSPHORYLATION; PROGRESSION; INHIBITION; MECHANISM; DOCKING; CANCER; PART	Polo-like kinase 3 (Plk3), an immediate early response gene product, plays an important role in the regulation of mitosis, DNA damage checkpoint activation, and Golgi dynamics. Similar to other members of the Plk family, Plk3 has a conserved kinase domain at the N terminus and a Polo box domain consisting of two Polo boxes at the C terminus. In this study, we demonstrate that the Polo box domain of Plk3 is sufficient for subcellular localization of this kinase to the centrosomes, the spindle poles, and the midbody when ectopically expressed in HeLa and U2OS cells. Both Polo boxes are required for the subcellular localization. Overexpression of the Polo box domain, not the kinase domain, of Plk3 causes significant cell cycle arrest and cytokinesis defects, eventually leading to mitotic catastrophe/apoptosis. Interestingly, the Polo box domain of Plk3 is more potent in inhibiting cell proliferation and inducing apoptosis than that of Plk1, suggesting that this domain can provide an additional structural basis for discovery of new anticancer drugs given the current emphasis on Plk1 as a therapeutic target.	New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Dept Neurosurg, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Brander Canc Inst, Div Mol Carcinogenesis, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Basic Sci Bldg,Rm A22, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA074229, R01CA028704] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704, R01 CA028704-27, CA 74229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2005, ONCOGENE, V24, P214, DOI 10.1038/sj.onc.1208270; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; JULIAN M, 1993, J CELL SCI, V105, P145; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Levitzki A, 2002, EUR J CANCER, V38, pS11, DOI 10.1016/S0959-8049(02)80598-6; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yuan JP, 2002, CANCER RES, V62, P4186; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	34	49	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10577	10582		10.1074/jbc.M513156200	http://dx.doi.org/10.1074/jbc.M513156200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478733	hybrid			2022-12-27	WOS:000236594300089
J	Loriot, A; De Plaen, E; Boon, T; De Smet, C				Loriot, A; De Plaen, E; Boon, T; De Smet, C			Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; HUMAN CANCER-CELLS; DNA METHYLATION; CPG ISLANDS; DEPENDENT MECHANISM; MOUSE EMBRYO; GERM LINE; GENE; EXPRESSION	MAGE-A1 belongs to a group of germ line-specific genes that rely primarily on DNA methylation for repression in somatic tissues. In many types of tumors, the promoter of these genes becomes demethylated and transcription becomes activated. We showed previously that, although MZ2-MEL melanoma cells contain an active unmethylated MAGE-A1 gene, they lack the ability to induce demethylation of newly integrated MAGE-A1 transgenes that were methylated in vitro before transfection. In the same cells, unmethylated MAGE-A1 transgenes were protected against remethylation, and this appeared to depend on the level of transcriptional activity. We therefore proposed that hypomethylation of MAGE-A1 in tumors relies on a past demethylation event and on the presence of appropriate transcription factors that maintain the promoter unmethylated. Here, we tested this hypothesis further by examining whether induction of a transient demethylation phase in MZ2-MEL would suffice to convert a previously methylated MAGE-A1 transgene into a permanently hypomethylated and active one. For induction of the demethylation phase, we used antisense oligonucleotides targeting the three known human DNA methyltransferases. We found that down-regulation of DNMT1, but not of DNMT3A and DNMT3B, induces activation of the MAGE-A1 transgene, suggesting that DNMT1 has a predominant role for methylation maintenance in MZ2-MEL cells. By using a selectable MAGE-A1 transgene construct, we were able to isolate a cell population in which DNMT1 depletion had resulted in transgene activation. The promoter region of the transgene was almost completely unmethylated in these cells, and this active and unmethylated state was maintained for over 60 days after restoration of normal DNMT1 expression.	Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; Catholic Univ Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	De Smet, C (corresponding author), Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, 74 Ave Hippocrate, B-1200 Brussels, Belgium.	charles.desmet@bru.licr.org						ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Conway KE, 2000, CANCER RES, V60, P6236; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; FLATAU E, 1984, MOL CELL BIOL, V4, P2098, DOI 10.1128/MCB.4.10.2098; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girault I, 2003, CLIN CANCER RES, V9, P4415; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hattori N, 2004, GENOME RES, V14, P1733, DOI 10.1101/gr.2431504; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lin CH, 2001, CANCER RES, V61, P4238; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; MONK M, 1987, DEVELOPMENT, V99, P371; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Shi HD, 2003, CANCER RES, V63, P2164; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WEYNANTS P, 1994, INT J CANCER, V56, P826, DOI 10.1002/ijc.2910560612; WILSON VL, 1983, SCIENCE, V220, P1054; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	52	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10118	10126		10.1074/jbc.M510469200	http://dx.doi.org/10.1074/jbc.M510469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16497664	hybrid			2022-12-27	WOS:000236594300037
J	Fountain, SJ; North, RA				Fountain, Samuel J.; North, R. Alan			A C-terminal lysine that controls human P2X(4) receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SYNAPTIC TRANSMISSION; RAT SPINAL-CORD; DORSAL-HORN; ION-CHANNEL; ATP-BINDING; IDENTIFICATION; ECTODOMAIN; RESIDUES; DOMAIN; SUBUNITS	Receptor desensitization can determine the time course of transmitter action and profoundly alter sensitivity to drugs. Among P2X receptors, ion currents through homomeric P2X(4) receptors exhibit intermediate desensitization when compared with P2X(1) and P2X(3) ( much faster) and P2X(2) and P2X(7) ( slower). We recorded membrane currents in HEK293 cells transfected to express the human P2X4 receptor. The decline in current during a 4-s application of ATP ( 100 mu M) was about 30%; this was not different during whole-cell or perforated patch recording. Alanine-scanning mutagenesis of the intracellular C terminus identified two positions with much accelerated desensitization kinetics (Lys(373): 92% and Tyr(374): 74%). At position 373, substitution of Arg or Cys also strongly accelerated desensitization: however, in the case of K373C the wild-type phenotype was fully restored by adding ethylammonium methanethiosulfonate. At position 374, phenylalanine could replace tyrosine. These results indicate that wild-type desensitization properties requires an aromatic moiety at position 374 and an amino rather than a guanidino group at position 373. These residues lie between previously identified motifs involved in membrane trafficking (YXXXK and YXXGL) and implicates the C-terminal also in rearrangements leading to channel closing during the presence of agonist.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Fountain, SJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	Samuel.fountain@manchester.ac.uk	Fountain, Samuel J/C-2142-2011; North, Richard/GQA-6156-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bardoni R, 1997, J NEUROSCI, V17, P5297; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Egan TM, 1998, J NEUROSCI, V18, P2350; Ennion SJ, 2002, BIOCHEM BIOPH RES CO, V291, P611, DOI 10.1006/bbrc.2002.6488; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Fabbretti E, 2004, J BIOL CHEM, V279, P53109, DOI 10.1074/jbc.M409772200; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Hugel S, 2000, J NEUROSCI, V20, P2121; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; King B, 1997, NEUROREPORT, V8, P1099, DOI 10.1097/00001756-199703240-00007; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Lewis CJ, 2000, BRIT J PHARMACOL, V131, P1659, DOI 10.1038/sj.bjp.0703744; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pankratov YV, 2002, J NEUROSCI, V22, P8363; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; Royle SJ, 2005, J CELL SCI, V118, P3073, DOI 10.1242/jcs.02451; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Seguela P, 1996, J NEUROSCI, V16, P448; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Stojilkovic SS, 2005, ANN NY ACAD SCI, V1048, P116, DOI 10.1196/annals.1342.011; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Wang Y, 2004, NEUROREPORT, V15, P633, DOI 10.1097/00001756-200403220-00012; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zemkova H, 2004, J NEUROSCI, V24, P6968, DOI 10.1523/JNEUROSCI.1471-04.2004	36	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15044	15049		10.1074/jbc.M600442200	http://dx.doi.org/10.1074/jbc.M600442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16533808	hybrid			2022-12-27	WOS:000237922200005
J	Ruban, AV; Solovieva, S; Lee, PJ; Ilioaia, C; Wentworth, M; Ganeteg, U; Klimmek, F; Chow, WS; Anderson, JM; Jansson, S; Horton, P				Ruban, Alexander V.; Solovieva, Svetlana; Lee, Pamela J.; Ilioaia, Cristian; Wentworth, Mark; Ganeteg, Ulrika; Klimmek, Frank; Chow, Wah Soon; Anderson, Jan M.; Jansson, Stefan; Horton, Peter			Plasticity in the composition of the light harvesting antenna of higher plants preserves structural integrity and biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; PHOTOSYSTEM-II; SUPRAMOLECULAR ORGANIZATION; SPECTROSCOPIC ANALYSIS; CRYSTAL-STRUCTURE; COMPLEX-II; ACCLIMATION; ARABIDOPSIS; ENERGY; XANTHOPHYLLS	Arabidopsis plants in which the major trimeric light harvesting complex ( LHCIIb) is eliminated by antisense expression still exhibit the typical macrostructure of photosystem II in the granal membranes. Here the detailed analysis of the composition and the functional state of the light harvesting antennae of both photosystem I and II of these plants is presented. Two new populations of trimers were found, both functional in energy transfer to the PSII reaction center, a homotrimer of CP26 and a heterotrimer of CP26 and Lhcb3. These trimers possess characteristic features thought to be specific for the native LHCIIb trimers they are replacing: the long wavelength form of lutein and at least one extra chlorophyll b, but they were less stable. A new population of loosely bound LHCI was also found, contributing to an increased antenna size for photosystem I, which may in part compensate for the loss of the phosphorylated LHCIIb that can associate with this photosystem. Thus, the loss of LHCIIb has triggered concerted compensatory responses in the composition of antennae of both photosystems. These responses clearly show the importance of LHCIIb in the structure and assembly of the photosynthetic membrane and illustrate the extreme plasticity at the level of the composition of the light harvesting system.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Umea Univ, Dept Plant Physiol, Plant Sci Ctr, S-90187 Umea, Sweden; Australian Natl Univ, Res Sch Biol Sci, Photobioenerget Grp, Canberra, ACT 2601, Australia	University of Sheffield; Umea University; Australian National University	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	Chow, Wah Soon/D-2010-2009; Jansson, Stefan/A-1119-2009; Horton, Peter/A-3958-2012	Jansson, Stefan/0000-0002-7906-6891; Horton, Peter/0000-0002-6095-1460; ILIOAIA, Cristian/0000-0001-7505-1900				Allemeersch J, 2005, PLANT PHYSIOL, V137, P588, DOI 10.1104/pp.104.051300; Anderson JM, 1995, PHOTOSYNTH RES, V46, P129, DOI 10.1007/BF00020423; Andersson J, 2003, PLANT J, V35, P350, DOI 10.1046/j.1365-313X.2003.01811.x; Andersson J, 2001, PLANT CELL, V13, P1193, DOI 10.1105/tpc.13.5.1193; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; de Weerd FL, 2002, BIOCHEMISTRY-US, V41, P15224, DOI 10.1021/bi0261948; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Dudley AM, 2002, P NATL ACAD SCI USA, V99, P7554, DOI 10.1073/pnas.112683499; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hilson P, 2004, GENOME RES, V14, P2176, DOI 10.1101/gr.2544504; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KITAJIMA M, 1975, BIOCHIM BIOPHYS ACTA, V408, P297, DOI 10.1016/0005-2728(75)90131-0; Klimmek F, 2005, BIOCHEMISTRY-US, V44, P3065, DOI 10.1021/bi047873g; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Novoderezhkin VI, 2005, J PHYS CHEM B, V109, P10493, DOI 10.1021/jp044082f; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; Palacios MA, 2003, BBA-BIOENERGETICS, V1605, P83, DOI 10.1016/S0005-2728(03)00080-X; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rodermel S, 2001, TRENDS PLANT SCI, V6, P471, DOI 10.1016/S1360-1385(01)02085-4; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; RUBAN AV, 1991, BIOCHIM BIOPHYS ACTA, V1058, P411, DOI 10.1016/S0005-2728(05)80137-9; RUBAN AV, 1991, PHOTOSYNTH RES, V29, P157, DOI 10.1007/BF00036219; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P30, DOI 10.1016/0005-2728(92)90061-6; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; SJODIN A, 2005, UPSC BASE; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; van Amerongen H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/jp0028406; Wentworth M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/bi034975i; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; Zelisko A, 2005, P NATL ACAD SCI USA, V102, P13699, DOI 10.1073/pnas.0503472102	50	41	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14981	14990		10.1074/jbc.M511415200	http://dx.doi.org/10.1074/jbc.M511415200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551629	Green Published, hybrid			2022-12-27	WOS:000237671300051
J	Page, S; Judson, A; Melford, K; Bensadoun, A				Page, Shallee; Judson, Andrea; Melford, Kristan; Bensadoun, Andre			Interaction of lipoprotein lipase and receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PLASMON RESONANCE BIOSENSORS; RAT HEPATOMA-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; IN-VIVO; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; CULTURED ADIPOCYTES; BINDING DOMAIN; ER RETENTION	Receptor-associated protein ( RAP) is a recognized chaperone/escort protein for members of the low density lipoprotein receptor family. In this report, we show that RAP binds to lipoprotein lipase (LPL) and may play a role in the maturation of LPL. Binding of highly purified RAP to LPL was demonstrated in vitro by solid phase assays, surface plasmon resonance, and rate zonal centrifugation. The dissociation constant for this interaction measured by the first two techniques ranged between 2.4 and 13 nM, values similar to those reported for the binding of RAP to LRP or gp330. The specificity of the interaction was demonstrated by competition with a panel of LPL monoclonal antibodies. Rate zonal centrifugation demonstrated the presence of a stable complex with an apparent M-r consistent with the formation of a complex between monomeric LPL and RAP.RAP center dot LPL complexes were co-immunoprecipitated in adipocyte lysates or from solutions of purified LPL and RAP. The interaction was also demonstrated in whole cells by cross-linking experiments. RAP-deficient adipocytes secreted LPL with a specific activity 2.5-fold lower than the lipase secreted by control cells. Heparin addition to cultured RAP-deficient adipocytes failed to stimulate LPL secretion in the medium, suggesting defective binding of the lipase to the plasma membrane. These studies demonstrate that RAP binds to LPL with high affinity both in purified systems and cell extracts and that RAP-deficient adipocytes secrete poorly assembled LPL. A function of RAP may be to prevent premature interaction of LPL with binding partners in the secretory pathway, namely LRP and heparan sulfate proteoglycan.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Bensadoun, A (corresponding author), Cornell Univ, Div Nutr Sci, 321 Savage Hall, Ithaca, NY 14853 USA.	ab55@cornell.edu	Page, Shallee/AAA-6855-2019	Page, Shallee/0000-0002-3557-4122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14990] Funding Source: Medline; NIDDK NIH HHS [DK7158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; Bensadoun A, 1999, METH MOL B, V109, P145; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; Bu GJ, 1997, J CELL SCI, V110, P65; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CISAR LA, 1987, BIOCHIM BIOPHYS ACTA, V927, P305, DOI 10.1016/0167-4889(87)90094-2; CISAR LA, 1989, J BIOL CHEM, V264, P1767; FIELDING CJ, 1973, BIOCHIM BIOPHYS ACTA, V316, P66, DOI 10.1016/0005-2760(73)90167-7; GERSHENWALD JE, 1985, BIOCHIM BIOPHYS ACTA, V836, P286, DOI 10.1016/0005-2760(85)90132-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; HATA A, 1992, J BIOL CHEM, V267, P20132; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JI ZS, 1994, J BIOL CHEM, V269, P13429; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Landry R, 2001, CELL GROWTH DIFFER, V12, P497; LITTHAUER D, 1992, COMP BIOCHEM PHYS A, V101, P59, DOI 10.1016/0300-9629(92)90628-4; Mahley RW, 1999, J LIPID RES, V40, P1; Mason T, 1999, MATH BIOSCI, V159, P123, DOI 10.1016/S0025-5564(99)00023-1; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1993, BIOCHEM SOC T, V21, P509, DOI 10.1042/bst0210509; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1992, J LIPID RES, V33, P1165; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Sendak RA, 1998, J LIPID RES, V39, P1310; Sendak RA, 1998, J LIPID RES, V39, P633; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Zhang LY, 2003, J BIOL CHEM, V278, P29344, DOI 10.1074/jbc.M300455200	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13931	13938		10.1074/jbc.M600995200	http://dx.doi.org/10.1074/jbc.M600995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16517593	hybrid			2022-12-27	WOS:000237512300014
J	Alone, PV; Dever, TE				Alone, PV; Dever, TE			Direct binding of translation initiation factor eIF2 gamma-G domain to its GTPase- activating and GDP-GTP exchange factors eIF5 and eIF2B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; TERMINAL DOMAIN; TRANSFER-RNA; FACTOR 2B; RECOGNITION; COMPLEX; ARCHAEAL; RELEASE; IDENTIFICATION; EIF2-ALPHA	The GTP-binding eukaryotic translation initiation factor eIF2 delivers initiator methionyl-tRNA to the 40 S ribosomal subunit. The factor eIF5 stimulates hydrolysis of GTP by eIF2 upon AUG codon recognition, whereas the factor eIF2B promotes guanine nucleotide exchange on eIF2 to recycle the factor for additional rounds of translation initiation. The GTP-binding (G) domain resides in the gamma subunit of the heterotrimeric eIF2; however, only eIF2 beta, and not eIF2 gamma, has been reported to directly bind to eIF5 or eIF2B. Using proteins expressed in yeast or recombinant systems we show that full-length yeast eIF2 gamma, as well as its isolated G domain, binds directly to eIF5 and the epsilon subunit of eIF2B, and we map the interaction sites to the catalytically important regions of these factors. Consistently, an internal deletion of residues 50-100 of yeast eIF5 impairs the interaction with recombinant eIF2 gamma-G domain and abolishes the ability of eIF5 to stimulate eIF2 GTPase activity in translation initiation complexes in vitro. Thus, rather than allosterically regulating eIF2 gamma-G domain function via eIF2 beta, our data support a model in which the GTPase-activating factor eIF5 and the guanine-nucleotide exchange factor eIF2B modulate eIF2 function through direct interactions with the eIF2 gamma-G domain.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dever, TE (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-03, Bethesda, MD 20892 USA.	tdever@nih.gov	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Algire MA, 2005, MOL CELL, V20, P251, DOI 10.1016/j.molcel.2005.09.008; Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; Boesen T, 2004, J BIOL CHEM, V279, P10584, DOI 10.1074/jbc.M311055200; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Das S, 2001, J BIOL CHEM, V276, P6720, DOI 10.1074/jbc.M008863200; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kapp LD, 2004, J MOL BIOL, V335, P923, DOI 10.1016/j.jmb.2003.11.025; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; Maag D, 2005, MOL CELL, V17, P265, DOI 10.1016/j.molcel.2004.11.051; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Pedulla N, 2005, NUCLEIC ACIDS RES, V33, P1804, DOI 10.1093/nar/gki321; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Roll-Mecak A, 2004, J BIOL CHEM, V279, P10634, DOI 10.1074/jbc.M310418200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmitt E, 2002, EMBO J, V21, P1821, DOI 10.1093/emboj/21.7.1821; Singh CR, 2004, J BIOL CHEM, V279, P49644, DOI 10.1074/jbc.M409609200; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Yatime L, 2004, J BIOL CHEM, V279, P15984, DOI 10.1074/jbc.M311561200	34	50	53	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12636	12644		10.1074/jbc.M511700200	http://dx.doi.org/10.1074/jbc.M511700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522633	hybrid			2022-12-27	WOS:000237134700054
J	Irazusta, V; Cabiscol, E; Reverter-Branchat, G; Ros, J; Tamarit, J				Irazusta, V; Cabiscol, E; Reverter-Branchat, G; Ros, J; Tamarit, J			Manganese is the link between frataxin and iron-sulfur deficiency in the yeast model of Friedreich ataxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED PROTEINS; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; MITOCHONDRIAL ACONITASE; STRESS; CELLS; ACCUMULATION; EXPRESSION; HOMOLOG; STRAIN	Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin. Proteomic analysis of the mutant yeast model of Friedreich ataxia presented in this paper reveals that these cells display increased amounts of proteins involved in antioxidant defenses, including manganese-superoxide dismutase. This enzyme shows, however, lower activity than that found in wild type cells. Our results indicate that this lack of activity is a consequence of cellular manganese deficiency, because in manganese-supplemented cultures, cell manganese content, and manganese-superoxide dismutase activity were restored. One of the hallmarks of Friedreich ataxia is the decreased activity of iron/sulfur-containing enzymes. The activities of four enzymes of this group (aconitase, glutamate synthase, succinate dehydrogenase, and isopropylmalate dehydratase) have been analyzed for the effects of manganese supplementation. Enzyme activities were recovered by manganese treatment, except for aconitase, for which, a specific interaction with frataxin has been demonstrated previously. Similar results were obtained when cells were grown in iron-limited media suggesting that manganese-superoxide dismutase deficiency is a consequence of iron overload. In conclusion, these data indicate that generalized deficiency of iron-sulfur protein activity could be a consequence of manganese-superoxide dismutase deficiency, and consequently, it opens new strategies for Friedreich ataxia treatment.	Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Grp Bioquim Estres Oxidatiu, Lleida 25008, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Grp Bioquim Estres Oxidatiu, Montserrat Roig,2, Lleida 25008, Spain.	joaquim.ros@cmb.udl.es	Cabiscol, Elisa/A-4584-2009; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; ROS, Joaquim/ABG-7487-2020	Cabiscol, Elisa/0000-0003-2795-7999; Tamarit, Jordi/0000-0003-3227-6928; ROS, Joaquim/0000-0003-0901-8648; Irazusta, Veronica/0000-0001-7436-8543				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bulteau AL, 2005, P NATL ACAD SCI USA, V102, P5987, DOI 10.1073/pnas.0501519102; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; de Nobel H, 2001, YEAST, V18, P1413, DOI 10.1002/yea.793; Ding HG, 2005, J BIOL CHEM, V280, P30432, DOI 10.1074/jbc.M504638200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Finley JW, 2004, NUTR REV, V62, P148, DOI 10.1301/nr.2004.apr.148-153; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; MacEvilly CJ, 1997, RESTOR NEUROL NEUROS, V11, P131, DOI 10.3233/RNN-1997-11303; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; Santos MM, 2001, HUM MOL GENET, V10, P1935, DOI 10.1093/hmg/10.18.1935; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Sturm B, 2005, J BIOL CHEM, V280, P6701, DOI 10.1074/jbc.M408717200; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; Tamarit J, 2006, ANAL BIOCHEM, V351, P149, DOI 10.1016/j.ab.2005.12.001; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200	50	56	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12227	12232		10.1074/jbc.M511649200	http://dx.doi.org/10.1074/jbc.M511649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16510442	Green Published, hybrid			2022-12-27	WOS:000237134700005
J	Wenstrup, RJ; Florer, JB; Davidson, JM; Phillips, CL; Pfeiffer, BJ; Menezes, DW; Chervoneva, I; Birk, DE				Wenstrup, RJ; Florer, JB; Davidson, JM; Phillips, CL; Pfeiffer, BJ; Menezes, DW; Chervoneva, I; Birk, DE			Murine model of the Ehlers-Danlos syndrome - col5a1 haploinsufficiency disrupts collagen fibril assembly at multiple stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPES-I; V COLLAGEN; EXTRACELLULAR COMPARTMENTS; GENE COL5A1; GRAVIS FORM; MUTATION; FIBRILLOGENESIS; SKIN; DEPOSITION; ALPHA-1(V)	The most commonly identified mutations causing Ehlers-Danlos syndrome (EDS) classic type result in haploinsufficiency of pro alpha 1(V) chains of type V collagen, a quantitatively minor collagen that co-assembles with type I collagen as heterotypic fibrils. To determine the role(s) of type I/V collagen interactions in fibrillogenesis and elucidate the mechanism whereby half-reduction of type V collagen causes abnormal connective tissue biogenesis observed in EDS, we analyzed mice heterozygous for a targeted inactivating mutation in col5a1 that caused 50% reduction in col5a1 mRNA and collagen V. Comparable with EDS patients, they had decreased aortic stiffness and tensile strength and hyperextensible skin with decreased tensile strength of both normal and wounded skin. In dermis, 50% fewer fibrils were assembled with two subpopulations: relatively normal fibrils with periodic immunoreactivity for collagen V where type I/V interactions regulate nucleation of fibril assembly and abnormal fibrils, lacking collagen V, generated by unregulated sequestration of type I collagen. The presence of the aberrant fibril subpopulation disrupts the normal linear and lateral growth mediated by fibril fusion. Therefore, abnormal fibril nucleation and dysfunctional fibril growth with potential disruption of cell-directed fibril organization leads to the connective tissue dysfunction associated with EDS.	Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Vanderbilt Univ, Dept Lab Med, Nashville, TN 37232 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Vanderbilt University; University of Missouri System; University of Missouri Columbia; Jefferson University; Jefferson University	Wenstrup, RJ (corresponding author), Childrens Hosp Res Fdn, Div Human Genet, 3333 Burnet Ave,ML 4006, Cincinnati, OH 45229 USA.	richard.wenstrup@cchmc.org	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088; Phillips, Charlotte/0000-0002-7761-3783	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG019475] Funding Source: NIH RePORTER; NEI NIH HHS [EY05129] Funding Source: Medline; NIAMS NIH HHS [AR47054] Funding Source: Medline; NIA NIH HHS [AG19475] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BEIGHTON P, 1992, MCKUSICKS HERITABLE, P189; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1995, DEV DYNAM, V202, P229, DOI 10.1002/aja.1002020303; Birk DE, 1996, MATRIX BIOL, V15, P111, DOI 10.1016/S0945-053X(96)90152-3; BIRK DE, 1984, J CELL BIOL, V99, P2024, DOI 10.1083/jcb.99.6.2024; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; Bouma P, 2001, J BIOL CHEM, V276, P13356, DOI 10.1074/jbc.M011742200; Burrows NP, 1996, J INVEST DERMATOL, V106, P1273, DOI 10.1111/1523-1747.ep12348978; Burrows NP, 1997, CLIN EXP DERMATOL, V22, P174, DOI 10.1046/j.1365-2230.1997.2290654.x; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Chanut-Delalande H, 2004, MOL CELL BIOL, V24, P6049, DOI 10.1128/MCB.24.13.6049-6057.2004; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; CLARK JM, 1985, ARTERIOSCLEROSIS, V5, P19, DOI 10.1161/01.ATV.5.1.19; DePaepe A, 1997, AM J HUM GENET, V60, P547; DOBRIN PB, 1984, ARCH SURG-CHICAGO, V119, P405; Dobrin Philip B., 1997, P69; HAUSSER I, 1994, HUM GENET, V93, P394; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kadler KE, 2000, MATRIX BIOL, V19, P359, DOI 10.1016/S0945-053X(00)00082-2; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LEES JF, 1994, J BIOL CHEM, V269, P24354; Liaw L, 1998, J CLIN INVEST, V101, P1468; Malfait F, 2005, HUM MUTAT, V25, P28, DOI 10.1002/humu.20107; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; PLOETZ C, 1991, J STRUCT BIOL, V106, P73, DOI 10.1016/1047-8477(91)90064-4; Richards AJ, 1998, J MED GENET, V35, P846, DOI 10.1136/jmg.35.10.846; Schwarze U, 2000, AM J HUM GENET, V66, P1757, DOI 10.1086/302933; Segev F, 2006, INVEST OPHTH VIS SCI, V47, P565, DOI 10.1167/iovs.05-0771; Steinmann B., 2002, CONNECTIVE TISSUE IT, P431, DOI DOI 10.1002/0471221929.CH9; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; VOGEL A, 1979, LAB INVEST, V40, P201; Vonesh E.F., 1997, LINEAR NONLINEAR MOD; Vouyouka AG, 2001, J VASC SURG, V33, P1263, DOI 10.1067/mva.2001.113579; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wenstrup RJ, 2004, J CELL BIOCHEM, V92, P113, DOI 10.1002/jcb.20024; Wenstrup RJ, 2002, GENET MED, V4, P112, DOI 10.1097/00125817-200205000-00003; Wenstrup RJ, 2000, AM J HUM GENET, V66, P1766, DOI 10.1086/302930; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200	47	117	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12888	12895		10.1074/jbc.M511528200	http://dx.doi.org/10.1074/jbc.M511528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16492673	hybrid			2022-12-27	WOS:000237134700084
J	Aboulaich, N; Vener, AV; Stralfors, P				Aboulaich, N; Vener, AV; Stralfors, P			Hormonal control of reversible translocation of perilipin B to the plasma membrane in primary human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SENSITIVE LIPASE; RAT ADIPOCYTES; STIMULATED LIPOLYSIS; LIPID DROPLETS; PHOSPHORYLATION; CAVEOLAE; INSULIN; DOMAINS	In adipocytes, perilipin coats and protects the central lipid droplet, which stores triacylglycerol. Alternative mRNA splicing gives rise to perilipin A and B. Hormones such as catecholamines and insulin regulate triacylglycerol metabolism through reversible serine phosphorylation of perilipin A. It was recently shown that perilipin was also located in triacylglycerol-synthesizing caveolae of the plasma membrane. We now report that perilipin at the plasma membrane of primary human adipocytes was phosphorylated on a cluster of threonine residues ( 299, 301, and 306) within an acidic domain that forms part of the lipid targeting domain. Perilipin B comprised <10% of total perilipin but was the major isoform associated with the plasma membrane of human adipocytes. This association was controlled by insulin and catecholamine: perilipin B was specifically depleted from the plasma membrane in response to the catecholamine isoproterenol, while insulin increased the amount of threonine phosphorylated perilipin at the plasma membrane. The reversible translocation of perilipin B to and from the plasma membrane in response to insulin and isoproterenol, respectively, suggests a specific function for perilipin B to protect newly synthesized triacylglycerol in the plasma membrane.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Ctr Diabet Res, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Stralfors, Peter/0000-0002-1196-1806				Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Clifford GM, 1997, BIOCHEM SOC T, V25, pS672, DOI 10.1042/bst025s672; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; MOONEY RA, 1991, BIOCHEM J, V274, P433, DOI 10.1042/bj2740433; OKA Y, 1984, J BIOL CHEM, V259, P8125; Ost A, 2005, J BIOL CHEM, V280, P5, DOI 10.1074/jbc.C400429200; Robenek H, 2005, J BIOL CHEM, V280, P26330, DOI 10.1074/jbc.M413312200; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Vainonen JP, 2004, BIOCHEM BIOPH RES CO, V320, P480, DOI 10.1016/j.bbrc.2004.05.196; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	22	31	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11446	11449		10.1074/jbc.C500461200	http://dx.doi.org/10.1074/jbc.C500461200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16527823	hybrid			2022-12-27	WOS:000236988100004
J	Sao-Jose, C; Lhuillier, S; Lurz, R; Melki, R; Lepault, J; Santos, MA; Tavares, P				Sao-Jose, C; Lhuillier, S; Lurz, R; Melki, R; Lepault, J; Santos, MA; Tavares, P			The ectodomain of the viral receptor YueB forms a fiber that triggers ejection of bacteriophage SPP1 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS 168; COILED-COIL STRUCTURE; CELL-WALL; PROTEIN; PHAGE; ADSORPTION; RESOLUTION; MECHANISM; TRANSPORT; RELEASE	The irreversible binding of bacteriophages to their receptor( s) in the host cell surface triggers release of the naked genome from the virion followed by transit of viral DNA to the host cell cytoplasm. We have purified, for the first time, a receptor from a Gram-positive bacterium that is active to trigger viral DNA ejection in vitro. This extracellular region ("ectodomain") of the Bacillus subtilis protein YueB ( YueB780) was a 7 S elongated dimer forming a 36.5-nm-long fiber. YueB780 bound to the tail tip of bacteriophage SPP1. Although a stable receptor-phage interaction occurred between 0 and 37 degrees C, complete blocking of phage DNA release or partial ejection events were observed at temperatures below 15 degrees C. We also showed that the receptor was exposed to the B. subtilis surface. YueB differed structurally from phage receptors from Gram-negative bacteria. Its properties revealed a fiber spanning the full length of the 30-nm-thick peptidoglycan layer. The fiber is predicted to be anchored in the cell membrane through transmembrane segments. These features, highly suitable for a virus receptor in Gram-positive bacteria, are very likely shared by a large number of phage receptors.	CNRS, INRA, UMR 1157,UMR 2472, Unite Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Fac Ciencias Lisboa, Inst Ciencia Aplicada & Tecnol, P-1749016 Lisbon, Portugal; Dept Biol Vegetal, Inst Ciencia Aplicada & Tecnol, P-1749016 Lisbon, Portugal; Inst Federat Rech 115, F-91198 Gif Sur Yvette, France; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universidade de Lisboa; Universidade de Lisboa; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Tavares, P (corresponding author), CNRS, INRA, UMR 1157,UMR 2472, Unite Virol Mol & Struct, Bat 14B,Av Terrasse, F-91198 Gif Sur Yvette, France.	tavares@vmc.cnrs-gif.fr	Sao-Jose, Carlos Jorge/J-6703-2012; iMed.ULisboa, M2B/B-5277-2014; Lepault, Jean/AAN-8859-2020	Sao-Jose, Carlos Jorge/0000-0002-4890-9446; iMed.ULisboa, M2B/0000-0002-1245-3715; Santos, Mario/0000-0002-9447-1553; Tavares, Paulo/0000-0002-2566-4546				Adams MH, 1959, BACTERIOPHAGES; Andrews D, 2005, J BIOL CHEM, V280, P5929, DOI 10.1074/jbc.C400513200; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Davison S, 2005, J BACTERIOL, V187, P6742, DOI 10.1128/JB.187.19.6742-6749.2005; de Frutos M, 2005, EUR PHYS J E, V17, P429, DOI 10.1140/epje/i2005-10019-5; de Frutos M, 2005, BIOPHYS J, V88, P1364, DOI 10.1529/biophysj.104.048785; EFIMOV VP, 1994, J MOL BIOL, V242, P470, DOI 10.1006/jmbi.1994.1595; Evilevitch A, 2003, P NATL ACAD SCI USA, V100, P9292, DOI 10.1073/pnas.1233721100; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GELLER BL, 1993, J BACTERIOL, V175, P5510, DOI 10.1128/JB.175.17.5510-5519.1993; GRAHAM LL, 1994, J BACTERIOL, V176, P1413, DOI 10.1128/jb.176.5.1413-1421.1994; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; JACOBSON ED, 1977, J VIROL, V21, P1223, DOI 10.1128/JVI.21.3.1223-1227.1977; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Kemp P, 2004, MOL MICROBIOL, V53, P1251, DOI 10.1111/j.1365-2958.2004.04204.x; LEPAULT J, 1981, J MOL BIOL, V149, P275, DOI 10.1016/0022-2836(81)90302-8; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lurz R, 2001, J MOL BIOL, V310, P1027, DOI 10.1006/jmbi.2001.4800; MACKAY DJ, 1976, VIROLOGY, V72, P167, DOI 10.1016/0042-6822(76)90321-4; Mangenot S, 2005, CURR BIOL, V15, P430, DOI 10.1016/j.cub.2004.12.080; MONTEVILLE MR, 1994, APPL ENVIRON MICROB, V60, P3204, DOI 10.1128/AEM.60.9.3204-3211.1994; Orlova EV, 2003, EMBO J, V22, P1255, DOI 10.1093/emboj/cdg123; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; Poranen MM, 2002, ANNU REV MICROBIOL, V56, P521, DOI 10.1146/annurev.micro.56.012302.160643; PORTMANN R, 1974, FEBS LETT, V45, P646; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; SANTOS MA, 1983, J GEN MICROBIOL, V129, P3499; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STEVEN AC, 1988, J MOL BIOL, V200, P351, DOI 10.1016/0022-2836(88)90246-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; Vinga I, 2006, BACTERIOPHAGE BIOL B, P165; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8; [No title captured]	39	86	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11464	11470		10.1074/jbc.M513625200	http://dx.doi.org/10.1074/jbc.M513625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16481324	Green Published, hybrid			2022-12-27	WOS:000236988100007
J	Ge, GX; Zhang, Y; Steiglitz, BM; Greenspan, DS				Ge, GX; Zhang, Y; Steiglitz, BM; Greenspan, DS			Mammalian tolloid-like 1 binds procollagen C-proteinase enhancer protein 1 and differs from bone morphogenetic protein 1 in the functional roles of homologous protein domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; TERMINAL PROTEINASE; MOUSE FIBROBLASTS; GENE; DROSOPHILA; IDENTIFICATION; PURIFICATION; BMP-1; METALLOPROTEINASES; EXPRESSION	Bone morphogenetic protein 1 (BMP1) is the prototype of a subgroup of metalloproteinases with manifold roles in morphogenesis. Four mammalian subgroup members exist, including BMP1 and mammalian Tolloid-like 1 (mTLL1). Subgroup members have a conserved protein domain structure: an NH2-terminal astacin-like protease domain, followed by a fixed order of CUB and epidermal growth factor-like protein-protein interaction motifs. Previous structure/function studies have documented those BMP1 protein domains necessary for secretion, and activity against various substrates. Here we demonstrate that, in contradiction to previous reports, the most NH2-terminal CUB domain (CUB1) is not required for BMP1 secretion nor is the next CUB domain (CUB2) required for enzymatic activity. The same is true for mTLL1. In fact, secreted protease domains of BMP1 and mTLL1, devoid of CUB or epidermal growth factor-like domains, have procollagen C-proteinase (pCP) activity and activity for biosynthetic processing of biglycan, the latter with kinetics superior to those of the full-length proteins. Structure-function analyses herein also suggest differences in the functional roles played by some of the homologous domains in BMP1 and mTLL1. Surprisingly, although BMP1 has long been known to be Ca2+-dependent, a property previously assumed to apply to all members of the subgroup, mTLL1 is demonstrated to be independent of Ca-2 levels in its ability to cleave some, but not all, substrates. We also show that pCP activities of only versions of BMP1 and mTLL1 with intact COOH termini are enhanced by the procollagen C-proteinase enhancer 1 (PCOLCE1) and that mTLL1 binds PCOLCE1, thus suggesting reappraisal of the accepted paradigm for how PCOLCE1 enhances pCP activities.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu		Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Clark TG, 1999, DEVELOPMENT, V126, P2631; Dale L, 2002, MECH DEVELOP, V119, P177, DOI 10.1016/S0925-4773(02)00359-3; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Ge GX, 2005, MOL CELL BIOL, V25, P5846, DOI 10.1128/MCB.25.14.5846-5858.2005; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; GREENSPAN DS, 2004, HDB PROTEOLYTIC ENZY, P621; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Lin JJ, 1997, DEV GROWTH DIFFER, V39, P43; Moali C, 2005, J BIOL CHEM, V280, P24188, DOI 10.1074/jbc.M501486200; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Petropoulou V, 2005, J BIOL CHEM, V280, P22616, DOI 10.1074/jbc.M413468200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Serpe M, 2005, DEVELOPMENT, V132, P2645, DOI 10.1242/dev.01838; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200	31	26	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10786	10798		10.1074/jbc.M511111200	http://dx.doi.org/10.1074/jbc.M511111200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16507574	hybrid			2022-12-27	WOS:000236822200018
J	Wesche, J; Malecki, J; Wiedlocha, A; Skjerpen, CS; Claus, P; Olsnes, S				Wesche, J; Malecki, J; Wiedlocha, A; Skjerpen, CS; Claus, P; Olsnes, S			FGF-1 and FGF-2 require the cytosolic chaperone Hsp90 for translocation into the cytosol and the cell nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; PROTEIN TRANSLOCATION; TOXIN; TRANSPORT; RADICICOL; MEMBRANES; MUTANTS; COMPLEX; ENTRY; AFGF	Similarly to many protein toxins, the growth factors fibroblast growth factor 1 (FGF-1) and FGF-2 translocate from endosomes into the cytosol. It was recently found that certain toxins are dependent on cytosolic Hsp90 for efficient translocation across the endosomal membrane. We therefore investigated the requirement for Hsp90 in FGF translocation. We found that low concentrations of the specific Hsp90 inhibitors, geldanamycin and radicicol, completely blocked the translocation of FGF-1 and FGF-2 to the cytosol and the nucleus. The drugs did not interfere with the initial binding of FGF-1 to the growth factor receptors at the cell-surface or with the subsequent internalization of the growth factors into endosomes. The activation of known signaling cascades downstream of the growth factor receptors was also not affected by the drugs. The data indicate that the drugs block translocation from endosomes to the cytosol implying that Hsp90 is required for translocation of FGF-1 and FGF-2 across the endosomal membrane.	Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway; Hannover Med Sch, Dept Neuroanat, D-30625 Hannover, Germany	University of Oslo; Hannover Medical School	Wesche, J (corresponding author), Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.	jorgen.wesche@labmed.uio.no	Wesche, Jorgen/ABH-7524-2020; Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445; Wesche, Jorgen/0000-0002-9200-9162; Malecki, Jedrzej/0000-0003-0825-7962				Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Haug G, 2004, INFECT IMMUN, V72, P3066, DOI 10.1128/IAI.72.5.3066-3068.2004; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; Thomas-Mudge RJ, 2004, ONCOGENE, V23, P4771, DOI 10.1038/sj.onc.1207638; Wesche J, 2005, BIOCHEMISTRY-US, V44, P6071, DOI 10.1021/bi047403m; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wesche J, 2000, BIOCHEMISTRY-US, V39, P15091, DOI 10.1021/bi001831k; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 2005, MOL BIOL CELL, V16, P794; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	30	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11405	11412		10.1074/jbc.M600477200	http://dx.doi.org/10.1074/jbc.M600477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495214	hybrid			2022-12-27	WOS:000236822200083
J	Zhuang, DZ; Qiu, YL; Kogan, SC; Dong, F				Zhuang, DZ; Qiu, YL; Kogan, SC; Dong, F			Increased CCAAT enhancer-binding protein epsilon(C/EBP epsilon) expression and premature apoptosis in myeloid cells expressing Gfi-1 N382S mutant associated with severe congenital neutropenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING-FACTOR; G-CSF RECEPTOR; ZINC-FINGER PROTEIN; DISTINCT CYTOPLASMIC REGIONS; HEMATOPOIETIC STEM-CELLS; TRANSCRIPTIONAL REPRESSOR; GENE; DIFFERENTIATION; MUTATIONS; LEUKEMIA	Granulocyte-colony-stimulating factor (G-CSF) stimulates the activation of multiple signaling pathways, leading to alterations in the activities of transcription factors. Gfi-1 is a zinc finger transcriptional repressor that is required for granulopoiesis. How Gfi-1 acts in myeloid cells is poorly understood. We show here that the expression of Gfi-1 was up-regulated during G-CSF-induced granulocytic differentiation in myeloid 32D cells. Truncation of the carboxyl terminus of the G-CSF receptor, as seen in patients with acute myeloid leukemia evolving from severe congenital neutropenia, disrupted Gfi-1 up-regulation by G-CSF. Ectopic expression of a dominant negative Gfi-1 mutant, N382S, which was associated with severe congenital neutropenia, resulted in premature apoptosis and reduced proliferation of cells induced to differentiate with G-CSF. The expression of neutrophil elastase (NE) and CCAAT enhancer-binding protein epsilon (C/EBP epsilon) was significantly increased in 32D cells expressing N382S. In contrast, overexpression of wild type Gfi-1 abolished G-CSF-induced up-regulation of C/EBP epsilon but had no apparent effect on NE up-regulation by G-CSF. Notably, G-CSF-dependent proliferation and survival were inhibited upon overexpression of C/EBP epsilon but not NE. These data indicate that Gfi-1 down-regulates C/EBP epsilon expression and suggest that increased expression of C/EBP epsilon as a consequence of loss of Gfi-1 function may be deleterious to the proliferation and survival of early myeloid cells.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University System of Ohio; University of Toledo; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Dong, F (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	fdong@utnet.utoledo.edu		Kogan, Scott/0000-0002-2395-8479	NATIONAL CANCER INSTITUTE [R01CA092172] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA92172, R01 CA092172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbarzadeh S, 2001, VITAM HORM, V63, P159, DOI 10.1016/S0083-6729(01)63006-1; Aprikyan AAG, 2003, EXP HEMATOL, V31, P372, DOI 10.1016/S0301-472X(03)00048-1; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Bellanne-Chantelot C, 2004, BLOOD, V103, P4119, DOI 10.1182/blood-2003-10-3518; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dale DC, 2003, AM J HEMATOL, V72, P82, DOI 10.1002/ajh.10255; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Dong F, 1997, LEUKEMIA, V11, P120, DOI 10.1038/sj.leu.2400537; Dong F, 1998, J IMMUNOL, V161, P6503; Dong F, 1996, EXP HEMATOL, V24, P214; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Horwitz M, 2004, TRENDS MOL MED, V10, P163, DOI 10.1016/j.molmed.2004.02.002; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Massullo P, 2005, BLOOD, V105, P3397, DOI 10.1182/blood-2004-07-2618; Mitsui T, 2003, BLOOD, V101, P2990, DOI 10.1182/blood.V101.8.2990; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Moroy T, 2005, INT J BIOCHEM CELL B, V37, P541, DOI 10.1016/j.biocel.2004.08.011; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Qiu YL, 2005, LEUKEMIA RES, V29, P1153, DOI 10.1016/j.leukres.2005.03.005; SCOTT LM, 1992, BLOOD, V80, P1725; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tidow N, 1997, BLOOD, V89, P2369, DOI 10.1182/blood.V89.7.2369; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zhuang DZ, 2005, J LEUKOCYTE BIOL, V78, P1008, DOI 10.1189/jlb.0105032; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	46	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10745	10751		10.1074/jbc.M510924200	http://dx.doi.org/10.1074/jbc.M510924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500901	hybrid			2022-12-27	WOS:000236822200013
J	Rybakova, IN; Humston, JL; Sonnemann, KJ; Ervasti, JM				Rybakova, IN; Humston, JL; Sonnemann, KJ; Ervasti, JM			Dystrophin and utrophin bind actin through distinct modes of contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MDX MICE; SKELETAL-MUSCLE; F-ACTIN; GLYCOPROTEIN COMPLEX; MUSCULAR-DYSTROPHY; FULL-LENGTH; DOMAIN; EXPRESSION; PROTEIN; SARCOLEMMA	This study was designed to define the molecular epitopes of dystrophin-actin interaction and to directly compare the actin binding properties of dystrophin and utrophin. According to our data, dystrophin and utrophin both bound alongside actin filaments with sub-micromolar affinities. However, the molecular epitopes involved in actin binding differed between the two proteins. In utrophin, the amino-terminal domain and an adjacent string of the first 10 spectrin-like repeats more fully recapitulated the activities measured for full-length protein. The homologous region of dystrophin bound actin with low affinity and near 1: 1 stoichiometry as previously measured for the isolated amino-terminal, tandem ( CH) domain. In contrast, a dystrophin construct including a cluster of basic spectrin-like repeats and spanning from the amino terminus through repeat 17, bound actin with properties most similar to full-length dystrophin. Dystrophin and utrophin both stabilized preformed actin filaments from forced depolymerization with similar efficacies but did not appear to compete for binding sites on actin. We also found that dystrophin binding to F-actin was markedly sensitive to increasing ionic strength, although utrophin binding was unaffected. Although dystrophin and utrophin are functionally homologous actin-binding proteins, these results indicate that their respective modes of contact with actin filaments are markedly different. Finally, we reassessed the abundance of dystrophin in striated muscle using full-length protein as the standard and measured greater than 10-fold higher values than previously reported.	Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, 1300 Univ Ave, Madison, WI 53706 USA.	ervasti@physiology.wisc.edu	Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [AR 042423] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; BARCHI RL, 1979, J PHYSIOL-LONDON, V295, P383, DOI 10.1113/jphysiol.1979.sp012975; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; CLERK A, 1993, HISTOCHEM J, V25, P554; CLERK A, 1992, DEVELOPMENT, V114, P395; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Ishikawa-Sakurai M, 2004, HUM MOL GENET, V13, P693, DOI 10.1093/hmg/ddh087; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Iwata Y, 1998, FEBS LETT, V423, P173, DOI 10.1016/S0014-5793(98)00085-4; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; McDearmon EL, 2001, J BIOL CHEM, V276, P35078, DOI 10.1074/jbc.M103843200; Moores CA, 2000, CELL MOTIL CYTOSKEL, V46, P116, DOI 10.1002/1097-0169(200006)46:2<116::AID-CM4>3.0.CO;2-L; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Radojevic V, 2000, CELL TISSUE RES, V300, P447, DOI 10.1007/s004410000213; Renley BA, 1998, CELL MOTIL CYTOSKEL, V41, P264, DOI 10.1002/(SICI)1097-0169(1998)41:3<264::AID-CM7>3.3.CO;2-Q; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Rybakova IN, 2005, J BIOL CHEM, V280, P23018, DOI 10.1074/jbc.M502530200; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 2002, MOL BIOL CELL, V13, P1512, DOI 10.1091/mbc.01-09-0446; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, J CELL SCI, V108, P63	30	75	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9996	10001		10.1074/jbc.M513121200	http://dx.doi.org/10.1074/jbc.M513121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478721	hybrid			2022-12-27	WOS:000236594300022
J	Schneiders, T; Levy, SB				Schneiders, T; Levy, SB			MarA-mediated transcriptional repression of the rob promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; ORGANIC-SOLVENT TOLERANCE; ESCHERICHIA-COLI SOXS; RNA-POLYMERASE; DNA-BINDING; COMPLEX-FORMATION; P-R; PROTEIN; ACTIVATION; EXPRESSION	The Escherichia coli transcriptional regulator MarA affects functions that include antibiotic resistance, persistence, and survival. MarA functions as an activator or repressor of transcription utilizing similar degenerate DNA sequences (marboxes) with three different binding site configurations with respect to the RNA polymerase-binding sites. We demonstrate that MarA down-regulates rob transcripts both in vivo and in vitro via a MarA-binding site within the rob promoter that is positioned between the -10 and -35 hexamers. As for the hdeA and purA promoters, which are repressed by MarA, the rob marbox is also in the "backward" orientation. Protein-DNA interactions show that SoxS and Rob, like MarA, bind the same marbox in the rob promoter. Electrophoretic mobility shift analyses with a MarA-specific antibody demonstrate that MarA and RNA polymerase form a ternary complex with the rob promoter DNA. Transcription experiments in vitro and potassium permanganate footprinting analysis show that MarA affects the RNA polymerase-mediated closed to open complex formation at the rob promoter.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.	stuart.levy@tufts.edu		Schneiders, Thamarai/0000-0002-7758-7925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 56021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali Azam T., 1999, J BACTERIOL, V181, P6361; ANSARI AZ, 1995, NATURE, V374, P371; ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; Azam TA, 2000, GENES CELLS, V5, P613, DOI 10.1046/j.1365-2443.2000.00350.x; Bennik MHJ, 2000, J BACTERIOL, V182, P3794, DOI 10.1128/JB.182.13.3794-3801.2000; Dangi B, 2004, MOL MICROBIOL, V54, P45, DOI 10.1111/j.1365-2958.2004.04250.x; Escolar L, 1997, MOL MICROBIOL, V26, P799, DOI 10.1046/j.1365-2958.1997.6211987.x; Gillette WK, 2000, J MOL BIOL, V299, P1245, DOI 10.1006/jmbi.2000.3827; GRALLA JD, 1996, ESCHERICHIA COLI SAL, V1, P1232; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; Griffith KL, 2002, BIOCHEM BIOPH RES CO, V291, P979, DOI 10.1006/bbrc.2002.6559; Griffith KL, 2001, MOL MICROBIOL, V40, P1141, DOI 10.1046/j.1365-2958.2001.02456.x; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; Jair KW, 1996, J BACTERIOL, V178, P2507, DOI 10.1128/jb.178.9.2507-2513.1996; KAKEDA M, 1995, MOL GEN GENET, V248, P629, DOI 10.1007/BF02423459; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Li ZY, 1996, MOL MICROBIOL, V20, P937, DOI 10.1111/j.1365-2958.1996.tb02535.x; Martin RG, 1996, J BACTERIOL, V178, P2216, DOI 10.1128/jb.178.8.2216-2223.1996; Martin RG, 1999, MOL MICROBIOL, V34, P431, DOI 10.1046/j.1365-2958.1999.01599.x; Martin RG, 2002, MOL MICROBIOL, V43, P355, DOI 10.1046/j.1365-2958.2002.02748.x; Martin RG, 2002, MOL MICROBIOL, V44, P1611, DOI 10.1046/j.1365-2958.2002.02985.x; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Michan C, 2002, J BACTERIOL, V184, P4733, DOI 10.1128/JB.184.17.4733-4738.2002; MILLER PF, 1994, ANTIMICROB AGENTS CH, V38, P1773, DOI 10.1128/AAC.38.8.1773; Monsalve M, 1998, J MOL BIOL, V283, P559, DOI 10.1006/jmbi.1998.2084; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; NAKAJIMA H, 1995, APPL ENVIRON MICROB, V61, P2302, DOI 10.1128/AEM.61.6.2302-2307.1995; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Rosenberg EY, 2003, MOL MICROBIOL, V48, P1609, DOI 10.1046/j.1365-2958.2003.03531.x; Rosner JL, 2002, J BACTERIOL, V184, P1407, DOI 10.1128/JB.184.5.1407-1416.2002; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; Savery N. J., 1996, ESSENTIAL TECHNIQUES, P1; Schneiders T, 2004, J BIOL CHEM, V279, P9037, DOI 10.1074/jbc.M313602200; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; White DG, 1997, J BACTERIOL, V179, P6122, DOI 10.1128/jb.179.19.6122-6126.1997; Xu J, 2000, J BACTERIOL, V182, P3165, DOI 10.1128/JB.182.11.3165-3174.2000; Xu J, 2001, J MOL BIOL, V309, P573, DOI 10.1006/jmbi.2001.4702; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x	46	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10049	10055		10.1074/jbc.M512097200	http://dx.doi.org/10.1074/jbc.M512097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478729	hybrid			2022-12-27	WOS:000236594300029
J	van Bloois, E; Haan, GJ; de Gier, JW; Oudega, B; Luirink, J				van Bloois, E; Haan, GJ; de Gier, JW; Oudega, B; Luirink, J			Distinct requirements for translocation of the N-tail and C-tail of the Escherichia coli inner membrane protein CyoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; SYNTHASE SUBUNIT-C; UBIQUINOL OXIDASE; NASCENT MEMBRANE; YIDC; INSERTION; EXPORT; BIOGENESIS; SECY; LIPOPROTEINS	Inner membrane proteins (IMPs) of Escherichia coli use different pathways for membrane targeting and integration. YidC plays an essential but poorly defined role in the integration and folding of IMPs both in conjunction with the Sec translocon and as a Sec-independent insertase. Depletion of YidC only marginally affects the insertion of Sec-dependent IMPs, whereas it blocks the insertion of a subset of Sec-independent IMPs. Substrates of this latter "YidC-only" pathway include the relatively small IMPs M13 procoat, Pf3 coat protein, and subunit c of the F1F0 ATPase. Recently, it has been shown that the steady state level of the larger and more complex CyoA subunit of the cytochrome o oxidase is also severely affected upon depletion of YidC. In the present study we have analyzed the biogenesis of the integral lipoprotein CyoA. Collectively, our data suggest that the first transmembrane segment of CyoA rather than the signal sequence recruits the signal recognition particle for membrane targeting. Membrane integration and assembly appear to occur in two distinct sequential steps. YidC is sufficient to catalyze insertion of the N-terminal domain consisting of the signal sequence, transmembrane segment 1, and the small periplasmic domain in between. Translocation of the large C-terminal periplasmic domain requires the Sec translocon and SecA, suggesting that for this particular IMP the Sec translocon might operate downstream of YidC.	Vrije Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Vrije Universiteit Amsterdam; Stockholm University	Luirink, J (corresponding author), Vrije Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl	Luirink, Joen/AAB-8658-2021	Luirink, J./0000-0001-8431-0804				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2005, BIOCHEMISTRY-US, V44, P10741, DOI 10.1021/bi047418k; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Funes S, 2004, MOL BIOL CELL, V15, P1853, DOI 10.1091/mbc.e03-11-0789; GIER JW, 2005, ANNU REV MICROBIOL, V59, P329; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LEE JI, 1992, J BIOL CHEM, V267, P938; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Preuss M, 2005, J BIOL CHEM, V280, P13004, DOI 10.1074/jbc.M414093200; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; Tian HP, 2002, J BACTERIOL, V184, P111, DOI 10.1128/JB.184.1.111-118.2002; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; van Bloois E, 2005, J BIOL CHEM, V280, P12996, DOI 10.1074/jbc.M414094200; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Yi L, 2004, J BIOL CHEM, V279, P39260, DOI 10.1074/jbc.M405490200; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	46	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10002	10009		10.1074/jbc.M511357200	http://dx.doi.org/10.1074/jbc.M511357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481320	hybrid, Green Published			2022-12-27	WOS:000236594300023
J	Mazurkiewicz, J; Kepert, JF; Rippe, K				Mazurkiewicz, Jacek; Kepert, J. Felix; Rippe, Karsten			On the mechanism of nucleosome assembly by histone chaperone NAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; DNA-REPLICATION; CORE PARTICLE; H2A-H2B DIMERS; H2A/H2B DIMER; IN-VITRO; CHROMATIN; PROTEIN; H2A.Z; VARIANT	The process of mononucleosome assembly mediated by histone chaperone NAP1 was investigated using DNA fragments 146 and 207 bp in length containing the Lytechinus variegatus 5 S rDNA nucleosome positioning sequence. A quantitative description was derived using gel electrophoresis and fluorescent anisotropy data. First, NAP1-bound H3.H4 was released forming a DNA-histone tetramer complex with a time constant of k(1) = (2.5 +/- 0.7) . 10(M)(4)(-1) s(-1). The tetrasome was converted quickly (k(2) = (4.1 +/- 3.5) . 10(5) (-1)(M) s(-1)), by the addition of a single H2A.H2B dimer, into a "hexasome," i.e. a nucleosome lacking one H2A.H2B dimer. From this intermediate a nucleosome was formed by the addition of a second H2A.H2B dimer with an average rate constant k(3) = (6.6 +/- 1.4) . 10(3) M-1 s(-1). For the back-reaction, significant differences were observed between the 146- and 207-bp DNA upon substitution of the canonical H2A histone with H2A.Z. The distinct nucleosome/ hexasome ratios were reflected in the corresponding equilibrium dissociation constants and revealed some differences in nucleosome stability. In a fourth reaction, NAP1 mediated the binding of linker histone H1 to the nucleosome, completing the chromatosome structure with k(4) = (7.7 +/- 3.7) . 10(M)(3)(-1) s(-1). The activity of the chromatin remodeling complex ACF did not increase the kinetics of the mononucleosome assembly process.	Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Rippe, K (corresponding author), Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, Neuenheimer Feld 227, D-69120 Heidelberg, Germany.	Karsten.Rippe@kip.uni-heidelberg.de	Rippe, Karsten/A-3562-2012	Rippe, Karsten/0000-0001-9951-9395				Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Annunziato AT, 2005, J BIOL CHEM, V280, P12065, DOI 10.1074/jbc.R400039200; ANNUNZIATO AT, 1984, NUCLEIC ACIDS RES, V12, P6179, DOI 10.1093/nar/12.15.6179; Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; BONNER WM, 1975, J CELL BIOL, V64, P431, DOI 10.1083/jcb.64.2.431; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CREMISI C, 1980, BIOCHEM BIOPH RES CO, V92, P1117, DOI 10.1016/0006-291X(80)90402-7; DABAN JR, 1982, J MOL BIOL, V156, P749, DOI 10.1016/0022-2836(82)90140-1; DABAN JR, 1982, J MOL BIOL, V156, P771, DOI 10.1016/0022-2836(82)90141-3; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Dryhurst D, 2004, BIOCHEM CELL BIOL, V82, P490, DOI 10.1139/O04-043; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6930, DOI 10.1021/bi00345a027; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; JORCANO JL, 1979, BIOCHEMISTRY-US, V18, P768, DOI 10.1021/bi00572a005; Kepert JF, 2005, J BIOL CHEM, V280, P34063, DOI 10.1074/jbc.M507322200; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; Ladoux B, 2000, P NATL ACAD SCI USA, V97, P14251, DOI 10.1073/pnas.250471597; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P308; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PARK YJ, 2004, J BIOL CHEM; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Pennings S, 1997, METHODS, V12, P20, DOI 10.1006/meth.1997.0443; Pennings S, 1999, METHOD ENZYMOL, V304, P298; Prado A, 2004, BIOCHEM CELL BIOL, V82, P437, DOI 10.1139/O04-042; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SENSHU T, 1978, J BIOCHEM-TOKYO, V84, P985, DOI 10.1093/oxfordjournals.jbchem.a132213; SHERWOOD PW, 1991, GENETICS, V128, P729; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Strohner R, 2005, NAT STRUCT MOL BIOL, V12, P683, DOI 10.1038/nsmb966; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; Toth KF, 2005, J BIOL CHEM, V280, P15690, DOI 10.1074/jbc.M413329200; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VANHOLDE KE, 1989, CHROMATIN, P241; Verreault A, 2000, GENE DEV, V14, P1430; Vogel SK, 2002, NUCLEIC ACIDS RES, V30, P4094, DOI 10.1093/nar/gkf519; Wagner G, 2005, BIOPHYS J, V89, P3647, DOI 10.1529/biophysj.105.062786; Weidemann T, 2003, J MOL BIOL, V334, P229, DOI 10.1016/j.jmb.2003.08.063; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WILHELM FX, 1978, NUCLEIC ACIDS RES, V5, P505, DOI 10.1093/nar/5.2.505; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; Yodh JG, 2002, BIOCHEMISTRY-US, V41, P3565, DOI 10.1021/bi011612e; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90	89	78	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16462	16472		10.1074/jbc.M511619200	http://dx.doi.org/10.1074/jbc.M511619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16531623	Green Submitted, hybrid			2022-12-27	WOS:000238165700036
J	Boll, R; Hofmann, C; Heitmann, B; Hauser, G; Glaser, S; Koslowski, T; Friedrich, T; Bechthold, A				Boll, Raija; Hofmann, Carsten; Heitmann, Bjoern; Hauser, Gerd; Glaser, Steffen; Koslowski, Thorsten; Friedrich, Thorsten; Bechthold, Andreas			The active conformation of avilamycin A is conferred by AviX12, a radical AdoMet enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI; H-1-NMR SPECTRA; BIOSYNTHESIS; STREPTOMYCES; EVERNIMICIN; SUBUNIT; SPECTROSCOPY; ANTIBIOTICS; EUREKANATE	The antibiotic avilamycin A is produced by Streptomyces virido-chromogenes Tu57. Avilamycin belongs to the family of orthosomycins with a linear heptasaccharide chain linked to a terminal dichloroisoeverninic acid as aglycone. The gene cluster for avilamycin biosynthesis contains 54 open reading frames. Inactivation of one of these genes, namely aviX12, led to the formation of a novel avilamycin derivative named gavibamycin N1. The structure of the new metabolite was confirmed by mass spectrometry ( MS) and NMR analysis. It harbors glucose as a component of the heptasaccharide chain instead of a mannose moiety in avilamycin A. Antibacterial activity tests against a spectrum of Gram-positive organisms showed that the new derivative possesses drastically decreased biological activity in comparison to avilamycin A. Thus, AviX12 seems to be implicated in converting avilamycin to its bioactive conformation by catalyzing an unusual epimerization reaction. Sequence comparisons grouped AviX12 in the radical S-adenosylmethionine protein family. AviX12 engineered with a His tag was overexpressed in Escherichia coli and purified by affinity chromatography. The iron sulfur cluster [Fe-S] present in radical AdoMet enzymes was detected in purified AviX12 by means of electron paramagnetic resonance spectroscopy.	Univ Freiburg, Inst Pharmazeut Wissensch Pharmazeut Biol & Biote, D-79104 Freiburg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg; Technical University of Munich; University of Freiburg; University of Freiburg	Bechthold, A (corresponding author), Univ Freiburg, Inst Pharmazeut Wissensch Pharmazeut Biol & Biote, Stefan Meier Str 19, D-79104 Freiburg, Germany.	andreas.bechthold@pharmazie.uni-freiburg.de	Bechthold, Andreas/P-4199-2019; Glaser, Steffen J/B-7335-2009	Glaser, Steffen J/0000-0003-4099-3177; Heitmann, Berit Lilienthal/0000-0002-6809-4504				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belova L, 2001, P NATL ACAD SCI USA, V98, P3726, DOI 10.1073/pnas.071527498; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEWIT CJ, 1992, J AM CHEM SOC, V114, P10035, DOI 10.1021/ja00051a041; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Hoffmeister D, 2001, CHEM BIOL, V8, P557, DOI 10.1016/S1074-5521(01)00039-4; Hofmann C, 2005, CHEM BIOL, V12, P1137, DOI 10.1016/j.chembiol.2005.08.016; Hopwood D.A., 1985, GENETIC MANIPULATION; Kofoed CB, 2002, ANTIMICROB AGENTS CH, V46, P3339, DOI 10.1128/AAC.46.11.3339-3342.2002; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; McNicholas PM, 2000, ANTIMICROB AGENTS CH, V44, P1121, DOI 10.1128/AAC.44.5.1121-1126.2000; McNicholas PM, 2001, ANTIMICROB AGENTS CH, V45, P79, DOI 10.1128/AAC.45.1.79-83.2001; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; Pelter S, 1997, J BIOTECHNOL, V56, P115, DOI 10.1016/S0168-1656(97)00082-5; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; THOMPSON MA, 1994, J PHYS CHEM-US, V98, P10465, DOI 10.1021/j100092a015; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; Treede I, 2005, APPL ENVIRON MICROB, V71, P400, DOI 10.1128/AEM.71.1.400-406.2005; Treede I, 2003, MOL MICROBIOL, V49, P309, DOI 10.1046/j.1365-2958.2003.03558.x; Weitnauer G, 2004, CHEM BIOL, V11, P1403, DOI 10.1016/j.chembiol.2004.08.016; Weitnauer G, 2001, CHEM BIOL, V8, P569, DOI 10.1016/S1074-5521(01)00040-0; WRIGHT DE, 1979, TETRAHEDRON, V35, P1207, DOI 10.1016/0040-4020(79)80046-0; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	30	23	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14756	14763		10.1074/jbc.M601508200	http://dx.doi.org/10.1074/jbc.M601508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16537546	Green Published, hybrid			2022-12-27	WOS:000237671300029
J	Dittmer, A; Vetter, M; Schunke, D; Span, PN; Sweep, F; Thomssen, C; Dittmer, J				Dittmer, Angela; Vetter, Martina; Schunke, Dario; Span, Paul N.; Sweep, Fred; Thomssen, Christoph; Dittmer, Jurgen			Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; PTH-RELATED PROTEIN; BONE METASTASES; NUCLEAR-LOCALIZATION; INTRACRINE PATHWAY; CARCINOMA INVASION; IMPORTIN BETA; SMOOTH-MUSCLE; EXPRESSION; RECEPTOR	The effect of endogenous parathyroid hormone-related protein (PTHrP) on gene expression in breast cancer cells was studied. We suppressed PTHrP expression in MDA-MB-231 cells by RNA interference and analyzed changes in gene expression by microarray analysis. More than 200 genes showed altered expression in response to a PTHrP-specific small interfering (si) RNA (siPTHrP). Cell cycle-regulating gene CDC2 and genes (CDC25B and Tome-1) that control CDC2 activity showed increased expression in the presence of siPTHrP. CDC2 activity was also found to be higher in siPTHrP-treated cells. Studies with PTHrP peptides 1-34 and 67-86, forskolin, and a PTH1 receptor (PTH1R)-specific siRNA showed that PTHrP regulates CDC2 and CDC25B, at least in part, via PTH1R in a cAMP-independent manner. Other siPTHrP-responsive genes included integrin alpha 6 (ITGA6), KISS-1, and PAI-1. When combined, siRNAs against ITGA6, PAI-1, and KISS-1 could mimic the negative effect of siPTHrP on migration, whereas siKISS-1 and siPTHrP similarly reduced the proliferative activity of the cells. Comparative expression analyses with 50 primary breast carcinomas revealed that the RNA level of ITGA6 correlates with that of PTHrP, and higher CDC2 and CDC25B values are found at low PTHrP expression. Our data suggest that PTHrP has a profound effect on gene expression in breast cancer cells and, as a consequence, contributes to the regulation of important cellular activities, such as migration and proliferation.	Univ Halle, Klin Gynakol, D-06120 Halle, Germany; Radboud Univ, Nijmegen Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands	Martin Luther University Halle Wittenberg; Radboud University Nijmegen	Dittmer, J (corresponding author), Univ Halle, Klin Gynakol, Ernst Grube Str 40, D-06120 Halle, Germany.	juergen.dittmer@medizin.uni-halle.de	Dittmer, Juergen/G-1160-2011; Sweep, C.G.J./H-8096-2014; Thomssen, Christoph/ABC-3102-2021; Span, Paul/G-4710-2012; Span, Paul N./A-3143-2009	Sweep, C.G.J./0000-0003-1103-3070; Span, Paul/0000-0002-1930-6638; 				Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756-3282(03)00086-3; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Cataisson C, 2000, J BONE MINER RES, V15, P2129, DOI 10.1359/jbmr.2000.15.11.2129; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Conlan LA, 2002, FEBS LETT, V527, P71, DOI 10.1016/S0014-5793(02)03164-2; de Witte JH, 1999, BRIT J CANCER, V79, P1190, DOI 10.1038/sj.bjc.6690191; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DIEFENBACHJAGGER H, 1995, EUR J BIOCHEM, V229, P91, DOI 10.1111/j.1432-1033.1995.tb20442.x; Ditmer LS, 1996, ENDOCRINOLOGY, V137, P1608, DOI 10.1210/en.137.5.1608; DITTMER A, 2006, IN PRESS ELECTROPHOR; Dittmer J., 2004, GENE THER MOL BIOL, V8, P451; Doree M, 2002, J CELL SCI, V115, P2461; Falzon M, 2000, ENDOCRINOLOGY, V141, P1882, DOI 10.1210/en.141.5.1882; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fiaschi-Taesch N, 2004, CIRCULATION, V110, P177, DOI 10.1161/01.CIR.0000134483.30849.B7; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Givant-Horwitz V, 2004, CANCER RES, V64, P3572, DOI 10.1158/0008-5472.CAN-03-3424; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guerra L, 2005, J BIOL CHEM, V280, P40925, DOI 10.1074/jbc.M505103200; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Han SJ, 2006, CELL CYCLE, V5, P227, DOI 10.4161/cc.5.3.2395; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; HASTINGS RH, 2003, AM J PHYSIOL, V285, P61312; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Henderson MA, 2001, JNCI-J NATL CANCER I, V93, P234, DOI 10.1093/jnci/93.3.234; Hoey RP, 2003, BRIT J CANCER, V88, P567, DOI 10.1038/sj.bjc.6600757; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; Ito J, 2004, REPRODUCTION, V128, P409, DOI 10.1530/rep.1.00230; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Juliano R, 2003, NAT CELL BIOL, V5, P589, DOI 10.1038/ncb0703-589; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kakonen SM, 2003, CANCER-AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kikkawa Y, 2004, EXP CELL RES, V300, P94, DOI 10.1016/j.yexcr.2004.06.031; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; Klymkowsky MW, 2005, HUM PATHOL, V36, P225, DOI 10.1016/j.humpath.2005.02.002; Kodama R, 2005, GENES CELLS, V10, P1211, DOI 10.1111/j.1365-2443.2005.00911.x; Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lim HH, 2003, MOL CELL, V11, P845, DOI 10.1016/S1097-2765(03)00149-7; Lindemann RK, 2003, INT J ONCOL, V22, P799; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Linforth R, 2002, CLIN CANCER RES, V8, P3172; Maioli E, 2004, CELL MOL LIFE SCI, V61, P257, DOI 10.1007/s00018-003-3233-2; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Martin TA, 2005, CLIN EXP METASTAS, V22, P503, DOI 10.1007/s10585-005-4180-0; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1564::AID-CNCR6>3.0.CO;2-K; Richard V, 2005, CRIT REV EUKAR GENE, V15, P115, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.30; Seddighzadeh M, 1999, CLIN EXP METASTAS, V17, P649, DOI 10.1023/A:1006741228402; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shen XL, 2004, EXP CELL RES, V294, P420, DOI 10.1016/j.yexcr.2003.11.028; Shen XL, 2003, REGUL PEPTIDES, V113, P17, DOI 10.1016/S0167-0115(02)00293-8; Skog S, 2004, TUMOR BIOL, V25, P41, DOI 10.1159/000077722; SOUTHBY J, 1995, BRIT J CANCER, V72, P702, DOI 10.1038/bjc.1995.397; Stafford LJ, 2002, CANCER RES, V62, P5399; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Truong NU, 2003, AM J MED, V115, P115, DOI 10.1016/S0002-9343(03)00310-3; Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Whitley BR, 2005, INT J ONCOL, V27, P749; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285; WYSOLMERSKI JJ, 1994, ANNU REV MED, V45, P189, DOI 10.1146/annurev.med.45.1.189; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	86	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14563	14572		10.1074/jbc.M510527200	http://dx.doi.org/10.1074/jbc.M510527200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551631	hybrid, Green Published			2022-12-27	WOS:000237671300007
J	Gattis, JL; Washington, AV; Chisholm, MM; Quigley, L; Szyk, A; McVicar, DW; Lubkowski, J				Gattis, JL; Washington, AV; Chisholm, MM; Quigley, L; Szyk, A; McVicar, DW; Lubkowski, J			The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INHIBITORY RECEPTOR; TREM-1; PLATELETS; CLUSTER; SYSTEM; NKP44	Triggering receptor expressed on myeloid cells like transcript- 1 ( TLT- 1) is an abundant platelet- specific, type I transmembrane receptor. The extracellular fragment of TLT- 1 consists of a single, immunoglobulin- like domain connected to the platelet cell membrane by a linker region called the stalk. Here we present evidence that a soluble fragment of the TLT- 1extracellular domain is found in serum of humans and mice and that an isoform of similar mass is released from platelets following activation with thrombin. We also report the crystal structure of the immunoglobulin domain of TLT- 1 determined at the resolution of 1.19 angstrom. The structure of TLT- 1 is similar to other immunoglobulin- like variable domains, particularly those of triggering receptor expressed on myeloid cells- 1 ( TREM- 1), the natural killer cell- activating receptor NKp44, and the polymeric immunoglobulin receptor. Particularly interesting is a 17- amino acid segment of TLT- 1, homologous to a fragment of murine TREM- 1, which, in turn, showed activity in blocking the TREM- 1- mediated inflammatory responses in mice. Structural similarity to TREM- 1and polymeric immunoglobulin receptor, and evidence for a naturally occurring soluble fragment of the TLT- 1 extracellular domain, suggest that this immunoglobulin- like domain autonomously plays an as yet unidentified, functional role.	NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, NIH, Ft Detrick,7th St,Bldg 539,POB B,Rm 150, Frederick, MD 21702 USA.	jacek@ncifcrf.gov	McVicar, Daniel/G-1970-2015	McVicar, Daniel/0000-0002-1112-5111	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010300, Z01BC010300] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allcock RJN, 2003, EUR J IMMUNOL, V33, P567, DOI 10.1002/immu.200310033; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantoni C, 2003, STRUCTURE, V11, P725, DOI 10.1016/S0969-2126(03)00095-9; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Gibot S, 2005, INTENS CARE MED, V31, P594, DOI 10.1007/s00134-005-2572-x; Gibot S, 2004, J EXP MED, V200, P1419, DOI 10.1084/jem.20040708; Gibot Sebastien, 2004, Clin Med Res, V2, P181; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hoover DM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e43; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Kelker MS, 2004, J MOL BIOL, V342, P1237, DOI 10.1016/j.jmb.2004.07.089; Kelker MS, 2004, J MOL BIOL, V344, P1175, DOI 10.1016/j.jmb.2004.10.009; KLEYWEGT GJ, 1996, ACTA CRYSTALLOGR A, V47, P110; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Meiler J, 2001, J MOL MODEL, V7, P360, DOI 10.1007/s008940100038; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; *NAT RES COUNC, 1996, NIH PUBL, V8623; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASI JK, 1999, HEMOSTASIS THROMBOSI, P3; Paul SP, 2000, BLOOD, V96, P483; Radaev S, 2003, STRUCTURE, V11, P1527, DOI 10.1016/j.str.2003.11.001; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Washington AV, 2004, BLOOD, V104, P1042, DOI 10.1182/blood-2004-01-0315; Washington AV, 2002, BLOOD, V100, P3822, DOI 10.1182/blood-2002-02-0523; Zhou GF, 1997, PROTEIN SCI, V6, P444	32	42	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13396	13403		10.1074/jbc.M600489200	http://dx.doi.org/10.1074/jbc.M600489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16505478	hybrid			2022-12-27	WOS:000237336600046
J	Urata, Y; Ihara, Y; Murata, H; Goto, S; Koji, T; Yodoi, J; Inoue, S; Kondo, T				Urata, Y; Ihara, Y; Murata, H; Goto, S; Koji, T; Yodoi, J; Inoue, S; Kondo, T			17 beta-estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; ENDOTHELIAL-CELLS; KINASE-B; BREAST-CANCER; GLUTAREDOXIN; APOPTOSIS; BETA; RESISTANCE; EXPRESSION; THIOREDOXIN	The GSH/glutaredoxin (GRX) system is involved in the redox regulation of certain enzyme activities, and this system protects cells from H2O2-induced apoptosis by regulating the redox state of Akt (Murata, H., Ihara, Y., Nakamura, H., Yodoi, J., Sumikawa, K., and Kondo, T. (2003) J. Biol. Chem. 278, 50226-50233). Estrogens, such as 17 beta-estradiol (E-2), play an important role in development, growth, and differentiation and appear to have protective effects on oxidative stress mediated by estrogen receptor alpha( ER alpha). However, the role of the ER beta-mediated pathway in this cytoprotection and the involvement of E-2 in the redox regulation are not well understood. In the present study, we demonstrated that E-2 protected cardiac H9c2 cells, expressing ER beta from H2O2-induced apoptosis concomitant with an increase in the activity of Akt. E-2 induced the expression of glutaredoxin ( GRX) as well as gamma-glutamylcysteine synthetase, a rate-limiting enzyme for the synthesis of GSH. Inhibitors for both gamma-glutamylcysteine synthetase and GRX and ICI182,780, a specific inhibitor of ERs, abolished the protective effect of E-2 on cell survival as well as the activity of Akt, suggesting that ER beta is involved in the cytoprotection and redox regulation by E-2. Transcription of the GRX gene was enhanced by E-2. The promoter activity of GRX was up-regulated by an ER beta-dependent element. These results suggest that the GRX/GSH system is involved in the cytoprotective and genomic effects of E-2 on the redox state of Akt, a pathway that is mediated, at least in part, by ER beta. This mechanism may also play an antiapoptotic role in cancer cells during carcinogenesis or chemotherapy.	Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, Nagasaki 8528523, Japan; Kyoto Univ, Grad Sch Med, Inst Viral Res, Dept Biol Responses,Sakyo Ku, Kyoto 6068397, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan	Nagasaki University; Nagasaki University; Kyoto University; University of Tokyo	Urata, Y (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	urata@net.nagasaki-u.ac.jp	Murata, Hiroaki/AAA-8374-2020	Murata, Hiroaki/0000-0002-6185-5059				Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Baba T, 2005, J BIOL CHEM, V280, P16417, DOI 10.1074/jbc.M500924200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Connor EE, 2005, J ENDOCRINOL, V185, P593, DOI 10.1677/joe.1.06139; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Ejima K, 1999, EUR J ENDOCRINOL, V140, P608, DOI 10.1530/eje.0.1400608; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FOSTER C, 2004, P NATL ACAD SCI USA, V101, P14233; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; GAN ZR, 1986, J BIOL CHEM, V261, P996; Gibson LL, 2005, CIRC RES, V96, P518, DOI 10.1161/01.RES.0000158967.96231.88; Goto S, 2002, JPN J CANCER RES, V93, P1047, DOI 10.1111/j.1349-7006.2002.tb02482.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Iida T, 2001, CANCER GENE THER, V8, P803, DOI 10.1038/sj.cgt.7700371; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kenchappa RS, 2004, FASEB J, V18, P1102, DOI 10.1096/fj.03-1075fje; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Padilla CA, 1996, GENOMICS, V32, P455, DOI 10.1006/geno.1996.0141; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schultz JR, 2005, J BIOL CHEM, V280, P347, DOI 10.1074/jbc.M407879200; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Smith LH, 2004, CIRC RES, V95, P269, DOI 10.1161/01.RES.0000136521.70093.f1; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Tamaru N, 2004, LAB INVEST, V84, P1460, DOI 10.1038/labinvest.3700166; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200; Yasuoka C, 2004, J BIOL CHEM, V279, P51182, DOI 10.1074/jbc.M407225200; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200	50	97	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13092	13102		10.1074/jbc.M601984200	http://dx.doi.org/10.1074/jbc.M601984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549430	hybrid			2022-12-27	WOS:000237336600013
J	Glithero, A; Tormo, J; Doering, K; Kojima, M; Jones, EY; Elliott, T				Glithero, A; Tormo, J; Doering, K; Kojima, M; Jones, EY; Elliott, T			The crystal structure of H-2D(b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; T-CELL RECOGNITION; 3-DIMENSIONAL STRUCTURE; MHC; MOLECULES; BINDING; RESOLUTION; EXPRESSION; STABILITY; TAPASIN	In the absence of bound peptide ligands, major histocompatibility complex (MHC) class I molecules are unstable. In an attempt to determine the minimum requirement for peptide-dependent MHC class I stabilization, we have used short synthetic peptides derived from the Sendai virus nucleoprotein epitope ( residues 324-332, (1)FAPGNYPAL(9)) to promote its folding in vitro of H-2D(b). We found that H-2D(b) can be stabilized by the pentapeptide (5)NYPAL(9), which is equivalent to the C-terminal portion of the optimal nonapeptide and includes both the P5 and P9 anchor residues. We have crystallized the complex of the H-2D(b) molecule with the pentamer and determined the structure to show how a quasi-stable MHC class I molecule can be formed by occupancy of a single binding pocket in the peptide-binding groove.	Univ Southampton, Sch Med, Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England; Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 4RU, England	University of Southampton; University of Oxford; University of Oxford	Elliott, T (corresponding author), Univ Southampton, Sch Med, Southampton Gen Hosp, Canc Sci Div, Somers Canc Res Bldg,MP 824, Southampton SO16 6YD, Hants, England.	tje@soton.ac.uk	Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Elliott, Tim/0000-0003-1097-0222	MRC [G9900061] Funding Source: UKRI; Medical Research Council [G9900061] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busch R, 2005, IMMUNOL REV, V207, P242, DOI 10.1111/j.0105-2896.2005.00306.x; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; CATIPOVIC B, 1994, J EXP MED, V180, P1753, DOI 10.1084/jem.180.5.1753; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Gillanders WE, 1997, INT IMMUNOL, V9, P81, DOI 10.1093/intimm/9.1.81; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Hansen TH, 2005, IMMUNOL REV, V207, P100, DOI 10.1111/j.0105-2896.2005.00315.x; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGNEY E, 1998, J BIOL CHEM, P273; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULZ M, 1991, EUR J IMMUNOL, V21, P1181, DOI 10.1002/eji.1830210513; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; Zacharias M, 2004, BIOPHYS J, V87, P2203, DOI 10.1529/biophysj.104.044743	33	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12699	12704		10.1074/jbc.M511683200	http://dx.doi.org/10.1074/jbc.M511683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16478731	hybrid			2022-12-27	WOS:000237134700061
J	Yang, XH; Kovalenko, OV; Kolesnikova, TV; Andzelm, MM; Rubinstein, E; Strominger, JL; Hemler, ME				Yang, XH; Kovalenko, OV; Kolesnikova, TV; Andzelm, MM; Rubinstein, E; Strominger, JL; Hemler, ME			Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE 4 SUPERFAMILY; MHC CLASS-II; MONOCLONAL-ANTIBODIES; TETRASPANIN CD9; TM4SF PROTEINS; MRP-1/CD9 EXPRESSION; CD9-DEFICIENT MICE; BETA(1) INTEGRINS; GM3 GANGLIOSIDE; POOR-PROGNOSIS	CD9, a tetraspanin protein, makes crucial contributions to sperm egg fusion, other cellular fusions, epidermal growth factor receptor signaling, cell motility, and tumor suppression. Here we characterize a low affinity anti-CD9 antibody, C9BB, which binds preferentially to homoclustered CD9. Using mAb C9BB as a tool, we show that cell surface CD9 homoclustering is promoted by expression of alpha 3 beta 1 and alpha 6 beta 4 integrins and by palmitoylation of the CD9 and beta 4 proteins. Conversely, CD9 is shifted toward heteroclusters upon expression of CD9 partner proteins (EWI-2 and EWI-F) or other tetraspanins, or upon ablation of CD9 palmitoylation. Furthermore, unpalmitoylated CD9 showed enhanced EWI-2 association, thereby demonstrating a previously unappreciated role for tetraspanin palmitoylation, and underscoring how depalmitoylation and EWI-2 association may collaborate to shift CD9 from homo- to heteroclusters. In conclusion, we have used a novel molecular probe ( mAb C9BB) to demonstrate the existence of multiple types of CD9 complex on the cell surface. A shift from homo- to heteroclustered CD9 may be functionally significant because the latter was especially obvious on malignant epithelial tumor cells. Hence, because of its specialized properties, C9BB may be more useful than other anti-CD9 antibodies for monitoring CD9 during tumor progression.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Paris 11, INSERM, U268, Inst Andre Lwoff, F-94807 Villejuif, France	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hemler, ME (corresponding author), Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@DFCI.Harvard.edu	Rubinstein, Eric/B-4650-2019	Rubinstein, Eric/0000-0001-7623-9665	NCI NIH HHS [CA42368] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZORSA DO, 1998, CD9 WORKSH AN ANT RE, V6; Baudoux B, 2000, EUR J CELL BIOL, V79, P41, DOI 10.1078/S0171-9335(04)70006-0; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2001, J CELL SCI, V114, P4143; Charrin S, 2003, EUR J IMMUNOL, V33, P2479, DOI 10.1002/eji.200323884; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Cherukuri A, 2004, J BIOL CHEM, V279, P31973, DOI 10.1074/jbc.M404410200; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; Drbal K, 1999, INT IMMUNOL, V11, P491, DOI 10.1093/intimm/11.4.491; Drbal K, 2000, TISSUE ANTIGENS, V56, P258, DOI 10.1034/j.1399-0039.2000.560308.x; Erovic BM, 2003, HEAD NECK-J SCI SPEC, V25, P848, DOI 10.1002/hed.10306; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Ishibashi T, 2004, J NEUROSCI, V24, P96, DOI 10.1523/JNEUROSCI.1484-03.2004; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; KAUFMAN EN, 1992, CANCER RES, V52, P4157; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Kovalenko OV, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-11; Kovalenko OV, 2004, BIOCHEM J, V377, P407, DOI 10.1042/BJ20031037; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Mhawech P, 2004, BRIT J CANCER, V90, P471, DOI 10.1038/sj.bjc.6601542; Mhawech P, 2003, CANCER, V98, P1649, DOI 10.1002/cncr.11698; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; Murayama Y, 2004, J CELL SCI, V117, P3379, DOI 10.1242/jcs.01201; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; Stipp CS, 2003, J CELL BIOL, V163, P1167, DOI 10.1083/jcb.200309113; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Szollosi J, 1996, J IMMUNOL, V157, P2939; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; Willett B, 1997, J GEN VIROL, V78, P611, DOI 10.1099/0022-1317-78-3-611; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	67	46	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12976	12985		10.1074/jbc.M510617200	http://dx.doi.org/10.1074/jbc.M510617200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537545	hybrid			2022-12-27	WOS:000237134700093
J	Madziva, MT; Birnbaumer, M				Madziva, MT; Birnbaumer, M			A role for ADP-ribosylation factor 6 in the processing of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V2 VASOPRESSIN RECEPTOR; NEPHROGENIC DIABETES-INSIPIDUS; PLASMA-MEMBRANE; WILD-TYPE; ARF6; CELLS; ENDOCYTOSIS; PHOSPHORYLATION; GLYCOSYLATION; GTPASE	After agonist-induced internalization, the vasopressin V-2 receptor (V2R) does not recycle to the plasma membrane. The ADP-ribosylation factor (ARF) proteins initiate vesicular intracellular traffic by promoting the recruitment of adaptor proteins; thus, we sought to determine whether ARF6 could promote V2R recycling. Neither the agonist-induced internalization nor the recycling of the V2R was regulated by ARF6, but a constitutively active mutant of ARF6 reduced cell-surface V(2)Rs 10-fold in the absence of agonist treatment. Visualization of the ARF6 mutant-expressing cells revealed a vacuolar-staining pattern of the V2R instead of the normal plasma-membrane expression. Analysis of V2R maturation revealed that reduced cell-surface expression was due to the diminished ability of the newly synthesized receptor to migrate from the endoplasmic reticulum to the Golgi network. The same mechanism affected processing of the V1aR and acetylcholine M2 receptors. Therefore, ARF6 controls the exit of the V-2 and other receptors from the endoplasmic reticulum in addition to its established role in the trafficking of plasma-membrane-derived vesicles.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Birnbaumer, M (corresponding author), NIEHS, Lab Signal Transduct, NIH, MD F1-10, Res Triangle Pk, NC 27709 USA.	birnbau2@niehs.nih.gov						BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krause G, 2000, MOL PHARMACOL, V57, P232; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12178	12186		10.1074/jbc.M601357200	http://dx.doi.org/10.1074/jbc.M601357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497672	hybrid			2022-12-27	WOS:000236988100088
J	Yin, H; Glass, J				Yin, H; Glass, J			In prostate cancer cells the interaction of C/EBP alpha with Ku70, Ku80, and poly(ADP-ribose) polymerase-1 increases sensitivity to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; DOUBLE-STRAND BREAKS; BETA ISOFORM EXPRESSION; GENE-EXPRESSION; 3T3-L1 ADIPOCYTES; MYELOID-LEUKEMIA; GROWTH ARREST; PROLIFERATION; DIFFERENTIATION; REPAIR	Prostate cancer cell lines were examined for proteins that partnered with the transcription factor C/EBP alpha by use of a pull-down assay with S-tagged C/EBP alpha combined with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy analysis. Ku70, Ku80, and poly( ADP-ribose) polymerase-1 ( PARP-1) were identified as proteins that associated with C/EBP alpha. The physical interaction of C/EBP alpha with these partner proteins was further demonstrated by glutathione S-transferase ( GST) pull-downs using purified protein expressed in Escherichia coli. The strongest binding was between C/EBP alpha and PARP-1. Immunoprecipitation of C/EBP alpha expressed in prostate cancer cells co-precipitated Ku70, Ku80, and PARP-1. Deletion analysis of C/EBP alpha indicated that the C terminus of C/EBP alpha was essential for the interaction of C/EBP alpha with Ku70, Ku80, and PARP-1. Functional analysis of the interaction between C/EBP alpha and the Ku proteins as well as PARP-1 showed that cells exhibiting these interactions had increased radiation sensitivity and decreased ability to repair double strand DNA breaks. Deficient DNA repair was dependent on the prostate cancer cell line tested, suggesting a complex process. We conclude that the association of C/EBP alpha with Ku proteins and PARP-1 raises the likelihood that C/EBP alpha-expressing prostate cancer cells may be more sensitive to DNA-damaging agents and may be important in the design of new prostate cancer therapies.	Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Shreveport, LA 71130 USA; Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Yin, H (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, 1501 Kings Highway, Shreveport, LA 71130 USA.	hyin@lsuhsc.edu						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; An MR, 1996, MOL CELL BIOL, V16, P2295; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bertinato J, 2003, GENE, V302, P53, DOI 10.1016/S0378111902010892; Bromfield GP, 2003, PROSTATE CANCER P D, V6, P73, DOI 10.1038/sj.pcan.4500628; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Halmos B, 2002, CANCER RES, V62, P528; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Koike M, 2002, J RADIAT RES, V43, P223, DOI 10.1269/jrr.43.223; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mayeur GL, 2005, J BIOL CHEM, V280, P10827, DOI 10.1074/jbc.M413336200; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Myung K, 2004, MOL CELL BIOL, V24, P5050, DOI 10.1128/MCB.24.11.5050-5059.2004; Noel G, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-7; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pastwa E, 2003, RADIAT RES, V159, P251, DOI 10.1667/0033-7587(2003)159[0251:RORIDD]2.0.CO;2; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; RADTKE K, 1994, BIOCHEM J, V302, P655, DOI 10.1042/bj3020655; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Watkins PJ, 1996, CANCER RES, V56, P1063; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; YIN H, 2003, P 94 ANN M AM ASS CA, V44, P542; Yin Hong, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P115; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	55	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11496	11505		10.1074/jbc.M511138200	http://dx.doi.org/10.1074/jbc.M511138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490787	hybrid			2022-12-27	WOS:000236988100011
J	Besteiro, S; Williams, RAM; Morrison, LS; Coombs, GH; Mottram, JC				Besteiro, S; Williams, RAM; Morrison, LS; Coombs, GH; Mottram, JC			Endosome sorting and autophagy are essential for differentiation and virulence of Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; MULTIVESICULAR-BODY; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; CYSTEINE PROTEINASES; FLAGELLAR POCKET; YEAST; COMPLEX; COMPARTMENT; PATHWAY	Cellular remodeling during differentiation is essential for life-cycle progression of many unicellular eukaryotic pathogens such as Leishmania, but the mechanisms involved are largely uncharacterized. The role of endosomal sorting in differentiation was analyzed in Leishmania major by overexpression of a dominant-negative ATPase, VPS4. VPS4(E235Q) accumulated in vesicles from the endocytic pathway, and the mutant L. major was deficient in endosome sorting. Mutant parasites failed to differentiate to the obligate infective metacyclic promastigote form. Furthermore, the autophagy pathway, monitored via the expression of autophagosome marker GFP-ATG8, and shown to normally peak during initiation of metacyclogenesis, was disrupted in the mutants. The defect in late endosome-autophagosome function in the VPS4(E235Q) parasites made them less able to withstand starvation than wild-type L. major. In addition, a L. major ATG4-deficient mutant was found also to be defective in the ability to differentiate. This finding, that transformation to the infective metacyclic form is dependent on late endosome function and, more directly, autophagy, makes L. major a good model for studying the roles of these processes in differentiation.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland; Univ Glasgow, Glasgow Biomed Res Ctr, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow; University of Glasgow	Mottram, JC (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	jmottram@bio.gla.ac.uk	Besteiro, Sébastien/F-3622-2014; Williams, Roderick/V-4317-2019	Besteiro, Sébastien/0000-0003-1853-1494; Williams, Roderick/0000-0001-5065-9768; Mottram, Jeremy/0000-0001-5574-3766	MRC [G0000508] Funding Source: UKRI; Medical Research Council [G0000508] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alexander J, 1999, J CELL SCI, V112, P2993; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Besteiro S, 2004, MOL MICROBIOL, V54, P1224, DOI 10.1111/j.1365-2958.2004.04355.x; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Conibear E, 2002, MOL CELL, V10, P215, DOI 10.1016/S1097-2765(02)00601-9; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Denny PW, 2002, MOL BIOCHEM PARASIT, V123, P105, DOI 10.1016/S0166-6851(02)00133-0; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; FinkenEigen M, 1997, CURR GENET, V31, P469, DOI 10.1007/s002940050232; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; FRANKE ED, 1985, J IMMUNOL, V134, P2713; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Herman M, 2006, AUTOPHAGY, V2, P107, DOI 10.4161/auto.2.2.2369; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KIDERLEN AF, 1990, J IMMUNOL METHODS, V127, P11, DOI 10.1016/0022-1759(90)90334-R; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2004, AUTOPHAGY; Knuepfer E, 2001, BIOCHEM J, V356, P335, DOI 10.1042/0264-6021:3560335; Krishnamurthy G, 2005, J BIOL CHEM, V280, P5884, DOI 10.1074/jbc.M411845200; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Overath P, 2004, MOL MICROBIOL, V53, P735, DOI 10.1111/j.1365-2958.2004.04224.x; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Shirahama K, 1997, CELL STRUCT FUNCT, V22, P501, DOI 10.1247/csf.22.501; Singh SB, 2003, EMBO J, V22, P5712, DOI 10.1093/emboj/cdg557; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Tetaud E, 2002, MOL BIOCHEM PARASIT, V120, P195, DOI 10.1016/S0166-6851(02)00002-6; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Weise F, 2000, J CELL SCI, V113, P4587; Yang M, 2004, J CELL SCI, V117, P3831, DOI 10.1242/jcs.01237; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	53	167	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11384	11396		10.1074/jbc.M512307200	http://dx.doi.org/10.1074/jbc.M512307200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497676	hybrid			2022-12-27	WOS:000236822200081
J	Devel, L; Rogakos, V; David, A; Makaritis, A; Beau, F; Cuniasse, P; Yiotakis, A; Dive, V				Devel, L; Rogakos, V; David, A; Makaritis, A; Beau, F; Cuniasse, P; Yiotakis, A; Dive, V			Development of selective inhibitors and substrate of matrix metalloproteinase-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABDOMINAL AORTIC-ANEURYSMS; PHOSPHINIC PEPTIDES; MACROPHAGE ELASTASE; DEFICIENT MICE; GELATINASE-A; CANCER; MMP-12; ACTIVATION; EXPRESSION; EMPHYSEMA	Four phosphinic peptide libraries with compounds having the general formula p-Br-Ph-(PO2-CH2)-Xaa'-Yaa'-Zaa'-NH2 have been prepared and screened against 10 matrix metalloproteinases ( MMPs). We identified two phosphinic peptides with K-i values of 0.19 and 4.4 nM toward MMP-12 ( macrophage elastase) that are more than 2 - 3 orders of magnitude less potent toward the other MMPs tested. These highly selective MMP-12 inhibitors contain a Glu-Glu motif in their Yaa'-Zaa' positions. Incorporation of this Glu-Glu motif into the sequence of a nonspecific fluorogenic peptide cleaved by MMPs provides a highly selective substrate for MMP-12. A model of one of these inhibitors interacting with MMP-12 suggests that the selectivity observed might be due, in part, to the presence of two unique polar residues in MMP-12, Thr(239) and Lys(177). These MMP-12-selective inhibitors may have important therapeutic applications to diseases in which MMP-12 has been suggested to play a key role, such as in emphysema, atherosclerosis, and aortic abdominal aneurysm.	Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Univ Athens, Dept Organ Chem, Organ Chem Lab, GR-15771 Athens, Greece	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; National & Kapodistrian University of Athens	Dive, V (corresponding author), Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, Bat 152, F-91191 Gif Sur Yvette, France.	vincent.dive@cea.fr						Bertini I, 2005, P NATL ACAD SCI USA, V102, P5334, DOI 10.1073/pnas.0407106102; Bode W, 2003, BIOCHEM SOC SYMP, V70, P1; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brown S, 2004, CURR TOP MED CHEM, V4, P1227, DOI 10.2174/1568026043387854; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Butler GS, 2004, J BIOL CHEM, V279, P15615, DOI 10.1074/jbc.M312727200; Cook GR, 2004, BIOORG MED CHEM LETT, V14, P4935, DOI 10.1016/j.bmcl.2004.07.023; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cuniasse P, 2005, BIOCHIMIE, V87, P393, DOI 10.1016/j.biochi.2004.09.025; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Daheshia M, 2005, CURR MED RES OPIN, V21, P587, DOI 10.1185/030079905X41417; Dive V, 2004, CELL MOL LIFE SCI, V61, P2010, DOI 10.1007/s00018-004-4050-y; Dollery CM, 2006, CARDIOVASC RES, V69, P625, DOI 10.1016/j.cardiores.2005.11.003; Dublanchet AC, 2005, BIOORG MED CHEM LETT, V15, P3787, DOI 10.1016/j.bmcl.2005.05.079; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engel CK, 2005, CHEM BIOL, V12, P181, DOI 10.1016/j.chembiol.2004.11.014; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Frisch MJ, 2003, GAUSSIAN03; Gall AL, 2001, J MOL BIOL, V307, P577, DOI 10.1006/jmbi.2001.4493; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hofmann HS, 2005, CLIN CANCER RES, V11, P1086; HOROVITZ A, 1987, P NATL ACAD SCI USA, V84, P6654, DOI 10.1073/pnas.84.19.6654; Ikejiri M, 2005, J ORG CHEM, V70, P5709, DOI 10.1021/jo050339+; Johnson JL, 2005, P NATL ACAD SCI USA, V102, P15575, DOI 10.1073/pnas.0506201102; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; Kerkela E, 2001, BONE, V29, P487, DOI 10.1016/S8756-3282(01)00595-6; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Longo GM, 2005, SURGERY, V137, P457, DOI 10.1016/j.surg.2004.12.004; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Makaritis A, 2003, CHEM-EUR J, V9, P2079, DOI 10.1002/chem.200204456; Mannello F, 2005, CURR CANCER DRUG TAR, V5, P285, DOI 10.2174/1568009054064615; Montchamp JL, 2001, J AM CHEM SOC, V123, P510, DOI 10.1021/ja005721c; Morales R, 2004, J MOL BIOL, V341, P1063, DOI 10.1016/j.jmb.2004.06.039; Morgan AR, 2004, STROKE, V35, P1310, DOI 10.1161/01.STR.0000126822.01756.99; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Moy FJ, 2002, J AM CHEM SOC, V124, P12658, DOI 10.1021/ja027391x; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Rosenberg GA, 2005, LANCET, V365, P1291, DOI 10.1016/S0140-6736(05)61008-2; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; STETTER H, 1979, SYNTHESIS-STUTTGART, P29; Tanaka A, 1998, BIOORGAN MED CHEM, V6, P15, DOI 10.1016/S0968-0896(97)10009-8; Tayebjee MH, 2005, CURR MED CHEM, V12, P917, DOI 10.2174/0929867053507270; Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P1259; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Whelan Clifford J, 2004, Curr Opin Investig Drugs, V5, P511; Yiotakis A, 1996, J ORG CHEM, V61, P6601, DOI 10.1021/jo9603439; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	55	130	138	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11152	11160		10.1074/jbc.M600222200	http://dx.doi.org/10.1074/jbc.M600222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481329	hybrid			2022-12-27	WOS:000236822200058
J	Filipeanu, CM; Zhou, F; Lam, ML; Kerut, KE; Claycomb, WC; Wu, GY				Filipeanu, CM; Zhou, F; Lam, ML; Kerut, KE; Claycomb, WC; Wu, GY			Enhancement of the recycling and activation of beta-adrenergic receptor by Rab4 GTPase in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ANGIOTENSIN-II; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; ENDOPLASMIC-RETICULUM; REGULATORY MECHANISMS; HEART-FAILURE; CELL-SURFACE; EXPRESSION; TRAFFICKING	We investigate the role of Rab4, a Ras-like small GTPase coordinating protein transport from the endosome to the plasma membrane, on the recycling and activation of endogenous beta-adrenergic receptor (beta-AR) in HL-1 cardiac myocytes in vitro and transgenic mouse hearts in vivo. beta(1)-AR, the predominant subtype of beta-AR in HL-1 cardiac myocytes, was internalized after stimulation with isoproterenol (ISO) and fully recycled at 4 h upon ISO removal. Transient expression of Rab4 markedly facilitated recycling of internalized beta-AR to the cell surface and enhanced beta-AR signaling as measured by ISO-stimulated cAMP production. Transgenic overexpression of Rab4 in the mouse myocardium significantly increased the number of beta-AR in the plasma membrane and augmented cAMP production at the basal level and in response to ISO stimulation. Rab4 overexpression induced concentric cardiac hypertrophy with a moderate increase in ventricle/body weight ratio and posterior wall thickness and a selective up-regulation of the beta-myosin heavy chain gene. These data provide the first evidence indicating that Rab4 is a rate-limiting factor for the recycling of endogenous beta-AR and augmentation of Rab4-mediated traffic enhances beta-AR function in cardiac myocytes.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu		Filipeanu, Catalin/0000-0002-7298-9327	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076167] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR018766, 1P20RR018766] Funding Source: Medline; NIGMS NIH HHS [R01 GM076167-01, R01 GM076167] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohm SK, 1997, BIOCHEM J, V322, P1; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; Filipeanu CM, 2004, J BIOL CHEM, V279, P41077, DOI 10.1074/jbc.M405988200; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1983, J CELL BIOL, V97, P1538, DOI 10.1083/jcb.97.5.1538; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Mace T, 2005, EMBO J, V24, P3235, DOI 10.1038/sj.emboj.7600799; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Odley A, 2004, P NATL ACAD SCI USA, V101, P7082, DOI 10.1073/pnas.0308335101; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; Post SR, 1999, ANNU REV PHARMACOL, V39, P343, DOI 10.1146/annurev.pharmtox.39.1.343; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sato M, 2004, J BIOL CHEM, V279, P13375, DOI 10.1074/jbc.M312660200; SCHWINGER RHG, 1990, AM HEART J, V119, P899, DOI 10.1016/S0002-8703(05)80329-1; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; vandenHoff MJB, 1997, J MOL CELL CARDIOL, V29, P629, DOI 10.1006/jmcc.1996.0306; Wozniak M, 2002, METHOD ENZYMOL, V343, P530; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206	37	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11097	11103		10.1074/jbc.M511460200	http://dx.doi.org/10.1074/jbc.M511460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484224	hybrid, Green Accepted			2022-12-27	WOS:000236822200052
J	Teixeira, M; Viengchareun, S; Butlen, D; Ferreira, C; Cluzeaud, F; Blot-Chabaud, M; Lombes, M; Ferrary, E				Teixeira, M; Viengchareun, S; Butlen, D; Ferreira, C; Cluzeaud, F; Blot-Chabaud, M; Lombes, M; Ferrary, E			Functional I-sK/KvLQT1 potassium channel in a new corticosteroid-sensitive cell line derived from the inner ear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LANGE-NIELSEN-SYNDROME; VESTIBULAR DARK CELLS; HUMAN MINERALOCORTICOID RECEPTOR; TRANSGENIC MOUSE MODELS; STRIAL MARGINAL CELLS; GUINEA-PIG; TARGETED ONCOGENESIS; MENIERES-DISEASE; XENOPUS-OOCYTES; PROTEIN-KINASE	Endolymph, a high K+/low Na+ fluid, participates in mechanoelectrical transduction in inner ear. Molecular mechanisms controlling endolymph ion homeostasis remain elusive, hampered by the lack of appropriate cellular models. We established an inner ear cell line by targeted oncogenesis. The expression of SV40 T antigen was driven by the proximal promoter of the human mineralocorticoid receptor (MR) gene, a receptor expressed in the inner ear. The EC5v cell line, microdissected from the semicircular canal, grew as a monolayer of immortalized epithelial cells forming domes. EC5v cells exhibited on filters of high transepithelial resistance and promoted K+ secretion and Na+ absorption. Functional MR and the 11 beta-hydroxysteroid dehydrogenase type 2, a key enzyme responsible for MR selectivity were identified. Expression of the epithelial sodium channel and serum glucocorticoid-regulated kinase 1 was shown to be up-regulated by aldosterone, indicating that EC5v represents a novel corticosteroid-sensitive cell line. Ionic measurements and Rb-86 transport assays revealed an apical secretion of K+ at least in part through the I-sK/KvLQT1 potassium channel under standard culture conditions. However, when cells were apically exposed to high K+/low Na+ fluid, mimicking endolymph exposure, I-sK/KvLQT1 actually functioned as a strict apical to basolateral K+ channel inhibited by clofilium. Quantitative reverse transcriptase-PCR further demonstrated that expression of KvLQT1 but not of I-sK was down-regulated by high K+ concentration. This first vestibular cellular model thus constitutes a valuable system to further investigate the molecular mechanisms controlling ionic transports in the inner ear and the pathophysiological consequences of their dysfunctions in vertigo and hearing loss.	Univ Paris 07, Fac Med Xavier Bichat, INSERM, EMI U0112, F-75870 Paris 18, France; Univ Paris 07, Fac Med Xavier Bichat, INSERM, U478, F-75870 Paris 18, France; Univ Paris 11, Fac Med Paris Sud, INSERM, U693, F-94276 Le Kremlin Bicetre, France; Univ Paris 07, Inst Federat Rech Claude Bernard, F-75870 Paris 18, France; Fac Pharm Marseille, INSERM, U608, F-13005 Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferrary, E (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM, EMI U0112, 16 Rue Henri Huchard, F-75870 Paris 18, France.	ferrary@bichat.inserm.fr	Lombes, Marc/L-5933-2018; Viengchareun, Say/M-6612-2017; Viengchareun, Say/GOV-6812-2022; Blot-Chabaud, Marcel/D-4064-2017	Lombes, Marc/0000-0003-3189-023X; Ferrary, Evelyne/0000-0003-0066-8556; viengchareun, say/0000-0003-4280-3250; Ferreira, Chrystophe/0000-0002-1990-278X				ACHOUCHE J, 1991, ANN OTO RHINOL LARYN, V100, P999, DOI 10.1177/000348949110001208; Agrup C, 1996, HEARING RES, V102, P155, DOI 10.1016/S0378-5955(96)00156-6; ANNIKO M, 1979, ARCH OTO-RHINO-LARYN, V225, P161, DOI 10.1007/BF00455250; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; Bosch RF, 2002, CARDIOVASC RES, V56, P393, DOI 10.1016/S0008-6363(02)00601-6; BRIAND P, 1995, KIDNEY INT, V47, P388, DOI 10.1038/ki.1995.51; Couloigner V, 2001, AM J PHYSIOL-RENAL, V280, pF214, DOI 10.1152/ajprenal.2001.280.2.F214; Dunnebier EA, 1997, ACTA OTO-LARYNGOL, V117, P13, DOI 10.3109/00016489709117984; FERRARY E, 1989, AM J PHYSIOL, V257, pF182, DOI 10.1152/ajprenal.1989.257.2.F182; Feunteun J, 1997, HORM RES, V47, P137, DOI 10.1159/000185456; FURUTA H, 1994, HEARING RES, V78, P175, DOI 10.1016/0378-5955(94)90023-X; Kathofer S, 2003, N-S ARCH PHARMACOL, V368, P119, DOI 10.1007/s00210-003-0772-x; Le Menuet D, 2004, MOL CELL ENDOCRINOL, V217, P127, DOI 10.1016/j.mce.2003.10.045; Le Menuet D, 2000, KIDNEY INT, V57, P1299, DOI 10.1046/j.1523-1755.2000.00966.x; Lee JH, 2002, AUDIOL NEURO-OTOL, V7, P100, DOI 10.1159/000057657; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; Mateijsen DJM, 2001, ORL-J OTO-RHIN-LARYN, V63, P280, DOI 10.1159/000055758; MELLON PL, 1991, RECENT PROG HORM RES, V47, P69; Milhaud PG, 1999, PFLUG ARCH EUR J PHY, V437, P823, DOI 10.1007/s004240050851; MIZUTA K, 1995, HEARING RES, V88, P199, DOI 10.1016/0378-5955(95)00113-I; MORI N, 1993, EUR ARCH OTO-RHINO-L, V250, P186; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Nicolas MT, 2001, HEARING RES, V153, P132, DOI 10.1016/S0378-5955(00)00268-9; PAPARELLA MM, 1985, ACTA OTO-LARYNGOL, V99, P445, DOI 10.3109/00016488509108936; PITOVSKI DZ, 1993, HEARING RES, V69, P10, DOI 10.1016/0378-5955(93)90088-I; Pitovski DZ, 1996, ACTA OTO-LARYNGOL, V116, P737, DOI 10.3109/00016489609137916; Pondugula SR, 2004, AM J PHYSIOL-RENAL, V286, pF1127, DOI 10.1152/ajprenal.00387.2003; Potet F, 2001, AM J PHYSIOL-HEART C, V280, pH2038, DOI 10.1152/ajpheart.2001.280.5.H2038; RAREY KE, 1989, HEARING RES, V41, P217, DOI 10.1016/0378-5955(89)90013-0; Rivas A, 2005, OTOL NEUROTOL, V26, P415, DOI 10.1097/01.mao.0000169764.00798.84; Rivolta MN, 2002, J NEUROBIOL, V53, P306, DOI 10.1002/neu.10111; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tadros SF, 2005, AUDIOL NEURO-OTOL, V10, P44, DOI 10.1159/000082307; TENCATE WJF, 1991, ARCH OTOLARYNGOL, V117, P96; Tu TY, 1999, HEARING RES, V127, P149, DOI 10.1016/S0378-5955(98)00192-0; Tu TY, 1999, ACTA OTO-LARYNGOL, V119, P544; Tu TY, 1998, HEARING RES, V123, P97, DOI 10.1016/S0378-5955(98)00101-4; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANGEMANN P, 1995, HEARING RES, V84, P19, DOI 10.1016/0378-5955(95)00009-S; Wangemann P, 1996, HEARING RES, V100, P201, DOI 10.1016/0378-5955(96)00127-X; Wangemann P, 2002, AUDIOL NEURO-OTOL, V7, P199, DOI 10.1159/000063736; WANGEMANN P, 1994, AM J PHYSIOL, V266, pC1046, DOI 10.1152/ajpcell.1994.266.4.C1046; Yao XF, 1996, ACTA OTO-LARYNGOL, V116, P493, DOI 10.3109/00016489609137879; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; [No title captured]	47	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10496	10507		10.1074/jbc.M512254200	http://dx.doi.org/10.1074/jbc.M512254200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478723	hybrid			2022-12-27	WOS:000236594300079
J	Zygadlo, A; Robinson, C; Scheller, HV; Mant, A; Jensen, PE				Zygadlo, A; Robinson, C; Scheller, HV; Mant, A; Jensen, PE			The properties of the positively charged loop region in PSI-G are essential for its "spontaneous" insertion into thylakoids and rapid assembly into the photosystem I complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SEC-INDEPENDENT INSERTION; MEMBRANE-PROTEINS; SUBUNIT; TRANSLOCATION; CONFORMATION; COMPONENT; PEPTIDES; PSBW	The PSI-G subunit of photosystem I (PSI) is an 11-kDa membrane protein that plays an important role in electron transport between plastocyanin and PSI and is involved in the stability of the PSI complex. Within the complex, the PSI-G subunit is bound to PSI-B and is in contact with Lhca1. PSI-G has two transmembrane spans connected by a positively charged stromal loop. The loop is inaccessible to proteases, indicating a tightly bound location within the PSI complex. Here, we have studied the insertion mechanism and assembly of PSI-G. We show that the protein inserts into thylakoids by a direct or "spontaneous" pathway that does not involve the activities of any known chloroplast protein-targeting machinery. Surprisingly, the positively charged stromal loop region plays a major role in this process. Mutagenesis or deletions within this region almost invariably lead to a marked lowering of insertion efficiency, strongly indicating a critical role for the loop in the organization of the transmembrane regions prior to or during membrane insertion. Finally, we have examined the assembly of newly inserted PSI-G into the PSI complex, since very little is known of the assembly pathway for this large multimeric complex. Interestingly, we find that inserted PSI-G can be found within the full PSI complex within the import assay time frame after insertion into thylakoids, strongly suggesting that PSI-G normally associates at the end of the assembly process. This is consistent with its location on the periphery of the complex.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1870 Frederiksberg, Denmark; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Copenhagen; University of Warwick; University of Southampton	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1870 Frederiksberg, Denmark.	peje@kvl.dk	Scheller, Henrik V/A-8106-2008; Jensen, Poul Erik/A-4862-2014; Scheller, Henrik/AAH-4770-2020; Zygadlo Nielsen, Agnieszka/J-4850-2016	Scheller, Henrik V/0000-0002-6702-3560; Jensen, Poul Erik/0000-0001-6524-7723; Scheller, Henrik/0000-0002-6702-3560; Zygadlo Nielsen, Agnieszka/0000-0002-7948-8912; Mant, Alexandra/0000-0001-7169-209X				Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Brambillasca S, 2005, EMBO J, V24, P2533, DOI 10.1038/sj.emboj.7600730; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; CLINE K, 1989, J BIOL CHEM, V264, P14225; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; HOYERHANSEN G, 1988, PLANTA, V173, P12, DOI 10.1007/BF00394481; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Jarvis P, 2004, CURR BIOL, V14, pR1064, DOI 10.1016/j.cub.2004.11.049; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jolley C, 2005, J BIOL CHEM, V280, P33627, DOI 10.1074/jbc.M500937200; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Nielsen VS, 1996, PHYSIOL PLANTARUM, V98, P637, DOI 10.1111/j.1399-3054.1996.tb05721.x; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Robinson C, 2002, PRACT APPROACH SER, V259, P123; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; Rosgaard L, 2005, FEBS J, V272, P4002, DOI 10.1111/j.1742-4658.2005.04824.x; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Tissier C, 2002, EUR J BIOCHEM, V269, P3131, DOI 10.1046/j.1432-1033.2002.02943.x; Woolhead CA, 2001, J BIOL CHEM, V276, P14607, DOI 10.1074/jbc.M009600200; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Zygadlo A, 2005, BBA-BIOENERGETICS, V1708, P154, DOI 10.1016/j.bbabio.2005.02.003	33	14	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10548	10554		10.1074/jbc.M512687200	http://dx.doi.org/10.1074/jbc.M512687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478728	hybrid			2022-12-27	WOS:000236594300085
J	Skoufias, DA; DeBonis, S; Saoudi, Y; Lebeau, L; Crevel, I; Cross, R; Wade, RH; Hackney, D; Kozielski, F				Skoufias, Dimitrios A.; DeBonis, Salvatore; Saoudi, Yasmina; Lebeau, Luc; Crevel, Isabelle; Cross, Robert; Wade, Richard H.; Hackney, David; Kozielski, Frank			S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIONAL-CANCER-INSTITUTE; ANTITUMOR-ACTIVITY; DRUG DISCOVERY; PROTEIN; MOTOR; IDENTIFICATION; MONASTROL; POTENT; MICROTUBULES; EXPRESSION	Human Eg5, responsible for the formation of the bipolar mitotic spindle, has been identified recently as one of the targets of S-trityl-L-cysteine, a potent tumor growth inhibitor in the NCI 60 tumor cell line screen. Here we show that in cell-based assays S-trityl-L-cysteine does not prevent cell cycle progression at the S or G(2) phases but inhibits both separation of the duplicated centrosomes and bipolar spindle formation, thereby blocking cells specifically in the M phase of the cell cycle with monoastral spindles. Following removal of S-trityl-L-cysteine, mitotically arrested cells exit mitosis normally. In vitro, S-trityl-L-cysteine targets the catalytic domain of Eg5 and inhibits Eg5 basal and microtubule- activated ATPase activity as well as mant-ADP release. S-Trityl-L-cysteine is a tight binding inhibitor (estimation of K-i,K-app < 150 nM at 300mM NaCl and 600 nM at 25 mM KCl). S-Trityl-L-cysteine binds more tightly than monastrol because it has both an similar to 8-fold faster association rate and similar to 4-fold slower release rate (6.1 mu M-1 s(-1) and 3.6 s(-1) for S-trityl-L-cysteine versus 0.78 mu M-1 s(-1) and 15 s(-1) for monastrol). S-Trityl-L-cysteine inhibits Eg5-driven microtubule sliding velocity in a reversible fashion with an IC50 of 500 nM. The S and D-enantiomers of S-tritylcysteine are nearly equally potent, indicating that there is no significant stereospecificity. Among nine different human kinesins tested, S-trityl-L-cysteine is specific for Eg5. The results presented here together with the proven effect on human tumor cell line growth make S-trityl-L-cysteine a very attractive starting point for the development of more potent mitotic inhibitors.	CNRS, UJF, Lab Moteurs Mol, Inst Biol Struct, F-38027 Grenoble 01, France; Commiss Energie Atom, INSERM, U336, Lab Cytosquelette, F-38054 Grenoble 9, France; Univ Louis Pasteur Strasbourg 1, Fac Pharm, Inst Gilbert Laustriat, Lab Chim Organ Appl, F-67401 Illkirch Graffenstaden, France; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Marie Curie Res Inst, Oxted RH8 0TL, England	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Carnegie Mellon University	Kozielski, F (corresponding author), 41 Rue Jules Horowitz, F-38027 Grenoble, France.	Frank.kozielski@ibs.fr	saoudi, yasmina/AAW-7354-2020; Lebeau, Luc/M-9964-2019; Skoufias, Dimitrios A/A-5535-2016; Cross, Robert A/F-1798-2011	Cross, Robert A/0000-0002-0004-7832; Lebeau, Luc/0000-0002-3276-6727; Skoufias, Dimitrios/0000-0001-5595-3413				ALLEY MC, 1988, CANCER RES, V48, P589; Andreassen Paul R, 2004, Methods Mol Biol, V281, P213; Bergnes G, 2005, CURR TOP MED CHEM, V5, P127, DOI 10.2174/1568026053507697; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Copeland R.A., 2000, ENZYMES PRACTICAL IN, P305; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DeBonis S, 2004, MOL CANCER THER, V3, P1079; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; Garcia-Saez I, 2004, J MOL BIOL, V340, P1107, DOI 10.1016/j.jmb.2004.05.053; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Goshima G, 2005, CURR BIOL, V15, P1979, DOI 10.1016/j.cub.2005.09.054; GREVER MR, 1992, SEMIN ONCOL, V19, P622; Hackney DD, 2001, METH MOL B, V164, P65; Hotha S, 2003, ANGEW CHEM INT EDIT, V42, P2379, DOI 10.1002/anie.200351173; Kelner MJ, 2002, INVEST NEW DRUG, V20, P271, DOI 10.1023/A:1016201807796; Kim IG, 1997, BBA-MOL CELL RES, V1359, P181, DOI 10.1016/S0167-4889(97)00103-1; Kozielski F, 2001, J BIOL CHEM, V276, P1267, DOI 10.1074/jbc.M007169200; Lai F, 2000, GENE, V248, P117, DOI 10.1016/S0378-1119(00)00135-9; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miyamoto David T, 2003, Prog Cell Cycle Res, V5, P349; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Nakazawa J, 2003, CHEM BIOL, V10, P131, DOI 10.1016/S1074-5521(03)00020-6; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; PAULL KD, 1992, CANCER RES, V52, P3892; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Xiao DH, 2005, MOL CANCER THER, V4, P1388, DOI 10.1158/1535-7163.MCT-05-0152; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	48	184	189	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17559	17569		10.1074/jbc.M511735200	http://dx.doi.org/10.1074/jbc.M511735200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16507573	hybrid			2022-12-27	WOS:000238490300005
J	Wajapeyee, N; Britto, R; Ravishankar, HM; Somasundaram, K				Wajapeyee, Narendra; Britto, Ramona; Ravishankar, Halasahalli M.; Somasundaram, Kumaravel			Apoptosis induction by activator protein 2 alpha involves transcriptional repression of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR AP-2; DNA-BINDING; SIGNAL-TRANSDUCTION; PHOSPHATASE 2A; HUMAN-MELANOMA; UP-REGULATION; CYCLE ARREST; TUMOR-GROWTH; KINASE-C	Activator protein 2 alpha ( AP-2 alpha) induces cytotoxicity by inducing cell cycle arrest and apoptosis. In this study we investigated the mechanism of apoptosis induction by AP-2 alpha. We found that AP-2 alpha induced apoptosis efficiently in cells treated with benzyloxycarbonyl-IETD-fluoromethyl ketone or FADD-silenced cells but failed to do so in benzyloxycarbonyl-LEHD-fluoromethyl ketone-treated or apoptosis protease activation factor-1 ( Apaf1)-silenced cells, suggesting the central role of mitochondria in AP-2 alpha-induced apoptosis. In good correlation, cells overexpressing AP-2 alpha showed a reduction in mitochondrial membrane potential ( Delta Psi(m)), cytochrome c and Smac/DIABLO release into cytosol, and Bax translocation into mitochondria. We found that the pro-apoptotic protein Bax is important for AP-2 alpha-induced apoptosis as adenovirus AP2 failed to induce apoptosis in HCT116 Bax(-/-) cells. However, we found the IAP ( inhibitor of apoptosis) inhibitor Smac/DIABLO may have a limited role in AP-2 alpha-induced apoptosis as we found the IAP member Survivin down-regulated by AP-2 alpha. Although the total Bax level remains unaltered, we found a time-dependent increase in the activated form of Bax in adenovirus AP2-infected cells. In addition, we show that AP-2 alpha transcriptionally represses Bcl-2 by binding to its promoter both in vitro and in vivo and that this is essential for AP-2 alpha-induced apoptosis as ectopic expression of Bcl-2 efficiently inhibited apoptosis induced by AP-2 alpha. Furthermore, we show that chemotherapy-induced endogenous AP-2 alpha down-regulates Bcl-2 and induces apoptosis in an AP-2 alpha-dependent manner. Moreover, we demonstrate that inhibition of okadaic acid or staurosporine-sensitive pathways in AP-2 alpha overexpressing breast cancer cells resulted in AP-2 alpha-dependent apoptosis induction. These results suggest that AP-2 alpha induces apoptosis by down-regulating Bcl-2 and utilizing a bax/cytochrome c/Apaf1/caspase 9-dependent mitochondrial pathway.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	Wajapeyee, Narendra/F-3011-2012	Britto, Ramona/0000-0003-1011-5410				Anttila MA, 2000, BRIT J CANCER, V82, P1974; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Garcia MA, 2000, J MOL BIOL, V301, P807, DOI 10.1006/jmbi.2000.4019; Garcia-Quesada JC, 1999, J VINYL ADDIT TECHN, V5, P31, DOI 10.1002/vnl.10303; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Heimberger AB, 2005, CLIN CANCER RES, V11, P267; HIGLEREVERSHEIM K, 2000, GENE, V260, P1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li M, 2006, INT J CANCER, V118, P802, DOI 10.1002/ijc.21426; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MacLachlan Timothy K, 2003, Methods Mol Biol, V223, P129; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; Piao Z, 2001, GENE CHROMOSOME CANC, V30, P113, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.3.CO;2-Y; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wajapeyee N, 2005, CANCER RES, V65, P8628, DOI 10.1158/0008-5472.CAN-05-1059; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang XH, 2001, CANCER RES, V61, P348; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	55	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16207	16219		10.1074/jbc.M600539200	http://dx.doi.org/10.1074/jbc.M600539200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16533807	hybrid			2022-12-27	WOS:000238165700006
J	Machida, K; Ohta, Y; Osada, H				Machida, Kiyotaka; Ohta, Yoshihiro; Osada, Hiroyuki			Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION-PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BOUND HEXOKINASE; BAX; DEATH; ACTIVATION; INHIBITOR; COMPONENT	The permeability transition pore is involved in the mitochondrial pathway of apoptosis. Cyclophilin D, a pore component, has catalytic activity as a peptidyl prolyl cis, trans-isomerase (PPIase), which is essential to the pore opening. It has been reported that cyclophilin D overexpression suppresses apoptosis in cancer cells. To clarify the mechanism of this effect, we generated glioma cells overexpressing wild-type or a PPIase-deficient mutant of cyclophilin D. Interestingly, we found that the PPIase-dependent apoptosis suppression by cyclophilin D correlated with the amounts of mitochondrial-bound hexokinase II, which has anti-apoptotic activity. Inactivation of endogenous cyclophilin D by small interference RNA or a cyclophilin inhibitor was found to release hexokinase II from mitochondria and to enhance Bax-mediated apoptosis. The anti-apoptotic effects of cyclophilin D were canceled out by the detachment of hexokinase II from mitochondria, demonstrating that mitochondrial binding of hexokinase II is essential to the apoptosis suppression by cyclophilin D. Furthermore, cyclophilin D dysfunction appears to abrogate hexokinase II-mediated apoptosis suppression, indicating that cyclophilin D is required for the anti-apoptotic activity of hexokinase II. Based on the above, we propose here that cyclophilin D suppresses apoptotic cell death via a mitochondrial hexokinase II-dependent mechanism in cancer cells.	RIKEN, Antiobiot Lab, Discovery Res Inst, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Div Biotechnol & Life Sci, Inst Symbiot Sci & Technol, Koganei, Tokyo 1848588, Japan	RIKEN; Tokyo University of Agriculture & Technology	Osada, H (corresponding author), RIKEN, Antiobiot Lab, Discovery Res Inst, Hirosawa 2-1, Saitama 3510198, Japan.	hisyo@riken.jp	Ohta, Yoshihiro/C-8741-2013; Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Ohta, Yoshihiro/0000-0001-7416-0507; 				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hashimoto M, 2000, ARCH BIOCHEM BIOPHYS, V384, P163, DOI 10.1006/abbi.2000.2085; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; MAGNANI M, 1994, BBA-PROTEIN STRUCT M, V1206, P180, DOI 10.1016/0167-4838(94)90206-2; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Vyssokikh M, 2004, BBA-MOL CELL RES, V1644, P27, DOI 10.1016/j.bbamcr.2003.10.007; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287	37	103	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14314	14320		10.1074/jbc.M513297200	http://dx.doi.org/10.1074/jbc.M513297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551620	hybrid			2022-12-27	WOS:000237512300057
J	Engel, S; Neumann, S; Kaur, N; Monga, V; Jain, R; Northup, J; Gershengorn, MC				Engel, S; Neumann, S; Kaur, N; Monga, V; Jain, R; Northup, J; Gershengorn, MC			Low affinity analogs of thyrotropin-releasing hormone are super-agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CONFORMATIONAL STATES; EXTRACELLULAR LOOPS; SEQUENTIAL BINDING; DESENSITIZATION; MECHANISMS; INHIBITOR; MODEL; TRH; INTERNALIZATION	We show that several analogs of thyrotropin-releasing hormone (TRH) are more efficacious agonists at TRH receptors R1 and R2 than TRH itself. The apparent efficacies of the analogs were inversely related to their potencies and were independent of the nature of the modifications in TRH structure. In studies in intact cells, we showed that the differences in apparent efficacies were not due to differences in G-protein coupling, receptor desensitization, or recycling. Moreover, the differences in efficacies persisted in experiments using accessory protein-free membranes. We conclude that the efficacy differences of TRH analogs originated from the enhanced ability of TRH-R complexed to the low affinity agonists to directly activate G-protein(s), and not by a modulation of the activity of accessory proteins, and propose possible mechanisms for this phenomenon.	NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, Bethesda, MD 20892 USA; Natl Inst Pharmaceut Educ & Res, Dept Med Chem, Sas Nagar 160062, Punjab, India; NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Gershengorn, MC (corresponding author), NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, 50 S Dr,Rm 4134, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov	Neumann, Susanne/GPK-6035-2022; Engel, Stanislav/G-2799-2013	Engel, Stanislav/0000-0001-5916-5190; Jain, Rahul/0000-0002-9180-2812; monga, Vikram Deep/0000-0003-4004-6241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006, Z01DK011006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000047, ZIADC000047] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Clark WA, 2001, BIOCHEM J, V358, P389, DOI 10.1042/0264-6021:3580389; Colson AO, 1998, BIOPHYS J, V74, P1087, DOI 10.1016/S0006-3495(98)77827-0; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; Garland AM, 1996, MOL PHARMACOL, V49, P438; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hassan A, 2005, J ENDOCRINOL, V184, P29, DOI 10.1677/joe.1.05654; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Jain R, 2002, BIOORGAN MED CHEM, V10, P189, DOI 10.1016/S0968-0896(01)00265-6; Jarv J, 2005, NEUROSCI LETT, V373, P150, DOI 10.1016/j.neulet.2004.10.003; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lu XP, 2004, MOL PHARMACOL, V66, P1192, DOI 10.1124/mol.104.000349; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; O'Dowd BF, 2000, MOL ENDOCRINOL, V14, P183, DOI 10.1210/me.14.1.183; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Perlman JH, 1997, BIOCHEMISTRY-US, V36, P15670, DOI 10.1021/bi9713310; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sun Y, 2003, J MOL ENDOCRINOL, V30, P87, DOI 10.1677/jme.0.0300087; Sun YH, 2002, ENDOCRINOLOGY, V143, P2886, DOI 10.1210/en.143.8.2886; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	33	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13103	13109		10.1074/jbc.M600440200	http://dx.doi.org/10.1074/jbc.M600440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551618	hybrid			2022-12-27	WOS:000237336600014
J	Hua, H; Zhang, YQ; Dabernat, S; Kritzik, M; Dietz, D; Sterling, L; Sarvetnick, N				Hua, H; Zhang, YQ; Dabernat, S; Kritzik, M; Dietz, D; Sterling, L; Sarvetnick, N			BMP4 regulates pancreatic progenitor cell expansion through Id2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; LOOP-HELIX PROTEINS; SIGNAL-TRANSDUCTION; SELF-RENEWAL; STEM-CELLS; GROWTH; DIFFERENTIATION; EXPRESSION; BETA; PATHWAY	Inhibitor of DNA binding (Id) proteins bind to and inhibit the function of basic helix-loop-helix (bHLH) transcription factors including those that regulate pancreatic development. Moreover, bone morphogenetic proteins (BMPs) regulate the expression of Ids. We hypothesized that BMP4 and Id proteins play a role in the expansion and differentiation of epithelial progenitor cells. We demonstrate that BMP4 induces the expression of Id2 along with the expansion of AR42J pancreatic epithelial cells. Furthermore, neutralization of BMP4 significantly reduced duct epithelial cell expansion in a mouse model of islet regeneration. BMP4 stimulation promotes Id2 binding to the bHLH transcription factor NeuroD, which is required for the differentiation of pancreatic islet cells. Therefore, our results indicate that BMP4 stimulation blocks the differentiation of endocrine progenitor cells and instead promotes their expansion thereby revealing a novel paradigm of signaling explaining the balance between expansion and differentiation of pancreatic duct epithelial progenitors. Understanding the mechanisms of BMPand Id function elucidates a key step during pancreas embryogenesis, which is important knowledge for expanding pancreatic progenitors in vitro.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, IMM 23, La Jolla, CA 90237 USA.	noras@scripps.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK066511, R01DK060746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK066511, DK060746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery-Padan R, 2004, DEV BIOL, V269, P479, DOI 10.1016/j.ydbio.2004.01.040; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; Brorson M, 2001, HISTOCHEM CELL BIOL, V116, P263, DOI 10.1007/s004180100316; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chae JH, 2004, MOL CELLS, V18, P271; Chen C, 2005, AM J PHYSIOL-LUNG C, V288, pL1033, DOI 10.1152/ajplung.00277.2004; Dichmann DS, 2003, DEV DYNAM, V226, P663, DOI 10.1002/dvdy.10270; Ghil SH, 2002, EXP MOL MED, V34, P367, DOI 10.1038/emm.2002.52; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GU DL, 1994, RECENT PROG HORM RES, V49, P161; GU DL, 1993, DEVELOPMENT, V118, P33; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Huang HP, 2002, MOL ENDOCRINOL, V16, P541, DOI 10.1210/me.16.3.541; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Jiang FX, 2002, J CELL SCI, V115, P753; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kayali AG, 2005, J ENDOCRINOL, V185, P45, DOI 10.1677/joe.1.05949; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu SY, 2004, EXP NEUROL, V190, P109, DOI 10.1016/j.expneurol.2004.07.015; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marsich E, 2003, BIOCHEM J, V376, P707, DOI 10.1042/BJ20031021; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; ROSEWICZ S, 1992, CLIN INVESTIGATOR, V70, P205; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sadlon TJ, 2004, STEM CELLS, V22, P457, DOI 10.1634/stemcells.22-4-457; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang YQ, 1999, DIABETOLOGIA, V42, P719, DOI 10.1007/s001250051220; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	48	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13574	13580		10.1074/jbc.M600526200	http://dx.doi.org/10.1074/jbc.M600526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547003	hybrid			2022-12-27	WOS:000237336600066
J	Kersting, MC; Carman, GM				Kersting, MC; Carman, GM			Regulation of the Saccharomyces cerevisiae EKI1-encoded ethanolamine kinase by zinc depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PHOSPHOLIPID BIOSYNTHESIS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; TRANSCRIPTIONAL ACTIVATOR; TRANSPORTER PROTEIN; GENETIC-REGULATION; YEAST; INOSITOL; ENCODES; VACUOLE	Ethanolamine kinase catalyzes the committed step in the synthesis of phosphatidylethanolamine via the CDP-ethanolamine branch of the Kennedy pathway. Regulation of the EKI1-encoded ethanolamine kinase by the essential nutrient zinc was examined in Saccharomyces cerevisiae. The level of ethanolamine kinase activity increased when zinc was depleted from the growth medium. This regulation correlated with increases in the CDP-ethanolamine pathway intermediates phosphoethanolamine and CDP-ethanolamine, and an increase in the methylated derivative of phosphatidylethanolamine, phosphatidylcholine. The beta-galactosidase activity driven by the P-EKI1-lacZ reporter gene was elevated in zinc-depleted cells, indicating that the increase in ethanolamine kinase activity was attributed to a transcriptional mechanism. The expression level of P-EKI1-lacZ reporter gene activity in the zrt1 Delta zrt2 Delta mutant ( defective in plasma membrane zinc transport) cells grown with zinc was similar to the activity expressed in wild-type cells grown without zinc. This indicated that EKI1 expression was sensitive to intracellular zinc. The zinc-mediated regulation of EKI1 expression was attenuated in the zap1 Delta mutant defective in the zinc-regulated transcription factor Zap1p. Direct interactions between Zap1p and putative zinc-responsive elements in the EKI1 promoter were demonstrated by electrophoretic mobility shift assays. Mutations of these elements to a nonconsensus sequence abolished Zap1p-DNA interactions. Taken together, this work demonstrated that the zinc-mediated regulation of ethanolamine kinase and the synthesis of phospholipids via the CDP-ethanolamine branch of the Kennedy pathway were controlled in part by Zap1p.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM028140, GM-28140, R37 GM028140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BECKER GW, 1977, J BIOL CHEM, V252, P8684; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHEN CC, 1984, J BIOL CHEM, V259, P150; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; Devirgiliis C, 2004, BIOCHEM BIOPH RES CO, V323, P58, DOI 10.1016/j.bbrc.2004.08.051; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Griac P, 1999, NUCLEIC ACIDS RES, V27, P2043, DOI 10.1093/nar/27.9.2043; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Kersting MC, 2004, J BIOL CHEM, V279, P35353, DOI 10.1074/jbc.M405704200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MENON AK, 1992, J BIOL CHEM, V267, P15277; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	69	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13110	13116		10.1074/jbc.M601612200	http://dx.doi.org/10.1074/jbc.M601612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551612	Green Accepted, hybrid			2022-12-27	WOS:000237336600015
J	Poteser, M; Graziani, A; Rosker, C; Eder, P; Derler, I; Kahr, H; Zhu, MX; Romanin, C; Groschner, K				Poteser, M; Graziani, A; Rosker, C; Eder, P; Derler, I; Kahr, H; Zhu, MX; Romanin, C; Groschner, K			TRPC3 and TRPC4 associate to form a redox-sensitive cation channel - Evidence for expression of native TRPC3-TRPC4 heteromeric channels in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED HTRP3 CHANNELS; CA2+ ENTRY; ACTIVATION; PROTEINS; DIACYLGLYCEROL; RECEPTORS; CALCIUM; STRESS; DOMAIN; BRAIN	Canonical transient receptor potential proteins (TRPC) have been proposed to form homo- or heteromeric cation channels in a variety of tissues, including the vascular endothelium. Assembly of TRPC multimers is incompletely understood. In particular, heteromeric assembly of distantly related TRPC isoforms is still a controversial issue. Because we have previously suggested TRPC proteins as the basis of the redox-activated cation conductance of porcine aortic endothelial cells (PAECs), we set out to analyze the TRPC subunit composition of endogenous endothelial TRPC channels and report here on a redox- sensitive TRPC3-TRPC4 channel complex. The ability of TRPC3 and TRPC4 proteins to associate and to form a cation-conducting pore complex was supported by four lines of evidence as follows: 1) Co-immunoprecipitation experiments in PAECs and in HEK293 cells demonstrated the association of TRPC3andTRPC4in the same complex. 2) Fluorescence resonance energy transfer analysis demonstrated TRPC3-TRPC4 association, involving close proximity between the N terminus of TRPC4 and the C terminus of TRPC3 subunits. 3) Co expression of TRPC3 and TRPC4 in HEK293 cells generated a channel that displayed distinct biophysical and regulatory properties. 4) Expression of dominantnegative TRPC4 proteins suppressed TRPC3-related channel activity in the HEK293 expression system and in native endothelial cells. Specifically, an extracellularly hemagglutinin (HA)-tagged TRPC4 mutant, which is sensitive to blockage by anti-HA-antibody, was found to transfer anti- HA sensitivity to both TRPC3-related currents in the HEK293 expression system and the redox-sensitive cation conductance of PAECs. We propose TRPC3 and TRPC4 as subunits of native endothelial cation channels that are governed by the cellular redox state.	Karl Franzens Univ Graz, Inst Pharmaceut Sci Pharmacol & Toxicol, A-8010 Graz, Austria; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Linz, Inst Biophys, A-4020 Linz, Austria	University of Graz; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Johannes Kepler University Linz	Graziani, A (corresponding author), Karl Franzens Univ Graz, Inst Pharmaceut Sci Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	klaus.groschner@uni-graz.at	Derler, Isabella/B-7871-2019; Romanin, Christoph/D-5399-2009; Groschner, Klaus/A-2550-2010	Derler, Isabella/0000-0002-4768-146X; Romanin, Christoph/0000-0003-3756-4136; Groschner, Klaus/0000-0002-8659-377X; Poteser, Michael/0000-0002-9962-1098				Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Chang AS, 1997, FEBS LETT, V415, P335, DOI 10.1016/S0014-5793(97)01155-1; ELLIOTT SJ, 1989, J BIOL CHEM, V264, P3806; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Groschner Klaus, 2004, Novartis Found Symp, V258, P222; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohler R, 2001, CARDIOVASC RES, V51, P160, DOI 10.1016/S0008-6363(01)00281-4; Koliwad SK, 1996, J PHYSIOL-LONDON, V495, P37, DOI 10.1113/jphysiol.1996.sp021572; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Rosker C, 2004, J BIOL CHEM, V279, P13696, DOI 10.1074/jbc.M308108200; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Schilling William P, 2004, Novartis Found Symp, V258, P18; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Zhang ZM, 2001, BIOCHEM J, V354, P717, DOI 10.1042/0264-6021:3540717; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	28	163	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13588	13595		10.1074/jbc.M512205200	http://dx.doi.org/10.1074/jbc.M512205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537542	hybrid			2022-12-27	WOS:000237336600068
J	Maccarana, M; Olander, B; Malmstrom, J; Tiedemann, K; Aebersold, R; Lindahl, U; Li, JP; Malmstrom, A				Maccarana, M; Olander, B; Malmstrom, J; Tiedemann, K; Aebersold, R; Lindahl, U; Li, JP; Malmstrom, A			Biosynthesis of dermatan sulfate - Chondroitin-glucuronate C5-epimerase is identical to SART2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-REJECTION ANTIGENS; STATISTICAL-MODEL; HEPARIN; PROTEOGLYCANS; EXPRESSION; SUBSTRATE; POLYSACCHARIDE; EPIMERIZATION; SEQUENCES; PEPTIDES	We identified the gene encoding chondroitin-glucuronate C5-epimerase ( EC 5.1.3.19) that converts D-glucuronic acid to L-iduronic acid residues in dermatan sulfate biosynthesis. The enzyme was solubilized from bovine spleen, and an similar to 43,000-fold purified preparation containing a major 89-kDa candidate component was subjected to mass spectrometry analysis of tryptic peptides. SART2 ( squamous cell carcinoma antigen recognized by T cell 2), a protein with unknown function highly expressed in cancer cells and tissues, was identified by 18 peptides covering 26% of the sequence. Transient expression of cDNA resulted in a 22-fold increase in epimerase activity in 293HEK cell lysate. Moreover, overexpressing cells produced dermatan sulfate chains with 20% of iduronic acid-containing disaccharide units, as compared with 5% for mock-transfected cells. The iduronic acid residues were preferentially clustered in blocks, as in naturally occurring dermatan sulfate. Given the discovered identity, we propose to rename SART2 ( Nakao, M., Shichijo, S., Imaizumi, T., Inoue, Y., Matsunaga, K., Yamada, A., Kikuchi, M., Tsuda, N., Ohta, K., Takamori, S., Yamana, H., Fujita, H., and Itoh, K. ( 2000) J. Immunol. 164, 2565-2574) with a functional designation, chondroitin-glucuronate C5-epimerase ( or DS epimerase). DS epimerase activity is ubiquitously present in normal tissues, although with marked quantitative differences. It is highly homologous to part of the NCAG1 protein, encoded by the C18orf4 gene, genetically linked to bipolar disorder. NCAG1 also contains a putative chondroitin sulfate sulfotransferase domain and thus may be involved in dermatan sulfate biosynthesis. The functional relation between dermatan sulfate and cancer is unknown but may involve known iduronic acid-dependent interactions with growth factors, selectins, cytokines, or coagulation inhibitors.	Lund Univ, Dept Expt Med Sci, SE-22184 Lund, Sweden; ETH Honggerberg, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Lund University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Uppsala University	Maccarana, M (corresponding author), Lund Univ, Dept Expt Med Sci, BMC C13, SE-22184 Lund, Sweden.	marco.maccarana@med.lu.se	Malmström, Johan A/B-7660-2009; maccarana, marco/AAB-4764-2021; Tiedemann, one/A-9739-2016	Malmström, Johan A/0000-0002-2889-7169; Malmstrom, Anders/0000-0002-6691-146X; Maccarana, Marco/0000-0003-3549-8921				Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Eklund E, 2000, ARCH BIOCHEM BIOPHYS, V383, P171, DOI 10.1006/abbi.2000.2043; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; FERRO DR, 1990, CARBOHYD RES, V195, P157, DOI 10.1016/0008-6215(90)84164-P; Goossens D, 2003, MOL PSYCHIATR, V8, P83, DOI 10.1038/sj.mp.4001190; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; Hagner-McWhirter A, 2004, J BIOL CHEM, V279, P14631, DOI 10.1074/jbc.M313760200; Hannesson HH, 1996, BIOCHEM J, V313, P589, DOI 10.1042/bj3130589; HOOK M, 1974, J BIOL CHEM, V249, P3908; HOOK M, 1975, J BIOL CHEM, V250, P6065; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Isogai Z, 1996, CANCER RES, V56, P3902; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lee H, 2004, J CHROMATOGR B, V803, P101, DOI 10.1016/j.jchromb.2003.09.005; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1982, BIOCHEM J, V201, P489, DOI 10.1042/bj2010489; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; MALMSTROM L, 2006, IN PRESS BMC BIOINFO; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakao M, 2000, J IMMUNOL, V164, P2565, DOI 10.4049/jimmunol.164.5.2565; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Noguchi M, 2003, PROSTATE, V57, P80, DOI 10.1002/pros.10276; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SARRAZIN S, 2005, IN PRESS BIOCH BIOPH; Sasatomi T, 2002, CANCER, V94, P1636, DOI 10.1002/cncr.10421; Seidler DG, 2002, J BIOL CHEM, V277, P42409, DOI 10.1074/jbc.M208442200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Suzuki N, 2002, INT J CANCER, V98, P45, DOI 10.1002/ijc.10145; Svanem BIG, 2001, J BIOL CHEM, V276, P31542, DOI 10.1074/jbc.M102562200; Tanaka S, 2000, JPN J CANCER RES, V91, P1177, DOI 10.1111/j.1349-7006.2000.tb00902.x; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Tiedemann K, 2005, GLYCOBIOLOGY, V15, P1277, DOI 10.1093/glycob/cwj027; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	50	99	103	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11560	11568		10.1074/jbc.M513373200	http://dx.doi.org/10.1074/jbc.M513373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505484	Green Submitted, hybrid			2022-12-27	WOS:000236988100018
J	Marcinkiewicz, A; Gauthier, D; Garcia, A; Brasaemle, DL				Marcinkiewicz, A; Gauthier, D; Garcia, A; Brasaemle, DL			The phosphorylation of serine 492 of perilipin A directs lipid droplet fragmentation and dispersion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DIFFERENTIATION-RELATED PROTEIN; LIPOLYTIC STIMULATION; CHOLESTERYL ESTER; MEDIATED LIPOLYSIS; VESICLE TRANSPORT; TRANSLOCATION; STORAGE; MODULATION; ADIPOCYTES	Perilipin A is a key regulator of triacylglycerol storage and hydrolysis in adipocytes; phosphorylation of perilipin A by protein kinase A facilitates maximal lipolysis. Chronic stimulation of lipolysis in 3T3-L1 adipocytes causes large perinuclear lipid droplets to fragment into myriad dispersed perilipin A-covered microlipid droplets. In cultured fibroblasts stably expressing ectopic perilipin A, clustered lipid droplets disperse throughout the cytoplasm upon incubation of the cells with forskolin and isobutylmethylxanthine (IBMX) to elevate levels of cAMP and activate protein kinase A, mirroring events observed in adipocytes. Furthermore, diethylumbelliferyl phosphate inhibits stimulated lipolysis but not the dispersion of lipid droplets, suggesting that products of lipolysis are not required for this remodeling process. We hypothesized that protein kinase A-mediated phosphorylation of perilipin A triggers the remodeling of lipid droplets. The mutation of serine 492 of perilipin A to alanine prevented the dispersion of clustered lipid droplets in fibroblasts stably expressing the mutated perilipin upon incubation with forskolin and IBMX. In contrast, the substitution of serines 81, 222, 276, or 433 with alanine, either singly or in combinations, did not affect the protein kinase A-mediated remodeling of lipid droplets. Interestingly, substitution of serines 433, 492, and 517 of perilipin A with glutamic acid residues blocked the dispersion of clustered lipid droplets in cells incubated with forskolin and IBMX, indicating that the addition of a negative charge does not mimic a phosphate group. We conclude that protein kinase A-mediated phosphorylation of serine 492 of perilipin A drives the fragmentation and dispersion of lipid droplets.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	Brasaemle@AESOP.Rutgers.edu		Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54797] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Clifford GM, 2001, METABOLISM, V50, P1264, DOI 10.1053/meta.2001.27216; Clifford GM, 1997, BIOCHEM SOC T, V25, pS672, DOI 10.1042/bst025s672; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Granneman JG, 2004, AM J PHYSIOL-ENDOC M, V287, pE574, DOI 10.1152/ajpendo.00567.2003; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gross SP, 2000, J CELL BIOL, V148, P945, DOI 10.1083/jcb.148.5.945; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HARRISON EH, 1990, J LIPID RES, V31, P2187; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401; Patel RT, 2005, J BIOL CHEM, V280, P22624, DOI 10.1074/jbc.M413128200; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Welte MA, 2005, CURR BIOL, V15, P1266, DOI 10.1016/j.cub.2005.06.062; Welte MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	55	186	191	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11901	11909		10.1074/jbc.M600171200	http://dx.doi.org/10.1074/jbc.M600171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16488886	hybrid			2022-12-27	WOS:000236988100058
J	Ju, DH; Xie, YM				Ju, DH; Xie, YM			Identification of the preferential ubiquitination site and ubiquitin-dependent degradation signal of Rpn4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CELL-CYCLE; SUBSTRATE; MECHANISMS; PROTEOLYSIS; PROTEASOME; EXPRESSION; BINDING; DOMAIN	Lysine selection is a long-standing problem in protein ubiquitination catalyzed by the RING ubiquitin ligases. It is well known that many substrates carry multiple lysines that can be ubiquitinated. However, it has seldom been addressed whether one lysine is preferred for ubiquitin conjugation when all other lysines exist. Here we studied the mechanism underlying ubiquitin-dependent degradation of Rpn4, a transcription activator of the Saccharomyces cerevisiae proteasome genes. We found that the ubiquitin-dependent degradation of Rpn4 can be mediated by six different lysines. Interestingly, we showed through in vivo and in vitro assays that lysine 187 is selected for ubiquitination when all other lysines are available. To the best of our knowledge, this is the first demonstration of a preferential ubiquitination site chosen from a group of lysines susceptible for ubiquitination. We further demonstrated that lysine 187 and a proximal acidic domain constitute a portable degradation signal. The implications of our data are discussed.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Xie, YM (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, 110 E Warren Ave, Detroit, MI 48201 USA.	xiey@karmanos.org						Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; Ju DH, 2004, BIOCHEM BIOPH RES CO, V321, P51, DOI 10.1016/j.bbrc.2004.06.105; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Madura K, 2004, TRENDS BIOCHEM SCI, V29, P637, DOI 10.1016/j.tibs.2004.10.008; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Wang L, 2004, J BIOL CHEM, V279, P55218, DOI 10.1074/jbc.M410085200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298	30	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10657	10662		10.1074/jbc.M513790200	http://dx.doi.org/10.1074/jbc.M513790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492666	hybrid			2022-12-27	WOS:000236822200003
J	Kim, JY; Zhang, XW; Rieger-Christ, KM; Summerhayes, IC; Wazer, DE; Paulson, KE; Yee, AS				Kim, JY; Zhang, XW; Rieger-Christ, KM; Summerhayes, IC; Wazer, DE; Paulson, KE; Yee, AS			Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells - Requirement of the transcriptional repressor HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; C-MYC; BETA-CATENIN; PATHWAY; GENE; TARGET; PROLIFERATION; ACTIVATION; EXPRESSION; MECHANISM	Genetic and biochemical de-regulation of Wnt signaling is correlated with breast and other cancers. Our goal was to identify compounds that block Wnt signaling as a first step toward investigating new strategies for suppression of invasive and other breast cancers. In a limited phytonutrient screen, EGCG ((-)- epigallocatechin 3-gallate), the major phytochemical in green tea, emerged as an intriguing candidate. Epidemiological studies have associated green tea consumption with reduced recurrence of invasive and other breast cancers. Wnt signaling was inhibited by EGCG in a dose-dependent manner in breast cancer cells. The apparent mechanism targeted the HBP1 transcriptional repressor, which we had previously characterized as a suppressor of Wnt signaling. EGCG treatment induced HBP1 transcriptional repressor levels through an increase in HBP1 mRNA stability, but not transcriptional initiation. To test functionality, DNA-based short hairpin RNA (shRNA) was used to knockdown the endogenous HBP1 gene. Consistently, the HBP1 knockdown lines had reduced sensitivity to EGCG in the suppression of Wnt signaling and of a target gene (c-MYC). Because our ongoing studies clinically link abrogation of HBP1 with invasive breast cancer, we tested if EGCG also regulated biological functions associated with de-regulated Wnt signaling and with invasive breast cancer. EGCG reduced both breast cancer cell tumorigenic proliferation and invasiveness in an HBP1-dependent manner. Together, the emerging mechanism is that EGCG blocks Wnt signaling by inducing the HBP1 transcriptional repressor and inhibits aspects of invasive breast cancer. These studies provide a framework for considering future studies in breast cancer treatment and prevention.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Nutr Sci & Policy, Program Cell & Mol Nutr, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Lahey Clin Fdn, Cell & Mol Biol Lab, RE Wise MD Res & Educ Inst, Burlington, MA 01805 USA	Tufts University; Tufts University; Tufts Medical Center; Lahey Hospital & Medical Center	Yee, AS (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	amy.yee@tufts.edu		Kim, Jiyoung/0000-0002-0049-2039	NCI NIH HHS [CA-94187, CA-104236] Funding Source: Medline; NIDDK NIH HHS [1DK59400, P30-DK34928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104236, R01CA094187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059400, P30DK034928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arends JW, 2000, J PATHOL, V190, P412; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Chow HHS, 2003, CLIN CANCER RES, V9, P3312; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harris J.R., 2000, DIS BREAST; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Howe LR, 2003, CANCER RES, V63, P1906; Inoue M, 2001, CANCER LETT, V167, P175, DOI 10.1016/S0304-3835(01)00486-4; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; Musgrove EA, 2004, BREAST CANCER RES, V6, P65, DOI 10.1186/bcr737; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Pisters KMW, 2001, J CLIN ONCOL, V19, P1830, DOI 10.1200/JCO.2001.19.6.1830; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Robanus-Maandag EC, 2003, J PATHOL, V201, P75, DOI 10.1002/path.1385; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Sartippour MR, 2001, NUTR CANCER, V40, P149, DOI 10.1207/S15327914NC402_11; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Wu AH, 2003, INT J CANCER, V106, P574, DOI 10.1002/ijc.11259; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yee AS, 1999, PEDIATR PATHOL MOL M, V18, P275; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	49	154	160	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10865	10875		10.1074/jbc.M513378200	http://dx.doi.org/10.1074/jbc.M513378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495219	hybrid			2022-12-27	WOS:000236822200026
J	Assmann, EM; Alborghetti, MR; Camargo, MER; Kobarg, J				Assmann, EM; Alborghetti, MR; Camargo, MER; Kobarg, J			FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 2-HYBRID SYSTEM; RETINOIC ACID; MOUSE CDNA; COMPLEX; IDENTIFICATION; DOMAIN; SCHIZOPHRENIA; CELLS; GENE	The fasciculation and elongation protein zeta 1 (FEZ1) is a mammalian orthologue of the Caenorhabditis elegans protein UNC-76, which is necessary for axon growth in that nematode. In previous studies FEZ1 has been found to interact with protein kinase C zeta, DISC1, the agnoprotein of the human polyomavirus JC virus, and E4B, a U-box-type ubiquitin-protein isopeptide ligase. We reported previously that FEZ1 and its paralogue FEZ2 are proteins that interact with NEK1, a protein kinase involved in polycystic kidney disease and DNA repair mechanisms at the G(2)/M phase of the cell cycle. Here we report the identification of 16 proteins that interact with human FEZ1-( 221 - 396) in a yeast two-hybrid assay of a human fetal brain cDNA library. The 13 interacting proteins of known functions take part either in transcription regulation and chromatin remodeling ( 6 proteins), the regulation of neuronal cell development ( 2 proteins) and cellular transport mechanisms ( 3 proteins) or participate in apoptosis ( 2 proteins). We were able to confirm eight of the observed interactions by in vitro pull-down assays with recombinant fusion proteins. The confirmed interacting proteins include FEZ1 itself and three transcription controlling proteins (SAP30L, DRAP1, and BAF60a). In mapping studies we found that the C-terminal regions of FEZ1, and especially its coiled-coil region, are involved in its dimerization, its heterodimerization with FEZ2, and in the interaction with 10 of the identified interacting proteins. Our results give further support to the previous speculation of the functional involvement of FEZ1 in neuronal development but suggest further that FEZ1 may also be involved in transcriptional control.	Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, BR-13084970 Campinas, SP, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas	Kobarg, J (corresponding author), Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, Rua Giuseppe Maximo Scolfaro 10-000,CP 6192, BR-13084971 Campinas, SP, Brazil.	jkobarg@lnls.br	Alborghetti, Marcos/K-7547-2012; Kobarg, Jörg/T-4736-2019	Alborghetti, Marcos/0000-0003-4517-5579; Kobarg, Jörg/0000-0002-9419-0145				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Buther K, 2004, BIOCHEM BIOPH RES CO, V317, P703, DOI 10.1016/j.bbrc.2004.03.107; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Clabecq A, 2000, J BIOL CHEM, V275, P31786, DOI 10.1074/jbc.M003705200; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Fujita T, 2004, BIOCHEM BIOPH RES CO, V313, P738, DOI 10.1016/j.bbrc.2003.12.006; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Gindhart JG, 2003, MOL BIOL CELL, V14, P3356, DOI 10.1091/mbc.E02-12-0800; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jung HY, 2005, HEPATOL RES, V31, P143, DOI 10.1016/j.hepres.2004.12.006; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kamiya A, 2005, NAT CELL BIOL, V7, P1167, DOI 10.1038/ncb1328; Kitamura M, 2002, NEPHROL DIAL TRANSPL, V17, P84, DOI 10.1093/ndt/17.suppl_9.84; Kremerskothen J, 2003, BIOCHEM BIOPH RES CO, V300, P862, DOI 10.1016/S0006-291X(02)02945-5; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Lindfors K, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-53; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Naghavi MH, 2005, GENE DEV, V19, P1105, DOI 10.1101/gad.1290005; Oishi H, 1998, J BIOL CHEM, V273, P34580, DOI 10.1074/jbc.273.51.34580; Okumura F, 2004, J BIOL CHEM, V279, P53533, DOI 10.1074/jbc.M402916200; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Park EJ, 1999, NUCLEIC ACIDS RES, V27, P1524, DOI 10.1093/nar/27.6.1524; Quarmby LM, 2005, J CELL SCI, V118, P5161, DOI 10.1242/jcs.02681; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Surpili MJ, 2003, BIOCHEMISTRY-US, V42, P15369, DOI 10.1021/bi034575v; Suzuki T, 2005, J BIOL CHEM, V280, P24948, DOI 10.1074/jbc.M411499200; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	51	37	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9869	9881		10.1074/jbc.M513280200	http://dx.doi.org/10.1074/jbc.M513280200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484223	hybrid			2022-12-27	WOS:000236594300008
J	Han, J; Goldstein, LA; Gastman, BR; Rabinowich, H				Han, J; Goldstein, LA; Gastman, BR; Rabinowich, H			Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GRANZYME-B; T-CELLS; BAX; CLEAVAGE; PROTEINS; DEATH; SMAC/DIABLO; BCL-2; MECHANISMS	The current study demonstrates a novel cross-talk mechanism between the TRAIL receptor death signaling pathway and the mitochondria. This newly identified pathway is regulated at the mitochondrial outer membrane by a complex between the prosurvival Bcl-2 member, Mcl-1 and the BH3-only protein, Bim. Under non-apoptotic conditions, Bim is sequestered by Mcl-1. Direct degradation of Mcl-1 by TRAIL-activated caspase-8 or caspase-3 produces Mcl-1-free Bim that mediates a Bax-dependent apoptotic cascade. Using Mcl-1 or Bim RNAi, we demonstrate that a loss in Mcl-1 expression significantly enhances the mitochondrial apoptotic response to TRAIL that is now mediated by freed Bim. Whereas overexpression of Mcl-1 contributes to the preservation of the mitochondrial membrane potential, Mcl-1 knockdown facilitates the Bim-mediated dissipation of this potential. Loss of Mcl-1 contributes to an increased level of caspase activity downstream of the mitochondrial response to TRAIL. Furthermore, the Mcl-1 expression level at the mitochondrial outer membrane determines the release efficiency for the apoptogenic proteins cytochrome c, Smac, and HtrA2 in response to Bim. These are the first findings to demonstrate the involvement of Bim in the TRAIL-mediated mitochondrial cascade. They also suggest that Mcl-1 may serve as a direct substrate for TRAIL-activated caspases implying the existence of a novel TRAIL/caspase-8/Mcl-1/Bim communication mechanism between the extrinsic and the intrinsic apoptotic pathways.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Plast Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil Rm G17c,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NCI NIH HHS [R01 CA 109285] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Johnson DE, 2000, CANCER RES, V60, P1818; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Ravi R, 2002, CANCER RES, V62, P1583; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200	29	160	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10153	10163		10.1074/jbc.M510349200	http://dx.doi.org/10.1074/jbc.M510349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478725	hybrid			2022-12-27	WOS:000236594300041
J	Hecker, CM; Rabiller, M; Haglund, K; Bayer, P; Dikic, I				Hecker, Christina-Maria; Rabiller, Matthias; Haglund, Kaisa; Bayer, Peter; Dikic, Ivan			Specification of SUMO1- and SUMO2-interacting motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; SUMO-BINDING MOTIF; COVALENT MODIFICATION; GENE-EXPRESSION; E3 LIGASE; MECHANISM; HELICASE; SYSTEM; PML	SUMO proteins are ubiquitin-related modifiers implicated in the regulation of gene transcription, cell cycle, DNA repair, and protein localization. The molecular mechanisms by which the sumoylation of target proteins regulates diverse cellular functions remain poorly understood. Here we report isolation and characterization of SUMO1- and SUMO2-binding motifs. Using yeast two-hybrid system, bioinformatics, and NMR spectroscopy we define a common SUMO-interacting motif (SIM) and map its binding surfaces on SUMO1 and SUMO2. This motif forms a beta-strand that could bind in parallel or antiparallel orientation to the beta(2)-strand of SUMO due to the environment of the hydrophobic core. A negative charge imposed by a stretch of neighboring acidic amino acids and/or phosphorylated serine residues determines its specificity in binding to distinct SUMO paralogues and can modulate the spatial orientation of SUMO-SIM interactions.	Univ Duisburg Essen, Fachbereich Biol & Geog Strukturelle & Med Bioche, D-45117 Essen, Germany; Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	University of Duisburg Essen; Goethe University Frankfurt	Bayer, P (corresponding author), Univ Duisburg Essen, Fachbereich Biol & Geog Strukturelle & Med Bioche, Univ Str, D-45117 Essen, Germany.	Peter.Bayer@uni-due.de; Ivan.Dikic@biochem2.de	Bayer, Peter/B-8803-2009; Haglund, Kaisa/B-3927-2017; Dikic, Ivan/O-4650-2015	Bayer, Peter/0000-0003-0435-7202; Haglund, Kaisa/0000-0002-7946-3299; Dikic, Ivan/0000-0001-8156-9511				Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eladad S, 2005, HUM MOL GENET, V14, P1351, DOI 10.1093/hmg/ddi145; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Hofmann K, 2000, Brief Bioinform, V1, P167, DOI 10.1093/bib/1.2.167; Huang WC, 2004, EUR J BIOCHEM, V271, P4114, DOI 10.1111/j.1432-1033.2004.04349.x; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kunapuli P, 2003, ONCOGENE, V22, P3417, DOI 10.1038/sj.onc.1206408; Macauley MS, 2004, J BIOL CHEM, V279, P49131, DOI 10.1074/jbc.M408705200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moreira MC, 2004, NAT GENET, V36, P225, DOI 10.1038/ng1303; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Shou ZF, 2004, BIOCHEM BIOPH RES CO, V314, P885, DOI 10.1016/j.bbrc.2003.12.162; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1	40	390	403	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16117	16127		10.1074/jbc.M512757200	http://dx.doi.org/10.1074/jbc.M512757200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16524884	hybrid			2022-12-27	WOS:000237996000065
J	Kartvelishvily, E; Shleper, M; Balan, L; Dumin, E; Wolosker, H				Kartvelishvily, Elena; Shleper, Maria; Balan, Livia; Dumin, Elena; Wolosker, Herman			Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; GLYCINE TRANSPORTER GLYT1; NEUROMODULATOR D-SERINE; RAT-BRAIN; SYNAPTIC VESICLES; AMINO-ACIDS; POSTNATAL-DEVELOPMENT; HIPPOCAMPAL-NEURONS; PROTON GRADIENT; NMDA RECEPTORS	D-Serine is a coagonist of N-methyl-D-aspartate ( NMDA) receptors that occurs at high levels in the brain. Biosynthesis of D-serine is carried out by serine racemase, which converts L-to D-serine. D-Serine has been demonstrated to occur in glial cells, leading to the proposal that astrocytes are the only source of D-serine. We now report significant amounts of serine racemase and D-serine in primary neuronal cultures and neurons in vivo. Several neuronal culture types expressed serine racemase, and D-serine synthesis was comparable with that in glial cultures. Immunohistochemical staining of brain sections with new antibodies revealed the presence of serine racemase and D-serine in neurons. Cortical neurons expressing serine racemase also expressed the NR2a subunit in situ. Neuron-derived D-serine contributes to NMDA receptor activation in cortical neuronal cultures. Degradation of endogenous D-serine by addition of the recombinant enzyme D-serine deaminase diminished NMDA-elicited excitotoxicity. Release of neuronal D-serine was mediated by ionotropic glutamate receptor agonists such as NMDA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, and kainate. Removal of either external Ca2+ or Na+ blocked D-serine release. Release of D-serine was mostly through a cytosolic route because it was insensitive to bafilomycin A(1), a potent inhibitor of vesicular neurotransmitter uptake. D-Serine was also not transported into purified synaptic vesicles under conditions optimal for the uptake of known transmitters. Our results suggest that neurons are a major source of D-serine. Glutamate-induced neuronal D-serine release provides a novel mechanism for activating NMDA receptors by an autocrine or paracrine way.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Wolosker, H (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel.	hwolosker@tx.technion.ac.il		Wolosker, Herman/0000-0001-5508-9194				ADAMS RH, 1995, J NEUROSCI, V15, P2524, DOI 10.1523/JNEUROSCI.15-03-02524.1995; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; Bradford SE, 2004, NEUROSCIENCE, V128, P751, DOI 10.1016/j.neuroscience.2004.06.065; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CARLSON MD, 1990, NEUROSCI LETT, V110, P325, DOI 10.1016/0304-3940(90)90868-A; Ciriacks CM, 2006, NEUROSCI LETT, V393, P200, DOI 10.1016/j.neulet.2005.09.080; Danysz W, 1998, PHARMACOL REV, V50, P597; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; de Miranda J, 2002, P NATL ACAD SCI USA, V99, P14542, DOI 10.1073/pnas.222421299; de Tomasi JA, 1936, STAIN TECHNOL, V11, P137, DOI 10.3109/10520293609110513; Dravid SM, 2003, NEUROSCI LETT, V351, P145, DOI 10.1016/j.neulet.2003.07.017; Foltyn VN, 2005, J BIOL CHEM, V280, P1754, DOI 10.1074/jbc.M405726200; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Furuya S, 2000, P NATL ACAD SCI USA, V97, P11528, DOI 10.1073/pnas.200364497; GIUFFRIDA AM, 1975, ITAL J BIOCHEM, V24, P288; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Harlow E., 1988, ANTIBODIES LAB MANUA, P343; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HASHIMOTO A, 1993, J NEUROCHEM, V60, P783, DOI 10.1111/j.1471-4159.1993.tb03219.x; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JOHNSON RG, 1981, J BIOL CHEM, V256, P5773; Kim PM, 2005, P NATL ACAD SCI USA, V102, P2105, DOI 10.1073/pnas.0409723102; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; Matsuo H, 2004, NEUROSCI LETT, V358, P123, DOI 10.1016/j.neulet.2004.01.014; Molina JA, 1998, J NEURAL TRANSM, V105, P279, DOI 10.1007/s007020050057; Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; OTTERSEN OP, 1990, GLYCINE NEUROTRANSMI; Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; RAO VLR, 1995, J NEUROCHEM, V65, P1221; Ribeiro CS, 2002, BRAIN RES, V929, P202, DOI 10.1016/S0006-8993(01)03390-X; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Snyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; Strisovsky K, 2005, BIOCHEMISTRY-US, V44, P13091, DOI 10.1021/bi051201o; Tagliaferro P, 1997, J NEUROSCI METH, V77, P191, DOI 10.1016/S0165-0270(97)00126-X; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Troyer H., 1980, PRINCIPLES TECHNIQUE; Verleysdonk S, 1999, GLIA, V27, P239, DOI 10.1002/(SICI)1098-1136(199909)27:3<239::AID-GLIA5>3.0.CO;2-K; Wang LZ, 2003, ACTA PHARMACOL SIN, V24, P965; Williams SM, 2006, GLIA, V53, P401, DOI 10.1002/glia.20300; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 2002, NEUROCHEM INT, V41, P327, DOI 10.1016/S0197-0186(02)00055-4; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; Wolosker H, 1996, J BIOL CHEM, V271, P11726, DOI 10.1074/jbc.271.20.11726; Wood PL, 1996, J NEUROCHEM, V67, P1485; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Yasuda E, 2001, NEUROSCI LETT, V299, P162, DOI 10.1016/S0304-3940(01)01502-6; Zafra F, 1997, GLIA, V20, P155, DOI 10.1002/(SICI)1098-1136(199706)20:2<155::AID-GLIA7>3.0.CO;2-8; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	65	219	225	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14151	14162		10.1074/jbc.M512927200	http://dx.doi.org/10.1074/jbc.M512927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551623	hybrid			2022-12-27	WOS:000237512300039
J	Hawkins, KM; Smolke, CD				Hawkins, KM; Smolke, CD			The regulatory roles of the galactose permease and kinase in the induction response of the GAL network in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; QUANTITATIVE MODEL; ESCHERICHIA-COLI; YEAST; PROMOTER; SYSTEM; TRANSPORTER; SWITCH; GALACTOKINASE	The GAL genetic switch of Saccharomyces cerevisiae exhibits an ultrasensitive response to the inducer galactose as well as the " all-or-none" behavior characteristic of many eukaryotic regulatory networks. We have constructed a strain that allows intermediate levels of gene expression from a tunable GAL1 promoter at both the population and the single cell level by altering the regulation of the galactose permease Gal2p. Similar modifications to other feedback loops regulating the Gal80p repressor and the Gal3p signaling protein did not result in similarly tuned responses, indicating that the level of inducer transport is unique in its ability to control the switch response of the network. In addition, removal of the Gal1p galactokinase from the network resulted in a regimed response due to the dual role of this enzyme in galactose catabolism and transport. These two activities have competing effects on the response of the network to galactose such that the transport effects of Gal1p are dominant at low galactose concentrations, whereas its catabolic effects are dominant at high galactose concentrations. In addition, flow cytometry analysis revealed the unexpected phenomenon of multiple populations in the gal1 Delta strains, which were not present in the isogenic GAL1 background. This result indicates that Gal1p may play a previously undescribed role in the stability of the GAL network response.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Smolke, CD (corresponding author), CALTECH, Dept Chem Engn, 1200 E Calif Blvd,MC 210-41, Pasadena, CA 91125 USA.	smolke@cheme.caltech.edu						Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; BHAT PJ, 1990, GENETICS, V125, P281; Bhat PJ, 2005, FEBS LETT, V579, P597, DOI 10.1016/j.febslet.2004.12.038; Funk M, 2002, METHOD ENZYMOL, V350, P248, DOI 10.1016/S0076-6879(02)50967-8; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; JOHNSTON M, 2004, METHOD ENZYMOL, V194, P290; Khlebnikov A, 2001, MICROBIOL-SGM, V147, P3241, DOI 10.1099/00221287-147-12-3241; Koller A, 2000, YEAST, V16, P651, DOI 10.1002/(SICI)1097-0061(200005)16:7<651::AID-YEA580>3.3.CO;2-6; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; Li JC, 2000, BIOTECHNOL BIOENG, V70, P187, DOI 10.1002/1097-0290(20001020)70:2<187::AID-BIT8>3.0.CO;2-H; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOUIS M, 2002, SCI STKE, pPE33; MascorroGallardo JO, 1996, GENE, V172, P169, DOI 10.1016/0378-1119(96)00059-5; Mateus C, 2000, YEAST, V16, P1313, DOI 10.1002/1097-0061(200010)16:14<1313::AID-YEA626>3.0.CO;2-O; Morgan-Kiss RM, 2002, P NATL ACAD SCI USA, V99, P7373, DOI 10.1073/pnas.122227599; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Peng G, 2002, P NATL ACAD SCI USA, V99, P8548, DOI 10.1073/pnas.142100099; RAMOS J, 1989, J BACTERIOL, V171, P3539, DOI 10.1128/jb.171.6.3539-3544.1989; Ruhela A, 2004, FEBS LETT, V576, P119, DOI 10.1016/j.febslet.2004.09.001; SCHELL MA, 1977, J BIOL CHEM, V252, P1162; SIKORSKI RS, 1989, GENETICS, V122, P19; Solow SP, 2005, BIOTECHNOL PROGR, V21, P617, DOI 10.1021/bp049916q; Stagoj MN, 2005, FEMS MICROBIOL LETT, V244, P105, DOI 10.1016/j.femsle.2005.01.041; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; Venkatesh KV, 1999, BIOTECHNOL PROGR, V15, P51, DOI 10.1021/bp9801042; Verma M, 2004, BIOTECHNOL APPL BIOC, V39, P89, DOI 10.1042/BA20030119; Verma M, 2003, J BIOL CHEM, V278, P48764, DOI 10.1074/jbc.M303526200; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yen KY, 2003, YEAST, V20, P1255, DOI 10.1002/yea.1037	33	40	48	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13485	13492		10.1074/jbc.M512317200	http://dx.doi.org/10.1074/jbc.M512317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524886	hybrid, Green Accepted			2022-12-27	WOS:000237336600056
J	Lu, B; Garrido, N; Spelbrink, JN; Suzuki, CK				Lu, B; Garrido, N; Spelbrink, JN; Suzuki, CK			Tid1 isoforms are mitochondrial DnaJ-like chaperones with unique carboxyl termini that determine cytosolic fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TUMOR-SUPPRESSOR; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; BINDING PROTEIN; HUMAN HOMOLOG; T-ANTIGENS; J-DOMAIN; HTID-1; HSP70; YEAST	Tid1 is a human homolog of bacterial DnaJ and the Drosophila tumor suppressor Tid56 that has two alternatively spliced isoforms, Tid1-long and -short (Tid1-L and -S), which differ only at their carboxyl termini. Although Tid1 proteins localize overwhelmingly to mitochondria, published data demonstrate principally nonmito-chondrial protein interactions and activities. This study was undertaken to determine whether Tid1 proteins function as mitochondrial DnaJ-like chaperones and to resolve the paradox of how proteins targeted primarily to mitochondria function in nonmito-chondrial pathways. Here we demonstrate that Tid1 isoforms exhibit a conserved mitochondrial DnaJ-like function substituting for the yeast mitochondrial DnaJ-like protein Mdj1p. Like Mdj1p, Tid1 localizes to human mitochondrial nucleoids, which are large protein complexes bound to mitochondrial DNA. Unlike other DnaJs, Tid1-L and -S form heterocomplexes; both unassembled and complexed Tid1 are observed in human cells. Results demonstrate that Tid1-L has a longer residency time in the cytosol prior to mitochondrial import as compared with Tid1-S; Tid1-L is also significantly more stable in the cytosol than Tid1-S, which is rapidly degraded. The longer cytosolic residency time and the half-life of Tid1-L are explained by its interaction with cytosolic Hsc70 and potential protein substrates such as the STAT1 and STAT3 transcription factors. We show that the unique carboxyl terminus of Tid1-L is required for interaction with Hsc70 and STAT1 and -3. We propose that the association of Tid1 with chaperones and/or protein substrates in the cytosol provides a mechanism for the alternate fates and functions of Tid1 in mitochondrial and nonmito-chondrial pathways.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Tampere Univ Hosp, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ, FIN-33014 Tampere, Finland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Tampere University; Tampere University Hospital; Tampere University	Suzuki, CK (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	suzukick@umdnj.edu	Spelbrink, Johannes N/L-4661-2015; Lu, Bin/GQQ-3590-2022	Spelbrink, Johannes N/0000-0002-9756-2602; 				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Asai T, 2004, J BIOL CHEM, V279, P19464, DOI 10.1074/jbc.M401291200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duchniewicz M, 1999, MOL CELL BIOL, V19, P8201; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Germaniuk A, 2002, J BIOL CHEM, V277, P27801, DOI 10.1074/jbc.M201756200; Gething MJ., 1997, GUIDE BOOK SERIES, P89; Hayashi M, 2006, NAT MED, V12, P128, DOI 10.1038/nm1327; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kim SW, 2005, CANCER RES, V65, P8784, DOI 10.1158/0008-5472.CAN-04-4422; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Lemmon SK, 2001, CURR BIOL, V11, pR49, DOI 10.1016/S0960-9822(01)00010-0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Lo JF, 2005, J IMMUNOL, V174, P6105, DOI 10.4049/jimmunol.174.10.6105; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; McBride Kevin M, 2003, Sci STKE, V2003, pRE13; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Tarunina M, 2004, MOL CELL BIOL, V24, P10792, DOI 10.1128/MCB.24.24.10792-10801.2004; Torregroza I, 2006, BIOCHEM J, V393, P311, DOI 10.1042/BJ20050785; Trentin GA, 2004, FEBS LETT, V578, P323, DOI 10.1016/j.febslet.2004.11.034; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Voos W, 2003, MOL CELL, V11, P1, DOI 10.1016/S1097-2765(03)00002-9; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Westermann B, 1996, MOL CELL BIOL, V16, P7063; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	48	49	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13150	13158		10.1074/jbc.M509179200	http://dx.doi.org/10.1074/jbc.M509179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531398	hybrid			2022-12-27	WOS:000237336600020
J	Misra, UK; Deedwania, R; Pizzo, SV				Misra, UK; Deedwania, R; Pizzo, SV			Activation and cross-talk between Akt, NF-kappa B, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; RECEPTOR-RECOGNIZED FORMS; MOLECULAR-MECHANISMS; BINDING-PROTEIN; GROWTH-FACTOR; UP-REGULATION; ER-STRESS; KINASE; ALPHA(2)-MACROGLOBULIN; PHOSPHORYLATION	Binding of activated forms of the proteinase inhibitor alpha(2)-macroglobulin (alpha M-2*) to cell surface-associated GRP78 on 1-LN human prostate cancer cells causes their proliferation. We have now examined the interplay between Akt activation, regulation of apoptosis, the unfolded protein response, and activation of NF-KB in alpha M-2*-induced proliferation of 1-LN cells. Exposure of cells to alpha M-2* (50 pM) induced phosphatidylinositol 3-kinase-dependent activation of Akt by phosphorylation at Thr-308 and Ser-473 with a concomitant 60-80% increase in Akt associated kinase activity. ERK1/2 and p38 MAPK were also activated, but there was only a marginal effect on JNK activation. Treatment of 1-LN cells with alpha M-2* down-regulated apoptosis and promoted NF-KB activation as shown by increases of Bcl-2, p-BadSer-136, p- FOXO1(Ser-) 253, p-GSK3 beta Ser-9, XIAP, NF-KB, cyclin D1, GADD45 beta, p- ASK1Ser-83, and TRAF2 in a time of incubation-dependent manner. alpha 2M* treatment of 1-LN cells, however, showed no increase in the activation of caspase- 3, - 9, or -12. Under these conditions, we observed increased unfolded protein response signaling as evidenced by elevated levels of GRP78, IRE1 alpha, XBP-1, ATF4, ATF6, p- PERK, p-eIF2 alpha, and GADD34 and reduced levels of GADD153. Silencing of GRP78 gene expression by RNAi suppressed activation of Akt(Thr-308), Akt(Ser-473), and IKB kinase alpha kinase. The effects of alpha M-2* on the NF-K B activation, antiapoptotic signaling, unfolded protein response signaling, and proapoptotic signaling were also reversed by this treatment. In conclusion, alpha M-2* promotes cellular proliferation of 1-LN prostate cancer cells by activating MAPK and Akt-dependent signaling, down-regulating apoptotic signaling, and activating unfolded protein response signaling.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	Pizzo001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Arai K, 2004, J NEUROCHEM, V89, P232, DOI 10.1111/j.1471-4159.2004.02317.x; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Asplin IR, 2000, ARCH BIOCHEM BIOPHYS, V383, P135, DOI 10.1006/abbi.2000.2052; Bhattacharjee G, 2001, J CELL BIOCHEM, V82, P260, DOI 10.1002/jcb.1152; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chung JY, 2002, J CELL SCI, V115, P679; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Eisenmann KM, 2003, CANCER RES, V63, P8330; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hill MM, 2002, METHOD ENZYMOL, V345, P448; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kaneko M, 2003, BIOL PHARM BULL, V26, P931, DOI 10.1248/bpb.26.931; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LU B, 2006, NAT IMMUNOL, V5, P38; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1999, J BIOL CHEM, V274, P25785, DOI 10.1074/jbc.274.36.25785; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Misra UK, 2005, J LEUKOCYTE BIOL, V78, P187, DOI 10.1189/jlb.1104685; Misra UK, 2005, J IMMUNOL, V174, P2092, DOI 10.4049/jimmunol.174.4.2092; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; Misra UK, 2004, CELL SIGNAL, V16, P487, DOI 10.1016/j.cellsig.2003.09.010; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; Misra UK, 2002, J BIOL CHEM, V277, P36509, DOI 10.1074/jbc.M203543200; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakayama K, 2003, BIOCHEM BIOPH RES CO, V308, P353, DOI 10.1016/S0006-291X(03)01393-7; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243; PIZZO SV, 2006, HEMOSTASIS THROMBOSE, P395; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZQ, 2003, J BIOL CHEM, V278, P11138, DOI 10.1074/jbc.M209108200; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang WM, 1998, CLIN CHEM, V44, P2471; ZU K, 2005, ONCOGENE, V24, P1	91	203	209	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13694	13707		10.1074/jbc.M511694200	http://dx.doi.org/10.1074/jbc.M511694200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543232	hybrid			2022-12-27	WOS:000237336600080
J	Miyagi, S; Nishimoto, M; Saito, T; Ninomiya, M; Sawamoto, K; Okano, H; Muramatsu, M; Oguro, H; Iwama, A; Okuda, A				Miyagi, S; Nishimoto, M; Saito, T; Ninomiya, M; Sawamoto, K; Okano, H; Muramatsu, M; Oguro, H; Iwama, A; Okuda, A			The Sox2 regulatory region 2 functions as a neural stem cell-specific enhancer in the telencephalon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DIFFERENTIATION; PROLIFERATION; NEUROGENESIS; PRECURSORS; LINEAGES; EMBRYO	Sox2 is expressed at high levels in neuroepithelial stem cells and persists in neural stem/ progenitor cells throughout adulthood. We showed previously that the Sox2 regulatory region 2 ( SRR2) drives strong expression in these cells. Here we generated transgenic mouse strains with the beta- geo reporter gene under the control of the SRR2 in order to examine the spatiotemporal function of this regulatory region. We show that the SRR2 functions specifically in neural stem/ progenitor cells. However, unlike Nestin 2nd intronic enhancer, the SRR2 shows strong regional specificity functioning only in restricted areas of the telencephalon but not in any other portions of the central nervous system such as the spinal cord. We also show by in vitro clonogenic assay that at least some of these SRR2- functioning cells possess the hallmark properties of neural stem cells. In adult brains, we could detect strong beta- geo expression in the subventricular zone of the lateral ventricle and along the rostral migrating stream where actively dividing cells reside. Chromatin immunoprecipitation assays reveal interactions of POU and Sox factors with SRR2 in neural stem/ progenitor cells. Our data also suggest that the specific recruitment of these proteins to the SRR2 in the telencephalon defines the spatiotemporal activity of the enhancer in the developing nervous system.	Saitama Med Univ, Res Ctr Genom Med, Div Dev Biol, Hidaka, Saitama 3501241, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dev Biol, Chiba 2608670, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Bridgestone Lab Dev & Regenerat Neurobiol, Shinjuku Ku, Tokyo 1608582, Japan; Saitama Small Enterprise Promot Corp, REDS Grp, Kawaguchi, Saitama 3330844, Japan	Saitama Medical University; Chiba University; Chiba University; Keio University; Keio University	Okuda, A (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Dev Biol, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	akiokuda@saitama-med.ac.jp	Oguro, Hideyuki/Q-5478-2019; Okano, Hideyuki/I-7584-2019	Oguro, Hideyuki/0000-0002-9070-4575; Saito, Tetsuichiro/0000-0002-1538-1454; Sawamoto, Kazunobu/0000-0003-1984-5129				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hanashima C, 2002, J NEUROSCI, V22, P6526; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Hitoshi S, 2002, DEVELOPMENT, V129, P233; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Johansson CB, 2002, J NEUROSCI RES, V69, P784, DOI 10.1002/jnr.10376; Josephson R, 1998, DEVELOPMENT, V125, P3087; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Komitova M, 2004, NEUROSCI LETT, V369, P24, DOI 10.1016/j.neulet.2004.07.035; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miyagi S, 2004, MOL CELL BIOL, V24, P4207, DOI 10.1128/MCB.24.10.4207-4220.2004; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Pevny L, 2005, CURR OPIN NEUROBIOL, V15, P7, DOI 10.1016/j.conb.2005.01.016; Pevny L, 2003, TRENDS NEUROSCI, V26, P351, DOI 10.1016/S0166-2236(03)00169-3; Saba R, 2005, DEVELOPMENT, V132, P2147, DOI 10.1242/dev.01781; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Uchikawa M, 2003, DEV CELL, V4, P509, DOI 10.1016/S1534-5807(03)00088-1; Wiebe MS, 2000, GENE, V246, P383, DOI 10.1016/S0378-1119(00)00086-X; Yoshizaki T, 2004, NEUROSCI LETT, V363, P33, DOI 10.1016/j.neulet.2004.03.074; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zappone MV, 2000, DEVELOPMENT, V127, P2367	38	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13374	13381		10.1074/jbc.M512669200	http://dx.doi.org/10.1074/jbc.M512669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547000	hybrid			2022-12-27	WOS:000237336600043
J	Puranik, M; Weeks, CL; Lahaye, D; Kabil, O; Taoka, S; Nielsen, SB; Groves, JT; Banerjee, R; Spiro, TG				Puranik, M; Weeks, CL; Lahaye, D; Kabil, O; Taoka, S; Nielsen, SB; Groves, JT; Banerjee, R; Spiro, TG			Dynamics of carbon monoxide binding to cystathionine beta-synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX REGULATION; HEME; PROTEIN; ENZYME; MUTATIONS; DOMAIN; MODEL; CO	Cystathionine beta- synthase ( CBS) condenses homocysteine, a toxic metabolite, with serine in a pyridoxal phosphate- dependent reaction. It also contains a heme cofactor to which carbon monoxide ( CO) or nitric oxide can bind, resulting in enzyme inhibition. To understand the mechanism of this regulation, we have investigated the equilibria and kinetics of CO binding to the highly active catalytic core of CBS, which is dimeric. CBS exhibits strong anticooperativity in CO binding with successive association constants of 0.24 and 0.02 mu M-1. Stopped flow measurements reveal slow CO association ( 0.0166 s (-1)) limited by dissociation of the endogenous ligand, Cys- 52. Rebinding of CO and of Cys- 52 following CO photodissociation were independently monitored via time- resolved resonance Raman spectroscopy. The Cys- 52 rebinding rate, 4000 s(-1), is essentially unchanged between pH7.6 and 10.5, indicating that the pK(a) of Cys- 52 is shifted below pH7.6. This effect is attributed to the nearby Arg- 266 residue, which is proposed to form a salt bridge with the dissociated Cys- 52, thereby inhibiting its protonation and slowing rebinding to the Fe. This salt bridge suggests a pathway for enzyme inactivation upon CO binding, because Arg- 266 is located on a helix that connects the heme and pyridoxal phosphate cofactor domains.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	University of Nebraska System; University of Nebraska Lincoln; Princeton University	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu; spiro@princeton.edu	Kabil, Omer/AAJ-1435-2020; Nielsen, Steen Brondsted/G-5844-2016; Groves, John T./GPP-7588-2022	Groves, John T./0000-0002-9944-5899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033576] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058984, HL58984, R01 HL058984-08] Funding Source: Medline; NIGMS NIH HHS [R01 GM033576-40, R01 GM033576, GM33576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R, 2005, ARCH BIOCHEM BIOPHYS, V433, P144, DOI 10.1016/j.abb.2004.08.037; Evande R, 2002, BIOCHEMISTRY-US, V41, P11832, DOI 10.1021/bi026248d; Evande R, 2004, ARCH BIOCHEM BIOPHYS, V427, P188, DOI 10.1016/j.abb.2004.04.027; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Ingi T, 1996, J NEUROSCI, V16, P5621; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Meier M, 2003, BBA-PROTEINS PROTEOM, V1647, P206, DOI 10.1016/S1570-9639(03)00048-7; Miles EW, 2004, J BIOL CHEM, V279, P29871, DOI 10.1074/jbc.R400005200; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Pazicni S, 2004, BIOCHEMISTRY-US, V43, P14684, DOI 10.1021/bi0488496; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2002, BIOCHEMISTRY-US, V41, P10454, DOI 10.1021/bi026052d; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Zhao XJ, 1999, APPL SPECTROSC, V53, P1200, DOI 10.1366/0003702991945669; Zhao XJ, 2000, J RAMAN SPECTROSC, V31, P349, DOI 10.1002/(SICI)1097-4555(200004)31:4<349::AID-JRS548>3.0.CO;2-6	21	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13433	13438		10.1074/jbc.M600246200	http://dx.doi.org/10.1074/jbc.M600246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16505479	Green Accepted, hybrid			2022-12-27	WOS:000237336600050
J	Wang, XH; Wang, F; Arterburn, L; Wollmann, R; Ma, JY				Wang, XH; Wang, F; Arterburn, L; Wollmann, R; Ma, JY			The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRPSC-LIKE CONFORMATION; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE A(2); PROTEASOMAL DEGRADATION; TRANSGENIC MICE; PRIMARY NEURONS; CELL-DEATH; SCRAPIE; NEURODEGENERATION; CONVERSION	Prion protein ( PrP), normally a cell surface protein, has been detected in the cytosol of a subset of neurons. The appearance of PrP in the cytosol could result from either retro- translocation of misfolded PrP from the endoplasmic reticulum ( ER) or impaired import of PrP into the ER. Transgenic mice expressing cytoplasmic PrP ( cyPrP) developed neurodegeneration in cerebellar granular neurons, although no detectable pathology was observed in other brain regions. In order to understand why granular neurons in the cerebellum were most susceptible to cyPrP- induced degeneration, we investigated the subcellular localization of cyPrP. Interestingly, we found that cyPrP is membrane- bound. In transfected cells, it binds to the ER and plasma/ endocytic vesicular membranes. In transgenic mice, it is associated with synaptic and microsomal membranes. Furthermore, the cerebellar neurodegeneration in transgenic mice correlates with the interaction between cyPrP and the hydrophobic lipid core of the membrane but not with either the aggregation status or the dosage of cyPrP. These results suggest that lipid membrane perturbation could be a cellular mechanism for cyPrP- induced neurotoxicity and explain the seemingly conflicting results concerning cyPrP.	Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University System of Ohio; Ohio State University; University of Chicago	Ma, JY (corresponding author), Ohio State Univ, Dept Mol & Cellular Biol, 1645 Neil Ave, Columbus, OH 43210 USA.	ma.131@osu.edu	Wang, Fei/D-9550-2013	Ma, Jiyan/0000-0001-7150-1898				Barmada SJ, 2005, J NEUROSCI, V25, P5824, DOI 10.1523/JNEUROSCI.1192-05.2005; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; Bate C, 2004, J GEN VIROL, V85, P3797, DOI 10.1099/vir.0.80366-0; Bate C, 2004, J BIOL CHEM, V279, P36405, DOI 10.1074/jbc.M404086200; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Critchley P, 2004, BIOCHEM BIOPH RES CO, V313, P559, DOI 10.1016/j.bbrc.2003.12.004; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Heske J, 2004, J BIOL CHEM, V279, P5435, DOI 10.1074/jbc.M309570200; Ito D, 2004, MOL CELL BIOL, V24, P9456, DOI 10.1128/MCB.24.21.9456-9469.2004; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kristiansen M, 2005, J BIOL CHEM, V280, P38851, DOI 10.1074/jbc.M506600200; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mange A, 2004, J CELL SCI, V117, P2411, DOI 10.1242/jcs.01094; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Nishiyama A, 2004, MOL BRAIN RES, V125, P1, DOI 10.1016/j.molbrainres.2004.01.012; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Polymenidou M, 2005, LANCET NEUROL, V4, P805, DOI 10.1016/S1474-4422(05)70225-8; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Seeger H, 2005, SCIENCE, V310, P324, DOI 10.1126/science.1118829; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	46	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13559	13565		10.1074/jbc.M512306200	http://dx.doi.org/10.1074/jbc.M512306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537534	hybrid			2022-12-27	WOS:000237336600064
J	Cowburn, AS; Sobolewski, A; Reedo, BJ; Deighton, J; Murray, J; Cadwallader, KA; Bradley, JR; Chilvers, ER				Cowburn, AS; Sobolewski, A; Reedo, BJ; Deighton, J; Murray, J; Cadwallader, KA; Bradley, JR; Chilvers, ER			Aminopeptidase N (CD13) regulates tumor necrosis factor-alpha-induced apoptosis in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD NEUTROPHILS; TNF RECEPTOR; POLYMORPHONUCLEAR LEUKOCYTES; GRANULOCYTE APOPTOSIS; AGING NEUTROPHILS; DOWN-REGULATION; IN-VITRO; BESTATIN; INHIBITION; ACTIVATION	Neutrophil apoptosis plays a central role in the resolution of granulocytic inflammation. We have shown previously that tumor necrosis factor-alpha(TNF alpha) enhances the rate of neutrophil apoptosis at early time points via a mechanism involving both TNF receptor ( TNFR) I and TNFRII. Here we reveal a marked but consistent variation in the magnitude of the pro-apoptotic effect of TNF alpha in neutrophils isolated from healthy donors, and we show that inhibition of cell surface aminopeptidaseN(APN) using actinonin, bestatin, or inhibitory peptides significantly enhanced the efficacy of TNF alpha-induced killing. Notably, an inverse correlation is shown to exist between neutrophil APN activity and the sensitivity of donor cells to TNF alpha-induced apoptosis. Inhibition of cell surface APN appears to interfere with the shedding of TNFRI, and as a consequence results in augmented TNF alpha-induced apoptosis, cell polarization, and TNF alpha-primed, formyl-methionyl-leucyl-phenylalanine-stimulated respiratory burst. Of note, actinonin and bestatin had no effect on TNFRII expression under resting or TNF alpha-stimulated conditions and did not alter CXCRI or CXCRII expression. These data suggest significant variation in the activity of APN/CD13 on the cell surface of neutrophils in normal individuals and reveal a novel mechanism whereby APN/CD13 regulates TNF alpha-induced apoptosis via inhibition of TNFRI shedding. This has therapeutic relevance for driving neutrophil apoptosis in vivo.	Univ Cambridge, Addenbrookes Hosp, Resp Med Div, Dept Med,Sch Clin Med, Cambridge CB2 2QQ, England; Univ Cambridge, Papworth Hosp, Resp Med Div, Dept Med,Sch Clin Med, Cambridge CB2 2QQ, England; Univ Edinburgh, Resp Med Unit, MRC, Ctr Inflammat,Sch Med, Edinburgh EH16 4TJ, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Papworth Hospital; University of Cambridge; University of Edinburgh	Cowburn, AS (corresponding author), Univ Cambridge, Addenbrookes Hosp, Resp Med Div, Dept Med,Sch Clin Med, Box 157,Hills Rd, Cambridge CB2 2QQ, England.	asc32@cam.ac.uk		Chilvers, Edwin/0000-0002-4230-9677; Bradley, John/0000-0002-7774-8805; Cowburn, Andrew/0000-0001-9145-4275; Sobolewski, Anastasia/0000-0002-8531-1240	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aleman M, 2001, CLIN IMMUNOL, V100, P87, DOI 10.1006/clim.2001.5044; Amoscato AA, 1998, J IMMUNOL, V161, P4023; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; Balog T, 1999, IMMUNOPHARMACOLOGY, V41, P11, DOI 10.1016/S0162-3109(98)00050-2; Bhattacharya C, 1997, INDIAN J BIOCHEM BIO, V34, P214; Bhattacharya C, 1997, J IMMUNOL, V158, P1293; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; Cowburn AS, 2005, BLOOD, V105, P2970, DOI 10.1182/blood-2004-07-2870; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DREXLER HG, 1987, LEUKEMIA, V1, P697; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Dybkaer K, 2001, BRIT J HAEMATOL, V112, P691, DOI 10.1046/j.1365-2141.2001.02613.x; Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005; Ezawa K, 1996, BIOMED PHARMACOTHER, V50, P283, DOI 10.1016/0753-3322(96)84827-X; Gon S, 1996, MICROBIOL IMMUNOL, V40, P463, DOI 10.1111/j.1348-0421.1996.tb01095.x; Goodman ER, 1998, ARCH SURG-CHICAGO, V133, P1234, DOI 10.1001/archsurg.133.11.1234; Grujic M, 2005, CANCER LETT, V223, P211, DOI 10.1016/j.canlet.2004.10.048; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Hart SP, 2000, CELL DEATH DIFFER, V7, P493, DOI 10.1038/sj.cdd.4400680; Haslett C, 1997, BRIT MED BULL, V53, P669; HASLETT C, 1985, AM J PATHOL, V119, P101; Huschak G, 2003, CLIN EXP IMMUNOL, V134, P491, DOI 10.1111/j.1365-2249.2003.02302.x; Jimenez MF, 1997, ARCH SURG-CHICAGO, V132, P1263; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Khreiss T, 2004, CELL SIGNAL, V16, P801, DOI 10.1016/j.cellsig.2003.12.005; Larsen SL, 1996, J EXP MED, V184, P183, DOI 10.1084/jem.184.1.183; Lerche C, 1996, MAMM GENOME, V7, P712, DOI 10.1007/s003359900219; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MACEY MG, 1994, EXP HEMATOL, V22, P967; Marotti T, 2000, NEUROPEPTIDES, V34, P121, DOI 10.1054/npep.2000.0801; MATHE G, 1991, BIOMED PHARMACOTHER, V45, P49, DOI 10.1016/0753-3322(91)90122-A; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nolan B, 2000, SHOCK, V14, P290, DOI 10.1097/00024382-200014030-00008; OCONNELL PJ, 1991, J BIOL CHEM, V266, P4593; ORNING L, 1991, J BIOL CHEM, V266, P16507; Petrovic N, 2003, J BIOL CHEM, V278, P49358, DOI 10.1074/jbc.M308071200; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QU J, 1995, J PERIODONTAL RES, V30, P153, DOI 10.1111/j.1600-0765.1995.tb01267.x; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; SAITO M, 1995, LEUKEMIA, V9, P1508; Salamone G, 2001, J IMMUNOL, V166, P3476, DOI 10.4049/jimmunol.166.5.3476; Santos AN, 2000, CELL IMMUNOL, V201, P22, DOI 10.1006/cimm.2000.1629; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SCHORLEMMER HU, 1979, CANCER RES, V39, P1847; Scornik OA, 2001, CURR DRUG METAB, V2, P67, DOI 10.2174/1389200013338748; Sekine K, 1999, LEUKEMIA, V13, P729, DOI 10.1038/sj.leu.2401388; Sekine K, 2001, INT J CANCER, V94, P485, DOI 10.1002/ijc.1492; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; TALMADGE JE, 1986, CANCER RES, V46, P4505; TALMADGE JE, 1993, J IMMUNOTHER, V14, P258, DOI 10.1097/00002371-199311000-00002; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TAYLOR A, 1993, BIOCHEMISTRY-US, V32, P784, DOI 10.1021/bi00054a007; TIEKU S, 1992, BIOCHEM PHARMACOL, V44, P1725, DOI 10.1016/0006-2952(92)90065-Q; van der Velden VHJ, 1999, CLIN EXP ALLERGY, V29, P445; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; XU Y, 1995, BIOCHEM BIOPH RES CO, V208, P664, DOI 10.1006/bbrc.1995.1390; Xu Y, 1998, CLIN CANCER RES, V4, P171	68	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12458	12467		10.1074/jbc.M511277200	http://dx.doi.org/10.1074/jbc.M511277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533817	hybrid			2022-12-27	WOS:000237134700033
J	Prigge, JR; Schmidt, EE				Prigge, JR; Schmidt, EE			Interaction of protein inhibitor of activated STAT (PIAS) proteins with the TATA-binding protein, TBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; GENE-ACTIVATION; IMMUNE-SYSTEM; YEAST-CELLS; FAMILY; SUMO; SUMOYLATION; COMPLEX; DOMAIN	Transcription activators often recruit promoter-targeted assembly of a pre-initiation complex; many repressors antagonize recruitment. These activities can involve direct interactions with proteins in the pre-initiation complex. We used an optimized yeast two-hybrid system to screen mouse pregnancy-associated libraries for proteins that interact with TATA-binding protein (TBP). Screens revealed an interaction between TBP and a single member of the zinc finger family of transcription factors, ZFP523. Two members of the protein inhibitor of activated STAT (PIAS) family, PIAS1 and PIAS3, also interacted with TBP in screens. Endogenous PIAS1 and TBP co-immunoprecipitated from nuclear extracts, suggesting the interaction occurred in vivo. In vitro-translated PIAS1 and TBP co-immunopreciptated, which indicated that other nuclear proteins were not required for the interaction. Deletion analysis mapped the PIAS-interacting domain of TBP to the conserved TBPCORE and the TBP-interacting domain on PIAS1 to a 39-amino acid C-terminal region. Mammals issue seven known PIAS proteins from four pias genes, pias1, pias3, piasx, and piasy, each with different cell type-specific expression patterns; the TBP-interacting domain reported here is the only part of the PIAS C-terminal region shared by all seven PIAS proteins. Direct analyses indicated that PIASx and PIASy also interacted with TBP. Our results suggest that all PIAS proteins might mediate situation-specific regulatory signaling at the TBP interface and that previously unknown levels of complexity could exist in the gene regulatory interplay between TBP, PIAS proteins, ZFP523, and other transcription factors.	Montana State Univ, Bozeman, MT 59717 USA; Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA	Montana State University System; Montana State University Bozeman; Washington State University	Schmidt, EE (corresponding author), Montana State Univ, Mol Biosci Bldg, Bozeman, MT 59717 USA.	eschmidt@montana.edu			NIAID NIH HHS [R01 AI055739-01A1, R01 AI055739-03, R01 AI055739-02, R01 AI055739] Funding Source: Medline; NICHD NIH HHS [R03 HD035824-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bondareva AA, 2003, MOL BIOL EVOL, V20, P1932, DOI 10.1093/molbev/msg205; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; FIELDS S, 1993, YEAST METHOS ANAL PR; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hobbs NK, 2002, CELL, V110, P43, DOI 10.1016/S0092-8674(02)00806-1; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Klejman MP, 2004, MOL CELL BIOL, V24, P10072, DOI 10.1128/MCB.24.22.10072-10082.2004; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, NAT CELL BIOL, V2, pE161, DOI 10.1038/35023639; Mittal V, 1996, MOL CELL BIOL, V16, P1955; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Ohbayashi T, 1996, BIOCHEM BIOPH RES CO, V225, P275, DOI 10.1006/bbrc.1996.1166; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Pereira LA, 2003, GENE, V315, P1, DOI 10.1016/S0378-1119(03)00714-5; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schmidt EE, 2003, J BIOL CHEM, V278, P6168, DOI 10.1074/jbc.M211205200; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; SUMITA K, 1993, NUCLEIC ACIDS RES, V21, P2769, DOI 10.1093/nar/21.11.2769; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Zheng G, 2004, J BIOL CHEM, V279, P42410, DOI 10.1074/jbc.M407287200	46	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12260	12269		10.1074/jbc.M510835200	http://dx.doi.org/10.1074/jbc.M510835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522640	hybrid, Green Accepted			2022-12-27	WOS:000237134700010
J	Chen, JY; Park, CS; Tang, SJ				Chen, JY; Park, CS; Tang, SJ			Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; SIGNALING PATHWAY; DENDRITIC SPINES; PREFRONTAL CORTEX; ALZHEIMER-DISEASE; MOUSE DEVELOPMENT; FZD3 GENE; EXPRESSION; SCHIZOPHRENIA; RYK	Wnts are important for various developmental and oncogenic processes. Here we show that Wnt signaling functions at synapses in hippocampal neurons. Tetanic stimulations induce N-methyl-D-aspartate receptor-dependent synaptic Wnt3a release, nuclear beta-catenin accumulations, and the activation of Wnt target genes. Suppression of Wnt signaling impairs long term potentiation. Conversely, activation of Wnt signaling facilitates long term potentiation. These findings suggest that Wnt signaling plays a critical role in regulating synaptic plasticity.	Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Qureshey Res Lab 303, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tang, SJ (corresponding author), Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Qureshey Res Lab 303, Dept Neurobiol & Behav, Irvine, CA 92697 USA.	stang@uci.edu						Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Bamji SX, 2003, NEURON, V40, P719, DOI 10.1016/S0896-6273(03)00718-9; Behrens J, 2003, WNT SIGNALING DEV, P1; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; Dreier L, 2005, NEURON, V46, P51, DOI 10.1016/j.neuron.2004.12.058; DURA JM, 1995, FEBS LETT, V370, P250, DOI 10.1016/0014-5793(95)00847-3; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Fraser PE, 2001, BIOCHEM SOC SYMP, V67, P89, DOI 10.1042/bss0670089; Ftouh S, 2005, J NEUROCHEM, V94, P520, DOI 10.1111/j.1471-4159.2005.03239.x; Fuentealba RA, 2004, BRAIN RES REV, V47, P275, DOI 10.1016/j.brainresrev.2004.07.018; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Galceran J, 2000, DEVELOPMENT, V127, P469; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Grimwood PD, 2001, SYNAPSES, P519; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hering H, 2002, FEBS LETT, V521, P185, DOI 10.1016/S0014-5793(02)02831-4; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017; Kawamura Y, 2001, EUR J BIOCHEM, V268, P3036, DOI 10.1046/j.1432-1327.2001.02197.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1583, DOI 10.1007/s00702-004-0166-3; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; Liu YB, 2005, NAT NEUROSCI, V8, P1151, DOI 10.1038/nn1520; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Novikova SI, 2005, SYNAPSE, V56, P105, DOI 10.1002/syn.20134; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Schmitt AM, 2006, NATURE, V439, P31, DOI 10.1038/nature04334; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006-3223(03)00291-9; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang YB, 2004, AM J MED GENET B, V129B, P16, DOI 10.1002/ajmg.b.30076; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou CJ, 2004, J NEUROSCI, V24, P121, DOI 10.1523/JNEUROSCI.4071-03.2004; Ziegler S, 2005, FEBS J, V272, P1600, DOI 10.1111/j.1742-4658.2005.04581.x	58	229	237	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11910	11916		10.1074/jbc.M511920200	http://dx.doi.org/10.1074/jbc.M511920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16501258	hybrid			2022-12-27	WOS:000236988100059
J	Maeda, I; Delessert, S; Hasegawa, S; Seto, Y; Zuber, S; Poirier, Y				Maeda, I; Delessert, S; Hasegawa, S; Seto, Y; Zuber, S; Poirier, Y			The peroxisomal acyl-CoA thioesterase pte1p from Saccharomyces cerevisiae is required for efficient degradation of short straight chain and branched chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; MULTIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; LIPID-METABOLISM; YEAST; BIOSYNTHESIS; POLYHYDROXYALKANOATE; PROTEINS	The role of the Saccharomyces cerevisae peroxisomal acyl-coenzyme A (acyl-CoA) thioesterase (Pte1p) in fatty acid beta-oxidation was studied by analyzing the in vitro kinetic activity of the purified protein as well as by measuring the carbon flux through the beta-oxidation cycle in vivo using the synthesis of peroxisomal polyhydroxyalkanoate (PHA) from the polymerization of the 3-hydroxyacyl-CoAs as a marker. The amount of PHA synthesized from the degradation of 10-cis-heptadecenoic, tridecanoic, undecanoic, or nonanoic acids was equivalent or slightly reduced in the pte1 Delta strain compared with wild type. In contrast, a strong reduction in PHA synthesized from heptanoic acid and 8-methyl-nonanoic acid was observed for the pte1 Delta strain compared with wild type. The poor catabolism of 8-methyl-nonanoic acid via beta-oxidation in pte1 Delta negatively impacted the degradation of 10-cis-heptadecenoic acid and reduced the ability of the cells to efficiently grow in medium containing such fatty acids. An increase in the proportion of the short chain 3-hydroxyacid monomers was observed in PHA synthesized in pte1 Delta cells grown on a variety of fatty acids, indicating a reduction in the metabolism of short chain acyl-CoAs in these cells. A purified histidine-tagged Pte1p showed high activity toward short and medium chain length acyl-CoAs, including butyryl-CoA, decanoyl-CoA and 8-methyl-nonanoyl-CoA. The kinetic parameters measured for the purified Pte1p fit well with the implication of this enzyme in the efficient metabolism of short straight and branched chain fatty acyl-CoAs by the beta-oxidation cycle.	Univ Lausanne, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland; Utsunomiya Univ, Fac Agr, Dept Bioprod Sci, Utsunomiya, Tochigi 3218505, Japan	University of Lausanne; Utsunomiya University	Poirier, Y (corresponding author), Univ Lausanne, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland.	yves.poirier@unil.ch		Maeda, Isamu/0000-0003-0723-1752				Bogdawa H, 2005, BBA-MOL CELL BIOL L, V1735, P204, DOI 10.1016/j.bbalip.2005.06.003; GARTON GA, 1985, CHEM IND, V9, P295; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Herbert D, 1996, BIOCHEM J, V318, P997, DOI 10.1042/bj3180997; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Ishizuka M, 2004, EXP CELL RES, V297, P127, DOI 10.1016/j.yexcr.2004.02.029; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kal AJ, 2000, CELL BIOCHEM BIOPHYS, V32, P1, DOI 10.1385/CBB:32:1-3:01; KANEDA T, 1991, MICROBIOL REV, V55, P288, DOI 10.1128/MMBR.55.2.288-302.1991; Kurosawa T, 1998, ANAL CHIM ACTA, V365, P249, DOI 10.1016/S0003-2670(97)00601-6; Marchesini S, 2003, APPL ENVIRON MICROB, V69, P6495, DOI 10.1128/AEM.69.11.6495-6499.2003; Marchesini S, 2003, J BIOL CHEM, V278, P32596, DOI 10.1074/jbc.M305574200; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Poirier Y, 2001, APPL ENVIRON MICROB, V67, P5254, DOI 10.1128/AEM.67.11.5254-5260.2001; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Robert J, 2005, BBA-MOL CELL BIOL L, V1734, P169, DOI 10.1016/j.bbalip.2005.02.010; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; Tilton GB, 2004, J BIOL CHEM, V279, P7487, DOI 10.1074/jbc.M309532200	20	26	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11729	11735		10.1074/jbc.M511762200	http://dx.doi.org/10.1074/jbc.M511762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490786	hybrid			2022-12-27	WOS:000236988100037
J	Zeeh, JC; Zeghouf, M; Grauffel, C; Guibert, B; Martin, E; Dejaegere, A; Cherfils, J				Zeeh, JC; Zeghouf, M; Grauffel, C; Guibert, B; Martin, E; Dejaegere, A; Cherfils, J			Dual specificity of the interfacial inhibitor brefeldin A for Arf proteins and Sec7 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTORS; RIBOSYLATION FACTOR-I; GUANINE-NUCLEOTIDE; ADP-RIBOSYLATION; STRUCTURAL BASIS; CHOLERA-TOXIN; RHO-GTPASES; ARNO; GDP; LOCALIZATION	Guanine nucleotide exchange factors (GEFs), which activate small GTP-binding proteins (SMG) by stimulating their GDP/GTP exchange, are emerging as candidate targets for the inhibition of cellular pathways involved in diseases. However, their specific inhibition by competitive inhibitors is challenging, because GEF and SMG families comprise highly similar members. Nature shows us an alternative strategy called interfacial inhibition, exemplified by Brefeldin A (BFA). BFA inhibits the activation of Arf1 by its GEFs in vivo by stabilizing an abortive complex between Arf-GDP and the catalytic Sec7 domain of some of its GEFs. Here we characterize the specificity of BFA toward wild-type ( ARNO and BIG1) and mutant Sec7 domains and toward class I, II, and III Arfs. We find that BFA sensitivity of the exchange reaction depends on the nature of both the Sec7 domain and the Arf protein. A single Phe/Tyr substitution is sufficient to achieve BFA sensitivity of the Sec7 domain, which is supported by our characterization of brefeldin C (BFC), a BFA analog that cannot interact with the Tyr residue, and by free energy computations. We further show that Arf1 and Arf5, but not Arf6, are BFA-sensitive, despite their having every BFA-interacting residue in common. Analysis of Arf6 mutants points to the dynamics of the interswitch, which is involved in membrane-to-nucleotide signal propagation, as contributing to, although not sufficient for, BFA sensitivity. Altogether, our results reveal the Tyr/Phe substitution as a novel tool for monitoring BFA sensitivity of cellular ArfGEFs and document the exquisite and dual specificity that can be achieved by an interfacial inhibitor.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Inst Genet & Biol Mol & Cellulaire, Struct Biol & Genom Dept, Biocomp Grp, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Cherfils, J (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	cherfils@lebs.cnrs-gif.fr		Zeghouf, Mahel/0000-0003-3686-2510				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Archambaud S, 2005, SYNLETT, P139, DOI 10.1055/s-2004-835669; Balana ME, 2005, J CELL SCI, V118, P2201, DOI 10.1242/jcs.02351; Belov GA, 2005, J VIROL, V79, P7207, DOI 10.1128/JVI.79.11.7207-7216.2005; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunet N, 2002, TRAFFIC, V3, P342, DOI 10.1034/j.1600-0854.2002.30504.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; Donaldson JG, 2005, BBA-MOL CELL RES, V1744, P364, DOI 10.1016/j.bbamcr.2005.03.001; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Faure J, 2004, CURR BIOL, V14, P1056, DOI 10.1016/j.cub.2004.06.021; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hendsch ZS, 1999, PROTEIN SCI, V8, P1381, DOI 10.1110/ps.8.7.1381; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16; Jackson C L, 2000, Subcell Biochem, V34, P233; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LEE FJS, 1994, J BIOL CHEM, V269, P21555; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Marinissen MJ, 2005, TRENDS BIOCHEM SCI, V30, P423, DOI 10.1016/j.tibs.2005.06.006; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Mouratou B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-20; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; O'Neal CJ, 2005, SCIENCE, V309, P1093, DOI 10.1126/science.1113398; PASQUALATO S, 2004, ARF BOOK, P23; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; Shin HW, 2004, J BIOCHEM, V136, P761, DOI 10.1093/jb/mvh185; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; Tague SE, 2004, P NATL ACAD SCI USA, V101, P9671, DOI 10.1073/pnas.0403531101; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Zeghouf M, 2005, BIOCHEM SOC T, V33, P1265, DOI 10.1042/BST0331265; Zhao XH, 2002, MOL BIOL CELL, V13, P119, DOI 10.1091/mbc.01-08-0420; Zhu JW, 2000, BIOORGAN MED CHEM, V8, P455, DOI 10.1016/S0968-0896(99)00297-7	54	63	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11805	11814		10.1074/jbc.M600149200	http://dx.doi.org/10.1074/jbc.M600149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16484231	hybrid			2022-12-27	WOS:000236988100046
J	Zhao, J; Kong, HJ; Li, HX; Huang, B; Yang, M; Zhu, C; Bogunovic, M; Zheng, F; Mayer, L; Ozato, K; Unkeless, J; Xiong, HB				Zhao, J; Kong, HJ; Li, HX; Huang, B; Yang, M; Zhu, C; Bogunovic, M; Zheng, F; Mayer, L; Ozato, K; Unkeless, J; Xiong, HB			IRF-8/interferon (IFN) consensus sequence-binding protein is involved in toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-7; IMMUNE-RESPONSES; HOST-DEFENSE; ALPHA GENES; KAPPA-B; ACTIVATION; INDUCTION; MURINE; VIRUS; CELLS	Toll-like receptor (TLR) and interferon-gamma (IFN-gamma) signaling pathways are important for both innate and adaptive immune responses. However, the cross-talk between these two signaling pathways is incompletely understood. Here we show that IFN-gamma and LPS synergistically induce the expression of proinflammatory factors, including interleukin-1 (IL-1), IL-6, IL-12, NO, and tumor necrosis factor-alpha (TNF-alpha). Comparable synergism was observed between IFN-gamma and peptidoglycan (PGN; a TLR2 ligand) and poly(I:C) (a TLR3 ligand) in the induction of IL-12 promoter activity. IFN-gamma enhanced lipopolysaccharide (LPS)-induced ERK and JNK phosphorylation but had no effect on LPS-induced NF-kappa B activation. Interestingly, we found that IRF-8-/- macrophages were impaired in the activation of LPS-induced ERK and JNK and the production of proinflammatory cytokines induced by LPS or IFN-gamma plus LPS. Retroviral transduction of IRF-8 into IRF-8-/- macrophages rescued ERK and JNK activation. Furthermore, co-immunoprecipitation experiments show that IRF-8 physically interacts with TRAF6 at a binding site between amino acid residues 356 and 305 of IRF-8. Transfection of IRF-8 enhanced TRAF6 ubiquitination, which is consistent with a physical interaction of IRF-8 with TRAF6. Taken together, the results suggest that the interaction of IRF-8 with TRAF6 modulates TLR signaling and may contribute to the crosstalk between IFN-gamma and TLR signal pathways.	Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; NICHHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA; Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai	Xiong, HB (corresponding author), Mt Sinai Sch Med, Immunobiol Ctr, Box 1630,1 Gustave L Levy Pl, New York, NY 10029 USA.	Huabao.Xiong@mssm.edu						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Le Page C, 2000, Rev Immunogenet, V2, P374; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200	37	115	120	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10073	10080		10.1074/jbc.M507788200	http://dx.doi.org/10.1074/jbc.M507788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484229	hybrid			2022-12-27	WOS:000236594300032
J	Dialynas, GK; Makatsori, D; Kourmouli, N; Theodoropoulos, PA; McLean, K; Terjung, S; Singh, PB; Georgatos, SD				Dialynas, George K.; Makatsori, Dimitra; Kourmouli, Niki; Theodoropoulos, Panayiotis A.; McLean, Kevin; Terjung, Stefan; Singh, Prim B.; Georgatos, Spyros D.			Methylation-independent binding to histone H3 and cell cycle-dependent incorporation of HP1 beta into heterochromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HP1 CHROMO DOMAIN; LYSINE-9 METHYLATION; MAMMALIAN-CELLS; PERICENTRIC HETEROCHROMATIN; NUCLEAR-ENVELOPE; DNA INTERACTIONS; NUCLEOSOME; DROSOPHILA; PROTEINS; MECHANISMS	We have examined HP1 beta-chromatin interactions in different molecular contexts in vitro and in vivo. Employing purified components we show that HP1 beta exhibits selective, stoichiometric, and salt-resistant binding to recombinant histone H3, associating primarily with the helical "histone fold" domain. Furthermore, using "bulk" nucleosomes released by MNase digestion, S-phase extracts, and fragments of peripheral heterochromatin, we demonstrate that HP1 beta associates more tightly with destabilized or disrupted nucleosomes (H3/H4 subcomplexes) than with intact particles. Western blotting and mass spectrometry data indicate that HP1 beta-selected H3/H4 particles and subparticles possess a complex pattern of post-translational modifications but are not particularly enriched in me(3)K9-H3. Consistent with these results, mapping of HP1 beta and me(3)K9-H3 sites in vivo reveals overlapping, yet spatially distinct patterns, while transient transfection assays with synchronized cells show that stable incorporation of HP1 beta-gfp into heterochromatin requires passage through the S-phase. The data amassed challenge the dogma that me(3)K9H3 is necessary and sufficient for HP1 binding and unveil a new mode of HP1-chromatin interactions.	Univ Ioannina, Biol Lab, Sch Med, Stem Cell & Chromatin Grp, GR-45110 Ioannina, Greece; Ioannina Biomed Res Inst, Fdn Res & Technol, Ioannina 45110, Greece; Univ Crete, Dept Basic Sci, Sch Med, Iraklion 95110, Crete, Greece; Moredun Res Inst, Funct Genom Unit, Penicuik EH26 0PZ, Midlothian, Scotland; ALMF, European Mol Biol Lab, D-69117 Heidelberg, Germany; Roslin Inst, Nucl Reprogramming Lab, Dept Gen Express & Dev, Edinburgh EH25 9PS, Midlothian, Scotland	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Moredun Research Institute; European Molecular Biology Laboratory (EMBL); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Georgatos, SD (corresponding author), Univ Ioannina, Biol Lab, Sch Med, Stem Cell & Chromatin Grp, GR-45110 Ioannina, Greece.	sgeorgat@cc.uoi.gr	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Terjung, Stefan/0000-0002-0018-1804; Georgatos, Spyros/0000-0002-2078-7467				Ahmad K, 2004, MOL CELL, V15, P494, DOI 10.1016/j.molcel.2004.08.012; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cheutin T, 2004, MOL CELL BIOL, V24, P3157, DOI 10.1128/MCB.24.8.3157-3167.2004; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Danzer JR, 2004, DEVELOPMENT, V131, P3571, DOI 10.1242/dev.01223; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Flaus A, 2004, CURR OPIN GENET DEV, V14, P165, DOI 10.1016/j.gde.2004.01.007; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Greil F, 2003, GENE DEV, V17, P2825, DOI 10.1101/gad.281503; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Korber P, 2004, J BIOL CHEM, V279, P35113, DOI 10.1074/jbc.M405446200; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luger K, 2005, CURR OPIN STRUC BIOL, V15, P188, DOI 10.1016/j.sbi.2005.03.006; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; Makatsori D, 2004, J BIOL CHEM, V279, P25567, DOI 10.1074/jbc.M313606200; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; OOHARA I, 1987, J MOL BIOL, V196, P399, DOI 10.1016/0022-2836(87)90700-5; OOHARA I, 1987, J MOL BIOL, V196, P389, DOI 10.1016/0022-2836(87)90699-1; Oudet P, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 1, P287; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Perrini B, 2004, MOL CELL, V15, P467, DOI 10.1016/j.molcel.2004.06.036; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Singh PB, 2002, J STRUCT BIOL, V140, P10, DOI 10.1016/S1047-8477(02)00536-1; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; YAGER TD, 1984, J BIOL CHEM, V259, P4212	57	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14350	14360		10.1074/jbc.M600558200	http://dx.doi.org/10.1074/jbc.M600558200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547356	hybrid			2022-12-27	WOS:000237512300061
J	Falomir-Lockhart, LJ; Laborde, L; Kahn, PC; Storch, J; Corsico, B				Falomir-Lockhart, Lisandro J.; Laborde, Lisandro; Kahn, Peter C.; Storch, Judith; Corsico, Betina			Protein-membrane interaction and fatty acid transfer from intestinal fatty acid-binding protein to membranes - Support for a multistep process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE LYSINE RESIDUES; PHOSPHOLIPID-MEMBRANES; HELICAL DOMAIN; COLLISIONAL TRANSFER; DIFFERENT MECHANISMS; LIVER; ADIPOCYTE; VESICLES; HEART; STABILITY	Fatty acid transfer from intestinal fatty acid-binding protein ( IFABP) to phospholipid membranes occurs during protein-membrane collisions. Electrostatic interactions involving the alpha-helical "portal" region of the protein have been shown to be of great importance. In the present study, the role of specific lysine residues in the alpha-helical region of IFABP was directly examined. A series of point mutants in rat IFABP was engineered in which the lysine positive charges in this domain were eliminated or reversed. Using a fluorescence resonance energy transfer assay, we analyzed the rates and mechanism of fatty acid transfer from wild type and mutant proteins to acceptor membranes. Most of the alpha-helical domain mutants showed slower absolute fatty acid transfer rates to zwitterionic membranes, with substitution of one of the lysines of the alpha(2) helix, Lys(27), resulting in a particularly dramatic decrease in the fatty acid transfer rate. Sensitivity to negatively charged phospholipid membranes was also reduced, with charge reversal mutants in the alpha(2) helix the most affected. The results support the hypothesis that the portal region undergoes a conformational change during protein-membrane interaction, which leads to release of the bound fatty acid to the membrane and that the alpha(2) segment is of particular importance in the establishment of charge-charge interactions between IFABP and membranes. Cross-linking experiments with a phospholipid-photoactivable reagent underscored the importance of charge-charge interactions, showing that the physical interaction between wild-type intestinal fatty acid-binding protein and phospholipid membranes is enhanced by electrostatic interactions. Protein-membrane interactions were also found to be enhanced by the presence of ligand, suggesting different collisional complex structures for holo- and apo-IFABP.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA; Natl Univ La Plata, Fac Ciencias Med, CONICET, INIBIOLP, RA-1900 La Plata, Argentina	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu; bcorsico@atlas.med.unlp.edu.ar	Falomir Lockhart, Lisandro Jorge/V-7730-2019	Falomir Lockhart, Lisandro Jorge/0000-0003-4815-5768; Storch, Judith/0000-0001-5482-1777	FIC NIH HHS [TW01100-01] Funding Source: Medline; NIDDK NIH HHS [DK 38389, R01 DK038389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; Clerico EM, 2000, BBA-PROTEIN STRUCT M, V1476, P203, DOI 10.1016/S0167-4838(99)00247-2; Corsico B, 2005, J LIPID RES, V46, P1765, DOI 10.1194/jlr.M500140-JLR200; Corsico B, 2004, BIOCHEMISTRY-US, V43, P3600, DOI 10.1021/bi0357356; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P8192, DOI 10.1021/bi034213n; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; FRIEDEN C, 1995, BIOCHEMISTRY-US, V34, P2724, DOI 10.1021/bi00008a040; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang C, 1974, Methods Enzymol, V32, P485; Kajander T, 2000, STRUCTURE, V8, P1203, DOI 10.1016/S0969-2126(00)00520-7; KIM HK, 1992, J BIOL CHEM, V267, P77; Kim K, 1996, BIOCHEMISTRY-US, V35, P7553, DOI 10.1021/bi9529115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LiCata VJ, 1998, PROTEINS, V33, P577, DOI 10.1002/(SICI)1097-0134(19981201)33:4<577::AID-PROT10>3.0.CO;2-2; Liou HL, 2002, J BIOL CHEM, V277, P1806, DOI 10.1074/jbc.M107987200; Liou HL, 2001, BIOCHEMISTRY-US, V40, P6475, DOI 10.1021/bi0101042; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; RICHARDS FM, 1985, METHOD ENZYMOL, V115, P440; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHARDS FM, 1971, J MOL BIOL, V6, P151; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; Schlattner U, 2004, J BIOL CHEM, V279, P24334, DOI 10.1074/jbc.M314158200; STORCH J, 1990, HEPATOLOGY, V12, P1447, DOI 10.1002/hep.1840120632; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thumser AEA, 2000, J LIPID RES, V41, P647; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	50	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13979	13989		10.1074/jbc.M511943200	http://dx.doi.org/10.1074/jbc.M511943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551626	Green Published, hybrid			2022-12-27	WOS:000237512300020
J	Zhao, Y; Yin, P; Bach, LA; Duan, CM				Zhao, Yang; Yin, Ping; Bach, Leon A.; Duan, Cunming			Several acidic amino acids in the N-domain of insulin-like growth factor-binding protein-5 are important for its transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; FACTOR-I; FUNCTIONAL DISSECTION; NUCLEAR-LOCALIZATION; FACTOR (IGF)-I; CELL-DEATH; IGF; IGFBP-5; PHOSPHORYLATION; PROTEASE	Insulin-like growth factor-binding protein ( IGFBP)-5 is a secreted protein that binds to IGFs and modulates IGF actions. IGFBP-5 is also found in the nuclei of cultured cells and has transactivation activity. Here we report the nuclear localization of endogenous IGFBP-5 in mouse embryonic skeletal cells. Chromatin immunoprecipitation experiments indicated that IGFBP-5 interacts with the nuclear histone-DNA complex. Using a series of deletion mutants, the transactivation domain of IGFBP-5 was mapped to its N-terminal region. Intriguingly, the transactivation activity of IGFBP-5 is masked by negative regulatory elements located in the L- and C-domains. Among the other IGFBPs, the N-domains of IGFBP-2 and -3 also had strong transactivation activity, whereas those of IGFBP-1 and -6 had no activity. The IGFBP-4 N-domain had modest activity. Sequence analysis revealed several amino acids in the IGFBP-5 N-domain that are not present in IGFBP-1. The activities of mutants in which these residues were changed to the corresponding IGFBP-1 sequence were determined. Mutations that changed acidic residues to neutral residues ( e. g. E8A, D11S, E12A, E30S/P31A, E43L, and E52A) or a polar to a basic residue ( e. g. Q56R) significantly reduced transactivation activity. The E8A/D11S/E12A triple mutant and E52A/Q56R double mutants showed further reduced activity. The combinatory mutants had essentially no transactivation activity. Taken together, our results indicate that there are several conserved residues in the IGFBP-5 N-terminal region that are critical for transactivation and that IGFBP-2 and -3 also have strong transactivation activity in their N-domains.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Monash Univ, Alfred Hosp, Dept Med, Melbourne, Vic 3004, Australia; Monash Univ, Alfred Hosp, Dept Endocrinol & Diabet, Melbourne, Vic 3004, Australia	University of Michigan System; University of Michigan; Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Room 3065B,830 N Univ St, Ann Arbor, MI 48109 USA.	cduan@umich.edu		Bach, Leon/0000-0002-9062-1518	NHLBI NIH HHS [2R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi M, 2001, BMC Mol Biol, V2, P10, DOI 10.1186/1471-2199-2-10; Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Hsieh JC, 2004, BIOCHEM BIOPH RES CO, V324, P801, DOI 10.1016/j.bbrc.2004.09.139; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2003, ENDOCRINOLOGY, V144, P1984, DOI 10.1210/en.2002-220798; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; Sherman MA, 2002, J IMMUNOL, V169, P3811, DOI 10.4049/jimmunol.169.7.3811; Siwanowicz I, 2005, STRUCTURE, V13, P155, DOI 10.1016/j.str.2004.11.009; Sprenger-Haussels M, 2000, PLANT J, V22, P1, DOI 10.1046/j.1365-313x.2000.00687.x; Suzuki K, 2002, J EXP MED, V196, P27, DOI 10.1084/jem.20011682; Tonner E, 2002, DEVELOPMENT, V129, P4547; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Wiesner C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf079; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Yin P, 2004, J BIOL CHEM, V279, P32660, DOI 10.1074/jbc.M401378200; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14184	14191		10.1074/jbc.M506941200	http://dx.doi.org/10.1074/jbc.M506941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543235	hybrid			2022-12-27	WOS:000237512300042
J	Fath, DM; Kong, XG; Liang, DM; Lin, Z; Chou, A; Jiang, YB; Fang, J; Caro, J; Sang, NL				Fath, DM; Kong, XG; Liang, DM; Lin, Z; Chou, A; Jiang, YB; Fang, J; Caro, J; Sang, NL			Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SUBEROYLANILIDE HYDROXAMIC ACID; TRANSCRIPTIONAL ACTIVITY; FACTOR 1-ALPHA; INDUCED ANGIOGENESIS; TUMOR ANGIOGENESIS; DNA-DAMAGE; PROTEASOMAL DEGRADATION; STRUCTURAL BASIS; IN-VITRO	Hypoxia- inducible factors (HIFs) are heterodimeric transcription factors regulating the oxygen supply, glucose metabolism, and angiogenesis. HIF function requires the recruitment of p300/CREB-binding protein, two coactivators with histone acetyltransferase activity, by the C-terminal transactivation domain of HIF-alpha (HIF-alpha CAD). Histone deacetylase inhibitors (HDAIs) induce differentiation or apoptosis and repress tumor growth and angiogenesis, hence being explored intensively as anti-cancer agents. Using combined pharmacological, biochemical, and genetic approaches, here we show that HDAIs repress the transactivation potential of HIF-alpha CAD. This repression is independent of the function of tumor suppressors von Hippel-Lindau or p53 or the degradation of HIF-alpha. We also demonstrate the sufficiency of low concentrations of HDAIs in repression of HIF target genes in tumor cells. We further show that HDAIs induce hyperacetylation of p300 and repress the HIF-1 alpha p300 complex in vivo. In vitro acetylation analysis reveals that the p300CH1 region, but not HIF-alpha CAD, is susceptible to acetylation. Taken together, our data demonstrate that a deacetylase activity is indispensable for the transactivation potential of HIF-CAD and support a model that acetylation regulates HIF function by targeting HIF-alpha p300 complex, not by direct acetylating HIF-alpha. The demonstration that HDAIs repress both HIF-1 alpha and HIF-2 alpha transactivation potential independently of von Hippel-Lindau tumor suppressor and p53 function indicates that HDAIs may have biological effects in a broad range of tissues in addition to tumors.	Cardeza Fdn, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Sang, NL (corresponding author), Cardeza Fdn, 1015 Walnut St,Curtis Bldg,Rm 711, Philadelphia, PA 19107 USA.	nianli.sang@jefferson.edu			NCI NIH HHS [R25CA048010, K01 CA098809, R01-CA89212, K01-CA098809, R01 CA089212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098809, R25CA048010, R01CA089212] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heinl-Green A, 2005, EUR HEART J, V26, P1327, DOI 10.1093/eurheartj/ehi223; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luttun A, 2004, CURR OPIN HEMATOL, V11, P262, DOI 10.1097/01.moh.0000126936.58889.95; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Powis G, 2004, MOL CANCER THER, V3, P647; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sasakawa Y, 2003, BIOCHEM PHARMACOL, V66, P897, DOI 10.1016/S0006-2952(03)00411-8; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SEMENZA GL, 2000, PHYSL, V19, P176; Simone C, 2004, ONCOGENE, V23, P2177, DOI 10.1038/sj.onc.1207327; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vincent KA, 2000, CIRCULATION, V102, P2255; Williams RJ, 2001, EXPERT OPIN INV DRUG, V10, P1571, DOI 10.1517/13543784.10.8.1571; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yu XD, 2002, J NATL CANCER I, V94, P504; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zgouras D, 2003, BIOCHEM BIOPH RES CO, V300, P832, DOI 10.1016/S0006-291X(02)02916-9	71	93	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13612	13619		10.1074/jbc.M600456200	http://dx.doi.org/10.1074/jbc.M600456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543236	Green Accepted, hybrid			2022-12-27	WOS:000237336600071
J	Weber, C; de Queiroz, FM; Downie, BR; Suckow, A; Stuhmer, W; Pardo, LA				Weber, C; de Queiroz, FM; Downie, BR; Suckow, A; Stuhmer, W; Pardo, LA			Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; GENE-EXPRESSION; K+ CHANNELS; ACTIVATION; ETHER; CELLS; DROSOPHILA; BLOCK; INHIBITION; IMIPRAMINE	EagI potassium channels are natively expressed in the mammalian brain as well as in many cancer cell lines and tumor tissues. The role of EagI in malignant transformation has been suggested by several experiments, but the lack of specific EagI inhibitors has made it difficult to examine the influence of the channel on oncogenesis and its potential as a therapeutic target. We have used short interfering RNA to test the effects of EagI reduction on the behavior of tumor cells in vitro. By generating and optimizing an EagI-specific short interfering RNA system, we were able to study the effects of EagI depletion on several cancer cell lines that endogenously express this protein. We show here that our short interfering RNA sequences act specifically on EagI, reproducibly induce a significant decrease in the proliferation of tumor cell lines, and do not trigger any observable nonspecific responses.	Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany	Max Planck Society	Pardo, LA (corresponding author), Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, Hermann Rein Str 3, D-37075 Gottingen, Germany.	Pardo@em.mpg.de	Stuehmer, Walter/A-2176-2009; Pardo, Luis/C-5066-2013	Stuehmer, Walter/0000-0002-0642-7764; Pardo, Luis/0000-0003-1375-4349; Downie, Bryan/0000-0001-8278-722X				[Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; Bauer CK, 2001, J MEMBRANE BIOL, V182, P1; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Choi I, 2005, J BIOTECHNOL, V120, P251, DOI 10.1016/j.jbiotec.2005.06.014; Daude N, 2003, J CELL SCI, V116, P2775, DOI 10.1242/jcs.00494; Eckstein F, 2005, TRENDS BIOCHEM SCI, V30, P445, DOI 10.1016/j.tibs.2005.06.008; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Garcia-Ferreiro RE, 2004, J GEN PHYSIOL, V124, P301, DOI 10.1085/jgp.200409041; Gavrilova-Ruch O, 2002, J MEMBRANE BIOL, V188, P137, DOI 10.1007/s00232-001-0181-3; Gurney Alison M., 2005, Journal of Pharmacological and Toxicological Methods, V51, P253, DOI 10.1016/j.vascn.2004.08.012; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huesken D, 2005, NAT BIOTECHNOL, V23, P995, DOI 10.1038/nbt1118; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; Izquierdo M, 2005, CANCER GENE THER, V12, P217, DOI 10.1038/sj.cgt.7700791; KAPLAN WD, 1969, GENETICS, V61, P399; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MINKS MA, 1979, J BIOL CHEM, V254, P180; Napp J, 2005, J BIOL CHEM, V280, P29506, DOI 10.1074/jbc.M504228200; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Peyrl A, 2003, PROTEOMICS, V3, P1781, DOI 10.1002/pmic.200300460; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saganich MJ, 2001, J NEUROSCI, V21, P4609, DOI 10.1523/JNEUROSCI.21-13-04609.2001; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2; Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Terlau H, 1996, PFLUG ARCH EUR J PHY, V432, P301, DOI 10.1007/s004240050137; Tulac S, 2004, MOL HUM REPROD, V10, P705, DOI 10.1093/molehr/gah105; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x; Ziechner U, 2006, FEBS J, V273, P1074, DOI 10.1111/j.1742-4658.2006.05134.x	37	95	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13030	13037		10.1074/jbc.M600883200	http://dx.doi.org/10.1074/jbc.M600883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537547	hybrid			2022-12-27	WOS:000237336600006
J	Imai, K; Okamoto, T				Imai, K; Okamoto, T			Transcriptional repression of human immunodeficiency virus type 1 by AP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RNA-POLYMERASE-II; NF-KAPPA-B; HISTONE DEACETYLASE; GENE-EXPRESSION; MEDIATED TRANSCRIPTION; BINDING PROTEINS; HIV-1 LTR; TATA BOX; T-CELLS	Elucidation of the mechanism of transcriptional silencing of human immunodeficiency virus type 1 (HIV-1) provirus in latently infected cells is crucial to understand the pathophysiology of HIV-1 infection and to develop novel therapies. Here we demonstrate that AP-4 is responsible for the transcriptional repression of HIV-1. We found that AP-4 site within the viral long terminal repeat (LTR) is well conserved in the majority of HIV-1 subtypes and that AP-4 represses HIV-1 gene expression by recruiting histone deacetylase ( HDAC) 1 as well as by masking TATA-binding protein to TATA box. AP-4-mediated transcriptional repression was inhibited by an HDAC inhibitor, tricostatin A, and could be exerted even at distant locations from the TATA box. In addition, AP-4 interacted with HDAC1 both in vivo and in vitro. Moreover, chromatin immuno-precipitation assays have revealed that AP-4 and HDAC1 are present in the HIV-1 LTR promoter in latently infected ACH2 and U1 cells, and they are dissociated from the promoter concomitantly with the association of acetylated histone H3, TBP, and RNA polymerase II upon TNF-alpha stimulation of HIV-1 replication. Furthermore, when AP-4 is knocked down by siRNA, HIV-1 production was greatly augmented in cells transfected with a full-length HIV-1 clone. These results suggest that AP-4 may be responsible for transcriptional quiescence of latent HIV-1 provirus and give a molecular basis to the reported efficacy of combination therapy of conventional anti-HIV drugs with an HDAC inhibitor in accelerating the clearance of HIV-1 from individuals infected with the virus.	Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp						Andriamanalijaona R, 2003, ARTHRITIS RHEUM, V48, P1569, DOI 10.1002/art.11020; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Courey AJ, 2001, GENE DEV, V15, P2786; Cui Y, 1998, GENE, V224, P97, DOI 10.1016/S0378-1119(98)00512-5; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; Dreikhausen U, 2005, MOL CELL BIOL, V25, P7473, DOI 10.1128/MCB.25.17.7473-7483.2005; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Glahder JA, 2003, J GEN VIROL, V84, P3429, DOI 10.1099/vir.0.19250-0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Imai K, 2005, J BIOL CHEM, V280, P26701, DOI 10.1074/jbc.M503313200; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KUIKEN C, 2002, HIV SEQUENCE COMPEND, P370; Kumar PP, 2005, MOL CELL BIOL, V25, P1620, DOI 10.1128/MCB.25.5.1620-1633.2005; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; Pomerantz RJ, 2004, ARCH IMMUNOL THER EX, V52, P297; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; SAKAGUCHI M, 1991, J VIROL, V65, P5448, DOI 10.1128/JVI.65.10.5448-5456.1991; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Takada N, 2002, J VIROL, V76, P8019, DOI 10.1128/JVI.76.16.8019-8030.2002; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; van Opijnen T, 2004, J VIROL, V78, P6883, DOI 10.1128/JVI.78.13.6883-6890.2004; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	54	118	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12495	12505		10.1074/jbc.M511773200	http://dx.doi.org/10.1074/jbc.M511773200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16540471	hybrid			2022-12-27	WOS:000237134700037
J	Khan, AN; Lewis, PN				Khan, AN; Lewis, PN			Use of substrate analogs and mutagenesis to study substrate binding and catalysis in the Sir2 family of NAD-dependent protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; HISTONE DEACETYLATION; STRUCTURAL BASIS; IN-VITRO; YEAST; MECHANISM; NICOTINAMIDE; RESTRICTION; ACETYLATION	The Sir2 family of enzymes is highly conserved throughout evolution and functions in silencing, control of life span, apoptosis, and many other cellular processes. Since the discovery of the NAD-dependent deacetylase activity of Sir2 proteins, there has been a flurry of activity aiming to uncover the mode of substrate binding and catalysis. Structural and biochemical studies have led to several proposed reaction mechanisms, yet the exact catalytic steps remain unclear. Here we present in vitro studies of yeast homolog Hst2 that shed light on the mechanism of Sir2 proteins. Using acetyl-lysine substrate analogs, we demonstrate that the Hst2 reaction proceeds via an initial S(N)2-type mechanism with the direct formation of an ADP-ribose-acetyl-lysine intermediate. Kinetic studies further suggest that ADP-ribose inhibits the Hst2 reaction in a biologically relevant manner. Through biochemical and kinetic analyses of point mutants, we also clarify the role of several conserved core domain residues in substrate binding, stabilization of the ADP-ribose-acetyl-lysine intermediate, and catalysis. These findings bring us a few steps closer to understanding Sir2 activity and may provide a useful platform for the design of Sir2-specific inhibitors for analysis of Sir2 function and possibly therapeutic applications.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Lewis, PN (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	peter.lewis@utoronto.ca						Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Avalos JL, 2004, MOL CELL, V13, P639, DOI 10.1016/S1097-2765(04)00082-6; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2005, J BIOL CHEM, V280, P9780, DOI 10.1074/jbc.M414080200; Borra MT, 2004, BIOCHEMISTRY-US, V43, P9877, DOI 10.1021/bi049592e; Chang JH, 2002, J BIOL CHEM, V277, P34489, DOI 10.1074/jbc.M205460200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Gallo CA, 2004, MOL CELL BIOL, V24, P1301, DOI 10.1128/MCB.24.3.1301-1312.2004; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Khan AN, 2005, J BIOL CHEM, V280, P36073, DOI 10.1074/jbc.M508247200; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; LEWIS PN, 1988, EUR J BIOCHEM, V172, P135, DOI 10.1111/j.1432-1033.1988.tb13865.x; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Smith BC, 2006, BIOCHEMISTRY-US, V45, P272, DOI 10.1021/bi052014t; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Zhao KH, 2003, NAT STRUCT BIOL, V10, P864, DOI 10.1038/nsb978; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101; Ziegler Mathias, 2004, Biochem J, V382, pe5	33	23	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11702	11711		10.1074/jbc.M511482200	http://dx.doi.org/10.1074/jbc.M511482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520376	hybrid			2022-12-27	WOS:000236988100034
J	Klco, JM; Nikiforovich, GV; Baranski, TJ				Klco, JM; Nikiforovich, GV; Baranski, TJ			Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; 1ST EXTRACELLULAR LOOP; TRANSMEMBRANE HELICES; MOLECULAR-MECHANISM; BINDING; ACTIVATION; RESIDUES; IDENTIFICATION; RHODOPSIN	The extracellular loops of G protein-coupled receptors (GPCRs) frequently contain binding sites for peptide ligands. However, the mechanism of receptor activation following ligand binding and the influence of the extracellular loops in other aspects of receptor function are poorly understood. Here we report a structure-function analysis of the first and third extracellular loops of the human C5a receptor, a GPCR that binds a 74-amino acid peptide ligand. Amino acid substitutions were randomly incorporated into each loop, and functional receptors were identified in yeast. The first extracellular loop contains a large number of positions that cannot tolerate amino acid substitutions, especially residues within the WXFG motif found in many rhodopsin-like GPCRs, yet disruption of these residues does not alter C5a binding affinity. These results demonstrate an unanticipated role for the first extracellular loop, and the WXFG motif in particular, in ligand-mediated activation of the C5a receptor. This motif likely serves a similar role in other GPCRs. The third extracellular loop, in contrast, contains far fewer preserved residues and appears to play a less essential role in receptor activation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	baranski@wustl.edu	Klco, Jeffery/M-9717-2018	Klco, Jeffery/0000-0003-2961-6960	NIGMS NIH HHS [GM63720-01, GM068460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720, R01GM068460] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Akal-Strader A, 2002, J BIOL CHEM, V277, P30581, DOI 10.1074/jbc.M204089200; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1989, J BIOL CHEM, V264, P1760; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Huber-Lang MS, 2003, J IMMUNOL, V170, P6115, DOI 10.4049/jimmunol.170.12.6115; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Labrou NE, 2001, J BIOL CHEM, V276, P37944; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; MATSUI H, 1995, MOL PHARMACOL, V47, P88; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Nicastro G, 2003, J PEPT SCI, V9, P229, DOI 10.1002/psc.449; Nikiforovich GV, 2005, BIOPHYS J, V89, P3780, DOI 10.1529/biophysj.105.070722; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unson CG, 2000, J BIOL CHEM, V275, P21631, DOI 10.1074/jbc.M002093200	34	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12010	12019		10.1074/jbc.M600548200	http://dx.doi.org/10.1074/jbc.M600548200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505476	hybrid			2022-12-27	WOS:000236988100071
J	Wang, YF; Tan, CG; Fagan, RJ; Klein, PS				Wang, YF; Tan, CG; Fagan, RJ; Klein, PS			Phosphorylation of frizzled-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR CELL POLARITY; WNT PATHWAY; DISHEVELLED PHOSPHORYLATION; RECEPTOR ENDOCYTOSIS; KINASE; BETA-ARRESTIN-2; TRANSDUCTION; MECHANISMS; FAMILY	Wnts are secreted proteins important to many biological processes. frizzled genes encode a family of Wnt receptors that signal to the intracellular compartment through the cytosolic protein Disheveled. Limited information is available concerning the regulation of Frizzleds at a biochemical level. We report here that Xenopus Frizzled-3 is phosphorylated in a Disheveled-dependent manner that appears to require the DEP domain of Disheveled. Phosphorylation of serine 576 causes a decrease in electrophoretic mobility and accounts for a significant fraction of receptor phosphorylation, although additional residues in the C-terminal tail are also phosphorylated. In addition, mutations that interfere with Frizzled-3 function also interfere with phosphorylation, but these inactive mutants can be phosphorylated when an active form of Frizzled-3 is co-expressed. Mutation of C-terminal serines including serine 576 significantly enhances Frizzled-3-mediated induction of neural crest markers, suggesting that C-terminal phosphorylation plays a role in down-regulating Frizzled signaling.	Univ Penn, Sch Med, Cell & Mol Biol Grad Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Klein, PS (corresponding author), 364 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	pklein@mail.med.upenn.edu		Tan, Change/0000-0001-8291-3337	NIMH NIH HHS [R01MH58324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058324] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; Djiane A, 2005, CELL, V121, P621, DOI 10.1016/j.cell.2005.03.014; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Huang HC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-234; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shi DL, 1998, MECH DEVELOP, V70, P35, DOI 10.1016/S0925-4773(97)00166-4; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tada M, 2000, DEVELOPMENT, V127, P2227; Tan C, 2001, DEVELOPMENT, V128, P3665; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wang YS, 2002, J NEUROSCI, V22, P8563; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yamamoto A, 2005, CELL, V120, P223, DOI 10.1016/j.cell.2004.11.051	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11603	11609		10.1074/jbc.M600713200	http://dx.doi.org/10.1074/jbc.M600713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513654	hybrid			2022-12-27	WOS:000236988100023
J	Grosshans, BL; Grotsch, H; Mukhopadhyay, D; Fernandez, IM; Pfannstiel, J; Idrissi, FZ; Lechner, J; Riezman, H; Geli, MI				Grosshans, BL; Grotsch, H; Mukhopadhyay, D; Fernandez, IM; Pfannstiel, J; Idrissi, FZ; Lechner, J; Riezman, H; Geli, MI			TEDS site phosphorylation of the yeast myosins I is required for ligand-induced but not for constitutive endocytosis of the G protein-coupled receptor Ste2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIN CYTOSKELETON ORGANIZATION; SACCHAROMYCES-CEREVISIAE; P21-ACTIVATED KINASE; BUDDING-YEAST; CELL-GROWTH; UNCONVENTIONAL MYOSINS; MEDIATED ENDOCYTOSIS; ASPERGILLUS-NIDULANS; SIGNAL-TRANSDUCTION	The yeast myosins I Myo3p and Myo5p have well established functions in the polarization of the actin cytoskeleton and in the endocytic uptake of the G protein-coupled receptor Ste2p. A number of results suggest that phosphorylation of the conserved TEDS serine of the myosin I motor head by the Cdc42p activated p21-activated kinases Ste20p and Cla4p is required for the organization of the actin cytoskeleton. However, the role of this signaling cascade in the endocytic uptake has not been investigated. Interestingly, we find that Myo5p TEDS site phosphorylation is not required for slow, constitutive endocytosis of Ste2p, but it is essential for rapid, ligand-induced internalization of the receptor. Our results strongly suggest that a kinase activates the myosins I to sustain fast endocytic uptake. Surprisingly, however, despite the fact that only p21-activated kinases are known to phosphorylate the conserved TEDS site, we find that these kinases are not essential for ligand-induced internalization of Ste2p. Our observations indicate that a different signaling cascade, involving the yeast homologues of the mammalian PDK1 (3-phosphoinositide-dependent-protein kinase-1), Phk1p and Pkh2p, and serum and glucocorticoid-induced kinase, Ypk1p and Ypk2p, activate Myo3p and Myo5p for their endocytic function.	CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Dept Biochim, CH-1211 Geneva, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Ruprecht Karls University Heidelberg; University of Geneva	Geli, MI (corresponding author), CSIC, Inst Biol Mol Barcelona, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	mgfbmc@ibmb.csic.es	Geli, Maria Isabel/L-3246-2014; Fernández-Golbano, Isabel M/J-7409-2017; Idrissi Azami, Fatima Zohra/P-5627-2015	Geli, Maria Isabel/0000-0002-3452-6700; Fernández-Golbano, Isabel M/0000-0002-8525-6376; Idrissi Azami, Fatima Zohra/0000-0003-3672-7618; Riezman, Howard/0000-0003-4680-9422; Grotsch, Helga/0000-0003-1948-3922				Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Geli MI, 1998, EMBO J, V17, P635, DOI 10.1093/emboj/17.3.635; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Geli MI, 2000, EMBO J, V19, P4281, DOI 10.1093/emboj/19.16.4281; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gliksman NR, 2001, J BIOL CHEM, V276, P5235, DOI 10.1074/jbc.M008319200; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Idrissi FZ, 2002, MOL BIOL CELL, V13, P4074, DOI 10.1091/mbc.02-04-0052; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu X, 2001, P NATL ACAD SCI USA, V98, P9122, DOI 10.1073/pnas.161285698; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MARUTA H, 1977, J BIOL CHEM, V252, P8329; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Osherov N, 1998, J BIOL CHEM, V273, P27017, DOI 10.1074/jbc.273.41.27017; Ostap EM, 2002, BIOCHEMISTRY-US, V41, P12450, DOI 10.1021/bi0262193; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Pruyne D, 2000, J CELL SCI, V113, P571; Redowicz MJ, 2001, J MUSCLE RES CELL M, V22, P163; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN S, 1974, METHODS YEAST GENETI; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yamashita RA, 1998, J BIOL CHEM, V273, P14644, DOI 10.1074/jbc.273.23.14644; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	67	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11104	11114		10.1074/jbc.M508933200	http://dx.doi.org/10.1074/jbc.M508933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478726	hybrid			2022-12-27	WOS:000236822200053
J	Sutherland, MSK; Sanderson, RJ; Gordon, KA; Andreyka, J; Cerveny, CG; Yu, CP; Lewis, TS; Meyer, DL; Zabinski, RF; Doronina, SO; Senter, PD; Law, CL; Wahl, AF				Sutherland, MSK; Sanderson, RJ; Gordon, KA; Andreyka, J; Cerveny, CG; Yu, CP; Lewis, TS; Meyer, DL; Zabinski, RF; Doronina, SO; Senter, PD; Law, CL; Wahl, AF			Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CARCINOMA; SELECTIVE ANTITUMOR-ACTIVITY; IN-VITRO; MEDIATED ENDOCYTOSIS; LYMPHOMA-CELLS; INTERNALIZATION; IMMUNOCONJUGATE; CANCER; EFFICACY; POTENT	The chimeric anti-CD30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo. These drugs are appended via a valinecitrulline (vc) dipeptide linkage designed for high stability in serum and conditional cleavage and putative release of fully active drugs by lysosomal cathepsins. To characterize the biochemical processes leading to effective drug delivery, we examined the intracellular trafficking, internalization, and metabolism of the parent antibody and two antibody-drug conjugates, cAC10vc-MMAE and cAC10vc-MMAF, following CD30 surface antigen interaction with target cells. Both cAC10 and its conjugates bound to target cells and internalized in a similar manner. Subcellular fractionation and immunofluorescence studies demonstrated that the antibody and antibody-drug conjugates entering target cells migrated to the lysosomes. Trafficking of both species was blocked by inhibitors of clathrin-mediated endocytosis, suggesting that drug conjugation does not alter the fate of antibody-antigen complexes. Incubation of cAC10vc-MMAE or cAC10vc-MMAF with purified cathepsin B or with enriched lysosomal fractions prepared by subcellular fractionation resulted in the release of active, free drug. Cysteine protease inhibitors, but not aspartic or serine protease inhibitors, blocked antibody-drug conjugate metabolism and the ensuing cytotoxicity of target cells and yielded enhanced intracellular levels of the intact conjugates. These findings suggest that in addition to trafficking to the lysosomes, cathepsin B and perhaps other lysosomal cysteine proteases are requisite for drug release and provide a mechanistic basis for developing antibody-drug conjugates cleavable by intracellular proteases for the targeted delivery of anti-cancer therapeutics.	Seattle Genet Inc, Dept Mol Oncol & Immunol, Bothell, WA 98021 USA; Seattle Genet Inc, Dept Chem, Bothell, WA 98021 USA	Seattle Genetics; Seattle Genetics	Wahl, AF (corresponding author), Seattle Genet Inc, Dept Mol Oncol & Immunol, 21823 30th Dr SE, Bothell, WA 98021 USA.	awahl@seagen.com						Afar DEH, 2004, MOL CANCER THER, V3, P921; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; BRASLAWSKY GR, 1991, CANCER IMMUNOL IMMUN, V33, P367, DOI 10.1007/BF01741596; CASTLE JD, 2004, CURRENT PROTOCOLS PR, V1; Chan SY, 2003, CANCER IMMUNOL IMMUN, V52, P243, DOI 10.1007/s00262-002-0343-x; Coffey GP, 2004, J PHARMACOL EXP THER, V310, P896, DOI 10.1124/jpet.104.067611; Davis EC, 1998, MATRIX BIOL, V17, P245, DOI 10.1016/S0945-053X(98)90078-6; Di Paolo C, 2003, CLIN CANCER RES, V9, P2837; Doronina SO, 2006, BIOCONJUGATE CHEM, V17, P114, DOI 10.1021/bc0502917; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j; Durrbach A, 1996, J CELL SCI, V109, P457; Francisco JA, 2003, BLOOD, V102, P1458, DOI 10.1182/blood-2003-01-0039; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Goulet AC, 1997, BLOOD, V90, P2364, DOI 10.1182/blood.V90.6.2364.2364_2364_2375; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Jeitner TM, 2005, BIOCHEM PHARMACOL, V69, P961, DOI 10.1016/j.bcp.2004.12.011; Law CL, 2004, CLIN CANCER RES, V10, P7842, DOI 10.1158/1078-0432.CCR-04-1028; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Omelyanenko V, 1998, INT J CANCER, V75, P600, DOI 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Sapra P, 2002, CANCER RES, V62, P7190; Semac I, 2003, CANCER RES, V63, P534; SHIH LB, 1994, CANCER IMMUNOL IMMUN, V38, P92, DOI 10.1007/BF01526203; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; Sievers EL, 2001, J CLIN ONCOL, V19, P3244, DOI 10.1200/JCO.2001.19.13.3244; Szpaderska AM, 2001, CANCER RES, V61, P3493; Tolcher AW, 2003, J CLIN ONCOL, V21, P211, DOI 10.1200/JCO.2003.05.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wahl AF, 2002, CANCER RES, V62, P3736	37	208	237	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10540	10547		10.1074/jbc.M510026200	http://dx.doi.org/10.1074/jbc.M510026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484228	hybrid			2022-12-27	WOS:000236594300084
J	Burridge, K; Sastry, SK; Sallee, JL				Burridge, Keith; Sastry, Sarita K.; Sallee, Jennifer L.			Regulation of cell adhesion by protein-tyrosine phosphatases - I. Cell-matrix adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SRC-FAMILY KINASES; PTP-PEST; FOCAL ADHESIONS; TAIL RETRACTION; DOWN-REGULATION; INTEGRIN; ACTIVATION; SHP-2; RHO; PAXILLIN	Protein-tyrosine phosphatases are key regulators of protein tyrosine phosphorylation. More than merely terminating the pathways initiated by protein-tyrosine kinases, phosphatases are active participants in many signaling pathways. Signals involving tyrosine phosphorylation are frequently generated in response to cell-matrix adhesion. In addition, high levels of protein tyrosine phosphorylation generally promote disassembly or turnover of adhesions. In this brief review, we will discuss the role of protein-tyrosine phosphatases in cell-matrix adhesions.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Medical Branch Galveston	Burridge, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	keith_burridge@med.unc.edu	Sastry, Sarita/A-1291-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arias-Salgado EG, 2005, J CELL BIOL, V170, P837, DOI 10.1083/jcb.200503125; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH192, DOI 10.1152/ajpheart.1999.277.1.H192; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILLC D, 1995, NATURE, V377, P539; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Jamieson JS, 2005, J CELL SCI, V118, P5835, DOI 10.1242/jcs.02693; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Sallee JL, 2006, J BIOL CHEM, V281, P16189, DOI 10.1074/jbc.R600003200; Sastry SK, 2006, J BIOL CHEM, V281, P11627, DOI 10.1074/jbc.M600897200; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	64	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15593	15596		10.1074/jbc.R500030200	http://dx.doi.org/10.1074/jbc.R500030200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16497668	hybrid			2022-12-27	WOS:000237996000002
J	Arjunan, P; Sax, M; Brunskill, A; Chandrasekhar, K; Nemeria, N; Zhang, S; Jordan, F; Furey, W				Arjunan, Palaniappa; Sax, Martin; Brunskill, Andrew; Chandrasekhar, Krishnamoorthy; Nemeria, Natalia; Zhang, Sheng; Jordan, Frank; Furey, William			A thiamin-bound, pre-decarboxylation reaction intermediate analogue in the pyruvate dehydrogenase E1 subunit induces large scale disorder-to-order transformations in the enzyme and reveals novel structural features in the covalently bound adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEXES; ANGSTROM RESOLUTION; DIPHOSPHATE BINDING; ACTIVE-SITES; CATALYSIS; CRYSTALLOGRAPHY; TRANSKETOLASE	The crystal structure of the E1 component from the Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc) has been determined with phosphonolactylthiamin diphosphate (PLThDP) in its active site. PLThDP serves as a structural and electrostatic analogue of the natural intermediate alpha-lactylthiamin diphosphate (LThDP), in which the carboxylate from the natural substrate pyruvate is replaced by a phosphonate group. This represents the first example of an experimentally determined, three-dimensional structure of a thiamin diphosphate (ThDP)-dependent enzyme containing a covalently bound, pre-decarboxylation reaction intermediate analogue and should serve as a model for the corresponding intermediates in other ThDP-dependent decarboxylases. Regarding the PDHc-specific reaction, the presence of PLThDP induces large scale conformational changes in the enzyme. In conjunction with the E1-PLThDP and E1-ThDP structures, analysis of a H407AE1-PLThDP variant structure shows that an interaction between His-407 and PLThDP is essential for stabilization of two loop regions in the active site that are otherwise disordered in the absence of intermediate analogue. This ordering completes formation of the active site and creates a new ordered surface likely involved in interactions with the lipoyl domains of E2s within the PDHc complex. The tetrahedral intermediate analogue is tightly held in the active site through direct hydrogen bonds to residues His-407, Tyr-599, and His-640 and reveals a new, enzyme-induced, strain-related feature that appears to aid in the decarboxylation process. This feature is almost certainly present in all ThDP- dependent decarboxylases; thus its inclusion in our understanding of general thiamin catalysis is important.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University Newark; Rutgers State University New Brunswick	Furey, W (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, 1340W BSTWR, Pittsburgh, PA 15261 USA.	fureyw@pitt.edu			NIGMS NIH HHS [GM-62330, GM-61791] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791, R01GM062330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Arjunan P, 2005, ACTA CRYSTALLOGR A, V61, pC202, DOI 10.1107/S0108767305091415; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; FUREY W, 2004, THIAMINE CATALYTIC M, P407; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Jones DD, 2001, J MOL BIOL, V305, P49, DOI 10.1006/jmbi.2000.4257; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2005, BIOORG CHEM, V33, P190, DOI 10.1016/j.bioorg.2005.02.001; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLETCHER J, 1977, J AM CHEM SOC, V99, P1396, DOI 10.1021/ja00447a019; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; TURANO A, 1982, J AM CHEM SOC, V104, P3089, DOI 10.1021/ja00375a024; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Zhang S, 2004, J BIOL CHEM, V279, P54312, DOI 10.1074/jbc.M409278200	34	84	85	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15296	15303		10.1074/jbc.M600656200	http://dx.doi.org/10.1074/jbc.M600656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16531404	hybrid			2022-12-27	WOS:000237922200033
J	Chaurasia, P; Aguirre-Ghiso, JA; Liang, OD; Gardsvoll, H; Ploug, M; Ossowski, L				Chaurasia, Pratima; Aguirre-Ghiso, Julio A.; Liang, Olin D.; Gardsvoll, Henrik; Ploug, Michael; Ossowski, Liliana			A region in urokinase plasminogen receptor domain III controlling a functional association with alpha 5 beta 1 integrin and tumor growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR RECEPTOR; INTEGRIN FUNCTION; CELL-ADHESION; MONOCLONAL-ANTIBODY; BETA(3) INTEGRINS; CRYSTAL-STRUCTURE; HUMAN CARCINOMA; LIGAND-BINDING; IN-VIVO; FIBRONECTIN	Highly expressed urokinase plasminogen activator receptor (uPAR) can interact with alpha 5 beta 1 integrin leading to persistent ERK activation and tumorigenicity. Disrupting this interaction reduces ERK activity, forcing cancer cells into dormancy. We identified a site in uPAR domain III that is indispensable for these effects. A 9-mer peptide derived from a sequence in domain III ( residues 240-248) binds purified alpha 5 beta 1 integrin. Substituting a single amino acid ( S245A) in this peptide, or in full-length soluble uPAR, impairs binding of the purified integrin. In the recently solved crystal structure of uPAR the Ser-245 is confined to the large external surface of the receptor, a location that is well separated from the central urokinase plasminogen binding cavity. The impact of this site on alpha 5 beta 1 integrin-dependent cell functions was examined by comparing cells induced to express uPAR(wt) or the uPAR(S245A) mutant. Transfecting uPARwt into cells with low endogenous levels of uPAR, inactive integrin, lowERK activity, and a dormant phenotype in vivo restores these functions and reinstates growth in vivo. In contrast, transfection of the same cells with uPAR(S245A) elicits only very small changes. Incubation of highly malignant cells with the wild-type, but not the S245A mutant peptide, disrupts the uPAR integrin interaction leading to down-regulation of ERK activity. The relevance of this binding site, and of the lateral uPAR-alpha 5 beta 1 integrin interaction, to ERK pathway activation and tumor growth implicates it as a possible specific target for cancer therapy.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Univ Giessen, Fachbereich Human Med, Inst Biochem, D-35392 Giessen, Germany; Copenhagen Univ Hosp, Finsen Lab, DK-2100 Copenhagen, Denmark	Icahn School of Medicine at Mount Sinai; Justus Liebig University Giessen; University of Copenhagen	Ossowski, L (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	Liliana.Ossowski@mssm.edu		Aguirre-Ghiso, Julio/0000-0002-6694-6507; Ploug, Michael/0000-0003-2215-4265	NCI NIH HHS [CA 40578] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hansen LV, 2004, BIOCHEM J, V380, P845, DOI 10.1042/BJ20031478; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Liang OD, 2003, J BIOCHEM, V134, P661, DOI 10.1093/jb/mvg190; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; NISHIDA T, 1988, INVEST OPHTH VIS SCI, V29, P1820; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xue W, 1997, CANCER RES, V57, P1682; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	45	103	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14852	14863		10.1074/jbc.M512311200	http://dx.doi.org/10.1074/jbc.M512311200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547007	hybrid			2022-12-27	WOS:000237671300039
J	Douillette, A; Bibeau-Poirier, A; Gravel, SP; Clement, JF; Chenard, V; Moreau, P; Servant, MJ				Douillette, A; Bibeau-Poirier, A; Gravel, SP; Clement, JF; Chenard, V; Moreau, P; Servant, MJ			The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HERITABLE HYPERLIPIDEMIC RABBIT; EGF RECEPTOR TRANSACTIVATION; CELL-ADHESION MOLECULE-1; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; IKK-ALPHA; P38 MAPK	The vasoactive hormone angiotensin II ( Ang II) probably triggers inflammatory cardiovascular diseases by activating transcription factors such as NF-kappa B. We describe here a novel mode of NF-kappa B activation in cultured vascular smooth muscle cells exposed to Ang II. Ang II treatment resulted in an increase in the phosphotransferase activity of the IKK complex, which was mediated through the AT1 receptor subtype. The typical phosphorylation and proteasome-dependent degradation of the NF-kappa B inhibitor I kappa B alpha were not observed. Rather, Ang II treatment of vascular smooth muscle cells led to the phosphorylation of p65 on serine 536, a signal detected in both the cytoplasm and the nuclear compartments. The use of pharmacological inhibitors that inhibit the activation of MEK by Ang II revealed that phosphorylation of p65 on serine 536 did not require the MEK-ERK-RSK signaling pathway. On the other hand, specifically targeting the IKK beta subunit of the IKK complex by overexpression of a dominant negative version of IKK beta( IKK beta K44A) or silencing RNA technology demonstrated that the IKK beta subunit of the IKK complex was responsible for the detected phosphoserine 536 signal in Ang II-treated cells. Characterization of the signaling pathway leading to activation of the IKK complex by Ang II revealed that neither epidermal growth factor receptor transactivation nor the phosphatidylinositol 3-kinase-AKT signaling cascade were involved. Collectively, our data demonstrate that the proinflammatory activity of Ang II is independent of the classical pathway leading to I kappa B alpha phosphorylation and degradation but clearly depends on the recruitment of an IKK complex signaling cascade leading to phosphorylation of p65 on serine 536.	Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Servant, MJ (corresponding author), POB 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	marc.servant@umontreal.ca		Chenard, Valerie/0000-0002-2073-1279; Gravel, Simon-Pierre/0000-0001-8411-8054; Moreau, Pierre/0000-0002-3604-721X				ABERG G, 1990, J CARDIOVASC PHAR S5, V15, P65; Alderman M H, 1995, Curr Opin Nephrol Hypertens, V4, P201, DOI 10.1097/00041552-199503000-00015; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; CHOBANIAN AV, 1992, HYPERTENSION, V20, P473, DOI 10.1161/01.HYP.20.4.473; CHOBANIAN AV, 1990, HYPERTENSION, V15, P327, DOI 10.1161/01.HYP.15.3.327; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; Funakoshi Y, 2001, HYPERTENSION, V38, P100, DOI 10.1161/01.HYP.38.1.100; Furukawa Y, 1996, CIRCULATION, V93, P333, DOI 10.1161/01.CIR.93.2.333; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Gravel SP, 2005, J BIOL CHEM, V280, P7477, DOI 10.1074/jbc.M410392200; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jiang BB, 2004, J BIOL CHEM, V279, P20363, DOI 10.1074/jbc.M314172200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kon V, 2004, CURR OPIN NEPHROL HY, V13, P291, DOI 10.1097/00041552-200405000-00005; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lemarie CA, 2003, CIRC RES, V93, P207, DOI 10.1161/01.RES.0000086942.13523.88; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Maas R, 2003, ATHEROSCLEROSIS SUPP, V4, P5, DOI 10.1016/S1567-5688(03)00028-X; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; MEADE TW, 1993, NEW ENGL J MED, V329, P616, DOI 10.1056/NEJM199308263290905; Meloche S, 2000, MOL CELL BIOCHEM, V212, P99, DOI 10.1023/A:1007140606333; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schmidt-Ott KM, 2000, REGUL PEPTIDES, V93, P65, DOI 10.1016/S0167-0115(00)00178-6; Shah BH, 2006, J CELL PHYSIOL, V206, P47, DOI 10.1002/jcp.20423; SHCELLIGN P, 1991, J HYPERTENS, V9, P3; Skurk T, 2004, ARTERIOSCL THROM VAS, V24, P1199, DOI 10.1161/01.ATV.0000131266.38312.2e; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wassmann S, 2004, CIRCULATION, V110, P3062, DOI 10.1161/01.CIR.0000137970.47771.AF; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Wolf G, 2002, KIDNEY INT, V61, P1986, DOI 10.1046/j.1523-1755.2002.00365.x; Wu L, 2004, MOL ENDOCRINOL, V18, P666, DOI 10.1210/me.2003-0053; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhang LP, 2005, ARTERIOSCL THROM VAS, V25, P1148, DOI 10.1161/01.ATV.0000164624.00099.e7; Zhang LP, 2005, CIRC RES, V97, P975, DOI 10.1161/01.RES.0000190589.52286.41; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	63	64	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13275	13284		10.1074/jbc.M512815200	http://dx.doi.org/10.1074/jbc.M512815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16513650	hybrid			2022-12-27	WOS:000237336600033
J	Singh, A; Severance, S; Kaur, N; Wiltsie, W; Kosman, DJ				Singh, A; Severance, S; Kaur, N; Wiltsie, W; Kosman, DJ			Assembly, activation, and trafficking of the Fet3p center dot Ftr1p high affinity iron permease complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICOPPER OXIDASE FET3P; RESONANCE ENERGY-TRANSFER; PROTEIN-COUPLED RECEPTOR; FERROXIDASE ACTIVITY; PLASMA-MEMBRANE; QUALITY-CONTROL; COPPER UPTAKE; YEAST; TRANSPORT; GENE	The high affinity iron uptake complex in the yeast plasma membrane ( PM) consists of the ferroxidase, Fet3p, and the ferric iron permease, Ftr1p. We used a combination of yeast two- hybrid analysis, confocal fluorescence microscopy, and fluorescence resonance energy transfer ( FRET) quantification to delineate the motifs in the two proteins required for assembly and maturation into an uptake-competent complex. The cytoplasmic, carboxyl- terminal domain of each protein contains a four- residue motif adjacent to the cytoplasm-PM interface that supports an interaction between the proteins. This interaction has been quantified by two- hybrid analysis and is required for assembly and trafficking of the complex to the PM and for the similar to 13% maximum FRET efficiency determined. In contrast, the Fet3p transmembrane domain ( TM) can be exchanged with the TM domain from the vacuolar ferroxidase, Fet5p, with no loss of assembly and trafficking. A carboxyl- terminal interaction between the vacuolar proteins, Fet5p and Fth1p, also was quantified. As a measure of the specificity of interaction, no interaction between heterologous ferroxidase permease pairs was observed. Also, whereas FRET was quantified between fluorescent fusions of the copper permease ( monomers), Ctr1p, none was observed between Fet3p and Ctr1p. The results are consistent with a ( minimal) heterodimer model of the Fet3p center dot Ftr1p complex that supports the trafficking of iron from Fet3p to Ftr1p for iron permeation across the yeast PM.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@buffalo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Askwith C, 1997, J BIOL CHEM, V272, P401; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; di Patti MCB, 2000, FEBS LETT, V472, P283, DOI 10.1016/S0014-5793(00)01435-6; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Frieden E, 1974, Adv Exp Med Biol, V48, P235; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Kosman DJ, 2002, ADV PROTEIN CHEM, V60, P221; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Miller J. H, 1972, EXPT MOL GENETICS; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Overton MC, 2002, METHODS, V27, P324, DOI 10.1016/S1046-2023(02)00090-7; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Quintanar L, 2004, J AM CHEM SOC, V126, P6579, DOI 10.1021/ja049220t; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Sato M, 2004, MOL BIOL CELL, V15, P1417, DOI 10.1091/mbc.E03-10-0765; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shi XL, 2003, J BIOL CHEM, V278, P50309, DOI 10.1074/jbc.M307019200; SIKORSKI RS, 1989, GENETICS, V122, P19; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Taylor AB, 2005, P NATL ACAD SCI USA, V102, P15459, DOI 10.1073/pnas.0506227102; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang TP, 2003, J BIOL INORG CHEM, V8, P611, DOI 10.1007/s00775-003-0456-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; [No title captured], DOI DOI 10.1002/0470862106.IA055	38	59	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13355	13364		10.1074/jbc.M512042200	http://dx.doi.org/10.1074/jbc.M512042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16522632	hybrid			2022-12-27	WOS:000237336600041
J	Tremblay, MR; Carbonetto, S				Tremblay, MR; Carbonetto, S			An extracellular pathway for dystroglycan function in acetylcholine receptor aggregation and laminin deposition in skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; NEUROMUSCULAR-JUNCTIONS; POSTSYNAPTIC PROTEINS; AGRIN; MUSCLE; RAPSYN; EXPRESSION; MEMBRANE	The dystroglycan ( DG) complex is involved in agrin- induced acetylcholine receptor clustering downstream of muscle- specific kinase where it regulates the stability of acetylcholine receptor aggregates as well as assembly of the synaptic basement membrane. We have previously proposed that this entails coordinate extracellular and intracellular interactions of its two subunits, alpha- and beta- DG. To assess the contribution of the extracellular and intracellular portions of DG, we have used adenoviruses to express full- length and deletion mutants of beta- DG in myotubes derived from wild- type embryonic stem cells or from cells null for DG. We show that alpha- DG is properly glycosylated and targeted to the myotube surface in the absence of beta- DG. Extracellular interactions of DG modulate the size and the microcluster density of agrin- induced acetylcholine receptor aggregates and are responsible for targeting laminin to these clusters. Thus, the association of alpha- and beta- DG in skeletal muscle may coordinate independent roles in signaling. We discuss how DG may regulate synapses through extracellular signaling functions of its alpha subunit.	McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Biol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar, Montreal, PQ H3G 1A4, Canada.	Sal.carbonetto@mcgill.ca						APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BALDWIN TJ, 1988, DEVELOPMENT, V104, P557; Bartoli M, 2001, J BIOL CHEM, V276, P24911, DOI 10.1074/jbc.M103258200; Borges LS, 2001, J CELL BIOL, V153, P1, DOI 10.1083/jcb.153.1.1; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Cluchague N, 2004, FEBS LETT, V572, P216, DOI 10.1016/j.febslet.2004.07.032; COHEN MW, 1995, DEV BIOL, V167, P458, DOI 10.1006/dbio.1995.1041; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esapa CT, 2003, FEBS LETT, V555, P209, DOI 10.1016/S0014-5793(03)01230-4; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Francis MM, 2005, NEURON, V46, P581, DOI 10.1016/j.neuron.2005.04.010; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Gally C, 2004, NATURE, V431, P578, DOI 10.1038/nature02893; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heathcote RD, 2000, DEV BIOL, V227, P595, DOI 10.1006/dbio.2000.9906; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, HUM PATHOL, V32, P791, DOI 10.1053/hupa.2001.26468; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jacobson C, 1998, J NEUROSCI, V18, P6340; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Leschziner A, 2000, J NEUROCHEM, V74, P70, DOI 10.1046/j.1471-4159.2000.0740070.x; Levedakou EN, 2005, MOL CELL NEUROSCI, V28, P757, DOI 10.1016/j.mcn.2004.12.007; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Marchand S, 2002, J NEUROSCI, V22, P8891; Martin PT, 2003, GLYCOBIOLOGY, V13, p55R, DOI 10.1093/glycob/cwg076; MARTIN PT, 1995, SCIENCE, V269, P413, DOI 10.1126/science.7618109; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; Muschler J, 2002, CANCER RES, V62, P7102; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Palmai-Pallag T, 2005, FEBS J, V272, P2901, DOI 10.1111/j.1742-4658.2005.04711.x; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Pereboev AV, 2001, BBA-GEN SUBJECTS, V1527, P54, DOI 10.1016/S0304-4165(01)00147-7; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; Shiao T, 2004, HUM MOL GENET, V13, P1873, DOI 10.1093/hmg/ddh204; Smirnov SP, 2005, J BIOL CHEM, V280, P41449, DOI 10.1074/jbc.M508939200; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VATER R, 1995, J NEUROPATH EXP NEUR, V54, P557, DOI 10.1097/00005072-199507000-00010; VOGEL Z, 1983, J NEUROSCI, V3, P1058; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Xu RF, 1997, J NEUROSCI, V17, P8194; Xu RF, 1999, J CELL PHYSIOL, V181, P107, DOI 10.1002/(SICI)1097-4652(199910)181:1<107::AID-JCP11>3.3.CO;2-0; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	89	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13365	13373		10.1074/jbc.M600912200	http://dx.doi.org/10.1074/jbc.M600912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531403	hybrid			2022-12-27	WOS:000237336600042
J	Cajo, GC; Horne, BE; Kelley, WL; Schwager, F; Georgopoulos, C; Genevaux, P				Cajo, GC; Horne, BE; Kelley, WL; Schwager, F; Georgopoulos, C; Genevaux, P			The role of the DIF motif of the DnaJ (Hsp40) co-chaperone in the regulation of the DnaK (Hsp70) chaperone cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; FINGER-LIKE DOMAIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; YEAST HSP40; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; ATPASE ACTIVITY; RICH REGION	To perform effectively as a molecular chaperone, DnaK (Hsp70) necessitates the assistance of its DnaJ (Hsp40) co-chaperone partner, which efficiently stimulates its intrinsically weak ATPase activity and facilitates its interaction with polypeptide substrates. In this study, we address the function of the conserved glycine- and phenyalanine-rich (G/F-rich) region of the Escherichia coli DnaJ in the DnaK chaperone cycle. We show that the G/F-rich region is critical for DnaJ co-chaperone functions in vivo and that despite a significant degree of sequence conservation among the G/F-rich regions of Hsp40 homologs from bacteria, yeast, or humans, functional complementation in the context of the E. coli DnaJ is limited. Furthermore, we found that the deletion of the whole G/F-rich region is mirrored by mutations in the conserved Asp-Ile/Val-Phe (DIF) motif contained in this region. Further genetic and biochemical analyses revealed that this amino acid triplet plays a critical role in regulation of the DnaK chaperone cycle, possibly by modulating a crucial step subsequent to DnaK-mediated ATP hydrolysis.	Univ Geneva, Ctr Med, Dept Microbiol & Med Mol, CH-1211 Geneva 4, Switzerland; Tulane Univ, Dept Biochem, Hlth Sci Ctr, New Orleans, LA 70112 USA	University of Geneva; Tulane University	Genevaux, P (corresponding author), Univ Geneva, Ctr Med, Dept Microbiol & Med Mol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	pierre.genevaux@medecine.unige.ch	Genevaux, Pierre/A-4851-2015	GENEVAUX, Pierre/0000-0001-7539-3126				ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Aron R, 2005, GENETICS, V169, P1873, DOI 10.1534/genetics.104.037242; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deloche O, 1997, J BIOL CHEM, V272, P28539, DOI 10.1074/jbc.272.45.28539; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Genevaux P, 2002, GENETICS, V162, P1045; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; Genevaux P, 2001, J BACTERIOL, V183, P5747, DOI 10.1128/JB.183.19.5747-5750.2001; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hennessy F, 2005, PROTEIN SCI, V14, P1697, DOI 10.1110/ps.051406805; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Shi YY, 2005, J BIOL CHEM, V280, P22761, DOI 10.1074/jbc.M503643200; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; Wu YK, 2005, J MOL BIOL, V346, P1005, DOI 10.1016/j.jmb.2004.12.040; Yan W, 1999, MOL CELL BIOL, V19, P7751; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	42	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12436	12444		10.1074/jbc.M511192200	http://dx.doi.org/10.1074/jbc.M511192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533811	Green Published, hybrid			2022-12-27	WOS:000237134700030
J	Heyduk, E; Kuznedelov, K; Severinov, K; Heyduk, T				Heyduk, E; Kuznedelov, K; Severinov, K; Heyduk, T			A consensus adenine at position-11 of the nontemplate strand of bacterial promoter is important for nucleation of promoter melting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; SIGMA-FACTOR MUTATIONS; OPEN COMPLEX-FORMATION; CONFORMATIONAL-CHANGES; CORE ENZYME; DNA; BINDING; RECOGNITION; KINETICS	Numerous studies have suggested an important role of adenine at position -11 of the nontemplate strand of bacterial promoters for sequence-specific recognition of the -10 promoter element in single-stranded form. In this work, we attempted to identify a specific step in transcription initiation reaction that is most critically dependent on specific recognition of -11A. Mutating -11A in the context of a model promoter resulted in a profound decrease of the rate of heparin-resistant promoter complex formation and in a modest increase of the rate of heparin-resistant complex dissociation. The identity of nontemplate base at position -11 became relatively unimportant when the duplex in the vicinity of this position was destabilized by base pair mismatches. For promoters with a nonnative thymine at nontemplate position -11, we observed a remarkable correlation between the rate of heparin-resistant complex formation (or transcription activity) and the free energy of duplex stability in the vicinity of this residue, indicating that the replacement of -11A with a T affected a step in the reaction that involves local melting of DNA duplex. These data show that a promoter melting defect caused by a loss of RNA polymerase contact with -11A can be rescued by artificially induced local destabilization of the DNA duplex. These results are consistent with and support the idea that specific recognition of adenine at the nontemplate -11-position is important only for the initial nucleation of melting, which probably involves the flipping of this adenine out from the DNA duplex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Saint Louis University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@slu.edu	Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R01GM064530] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 64530, R01 GM 50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan-Bonet G., 2003, PHYS REV LETT, V90, P1; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Lee HJ, 2004, J BIOL CHEM, V279, P16899, DOI 10.1074/jbc.C400054200; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Niedziela-Majka A, 2005, J BIOL CHEM, V280, P38219, DOI 10.1074/jbc.M507984200; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Rowe-Magnus DA, 1998, P NATL ACAD SCI USA, V95, P5305, DOI 10.1073/pnas.95.9.5305; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462	34	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12362	12369		10.1074/jbc.M601364200	http://dx.doi.org/10.1074/jbc.M601364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531399	hybrid			2022-12-27	WOS:000237134700021
J	Kaye, SL; Sansom, MSP; Biggin, PC				Kaye, SL; Sansom, MSP; Biggin, PC			Molecular dynamics simulations of the ligand-binding domain of an N-methyl-D aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; PROTEIN-STRUCTURE; MECHANISMS; ACTIVATION; COMPLEX; SUBUNITS; CLOSURE; GLUR5	The mechanism of partial agonism at N-methyl-D-aspartate receptors is an unresolved issue, especially with respect to the role of protein dynamics. We have performed multiple molecular dynamics simulations (7 x 20 ns) to examine the behavior of the ligand-binding core of the NR1 subunit with a series of ligands. Our results show that water plays an important role in stabilizing different conformations of the core and how a closed cleft conformation of the protein might be stabilized in the absence of ligands. In the case of ligand-bound simulations with both full and partial agonists, we observed that ligands within the binding cleft may undergo distinct conformational changes, without grossly influencing the degree of cleft closure within the ligand-binding domain. In agreement with recently published crystallographic data, we also observe similar changes in backbone torsions corresponding to the hinge region between the two lobes for the partial agonist, D-cycloserine. This observation rationalizes the classification of D-cycloserine as a partial agonist and should provide a basis with which to predict partial agonism in this class of receptor by analyzing the behavior of these torsions with other potential ligands.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Biggin, PC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	philip.biggin@bioch.ox.ac.uk	Sansom, Mark S.P./C-5157-2009	Sansom, Mark S.P./0000-0001-6360-7959; Biggin, Philip/0000-0001-5100-8836	Biotechnology and Biological Sciences Research Council [B19456, BEP17032, BBS/B/16011] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Arinaminpathy Y, 2006, MOL PHARMACOL, V69, P5, DOI 10.1124/mol.105.016691; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dingledine R, 1999, PHARMACOL REV, V51, P7; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Hashimoto K, 2003, ARCH GEN PSYCHIAT, V60, P572, DOI 10.1001/archpsyc.60.6.572; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Laruelle M, 2003, ANN NY ACAD SCI, V1003, P138, DOI 10.1196/annals.1300.063; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Madden DR, 2005, J BIOL CHEM, V280, P23637, DOI 10.1074/jbc.M414523200; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; Mayer ML, 2005, CURR OPIN NEUROBIOL, V15, P282, DOI 10.1016/j.conb.2005.05.004; Mueller HT, 2004, MOL BRAIN RES, V121, P60, DOI 10.1016/j.molbrainres.2003.11.004; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nanao MH, 2005, P NATL ACAD SCI USA, V102, P1708, DOI 10.1073/pnas.0409573102; Naur P, 2005, FEBS LETT, V579, P1154, DOI 10.1016/j.febslet.2005.01.012; Pang A, 2005, PROTEINS, V61, P809, DOI 10.1002/prot.20672; Pang A, 2003, FEBS LETT, V550, P168, DOI 10.1016/S0014-5793(03)00866-4; Roccatano D, 2001, J MOL BIOL, V310, P1039, DOI 10.1006/jmbi.2001.4808; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735	34	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12736	12742		10.1074/jbc.M512728200	http://dx.doi.org/10.1074/jbc.M512728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513640	hybrid			2022-12-27	WOS:000237134700066
J	Zhang, YJ; Tu, YZ; Gkretsi, V; Wu, CY				Zhang, YJ; Tu, YZ; Gkretsi, V; Wu, CY			Migfilin interacts with vasodilator-stimulated phosphoprotein (VASP) and regulates VASP localization to cell-matrix adhesions and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; ENA/VASP PROTEINS; LISTERIA-MONOCYTOGENES; AXON GUIDANCE; SHAPE MODULATION; TYROSINE KINASE; FOCAL ADHESIONS; CYTOSKELETON; FAMILY; RECEPTOR	Cell migration is a complex process that is coordinately regulated by cell-matrix adhesion and actin cytoskeleton. We report here that migfilin, a recently identified component of cell-matrix adhesions, is a biphasic regulator of cell migration. Loss of migfilin impairs cell migration. Surprisingly, overexpression of migfilin also reduces cell migration. Molecularly, we have identified vasodilator-stimulated phosphoprotein (VASP) as a new migfilin-binding protein. The interaction is mediated by the VASP EVH1 domain and a single (LPPPPP)-P-104 site located within the migfilin proline-rich domain. Migfilin and VASP form a complex in both suspended and adhered cells, and in the latter, they co-localize in cell-matrix adhesions. Functionally, migfilin facilitates VASP localization to cell-matrix adhesions. Using two different approaches (VASP-binding defective migfilin mutants and small interfering RNA-mediated VASP knockdown), we show that the interaction with VASP is crucially involved in migfilin-mediated regulation of cell migration. Our results identify migfilin as an important regulator of cell migration and provide new information on the mechanism by which migfilin regulates this process.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu	Gkretsi, Vasiliki/Q-2158-2019	Gkretsi, Vasiliki/0000-0002-3671-4078	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cossart P, 2001, CURR OPIN IMMUNOL, V13, P96, DOI 10.1016/S0952-7915(00)00188-6; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gitai Z, 2003, NEURON, V37, P53, DOI 10.1016/S0896-6273(02)01149-2; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Goh KL, 2002, CURR BIOL, V12, P565, DOI 10.1016/S0960-9822(02)00725-X; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; HUMPHRIES MJ, 1998, CURRENT PROTOCOLS CE; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Menzies AS, 2004, J NEUROSCI, V24, P8029, DOI 10.1523/JNEUROSCI.1057-04.2004; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Sechi AS, 2004, FRONT BIOSCI, V9, P1294, DOI 10.2741/1324; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takafuta T, 2003, J BIOL CHEM, V278, P12175, DOI 10.1074/jbc.M209339200; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Withee J, 2004, GENETICS, V167, P1165, DOI 10.1534/genetics.103.025676; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2005, J CELL SCI, V118, P659, DOI 10.1242/jcs.01639; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	48	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12397	12407		10.1074/jbc.M512107200	http://dx.doi.org/10.1074/jbc.M512107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531412	hybrid			2022-12-27	WOS:000237134700025
J	Brown, MR; Sullivan, PG; Geddes, JW				Brown, MR; Sullivan, PG; Geddes, JW			Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2&-INDUCED MEMBRANE TRANSITION; INDUCED PERMEABILITY TRANSITION; CULTURED HIPPOCAMPAL-NEURONS; PERCOLL GRADIENT PROCEDURE; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; LIVER-MITOCHONDRIA; RAT-BRAIN; QUANTITATIVE-EVALUATION; ALZHEIMERS-DISEASE	Mitochondria in nerve terminals are subjected to extensive Ca2+ fluxes and high energy demands, but the extent to which the synaptic mitochondria buffer Ca2+ is unclear. In this study, we identified a difference in the Ca2+ clearance ability of nonsynaptic versus synaptic mitochondrial populations enriched from rat cerebral cortex. Mitochondria were isolated using Percoll discontinuous gradients in combination with high pressure nitrogen cell disruption. Mitochondria in the nonsynaptic fraction originate from neurons and other cell types including glia, whereas mitochondria enriched from a synaptosomal fraction are predominantly neuronal and presynaptic in origin. There were no differences in respiration or initial Ca2+ loads between nonsynaptic and synaptic mitochondrial populations. Following both bolus and infusion Ca2+ addition, nonsynaptic mitochondria were able to accumulate significantly more exogenously added Ca2+ than the synaptic mitochondria before undergoing mitochondrial permeability transition, observed as a loss in mitochondrial membrane potential and decreased Ca2+ uptake. The limited ability of synaptic mitochondria to accumulate Ca2+ could result from several factors including a primary function of ATP production to support the high energy demand of presynaptic terminals, their relative isolation in comparison with the threads or clusters of mitochondria found in the soma of neurons and glia, or the older age and increased exposure to oxidative damage of synaptic versus nonsynaptic mitochondria. By more readily undergoing permeability transition, synaptic mitochondria may initiate neuron death in response to insults that elevate synaptic levels of intracellular Ca2+, consistent with the early degeneration of distal axon segments in neurodegenerative disorders.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Gerontol, Lexington, KY 40536 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Geddes, JW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, B379 BBSRB, Lexington, KY 40536 USA.	jgeddes@uky.edu			NIA NIH HHS [AG10836] Funding Source: Medline; NINDS NIH HHS [NS048191, NS046426, NS045276] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048191, R21NS046426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010836] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BATTINO M, 1991, J BIOENERG BIOMEMBR, V23, P345, DOI 10.1007/BF00762227; Battino M, 2000, J BIOENERG BIOMEMBR, V32, P163, DOI 10.1023/A:1005559930210; Battino M, 2002, FREE RADICAL RES, V36, P479, DOI 10.1080/10715760290021351; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Billups B, 2002, J NEUROSCI, V22, P5840; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CHANCE B, 1955, J BIOL CHEM, V217, P383; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; David G, 2003, CELL CALCIUM, V33, P197, DOI 10.1016/S0143-4160(02)00229-4; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; Drummond RM, 2000, J PHYSIOL-LONDON, V522, P375, DOI 10.1111/j.1469-7793.2000.t01-2-00375.x; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friel DD, 2000, CELL CALCIUM, V28, P307, DOI 10.1054/ceca.2000.0172; Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014; GRAY EG, 1963, J ANAT, V97, P101; GRAY EG, 1962, J ANAT, V96, P79; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; ITZHAK Y, 1995, DEV BRAIN RES, V84, P62, DOI 10.1016/0165-3806(94)00163-T; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kong DJ, 2005, MOL CELL BIOCHEM, V272, P187, DOI 10.1007/s11010-005-7323-3; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Lai J C, 1979, Methods Enzymol, V55, P51; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LAI JCK, 1989, CARBOHYDRATES ENERGY, P43; LEONG SF, 1984, J NEUROCHEM, V42, P1306, DOI 10.1111/j.1471-4159.1984.tb02788.x; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Ligon LA, 2000, J COMP NEUROL, V427, P340, DOI 10.1002/1096-9861(20001120)427:3<340::AID-CNE2>3.0.CO;2-Y; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; MASLIAH E, 1995, HISTOL HISTOPATHOL, V10, P509; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; MORRIS RL, 1993, J CELL SCI, V104, P917; Muller M, 2005, EXP CELL RES, V303, P114, DOI 10.1016/j.yexcr.2004.09.025; Murchison D, 2004, CELL CALCIUM, V36, P61, DOI 10.1016/j.ceca.2003.11.010; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Panov AV, 2004, ARCH BIOCHEM BIOPHYS, V424, P44, DOI 10.1016/j.abb.2004.01.013; Peinado MA, 1997, ANAT REC, V247, P420; RENDON A, 1985, J NEUROSCI METH, V14, P41, DOI 10.1016/0165-0270(85)90113-X; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; Rowland KC, 2000, J NEUROSCI, V20, P9135; SCOTT ID, 1980, BIOCHEM J, V192, P873, DOI 10.1042/bj1920873; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SULLIVAN PG, 2004, J BIOL CHEM, P79200; Talbot JD, 2003, J NEUROPHYSIOL, V90, P491, DOI 10.1152/jn.00012.2003; Vergun O, 2005, BBA-BIOENERGETICS, V1709, P127, DOI 10.1016/j.bbabio.2005.07.006; Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018; WAATAJA JJ, 2005, 35 ANN M NOV 12 16 2; WERTH JL, 1994, J NEUROSCI, V14, P348; Yang F, 2003, J CELL BIOL, V163, P511, DOI 10.1083/jcb.200307027; Zenisek D, 2000, NEURON, V25, P229, DOI 10.1016/S0896-6273(00)80885-5; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	85	207	207	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11658	11668		10.1074/jbc.M510303200	http://dx.doi.org/10.1074/jbc.M510303200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517608	hybrid			2022-12-27	WOS:000236988100029
J	Ecker, M; Deutzmann, R; Lehle, L; Mrsa, V; Tanner, W				Ecker, M; Deutzmann, R; Lehle, L; Mrsa, V; Tanner, W			Pir proteins of Saccharomyces cerevisiae are attached to beta-1,3-glucan by a new protein-carbohydrate linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL WALL; SECRETORY GLYCOPROTEIN; CROSS-LINKING; HEAT-SHOCK; IDENTIFICATION; ARCHITECTURE; BINDING; TRANSGLUTAMINASES; GLYCOSYLATION; MANNOPROTEIN	A family of covalently linked cell wall proteins of Saccharomyces cerevisiae, called Pir proteins, are characterized by up to 10 conserved repeating units. Ccw5/Pir4p contains only one complete repeating sequence and its deletion caused a release of the protein into the medium. The exchange of each of three glutamines ( Gln(69), Gln(74), Gln(76)) as well as one aspartic acid ( Asp(72)) within the repeating unit leads to a loss of the protein from the cell wall. Amino acid sequencing revealed that only Gln(74) is modified. Release of the protein with mild alkali, changed Gln(74) to glutamic acid, suggesting that Gln(74) is involved in the linkage. Analysis by mass spectrometry showed that 5 hexoses are attached to Gln/Glu(74). Sugar analysis revealed glucose as the only constituent. It is suggested that Pir proteins form novel, alkali labile ester linkages between the gamma-carboxyl group of glutamic acids, arising from specific glutamines, with hydroxyl groups of glucoses of beta-1,3-glucan chains. This transglutaminase-type reaction could take place extracellularly and would energetically proceed on the account of amido group elimination.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Biochem, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Tanner, W (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	sekretariat.tanner@biologie.uni-regensburg.de		Mrsa, Vladimir/0000-0002-3989-6938				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; [Anonymous], 1982, METABOLISM GENE EXPR; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Castillo L, 2003, YEAST, V20, P973, DOI 10.1002/yea.1016; De Groot PWJ, 2005, FUNGAL GENET BIOL, V42, P657, DOI 10.1016/j.fgb.2005.04.002; EAMUS D, 1986, WATER FUNGI PLANTS, P27; Ecker M, 2003, EMBO REP, V4, P628, DOI 10.1038/sj.embor.embor864; Esposito C, 2005, FEBS J, V272, P615, DOI 10.1111/j.1742-4658.2004.04476.x; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KOPECKA M, 1974, J CELL BIOL, V62, P66, DOI 10.1083/jcb.62.1.66; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; Molina M, 2000, MICROSC RES TECHNIQ, V51, P601, DOI 10.1002/1097-0029(20001215)51:6<601::AID-JEMT9>3.3.CO;2-9; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Moukadiri I, 1999, J BACTERIOL, V181, P4741, DOI 10.1128/JB.181.16.4741-4745.1999; Mrsa V, 1997, YEAST, V13, P1145; Mrsa V, 1999, YEAST, V15, P813, DOI 10.1002/(SICI)1097-0061(199907)15:10A<813::AID-YEA421>3.0.CO;2-Y; MRSA V, 2001, MOL MECH FUNGAL CELL; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; RUSSO P, 1993, MOL GEN GENET, V239, P273, DOI 10.1007/BF00281628; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sumita T, 2005, EUKARYOT CELL, V4, P1872, DOI 10.1128/EC.4.11.1872-1881.2005; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TOHE A, 1993, YEAST, V9, P481, DOI 10.1002/yea.320090504; VALENTIN E, 1984, J GEN MICROBIOL, V130, P1419; Yin QY, 2005, J BIOL CHEM, V280, P20894, DOI 10.1074/jbc.M500334200; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082	31	128	137	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11523	11529		10.1074/jbc.M600314200	http://dx.doi.org/10.1074/jbc.M600314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495216	hybrid			2022-12-27	WOS:000236988100014
J	Sorrell, AM; Shand, JH; Tonner, E; Gamberoni, M; Accorsi, PA; Beattie, J; Allan, GJ; Flint, DJ				Sorrell, AM; Shand, JH; Tonner, E; Gamberoni, M; Accorsi, PA; Beattie, J; Allan, GJ; Flint, DJ			Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-5; FIBRIN-DEPENDENT ENHANCEMENT; MAMMARY-GLAND; HORMONAL-CONTROL; MEDIATED STIMULATION; AMIDOLYTIC ACTIVITY; TERMINAL DOMAINS; AMINO-ACIDS; CELL-DEATH; IGF	Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.	Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Bologna, Fac Med Vet, Dipartimento Morfofisiol Vet & Prod Anim, I-40064 Ozzano Dell Emilia, BO, Italy	University of Bologna	Flint, DJ (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.	d.flint@hannah.ac.uk						Allan GJ, 2002, ENDOCRINOLOGY, V143, P4310, DOI 10.1210/en.2001-211191; Allan GJ, 2006, ENDOCRINOLOGY, V147, P338, DOI 10.1210/en.2005-0582; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Beattie J, 2005, J MOL ENDOCRINOL, V34, P163, DOI 10.1677/jme.1.01656; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Boutinaud M, 2004, J MOL ENDOCRINOL, V33, P195, DOI 10.1677/jme.0.0330195; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; BUSSO N, 1989, J BIOL CHEM, V264, P7455; CHRISTY JRE, 1989, CARDIOVASC RES, V23, P949, DOI 10.1093/cvr/23.11.949; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Deugnier MA, 1999, J CELL SCI, V112, P1035; FISCHER B, 1990, BIOL CHEM H-S, V371, P1067, DOI 10.1515/bchm3.1990.371.2.1067; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; Flint DJ, 2000, J MAMMARY GLAND BIOL, V5, P65, DOI 10.1023/A:1009567316520; Heegaard CW, 1997, FIBRINOLYSIS PROTEOL, V11, P29, DOI 10.1016/S0268-9499(97)80006-9; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; Lund LR, 1996, DEVELOPMENT, V122, P181; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P988, DOI 10.1016/S0006-291X(02)00569-7; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Phillips K, 2003, J MOL ENDOCRINOL, V31, P197, DOI 10.1677/jme.0.0310197; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Song H, 2000, J MOL ENDOCRINOL, V24, P43, DOI 10.1677/jme.0.0240043; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 2000, J ENDOCRINOL, V167, P265, DOI 10.1677/joe.0.1670265; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10883	10889		10.1074/jbc.M508505200	http://dx.doi.org/10.1074/jbc.M508505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505491	hybrid			2022-12-27	WOS:000236822200028
J	Vlasova, II; Tyurin, VA; Kapralov, AA; Kurnikov, IV; Osipov, AN; Potapovich, MV; Stoyanovsky, DA; Kagan, VE				Vlasova, Irina I.; Tyurin, Vladimir A.; Kapralov, Alexandr A.; Kurnikov, Igor V.; Osipov, Anatoly N.; Potapovich, Maxim V.; Stoyanovsky, Detcho A.; Kagan, Valerian E.			Nitric oxide inhibits peroxidase activity of cytochrome c(center dot) cardiolipin complex and blocks cardiolipin oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HYDROGEN-PEROXIDE; ORGANIC-MOLECULES; MEMBRANE; STRESS; PEROXYNITRITE; MECHANISM; STATE; EPR; NO	The increased production of NO during the early stages of apoptosis indicates its potential involvement in the regulation of programmed cell death through yet to be identified mechanisms. Recently, an important role for catalytically competent peroxidase form of pentacoordinate cytochrome c (cyt c) in a complex with a mitochondriaspecific phospholipid, cardiolipin (CL), has been demonstrated during execution of the apoptotic program. Because the cyt c(.)CL complex acts as CL oxygenase and selectively oxidizes CL in apoptotic cells in a reaction dependent on the generation of protein-derived (tyrosyl) radicals, we hypothesized that binding and nitrosylation of cyt c regulates CL oxidation. Here we demonstrate by low temperature electron paramagnetic resonance spectroscopy that CL facilitated interactions of ferro-and ferri-states of cyt c with NO and NO-, respectively, to yield a mixture of penta- and hexa-coordinate nitrosylated cyt c. In the nitrosylated cyt c(.)CL complex, NO chemically reacted with H2O2-activated peroxidase intermediates resulting in their reduction. A dose-dependent quenching of H2O2-induced protein-derived radicals by NO donors was shown using direct electron paramagnetic resonance measurements as well as immuno-spin trapping with antibodies against protein 5,5-dimethyl-1-pyrrolineN-oxide-nitrone adducts. In the presence of NO donors, H2O2-induced oligomeric forms of cyt c positively stained for 3-nitrotyrosine confirming the reactivity of NO toward tyrosyl radicals of cyt c. Interaction of NO with the cyt c(.)CL complex inhibited its peroxidase activity with three different substrates: CL, etoposide, and 3,3'-diaminobenzidine. Given the importance of CL oxidation in apoptosis, mass spectrometry analysis was utilized to assess the effects of NO on oxidation of 1,1'2,2'-tertalinoleoyl cardiolipin. NO effectively inhibited 1,1'2,2'-tertalinoleoyl cardiolipin oxidation catalyzed by the peroxidase activity of cyt c. Thus, NO can act as a regulator of peroxidase activity of cyt c(.)CL complexes.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, 100 Technol Dr,CLMCL, Pittsburgh, PA 15260 USA.	vkagan@eoh.pitt.edu		Stoyanovsky, Detcho/0000-0001-5591-4780; Kagan, Valerian E./0000-0002-7245-1885; Tyurin, Vladimir/0000-0002-3474-1697; Kapralov, Oleksandr/0000-0002-3006-916X	NHLBI NIH HHS [HL 70755] Funding Source: Medline; NIAID NIH HHS [U19 AI 068021] Funding Source: Medline; NIEHS NIH HHS [ES 09648-01A2] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; BABBS CF, 1991, AM J PHYSIOL, V260, pH123, DOI 10.1152/ajpheart.1991.260.1.H123; Batthyany C, 2005, BIOCHEMISTRY-US, V44, P8038, DOI 10.1021/bi0474620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Castro L, 2004, ARCH BIOCHEM BIOPHYS, V421, P99, DOI 10.1016/j.abb.2003.08.033; Chamulitrat W, 2001, ANTIOXID REDOX SIGN, V3, P177, DOI 10.1089/152308601300185151; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Clark SR, 2002, J IMMUNOL, V169, P5889, DOI 10.4049/jimmunol.169.10.5889; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Diederix REM, 2002, BIOCHEMISTRY-US, V41, P13067, DOI 10.1021/bi0260841; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; GOLDMAN R, 1997, ENV NUTR INTERACT, V1, P97; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; Haynes V, 2004, J BIOENERG BIOMEMBR, V36, P341, DOI 10.1023/B:JOBB.0000041765.27145.08; Herold S, 2001, J BIOL INORG CHEM, V6, P543, DOI 10.1007/s007750100231; Hoang L, 2002, P NATL ACAD SCI USA, V99, P12173, DOI 10.1073/pnas.152439199; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; Jang B, 2006, BIOCHIMIE, V88, P53, DOI 10.1016/j.biochi.2005.06.016; Jantschko W, 2005, BIOCHEM PHARMACOL, V69, P1149, DOI 10.1016/j.bcp.2005.02.006; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 1999, MOL PHARMACOL, V56, P494, DOI 10.1124/mol.56.3.494; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kagan VE, 2001, ANTIOXID REDOX SIGN, V3, P189, DOI 10.1089/152308601300185160; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; KON H, 1968, J BIOL CHEM, V243, P4350; Kumar R, 2005, BIOCHEMISTRY-US, V44, P3024, DOI 10.1021/bi0478998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence A, 2003, J BIOL CHEM, V278, P29410, DOI 10.1074/jbc.M300054200; Maity H, 2004, J MOL BIOL, V343, P223, DOI 10.1016/j.jmb.2004.08.005; Mannick JB, 2004, FREE RADICAL RES, V38, P1, DOI 10.1080/10715760310001629065; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Oellerich S, 2002, J PHYS CHEM B, V106, P6566, DOI 10.1021/jp013841g; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RAMIREZ DC, 2005, CURR PROTOCOLS TOXIC; RITOV VB, 1938, TOXICOL SCI S1, V78, P114; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shvedova AA, 1999, BIOCHEM PHARMACOL, V57, P989, DOI 10.1016/S0006-2952(99)00007-6; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; SMITH PAS, 1960, J AM CHEM SOC, V82, P5731, DOI 10.1021/ja01506a043; Stoyanovsky DA, 2004, J MED CHEM, V47, P210, DOI 10.1021/jm030192j; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Wink David A., 1999, P245; YOSHIMURA T, 1988, ARCH BIOCHEM BIOPHYS, V264, P450, DOI 10.1016/0003-9861(88)90310-4; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	63	77	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14554	14562		10.1074/jbc.M509507200	http://dx.doi.org/10.1074/jbc.M509507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16543234	hybrid			2022-12-27	WOS:000237671300006
J	Bossen, C; Ingold, K; Tardivel, A; Bodmer, JL; Gaide, O; Hertig, S; Ambrose, C; Tschopp, J; Schneider, P				Bossen, Claudia; Ingold, Karine; Tardivel, Aubry; Bodmer, Jean-Luc; Gaide, Olivier; Hertig, Sylvie; Ambrose, Christine; Tschopp, Juerg; Schneider, Pascal			Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELL-DEATH; T-CELL; FAS LIGAND; BINDING; TWEAK; IDENTIFICATION; ACTIVATION; APRIL; BAFF	Ligands of the tumor necrosis factor superfamily (TNFSF) (4-1BBL, APRIL, BAFF, CD27L, CD30L, CD40L, EDA1, EDA2, FasL, GITRL, LIGHT, lymphotoxin alpha, lymphotoxin alpha beta, OX40L, RANKL, TL1A, TNF, TWEAK, and TRAIL) bind members of the TNF receptor superfamily (TNFRSF). A comprehensive survey of ligand-receptor interactions was performed using a flow cytometry-based assay. All ligands engaged between one and five receptors, whereas most receptors only bound one to three ligands. The receptors DR6, RELT, TROY, NGFR, and mouse TNFRH3 did not interact with any of the known TNFSF ligands, suggesting that they either bind other types of ligands, function in a ligand-independent manner, or bind ligands that remain to be identified. The study revealed that ligand-receptor pairs are either cross-reactive between human and mouse (e.g. Tweak/Fn14, RANK/RANKL), strictly species-specific (GITR/GITRL), or partially species-specific (e.g. OX40/OX40L, CD40/CD40L). Interestingly, the receptor binding patterns of lymphotoxin alpha and alpha beta are redundant in the human but not in the mouse system. Ligand oligomerization allowed detection of weak interactions, such as that of human TNF with mouse TNFR2. In addition, mouse APRIL exists as two different splice variants differing by a single amino acid. Although human APRIL does not interact with BAFF-R, the shorter variant of mouse APRIL exhibits weak but detectable binding to mouse BAFF-R.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Biogenldec, Cambridge, MA 02142 USA	University of Lausanne	Schneider, P (corresponding author), Univ Lausanne, Dept Biochem, Boveresses 155, CH-1066 Epalinges, Switzerland.	pascal.schneider@unil.ch		Schneider, Pascal/0000-0003-0677-9409				Ameloot P, 2001, J BIOL CHEM, V276, P37426, DOI 10.1074/jbc.M102020200; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Bischof D, 2006, BLOOD, V107, P3235, DOI 10.1182/blood-2005-01-0256; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Brandt SM, 2004, PLOS BIOL, V2, P2067, DOI 10.1371/journal.pbio.0020418; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Brunetti CR, 2003, P NATL ACAD SCI USA, V100, P4831, DOI 10.1073/pnas.0737244100; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Compaan DM, 2005, J BIOL CHEM, V280, P39553, DOI 10.1074/jbc.M507629200; Feldmann M, 2005, J AUTOIMMUN, V25, P26, DOI 10.1016/j.jaut.2005.09.006; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hurle B, 1998, GENOMICS, V52, P79, DOI 10.1006/geno.1998.5407; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kalled SL, 2005, IMMUNOL REV, V204, P43, DOI 10.1111/j.0105-2896.2005.00219.x; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; Pispa J, 2003, DEV BIOL, V262, P195, DOI 10.1016/S0012-1606(03)00325-7; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; POWELL EE, 1994, MAMM GENOME, V5, P726, DOI 10.1007/BF00426081; Pradet-Balade B, 2002, EMBO J, V21, P5711, DOI 10.1093/emboj/cdf565; RANGES GE, 1989, J IMMUNOL, V142, P1203; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; Shrivastava P, 2004, MOL CELL BIOL, V24, P6763, DOI 10.1128/MCB.24.15.6763-6772.2004; Tamada K, 2006, CANCER IMMUNOL IMMUN, V55, P355, DOI 10.1007/s00262-005-0081-y; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wroblewski VJ, 2003, DRUG METAB DISPOS, V31, P502, DOI 10.1124/dmd.31.4.502; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	58	325	355	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13964	13971		10.1074/jbc.M601553200	http://dx.doi.org/10.1074/jbc.M601553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547002	hybrid, Green Published			2022-12-27	WOS:000237512300018
J	Kassavetis, GA; Driscoll, R; Geiduschek, EP				Kassavetis, George A.; Driscoll, Robert; Geiduschek, E. Peter			Mapping the principal interaction site of the Brf1 and Bdp1 subunits of Saccharomyces cerevisiae TFIIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; INITIATION-FACTOR-TFIIIB; TATA-BINDING PROTEIN; U6 SNRNA GENE; SANT DOMAIN; COMPLEX; PROMOTER; RECRUITMENT; BOX	The Brf1 subunit of the central RNA polymerase (pol) III transcription initiation factor TFIIIB is bipartite; its N-terminal TFIIB-related half is principally responsible for recruiting pol III to the promoter and for promoter opening near the transcriptional start site, whereas its pol III-specific C-terminal half contributes most of the affinities that hold the three subunits of TFIIIB together. Here, the principal attachment site of Brf1 for the Bdp1 subunit of TFIIIB has been mapped by a combination of structure-informed, site-directed mutagenesis and photochemical protein-DNA cross-linking. A 66-amino acid segment of Brf1 is shown to serve as a two-sided adhesive surface, with the side chains projecting away from its extended interface with TATA-binding protein anchoring Bdp1 binding. An extensive collection of N-terminal, C-terminal, and internal deletion proteins has been used to demarcate the interacting Bdp1 domain to a 66-amino acid segment that includes the SANT domain of this subunit and is phylogenetically the most conserved region of Bdp1.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gak@biomail.ucsd.edu						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Ding ZH, 2004, J BIOL CHEM, V279, P28009, DOI 10.1074/jbc.M403793200; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; Ishiguro A, 2002, MOL CELL BIOL, V22, P3264, DOI 10.1128/MCB.22.10.3264-3275.2002; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; Kassavetis GA, 2005, P NATL ACAD SCI USA, V102, P15406, DOI 10.1073/pnas.0507653102; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mo XM, 2005, GENE DEV, V19, P2447, DOI 10.1101/gad.355405; Padovan ACB, 2005, J MOL EVOL, V60, P726, DOI 10.1007/s00239-004-0164-y; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Saxena A, 2005, MOL CELL BIOL, V25, P9406, DOI 10.1128/MCB.25.21.9406-9418.2005; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Schroder O, 2003, EMBO J, V22, P5115, DOI 10.1093/emboj/cdg476; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shivaswamy S, 2004, MOL CELL BIOL, V24, P3596, DOI 10.1128/MCB.24.9.3596-3606.2004; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITE RJ, 2002, RNA POLYMERASE 3 TRA; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yieh L, 2002, J BIOL CHEM, V277, P25920, DOI 10.1074/jbc.M202729200	41	19	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14321	14329		10.1074/jbc.M601702200	http://dx.doi.org/10.1074/jbc.M601702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551611	hybrid			2022-12-27	WOS:000237512300058
J	Cruciat, CM; Hassler, C; Niehrs, C				Cruciat, CM; Hassler, C; Niehrs, C			The MRH protein Erlectin is a member of the endoplasmic reticulum synexpression group and functions in N-glycan recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; ER-ASSOCIATED DEGRADATION; POLYCYSTIC LIVER-DISEASE; GLUCOSIDASE-II; MISFOLDED GLYCOPROTEINS; GENE-EXPRESSION; QUALITY-CONTROL; SUBCELLULAR-LOCALIZATION; HETERODIMERIC STRUCTURE; IDENTIFIES YOS9P	Kremen1 and 2 (Krm1/2) are coreceptors for Dickkopf1 (Dkk1), an antagonist of Wnt/beta-catenin signaling, and play a role in head induction during early Xenopus development. In a proteomic approach we identified Erlectin, a novel protein that interacts with Krm2. Erlectin (XTP3-B) is member of a protein family containing mannose 6-phosphate receptor homology (MRH-, or PRKCSH-) domains implicated in N-glycan binding. Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum. It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation. The overexpression of Erlectin inhibits transport of Krm2 to the cell surface. Analysis of its embryonic expression pattern in Xenopus reveals that Erlectin is member of the endoplasmic reticulum synexpression group. Erlectin morpholino antisense injection leads to head and axial defects during organogenesis stages in Xenopus embryos. The results indicate that Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic.	German Canc Res Ctr, Dept Mol Embryol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), German Canc Res Ctr, Dept Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	niehrs@dkfz-heidelberg.de						Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Baldessari D, 2005, MECH DEVELOP, V122, P441, DOI 10.1016/j.mod.2004.11.007; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; Buschhorn BA, 2004, FEBS LETT, V577, P422, DOI 10.1016/j.febslet.2004.10.039; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Drenth JPH, 2004, GASTROENTEROLOGY, V126, P1819, DOI 10.1053/j.gastro.2004.02.023; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GONT LK, 1993, DEVELOPMENT, V119, P991; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Litovchick L, 2002, J BIOL CHEM, V277, P34413, DOI 10.1074/jbc.M203986200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Munro S, 2001, CURR BIOL, V11, pR499, DOI 10.1016/S0960-9822(01)00302-5; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Pelissier A, 2003, CURR BIOL, V13, P1848, DOI 10.1016/j.cub.2003.10.023; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; Pollet N, 2005, MECH DEVELOP, V122, P365, DOI 10.1016/j.mod.2004.11.009; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Schirle M, 2003, MOL CELL PROTEOMICS, V2, P1297, DOI 10.1074/mcp.M300087-MCP200; Scholpp S, 2004, CURR BIOL, V14, P1834, DOI 10.1016/j.cub.2004.09.084; Sen J, 2000, DEVELOPMENT, V127, P5541; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; Starr CJ, 2004, P NATL ACAD SCI USA, V101, P2572, DOI 10.1073/pnas.0308474100; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Treml K, 2000, GLYCOBIOLOGY, V10, P493, DOI 10.1093/glycob/10.5.493; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Weissman JT, 2001, TRAFFIC, V2, P465, DOI 10.1034/j.1600-0854.2001.20704.x; Wilkinson BM, 2006, J BIOL CHEM, V281, P6325, DOI 10.1074/jbc.M510455200; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Yamamoto A, 2005, CELL, V120, P223, DOI 10.1016/j.cell.2004.11.051	54	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12986	12993		10.1074/jbc.M511872200	http://dx.doi.org/10.1074/jbc.M511872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531414	hybrid			2022-12-27	WOS:000237134700094
J	Mao, JN; Qiao, XY; Luo, HY; Wu, JP				Mao, JN; Qiao, XY; Luo, HY; Wu, JP			Transgenic Drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SERINE/THREONINE KINASE; DAP KINASE; DEATH; BETA; AUTOIMMUNITY; ACTIVATION; BINDING; SIGNAL	Drak2 is a death-associated protein family serine-threonine kinase. Its expression and roles in the immune system were investigated in this study. According to in situ hybridization, Drak2 expression was ubiquitous at the mid-gestation stage in embryos, followed by more focal expression in various organs in the perinatal period and adulthood, notably in the thymus, spleen, lymph nodes, cerebellum, suprachiasmatic nuclei, pituitary, olfactory lobes, adrenal medulla, stomach, skin, and testes. Drak2 transgenic (Tg) mice were generated using the human beta-actin promoter. These Tg mice showed normal T cell versus B cell and CD4 versus CD8 populations in the spleen, but their spleen weight cellularity was lower in comparison with wild type mice. After TCR activation, the proliferation response in Drak2 Tg T cells was normal, although their interleukin (IL)-2 and IL-4 but not interferon-gamma production was augmented. Activated Drak2 Tg T cells demonstrated significantly enhanced apoptosis in the presence of exogenous IL-2. At the molecular level, Drak2 Tg T cells manifested a lower increase of anti-apoptotic factors during activation; such a change probably rendered the cells vulnerable to subsequent IL-2 insults. The compromised apoptosis in Drak2 Tg T cells was associated with reduced numbers of T cells with the memory cell phenotype ( CD62L(lo)) and repressed secondary T cell responses in delayed type hypersensitivity. Our study demonstrates that Drak2 expresses in the T cell compartment but is not T cell- specific; it plays critical roles in T cell apoptosis and memory T cell development.	CHUM, Immunol Lab, Res Ctr, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada; CHUM, Serv Nephrol, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Luo, HY (corresponding author), CHUM, Immunol Lab, Res Ctr, Notre Dame Hosp, Pavill DeSeve,Rm Y-5616,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	hongyu.luo@umontreal.ca	mao, jianning/A-4254-2011					DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Friedrich ML, 2005, INT IMMUNOL, V17, P1379, DOI 10.1093/intimm/dxh315; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; HULI J, 1989, J IMMUNOL, V142, P800; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794; Laemle LK, 1998, PHYSIOL BEHAV, V64, P165, DOI 10.1016/S0031-9384(98)00045-6; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2004, J CLIN INVEST, V114, P1762, DOI 10.1172/JCI200421846; Marcinkiewicz M, 2002, J NEUROPATH EXP NEUR, V61, P815, DOI 10.1093/jnen/61.9.915; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; McGargill MA, 2004, IMMUNITY, V21, P781, DOI 10.1016/j.immuni.2004.10.008; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771	23	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12587	12595		10.1074/jbc.M600497200	http://dx.doi.org/10.1074/jbc.M600497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517594	hybrid			2022-12-27	WOS:000237134700048
J	Ponthier, JL; Schluepen, C; Chen, WG; Lerscho, RA; Gee, SL; Hou, VC; Lo, AJ; Short, SA; Chasis, JA; Winkelmann, JC; Conboy, JG				Ponthier, JL; Schluepen, C; Chen, WG; Lerscho, RA; Gee, SL; Hou, VC; Lo, AJ; Short, SA; Chasis, JA; Winkelmann, JC; Conboy, JG			Fox-2 splicing factor binds to a conserved intron motif to promote inclusion of protein 4.1R alternative exon 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; EXPRESSION; SPECTRIN; INTERACTS; ISOFORMS; HOMOLOGS; COMPLEX; FAMILY; REGULATOR	Activation of protein 4.1R exon 16 (E16) inclusion during erythropoiesis represents a physiologically important splicing switch that increases 4.1R affinity for spectrin and actin. Previous studies showed that negative regulation of E16 splicing is mediated by the binding of heterogeneous nuclear ribonucleoprotein ( hnRNP) A/B proteins to silencer elements in the exon and that down-regulation of hnRNP A/B proteins in erythroblasts leads to activation of E16 inclusion. This article demonstrates that positive regulation of E16 splicing can be mediated by Fox-2 or Fox-1, two closely related splicing factors that possess identical RNA recognition motifs. SELEX experiments with human Fox-1 revealed highly selective binding to the hexamer UGCAUG. Both Fox-1 and Fox-2 were able to bind the conserved UGCAUG elements in the proximal intron downstream of E16, and both could activate E16 splicing in HeLa cell co-transfection assays in a UGCAUG-dependent manner. Conversely, knockdown of Fox- 2 expression, achieved with two different siRNA sequences resulted in decreased E16 splicing. Moreover, immunoblot experiments demonstrate mouse erythroblasts express Fox-2. These findings suggest that Fox- 2 is a physiological activator of E16 splicing in differentiating erythroid cells in vivo. Recent experiments show that UGCAUG is present in the proximal intron sequence of many tissue-specific alternative exons, and we propose that the Fox family of splicing enhancers plays an important role in alternative splicing switches during differentiation in metazoan organisms.	Lawrence Berkeley Natl Lab, Life Sci Div, Berkeley, CA 94720 USA; Univ Cincinnati, Coll Med, Div Hematol Oncol, Dept Internal Med,Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University System of Ohio; University of Cincinnati	Conboy, JG (corresponding author), Lawrence Berkeley Natl Lab, Life Sci Div, 1 Cyclotron Rd,Mail Stop 74-157, Berkeley, CA 94720 USA.	jgconboy@lbl.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045182, R56HL045182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45182, R01 HL045182] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auweter SD, 2006, EMBO J, V25, P163, DOI 10.1038/sj.emboj.7600918; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Brudno M, 2001, NUCLEIC ACIDS RES, V29, P2338, DOI 10.1093/nar/29.11.2338; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DISCHER D, 1993, J BIOL CHEM, V268, P7186; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Gee SL, 2000, BLOOD, V95, P692, DOI 10.1182/blood.V95.2.692; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Guo NH, 2000, J BIOL CHEM, V275, P33641, DOI 10.1074/jbc.M005597200; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HORNE WC, 1993, BLOOD, V82, P2558; Hou VC, 2001, CURR OPIN HEMATOL, V8, P74, DOI 10.1097/00062752-200103000-00003; Hou VC, 2002, EMBO J, V21, P6195, DOI 10.1093/emboj/cdf625; HUANG JP, 1993, J BIOL CHEM, V268, P3758; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529; Lieberman AP, 2001, BIOCHEM BIOPH RES CO, V282, P499, DOI 10.1006/bbrc.2001.4617; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Minovitsky S, 2005, NUCLEIC ACIDS RES, V33, P714, DOI 10.1093/nar/gki210; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Ramez M, 2003, KIDNEY INT, V63, P1321, DOI 10.1046/j.1523-1755.2003.00870.x; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shibata H, 2000, HUM MOL GENET, V9, P1303, DOI 10.1093/hmg/9.9.1303; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Underwood JG, 2005, MOL CELL BIOL, V25, P10005, DOI 10.1128/MCB.25.22.10005-10016.2005; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; Winkelmann JC, 2000, BLOOD, V96, p592A; Yang G, 2005, BLOOD, V105, P2146, DOI 10.1182/blood-2004-05-1757; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102	51	87	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12468	12474		10.1074/jbc.M511556200	http://dx.doi.org/10.1074/jbc.M511556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537540	Green Submitted, hybrid			2022-12-27	WOS:000237134700034
J	Swiatek, W; Kang, H; Garcia, BA; Shabanowitz, J; Coombs, GS; Hunt, DF; Virshup, DM				Swiatek, W; Kang, H; Garcia, BA; Shabanowitz, J; Coombs, GS; Hunt, DF; Virshup, DM			Negative regulation of LRP6 function by casein kinase I epsilon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; SLEEP PHASE SYNDROME; BETA-CATENIN; MASS-SPECTROMETRY; ACTIVATION; MECHANISM; MUTATION; DENSITY; CKI	Wnt signaling acts in part through the low density lipoprotein receptor-related transmembrane proteins LRP5 and LRP6 to regulate embryonic development and stem cell proliferation. Up-regulated signaling is associated with many forms of cancer. Casein kinase I epsilon (CKI epsilon) is a known component of the Wnt-beta-catenin signaling pathway. We find that CKI epsilon binds to LRP5 and LRP6 in vitro and in vivo and identify three CKI epsilon-specific phosphorylation sites in LRP6. Two of the identified phosphorylation sites, Ser(1420) and Ser(1430), influence Wnt signaling in vivo, since LRP6 with mutation of these sites is a more potent activator of both beta-catenin accumulation and Lef-1 reporter activity. Whereas Wnt3a regulates CKI epsilon kinase activity, LRP6 does not, placing CKI epsilon upstream of LRP6. Mutation of LRP6 Ser(1420) and Ser(1430) to alanine strengthens its interaction with axin, suggesting a mechanism by which CKI epsilon may negatively regulate Wnt signaling. The role of CKI epsilon is therefore more complex than was previously appreciated. Generation of active CKI epsilon may induce a negative feedback loop by phosphorylation of sites on LRP5/6 that modulate axin binding and hence beta-catenin degradation.	Univ Utah, Huntsman Canc Inst, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Virginia; University of Virginia	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Pediat, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009; Hunt, Donald F/I-6936-2012	Virshup, David M/0000-0001-6976-850X; Hunt, Donald F/0000-0003-2815-6368; Coombs, Gary/0000-0002-0711-185X	NATIONAL CANCER INSTITUTE [P30CA042014, P01CA073992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA73992, P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM37537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946-4955.2005; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hodgkin J, 1998, INT J DEV BIOL, V42, P501; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Matsubayashi H, 2004, MOL CELL BIOL, V24, P2012, DOI 10.1128/MCB.24.5.2012-2024.2004; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	46	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12233	12241		10.1074/jbc.M510580200	http://dx.doi.org/10.1074/jbc.M510580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513652	hybrid			2022-12-27	WOS:000237134700006
J	Agapkina, J; Smolov, M; Barbe, S; Zubin, E; Zatsepin, T; Deprez, E; Le Bret, M; Mouscadet, JF; Gottikh, M				Agapkina, J; Smolov, M; Barbe, S; Zubin, E; Zatsepin, T; Deprez, E; Le Bret, M; Mouscadet, JF; Gottikh, M			Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; METAL-DEPENDENT INHIBITION; ACTIVE-SITE; IN-VITRO; RETROVIRAL INTEGRASES; STRUCTURAL-PROPERTIES; PROTEIN; SEQUENCE; BINDING; RECOGNITION	The specific activity of the human immunodeficiency virus, type 1 ( HIV-1), integrase on the viral long terminal repeat requires the binding of the enzyme to certain sequences located in the U3 and U5 regions at the ends of viral DNA, but the determinants of this specific DNA-protein recognition are not yet completely understood. We synthesized DNA duplexes mimicking the U5 region and containing either 2'-modified nucleosides or 1,3-propanediol insertions and studied their interactions with HIV-1 integrase, using Mn2+ or Mg2+ ions as integrase cofactors. These DNA modifications had no strong effect on integrase binding to the substrate analogs but significantly affected 3'-end processing rate. The effects of nucleoside modifications at positions 5, 6, and especially 3 strongly depended on the cationic cofactor used. These effects were much more pronounced in the presence of Mg2+ than in the presence of Mn2+. Modifications of base pairs 7-9 affected 3'-end processing equally in the presence of both ions. Adenine from the 3rd bp is thought to form at least two hydrogen bonds with integrase that are crucial for specific DNA recognition. The complementary base, thymine, is not important for integrase activity. For other positions, our results suggest that integrase recognizes a fine structure of the sugar-phosphate backbone rather than heterocyclic bases. Integrase interactions with the unprocessed strand at positions 5-8 are more important than interactions with the processed strand for specific substrate recognition. Based on our results, we suggest a model for integrase interaction with the U5 substrate.	Ecole Normale Super, CNRS, LBPA, UMR8113, F-94235 Cachan, France; Moscow MV Lomonosov State Univ, Belozersky Inst Physiochem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Lomonosov Moscow State University	Mouscadet, JF (corresponding author), Ecole Normale Super, CNRS, LBPA, UMR8113, 61 Ave President Wilson, F-94235 Cachan, France.	mouscadet@lbpa.ens-cachan.fr	Zubin, Evgeny/I-3880-2012; Gottikh, Marina/D-7575-2012; Agapkina, Julia/I-5558-2012; Zatsepin, Timofei S/I-2821-2012; Barbe, Sophie/ABD-9530-2020	Zatsepin, Timofei S/0000-0003-0030-9174; Barbe, Sophie/0000-0003-2581-5022				Agapkina J, 2004, EUR J BIOCHEM, V271, P205, DOI 10.1046/j.1432-1033.2003.03921.x; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; Bailly C, 1998, NUCLEIC ACIDS RES, V26, P4309, DOI 10.1093/nar/26.19.4309; Brodin P, 2002, BIOCHEMISTRY-US, V41, P1529, DOI 10.1021/bi015732y; Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Gao K, 2004, J VIROL, V78, P6715, DOI 10.1128/JVI.78.13.6715-6722.2004; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; Gerton JL, 1998, J VIROL, V72, P5046, DOI 10.1128/JVI.72.6.5046-5055.1998; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; HENDRIX C, 1995, NUCLEIC ACIDS RES, V23, P51, DOI 10.1093/nar/23.1.51; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAN LS, 1993, J CHIN CHEM SOC-TAIP, V40, P469, DOI 10.1002/jccs.199300074; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; Katzman M, 1996, J VIROL, V70, P9069, DOI 10.1128/JVI.70.12.9069-9073.1996; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUZNETSOVA LG, 1991, BIOORG KHIM+, V17, P1289; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Neamati N, 2002, J MED CHEM, V45, P5661, DOI 10.1021/jm0201417; Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Renisio JG, 2005, NUCLEIC ACIDS RES, V33, P1970, DOI 10.1093/nar/gki346; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; Venkateswarlu D, 1999, NUCLEIC ACIDS RES, V27, P2189, DOI 10.1093/nar/27.10.2189; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Zubin EM, 1998, NUCLEOS NUCLEOT, V17, P425, DOI 10.1080/07328319808005188	50	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11530	11540		10.1074/jbc.M512271200	http://dx.doi.org/10.1074/jbc.M512271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500899	Green Published, hybrid			2022-12-27	WOS:000236988100015
J	Fryer, BH; Wang, CH; Vedantam, S; Zhou, GL; Jin, SH; Fletcher, L; Simon, MC; Field, J				Fryer, BH; Wang, CH; Vedantam, S; Zhou, GL; Jin, SH; Fletcher, L; Simon, MC; Field, J			CGMP-dependent protein kinase phosphorylates p21-activated kinase (Pak) 1, inhibiting Pak/Nck binding and stimulating Pak/vasodilator-stimulated phosphoprotein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; RHO-GTPASES; ACTIN CYTOSKELETON; ENA/VASP PROTEINS; PAK1; ANGIOGENESIS; NCK; SIGNALS; RAS; MECHANISMS	Endothelial cells are normally non-motile and quiescent; however, endothelial cells will become permeable and invade and proliferate to form new blood vessels ( angiogenesis) in response to wounding, cancer, diabetic retinopathy, age-related macular degeneration, or rheumatoid arthritis. p21-activated kinase ( Pak), an effector for the Rho GTPases Rac and Cdc42, is required for angiogenesis and regulates endothelial cell permeability and motility. Although Pak is primarily activated by Rac and Cdc42, there are additional proteins that regulate Pak activity and localization, including three AGC protein kinase family members, Akt-1, PDK-1, and cAMP-dependent protein kinase. We describe phosphorylation and regulation of Pak localization by a fourth AGC kinase family member, cGMP-dependent protein kinase ( PKG). Using in vitro mapping, a phosphospecific antibody, co-transfection assays, and untransfected bovine aortic endothelial cells we determined thatPKGphosphorylates Pak at serine 21. Phosphorylation was accompanied by changes in proteins associated with Pak. The adaptor protein Nck was released, whereas a novel complex with vasodilator-stimulated phosphoprotein was stimulated. Furthermore Ser-21 phosphorylation of Pak appears to be important for regulation of cell morphology. In both human umbilical vein endothelial cells and HeLa cells, activation of PKG in the presence of Pak stimulated tail retraction and cell polarization. However, in cells expressing S21A mutant Pak1, PKG activation or treatment with a peptide that blocks Nck/Pak binding caused aberrant cell morphology, blocked cell retraction, and mislocalized Pak, producing uropod ( tail-like) structures. These data suggest that PKG regulates Pak and that the interaction plays a role in tail retraction.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Field, J (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, John Morgan Bldg,Rm 149, Philadelphia, PA 19104 USA.	field@pharm.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [T32CA009677] Funding Source: NIH RePORTER; NCI NIH HHS [CA09677] Funding Source: Medline; NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Mazumdar A, 2003, FEBS LETT, V535, P6, DOI 10.1016/S0014-5793(02)03846-2; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Murthy KS, 2003, AM J PHYSIOL-GASTR L, V284, pG1006, DOI 10.1152/ajpgi.00465.2002; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	37	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11487	11495		10.1074/jbc.M600279200	http://dx.doi.org/10.1074/jbc.M600279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490784	hybrid			2022-12-27	WOS:000236988100010
J	Daikoku, T; Kudoh, A; Sugaya, Y; Iwahori, S; Shirata, N; Isomura, H; Tsurumi, T				Daikoku, T; Kudoh, A; Sugaya, Y; Iwahori, S; Shirata, N; Isomura, H; Tsurumi, T			Postreplicative mismatch repair factors are recruited to Epstein-Barr virus replication compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; BMRF1 GENE-PRODUCTS; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; LYTIC REPLICATION; ESCHERICHIA-COLI; BINDING PROTEIN; HOMEOLOGOUS RECOMBINATION; RECOGNITION COMPLEX	The mismatch repair (MMR) system, highly conserved throughout evolution, corrects nucleotide mispairing that arise during cellular DNA replication. We report here that proliferating cell nuclear antigen (PCNA), the clamp loader complex (RF-C), and a series of MMR proteins like MSH-2, MSH-6, MLH1, and hPSM2 can be assembled to Epstein-Barr virus replication compartments, the sites of viral DNA synthesis. Levels of the DNA-bound form of PCNA increased with progression of viral productive replication. Bromodeoxyuridine-labeled chromatin immunodepletion analyses confirmed that PCNA is loaded onto newly synthesized viral DNA as well as BALF2 and BMRF1 viral proteins during lytic replication. Furthermore, the anti-PCNA, - MSH2, - MSH3, or - MSH6 antibodies could immunoprecipitate BMRF1 replication protein probably via the viral DNA genome. PCNA loading might trigger transfer of a series of host MMR proteins to the sites of viral DNA synthesis. The MMR factors might function for the repair of mismatches that arise during viral replication or act to inhibit recombination between moderately divergent ( homologous) sequences.	Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Tsurumi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	Iwahori, Satoko/L-1948-2019					ABBOTTS J, 1987, NUCLEIC ACIDS RES, V15, P1185, DOI 10.1093/nar/15.3.1185; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; Chen WL, 1999, GENETICS, V151, P1299; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Daikoku T, 2005, J VIROL, V79, P3409, DOI 10.1128/JVI.79.6.3409-3418.2005; Daikoku T, 2004, J BIOL CHEM, V279, P54817, DOI 10.1074/jbc.M405911200; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Harland J, 2003, J NEUROVIROL, V9, P477, DOI 10.1080/13550280390218788; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Jiricny J, 2000, NAT GENET, V24, P6, DOI 10.1038/71698; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nicholson A, 2000, GENETICS, V154, P133; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Peterson-Roth E, 2005, MOL CELL BIOL, V25, P3596, DOI 10.1128/MCB.25.9.3596-3607.2005; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; SU SS, 1988, J BIOL CHEM, V263, P6829; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TAKAGI S, 1991, VIROLOGY, V185, P309, DOI 10.1016/0042-6822(91)90778-A; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; TSURUMI T, 1993, J VIROL, V67, P1681, DOI 10.1128/JVI.67.3.1681-1687.1993; TSURUMI T, 1993, J VIROL, V67, P4651, DOI 10.1128/JVI.67.8.4651-4658.1993; TSURUMI T, 1991, VIROLOGY, V182, P376, DOI 10.1016/0042-6822(91)90685-5; Tsurumi T, 1998, J GEN VIROL, V79, P1257, DOI 10.1099/0022-1317-79-5-1257; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Xie YL, 1999, GENETICS, V151, P499; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869; ZIMMERMANN J, 1995, J VIROL, V69, P3147, DOI 10.1128/JVI.69.5.3147-3155.1995	62	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11422	11430		10.1074/jbc.M510314200	http://dx.doi.org/10.1074/jbc.M510314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16510450	hybrid			2022-12-27	WOS:000236822200085
J	Westphal, AH; Matorin, A; Hink, MA; Borst, JW; van Berkel, WJH; Visser, AJWG				Westphal, AH; Matorin, A; Hink, MA; Borst, JW; van Berkel, WJH; Visser, AJWG			Real-time enzyme dynamics illustrated with fluorescence spectroscopy of p-hydroxybenzoate hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-MOLECULE; PSEUDOMONAS-FLUORESCENS; CONFORMATIONAL DYNAMICS; CRYSTAL-STRUCTURE; ENERGY-TRANSFER; WILD-TYPE; PROTEIN; BINDING; SUBSTRATE; CATALYSIS	We have used the flavoenzyme p-hydroxybenzoate hydroxylase (PHBH) to illustrate that a strongly fluorescent donor label can communicate with the flavin via single-pair Forster resonance energy transfer (spFRET). The accessible Cys-116 of PHBH was labeled with two different fluorescent maleimides with full preservation of enzymatic activity. One of these labels shows overlap between its fluorescence spectrum and the absorption spectrum of the FAD prosthetic group in the oxidized state, while the other fluorescent probe does not have this spectral overlap. The spectral overlap strongly diminished when the flavin becomes reduced during catalysis. The donor fluorescence properties can then be used as a sensitive antenna for the flavin redox state. Time-resolved fluorescence experiments on ensembles of labeled PHBH molecules were carried out in the absence and presence of enzymatic turnover. Distinct changes in fluorescence decays of spFRET-active PHBH can be observed when the enzyme is performing catalysis using both substrates p-hydroxybenzoate and NADPH. Single-molecule fluorescence correlation spectroscopy on spFRET-active PHBH showed the presence of a relaxation process (relaxation time of 23 mu s) that is related to catalysis. In addition, in both labeled PHBH preparations the number of enzyme molecules reversibly increased during enzymatic turnover indicating that the dimer-monomer equilibrium is affected.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Microspect Ctr, NL-6700 ET Wageningen, Netherlands; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, NL-1081 HV Amsterdam, Netherlands	Wageningen University & Research; Vrije Universiteit Amsterdam	Visser, AJWG (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	ton.visser@wur.nl	Borst, Jan Willem/B-1259-2011; Westphal, Adrie Herman/L-3517-2019; van Berkel, Willem J.H./O-2431-2014	Westphal, Adrie Herman/0000-0003-4264-6267; van Berkel, Willem J.H./0000-0002-6551-2782				Antikainen NM, 2005, BIOCHEMISTRY-US, V44, P16835, DOI 10.1021/bi051378i; BASTIAENS PIH, 1992, BIOPHYS J, V63, P839, DOI 10.1016/S0006-3495(92)81659-4; Borst JW, 2005, J FLUORESC, V15, P153, DOI 10.1007/s10895-005-2523-5; Brender JR, 2005, J AM CHEM SOC, V127, P18171, DOI 10.1021/ja055171o; Chattopadhyay K, 2005, P NATL ACAD SCI USA, V102, P2385, DOI 10.1073/pnas.0500127102; Chattopadhyay K, 2002, P NATL ACAD SCI USA, V99, P14171, DOI 10.1073/pnas.172524899; Deniz AA, 2001, ANNU REV PHYS CHEM, V52, P233, DOI 10.1146/annurev.physchem.52.1.233; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Digris AV, 1999, EUR BIOPHYS J BIOPHY, V28, P526, DOI 10.1007/s002490050235; Edman L, 1999, CHEM PHYS, V247, P11, DOI 10.1016/S0301-0104(99)00098-1; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; Entsch B, 2005, ARCH BIOCHEM BIOPHYS, V433, P297, DOI 10.1016/j.abb.2004.09.029; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; Eppink MHM, 1998, J BIOL CHEM, V273, P21031, DOI 10.1074/jbc.273.33.21031; ESCHRICH K, 1990, FEBS LETT, V277, P197, DOI 10.1016/0014-5793(90)80843-8; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Ha T, 2001, METHODS, V25, P78, DOI 10.1006/meth.2001.1217; Ha TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/pnas.96.3.893; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P369, DOI DOI 10.1007/978-1-4757-3061-6; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Michalet X, 2003, ANNU REV BIOPH BIOM, V32, P161, DOI 10.1146/annurev.biophys.32.110601.142525; MULLER F, 1982, EUR J BIOCHEM, V128, P21; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; Shi J, 2004, J AM CHEM SOC, V126, P6914, DOI 10.1021/ja038902y; Skakun VV, 2005, EUR BIOPHYS J BIOPHY, V34, P323, DOI 10.1007/s00249-004-0453-9; SZABO A, 1984, J CHEM PHYS, V81, P150, DOI 10.1063/1.447378; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; van den Berg PAW, 2004, BIOPHYS J, V87, P2577, DOI 10.1529/biophysj.104.040030; Van Den Berg PAW, 2001, SPR S FLUOR, V1, P457; van den Berg PAW, 2001, SPECTROCHIM ACTA A, V57, P2135, DOI 10.1016/S1386-1425(01)00494-2; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; Visser AJWG, 2001, SPRINGER SERIES CHEM, V65, P9; Wang J, 2002, P NATL ACAD SCI USA, V99, P608, DOI 10.1073/pnas.022640199; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009; Xie XS, 1999, J BIOL CHEM, V274, P15967, DOI 10.1074/jbc.274.23.15967; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	50	17	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11074	11081		10.1074/jbc.M600609200	http://dx.doi.org/10.1074/jbc.M600609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492664	hybrid, Green Published			2022-12-27	WOS:000236822200049
J	Lee, EH; Cherednichenko, G; Pessah, IN; Allen, PD				Lee, EH; Cherednichenko, G; Pessah, IN; Allen, PD			Functional coupling between TRPC3 and RyR1 regulates the expressions of key triadic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORE-OPERATED CHANNELS; ACTIVATED CA2+ INFLUX; RYANODINE RECEPTOR; CALCIUM-RELEASE; TRANSIENT RECEPTOR; SKELETAL; CALSEQUESTRIN; ENTRY; CONTRACTION; DEPOLARIZATION	We have shown that TRPC3( transient receptor potential channel canonical type 3) is sharply up-regulated during the early part of myotube differentiation and remains elevated in mature myotubes compared with myoblasts. To examine its functional roles in muscle, TRPC3 was "knocked down" in mouse primary skeletal myoblasts using retroviral-delivered small interference RNAs and single cell cloning. TRPC3 knockdown myoblasts (97.6 +/- 1.9% reduction in mRNA) were differentiated into myotubes ( TRPC3 KD) and subjected to functional and biochemical assays. By measuring rates of Mn2+ influx with Fura-2 and Ca2+ transients with Fluo-4, we found that neither excitation-coupled Ca2+ entry nor thapsigargin-induced store-operated Ca2+ entry was significantly altered in TRPC3 KD, indicating that expression of TRPC3 is not required for engaging either Ca2+ entry mechanism. In Ca2+ imaging experiments, the gain of excitation-contraction coupling and the amplitude of the Ca2+ release seen after direct RyR1 activation with caffeine was significantly reduced in TRPC3 KD. The decreased gain appears to be due to a decrease in RyR1 Ca2+ release channel activity, because sarcoplasmic reticulum (SR) Ca2+ content was not different between TRPC3 KD and wild-type myotubes. Immunoblot analysis demonstrated that TRPC1, calsequestrin, triadin, and junctophilin 1 were up-regulated (1.46 +/- 1.91-, 1.42 +/- 0.08-, 2.99 +/- 0.32-, and 1.91 +/- 0.26-fold, respectively) in TRPC3 KD. Based on these data, we conclude that expression of TRPC3 is tightly regulated during muscle cell differentiation and propose that functional interaction between TRPC3 and RyR1 may regulate the gain of SR Ca2+ release independent of SR Ca2+ load.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth, Davis, CA 95616 USA; Catholic Univ Korea, Coll Med, Dept Physiol, Lab Calcium Commun, Seoul 137701, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Davis; Catholic University of Korea	Allen, PD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.	allen@zeus.bwh.harvard.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Lee, Eun Hui/0000-0003-4555-1730	NIAMS NIH HHS [P01 AR 17605] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beard NA, 2004, PROG BIOPHYS MOL BIO, V85, P33, DOI 10.1016/j.pbiomolbio.2003.07.001; Beard NA, 2002, BIOPHYS J, V82, P310, DOI 10.1016/S0006-3495(02)75396-4; BRADY AJ, 1964, ANNU REV PHYSIOL, V26, P341, DOI 10.1146/annurev.ph.26.030164.002013; Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COLLINS JH, 1990, BIOCHEM BIOPH RES CO, V167, P189, DOI 10.1016/0006-291X(90)91749-I; Felder E, 2002, BIOPHYS J, V82, P3144, DOI 10.1016/S0006-3495(02)75656-7; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Lee EH, 2004, BIOPHYS J, V86, p61A; Lee EH, 2004, J BIOL CHEM, V279, P26481, DOI 10.1074/jbc.M309574200; Lee EH, 2004, AM J PHYSIOL-CELL PH, V286, pC179, DOI 10.1152/ajpcell.00176.2003; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nishida M, 2003, EMBO J, V22, P4677, DOI 10.1093/emboj/cdg457; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Reading SA, 2005, AM J PHYSIOL-HEART C, V288, pH2055, DOI 10.1152/ajpheart.00861.2004; Rezgui SS, 2005, J BIOL CHEM, V280, P39302, DOI 10.1074/jbc.M506566200; Sampieri A, 2005, J BIOL CHEM, V280, P24804, DOI 10.1074/jbc.M501487200; SANDOW A, 1965, PHARMACOL REV, V17, P265; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Yildirim E, 2005, P NATL ACAD SCI USA, V102, P3307, DOI 10.1073/pnas.0409908102; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	39	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10042	10048		10.1074/jbc.M600981200	http://dx.doi.org/10.1074/jbc.M600981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484216	hybrid			2022-12-27	WOS:000236594300028
J	Nieto-Miguel, T; Gajate, C; Mollinedo, F				Nieto-Miguel, Teresa; Gajate, Consuelo; Mollinedo, Faustino			Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; LIPID RAFTS; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; ET-18-OCH3 EDELFOSINE; CANCER-CELLS; C-JUN; PHOSPHOLIPID 1-O-OCTADECYL-2-O-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE; KINASE ACTIVATION; INDUCED APOPTOSIS	Synthetic alkyl-lysophospholipids represent a family of promising anticancer drugs that induce apoptosis in a variety of tumor cells. Here we have found a differential subcellular distribution of the alkyl-lysophospholipid edelfosine in leukemic and solid tumor cells that leads to distinct anticancer responses. Edelfosine induced rapid apoptosis in human leukemic cells, including acute T-cell leukemia Jurkat and Peer cells, but promoted a late apoptotic response, preceded by G(2)/M arrest, in human solid tumor cells such as cervix epitheloid carcinoma HeLa cells and lung carcinoma A549 cells. c-Jun amino-terminal kinase (JNK) and caspase-3 were accordingly activated at earlier times in edelfosine-treated Jurkat cells as compared with drug-treated HeLa cells. Both leukemic and solid tumor cells took up this alkyl-lysophospholipid and expressed the two putative edelfosine targets, namely cell surface Fas death receptor (also known as APO-1 or CD95) and endoplasmic reticulum CTP: phosphocholine cytidylyltransferase. However, edelfosine was mainly located to plasma membrane lipid rafts in Jurkat and Peer leukemic cells and to endoplasmic reticulum in solid tumor HeLa and A549 cells. Edelfosine induced translocation of Fas, Fas-associated death domain-containing protein, and JNK into membrane rafts in Jurkat cells, but not in HeLa cells. In contrast, edelfosine inhibited phosphatidylcholine biosynthesis in both HeLa and A549 cells, but not in Jurkat or Peer leukemic cells, before the triggering of apoptosis. These data indicate that edelfosine targets two different subcellular structures in a cell type-dependent manner, namely cell surface lipid rafts in leukemic cells and endoplasmic reticulum in solid tumor cells.	Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, E-37007 Salamanca, Spain; Hosp Univ Salamanca, Unidad Invest, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2006, Secribsal/A-1263-2012; Nieto Miguel, Teresa/L-1496-2016	Nieto Miguel, Teresa/0000-0002-8374-5379; Gajate, Consuelo/0000-0003-0604-6459				Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FRA AM, 1994, J BIOL CHEM, V269, P30745; Gabel BR, 2004, INFECT IMMUN, V72, P7367, DOI 10.1128/IAI.72.12.7367-7373.2004; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jendrossek V., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P343, DOI 10.2174/1568011033482341; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Kiss Z, 1997, FEBS LETT, V412, P313, DOI 10.1016/S0014-5793(97)00817-X; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MAGISTRELLI A, 1995, DRUG METAB DISPOS, V23, P113; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; MOLLINEDO F, 2004, FAS SIGNALING, P1; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; POWIS G, 1992, CANCER RES, V52, P2835; Quesada E, 2004, J MED CHEM, V47, P5333, DOI 10.1021/jm049808a; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Ruiter GA, 1999, CANCER RES, V59, P2457; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Van der Luit AH, 2003, BIOCHEM J, V374, P747, DOI 10.1042/BJ20030179; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; ZHOU X, 1995, EUR J BIOCHEM, V232, P881, DOI 10.1111/j.1432-1033.1995.881zz.x	57	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14833	14840		10.1074/jbc.M511251200	http://dx.doi.org/10.1074/jbc.M511251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540473	hybrid			2022-12-27	WOS:000237671300037
J	Koteiche, HA; Mchaourab, HS				Koteiche, Hanane A.; Mchaourab, Hassane S.			Mechanism of a hereditary cataract phenotype - Mutations in alpha A-crystallin activate substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DESMIN-RELATED MYOPATHY; CHAPERONE-LIKE FUNCTION; B-CRYSTALLIN; T4 LYSOZYME; LENS CRYSTALLINS; SUBUNIT INTERACTIONS; MISSENSE MUTATION; BETA-CRYSTALLIN; EXCITED-STATES	We present a novel hypothesis for the molecular mechanism of autosomal dominant cataract linked to two mutations in the alpha A-crystallin gene of the ocular lens. alpha A-crystallin is a molecular chaperone that plays a critical role in the suppression of protein aggregation and hence in the long termmaintenance of lens optical properties. Using a steady state binding assay in which the chaperone-substrate complex is directly detected, we demonstrate that the mutations result in a substantial increase in the level of binding to non-native states of the model substrate T4 lysozyme. The structural basis of the enhanced binding is investigated through equivalent substitutions in the homologous heat shock protein 27. The mutations shift the oligomeric equilibrium toward a dissociated multimeric form previously shown to be the binding-competent state. In the context of a recent thermodynamic model of chaperone function that proposes the coupling of small heat shock protein activation to the substrate folding equilibrium (Shashidharamurthy, R., Koteiche, H. A., Dong, J., and McHaourab, H.S. (2005) J. Biol. Chem. 280, 5281-5289), the enhanced binding by the alpha A-crystallin mutants is predicted to shift the substrate folding equilibrium toward non-native intermediates, i.e. the mutants promote substrate unfolding. Given the high concentration of alpha A-crystallin in the lens, the molecular basis of pathogenesis implied by our results is a gain of function that leads to the binding of undamaged proteins and subsequent precipitation of the saturated alpha-crystallin complexes in the developing lens of affected individuals.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 221 Garland Ave,741 Light Hall, Nashville, TN 37232 USA.	Hassane.mchaourab@vanderbilt.edu			PHS HHS [R01-12018, R01-12683] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ajaz MS, 1997, J BIOL CHEM, V272, P11250; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Bassnett S, 1997, INVEST OPHTH VIS SCI, V38, P1678; Benedek GB, 1997, INVEST OPHTH VIS SCI, V38, P1911; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; David LL, 1996, J BIOL CHEM, V271, P4273; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Giese KC, 2004, J BIOL CHEM, V279, P32674, DOI 10.1074/jbc.M404455200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim YH, 2002, BIOCHEMISTRY-US, V41, P14076, DOI 10.1021/bi026288h; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; KOTEICHE HA, 2003, INVEST OPHTHALMOL VI, V44; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216; Lampi KJ, 2001, EXP EYE RES, V72, P279, DOI 10.1006/exer.2000.0950; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Sathish HA, 2004, J BIOL CHEM, V279, P16425, DOI 10.1074/jbc.M313402200; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	52	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14273	14279		10.1074/jbc.M512938200	http://dx.doi.org/10.1074/jbc.M512938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16531622	hybrid			2022-12-27	WOS:000237512300052
J	Lim, CM; Cater, MA; Mercer, JFB; La Fontaine, S				Lim, Chris M.; Cater, Michael A.; Mercer, Julian F. B.; La Fontaine, Sharon			Copper-dependent interaction of dynactin subunit p62 with the N terminus of ATP7B but not ATP7A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSONS-DISEASE PROTEIN; METAL-BINDING SITES; P-TYPE ATPASE; POLARIZED HEPATIC CELLS; MENKES PROTEIN; CYTOPLASMIC DYNEIN; INTRACELLULAR TRAFFICKING; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE	The P-type ATPase affected in Wilson disease, ATP7B, is a key liver protein required to regulate and maintain copper homeostasis. When hepatocytes are exposed to elevated copper levels, ATP7B traffics from the trans-Golgi network toward the biliary canalicular membrane to excrete excess copper into bile. The N-terminal region of ATP7B contains six metal-binding sites (MBS), each with the copper-binding motif MXCXXC. These sites are required for the activity and copper-regulated intracellular redistribution of ATP7B. Two proteins are known to interact with the ATP7B N-terminal region: the copper chaperone ATOX1 that delivers copper to ATP7B, and COMMD1 (MURR1) that is potentially involved in vesicular copper sequestration. To identify additional proteins that interact with ATP7B and hence are involved in copper homeostasis, a yeast two-hybrid approach was employed to screen a human liver cDNA library. The dynactin subunit p62 (dynactin 4; DCTN4) was identified as an interacting partner, and this interaction was confirmed by co-immunoprecipitation from mammalian cells. The dynactin complex binds cargo, such as vesicles and organelles, to cytoplasmic dynein for retrograde microtubule-mediated trafficking and could feasibly be involved in the copper-regulated trafficking of ATP7B. The ATP7B/p62 interaction required copper, the metal-binding CXXC motifs, and the region between MBS 4 and MBS 6 of ATP7B. The p62 subunit did not interact with the related copper ATPase, ATP7A. We propose that the ATP7B interaction with p62 is a key component of the copper-induced trafficking pathway that delivers ATP7B to subapical vesicles of hepatocytes for the removal of excess copper into bile.	Deakin Univ, Sch Life & Environm Sci, Ctr Cellular & Mol Biol, Burwood, Vic 3125, Australia	Deakin University	La Fontaine, S (corresponding author), Deakin Univ, Sch Life & Environm Sci, Ctr Cellular & Mol Biol, 221 Burwood Hwy, Burwood, Vic 3125, Australia.	sharonl@deakin.edu.au	La Fontaine, Sharon/G-7113-2018; Mercer, Julian/R-8583-2019	La Fontaine, Sharon/0000-0002-9948-074X; 				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bastaki M, 2002, MOL BIOL CELL, V13, P225, DOI 10.1091/mbc.01-07-0376; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Burke D., 2000, METHODS YEAST GENETI, P171; Cater MA, 2006, GASTROENTEROLOGY, V130, P493, DOI 10.1053/j.gastro.2005.10.054; Cater MA, 2004, BIOCHEM J, V380, P805, DOI 10.1042/BJ20031804; *CLONT, 2000, PUBL; Cobine PA, 2000, BIOCHEMISTRY-US, V39, P6857, DOI 10.1021/bi000015+; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; Guo Y, 2005, AM J PHYSIOL-GASTR L, V289, pG904, DOI 10.1152/ajpgi.00262.2005; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARADA M, 1993, HEPATOLOGY, V17, P111, DOI 10.1016/0270-9139(93)90200-7; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 2000, J BIOL CHEM, V275, P4834, DOI 10.1074/jbc.275.7.4834; Ke BX, 2006, AM J PHYSIOL-REG I, V290, pR1460, DOI 10.1152/ajpregu.00806.2005; Kim BE, 2002, J BIOL CHEM, V277, P44079, DOI 10.1074/jbc.M208737200; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lee IH, 2001, MOL BIOL CELL, V12, P2195, DOI 10.1091/mbc.12.7.2195; Lindenbaum P, 2002, LIBRARY, V3, P32, DOI 10.1093/library/3.1.32; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MURATA Y, 1995, BIOCHEM BIOPH RES CO, V209, P349, DOI 10.1006/bbrc.1995.1510; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Scriver C. R., 2001, METABOLIC MOL BASES, V2, P3105; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; TAO TY, 1993, J BIOL CHEM, V278, P415; Vallee RB, 2003, NATURE, V421, P701, DOI 10.1038/421701a; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045	64	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14006	14014		10.1074/jbc.M512745200	http://dx.doi.org/10.1074/jbc.M512745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554302	hybrid, Green Published			2022-12-27	WOS:000237512300023
J	Chen, C; Saxena, AK; Simcoke, WN; Garboczi, DN; Pedersen, PL; Ko, YH				Chen, C; Saxena, AK; Simcoke, WN; Garboczi, DN; Pedersen, PL; Ko, YH			Mitochondrial ATP synthase - Crystal structure of the catalytic F-1 unit in a vanadate-induced transition-like state and implications for mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; MYOSIN MOTOR DOMAIN; ADENOSINE-TRIPHOSPHATASE; LIVER MITOCHONDRIA; CHEMICAL MECHANISM; P-I; COMPLEX; PROTEIN; ADP; PURIFICATION	ATP synthesis from ADP, P-i, and Mg2+ takes place in mitochondria on the catalytic F-1 unit (alpha 3 beta 3 gamma delta epsilon) of the ATP synthase complex ( F0F1), a remarkable nanomachine that interconverts electrochemical and mechanical energy, producing the high energy terminal bond of ATP. In currently available structural models of F1, the P- loop ( amino acid residues (156)GGAGVGKT(163)) contributes to substrate binding at the beta subunit catalytic sites. Here, we report the first transition state- like structure of F-1 ( ADP center dot V-i center dot Mg center dot F-1) from rat liver that was crystallized with the phosphate ( Pi) analog vanadate ( VO43- or V-i). Compared with earlier " ground state" structures, this new F1 structure reveals that the active site region has undergone significant remodeling. P- loop residue alanine 158 is located much closer to Vi than it is to Pi in a previous structural model. No significant movements of P- loop residues of the alpha subunit were observed at its analogous but noncatalytic sites. Under physiological conditions, such active site remodeling involving the small hydrophobic alanine residue may promote ATP synthesis by lowering the local dielectric constant, thus facilitating the dehydration of ADP and Pi. This new crystallographic study provides strong support for the catalytic mechanism of ATP synthesis deduced from earlier biochemical studies of liver F-1 conducted in the presence of V-i.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; NIAID, Immunogenet Lab, Struct Biol Sect, NIH, Rockville, MD 20852 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [CA010951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 2000, J BIOENERG BIOMEMBR, V32, P531, DOI 10.1023/A:1005677310791; AMZEL LM, 1978, J BIOL CHEM, V253, P2067; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BRAIG K, 2000, STRUCTURE, V15, P567; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; COLLINSON IR, 1994, J MOL BIOL, V242, P408; CREMO CR, 1989, J BIOL CHEM, V264, P6608; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Ko YH, 1999, J BIOL CHEM, V274, P28853, DOI 10.1074/jbc.274.41.28853; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PUYOU AG, 1986, EUR J BIOCHEM, V159, P133, DOI 10.1111/j.1432-1033.1986.tb09843.x; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TENNER JJ, 1997, CELL, V89, P251; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	38	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13777	13783		10.1074/jbc.M513369200	http://dx.doi.org/10.1074/jbc.M513369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531409	hybrid			2022-12-27	WOS:000237336600088
J	Kang, HJ; Kim, HJ; Rih, JK; Mattson, TL; Kim, KW; Cho, CH; Isaacs, JS; Bae, I				Kang, HJ; Kim, HJ; Rih, JK; Mattson, TL; Kim, KW; Cho, CH; Isaacs, JS; Bae, I			BRCA1 plays a role in the hypoxic response by regulating HIF-1 alpha stability and by modulating vascular endothelial growth factor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; TRANSCRIPTIONAL COACTIVATORS; TUMOR ANGIOGENESIS; GENE-EXPRESSION; OVARIAN-CANCER; BREAST; ACTIVATION; PROTEIN; INHIBITION; MUTATIONS	A recent study of breast cancer patients with and without BRCA1 gene mutations found significantly lower levels of VEGF in serum from patients with BRCA1 mutations (Tarnowski, B., Chudecka-Glaz, A., Gorski, B., and Rzepka-Gorska, I. (2004) Breast Cancer Res. Treat. 88, 287-288). Here, we describe a possible mechanistic explanation for this correlation. Because hypoxia in tumors stimulates VEGF expression and secretion we hypothesized that altered BRCA1 protein levels in breast tumors could affect hypoxia-stimulated VEGF promoter activity. This possibility was tested in cells transfected with various combinations of expression plasmids for BRCA1, BRCA1 specific inhibitory RNAs (BRCA1-siRNAs), HIF-1 alpha, and a VEGF promoter-reporter and then incubated in normoxia (21%, O-2) or hypoxia (0.1%, O-2). As predicted, increased BRCA1 levels enhanced both hypoxia-stimulated VEGF promoter activity and the amounts of VEGF mRNA, as determined by semiquantitative RT-PCR and quantitative real time PCR. Using the ChIP assay, we discovered that BRCA1 could be recruited to the endogenous human VEGF promoter along with HIF-1 alpha following hypoxia. An interaction between BRCA1 and HIF-1 alpha was found in human breast cancer cells. We also found that hypoxia-stimulated VEGF promoter activity and secretion was reduced in cells containing reduced amounts of endogenous BRCA1 protein (obtained by transfecting with BRCA1 siRNAs). A mechanistic explanation for these effects is provided by our finding a reduced half-life and reduced accumulation of HIF-1 alpha in hypoxic cells transfected with BRCA1-siRNAs and that proteasome inhibitors blocked these effects of BRCA1-siRNAs. Thus, our results suggest that normal amounts of BRCA1 function in hypoxia to regulate HIF-1 alpha stability, probably by interacting with HIF-1 alpha.	Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Seoul Natl Univ, Pharmaceut Sci Res Inst, Div Pharmaceut Biosci, Coll Pharm, Seoul 135725, South Korea; Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu 700712, South Korea; Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA	Georgetown University; Seoul National University (SNU); Keimyung University; Medical University of South Carolina	Bae, I (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd,NW, Washington, DC 20057 USA.	ib42@georgetown.edu			PHS HHS [E014440-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bachelder RE, 2001, CANCER RES, V61, P5736; Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; DACHS GU, 2003, METH MOLEC MED, V90, P371; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hesling C, 2004, J INVEST DERMATOL, V122, P369, DOI 10.1046/j.0022-202X.2004.22212.x; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kranz A, 1999, INT J CANCER, V84, P293, DOI 10.1002/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lynch BJ, 1998, HUM PATHOL, V29, P1140, DOI 10.1016/S0046-8177(98)90427-0; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tarnowski B, 2004, BREAST CANCER RES TR, V88, P287, DOI 10.1007/s10549-004-0779-0; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; VAUPEL P, 1991, CANCER RES, V51, P3316; Vujaskovic Z, 2003, INT J HYPERTHER, V19, P498, DOI 10.1080/0265673031000121517; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoshiji H, 1997, CANCER RES, V57, P3924; Yoshiji H, 1996, CANCER RES, V56, P2013; Yudoh K, 2005, ARTHRITIS RES THER, V7, pR904, DOI 10.1186/ar1765	55	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13047	13056		10.1074/jbc.M513033200	http://dx.doi.org/10.1074/jbc.M513033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543242	hybrid, Green Published			2022-12-27	WOS:000237336600008
J	Cox, JM; Abbott, SN; Chitteni-Pattu, S; Inman, RB; Cox, MM				Cox, JM; Abbott, SN; Chitteni-Pattu, S; Inman, RB; Cox, MM			Complementation of one RecA protein point mutation by another - Evidence for trans catalysis of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; CRYSTAL-STRUCTURE; REPLICATION FORKS; BRANCH MIGRATION; BINDING-PROTEIN; IN-VIVO; HELICASE; MECHANISM; RUVB; COMPLEXES	The RecA residues Lys248 and Glu96 are closely opposed across the RecA subunit-subunit interface in some recent models of the RecA nucleoprotein filament. The K248R and E96D single mutant proteins of the Escherichia coli RecA protein each bind to DNA and form nucleoprotein filaments but do not hydrolyze ATP or dATP. A mixture of K248R and E96D single mutant proteins restores dATP hydrolysis to 25% of the wild type rate, with maximum restoration seen when the proteins are present in a 1: 1 ratio. The K248R/E96D double mutant RecA protein also hydrolyzes ATP and dATP at rates up to 10-fold higher than either single mutant, although at a reduced rate compared with the wild type protein. Thus, the K248R mutation partially complements the inactive E96D mutation and vice versa. The complementation is not sufficient to allow DNA strand exchange. The K248R and E96D mutations originate from opposite sides of the subunit-subunit interface. The functional complementation suggests that Lys248 plays a significant role in ATP hydrolysis in trans across the subunit-subunit interface in the RecA nucleoprotein filament. This could be part of a mechanism for the long range coordination of hydrolytic cycles between subunits within the RecA filament.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM52725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; Campbell MJ, 1999, J MOL BIOL, V286, P417, DOI 10.1006/jmbi.1998.2456; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Cox JM, 2005, PLOS BIOL, V3, P231, DOI 10.1371/journal.pbio.0030052; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Crampton DJ, 2004, P NATL ACAD SCI USA, V101, P4373, DOI 10.1073/pnas.0400968101; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; Leipe DD, 2000, GENOME RES, V10, P5; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Schlacher K, 2005, MOL CELL, V17, P561, DOI 10.1016/j.molcel.2005.01.006; Schnos M, 2000, MOL BIOTECHNOL, V16, P77, DOI 10.1385/MB:16:1:77; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003	36	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12968	12975		10.1074/jbc.M513736200	http://dx.doi.org/10.1074/jbc.M513736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527806	hybrid			2022-12-27	WOS:000237134700092
J	Duan, HO; Simpson-Haidaris, PJ				Duan, HO; Simpson-Haidaris, PJ			Cell type-specific differential induction of the human gamma-fibrinogen promoter by interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; LUNG EPITHELIAL-CELLS; B MESSENGER-RNA; GENE-EXPRESSION; CARCINOMA-CELLS; STAT3; PROTEIN; DEXAMETHASONE; TRANSCRIPTION; ACTIVATION	During an acute phase response, interleukin-6 (IL-6) and glucocorticoids up-regulate expression of the three fibrinogen (FBG) genes (fga, fgb, and fgg) in liver and lung epithelium; however, little constitutive lung expression occurs. Recently, we showed that the magnitude of Stat3 binding to three IL-6 motifs on the human gamma FBG promoter correlates negatively with their functional activity in hepatocytes, although these cis-elements are critical for promoter activity. We determined the role of IL-6-receptor-gp130-Stat3 signaling in IL-6 activation of the gamma FBG promoter in liver and lung epithelial cells. Although IL-6 induced gamma FBG promoter activity similar to 30-fold in HepG2 cells, it was increased only 2-fold in lung A549 cells. Equivalent production of gp130 was demonstrated in both cell types by Western blotting; however, lower production of both IL-6-receptor and Stat3 explains, in part, reduced activity of the gamma FBG promoter in lung cells. Dexamethasone potentiated IL-6 induction of the gamma FBG promoter 2.3-fold in both HepG2 and A549 cells for a combined increase in promoter activity of 70-fold or 4.5-fold, respectively. Dexamethasone potentiation is likely due to the induction of IL-6-receptor expression as well as prolonged intensity and duration of Stat3 activation. By circumventing IL-6-receptor-gp130-coupled signaling with ectopic expression of the granulocyte colony-stimulating factor receptor (GCSFR)-gp130(133) chimeric receptor, overexpression of Stat3 induced gamma FBG promoter activity similar to 30-fold in A549 cells. Together, the data suggest tissue-specific differences in IL-6-receptor-gp130-coupled signaling, thereby limiting the extent of Stat3 activation and gamma FBG expression during lung inflammation.	Univ Rochester, Sch Med & Dent, Dept Med, Div Hematol Oncol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Div Hematol Oncol, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	pj_simpsonhaidaris@urmc.rochester.edu		, PJ/0000-0003-2778-2500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50616, P01-HL30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Asselta R, 1998, THROMB HAEMOSTASIS, V79, P1144, DOI 10.1055/s-0037-1615031; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BINI A, 2000, ENCY REFERENCE VASCU, P107; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; DAUER DJ, 2005, ONCOGENE, V28, P28; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; DONALDSON DJ, 1989, J CELL SCI, V94, P101; Duan HO, 2003, J BIOL CHEM, V278, P41270, DOI 10.1074/jbc.M304210200; GRAY AJ, 1993, J CELL SCI, V104, P409; Guadiz G, 1997, AM J RESP CELL MOL, V17, P60, DOI 10.1165/ajrcmb.17.1.2730; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HUBER P, 1990, J BIOL CHEM, V265, P5695; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Lawrence SO, 2004, THROMB HAEMOSTASIS, V92, P234, DOI 10.1160/TH04-01-0024; Lee SY, 1996, THROMB HAEMOSTASIS, V75, P466; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Nguyen MDT, 2000, AM J RESP CELL MOL, V22, P209, DOI 10.1165/ajrcmb.22.2.3746; Odrljin TM, 1996, BBA-PROTEIN STRUCT M, V1298, P69, DOI 10.1016/S0167-4838(96)00090-8; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PARROTT JA, 1993, ENDOCRINOLOGY, V133, P1645, DOI 10.1210/en.133.4.1645; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; Ramin SM, 2004, AM J OBSTET GYNECOL, V190, P952, DOI 10.1016/j.ajog.2004.01.015; Rubenstein NM, 2003, J BIOL CHEM, V278, P10353, DOI 10.1074/jbc.M213121200; Rybarczyk BJ, 2003, BLOOD, V102, P4035, DOI 10.1182/blood-2003-03-0822; Rybarczyk BJ, 2000, CANCER RES, V60, P2033; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Shi RJ, 1998, INFECT IMMUN, V66, P1070, DOI 10.1128/IAI.66.3.1070-1075.1998; Simpson-Haidaris PJ, 1998, INFECT IMMUN, V66, P4431; SimpsonHaidaris PJ, 1995, GENE, V167, P273, DOI 10.1016/0378-1119(95)00679-6; SIMPSONHAIDARIS PJ, 1990, BLOOD COAGUL FIBRIN, V1, P433; SIMPSONHAIDARIS PJ, 1997, BLOOD, V89, P873; Sloboda DM, 2005, CURR PHARM DESIGN, V11, P1459, DOI 10.2174/1381612053507873; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan C, 2002, J BIOL CHEM, V277, P10967, DOI 10.1074/jbc.M109986200; YANG FM, 1995, LAB INVEST, V73, P433; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	50	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12451	12457		10.1074/jbc.M600294200	http://dx.doi.org/10.1074/jbc.M600294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524883	hybrid			2022-12-27	WOS:000237134700032
J	Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apteo, SS				Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apteo, SS			Cell-surface processing of pro-ADAMTS9 by furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAMTS FAMILY; INTRACELLULAR MATURATION; CAENORHABDITIS-ELEGANS; PROPROTEIN CONVERTASES; EXTRACELLULAR-MATRIX; PRECURSOR PROTEINS; SECRETORY PATHWAY; PLASMA-MEMBRANE; METALLOPROTEASE; ACTIVATION	Processing of polypeptide precursors by proprotein convertases (PCs) such as furin typically occurs within the trans-Golgi network. Here, we show in a variety of cell types that the propeptide of ADAMTS9 is not excised intracellularly. Pulse-chase analysis in HEK293F cells indicated that the intact zymogen was secreted to the cell surface and was subsequently processed there before release into the medium. The processing occurred via a furin-dependent mechanism as shown using PC inhibitors, lack of processing in furin-deficient cells, and rescue by furin in these cells. Moreover, down-regulation of furin by small interference RNA reduced ADAMTS9 processing in HEK293F cells. PC5A could also process pro-ADAMTS9, but similarly to furin, processed forms were absent intracellularly. Cell-surface, furin-dependent processing of pro-ADAMTS9 creates a precedent for extracellular maturation of endogenously produced secreted proproteins. It also indicates the existence of a variety of mechanisms for processing of ADAMTS proteases.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Triple Point Biol, Portland, OR 97116 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke	Apteo, SS (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; Demircan K, 2005, ARTHRITIS RHEUM-US, V52, P1451, DOI 10.1002/art.21010; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Huxley-Jones J, 2005, INT J BIOCHEM CELL B, V37, P1838, DOI 10.1016/j.biocel.2005.03.009; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; Longpre JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Mayer G, 2004, J HISTOCHEM CYTOCHEM, V52, P567, DOI 10.1177/002215540405200502; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; MILEWICZ DM, 1995, J CLIN INVEST, V95, P2373, DOI 10.1172/JCI117930; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Somerville RPT, 2004, J BIOL CHEM, V279, P51208, DOI 10.1074/jbc.M409036200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	47	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12485	12494		10.1074/jbc.M511083200	http://dx.doi.org/10.1074/jbc.M511083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537537	hybrid			2022-12-27	WOS:000237134700036
J	Pan, CQ; Buxton, JM; Yung, SL; Tom, I; Yang, L; Chen, HX; MacDougall, M; Bell, A; Claus, TH; Clairmont, KB; Whelan, JP				Pan, CQ; Buxton, JM; Yung, SL; Tom, I; Yang, L; Chen, HX; MacDougall, M; Bell, A; Claus, TH; Clairmont, KB; Whelan, JP			Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLACEMENT ANALOGS; BIOLOGICAL-ACTIVITIES; EXPRESSION CLONING; LIRAGLUTIDE NN2211; ADENYLATE-CYCLASE; CHARGED RESIDUES; GLYCEMIC CONTROL; IN-VIVO; AMIDE; POTENCY	The closely related peptides glucagon-like peptide (GLP-1) and glucagon have opposing effects on blood glucose. GLP-1 induces glucose-dependent insulin secretion in the pancreas, whereas glucagon stimulates gluconeogenesis and glycogenolysis in the liver. The identification of a hybrid peptide acting as both a GLP-1 agonist and a glucagon antagonist would provide a novel approach for the treatment of type 2 diabetes. Toward this end a series of hybrid peptides made up of glucagon and either GLP-1 or exendin-4, a GLP-1 agonist, was engineered. Several peptides that bind to both the GLP-1 and glucagon receptors were identified. The presence of glucagon sequence at the N terminus removed the dipeptidylpeptidase IV cleavage site and increased plasma stability compared with GLP-1. Targeted mutations were incorporated into the optimal dual-receptor binding peptide to identify a peptide with the highly novel property of functioning as both a GLP-1 receptor agonist and a glucagon receptor antagonist. To overcome the short half-life of this mutant peptide in vivo, while retaining dual GLP-1 agonist and glucagon antagonist activities, site-specific attachment of long chained polyethylene glycol (PEGylation) was pursued. PEGylation at the C terminus retained the in vitro activities of the peptide while dramatically prolonging the duration of action in vivo. Thus, we have generated a novel dual-acting peptide with potential for development as a therapeutic for type 2 diabetes.	Bayer HealthCare, Dept Metab Dis Res, West Haven, CT 06516 USA; Bayer HealthCare, Dept Biotechnol, Berkeley, CA 94701 USA	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Whelan, JP (corresponding author), Bayer HealthCare, Dept Metab Dis Res, 400 Morgan Lane, West Haven, CT 06516 USA.	james.whelan.b@bayer.com	Clairmont, Kevin/ABG-6161-2021	Clairmont, Kevin/0000-0003-4198-2437				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; Azizeh BY, 1997, J MED CHEM, V40, P2555, DOI 10.1021/jm960800d; Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Feinglos MN, 2005, DIABETIC MED, V22, P1016, DOI 10.1111/j.1464-5491.2005.01567.x; GALLWITZ B, 1994, EUR J BIOCHEM, V225, P1151, DOI 10.1111/j.1432-1033.1994.1151b.x; GOKE R, 1993, J BIOL CHEM, V268, P19650; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; GYSIN B, 1986, BIOCHEMISTRY-US, V25, P8278, DOI 10.1021/bi00373a023; GYSIN B, 1987, J MED CHEM, V30, P1409, DOI 10.1021/jm00391a024; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; Hruby V. J., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P199, DOI 10.2174/1568013013359041; HRUBY VJ, 1997, PRINCIPLES MED BIOL, P387; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; Knudsen LB, 2000, J MED CHEM, V43, P1664, DOI 10.1021/jm9909645; KRSTENANSKY JL, 1986, J AM CHEM SOC, V108, P1696, DOI 10.1021/ja00267a053; Madsbad S, 2004, DIABETES CARE, V27, P1335, DOI 10.2337/diacare.27.6.1335; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Parker JC, 1998, J PEPT RES, V52, P398; Ribel U, 2002, EUR J PHARMACOL, V451, P217, DOI 10.1016/S0014-2999(02)02189-1; Ritzel U, 1998, J ENDOCRINOL, V159, P93, DOI 10.1677/joe.0.1590093; Roges OA, 2005, EXPERT OPIN INV DRUG, V14, P705, DOI 10.1517/13543784.14.6.705; SMITH RA, 1993, MOL PHARMACOL, V43, P741; Sturm NS, 1998, J MED CHEM, V41, P2693, DOI 10.1021/jm980084a; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; THORNTON K, 1994, BIOCHEMISTRY-US, V33, P3532, DOI 10.1021/bi00178a009; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, BIOCHEMISTRY-US, V33, P6884, DOI 10.1021/bi00188a018; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; Unson CG, 2002, BIOPOLYMERS, V66, P218, DOI 10.1002/bip.10259; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; Unson CG, 1998, J BIOL CHEM, V273, P10308, DOI 10.1074/jbc.273.17.10308; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; Xiao Q, 2001, BIOCHEMISTRY-US, V40, P2860, DOI 10.1021/bi0014498; Ying JF, 2003, BIOCHEMISTRY-US, V42, P2825, DOI 10.1021/bi026629r	45	63	131	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12506	12515		10.1074/jbc.M600127200	http://dx.doi.org/10.1074/jbc.M600127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505481	hybrid			2022-12-27	WOS:000237134700038
J	Kim, BJ; Lee, H				Kim, BJ; Lee, H			Importin-beta mediates Cdc7 nuclear import by binding to the kinase insert II domain, which can be antagonized by importin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; DNA-REPLICATION; S-PHASE; LOCALIZATION SIGNALS; TRANSCRIPTION FACTOR; CDC7P-DBF4P KINASE; G(1)/S TRANSITION; COMPLEX; TRANSPORT	We investigated the nuclear import mechanism of Cdc7, which is essential for the initiation of DNA replication. Here we report that importin-beta binds directly to Cdc7 via the Kinase Insert II domain, promoting its nuclear import. Although both importin-alpha and -beta bind to Cdc7 via the Kinase Insert II domain in a mutually independent manner, the binding affinity of Cdc7 for importin-beta is similar to 10 times higher than for importin-alpha at low protein concentrations of an equimolar ratio. Immunodepletion of importin-beta, but not importin-alpha, abrogates Cdc7 nuclear import, and the addition of importin-beta to the importin-depleted cytosol restores Cdc7 nuclear import. Furthermore, transduction of anti-importin-beta, but not anti-importin-alpha antibodies, into live cells inhibits Cdc7 nuclear import. Unexpectedly, we found that Cdc7 nuclear import is inhibited by competitive binding of importin-alpha to Cdc7. Further studies by site-directed mutagenesis suggest that Lys(306) and Lys(309) within the Kinase Insert II domain are critical for Cdc7 nuclear localization.	Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Sudbury, ON P3E 2C6, Canada; Sudbury Reg Hosp, NE Ontario Reg Canc Program, Tumour Biol Grp, Sudbury, ON P3E 5J1, Canada; No Ontario Sch Med, Dept Med Sci, Sudbury, ON P3E 2C6, Canada	University of Ottawa; Health Sciences North; Northern Ontario School of Medicine	Lee, H (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Sudbury, ON P3E 2C6, Canada.	hlee@hrsrh.on.ca						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guo B, 2001, BIOTECHNIQUES, V31, P314, DOI 10.2144/01312st02; Guo BQ, 1999, SOMAT CELL MOLEC GEN, V25, P159, DOI 10.1023/A:1018841506868; Guo BQ, 2001, GENE, V264, P249, DOI 10.1016/S0378-1119(01)00332-8; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; Kotera I, 2005, EMBO J, V24, P942, DOI 10.1038/sj.emboj.7600587; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; MARX J, 1995, SCIENCE, V270, P1585, DOI 10.1126/science.270.5242.1585; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai Hisao, 1999, Frontiers in Bioscience, V4, pd834, DOI 10.2741/Masai; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12041	12049		10.1074/jbc.M512630200	http://dx.doi.org/10.1074/jbc.M512630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16492669	hybrid			2022-12-27	WOS:000236988100074
J	Thrash, BR; Menges, CW; Pierce, RH; McCance, DJ				Thrash, BR; Menges, CW; Pierce, RH; McCance, DJ			AKT1 provides an essential survival signal required for differentiation and stratification of primary human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; EPITHELIAL-CELL DIFFERENTIATION; TERMINAL DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL-KERATINOCYTES; MICE LACKING; ACTIVATION; GROWTH; SKIN	Keratinocyte differentiation and stratification are complex processes involving multiple signaling pathways, which convert a basal proliferative cell into an inviable rigid squame. Loss of attachment to the basement membrane triggers keratinocyte differentiation, while in other epithelial cells, detachment from the extracellular matrix leads to rapid programmed cell death or anoikis. The potential role of AKT in providing a survival signal necessary for stratification and differentiation of primary human keratinocytes was investigated. AKT activity increased during keratinocyte differentiation and was attributed to the specific activation of AKT1 and AKT2. Targeted reduction of AKT1 expression, but not AKT2, by RNA interference resulted in an abnormal epidermis in organotypic skin cultures with a thin parabasal region and a pronounced but disorganized cornified layer. This abnormal stratification was due to significant cell death in the suprabasal layers and was alleviated by caspase inhibition. Normal expression patterns of both early and late markers of keratinocyte differentiation were also disrupted, producing a poorly developed stratum corneum.	Univ Rochester, Sch Med & Dent, James P Wilmont Canc Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Univ Rochester, Sch Med & Dent, James P Wilmont Canc Ctr, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	dennis_mccance@urmc.rochester.edu		Pierce, MD, Robert Hamilton/0000-0002-2677-144X	NIAID NIH HHS [R01 AI 30798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alibardi L, 2004, J HISTOCHEM CYTOCHEM, V52, P1561, DOI 10.1369/jhc.4A6300.2004; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Mack JA, 2005, J BIOL CHEM, V280, P29904, DOI 10.1074/jbc.M505262200; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6	46	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12155	12162		10.1074/jbc.M512116200	http://dx.doi.org/10.1074/jbc.M512116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517604	hybrid			2022-12-27	WOS:000236988100085
J	Velazquez, F; Fernandez, S; de Lorenzo, V				Velazquez, F; Fernandez, S; de Lorenzo, V			The upstream-activating sequences of the sigma(54) promoter Pu of Pseudomonas putida filter transcription readthrough from upstream genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-INDEPENDENT TERMINATORS; COLI RNA-POLYMERASE; ENHANCER-BINDING PROTEIN; TOL PLASMID PWW0; ESCHERICHIA-COLI; PROKARYOTIC ENHANCER; PROMOTER PU; CONDITIONAL PHENOTYPES; NUCLEAR-ORGANIZATION; CATABOLIC OPERONS	Although the m-xylene-responsive sigma(54) promoter Pu of Pseudomonas putida mt-2, borne by the TOL plasmid pWWO, is one of the strongest known promoters in vivo, its base-line level in the absence of its aromatic inducer is below the limit of any detection procedure. This is unusual because regulatory networks ( such as the one to which Pu belongs) can hardly escape the noise caused by intrinsic fluctuations in background transcription, including that transmitted from upstream promoters. This study provides genetic evidence that the upstream-activating sequences (UAS), which serve as the binding sites for the pWW0-encoded XylR protein ( the m-xylene-responsive sigma(54)-dependent activator of Pu), isolate expression of the upper TOL genes from any adventitious transcriptional flow originating further upstream. An in vivo test system was developed in which different segments of the Pu promoter were examined for the inhibition of incoming transcription products from an upstream promoter in P. putida and Escherichia coli. Minimal transcription filter ability was located within a 105-bp fragment encompassing the UAS of Pu. Although S1 nuclease assays showed that the UAS prevented the buildup of downstream transcripts, the mechanism seems to diverge from a typical termination system. This was shown by the fact that the UAS did not halt transcription in vitro and that the filter effect could not be relieved by the anti-termination system of lambda phage. Because the Pu promoter lies adjacent to the edge of a transposon in pWW0, the preset transcriptional filter in the UAS may isolate the upper TOL operon from undue expression after random insertion of the mobile genetic element in a new replicon.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; CSIC, Inst Neurobiol Ramon & Cajal, Madrid 28002, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC)	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus UAM Cantoblanco, E-28049 Madrid, Spain.	vdlorenzo@cnb.uam.es		de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; Ausubel FM, 1988, MOL REPROD DEV; Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004; Barrick JE, 2004, P NATL ACAD SCI USA, V101, P6421, DOI 10.1073/pnas.0308014101; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Capelson M, 2004, BIOL CELL, V96, P617, DOI 10.1016/j.biolcel.2004.06.004; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Carmona M, 2005, J BACTERIOL, V187, P125, DOI 10.1128/JB.187.1.125-134.2005; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; Cases I, 2005, NAT REV MICROBIOL, V3, P105, DOI 10.1038/nrmicro1084; Cases I, 2003, ENVIRON MICROBIOL, V5, P1281, DOI 10.1111/j.1462-2920.2003.00528.x; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cebolla A, 1996, APPL ENVIRON MICROB, V62, P214, DOI 10.1128/AEM.62.1.214-220.1996; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; DAS A, 1984, CELL, V38, P165, DOI 10.1016/0092-8674(84)90537-3; Delgado A, 1992, Microb Releases, V1, P23; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; Devos D, 2002, ENVIRON MICROBIOL, V4, P29, DOI 10.1046/j.1462-2920.2002.00265.x; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; DOMINGUEZCUEVAS P, 2006, J BIOL CHEM; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; Dworkin J, 1998, GENE DEV, V12, P894, DOI 10.1101/gad.12.6.894; ELLEDGE SJ, 1989, P NATL ACAD SCI USA, V86, P3689, DOI 10.1073/pnas.86.10.3689; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Fraile S, 2001, J BACTERIOL, V183, P5571, DOI 10.1128/JB.183.19.5571-5579.2001; Garmendia J, 2000, MOL MICROBIOL, V38, P401, DOI 10.1046/j.1365-2958.2000.02139.x; Garmendia J, 2000, MICROBIOL-SGM, V146, P2555, DOI 10.1099/00221287-146-10-2555; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Geyer PK, 2002, CELL MOL LIFE SCI, V59, P2112, DOI 10.1007/s000180200011; Greated A, 2002, ENVIRON MICROBIOL, V4, P856, DOI 10.1046/j.1462-2920.2002.00305.x; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; INGHAM CJ, 1995, NUCLEIC ACIDS RES, V23, P370, DOI 10.1093/nar/23.3.370; Jurado P, 2003, J BACTERIOL, V185, P3379, DOI 10.1128/JB.185.11.3379-3383.2003; KESSLER B, 1994, J BACTERIOL, V176, P3171, DOI 10.1128/jb.176.11.3171-3176.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lai J, 2003, CURR OPIN NEUROBIOL, V13, P291, DOI 10.1016/S0959-4388(03)00074-6; Macchi R, 2003, J BIOL CHEM, V278, P27695, DOI 10.1074/jbc.M303031200; MACIAN F, 1994, GENE, V145, P17, DOI 10.1016/0378-1119(94)90317-4; MEIKLEJOHN AL, 1985, CELL, V43, P769, DOI 10.1016/0092-8674(85)90250-8; Moller S, 1998, APPL ENVIRON MICROB, V64, P721; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; PerezMartin J, 1996, GENE, V172, P81, DOI 10.1016/0378-1119(96)00193-X; PerezMartin J, 1996, J MOL BIOL, V258, P562, DOI 10.1006/jmbi.1996.0269; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; RAMOS JL, 1991, APPL ENVIRON MICROB, V57, P260, DOI 10.1128/AEM.57.1.260-266.1991; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Regenhardt D, 2002, ENVIRON MICROBIOL, V4, P912, DOI 10.1046/j.1462-2920.2002.00368.x; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RUIZ R, 2004, TRANSCRIPTIONAL REGU, P509; Rutberg B, 1997, MOL MICROBIOL, V23, P413, DOI 10.1046/j.1365-2958.1997.d01-1867.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Valls M, 2003, NUCLEIC ACIDS RES, V31, P6926, DOI 10.1093/nar/gkg912; Velazquez F, 2005, MOL MICROBIOL, V57, P1557, DOI 10.1111/j.1365-2958.2005.04787.x; Vilar JMG, 2005, CURR OPIN GENET DEV, V15, P136, DOI 10.1016/j.gde.2005.02.005; Wikstrom P, 2001, J MOL BIOL, V314, P971, DOI 10.1006/jmbi.2000.5212; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; Xia Y, 2004, ANNU REV BIOCHEM, V73, P1051, DOI 10.1146/annurev.biochem.73.011303.073950; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; ZHENG CH, 1994, P NATL ACAD SCI USA, V91, P7543, DOI 10.1073/pnas.91.16.7543; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	80	4	5	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11940	11948		10.1074/jbc.M511782200	http://dx.doi.org/10.1074/jbc.M511782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510445	hybrid			2022-12-27	WOS:000236988100063
J	Wen, WY; Yang, J; Zhang, MJ				Wen, WY; Yang, J; Zhang, MJ			Structural characterization of the split pleckstrin homology domain in phospholipase C-gamma 1 and its interaction with TRPC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; PH DOMAIN; PHOSPHOINOSITIDE BINDING; PROTEIN STRUCTURES; NMR-SPECTROSCOPY; C-GAMMA-1; PROGRAM; SPECIFICITY; RESOLUTION; DYNAMIN	Phospholipase C ( PLC)-gamma is unique among the PLC enzymes because each PLC-gamma isozyme contains a split pleckstrin homology ( PH) domain with an SH2SH2SH3 tandem repeat insertion ( where SH indicates Src homology domain) in the middle of its sequence. Split PH domains exist in a number of other proteins that play crucial signaling roles. However, little is known about the structure and function of split PH domains. The C-terminal half of the PLC-gamma split PH domain has been implicated to interact directly with the TRPC3 calcium channel, thereby providing a direct coupling mechanism between PLC-gamma and agonist-induced calcium entry. However, this interaction has not been proved by direct biochemical or structural studies. Here we determined the three-dimensional structure of the split PH domain of PLC-gamma 1, and we found that the split PH domain of the enzyme folds into a canonical PH domain fold with high thermostability. The SH2SH2SH3 insertion between the beta 3 and beta 4 strands does not change the structure of the split PH domain. In contrast to the majority of phospholipid-binding PH domains, the PLC-gamma 1 split PH domain lacks the signature lipid-binding motif located between the beta 1 and beta 2 strands. Consistent with this structural feature, the split PH domain of PLC-gamma 1 does not bind to phospholipids. Multiple biochemical and biophysical experiments have argued against a direct interaction between TRPC3 and the C-terminal half of the PLC-gamma 1 split PH domain. Our data pointed to the existence of a yet to be elucidated interaction mechanism between TRPC3 and PLC-gamma 1.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	mzhang@ust.hk		Zhang, Mingjie/0000-0001-9404-0190				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Berg JS, 2000, J CELL SCI, V113, P3439; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cronin TC, 2004, EMBO J, V23, P3711, DOI 10.1038/sj.emboj.7600388; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemmon MA, 2005, CELL, V120, P574, DOI 10.1016/j.cell.2005.02.023; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Yan J, 2005, EMBO J, V24, P3985, DOI 10.1038/sj.emboj.7600858; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	40	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12060	12068		10.1074/jbc.M600336200	http://dx.doi.org/10.1074/jbc.M600336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500902	hybrid			2022-12-27	WOS:000236988100076
J	Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L				Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L			Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE OXIDATION; MODIFIED PROTEINS; NEURODEGENERATIVE DISORDERS; CRYSTAL-STRUCTURE; STRESS; MUTATIONS; L166P; IDENTIFICATION; CARBONYLATION; DYSFUNCTION	Mutations in DJ-1 cause an autosomal recessive, early onset familial form of Parkinson disease (PD). However, little is presently known about the role of DJ-1 in the more common sporadic form of PD and in other age-related neurodegenerative diseases, such as Alzheimer disease (AD). Here we report that DJ-1 is oxidatively damaged in the brains of patients with idiopathic PD and AD. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified 10 different DJ-1 isoforms, of which the acidic isoforms (pI 5.5 and 5.7) of DJ-1 monomer and the basic isoforms (pI 8.0 and 8.4) of SDS-resistant DJ-1 dimer are selectively accumulated in PD and AD frontal cortex tissues compared with age-matched controls. Quantitative Western blot analysis shows that the total level of DJ-1 protein is significantly increased in PD and AD brains. Mass spectrometry analyses reveal that DJ-1 is not only susceptible to cysteine oxidation but also to previously unsuspected methionine oxidation. Furthermore, we show that DJ-1 protein is irreversibly oxidized by carbonylation as well as by methionine oxidation to methionine sulfone in PD and AD. Our study provides new insights into the oxidative modifications of DJ-1 and indicates association of oxidative damage to DJ-1 with sporadic PD and AD.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Chem & Biochem, Parker H Petit Inst Bioengn & Biosci, Bioanalyt Mass Spectrometry Facil, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Emory University; Emory University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Texas System; University of Texas Health San Antonio	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Li, Lian/0000-0003-4700-1134; Olzmann, James/0000-0001-7751-8316; Chin, Lih-Shen/0000-0002-0817-0368	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054597, R01NS047199, R01NS050650, R01NS047575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG025688, R01AG021489] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA054174, CA54174] Funding Source: Medline; NIA NIH HHS [R01 AG021489, P50 AG025688, AG021489, AG025688] Funding Source: Medline; NINDS NIH HHS [R01 NS047575, NS047575, R01 NS047199, F31 NS054597, NS047199, F31 NS054597-01, NS050650, R01 NS050650, F31 NS054597-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Beardsley RL, 2002, ANAL CHEM, V74, P1884, DOI 10.1021/ac015613o; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Butterfield DA, 2003, AMINO ACIDS, V25, P419, DOI 10.1007/s00726-003-0027-7; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Cordato DJ, 2004, J CLIN NEUROSCI, V11, P119, DOI 10.1016/j.jocn.2003.10.009; Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5; Dalle-Donne I, 2002, FREE RADICAL BIO MED, V32, P927, DOI 10.1016/S0891-5849(02)00799-2; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7; Hedrich K, 2004, ANN NEUROL, V55, P145, DOI 10.1002/ana.10816; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664	52	367	381	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10816	10824		10.1074/jbc.M509079200	http://dx.doi.org/10.1074/jbc.M509079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16517609	Green Accepted, hybrid			2022-12-27	WOS:000236822200021
J	Shi-Wen, X; Stanton, LA; Kennedy, L; Pala, D; Chen, YL; Howat, SL; Renzoni, EA; Carter, DE; Bou-Gharios, G; Stratton, RJ; Pearson, JD; Beier, F; Lyons, KM; Black, CM; Abraham, DJ; Leask, A				Shi-Wen, X; Stanton, LA; Kennedy, L; Pala, D; Chen, YL; Howat, SL; Renzoni, EA; Carter, DE; Bou-Gharios, G; Stratton, RJ; Pearson, JD; Beier, F; Lyons, KM; Black, CM; Abraham, DJ; Leask, A			CCN2 is necessary for adhesive responses to transforming growth factor-beta 1 in embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; VIABILITY SIGNALING PATHWAY; INTEGRIN-LINKED KINASE; HUMAN SKIN FIBROBLASTS; FACTOR GENE-EXPRESSION; HUMAN MESANGIAL CELLS; I COLLAGEN MATRICES; FACTOR-BETA; SCLERODERMA FIBROBLASTS; TGF-BETA	CCN2 is induced by transforming growth factor-beta (TGF beta) in fibroblasts and is overexpressed in connective tissue disease. CCN2 has been proposed to be a downstream mediator of TGF beta action in fibroblasts; however, the role of CCN2 in regulating this process unclear. By using embryonic fibroblasts isolated from ccn2-/- mice, we showed that CCN2 is required for a subset of responses to TGF beta. Affymetrix genome-wide expression profiling revealed that 942 transcripts were induced by TGF beta greater than 2-fold in ccn2-/- fibroblasts, of which 345 were not induced in ccn2-/- fibroblasts, including pro-adhesive and matrix remodeling genes. Whereas TGF beta properly induced a generic Smad3-responsive promoter in ccn2-/- fibroblasts, TGF beta-induced activation of focal adhesion kinase (FAK) and Akt was reduced in ccn2-/- fibroblasts. Emphasizing the importance of FAK and Akt activation in CCN2-dependent transcriptional responses to TGF beta in fibroblasts, CCN2 dependent transcripts were not induced by TGF beta in fak-/- fibroblasts and were reduced by wortmannin in wild-type fibroblasts. Akt1 overexpression in ccn2-/- fibroblasts rescued the TGF beta-induced transcription of CCN2-dependent mRNA. Finally, induction of TGF beta-induced fibroblast adhesion to fibronectin and type I collagen was significantly diminished in ccn2-/- fibroblasts. Thus in embryonic fibroblasts, CCN2 is a necessary cofactor required for TGF beta to activate the adhesive FAK/Akt/phosphatidylinositol 3-kinase cascade, FAK/Akt-dependent genes, and adhesion to matrix.	Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; UCL, Dept Med, Ctr Rheumatol, London NW3 2PF, England; Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Interstitial Lung Dis Unit, London SW3 6LR, England; Univ Western Ontario, London Reg Genom Ctr, London, ON N6A 5C1, Canada; Imperial Coll London, Dept Med, London W12 0NN, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA	Western University (University of Western Ontario); University of London; University College London; University of London; King's College London; Imperial College London; Royal Brompton Hospital; Western University (University of Western Ontario); Imperial College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leask, A (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	Andrew.Leask@schulich.uwo.ca	Leask, Andy/ABH-9433-2020; Lyons, Karen M/P-1843-2014; Leask, Andrew/G-5217-2015; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Lyons, Karen M/0000-0001-9420-5813; Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Renzoni, Elisabetta/0000-0002-1118-797X	NIAMS NIH HHS [R01 AR052686] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052686] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chen YL, 2005, AM J PATHOL, V167, P1699, DOI 10.1016/S0002-9440(10)61252-7; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dziadzio M, 2005, QJM-INT J MED, V98, P485, DOI 10.1093/qjmed/hci078; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2005, GASTROENTEROLOGY, V129, P1019, DOI 10.1053/j.gastro.2005.06.067; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gao Runping, 2005, Cell Commun Signal, V3, P14; Grashoff C, 2004, CURR OPIN CELL BIOL, V16, P565, DOI 10.1016/j.ceb.2004.07.004; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; HIGLEY H, 1994, ARTHRITIS RHEUM, V37, P278, DOI 10.1002/art.1780370218; Hinz B, 2003, CURR OPIN BIOTECH, V14, P538, DOI 10.1016/j.copbio.2003.08.006; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jun JB, 2005, J INVEST DERMATOL, V124, P298, DOI 10.1111/j.0022-202X.2004.23559.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; LIEN SC, 2005, IN PRESS CELL SIGNAL; MCWHIRTER A, 1994, LAB INVEST, V71, P885; Mimura Y, 2005, J INVEST DERMATOL, V124, P886, DOI 10.1111/j.0022-202X.2005.23701.x; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Spessotto P, 2003, J BIOL CHEM, V278, P6160, DOI 10.1074/jbc.M208322200; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702	53	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10715	10726		10.1074/jbc.M511343200	http://dx.doi.org/10.1074/jbc.M511343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484225	hybrid			2022-12-27	WOS:000236822200010
J	Milanesi, E; Costantini, P; Gamblunga, A; Colonna, R; Petronilli, V; Cabrelle, A; Semenzato, G; Cesura, AM; Pinard, E; Bernardi, P				Milanesi, E; Costantini, P; Gamblunga, A; Colonna, R; Petronilli, V; Cabrelle, A; Semenzato, G; Cesura, AM; Pinard, E; Bernardi, P			The mitochondrial effects of small organic ligands of BCL-2 - Sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DEATH; INHIBITOR; RESISTANCE; IDENTIFICATION; MEMBRANE; COMPOUND; LEUKEMIA	We have investigated the mitochondrial effects of BH3I-2', Chelerythrine, and HA14-1, small organic molecules that share the ability to bind the BH3 domain of BCL-2. All compounds displayed a biphasic effect on mitochondrial respiration with uncoupling at low concentrations and respiratory inhibition at higher concentrations, the relative uncoupling potency being BH3I-2' (half-maximal uncoupling at about 80 nM) > Chelerythrine (half-maximal uncoupling at about 2 mu M) > HA14-1 (half-maximal uncoupling at about 20 mu M). At concentrations lower than required for uncoupling all compounds sensitized the permeability transition pore (PTP) to opening both in isolated mitochondria and intact cells. To assess whether the effects on BCL-2 binding, PTP induction and respiration could be due to different structural determinants we have tested a set of HA14-1 analogs from the Hoffmann-La Roche chemical library. We have identified 5-(6-chloro-2,4-dioxo-1,3,4,10-tetrahydro-2H-9-oxa-1,3-diaza-anthracen-10-yl)-pyrimidine-2,4,6-trione (EM20-25) as a molecule devoid of effects on respiration that is able to induce PTP opening, to disrupt the BCL-2/BAX interactions in situ and to activate caspase-9 in BCL-2-overexpressing cells. EM20-25 neutralized the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitized BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine. These results provide a proof of principle that the potentially toxic effects of BCL-2 ligands on mitochondrial respiration are not essential for their antiapoptotic activity and represent an important step forward in the development of tumor-selective drugs acting on BCL-2.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; F Hoffmann La Roche & Co Ltd, Div Pharma, CH-4070 Basel, Switzerland	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Veneto Institute Molecular Medicine; Roche Holding	Bernardi, P (corresponding author), Univ Padua, Dept Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	SEMENZATO, GIANPIETRO C/J-7727-2016; Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	SEMENZATO, GIANPIETRO C/0000-0002-6061-4595; Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cerutti A, 1996, J IMMUNOL, V157, P1854; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; De Marchi U, 2004, J BIOL CHEM, V279, P37415, DOI 10.1074/jbc.M314093200; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Feng WY, 2003, BRIT J HAEMATOL, V121, P332, DOI 10.1046/j.1365-2141.2003.04268.x; FIGUEROAVILLAR JD, 1993, TETRAHEDRON, V49, P2855, DOI 10.1016/S0040-4020(01)80384-7; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TRENTIN L, 1994, BLOOD, V84, P4249, DOI 10.1182/blood.V84.12.4249.bloodjournal84124249; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; YANG J, 1997, SCIENCE, V275, P1132	29	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10066	10072		10.1074/jbc.M513708200	http://dx.doi.org/10.1074/jbc.M513708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481323	hybrid			2022-12-27	WOS:000236594300031
J	Chandrasekar, B; Mummidi, S; Mahimainathan, L; Patel, DN; Bailey, SR; Imam, SZ; Greene, WC; Valente, AJ				Chandrasekar, Bysani; Mummidi, Srinivas; Mahimainathan, Lenin; Patel, Devang N.; Bailey, Steven R.; Imam, Syed Z.; Greene, Warner C.; Valente, Anthony J.			Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappa B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; STATIN THERAPY; INVASIVENESS; CHOLESTEROL; EVENTS; MMP-9; ATHEROSCLEROSIS; ACTIVATION	The proliferation and migration of arterial smooth muscle cells (SMCs) are key events in the vascular restenosis that frequently follows angioplasty. Furthermore, SMC migration and neointimal hyperplasia are promoted by degradation of the extracellular matrix by matrix metalloproteinases ( MMPs). Because we demonstrated previously that the proinflammatory and proatherogenic cytokine interleukin-18 (IL-18) stimulates SMC proliferation ( Chandrasekar, B., Mummidi, S., Valente, A. J., Patel, D. N., Bailey, S. R., Freeman, G. L., Hatano, M., Tokuhisa, T., and Jensen, L. E. ( 2005) J. Biol. Chem. 280, 26263 - 26277), we investigated whether IL-18 induces SMC migration in an MMP-dependent manner and whether the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin can inhibit this response. IL-18 treatment increased both mRNA and protein expression of MMP9 in human coronary artery SMCs. Gel shift, enzyme-linked immunosorbent, and chromatin immunoprecipitation assays revealed a strong induction of IL-18-mediated AP-1 (c-Fos, c-Jun, and Fra-1) and NF-kappa B (p50 and p65) activation and stimulation of MMP9 promoter-dependent reporter gene activity in an AP-1- and NF-kappa B-dependent manner. Ectopic expression of p65, c-Fos, c-Jun, and Fra-1 induced MMP9 promoter activity. Specific antisense or small interfering RNA reagents for these transcription factors reduced IL-18-mediated MMP9 transcription. Furthermore, IL-18 stimulated SMC migration in an MMP9-dependent manner. Atorvastatin effectively suppressed IL-18-mediated AP-1 and NF-kappa B-activation, MMP9 expression, and SMC migration. Together, our results indicate for the first time that the proatherogenic cytokine IL-18 induces human coronary artery SMC migration in an MMP9-dependent manner. Atorvastatin inhibits IL-18-mediated aortic SMC migration and has therapeutic potential for attenuating the progression of atherosclerosis and restenosis.	S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, Dept Immunol & Microbiol, San Francisco, CA 94158 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Francisco; The J David Gladstone Institutes	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; /0000-0001-5077-3552	NHLBI NIH HHS [HL68020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaud C, 2005, TRENDS CARDIOVAS MED, V15, P202, DOI 10.1016/j.tcm.2005.07.002; Auge N, 2004, CIRCULATION, V110, P571, DOI 10.1161/01.CIR.0000136995.83451.1D; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Chandrasekar B, 2006, BIOCHEM BIOPH RES CO, V339, P956, DOI 10.1016/j.bbrc.2005.11.100; Chandrasekar B, 2005, J BIOL CHEM, V280, P26263, DOI 10.1074/jbc.M502586200; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chandrasekar B, 2004, J BIOL CHEM, V279, P20221, DOI 10.1074/jbc.M313980200; Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20; Dinarello CA, 2000, EUR CYTOKINE NETW, V11, P483; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Hellwig-Burgel T, 2005, J INTERF CYTOK RES, V25, P297, DOI 10.1089/jir.2005.25.297; Ikeda U, 2003, CLIN CARDIOL, V26, P55, DOI 10.1002/clc.4960260203; Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04-0929; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Lefer AM, 2001, CARDIOVASC RES, V49, P281, DOI 10.1016/S0008-6363(00)00247-9; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mallat Z, 2002, HEART, V88, P467, DOI 10.1136/heart.88.5.467; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Mandler RN, 2001, BRAIN, V124, P493, DOI 10.1093/brain/124.3.493; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nold M, 2003, N-S ARCH PHARMACOL, V367, P68, DOI 10.1007/s00210-002-0648-5; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakata K, 2000, INT J ONCOL, V17, P673; Sanceau J, 2003, J BIOL CHEM, V278, P36537, DOI 10.1074/jbc.M304300200; SATO H, 1993, ONCOGENE, V8, P395; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Sever PS, 2005, DIABETES CARE, V28, P1151, DOI 10.2337/diacare.28.5.1151; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Sumi D, 2001, ATHEROSCLEROSIS, V155, P347, DOI 10.1016/S0021-9150(00)00597-9; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Yamagami H, 2005, ARTERIOSCL THROM VAS, V25, P1458, DOI 10.1161/01.ATV.0000168417.52486.56; Zhang B, 2004, LEUKEMIA RES, V28, P91, DOI 10.1016/S0145-2126(03)00121-8	42	168	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15099	15109		10.1074/jbc.M600200200	http://dx.doi.org/10.1074/jbc.M600200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16554298	hybrid			2022-12-27	WOS:000237922200012
J	Stempien-Otero, A; Plawman, A; Meznarich, J; Dyamenahalli, T; Otsuka, G; Dichek, DA				Stempien-Otero, April; Plawman, Abigail; Meznarich, Jessica; Dyamenahalli, Teja; Otsuka, Goro; Dichek, David A.			Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; IDIOPATHIC DILATED CARDIOMYOPATHY; MATRIX-METALLOPROTEINASE ACTIVITY; MYOCARDIAL-INFARCTION; TRANSGENIC MICE; HUMAN HEART; PHARMACOLOGICAL INHIBITION; TRANSCRIPTION FACTORS; TARGETED DELETION; ENDOTHELIAL-CELLS	Human hearts with end-stage failure and fibrosis have macrophage accumulation and elevated plasminogen activator activity. However, the mechanisms that link macrophage accumulation and plasminogen activator activity with cardiac fibrosis are unclear. We previously reported that mice with macrophage-targeted overexpression of urokinase plasminogen activator (SR-uPA(+/0) mice) develop cardiac macrophage accumulation by 5 weeks of age and cardiac fibrosis by 15 weeks. We used (SR-uPA(+/o) mice) to investigate mechanisms through which macrophage-expressed uPA causes cardiac macrophage accumulation and fibrosis. We hypothesized that: 1) macrophage accumulation and cardiac fibrosis in (SR-uPA +/o mice) are dependent on localization of uPA by the uPA receptor (uPAR); 2) activation of plasminogen by uPA and subsequent activation of transforming growth factor-beta 1 (TGF-beta 1) and matrix metalloproteinase (MMP)-2 and -9 by plasmin are critical pathways through which uPA-expressing macrophages accumulate in the heart and cause fibrosis; and 3) uPA-induced cardiac fibrosis can be attenuated by treatment with verapamil. To test these hypotheses, we bred the SR-uPA(+/o) transgene into mice deficient in either uPAR or plasminogen and measured cardiac macrophage accumulation and fibrosis. We also measured cardiac TGF-beta 1 protein ( total and active), Smad2 phosphorylation, and MMP activity after the onset of macrophage accumulation but before the onset of cardiac fibrosis. Finally, we treated mice with verapamil. Our studies revealed that plasminogen is necessary for uPA-induced cardiac fibrosis and macrophage accumulation but uPAR is not. We did not detect plasmin-mediated activation of TGF- beta 1, MMP-2, or MMP-9 in hearts of SR-uPA(+/o) mice. However, verapamil treatment significantly attenuated both cardiac fibrosis and macrophage accumulation.	Univ Washington, Sch Med, Med Ctr, Dept Med,Div Cardiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stempien-Otero, A (corresponding author), Univ Washington, Sch Med, Med Ctr, Dept Med,Div Cardiol, Box 357710, Seattle, WA 98195 USA.	april@u.washington.edu		Dichek, David/0000-0002-5224-2736	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080597, K08HL070941] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70941, HL080597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azzawi M, 2005, HISTOPATHOLOGY, V46, P314, DOI 10.1111/j.1365-2559.2005.02075.x; BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P289; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Brown DM, 2004, AM J PHYSIOL-LUNG C, V286, pL344, DOI 10.1152/ajplung.00139.2003; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Coker ML, 1998, AM J PHYSIOL-HEART C, V274, pH1516, DOI 10.1152/ajpheart.1998.274.5.H1516; Cozen AE, 2004, CIRCULATION, V109, P2129, DOI 10.1161/01.CIR.0000127369.24127.03; Creemers E, 2000, AM J PATHOL, V156, P1865, DOI 10.1016/S0002-9440(10)65060-2; DONG R, 1992, J CLIN INVEST, V90, P2022, DOI 10.1172/JCI116082; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; East E, 2005, AM J PATHOL, V167, P545, DOI 10.1016/S0002-9440(10)62996-3; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Falkenberg M, 2002, P NATL ACAD SCI USA, V99, P10665, DOI 10.1073/pnas.162236599; Gaertner R, 2005, J MOL CELL CARDIOL, V38, P193, DOI 10.1016/j.yjmcc.2004.10.017; Gu JM, 2005, J CELL PHYSIOL, V204, P73, DOI 10.1002/jcp.20262; GunjaSmith Z, 1996, AM J PATHOL, V148, P1639; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Heymans S, 2005, AM J PATHOL, V166, P15, DOI 10.1016/S0002-9440(10)62228-6; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kamkin A, 2005, BASIC RES CARDIOL, V100, P337, DOI 10.1007/s00395-005-0529-4; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; KOBAYASHI A, 1987, J AM COLL CARDIOL, V10, P1128, DOI 10.1016/S0735-1097(87)80356-X; Kuhl U, 1995, EUR HEART J, V16, P100, DOI 10.1093/eurheartj/16.suppl_O.100; Lee S, 2006, J MOL CELL CARDIOL, V40, P148, DOI 10.1016/j.yjmcc.2005.09.015; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Matrat M, 1998, J TOXICOL ENV HEAL A, V55, P359; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Moriwaki H, 2004, CIRC RES, V95, P637, DOI 10.1161/01.RES.0000141427.61023.f4; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Pogwizd SM, 1998, CIRCULATION, V98, P2404, DOI 10.1161/01.CIR.98.22.2404; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Rosenkranz S, 2002, AM J PHYSIOL-HEART C, V283, pH1253, DOI 10.1152/ajpheart.00578.2001; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; Schulze PC, 2004, CIRC RES, V95, P552, DOI 10.1161/01.RES.0000143420.87587.9e; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; Tyagi SC, 1996, J MOL CELL CARDIOL, V28, P1415, DOI 10.1006/jmcc.1996.0132; Tyagi SC, 1996, J CELL PHYSIOL, V167, P137, DOI 10.1002/(SICI)1097-4652(199604)167:1<137::AID-JCP16>3.0.CO;2-8; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wang B, 2005, AM J PHYSIOL-HEART C, V289, pH108, DOI 10.1152/ajpheart.00001.2005; WANG DL, 1995, CIRC RES, V77, P294, DOI 10.1161/01.RES.77.2.294; Weber KT, 2004, HYPERTENSION, V43, P716, DOI 10.1161/01.HYP.0000118586.38323.5b; WEBER KT, 1993, CARDIOVASC RES, V27, P341, DOI 10.1093/cvr/27.3.341; Weisberg AD, 2005, ARTERIOSCL THROM VAS, V25, P365, DOI 10.1161/01.ATV.0000152356.85791.52; Wheeler MT, 2004, J CLIN INVEST, V113, P668, DOI 10.1172/JCI200420410; Wheeler MT, 2004, AM J PATHOL, V164, P1063, DOI 10.1016/S0002-9440(10)63193-8; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D; Yamaguchi M, 1997, TRANSPLANTATION, V63, P759, DOI 10.1097/00007890-199703150-00024; Zhang GQ, 2003, J AM SOC NEPHROL, V14, P1234, DOI 10.1097/01.ASN.0000064701.70231.3F	64	36	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15345	15351		10.1074/jbc.M512818200	http://dx.doi.org/10.1074/jbc.M512818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16554301	hybrid			2022-12-27	WOS:000237922200039
J	Chang, TH; Guo, RT; Ko, TP; Wang, AHJ; Liang, PH				Chang, Tao-Hsin; Guo, Rey-Ting; Ko, Tzu-Ping; Wang, Andrew H. -J.; Liang, Po-Huang			Crystal structure of type-III geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae and the mechanism of product chain length determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; ELONGATION; SUBSTRATE; CATALYSIS; MARITIMA; DENSITY; PATHWAY; ENZYME; MODE	Geranylgeranyl pyrophosphate synthase ( GGPPs) catalyzes a condensation reaction of farnesyl pyrophosphate with isopentenyl pyrophosphate to generate C-20 geranylgeranyl pyrophosphate, which is a precursor for carotenoids, chlorophylls, geranylgeranylated proteins, and archaeal ether-linked lipid. For short-chain trans-prenyltransferases that synthesize C-10-C-25 products, bulky amino acid residues generally occupy the fourth or fifth position upstream from the first DDXXD motif to block further elongation of the final products. However, the short-chain type-III GGPPs in eukaryotes lack any large amino acid at these positions. In this study, the first structure of type-III GGPPs from Saccharomyces cerevisiae has been determined to 1.98 (A) over circle resolution. The structure is composed entirely of 15 alpha-helices joined by connecting loops and is arranged with alpha-helices around a large central cavity. Distinct from other known structures of trans-prenyltransferases, the N-terminal 17 amino acids ( 9-amino acid helix A and the following loop) of this GGPPs protrude from the helix core into the other subunit and contribute to the tight dimer formation. Deletion of the first 9 or 17 amino acids caused the dissociation of dimer into monomer, and the Delta( 1 - 17) mutant showed abolished enzyme activity. In each subunit, an elongated hydrophobic crevice surrounded by D, F, G, H, and I alpha-helices contains two DDXXD motifs at the top for substrate binding with one Mg2+ coordinated by Asp(75), Asp(79), and four water molecules. It is sealed at the bottom with three large residues of Tyr(107), Phe(108), and His(139). Compared with the major product C-30 synthesized by mutant H139A, the products generated by mutant Y107A and F108A are predominantly C-40 and C-30, respectively, suggesting the most important role of Tyr(107) in determining the product chain length.	Acad Sinica, Inst Biol Chem, Taiwan Int Grad Program, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taiwan Int Grad Program, 128 Acad Rd, Taipei 115, Taiwan.	ahjwang@gate.sinica.edu.tw; phliang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Chang, Tao-Hsin/0000-0001-7242-2585; Guo, Rey-Ting/0000-0003-2942-7246				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200; Guo RT, 2004, J BIOL CHEM, V279, P4903, DOI 10.1074/jbc.M310161200; Guo RT, 2004, BIOCHEMISTRY-US, V43, P7678, DOI 10.1021/bi036336d; Hemmi H, 2003, EUR J BIOCHEM, V270, P2186, DOI 10.1046/j.1432-1033.2003.03583.x; Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200; JIANG Y, 1995, J BIOL CHEM, V270, P21793, DOI 10.1074/jbc.270.37.21793; Kellogg BA, 1997, CURR OPIN CHEM BIOL, V1, P570, DOI 10.1016/S1367-5931(97)80054-3; Ko TP, 2001, J BIOL CHEM, V276, P47474, DOI 10.1074/jbc.M106747200; Kuo TH, 2002, BBA-PROTEINS PROTEOM, V1599, P125, DOI 10.1016/S1570-9639(02)00410-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sun HY, 2005, J BACTERIOL, V187, P8137, DOI 10.1128/JB.187.23.8137-8148.2005; Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968-0004(99)01464-4	34	79	81	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14991	15000		10.1074/jbc.M512886200	http://dx.doi.org/10.1074/jbc.M512886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16554305	hybrid, Green Published			2022-12-27	WOS:000237671300052
J	Lauer, JM; Dalal, S; Marz, KE; Nonet, ML; Hanson, PI				Lauer, Joshua M.; Dalal, Seema; Marz, Karla E.; Nonet, Michael L.; Hanson, Phyllis I.			SNARE complex zero layer residues are not critical for N-ethylmaleimide-sensitive factor-mediated disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; CRYSTAL-STRUCTURE; ALPHA-SNAP; NEUROTRANSMITTER RELEASE; FUSION COMPLEX; MEMBRANE; SYNTAXIN; EXOCYTOSIS; PROTEIN; TRANSMISSION	Membrane-anchored SNAREs assemble into SNARE complexes that bring membranes together to promote fusion. SNARE complexes are parallel four-helix bundles stabilized in part by hydrophobic interactions within their core. At the center of SNARE complexes is a distinctive zero layer that consists of one arginine and three glutamines. This zero layer is thought to play a special role in the biology of the SNARE complex. One proposal is that the polar residues of the zero layer enable N-ethylmaleimide-sensitive factor (NSF)-mediated SNARE complex disassembly. Here, we studied the effects of manipulating the zero layer of the well studied synaptic SNARE complex in vitro and in vivo. Using a fluorescence-based assay to follow SNARE complex disassembly in real time, we found that the maximal rate at which NSF disassembles complexes was unaffected by mutations in the zero layer, including single replacement of the syntaxin glutamine with arginine as well as multiple replacement of all four layer residues with non-polar amino acids. To determine whether syntaxin with arginine instead of glutamine in its zero layer can support SNARE function in vivo, we introduced it as a transgene into a Caenorhabditis elegans syntaxin-null strain. Mutant syntaxin rescued viability and locomotory defects similarly to wild-type syntaxin, demonstrating that SNARE complexes with two glutamines and two arginines in the zero layer can support neurotransmission. These findings show that residues of the zero layer do not play an essential role in NSF-mediated disassembly.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid,Campus Box 8228, St Louis, MO 63110 USA.	phanson@cellbiology.wustl.edu	Hanson, Phyllis/E-9420-2012					Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; Dilcher M, 2001, J BIOL CHEM, V276, P34537, DOI 10.1074/jbc.M101551200; Dybbs M, 2005, PLOS GENET, V1, P6, DOI 10.1371/journal.pgen.0010002; Ernst JA, 2003, J BIOL CHEM, V278, P8630, DOI 10.1074/jbc.M211889200; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Graf CT, 2005, MOL BIOL CELL, V16, P2263, DOI 10.1091/mbc.E04-09-0830; Graham ME, 2001, J CELL SCI, V114, P4397; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Martinez-Arca S, 2004, TRAFFIC, V5, P371, DOI 10.1111/j.1398-9219.2004.00180.x; Marz KE, 2003, J BIOL CHEM, V278, P27000, DOI 10.1074/jbc.M302003200; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; Mello C, 1995, METHOD CELL BIOL, V48, P451; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Nonet ML, 1998, J NEUROSCI, V18, P70; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NONET ML, 1999, FR MOLEC B, V23, P265; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swanton E, 2000, J CELL SCI, V113, P1783; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; van Swinderen B, 1999, P NATL ACAD SCI USA, V96, P2479, DOI 10.1073/pnas.96.5.2479; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100	51	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14823	14832		10.1074/jbc.M512706200	http://dx.doi.org/10.1074/jbc.M512706200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16522630	hybrid			2022-12-27	WOS:000237671300036
J	Silvaggi, NR; Zhang, CC; Lu, ZB; Dai, JY; Dunaway-Mariano, D; Allen, KN				Silvaggi, Nicholas R.; Zhang, Chunchun; Lu, Zhibing; Dai, Jianying; Dunaway-Mariano, Debra; Allen, Karen N.			The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PHOSPHOGLUCOMUTASE; MUTATIONS; PHOSPHATASE; PMM2; 1A; DIVERSIFICATION; GLYCOFORMS; EVOLUTION; INSIGHT; IA	Congential disorder of glycosylation type 1a (CDG-1a) is a congenital disease characterized by severe defects in nervous system development. It is caused by mutations in alpha-phosphomannomutase (of which there are two isozymes, alpha-PMM1 and alpha-PPM2). Here we report the x-ray crystal structures of human alpha-PMM1 in the open conformation, with and without the bound substrate, alpha-D-mannose 1-phosphate. alpha-PMM1, like most haloalkanoic acid dehalogenase superfamily (HADSF) members, consists of two domains, the cap and core, which open to bind substrate and then close to provide a solvent-exclusive environment for catalysis. The substrate phosphate group is observed at a positively charged site of the cap domain, rather than at the core domain phosphoryl-transfer site defined by the Asp19 nucleophile and Mg2+ cofactor. This suggests that substrate binds first to the cap and then is swept into the active site upon cap closure. The orientation of the acid/base residue Asp(21) suggests that alpha-phosphomannomutase (alpha-PMM) uses a different method of protecting the aspartylphosphate from hydrolysis than the HADSF member beta-phosphoglucomutase. It is hypothesized that the electrostatic repulsion of positive charges at the interface of the cap and core domains stabilizes alpha-PMM1 in the open conformation and that the negatively charged substrate binds to the cap, thereby facilitating its closure over the core domain. The two isozymes, alpha-PMM1 and alpha-PMM2, are shown to have a conserved active-site structure and to display similar kinetic properties. Analysis of the known mutation sites in the context of the structures reveals the genotype- phenotype relationship underlying CDG-1a.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87103 USA	Boston University; University of New Mexico	Allen, KN (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA.	allen@med-xtal.bu.edu	Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551	NHLBI NIH HHS [HL 07291] Funding Source: Medline; NIGMS NIH HHS [GM 61099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bjursell C, 2000, HUM MUTAT, V16, P395, DOI 10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.0.CO;2-T; BROOKS SA, 1994, BIOCHEM SOC T, V22, pS95, DOI 10.1042/bst022095s; DAI JB, 1992, J BIOL CHEM, V267, P6322; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P8684, DOI 10.1021/bi050009j; Matthijs G, 1998, AM J HUM GENET, V62, P542, DOI 10.1086/301763; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; Matthijs G, 2000, HUM MUTAT, V16, P386, DOI 10.1002/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Neumann LM, 2003, EUR J PEDIATR, V162, P710, DOI 10.1007/s00431-003-1278-8; Noelle V, 2005, EUR J PEDIATR, V164, P223, DOI 10.1007/s00431-004-1611-x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peisach E, 2004, BIOCHEMISTRY-US, V43, P12770, DOI 10.1021/bi0490688; Pirard M, 1999, FEBS LETT, V452, P319, DOI 10.1016/S0014-5793(99)00673-0; Pirard M, 1999, BIOCHEM J, V339, P201, DOI 10.1042/0264-6021:3390201; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; RUDD PM, 1994, IMMUNOLOGY, V83, P99; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Tremblay LW, 2006, BIOCHEMISTRY-US, V45, P1183, DOI 10.1021/bi051842j; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; VARIKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI DOI 10.1093/GLYCOB/3.2.97; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; WOODS RJ, 1994, NAT STRUCT BIOL, V1, P499, DOI 10.1038/nsb0894-499; Zhang GF, 2005, BIOCHEMISTRY-US, V44, P9404, DOI 10.1021/bi050558p	39	58	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14918	14926		10.1074/jbc.M601505200	http://dx.doi.org/10.1074/jbc.M601505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540464	hybrid			2022-12-27	WOS:000237671300045
J	Novitskaya, V; Bocharova, OV; Bronstein, I; Baskakov, IV				Novitskaya, V; Bocharova, OV; Bronstein, I; Baskakov, IV			Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CONVERSION; ALPHA-SYNUCLEIN; NEURITE OUTGROWTH; COMMON MECHANISM; NEUROTOXICITY; DISEASE; OLIGOMERS; APOPTOSIS; SCRAPIE; RECEPTOR	A growing body of evidence indicates that small, soluble oligomeric species generated from a variety of proteins and peptides rather than mature amyloid fibrils are inherently highly cytotoxic. Here, we show for the first time that mature amyloid fibrils produced from full- length recombinant mammalian prion protein ( rPrP) were highly toxic to cultured cells and primary hippocampal and cerebella neurons. Fibrils induced apoptotic cell death in a time- and dose- dependent manner. The toxic effect of fibrils was comparable with that exhibited by soluble small beta- oligomers generated from the same protein. Fibrils prepared from insulin were not toxic, suggesting that the toxic effect was not solely due to the highly polymeric nature of the fibrillar form. The cell death caused by rPrP fibrils or beta- oligomers was substantially reduced when expression of endogenous PrPC was down- regulated by small interfering RNAs. In opposition to the beta- oligomer and amyloid fibrils of rPrP, the monomeric alpha- helical form of rPrP stimulated neurite outgrowth and survival of neurons. These studies illustrated that both soluble beta- oligomer and amyloid fibrils of the prion protein are intrinsically toxic and confirmed that endogenously expressed PrPC is required for mediating the toxicity of abnormally folded external PrP aggregates.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; MRC National Institute for Medical Research	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Bocharova, Olga V./J-8284-2018	Bocharova, Olga V./0000-0002-5056-1506	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585, R21NS046291] Funding Source: NIH RePORTER; NINDS NIH HHS [NS046291, NS045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON M, 2006, IN PRESS J MOL BIOL; Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bocharova OV, 2005, BIOCHEMISTRY-US, V44, P6776, DOI 10.1021/bi050251q; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DOBSON M, 2002, TRENDS BIOCHEM SCI, V24, P329; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gatti R, 1998, J HISTOCHEM CYTOCHEM, V46, P895, DOI 10.1177/002215549804600804; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Giese A, 1998, BRAIN PATHOL, V8, P449; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hug H, 1999, BIOCHEMISTRY-US, V38, P13906, DOI 10.1021/bi9913395; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Kanaani J, 2005, J NEUROCHEM, V95, P1373, DOI 10.1111/j.1471-4159.2005.03469.x; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Krebs MRH, 2004, P NATL ACAD SCI USA, V101, P14420, DOI 10.1073/pnas.0405933101; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Li AM, 2005, J BIOL CHEM, V280, P17430, DOI 10.1074/jbc.C500058200; MAAR T, 1995, INT J DEV NEUROSCI, V13, P491, DOI 10.1016/0736-5748(95)00068-R; Malisauskas M, 2005, J BIOL CHEM, V280, P6269, DOI 10.1074/jbc.M407273200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2005, J MOL MED, V83, P3, DOI 10.1007/s00109-004-0605-5; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Sousa MM, 2001, AM J PATHOL, V159, P1993; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Thellung S, 2002, NEUROBIOL DIS, V9, P69, DOI 10.1006/nbdi.2001.0461; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zhu M, 2004, J BIOL CHEM, V279, P24452, DOI 10.1074/jbc.M400004200; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100	74	201	205	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13828	13836		10.1074/jbc.M511174200	http://dx.doi.org/10.1074/jbc.M511174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554307	hybrid			2022-12-27	WOS:000237336600093
J	Aranovich, A; Gdalevsky, GY; Cohen-, R; Fishov, I; Parola, AH				Aranovich, A; Gdalevsky, GY; Cohen-, R; Fishov, I; Parola, AH			Membrane-catalyzed nucleotide exchange on DnaA - Effect of surface molecular crowding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAA; CHROMOSOMAL REPLICATION; FUNCTIONAL INTERACTION; IN-VITRO; PROTEIN; INITIATOR; DOMAINS; BINDING; PHOSPHOLIPIDS; ADSORPTION	DnaA is the initiator protein for chromosomal replication in bacteria; its activity plays a central role in the timing of the primary initiations within the Escherichia coli cell cycle. A controlled, reversible conversion between the active ATP-DnaA and the inactive ADP forms modulates this activity. In a DNA-dependent manner, bound ATP is hydrolyzed to ADP. Acidic phospholipids with unsaturated fatty acids are capable of reactivating ADP-DnaA by promoting the release of the tightly bound ADP. The nucleotide dissociation kinetics, measured in the present study with the fluorescent derivative 3'-O-(N-methylantraniloyl)-5'-adenosine triphosphate, was dependent on the density of DnaA on the membrane in a cooperative manner: it increased 5-fold with decreased protein density. At all surface densities the nucleotide was completely released, presumably due to protein exchange on the membrane. Distinct temperature dependences and the effect of the crowding agent Ficoll suggest that two functional states of DnaA exist at high and low membrane occupancy, ascribed to local macromolecular crowding on the membrane surface. These novel phenomena are thought to play a major role in the mechanism regulating the initiation of chromosomal replication in bacteria.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Fishov, I (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	fishov@bgu.ac.il	FISHOV, ITZHAK/F-2264-2012	Fishov, Itzhak/0000-0002-2125-0012; Parola, Abraham H./0000-0002-3953-5454				AMES BN, 1960, J BIOL CHEM, V235, P769; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Boeneman K, 2005, CURR OPIN MICROBIOL, V8, P143, DOI 10.1016/j.mib.2005.02.006; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camara JE, 2005, EMBO REP, V6, P736, DOI 10.1038/sj.embor.7400467; CARTY CE, 1981, J BACTERIOL, V145, P472, DOI 10.1128/JB.145.1.472-478.1981; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; Crooke E, 2001, BIOCHIMIE, V83, P19, DOI 10.1016/S0300-9084(00)01224-4; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Dauty E, 2004, J MOL RECOGNIT, V17, P441, DOI 10.1002/jmr.709; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Felczak MM, 2005, J BIOL CHEM, V280, P24627, DOI 10.1074/jbc.M503684200; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hall D, 2003, BBA-PROTEINS PROTEOM, V1649, P127, DOI 10.1016/S1570-9639(03)00167-5; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Kadner R. J., 1996, ESCHERICHIA COLI SAL, P58; Katayama T, 1999, BIOCHIMIE, V81, P835, DOI 10.1016/S0300-9084(99)00213-8; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kim PD, 2003, J BACTERIOL, V185, P1817, DOI 10.1128/JB.185.6.1817-1824.2003; Kitagawa R, 1996, MOL MICROBIOL, V19, P1137, DOI 10.1046/j.1365-2958.1996.453983.x; Kitchen JL, 1999, BIOCHEMISTRY-US, V38, P6213, DOI 10.1021/bi982733q; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; KUNG HF, 1972, P NATL ACAD SCI USA, V69, P925, DOI 10.1073/pnas.69.4.925; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P276; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Li ZY, 2005, J BIOL CHEM, V280, P9796, DOI 10.1074/jbc.M413923200; Li ZY, 1999, PROTEIN EXPRES PURIF, V17, P41, DOI 10.1006/prep.1999.1094; LIDE DR, 1990, HDB CHEM PHYS, pD264; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Minton AP, 2000, BIOPHYS CHEM, V86, P239, DOI 10.1016/S0301-4622(00)00151-4; Minton AP, 2001, BIOPHYS J, V80, P1641, DOI 10.1016/S0006-3495(01)76136-X; Minton AP, 1999, BIOPHYS J, V76, P176, DOI 10.1016/S0006-3495(99)77187-0; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Morigen, 2005, J BACTERIOL, V187, P3913, DOI 10.1128/JB.187.12.3913-3920.2005; MOZHAROV AD, 1985, FEBS LETT, V186, P103, DOI 10.1016/0014-5793(85)81348-X; Newman G, 2000, J BACTERIOL, V182, P2604, DOI 10.1128/JB.182.9.2604-2610.2000; Norris V, 2001, BIOCHIMIE, V83, P91, DOI 10.1016/S0300-9084(00)01203-7; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; THOMAS DD, 1978, P NATL ACAD SCI USA, V75, P5746, DOI 10.1073/pnas.75.12.5746; Vanounou S, 2003, MOL MICROBIOL, V49, P1067, DOI 10.1046/j.1365-2958.2003.03614.x; Vanounou S, 2002, PHOTOCHEM PHOTOBIOL, V76, P1, DOI 10.1562/0031-8655(2002)076<0001:CODWDO>2.0.CO;2; Walz AC, 2002, BIOCHEM J, V365, P471, DOI 10.1042/BJ20011853; Wenner JR, 1999, BIOPHYS J, V77, P3234, DOI 10.1016/S0006-3495(99)77154-7; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433	63	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12526	12534		10.1074/jbc.M510266200	http://dx.doi.org/10.1074/jbc.M510266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517983	hybrid			2022-12-27	WOS:000237134700041
J	Chapman-Smith, A; Whitelaw, ML				Chapman-Smith, A; Whitelaw, ML			Novel DNA binding by a basic helix-loop-helix protein - The role of the dioxin receptor PAS domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVE YELLOW PROTEIN; AH-RECEPTOR; CRYSTAL-STRUCTURE; NUCLEAR TRANSLOCATOR; TRANSCRIPTION; DIMERIZATION; IDENTIFICATION; RECOGNITION; SPECIFICITY; REGION	Central issues surrounding the basic helix-loop-helix ( bHLH) superfamily of dimeric transcription factors concern how specificity of partner selection and DNA binding are achieved. bHLH proteins bind DNA through the basic sequence that is contiguous with a helix-loop-helix dimerization domain. For the two subgroups within the family, dimerization is further regulated by an adjacent Per-Arnt-Sim homology ( PAS) or leucine zipper (LZ) domain. We provide evidence that for the bHLH(.)PAS transcription factors Dioxin Receptor (DR) and Arnt, the DR PAS A domain has a unique interaction with the bHLH region that underpins both dimerization strength and affinity for an atypical E-box DNA sequence. A PAS swap heterodimer, where the DR bHLH domain was fused to Arnt PAS A and the Arnt bHLH fused to DR PAS A, gave strong DNA binding, but dimerization was only effective with the native arrangement, suggesting the PAS A domain is critical for each process via distinct mechanisms. LZ domains, which regulate heterodimerization for the bHLH(.)LZ family members Myc and Max, could not replace the PAS domains for either dimerization or DNA binding in the DR/Arnt heterodimer. In vitro footprinting revealed that the PAS domains influence the conformation of target DNA in a manner consistent with DNA bending. These results provide the first insights for understanding mechanisms of selective dimerization and DNA interaction that distinguish bHLH(.)PAS proteins from the broader bHLH superfamily.	Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Australian Res Council, Special Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Chapman-Smith, A (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia.	anne.chapmansmith@adelaide.edu.au						ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Chapman-Smith A, 2004, J BIOL CHEM, V279, P5353, DOI 10.1074/jbc.M310041200; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DAMARE ARF, 1994, EMBO J, V13, P180; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DONG QP, 1994, EMBO J, V13, P200, DOI 10.1002/j.1460-2075.1994.tb06249.x; Dove SL, 1998, GENE DEV, V12, P745, DOI 10.1101/gad.12.5.745; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Rishi V, 2004, J BIOL CHEM, V279, P11863, DOI 10.1074/jbc.M308000200; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; Yildiz O, 2005, MOL CELL, V17, P69, DOI 10.1016/j.molcel.2004.11.022; Yindeeyoungyeon W, 2000, BIOTECHNIQUES, V29, P1034, DOI 10.2144/00295st05; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	45	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12535	12545		10.1074/jbc.M512145200	http://dx.doi.org/10.1074/jbc.M512145200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520375	hybrid			2022-12-27	WOS:000237134700042
J	Kanjilal-Kolar, S; Basu, SS; Kanipes, MI; Guan, ZQ; Garrett, TA; Raetz, CRH				Kanjilal-Kolar, S; Basu, SS; Kanipes, MI; Guan, ZQ; Garrett, TA; Raetz, CRH			Expression cloning of three Rhizobium leguminosarum lipopolysaccharide core galacturonosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTURONIC ACID; ESCHERICHIA-COLI; LIPID-A; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; SURFACE POLYSACCHARIDES; SALMONELLA-TYPHIMURIUM; MEMBRANE ENZYME; INNER MEMBRANE; COG DATABASE; GENE	The lipid A and core regions of the lipopolysaccharide in Rhizobium leguminosarum, a nitrogen-fixing plant endosymbiont, are strikingly different from those of Escherichia coli. In R. leguminosarum lipopolysaccharide, the inner core is modified with three galacturonic acid ( GalA) moieties, two on the distal 3-deoxy-D-manno-octulosonic acid (Kdo) unit and one on the mannose residue. Here we describe the expression cloning of three novel GalA transferases from a 22-kb R. leguminosarum genomic DNA insert-containing cosmid (pSGAT). Two of these enzymes modify the substrate, Kdo2-[4'-P-32] lipid IVA and its 1-dephosphorylated derivative on the distal Kdo residue, as indicated by mild acid hydrolysis. The third enzyme modifies the mannose unit of the substrate mannosyl-Kdo(2)-1-dephospho-[4'-P-32] lipid IVA. Sequencing of a 7-kb subclone derived from pSGAT revealed three putative membrane-bound glycosyltransferases, now designated RgtA, RgtB, and RgtC. Transfer by tri-parental mating of these genes into Sinorhizobium meliloti 1021, a strain that lacks these particular GalA residues, results in the heterologous expression of the GalA transferase activities seen in membranes of cells expressing pSGAT. Reconstitution experiments with the individual genes demonstrated that the activity of RgtA precedes and is necessary for the subsequent activity of RgtB, which is followed by the activity of RgtC. Electrospray ionization-tandem mass spectrometry and gas-liquid chromatography of the product generated in vitro by RgtA confirmed the presence of a GalA moiety. No in vitro activity was detected when RgtA was expressed in Escherichia coli unless Rhizobiaceae membranes were also included.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu	Guan, Ziqiang/AAE-5110-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796, R37-GM-51796, U54 GM069338, GM-069338, R37 GM051796-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P927; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; Choma A, 2004, EUR J BIOCHEM, V271, P1310, DOI 10.1111/j.1432-1033.2004.04038.x; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DJORDJEVIC SP, 1987, J BACTERIOL, V169, P53, DOI 10.1128/jb.169.1.53-60.1987; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; Kanjilal-Kolar S, 2006, J BIOL CHEM, V281, P12879, DOI 10.1074/jbc.M513865200; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; Keating DH, 2002, J BACTERIOL, V184, P6681, DOI 10.1128/JB.184.23.6681-6689.2002; Laus MC, 2004, J BACTERIOL, V186, P6617, DOI 10.1128/JB.186.19.6617-6625.2004; Mohnen D, 1993, Semin Cell Biol, V4, P93, DOI 10.1006/scel.1993.1012; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Niehaus K, 1998, Subcell Biochem, V29, P73; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P498; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; ROANTREE RJ, 1967, ANNU REV MICROBIOL, V21, P443, DOI 10.1146/annurev.mi.21.100167.002303; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; RUSSOMANDO G, 1992, AN ASOC QUIM ARGENT, V80, P175; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	70	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12865	12878		10.1074/jbc.M513864200	http://dx.doi.org/10.1074/jbc.M513864200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497674	Green Accepted, hybrid			2022-12-27	WOS:000237134700082
J	Pirner, HM; Stolz, J				Pirner, HM; Stolz, J			Biotin sensing in Saccharomyces cerevisiae is mediated by a conserved DNA element and requires the activity of biotin-protein ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA-CARBOXYLASE; PLASMA-MEMBRANE; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; YEAST; BINDING; BIOSYNTHESIS; TRANSPORTER; IDENTIFICATION; GLUCOKINASE	Biotin is a water-soluble vitamin that functions as a prosthetic group in carboxylation reactions. In addition to its role as a cofactor, biotin has multiple roles in gene regulation. We analyzed biotin effects on gene expression in the yeast Saccharomyces cerevisiae and demonstrated by microarray, Northern, and Western analyses that all yeast genes encoding proteins involved in biotin metabolism are up-regulated following biotin depletion. Many of these genes contain a palindromic promoter element that is necessary and sufficient for mediating the biotin response and functions as an upstream-activating sequence. Mutants lacking the plasma membrane biotin transporter Vht1p display constitutively high expression levels of biotin-responsive genes. However, they react normally to biotin precursors that do not require Vht1p for uptake. The biotin-like effect of precursors with regard to gene expression requires their intracellular conversion to biotin. This demonstrates that Vht1p does not act as a sensor for biotin and that intracellular biotin is crucial for gene expression. Mutants with defects in biotin-protein ligase, similar to vht1 Delta mutants, also display aberrantly high expression of biotin-responsive genes. Like vht1 Delta cells, they have reduced levels of protein biotinylation, but unlike vht1 Delta mutants, they possess normal levels of free intracellular biotin. This indicates that free intracellular biotin is irrelevant for gene regulation and identifies biotin-protein ligase as an important element of the biotin-sensing pathway in yeast.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Stolz, J (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93040 Regensburg, Germany.	juergen.stolz@biologie.uni-regensburg.de						Boles E, 2004, TOP CURR GENET, V9, P121; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; Che P, 2003, PLANT PHYSIOL, V131, P1479, DOI 10.1104/pp.013243; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; DAKSHINAMURTI K, 1968, CAN J BIOCHEM CELL B, V46, P75, DOI 10.1139/o68-012; Donaton MCV, 2003, MOL MICROBIOL, V50, P911, DOI 10.1046/j.1365-2958.2003.03732.x; DUVAL M, 1994, BIOCHEM J, V299, P141, DOI 10.1042/bj2990141; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guillen-Navarro K, 2005, FEMS MICROBIOL LETT, V246, P159, DOI 10.1016/j.femsle.2005.04.020; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; Hoja U, 2004, J BIOL CHEM, V279, P21779, DOI 10.1074/jbc.M401071200; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Holsbeeks I, 2004, TRENDS BIOCHEM SCI, V29, P556, DOI 10.1016/j.tibs.2004.08.010; Hoppen J, 2005, YEAST, V22, P601, DOI 10.1002/yea.1209; Hymes J, 1996, CLIN CHIM ACTA, V255, P1, DOI 10.1016/0009-8981(96)06396-6; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; Kaiser C., 1994, METHODS YEAST GENETI; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kim HS, 2004, J BIOL CHEM, V279, P42445, DOI 10.1074/jbc.M407137200; Koser S.A., 1968, VITAMIN REQUIREMENTS; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Melcher K, 2000, GENE, V247, P53, DOI 10.1016/S0378-1119(00)00124-4; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OHSUGI M, 1985, J NUTR SCI VITAMINOL, V31, P563, DOI 10.3177/jnsv.31.563; OTSUKA A, 1978, NATURE, V276, P689, DOI 10.1038/276689a0; Pacheco-Alvarez D, 2005, MOL GENET METAB, V85, P301, DOI 10.1016/j.ymgme.2005.04.001; Pacheco-Alvarez D, 2004, J BIOL CHEM, V279, P52312, DOI 10.1074/jbc.M407056200; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Rodionov DA, 2002, GENOME RES, V12, P1507, DOI 10.1101/gr.314502; Rodriguez-Melendez R, 2003, J NUTR BIOCHEM, V14, P680, DOI 10.1016/j.jnutbio.2003.07.001; Rodriguez-Melendez R, 2003, J NUTR, V133, P1259; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; Santiago TC, 2003, J BIOL CHEM, V278, P38723, DOI 10.1074/jbc.M303008200; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; Shakoury-Elizeh M, 2004, MOL BIOL CELL, V15, P1233, DOI 10.1091/mbc.E03-09-0642; Solorzano-Vargas RS, 2002, P NATL ACAD SCI USA, V99, P5325, DOI 10.1073/pnas.082097699; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SUMRADA RA, 1982, J BIOL CHEM, V257, P9119; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WICKERHAM LJ, 1948, J BACTERIOL, V56, P363, DOI 10.1128/JB.56.3.363-371.1948; Wu H, 2005, APPL ENVIRON MICROB, V71, P6845, DOI 10.1128/AEM.71.11.6845-6855.2005; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZHANG SG, 1994, ARCH BIOCHEM BIOPHYS, V309, P29, DOI 10.1006/abbi.1994.1079	58	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12381	12389		10.1074/jbc.M511075200	http://dx.doi.org/10.1074/jbc.M511075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531611	hybrid			2022-12-27	WOS:000237134700023
J	Roy, BB; Hu, J; Guo, XF; Russell, RS; Guo, F; Kleiman, L; Liang, C				Roy, BB; Hu, J; Guo, XF; Russell, RS; Guo, F; Kleiman, L; Liang, C			Association of RNA helicase a with human immunodeficiency virus type 1 particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; CELLULAR COFACTOR; MALELESS PROTEIN; HIV-1 GAG; APOBEC3G; REGION; DIMERIZATION; REPLICATION; DELETION; COMPLEX	RNA helicase A (RHA) belongs to the DEAH family of proteins that are capable of unwinding double-stranded RNA structure. In addition to its involvement in the metabolism of cellular RNA, RHA has been shown to stimulate RNA transcription from the long terminal repeat promoter of human immunodeficiency virus type 1 (HIV-1) as well as to enhance Rev/Rev response element-mediated gene expression. In this study, we provide evidence that RHA associates with HIV-1 Gag in an RNA-dependent manner. This interaction results in specific incorporation of RHA into HIV-1 particles. Knockdown of endogenous RHA in virus producer cells leads to generation of HIV-1 particles that are less infectious in part as a result of restricted reverse transcription. Therefore, RHA represents the first example of cellular RNA helicases that participate in HIV-1 particle production and promote viral reverse transcription.	Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University	Liang, C (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, Rm 326,3755 Cote Ste, Montreal, PQ H3T 1E2, Canada.	chen.liang@mcgill.ca	Russell, Rod/AAU-3109-2021					Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Cen Shan, 2004, Retrovirology, V1, P33, DOI 10.1186/1742-4690-1-33; Cocude C, 2003, J GEN VIROL, V84, P3215, DOI 10.1099/vir.0.19300-0; Fang JH, 2004, VIROLOGY, V330, P471, DOI 10.1016/j.virol.2004.09.039; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Guo XF, 2005, VIROLOGY, V335, P232, DOI 10.1016/j.virol.2005.03.004; Guo XF, 2004, J VIROL, V78, P551, DOI 10.1128/JVI.78.2.551-560.2004; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Krishnan Vyjayanthi, 2004, Retrovirology, V1, P42, DOI 10.1186/1742-4690-1-42; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Liang C, 2002, AIDS RES HUM RETROV, V18, P1117, DOI 10.1089/088922202320567851; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rong LW, 2003, VIROLOGY, V314, P221, DOI 10.1016/S0042-6822(03)00405-7; Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; SHENG NJ, 1994, J VIROL, V68, P6207, DOI 10.1128/JVI.68.10.6207-6214.1994; Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 2000, J BIOL CHEM, V275, P32694, DOI 10.1074/jbc.M003933200; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Walstrom KM, 2005, MECH DEVELOP, V122, P707, DOI 10.1016/j.mod.2004.12.002; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Yang JP, 2001, J BIOL CHEM, V276, P30694, DOI 10.1074/jbc.M102809200; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, ACTA BIOCH BIOPH SIN, V36, P177, DOI 10.1093/abbs/36.3.177	48	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12625	12635		10.1074/jbc.M510596200	http://dx.doi.org/10.1074/jbc.M510596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527808	hybrid			2022-12-27	WOS:000237134700053
J	Shiau, CW; Huang, JW; Wang, DS; Weng, JR; Yang, CC; Lin, CH; Li, CL; Chen, CS				Shiau, CW; Huang, JW; Wang, DS; Weng, JR; Yang, CC; Lin, CH; Li, CL; Chen, CS			alpha-tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-SUCCINATE; SIGNAL-REGULATED KINASE; MOLECULAR-BASIS; IN-VIVO; ACTIVATION; DORMANCY; PATHWAY; AGENT	Although the antitumor effect of alpha-tocopheryl succinate ( vitamin E succinate) has been well demonstrated, its underlying mechanism remains elusive. This study provides evidence that inhibition of Bcl-xL/Bcl- 2 function represents a major pathway whereby alpha-tocopheryl succinate mediates apoptosis induction in prostate cancer cells. In vitro data indicate that alpha-tocopheryl succinate was able to disrupt the binding of Bak BH3 peptide to Bcl-xL and Bcl-2 with IC50 of 26 mu M, in line with its potency in antiproliferation. Treatment of PC-3 cells with this agent led to reduced association of Bcl-2 and Bcl-xL with Bak, leading to caspase-dependent apoptosis. Moreover, overexpression of Bcl-xL protected LNCaP cells from the apoptosis induction. This mechanistic finding provided a basis to develop potent Bcl-xL/Bcl- 2 inhibitors. Docking of alpha-tocopheryl succinate into the Bak peptide-binding site indicates that it adopted a unique hairpin-shaped conformation for protein interactions. We rationalized that the hemisuccinate and the two proximal isopranyl units of the side chain played a crucial role in ligand anchoring and protein-ligand complex stabilization, respectively. However, exposure of the distal isopranyl unit to a polar environment might diminish the binding affinity of alpha-tocopheryl succinate. This premise was corroborated by a structure-activity analysis of a series of derivatives with truncated side chains and/or altered carboxyl terminus. This computer model predicted that the removal of the distal isopranyl unit from the side chain would improve binding affinity, leading to two agents with significantly higher potency in inhibiting Bak peptide binding and in suppressing prostate cancer cell proliferation.	Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA; China Med Univ & Hosp, Dept Biol Sci & Technol, Taichung 404, Taiwan	University System of Ohio; Ohio State University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem, 336 Pk Hall,500 W 12th Ave, Columbus, OH 43210 USA.	chen.844@osu.edu	Weng, Jing-Ru/L-1743-2013; Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719	NATIONAL CANCER INSTITUTE [R01CA112250] Funding Source: NIH RePORTER; NCI NIH HHS [CA-112250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bang OS, 2001, BIOCHEM BIOPH RES CO, V288, P789, DOI 10.1006/bbrc.2001.5839; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; Dalen H, 2003, BRIT J CANCER, V88, P153, DOI 10.1038/sj.bjc.6600683; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Kogure K, 2003, CANCER LETT, V192, P19, DOI 10.1016/S0304-3835(02)00683-3; Li XY, 2001, CANCER RES, V61, P1699; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; Malafa MP, 2002, ANN SURG ONCOL, V9, P1023, DOI 10.1245/ASO.2002.03.580; Malafa MP, 2000, J SURG RES, V93, P163, DOI 10.1006/jsre.2000.5948; Manion MK, 2004, J BIOL CHEM, V279, P2159, DOI 10.1074/jbc.M306021200; Neuzil H, 2002, BIOCHEM BIOPH RES CO, V293, P1309, DOI 10.1016/S0006-291X(02)00358-3; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Prasad KN, 2003, J AM COLL NUTR, V22, P108, DOI 10.1080/07315724.2003.10719283; PRASAD KN, 1982, CANCER RES, V42, P550; Qian M, 1997, ONCOGENE, V15, P223, DOI 10.1038/sj.onc.1201181; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Turley JM, 1997, CANCER RES, V57, P2668; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; You HH, 2002, MOL CARCINOGEN, V33, P228, DOI 10.1002/mc.10040; Yu WP, 2001, CANCER RES, V61, P6569	25	97	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11819	11825		10.1074/jbc.M511015200	http://dx.doi.org/10.1074/jbc.M511015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520381	hybrid			2022-12-27	WOS:000236988100048
J	Rava, P; Ojakian, GK; Shelness, GS; Hussain, MM				Rava, P; Ojakian, GK; Shelness, GS; Hussain, MM			Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; CARBOXYL-TERMINAL TRUNCATION; ESTER TRANSFER PROTEIN; DISULFIDE-ISOMERASE; LIVER-MICROSOMES; LIPID TRANSPORT; SREBP PATHWAY; CELL-LINES; ABETALIPOPROTEINEMIA; MICE	Human microsomal triacylglycerol transfer protein (hMTP) is essential for apolipoprotein B (apoB)-lipoprotein assembly and secretion and is known to transfer triacylglycerols, cholesterol esters, and phospholipids. To understand the relative importance of each lipid transfer activity, we compared the ability of hMTP and its Drosophila ortholog (dMTP) to assemble apoB lipoproteins and to transfer various lipids. apoB48 secretion was induced when co-expressed with either hMTP or dMTP in COS cells, and oleic acid supplementation further augmented secretion without altering particle density. C-terminal epitope-tagged dMTP (dMTP-FLAG) facilitated the secretion of apoB polypeptides in the range of apoB48 to apoB72 but was similar to 50% as efficient as hMTP-FLAG. Comparison of lipid transfer activities revealed that although phospholipid transfer was similar in both orthologs, dMTP was unable to transfer neutral lipids. We conclude that the phospholipid transfer activity of MTP is sufficient for the assembly and secretion of primordial apoB lipoproteins and may represent its earliest function evolved for the mobilization of lipid in invertebrates. Identification of MTP inhibitors, which selectively affect transfer of a specific lipid class, may have therapeutic potential.	SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Wake Forest University	Hussain, MM (corresponding author), SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA.	Mahmood.Hussain@downstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64272, HL49373] Funding Source: Medline; NIDDK NIH HHS [DK46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; ATZEL A, 1994, BIOCHEMISTRY-US, V33, P15382, DOI 10.1021/bi00255a019; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chang G, 2002, CURR OPIN DRUG DISC, V5, P562; Crooke RM, 2005, J LIPID RES, V46, P872, DOI 10.1194/jlr.M400492-JLR200; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Lieu HD, 2003, CIRCULATION, V107, P1315, DOI 10.1161/01.CIR.0000054781.50889.0C; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ohashi K, 2000, J LIPID RES, V41, P1199; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Sellers JA, 2005, J BIOL CHEM, V280, P13902, DOI 10.1074/jbc.M500769200; Sellers JA, 2003, J BIOL CHEM, V278, P20367, DOI 10.1074/jbc.M300271200; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; Vance JE, 2005, J BIOL CHEM, V280, P10877, DOI 10.1074/jbc.R400038200; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863	50	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11019	11027		10.1074/jbc.M512823200	http://dx.doi.org/10.1074/jbc.M512823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478722	hybrid			2022-12-27	WOS:000236822200043
J	Sazinsky, MH; Mandal, AK; Arguello, JM; Rosenzweig, AC				Sazinsky, MH; Mandal, AK; Arguello, JM; Rosenzweig, AC			Structure of the ATP binding domain from the Archaeoglobus fulgidus Cu+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSONS-DISEASE PROTEIN; P-TYPE ATPASES; HEAVY-METAL TRANSPORT; N-TERMINAL DOMAIN; ESCHERICHIA-COLI; CYTOPLASMIC LOOP; MENKES-DISEASE; CALCIUM-PUMP; COPPER; IDENTIFICATION	The P-type ATPases translocate cations across membranes using the energy provided by ATP hydrolysis. CopA from Archaeoglobus fulgidus is a hyperthermophilic ATPase responsible for the cellular export of Cu+ and is a member of the heavy metal P-1B-type ATPase subfamily, which includes the related Wilson and Menkes diseases proteins. The Cu+-ATPases are distinct from their P-type counterparts in ion binding sequences, membrane topology, and the presence of cytoplasmic metal binding domains, suggesting that they employ alternate forms of regulation and novel mechanisms of ion transport. To gain insight into Cu+-ATPase function, the structure of the CopA ATP binding domain (ATPBD) was determined to 2.3 angstrom resolution. Similar to other P-type ATPases, the ATPBD includes nucleotide binding (N-domain) and phosphorylation ( P-domain) domains. The ATPBD adopts a closed conformation similar to the nucleotide-bound forms of the Ca2+-ATPase. The CopA ATPBD is much smaller and more compact, however, revealing the minimal elements required for ATP binding, hydrolysis, and enzyme phosphorylation. Structural comparisons to the AMP-PMP-bound form of the Escherichia coli K+-transporting Kdp-ATPase and to the Wilson disease protein N-domain indicate that the five conserved N-domain residues found in P-1B-type ATPases, but not in the other families, most likely participate in ATP binding. By contrast, the P-domain includes several residues conserved among all P-type ATPases. Finally, the CopA ATPBD structure provides a basis for understanding the likely structural and functional effects of various mutations that lead to Wilson and Menkes diseases.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA; Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol & Chem, Evanston, IL 60208 USA	Worcester Polytechnic Institute; Northwestern University; Northwestern University; Northwestern University	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA.	arguello@wpi.edu; amyr@northwestern.edu	Johnson, Michael D. L./B-4352-2012; Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NIGMS NIH HHS [GM073457, GM58518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518, F32GM073457] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P12289, DOI 10.1021/bi048727d; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; DeLano W.L, PYMOL MOL GRAPHICS S; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; Haupt M, 2004, J MOL BIOL, V342, P1547, DOI 10.1016/j.jmb.2004.07.060; Kim BE, 2002, J BIOL CHEM, V277, P44079, DOI 10.1074/jbc.M208737200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lutsenko S, 2003, ANN NY ACAD SCI, V986, P204, DOI 10.1111/j.1749-6632.2003.tb07161.x; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; Okkeri J, 2004, BIOCHEM J, V377, P95, DOI 10.1042/BJ20030740; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POST RL, 1972, J BIOL CHEM, V247, P6530; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4	46	77	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11161	11166		10.1074/jbc.M510708200	http://dx.doi.org/10.1074/jbc.M510708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495228	hybrid			2022-12-27	WOS:000236822200059
J	Waga, S; Zembutsu, A				Waga, S; Zembutsu, A			Dynamics of DNA binding of replication initiation proteins during de novo formation of pre-replicative complexes in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; MINICHROMOSOME MAINTENANCE PROTEINS; LICENSING SYSTEM; CHROMOSOMAL DNA; ATP HYDROLYSIS; CELL-CYCLE; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MULTIPROTEIN COMPLEX	We investigated the dynamics of DNA binding of replication initiation proteins during formation of the pre-replicative complex (pre-RC) on plasmids in Xenopus egg extracts. The pre-RC was efficiently formed on plasmids at 23 degrees C, with one or a few origin recognition complex (ORC) molecules and similar to 10-20 mini-chromosome maintenance 2 (MCM2) molecules loaded onto each plasmid. Although geminin inhibited MCM loading, MCM interacted weakly but stoichiometrically with the plasmid in an ORC-dependent manner, even in the presence of geminin (with similar to 10 MCM2 molecules per plasmid). Interestingly, DNA binding of ORC, CDC6, and CDT1 was significantly stabilized in the presence of geminin, under which conditions similar to 10-20 molecules each of ORC and CDC6 were bound. Moreover, a similarly stable ORC-CDC6-CDT1 complex rapidly formed on DNA at lower temperature (0 degrees C) without geminin, with similar to 10-20 molecules each of ORC and CDC6 bound to the plasmid, but almost no binding of MCM. However, upon shifting the temperature to 23 degrees C, most ORC, CDC6, and CDT1 molecules were displaced from the DNA, leaving about one ORC molecule on the plasmid, whereas similar to 10 MCM2 molecules were loaded onto each plasmid. Furthermore, it was possible to load MCM onto DNA when the isolated ORC-CDC6-CDT1-DNA complex was mixed with purified MCM proteins. These results suggest that an ORC-CDC6-CDT1 complex pre-formed on DNA is directly involved in MCM loading and imply that each DNA-bound ORC molecule loads only one or a few MCM2-7 complexes during metazoan pre-RC formation.	Osaka Univ, Grad Sch Frontier Biosci, Lab Biomol Network, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Osaka University; Osaka University	Waga, S (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Lab Biomol Network, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	swaga@fbs.osaka-u.ac.jp		Waga, Shou/0000-0003-4986-8735				Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chong JPJ, 1997, METHOD ENZYMOL, V283, P549; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Crowe AJ, 1999, METHOD ENZYMOL, V304, P63; Davey MJ, 2003, CURR BIOL, V13, pR594, DOI 10.1016/S0960-9822(03)00523-2; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Frolova NS, 2002, MOL BIOL CELL, V13, P1298, DOI 10.1091/mbc.01-08-0382; Furukohri A, 2003, J BIOCHEM, V134, P447, DOI 10.1093/jb/mvg163; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Harvey KJ, 2003, J BIOL CHEM, V278, P48524, DOI 10.1074/jbc.M307661200; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; Kong DC, 2003, EMBO J, V22, P3441, DOI 10.1093/emboj/cdg319; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McNairn AJ, 2005, EXP CELL RES, V308, P345, DOI 10.1016/j.yexcr.2005.05.009; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Neuwald AF, 1999, GENOME RES, V9, P27; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Ray-Gallet D, 2004, METHOD ENZYMOL, V375, P117; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; Takahashi N, 2002, J BIOL CHEM, V277, P16033, DOI 10.1074/jbc.M108615200; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda DY, 2005, GENE DEV, V19, P2827, DOI 10.1101/gad.1369805; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; You ZY, 1999, MOL CELL BIOL, V19, P8003	67	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10926	10934		10.1074/jbc.M600299200	http://dx.doi.org/10.1074/jbc.M600299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497662	hybrid			2022-12-27	WOS:000236822200033
J	Li, H; Xie, B; Zhou, YJ; Rahmeh, A; Trusa, S; Zhang, SF; Gao, Y; Lee, EYC; Lee, MYWT				Li, Hao; Xie, Bin; Zhou, Yajing; Rahmeh, Amal; Trusa, Sandra; Zhang, Sufang; Gao, Yan; Lee, Ernest Y. C.; Lee, Marietta Y. W. T.			Functional roles of p12, the fourth subunit of human DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; PCNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; 3RD SUBUNIT; REPLICATION; IDENTIFICATION; RECONSTITUTION; CHROMATOGRAPHY; DOMAINS; PROTEIN	Mammalian DNA polymerase delta(pol delta), a key enzyme of chromosomal DNA replication, consists of four subunits as follows: the catalytic subunit; p125, which is tightly associated with the p50 subunit; p68, a proliferating cell nuclear antigen ( PCNA)- binding protein; and a fourth subunit, p12. In this study, the functional roles of the p12 subunit of pol delta were studied. The inter-subunit interactions of the p12 subunit were determined by yeast two-hybrid assays and by pulldown assays. These assays revealed that p12 interacts with p125 as well as p50. This dual interaction of p12 suggests that it may serve to stabilize the p125-p50 interaction. p12 was shown to be a novel PCNA-binding protein. This was confirmed by identification of a PCNA-binding motif at its N terminus by binding assays and by site-directed mutagenesis. The activities and reaction products of recombinant pol delta containing a p12 mutant defective in PCNA binding, as well as purified recombinant pol delta and its subassemblies, were analyzed. Our results indicate that p12 contributes to PCNA-dependent pol delta activity, i.e. the p12-PCNA interaction is functional. Our data indicate that both p12 and p68 are required for optimal pol delta activity. This supports the hypothesis that the interaction between pol delta and PCNA is a divalent one that involves p12 and p68. We propose a model in which pol delta interacts with PCNA via at least two of its subunits, and one in which p12 could play a role in stabilizing the overall pol delta- PCNA complex as well as pol delta itself.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@nymc.edu		Rahmeh, Amal/0000-0003-0985-7978; Zhang, Sufang/0000-0003-3883-023X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18512] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1995, METHOD ENZYMOL, V262, P270; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Johansson E, 2004, J BIOL CHEM, V279, P22204, DOI 10.1074/jbc.M402652200; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Naryzhny SN, 2005, J BIOL CHEM, V280, P13888, DOI 10.1074/jbc.M500304200; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; TAN CK, 1986, J BIOL CHEM, V261, P2310; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	36	66	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14748	14755		10.1074/jbc.M600322200	http://dx.doi.org/10.1074/jbc.M600322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16510448	hybrid			2022-12-27	WOS:000237671300028
J	Jin, ZH; May, WS; Gao, FQ; Flagg, T; Deng, XM				Jin, Zhaohui; May, W. Stratford; Gao, Fengqin; Flagg, Tammy; Deng, Xingming			Bcl2 Suppresses DNA Repair by Enhancing c-Myc Transcriptional Activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Bcl2 and c-Myc are two major oncogenic proteins that can functionally promote DNA damage, genetic instability, and tumorigenesis. However, the mechanism(s) remains unclear. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is the most potent carcinogen contained in cigarette smoke that induces cellular DNA damage. Here we found that Bcl2 potently suppresses the repair of NNK-induced abasic sites of DNA lesions in association with increased c-Myc transcriptional activity. The Bcl2 BH4 domain (amino acids 6-31) was found to bind directly to c-Myc MBII domain (amino acids 106-143), and this interaction is required for Bcl2 to enhance c-Myc transcriptional activity and inhibit DNA repair. In addition to mitochondria, Bcl2 is also expressed in the nucleus, where it co-localizes with c-Myc. Expression of nuclear-targeted Bcl2 enhances c-Myc transcriptional activity with suppression of DNA repair but fails to prolong cell survival. Depletion of c-Myc expression from cells overexpressing Bcl2 significantly accelerates the repair of NNK-induced DNA damage, indicating that c-Myc may be essential for the Bcl2 effect on DNA repair. It is known that apurinic/apyrimidinic endonuclease (APE1) plays a crucial role in the repair of abasic sites of DNA lesions. That overexpression of Bcl2 results in up-regulation of c-Myc and down-regulation of APE1 suggests APE1 may function as the downstream target of Bcl2/c-Myc in the DNA repair machinery. Thus, Bcl2, in addition to its survival function, may also suppress DNA repair in a novel mechanism involving c-Myc and APE1, which may lead to an accumulation of DNA damage in living cells, genetic instability, and tumorigenesis.	[Deng, Xingming] Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAQ-2893-2021; Jin, Zhaohui/AAI-5562-2020	Jin, Zhaohui/0000-0001-7844-5833	NCI; National Institutes of Health [R01 CA112183]; Flight Attendant Medical Research Institute Clinical Innovator Award; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute Clinical Innovator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI, National Institutes of Health Grant R01 CA112183 and by a Flight Attendant Medical Research Institute Clinical Innovator Award (to X. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Boiteux S, 2004, DNA REPAIR, V3, P1, DOI 10.1016/j.dnarep.2003.10.002; Brunnemann KD, 1996, CRIT REV TOXICOL, V26, P121, DOI 10.3109/10408449609017926; Carmella SG, 1997, CARCINOGENESIS, V18, P587, DOI 10.1093/carcin/18.3.587; CASTONGUAY A, 1985, ENVIRON HEALTH PERSP, V62, P197, DOI 10.2307/3430113; CHEBONNELLASSER.C, 1996, ONCOGENE, V13, P1489; Cheng NL, 2004, ONCOGENE, V23, P3770, DOI 10.1038/sj.onc.1207478; CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DOBRZANSKI KD, 1992, CARCINOGENESIS, V13, P1447; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht S S, 1991, IARC Sci Publ, P54; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; HOFFMANN D, 1991, CRIT REV TOXICOL, V21, P305, DOI 10.3109/10408449109017917; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; JORQUERA R, 1994, CARCINOGENESIS, V15, P389, DOI 10.1093/carcin/15.2.389; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Li Q, 1999, MOL CELL BIOL, V19, P5339; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LIU L, 1990, CANCER RES, V50, P1810; Liu YF, 1997, CANCER RES, V57, P1650; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mai S, 1996, ONCOGENE, V12, P277; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOISSAC D, 1999, J BIOL CHEM, V274, P29505; Mol C. D., 2000, MUTAT RES; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 1999, CANCER RES, V59, P2522; Papadimitriou JC, 1996, CANC DETECT PREV, V2, P529; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; STRASSER A, 1993, ONCOGENE, V8, P1; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; WASEEM NH, 1990, J CELL SCI, V96, P121; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	62	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14446	14456		10.1074/jbc.M511914200	http://dx.doi.org/10.1074/jbc.M511914200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16554306	hybrid			2022-12-27	WOS:000207179300003
J	Hernandez-Pigeon, H; Jean, C; Charruyer, A; Haure, MJ; Titeux, M; Tonasso, L; Quillet-Mary, A; Baudouin, C; Charveron, M; Laurent, G				Hernandez-Pigeon, H; Jean, C; Charruyer, A; Haure, MJ; Titeux, M; Tonasso, L; Quillet-Mary, A; Baudouin, C; Charveron, M; Laurent, G			Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation - Implication of granzyme B and perforin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; SKIN-CANCER; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; SERINE PROTEASES; OXIDATIVE STRESS; LEUKEMIC-CELLS	Ultraviolet ( UV) radiation from the sun is widely considered as a major cause of human skin photoaging and skin cancer. Granzyme B ( GrB) and perforin ( PFN) are two proteins contained in granules and implicated in one of the mechanisms by which cytotoxic lymphocytes and natural killer cells exert their cytotoxicity against virus- infected, alloreactive, or transformed cells. The distribution of GrB and PFN in the skin has received little attention. However, Berthou and co- workers ( Berthou, C., Michel, L., Soulie, A., Jean-Louis, F., Flageul, B., Dubertret, L., Sigaux, F., Zhang, Y., and Sasportes, M. ( 1997) J. Immunol. 159, 5293 - 5300) described that, whereas freshly isolated epidermal cells did not express GrB or PFN, keratinocyte growth to confluence was associated with GrB and PFN mRNA and protein synthesis. In this work, we have investigated the possible role of UV- B on GrB and PFN expression in keratinocytes. We found that UV- B induces GrB and PFN expression in these cells through redox-, epidermal growth factor receptor-, and mitogen- activated protein kinase- dependent signaling. Furthermore, under UV irradiation, keratinocytes acquire a significant cytotoxicity, which is GrB and PFN dependent, toward a variety of cellular targets including transformed T- lymphocytes, melanocytes, and keratinocytes. This phenomenon may have important functional consequences in the regulation of skin inflammatory response and in the emergence of cancer skin.	CHU Purpan, Hematol Serv, F-31059 Toulouse, France; Inst Rech Pierre Fabre, CERPER, Lab Biol Cellulaire Cutanee, Toulouse, France	CHU de Toulouse; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hernandez-Pigeon, H (corresponding author), CHU Purpan, INSERM, U563, CPTP, Bat B,Pavillon Lefebvre,Pl Dr Baylac,BP 3028, F-31024 Toulouse 3, France.	helene.hernandez@toulouse.inserm.fr	QUILLET-MARY, Anne/H-4690-2013; jean, christine/P-2920-2014; Titeux, Matthias/K-8411-2017	jean, christine/0000-0002-6936-289X; Titeux, Matthias/0000-0001-7386-2769				ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; Andre ND, 2004, J CLIN LAB ANAL, V18, P27, DOI 10.1002/jcla.20006; Ashida M, 2003, EXP DERMATOL, V12, P445, DOI 10.1034/j.1600-0625.2003.00101.x; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Berthou C, 1997, J IMMUNOL, V159, P5293; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRANDER C, 1993, EUR J IMMUNOL, V23, P3217, DOI 10.1002/eji.1830231226; Bruno AP, 2000, BLOOD, V96, P1914, DOI 10.1182/blood.V96.5.1914.h8001914_1914_1920; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; COHENKNAFO E, 1995, J CLIN PATHOL, V48, P826, DOI 10.1136/jcp.48.9.826; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; GoihmanYahr M, 1996, CLIN DERMATOL, V14, P153, DOI 10.1016/0738-081X(95)00150-E; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Hart PH, 2001, CLIN EXP PHARMACOL P, V28, P1, DOI 10.1046/j.1440-1681.2001.03392.x; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; Horiuchi K, 2003, J RHEUMATOL, V30, P1799; HUDIG D, 1991, J IMMUNOL, V147, P1360; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; LEONARD M, 1993, BLOOD, V82, P1071; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; LICHTENHELD MG, 1989, J IMMUNOL, V143, P4267; MUNKER R, 1987, BLOOD, V70, P1730; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Ronday HK, 2001, RHEUMATOLOGY, V40, P55, DOI 10.1093/rheumatology/40.1.55; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Sasson R, 2003, BIOCHEM PHARMACOL, V66, P1393, DOI 10.1016/S0006-2952(03)00489-1; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Simon T, 2003, AM J TRANSPLANT, V3, P1121, DOI 10.1034/j.1600-6143.2003.00187.x; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; van den Broek MF, 2000, EXP PHYSIOL, V85, P681; WATT FM, 1987, ARCH DERMATOL RES, V279, P335, DOI 10.1007/BF00431227; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YOUN BS, 1991, J EXP MED, V173, P813, DOI 10.1084/jem.173.4.813; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25	54	65	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13525	13532		10.1074/jbc.M512694200	http://dx.doi.org/10.1074/jbc.M512694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524880	hybrid			2022-12-27	WOS:000237336600060
J	Jamburuthugoda, VK; Chugh, P; Kim, B				Jamburuthugoda, VK; Chugh, P; Kim, B			Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; IN-VIVO; CANCER; ADENOVIRUS; FIDELITY; THERAPY; VECTOR; PROCESSIVITY; REPLICATION; REGRESSION	Retroviruses and DNA viruses utilize cellular dNTPs as substrates for their DNA polymerases during viral replication in infected cells. However, because of S phase- dependent dNTP biosynthesis, the availability of cellular dNTPs significantly varies among cell types ( e. g. dividing versus nondividing cells and normal versus tumor cells). Here we tested whether alterations in the dNTP utilization efficiency and dNTP binding affinity of viral DNA polymerases can switch viral infection specificity to cell types with different dNTP concentrations. We employed an HIV- 1 reverse transcriptase ( RT) mutant ( Q151N), which is catalytically active only at high dNTP concentrations because of its reduced dNTP binding affinity. Indeed, the modified HIV- 1 vector harboring the Q151N mutant RT preferentially transduced tumor cells containing higher cellular dNTP concentrations than primary cells ( e. g. human lung fibroblasts ( HLFs) and human keratinocytes). Although the wild type HIV- 1vector transduced both HLFs and tumor cells, the Q151N vector failed to transduce HLFs and keratinocytes but efficiently transduced tumor cells. Pretreatment of HLFs with deoxynucleosides, which increase cellular dNTP pools, enabled the mutant vector to transduce HLFs, suggesting that the transduction failure of the RT mutant vector to primary cells is because of inefficient reverse transcription in low cellular dNTP environments. We also observed that the Q151N vector expressing herpes simplex virus- thymidine kinase renders tumor cells sensitive to gancyclovir. This study validates a novel strategy in which modifications of viral DNA polymerases in various vector systems allow the delivery of target genes exclusively to tumor cells exploiting elevated cellular dNTP concentration as a tumor cell- specific host factor.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049781] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49781] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Baglole CJ, 2005, METH MOLEC MED, V117, P115; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Diamond TL, 2003, J BIOL CHEM, V278, P29913, DOI 10.1074/jbc.M211754200; FULLER SA, 1982, BIOCHEM J, V206, P131, DOI 10.1042/bj2060131; Ghaneh P, 2001, GENE THER, V8, P199, DOI 10.1038/sj.gt.3301394; Gottesman MM, 2003, CANCER GENE THER, V10, P501, DOI 10.1038/sj.cgt.7700602; Hauschka P V, 1973, Methods Cell Biol, V7, P361; Ho IAW, 2004, HUM GENE THER, V15, P495, DOI 10.1089/10430340460745810; Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987; JACKSON RC, 1980, CANCER RES, V40, P1286; Jamburuthugoda VK, 2005, BIOCHEMISTRY-US, V44, P10635, DOI 10.1021/bi050611+; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Kaplitt Michael G., 1996, Methods (Orlando), V10, P343, DOI 10.1006/meth.1996.0112; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Li HH, 2005, GASTROENTEROLOGY, V128, P2029, DOI 10.1053/j.gastro.2005.03.001; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Okada T, 2002, METHODS, V28, P237, DOI 10.1016/S1046-2023(02)00228-1; Putral LN, 2005, MOL PHARMACOL, V68, P1311, DOI 10.1124/mol.105.014191; Renda MJ, 2001, J VIROL, V75, P9671, DOI 10.1128/JVI.75.20.9671-9678.2001; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Skasko M, 2005, J BIOL CHEM, V280, P12190, DOI 10.1074/jbc.M412859200; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Maele B, 2003, J VIROL, V77, P4685, DOI 10.1128/JVI.77.8.4685-4694.2003; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200	35	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13388	13395		10.1074/jbc.M600291200	http://dx.doi.org/10.1074/jbc.M600291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16497663	hybrid			2022-12-27	WOS:000237336600045
J	Kim, KY; Cheon, HG				Kim, KY; Cheon, HG			Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; NITRIC-OXIDE; POTASSIUM CHANNELS; LIGANDS; GROWTH; PHOSPHORYLATION; MODULATION; APOPTOSIS; MIGRATION; PROTEIN	Recent evidence shows that peroxisome proliferator- activated receptor gamma ( PPAR gamma) ligands induce the antiangiogenic effect in endothelial cells and tumors. In the present study, we elucidated the involvement of maxi- K channel activation in the antiangiogenic effect of rosiglitazone, a well known PPAR gamma ligand in human umbilical vein endothelial cells. We found that the antiangiogenic effects of rosiglitazone were reversed by either bisphenol A diaglycidyl ether, a PPAR gamma antagonist, or iberiotoxin, a maxi- K channel blocker. Knockdown of maxi- K channel expression also reversed the antiangiogenic effects. Iberiotoxin reversed the rosiglitazone- induced hyperpolarization while having no effect on the endogenous PPAR gamma activation, suggesting that rosiglitazone activates maxi- K channel via PPAR gamma. In the rosiglita-zone-induced antiangiogenic process, endothelial nitric- oxide synthase- Ser(1179) phosphorylation and NO production were significantly elevated, and treatment with the NOS inhibitor N-G-monomethyl-(L)- arginine acetate abolished the antiangiogenic and apoptotic effects of rosiglitazone, indicating NO as a key mediator of the rosiglitazone actions. In conclusion, rosiglitazone significantly inhibited VEGF(165)- induced angiogenesis by a proapoptotic mechanism via PPAR gamma- mediated NO production, followed by maxi- K channel opening.	Korea Res Inst Chem Technol, Div Med Sci, Taejon 305600, South Korea	Korea Research Institute of Chemical Technology (KRICT)	Cheon, HG (corresponding author), Korea Res Inst Chem Technol, Div Med Sci, POB 107, Taejon 305600, South Korea.	hgcheon@krict.re.kr						Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brakemeier S, 2003, KIDNEY INT, V64, P199, DOI 10.1046/j.1523-1755.2003.00051.x; Calnek DS, 2003, ARTERIOSCL THROM VAS, V23, P52, DOI 10.1161/01.ATV.0000044461.01844.C9; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cho DH, 2004, J BIOL CHEM, V279, P2499, DOI 10.1074/jbc.M309451200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3; Haburcak M, 1997, CELL CALCIUM, V21, P291, DOI 10.1016/S0143-4160(97)90117-2; Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261; Huang HH, 2004, MOL CANCER RES, V2, P541; Kalvelyte A, 2003, BIOCHEM PHARMACOL, V66, P1661, DOI 10.1016/S0006-2952(03)00540-9; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kraft R, 2003, PFLUG ARCH EUR J PHY, V446, P248, DOI 10.1007/s00424-003-1012-4; Krick S, 2001, AM J PHYSIOL-CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Loviscach M, 2000, DIABETOLOGIA, V43, P304, DOI 10.1007/s001250050048; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Poolos NP, 1999, J NEUROSCI, V19, P5205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wolfram CR, 2004, THROMB HAEMOSTASIS, V92, P1099, DOI 10.1160/TH04-03-0196; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Zhang XF, 2003, NEUROSCIENCE, V122, P1003, DOI 10.1016/j.neuroscience.2003.08.035	36	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13503	13512		10.1074/jbc.M510357200	http://dx.doi.org/10.1074/jbc.M510357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527820	hybrid			2022-12-27	WOS:000237336600058
J	Kobayashi, T; Solaro, RJ				Kobayashi, T; Solaro, RJ			Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; ENERGY-TRANSFER SPECTROSCOPY; PROTEIN-KINASE-C; SKELETAL-MUSCLE; RESTRICTIVE CARDIOMYOPATHY; REGULATORY DOMAIN; INHIBITORY REGION; CALCIUM-BINDING; ACTIN-TROPOMYOSIN; ATPASE ACTIVITY	To understand the molecular mechanisms whereby cardiomyopathy-related cardiac troponin I ( cTnI) mutations affect myofilament activity, we have investigated the Ca2+ binding properties of various assemblies of the regulatory components that contain one of the cardiomyopahty- related mutant cTnI. Acto- S1 ATPase activities in reconstituted systems were also determined. We investigated R145G and R145W mutations from the inhibitory region and D190H and R192H mutations from the second actin- tropomyosin-binding site. Each of the four mutations sensitized the acto- S1 ATPase to Ca2+. Whereas the mutations from the inhibitory region increased the basal level of ATPase activity, those from the second actin- tropomyosin- binding site did not. The effects on the Ca2+ binding properties of the troponin ternary complex and the troponin-tropomyosin complex with one of four mutations were either desensitization or no effect compared with those with wild- type cTnI. All of the mutations, however, affected the Ca2+ sensitivities of the reconstituted thin filaments in the same direction as the acto- S1 ATPase activity. Also the thin filaments with one of the mutant cTnIs bound Ca2+ with less cooperativity compared with those with wild- type cTnI. These data indicate that the mutations found in the inhibitory region and those from the second actin-tropomyosin site shift the equilibrium of the states of the thin filaments differently. Moreover, the increased Ca2+ bound to myofilaments containing the mutant cTnIs may be an important factor in triggered arrhythmias associated with the cardiomyopathy.	Univ Illinois, Dept Physiol & Biophys, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Cardiovasc Res Ctr, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kobayashi, T (corresponding author), Univ Illinois, Dept Physiol & Biophys, Coll Med, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.	tkoba@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022231, P01HL062426] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL 22231, P01 HL 62426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Deng Y, 2001, BIOCHEMISTRY-US, V40, P14593, DOI 10.1021/bi0115232; Digel J, 2001, ARCH BIOCHEM BIOPHYS, V387, P243, DOI 10.1006/abbi.2000.2259; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; Dvoretsky A, 2002, J BIOL CHEM, V277, P38565, DOI 10.1074/jbc.M205306200; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Foster DB, 2003, CIRC RES, V93, P917, DOI 10.1161/01.RES.0000099889.35340.6F; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gomes AV, 2005, J BIOL CHEM, V280, P30909, DOI 10.1074/jbc.M500287200; Gong HY, 2005, P NATL ACAD SCI USA, V102, P656, DOI 10.1073/pnas.0407225102; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; GUTH K, 1987, J BIOL CHEM, V262, P13627; Hai H, 2002, J BIOCHEM, V131, P407, DOI 10.1093/oxfordjournals.jbchem.a003116; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC90; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; Kimura C, 2002, J BIOCHEM, V132, P93, DOI 10.1093/oxfordjournals.jbchem.a003204; Kobayashi T, 2005, ANNU REV PHYSIOL, V67, P39, DOI 10.1146/annurev.physiol.67.040403.114025; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; Kobayashi T, 2004, BIOCHEMISTRY-US, V43, P5996, DOI 10.1021/bi036073n; Kobayashi T, 2001, BBA-PROTEIN STRUCT M, V1549, P148, DOI 10.1016/S0167-4838(01)00254-0; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; Kobayashi T, 1999, BIOCHEMISTRY-US, V38, P5386, DOI 10.1021/bi981320m; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kruger M, 2005, J PHYSIOL-LONDON, V564, P347, DOI 10.1113/jphysiol.2004.079095; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Li MX, 2003, BIOCHEMISTRY-US, V42, P14460, DOI 10.1021/bi035408y; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 1999, BIOCHEMISTRY-US, V38, P6678, DOI 10.1021/bi9824341; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; Martyn DA, 2001, BIOPHYS J, V80, P360, DOI 10.1016/S0006-3495(01)76020-1; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2003, J BIOL CHEM, V278, P6696, DOI 10.1074/jbc.M210690200; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MIKI M, 1990, EUR J BIOCHEM, V187, P155, DOI 10.1111/j.1432-1033.1990.tb15289.x; Miki M, 1998, J BIOCHEM-TOKYO, V123, P324; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Murakami K, 2005, J MOL BIOL, V352, P178, DOI 10.1016/j.jmb.2005.06.067; PAN BS, 1987, J BIOL CHEM, V262, P7839; Patchell VB, 2005, J BIOL CHEM, V280, P14469, DOI 10.1074/jbc.M414202200; Pirani A, 2005, J MOL BIOL, V346, P761, DOI 10.1016/j.jmb.2004.12.013; Putkey JA, 1997, BIOCHEMISTRY-US, V36, P970, DOI 10.1021/bi9617466; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Takahashi-Yanaga F, 2001, J MOL CELL CARDIOL, V33, P2095, DOI 10.1006/jmcc.2001.1473; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; ter Keurs HEDJ, 2006, PROG BIOPHYS MOL BIO, V90, P151, DOI 10.1016/j.pbiomolbio.2005.07.002; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; WNUK W, 1984, J BIOL CHEM, V259, P9017; Yumoto F, 2005, BIOCHEM BIOPH RES CO, V338, P1519, DOI 10.1016/j.bbrc.2005.10.116; Zhou X, 2000, BIOCHEMISTRY-US, V39, P1128, DOI 10.1021/bi992327m	73	102	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13471	13477		10.1074/jbc.M509561200	http://dx.doi.org/10.1074/jbc.M509561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531415	hybrid			2022-12-27	WOS:000237336600054
J	Ono, K; Okajima, T; Tani, M; Kuroda, S; Sun, D; Davidson, VL; Tanizawa, K				Ono, K; Okajima, T; Tani, M; Kuroda, S; Sun, D; Davidson, VL; Tanizawa, K			Involvement of a putative [Fe-S]-cluster-binding protein in the biogenesis of quinohemoprotein amine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN TRYPTOPHYLQUINONE BIOGENESIS; QUINONE COFACTOR BIOGENESIS; PARACOCCUS-DENITRIFICANS; METHYLAMINE DEHYDROGENASE; PSEUDOMONAS-PUTIDA; REDOX COFACTOR; ACTIVE-SITE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LYSYL OXIDASE	Quinohemoprotein amine dehydrogenase (QHNDH) of Paracoccus denitrificans contains a peptidyl quinone cofactor, cysteine tryptophylquinone, as well as intrapeptidyl thioether cross-links between Cys and Asp/Glu residues within the smallest gamma-subunit of the alpha beta gamma heterotrimeric protein. A putative [Fe-S]-cluster-binding protein (ORF2 protein) encoded between the structural genes for the alpha- and gamma-subunitsof QHNDH in the n-butylamine-utilizing operon likely belongs to a Radical SAM (S-Ado Met) superfamily that includes many proteins involved in vitamin biosynthesis and enzyme activation. In this study the role of ORF2 protein in the biogenesis of QHNDH has been explored. Although the wild-type strain of Paracoccus denitrificans produced an active, mature enzyme upon induction with n-butylamine, a mutant strain in which the ORF2 gene had been mostly deleted, neither grew in the n-butylamine medium nor showed QHNDH activity. When the mutant strain was transformed with an expression plasmid for the ORF2 protein, n butylamine-dependent bacterial growth and QHNDH activity were restored. Site-specific mutations in the putative [Fe-S]-cluster or SAM binding motifs in the ORF2 protein failed to support bacterial growth. The alpha- and beta subunits were both detected in the periplasm of the mutant strain, whereas the gamma-subunit polypeptide was accumulated in the cytoplasm and stained negatively for redox-cycling quinone staining. Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis revealed that the gamma-subunit isolated from the mutant strain had not undergone post-translational modification. These results unequivocally show that the putative [ Fe-S]-cluster- and SAM-binding ORF2 protein is necessary for the posttranslational processing of gamma-subunit, most likely participating in the formation of the intrapeptidyl thioether cross-links.	Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	Osaka University; University of Mississippi; University of Mississippi Medical Center	Okajima, T (corresponding author), Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan.	tokajima@sanken.osaka-u.ac.jp; tanizawa@sanken.osaka-u.ac.jp		Okajima, Toshihide/0000-0003-1733-9580; Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM-41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, BIOSCI BIOTECH BIOCH, V62, P469, DOI 10.1271/bbb.62.469; ALEFOUNDER PR, 1981, BIOCHEM BIOPH RES CO, V98, P778, DOI 10.1016/0006-291X(81)91179-7; Bollinger JA, 2005, BIOCHEMISTRY-US, V44, P11708, DOI 10.1021/bi0504310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buis JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P288, DOI 10.1016/j.abb.2004.09.028; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Cianciotto NP, 2005, MOL MICROBIOL, V56, P1408, DOI 10.1111/j.1365-2958.2005.04650.x; Datta S, 2003, ACTA CRYSTALLOGR D, V59, P1551, DOI 10.1107/S090744490301429X; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Davidson VL, 2004, ARCH BIOCHEM BIOPHYS, V428, P32, DOI 10.1016/j.abb.2004.03.022; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Fujieda N, 2002, BIOCHEMISTRY-US, V41, P13736, DOI 10.1021/bi026387v; HARMS N, 1985, J BACTERIOL, V164, P1064, DOI 10.1128/JB.164.3.1064-1070.1985; HARMS N, 1991, J BIOENERG BIOMEMBR, V23, P187, DOI 10.1007/BF00762217; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Jones LH, 2005, J BIOL CHEM, V280, P17392, DOI 10.1074/jbc.M500943200; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marsh ENG, 2004, BIOORG CHEM, V32, P326, DOI 10.1016/j.bioorg.2004.06.001; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PAZ MA, 1991, J BIOL CHEM, V266, P689; Pearson AR, 2004, BIOCHEMISTRY-US, V43, P5494, DOI 10.1021/bi049863l; Pearson AR, 2003, BIOCHEMISTRY-US, V42, P3224, DOI 10.1021/bi027073a; Satoh A, 2003, BBA-PROTEINS PROTEOM, V1647, P272, DOI 10.1016/S1570-9639(03)00069-4; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Takagi K, 1999, BIOCHEMISTRY-US, V38, P6935, DOI 10.1021/bi9828268; Takagi K, 2001, EUR J BIOCHEM, V268, P470, DOI 10.1046/j.1432-1033.2001.01912.x; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Vandenberghe I, 2001, J BIOL CHEM, V276, P42923, DOI 10.1074/jbc.M107164200; VANDERPALEN CJNM, 1995, EUR J BIOCHEM, V230, P860; vanderPalen CJNM, 1997, ANTON LEEUW INT J G, V72, P219, DOI 10.1023/A:1000441925796; VANSPANNING RJM, 1994, EUR J BIOCHEM, V226, P201; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6962, DOI 10.1128/jb.173.21.6962-6970.1991; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Wang YT, 2005, J AM CHEM SOC, V127, P8258, DOI 10.1021/ja051734k; Wang YT, 2003, BIOCHEMISTRY-US, V42, P7318, DOI 10.1021/bi034243q; Whittaker MM, 2003, J BIOL CHEM, V278, P22090, DOI 10.1074/jbc.M300112200	41	28	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13672	13684		10.1074/jbc.M600029200	http://dx.doi.org/10.1074/jbc.M600029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16546999	hybrid			2022-12-27	WOS:000237336600078
J	Sanders, RJ; Ofman, R; Duran, M; Kemp, S; Wanders, RJA				Sanders, RJ; Ofman, R; Duran, M; Kemp, S; Wanders, RJA			omega-oxidation of very long-chain fatty acids in human liver microsomes - Implications for X-linked adrenoleukodystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROMES P450; RAT-LIVER; ACETYLSALICYLIC-ACID; MONOCARBOXYLIC ACIDS; SELECTIVE INHIBITORS; DICARBOXYLIC-ACIDS; SKIN FIBROBLASTS; BETA-OXIDATION; METABOLISM; EXPRESSION	X-linked adrenoleukodystrophy ( X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids ( VLCFA). Excess levels of VLCFAs are thought to play an important role in the pathogenesis of X-ALD. Therefore, therapeutic approaches for X-ALD are focused on the reduction or normalization of VLCFAs. In this study, we investigated an alternative oxidation route for VLCFAs, namely omega-oxidation. The results described in this study show that VLCFAs are substrates for the omega-oxidation system in human liver microsomes. Moreover, VLCFAs were not only converted into omega-hydroxy fatty acids, but they were also further oxidized to dicarboxylic acids via cytochrome P450-mediated reactions. High sensitivity toward the specific P450 inhibitor 17-octadecynoic acid suggested that omega-hydroxylation of VLCFAs is catalyzed by P450 enzymes belonging to the CYP4A/F subfamilies. Studies with individually expressed human recombinant P450 enzymes revealed that two P450 enzymes, i.e. CYP4F2 and CYP4F3B, participate in the omega-hydroxylation of VLCFAs. Both enzymes belong to the cytochrome P450 4F subfamily and have a high affinity for VLCFAs. In summary, this study demonstrates that VLCFAs are substrates for the human omega-oxidation system, and for this reason, stimulation of the in vivo VLCFA omega-oxidation pathway may provide an alternative mode of treatment to reduce the levels of VLCFAs in patients with X-ALD.	Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Meibergdreef 9,Rm F0-224, NL-1105 AZ Amsterdam, Netherlands.	r.j.wanders@amc.uva.nl	Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X				Adas F, 1999, J LIPID RES, V40, P1990; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; BALDWIN SJ, 1995, XENOBIOTICA, V25, P261, DOI 10.3109/00498259509061850; BJORKHEM I, 1978, J LIPID RES, V19, P585; CHEN LP, 1993, ARCH BIOCHEM BIOPHYS, V300, P18, DOI 10.1006/abbi.1993.1003; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; Collins XH, 2005, J BIOL CHEM, V280, P33157, DOI 10.1074/jbc.M504055200; Dickins M, 2004, CURR TOP MED CHEM, V4, P1745, DOI 10.2174/1568026043387115; Eagling VA, 1998, BRIT J CLIN PHARMACO, V45, P107, DOI 10.1046/j.1365-2125.1998.00679.x; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; IGARASHI M, 1976, J NEUROCHEM, V26, P851, DOI 10.1111/j.1471-4159.1976.tb04462.x; JAKOBS C, 1981, CLIN CHIM ACTA, V111, P169, DOI 10.1016/0009-8981(81)90184-4; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Kemp S, 2004, CLIN CHEM, V50, P1824, DOI 10.1373/clinchem.2004.038539; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; Korman SH, 2000, J INHERIT METAB DIS, V23, P425, DOI 10.1023/A:1005624523611; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Kroetz DL, 2005, ANNU REV PHARMACOL, V45, P413, DOI 10.1146/annurev.pharmtox.45.120403.100045; KUNDU RK, 1993, J LIPID RES, V34, P1187; KUNDU RK, 1991, J CLIN INVEST, V88, P1865, DOI 10.1172/JCI115508; Lewis DFV, 2004, PHARMACOGENOMICS, V5, P305, DOI 10.1517/phgs.5.3.305.29827; MITZ MA, 1961, BIOCHIM BIOPHYS ACTA, V46, P45, DOI 10.1016/0006-3002(61)90644-8; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Okita RT, 2001, CURR DRUG METAB, V2, P265; ROBBINS KC, 1968, ARCH BIOCHEM BIOPHYS, V123, P531, DOI 10.1016/0003-9861(68)90174-4; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; SINGH I, 1984, PEDIATR RES, V18, P286, DOI 10.1203/00006450-198403000-00016; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wen X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/dmd.30.6.631; Xu FY, 2004, J PHARMACOL EXP THER, V308, P887, DOI 10.1124/jpet.103.059626; Zhang XL, 2000, ARCH BIOCHEM BIOPHYS, V378, P364, DOI 10.1006/abbi.2000.1836	43	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13180	13187		10.1074/jbc.M513481200	http://dx.doi.org/10.1074/jbc.M513481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547005	Green Submitted, hybrid			2022-12-27	WOS:000237336600023
J	Imai, M; Mizuno, T; Kawasaki, K				Imai, M; Mizuno, T; Kawasaki, K			Membrane fusion by single influenza hemagglutinin trimers - Kinetic evidence from image analysis of hemagglutinin-reconstituted vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL ENVELOPE PROTEIN; VIRUS HEMAGGLUTININ; CELL-FUSION; RECEPTOR-BINDING; SURFACE-DENSITY; INITIAL-STAGES; FLUORESCENCE; PORE; GLYCOPROTEIN; PH	Influenza hemagglutinin, the receptor-binding and membrane fusion protein of the virus, is a prototypic model for studies of biological membrane fusion in general. To elucidate the minimum number of hemagglutinin trimers needed for fusion, the kinetics of fusion induced by reconstituted vesicles of hemagglutinin was studied by using single-vesicle image analysis. The surface density of hemagglutinin fusion-activity sites on the vesicles was varied, while keeping the surface density of receptor-binding activity sites constant, by co-reconstitution of the fusogenic form of hemagglutinin, HA(1,2), and the non-fusogenic form, HA(0), at various HA(1,2):(HA(1,2) + HA(0)) ratios. The rate of fusion between the hemagglutinin vesicles containing a fluorescent lipid probe, octadecylrhodamine B, and red blood cell ghost membranes was estimated from the time distribution of fusion events of single vesicles observed by fluorescence microscopy. The best fit of a log-log plot of fusion rate versus the surface density of HA(1,2) exhibited a slope of 0.85, strongly supporting the hypothesis that single hemagglutinin trimers are sufficient for fusion. When only HA(1,2) (without HA(0)) was reconstituted on vesicles, the dependence of fusion rate on the surface density of HA(1,2) was distinct from that for the HA(1,2)-HA(0) co-reconstitution. The latter result suggested interference with fusion activity by hemagglutinin-receptor binding, without having to assume a fusion mechanism involving multiple hemagglutinin trimers.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, AIST, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 2080011, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Infectious Diseases (NIID)	Kawasaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, AIST, Tsukuba, Ibaraki 3058566, Japan.	kawasaki.k@aist.go.jp	Kawasaki, Kazunori/L-7007-2018	Kawasaki, Kazunori/0000-0001-8708-2261				ALFORD D, 1994, BIOCHEMISTRY-US, V33, P1977, DOI 10.1021/bi00174a002; Bentz J, 2000, BIOPHYS J, V78, P227, DOI 10.1016/S0006-3495(00)76587-8; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; CLAGUE MJ, 1991, J VIROL, V65, P2402, DOI 10.1128/JVI.65.5.2402-2407.1991; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; EDKERT DM, 2001, ANNU REV BIOCHEM, V70, P777; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GEORGIOU GN, 1989, FEBS LETT, V250, P487, DOI 10.1016/0014-5793(89)80782-3; Gunther-Ausborn S, 2000, J VIROL, V74, P2714, DOI 10.1128/JVI.74.6.2714-2720.2000; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Kanaseki T, 1997, J CELL BIOL, V137, P1041, DOI 10.1083/jcb.137.5.1041; KAWASAKI K, 1983, BIOCHIM BIOPHYS ACTA, V733, P286, DOI 10.1016/0005-2736(83)90534-5; KAWASAKI K, 1992, BIOCHEM BIOPH RES CO, V186, P378, DOI 10.1016/S0006-291X(05)80818-6; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Leikina E, 2000, BIOPHYS J, V79, P1415, DOI 10.1016/S0006-3495(00)76393-4; Lindau M, 2003, BBA-MOL CELL RES, V1641, P167, DOI 10.1016/S0167-4889(03)00085-5; LOWY RJ, 1990, P NATL ACAD SCI USA, V87, P1850, DOI 10.1073/pnas.87.5.1850; LUDWIG K, 1995, EUR BIOPHYS J BIOPHY, V24, P55, DOI 10.1007/BF00211399; MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133; Markosyan RM, 2000, MOL BIOL CELL, V11, P1143, DOI 10.1091/mbc.11.4.1143; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELIKYAN GB, 1995, J GEN PHYSIOL, V106, P783, DOI 10.1085/jgp.106.5.783; Millar BMG, 1999, VIROLOGY, V257, P415, DOI 10.1006/viro.1999.9624; Mittal A, 2001, BIOPHYS J, V81, P1521, DOI 10.1016/S0006-3495(01)75806-7; MIZUNO T, 1992, ANAL BIOCHEM, V207, P208, DOI 10.1016/0003-2697(92)90002-O; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; Ohki S, 1998, BIOCHEMISTRY-US, V37, P7496, DOI 10.1021/bi972016g; Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769; Sakai T, 2006, J VIROL, V80, P2013, DOI 10.1128/JVI.80.4.2013-2018.2006; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; Schoen P, 1996, FEBS LETT, V390, P315, DOI 10.1016/0014-5793(96)00682-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1995, BIOCHEMISTRY-US, V34, P1825, DOI 10.1021/bi00006a002; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VOLSKY DJ, 1978, FEBS LETT, V92, P190, DOI 10.1016/0014-5793(78)80751-0; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005	55	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12729	12735		10.1074/jbc.M600902200	http://dx.doi.org/10.1074/jbc.M600902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505474	hybrid			2022-12-27	WOS:000237134700065
J	Kurihara, R; Tohyama, Y; Matsusaka, S; Naruse, H; Kinoshita, E; Tsujioka, T; Katsumata, Y; Yamamura, H				Kurihara, R; Tohyama, Y; Matsusaka, S; Naruse, H; Kinoshita, E; Tsujioka, T; Katsumata, Y; Yamamura, H			Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION; RHO; ACTIVATION; EXPRESSION; KINASE; HL-60; CB2; 2-ARACHIDONOYLGLYCEROL; PHOSPHORYLATION; DIFFERENTIATION	The possible role of the peripheral cannabinoid receptor (CB2) in neutrophil migration was investigated by using human promyelocytic HL60 cells differentiated into neutrophil-like cells and human neutrophils isolated from whole blood. Cell surface expression of CB2 on HL60 cells, on neutrophil-like HL60 cells, and on human neutrophils was confirmed by flow cytometry. Upon stimulation with either of the CB2 ligands JWH015 and 2-arachidonoylglycerol (2-AG), neutrophil-like HL60 cells rapidly extended and retracted one or more pseudopods containing F-actin in different directions instead of developing front/rear polarity typically exhibited by migrating leukocytes. Activity of the Rho-GTPase RhoA decreased in response to CB2 stimulation, whereas Rac1, Rac2, and Cdc42 activity increased. Moreover, treatment of cells with RhoA-dependent protein kinase (p160-ROCK) inhibitor Y27632 yielded cytoskeletal organization similar to that of CB2-stimulated cells. In human neutrophils, neither JWH015 nor 2-AG induced motility or morphologic alterations. However, pretreatment of neutrophils with these ligands disrupted N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-induced front/rear polarization and migration and also substantially suppressed fMLP-induced RhoA activity. These results suggest that CB2 might play a role in regulating excessive inflammatory response by controlling RhoA activation, thereby suppressing neutrophil migration.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom, Kobe, Hyogo 6500017, Japan; Nagoya Univ, Grad Sch Med, Dept Legal Med & Bioeth, Nagoya, Aichi 4668550, Japan; Kawasaki Med Sch, Dept Lab Med & Clin Pathol, Kurashiki, Okayama 7010192, Japan	Kobe University; Nagoya University; Kawasaki Medical School	Tohyama, Y (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom, Kobe, Hyogo 6500017, Japan.	ytohyama@med.kobe-u.ac.jp						Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; Derocq JM, 2000, J BIOL CHEM, V275, P15621, DOI 10.1074/jbc.275.21.15621; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Deusch E, 2003, J NEUROIMMUNOL, V141, P99, DOI 10.1016/S0165-5728(03)00259-5; Dong XM, 2005, CURR BIOL, V15, P1874, DOI 10.1016/j.cub.2005.09.014; Eddy RJ, 2002, MOL BIOL CELL, V13, P4470, DOI 10.1091/mbc.E02-04-0241; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; Jorda MA, 2004, BLOOD, V104, P526, DOI 10.1182/blood-2003-12-4257; Jorda MA, 2002, BLOOD, V99, P2786; Joseph J, 2004, CANCER IMMUNOL IMMUN, V53, P723, DOI 10.1007/s00262-004-0509-9; Kaminski NE, 1998, J NEUROIMMUNOL, V83, P124, DOI 10.1016/S0165-5728(97)00228-2; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matsusaka S, 2005, BIOCHEM BIOPH RES CO, V328, P1163, DOI 10.1016/j.bbrc.2005.01.076; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; Miura Y, 2000, BLOOD, V96, P1733, DOI 10.1182/blood.V96.5.1733.h8001733_1733_1739; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Niggli V, 2003, J CELL SCI, V116, P813, DOI 10.1242/jcs.00306; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sacerdote P, 2000, J NEUROIMMUNOL, V109, P155, DOI 10.1016/S0165-5728(00)00307-6; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sugiura T, 2004, J PHARMACOL SCI, V96, P367, DOI 10.1254/jphs.FMJ04003X3; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Valk PJM, 1997, J VIROL, V71, P6796, DOI 10.1128/JVI.71.9.6796-6804.1997; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Xu JS, 2005, P NATL ACAD SCI USA, V102, P6884, DOI 10.1073/pnas.0502106102; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5	42	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12908	12918		10.1074/jbc.M510871200	http://dx.doi.org/10.1074/jbc.M510871200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513651	hybrid			2022-12-27	WOS:000237134700086
J	Kwon, JE; La, M; Oh, KH; Oh, YM; Kim, GR; Seol, JH; Baek, SH; Chiba, T; Tanaka, K; Bang, OS; Joe, CO; Chung, CH				Kwon, JE; La, M; Oh, KH; Oh, YM; Kim, GR; Seol, JH; Baek, SH; Chiba, T; Tanaka, K; Bang, OS; Joe, CO; Chung, CH			BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; E3 LIGASE; CELL-CYCLE; C-ELEGANS; TGF-BETA; GENE; COMPLEX; P53; DEGRADATION; FAMILY	Daxx is a multifunctional protein that regulates a variety of cellular processes, including transcription, cell cycle, and apoptosis. SPOP is a BTB (Bric-a-brac/Tramtrack/Broad complex) protein that constitutes Cul3-based ubiquitin ligases. Here we show that SPOP serves as an adaptor of Daxx for the ubiquitination by Cul3-based ubiquitin ligase and subsequent degradation by the proteasome. Expression of SPOP with Cul3 markedly reduced Daxx level, and this degradation was blocked by SPOP-specific short hairpin RNAs. Inhibition of the proteasome by MG132 caused the prevention of Daxx degradation in parallel with the accumulation of ubiquitinated Daxx. Expression of SPOP with Cul3 reversed Daxx-mediated repression of ETS1- and p53-dependent transcription, and short hairpin RNA-mediated knock down of SPOP blocked the recovery of their transcriptional activation. Furthermore, Daxx degradation led to the cleavage of poly(ADP-ribose) polymerase and the increase in the number of terminal deoxynucleotidyltransferase-mediated dUTP-fluorescein nick end-labeling-positive apoptotic cells. These results suggest that SPOP/Cul3-ubiquitin ligase plays an essential role in the control of Daxx level and, thus, in the regulation of Daxx-mediated cellular processes, including transcriptional regulation and apoptosis.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Tokyo Metropolitan Institute of Medical Science	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	cojoe@kaist.ac.kr; chchung@snu.ac.kr	Joe, Cheol O/C-1917-2011					Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Buttice G, 1996, ONCOGENE, V13, P2297; Cermak L, 2002, J BIOL CHEM, V277, P7955, DOI 10.1074/jbc.M108048200; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; La M, 2004, BIOCHEM BIOPH RES CO, V320, P760, DOI 10.1016/j.bbrc.2004.06.022; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; MIYASHITA T, 1995, CELL, V80, P293; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Srayko M, 2000, GENE DEV, V14, P1072; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhao LY, 2004, J BIOL CHEM, V279, P50566, DOI 10.1074/jbc.M406743200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	47	150	161	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12664	12672		10.1074/jbc.M600204200	http://dx.doi.org/10.1074/jbc.M600204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524876	hybrid			2022-12-27	WOS:000237134700057
J	Sun, W; Singh, S; Zhang, RG; Turnbull, JL; Christendat, D				Sun, W; Singh, S; Zhang, RG; Turnbull, JL; Christendat, D			Crystal structure of prephenate dehydrogenase from Aquifex aeolicus - Insights into the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORISMATE MUTASE; ESCHERICHIA-COLI; AUXIN TRANSPORT; PROTEIN; BIOSYNTHESIS; FLAVONOIDS; TYROSINE; BINDING; GENE; EXPRESSION	The enzyme prephenate dehydrogenase catalyzes the oxidative decarboxylation of prephenate to 4-hydroxyphenylpyruvate for the biosynthesis of tyrosine. Prephenate dehydrogenases exist as either monofunctional or bifunctional enzymes. The bifunctional enzymes are diverse, since the prephenate dehydrogenase domain is associated with other enzymes, such as chorismate mutase and 3-phosphoskimate 1-carboxyvinyltransferase. We report the first crystal structure of a monofunctional prephenate dehydrogenase enzyme from the hyper-thermophile Aquifex aeolicus in complex with NAD(+). This protein consists of two structural domains, a modified nucleotide-binding domain and a novel helical prephenate binding domain. The active site of prephenate dehydrogenase is formed at the domain interface and is shared between the subunits of the dimer. We infer from the structure that access to the active site is regulated via a gated mechanism, which is modulated by an ionic network involving a conserved arginine, Arg(250). In addition, the crystal structure reveals for the first time the positions of a number of key catalytic residues and the identity of other active site residues that may participate in the reaction mechanism; these residues include Ser(126) and Lys(246) and the catalytic histidine, His(147). Analysis of the structure further reveals that two secondary structure elements, beta 3 and beta 7, are missing in the prephenate dehydrogenase domain of the bifunctional chorismate mutase-prephenate dehydrogenase enzymes. This observation suggests that the two functional domains of chorismate mutase- prephenate dehydrogenase are interdependent and explains why these domains cannot be separated.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Midwest Ctr Struct Genom & Struct Biol, Argonne Natl Lab, Argonne, IL 60440 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H4B 1R6, Canada	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; Concordia University - Canada	Christendat, D (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	dinesh.christendat@utoronto.ca	Singh, Sasha/H-3612-2012	Singh, Sasha/0000-0003-0929-3164				Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; Bonner CA, 2004, BIOCHEM J, V382, P279, DOI 10.1042/BJ20031809; Brown DE, 2001, PLANT PHYSIOL, V126, P524, DOI 10.1104/pp.126.2.524; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buer CS, 2004, PLANT CELL, V16, P1191, DOI 10.1105/tpc.020313; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Chen SQ, 2003, EUR J BIOCHEM, V270, P757, DOI 10.1046/j.1432-1033.2003.03438.x; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Christendat D, 1998, BIOCHEMISTRY-US, V37, P15703, DOI 10.1021/bi981412b; Christendat D, 1999, BIOCHEMISTRY-US, V38, P4782, DOI 10.1021/bi982673o; COTTON RGH, 1965, BIOCHIM BIOPHYS ACTA, V100, P76, DOI 10.1016/0304-4165(65)90429-0; Dill GM, 2005, PEST MANAG SCI, V61, P219, DOI 10.1002/ps.1008; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; Guyon V, 2004, PLANT J, V39, P643, DOI 10.1111/j.1365-313X.2004.02162.x; HERMES JD, 1984, BIOCHEMISTRY-US, V23, P6263, DOI 10.1021/bi00320a057; HEYDE E, 1979, BIOCHEMISTRY-US, V18, P2766, DOI 10.1021/bi00580a012; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko M, 2003, J IND MICROBIOL BIOT, V30, P456, DOI 10.1007/s10295-003-0061-1; Kobayashi H, 2004, MOL MICROBIOL, V51, P335, DOI 10.1046/j.1365-2958.2003.03841.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Liu JS, 1997, NAT STRUCT BIOL, V4, P896, DOI 10.1038/nsb1197-896; Lokanath NK, 2005, J MOL BIOL, V352, P905, DOI 10.1016/j.jmb.2005.07.068; Matak-Vinkovic D, 2001, BIOCHEMISTRY-US, V40, P14493, DOI 10.1021/bi011020w; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; Memelink J, 2004, NAT BIOTECHNOL, V22, P1526, DOI 10.1038/nbt1204-1526; Mobley EM, 1999, GENE, V240, P115, DOI 10.1016/S0378-1119(99)00423-0; MOLLER BL, 1979, J BIOL CHEM, V254, P8575; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NOCEK B, 2005, J MOL BIOL; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rescigno A, 1998, BIOCHEM PHARMACOL, V56, P1089, DOI 10.1016/S0006-2952(98)00170-1; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Song J, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-13; Taylor LP, 2005, CURR OPIN PLANT BIOL, V8, P317, DOI 10.1016/j.pbi.2005.03.005; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TURNBULL J, 1991, BIOCHEMISTRY-US, V30, P7777, DOI 10.1021/bi00245a016; XIA TH, 1992, J GEN MICROBIOL, V138, P1309, DOI 10.1099/00221287-138-7-1309; Xie G, 2000, COMP BIOCHEM PHYS C, V125, P65, DOI 10.1016/S0742-8413(99)00090-0	45	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12919	12928		10.1074/jbc.M511986200	http://dx.doi.org/10.1074/jbc.M511986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513644	hybrid			2022-12-27	WOS:000237134700087
J	Huang, Y; Niwa, J; Sobue, G; Breitwieser, GE				Huang, Y; Niwa, J; Sobue, G; Breitwieser, GE			Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; N-LINKED GLYCOSYLATION; EXTRACELLULAR DOMAIN; UBIQUITYLATED INCLUSIONS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; CELL-SURFACE; LEWY BODIES; PROTEIN; DIMERIZATION	Calcium-sensing receptors ( CaR) contribute to regulation of systemic calcium homeostasis by activation of G(q)- and G(i)-linked signaling pathways in the parathyroids, kidney, and intestine. Little is known about the mechanisms regulating CaR synthesis and degradation. Screening of a human kidney yeast two-hybrid library identified the E3 ubiquitin ligase dorfin as a binding partner for the intracellular carboxyl terminus of CaR. Interaction between CaR and dorfin was confirmed by coimmunoprecipitation from HEK293 cells. Ubiquitination of CaR was observed in the presence of the proteasomal inhibitor MG132; mutation of all putative intracellular loop and carboxyl-terminal lysine residues abolished ubiquitination of CaR. Coexpression with dorfin decreased the amount of total CaR protein and increased CaR ubiquitination, whereas a dominant negative fragment of dorfin had opposite effects. The AAA-ATPase p97/valosin-containing protein associates with both CaR and dorfin in HEK293 cells. Treatment with tunicamycin, ininhibitor of N-linked glycosylation, induced the appearance of the unglycosylated 115-kDa CaR form, which was further increased by exposure to MG132, or upon transfection with a dorfin dominant negative construct, suggesting that dorfin-mediated proteasomal degradation of immature CaR occurs from the endoplasmic reticulum. Because endogenous CaR in Madin-Darby canine kidney cells is also subject to degradation from the endoplasmic reticulum, dorfin-mediated ubiquitination may contribute to a general mechanism for CaR quality control during biosynthesis.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan	Geisinger Medical Center; Syracuse University; Nagoya University	Breitwieser, GE (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	gebreitwieser@geisinger.edu		Breitwieser, Gerda/0000-0001-9081-0362	NIGMS NIH HHS [R01 GM077563, R01 GM077563-02, GM58578] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578, R01GM077563] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur JM, 2000, BIOCHEM BIOPH RES CO, V275, P538, DOI 10.1006/bbrc.2000.3226; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hishikawa N, 2003, AM J PATHOL, V163, P609, DOI 10.1016/S0002-9440(10)63688-7; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Ishigaki S, 2004, J BIOL CHEM, V279, P51376, DOI 10.1074/jbc.M406683200; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; PEACE SHS, 1997, J ENDOCRINOL, V154, P371; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Saliba RS, 2002, J CELL SCI, V115, P2907; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200	43	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11610	11617		10.1074/jbc.M513552200	http://dx.doi.org/10.1074/jbc.M513552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513638	hybrid			2022-12-27	WOS:000236988100024
J	Kudo, M; Canfield, WM				Kudo, M; Canfield, WM			Structural requirements for efficient processing and activation of recombinant human UDP-N-acetylglucosamine : Lysosomal-enzyme-N-acetylglucosamine-1-phosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE ALPHA/BETA-SUBUNITS; PSEUDO-HURLER POLYDYSTROPHY; MUCOLIPIDOSIS-II; PURIFICATION; MUTATIONS; OLIGOSACCHARIDES; IDENTIFICATION; ENDOPROTEASE; PROTEINS	Mannose 6-phosphate-modified N-glycans are the determinant for intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome. The enzyme responsible for the initial step in the synthesis of mannose 6-phosphate is UDP-N-acetylglucosamine: lysosomalenzyme-N- acetylglucosmine-1-phosphotransferase(GlcNAc-phosphotransferase). GlcNAc-phosphotransferase is a multisubunit enzyme with an alpha(2)beta(2)gamma(2) arrangement that requires a detergent for solubilization. Recent cloning of cDNAs and genes encoding these subunits revealed that the alpha- and beta-subunits are encoded by a single gene as a precursor, whereas the gamma-subunit is encoded by a second gene. The hydropathy plots of the deduced amino acid sequences suggested that the alpha- and beta-subunits but not the gamma-subunit contain transmembrane domains. Access to these cDNAs allowed us to express a soluble form of human recombinant GlcNAc-phosphotransferase by removing the putative transmembrane and cytoplasmic domains from the alpha- and beta-subunits. Because this modification prevented precursor processing to mature alpha- and beta-subunits, the native cleavage sequence was replaced by a cleavage site for furin. When the modified alpha/beta-subunits (alpha'/beta'-subunits) precursor and wild type gamma-subunit cDNAs were co-expressed in 293T or CHO-K1 cells, a furin-like protease activity in these cells cleaved the precursor and produced an active and processed soluble GlcNAc-phosphotransferase with an alpha'(2)beta'(2)gamma(2)-subunits arrangement. Recombinant soluble GlcNAc-phosphotransferase exhibited specific activity and substrate preferences similar to the wild type bovine GlcNAc-phosphotransferase and was able to phosphorylate a lysosomal hydrolase, acid alpha-glucosidase in vitro.	Genzyme Corp, Oklahoma City, OK 73104 USA	Sanofi-Aventis; Genzyme Corporation	Canfield, WM (corresponding author), Genzyme Corp, 800 Res Pkwy,Suite 200, Oklahoma City, OK 73104 USA.	William.Canfield@genzyme.com						Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kudo M, 2006, AM J HUM GENET, V78, P451, DOI 10.1086/500849; Kudo M, 2005, J BIOL CHEM, V280, P36141, DOI 10.1074/jbc.m509008200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Tiede S, 2005, NAT MED, V11, P1109, DOI 10.1038/nm1305; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1980, J BIOL CHEM, V255, P847; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717	24	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11761	11768		10.1074/jbc.M513717200	http://dx.doi.org/10.1074/jbc.M513717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507578	hybrid			2022-12-27	WOS:000236988100041
J	Kumari, K; Baggenstoss, BA; Parker, AL; Weigel, PH				Kumari, K; Baggenstoss, BA; Parker, AL; Weigel, PH			Mutation of two intramembrane polar residues conserved within the hyaluronan synthase family alters hyaluronan product size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; MOLECULAR-CLONING; EXPRESSION; GENE; BIOSYNTHESIS; PROTEINS; IDENTIFICATION; ISOFORMS; CELLS; LOOP	We identified two conserved polar amino acids within different membrane domains (MD) of Streptococcus equisimilis hyaluronan synthase (seHAS), Lys(48) in MD2 and Glu(327) in MD4. In eukaryotic HASs, the position of the Glu is very similar and the Lys is replaced by a conserved polar Gln. To assess whether Lys(48) and Glu(327) interact or influence seHAS activity, we investigated the effects of changing Lys(48) to Arg or Glu and Glu(327) to Lys, Asp, or Gln. Mutants, including a double switch variant with Lys(48) and Glu(327) exchanged, were expressed and assayed in Escherichia coli membranes. SeHAS(E327Q) and seHAS(E327K) were expressed at low levels, whereas seHAS(E327D) and the Lys(48) mutants were expressed well. The specific enzyme activities ( relative to wild type) were 17 and 7% for the K48R and K48E mutants and 26 and 38% for the E327Q and E327D mutants, respectively. In contrast, seHAS( E327K) showed only 0.16% of wild-type activity but was rescued over 46-fold by changing Lys(48) to Glu. Expression of the seHAS( E327K, K48E) protein was also rescued to near wild-type levels. Based on size exclusion chromatography coupled to multiangle laser light scattering analysis, all the variants synthesized hyaluronan ( HA) of smaller weight-average molar mass than wild-type enzyme (3.6 MDa); the smallest HA ( similar to 0.6 MDa) was made by seHAS( E327K, K48E) and seHAS( K48E). The results indicate that Glu(327) within MD4 is a critical residue for the stability of seHAS, that it may interact with Lys(48) within MD2, and that these residues are involved in the ability of HAS to synthesize very large HA.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	paul-weigel@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Abramson J, 2004, MOL MEMBR BIOL, V21, P227, DOI 10.1080/09687680410001716862; BAGGENSTOSS BA, 2006, IN PRESS ANAL BIOCH; Bodevin-Authelet S, 2005, J BIOL CHEM, V280, P8813, DOI 10.1074/jbc.M412803200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Heldermon C, 2000, INT CONGR SER, V1196, P41; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; Kumari K, 2005, GLYCOBIOLOGY, V15, P529, DOI 10.1093/glycob/cwi030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Meyer K, 1934, J BIOL CHEM, V107, P629; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Nardini M, 2004, GENE EXPR PATTERNS, V4, P303, DOI 10.1016/j.modgep.2003.10.006; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Tien JYL, 2005, DEV DYNAM, V233, P130, DOI 10.1002/dvdy.20328; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005	44	25	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11755	11760		10.1074/jbc.M600727200	http://dx.doi.org/10.1074/jbc.M600727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505475	hybrid			2022-12-27	WOS:000236988100040
J	Ostareck-Lederer, A; Ostareck, DH; Rucknagel, KP; Schierhorn, A; Moritz, B; Huttelmaier, S; Flach, N; Handoko, L; Wahle, E				Ostareck-Lederer, A; Ostareck, DH; Rucknagel, KP; Schierhorn, A; Moritz, B; Huttelmaier, S; Flach, N; Handoko, L; Wahle, E			Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; N-METHYLTRANSFERASE; HNRNP-K; IN-VITRO; ERYTHROID-DIFFERENTIATION; METHYLATION; EXPORT; SUBSTRATE; PRMT1; PHOSPHORYLATION	Arginine methylation is a post-translational modification found in many RNA-binding proteins. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) from HeLa cells was shown, by mass spectrometry and Edman degradation, to contain asymmetric N-G,N-G-dimethylarginine at five positions in its amino acid sequence (Arg(256), Arg(258), Arg(268), Arg(296), and Arg(299)). Whereas these five residues were quantitatively modified, Arg(303) was asymmetrically dimethylated in <33% of hnRNP K and Arg(287) was monomethylated in <10% of the protein. All other arginine residues were unmethylated. Protein-arginine methyltransferase 1 was identified as the only enzyme methylating hnRNP K in vitro and in vivo. An hnRNP K variant in which the five quantitatively modified arginine residues had been substituted was not methylated. Methylation of arginine residues by protein-arginine methyltransferase 1 did not influence the RNA-binding activity, the translation inhibitory function, or the cellular localization of hnRNP K but reduced the interaction of hnRNP K with the tyrosine kinase c-Src. This led to an inhibition of c-Src activation and hnRNP K phosphorylation. These findings support the role of arginine methylation in the regulation of protein-protein interactions.	Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Saale, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Saale, Germany; Univ Halle Wittenberg, ZAMED, D-06120 Halle, Saale, Germany; Univ Wurzburg, Bioctr, Inst Biochem, D-97074 Wurzburg, Germany	Martin Luther University Halle Wittenberg; Max Planck Society; Martin Luther University Halle Wittenberg; University of Wurzburg	Ostareck-Lederer, A (corresponding author), Univ Halle Wittenberg, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.	aostareck@biochemtech.uni-halle.de	Handoko, Lusy/C-3645-2017; Hüttelmaier, Stefan/AAQ-1203-2021	Handoko, Lusy/0000-0001-7989-4243; Ostareck-Lederer, Antje/0000-0003-0733-7071; Wahle, Elmar/0000-0003-2504-0677; Ostareck, Dirk/0000-0001-9406-7190				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen WG, 2004, J IMMUNOL, V172, P6744, DOI 10.4049/jimmunol.172.11.6744; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Hsu IW, 2005, J BIOL CHEM, V280, P34507, DOI 10.1074/jbc.M507658200; Huang HM, 2002, J BIOCHEM, V132, P813, DOI 10.1093/oxfordjournals.jbchem.a003291; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Huttelmaier S, 2001, J CELL BIOL, V155, P775, DOI 10.1083/jcb.200105044; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; LEE TD, 1990, METHOD ENZYMOL, V193, P361, DOI 10.1016/0076-6879(90)93427-M; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McBride AE, 2005, J BIOL CHEM, V280, P30888, DOI 10.1074/jbc.M505831200; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu C, 2004, MOL CELL BIOL, V24, P10742, DOI 10.1128/MCB.24.24.10742-10756.2004; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6	73	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11115	11125		10.1074/jbc.M513053200	http://dx.doi.org/10.1074/jbc.M513053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492668	hybrid			2022-12-27	WOS:000236822200054
J	Prechtel, AT; Chemnitz, J; Schirmer, S; Ehlers, C; Langbein-Detsch, I; Stulke, J; Dabauvalle, MC; Kehlenbach, RH; Hauber, J				Prechtel, AT; Chemnitz, J; Schirmer, S; Ehlers, C; Langbein-Detsch, I; Stulke, J; Dabauvalle, MC; Kehlenbach, RH; Hauber, J			Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BINDING PROTEIN HUR; IMMUNODEFICIENCY-VIRUS REV; DEPENDENT MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; EXPORT RECEPTOR CRM1; NUCLEAR-PORE COMPLEX; DENDRITIC CELLS; GENE-EXPRESSION; NUCLEOCYTOPLASMIC TRANSPORT	Dendritic cells are the most potent of the antigen-presenting cells and are characterized by surface expression of CD83. Here, we show that the coding region of CD83 mRNA contains a novel cis-acting structured RNA element that binds to HuR, a member of the ELAV family of AU-rich element RNA-binding proteins. Transient transfection of mammalian cells demonstrated that this CD83 mRNA-derived element acts as a post-transcriptional regulatory element in cells over-expressing HuR. Notably, binding of HuR to the CD83 post-transcriptional regulatory element did not affect mRNA stability. Using RNA interference, we show that HuR mediated efficient expression of CD83. In particular, HuR was required for cytoplasmic accumulation of CD83 transcripts. Likewise, inhibition of the CRM1 nuclear export pathway by leptomycin B or overexpression of a defective form of the nucleoporin Nup214/CAN diminished cytoplasmic CD83 mRNA levels. In summary, the data presented demonstrate that the HuR-CRM1 axis affects the nucleocytoplasmic translocation of CD83 mRNA under regular physiological conditions.	Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Erlangen Nurnberg, Inst Microbiol Biochem & Genet, D-91054 Erlangen, Germany; Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	Heinrich Pette Institute; University of Erlangen Nuremberg; University of Gottingen; University of Wurzburg; University of Gottingen	Hauber, J (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	joachim.hauber@hpi.uni-hamburg.de	Stülke, Jörg/AAD-1600-2021	Stulke, Jorg/0000-0001-5881-5390; Kehlenbach, Ralph/0000-0003-4920-9916				Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Berchtold S, 2002, IMMUNOBIOLOGY, V205, P231, DOI 10.1078/0171-2985-00128; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fan XHC, 1997, GENE DEV, V11, P2557, DOI 10.1101/gad.11.19.2557; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Hieronymus H, 2004, GENE DEV, V18, P2845, DOI 10.1101/gad.1256904; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kimura T, 2004, J CELL SCI, V117, P2259, DOI 10.1242/jcs.01076; KING PH, 1994, J NEUROSCI, V14, P1943; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZLOW EJ, 1993, BLOOD, V81, P454, DOI 10.1182/blood.V81.2.454.454; Kruse M, 2000, J VIROL, V74, P7127, DOI 10.1128/JVI.74.15.7127-7136.2000; Kruse M, 2000, J EXP MED, V191, P1581, DOI 10.1084/jem.191.9.1581; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Lechmann M, 2002, INT ARCH ALLERGY IMM, V129, P113, DOI 10.1159/000065883; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lewis T, 1998, J BIOL CHEM, V273, P13781, DOI 10.1074/jbc.273.22.13781; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; Quinn JG, 2001, ANAL BIOCHEM, V290, P36, DOI 10.1006/abio.2000.4919; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rosorius O, 1999, J CELL SCI, V112, P2369; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Sarkar B, 2003, J BIOL CHEM, V278, P20700, DOI 10.1074/jbc.M301176200; Scholler N, 2002, J IMMUNOL, V168, P2599, DOI 10.4049/jimmunol.168.6.2599; SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; ZHOU LJ, 1992, J IMMUNOL, V149, P735; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	96	63	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10912	10925		10.1074/jbc.M510306200	http://dx.doi.org/10.1074/jbc.M510306200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484227	hybrid			2022-12-27	WOS:000236822200032
J	Ahn, JW; Verma, R; Kim, M; Lee, JY; Kim, YK; Bang, JW; Reiter, WD; Pai, HS				Ahn, JW; Verma, R; Kim, M; Lee, JY; Kim, YK; Bang, JW; Reiter, WD; Pai, HS			Depletion of UDP-D-apiose/UDP-D-xylose synthases results in rhamnogalacturonan-II deficiency, cell wall thickening, and cell death in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; PECTIC POLYSACCHARIDE; GENE-EXPRESSION; MUTANT; BORON; DIFFERENTIATION; PROLIFERATION; PROTOPLASTS; ACTIVATION; PROTEASOME	(D)- Apiose serves as the binding site for borate cross- linking of rhamnogalacturonan II ( RG- II) in the plant cell wall, and biosynthesis of (D)- apiose involves UDP- (D)- apiose/ UDP- (D)- xylose synthase catalyzing the conversion of UDP- (D)- glucuronate to a mixture of UDP- (D)- apiose and UDP- (D)- xylose. In this study we have analyzed the cellular effects of depletion of UDP- D- apiose/ UDP- (D)- xylose synthases in plants by using virus- induced gene silencing ( VIGS) of NbAXS1 in Nicotiana benthamiana. The recombinant NbAXS1 protein exhibited UDP- (D)-apiose/ UDP- (D)- xylose synthase activity in vitro. The NbAXS1 gene was expressed in all major plant organs, and an NbAXS1- green fluorescent protein fusion protein was mostly localized in the cytosol. VIGS of NbAXS1 resulted in growth arrest and leaf yellowing. Microscopic studies of the leaf cells of the NbAXS1 VIGS lines revealed cell death symptoms including cell lysis and disintegration of cellular organelles and compartments. The cell death was accompanied by excessive formation of reactive oxygen species and by induction of various protease genes. Furthermore, abnormal wall structure of the affected cells was evident including excessive cell wall thickening and wall gaps. The mutant cell walls contained significantly reduced levels of D- apiose as well as 2- O- methyl- (L)- fucose and 2- O- methyl- (D)- xylose, which serve as markers for the RG- II side chains B and A, respectively. These results suggest that VIGS of NbAXS1 caused a severe deficiency in the major side chains of RG- II and that the growth defect and cell death was likely caused by structural alterations in RG- II due to a (D)- apiose deficiency.	Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Korea Res Inst Biosci & Biotechnol, BioNanotechnol Ctr, Taejon 305333, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Connecticut; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Pai, HS (corresponding author), Yonsei Univ, Dept Biol, Seoul 120749, South Korea.	hspai@yonsei.ac.kr						Abel S, 1998, METH MOL B, V82, P209; Ahn JW, 2004, PLANT J, V38, P969, DOI 10.1111/j.1365-313X.2004.02102.x; Beers EP, 2000, PLANT MOL BIOL, V44, P399, DOI 10.1023/A:1026556928624; Bethke PC, 2001, PLANT J, V25, P19, DOI 10.1046/j.1365-313x.2001.00930.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Demura T, 2002, P NATL ACAD SCI USA, V99, P15794, DOI 10.1073/pnas.232590499; Dormann P, 1998, PLANT J, V13, P641, DOI 10.1046/j.1365-313X.1998.00067.x; Ellis C, 2002, PLANT CELL, V14, P1557, DOI 10.1105/tpc.002022; Golovchenko VV, 2002, PHYTOCHEMISTRY, V60, P89, DOI 10.1016/S0031-9422(02)00040-7; HAHLBROCK K, 1976, EUR J BIOCHEM, V61, P199, DOI 10.1111/j.1432-1033.1976.tb10012.x; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Ishii T, 2001, PLANT PHYSIOL, V126, P1698, DOI 10.1104/pp.126.4.1698; Iwai H, 2002, P NATL ACAD SCI USA, V99, P16319, DOI 10.1073/pnas.252530499; Kim M, 2003, J BIOL CHEM, V278, P19406, DOI 10.1074/jbc.M210539200; Kobayashi M, 1996, PLANT PHYSIOL, V110, P1017, DOI 10.1104/pp.110.3.1017; Lee HS, 1996, PLANT J, V9, P613, DOI 10.1046/j.1365-313X.1996.9050613.x; Lee SS, 2003, PLANT J, V33, P825, DOI 10.1046/j.1365-313X.2003.01672.x; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Matoh T, 2000, PLANT CELL PHYSIOL, V41, P363, DOI 10.1093/pcp/41.3.363; Molhoj M, 2003, PLANT J, V35, P693, DOI 10.1046/j.1365-313X.2003.01841.x; Noguchi K, 2003, J PLANT NUTR SOIL SC, V166, P175, DOI 10.1002/jpln.200390025; O'Neill MA, 2004, ANNU REV PLANT BIOL, V55, P109, DOI 10.1146/annurev.arplant.55.031903.141750; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; Park JA, 2005, PLANT J, V42, P153, DOI 10.1111/j.1365-313X.2005.02361.x; Pellerin P, 1996, CARBOHYD RES, V290, P183, DOI 10.1016/0008-6215(96)00139-5; Perez S, 2003, BIOCHIMIE, V85, P109, DOI 10.1016/S0300-9084(03)00053-1; Pontier D, 1998, MOL PLANT MICROBE IN, V11, P544, DOI 10.1094/MPMI.1998.11.6.544; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ratcliff F, 2001, PLANT J, V25, P237, DOI 10.1046/j.0960-7412.2000.00942.x; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; STEVENSON TT, 1988, CARBOHYD RES, V182, P207, DOI 10.1016/0008-6215(88)84004-7; Takano J, 2002, NATURE, V420, P337, DOI 10.1038/nature01139; Vanzin GF, 2002, P NATL ACAD SCI USA, V99, P3340, DOI 10.1073/pnas.052450699; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Willats WGT, 2001, PLANT MOL BIOL, V47, P9, DOI 10.1023/A:1010662911148; Ye ZH, 1996, PLANT MOL BIOL, V30, P1233, DOI 10.1007/BF00019555; Zhang H, 2001, ANAL BIOCHEM, V298, P170, DOI 10.1006/abio.2001.5348	37	80	86	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13708	13716		10.1074/jbc.M512403200	http://dx.doi.org/10.1074/jbc.M512403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549428	hybrid			2022-12-27	WOS:000237336600081
J	Jensen, PJ; Gitlin, JD; Carayannopoulos, MO				Jensen, PJ; Gitlin, JD; Carayannopoulos, MO			GLUT1 deficiency links nutrient availability and apoptosis during embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTERS; ZEBRAFISH; SURVIVAL; MODEL; PHOSPHORYLATION; EMBRYOGENESIS; GLUCOKINASE; GLYCOLYSIS; SIGNALS; SYSTEM	GLUT1 is essential for human brain development and function, as evidenced by the severe epileptic encephalopathy observed in children with GLUT1 deficiency syndrome resulting from inherited loss- of- function mutations in the gene encoding this facilitative glucose transporter. To further elucidate the pathophysiology of this disorder, the zebrafish orthologue of human GLUT1 was identified, and expression of this gene was abrogated during early embryonic development, resulting in a phenotype of aberrant brain organogenesis consistent with the observed expression of Glut1 in the embryonic tectum and specifically rescued by human GLUT1 mRNA. Affected embryos displayed impaired glucose uptake concomitant with increased neural cell apoptosis and subsequent ventricle enlargement, trigeminal ganglion cell loss, and abnormal hindbrain architecture. Strikingly, inhibiting expression of the zebrafish orthologue of the proapoptotic protein Bad resulted in complete rescue of this phenotype, and this occurred even in the absence of restoration of apparent glucose uptake. Taken together, these studies describe a tractable system for elucidating the cellular and molecular mechanisms of Glut1 deficiency and provide compelling in vivo genetic evidence directly linking nutrient availability and activation of mitochondria- dependent apoptotic mechanisms during embryonic brain development.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Carayannopoulos, MO (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave,Campus, St Louis, MO 63110 USA.	carayannopoulos@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01459] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, DK44464, P30 DK056341-05S2, P30 DK056341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelilah S, 1996, DEVELOPMENT, V123, P217; Ackermann GE, 2003, FRONT BIOSCI-LANDMRK, V8, pD1227, DOI 10.2741/1092; Bernhardt RR, 1999, J NEUROBIOL, V38, P137, DOI 10.1002/(SICI)1097-4695(199901)38:1<137::AID-NEU11>3.0.CO;2-P; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Driever W, 1996, DEVELOPMENT, V123, P37; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KELLER K, 1989, J BIOL CHEM, V264, P18884; Kim WH, 2005, DIABETES, V54, P2602, DOI 10.2337/diabetes.54.9.2602; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Nusslein-Volhard C, 2002, ZEBRAFISH; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Scholpp S, 2001, GENESIS, V30, P129, DOI 10.1002/gene.1047; Taylor MR, 2004, P NATL ACAD SCI USA, V101, P4584, DOI 10.1073/pnas.0307074101; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Virgintino D, 2000, DEV BRAIN RES, V123, P95, DOI 10.1016/S0165-3806(00)00086-9; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; WILSON SW, 1990, DEVELOPMENT, V108, P121; Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763	25	64	66	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13382	13387		10.1074/jbc.M601881200	http://dx.doi.org/10.1074/jbc.M601881200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543226	hybrid			2022-12-27	WOS:000237336600044
J	Choi, S; Kim, JH; Roh, EJ; Ko, MJ; Jung, JE; Kim, HJ				Choi, S; Kim, JH; Roh, EJ; Ko, MJ; Jung, JE; Kim, HJ			Nuclear factor-kappa B activated by capacitative Ca2+ entry enhances muscarinic receptor-mediated soluble amyloid precursor protein (sAPP alpha) release in SH-SY5Y cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; POTENT INHIBITORS; CALCIUM; KINASE; SURVIVAL; NEURONS; COMPLEX; FORM; PHOSPHORYLATION	Gq/11 protein-coupled muscarinic receptors are known to regulate the release of soluble amyloid precursor protein (sAPP alpha) produced by alpha-secretase processing; however, their signaling mechanisms remain to be elucidated. It has been reported that a muscarinic agonist activates nuclear factor (NF)-kappa B, a transcription factor that has been shown to play an important role in the Alzheimer disease brain, and that NF-kappa B activation is regulated by intracellular Ca2+ level. In the present study, we investigated whether NF-kappa B activation plays a role in muscarinic receptor-mediated sAPP alpha release enhancement and contributes to a changed capacitative Ca2+ entry (CCE), which was suggested to be involved in the muscarinic receptor-mediated stimulation of sAPP alpha release. Muscarinic receptor-mediated NF-kappa B activation was confirmed by observing the translocation of the active subunit (p65) of NF-kappa B to the nucleus by the muscarinic agonist, oxotremorine M (oxoM), in SH-SY5Y neuroblastoma cells expressing muscarinic receptors that are predominantly of the M3 subtype. NF-kappa B activation and sAPP alpha release enhancement induced by oxoM were inhibited by NF-kappa B inhibitors, such as an NF-kappa B peptide inhibitor (SN50), an I kappa B alpha kinase inhibitor (BAY11-7085), a proteasome inhibitor (MG132), the inhibitor of proteasome activity and I kappa B phosphorylation, pyrrolidine dithiocarbamate, the novel NF-kappa B activation inhibitor (6-amino-4-(4-phenoxyphenylethylamino) quinazoline), and by an intracellular Ca2+ chelator (TMB-8). Furthermore, both oxoM-induced NF-kappa B activation and sAPP alpha release were antagonized by CCE inhibitors (gadolinium or SKF96365) but not by voltage-gated Ca2+-channel blockers. On the other hand, treatment of cells with NF-kappa B inhibitors (SN50, BAY11-7085, MG132, or pyrrolidine dithiocarbamate) did not inhibit muscarinic receptor-mediated CCE. These findings provide evidence for the involvement of NF-kappa B regulated by CCE in muscarinic receptor-mediated sAPP alpha release enhancement.	Ewha Womans Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 120750, South Korea	Ewha Womans University	Kim, HJ (corresponding author), Ewha Womans Univ, Coll Pharm, Pharmaceut Sci Res Inst, 11-1 Daehyun Dong, Seoul 120750, South Korea.	hjkim@ewha.ac.kr						Barger SW, 1996, MOL BRAIN RES, V40, P116; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Camandola S, 2005, J BIOL CHEM, V280, P22287, DOI 10.1074/jbc.M410923200; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Daniel KG, 2005, BREAST CANCER RES, V7, pR897, DOI 10.1186/bcr1322; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FERNANDO KC, 1994, BBA-MOL CELL RES, V1222, P383, DOI 10.1016/0167-4889(94)90044-2; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kim JH, 2006, J NEUROCHEM, V97, P245, DOI 10.1111/j.1471-4159.2006.03734.x; Kim Y, 2004, BIOCHEM BIOPH RES CO, V314, P695, DOI 10.1016/j.bbrc.2003.12.153; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Li XH, 1996, J NEUROSCI, V16, P5914; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MASON MJ, 1993, AM J PHYSIOL, V264, pC564; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Okamura H, 2001, CURR OPIN CELL BIOL, V13, P239, DOI 10.1016/S0955-0674(00)00203-9; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Petegnief V, 2004, NEUROCHEM INT, V44, P287, DOI 10.1016/S0197-0186(03)00136-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Stein TD, 2002, J NEUROSCI, V22, P7380; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Todisco A, 1999, BIOCHEM BIOPH RES CO, V261, P877, DOI 10.1006/bbrc.1999.1141; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; UNLAP T, 1995, NEUROSCI LETT, V198, P41, DOI 10.1016/0304-3940(95)11963-W; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	53	31	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12722	12728		10.1074/jbc.M601018200	http://dx.doi.org/10.1074/jbc.M601018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16490783	hybrid			2022-12-27	WOS:000237134700064
J	du Plessis, DJF; Nouwen, N; Driessen, AJM				du Plessis, DJF; Nouwen, N; Driessen, AJM			Subunit a of cytochrome o oxidase requires both YidC and SecYEG for membrane insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; BO(3) UBIQUINOL OXIDASE; COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN INSERTION; PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; NASCENT FTSQ; SECA; BIOGENESIS	The Escherichia coli YidC protein belongs to the Oxa1 family of membrane proteins that facilitate the insertion of membrane proteins. Depletion of YidC in E. coli leads to a specific defect in the functional assembly of major energy transducing complexes such as the F1F0 ATPase and cytochrome bo(3) oxidase. Here we report on the in vitro reconstitution of the membrane insertion of the CyoA subunit of cytochrome bo(3) oxidase. Efficient insertion of in vitro synthesized pre-CyoA into proteoliposomes requires YidC, SecYEG, and SecA and occurs independently of the proton motive force. These data demonstrate that pre-CyoA is a substrate of a novel pathway that involves both SecYEG and YidC.	Univ Groningen, Groningen Biomol Sci & Biotechnol, Dept Mol Microbiol, Inst Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol, Dept Mol Microbiol, Inst Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Abramson J, 2000, ACTA CRYSTALLOGR D, V56, P1076, DOI 10.1107/S0907444900007605; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shimohata N, 2005, J BACTERIOL, V187, P3997, DOI 10.1128/JB.187.12.3997-4004.2005; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Laan M, 2005, CURR OPIN MICROBIOL, V8, P182, DOI 10.1016/j.mib.2005.02.004; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2004, J BIOL CHEM, V279, P1659, DOI 10.1074/jbc.M306527200; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	31	70	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12248	12252		10.1074/jbc.M600048200	http://dx.doi.org/10.1074/jbc.M600048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513637	hybrid, Green Published			2022-12-27	WOS:000237134700008
J	Gomes, B; Savignac, M; Cabral, MD; Paulet, P; Moreau, M; Leclerc, C; Feil, R; Hofmann, F; Guery, JC; Dietrich, G; Pelletier, L				Gomes, B; Savignac, M; Cabral, MD; Paulet, P; Moreau, M; Leclerc, C; Feil, R; Hofmann, F; Guery, JC; Dietrich, G; Pelletier, L			The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; SIGNALING PATHWAY; IL-4 PRODUCTION; NITRIC-OXIDE; PROTEIN; CHANNELS; CGMP; ACTIVATION; PHOSPHODIESTERASE-4; DIFFERENTIATION	Th2 lymphocytes differ from other CD4(+) T lymphocytes not only by their effector tasks but also by their T cell receptor (TCR)-dependent signaling pathways. We previously showed that dihydropyridine receptors ( DHPR) involved in TCR-induced calcium inflow were selectively expressed in Th2 cells. In this report, we studied whether cGMP-dependent protein kinase G (PKG) activation was implicated in the regulation of DHPR-dependent calcium response and cytokine production in Th2 lymphocytes. The contribution of cGMP in Th2 signaling was supported by the following results: 1) TCR activation elicited cGMP production, which triggered calcium increase responsible for nuclear factor of activated T cell translocation and Il4 gene expression; 2) guanylate cyclase activation by nitric oxide donors increased intracellular cGMP concentration and induced calcium inflow and IL-4 production; 3) reciprocally, guanylate cyclase inhibition reduced calcium response and Th2 cytokine production associated with TCR activation. In addition, DHPR blockade abolished cGMP-induced [Ca2+](i) increase, indicating that TCR-induced DHP-sensitive calcium inflow is dependent on cGMP in Th2 cells. Th2 lymphocytes from PKG1-deficient mice displayed impaired calcium signaling and IL-4 production, as did wild-type Th2 cells treated with PKG inhibitors. Altogether, our data indicate that, in Th2 cells, cGMP is produced upon TCR engagement and activates PKG, which controls DHP-sensitive calcium inflow and Th2 cytokine production.	INSERM, Ctr Physiopathol Toulouse Purpan, U563, F-31024 Toulouse 3, France; Univ Toulouse 3, CNRS, UMR 5547, F-31062 Toulouse 4, France; Tech Univ Munich, Inst Pharmakol & Toxikol, G-80802 Munich, Germany	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Technical University of Munich	Pelletier, L (corresponding author), CHU Purpan, INSERM, U563, Dept Genet, Pl Dr Baylac,Pavill Lefebvre,BP 3028, F-31024 Toulouse 3, France.	Lucette.Pelletier@toulouse.inserm.fr	Dietrich, Gilles/AAC-2119-2020; Feil, Robert/B-8918-2014; Leclerc, Catherine/O-6514-2015; Savignac, Magali/K-1757-2014; GUERY, Jean-Charles/G-1452-2013; Pelletier, Lucette/L-2956-2014	Dietrich, Gilles/0000-0002-2232-1716; Feil, Robert/0000-0002-7335-4841; GUERY, Jean-Charles/0000-0003-4499-3270; 				Abrahamsen H, 2004, J IMMUNOL, V173, P4847, DOI 10.4049/jimmunol.173.8.4847; Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Boswell-Smith V, 2006, BRIT J PHARMACOL, V147, pS252, DOI 10.1038/sj.bjp.0706495; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Faroudi M, 2003, P NATL ACAD SCI USA, V100, P14145, DOI 10.1073/pnas.2334336100; Fischer TA, 2001, J BIOL CHEM, V276, P5967, DOI 10.1074/jbc.M009781200; Gomes B, 2004, CRIT REV IMMUNOL, V24, P425, DOI 10.1615/CritRevImmunol.v24.i6.30; Grafton G, 2003, BIOCHEM PHARMACOL, V66, P2001, DOI 10.1016/j.bcp.2003.07.005; Guo LY, 2004, IMMUNITY, V20, P193, DOI 10.1016/S1074-7613(04)00025-1; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kotturi MF, 2003, J BIOL CHEM, V278, P46949, DOI 10.1074/jbc.M309268200; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUBO RT, 1989, J IMMUNOL, V142, P2736; Madrenas J, 2003, IMMUNITY, V18, P459, DOI 10.1016/S1074-7613(03)00089-X; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Poggi A, 1998, J BIOL CHEM, V273, P7205, DOI 10.1074/jbc.273.13.7205; Rosenthal R, 2002, ADV EXP MED BIOL, V514, P225; Savignac M, 2004, J IMMUNOL, V172, P5206, DOI 10.4049/jimmunol.172.9.5206; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; SCHMIDT J, 1995, IMMUNOPHARMACOLOGY, V30, P191, DOI 10.1016/0162-3109(95)00022-L; Singh RAK, 1999, J IMMUNOL, V163, P6393; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Stokes L, 2004, J BIOL CHEM, V279, P19566, DOI 10.1074/jbc.M401481200; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Tamura T, 2001, J IMMUNOL, V167, P1962, DOI 10.4049/jimmunol.167.4.1962; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Urban J, 2000, J IMMUNOL, V164, P4250, DOI 10.4049/jimmunol.164.8.4250; Wang YG, 2000, CARDIOVASC RES, V48, P310, DOI 10.1016/S0008-6363(00)00178-4; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; White RA, 2003, FASEB J, V17, P482, DOI 10.1096/fj.02-0622fje; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Zocchi MR, 1998, J IMMUNOL, V161, P2938; ZWILLER J, 1985, J BIOL CHEM, V260, P1350	47	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12421	12427		10.1074/jbc.M510653200	http://dx.doi.org/10.1074/jbc.M510653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533816	hybrid			2022-12-27	WOS:000237134700028
J	Matsuura, B; Dong, MQ; Naik, S; Miller, LJ; Onji, M				Matsuura, B; Dong, MQ; Naik, S; Miller, LJ; Onji, M			Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETAGOGUE; LIGAND-BINDING; ERYTHROMYCIN; GHRELIN	The family of G protein-coupled receptors that includes receptors for motilin, ghrelin, and growth hormone secretagogue has substantial potential importance as drug targets. Understanding of the molecular basis of hormone binding and receptor activation should provide insights that are helpful in the development of such drugs. We previously examined the unique second extracellular loop domain of the motilin receptor, identifying key epitopes in perimembranous locations at each end of this long loop (Matsuura, B., Dong, M., and Miller, L. J. (2002) J. Biol. Chem. 277, 9834-9839). Here, we have extended that work, examining the other predicted extracellular domains of the motilin receptor by using sequential deletions of segments ranging from one to six amino acid residues and site-directed alanine replacement mutagenesis approaches. Each construct was transiently expressed in COS cells, and characterized for motilin- and erythromycin-stimulated intracellular calcium responses and motilin radioligand binding. Only those receptor segments that included key Cys residues in positions 25, 30, and 111 or perimembranous regions at the ends of the amino terminus and the first and third extracellular loops disrupted motilin biological activity. Each of these Cys deletions also disrupted action of erythromycin. Alanine replacements for each of the potentially important amino acid residues in the perimembranous segments revealed that residues Gly(36), Pro(103), Leu(109), and Phe(332) were responsible for the selective negative impact on motilin biological activity, while responding normally to erythromycin. These results support the presence of functionally important disulfide bonds in the motilin receptor ectodomain and demonstrate that the structural determinants for binding and biological activity of peptide and non-peptidyl agonist ligands are distinct, with a broad extracellular perimembranous base contributing to normal motilin binding.	Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; Ehime Univ, Sch Med, Dept Internal Med 3, Tohon, Ehime 7910295, Japan	Mayo Clinic; Mayo Clinic Phoenix; Ehime University	Miller, LJ (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu; onjimori@m.ehime-u.ac.jp		Naik, Shruthi/0000-0002-8593-9193				Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Matsuura B, 2005, J PHARMACOL EXP THER, V313, P1101, DOI 10.1124/jpet.104.081562; Matsuura B, 2002, J BIOL CHEM, V277, P9834, DOI 10.1074/jbc.M111051200; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533	15	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12390	12396		10.1074/jbc.M511921200	http://dx.doi.org/10.1074/jbc.M511921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531413	hybrid			2022-12-27	WOS:000237134700024
J	Valerio, A; Ghisi, V; Dossena, M; Tonello, C; Giordano, A; Frontini, A; Ferrario, M; Pizzi, M; Spano, P; Carruba, MO; Nisoli, E				Valerio, A; Ghisi, V; Dossena, M; Tonello, C; Giordano, A; Frontini, A; Ferrario, M; Pizzi, M; Spano, P; Carruba, MO; Nisoli, E			Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR MESSENGER-RNA; LONG-TERM POTENTIATION; BODY-MASS INDEX; NEUROENDOCRINE FUNCTION; LYSOPHOSPHATIDIC ACID; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; GAP-43 NEUROMODULIN; ENTORHINAL CORTEX	We examined the effects of the adipose hormone leptin on the development of mouse cortical neurons. Treatment of neonatal and adult mice with intraperitoneal leptin ( 5 mg/kg) induced extracellular signal-regulated kinase (ERK) 1/2 phosphorylation in pyriform and entorhinal cortex neurons. Stimulation of cultured embryonic cortical neurons with leptin evoked Janus kinase 2 and ERK1/2 phosphorylation and activated the downstream effector 90-kDa ribosomal protein S6 kinase. Moreover, leptin elicited the phosphorylation of the phosphatidylinositol 3-kinase effector Akt and evoked Ser-9 phosphorylation of glycogen synthase kinase-3 beta (GSK3 beta), an event inactivating this kinase. Leptin-mediated GSK3 beta phosphorylation was prevented by the MEK/ERK inhibitor PD98059, the phosphatidylinositol 3-kinase inhibitor LY294002, or the protein kinase C inhibitor GF109203X. Exposure of cortical neurons to leptin also induced Ser-41 phosphorylation of the neuronal growth-associated protein GAP-43, an effect prevented by LY294002 and GF109203X but not by PD98059. Ser-41-GAP-43 phosphorylation is usually high in expanding axonal growth cones. Neurons exposed to 100 ng/ml leptin for 72 h displayed reduced rate of growth cone collapse, a shift of growth cone size distribution toward higher values, and a 4-fold increase in mean growth cone surface area compared with control cultures. The leptin-induced growth cone spreading was hampered in cortical neurons from Lepr(db/db) mice lacking functional leptin receptors; it was associated with localized Ser-9-GSK3 beta phosphorylation and mimicked by the GSK3 beta inhibitor SB216763. At concentrations preventing GSK3 beta phosphorylation, PD98059, LY294002, or GF109203X reversed the leptin-induced growth cone surface enlargement. We concluded that the leptin-mediated regulation of growth cone morphogenesis in cortical neurons relies on upstream regulators of GSK3 beta activity.	Univ Milan, Dept Pharmacol, Sch Med, I-20129 Milan, Italy; Univ Milan, Ctr Study & Res Obes, I-20129 Milan, Italy; Univ Milan, Dept Preclin Sci, I-20157 Milan, Italy; Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Marche Polytech Univ, Sch Med, Inst Normal Human Morphol, I-60020 Ancona, Italy; Ist Auxol Italiano, I-20149 Milan, Italy	University of Milan; University of Milan; University of Milan; University of Brescia; Marche Polytechnic University; IRCCS Istituto Auxologico Italiano	Nisoli, E (corresponding author), Univ Milan, Dept Pharmacol, Sch Med, Via VanVitelli 32, I-20129 Milan, Italy.	enzo.nisoli@unimi.it	Nisoli, Enzo/D-6526-2014; Valerio, Alessandra/B-3413-2009; Dossena, Marta/I-2125-2012; Spano, Pier Franco A/E-7621-2010; Frontini, A/AAB-8767-2021; Pizzi, Marina/C-1452-2011; Spano, Pier Franco F/J-9944-2016; Pizzi, Marina/K-2064-2016	Nisoli, Enzo/0000-0002-6670-1630; Valerio, Alessandra/0000-0001-5844-2256; Spano, Pier Franco F/0000-0002-9906-0964; Carruba, Michele/0000-0003-4589-387X; Giordano, Antonio/0000-0003-1401-5855; Pizzi, Marina/0000-0002-4857-5204; Dossena, Marta/0000-0003-1717-8350; Frontini, Andrea/0000-0002-7381-4107				Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; Bates SH, 2003, TRENDS ENDOCRIN MET, V14, P447, DOI 10.1016/j.tem.2003.10.003; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471-4159.2004.02422.x; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Burguera B, 2000, NEUROENDOCRINOLOGY, V71, P187, DOI 10.1159/000054536; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dent EW, 1998, J NEUROBIOL, V35, P287, DOI 10.1002/(SICI)1097-4695(19980605)35:3<287::AID-NEU6>3.0.CO;2-V; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eiras S, 2004, J CELL PHYSIOL, V201, P214, DOI 10.1002/jcp.20046; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; Goold RG, 2004, BIOCHEM SOC T, V32, P809, DOI 10.1042/BST0320809; Gustafson D, 2004, NEUROLOGY, V63, P1876, DOI 10.1212/01.WNL.0000141850.47773.5F; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He Q, 1997, J NEUROSCI, V17, P3515; Hebert AE, 2002, LEARN MEMORY, V9, P156, DOI 10.1101/lm.48502; Henson MC, 2000, BIOL REPROD, V63, P1219, DOI 10.1095/biolreprod63.5.1219; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Huang XF, 1996, NEUROREPORT, V7, P2635, DOI 10.1097/00001756-199611040-00045; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Li XL, 2002, NEUROSCIENCE, V113, P607, DOI 10.1016/S0306-4522(02)00162-8; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Matsuda J, 1999, ENDOCRINOLOGY, V140, P5233, DOI 10.1210/en.140.11.5233; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Nordin S, 1998, ANN NY ACAD SCI, V855, P686, DOI 10.1111/j.1749-6632.1998.tb10646.x; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Shanley LJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0001.2001; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Takekoshi K, 2001, ENDOCRINOLOGY, V142, P4861, DOI 10.1210/en.142.11.4861; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Udagawa J, 2000, BRAIN RES, V868, P251, DOI 10.1016/S0006-8993(00)02334-9; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yamashita H, 2001, ENDOCRINOLOGY, V142, P2888, DOI 10.1210/en.142.7.2888	55	74	79	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12950	12958		10.1074/jbc.M508691200	http://dx.doi.org/10.1074/jbc.M508691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522636	hybrid			2022-12-27	WOS:000237134700090
J	Zhang, K; Zang, TZ; Yang, W; Sun, Y; Mu, Y; Liu, JQ; Shen, JC; Luo, GM				Zhang, K; Zang, TZ; Yang, W; Sun, Y; Mu, Y; Liu, JQ; Shen, JC; Luo, GM			Single chain antibody displays glutathione S-transferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM-CONTAINING ABZYME; HIGH CATALYTIC EFFICIENCY; PEROXIDASE; MECHANISM; MIMICS; CONJUGATION; GENERATION; EVOLUTION; KINETICS	Substrate binding and the subsequent reaction are the two principal phenomena that underlie the activity of enzymes, and many enzyme-like catalysts were generated based on the phenomena. The single chain variable region fragment of antibody 2F3 (scFv2F3) was elicited against hapten GSH-S-DN(2)phBu, a conjugate of glutathione (GSH), butyl alcohol, and 1-chloro-2,4-dinitrobenzene ( CDNB); it can therefore bind both GSH and CDNB, the substrates of native glutathione S-transferases (GSTs). It was shown previously that there is a serine residue that is the catalytic group of GST in the CDR regions of scFv2F3 close to the sulfhydryl of GSH. Thus, we anticipated that scFv2F3 will display GST activity. The experimental results showed that scFv2F3 indeed displayed GST activity that is equivalent to the rat theta-class GST T-2-2 and exhibited pH-and temperature-dependent catalytic activity. Steady-state kinetic studies showed that the Km values for the substrates are close to those of native GSTs, indicating that scFv2F3 has strong affinities for the substrates. Compared with some other GSTs, its k(cat) value was found to be low, which could be caused by the similarity between the GSH-S-DN2phBu and the reaction product of GSH and CDNB. These results showed that our approach to imitating enzymes is correct, which is that an active site may catalyze a chemical reaction when a catalytic group locates beside a substrate-binding site of a receptor. It is important to consider product inhibition in hapten design in order to obtain a mimic with a high catalytic efficiency.	Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China	Jilin University	Luo, GM (corresponding author), Jilin Univ, Key Lab Mol Enzymol & Engn, Minist Educ, 2519 Jiefeng Rd, Changchun 130023, Peoples R China.	luogm@jlu.edu.cn	Zhang, Kun/K-1218-2015	Sun, Ye/0000-0002-7674-9056				Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins JF, 2000, NATURE, V407, P463, DOI 10.1038/35035189; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Gallagher EP, 2000, ENVIRON TOXICOL CHEM, V19, P319, DOI 10.1002/etc.5620190211; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Habig W H, 1981, Methods Enzymol, V77, P398; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hoarau P, 2002, EUR J BIOCHEM, V269, P4359, DOI 10.1046/j.1432-1033.2002.03141.x; Jiang ZH, 2002, ACTA BIOCH BIOPH SIN, V34, P395; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; Liu JQ, 2004, ANAL CHIM ACTA, V504, P185, DOI 10.1016/S0003-2670(03)00763-3; Liu JQ, 1999, MAT SCI ENG C-BIO S, V10, P131, DOI 10.1016/S0928-4931(99)00095-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo GM, 1998, ANN NY ACAD SCI, V864, P136, DOI 10.1111/j.1749-6632.1998.tb10296.x; LUO GM, 1994, BIOCHEM BIOPH RES CO, V198, P1240, DOI 10.1006/bbrc.1994.1175; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Ren XJ, 2002, CHEM BIOL, V9, P789, DOI 10.1016/S1074-5521(02)00167-9; Ren XJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P250, DOI 10.1006/abbi.2000.2238; Ren XJ, 2001, BIOCHEM J, V359, P369, DOI 10.1042/0264-6021:3590369; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Singh SP, 2001, EUR J BIOCHEM, V268, P2912, DOI 10.1046/j.1432-1327.2001.02179.x; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Su D, 2001, ARCH BIOCHEM BIOPHYS, V395, P177, DOI 10.1006/abbi.2001.2551; Su D, 2001, BIOCHEM BIOPH RES CO, V285, P702, DOI 10.1006/bbrc.2001.5183; Sun Y, 2004, J BIOL CHEM, V279, P37235, DOI 10.1074/jbc.M403032200; Thanbichler M, 2002, METHOD ENZYMOL, V347, P3; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; Zhang K, 2003, CHINESE J CATAL+, V24, P97; Zhang Y, 2005, BBA-PROTEINS PROTEOM, V1747, P27, DOI 10.1016/j.bbapap.2004.09.022	34	12	12	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12516	12520		10.1074/jbc.M513596200	http://dx.doi.org/10.1074/jbc.M513596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507568	hybrid			2022-12-27	WOS:000237134700039
J	Dominguez-Cuevas, P; Gonzalez-Pastor, JE; Marques, S; Ramos, JL; de Lorenzo, V				Dominguez-Cuevas, P; Gonzalez-Pastor, JE; Marques, S; Ramos, JL; de Lorenzo, V			Transcriptional tradeoff between metabolic and stress-response programs in Pseudomonas putida KT2440 cells exposed to toluene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOL PLASMID PWW0; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI K-12; PATHWAY OPERON; RNA-POLYMERASE; EFFLUX PUMPS; PM PROMOTER; CRITICAL NUCLEOTIDES; SOLVENT TOLERANCE; OXIDATIVE STRESS	When Pseudomonas putida KT2440 cells encounter toluene in the growth medium, they perceive it simultaneously as a potential nutrient to be metabolized, as a membrane-damaging toxic drug to be extruded, and as a macromolecule-disrupting agent from which to protect proteins. Each of these inputs requires a dedicated transcriptional response that involves a large number of genes. We used DNA array technology to decipher the interplay between these responses in P. putida KT2440 subjected to a short challenge ( 15 min) with toluene. We then compared the results with those in cells exposed to o-xylene ( a non-biodegradable toluene counterpart) and 3-methylbenzoate ( a specific substrate of the lower TOL pathway of the P. putida pWW0 plasmid). The resulting expression profiles suggest that the bulk of the available transcriptional machinery is reassigned to endure general stress, whereas only a small share of the available machinery is redirected to the degradation of the aromatic compounds. Specifically, both toluene and o-xylene induce the TOL pathways and a dedicated but not always productive metabolic program. Similarly, 3-methylbenzoate induces the expression not only of the lower meta pathway but also of the non-productive and potentially deleterious genes for the metabolism of (nonsubstituted) benzoate. In addition, toluene ( and to a lesser extent o-xylene) inhibit motility functions as an unequivocal response to aromatic toxicity. We argue that toluene is sensed by P. putida KT2440 as a stressor rather than as a nutrient and that the inhibition by the aromatic compounds of many functions we tested is the tradeoff for activating stress tolerance genes at a minimal cost in terms of energy.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain; CSIC, Inst Nacl Tecn Aeroesp, Ctr Astrobiol, E-28850 Madrid, Spain; CSIC, Dept Microbiol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Ramos, JL (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Profesor Albareda 1, E-18008 Granada, Spain.	jlramos@eez.csic.es	González-Pastor, José/I-2118-2015; Marqués, Silvia/B-8079-2012; Dominguez-Cuevas, Patricia/D-6608-2017	González-Pastor, José/0000-0002-7615-7042; Marqués, Silvia/0000-0002-6289-3348; Dominguez-Cuevas, Patricia/0000-0002-9343-091X; Ramos, Juan L./0000-0002-8731-7435; de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; Allocati N, 2003, BIOCHEM J, V373, P305, DOI 10.1042/BJ20030184; Buege J A, 1978, Methods Enzymol, V52, P302; Cases I, 2005, NAT REV MICROBIOL, V3, P105, DOI 10.1038/nrmicro1084; Cowles CE, 2000, J BACTERIOL, V182, P6339, DOI 10.1128/JB.182.22.6339-6346.2000; Dominguez-Cuevas P, 2005, J BIOL CHEM, V280, P41315, DOI 10.1074/jbc.M505415200; DUETZ WA, 1991, J GEN MICROBIOL, V137, P1369, DOI 10.1099/00221287-137-6-1369; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fawcett J, 2000, SCIENCE, V290, P725, DOI 10.1126/science.290.5492.725; Gonzalez-Perez MM, 1999, J BIOL CHEM, V274, P2286, DOI 10.1074/jbc.274.4.2286; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; Greated A, 2002, ENVIRON MICROBIOL, V4, P856, DOI 10.1046/j.1462-2920.2002.00305.x; Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jimenez JI, 2004, PSEUDOMONAS, VOL 3: BIOSYNTHESIS OF MACROMOLECULES AND MOLECULAR METABOLISM, P425; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Junker F, 1999, J BACTERIOL, V181, P5693, DOI 10.1128/JB.181.18.5693-5700.1999; KESSLER B, 1994, J BACTERIOL, V176, P5578, DOI 10.1128/JB.176.17.5578-5582.1994; Kieboom J, 1998, J BACTERIOL, V180, P6769, DOI 10.1128/JB.180.24.6769-6772.1998; Kim K, 1998, J BACTERIOL, V180, P3692, DOI 10.1128/JB.180.14.3692-3696.1998; LI CY, 1993, J BACTERIOL, V175, P2229, DOI 10.1128/JB.175.8.2229-2235.1993; Liu YQ, 2005, J BACTERIOL, V187, P2501, DOI 10.1128/JB.187.7.2501-2507.2005; Marnett LJ, 2002, TOXICOLOGY, V181, P219, DOI 10.1016/S0300-483X(02)00448-1; Marques S, 1999, MOL MICROBIOL, V31, P1105, DOI 10.1046/j.1365-2958.1999.01249.x; MARQUES S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P227, DOI 10.1016/0167-4781(93)90149-8; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; Miller J. H, 1972, EXPT MOL GENETICS; Mosqueda G, 2000, J BACTERIOL, V182, P937, DOI 10.1128/JB.182.4.937-943.2000; Munoz-Rojas J, 2006, APPL ENVIRON MICROB, V72, P472, DOI 10.1128/AEM.72.1.472-477.2006; Nakazawa T, 2002, ENVIRON MICROBIOL, V4, P782, DOI 10.1046/j.1462-2920.2002.00310.x; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; Ramos JL, 1997, J BIOL CHEM, V272, P3887, DOI 10.1074/jbc.272.7.3887; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Ramos JL, 2001, CURR OPIN MICROBIOL, V4, P166, DOI 10.1016/S1369-5274(00)00183-1; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; ROJO F, 1987, SCIENCE, V238, P1395, DOI 10.1126/science.3479842; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Ruberg S, 2003, J BIOTECHNOL, V106, P255, DOI 10.1016/j.jbiotec.2003.08.005; Santos PM, 2004, PROTEOMICS, V4, P2640, DOI 10.1002/pmic.200300793; Segura A, 2005, J BACTERIOL, V187, P5937, DOI 10.1128/JB.187.17.5937-5945.2005; SEGURA A, 2004, PSEUDOMONAS, V2, P479; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; Velazquez F, 2005, MOL MICROBIOL, V57, P1557, DOI 10.1111/j.1365-2958.2005.04787.x; von Wallbrunn A, 2003, J BACTERIOL, V185, P1730, DOI 10.1128/JB.185.5.1730-1733.2003; Wen Y, 2003, INFECT IMMUN, V71, P5921, DOI 10.1128/IAI.71.10.5921-5939.2003; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7; Yuste L, 2006, ENVIRON MICROBIOL, V8, P165, DOI 10.1111/j.1462-2920.2005.00890.x	59	154	157	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11981	11991		10.1074/jbc.M509848200	http://dx.doi.org/10.1074/jbc.M509848200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495222	hybrid			2022-12-27	WOS:000236988100068
J	Miller, AG; Smith, DG; Bhat, M; Nagaraj, RH				Miller, AG; Smith, DG; Bhat, M; Nagaraj, RH			Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; METHYLGLYOXAL INDUCES APOPTOSIS; GLYCATION END-PRODUCTS; DIABETIC-RETINOPATHY; NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HIGH GLUCOSE; CANCER-CHEMOTHERAPY; MAILLARD REACTION	Retinal capillary pericytes undergo premature death, possibly by apoptosis, during the early stages of diabetic retinopathy. The alpha-oxoaldehyde, methylglyoxal (MGO), has been implicated as a cause of cell damage in diabetes. We have investigated the role of MGO and its metabolizing enzyme, glyoxalase I, in high glucose-induced apoptosis ( annexin V binding) of human retinal pericyte (HRP). HRP incubated with high glucose ( 30 mM D-glucose) for 7 days did not undergo apoptosis despite accumulation of MGO. However, treatment with a combination of high glucose and S-p-bromobenzylglutathione cyclopentyl diester, a competitive inhibitor of glyoxalase I, resulted in apoptosis along with a dramatic increase in MGO. Overexpression of glyoxalase I in HRP protected against S-p-bromobenzylglutathione cyclopentyl diester-induced apoptosis under high glucose conditions. Incubation of HRP with high concentrations of MGO resulted in an increase of apoptosis relative to untreated controls. We found an elevation of nitric oxide (NOcenter dot) in HRP that was incubated with high glucose when compared with those incubated with either the L-glucose or untreated controls. When HRP were incubated with an NOcenter dot donor, DETANONOATE ((Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-1-ium-1,2- diolate), we observed both decreased glyoxalase I expression and activity relative to untreated control cells. Further studies showed that HRP underwent apoptosis when incubated with DETANONOATE and that apoptosis increased further on co-incubation with high glucose. Our findings indicate that glyoxalase I is critical for pericyte survival under hyperglycemic conditions, and its inactivation and/or down-regulation by NOcenter dot may contribute to pericyte death by apoptosis during the early stages of diabetic retinopathy.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Visual Sci Res Ctr, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Wearn Bldg,Rm 653, Cleveland, OH 44106 USA.	ram.nagaraj@case.edu			NATIONAL EYE INSTITUTE [R01EY016219, P30EY011373, R01EY009912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068045] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY-016219, P30EY-11373, R01EY-09912] Funding Source: Medline; NIDDK NIH HHS [R21DK-068045] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADDISON DJ, 1970, BRIT MED J, V1, P264, DOI 10.1136/bmj.1.5691.264; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Beisswenger PJ, 2003, BBA-MOL BASIS DIS, V1637, P98, DOI 10.1016/S09254439(02)00219-3; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Creighton DJ, 2003, BIOCHEM SOC T, V31, P1378; Dagher Z, 2004, DIABETES, V53, P2404, DOI 10.2337/diabetes.53.9.2404; Davidson SD, 2002, UROL RES, V30, P116, DOI 10.1007/s00240-002-0244-7; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53; Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kasper M, 2000, AM J RESP CELL MOL, V23, P485, DOI 10.1165/ajrcmb.23.4.4117; Kern TS, 2000, INVEST OPHTH VIS SCI, V41, P3972; Kim J, 2005, EXP EYE RES, V81, P65, DOI 10.1016/j.exer.2005.01.010; Kim J, 2004, J KOREAN MED SCI, V19, P95, DOI 10.3346/jkms.2004.19.1.95; Kowluru RA, 2005, LIFE SCI, V76, P1051, DOI 10.1016/j.lfs.2004.10.017; Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353; Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572; Kusner LL, 2004, INVEST OPHTH VIS SCI, V45, P1553, DOI 10.1167/iovs.03-1294; Li WY, 1999, CELL MOL BIOL, V45, P59; Liu BF, 2004, INVEST OPHTH VIS SCI, V45, P1983, DOI 10.1167/iovs.03-0995; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitsumoto A, 2000, J BIOCHEM, V128, P647, DOI 10.1093/oxfordjournals.jbchem.a022797; Mitsumoto A, 1999, BIOCHEM J, V344, P837, DOI 10.1042/0264-6021:3440837; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; Morgan PE, 2002, ARCH BIOCHEM BIOPHYS, V403, P259, DOI 10.1016/S0003-9861(02)00222-9; MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Padayatti PS, 2001, CURR EYE RES, V23, P106, DOI 10.1076/ceyr.23.2.106.5472; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478; Rulli A, 2001, BREAST CANCER RES TR, V66, P67, DOI 10.1023/A:1010632919129; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Santilli F, 2004, HORM METAB RES, V36, P319, DOI 10.1055/s-2004-814489; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, BIOCHEM PHARMACOL, V51, P1365, DOI 10.1016/0006-2952(96)00059-7; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372, DOI 10.1042/BST0311372; Yamagishi S, 2005, FEBS LETT, V579, P4265, DOI 10.1016/j.febslet.2005.06.058; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010	58	91	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11864	11871		10.1074/jbc.M513813200	http://dx.doi.org/10.1074/jbc.M513813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505483	hybrid			2022-12-27	WOS:000236988100053
J	da Silva, GFZ; Reuille, RL; Ming, LJ; Livingston, BT				da Silva, GFZ; Reuille, RL; Ming, LJ; Livingston, BT			Overexpression and mechanistic characterization of blastula protease 10, a metalloprotease involved in sea urchin embryogenesis and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; ZINC-ENDOPEPTIDASE; CRYSTAL-STRUCTURE; LYSYL OXIDASE; ASTACIN; ACTIVATION; EXPRESSION; COLLAGEN; MATRIX; DERIVATIVES	Blastula protease 10 (BP10) is a metalloenzyme involved in sea urchin embryogenesis, which has been assigned to the astacin family of zinc-dependent endopeptidases. It shows greatest homology with the mammalian tolloid-like genes and contains conserved structural motifs consistent with astacin, tolloid, and bone morphogenetic protein 1. Astacin, a crustacean digestive enzyme, has been proposed to carry out hydrolysis via a metal-centered mechanism that involves a metal-coordinated "tyrosine switch." It has not been determined if the more structurally complex members of this family involved in eukaryotic development share this mechanism. The recombinant BP10 has been overexpressed in Escherichia coli, its metalloenzyme nature has been confirmed, and its catalytic properties have been characterized through kinetic studies. BP10 shows significant hydrolysis toward gelatin both in its native zinc-containing form and copper derivative. The copper derivative of BP10 shows a remarkable 960% rate acceleration toward the hydrolysis of the synthetic substrate N-benzoyl-arginine-p-nitroanilide when compared with the zinc form. The enzyme also shows calcium-dependent activation. These are the first thorough mechanistic studies reported on BP10 as a representative of the more structurally complex members of astacin-type enzymes in deuterostomes, which can add supporting data to corroborate the metal-centered mechanism proposed for astacin and the role of the coordinated Tyr. We have demonstrated the first mechanistic study of a tolloid-related metalloenzyme involved in sea urchin embryogenesis.	Univ S Florida, Dept Biol, Tampa, FL 33620 USA; Univ S Florida, Dept Chem, Tampa, FL 33620 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ming, LJ (corresponding author), Univ S Florida, Dept Biol, 4202 E Fowler Ave, Tampa, FL 33620 USA.	ming@shell.cas.usf.edu; blivings@cas.usf.edu						APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Bertini I., 1994, BIOINORG CHEM, P37; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; CALLOWAY C, 2003, BIOCHIM BIOPHYS ACTA, V1621, P67; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Frey ST, 1997, INORG CHEM, V36, P956, DOI 10.1021/ic961439o; Friedman M, 2004, J AGR FOOD CHEM, V52, P385, DOI 10.1021/jf030490p; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; GRUBB JD, 1994, METHOD ENZYMOL, V235, P602; Hanafy AI, 2005, INORG CHIM ACTA, V358, P1247, DOI 10.1016/j.ica.2004.10.024; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HEGG EL, 2005, COORDIN CHEM REV, V173, P133; HOOPER NM, 1996, ZINC METALLOPROTEASE, P23; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; KARAKIULAKIS G, 1993, J CELL BIOCHEM, V52, P92, DOI 10.1002/jcb.240520113; Kimura E, 1997, ADV INORG CHEM, V44, P229; KIMURA E, 1994, PROG INORG CHEM, V41, P443, DOI 10.1002/9780470166420.ch6; LEPAE T, 1996, EUR J BIOCHEM, V238, P744; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mayne J, 1998, J CELL BIOCHEM, V71, P546, DOI 10.1002/(SICI)1097-4644(19981215)71:4<546::AID-JCB9>3.0.CO;2-Y; Mohrlen F, 2003, EUR J BIOCHEM, V270, P4909, DOI 10.1046/j.1432-1033.2003.03891.x; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Park HI, 1998, J INORG BIOCHEM, V72, P57, DOI 10.1016/S0162-0134(98)10063-6; Park HI, 2002, J BIOL INORG CHEM, V7, P600, DOI 10.1007/s00775-002-0338-2; QUIGLEY JP, 1993, DIFFERENTIATION, V54, P19, DOI 10.1111/j.1432-0436.1993.tb00655.x; Sharpe C, 2001, BIOCHEM CELL BIOL, V79, P461; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOCKER W, 1995, PROTEIN SCI, V4, P823; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VAFA O, 1995, MOL REPROD DEV, V40, P36, DOI 10.1002/mrd.1080400106; Wardle FC, 1999, DEV BIOL, V206, P63, DOI 10.1006/dbio.1998.9127; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5	44	11	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10737	10744		10.1074/jbc.M510707200	http://dx.doi.org/10.1074/jbc.M510707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492671	hybrid			2022-12-27	WOS:000236822200012
J	Giesemann, T; Jank, T; Gerhard, R; Maier, E; Just, I; Benz, R; Aktories, K				Giesemann, T; Jank, T; Gerhard, R; Maier, E; Just, I; Benz, R; Aktories, K			Cholesterol-dependent pore formation of Clostridium difficile toxin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYER-MEMBRANES; BOTULINUM C2 TOXIN; DIPHTHERIA-TOXIN; PROTEIN TOXINS; LOW PH; ESCHERICHIA-COLI; BACTERIAL TOXINS; RETROGRADE TRANSPORT; CELLULAR UPTAKE; RHO-PROTEINS	The large clostridial cytotoxins toxin A and toxin B from Clostridium difficile are major virulence factors known to cause antibiotic-associated diarrhea and pseudomembranous colitis. Both toxins mono-glucosylate and thereby inactivate small GTPases of the Rho family. Recently, it was reported that toxin B, but not toxin A, induces pore formation in membranes of target cells under acidic conditions. Here, we reassessed data on pore formation of toxin A in cells derived from human colon carcinoma. Treatment of Rb-86(+)-loaded cells with native or recombinant toxin A resulted in an increased efflux of radioactive cations induced by an acidic pulse. The efficacy of pore formation was dependent on membrane cholesterol, since cholesterol depletion of membranes with methyl-beta-cyclodextrin inhibited Rb-86(+) efflux, and cholesterol repletion reconstituted pore-forming activity of toxin A. Similar results were obtained with toxin B. Consistently, methyl-beta-cyclodextrin treatment delayed intoxication of cells in a concentration-dependent manner. In black lipid membranes, toxin A induced ion-permeable pores only in cholesterol containing bilayers and at low pH. In contrast, release of glycosylphosphatidylinositol-anchored structures by phosphatidylinositol specific phospholipase C treatment did not reduce cell sensitivity toward toxins A and B. These data indicate that in colonic cells toxin A induces pore formation in an acidic environment (e.g. endosomes) similar to that reported for toxin B and suggest that pore formation by clostridial glucosylating toxins depends on the presence of cholesterol.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany; Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	University of Freiburg; Hannover Medical School; University of Wurzburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albert Str 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Jank, Thomas/R-9627-2017	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Andersen C, 2002, J BIOL CHEM, V277, P41318, DOI 10.1074/jbc.M206804200; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; Barth H, 2005, REV PHYSIOL BIOCH P, V152, P165, DOI 10.1007/s10254-004-0029-1; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; BARTLETT JG, 1978, GASTROENTEROLOGY, V75, P778; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1980, J MEMBRANE BIOL, V56, P19, DOI 10.1007/BF01869348; BENZ R, 1994, J BIOL CHEM, V269, P27231; Benz R., 2001, MICROBIAL TRANSPORT, P227; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; Burger S, 2003, BIOCHEM BIOPH RES CO, V307, P584, DOI 10.1016/S0006-291X(03)01234-8; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; ERIKSEN S, 1994, EMBO J, V13, P4433, DOI 10.1002/j.1460-2075.1994.tb06765.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; FLORIN I, 1983, BIOCHIM BIOPHYS ACTA, V763, P383, DOI 10.1016/0167-4889(83)90100-3; Gerhard R, 2005, MICROB PATHOGENESIS, V38, P77, DOI 10.1016/j.micpath.2004.12.002; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; Hayakawa E, 1998, BIOPHYS J, V74, P892, DOI 10.1016/S0006-3495(98)74012-3; HENRIQUES B, 1987, MICROB PATHOGENESIS, V2, P455, DOI 10.1016/0882-4010(87)90052-0; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; Just I, 2000, CURR TOP MICROBIOL, V250, P55; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Just I., 1997, BACTERIAL TOXINS TOO, P159; Kelly CP, 1998, ANNU REV MED, V49, P375; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIVAN HC, 1986, INFECT IMMUN, V53, P573, DOI 10.1128/IAI.53.3.573-581.1986; Lencer WI, 2004, INT J MED MICROBIOL, V293, P491, DOI 10.1078/1438-4221-00293; Lord JM, 1999, CELL MICROBIOL, V1, P85, DOI 10.1046/j.1462-5822.1999.00015.x; Lord JM, 1998, J CELL BIOL, V140, P733; Mylonakis E, 2001, ARCH INTERN MED, V161, P525, DOI 10.1001/archinte.161.4.525; NETZER A, 1993, RENAL PHYSIOL BIOCH, V16, P299; Palmer M, 2004, FEMS MICROBIOL LETT, V238, P281, DOI 10.1016/j.femsle.2004.07.059; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; Qa'Dan M, 2000, INFECT IMMUN, V68, P2470, DOI 10.1128/IAI.68.5.2470-2474.2000; Reinert DJ, 2005, J MOL BIOL, V351, P973, DOI 10.1016/j.jmb.2005.06.071; Rupnik M, 2005, MICROBIOL-SGM, V151, P199, DOI 10.1099/mic.0.27474-0; Sandvig K, 2004, INT J MED MICROBIOL, V293, P483, DOI 10.1078/1438-4221-00294; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHMID A, 1994, J BIOL CHEM, V269, P16706; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Thelestam M, 2000, CURR TOP MICROBIOL, V250, P85; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	61	65	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10808	10815		10.1074/jbc.M512720200	http://dx.doi.org/10.1074/jbc.M512720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16513641	hybrid			2022-12-27	WOS:000236822200020
J	Hashemy, SI; Ungerstedt, JS; Avval, FZ; Holmgren, A				Hashemy, SI; Ungerstedt, JS; Avval, FZ; Holmgren, A			Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHOLE-BRAIN RADIATION; MAMMALIAN THIOREDOXIN; IONIZING-RADIATION; RECOMBINANT MOUSE; INDUCED APOPTOSIS; ESCHERICHIA-COLI; ACTIVE-SITE; CELL-LINES; SELENOCYSTEINE; MECHANISM	Motexafin gadolinium (MGd) is a chemotherapeutic drug that selectively targets tumor cells and mediates redox reactions generating reactive oxygen species. Thioredoxin (Trx), NADPH, and thioredoxin reductase (TrxR) of the cytosol/nucleus or mitochondria are major thiol-dependent reductases with many functions in cell growth, defense against oxidative stress, and apoptosis. Mammalian TrxRs are selenocysteine-containing flavoenzymes; MGd was an NADPH-oxidizing substrate for human or rat TrxR1 with a K-m value of 8.65 mu M (k(cat)/K-m of 4.86 x 10(4) M-1 s(-1)). The reaction involved redox cycling of MGd by oxygen producing superoxide and hydrogen peroxide. MGd acted as a non-competitive inhibitor (IC50 of 6 mu M) for rat TrxR. In contrast, direct reaction between MGd and reduced human Trx was negligible. The corresponding reaction with reduced Escherichia coli Trx was also negligible, but MGd was a better substrate (k(cat)/K-m of 2.23 x 10(5) M-1 s(-1)) for TrxR from E. coli and a strong inhibitor of Trx-dependent protein disulfide reduction. Ribonucleotide reductase (RNR), a 1:1 complex of the non-identical R1- and R2-subunits, catalyzes the essential de novo synthesis of deoxyribonucleotides for DNA synthesis using electrons from Trx and TrxR. MGd inhibited recombinant mouse RNR activity with either 3 mu M reduced human Trx (IC50 2 mu M) or 4 mM dithiothreitol (IC50 6 mu M) as electron donors. Our results demonstrate MGd-induced enzymatic generation of reactive oxygen species by TrxR plus a powerful inhibition of RNR. This may explain the effects of the drug on cancer cells, which often overproduce TrxR and have induced RNR for replication and repair.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@mbb.ki.se	Ungerstedt, Johanna/C-7004-2014; Hashemy, Seyed Isaac/A-2693-2017	Hashemy, Seyed Isaac/0000-0002-1323-5250; Zahedi Avval, Farnaz/0000-0001-8915-3596				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Berggren M, 1996, ANTICANCER RES, V16, P3459; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Donnelly ET, 2004, INT J RADIAT ONCOL, V58, P1570, DOI 10.1016/j.ijrobp.2003.12.017; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Evens AM, 2005, BLOOD, V105, P1265, DOI 10.1182/blood-2004-03-0964; Evens Andrew M, 2005, Curr Treat Options Oncol, V6, P289, DOI 10.1007/s11864-005-0033-y; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 2003, SIGNAL TRANSDUCTION, P33; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kahlos K, 2001, INT J CANCER, V95, P198, DOI 10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; Magda D, 2005, CANCER RES, V65, P3837, DOI 10.1158/0008-5472.CAN-04-4099; Magda D, 2002, EUR J CANCER, V38, pS26; Magda D, 2001, INT J RADIAT ONCOL, V51, P1025, DOI 10.1016/S0360-3016(01)01810-7; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Mehta MP, 2002, J CLIN ONCOL, V20, P3445, DOI 10.1200/JCO.2002.07.500; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Miller FJ, 2002, METHOD ENZYMOL, V353, P220; Miller RA, 2001, CLIN CANCER RES, V7, P3215; Nilsson J, 2000, BLOOD, V95, P1420, DOI 10.1182/blood.V95.4.1420.004k12_1420_1426; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Sessler JL, 2000, BIOCHEM PHARMACOL, V59, P733, DOI 10.1016/S0006-2952(99)00314-7; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Xu S, 2001, INT J RADIAT ONCOL, V49, P1381, DOI 10.1016/S0360-3016(00)01566-2; Young SW, 1996, P NATL ACAD SCI USA, V93, P6610, DOI 10.1073/pnas.93.13.6610; ZAWIRSKA B, 1979, NEOPLASMA, V26, P223; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	48	136	151	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10691	10697		10.1074/jbc.M511373200	http://dx.doi.org/10.1074/jbc.M511373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481328	hybrid			2022-12-27	WOS:000236822200007
J	Takahashi, K; Kimura, Y; Kioka, N; Matsuo, M; Ueda, K				Takahashi, K; Kimura, Y; Kioka, N; Matsuo, M; Ueda, K			Purification and ATPase activity of human ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; APOLIPOPROTEIN-A-I; MULTIDRUG-RESISTANCE PROTEINS; HIGH-DENSITY-LIPOPROTEIN; P-GLYCOPROTEIN; NUCLEOTIDE-BINDING; EXTRACELLULAR DOMAIN; PHOSPHOLIPID EFFLUX; INORGANIC-PHOSPHATE; CHOLESTEROL EFFLUX	ATP-binding cassette protein A1 (ABCA1) plays a major role in cholesterol homeostasis and high density lipoprotein metabolism. Apolipoprotein A-I binds to ABCA1 and cellular cholesterol and phospholipids, mainly phosphatidylcholine, are loaded onto apoA-I to form pre-beta high density lipoprotein (HDL). It is proposed that ABCA1 translocates phospholipids and cholesterol directly or indirectly to form pre-beta HDL. To explore the mechanism of ABCA1-mediated pre-beta HDL formation, we expressed human ABCA1 in insect Sf9 cells and purified it. Trypsin limited-digestion of purified ABCA1 in the detergent-soluble form suggested that it retained conformation similar to ABCA1 expressed in the membranes of human fibroblast WI-38 cells. Purified ABCA1 showed robust ATPase activity when reconstituted in liposomes made of synthetic phosphatidylcholine. ABCA1 showed lower ATPase activity when reconstituted in liposomes containing phosphatidylserine, phosphatidylethanolamine, or phosphatidylglycerol and also showed weak specificity in acyl chain species. ATPase activity was reduced by the addition of cholesterol and decreased by 25% in the presence of 20% cholesterol. beta-Sitosterol and campesterol showed similar inhibitory effects but stigmasterol did not, suggesting structure-specific interaction between ABCA1 and sterols. Glibenclamide suppressed ABCA1 ATPase, suggesting that it inhibits apoA-I-dependent cellular cholesterol efflux by suppressing ABCA1 ATPase activity. These results suggest that the ATPase activity of ABCA1 is stimulated preferentially by phospholipids with choline head groups, phosphatidylcholine and sphingomyelin. This study with purified human ABCA1 provides the first biochemical basis of the mechanism for HDL formation mediated by ABCA1.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Kimura, Yasuhisa/0000-0001-6466-1324; Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DRUECKES P, 1995, ANAL BIOCHEM, V230, P173, DOI 10.1006/abio.1995.1453; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Francone OL, 2003, BIOCHEMISTRY-US, V42, P8569, DOI 10.1021/bi034540v; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hayashi M, 2005, J LIPID RES, V46, P1703, DOI 10.1194/jlr.M500092-JLR200; Julien M, 2000, BIOCHEMISTRY-US, V39, P75, DOI 10.1021/bi991726e; Kimura Y, 2004, ANAL BIOCHEM, V326, P262, DOI 10.1016/j.ab.2003.12.012; Kimura Y, 2004, CURR DRUG METAB, V5, P1, DOI 10.2174/1389200043489090; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Roosbeek S, 2004, J BIOL CHEM, V279, P37779, DOI 10.1074/jbc.M401821200; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7215; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	43	78	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10760	10768		10.1074/jbc.M513783200	http://dx.doi.org/10.1074/jbc.M513783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500904	hybrid			2022-12-27	WOS:000236822200015
J	Yamada, T; Ohtani, S; Sakurai, T; Tsuji, T; Kunieda, T; Yanagisawa, M				Yamada, T; Ohtani, S; Sakurai, T; Tsuji, T; Kunieda, T; Yanagisawa, M			Reduced expression of the endothelin receptor type B gene in piebald mice caused by insertion of a retroposon-like element in intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; NEURAL CREST DEVELOPMENT; 9-CIS RETINOIC ACID; AGANGLIONIC MEGACOLON; MOLECULAR-BIOLOGY; LEADER SEQUENCE; COAT COLOR; MOUSE; CELLS; MUTATIONS	Mice carrying the piebald mutation exhibit white coat spotting due to the regional absence of neural crest-derived melanocytes. We reported previously that the piebald locus encodes the Ednrb gene and that piebald mice express low levels of structurally intact Ednrb mRNA and EDNRB protein (Hosoda, K., Hammer, R. E., Richardson, J. A., Baynash, A. G., Cheung, J. C., Giaid, A., and Yanagisawa, M. (1994) Cell 79, 1267-1276). Here, we report that both the life span of the Ednrb mRNA and the promoter activity of the Ednrb gene are indistinguishable between wild-type and piebald mice. Introns 2-6 of the Ednrb gene in piebald mice were correctly excised with an efficiency indistinguishable from those in wild-type mice in exon trapping experiments. We found that the piebald allele of the Ednrb gene has a 5.5-kb retroposon-like element in intron 1 possessing canonical sequences of a polyadenylation signal and a splice acceptor site. Abnormal hybrid transcripts carrying exon 1 of the Ednrb gene and a portion of the 5.5-kb element are expressed in piebald mice. The insertion of the 5.5-kb element into a heterologous intron in a mammalian expression vector markedly reduced the expression of the reporter gene. Premature termination and aberrant splicing of the Ednrb transcript caused by the retroposon-like element in intron 1 lead to a reduced level of the normal Ednrb transcript, which is responsible for the partial loss-of-function phenotype of piebald mice.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Okayama University	Yamada, T (corresponding author), Kyoto Univ, Grad Sch Agr, Lab Anim Breeding & Genet, Sakyo Ku, Kyoto 6068502, Japan.	tyamada@kais.kyoto-u.ac.jp						ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; Baust C, 2003, J VIROL, V77, P11448, DOI 10.1128/JVI.77.21.11448-11458.2003; Baust C, 2002, MAMM GENOME, V13, P423, DOI 10.1007/s00335-002-2178-3; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Berg DE, 1989, MOBILE DNA; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Gariepy CE, 1996, P NATL ACAD SCI USA, V93, P867, DOI 10.1073/pnas.93.2.867; Gitler AD, 2002, COLD SPRING HARB SYM, V67, P57, DOI 10.1101/sqb.2002.67.57; HARRISON GP, 1995, J VIROL, V69, P2175, DOI 10.1128/JVI.69.4.2175-2186.1995; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hertz L., 1989, DISSECTION TISSUE CU, P105; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMOKAWA G, 1982, CANCER RES, V42, P1994; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; Kurihara H, 1999, CELL MOL BIOL, V45, P639; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; Le Douarin NM, 1999, NEURAL CREST, V2; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; Leong WL, 2000, MAMM GENOME, V11, P97, DOI 10.1007/s003350010020; LIM R, 1990, CELL CULTURE, V2, P47; Lyon M., 1989, GENETIC VARIANTS STR; Mager DL, 2000, J VIROL, V74, P7221, DOI 10.1128/JVI.74.16.7221-7229.2000; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; Maschhoff KL, 2000, AM J MED GENET, V97, P280, DOI 10.1002/1096-8628(200024)97:4<280::AID-AJMG1278>3.0.CO;2-N; Peterfy M, 1998, GENE, V216, P225, DOI 10.1016/S0378-1119(98)00321-7; Pla P, 2003, INT J DEV BIOL, V47, P315; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; UEHARA H, 1990, GENETICS, V126, P1093; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	52	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10799	10807		10.1074/jbc.M512618200	http://dx.doi.org/10.1074/jbc.M512618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500897	hybrid			2022-12-27	WOS:000236822200019
J	Alahyan, M; Webb, MR; Marston, SB; El-Mezgueldi, M				Alahyan, Mustapha; Webb, Martin R.; Marston, Steven B.; El-Mezgueldi, Mohammed			The mechanism of smooth muscle caldesmon-tropomyosin inhibition of the elementary steps of the actomyosin ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MYOSIN SUBFRAGMENT-1; HEAVY-MEROMYOSIN; THIN-FILAMENTS; ACTIN-TROPOMYOSIN; BINDING PROTEIN; TROPONIN TROPOMYOSIN; PHOSPHATE RELEASE; FLUORESCENT-PROBE; F-ACTIN	Caldesmon is a component of smooth muscle thin filaments that inhibits the actomyosin ATPase via its interaction with actin-tropomyosin. We have performed a comprehensive transient kinetic characterization of the actomyosin ATPase in the presence of smooth muscle caldesmon and tropomyosin. At physiological ratios of caldesmon to actin (1 caldesmon/7 actin monomers) actomyosin ATPase is inhibited by about 75%. Inhibitory caldesmon concentrations had little effect upon the rate of S1 binding to actin, actin-S1 dissociation by ATP, and dissociation of ADP from actin-S1(.)ADP; however the rate of phosphate release from the actin-S1(.)ADP(.)P(i) complex was decreased by more than 80%. In addition the transient of phosphate release displayed a lag of up to 200 ms. The presence of a lag phase indicates that a step on the pathway prior to phosphate release has become rate-limiting. Premixing the actin-tropomyosin filaments with myosin heads resulted in the disappearance of the lag phase. We conclude that caldesmon inhibition of the rate of phosphate release is caused by the thin filament being switched by caldesmon to an inactive state. The active and inactive states correspond to the open and closed states observed in skeletal muscle thin filaments with no evidence for the existence of a third, blocked state. Taken together these data suggest that at physiological concentrations, caldesmon controls the isomerization of the weak binding complex to the strong binding complex, and this causes the inhibition of the rate of phosphate release. This inhibition is sufficient to account for the inhibition of the steady state actomyosin ATPase by caldesmon and tropomyosin.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Myocardial Syst Biol Grp, London SW3 6LY, England; Natl Inst Med Res, MRC, London NW7 1AA, England	Imperial College London; MRC National Institute for Medical Research	El-Mezgueldi, M (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mem16@le.ac.uk		Webb, Martin/0000-0002-0134-9621	MRC [MC_U117512742] Funding Source: UKRI; Medical Research Council [MC_U117512742] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ansari S, 2003, J MUSCLE RES CELL M, V24, P513, DOI 10.1023/B:JURE.0000009812.74980.13; ANSARI SN, 2004, NATL HEART LUNG I, P256; BARANY M, 1993, ARCH BIOCHEM BIOPHYS, V305, P202, DOI 10.1006/abbi.1993.1412; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHACKO S, 1994, J BIOL CHEM, V269, P15803; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; Chalovich JM, 1998, ACTA PHYSIOL SCAND, V164, P427; CORRIE JET, 1991, J CHEM SOC P1, P2975; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; El-Mezgueldi M, 1998, BIOCHEM J, V332, P395, DOI 10.1042/bj3320395; Elmezgueldi M, 2005, BIOPHYS J, V88, p133A; ELMEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; ELMEZGUELDI M, 2001, WILEY ENCY MOL MED, V5, P428; Fersht A., 1985, ENZYME STRUCTURE MEC; Fredricksen S, 2003, BIOCHEMISTRY-US, V42, P6136, DOI 10.1021/bi0274017; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1995, BIOPHYS J, V68, pS196; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; He ZH, 1998, BIOPHYS J, V75, P3031, DOI 10.1016/S0006-3495(98)77744-6; Heeley DH, 2002, P NATL ACAD SCI USA, V99, P16731, DOI 10.1073/pnas.252236399; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON KA, 2004, INTRO KINETIC ANAL E; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Malmquist U, 1996, PFLUG ARCH EUR J PHY, V432, P241, DOI 10.1007/s004240050130; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; Pavlov D, 2003, J BIOL CHEM, V278, P5517, DOI 10.1074/jbc.M210889200; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9984; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Sen A, 2001, BIOCHEMISTRY-US, V40, P5757, DOI 10.1021/bi002724t; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Webb Martin R., 2003, P131; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yan B, 2003, BIOCHEMISTRY-US, V42, P4208, DOI 10.1021/bi0273009	68	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19433	19448		10.1074/jbc.M507602200	http://dx.doi.org/10.1074/jbc.M507602200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16540476	hybrid			2022-12-27	WOS:000238847000059
J	Frey, RS; Gao, XP; Javaid, K; Siddiqui, SS; Rahman, A; Malik, AB				Frey, Randall S.; Gao, Xiaopei; Javaid, Kamran; Siddiqui, Shahid S.; Rahman, Arshad; Malik, Asrar B.			Phosphatidylinositol 3-kinase gamma signaling through protein kinase C zeta induces NADPH oxidase-mediated oxidant generation and NF-kappa B activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE GAMMA; NEUTROPHIL RESPIRATORY BURST; DEPENDENT ACTIVATION; GENE-TRANSCRIPTION; MEMBRANE; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	We addressed the role of class 1B phosphatidylinositol 3-kinase (PI3K) isoform PI3K gamma in mediating NADPH oxidase activation and reactive oxidant species (ROS) generation in endothelial cells (ECs) and of PI3K gamma-mediated oxidant signaling in the mechanism of NF-kappa B activation and intercellular adhesion molecule (ICAM)-1 expression. We used lung microvascular ECs isolated from mice with targeted deletion of the p110 gamma catalytic subunit of PI3K gamma. Tumor necrosis factor (TNF)alpha challenge of wild type ECs caused p110 gamma translocation to the plasma membrane and phosphatidylinositol 1,4,5- trisphosphate production coupled to ROS production; however, this response was blocked in p110 gamma (-)/(-) ECs. ROS production was the result of TNF alpha activation of Ser phosphorylation of NADPH oxidase subunit p47(phox) and its translocation to EC membranes. NADPH oxidase activation failed to occur in p110 gamma(-/-) ECs. Additionally, the TNF alpha- activated NF-kappa B binding to the ICAM-1 promoter, ICAM- 1 protein expression, and PMN adhesion to ECs required functional PI3K gamma. TNF alpha challenge of p110 gamma(-/-) ECs failed to induce phosphorylation of PDK1 and activation of the atypical PKC isoform, PKC xi. Thus, PI3K gamma lies upstream of PKC xi in the endothelium, and its activation is crucial in signaling NADPH oxidase-dependent oxidant production and subsequent NF-kappa B activation and ICAM-1 expression.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Rochester; University of Rochester	Frey, RS (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,E403, Chicago, IL 60612 USA.	RFrey@uic.edu		Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678, R01HL067424] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07239, HL60678, HL67424] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cadwallader KA, 2002, J IMMUNOL, V169, P3336, DOI 10.4049/jimmunol.169.6.3336; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LO SK, 1993, AM J PHYSIOL, V264, P406; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Milne SB, 2005, J LIPID RES, V46, P1796, DOI 10.1194/jlr.D500010-JLR200; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 1999, MOL PHARMACOL, V55, P575; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Strassheim D, 2004, J IMMUNOL, V172, P5727, DOI 10.4049/jimmunol.172.9.5727; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601	52	117	121	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16128	16138		10.1074/jbc.M508810200	http://dx.doi.org/10.1074/jbc.M508810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16527821	hybrid			2022-12-27	WOS:000237996000066
J	Aritake, K; Kado, Y; Inoue, T; Miyano, M; Urade, Y				Aritake, Kosuke; Kado, Yuji; Inoue, Tsuyoshi; Miyano, Masashi; Urade, Yoshihiro			Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIALLERGIC DRUG HQL-79; ALLERGIC INFLAMMATION; PHORBOL ESTER; CELLS; PROTEIN; ACTIVATION; EXPRESSION; D-2; RECEPTORS; INDUCTION	We determined the crystal structure of human hematopoietic prostaglandin (PG) D synthase (H-PGDS) as the quaternary complex with glutathione (GSH), Mg2+, and an inhibitor, HQL-79, having anti-inflammatory activities in vivo, at a 1.45-angstrom resolution. In the quaternary complex, HQL-79 was found to reside within the catalytic cleft between Trp(104) and GSH. HQL-79 was stabilized by interaction of a phenyl ring of its diphenyl group with Trp104 and by its piperidine group with GSH and Arg(14) through water molecules, which form a network with hydrogen bonding and salt bridges linked to Mg2+. HQL-79 inhibited human H-PGDS competitively against the substrate PGH(2) and non-competitively against GSH with K-i of 5 and 3 mu(M), respectively. Surface plasmon resonance analysis revealed that HQL-79 bound to H-PGDS with an affinity that was 12-fold higher in the presence of GSH and Mg2+ (K-d, 0.8 mu(M)) than in their absence. Mutational studies revealed that Arg14 was important for the Mg2+-mediated increase in the binding affinity of H-PGDS for HQL-79, and that Trp(104), Lys(112), and Lys(198) were important for maintaining the HQL-binding pocket. HQL-79 selectively inhibited PGD(2) production by H-PGDS-expressing human megakaryocytes and rat mastocytoma cells with an IC50 value of about 100 mu(M) but only marginally affected the production of other prostanoids, suggesting the tight functional engagement between H-PGDS and cyclooxygenase. Orally administered HQL-79 (30 mg/kg body weight) inhibited antigen-induced production of PGD(2), without affecting the production of PGE(2) and PGF(2 alpha), and ameliorated airway inflammation in wild-type and human H-PGDS-overexpressing mice. Knowledge about this structure of quaternary complex is useful for understanding the inhibitory mechanism of HQL-79 and should accelerate the structure-based development of novel anti-inflammatory drugs that inhibit PGD2 production specifically.	Osaka Biosci Inst, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan; Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; RIKEN, SPring 8 Ctr, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	Osaka University; Japan Synchrotron Radiation Research Institute; RIKEN	Urade, Y (corresponding author), Osaka Biosci Inst, Dept Mol Behav Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	uradey@obi.or.jp	Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Fujimori K, 2005, J BIOL CHEM, V280, P18452, DOI 10.1074/jbc.M411755200; Guyton AG, 1991, TXB MED PHYSL, P38; Halter F, 2001, GUT, V49, P443, DOI 10.1136/gut.49.3.443; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Inoue T, 2004, J BIOCHEM, V135, P279, DOI 10.1093/jb/mvh033; Inoue T, 2003, NAT STRUCT BIOL, V10, P291, DOI 10.1038/nsb907; Inui T, 2003, J BIOL CHEM, V278, P2845, DOI 10.1074/jbc.M209934200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Lazarus M, 2002, ARCH BIOCHEM BIOPHYS, V397, P336, DOI 10.1006/abbi.2001.2614; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Li LX, 2003, J BIOL CHEM, V278, P4725, DOI 10.1074/jbc.C200635200; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Matsushita N, 1998, JPN J PHARMACOL, V78, P1, DOI 10.1254/jjp.78.1; Matsushita N, 1998, JPN J PHARMACOL, V78, P11, DOI 10.1254/jjp.78.11; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mohri I, 2006, J NEUROSCI, V26, P4383, DOI 10.1523/JNEUROSCI.4531-05.2006; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKANO M, 2006, IN PRESS AM J RHINOL; Okinaga T, 2002, ACTA NEUROPATHOL, V104, P377, DOI 10.1007/s00401-002-0567-z; Pinzar E, 2000, P NATL ACAD SCI USA, V97, P4903, DOI 10.1073/pnas.090093997; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; Psaty BM, 2005, NEW ENGL J MED, V352, P1133, DOI 10.1056/NEJMe058042; Shichijo M, 2003, J PHARMACOL EXP THER, V307, P518, DOI 10.1124/jpet.103.055442; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V241, P288, DOI 10.1006/bbrc.1997.7803; Takeuchi K, 2001, J PHARMACOL EXP THER, V297, P1160; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Taniike M, 2002, J NEUROSCI, V22, P4885, DOI 10.1523/JNEUROSCI.22-12-04885.2002; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; 2003, NAT STRUCT BIOL, V10, P233	46	88	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15277	15286		10.1074/jbc.M506431200	http://dx.doi.org/10.1074/jbc.M506431200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16547010	hybrid			2022-12-27	WOS:000237922200031
J	Andrew, AJ; Dutkiewicz, R; Knieszner, H; Craig, EA; Marszalek, J				Andrew, Amy J.; Dutkiewicz, Rafal; Knieszner, Helena; Craig, Elizabeth A.; Marszalek, Jaroslaw			Characterization of the interaction between the J-protein Jac1p and the scaffold for Fe-S cluster biogenesis, Isu1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CHAPERONE SYSTEM; SUBSTRATE-SPECIFICITY; SHUTTLE VECTORS; DNAK CHAPERONE; HSP70 SSQ1; ISCU; MITOCHONDRIA	Jac1p is a conserved, specialized J-protein that functions with Hsp70 in Fe-S cluster biogenesis in mitochondria of the yeast Saccharomyces cerevisiae. Although Jac1p as well as its specialized Hsp70 partner, Ssq1p, binds directly to the Fe-S cluster scaffold protein Isu, the Jac1p-Isu1p interaction is not well understood. Here we report that a C-terminal fragment of Jac1p lacking its J-domain is sufficient for interaction with Isu1p, and amino acid alterations in this domain affect interaction with Isu1p but not Ssq1p. In vivo, such JAC1 mutations had no obvious phenotypic effect. However, when present in combination with a mutation in SSQ1 that causes an alteration in the substrate binding cleft, growth was significantly compromised. Wild type Jac1p and Isu1p cooperatively stimulate the ATPase activity of Ssq1p. Jac1p mutant protein is only slightly compromised in this regard. Our in vivo and in vitro results indicate that independent interaction of Jac1p and the Isu client protein with Hsp70 is sufficient for robust growth under standard laboratory conditions. However, our results also support the idea that Isu protein can be "targeted" to Ssq1p after forming a complex with Jac1p. We propose that Isu protein targeting may be particularly important when environmental conditions place high demands on Fe-S cluster biogenesis or in organisms lacking specialized Hsp70s for Fe-S cluster biogenesis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Program Biomol Chem, Madison, WI 53706 USA; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 441E Biochem Addict,433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	Dutkiewicz, Rafal/ABE-6979-2020; Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/F-5956-2011	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870, T32GM008349] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 27870, 5T32 GM 08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; Dutkiewicz R, 2006, J BIOL CHEM, V281, P7801, DOI 10.1074/jbc.M513301200; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Erbse A, 2004, BIOCHEM SOC T, V32, P617, DOI 10.1042/BST0320617; HALL BG, 2004, PHYLOGENETIC TREES M, P9; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Knieszner H, 2005, J BIOL CHEM, V280, P28966, DOI 10.1074/jbc.M503031200; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; PTASHNE M, 2002, GENES SIGNALS; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHERMAN F, 1986, LAB COURSE MANUAL ME, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Skerra A, 2000, METHOD ENZYMOL, V326, P271; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	33	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14580	14587		10.1074/jbc.M600842200	http://dx.doi.org/10.1074/jbc.M600842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551614	hybrid			2022-12-27	WOS:000237671300009
J	Gong, PF; Cederbaum, AI				Gong, Pengfei; Cederbaum, Arthur I.			Transcription factor Nrf2 protects HepG2 cells against CYP2E1 plus arachidonic acid-dependent toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; CYTOCHROME-P450 2E1; LIPID-PEROXIDATION; RESPONSIVE ELEMENT; SUBUNIT GENE; G2 CELLS; FISH-OIL; EXPRESSION; LIVER	Nrf2 is a transcription factor that regulates important antioxidant and phase II detoxification genes. Arachidonic acid (AA) causes CYP2E1-dependent toxicity in HepG2 cells. The ability of Nrf2 to protect against CYP2E1-dependent AA toxicity and its possible mechanism were evaluated. AA activates Nrf2 in CYP2E1-expressing HepG2 cells (E47 cells), increasing Nrf2 protein and mRNA levels, Nrf2 nuclear translocation, and Nrf2-ARE binding activity. These increases in Nrf2 are associated with elevated expression of Nrf2-regulated antioxidant genes. Overexpression of Nrf2 by transient transfection of plasmid Nrf2 confers resistance of E47 cells against AA toxicity. Blocking Nrf2 with small interfering RNA (siRNA)-Nrf2 potentiates the CYP2E1-dependent AA toxicity. This enhanced toxicity is accompanied by decreases of cellular GSH levels and increases in production of reactive oxygen species and lipid peroxidation. There is also a potentiation of mitochondrial damage in the presence of siRNA-Nrf2. The protective effects of Nrf2 against CYP2E1-dependent toxicity can be blocked by L-buthionine(S,R)-sulfoximine, a specific inhibitor of glutamate-cysteine ligase, which is a rate-limiting enzyme in the synthesis of GSH and is regulated by Nrf2. Elevation of GSH by supplementing with glutathione ethyl ester can partially reverse the enhanced AA toxicity by siRNA-Nrf2. Moreover, in contrast to AA, L-buthionine(S,R)- sulfoximine toxicity is not prevented by plasmid Nrf2 probably because protective GSH cannot be synthesized. Together, these results suggest that Nrf2, through up-regulation of glutamate-cysteine ligase and increase of GSH levels, protects against CYP2E1-dependent AA toxicity.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu						Alam J, 2000, J BIOL CHEM, V275, P27694; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; CHOW SC, 1990, J BIOL CHEM, V265, P902; FRAGA CG, 1987, FREE RADICAL BIO MED, V3, P119, DOI 10.1016/S0891-5849(87)80006-0; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Gong PF, 2006, HEPATOLOGY, V43, P144, DOI 10.1002/hep.21004; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; Gong PF, 2004, FREE RADICAL BIO MED, V36, P307, DOI 10.1016/j.freeradbiomed.2003.10.017; Gong PF, 2003, J BIOL CHEM, V278, P29693, DOI 10.1074/jbc.M304728200; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Gonzalez FJ, 2005, MUTAT RES-FUND MOL M, V569, P101, DOI 10.1016/j.mrfmmm.2004.04.021; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; Kurose I, 1997, HEPATOLOGY, V25, P368; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Mari R, 2000, J BIOL CHEM, V275, P15563; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Novak RF, 2000, ARCH PHARM RES, V23, P267, DOI 10.1007/BF02975435; Primiano T, 1997, Adv Pharmacol, V38, P293; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9; TSUKAMOTO H, 1990, HEPATOLOGY, V12, P599, DOI 10.1002/hep.1840120325; Wu DF, 2000, MOL CELL BIOCHEM, V204, P157, DOI 10.1023/A:1007064706101; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082	38	26	27	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14573	14579		10.1074/jbc.M600613200	http://dx.doi.org/10.1074/jbc.M600613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551616	hybrid			2022-12-27	WOS:000237671300008
J	El-Mahdy, MA; Zhu, QZ; Wang, QE; Wani, G; Praetorius-Ibba, M; Wani, AA				El-Mahdy, MA; Zhu, QZ; Wang, QE; Wani, G; Praetorius-Ibba, M; Wani, AA			Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-E; GROUP-E CELLS; CYCLOBUTANE PYRIMIDINE DIMERS; GLOBAL GENOMIC REPAIR; GROUP-C PROTEIN; E GENE-PRODUCT; BINDING-PROTEIN; ESCHERICHIA-COLI; COP9 SIGNALOSOME	Xeroderma pigmentosum ( XP) complementation group E gene product, damaged DNA- binding protein 2 ( DDB2), is a subunit of the DDB heterodimeric protein complex with high specificity for binding to a variety of DNA helix- distorting lesions. DDB is believed to play a role in the initial step of damage recognition in mammalian nucleotide excision repair ( NER) of ultraviolet light ( UV)- induced photolesions. It has been shown that DDB2 is rapidly degraded after cellular UV irradiation. However, the relevance of DDB2 degradation to its functionality in NER is still unknown. Here, we have provided evidence that Cullin 4A ( CUL- 4A), a key component of CUL4A- based ubiquitin ligase, mediates DDB2 degradation at the damage sites and regulates the recruitment of XPC and the repair of cyclobutane pyrimidine dimers. We have shown that CUL- 4A can be identified in a UV- responsive protein complex containing both DDB subunits. CUL- 4A was visualized in localized UV- irradiated sites together with DDB2 and XPC. Degradation of DDB2 could be blocked by silencing CUL- 4A using small interference RNA or by treating cells with proteasome inhibitor MG132. This blockage resulted in prolonged retention of DDB2 at the subnuclear DNA damage foci within micropore irradiated cells. Knock down of CUL- 4A also decreased recruitment of the damage recognition factor, XPC, to the damaged foci and concomitantly reduced the removal of cyclobutane pyrimidine dimers from the entire genome. These results suggest that CUL- 4A mediates the proteolytic degradation of DDB2 and that this degradation event, initiated at the lesion sites, regulates damage recognition by XPC during the early steps of NER.	Ohio State Univ, Dept Radiol, Columbus, OH 43240 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43240 USA; Ohio State Univ, James Canc Hosp, Columbus, OH 43240 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43240 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Ohio State Univ, Dept Radiol, 2001 Polaris Pkwy, Columbus, OH 43240 USA.	wani.2@osu.edu	Zhu, Qianzheng/A-4902-2013		NCI NIH HHS [CA93413] Funding Source: Medline; NIEHS NIH HHS [ES12991, R01 ES012991, ES2388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Araujo SJ, 2000, GENE DEV, V14, P349; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kulaksiz G, 2005, MOL CELL BIOL, V25, P9784, DOI 10.1128/MCB.25.22.9784-9792.2005; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Matsuda N, 2005, DNA REPAIR, V4, P537, DOI 10.1016/j.dnarep.2004.12.012; Moser J, 2005, DNA REPAIR, V4, P571, DOI 10.1016/j.dnarep.2005.01.001; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Rapic-Otrin V, 2003, HUM MOL GENET, V12, P1507, DOI 10.1093/hmg/ddg174; Rapic-Otrin V, 2002, NUCLEIC ACIDS RES, V30, P2588, DOI 10.1093/nar/30.11.2588; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2005, CELL, V121, P387, DOI 10.1016/j.cell.2005.02.035; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wang QE, 2005, NUCLEIC ACIDS RES, V33, P4023, DOI 10.1093/nar/gki684; Wang QE, 2005, MOL CARCINOGEN, V42, P53, DOI 10.1002/mc.20065; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; WANI AA, 1987, PHOTOCHEM PHOTOBIOL, V46, P477, DOI 10.1111/j.1751-1097.1987.tb04798.x; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029	52	118	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13404	13411		10.1074/jbc.M511834200	http://dx.doi.org/10.1074/jbc.M511834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527807	hybrid			2022-12-27	WOS:000237336600047
J	Iijima, J; Zhao, Y; Isaji, T; Kameyama, A; Nakaya, S; Wang, X; Ihara, H; Cheng, X; Nakagawa, T; Miyoshi, E; Kondo, A; Narimatsu, H; Taniguchi, N; Gu, JG				Iijima, J; Zhao, Y; Isaji, T; Kameyama, A; Nakaya, S; Wang, X; Ihara, H; Cheng, X; Nakagawa, T; Miyoshi, E; Kondo, A; Narimatsu, H; Taniguchi, N; Gu, JG			Cell-cell interaction-dependent regulation of N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11 epithelial cells - Involvement of E-cadherin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PROTEIN GLYCOSYLATION; FACTOR RECEPTOR; OLIGOSACCHARIDES; ACTIVATION; EXPRESSION; SUPPRESSION; SURFACE; OVEREXPRESSION	Changes in oligosaccharide structures are associated with numerous physiological and pathological events. In this study, the effects of cell-cell interactions on N-linked oligosaccharides (N-glycans) were investigated in GE11 epithelial cells. N-glycans were purified from whole cell lysates by hydrazinolysis and then detected by high performance liquid chromatography and mass spectrometry. Interestingly, the population of the bisecting GlcNAc-containing N-glycans, the formation of which is catalyzed by N-acetylglucosaminyltransferase III (GnT-III), was substantially increased in cells cultured under dense conditions compared with those cultured under sparse conditions. The expression levels and activities of GnT-III but not other glycosyltransferases, such as GnT-V and alpha 1,6-fucosyltransferase, were also consistently increased in these cells. However, this was not observed in mouse embryonic fibroblasts or MDA-MB231 cells, in which E-cadherin is deficient. In contrast, perturbation of E-cadherin-mediated adhesion by treatment with EDTA or a neutralizing anti-E-cadherin antibody abolished the up-regulation of expression of GnT-III. Furthermore, we observed the significant increase in GnT-III activity under dense growth conditions after restoration of the expression of E-cadherin in MDA-MB231 cells. Our data together indicate that a E-cadherin-dependent pathway plays a critical role in regulation of GnT-III expression. Given the importance of GnT-III and the dynamic regulation of cell-cell interaction during tissue development and homeostasis, the changes in GnT-III expression presumably contribute to intracellular signaling transduction during such processes.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Glycotherapeut, Suita, Osaka 5650871, Japan; Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Sendai, Miyagi 9818558, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan	Osaka University; Osaka University; Tohoku Medical & Pharmaceutical University; National Institute of Advanced Industrial Science & Technology (AIST)	Taniguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, 2-2 Yamadaoka,B1, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp; jgu@tohoku-pharm.ac.jp	Kameyama, Akihiko/A-9641-2008; Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Isaji, Tomoya/ABC-9285-2021	Kameyama, Akihiko/0000-0002-8229-4449; Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Asada M, 1997, CANCER RES, V57, P1073; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Cooper CA, 2001, PROTEOMICS, V1, P340, DOI 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B; Dennis JW, 2002, BBA-GEN SUBJECTS, V1573, P414, DOI 10.1016/S0304-4165(02)00411-7; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; FEIGE JJ, 1987, J CELL PHYSIOL, V133, P461, DOI 10.1002/jcp.1041330306; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; Granovsky M, 2000, NAT MED, V6, P306; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; Ihara Y, 1997, J BIOL CHEM, V272, P9629; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Kang RJ, 2000, ARCH BIOCHEM BIOPHYS, V374, P52, DOI 10.1006/abbi.1999.1577; Kannagi R, 2001, ADV EXP MED BIOL, V491, P267; Kikuchi N, 2005, BIOINFORMATICS, V21, P1717, DOI 10.1093/bioinformatics/bti152; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Kobata A, 2000, GLYCOCONJUGATE J, V17, P443, DOI 10.1023/A:1011006122704; LARSSON O, 1993, J CELL SCI, V106, P299; Locascio A, 2001, CURR OPIN GENET DEV, V11, P464, DOI 10.1016/S0959-437X(00)00218-5; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lowe JB, 2002, BIOCHEM SOC SYMP, V69, P33; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; POCHEC E, 2003, BIOCHIM BIOPHYS ACTA, V7, P1; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; SHIRAYOSHI Y, 1983, CELL, V35, P631, DOI 10.1016/0092-8674(83)90095-8; Stanley P, 2002, BBA-GEN SUBJECTS, V1573, P363, DOI 10.1016/S0304-4165(02)00404-X; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Twal WO, 2001, J CELL SCI, V114, P4587; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Yagi T, 2000, GENE DEV, V14, P1169; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	53	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13038	13046		10.1074/jbc.M601961200	http://dx.doi.org/10.1074/jbc.M601961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537539	hybrid			2022-12-27	WOS:000237336600007
J	Wilson, AJ; Byun, DS; Popova, N; Murray, LB; L'Italien, K; Sowa, Y; Arango, D; Velcich, A; Augenlicht, LH; Mariadason, JM				Wilson, AJ; Byun, DS; Popova, N; Murray, LB; L'Italien, K; Sowa, Y; Arango, D; Velcich, A; Augenlicht, LH; Mariadason, JM			Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; BUTYRATE-INDUCED DIFFERENTIATION; MEMBRANE GLYCOPROTEIN SYNTHESIS; TRANSCRIPTIONAL REPRESSION; SURFACE MEMBRANE; CARCINOMA-CELLS; GENE PROMOTER; CACO-2 CELLS; SP1 SITES; CLASS-I	Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increasedapoptosis. SimilareffectswereobservedforHDAC2and, toa lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, amarker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growthinhibitory and apoptotic effects induced byHDACinhibitors are probably mediated through the inhibition of multiple HDACs.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto 6028566, Japan; Valle Hebron Hosp Res Inst, Program Funct Genom, Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Kyoto Prefectural University of Medicine; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Mariadason, JM (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	jmariada@aecom.yu.edu	Arango, Diego/M-5667-2016; Arango, Diego/AFW-0125-2022; Mariadason, John/N-2003-2013	Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Mariadason, John/0000-0001-9123-7684	NCI NIH HHS [CA100823-03, CA88104-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088104, R01CA100823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1047, DOI 10.1152/ajpgi.1992.262.6.G1047; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guenther MG, 2000, GENE DEV, V14, P1048; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HEERDT BG, 1994, CANCER RES, V54, P3288; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010; Jepsen K, 2002, J CELL SCI, V115, P689; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Mariadason JM, 2003, CANCER RES, V63, P8791; Mariadason JM, 1997, AM J PHYSIOL-GASTR L, V272, pG705, DOI 10.1152/ajpgi.1997.272.4.G705; Mariadason JM, 2001, CANCER RES, V61, P3465; Mariadason JM, 2001, GASTROENTEROLOGY, V120, P889, DOI 10.1053/gast.2001.22472; Mariadason JM, 2000, J CELL PHYSIOL, V183, P347, DOI 10.1002/(SICI)1097-4652(200006)183:3<347::AID-JCP7>3.0.CO;2-W; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mei SP, 2004, INT J ONCOL, V25, P1509; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tou LQ, 2004, MOL CELL BIOL, V24, P3132, DOI 10.1128/MCB.24.8.3132-3139.2004; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WEISER MM, 1973, J BIOL CHEM, V248, P2542; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Yang WC, 2001, CANCER RES, V61, P565; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	44	434	460	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13548	13558		10.1074/jbc.M510023200	http://dx.doi.org/10.1074/jbc.M510023200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533812	hybrid			2022-12-27	WOS:000237336600063
J	Choi, JY; Guengerich, FP				Choi, JY; Guengerich, FP			Kinetic evidence for inefficient and error-prone bypass across bulky N-2-guanine DNA adducts by human DNA polymerase iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; STEADY-STATE KINETICS; REPLICATION FIDELITY; NUCLEOTIDE INSERTION; KLENOW FRAGMENT; BASE-PAIR; Y-FAMILY; POL-IOTA; TEMPLATE; EXTENSION	DNA polymerase (pol) iota has been proposed to be involved in translesion synthesis past minor groove DNA adducts via Hoogsteen base pairing. The N2 position of G, located in minor groove side of duplex DNA, is a major site for DNA modification by various carcinogens. Oligonucleotides with varying adduct size at G N2 were analyzed for bypass ability and fidelity with human pol iota. Pol iota effectively bypassed N-2-methyl (Me) G and N-2-ethyl(Et)G, partially bypassed N-2-isobutyl(Ib)G and N-2-benzylG, and was blocked at N-2-CH2(2-naphthyl)G (N-2-NaphG), N-2-CH2(9-anthracenyl)G (N-2-AnthG), and N-2-CH2(6-benzo[a]pyrenyl)G. Steady-state kinetic analysis showed decreases of k(cat)/K-m for dCTP insertion opposite N-2-G adducts according to size, with a maximal decrease opposite N-2-AnthG (61-fold). dTTP misinsertion frequency opposite template G was increased 3-11-fold opposite adducts (highest with N2-NaphG), indicating the additive effect of bulk (or possibly hydrophobicity) on T misincorporation. N-2-IbG, N-2-NaphG, and N-2-AnthG also decreased the pre-steady-state kinetic burst rate compared with unmodified G. High kinetic thio effects (Sp-2'-deoxycytidine 5'-O-(1-thiotriphosphate)) opposite N-2-EtG and N-2-AnthG (but not G) suggest that the chemistry step is largely interfered with by adducts. Severe inhibition of polymerization opposite N-2, N-2-diMeG compared with N-2-EtG by pol eta but not by pol iota is consistent with Hoogsteen base pairing by pol iota. Thus, polymerization by pol iota is severely inhibited by a bulky group at G N2 despite an advantageous mode of Hoogsteen base pairing; pol iota may play a limited role in translesion synthesis on bulky N-2-G adducts in cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [R01 ES10375, P30 ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200; BORER PN, 1975, HDB BIOCH MOL BIOL; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; EARLE CE, 1984, CHEM CARCINOGENS, V1; EARLE CE, 1984, CHEM CARCINOGENS, V2; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KORNBERG A, 1992, DNA REPUBLICATION; Matsuda T, 1999, BIOCHEMISTRY-US, V38, P929, DOI 10.1021/bi982134j; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Nair DT, 2005, STRUCTURE, V13, P1569, DOI 10.1016/j.str.2005.08.010; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; RIEDBERG E, 2006, DNA REPAI MUTAGENESI; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Terashima I, 2001, BIOCHEMISTRY-US, V40, P4106, DOI 10.1021/bi002719p; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005; Wang M, 2004, CANCER RES, V64, P1924, DOI 10.1158/0008-5472.CAN-03-3080; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; Washington MT, 2004, MOL CELL BIOL, V24, P936, DOI 10.1128/MCB.24.2.936-943.2004; Wolfle WT, 2005, MOL CELL BIOL, V25, P8748, DOI 10.1128/MCB.25.19.8748-8754.2005; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yasui M, 2001, NUCLEIC ACIDS RES, V29, P1994, DOI 10.1093/nar/29.9.1994; Zang H, 2005, CHEM RES TOXICOL, V18, P389, DOI 10.1021/tx049683c; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	60	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12315	12324		10.1074/jbc.M600112200	http://dx.doi.org/10.1074/jbc.M600112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527824	hybrid			2022-12-27	WOS:000237134700016
J	Hiromasa, Y; Hu, LY; Roche, TE				Hiromasa, Y; Hu, LY; Roche, TE			Ligand-induced effects on pyruvate dehydrogenase kinase isoform 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER LIPOYL DOMAIN; ACETYL-COENZYME-A; DIHYDROLIPOYL ACETYLTRANSFERASE; TRANSACETYLASE COMPONENT; TRYPTOPHAN FLUORESCENCE; PHOSPHATASE ISOFORM-1; ACTIVATED FUNCTION; COMPLEX; BINDING; PROTEIN	Tryptophan fluorescence was used to analyze binding of ligands to human pyruvate dehydrogenase isoform 2 (PDHK2) and to demonstrate effects of ligand binding on distal structure of PDHK2 that is required for binding to the inner lipoyl domain (L2) of the dihydrolipoyl acetyltransferase. Ligand-altered binding of PDHK2 to L2 and effects of specific ligands on PDHK2 oligomeric state were characterized by analytical ultracentrifugation. ATP, ADP, and pyruvate markedly quenched the tryptophan fluorescence of PDHK2 and gave maximum quenching L-0.5 estimates: similar to 53%/3 mu M for ATP; similar to 49%/15 mu M for ADP; and similar to 71%/similar to 590 mu M for pyruvate. The conversion of Trp-383 to phenylalanine completely removed ATP- and ADP-induced quenching and >= 80% of the absolute decrease in fluorescence due to pyruvate. The W383F-PDHK2 mutant retained high catalytic activity. Pyruvate, added after ADP, quenched Trp fluorescence with an L-0.5 of 3.4 mu M pyruvate, >= 150-fold lower concentration than needed with pyruvate alone. ADP-enhanced binding of pyruvate was maintained with W383F-PDHK2. Binding of PDHK2 dimer to L2 is enhanced when L2 are housed in oligomeric structures, including the glutathione S-transferase (GST)-L2 dimer, and further strengthened by reduction of the lipoyl groups (GST-L2(red)) (Hiromasa and Roche (2003) J. Biol. Chem. 278, 33681 - 33693). Binding of PDHK2 to GST-L2(red) was modestly hindered by 200 mu M level of ATP or ADP or 5.0 mM pyruvate; a marked change to nearly complete prevention of binding was observed with ATP or ADP plus pyruvate at only 100 mu M levels, and these conditions caused PDHK2 dimer to associate to a tetramer. These changes should make major contributions to synergistic inhibition of PDHK2 activity by ADP and pyruvate. Ligand-induced changes that interfere with PDHK2 binding to GST-L2(red) may involve release of an interdomain cross arm between PDHK2 subunits in which Trp-383 plays a critical anchoring role.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.	bchter@ksu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher TD, 1999, J MED CHEM, V42, P2741, DOI 10.1021/jm9902584; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13442, DOI 10.1021/bi0494875; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13432, DOI 10.1021/bi049488x; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Callis PR, 2004, J PHYS CHEM B, V108, P4248, DOI 10.1021/jp0310551; Callis PR, 2003, CHEM PHYS LETT, V369, P409, DOI 10.1016/S0009-2614(02)02046-8; CATE RL, 1978, J BIOL CHEM, V253, P496; CATE RL, 1979, J BIOL CHEM, V254, P1659; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Correia JJ, 2000, METHOD ENZYMOL, V321, P81; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; Klyuyeva A, 2005, BIOCHEMISTRY-US, V44, P13573, DOI 10.1021/bi0505868; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; LIU TC, 1995, J BIOL CHEM, V270, P15545, DOI 10.1074/jbc.270.26.15545; LOEWENTHAL R, 1991, BIOCHEMISTRY-US, V30, P6775, DOI 10.1021/bi00241a021; ONO K, 1993, J BIOL CHEM, V268, P26135; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Popov KM, 1997, FEBS LETT, V419, P197, DOI 10.1016/S0014-5793(97)01453-1; PRATT ML, 1979, BIOCHEM BIOPH RES CO, V91, P289, DOI 10.1016/0006-291X(79)90616-8; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P168, DOI 10.1111/j.1749-6632.1989.tb14994.x; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Tuganova A, 2005, BIOCHEM J, V387, P147, DOI 10.1042/BJ20040805; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301; Turkan A, 2004, BIOCHEMISTRY-US, V43, P15073, DOI 10.1021/bi048901y; Turkan A, 2002, J BIOL CHEM, V277, P14976, DOI 10.1074/jbc.M108434200; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130	56	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12568	12579		10.1074/jbc.M513514200	http://dx.doi.org/10.1074/jbc.M513514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517984	hybrid			2022-12-27	WOS:000237134700046
J	Bampi, C; Bibillo, A; Wendeler, M; Divita, G; Gorelick, RJ; Le Grice, SFJ; Darlix, JL				Bampi, C; Bibillo, A; Wendeler, M; Divita, G; Gorelick, RJ; Le Grice, SFJ; Darlix, JL			Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA STRAND TRANSFER; RNASE-H ACTIVITY; IN-VITRO; VIRAL-DNA; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; CDNA INTEGRATION; MUTATION-RATE; LIFE-CYCLE; HOT-SPOT	During HIV replication, reverse transcriptase (RT), assisted by the nucleocapsid protein (NC), converts the genomic RNA into proviral DNA. This process appears to be the major source of genetic variability, as RT can misincorporate nucleotides during minus and plus strand DNA synthesis. To investigate nucleotide addition or substitution by RT, we set up in vitro models containing HIV-1 RNA, cDNA, NC, and various RTs. We used the wild type RT and azidothymidine- and didanosine-resistant RTs, because they represent the major forms of resistant RTs selected in patients undergoing therapies. Results show that all RTs can add nucleotides in a non-template fashion at the cDNA 3'end, a reaction stimulated by NC. Nucleotide substitutions were examined using in vitro systems where 3'-mutated cDNAs were extended by RT on an HIV-1 RNA template. With NC, RT extension of the mutated cDNAs was efficient, and surprisingly, mutations were frequently corrected. These results suggest for the first time that RT has excision-repair activity that is triggered by NC. Chaperoning of RT by NC might be explained by the fact that NC stabilizes an RT-DNA binary complex. In conclusion, RT-NC interactions appear to play critical roles in HIV-1 variability.	Ecole Normale Super Lyon, LaboRetro, INSERM, U412,Unite Virol Humaine,Inst Federat Rech 128, F-69364 Lyon 07, France; NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA; Ctr Rech Biochim Macromol, CNRS, Format Rech Evolut 2593, F-36293 Montpellier 05, France; NCI, AIDS Vaccine Program, Sci Applicat Int Corp Frederick Inc, NIH, Frederick, MD 21702 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Darlix, JL (corresponding author), Ecole Normale Super Lyon, LaboRetro, INSERM, U412,Unite Virol Humaine,Inst Federat Rech 128, 46 Allee Italie, F-69364 Lyon 07, France.	Jean-Luc.Darlix@ens-lyon.fr	LUC, DARLIX JEAN/AAE-9268-2020	Wendeler, Michaela/0000-0001-7503-5257	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BATTULA N, 1976, J BIOL CHEM, V251, P982; Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008; Darlix J L, 2000, Adv Pharmacol, V48, P345; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DeStefano JJ, 2000, VIROLOGY, V276, P7, DOI 10.1006/viro.2000.0533; Diaz L, 2000, ARCH VIROL, V145, P1117, DOI 10.1007/s007050070113; Diaz L, 1996, NUCLEIC ACIDS RES, V24, P3086, DOI 10.1093/nar/24.15.3086; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003; Golinelli MP, 2002, BIOCHEMISTRY-US, V41, P5894, DOI 10.1021/bi0160415; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Julias JG, 1997, J VIROL, V71, P4254, DOI 10.1128/JVI.71.6.4254-4263.1997; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Mansky LM, 2000, J VIROL, V74, P9532, DOI 10.1128/JVI.74.20.9532-9539.2000; Marchand B, 2004, INT J BIOCHEM CELL B, V36, P1823, DOI 10.1016/j.biocel.2004.02.029; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Oulton R, 2004, MOL BIOL CELL, V15, P3244, DOI 10.1091/mbc.E04-03-0178; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Poljak L, 2003, J MOL BIOL, V329, P411, DOI 10.1016/S0022-2836(03)00472-8; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; YU H, 1992, J BIOL CHEM, V267, P10888; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	50	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11736	11743		10.1074/jbc.M600290200	http://dx.doi.org/10.1074/jbc.M600290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500895	hybrid			2022-12-27	WOS:000236988100038
J	Bauer, R; Humphries, M; Fassler, R; Winklmeier, A; Craig, SE; Bosserhoff, AK				Bauer, R; Humphries, M; Fassler, R; Winklmeier, A; Craig, SE; Bosserhoff, AK			Regulation of integrin activity by MIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA INHIBITORY-ACTIVITY; MALIGNANT-MELANOMA; ALPHA-4 INTEGRIN; ADHESION; PROTEIN; CELLS; METASTASIS; MIGRATION; CLEAVAGE; INVASION	MIA ( melanoma inhibitory activity) has been identified as a small protein secreted from malignant melanoma cells, which interacts with extracellular matrix proteins including fibronectin. Here, we show that MIA negatively regulates the activity of the mitogen-activated protein kinase pathway in malignant melanoma. Using far Western blotting and co-immunoprecipitation we searched for MIA-binding cell surface proteins. We found that MIA interacts with integrin alpha 4 beta 1 and alpha 5 beta 1, leading to down-regulation of integrin activity and reduction of mitogen-activated protein kinase signaling. These findings also suggest that MIA may play a role in tumor progression and the spread of malignant melanomas via mediating detachment of cells from extracellular matrix molecules by modulating integrin activity. Inhibiting MIA functions in vivo may therefore provide a novel therapeutic strategy for metastatic melanoma disease.	Univ Regensburg, Sch Med, Inst Pathol, D-93053 Regensburg, Germany; Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Regensburg; University of Manchester; Max Planck Society	Bosserhoff, AK (corresponding author), Univ Regensburg, Sch Med, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Humphries, Martin/0000-0002-4331-6967; Bosserhoff, Anja/0000-0001-8147-394X				Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, INT ARCH ALLERGY IMM, V106, P323, DOI 10.1159/000236862; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hartstein ME, 1997, OPHTHAL PLAST RECONS, V13, P227, DOI 10.1097/00002341-199712000-00001; Humphries JD, 2005, J BIOL CHEM, V280, P10234, DOI 10.1074/jbc.M411102200; Hyduk SJ, 2002, J IMMUNOL, V168, P696, DOI 10.4049/jimmunol.168.2.696; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; MORETTI S, 1993, MELANOMA RES, V3, P235; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; NARUMIYA S, 1994, INT IMMUNOL, V6, P139, DOI 10.1093/intimm/6.1.139; Nikkola J, 2004, MELANOMA RES, V14, P29, DOI 10.1097/01.cmr.0000114662.02608.a5; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2000, J BIOMOL NMR, V17, P87, DOI 10.1023/A:1008306918293; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786	28	47	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11669	11677		10.1074/jbc.M511367200	http://dx.doi.org/10.1074/jbc.M511367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517605	hybrid			2022-12-27	WOS:000236988100030
J	Bunker, JM; Kamath, K; Wilson, L; Jordan, MA; Feinstein, SC				Bunker, JM; Kamath, K; Wilson, L; Jordan, MA; Feinstein, SC			FTDP-17 mutations compromise the ability of Tau to regulate microtubule dynamics in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL MICROTUBULES; FRONTOTEMPORAL DEMENTIA; PROTEIN; GENE; PHOSPHORYLATION; INSTABILITY; MODULATION; TUBULIN; BINDING; MISSENSE	The neural microtubule-associated protein Tau binds directly to microtubules and regulates their dynamic behavior. In addition to being required for normal development, maintenance, and function of the nervous system, Tau is associated with several neurodegenerative diseases, including Alzheimer disease. One group of neurodegenerative dementias known as FTDP-17 ( frontotemporal dementia with Parkinsonism linked to chromosome 17) is directly linked genetically to mutations in the tau gene, demonstrating that Tau misfunction can cause neuronal cell death and dementia. These mutations result either in amino acid substitutions in Tau or in altered Tau mRNA splicing that skews the expression ratio of wild-type 3-repeat and 4-repeat Tau isoforms. Because wild-type Tau regulates microtubule dynamics, one possible mechanism underlying Tau-mediated neurodegeneration is aberrant regulation of microtubule behavior. In this study, we microinjected normal and mutated Tau protein into cultured cells expressing fluorescent tubulin and measured the effects on the dynamic instability of individual microtubules. We found that the FTDP-17 amino acid substitutions G272V ( in both 3-repeat and 4-repeat Tau contexts), Delta K280, and P301L all exhibited markedly reduced abilities to regulate dynamic instability relative to wild-type Tau. In contrast, the FTDP-17 R406W mutation ( which maps in a regulatory region outside the microtubule binding domain of Tau) did not significantly alter the ability of 3-repeat or 4-repeat Tau to regulate microtubule dynamics. Overall, these data are consistent with a loss-of-function model in which both amino acid substitutions and altered mRNA splicing in Tau lead to neurodegeneration by diminishing the ability of Tau to properly regulate microtubule dynamics.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Bldg 571,Rm 6129, Santa Barbara, CA 93106 USA.	feinstei@lifesci.ucsb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035010, R01NS013560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35010, NS13560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Delobel P, 2002, J BIOL CHEM, V277, P9199, DOI 10.1074/jbc.M107716200; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Goedert M, 1999, NAT MED, V5, P454, DOI 10.1038/7454; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 2006, IN PRESS MICROTUBULE; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; Lamb NJC, 1997, METHOD ENZYMOL, V283, P72; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Luduena RF, 1998, INT REV CYTOL, V178, P207; Machesky LM, 2003, CURR OPIN CELL BIOL, V15, P2, DOI 10.1016/S0955-0674(02)00016-9; Maiato H, 2004, INT REV CYTOL, V241, P53, DOI 10.1016/S0074-7696(04)41002-X; Nakao C, 2004, J BIOL CHEM, V279, P23014, DOI 10.1074/jbc.M313693200; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Popov AV, 2003, TRENDS CELL BIOL, V13, P547, DOI 10.1016/j.tcb.2003.09.006; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; ROSE GG, 1958, J BIOPHYS BIOCHEM CY, V4, P761, DOI 10.1083/jcb.4.6.761; Ruiz-Canada C, 2004, NEURON, V42, P567, DOI 10.1016/S0896-6273(04)00255-7; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; ZHAI Y, 1994, J CELL SCI, V107, P881; Zhou FQ, 2005, SCIENCE, V308, P211, DOI 10.1126/science.1110301; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569	58	77	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11856	11863		10.1074/jbc.M509420200	http://dx.doi.org/10.1074/jbc.M509420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495230	Green Published, hybrid			2022-12-27	WOS:000236988100052
J	Kinlough, CL; McMahan, RJ; Poland, PA; Bruns, JB; Harkleroad, KL; Stremple, RJ; Kashlan, OB; Weixel, KM; Weisz, OA; Hughey, RP				Kinlough, CL; McMahan, RJ; Poland, PA; Bruns, JB; Harkleroad, KL; Stremple, RJ; Kashlan, OB; Weixel, KM; Weisz, OA; Hughey, RP			Recycling of MUC1 is dependent on its palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; ACYL-PROTEIN THIOESTERASE-1; TRANS-GOLGI NETWORK; BETA-CATENIN; MEDIATED ENDOCYTOSIS; BREAST-CARCINOMA; CYTOPLASMIC TAIL; COLON-CARCINOMA	MUC1 is a mucin-like transmembrane protein expressed on the apical surface of epithelia, where it protects the cell surface. The cytoplasmic domain has numerous sites for phosphorylation and docking of proteins involved in signal transduction. In a previous study, we showed that the cytoplasmic YXX phi motif (YHPM)-H-20 and the tyrosine-phosphorylated (YTNP)-T-60 motif are required for MUC1 clathrin-mediated endocytosis through binding AP-2 and Grb2, respectively ( Kinlough, C. L., Poland, P. A., Bruns, J. B., Harkleroad, K. L., and Hughey, R. P. ( 2004) J. Biol. Chem. 279, 53071-53077). Palmitoylation of transmembrane proteins can affect their membrane trafficking, and the MUC1 sequence CQC(3)RRK at the boundary of the transmembrane and cytoplasmic domains mimics reported site( s) of S-palmitoylation. [ H-3] Palmitate labeling of Chinese hamster ovary cells expressing MUC1 with mutations in CQC3RRK revealed that MUC1 is dually palmitoylated at the CQC motif independent of RRK. Lack of palmitoylation did not affect the cold detergent solubility profile of a chimera ( Tac ectodomain and MUC1 transmembrane and cytoplasmic domains), the rate of chimera delivery to the cell surface, or its half-life. Calculation of rate constants for membrane trafficking of wild-type and mutant Tac-MUC1 indicated that the lack of palmitoylation blocked recycling, but not endocytosis, and caused the chimera to accumulate in a EGFP-Rab11-positive endosomal compartment. Mutations CQC/AQA and Y20N inhibited Tac-MUC1 co-immunoprecipitation with AP-1, although mutant Y20N had reduced rates of both endocytosis and recycling, but a normal subcellular distribution. The double mutant chimera AQA+Y20N had reduced endocytosis and recycling rates and accumulated in EGFP-Rab11-positive endosomes, indicating that palmitoylation is the dominant feature modulating MUC1 recycling from endosomes back to the plasma membrane.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, 933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK078734, T32DK061296, R01DK054787, P50DK056490, R01DK054407] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA9044] Funding Source: Medline; NIDDK NIH HHS [K01 DK078734, DK054787, P50-DK056490, T32-DK061296, DK054407] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; ARCASOY SM, 1998, AM J RESP CRIT CARE, V157, pA582; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bhattacharya J, 2004, J VIROL, V78, P5500, DOI 10.1128/JVI.78.10.5500-5506.2004; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Cheung JC, 2004, BIOCHEM J, V378, P1015, DOI 10.1042/BJ20030847; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Dietrich LEP, 2004, EMBO REP, V5, P1053, DOI 10.1038/sj.embor.7400277; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dolganiuc V, 2003, J VIROL, V77, P12968, DOI 10.1128/JVI.77.24.12968-12979.2003; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Duncan JA, 2002, J BIOL CHEM, V277, P31740, DOI 10.1074/jbc.M202505200; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gubitosi-Klug RA, 2005, P NATL ACAD SCI USA, V102, P5964, DOI 10.1073/pnas.0501999102; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HANSKI C, 1995, CANCER RES, V55, P928; Herincs Z, 2005, J CELL SCI, V118, P1687, DOI 10.1242/jcs.02296; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; HILKENS J, 1988, J BIOL CHEM, V263, P4215; Hudson MJH, 1996, AM J PATHOL, V148, P951; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hull S R, 1989, Cancer Commun, V1, P261; JING SQ, 1990, J BIOL CHEM, V265, P11555; Julian J, 2002, BIOCHEM BIOPH RES CO, V293, P1183, DOI 10.1016/S0006-291X(02)00352-2; Kalinina EV, 2003, J BIOL CHEM, V278, P9244, DOI 10.1074/jbc.M209379200; Katzman RB, 2004, J VIROL, V78, P10878, DOI 10.1128/JVI.78.20.10878-10887.2004; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Lillehoj EP, 2002, AM J PHYSIOL-LUNG C, V282, pL751, DOI 10.1152/ajplung.00383.2001; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MANNORI G, 1995, CANCER RES, V55, P4425; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; Muller L, 1997, J BIOL CHEM, V272, P3669, DOI 10.1074/jbc.272.6.3749; Mulugeta S, 2003, J BIOL CHEM, V278, P47979, DOI 10.1074/jbc.M308210200; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; Pagano A, 2004, MOL BIOL CELL, V15, P4990, DOI 10.1091/mbc.E04-04-0355; Pemberton LF, 1996, J BIOL CHEM, V271, P2332, DOI 10.1074/jbc.271.4.2332; Poland PA, 1997, GLYCOCONJUGATE J, V14, P89, DOI 10.1023/A:1018569100438; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Rathenberg J, 2004, MOL CELL NEUROSCI, V26, P251, DOI 10.1016/j.mcn.2004.01.012; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Shmulevitz M, 2003, J VIROL, V77, P9769, DOI 10.1128/JVI.77.18.9769-9779.2003; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; van't Hof W, 2002, J VIROL, V76, P6382, DOI 10.1128/JVI.76.12.6382-6386.2002; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Veit M, 2001, VIROLOGY, V288, P89, DOI 10.1006/viro.2001.1063; Wagner R, 2005, J VIROL, V79, P6449, DOI 10.1128/JVI.79.10.6449-6458.2005; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	113	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12112	12122		10.1074/jbc.M512996200	http://dx.doi.org/10.1074/jbc.M512996200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507569	hybrid			2022-12-27	WOS:000236988100081
J	Takeuchi, R; Ruike, T; Nakamura, R; Shimanouchi, K; Kanai, Y; Abe, Y; Ihara, A; Sakaguchi, K				Takeuchi, R; Ruike, T; Nakamura, R; Shimanouchi, K; Kanai, Y; Abe, Y; Ihara, A; Sakaguchi, K			Drosophila DNA polymerase zeta interacts with recombination repair protein 1, the Drosophila homologue of human abasic endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; EXPRESSING ANTISENSE RNA; CATALYTIC SUBUNIT; EMBRYONIC LETHALITY; QUALITY-CONTROL; SOMATIC HYPERMUTATION; DECREASED FREQUENCY; POLY(A) POLYMERASE; REV1 PROTEIN	Abasic ( AP) sites are a threat to cellular viability and genomic integrity, since they impede transcription and DNA replication. In mammalian cells, DNA polymerase ( pol) beta plays an important role in the repair of AP sites. However, it is known that many organisms, including Drosophila melanogaster, do not have a pol beta homologue, and it is unclear how they repair AP sites. Here, we screened for DNA polymerases that interact with the Drosophila AP endonuclease 1 homologue, Rrp1 ( recombination repair protein 1), and found that Drosophila pol zeta ( Dmpol zeta), DmREV3 and DmREV7 bound to Rrp1 in a protein affinity column. Rrp1 directly interacted with DmREV7 in vitro and in vivo but not with DmREV3. These findings suggest that the DNA polymerase partner for Rrp1 is Dmpol zeta and that this interaction occurs through DmREV7. Interestingly, DmREV7 bound to the N-terminal region of Rrp1, which has no known protein homologue, suggesting that this binding is a species-specific event. Moreover, DmREV7 could stimulate the AP endonuclease activity of Rrp1, but not the 3'-exonuclease activity, and form a homomultimer. DmREV3 could not incorporate nucleotides at the 5'-incised tetrahydrofran sites but did show strand displacement activity for one-nucleotide-gapped DNA, which was not influenced by either DmREV7 or Rrp1. Methyl methanesulfonate and hydrogen peroxide treatments increased mRNA levels of DmREV3 and DmREV7. On the basis of the direct interaction between DmREV7 and Rrp1, we suggest that Dmpol zeta may be involved in the repair pathway of AP sites in DNA.	Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan	Tokyo University of Science	Sakaguchi, K (corresponding author), Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	kengo@rs.noda.tus.ac.jp						Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; Diaz M, 2003, MOL CANCER RES, V1, P836; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Eeken JCJ, 2001, MUTAT RES-DNA REPAIR, V485, P237, DOI 10.1016/S0921-8777(01)00062-3; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; HARRIS PV, 1987, MUTAT RES, V183, P53, DOI 10.1016/0167-8817(87)90045-9; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kajiwara K, 2001, GENES CELLS, V6, P99, DOI 10.1046/j.1365-2443.2001.00410.x; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; Li ZQ, 2002, MUTAT RES-FUND MOL M, V510, P71, DOI 10.1016/S0027-5107(02)00253-1; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Reardon BJ, 1998, J BIOL CHEM, V273, P33991, DOI 10.1074/jbc.273.51.33991; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Szakmary A, 1996, P NATL ACAD SCI USA, V93, P1607, DOI 10.1073/pnas.93.4.1607; Takeuchi R, 2004, BIOCHEM J, V382, P535, DOI 10.1042/BJ20031833; Uchiyama Y, 2004, EUR J BIOCHEM, V271, P2799, DOI 10.1111/j.1432-1033.2004.04214.x; Van Sloun PPH, 1999, MUTAT RES-DNA REPAIR, V433, P109, DOI 10.1016/S0921-8777(98)00067-6; Vanacova S, 2005, PLOS BIOL, V3, P986, DOI 10.1371/journal.pbio.0030189; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9; Wong D, 2003, J BIOL CHEM, V278, P36242, DOI 10.1074/jbc.M306065200; Wyers F, 2005, CELL, V121, P725, DOI 10.1016/j.cell.2005.04.030; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X	40	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11577	11585		10.1074/jbc.M512959200	http://dx.doi.org/10.1074/jbc.M512959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507570	hybrid			2022-12-27	WOS:000236988100020
J	Bugyi, B; Papp, G; Hild, G; Lorinczy, D; Nevalainen, EM; Lappalainen, P; Somogyi, B; Nyitrai, M				Bugyi, B; Papp, G; Hild, G; Lorinczy, D; Nevalainen, EM; Lappalainen, P; Somogyi, B; Nyitrai, M			Formins regulate actin filament flexibility through long range allosteric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DIAPHANOUS-RELATED FORMINS; F-ACTIN; INORGANIC-PHOSPHATE; HOMOLOGY-2 DOMAIN; DIVALENT-CATIONS; ATP HYDROLYSIS; FISSION YEAST; CELL-GROWTH; PROTEIN	The members of the formin family nucleate actin polymerization and play essential roles in the regulation of the actin cytoskeleton during a wide range of cellular and developmental processes. In the present work, we describe the effects of mDia1-FH2 on the conformation of actin filaments by using a temperature-dependent fluorescence resonance energy transfer method. Our results revealed that actin filaments were more flexible in the presence than in the absence of formin. The effect strongly depends on the mDia1-FH2 concentration in a way that indicates that more than one mechanism is responsible for the formin effect. In accordance with the more flexible filament structure, the thermal stability of actin decreased and the rate of phosphate dissociation from actin filaments increased in the presence of formin. The interpretation of the results supports a model in which formin binding to barbed ends makes filaments more flexible through long range allosteric interactions, whereas binding of formin to the sides of the filaments stabilizes the protomer-protomer interactions. These results suggest that formins can regulate the conformation of actin filaments and may thus also modulate the affinity of actin-binding proteins to filaments nucleated/capped by formins.	Univ Pecs, Fac Med, Dept Biophys, Res Grp Fluorescence Spect,Off Acad Res Grp Attac, H-7624 Pecs, Hungary; Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland	University of Pecs; University of Helsinki	Nyitrai, M (corresponding author), Univ Pecs, Fac Med, Dept Biophys, Res Grp Fluorescence Spect,Off Acad Res Grp Attac, Szigeti Str 12, H-7624 Pecs, Hungary.	miklos.nyitrai@aok.pte.hu		Nyitrai, Miklos/0000-0002-6229-4337; Lappalainen, Pekka/0000-0001-6227-0354	Wellcome Trust [079003] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hild G, 2002, EUR J BIOCHEM, V269, P842, DOI 10.1046/j.0014-2956.2001.02716.x; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nyitrai M, 2000, EUR J BIOCHEM, V267, P4334, DOI 10.1046/j.1432-1327.2000.01461.x; Nyitrai M, 1997, BIOPHYS J, V73, P2023, DOI 10.1016/S0006-3495(97)78232-8; Nyitrai M, 1999, J BIOL CHEM, V274, P12996, DOI 10.1074/jbc.274.19.12996; Nyitrai M, 2000, J BIOL CHEM, V275, P41143, DOI 10.1074/jbc.M004146200; Oosawa F, 1972, Nihon Seirigaku Zasshi, V34, P96; Orlova A, 2004, P NATL ACAD SCI USA, V101, P17664, DOI 10.1073/pnas.0407525102; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Prochniewicz E, 1996, J MOL BIOL, V260, P756, DOI 10.1006/jmbi.1996.0435; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Pruyne D, 2000, J CELL SCI, V113, P571; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; SOMOGYI B, 1984, BIOCHEMISTRY-US, V23, P3403, DOI 10.1021/bi00310a004; Somogyi B, 2000, J PHOTOCH PHOTOBIO B, V59, P26, DOI 10.1016/S1011-1344(00)00130-5; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Visegrady B, 2004, FEBS LETT, V565, P163, DOI 10.1016/j.febslet.2004.03.096; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000	60	53	55	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10727	10736		10.1074/jbc.M510252200	http://dx.doi.org/10.1074/jbc.M510252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490788	hybrid, Green Accepted			2022-12-27	WOS:000236822200011
J	Park, JH; Attardo, GM; Hansen, IA; Raikhel, AS				Park, JH; Attardo, GM; Hansen, IA; Raikhel, AS			GATA factor translation is the final downstream step in the amino acid/target-of-rapamycin-mediated vitellogenin gene expression in the anautogenous mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; DNA-BINDING; FAT-BODY; TOR; SERPENT; FAMILY; LINK; ACTIVATION; CULICIDAE; HIERARCHY	Ingestion of blood is required for vector mosquitoes to initiate reproductive cycles determining their role as vectors of devastating human diseases. Nutritional signaling plays a pivotal role in regulating mosquito reproduction. Transcription of yolk protein precursor genes is repressed until mosquitoes take blood. Previously, we have shown that to signal the presence of blood in the gut, mosquitoes utilize the target-of-rapamycin ( TOR) pathway. The TOR signaling pathway transduces the amino acid signal activating the major yolk protein precursor gene, vitellogenin (Vg). Here we report the identification of a GATA factor (AaGATAa) that is synthesized after a blood meal and acts as a transcriptional activator of Vg. We showed that AaGATAa bound specifically to GATA-binding sites present in the proximal promoter region of the Vg gene and positively regulated Vg expression in transfection assays. RNA interference-mediated knock down of AaGATAa transcript resulted in a significant inhibition of Vg expression in both fat-body tissue culture and blood-fed mosquitoes. AaGATAa mRNA accumulated in the fat body prior to blood feeding. However, translation of GATA was activated by blood feeding because the GATA protein increased dramatically in the fat body of blood-fed mosquitoes. This increase was also reproduced in the fat-body culture stimulated with amino acids. GATA translation was inhibited by rapamycin and cycloheximide as well as by RNA interference-mediated knock down of S6 kinase. These experiments have revealed that the TOR signaling pathway induced by nutritional signaling regulates the translation of a GATA factor, which is the specific transcriptional activator of the Vg gene.	Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, 3401 Watkins Dr, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Attardo, Geoffrey Michael/I-3320-2019	Attardo, Geoffrey Michael/0000-0001-6265-2969	NIAID NIH HHS [R01 AI024716, 5R37AI24716] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1993, DEVELOPMENT, V119, P623; Attardo GM, 2003, P NATL ACAD SCI USA, V100, P13374, DOI 10.1073/pnas.2235649100; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bell A, 2000, OBES RES, V8, P249, DOI 10.1038/oby.2000.29; Brodu V, 2001, DEVELOPMENT, V128, P2593; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carney GE, 2000, GENETICS, V154, P1203; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Chen L, 2004, J MOL ENDOCRINOL, V33, P743, DOI 10.1677/jme.1.01531; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Fossett N, 2003, P NATL ACAD SCI USA, V100, P11451, DOI 10.1073/pnas.1635050100; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; Kokoza VA, 2001, GENE, V274, P47, DOI 10.1016/S0378-1119(01)00602-3; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Martin D, 2001, MOL CELL ENDOCRINOL, V173, P75, DOI 10.1016/S0303-7207(00)00413-5; Miura K, 1999, MOL CELL ENDOCRINOL, V156, P111, DOI 10.1016/S0303-7207(99)00136-7; ORKIN SH, 1992, BLOOD, V80, P575; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Raikhel A. S., 1997, The molecular biology of insect disease vectors: a methods manual., P507; Raikhel AS, 2002, INSECT BIOCHEM MOLEC, V32, P1275, DOI 10.1016/S0965-1748(02)00090-5; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Sun GQ, 2004, MOL CELL ENDOCRINOL, V218, P95, DOI 10.1016/j.mce.2003.12.014; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; UCHIDA K, 1990, J MED ENTOMOL, V27, P302, DOI 10.1093/jmedent/27.3.302; Uchida K, 2001, J MED ENTOMOL, V38, P572, DOI 10.1603/0022-2585-38.4.572; Waltzer L, 2002, EMBO J, V21, P5477, DOI 10.1093/emboj/cdf545; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wang SF, 2005, REPRO BIOL, V12, P69	39	78	85	4	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11167	11176		10.1074/jbc.M601517200	http://dx.doi.org/10.1074/jbc.M601517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490782	hybrid			2022-12-27	WOS:000236822200060
J	Berry, FB; Mirzayans, F; Walter, MA				Berry, FB; Mirzayans, F; Walter, MA			Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD/WINGED-HELIX GENE; MUTATION CONGENITAL-HYDROCEPHALUS; CELL-DEATH; GLAUCOMA; PHOSPHORYLATION; DEGRADATION; MF1; PHENOTYPES; FKHL7; MAP	Mutations in the FOXC1 transcription factor gene result in Axenfeld Rieger malformations, a disorder that affects the anterior segment of the eye, the teeth, and craniofacial structures. Individuals with this disorder possess an elevated risk for developing glaucoma. Previous work in our laboratory has indicated that FOXC1 transcriptional activity may be regulated by phosphorylation. We report here that FOXC1 is a short-lived protein (t(1/2) <30 min), and serine 272 is a critical residue in maintaining proper stability of FOXC1. Furthermore, we have demonstrated that activation of the ERK1/2 mitogen-activated protein kinase through epidermal growth factor stimulation is required for maximal FOXC1 transcriptional activation and stability. Finally, we have demonstrated that FOXC1 is targeted to the ubiquitin 26 S proteasomal degradation pathway and that amino acid residues 367-553, which include the C-terminal transactivation domain of FOXC1, are essential for ubiquitin incorporation and proteolysis. These results indicate that FOXC1 protein levels and activity are tightly regulated by post-translational modifications.	Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berry, FB (corresponding author), Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada.	fberry@ualberta.ca						Berry FB, 2005, MOL CELL BIOL, V25, P1415, DOI 10.1128/MCB.25.4.1415-1424.2005; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Charles I, 2005, INVEST OPHTH VIS SCI, V46, P1330, DOI 10.1167/iovs.04-0363; Hong HK, 1999, HUM MOL GENET, V8, P625, DOI 10.1093/hmg/8.4.625; Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314; Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Lehmann OJ, 2000, AM J HUM GENET, V67, P1129; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nickells RW, 1996, J GLAUCOMA, V5, P345; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012-1606(03)00355-5; Saleem RA, 2001, AM J HUM GENET, V68, P627, DOI 10.1086/318792; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shields M B, 1983, Trans Am Ophthalmol Soc, V81, P736; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860	29	37	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10098	10104		10.1074/jbc.M513629200	http://dx.doi.org/10.1074/jbc.M513629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492674	hybrid			2022-12-27	WOS:000236594300035
J	Dahm, CC; Moore, K; Murphy, MP				Dahm, CC; Moore, K; Murphy, MP			Persistent S-nitrosation of complex I and other mitochondrial membrane proteins by S-nitrosothiols but not nitric oxide or peroxynitrite - Implications for the interaction of nitric oxide with mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; MEDIATED OXIDATION; RADICAL PRODUCTION; IRON-NITROSYLS; SUPEROXIDE; INHIBITION; OXYGEN; RESPIRATION; SYNTHASE; THIOLS	S-Nitrosation of mitochondrial proteins has been proposed to contribute to the pathophysiological interactions of nitric oxide (NO) and its derivatives with mitochondria but has not been shown directly. Furthermore, little is known about the mechanism of formation or the fate of these putative S-nitrosothiols. Here we have determined whether mitochondrial membrane protein thiols can be S-nitrosated on exposure to free NO from 3,3-bis(aminoethyl)1-hydroxy-2-oxo-1-triazene (DETA-NONOate) by interaction with S-nitrosoglutathione or S-nitroso-N-acetylpenicillamine (SNAP) and by the NO derivative peroxynitrite. S-Nitrosation of protein thiols was measured directly by chemiluminescence detection. S-Nitrosoglutathione and S-nitroso-N-acetylpenicillamine led to extensive protein thiol oxidation, with about 30% of the modified protein thiols persistently S-nitrosated. In contrast, there was no protein thiol oxidation or S-nitrosation on exposure to 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene. Peroxynitrite extensively oxidized protein thiols but produced negligible amounts of S-nitrosothiols. Therefore, mitochondrial membrane protein thiols are S-nitrosated by preformed S-nitrosothiols but not by NO or by peroxynitrite. These S-nitrosated protein thiols were readily reduced by glutathione, so S-nitrosation will only persist when the mitochondrial glutathione pool is oxidized. Respiratory chain complex I was S-nitrosated by S-nitrosothiols, consistent with it being an important target for S-nitrosation during nitrosative stress. The S-nitrosation of complex I correlated with a significant loss of activity that was reversed by thiol reductants. S-Nitrosation was also associated with increased superoxide production from complex I. These findings point to a significant role for complex I S-nitrosation and consequent dysfunction during nitrosative stress in disorders such as Parkinson disease and sepsis.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; UCL, Dept Med, London NW3 2PF, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of London; University College London	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Dahm, Christina C/G-9787-2014; Murphy, Michael P/C-2120-2009	Dahm, Christina C/0000-0003-0481-2893; Murphy, Michael P/0000-0003-1115-9618	MRC [MC_U105663142] Funding Source: UKRI; Medical Research Council [MC_U105663142] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BUTLER AR, 1995, TRENDS PHARMACOL SCI, V16, P18, DOI 10.1016/S0165-6147(00)88968-3; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cornwell TL, 2003, AM J PHYSIOL-CELL PH, V284, pC1516, DOI 10.1152/ajpcell.00268.2002; Costa NJ, 2003, ANTIOXID REDOX SIGN, V5, P291, DOI 10.1089/152308603322110878; Di Iorio E E, 1981, Methods Enzymol, V76, P57; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Hsu M, 2005, J NEUROCHEM, V92, P1091, DOI 10.1111/j.1471-4159.2004.02929.x; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; Kindig CA, 2002, RESP PHYSIOL NEUROBI, V132, P169, DOI 10.1016/S1569-9048(02)00068-X; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; LUCAS M, 1992, ANAL BIOCHEM, V206, P273, DOI 10.1016/0003-2697(92)90366-F; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Packer MA, 1996, BIOCHEM MOL BIOL INT, V40, P527; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Rogers SC, 2005, J BIOL CHEM, V280, P26720, DOI 10.1074/jbc.M501179200; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x; Shiva S, 2004, BIOCHEM J, V379, P359, DOI 10.1042/BJ20031758; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P874, DOI 10.1016/j.freeradbiomed.2004.12.012	75	160	166	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10056	10065		10.1074/jbc.M512203200	http://dx.doi.org/10.1074/jbc.M512203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481325	hybrid			2022-12-27	WOS:000236594300030
J	Iavarone, C; Acunzo, M; Carlomagno, F; Catania, A; Melillo, RM; Carlomagno, SM; Santoro, M; Chiariello, M				Iavarone, C; Acunzo, M; Carlomagno, F; Catania, A; Melillo, RM; Carlomagno, SM; Santoro, M; Chiariello, M			Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; C-JUN PROMOTER; CELLULAR-RESPONSE; FAMILY; ABL; DISEASE; SRC; EXPRESSION; INHIBITOR; MUTATIONS	Mitogen-activated protein (MAP) kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation, and apoptosis. Extracellular signal- regulated kinase 8 (Erk8) is a large MAP kinase whose activity is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate Erk8, and we demonstrate that such MAP kinase participated in RET/PTC3-dependent stimulation of the c-jun promoter. By using RET/PTC3 molecules mutated in specific tyrosine autophosphorylation sites, we characterized Tyr(981), a known binding site for c-Src, as a major determinant of RET/PTC3-induced Erk8 activation, although, surprisingly, the underlying mechanism did not strictly depend on the activity of Src. In contrast, we present evidence that RET/PTC3 acts on Erk8 through Tyr(981)-mediated activation of c-Abl. Furthermore, we localized the region responsible for the modulation of Erk8 activity by the RET/PTC3 and Abl oncogenes in the Erk8 C-terminal domain. Altogether, these results support a role for Erk8 as a novel effector of RET/PTC3 and, therefore, RET biological functions.	CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Chiariello, M (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	chiariel@unina.it	Chiariello, Mario/O-3642-2014; melillo, rosa marina/O-5255-2015; Acunzo, Mario/ABE-1739-2020	Chiariello, Mario/0000-0001-8434-5177; Acunzo, Mario/0000-0002-3942-9061; MELILLO, Rosa Marina/0000-0002-9233-5275				Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810; Carlomagno F, 2002, CANCER RES, V62, P1077; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1331, DOI 10.1016/0006-291X(91)91719-S; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; Lobo VJSA, 2005, BIOCHEM J, V387, P231, DOI 10.1042/BJ20040927; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16	32	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10567	10576		10.1074/jbc.M513397200	http://dx.doi.org/10.1074/jbc.M513397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484222	hybrid			2022-12-27	WOS:000236594300088
J	Viswanathan, K; Tomiya, N; Park, J; Singh, S; Lee, YC; Palter, K; Betenbaugh, MJ				Viswanathan, Karthik; Tomiya, Noboru; Park, Jung; Singh, Sundeep; Lee, Yuan C.; Palter, Karen; Betenbaugh, Michael J.			Expression of a functional Drosophila melanogaster CMP-sialic acid synthetase - Differential localization of the drosophila and human enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; CELL-ADHESION MOLECULE; PHOSPHATE SYNTHASE GENE; PROTEIN GLYCOSYLATION; BIOSYNTHETIC ABILITY; RECOMBINANT PROTEINS; INSECT CELLS; CLONING; SIGNAL; SEQUENCE	CMP-N-acetylneuraminic acid is a critical metabolite in the generation of glycoconjugates that play a role in development and other physiological processes. Whereas pathways for its generation are firmly established in vertebrates, the presence and function of the relevant synthetic enzyme in insects and other protostomes is unknown. In this study, we characterize the first functional CMP-sialic acid synthase (DmCSAS) from any protostome lineage expressed from a D. melanogaster cDNA clone. Homologous genes were subsequently identified in other insect species. The gene is developmentally regulated, with expression first appearing at 12 - 24 h of embryogenesis, low expression through larval and pupal stages, and greatly enriched expression in the adult head, suggesting a possible role in the central nervous system. Activity of the enzyme was verified by an increase in in vitro and in vivo CMP-N-acetylneuraminic acid levels when expressed in a heterologous host. Unlike all known vertebrate CMP-sialic acid synthetase (CSAS) proteins that localize to the nucleus, the D. melanogaster CSAS protein was targeted to the Golgi compartment when expressed in both heterologous mammalian and insect cell lines. Replacement of the N-terminal leader sequence of DmCSAS with the human CSAS N-terminal sequence resulted in the redirection of the chimeric CSAS protein to the nucleus but with a concomitant loss of enzymatic activity. The localization of CSAS orthologs to different intracellular organelles represents, to our knowledge, the first example of differential protein targeting of orthologs in eukaryotes and reveals how the sialylation pathway diverged during the evolution of protostomes and deuterostomes.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Temple Univ, Dept Biol, Philadelphia, PA 19122 USA	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Betenbaugh, MJ (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, MD221,3400 N Charles St, Baltimore, MD 21218 USA.	beten@jhu.edu	Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; Aumiller JJ, 2003, GLYCOBIOLOGY, V13, P497, DOI 10.1093/glycob/cwg051; Aumiller JJ, 2002, PROTEIN EXPRES PURIF, V26, P438, DOI 10.1016/S1046-5928(02)00550-8; Chen H, 2002, GLYCOBIOLOGY, V12, P65, DOI 10.1093/glycob/12.2.65; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P196; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; DAMICO P, 1995, TISSUE CELL, V27, P23, DOI 10.1016/S0040-8166(95)80005-0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fukuda M, 1996, CANCER RES, V56, P2237; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; Kean EL, 2004, BBA-GEN SUBJECTS, V1673, P56, DOI 10.1016/j.bbagen.2004.04.006; Kim K, 2002, GLYCOBIOLOGY, V12, P73, DOI 10.1093/glycob/12.2.73; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Krapp S, 2003, J MOL BIOL, V334, P625, DOI 10.1016/j.jmb.2003.09.080; Lawrence SM, 2000, J BIOL CHEM, V275, P17869, DOI 10.1074/jbc.M000217200; Lawrence SM, 2001, GLYCOCONJUGATE J, V18, P205, DOI 10.1023/A:1012452705349; Malykh YN, 1999, GLYCOCONJUGATE J, V16, P731, DOI 10.1023/A:1007115627708; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Palomares LA, 2003, BIOTECHNOL PROGR, V19, P185, DOI 10.1021/bp025598o; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; WARREN L, 1963, COMP BIOCHEM PHYSIOL, V10, P153, DOI 10.1016/0010-406X(63)90238-X; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; [No title captured]	51	31	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15929	15940		10.1074/jbc.M512186200	http://dx.doi.org/10.1074/jbc.M512186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16537535	hybrid			2022-12-27	WOS:000237996000044
J	Armishaw, CJ; Daly, NL; Nevin, ST; Adams, DJ; Craik, DJ; Alewood, PF				Armishaw, Christopher J.; Daly, Norelle L.; Nevin, Simon T.; Adams, David J.; Craik, David J.; Alewood, Paul F.			alpha-selenoconotoxins, a new class of potent alpha(7) neuronal nicotinic receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE CHEMICAL LIGATION; SOLID-PHASE SYNTHESIS; CONOTOXIN-IMI; THIOREDOXIN REDUCTASE; ACETYLCHOLINE-RECEPTORS; BIOLOGICAL-ACTIVITIES; STRUCTURAL STABILITY; CONTAINING PEPTIDE; CYCLIC-PEPTIDES; SELENOCYSTEINE	Disulfide bonds are important structural motifs that play an essential role in maintaining the conformational stability of many bioactive peptides. Of particular importance are the conotoxins, which selectively target a wide range of ion channels that are implicated in numerous disease states. Despite the enormous potential of conotoxins as therapeutics, their multiple disulfide bond frameworks are inherently unstable under reducing conditions. Reduction or scrambling by thiol-containing molecules such as glutathione or serum albumin in intracellular or extracellular environments such as blood plasma can decrease their effectiveness as drugs. To address this issue, we describe a new class of selenoconotoxins where cysteine residues are replaced by selenocysteine to form isosteric and non-reducible diselenide bonds. Three isoforms of alpha-conotoxin ImI were synthesized by t-butoxycarbonyl chemistry with systematic replacement of one([ Sec(2,8)] ImI or [Sec(3,12)] ImI), or both([Sec(2,3,8,12)] ImI) disulfide bonds with a diselenide bond. Each analogue demonstrated remarkable stability to reduction or scrambling under a range of chemical and biological reducing conditions. Three-dimensional structural characterization by NMR and CD spectroscopy indicates conformational preferences that are very similar to those of native ImI, suggesting fully isomorphic structures. Additionally, full bioactivity was retained at the alpha(7) nicotinic acetylcholine receptor, with each seleno-analogue exhibiting a dose-response curve that overlaps with wild-type ImI, thus further supporting an isomorphic structure. These results demonstrate that selenoconotoxins can be used as highly stable scaffolds for the design of new drugs.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Alewood, PF (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	P.Alewood@imb.uq.edu.au	Adams, David John/K-3578-2019; Adams, David/J-9125-2014; Daly, Norelle L/D-4302-2013; Alewood, Paul F/J-2412-2014; Nevin, Simon/B-2663-2014; Craik, David/B-1695-2010	Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Daly, Norelle L/0000-0002-4697-6602; Craik, David/0000-0003-0007-6796				Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Armishaw CJ, 2005, CURR PROTEIN PEPT SC, V6, P221, DOI 10.2174/1389203054065437; Besse D, 1997, ANGEW CHEM INT EDIT, V36, P883, DOI 10.1002/anie.199708831; Besse D, 1997, J PEPT SCI, V3, P442, DOI 10.1002/(SICI)1099-1387(199711)3:6<442::AID-PSC122>3.0.CO;2-2; Bondebjerg J, 2003, CHEMBIOCHEM, V4, P186, DOI 10.1002/cbic.200390030; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOCAT P, 1985, ANAL BIOCHEM, V148, P485, DOI 10.1016/0003-2697(85)90256-8; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; DRYLAND A, 1986, J CHEM SOC P1, V1, P125; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gehrmann J, 1999, J MED CHEM, V42, P2364, DOI 10.1021/jm990114p; Gieselman MD, 2001, ORG LETT, V3, P1331, DOI 10.1021/ol015712o; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hargittai B, 2000, J MED CHEM, V43, P4787, DOI 10.1021/jm990635c; HARTRODT B, 1980, TETRAHEDRON LETT, V21, P2393, DOI 10.1016/S0040-4039(00)93158-7; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hondal RJ, 2001, J AM CHEM SOC, V123, P5140, DOI 10.1021/ja005885t; HOUSE KL, 1992, J AM CHEM SOC, V114, P8573, DOI 10.1021/ja00048a033; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; KOIDE T, 1993, CHEM PHARM BULL, V41, P1596; LARSEN BD, 1994, INT J PEPT PROT RES, V43, P1; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LIPINSKI B, 1992, BIOORG MED CHEM LETT, V2, P919, DOI 10.1016/S0960-894X(00)80588-0; LIVE DH, 1977, J ORG CHEM, V42, P3556, DOI 10.1021/jo00442a025; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moroder L, 2005, BIOPOLYMERS, V80, P85, DOI 10.1002/bip.20174; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; NUTT RF, 1980, J AM CHEM SOC, V102, P6539, DOI 10.1021/ja00541a025; OIKAWA T, 1991, P NATL ACAD SCI USA, V88, P3057, DOI 10.1073/pnas.88.8.3057; OTAKA A, 1991, TETRAHEDRON LETT, V32, P1223, DOI 10.1016/S0040-4039(00)92050-1; Pegoraro S, 1998, J MOL BIOL, V284, P779, DOI 10.1006/jmbi.1998.2189; Pegoraro S, 1999, PROTEIN SCI, V8, P1605, DOI 10.1110/ps.8.8.1605; Quaderer R, 2001, HELV CHIM ACTA, V84, P1197, DOI 10.1002/1522-2675(20010516)84:5<1197::AID-HLCA1197>3.0.CO;2-#; Quinlan GJ, 2005, HEPATOLOGY, V41, P1211, DOI 10.1002/hep.20720; Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SIEBER P, 1980, HELV CHIM ACTA, V63, P2358, DOI 10.1002/hlca.19800630826; Singh RR, 2003, BBA-PROTEINS PROTEOM, V1651, P85, DOI 10.1016/S1570-9639(03)00238-3; Stadtman TC, 2002, ANNU REV BIOCHEM, V71, P1, DOI 10.1146/annurev.biochem.71.083101.134224; Stymiest JL, 2003, ORG LETT, V5, P47, DOI 10.1021/ol027160v; WALTER R, 1965, J AM CHEM SOC, V87, P4192, DOI 10.1021/ja01096a036; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	54	146	152	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14136	14143		10.1074/jbc.M512419200	http://dx.doi.org/10.1074/jbc.M512419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16500898	hybrid			2022-12-27	WOS:000237512300037
J	Shigi, N; Sakaguchi, Y; Suzuki, T; Watanabe, K				Shigi, Naoki; Sakaguchi, Yuriko; Suzuki, Tsutomu; Watanabe, Kimitsuna			Identification of two tRNA thiolation genes required for cell growth at extremely high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; THERMUS-THERMOPHILUS HB8; PSI-C LOOP; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; CRYSTAL-STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATION; PSEUDOURIDINE SYNTHASE; THIAMIN BIOSYNTHESIS; NUCLEOSIDES PRESENT	Thermostability of tRNA in thermophilic bacteria is effected by post-transcriptional modifications, such as 2-thioribothymidine (s2T) at position 54. Using a proteomics approach, we identified two genes (ttuA and ttuB; tRNA-two-thiouridine) that are essential for the synthesis of s(2)T in Thermus thermophilus. Mutation of either gene completely abolishes thio-modification of s2T, and these mutants exhibit a temperature-sensitive phenotype. These results suggest that bacterial growth at higher temperatures is achieved through the thermal stabilization of tRNA by a 2-thiolation modification. TtuA (TTC0106) is possibly an ATPase possessing a P-loop motif. TtuB (TTC0105) is a putative thio-carrier protein that exhibits significant sequence homology with ThiS of the thiamine synthesis pathway. Both TtuA and TtuB are required for in vitro s2T formation in the presence of cysteine and ATP. The addition of cysteine desulfurases such as IscS (TTC0087) or SufS (TTC1373) enhances the sulfur transfer reaction in vitro.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Watanabe, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, 2-42 Aomi, Tokyo 1350064, Japan.	kwatanab@jbirc.aist.go.jp	Suzuki, Tsutomu/J-1776-2015; Shigi, Naoki/L-7135-2018	Suzuki, Tsutomu/0000-0002-9731-1731; Shigi, Naoki/0000-0003-4452-8264				Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; De Bie LGS, 2003, J BACTERIOL, V185, P3238, DOI 10.1128/JB.185.10.3238-3243.2003; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; HORIE N, 1985, BIOCHEMISTRY-US, V24, P5711, DOI 10.1021/bi00342a004; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Ikeuchi Y, 2005, MOL CELL, V19, P235, DOI 10.1016/j.molcel.2005.06.007; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kaya Y, 2003, RNA, V9, P711, DOI 10.1261/rna.5230603; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Legge GB, 2004, J MOL BIOL, V343, P1081, DOI 10.1016/j.jmb.2004.08.087; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; NURSE K, 1995, RNA, V1, P102; Ortenberg R, 2003, ANTIOXID REDOX SIGN, V5, P403, DOI 10.1089/152308603768295140; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Settembre E, 2003, CURR OPIN STRUC BIOL, V13, P739, DOI 10.1016/j.sbi.2003.10.006; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shigi N, 2006, J BIOL CHEM, V281, P2104, DOI 10.1074/jbc.M510771200; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; Stefankova P, 2005, GEN PHYSIOL BIOPHYS, V24, P3; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Urbonavicius J, 2005, NUCLEIC ACIDS RES, V33, P3955, DOI 10.1093/nar/gki703; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1984, J BIOCHEM-TOKYO, V96, P1625, DOI 10.1093/oxfordjournals.jbchem.a134993; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; WATANABE K, 1979, BIOCHEM BIOPH RES CO, V91, P671, DOI 10.1016/0006-291X(79)91574-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	53	52	56	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14296	14306		10.1074/jbc.M511675200	http://dx.doi.org/10.1074/jbc.M511675200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547008	hybrid			2022-12-27	WOS:000237512300055
J	Azuma, M; Toyama, R; Laver, E; Dawid, IB				Azuma, M; Toyama, R; Laver, E; Dawid, IB			Perturbation of rRNA synthesis in the bap28 mutation leads to apoptosis mediated by p53 in the zebrafish central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; EMBRYONIC-DEVELOPMENT; XENOPUS-LAEVIS; PRE-RIBOSOMES; DANIO-RERIO; PROTEIN; GENES; BIOGENESIS; YEAST	Zebrafish is a powerful vertebrate model system for using forward genetics to elucidate mechanisms of early development. We have used chemical mutagenesis to screen for mutants that show defects in the CNS. Here we describe the isolation of the bap28 mutation that leads to abnormalities in the brain starting at mid-somitogenesis stages. Mutant embryos display excess apoptosis primarily in the central nervous system ( CNS) and die by days 6 - 7 after fertilization. The mutation was positionally cloned and shown to affect a gene that encodes a large protein with high similarity to the uncharacterized human protein BAP28 and lower similarity to yeast Utp10. Utp10 is a component of a nucleolar U3 small nucleolar RNA-containing RNP complex that is required for transcription of ribosomal DNA and for processing of 18 S rRNA. We show that zebrafish Bap28 likewise is required for rRNA transcription and processing, with a major effect on 18 S rRNA maturation. We suggest that bap28 is required for cell survival in the CNS through its role in rRNA synthesis and processing. Inhibition of p53 protein expression in bap28 mutants led to embryos with morphologically normal appearance, suggesting that p53 is involved in triggering apoptosis in the bap28 mutant CNS. The bap28 mutation provides a genetic approach to study the role of ribosome biogenesis in the development of a vertebrate embryo.	NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dawid, IB (corresponding author), NICHD, Mol Genet Lab, NIH, 9000 Rockville Pike Bldg,6B Rm 413, Bethesda, MD 20892 USA.	idawid@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008809, ZIAHD001002] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008809, Z01HD001002] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abdelilah S, 1996, DEVELOPMENT, V123, P217; Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Ando H, 1998, NEUROSCI LETT, V244, P81, DOI 10.1016/S0304-3940(98)00132-3; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; BROWN DD, 1964, P NATL ACAD SCI USA, V51, P139, DOI 10.1073/pnas.51.1.139; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; DAWID IB, 1988, SCIENCE, V240, P1443, DOI 10.1126/science.3287620; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Gallagher JEG, 2004, GENE DEV, V18, P2506, DOI 10.1101/gad.1226604; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kawahara A, 2001, CURR BIOL, V11, P1353, DOI 10.1016/S0960-9822(01)00398-0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KIRKLAND DJ, 1983, MUTAT RES, V116, P73, DOI 10.1016/0165-1218(83)90098-8; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Korzh V, 1998, DEV DYNAM, V213, P92, DOI 10.1002/(SICI)1097-0177(199809)213:1<92::AID-AJA9>3.0.CO;2-T; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Lekven AC, 2000, PHYSIOL GENOMICS, V2, P37, DOI 10.1152/physiolgenomics.2000.2.2.37; Matsuda N, 2004, DEVELOPMENT, V131, P1913, DOI 10.1242/dev.01085; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; Nechiporuk A, 1999, GENOME RES, V9, P1231, DOI 10.1101/gr.9.12.1231; Oeffinger M, 2004, GENE DEV, V18, P196, DOI 10.1101/gad.285604; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Postlethwait JH, 1997, TRENDS GENET, V13, P183, DOI 10.1016/S0168-9525(97)01129-3; Roman BL, 2002, DEVELOPMENT, V129, P3009; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Steward O, 2002, CELL, V110, P537, DOI 10.1016/S0092-8674(02)00934-0; Strahle U, 1996, INT J DEV BIOL, V40, P929; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P275, DOI 10.1016/0005-2787(76)90302-6; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P265, DOI 10.1016/0005-2787(76)90301-4; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker C, 1999, METHOD CELL BIOL, V60, P43; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	51	68	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13309	13316		10.1074/jbc.M601892200	http://dx.doi.org/10.1074/jbc.M601892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531401	hybrid			2022-12-27	WOS:000237336600036
J	Wendholt, D; Spilker, C; Schmitt, A; Dolnik, A; Smalla, KH; Proepper, C; Bockmann, J; Sobue, K; Gundelfinger, ED; Kreutz, MR; Boeckers, TM				Wendholt, D; Spilker, C; Schmitt, A; Dolnik, A; Smalla, KH; Proepper, C; Bockmann, J; Sobue, K; Gundelfinger, ED; Kreutz, MR; Boeckers, TM			ProSAP-interacting protein 1 (ProSAPiP1), a novel protein of the postsynaptic density that links the spine-associated rap-gap (SPAR) to the scaffolding protein ProSAP2/Shank3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHANK FAMILY; PDZ DOMAINS; SYNAPTIC PROTEINS; BINDING-PROTEIN; RECEPTOR; EXPRESSION; BRAIN; GENE; LOCALIZATION; PSD-ZIP70	ProSAPs/ Shanks are a family of proteins that have a major scaffolding function for components of the postsynaptic density ( PSD) of excitatory brain synapses. Members of the family harbor a variety of domains for protein- protein interactions, one of which is a unique PDZ domain that differs significantly from those of other proteins. We have identified a novel binding partner for this PDZ domain, termed ProSAPiP1, that is highly enriched in the PSD and shares significant sequence homology with the PSD protein PSDZip70. Both molecules code for a Fez1 domain that can be found in a total of four related proteins. ProSAPiP1 is widely expressed in rat brain and co- localizes with ProSAP2/ Shank3 in excitatory spines and synapses. ProSAP2/ Shank3 co- immunoprecipitates with ProSAPiP1 but not with PSD- Zip70. Both proteins, however, bind and recruit SPAR to synapses with a central coiled- coil region that harbors a leucine zipper motif. This region is also responsible for homo- and heteromultimerization of ProSAPiP1 and PSD- Zip70. Thus, ProSAPiP1 and PSD- Zip70 are founders of a novel family of scaffolding proteins, the " Fezzins," which adds further complexity to the organization of the PSD protein network.	Univ Ulm, Inst Anat & Cell Biol, D-89081 Ulm, Germany; AG Mol Mechanisms Plast, Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, D-39118 Magdeburg, Germany; Osaka Univ, Sch Med, Dept Neurosci, Suita, Osaka 565, Japan	Ulm University; Leibniz Institut fur Neurobiologie (LIN); Osaka University	Kreutz, MR (corresponding author), Univ Ulm, Inst Anat & Cell Biol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	michael.kreutz@ifn-magdeburg.de; tobias.boeckers@uni-ulm.de	Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; Spilker, Christina/0000-0002-7996-7673; Dolnik, Anna/0000-0003-4166-2900				Baron MK, 2006, SCIENCE, V311, P531, DOI 10.1126/science.1118995; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 2005, J NEUROCHEM, V92, P519, DOI 10.1111/j.1471-4159.2004.02910.x; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Harris BZ, 2001, J CELL SCI, V114, P3219; Helmuth M, 2001, ANAL BIOCHEM, V293, P149, DOI 10.1006/abio.2001.5107; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Konno D, 2002, J CELL SCI, V115, P4695, DOI 10.1242/jcs.00127; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Maruoka H, 2005, J NEUROSCI, V25, P1421, DOI 10.1523/JNEUROSCI.3920-04.2005; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Olson PA, 2005, J NEUROSCI, V25, P1050, DOI 10.1523/JNEUROSCI.3327-04.2005; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; Roussignol G, 2005, J NEUROSCI, V25, P3560, DOI 10.1523/JNEUROSCI.4354-04.2005; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Woolfson DN, 2005, ADV PROTEIN CHEM, V70, P79, DOI 10.1016/S0065-3233(04)70004-2; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zhang H, 2005, J NEUROSCI, V25, P1037, DOI 10.1523/JNEUROSCI.4554-04.2005; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	43	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13805	13816		10.1074/jbc.M601101200	http://dx.doi.org/10.1074/jbc.M601101200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16522626	hybrid			2022-12-27	WOS:000237336600091
J	Douchin, V; Bohn, C; Bouloc, P				Douchin, V; Bohn, C; Bouloc, P			Down-regulation of porins by a small RNA bypasses the essentiality of the regulated intramembrane proteolysis protease RseP in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACYTOPLASMIC-STRESS-RESPONSE; OUTER-MEMBRANE PROTEINS; ANTI-SIGMA FACTOR; NONCODING RNAS; COMPARATIVE GENOMICS; ANTISENSE RNA; PDZ DOMAIN; GENE; IDENTIFICATION; INHIBITION	Adaptation to extracytoplasmic stress in Escherichia coli depends on the activation of sigma(E), normally sequestered by the membrane protein RseA. sigma(E) is released in response to stress through the successive RseA cleavage by DegS and the RIP protease RseP. sigma(E) and proteases that free it from RseA are essential. We isolated a multicopy suppressor that alleviated RseP and DegS requirement. The suppressor encodes a novel small RNA, RseX. Its activity required the RNA-binding protein Hfq. We used the property that small RNAs are often involved in RNA-RNA interactions to capture RseX putative partners; ompA and ompC mRNA, which encode two major outer membrane proteins, were identified. RseX activity was shown to confer an Hfq-dependent coordinate OmpA and OmpC down-regulation. Because RseP is shown to be no longer essential in a strain lacking OmpA and OmpC, we conclude that RseP, which is required for normal sigma(E) activation, prevents toxicity due to the presence of two specific outer membrane proteins that are down-regulated by RseX.	Univ Paris Sud, Inst Genet & Microbiol, Signalisat & Reseaux Regulat Bacteriens, CNRS,UMR 8621,IFR115,Ctr Sci Orsay, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouloc, P (corresponding author), Univ Paris Sud, Inst Genet & Microbiol, Signalisat & Reseaux Regulat Bacteriens, CNRS,UMR 8621,IFR115,Ctr Sci Orsay, Batiment 400, F-91405 Orsay, France.	bouloc@infobiogen.fr	Bouloc, Philippe/ABA-5732-2021	Bouloc, Philippe/0000-0003-4601-3387; Bohn, Chantal/0000-0003-1569-9072				ABA T, 2006, MOL SYST BIOL   0221, DOI DOI 10.1038/MSB.4100050; Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; ANDERSEN J, 1987, NUCLEIC ACIDS RES, V15, P2089, DOI 10.1093/nar/15.5.2089; Antal M, 2005, J BIOL CHEM, V280, P7901, DOI 10.1074/jbc.M413071200; Argaman L, 2001, CURR BIOL, V11, P941, DOI 10.1016/S0960-9822(01)00270-6; Beck BJ, 1997, J BACTERIOL, V179, P6504, DOI 10.1128/jb.179.21.6862-6864.1997; Bensing BA, 1996, P NATL ACAD SCI USA, V93, P7794, DOI 10.1073/pnas.93.15.7794; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Chen S, 2004, J BACTERIOL, V186, P6689, DOI 10.1128/JB.186.20.6689-6697.2004; Chen S, 2002, BIOSYSTEMS, V65, P157, DOI 10.1016/S0303-2647(02)00013-8; Collier J, 2004, J BIOL CHEM, V279, P54193, DOI 10.1074/jbc.M314012200; Dartigalongue C, 2001, EMBO J, V20, P5908, DOI 10.1093/emboj/20.21.5908; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; Doerrler WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/jbc.M504796200; FERNANDEZMORA M, 1995, GENE, V158, P67, DOI 10.1016/0378-1119(95)00171-2; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Folichon M, 2003, NUCLEIC ACIDS RES, V31, P7302, DOI 10.1093/nar/gkg915; Gottesman S, 2004, ANNU REV MICROBIOL, V58, P303, DOI 10.1146/annurev.micro.58.030603.123841; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; Guillier M, 2006, MOL MICROBIOL, V59, P231, DOI 10.1111/j.1365-2958.2005.04929.x; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; Morita T, 2005, GENE DEV, V19, P2176, DOI 10.1101/gad.1330405; Rasmussen AA, 2005, MOL MICROBIOL, V58, P1421, DOI 10.1111/j.1365-2958.2005.04911.x; Repoila F, 2003, MOL MICROBIOL, V48, P855, DOI 10.1046/j.1365-2958.2003.03454.x; Rezuchova B, 2003, FEMS MICROBIOL LETT, V225, P1, DOI 10.1016/S0378-1097(03)00480-4; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Rivas E, 2001, CURR BIOL, V11, P1369, DOI 10.1016/S0960-9822(01)00401-8; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; Sambrook J., 2001, MOL CLONING LAB MANU; Udekwu KI, 2005, GENE DEV, V19, P2355, DOI 10.1101/gad.354405; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wassarman KM, 2001, GENE DEV, V15, P1637, DOI 10.1101/gad.901001; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Werner J, 2005, MOL MICROBIOL, V57, P1450, DOI 10.1111/j.1365-2958.2005.04775.x; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	56	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12253	12259		10.1074/jbc.M600819200	http://dx.doi.org/10.1074/jbc.M600819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513633	hybrid			2022-12-27	WOS:000237134700009
J	Jeltsch, M; Karpanen, T; Strandin, T; Aho, K; Lankinen, H; Alitalo, K				Jeltsch, M; Karpanen, T; Strandin, T; Aho, K; Lankinen, H; Alitalo, K			Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR VEGF; FACTOR-C; ANGSTROM RESOLUTION; KINASE DOMAIN; LYMPHANGIOGENESIS; ANGIOGENESIS; PROMOTES; ACTIVATION; VARIANTS	Vascular endothelial growth factors (VEGFs) and their receptors play key roles in angiogenesis and lymphangiogenesis. VEGF activates VEGF receptor-1 (VEGFR-1) and VEGFR-2, whereas VEGF-C activates VEGFR-2 and VEGFR-3. We have created a library of VEGF/VEGF-C mosaic molecules that contains factors with novel receptor binding profiles, notably proteins binding to all three VEGF receptors ("super-VEGFs"). The analyzed super-VEGFs show both angiogenic and lymphangiogenic effects in vivo, although weaker than the parental molecules. The composition of the VEGFR-3 binding molecules and scanning mutagenesis revealed determinants of receptor binding and specificity. VEGFR-2 and VEGFR-3 showed striking differences in their requirements for VEGF-C binding; extracellular domain 2 of VEGFR-2 was sufficient, whereas in VEGFR-3, both domains 1 and 2 were necessary.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomedicum Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, Peptide & Prot Lab, FIN-00014 Helsinki, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Alitalo, Kari K/J-5013-2014; Jeltsch, Michael/I-5340-2012; Strandin, Tomas/K-5322-2019	Alitalo, Kari K/0000-0002-7331-0902; Jeltsch, Michael/0000-0003-2890-7790; Strandin, Tomas/0000-0002-2454-7479; Karpanen, Terhi/0000-0002-2803-083X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075183] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 R01 HL075183-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; Eichmann A, 1998, DEVELOPMENT, V125, P743; Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joern JM, 2002, J MOL BIOL, V316, P643, DOI 10.1006/jmbi.2001.5349; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, CANCER RES, V61, P1786; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kiba A, 2003, J BIOL CHEM, V278, P13453, DOI 10.1074/jbc.M210931200; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MARAGOUDAKIS ME, 1995, MICROVASC RES, V50, P215, DOI 10.1006/mvre.1995.1054; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yamaguchi S, 2002, BIOCHEM BIOPH RES CO, V291, P554, DOI 10.1006/bbrc.2002.6478	51	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12187	12195		10.1074/jbc.M511593200	http://dx.doi.org/10.1074/jbc.M511593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505489	hybrid			2022-12-27	WOS:000236988100089
J	Longhurst, DM; Watanabe, M; Rothstein, JD; Jackson, M				Longhurst, DM; Watanabe, M; Rothstein, JD; Jackson, M			Interaction of PDZRhoGEF with microtubule-associated protein 1 light chains - Link between microtubules, actin cytoskeleton, and neuronal polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; LEUKEMIA-ASSOCIATED RHO; NEURITE RETRACTION; STRESS FIBERS; PDZ DOMAIN; FOCAL ADHESIONS; CELL POLARITY; AXON GUIDANCE; KINASE-C; BINDING	Rat (r) PDZRhoGEF, initially identified as a glutamate transporter EAAT4-associated protein, is a member of a novel RhoGEF subfamily. The N terminus of the protein contains a PDZ and a proline-rich domain, two motifs known to be involved in protein-protein interactions. By using the yeast two-hybrid approach, we screened for proteins that interact with the N terminus of rPDZRhoGEF. The light chain 2 of microtubule-associated protein 1 (LC2) was the only protein identified from the screen that does not contain a type I PDZ-binding motif at its extreme C terminus (-(S/T) X phi-COOH, where phi is a hydrophobic amino acid). However, the C terminus does conform to a type II-binding motif (-phi X phi). We report here that rPDZRhoGEF interacts with LC2 via the PDZ domain, and the interaction is abolished by mutations in the carboxylate-binding loop. The specificity of the interaction was confirmed using GST fusion protein pull-down assays and coimmunoprecipitations. Expression of rPDZRhoGEF mutants that are unable to interact with proteins via the carboxylate-binding loop induced changes in cell morphology and actin organization. These mutants alter the activation of RhoGTPases, and coexpression of dominant-negative RhoGTPases prevent the morphological changes. Furthermore, in cells expressing wild type rPDZRhoGEF, drug-induced microtubule depolymerization produces changes in cell morphology that are similar to those induced by rPDZRhoGEF mutants. These results indicate that modulation of the guanine nucleotide exchange activity of rPDZRhoGEF through interaction with microtubule-associated protein light chains may coordinate microtubule integrity and the reorganization of actin cytoskeleton. This coordinated action of the actin and microtubular cytoskeletons is essential for the development and maintenance of neuronal polarity.	Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland; Gunma Univ, Grad Sch Med, Dept Neurol, Maebashi, Gumma 3718511, Japan; Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21287 USA	University of Edinburgh; Gunma University; Johns Hopkins University	Jackson, M (corresponding author), Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland.	Mandy.Jackson@ed.ac.uk	rothstein, jeffrey d/C-9470-2013					Barac A, 2004, J BIOL CHEM, V279, P6182, DOI 10.1074/jbc.M309579200; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; Dev KK, 2004, J BIOL CHEM, V279, P41393, DOI 10.1074/jbc.M404499200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Franz CM, 2004, J BIOL CHEM, V279, P6588, DOI 10.1074/jbc.M312812200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kaufmann N, 1998, DEVELOPMENT, V125, P453; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1997, J CELL SCI, V110, P2417; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12030	12040		10.1074/jbc.M513756200	http://dx.doi.org/10.1074/jbc.M513756200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16478718	hybrid			2022-12-27	WOS:000236988100073
J	Malhi, H; Bronk, SF; Werneburg, NW; Gores, GJ				Malhi, H; Bronk, SF; Werneburg, NW; Gores, GJ			Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; OXIDATIVE STRESS; NONALCOHOLIC STEATOHEPATITIS; SYMPATHETIC NEURONS; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DIRECT ACTIVATION; RAT HEPATOCYTES	Elevated serum free fatty acids ( FFAs) and hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease. However, the mechanism by which FFAs mediate lipoapoptosis is unclear. Because JNK activation is pivotal in both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis, we examined the role of JNK activation in FFA-induced lipoapoptosis. Multiple hepatocyte cell lines and primary mouse hepatocytes were treated in culture with monounsaturated fatty acids and saturated fatty acids. Despite equal cellular steatosis, apoptosis and JNK activation were greater during exposure to saturated versus monounsaturated FFAs. Inhibition of JNK, pharmacologically as well as genetically, reduced saturated FFA-mediated hepatocyte lipoapoptosis. Cell death was caspase-dependent and associated with mitochondrial membrane depolarization and cytochrome c release indicating activation of the mitochondrial pathway of apoptosis. JNK-dependent lipoapoptosis was associated with activation of Bax, a known mediator of mitochondrial dysfunction. As JNK can activate Bim, a BH3 domain-only protein capable of binding to and activating Bax, its role in lipoapoptosis was also examined. Small interfering RNA-targeted knock-down of Bim attenuated both Bax activation and cell death. Collectively the data indicate that saturated FFAs induce JNK-dependent hepatocyte lipoapoptosis by activating the proapoptotic Bcl-2 proteins Bim and Bax, which trigger the mitochondrial apoptotic pathway.	Mayo Clin Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu			NIDDK NIH HHS [DK41876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041876, R37DK041876, R01DK041876] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Bruckner SR, 2002, J NEUROSCI RES, V70, P665, DOI 10.1002/jnr.10437; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; DASHTI N, 1987, J LIPID RES, V28, P423; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feldstein AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Keramaris E, 2005, J BIOL CHEM, V280, P1132, DOI 10.1074/jbc.M410127200; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Nanji AA, 2004, ALCOHOL, V34, P21, DOI 10.1016/j.alcohol.2004.08.005; Oh SH, 2003, ARCH TOXICOL, V77, P110, DOI 10.1007/s00204-002-0415-x; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zu K, 2005, MOL CANCER THER, V4, P43	50	528	564	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12093	12101		10.1074/jbc.M510660200	http://dx.doi.org/10.1074/jbc.M510660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505490	hybrid			2022-12-27	WOS:000236988100079
J	Shi, JX; Koeppe, JR; Komives, EA; Taylor, P				Shi, JX; Koeppe, JR; Komives, EA; Taylor, P			Ligand-induced conformational changes in the acetylcholine-binding protein analyzed by hydrogen-deuterium exchange mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRYPTOPHAN FLUORESCENCE; SOLVENT ACCESSIBILITY; NICOTINIC RECEPTORS; ACHBP; REVEALS; INTERFACES; COMPLEX; DOMAIN; IDENTIFICATION	Recent x-ray crystallographic studies of the acetylcholine-binding protein( AChBP) suggest that loop C, found at the circumference of the pentameric molecule, shows distinctive conformational changes upon antagonist and agonist occupation. We have employed hydrogen-deuterium exchange mass spectrometry to examine the influence of bound ligands on solvent exposure of AChBP. Quantitative measurements of deuterium incorporation are possible for similar to 56% of the Lymnaea AChBP sequence, covering primarily the outer surface of AChBP. In the apoprotein, two regions flanking the ligand occupation site at the subunit interface, loop C( residues 175 - 193) and loop F( residues 164 171), show greater extents of solvent exchange than other regions of the protein including the N- and C-terminal regions. Occupation by nicotinic agonists, epibatidine and lobeline, and nicotinic antagonists, methyllycaconitine, alpha-bungarotoxin, and alpha-cobratoxin, markedly restricts the exchange of loop C amide protons, influencing both the rates and degrees of exchange. Solvent exposure of loop C and its protection by ligand suggest that in the apoprotein, loop C exhibits rapid fluctuations in an open conformation. Bound agonists restrict solvent exposure through loop closure, whereas the larger antagonists restrict solvent exposure largely through occlusion of solvent. Loop F, found on the complementary subunit surface at the interface, also reveals ligand selective changes in amide proton exchange rates. Agonists do not affect solvent accessibility of loop F, whereas certain antagonists cause subtle accessibility changes. These results reveal dynamic states and fluctuating movements in the vicinity of the binding site for unligated AChBP that can be influenced selectively by ligands.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Mass Spectrometry Facil, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42-ES10337] Funding Source: Medline; NIGMS NIH HHS [R37-GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Henchman RH, 2005, BIOPHYS J, V88, P2564, DOI 10.1529/biophysj.104.053934; Hibbs RE, 2005, BIOCHEMISTRY-US, V44, P16602, DOI 10.1021/bi051735p; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523; Karlin A., 1969, J GEN PHYSIOL, V54, P245; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Mandell JG, 1998, ANAL CHEM, V70, P3987, DOI 10.1021/ac980553g; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	23	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12170	12177		10.1074/jbc.M600154200	http://dx.doi.org/10.1074/jbc.M600154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16484218	hybrid			2022-12-27	WOS:000236988100087
J	Zetterberg, H; Campbell, WA; Yang, HW; Xia, WM				Zetterberg, H; Campbell, WA; Yang, HW; Xia, WM			The cytosolic loop of the gamma-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVITY; FAS LIGAND; RELA P65; PRESENILIN; PEN-2; ACTIVATION; COMPLEX; NOTCH; EXPRESSION	The gamma-secretase complex, composed of presenilin, presenilin enhancer 2 (Pen-2), nicastrin, and Aph-1, catalyzes the final cleavage of amyloid precursor protein to generate the toxic amyloid beta protein, the major component of plaques in the brains of Alzheimer disease patients. To understand the in vivo function of Pen- 2, we used morphant technology available in zebrafish and transiently knocked down the expression of endogenous Pen- 2 by injecting the morpholino (MO) against Pen- 2. Two truncated Pen- 2 proteins lacking either the cytosolic or the C-terminal domain were expressed in MO-injected embryos. This deletion analysis demonstrated that the Pen- 2 cytosolic loop is essential for protecting developing embryos from caspase-dependent apoptosis caused by the reduction of Pen- 2. Twelve amino acids in the C terminus of Pen- 2 were dispensable and could not rescue the Pen- 2 knockdown-induced apoptotic phenotype. Surprisingly, double knockdown of Pen- 2 and nuclear factor kappa B component p65 abrogated the single Pen- 2 MO-induced caspase activation, indicating that a previously reported pro-apoptotic role of NF-kappa B in some cell types could be manifested in a whole animal and that knockdown of Pen- 2 may trigger pro-apoptotic activation of NF-kappa B.	Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Xia, WM (corresponding author), Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp,Sch Med, HIM 616,77 Ave Louis Pasteur, Boston, MA 02115 USA.	wxia@rics.bwh.harvard.edu	xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER; NIA NIH HHS [AG015379] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Campbell WA, 2006, J NEUROCHEM, V96, P1423, DOI 10.1111/j.1471-4159.2006.03648.x; Chen XF, 2003, CANCER RES, V63, P1059; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Correa RG, 2004, MOL CELL BIOL, V24, P5257, DOI 10.1128/MCB.24.12.5257-5268.2004; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Key Brian, 2003, Methods in Cell Science, V25, P1; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Matsui K, 1998, J IMMUNOL, V161, P3469; Negron JF, 2004, DEV DYNAM, V231, P161, DOI 10.1002/dvdy.20124; Prokop S, 2005, J NEUROCHEM, V94, P57, DOI 10.1111/j.1471-4159.2005.03165.x; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Westerfield M, 1994, ZEBRAFISH BOOK; Xia W, 2001, Curr Neurol Neurosci Rep, V1, P422, DOI 10.1007/s11910-001-0101-z; XIA W, 2004, AMYLOID PRECURSOR PR, P9; Xia Weiming, 2003, Curr Opin Investig Drugs, V4, P55; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	50	26	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11933	11939		10.1074/jbc.M512521200	http://dx.doi.org/10.1074/jbc.M512521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507571	hybrid			2022-12-27	WOS:000236988100062
J	Patel, HV; Vyas, KA; Savtchenko, R; Roseman, S				Patel, Himatkumar V.; Vyas, Kavita A.; Savtchenko, Regina; Roseman, Saul			The monomer/dimer transition of enzyme I of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; BACTERIAL PHOSPHOENOLPYRUVATE; CONFORMATIONAL STABILITY; FLUORESCENCE ANISOTROPY; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; PROTEIN; HPR	Enzyme I (EI) is the first protein in the phosphotransfer sequence of the bacterial phosphoenolpyruvate: glycose phosphotransferase system. This system catalyzes sugar phosphorylation/transport and is stringently regulated. Since EI homodimer accepts the phosphoryl group from phosphoenolpyruvate ( PEP), whereas the monomer does not, EI may be a major factor in controlling sugar uptake. Previous work from this and other laboratories (e.g. Dimitrova, M. N., Szczepanowski, R. H., Ruvinov, S. B., Peterkofsky, A., and Ginsburg A. (2002) Biochem. 41, 906 - 913), indicate that Ka is sensitive to several parameters. We report here a systematic study of Ka determined by sedimentation equilibrium, which showed that it varied by 1000-fold, responding to virtually every parameter tested, including temperature, phosphorylation, pH (6.5 versus 7.5), ionic strength, and especially the ligands Mg2+ and PEP. This variability may be required for a regulatory protein. Further insight was gained by analyzing EI by sedimentation velocity, by near UV CD spectroscopy, and with a nonphosphorylatable active site mutant, EI-H189Q, which behaved virtually identically to EI. The singular properties of EI are explained by a model consistent with the results reported here and in the accompanying paper (Patel, H. V., Vyas, K. A., Mattoo, R. L., Southworth, M., Perler, F. B., Comb, D., and Roseman, S. (2006) J. Biol. Chem. 281, 17579 17587). We suggest that EI and EI-H189Q each comprise a multiplicity of conformers and progressively fewer conformers as they dimerize and bind Mg2+ and finally PEP. Mg2+ alone induces small or no detectable changes in structure, but large conformational changes ensue with Mg2+/PEP. This effect is explained by a "swiveling mechanism" (similar to that suggested for pyruvate phosphate dikinase (Herzberg, O., Chen, C. C., Kapadia, G., McGuire, M., Carroll, L. J., Noh, S. J., and Dunaway-Mariano, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2652 - 2657)), which brings the C-terminal domain with the two bound ligands close to the active site His(189).	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charle St, Baltimore, MD 21218 USA.	roseman@jhu.edu	Vyas, Kavita/GRJ-4578-2022		NIGMS NIH HHS [GM 38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Chauvin F, 1996, P NATL ACAD SCI USA, V93, P7028, DOI 10.1073/pnas.93.14.7028; Dam J, 2004, METHOD ENZYMOL, V384, P185; Dimitrova MN, 2003, PROTEIN SCI, V12, P2047, DOI 10.1110/ps.0352103; Dimitrova MN, 2002, BIOCHEMISTRY-US, V41, P906, DOI 10.1021/bi011801x; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HAN MK, 1990, J BIOL CHEM, V265, P1985; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KEPES A, 1962, BACTERIA, V1, P179; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LIU KDF, 1983, P NATL ACAD SCI-BIOL, V80, P7142, DOI 10.1073/pnas.80.23.7142; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meadow ND, 2005, BIOCHEMISTRY-US, V44, P12790, DOI 10.1021/bi0502846; Oberholzer AE, 2005, J MOL BIOL, V346, P521, DOI 10.1016/j.jmb.2004.11.077; Patel HV, 2006, J BIOL CHEM, V281, P17579, DOI 10.1074/jbc.M508966200; Patel HV, 2004, P NATL ACAD SCI USA, V101, P17486, DOI 10.1073/pnas.0407865101; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIMONI RD, 1967, P NATL ACAD SCI USA, V58, P1963, DOI 10.1073/pnas.58.5.1963; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; Zhu PP, 1999, BIOCHEMISTRY-US, V38, P15470, DOI 10.1021/bi991680p	37	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17570	17578		10.1074/jbc.M508965200	http://dx.doi.org/10.1074/jbc.M508965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16547355	hybrid			2022-12-27	WOS:000238490300006
J	Peelman, F; Iserentant, H; De Smet, AS; Vandekerckhove, J; Zabeau, L; Tavernier, J				Peelman, Frank; Iserentant, Hannes; De Smet, Anne-Sophie; Vandekerckhove, JoeL; Zabeau, Lennart; Tavernier, Jan			Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin center dot leptin receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; STIMULATING FACTOR-RECEPTOR; MULTIPLE SEQUENCE ALIGNMENT; INHIBITORY FACTOR LIF; EXTRACELLULAR DOMAIN; OB-R; RECOMBINANT HUMAN; CRYSTAL-STRUCTURE; OBESE GENE; CYTOKINE	The leptin.leptin receptor ( LR) system shows strong similarities to the long chain cytokine interleukin-6 ( IL-6) and granulocyte colony-stimulating factor ( G-CSF) cytokine.cytokine receptor systems. The IL-6 family cytokines interact with their receptors through three different binding sites ( I-III). We demonstrated previously that leptin has similar binding sites I-III and mapped the interactions between binding site II and cytokine receptor homology domain II ( CRH2) ( Peelman, F., Van Beneden, K., Zabeau, L., Iserentant, H., Ulrichts, P., Defeau, D., Verhee, A., Catteeuw, D., Elewaut, D., and Tavernier, J. ( 2004) J. Biol. Chem. 279, 41038 41046). In this study, we built homology models for the CRH1 and Ig-like domains of the LR. The Ig-like domain shows a large conserved surface patch in the beta-sheet formed by beta-strands 3, 6, and 7. Mutations in this patch almost completely abolished the leptin-induced STAT3-dependent reporter activity. We propose that a conserved cluster of residues Leu(370), Ala(407), Tyr(409), His(417), and His(418) forms the center of binding site III of the LR. We built a hexameric leptin.LR complex model based on the hexameric IL-6 complex. In this model, a conserved hydrophobic protuberance of Val(36), Thr(37), Phe(41), and Phe(43) in the A-B loop of leptin fits perfectly in the CRH2 domain, corresponding to the IL-6 alpha-receptor, and forms the center of binding site I. The 2: 4 hexameric leptin.LR complex offers a rational explanation for mutagenesis studies and residue conservation.	State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Tavernier, J (corresponding author), State Univ Ghent VIB, Dept Med Prot Res, Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.tavernier@ugent.be	Tavernier, Jan/AAG-3636-2019					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Fruhbeck G, 2001, P NUTR SOC, V60, P301, DOI 10.1079/PNS200196; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; He W, 2005, FEBS LETT, V579, P4317, DOI 10.1016/j.febslet.2005.06.061; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Iserentant H, 2005, J CELL SCI, V118, P2519, DOI 10.1242/jcs.02386; Ishibashi M, 2001, PROTEIN EXPRES PURIF, V21, P317, DOI 10.1006/prep.2000.1381; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Niv-Spector L, 2005, BIOCHEM J, V391, P221, DOI 10.1042/BJ20050457; Niv-Spector L, 2005, BIOCHEM J, V390, P475, DOI 10.1042/BJ20050233; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Peelman F, 2004, J BIOL CHEM, V279, P41038, DOI 10.1074/jbc.M404962200; Peelman F, 2004, PROG LIPID RES, V43, P283, DOI 10.1016/j.plipres.2004.03.001; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sandowski Y, 2002, J BIOL CHEM, V277, P46304, DOI 10.1074/jbc.M207556200; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Zabeau L, 2005, J BIOL CHEM, V280, P22632, DOI 10.1074/jbc.M413308200; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078; Zabeau L, 2003, FEBS LETT, V546, P45, DOI 10.1016/S0014-5793(03)00440-X; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	44	63	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15496	15504		10.1074/jbc.M512622200	http://dx.doi.org/10.1074/jbc.M512622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16540470	hybrid			2022-12-27	WOS:000237922200056
J	Han, BW; Bingman, CA; Mahnke, DK; Bannen, RM; Bednarek, SY; Sabina, RL; Phillips, GN				Han, Byung Woo; Bingman, Craig A.; Mahnke, Donna K.; Bannen, Ryan M.; Bednarek, Sebastian Y.; Sabina, Richard L.; Phillips, George N., Jr.			Membrane association, mechanism of action, and structure of Arabidopsis embryonic factor 1 (FAC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEAMINASE ISOFORMS; AMINO-ACID-COMPOSITION; PLANT-CELL CULTURE; ADENOSINE-DEAMINASE; METABOLIC-REGULATION; ADENYLATE DEAMINASE; PURINE NUCLEOTIDES; SUBUNIT STRUCTURE; MOLECULAR-WEIGHT; TRANSITION-STATE	Embryonic factor 1 (FAC1) is one of the earliest expressed plant genes and encodes an AMP deaminase ( AMPD), which is also an identified herbicide target. This report identifies an N-terminal transmembrane domain in Arabidopsis FAC1, explores subcellular fractionation, and presents a 3.3-angstrom globular catalytic domain x-ray crystal structure with a bound herbicide-based transition state inhibitor that provides the first glimpse of a complete AMPD active site. FAC1 contains an (alpha/beta)(8)-barrel characterized by loops in place of strands 5 and 6 that places it in a small subset of the amidohydrolase superfamily with imperfect folds. Unlike tetrameric animal orthologs, FAC1 is a dimer and each subunit contains an exposed Walker A motif that may be involved in the dramatic combined Km (25 - 80-fold lower) and V-max (5-6-fold higher) activation by ATP. Normal mode analysis predicts a hinge motion that flattens basic surfaces on each monomer that flank the dimer interface, which suggests a reversible association between the FAC1 globular catalytic domain and intracellular membranes, with N-terminal transmembrane and disordered linker regions serving as the anchor and attachment to the globular catalytic domain, respectively.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Ctr Eukaryot Struct Genom, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	phillips@biochem.wisc.edu		Bannen, Ryan/0000-0002-6001-3060	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074901, P50GM064598] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007359] Funding Source: NIH RePORTER; NIGMS NIH HHS [1U54 GM 074901-01, P50 GM 64598] Funding Source: Medline; NLM NIH HHS [5T15 LM 007359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Athwal GS, 1998, PLANT PHYSIOL, V118, P1041, DOI 10.1104/pp.118.3.1041; BarPeled M, 1997, PLANT PHYSIOL, V114, P315, DOI 10.1104/pp.114.1.315; BAUSCHJURKEN MT, 1992, J BIOL CHEM, V267, P22407; Bazin R.J., 2003, UK Patent, Patent No. [GB2373504, 2373504]; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH BD, 1993, PHYTOCHEMISTRY, V32, P737, DOI 10.1016/S0031-9422(00)95163-X; BUTTERS JA, 1985, PHYSIOL PLANT PATHOL, V27, P65, DOI 10.1016/0048-4059(85)90057-8; Camoni L, 2001, J BIOL CHEM, V276, P31709, DOI 10.1074/jbc.M104194200; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Dancer JE, 1997, PLANT PHYSIOL, V114, P119, DOI 10.1104/pp.114.1.119; FRIEDEN C, 1980, BIOCHEMISTRY-US, V19, P5303, DOI 10.1021/bi00564a024; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Haas AL, 2003, PROTEIN EXPRES PURIF, V27, P293, DOI 10.1016/S1046-5928(02)00636-8; Haberer G, 2002, PLANT PHYSIOL, V128, P354, DOI 10.1104/pp.010773; Han BW, 2005, ACTA CRYSTALLOGR F, V61, P740, DOI 10.1107/S1744309105019792; Hinsen K, 1999, PROTEINS, V34, P369, DOI 10.1002/(SICI)1097-0134(19990215)34:3<369::AID-PROT9>3.0.CO;2-F; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISAAC BG, 1991, J ANTIBIOT, V44, P729, DOI 10.7164/antibiotics.44.729; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LEFLOCH F, 1983, Z PFLANZENPHYSIOL, V113, P61, DOI 10.1016/S0044-328X(83)80019-1; LEFLOCH F, 1983, PHYSIOL VEG, V21, P15; LEFLOCH F, 1982, PLANT SCI LETT, V27, P309, DOI 10.1016/0304-4211(82)90133-X; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Mahnke-Zizelman DK, 2001, BIOCHEM BIOPH RES CO, V285, P489, DOI 10.1006/bbrc.2001.5180; Mahnke-Zizelman DK, 1998, J BIOL CHEM, V273, P35118, DOI 10.1074/jbc.273.52.35118; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA H, 1974, J AM CHEM SOC, V96, P4327, DOI 10.1021/ja00820a049; ODRISCOLL D, 1976, BIOCHEM SOC T, V4, P928, DOI 10.1042/bst0040928; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OGASAWARA N, 1977, BIOCHEM BIOPH RES CO, V79, P671, DOI 10.1016/0006-291X(77)91164-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rancour DM, 2004, J BIOL CHEM, V279, P54264, DOI 10.1074/jbc.M405498200; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Sabina RL, 2000, PHARMACOL THERAPEUT, V87, P279, DOI 10.1016/S0163-7258(00)00040-1; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; STANKIEWICZ A, 1979, COMP BIOCHEM PHYS B, V62, P363, DOI 10.1016/0305-0491(79)90104-4; STANKIEWICZ A, 1981, INT J BIOCHEM, V13, P1177, DOI 10.1016/0020-711X(81)90211-1; SWAIN JL, 1982, AM J PHYSIOL, V242, P818; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; TURNER DH, 1961, BIOCHEM J, V79, P143, DOI 10.1042/bj0790143; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VALENTINE WN, 1985, P NATL ACAD SCI USA, V82, P6682, DOI 10.1073/pnas.82.19.6682; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Xu J, 2005, PLANT J, V42, P743, DOI 10.1111/j.1365-313X.2005.02411.x; YABUKI N, 1992, PHYTOCHEMISTRY, V31, P1905, DOI 10.1016/0031-9422(92)80332-9; YABUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1073, P474, DOI 10.1016/0304-4165(91)90218-6; YOSHINO M, 1980, Z PFLANZENPHYSIOL, V99, P331, DOI 10.1016/S0044-328X(80)80147-4	52	22	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14939	14947		10.1074/jbc.M513009200	http://dx.doi.org/10.1074/jbc.M513009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16543243	hybrid			2022-12-27	WOS:000237671300047
J	Jean-Louis, S; Akare, S; Ali, MA; Mash, EA; Meuillet, E; Martinez, JD				Jean-Louis, Samira; Akare, Sandeep; Ali, M. Ahad; Mash, Eugene A., Jr.; Meuillet, Emmanuelle; Martinez, Jesse D.			Deoxycholic acid induces intracellular signaling through membrane perturbations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; LIGAND-INDEPENDENT ACTIVATION; SECONDARY BILE-ACIDS; COLON-CANCER CELLS; URSODEOXYCHOLIC ACID; INDUCED APOPTOSIS; BINDING-PROTEIN; LIPID RAFTS; CHOLESTEROL	Secondary bile acids have long been postulated to be tumor promoters in the colon; however, their mechanism of action remains unclear. In this study, we examined the actions of bile acids at the cell membrane and found that they can perturb membrane structure by alteration of membrane microdomains. Depletion of membrane cholesterol by treating with methyl-beta-cyclodextrin suppressed deoxycholic acid (DCA)-induced apoptosis, and staining for cholesterol with filipin showed that DCA caused a marked rearrangement of this lipid in the membrane. Likewise, DCA was found to affect membrane distribution of caveolin-1, amarker protein that is enriched in caveolae membrane microdomains. Additionally, fluorescence anisotropy revealed that DCA causes a decrease in membrane fluidity consistent with the increase in membrane cholesterol content observed after 4 h of DCA treatment of HCT116 cells. Significantly, by using radiolabeled bile acids, we found that bile acids are able to interact with and localize to microdomains differently depending on their physicochemical properties. DCA was also found to induce tyrosine phosphorylation and activate the receptor tyrosine kinase epidermal growth factor receptor in a ligand-independent manner. In contrast, ursodeoxycholic acid did not exhibit any of these effects even though it interacted significantly with the microdomains. Collectively, these data suggest that bile acid-induced signaling is initiated through alterations of the plasma membrane structure and the redistribution of cholesterol.	Univ Arizona, Dept Cellular Biol & Anat, Tucson, AZ 85724 USA; Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ USA; Univ Arizona, Synth Chem Shared Serv, Tucson, AZ USA; Univ Arizona, Dept Nutrit Sci, Tucson, AZ USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Cellular Biol & Anat, POB 245024,1501 N Campbell Ave, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NCI NIH HHS [CA 72008-08S1, CA 72008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akare S, 2005, BBA-MOL CELL BIOL L, V1735, P59, DOI 10.1016/j.bbalip.2005.04.006; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BAYERDORFFER E, 1995, GUT, V36, P268, DOI 10.1136/gut.36.2.268; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BREUER N, 1985, KLIN WOCHENSCHR, V63, P97, DOI 10.1007/BF01734247; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cai CX, 2004, BIOCHEM BIOPH RES CO, V320, P868, DOI 10.1016/j.bbrc.2004.06.030; Carey Martin C., 1994, P719; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Chiou TJ, 2000, TOXICOLOGY, V154, P75, DOI 10.1016/S0300-483X(00)00321-8; COHEN BI, 1981, CANCER RES, V41, P3759; COLEMAN R, 1979, BIOCHEM J, V178, P201, DOI 10.1042/bj1780201; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; EARNEST DL, 1994, CANCER RES, V54, P5071; FITZER CJ, 1987, CARCINOGENESIS, V8, P217, DOI 10.1093/carcin/8.2.217; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; GUILLEM JG, 1987, ARCH SURG-CHICAGO, V122, P1475; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; HOFFMAN AF, 1994, BIOL PATHOPHYSIOLOGY, P677; HOOVER RL, 1983, J CELL BIOL, V97, P73, DOI 10.1083/jcb.97.1.73; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; Ikonen E, 2004, BIOCHEM SOC T, V32, P121, DOI 10.1042/BST0320121; Im E, 2004, J NUTR, V134, P483, DOI 10.1093/jn/134.2.483; JOHNSON SM, 1977, BIOCHEM BIOPH RES CO, V76, P869, DOI 10.1016/0006-291X(77)91581-9; KAMMER GM, 1983, J IMMUNOL, V130, P38; KORPELA JT, 1988, SCAND J GASTROENTERO, V23, P277, DOI 10.3109/00365528809093865; KRUTH HS, 1984, AM J PATHOL, V114, P201; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; LUCIANO L, 1989, CELL TISSUE RES, V258, P339; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; Merchant NB, 2005, SURGERY, V138, P415, DOI 10.1016/j.surg.2005.06.030; MILKIEWICZ PM, 1999, P FALK WORKSH LOND U, P1; MILLS CO, 1991, BIOCHIM BIOPHYS ACTA, V1115, P151, DOI 10.1016/0304-4165(91)90024-B; Mills CO, 1997, BBA-GEN SUBJECTS, V1336, P485, DOI 10.1016/S0304-4165(97)00063-9; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Morgan Winston A., 1997, Biochemical Society Transactions, V25, p75S; MORVAY K, 1989, DIS COLON RECTUM, V32, P860, DOI 10.1007/BF02554556; Moschetta A, 2001, J HEPATOL, V34, P492, DOI 10.1016/S0168-8278(00)00046-5; NARISAWA T, 1978, Gastroenterologia Japonica, V13, P206; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; Powell AA, 2001, BIOCHEM J, V356, P481, DOI 10.1042/0264-6021:3560481; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Qiao DH, 2001, CARCINOGENESIS, V22, P957, DOI 10.1093/carcin/22.6.957; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104; REDDY BS, 1977, CANCER RES, V37, P3238; Rizzo Giovanni, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P289, DOI 10.2174/1568008054863781; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; ROGERS AE, 1975, CANCER RES, V35, P3427; SAGAWA H, 1993, AM J PHYSIOL, V264, pG835, DOI 10.1152/ajpgi.1993.264.5.G835; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SHINITZKY M, 1974, J BIOL CHEM, V249, P2652; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; Tabas I, 2002, J CLIN INVEST, V110, P583, DOI 10.1172/JCI200216381; VANMUNSTER IP, 1993, EUR J CLIN INVEST, V23, P773; Veyron P, 1996, TRANSPLANTATION, V62, P1039, DOI 10.1097/00007890-199610270-00001; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; VYVODA OS, 1977, BIOCHIM BIOPHYS ACTA, V465, P68, DOI 10.1016/0005-2736(77)90356-X; Wang LF, 2005, HEPATOLOGY, V41, P1241, DOI 10.1002/hep.20697; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200	74	97	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14948	14960		10.1074/jbc.M506710200	http://dx.doi.org/10.1074/jbc.M506710200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547009	hybrid			2022-12-27	WOS:000237671300048
J	Waters, L; Yue, BG; Veverka, V; Renshaw, P; Bramham, J; Matsuda, S; Frenkiel, T; Kelly, G; Muskett, F; Carr, M; Heery, DM				Waters, Lorna; Yue, Baigong; Veverka, Vaclav; Renshaw, Philip; Bramham, Janice; Matsuda, Sachiko; Frenkiel, Thomas; Kelly, Geoffrey; Muskett, Frederick; Carr, Mark; Heery, David M.			Structural diversity in p160/CREB-binding protein coactivator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LXXLL MOTIF; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; RECEPTOR; DOMAIN; ALPHA; NMR; CBP; CBP/P300; SRC1	Ligand-induced transcription by nuclear receptors involves the recruitment of p160 coactivators such as steroid receptor coactivator 1 (SRC1), in complex with histone acetyltransferases such as CREB-binding protein (CBP) and p300. Here we describe the solution structure of a complex formed by the SRC1 interaction domain (SID) of CBP and the activation domain (AD1) of SRC1, both of which contain four helical regions (C alpha 1, C alpha 2, C alpha 3, and C alpha 3' in CBP and S alpha 1, S alpha 2', S alpha 2, and S alpha 3 in SRC1). A tight four-helix bundle is formed between S alpha 1, C alpha 1, C alpha 2, and C alpha 3 that is capped by S alpha 3. In contrast to the structure of the AD1 domain of the related p160 protein ACTR in complex with CBP SID, the sequences forming S alpha 2' and S alpha 2 in SRC1 AD1 are not involved in the interface between the two domains but rather serve to position S alpha 3. Thus, although the CBP SID domain adopts a similar fold in complex with different p160 proteins, the topologies of the AD1 domains are strikingly different, a feature that is likely to contribute to functional specificity of these coactivator complexes.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; MRC, Biomed NMR Ctr, Natl Inst Med Res, London NW7 1AA, England	University of Nottingham; University of Leicester; MRC National Institute for Medical Research	Heery, DM (corresponding author), Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England.	david.heery@nottingham.ac.uk	Veverka, Vaclav/G-9174-2014; Veverka, Vaclav/P-5251-2019	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Heery, David/0000-0002-5035-2392; Carr, Mark/0000-0002-3939-0996	MRC [MC_U117533887] Funding Source: UKRI; Medical Research Council [MC_U117533887] Funding Source: Medline; Wellcome Trust [063632, 054401/Z/98/B, 066047] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carr MD, 2003, J BIOL CHEM, V278, P43736, DOI 10.1074/jbc.M307235200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demarest SJ, 2004, PROTEIN SCI, V13, P203, DOI 10.1110/ps.03366504; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; FEENEY J, 1991, J MAGN RESON, V91, P607, DOI 10.1016/0022-2364(91)90388-A; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kung AL, 2000, GENE DEV, V14, P272; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Lucey MJ, 2005, NUCLEIC ACIDS RES, V33, P6393, DOI 10.1093/nar/gki940; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Matsuda S, 2004, J BIOL CHEM, V279, P14055, DOI 10.1074/jbc.M310188200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard HM, 2003, J MOL ENDOCRINOL, V30, P411, DOI 10.1677/jme.0.0300411; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	53	61	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14787	14795		10.1074/jbc.M600237200	http://dx.doi.org/10.1074/jbc.M600237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540468	hybrid			2022-12-27	WOS:000237671300032
J	Sturm, A; Schierhorn, A; Lindenstrauss, U; Lilie, H; Bruser, T				Sturm, Alexander; Schierhorn, Angelika; Lindenstrauss, Ute; Lilie, Hauke; Brueser, Thomas			YcdB from Escherichia coli reveals a novel class of Tat-dependently translocated hemoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-DECOLORIZING PEROXIDASE; CANDIDUM DEC 1; CYTOCHROME-C; HETEROLOGOUS EXPRESSION; PROTEIN TRANSLOCATION; PATHWAY; CATABOLISM; TRANSPORT; SEQUENCE; EXPORT	The Tat (twin-arginine translocation) system of Escherichia coli serves to translocate folded proteins across the cytoplasmic membrane. The reasons established so far for the Tat dependence are cytoplasmic cofactor assembly and/or heterodimerization of the respective proteins. We were interested in the reasons for the Tat dependence of novel Tat substrates and focused on two uncharacterized proteins, YcdO and YcdB. Both proteins contain predicted Tat signal sequences. However, we found that only YcdB was indeed Tat-dependently translocated, whereas YcdO was equally well translocated in a Tat-deficient strain. YcdB is a dimeric protein and contains a heme cofactor that was identified to be a high-spin Fe-III-protoporphyrin IX complex. In contrast to all other periplasmic hemoproteins analyzed so far, heme was assembled into YcdB in the cytoplasm, suggesting that heme assembly could take place prior to translocation. The function of YcdB in the periplasm may be related to a detoxification reaction under specific conditions because YcdB had peroxidase activity at acidic pH, which coincides well with the known acid-induced expression of the gene. The data demonstrate the existence of a class of heme-containing Tat substrates, the first member of which is YcdB.	Univ Halle Wittenberg, Inst Microbiol, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Max Planck Society	Bruser, T (corresponding author), Univ Halle Wittenberg, Inst Microbiol, Kurt Mothes Str 3, D-06120 Halle, Germany.	t.brueser@mikrobiologie.uni-halle.de		Sturm, Alexander/0000-0002-3818-0428; Bruser, Thomas/0000-0002-5889-8306				Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bruser T, 1998, FEMS MICROBIOL LETT, V164, P329; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Choe YK, 2005, J COMPUT CHEM, V26, P1600, DOI 10.1002/jcc.20302; Demirev PA, 2002, ANAL CHEM, V74, P3262, DOI 10.1021/ac025621k; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; Jongbloed JDH, 2004, MOL MICROBIOL, V54, P1319, DOI 10.1111/j.1365-2958.2004.04341.x; Kim SJ, 1999, APPL ENVIRON MICROB, V65, P1029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Sanders C, 2001, MOL MICROBIOL, V41, P241, DOI 10.1046/j.1365-2958.2001.02514.x; Sato T, 2004, ACTA CRYSTALLOGR D, V60, P149, DOI 10.1107/S0907444903025472; Stancik LM, 2002, J BACTERIOL, V184, P4246, DOI 10.1128/JB.184.15.4246-4258.2002; Sugano Y, 2004, BIOCHEM BIOPH RES CO, V322, P126, DOI 10.1016/j.bbrc.2004.07.090; Sugano Y, 2000, APPL ENVIRON MICROB, V66, P1754, DOI 10.1128/AEM.66.4.1754-1758.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	30	89	99	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13972	13978		10.1074/jbc.M511891200	http://dx.doi.org/10.1074/jbc.M511891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551627	hybrid			2022-12-27	WOS:000237512300019
J	Kessels, MM; Qualmann, B				Kessels, MM; Qualmann, B			Syndapin oligomers interconnect the machineries for endocytic vesicle formation and actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-WASP; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; BINDING-PROTEIN; ARP2/3 COMPLEX; DYNAMIN; CYTOSKELETON; FILAMENT; FAMILY; BAR	Syndapins were proposed to interconnect the machineries for vesicle formation and actin polymerization, as they interact with dynamin and the Arp2/3 complex activator N-WASP ( neural Wiskott-Aldrich syndrome protein). Syndapins, however, have only one Src homology 3 domain mediating both interactions. Here we show that syndapins self-associate via direct syndapin/syndapin interactions, providing a molecular mechanism for the coordinating role of syndapin. Cross-link studies with overexpressed and endogenous syndapins suggest that predominantly dimers form in vivo. Our analyses show that the N-terminal Fes/Cip4 homology domain but not the central coiled-coil domain is sufficient for oligomerization. Additionally, a second interface located further C-terminally mediated interactions with the N terminus. The Src homology 3 domain and the NPF region are not involved and thus available for further interactions interconnecting different syndapin binding partners. Our analyses showed that self-association is crucial for syndapin function. Both syndapin-mediated cytoskeletal rearrangements and endocytosis were disrupted by a self-association-deficient mutant. Consistent with a role of syndapins in linking actin polymerization bursts with endocytic vesicle formation, syndapin-containing complexes had a size of 300 - 500 kDa in gel filtration analysis and contained both dynamin and N-WASP. The existence of an interconnection of the GTPase dynamin with N-WASP via syndapin oligomers was demonstrated both by coimmunoprecipitations and by reconstitution at membranes in intact cells. The interconnection was disrupted by coexpression of syndapin mutants incapable of self-association. Syndapin oligomers may thus act as multivalent organizers spatially and temporally coordinating vesicle fission with local actin polymerization.	Leibniz Inst Neurobiol, Res Grp Cell Biol, D-39118 Magdeburg, Germany; Leibniz Inst Neurobiol, Res Grp Membrane Trafficking & Cytoskeleton, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany	Leibniz Institut fur Neurobiologie (LIN); Leibniz Institut fur Neurobiologie (LIN)	Qualmann, B (corresponding author), Leibniz Inst Neurobiol, Res Grp Cell Biol, Brenneckestr 6, D-39118 Magdeburg, Germany.	qualmann@ifn-magdeburg.de						Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; Braun A, 2005, MOL BIOL CELL, V16, P3642, DOI 10.1091/mbc.E05-01-0076; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; da Costa SR, 2003, MOL BIOL CELL, V14, P4397, DOI 10.1091/mbc.E03-05-0315; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Kessels MM, 2004, J CELL SCI, V117, P3077, DOI 10.1242/jcs.01290; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Modregger J, 2000, J CELL SCI, V113, P4511; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nikki M, 2002, BIOCHEMISTRY-US, V41, P6320, DOI 10.1021/bi015991n; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2004, J NEUROSCI, V24, P2481, DOI 10.1523/JNEUROSCI.5479-03.2004; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takenawa T, 2001, J CELL SCI, V114, P1801; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	41	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13285	13299		10.1074/jbc.M510226200	http://dx.doi.org/10.1074/jbc.M510226200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540475	hybrid			2022-12-27	WOS:000237336600034
J	Pan, YH; Liao, CC; Kuo, CC; Duan, KJ; Liang, PH; Yuan, HS; Hu, ST; Chak, KF				Pan, YH; Liao, CC; Kuo, CC; Duan, KJ; Liang, PH; Yuan, HS; Hu, ST; Chak, KF			The critical roles of polyamines in regulating ColE7 production and restricting ColE7 uptake of the colicin-producing Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE-BINDING-PROTEIN; OUTER-MEMBRANE PERMEABILITY; ARGININE DECARBOXYLASE; SYNTHESIZE PUTRESCINE; ION CHANNELS; DNASE DOMAIN; ACIDIC PH; SPERMIDINE; CELLS; OMPF	The ColE7 operon is an SOS response regulon, which encodes bacteriocin ColE7 to kill susceptible Escherichia coli and its related enterobacteria under conditions of stress. We have observed for the first time that polyamines confer limited resistance against ColE7 on E. coli cells. Thus, this study aims to investigate the role of polyamines in modulating the protective effect of the E. coli cells against colicin. In the experiments, we surprisingly found that endogenous polyamines are also essential for ColE7 production, and the rate of polyamine synthesis is directly related to the SOS response. Our experimental results further indicated that exogenous polyamines suppress the expression of TolA, BtuB, OmpF, and OmpC proteins that are responsible for ColE7 uptake. Moreover, two-dimensional gel electrophoresis revealed that the production of two periplasmic proteins, PotD and OppA, is increased in E. coli cells under ColE7 exposure. Based on these observations, we propose that endogenous polyamines may play a dual role in the ColE7 system. Polyamines may participate in initiating the expression of the SOS response of the ColE7 operon and simultaneously down-regulate proteins that are essential for colicin uptake, thus conferring a survival advantage on colicin-producing E. coli under stress conditions in the natural environment.	Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Tatung Univ, Inst Bioengn, Taipei 10452, Taiwan; Acad Sinica, Inst Biol Chem & Mol Biol, Taipei 1529, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Tatung University; Academia Sinica - Taiwan	Chak, KF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan.	kfchak@ym.edu.tw	Liang, Po-Huang/H-6610-2015; Pan, Yi-Hsuan/ABG-6271-2020; Yuan, Hanna S./AAA-4005-2021	Liang, Po-Huang/0000-0003-1207-5256; Pan, Yi-Hsuan/0000-0001-5156-9887; Yuan, Hanna S./0000-0001-9671-6967				ANDREWS JC, 1986, J BACTERIOL, V165, P428, DOI 10.1128/jb.165.2.428-433.1986; Bachrach U, 2001, NEWS PHYSIOL SCI, V16, P106, DOI 10.1152/physiologyonline.2001.16.3.106; Bolter B, 2001, EMBO J, V20, P935, DOI 10.1093/emboj/20.5.935; Bredin J, 2003, BIOCHEM J, V376, P245, DOI 10.1042/BJ20030814; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; CARPER SW, 1991, J BIOL CHEM, V266, P12439; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; Chak KF, 1998, PROTEINS, V32, P17, DOI 10.1002/(SICI)1097-0134(19980701)32:1<17::AID-PROT4>3.0.CO;2-B; Chen FC, 2003, BIOCHEM BIOPH RES CO, V312, P708, DOI 10.1016/j.bbrc.2003.10.155; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; de Zamaroczy M, 2001, MOL CELL, V8, P159, DOI 10.1016/S1097-2765(01)00276-3; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; Gibson KE, 1999, J BACTERIOL, V181, P563, DOI 10.1128/JB.181.2.563-571.1999; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; Igarashi K, 2001, RES MICROBIOL, V152, P271, DOI 10.1016/S0923-2508(01)01198-6; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Iyer R, 1997, J BIOL CHEM, V272, P18595, DOI 10.1074/jbc.272.30.18595; Iyer R, 2000, J MOL BIOL, V297, P933, DOI 10.1006/jmbi.2000.3599; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Ku WY, 2002, NUCLEIC ACIDS RES, V30, P1670, DOI 10.1093/nar/30.7.1670; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; KUZMINOV A, 1995, J THEOR BIOL, V177, P29, DOI 10.1006/jtbi.1995.0222; Lazdunski C, 2000, INT J MED MICROBIOL, V290, P337; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Liao CC, 2001, BIOCHEM BIOPH RES CO, V284, P556, DOI 10.1006/bbrc.2001.5016; Limsuwun K, 2000, J BACTERIOL, V182, P5373, DOI 10.1128/JB.182.19.5373-5380.2000; Liu NZ, 1997, BBA-BIOMEMBRANES, V1326, P201, DOI 10.1016/S0005-2736(97)00024-2; Liu XQ, 2001, MICROBIOL-SGM, V147, P2981, DOI 10.1099/00221287-147-11-2981; Lu FM, 1996, MOL GEN GENET, V251, P407, DOI 10.1007/BF02172368; MORGAN DML, 1998, POLAMINE PROTOCOLS, P119; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Oh TJ, 1999, BIOCHEM BIOPH RES CO, V264, P584, DOI 10.1006/bbrc.1999.1553; Oh TJ, 1999, CELL BIOL TOXICOL, V15, P291, DOI 10.1023/A:1007663701589; PANAGIOTIDIS CA, 1987, P NATL ACAD SCI USA, V84, P4423, DOI 10.1073/pnas.84.13.4423; PARK JT, 1993, J BACTERIOL, V175, P7, DOI 10.1128/JB.175.1.7-11.1993; Pasquali C, 1997, ELECTROPHORESIS, V18, P2573, DOI 10.1002/elps.1150181413; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; Riley MA, 1999, TRENDS MICROBIOL, V7, P129, DOI 10.1016/S0966-842X(99)01459-6; Samartzidou H, 1999, J BACTERIOL, V181, P791, DOI 10.1128/JB.181.3.791-798.1999; Samartzidou H, 2003, J BACTERIOL, V185, P13, DOI 10.1128/JB.185.1.13-19.2003; SOONG BW, 1994, MOL GEN GENET, V243, P477; TABOR CW, 1978, J BIOL CHEM, V253, P3671; TABOR H, 1980, J BACTERIOL, V144, P952, DOI 10.1128/JB.144.3.952-956.1980; TABOR H, 1981, J BACTERIOL, V147, P702, DOI 10.1128/JB.147.2.702-704.1981; Tkachenko A, 2001, ARCH MICROBIOL, V176, P155, DOI 10.1007/s002030100301; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723; Yu SL, 2000, J BACTERIOL, V182, P5962, DOI 10.1128/JB.182.21.5962-5968.2000; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334	62	21	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13083	13091		10.1074/jbc.M511365200	http://dx.doi.org/10.1074/jbc.M511365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549429	hybrid, Green Submitted			2022-12-27	WOS:000237336600012
J	Reddy, MA; Li, SL; Sahar, S; Kim, YS; Xu, ZG; Lanting, L; Natarajan, R				Reddy, MA; Li, SL; Sahar, S; Kim, YS; Xu, ZG; Lanting, L; Natarajan, R			Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; C-SRC; TYROSINE PHOSPHORYLATION; ADVANCED GLYCOSYLATION; SIGNAL TRANSDUCERS; POTENTIAL ROLE; RAGE; EXPRESSION	The receptor for advanced glycation end products (RAGE) and its ligands have been implicated in the activation of oxidant stress and inflammatory pathways in vascular smooth muscle cells (VSMCs) leading to the initiation and augmentation of atherosclerosis. Here we report that non-receptor Src tyrosine kinase and the membrane protein caveolin-1 (Cav-1) play a key role in the activation of RAGE by S100B in VSMCs. S100B increased the activation of Src kinase and tyrosine phosphorylation of caveolin-1 in VSMCs. A RAGE-specific antibody blocked both these effects. An inhibitor of Src kinase, PP2, significantly blocked S100B-induced activation of Src kinase, mitogen-activated protein kinases, transcription factors NF-B and STAT3, superoxide production, tyrosine phosphorylation of Cav-1, VSMC migration, and expression of the pro-inflammatory genes monocyte chemotactic protein-1 and interleukin-6. Cholesterol depletion also inhibited S100B-induced effects indicating the requirement for intact caveolae in RAGE-specific signaling. Nucleofection of either a Src dominant negative mutant, or a Cav-1 mutant lacking the scaffolding domain, or Cav-1 short hairpin RNA significantly reduced S100B- induced inflammatory gene expression in VSMCs. Furthermore, VSMCs derived from insulin-resistant and diabetic db/db mice displayed increased RAGE expression, Src activation, and migration compared with those from control db/(+) mice. The RAGE antibody blocked enhanced migration in db/db cells. These studies demonstrate for the first time that, in VSMCs, Src kinase and Cav-1 play important roles in RAGE- mediated inflammatory gene expression and migration, key events associated with diabetic vascular complications.	Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Natarajan, R (corresponding author), Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA.	RNatarajan@coh.org		Reddy, Marpadga A/0000-0001-9259-7243	NHLBI NIH HHS [P01-HL55798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson D, 2002, MED HYPOTHESES, V59, P297, DOI 10.1016/S0306-9877(02)00172-X; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007; Fan CG, 2004, J CLIN INVEST, V113, P746, DOI 10.1172/JCI200417337; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Funakoshi-Tago M, 2005, J BIOCHEM, V137, P189, DOI 10.1093/jb/mvi018; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Hattori Y, 2002, HYPERTENSION, V39, P22, DOI 10.1161/hy1201.097300; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huang JS, 2001, J CELL BIOCHEM, V81, P102, DOI 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Kim W, 2005, ANN NY ACAD SCI, V1043, P553, DOI 10.1196/annals.1338.063; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li SL, 2005, J LIPID RES, V46, P220, DOI 10.1194/jlr.M400328-JLR200; Li SW, 1996, J BIOL CHEM, V271, P3863; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu HF, 2004, ENDOCRINOLOGY, V145, P4934, DOI 10.1210/en.2004-0737; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mizutani K, 2000, BIOCHEM BIOPH RES CO, V274, P61, DOI 10.1006/bbrc.2000.3097; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; Natarajan R, 1996, J CELL PHYSIOL, V169, P391, DOI 10.1002/(SICI)1097-4652(199611)169:2<391::AID-JCP19>3.3.CO;2-Q; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Reddy MA, 2003, HYPERTENSION, V41, P1294, DOI 10.1161/01.HYP.0000069011.18333.08; Reddy MA, 2002, AM J PHYSIOL-RENAL, V283, pF985, DOI 10.1152/ajprenal.00181.2002; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Sahar S, 2005, CIRC RES, V96, P1064, DOI 10.1161/01.RES.0000168210.10358.f4; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seki Y, 2000, CIRC RES, V87, P12, DOI 10.1161/01.RES.87.1.12; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaw SS, 2003, DIABETES, V52, P2381, DOI 10.2337/diabetes.52.9.2381; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Srivastava AK, 2002, INT J MOL MED, V9, P85; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; VLASSARA H, 1994, LAB INVEST, V70, P138; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang Ruojiao, 2001, Journal of Nippon Medical School, V68, P472, DOI 10.1272/jnms.68.472; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855	58	129	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13685	13693		10.1074/jbc.M511425200	http://dx.doi.org/10.1074/jbc.M511425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551628	hybrid			2022-12-27	WOS:000237336600079
J	Tsui, J; Malenka, RC				Tsui, J; Malenka, RC			Substrate localization creates specificity in calcium/calmodulin-dependent protein kinase II signaling at synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RECEPTOR GLUR1 SUBUNIT; D-ASPARTATE RECEPTOR; BIDIRECTIONAL SYNAPTIC PLASTICITY; CULTURED HIPPOCAMPAL-NEURONS; AMPA RECEPTOR; NMDA RECEPTOR; POSTSYNAPTIC DENSITY; DENDRITIC SPINES; PHOSPHORYLATION SITE	Calcium/ calmodulin- dependent protein kinase II ( CaMKII), a major component of the postsynaptic density ( PSD) of excitatory synapses, plays a key role in the regulation of synaptic function in the mammalian brain. Although many postsynaptic substrates for CaMKII have been characterized in vitro, relatively little is known about their phosphorylation in vivo. By tagging synaptic proteins with a peptide substrate specific for CaMKII and expressing them in cultured neurons, we have visualized substrate phosphorylation by CaMKII at intact synapses. All substrates tested were strongly phosphorylated by CaMKII in HEK293 cells. However, activity- dependent phosphorylation of substrates at synapses was highly selective in that the glutamate receptor subunits NR2B and GluR1 were poorly phosphorylated whereas PSD- 95 and Stargazin, proteins implicated in the scaffolding and trafficking of AMPA receptors, were robustly phosphorylated. Phosphatase activity limited phosphorylation of Stargazin but not NR2B and GluR1. These results suggest that the unique molecular architecture of the PSD results in highly selective substrate discrimination by CaMKII.	Stanford Univ, Dept Psychiat & Behav Sci, Stanford Med Ctr, Nancy Pritzker Lab, Palo Alto, CA 94304 USA	Stanford University	Malenka, RC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford Med Ctr, Nancy Pritzker Lab, 1201 Welch Rd, Palo Alto, CA 94304 USA.	malenka@stanford.edu			NIMH NIH HHS [MH 063394] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH063394, R01MH063394] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Holtmaat AJGD, 2005, NEURON, V45, P279, DOI 10.1016/j.neuron.2005.01.003; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Inagaki N, 2000, J BIOL CHEM, V275, P27165; Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Noguchi J, 2005, NEURON, V46, P609, DOI 10.1016/j.neuron.2005.03.015; OH MC, 2005, NAT NEUROSCI; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Petersen JD, 2003, J NEUROSCI, V23, P11270; Pratt KG, 2003, NEURON, V39, P269, DOI 10.1016/S0896-6273(03)00422-7; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sobczyk A, 2005, J NEUROSCI, V25, P6037, DOI 10.1523/JNEUROSCI.1221-05.2005; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2005, NEURON, V45, P269, DOI 10.1016/j.neuron.2005.01.009; Tsui J, 2005, J BIOL CHEM, V280, P9210, DOI 10.1074/jbc.M407653200; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Yasuda R, 2003, NAT NEUROSCI, V6, P948, DOI 10.1038/nn1112; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	63	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13794	13804		10.1074/jbc.M600966200	http://dx.doi.org/10.1074/jbc.M600966200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551613	hybrid			2022-12-27	WOS:000237336600090
J	Abildayeva, K; Jansen, PJ; Hirsch-Reinshagen, V; Bloks, VW; Bakker, AHF; Ramaekers, FCS; de Vente, J; Groen, AK; Wellington, CL; Kuipers, F; Mulder, M				Abildayeva, K; Jansen, PJ; Hirsch-Reinshagen, V; Bloks, VW; Bakker, AHF; Ramaekers, FCS; de Vente, J; Groen, AK; Wellington, CL; Kuipers, F; Mulder, M			24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; BRAIN CHOLESTEROL; A-I; ADIPOSE-TISSUE; GLIAL-CELLS; MACROPHAGE CHOLESTEROL; GENE-EXPRESSION; ALPHA GENE; LXR-ALPHA	Both apolipoprotein E (apoE) and 24(S)-hydroxycholesterol are involved in the pathogenesis of Alzheimer disease (AD). It has been hypothesized that apoE affects AD development via isoform-specific effects on lipid trafficking between astrocytes and neurons. However, the regulation of the cholesterol supply of neurons via apoE-containing high density lipoproteins remains to be clarified. We show for the first time that the brain-specific metabolite of cholesterol produced by neurons, i.e. 24(S)-hydroxycholesterol, induces apoE transcription, protein synthesis, and secretion in a dose- and time-dependent manner in cells of astrocytic but not of neuronal origin. Moreover, 24(S)-hydroxycholesterol primes astrocytoma, but not neuroblastoma cells, to mediate cholesterol efflux to apoE. Similar results were obtained using the synthetic liver X receptor (LXR) agonist GW683965A, suggesting involvement of an LXR-controlled signaling pathway. A 10-20-fold higher basal LXR alpha and -beta expression level in astrocytoma compared with neuroblastoma cells may underlie these differential effects. Furthermore, apoE-mediated cholesterol efflux from astrocytoma cells may be controlled by the ATP binding cassette transporters ABCA1 and ABCG1, since their expression was also up-regulated by both compounds. In contrast, ABCG4 seems not to be involved, because its expression was induced only in neuronal cells. The expression of sterol regulatory element-binding protein (SREBP-2), low density lipoprotein receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, and SREBP-1c was transiently up-regulated by GW683965A in astrocytes but down-regulated by 24(S)-hydroxycholesterol, suggesting that cholesterol efflux and synthesis are regulated independently. In conclusion, evidence is provided that 24(S)-hydroxycholesterol induces apoE-mediated efflux of cholesterol in astrocytes via an LXR-controlled pathway, which may be relevant for chronic and acute neurological diseases.	Univ Maastricht, Dept Mol Cell Biol, European Grad Sch Neurosci EURON, Inst Brain & Behav, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands; Univ British Columbia, Dept Pathol & Lab Med, British Columbia Child & Family Res Inst, Vancouver, BC V4Z 5H5, Canada; Acad Med Ctr, Dept Med Biochem, NL-1105 BK Amsterdam, Netherlands; Univ Groningen, Med Ctr, Dept Pediat, NL-9713 GZ Groningen, Netherlands	Maastricht University; Maastricht University; Maastricht University; Child & Family Research Institute; University of British Columbia; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Mulder, M (corresponding author), Univ Maastricht, Dept Mol Cell Biol, European Grad Sch Neurosci EURON, Inst Brain & Behav, POB 616,Box 17, NL-6200 MD Maastricht, Netherlands.	M.Mulder@MOLCELB.unimaas.nl	Bloks, Vincent/A-7609-2012	Bloks, Vincent/0000-0001-6493-7482; Kuipers, Folkert/0000-0003-2518-737X				Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Argmann CA, 2005, J BIOL CHEM, V280, P22212, DOI 10.1074/jbc.M502761200; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Deumens R, 2004, NEUROSCIENCE, V125, P591, DOI 10.1016/j.neuroscience.2004.02.010; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dijkstra S, 1999, NEUROSCIENCE, V92, P1331, DOI 10.1016/S0306-4522(99)00060-3; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Groen AK, 2004, ANN MED, V36, P135, DOI 10.1080/07853890310020635; Harr SD, 1996, J NEUROCHEM, V66, P2429; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Jiang XC, 2003, J BIOL CHEM, V278, P49072, DOI 10.1074/jbc.M304274200; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; KRAUSE BR, 1984, J LIPID RES, V25, P97; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; MOCKEL B, 1994, J NEUROCHEM, V62, P788; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; Oldfield S, 2002, BBA-MOL CELL RES, V1591, P175, DOI 10.1016/S0167-4889(02)00269-0; Oram JF, 2001, J LIPID RES, V42, P1173; Panin LE, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1419, DOI 10.1023/A:1002861008363; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Rebeck GW, 2004, J MOL NEUROSCI, V23, P219, DOI 10.1385/JMN:23:3:219; Reiss AB, 2004, NEUROBIOL AGING, V25, P977, DOI 10.1016/j.neurobiolaging.2003.11.009; Reiss Allison B, 2005, Am J Alzheimers Dis Other Demen, V20, P91, DOI 10.1177/153331750502000208; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Slezak M, 2003, TRENDS NEUROSCI, V26, P531, DOI 10.1016/j.tins.2003.08.005; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Ulven SM, 2004, J LIPID RES, V45, P2052, DOI 10.1194/jlr.M400119-JLR200; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Walczak R, 2002, J LIPID RES, V43, P177; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Wolozin B, 2004, CNS DRUG REV, V10, P127; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200	66	181	191	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12799	12808		10.1074/jbc.M601019200	http://dx.doi.org/10.1074/jbc.M601019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524875	hybrid, Green Published			2022-12-27	WOS:000237134700074
J	Baltin, J; Leist, S; Odronitz, F; Wollscheid, HP; Baack, M; Kapitza, T; Schaarschmidt, D; Knippers, R				Baltin, J; Leist, S; Odronitz, F; Wollscheid, HP; Baack, M; Kapitza, T; Schaarschmidt, D; Knippers, R			DNA replication in protein extracts from human cells requires ORC and mcm proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; IN-VITRO REPLICATION; EUKARYOTIC CELLS; XENOPUS EGGS; FREE SYSTEM; HELA-CELLS; INITIATION; BINDING; SEQUENCE; INVITRO	We used protein extracts from proliferating human HeLa cells to support plasmid DNA replication in vitro. An extract with soluble nuclear proteins contains the major replicative chain elongation functions, whereas a high salt extract from isolated nuclei contains the proteins for initiation. Among the initiator proteins active in vitro are the origin recognition complex (ORC) and Mcm proteins. Recombinant Orc1 protein stimulates in vitro replication presumably in place of endogenous Orc1 that is known to be present in suboptimal amounts in HeLa cell nuclei. Partially purified endogenous ORC, but not recombinant ORC, is able to rescue immunodepleted nuclear extracts. Plasmid replication in the in vitro replication system is slow and of limited efficiency but robust enough to serve as a basis to investigate the formation of functional pre-replication complexes under biochemically defined conditions.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Schaarschmidt, D (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	daniel.schaarschmidt@uni-konstanz.de						ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; Biamonti G, 2003, CHROMOSOME RES, V11, P403, DOI 10.1023/A:1024910307162; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Gruss C, 1999, METH MOL B, V119, P291; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; Jenke ACW, 2004, P NATL ACAD SCI USA, V101, P11322, DOI 10.1073/pnas.0401355101; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mizushima T, 2000, GENE DEV, V14, P1631; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; PEARSON CE, 1994, SOMAT CELL MOLEC GEN, V20, P147, DOI 10.1007/BF02254755; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; Piechaczek C, 1999, NUCLEIC ACIDS RES, V27, P426, DOI 10.1093/nar/27.2.426; Price GB, 2003, J BIOL CHEM, V278, P19649, DOI 10.1074/jbc.M207002200; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu JR, 1997, METHODS, V13, P313, DOI 10.1006/meth.1997.0530; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	46	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12428	12435		10.1074/jbc.M510758200	http://dx.doi.org/10.1074/jbc.M510758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537544	hybrid			2022-12-27	WOS:000237134700029
J	Smyth, JT; Lemonnier, L; Vazquez, G; Bird, GS; Putney, JW				Smyth, JT; Lemonnier, L; Vazquez, G; Bird, GS; Putney, JW			Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; INOSITOL TRISPHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR; CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; FUNCTIONAL EXPRESSION; SIGNALING MECHANISM; STORE DEPLETION; B-LYMPHOCYTES; KINASE-C	Regulated translocation of canonical transient receptor potential ( TRPC) proteins to the plasma membrane has been proposed as a mechanism of their activation. By using total internal reflection fluorescence microscopy (TIRFM), we monitored green fluorescent protein-labeled TRPC3 (TRPC3-GFP) movement to the plasma membrane in HEK293 cells stably expressing this fusion protein. We observed no increase in TRPC3-GFP TIRFM in response to the muscarinic receptor agonist methacholine or the synthetic diacylglycerol, 1-oleoyl-2-acetyl-sn-glycerol, despite activation of TRPC3 by these agents. We did, however, observe a TIRFM response to epidermal growth factor (EGF). This TIRFM response to EGF was accompanied by increased Ba2+ entry and TRPC3 currents. However, 1-oleoyl-2-acetyl-sn-glycerol-induced TRPC3 activity was not increased. TIRFM also increased in response to Gd3+, a competitive inhibitor of TRPC3 channels. This may be indicative of constitutive trafficking of TRPC3, with Gd3+ acting to "trap" cycling TRPC3 molecules in the plasma membrane. Consistent with this interpretation, TRPC3-expressing cells exhibited large variance in membrane capacitance, and this variance was decreased by both Gd3+ and EGF. These results indicate the following: (i) trafficking of TRPC3 may play a role in regulating the concentration of channels in the plasma membrane but is not involved in activation through the phospholipase C pathway; (ii) TRPC3 undergoes constitutive cyclical trafficking in the plasma membrane, and the mechanism by which growth factors increase the number of plasma membrane channels may involve stabilizing them in the plasma membrane.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Lemonnier, Loic/L-7289-2018; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Lemonnier, Loic/0000-0001-6200-5382; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KREYE VAW, 1986, PFLUG ARCH EUR J PHY, V406, P308, DOI 10.1007/BF00640919; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; MONTELL C, 2001, SCI STKE, V90, P1; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Newton AC, 2002, METHOD ENZYMOL, V345, P499; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; UVELIUS B, 1974, BLOOD VESSELS, V11, P245; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; von Gersdorff H, 1999, ANNU REV PHYSIOL, V61, P725, DOI 10.1146/annurev.physiol.61.1.725; Wissenbach U, 2004, BIOL CELL, V96, P47, DOI 10.1016/j.biolcel.2003.12.003; Yildirim E, 2005, P NATL ACAD SCI USA, V102, P3307, DOI 10.1073/pnas.0409908102; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	44	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11712	11720		10.1074/jbc.M510541200	http://dx.doi.org/10.1074/jbc.M510541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522635	hybrid			2022-12-27	WOS:000236988100035
J	Chen, L; Shen, YH; Wang, XW; Wang, J; Gan, YH; Chen, NY; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL				Chen, L; Shen, YH; Wang, XW; Wang, J; Gan, YH; Chen, NY; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL			Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream stimulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; HUMAN TROPHOBLAST DIFFERENTIATION; FAMILIAL COMBINED HYPERLIPIDEMIA; PROLYL 4-HYDROXYLASE ISOENZYME; DISULFIDE-ISOMERASE SUBUNIT; AMERICAN-HEART-ASSOCIATION; BINDING PROTEIN-1 GENE; SMOOTH-MUSCLE-CELLS; ACID SYNTHASE GENE; COLLAGEN-SYNTHESIS	Prolyl-4-hydroxylase alpha(I) (P4H alpha(I)) is the rate-limiting subunit for P4H enzyme activity, which is essential for procollagen hydroxylation and secretion. In the current study, we have characterized the human P4H alpha(I) promoter for transcription factors and DNA elements regulating P4H alpha(I) expression. Using a progressive deletion cloning approach, we have constructed pGL3-P4H alpha(I) recombinant plasmids. We have identified a positive regulatory region at the positions of bp -184 to -97 responsible for similar to 80% of the P4H alpha(I) promoter efficiency. Three E-boxes were located within this region, and the E-box at position bp -135 explains most of the regulatory capacity. Upstream stimulatory factors (USF1/USF2) were shown to bind on the E-box using chromatin immunoprecipitation assay. Suppression of USF1 and/or USF2 using specific short interference RNA resulted in a significant reduction in P4H alpha(I) promoter activity, and overexpressed USF1 or USF2 increased P4H alpha(I) promoter activity significantly. Although transforming growth factor beta 1 increased the USF1/USF2-E-box binding and P4H alpha(I) promoter activity, this up-regulatory effect can be largely prevented by USF1/USF2-specific short interference RNA. On the other hand, cigarette smoking extracts, which have been shown to suppress P4H alpha(I) expression, inhibited the binding between the USF1/USF2 and E-box, resulting in a reduced P4H alpha(I) promoter activity. Furthermore, the E-box on the P4H alpha(I) promoter appeared to indiscriminately bind with either USF1 or USF2, with a similar outcome on the promoter efficiency. In conclusion, our study shows that USF1/USF2 plays a critical role in basal P4H alpha(I) expression, and both positive (transforming growth factor beta 1) and negative (cigarette smoking extract) regulators appear to influence the USF-E-box interaction and affect P4H alpha(I) expression.	Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiothorac Serv, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute; University of Texas System; UTMD Anderson Cancer Center	Wang, XL (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA.	xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022	LeMaire, Scott/0000-0002-8736-4266	NHLBI NIH HHS [R01 HL066053, HL066053, K08 HL080085-02, R01 HL071608, HL71608, K08 HL080085] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071608, R01HL066053, K08HL080085] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bengtsson SHM, 2002, BIOCHEM J, V365, P481, DOI 10.1042/BJ20020223; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; Coulson JM, 2003, BIOCHEM J, V369, P549, DOI 10.1042/BJ20021176; Crissey MAS, 1999, HEPATOLOGY, V30, P1187, DOI 10.1002/hep.510300520; Fabunmi RP, 1998, CIRC RES, V83, P270, DOI 10.1161/01.RES.83.3.270; Gao EW, 2003, AM J PHYSIOL-LUNG C, V284, pL1027, DOI 10.1152/ajplung.00219.2002; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Harris AN, 1998, MOL ENDOCRINOL, V12, P714, DOI 10.1210/me.12.5.714; HIRAMATSU M, 1982, ENDOCRINOLOGY, V111, P1810, DOI 10.1210/endo-111-6-1810; Jiang B, 2005, MOL CELL BIOL, V25, P8824, DOI 10.1128/MCB.25.20.8824-8833.2005; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; John DCA, 1999, NAT BIOTECHNOL, V17, P385, DOI 10.1038/7945; Kato Y, 1996, J GASTROENTEROL, V31, P565, DOI 10.1007/BF02355058; KAWAGUCHI Y, 1992, J RHEUMATOL, V19, P1195; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kyriacou CP, 2000, J BIOL RHYTHM, V15, P483, DOI 10.1177/074873000129001594; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Luo X, 1996, MOL CELL BIOL, V16, P1367; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; Mizutani K, 2000, BIOCHEM BIOPH RES CO, V274, P61, DOI 10.1006/bbrc.2000.3097; Muguerza B, 2001, BBA-MOL BASIS DIS, V1536, P185, DOI 10.1016/S0925-4439(01)00045-X; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Pajukanta P, 2004, NAT GENET, V36, P371, DOI 10.1038/ng1320; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Raveendran M, 2005, FEBS LETT, V579, P733, DOI 10.1016/j.febslet.2004.12.052; Raveendran M, 2004, BIOCHEM BIOPH RES CO, V323, P592, DOI 10.1016/j.bbrc.2004.08.129; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Rodriguez CI, 2003, J BIOL CHEM, V278, P43135, DOI 10.1074/jbc.M300053200; ROUSSEAU GG, 1992, HORM RES, V37, P88, DOI 10.1159/000182407; Sasaki Tetsuo, 1992, Journal of Dermatology (Tokyo), V19, P664; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Schweizer M, 2002, BIOCHEM SOC T, V30, P1070, DOI 10.1042/BST0301070; Sellak H, 2005, J BIOL CHEM, V280, P18425, DOI 10.1074/jbc.M500775200; Shoulders CC, 2004, TRENDS MOL MED, V10, P362, DOI 10.1016/j.molmed.2004.06.011; Shoulders CC, 2004, NAT GENET, V36, P322, DOI 10.1038/ng0404-322; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Takahashi S, 2002, BBA-GENE STRUCT EXPR, V1574, P354, DOI 10.1016/S0167-4781(01)00360-8; Takahashi Y, 2001, DRUG METAB REV, V33, P37, DOI 10.1081/DMR-100000139; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Weigert C, 2004, J BIOL CHEM, V279, P15908, DOI 10.1074/jbc.M313524200; Yan SQ, 2004, GENE, V337, P199, DOI 10.1016/j.gene.2004.05.005; Zhu YQ, 2005, DIABETES, V54, P1976, DOI 10.2337/diabetes.54.7.1976	60	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10849	10855		10.1074/jbc.M511237200	http://dx.doi.org/10.1074/jbc.M511237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488890	hybrid, Green Accepted			2022-12-27	WOS:000236822200024
J	Kamiyama, S; Sasaki, N; Goda, E; Ui-Tei, K; Saigo, K; Narimatsu, H; Jigami, Y; Kannagi, R; Irimura, T; Nishihara, S				Kamiyama, S; Sasaki, N; Goda, E; Ui-Tei, K; Saigo, K; Narimatsu, H; Jigami, Y; Kannagi, R; Irimura, T; Nishihara, S			Molecular cloning and characterization of a novel 3 '-phosphoadenosine 5 '-phosphosulfate transporter, PAPST2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SUGAR TRANSPORTER; HIGH ENDOTHELIAL VENULES; L-SELECTIN LIGAND; SIALYL-LEWIS-X; N-ACETYLGLUCOSAMINE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; HUMAN COLONIC SULFOMUCIN; SULFATE-TRANSPORTER; MONOCLONAL-ANTIBODY; HEPARAN-SULFATE	Sulfation is an important posttranslational modification associated with a variety of molecules. It requires the involvement of the high energy form of the universal sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS). Recently, we identified a PAPS transporter gene in both humans and Drosophila. Although human colonic epithelial tissues express many sulfated glycoconjugates, PAPST1 expression in the colon is trace. In the present study, we identified a novel human PAPS transporter gene that is closely related to human PAPST1. This gene, called PAPST2, is predominantly expressed in human colon tissues. The PAPST2 protein is localized on the Golgi apparatus in a manner similar to the PAPST1 protein. By using yeast expression studies, PAPST2 protein was shown to have PAPS transport activity with an apparent Km value of 2.2 mu M, which is comparable with that of PAPST1 (0.8 mu M). Overexpression of either the PAPST1 or PAPST2 gene increased PAPS transport activity in human colon cancer HCT116 cells. The RNA interference of the PAPST2 gene in the HCT116 cells significantly reduced the reactivity of G72 antibody directed against the sialyl 6-sulfo N-acetyllactosamine epitope and total sulfate incorporation into cellular proteins. These findings indicate that PAPST2 is a PAPS transporter gene involved in the synthesis of sulfated glycoconjugates in the colon.	Soka Univ, Dept Bioinformat, Cell Biol Lab, Tokyo 1928577, Japan; Res Assoc Biotechnol, Minato Ku, Tokyo 1050003, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058586, Japan; Aichi Canc Ctr, Program Mol Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan	Soka University; Japan Science & Technology Agency (JST); University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Aichi Cancer Center; University of Tokyo	Nishihara, S (corresponding author), Soka Univ, Dept Bioinformat, Cell Biol Lab, 1-236 Tangi Cho, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp	Kannagi, Reiji/Q-6459-2018; Narimatsu, Hisashi/M-4757-2018	Kannagi, Reiji/0000-0003-4202-2921; Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Antalis TM, 1998, CLIN CANCER RES, V4, P1857; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BAUERLE PA, 1987, J CELL BIOL, V105, P2655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; FLEISCHER B, 1974, J BIOL CHEM, V249, P5995; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; IMAI Y, 1993, NATURE, V361, P555; IRIMURA T, 1991, CANCER RES, V51, P5728; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 2004, PFLUG ARCH EUR J PHY, V447, P768, DOI 10.1007/s00424-003-1093-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izawa M, 2000, CANCER RES, V60, P1410; Kamiyama S, 2004, TRENDS GLYCOSCI GLYC, V16, P109, DOI 10.4052/tigg.16.109; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kannagi R, 1999, TRENDS GLYCOSCI GLYC, V11, P329, DOI 10.4052/tigg.11.329; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kumamoto K, 2001, CANCER RES, V61, P4620; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LANE N, 1964, J CELL BIOL, V21, P339, DOI 10.1083/jcb.21.3.339; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; MATSUSHITA Y, 1995, JPN J CANCER RES, V86, P1060, DOI 10.1111/j.1349-7006.1995.tb03021.x; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; NAKAYAMA T, 1995, CANCER, V75, P2051, DOI 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Seko A, 2000, GLYCOBIOLOGY, V10, P919, DOI 10.1093/glycob/10.9.919; Seko A, 2002, JPN J CANCER RES, V93, P507, DOI 10.1111/j.1349-7006.2002.tb01285.x; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; Superti-Furga A, 1999, J MED GENET, V36, P621; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tsuiji H, 1998, JPN J CANCER RES, V89, P1267, DOI 10.1111/j.1349-7006.1998.tb00523.x; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; UEMURA M, 1992, CANCER RES, V52, P6153; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Yamachika T, 1997, VIRCHOWS ARCH, V431, P25, DOI 10.1007/s004280050065; YAMORI T, 1989, CANCER RES, V49, P887; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	55	54	57	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10945	10953		10.1074/jbc.M508991200	http://dx.doi.org/10.1074/jbc.M508991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492677	hybrid			2022-12-27	WOS:000236822200035
J	Iuso, A; Scacco, S; Piccoli, C; Bellomo, F; Petruzzella, V; Trentadue, R; Minuto, M; Ripoli, M; Capitanio, N; Zeviani, M; Papa, S				Iuso, A; Scacco, S; Piccoli, C; Bellomo, F; Petruzzella, V; Trentadue, R; Minuto, M; Ripoli, M; Capitanio, N; Zeviani, M; Papa, S			Dysfunctions of cellular oxidative metabolism in patients with mutations in the NDUFS1 and NDUFS4 genes of complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQDQ SUBUNIT; UBIQUINONE OXIDOREDUCTASE; DEPENDENT PHOSPHORYLATION; HEART-MITOCHONDRIA; NONSENSE MUTATION; LEIGH-SYNDROME; DEFICIENCY; DISEASE; ACTIVATION; GENERATION	The pathogenic mechanism of a G44A nonsense mutation in the NDUFS4 gene and a C1564A mutation in the NDUFS1 gene of respiratory chain complex I was investigated in fibroblasts from human patients. As previously observed the NDUFS4 mutation prevented complete assembly of the complex and caused full suppression of the activity. The mutation (Q522K replacement) in NDUFS1 gene, coding for the 75-kDa Fe-S subunit of the complex, was associated with ( a) reduced level of the mature complex, (b) marked, albeit not complete, inhibition of the activity, ( c) accumulation of H2O2 and O-2(radical anion) in mitochondria, (d) decreased cellular content of glutathione, ( e) enhanced expression and activity of glutathione peroxidase, and (f) decrease of the mitochondrial potential and enhanced mitochondrial susceptibility to reactive oxygen species (ROS) damage. No ROS increase was observed in the NDUFS4 mutation. Exposure of the NDUFS1 mutant fibroblasts to dibutyryl-cAMP stimulated the residual NADH-ubiquinone oxidoreductase activity, induced disappearance of ROS, and restored the mitochondrial potential. These are relevant observations for a possible therapeutical strategy in NDUFS1 mutant patients.	Univ Bari, Dept Med Biochem Biol & Phys, I-70124 Bari, Italy; Univ Foggia, Dept Biomed Sci, I-71100 Foggia, Italy; Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20100 Milan, Italy; CNR, Inst Biomembrane & Bioenerget, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Foggia; IRCCS Istituto Neurologico Besta; Consiglio Nazionale delle Ricerche (CNR)	Papa, S (corresponding author), Univ Bari, Dept Med Biochem Biol & Phys, Policlin, Pzza G Cesare, I-70124 Bari, Italy.	papabchm@cimedoc.uniba.it	Zeviani, Massimo/AAU-2632-2021; petruzzella, vittoria/K-8863-2016; Zeviani, Massimo/K-2891-2014; Ripoli, Maria/J-6713-2012; Bellomo, Francesco/K-2142-2012; Scacco, Salvatore/AAC-7406-2022; Minuto, Michele/H-5398-2011	Zeviani, Massimo/0000-0002-9067-5508; petruzzella, vittoria/0000-0001-8771-6033; Bellomo, Francesco/0000-0003-2912-8764; Scacco, Salvatore/0000-0003-2717-2489; Minuto, Michele/0000-0002-4729-7636; Papa, Sergio/0000-0002-4417-1763; Ripoli, Maria/0000-0002-8132-0764				Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Benit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316; Benit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2; Benit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603; Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257; Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255; Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004; Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6; Pasdois P, 2003, J BIOENERG BIOMEMBR, V35, P439, DOI 10.1023/A:1027391831382; Petruzzella V, 2005, FEBS LETT, V579, P3770, DOI 10.1016/j.febslet.2005.05.035; Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1; Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; Scacco S, 2003, J BIOL CHEM, V278, P44161, DOI 10.1074/jbc.M307615200; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Technikova-Dobrova Z, 2001, BIOCHEMISTRY-US, V40, P13941, DOI 10.1021/bi011066p; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; Vinogradov AD, 2005, BIOCHEMISTRY-MOSCOW+, V70, P120, DOI 10.1007/s10541-005-0090-7; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698	39	115	117	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10374	10380		10.1074/jbc.M513387200	http://dx.doi.org/10.1074/jbc.M513387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478720	hybrid			2022-12-27	WOS:000236594300066
J	Yang, LM; Rinke, R; Korbmacher, C				Yang, LM; Rinke, R; Korbmacher, C			Stimulation of the epithelial sodium channel (ENaC) by cAMP involves putative ERK phosphorylation sites in the C termini of the channel's beta- and gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE INHIBITORS; CORTICAL COLLECTING DUCT; CELL-SURFACE EXPRESSION; NA+-CHANNEL; LIDDLES-SYNDROME; XENOPUS OOCYTES; DOWN-REGULATION; ALPHA-SUBUNIT; BREFELDIN-A; ACTIVATION	The mechanisms involved in the regulation of the epithelial sodium channel ( ENaC) via the cAMP pathway are not yet completely understood. The aim of the present study was to investigate cAMP-mediated ENaC regulation in Xenopus laevis oocytes heterologously expressing the three subunits (alpha beta gamma) of rat ENaC and to determine the ENaC regions important for mediating the stimulatory effect of cAMP. In oocytes treated for about 24 h with 1 mM 3-isobutyl-1-methylxanthine ( IBMX) and 1 mu M forskolin (FSK) so as to increase intracellular cAMP, the amiloride-sensitive whole cell current (Delta I-Ami) was on average 10-fold larger than Delta I-Ami in matched control oocytes. This effect on Delta I-Ami was paralleled by an increase in ENaC surface expression caused by a reduced rate of ENaC retrieval. In addition, IBMX/FSK also enhanced ENaC open probability from about 0.2 to 0.5. The stimulatory effect of IBMX/FSK was dependent on the presence of intact PY motifs in the C termini of the channel. Mutagenesis of putative protein kinase A and CK-2 consensus motifs in the cytosolic domains of the channel did not reveal critical sites involved in mediating the stimulatory effect of IBMX/FSK. In contrast, site-directed mutagenesis of two putative ERK-consensus motifs (T613A in beta ENaC and T623A in gamma ENaC) largely reduced the stimulatory effect of IBMX/FSK. Phosphorylation of these ERK sites has previously been reported to enhance the interaction of ENaC and Nedd4 (Shi, H., Asher, C., Chigaev, A., Yung, Y., Reuveny, E., Seger, R., and Garty, H. ( 2002) J. Biol. Chem. 277, 13539 - 13547). Using co-expression experiments we demonstrated that mutating the two ERK sites attenuates the inhibitory effect of Nedd4-2 on ENaC currents. We conclude that an increase in intracellular cAMP favors the dephosphorylation of the two ERK sites, which reduces channel retrieval and increases PO by modulating ENaC/Nedd4 interaction. This defines a novel regulatory pathway likely to be relevant for cAMP-induced stimulation of ENaC in vivo.	Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Korbmacher, C (corresponding author), Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de						Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bankir L, 2005, J AM SOC NEPHROL, V16, P1920, DOI 10.1681/ASN.2004121079; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Dinudom A, 2004, P NATL ACAD SCI USA, V101, P11886, DOI 10.1073/pnas.0402178101; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; Falin R, 2005, AM J PHYSIOL-CELL PH, V288, pC1003, DOI 10.1152/ajpcell.00213.2004; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Kansy JW, 2004, J NEUROCHEM, V91, P374, DOI 10.1111/j.1471-4159.2004.02723.x; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Michlig S, 2004, J BIOL CHEM, V279, P51002, DOI 10.1074/jbc.M405674200; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Pearce D, 2003, CELL PHYSIOL BIOCHEM, V13, P13, DOI 10.1159/000070245; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stevenson-Lindert LM, 2003, J BIOL CHEM, V278, P50956, DOI 10.1074/jbc.M306546200; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047; Volk T, 2004, PFLUG ARCH EUR J PHY, V447, P884, DOI 10.1007/s00424-003-1193-x; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang YH, 2005, AM J PHYSIOL-CELL PH, V288, pC141, DOI 10.1152/ajpcell.00343.2004	60	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9859	9868		10.1074/jbc.M512046200	http://dx.doi.org/10.1074/jbc.M512046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476738	hybrid			2022-12-27	WOS:000236594300007
J	Yu, G; Mao, JN; Wu, YL; Luo, HY; Wu, JP				Yu, G; Mao, JN; Wu, YL; Luo, HY; Wu, JP			Ephrin-B1 is critical in T-cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; THYMUS ORGAN-CULTURE; POSITIVE SELECTION; EPH RECEPTORS; NEGATIVE SELECTION; CROSS-LINKING; EXPRESSION; ACTIVATION; LIGANDS; FAMILY	Eph kinases are the largest family of receptor tyrosine kinases, and their ligands, ephrins (EFNs), are also cell surface molecules. In this study, we investigated the role of EFNB1 and the Ephs it interacts with (collectively called EFNB1 receptors) in mouse T-cell development. In the thymus, CD8 single positive (SP) and CD4CD8 double positive (DP) cells expressed high levels of EFNB1 and EFNB1 receptors, whereas CD4 SP cells had moderate expression of both. Soluble EFNB1-Fc in fetal thymus organ culture caused significant subpopulation ratio skew, with increased CD4 SP and CD8 SP and decreased DP percentage, while the cellularity of the thymus remained constant. Moreover, in EFNB1-treated fetal thymus organ culture, CD117(+), CD25(+), DP, CD4 SP, and CD8 SP cells all had significantly enhanced proliferation history, according to bromodeoxyuridine uptake. In vitro culture of isolated thymocytes revealed that EFNB1-Fc on solid-phase protected thymocytes from anti-CD3-induced apoptosis, with concomitant augmentation of several antiapoptotic factors, particularly in CD4 SP and CD8 SP cells; on the other hand, soluble EFNB1-Fc promoted anti-CD3-induced apoptosis, as was the case in vivo. This study reveals that EFNB1 and EFNB1 receptors are critical in thymocyte development.	CHUM, Notre Dame Hosp, Res Ctr, Immunol Lab, Montreal, PQ H2L 4M1, Canada; CHUM, Notre Dame Hosp, Serv Nephrol, Montreal, PQ H2L 4M1, Canada; Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou 310009, Peoples R China	Universite de Montreal; Universite de Montreal; Zhejiang University	Luo, HY (corresponding author), CHUM, Notre Dame Hosp, Res Ctr, Immunol Lab, Pavil DeSeve,Rm Y-5616,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	hongyu.luo@umontreal.ca	mao, jianning/A-4254-2011					Amsen D, 1998, IMMUNOL REV, V165, P209, DOI 10.1111/j.1600-065X.1998.tb01241.x; Anderson G, 1997, IMMUNOL TODAY, V18, P363; ANDRES AC, 1994, ONCOGENE, V9, P1461; Baldwin KK, 1999, J IMMUNOL, V163, P689; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; CIOSSEK T, 1995, ONCOGENE, V11, P2085; DELUCA D, 1995, J IMMUNOL METHODS, V178, P13, DOI 10.1016/0022-1759(94)00236-P; Dravis C, 2004, DEV BIOL, V271, P272, DOI 10.1016/j.ydbio.2004.03.027; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Germain RN, 2003, IMMUNOL RES, V27, P277, DOI 10.1385/IR:27:2-3:277; Gurniak CB, 1996, ONCOGENE, V13, P777; Hare KJ, 1999, J IMMUNOL, V162, P3978; Hare KJ, 2001, CELL MOL BIOL, V47, P119; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Lickliter JD, 1996, P NATL ACAD SCI USA, V93, P145, DOI 10.1073/pnas.93.1.145; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Luo HY, 2004, J CLIN INVEST, V114, P1762, DOI 10.1172/JCI200421846; Middlebrook AJ, 2002, J IMMUNOL, V169, P2915, DOI 10.4049/jimmunol.169.6.2915; Munoz JJ, 2002, J IMMUNOL, V169, P177, DOI 10.4049/jimmunol.169.1.177; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ober BT, 2000, INT IMMUNOL, V12, P1353, DOI 10.1093/intimm/12.9.1353; Prevost N, 2004, BLOOD, V103, P1348, DOI 10.1182/blood-2003-06-1781; SCOLLAY R, 1995, IMMUNOL TODAY, V16, P273; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Stefanski HE, 2001, J IMMUNOL, V166, P6602, DOI 10.4049/jimmunol.166.11.6602; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vergara-Silva Andrea, 2002, Gene Expression Patterns, V2, P261, DOI 10.1016/S1567-133X(02)00054-6; Viret C, 1999, Rev Immunogenet, V1, P91; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Yu G, 2003, J IMMUNOL, V171, P106, DOI 10.4049/jimmunol.171.1.106; Yu G, 2004, J BIOL CHEM, V279, P55531, DOI 10.1074/jbc.M410814200; Yu G, 2003, J BIOL CHEM, V278, P47209, DOI 10.1074/jbc.M306659200	43	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10222	10229		10.1074/jbc.M510320200	http://dx.doi.org/10.1074/jbc.M510320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476740	hybrid			2022-12-27	WOS:000236594300049
J	Miao, J; Fang, SS; Bae, Y; Kemper, JK				Miao, Ji; Fang, Sungsoon; Bae, Yangjin; Kemper, Jongsook Kim			Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CARBOXYKINASE GENE-TRANSCRIPTION; GAMMA COACTIVATOR-1-ALPHA; XENOBIOTIC INDUCTION; ACCESSORY FACTORS; FACTOR 4-ALPHA; CAR; CHOLESTEROL; GLUCONEOGENESIS; ACTIVATION	The role of the constitutive androstane receptor (CAR) in xenobiotic metabolism by inducing expression of cytochromes P450 is well known, but CAR has also been implicated in the down-regulation of key genes involved in bile acid synthesis, gluconeogenesis, and fatty acid beta-oxidation by largely unknown mechanisms. Because a key hepatic factor, hepatic nuclear factor-4 (HNF-4), is crucial for the expression of many of these genes, we examined whether CAR could suppress HNF-4 transactivation. Expression of CAR inhibited HNF-4 transactivation of CYP7A1, a key gene in bile acid synthesis, in HepG2 cells, and mutation of the DNA binding domain of CAR impaired this inhibition. Gel shift assays revealed that CAR competes with HNF-4 for binding to the DR1 motif in the CYP7A1 promoter. TCPOBOP, a CAR agonist that increases the interaction of CAR with coactivators, potentiated CAR inhibition of HNF-4 transactivation. Furthermore, inhibition by CAR was reversed by expression of increasing amounts of GRIP-1 or PGC-1 alpha, indicating that CAR competes with HNF-4 for these coactivators. Treatment of mice with phenobarbital or TCPOBOP resulted in decreased hepatic mRNA levels of the reported genes down-regulated by CAR, including Cyp7a1 and Pepck. In vivo recruitment of endogenous CAR to the promoters of Cyp7a1 and Pepck was detected in mouse liver after phenobarbital treatment, whereas association of HNF-4 and coactivators, GRIP-1, p300, and PGC-1 alpha, with these promoters was significantly decreased. Our data suggest that CAR inhibits HNF-4 activity by competing with HNF-4 for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1 alpha, which may be a general mechanism by which CAR down-regulates key genes in hepatic lipid and glucose metabolism.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, JK (corresponding author), Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA.	jongsook@uiuc.edu	Bae, Yangjin/AAO-1866-2021; Miao, Ji/F-9398-2015	Bae, Yangjin/0000-0003-2397-0192; Miao, Ji/0000-0003-0869-4492	NIDDK NIH HHS [DK 062777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062777, R01DK062777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; Bae YJ, 2004, DNA CELL BIOL, V23, P81, DOI 10.1089/104454904322759894; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Cancado ELR, 1998, AM J GASTROENTEROL, V93, P1510, DOI 10.1111/j.1572-0241.1998.00472.x; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Eloranta JJ, 2005, ARCH BIOCHEM BIOPHYS, V433, P397, DOI 10.1016/j.abb.2004.09.019; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004-0211; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; Marrapodi M, 2000, J LIPID RES, V41, P514; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rencurel F, 2005, J BIOL CHEM, V280, P4367, DOI 10.1074/jbc.M412711200; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Stroup D, 1997, J BIOL CHEM, V272, P9833; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Wang DP, 1996, J LIPID RES, V37, P1831; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	52	150	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14537	14546		10.1074/jbc.M510713200	http://dx.doi.org/10.1074/jbc.M510713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16492670	hybrid			2022-12-27	WOS:000237671300004
J	Salazar, M; Rojo, AI; Velasco, D; de Sagarra, RM; Cuadrado, A				Salazar, Maria; Rojo, Ana I.; Velasco, Diego; de Sagarra, Rosa Maria; Cuadrado, Antonio			Glycogen synthase kinase-3 beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SUBSTRATE ADAPTER PROTEIN; OXIDATIVE STRESS; HEME OXYGENASE-1; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE/AKT; PROTEASOMAL DEGRADATION; INDUCIBLE EXPRESSION; NEGATIVE REGULATION; HEAT-SHOCK	The transcription factor Nrf2 ( nuclear factor E2-related factor 2) regulates the expression of antioxidant phase II genes and contributes to preserve redox homeostasis and cell viability in response to oxidant insults. Nrf2 should be coordinated with the canonical cell survival pathway represented by phosphatidylinositol 3-kinase (PI3K) and the Ser/Thr kinase Akt but so far the mechanistic connections remain undefined. Here we identify glycogen synthase kinase-3 beta (GSK-3 beta), which is inhibited by Akt-mediated phosphorylation, as the link between both processes. Using heme oxygenase-1 (HO-1) as a model phase II gene, we found that both PI3K and Akt increased mRNA and protein levels of this enzyme. Pharmacological inhibitors (LiCl and PDZD-8) and genetic variants of GSK-3 beta ( constitutively active and dominant negative mutants) indicated that PI3K/Akt activates and GSK-3 beta inhibits the antioxidant response elements of the ho1 promoter and pointed Nrf2 as directly involved in this process. Indeed, GSK-3 beta phosphorylated Nrf2 in vitro and in vivo. Immunocytochemistry and subcellular fractionation analyses demonstrated that the effect of GSK-3 beta-mediated phosphorylation of Nrf2 is to exclude this transcription factor from the nucleus. Nrf2 up-regulated the expression of HO-1, glutathione peroxidase, glutathione S-transferase A1, NAD(P)H: quinone oxidoreductase and glutamate-cysteine ligase and protected against hydrogen peroxide-induced glutathione depletion and cell death, whereas co-expression of active GSK-3 beta attenuated both phase II gene expression and oxidant protection. These results contribute to clarify the cross-talk between the survival signal elicited by PI3K/Akt and the antioxidant phase II cell response, and introduce GSK-3 beta as the key mediator of this regulation mechanism.	Univ Autonoma Madrid, Dept Bioquim, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Inst Invest Biomed, Fac Med, Madrid 28029, Spain	Autonomous University of Madrid; Autonomous University of Madrid	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Dept Bioquim, Fac Med, Arzobispo Morcillo 4, Madrid 28029, Spain.	antonio.cuadrado@uam.es	Roa, Maria Salazar/I-1168-2015; Rojo, Ana I/AAA-5203-2019	Roa, Maria Salazar/0000-0001-6784-9541; Rojo, Ana I/0000-0002-0312-5867; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dennery PA, 2006, FREE RADICAL BIO MED, V40, P1, DOI 10.1016/j.freeradbiomed.2005.09.003; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; KIM HP, 2005, ANN REV PHARM TOXICO; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koh SH, 2004, NEUROTOXICOLOGY, V25, P793, DOI 10.1016/j.neuro.2004.02.001; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Schafer M, 2004, BRAIN RES, V1005, P84, DOI 10.1016/j.brainres.2004.01.037; Sebastia J, 2003, CYTOM PART A, V51A, P16, DOI 10.1002/cyto.a.10003; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zielonka J, 2005, FREE RADICAL BIO MED, V39, P853, DOI 10.1016/j.freeradbiomed.2005.05.001; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	58	377	383	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14841	14851		10.1074/jbc.M513737200	http://dx.doi.org/10.1074/jbc.M513737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551619	hybrid			2022-12-27	WOS:000237671300038
J	Vizeacoumar, FJ; Vreden, WN; Aitchison, JD; Rachubinski, RA				Vizeacoumar, Franco J.; Vreden, Wanda N.; Aitchison, John D.; Rachubinski, Richard A.			Pex19p binds Pex30p and Pex32p at regions required for their peroxisomal localization but separate from their peroxisomal targeting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; RAT-LIVER PEROXISOMES; NUCLEAR-PORE COMPLEX; ENDOPLASMIC-RETICULUM; ASCORBATE PEROXIDASE; POTENTIAL ROLE; YEAST; BIOGENESIS; MULTIPLE; TOPOGENESIS	The assembly of proteins in the peroxisomal membrane is amultistep process requiring their recognition in the cytosol, targeting to and insertion into the peroxisomal membrane, and stabilization within the lipid bilayer. The peroxin Pex19p has been proposed to be either the receptor that recognizes and targets newly synthesized peroxisomal membrane proteins (PMP) to the peroxisome or a chaperone required for stabilization of PMPs at the peroxisomal membrane. Differentiating between these two roles for Pex19p could be achieved by determining whether the peroxisomal targeting signal (PTS) and the region of Pex19p binding of a PMP are the same or different. We addressed the role for Pex19p in the assembly of two PMPs, Pex30p and Pex32p, of the yeast Saccharomyces cerevisiae. Pex30p and Pex32p control peroxisome size and number but are dispensable for peroxisome formation. Systematic truncations from the carboxyl terminus, together with in-frame deletions of specific regions, have identified PTSs essential for targeting Pex30p and Pex32p to peroxisomes. Both Pex30p and Pex32p interact with Pex19p in regions that do not overlap with their PTSs. However, Pex19p is required for localizing Pex30p and Pex32p to peroxisomes, because mutations that disrupt the interaction of Pex19p with Pex30p and Pex32p lead to their mislocalization to a compartment other than peroxisomes. Mutants of Pex30p and Pex32p that localize to peroxisomes but produce cells exhibiting the peroxisomal phenotypes of cells lacking these proteins demonstrate that the regions in these proteins that control peroxisomal targeting and cell biological activity are separable. Together, our data show that the interaction of Pex19p with Pex30p and Pex32p is required for their roles in peroxisome biogenesis and are consistent with a chaperone role for Pex19p in stabilizing or maintaining membrane proteins in peroxisomes.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Alberta; Institute for Systems Biology (ISB)	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca	Vizeacoumar, Franco/GLS-7161-2022		NIGMS NIH HHS [GM 067228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BODNAR AG, 1991, BIOCHEM CELL BIOL, V69, P499, DOI 10.1139/o91-074; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; Kragt A, 2005, J BIOL CHEM, V280, P34350, DOI 10.1074/jbc.M505432200; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Mullen RT, 2000, J BIOL CHEM, V275, P16337, DOI 10.1074/jbc.M001266200; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 2004, CURR BIOL, V14, pR397, DOI 10.1016/j.cub.2004.05.017; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; Tam YYC, 2005, J BIOL CHEM, V280, P34933, DOI 10.1074/jbc.M506208200; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Wang XD, 2004, MOL BIOL CELL, V15, P1702, DOI 10.1091/mbc.E03-11-0810; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200	51	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14805	14812		10.1074/jbc.M601808200	http://dx.doi.org/10.1074/jbc.M601808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551610	hybrid			2022-12-27	WOS:000237671300034
J	Lim, NS; Kozlov, G; Chang, TC; Groover, O; Siddiqui, N; Volpon, L; De Crescenzo, G; Shyu, AB; Gehring, K				Lim, Nadia S.; Kozlov, Guennadi; Chang, Tsung-Cheng; Groover, Olivia; Siddiqui, Nadeem; Volpon, Laurent; De Crescenzo, Gregory; Shyu, Ann-Bin; Gehring, Kalle			Comparative peptide binding studies of the PABC domains from the ubiquitin-protein isopeptide ligase HYD and poly(A)-binding protein - Implications for HYD function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERPLASTIC DISCS PROTEIN; TUMOR-SUPPRESSOR GENE; DNA-DAMAGE RESPONSE; C-TERMINAL DOMAIN; CELL-PROLIFERATION; GERM-CELLS; RAT TESTIS; FAMILY; IDENTIFICATION; RECOGNITION	The PABC domain is a peptide-binding domain that is specifically found in poly(A)-binding protein (PABP) and a HECT ubiquitin-protein isopeptide ligase (E3) known as HYD ( hyperplastic discs), EDD (E3 isolated by differential display), or Rat100. The PABC domain of PABP recruits various regulatory proteins and translation factors to poly(A) mRNAs through binding of a conserved 12-amino acid peptide motif, PAM2 (PABP-interacting motif 2). In contrast, little is known about the specificity or function of the domain from HYD. Here, we used isothermal calorimetry and surface plasmon resonance titrations to show that the PABC domain of HYD binds PAM2 peptides with micromolar affinity. NMR chemical shift perturbations were used to map the peptide-binding site in the PABC domain of HYD. The structural features of binding are very similar to those of the interactions with the domain of PABP, which explains the overlapping peptide specificity and binding affinity. We identified the anti-proliferative Tob proteins as potential binding partners of HYD. This was confirmed by glutathione S-transferase pulldown and immunoprecipitation experiments demonstrating the interaction with full-length Tob2. Altogether, our results point to a role of the PABC domain as a protein-protein interaction domain that brings together the processes of translation, ubiquitin-mediated protein degradation, and cell cycle control.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Ecole Polytech Montreal, Dept Genie Chim, Montreal, PQ H3T 1J4, Canada	McGill University; University of Texas System; Universite de Montreal; Polytechnique Montreal	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Mromenade Sir William Oslor, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@mcgill.ca	Gehring, Kalle/I-4403-2013; Chang, Tsung-Cheng/C-2761-2008; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Chang, Tsung-Cheng/0000-0003-4706-0468; Gehring, Kalle/0000-0001-6500-1184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht M, 2004, BIOCHEM BIOPH RES CO, V316, P129, DOI 10.1016/j.bbrc.2004.02.024; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; Eblen ST, 2003, J BIOL CHEM, V278, P14926, DOI 10.1074/jbc.M300485200; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kozlov G, 2004, EMBO J, V23, P272, DOI 10.1038/sj.emboj.7600048; Kozlov Guennadi, 2002, Journal of Biological Chemistry, V277, P22822, DOI 10.1074/jbc.M201230200; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Oughtred R, 2002, ENDOCRINOLOGY, V143, P3740, DOI 10.1210/en.2002-220262; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Siddiqui N, 2003, PROTEIN SCI, V12, P1925, DOI 10.1110/ps.0390103; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; YOSHIDA M, 2006, IN PRESS EMBO J	36	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14376	14382		10.1074/jbc.M600307200	http://dx.doi.org/10.1074/jbc.M600307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554297	hybrid			2022-12-27	WOS:000237512300064
J	Chen, YR; Chen, CL; Yeh, A; Liu, XP; Zweier, JL				Chen, YR; Chen, CL; Yeh, A; Liu, XP; Zweier, JL			Direct and indirect roles of cytochrome b in the mediation of superoxide generation and NO catabolism by mitochondrial succinate-cytochrome c reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; FREE-RADICAL GENERATION; OXYGEN-FREE RADICALS; NITRIC-OXIDE; ELECTRON-TRANSFER; BC(1) COMPLEX; NADH DEHYDROGENASE; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; UBIQUINOL	Mitochondrial superoxide (O-2(center dot)) production is an important mediator of oxidative cellular injury. Succinate-cytochrome c reductase (SCR) of the electron transport chain has been implicated as an essential part of the mediation of O-2(center dot) generation and an alternative target of nitric oxide (NO) in the regulation of mitochondrial respiration. The Q cycle mechanism plays a central role in controlling both events. In the present work, O-2(center dot) generation by SCR was measured with the EPR spin-trapping technique using DEPMPO (5-diethoxylphosphoryl-5-methyl-1-pyrroline N-oxide) as the spin trap. In the presence of succinate, O-2(center dot) generation from SCR was detected as the spin adduct DEPMPO/(OOH)-O-center dot. Inhibitors of the Q(o) site only marginally reduced (20-30%) this O-2(center dot) production, suggesting a secondary role of Qo. in the mediation of O-2(center dot) generation. Addition of cyanide significantly decreased (similar to 70%) O-2(center dot) production, indicating the involvement of the heme component. UV-visible spectral analysis revealed that oxidation of ferrocytochrome b was accompanied by cytochrome c(1) reduction, and the reaction was mediated by the formation of an O-2(center dot) intermediate, indicating a direct role for cytochrome b in O-2(center dot) generation. In the presence of NO, DEPMPO/(OOH)-O-center dot production was progressively diminished, implying that NO interacted with SCR or trapped the O-2(center dot). The consumption of NO by SCR was investigated by electrochemical detection using an NO electrode. In the presence of succinate, SCR-mediated NO consumption was observed and inhibited by the addition of superoxide dismutase, suggesting the involvement of O-2(center dot). Under the conditions of argon saturation, the NO consumption rate was not enhanced by succinate, suggesting a direct role for O-2(center dot) in the mediation of NO consumption. In the presence of succinate, oxidation of the ferrocytochrome b moiety of SCR was accelerated by the addition of NO, and was inhibited by argon saturation, indicating an indirect role for cytochrome b in the mediation of NO consumption.	Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Div Cardiovasc Med,Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Chen, YR (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Div Cardiovasc Med,Dept Internal Med, 473 W 12th Ave, Columbus, OH 43210 USA.	yeong-renn.chen@osumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083237, R29HL038324, P01HL065608, R01HL063744, R01HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744, R01 HL083237, HL083237] Funding Source: Medline; NIEHS NIH HHS [ES11031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BUTLER J, 1982, J BIOL CHEM, V257, P747; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; Chen YR, 2005, ARCH BIOCHEM BIOPHYS, V439, P200, DOI 10.1016/j.abb.2005.05.014; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200; Chen YR, 2005, J BIOL CHEM, V280, P37339, DOI 10.1074/jbc.M503936200; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GWAK SH, 1986, BIOCHEMISTRY-US, V25, P7675, DOI 10.1021/bi00371a059; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 2004, AM J PHYSIOL-HEART C, V287, pH2421, DOI 10.1152/ajpheart.00487.2004; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Villamena FA, 2004, ANTIOXID REDOX SIGN, V6, P619, DOI 10.1089/152308604773934387; Welter R, 1996, ARCH BIOCHEM BIOPHYS, V331, P9, DOI 10.1006/abbi.1996.0276; YU L, 1982, J BIOL CHEM, V257, P2016; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	47	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13159	13168		10.1074/jbc.M513627200	http://dx.doi.org/10.1074/jbc.M513627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531408	hybrid			2022-12-27	WOS:000237336600021
J	Tosha, T; Uchida, T; Brash, AR; Kitagawa, T				Tosha, T; Uchida, T; Brash, AR; Kitagawa, T			On the relationship of coral allene oxide synthase to catalase - A single active site mutation that induces catalase activity in coral allene oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; CYTOCHROME-C PEROXIDASE; MAGNETIC CIRCULAR-DICHROISM; LIPOXYGENASE FUSION PROTEIN; BOVINE LIVER CATALASE; HORSERADISH-PEROXIDASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; HYDROGEN-PEROXIDE; DISTAL HISTIDINE	A heme domain of coral allene oxide synthase (cAOS) catalyzes the formation of allene oxide from fatty acid hydroperoxide. Although cAOS has a similar heme active site to that of catalase, cAOS is completely lacking in catalase activity. A close look at the hydrogen-bonding possibilities around the distal His in cAOS suggested that the imidazole ring is rotated by 180 degrees relative to that of catalase because of the hydrogen bond between Thr-66 and the distal His-67. This could contribute to the functional differences between cAOS and catalase, and to examine this possibility, we mutated Thr-66 in cAOS to Val, the corresponding residue in catalase. In contrast to the complete absence of catalase activity in wild type (WT) cAOS, T66V had a modest catalase activity. On the other hand, the mutation suppressed the native enzymatic activity of the formation of allene oxide to 14% of that of WT cAOS. In the resonance Raman spectrum, whereas WT cAOS has only a 6-coordinate/high spin heme, T66V has a 5-coordinate/ high spin heme as a minor species. Because catalase adopts a 5-coordinate/ high spin structure, probably the 5-coordinate/ high spin portion of T66V showed the catalase activity. Furthermore, in accord with the fact that the CN affinity of catalase is higher than that of WTc AOS, the CN affinity of T66V was 8-fold higher than that of WT cAOS, indicating that the mutation could mimic the heme active site in catalase. We, therefore, propose that the hydrogen bond between Thr-66 and distal His-67 could modulate the orientation of distal His, thereby regulating the enzymatic activity in cAOS.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Vanderbilt University	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Tosha, Takehiko/AAR-2404-2020; Uchida, Takeshi/A-6455-2017	Tosha, Takehiko/0000-0002-8971-0759; Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Abraham BD, 2001, BIOCHEMISTRY-US, V40, P2251, DOI 10.1021/bi002121h; Bateman L, 2001, J AM CHEM SOC, V123, P9260, DOI 10.1021/ja0158612; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Boutaud O, 1999, J BIOL CHEM, V274, P33764, DOI 10.1074/jbc.274.47.33764; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRASH AR, 1995, J LIPID MEDIAT CELL, V12, P275, DOI 10.1016/0929-7855(95)00033-M; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; BROWETT WR, 1979, BIOCHIM BIOPHYS ACTA, V577, P291, DOI 10.1016/0005-2795(79)90033-3; Carpena X, 2003, PROTEINS, V50, P423, DOI 10.1002/prot.10284; Chang MS, 1996, BIOCHEMISTRY-US, V35, P464, DOI 10.1021/bi952081v; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; Dou Y, 1996, BIOCHEMISTRY-US, V35, P7107, DOI 10.1021/bi9600299; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; Hernandez-Ruiz J, 2001, BIOCHEM J, V354, P107, DOI 10.1042/0264-6021:3540107; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Kato S, 2004, J BIOL CHEM, V279, P52376, DOI 10.1074/jbc.M403532200; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; Maj M, 1996, BBA-PROTEIN STRUCT M, V1298, P241, DOI 10.1016/S0167-4838(96)00134-3; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Nelson D R, 1998, Methods Mol Biol, V107, P15; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Obinger C, 1997, ARCH BIOCHEM BIOPHYS, V342, P58, DOI 10.1006/abbi.1997.9988; Oldham ML, 2005, P NATL ACAD SCI USA, V102, P297, DOI 10.1073/pnas.0406352102; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Switala J, 2002, ARCH BIOCHEM BIOPHYS, V401, P145, DOI 10.1016/S0003-9861(02)00049-8; Wu FY, 2003, BIOCHEMISTRY-US, V42, P6871, DOI 10.1021/bi027427y	47	19	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12610	12617		10.1074/jbc.M600061200	http://dx.doi.org/10.1074/jbc.M600061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513636	hybrid			2022-12-27	WOS:000237134700051
J	Toth, J; Gombos, L; Simon, Z; Medveczky, P; Szilagyi, L; Graf, L; Malnasi-Csizmadia, A				Toth, J; Gombos, L; Simon, Z; Medveczky, P; Szilagyi, L; Graf, L; Malnasi-Csizmadia, A			Thermodynamic analysis reveals structural rearrangement during the acylation step in human trypsin 4 on 4-methylumbelliferyl 4-guanidinobenzoate substrate analogue Jbc. m512301200	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; TETRAHEDRAL INTERMEDIATE; PLASMINOGEN-ACTIVATOR; INHIBITOR RESISTANCE; ALPHA-CHYMOTRYPSIN; HUMAN MESOTRYPSIN; TRANSITION-STATE; MECHANISM; CATALYSIS; ENZYMES	Human trypsin 4 is an unconventional serine protease that possesses an arginine at position 193 in place of the highly conserved glycine. Although this single amino acid substitution does not affect steady-state activity on small synthetic substrates, it has dramatic effects on zymogen activation, interaction with canonical inhibitors, and substrate specificity toward macromolecular substrates. To study the effect of a non-glycine residue at position 193 on the mechanism of the individual enzymatic reaction steps, we expressed wild type human trypsin 4 and its R193G mutant. 4-Methylumbelliferyl 4-guanidinobenzoate has been chosen as a substrate analogue, where deacylation is rate-limiting, and transient kinetic methods were used to monitor the reactions. This experimental system allows for the separation of the individual reaction steps during substrate hydrolysis and the determination of their rate constants dependably. We suggest a refined model for the reaction mechanism, in which acylation is preceded by the reversible formation of the first tetrahedral intermediate. Furthermore, the thermodynamics of these steps were also investigated. The formation of the first tetrahedral intermediate is highly exothermic and accompanied by a large entropy decrease for the wild type enzyme, whereas the signs of the enthalpy and entropy changes are opposite and smaller for the R193G mutant. This difference in the energetic profiles indicates much more extended structural and/or dynamic rearrangements in the equilibrium step of the first tetrahedral intermediate formation in wild type human trypsin 4 than in the R193G mutant enzyme, which may contribute to the biological function of this protease.	Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	Eotvos Lorand University	Malnasi-Csizmadia, A (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.	amc26@le.ac.uk	Csizmadia, András Málnási/K-7632-2018	Csizmadia, András Málnási/0000-0002-2430-8398; Medveczky, Peter/0000-0002-1798-2595				BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; Bernardi F, 1996, HUM MUTAT, V8, P108; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Bott RR, 2003, BIOCHEMISTRY-US, V42, P10545, DOI 10.1021/bi034773m; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; ESTELL DA, 1980, BIOCHEMISTRY-US, V19, P124, DOI 10.1021/bi00542a019; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GRAF L, 1995, NATURAL SCI HUMAN TH, P139; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HIROHARA H, 1974, P NATL ACAD SCI USA, V71, P1643, DOI 10.1073/pnas.71.5.1643; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUNKAPILLER MW, 1976, BIOCHEMISTRY-US, V15, P5581, DOI 10.1021/bi00670a024; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KELETI T, 1983, BIOCHEM J, V209, P277, DOI 10.1042/bj2090277; KUROMIZU K, 1985, ANAL BIOCHEM, V151, P534, DOI 10.1016/0003-2697(85)90216-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGEL WF, 1990, BIOCHEMISTRY-US, V29, P8351, DOI 10.1021/bi00488a022; Medveczky P, 2006, FEBS LETT, V580, P545, DOI 10.1016/j.febslet.2005.12.067; MEDVECZKY P, 2003, PROTEIN STRUCTURE FU, P41; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; Payne MA, 1996, BIOCHEMISTRY-US, V35, P7100, DOI 10.1021/bi9529770; POLGAR L, 1969, P NATL ACAD SCI USA, V64, P1335, DOI 10.1073/pnas.64.4.1335; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Rowen L, 2005, MOL BIOL EVOL, V22, P1712, DOI 10.1093/molbev/msi166; RYAN TJ, 1976, BIOCHEMISTRY-US, V15, P1337, DOI 10.1021/bi00651a026; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmidt AE, 2004, J BIOL CHEM, V279, P29485, DOI 10.1074/jbc.M402971200; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; VAJDA T, 1988, ACTA BIOCHIM BIOPHYS, V23, P195; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246; ZIVELIN A, 2001, THROMB HAEMOSTASIS S	37	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12596	12602		10.1074/jbc.M512301200	http://dx.doi.org/10.1074/jbc.M512301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16492676	hybrid			2022-12-27	WOS:000237134700049
J	Vizeacoumar, FJ; Vreden, WN; Fagarasanu, M; Eitzen, GA; Aitchison, JD; Rachubinski, RA				Vizeacoumar, FJ; Vreden, WN; Fagarasanu, M; Eitzen, GA; Aitchison, JD; Rachubinski, RA			The dynamin-like protein Vps1p of the yeast Saccharomyces cerevisiae associates with peroxisomes in a Pex19p-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; NUCLEAR-PORE COMPLEX; REGULATING ACTIN DYNAMICS; YARROWIA-LIPOLYTICA; BUDDING YEAST; ENLARGED PEROXISOMES; TARGETING SIGNALS; HUMAN PEX19P; NUMBER; SIZE	Dynamins and dynamin-like proteins play important roles in organelle division. In Saccharomyces cerevisiae, the dynamin-like protein Vps1p ( vacuolar protein sorting protein 1) is involved in peroxisome fission, as cells deleted for the VPS1 gene contain reduced numbers of enlarged peroxisomes. What relationship Vps1p has with peroxisomes remains unclear. Here we show that Vps1p interacts with Pex19p, a peroxin that acts as a shuttling receptor for peroxisomal membrane proteins or as a chaperone assisting the assembly/stabilization of proteins at the peroxisome membrane. Vps1p contains two putative Pex19p recognition sequences at amino acids 509-523 and 633-647. Deletion of the first (but not the second) sequence results in reduced numbers of enlarged peroxisomes in cells, as in vps1 Delta cells. Deletion of either sequence has no effect on vacuolar morphology or vacuolar protein sorting, suggesting that the peroxisome and vacuole biogenic functions of Vps1p are separate and separable. Substitution of proline for valine at position 516 of Vps1p abrogates Pex19p binding and gives the peroxisome phenotype of vps1 Delta cells. Microscopic analysis showed that overexpression of Pex19p or redirection of Pex19p to the nucleus does not affect the normal cellular distribution of Vps1p in the cytosol and in punctate structures that are not peroxisomes, suggesting that Pex19p does not function in targeting Vps1p to peroxisomes. Subcellular fractionation showed that a fraction of Vps1p is associated with peroxisomes and that deletion or mutation of the first Pex19p recognition sequence abrogates this association. Our results are consistent with Pex19p acting as a chaperone to stabilize the association of Vps1p with peroxisomes and not as a receptor involved in targeting Vps1p to peroxisomes.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Alberta; Institute for Systems Biology (ISB)	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca	Eitzen, Gary/D-3682-2009; Vizeacoumar, Franco/GLS-7161-2022		NIGMS NIH HHS [GM067228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FJ, 1944, CURRENT PROTOCOLS MO; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Chang CC, 1999, J CELL SCI, V112, P1579; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Koch A, 2004, J CELL SCI, V117, P3995, DOI 10.1242/jcs.01268; Li XL, 2003, J BIOL CHEM, V278, P17012, DOI 10.1074/jbc.M212031200; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Marelli M, 2004, J CELL BIOL, V167, P1099, DOI 10.1083/jcb.200404119; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Osteryoung KW, 2001, CURR OPIN MICROBIOL, V4, P639, DOI 10.1016/S1369-5274(01)00263-6; Peters C, 2004, CELL, V119, P667, DOI 10.1016/j.cell.2004.11.023; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Rottensteiner H, 2003, MOL BIOL CELL, V14, P4316, DOI 10.1091/mbc.E03-03-0153; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Smith JJ, 2000, J BIOL CHEM, V275, P20168, DOI 10.1074/jbc.M909285199; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Tam YYC, 2003, MOL BIOL CELL, V14, P4089, DOI 10.1091/mbc.E03-03-0150; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Vizeacoumar FJ, 2003, J CELL BIOL, V161, P321, DOI 10.1083/jcb.200210130; Warren DT, 2002, J CELL SCI, V115, P1703; Yu XW, 2004, J CELL SCI, V117, P3839, DOI 10.1242/jcs.01239	57	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12817	12823		10.1074/jbc.M600365200	http://dx.doi.org/10.1074/jbc.M600365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520372	hybrid			2022-12-27	WOS:000237134700076
J	Marinissen, MJ; Tanos, T; Bolos, M; de Sagarra, MR; Coso, OA; Cuadrado, A				Marinissen, MJ; Tanos, T; Bolos, M; de Sagarra, MR; Coso, OA; Cuadrado, A			Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CARBON-MONOXIDE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; VASCULAR-PERMEABILITY; BILIVERDIN REDUCTASE; CHEMOKINE RECEPTOR; TIN-PROTOPORPHYRIN; OXIDATIVE STRESS; VEGF SYNTHESIS; C-JUN	Heme oxygenase-1 (HO-1), the inducible enzyme responsible for the rate-limiting step in the heme catabolism, is expressed in AIDS-Kaposi sarcoma (KS) lesions. Its expression is up-regulated by the Kaposi sarcoma-associated herpesvirus ( KSHV) in endothelial cells, but the mechanisms underlying KSHV-induced HO-1 expression are still unknown. In this study we investigated whether the oncogenic G protein-coupled receptor (KSHV-GPCR or vGPCR), one of the key KSHV genes involved in KS development, activated HO-1 expression. Here we show that vGPCR induces HO-1 mRNA and protein levels in fibroblasts and endothelial cells. Moreover, targeted knock-down gene expression of HO-1 by small hairpin RNA and chemical inhibition of HO-1 enzymatic activity by tin protoporphyrin IX ( SnPP), impaired vGPCR-induced survival, proliferation, transformation, and vascular endothelial growth factor (VEGF)-A expression. vGPCR-expressing cells implanted in the dorsal flank of nude mice developed tumors with elevated HO-1 expression and activity. Chronic administration of SnPP to the implanted mice, under conditions that effectively blocked HO-1 activity and VEGF-A expression in the transplanted cells, strikingly reduced tumor growth, without apparent side effects. On the contrary, administration of the HO-1 inducer cobalt protoporphyrin (CoPP) further enhanced vGPCR-induced tumor growth. These data postulate HO-1 as an important mediator of vGPCR-induced tumor growth and suggest that inhibition of intratumoral HO-1 activity by SnPP may be a potential therapeutic strategy.	Univ Autonoma Madrid, Inst Invest Biomed A Sols, CSIC,Dept Bioquim,, Fac Med,Lab C11, E-28029 Madrid, Spain; Univ Buenos Aires, Dept Fisiol Biol Mol Celular, Fac Ciencias Exactas Nat,Inst Fisiol Biol M, Consejo Nacl Invest Cient Tecn, RA-1428 Buenos Aires, DF, Argentina	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Marinissen, MJ (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed A Sols, CSIC,Dept Bioquim,, Fac Med,Lab C11, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	mjmarinissen@iib.uam.es	Bolos Jurado, Marta/J-7620-2014	Bolos Jurado, Marta/0000-0003-2652-8607; Cuadrado, Antonio/0000-0002-4039-7140; Tanos, Tamara/0000-0002-3217-3104; Cuadrado, Antonio/0000-0002-3444-9012				ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Alam J, 2004, ANTIOXID REDOX SIGN, V6, P924, DOI 10.1089/1523086041798114; Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; ANDERSON KE, 1984, J PHARMACOL EXP THER, V228, P327; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Burger M, 2005, ONCOGENE, V24, P2067, DOI 10.1038/SJ.ONC.1208442; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Cornali E, 1996, AM J PATHOL, V149, P1851; CORNELIUS CE, 1984, PEDIATR RES, V18, P728, DOI 10.1203/00006450-198408000-00010; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Devesa I, 2005, ARTHRITIS RHEUM-US, V52, P3230, DOI 10.1002/art.21356; Doi K, 1999, BRIT J CANCER, V80, P1945, DOI 10.1038/sj.bjc.6690624; Drummond GS, 2004, SEMIN PERINATOL, V28, P365, DOI 10.1053/j.semperi.2004.09.004; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Fang J, 2003, CANCER RES, V63, P3567; Fang J, 2004, APOPTOSIS, V9, P27, DOI 10.1023/B:APPT.0000012119.83734.4e; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; Jozkowicz A, 2002, ANTIOXID REDOX SIGN, V4, P577, DOI 10.1089/15230860260220076; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Kappas A, 2001, PEDIATRICS, V108, P25, DOI 10.1542/peds.108.1.25; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kreiser D, 2002, LAB INVEST, V82, P687, DOI 10.1097/01.LAB.0000017167.26718.F2; Kushida T, 2002, BIOCHEM BIOPH RES CO, V291, P68, DOI 10.1006/bbrc.2002.6403; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Lam CW, 2005, J IMMUNOL, V174, P2297, DOI 10.4049/jimmunol.174.4.2297; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; Loboda A, 2005, CELL MOL BIOL, V51, P347, DOI 10.1170/T637; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Malaguarnera L, 2004, J CELL BIOCHEM, V93, P197, DOI 10.1002/jcb.20167; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; McAllister SC, 2004, BLOOD, V103, P3465, DOI 10.1182/blood-2003-08-2781; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785; Nicholas J, 2003, J BIOMED SCI, V10, P475, DOI 10.1159/000072375; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Reeve VE, 1999, P NATL ACAD SCI USA, V96, P9317, DOI 10.1073/pnas.96.16.9317; Sacerdoti D, 2005, CELL MOL BIOL, V51, P363, DOI 10.1170/T639; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Sodhi A, 2000, CANCER RES, V60, P4873; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tang Rui-Fang, 2005, Hepatobiliary Pancreat Dis Int, V4, P460; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Volti GL, 2005, ANTIOXID REDOX SIGN, V7, P704, DOI 10.1089/ars.2005.7.704; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	72	64	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11332	11346		10.1074/jbc.M512199200	http://dx.doi.org/10.1074/jbc.M512199200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476737	Green Published, hybrid			2022-12-27	WOS:000236822200076
J	Metz, RP; Kwak, HI; Gustafson, T; Laffin, B; Porter, WW				Metz, RP; Kwak, HI; Gustafson, T; Laffin, B; Porter, WW			Differential transcriptional regulation by mouse single-minded 2s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-THERAPY TARGET; MURINE HOMOLOG; GENE; REPRESSION; RECEPTOR; EXPRESSION; ARNT; TRANSACTIVATION; IDENTIFICATION; CLONING	Single-minded 1 and 2 are unique members of the basic helix-loop-helix Per-Arnt-Sim family as they are transcriptional repressors. Here we report the identification and transcriptional characterization of mouse Sim2s, a splice variant of Sim2, which is missing the carboxyl Pro/Ala-rich repressive domain. Sim2s is expressed at high levels in kidney and skeletal muscle; however, the ratio of Sim2 to Sim2s mRNA differs between these tissues. Similar to full-length Sim2, Sim2s interacts with Arnt and to a lesser extent, Arnt2. The effects of Sim2s on transcriptional regulation through hypoxia, dioxin, and central midline response elements are different than that of full-length Sim2. Specifically, Sim2s exerts a less repressive effect on hypoxia-induced gene expression than full-length Sim2, but is just as effective as Sim2 at repressing TCDD-induced gene expression from a dioxin response element. Interestingly, Sim2s bind to and activates expression from a central midline response element-controlled reporter through an Arnt transactivation domain-dependent mechanism. The differences in expression pattern, protein interactions, and transcriptional activities between Sim2 and Sim2s may reflect differential roles each isoform plays during development or in tissue-specific effects on other protein-mediated pathways.	Texas A&M Univ, Coll Vet Med, Dept Integrated Biosci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Integrated Biosci, MS 4458, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu		Metz, Richard/0000-0002-9876-3385	NATIONAL CANCER INSTITUTE [R01CA111551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA111551] Funding Source: Medline; NIEHS NIH HHS [P30ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chrast R, 1997, GENOME RES, V7, P615, DOI 10.1101/gr.7.6.615; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Estes P, 2001, DEV BIOL, V232, P157, DOI 10.1006/dbio.2001.0174; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; McKay LM, 1999, NUCLEIC ACIDS RES, V27, P3064, DOI 10.1093/nar/27.15.3064; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; Moffett P, 1996, GENOMICS, V35, P144, DOI 10.1006/geno.1996.0333; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Moffett P, 2000, FEBS LETT, V466, P80, DOI 10.1016/S0014-5793(99)01750-0; Morrow D, 2004, J STEROID BIOCHEM, V88, P27, DOI 10.1016/j.jsbmb.2003.10.005; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200	22	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10839	10848		10.1074/jbc.M508858200	http://dx.doi.org/10.1074/jbc.M508858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484282	hybrid			2022-12-27	WOS:000236822200023
J	Tsuruma, K; Nakagawa, T; Morimoto, N; Minami, M; Hara, H; Uehara, T; Nomura, Y				Tsuruma, K; Nakagawa, T; Morimoto, N; Minami, M; Hara, H; Uehara, T; Nomura, Y			Glucocorticoid modulatory element-binding protein 1 binds to initiator procaspases and inhibits ischemia-induced apoptosis and neuronal injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; KAPPA-B ACTIVATION; CELL-DEATH; DISULFIDE ISOMERASE; PROTEASE; STRESS; INTERLEUKIN-1-BETA; INVOLVEMENT; CASPASE-9; KINASE	Caspases are divided into two classes: initiator caspases, which include caspase-8 and - 9 and possess long prodomains, and effector caspases, which include caspase-3 and - 7 and possess short prodomains. Recently, we demonstrated that glucocorticoid modulatory element-binding protein 1( GMEB1) interacts with the prodomain of procaspase-2, thereby disrupting its autoactivation and the induction of apoptosis. Here we show that GMEB1 is also capable of binding to procaspase-8 and - 9. GMEB1 attenuated the Fas-mediated activation of these caspases and the subsequent apoptosis. The knockdown of endogenous GMEB1 using RNA interference revealed that cells with decreased GMEB1 expression are more sensitive to stress and undergo accelerated apoptosis. Transgenic mice expressing a neurospecific GMEB1 had smaller cerebral infarcts and less brain swelling than wildtype mice in response to transient focal ischemia. These results suggest that GMEB1 is an endogenous regulator that selectively binds to initiator procaspases and inhibits caspase-induced apoptosis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan; Gifu Pharmaceut Univ, Dept Biofunct Mol, Gifu 5028585, Japan	Hokkaido University; Gifu Pharmaceutical University	Uehara, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, N12W6, Sapporo, Hokkaido 0600812, Japan.	uehara@pharm.hokudai.ac.jp; nomura@pharm.hokudai.ac.jp	Minami, Masabumi/A-3883-2012	Minami, Masabumi/0000-0002-0144-0679; Uehara, Takashi/0000-0002-8545-4006				Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen J, 2002, J BIOL CHEM, V277, P22053, DOI 10.1074/jbc.M202311200; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Furuta Y, 2003, J CEREBR BLOOD F MET, V23, P962, DOI 10.1097/01.WCB.0000073948.29308.F8; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Ko HS, 2004, FEBS LETT, V566, P110, DOI 10.1016/j.febslet.2004.04.031; Ko HS, 2002, J BIOL CHEM, V277, P35386, DOI 10.1074/jbc.M203412200; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Moriya R, 2000, FEBS LETT, V484, P253, DOI 10.1016/S0014-5793(00)02167-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ogino S, 2004, MOL PHARMACOL, V65, P1344, DOI 10.1124/mol.65.6.1344; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu T, 2004, J NEUROCHEM, V91, P167, DOI 10.1111/j.1471-4159.2004.02702.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Theriault JR, 1999, FEBS LETT, V452, P170, DOI 10.1016/S0014-5793(99)00634-1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsuruma K, 2004, BIOCHEM BIOPH RES CO, V325, P1246, DOI 10.1016/j.bbrc.2004.10.145; Uehara T, 1999, J BIOL CHEM, V274, P15875, DOI 10.1074/jbc.274.22.15875; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11397	11404		10.1074/jbc.M510597200	http://dx.doi.org/10.1074/jbc.M510597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497673	Green Published, hybrid			2022-12-27	WOS:000236822200082
J	Banchio, C; Lingrell, S; Vance, DE				Banchio, C; Lingrell, S; Vance, DE			Role of histone deacetylase in the expression of CTP : Phosphocholine cytidylyltransferase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; CELL-CYCLE; S-PHASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; REPRESS TRANSCRIPTION; E2F; PROMOTER; GENE; PROTEIN; REQUIREMENT	Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in cell-specific expression of CTP: phosphocholine cytidylyltransferase alpha (CT alpha) are not fully understood. In this study, we investigated whether or not histone deacetylation is involved in repression of CT alpha expression in quiescent C3H10T1/2 mouse embryo fibroblasts. We have examined the contributions of the Sp1 and E2F binding sites in the repression of CT alpha gene expression. Immunoprecipitation experiments showed that histone deacetylase 1 (HDAC1) and HDAC activity are associated with Sp1 in serum-starved cells or during serum stimulation. However, HDAC1 association with E2F was only detected in serum-starved cells. By chromatin immunoprecipitation assays, we detected both direct and indirect association of HDAC1 with the CT alpha promoter. Treatment with the HDAC inhibitor trichostatin A induced CT alpha expression. Our data suggest that HDAC1 plays a critical role in CT alpha repression and that Sp1 and E2F may serve as key targets for HDAC1-mediated CT alpha repression in fibroblasts.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst B, RA-2000 Rosario, Santa Fe, Argentina; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; University of Alberta; University of Alberta	Banchio, C (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst B, Suipacha 531,S2002LRK, RA-2000 Rosario, Santa Fe, Argentina.	cbanchio@fbioyf.unr.edu.ar; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Banchio C, 2004, J BIOL CHEM, V279, P40220, DOI 10.1074/jbc.M406468200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; Brehm A, 1999, BRIT J CANCER, V80, P38; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Magnaghi-Jaulin L, 1998, B CANCER, V85, P606; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; Sugimoto H, 2005, J BIOL CHEM, V280, P40857, DOI 10.1074/jbc.M503578200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TERCE F, 1994, J LIPID RES, V35, P2130; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhao SJ, 2003, CANCER RES, V63, P2624	43	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10010	10015		10.1074/jbc.M513503200	http://dx.doi.org/10.1074/jbc.M513503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484221	hybrid			2022-12-27	WOS:000236594300024
J	Yamamoto, K; Higashi, S; Kioi, M; Tsunezumi, J; Honke, K; Miyazaki, K				Yamamoto, K; Higashi, S; Kioi, M; Tsunezumi, J; Honke, K; Miyazaki, K			Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane-associated proteolytic action and induction of homotypic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE 7; COLON-CANCER CELLS; CARCINOMA-CELLS; GELATINASE-A; ACTIVATION; INHIBITOR; BETA; ANGIOGENESIS; PRECURSOR; TUMOR	Regulation of cell surface molecules by matrix metalloproteinases (MMPs), as well as MMPs-catalyzed degradation of extracellular matrix, is important for tumor invasion and metastasis. Our previous study (Kioi, M., Yamamoto, K., Higashi, S., Koshikawa, N., Fujita, K., and Miyazaki, K. (2003) Oncogene 22, 8662-8670) demonstrated that active matrilysin specifically binds to the surface of colon cancer cells and induces notable cell aggregation due to processing of the cell membrane protein(s). Furthermore, these aggregated cells showed a dramatically enhanced metastatic potential. To elucidate the mechanism of matrilysin-induced cell aggregation, we attempted to identify the matrilysin-binding substance on the cell surface. Here, we demonstrate that cholesterol sulfate on the cell surface is a major matrilysin-binding substance. We found that active matrilysin bound to the cell membrane and cholesterol sulfate incorporated into liposomes with similar affinities. Treatment of colon cancer cells with beta-cyclodextrin significantly reduced not only matrilysin binding to the cell surface but also matrilysin-dependent proteolysis and cell aggregation. Interestingly, replenishment of cholesterol sulfate, but not cholesterol, neutralized the effects of beta-cyclodextrin. Taken together, it is likely that binding of matrilysin to cholesterol sulfate facilitates the matrilysin-catalyzed modulation of cell surface proteins, thus inducing the cancer cell aggregation.	Yokohama City Univ, Div Cell Biol, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Kochi Univ, Sch Med, Dept Mol Genet, Nankoku, Kochi 7838505, Japan	Yokohama City University; Kochi University	Higashi, S (corresponding author), Yokohama City Univ, Div Cell Biol, Kihara Inst Biol Res, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	shigashi@yokohama-cu.ac.jp	Yamamoto, Kazuhiro/AAD-9650-2019	Kioi, Mitomu/0000-0002-7981-3340				ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; Kihira Y, 1996, Urol Oncol, V2, P20, DOI 10.1016/1078-1439(96)00030-0; Kioi M, 2003, ONCOGENE, V22, P8662, DOI 10.1038/sj.onc.1207181; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; MIYAZAKI K, 1990, CANCER RES, V50, P7758; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Oneda H, 1999, J BIOCHEM-TOKYO, V126, P905, DOI 10.1093/oxfordjournals.jbchem.a022533; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SHIMADA T, 1985, THROMB RES, V38, P21, DOI 10.1016/0049-3848(85)90004-0; Shiomi T, 2005, LAB INVEST, V85, P1489, DOI 10.1038/labinvest.3700351; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Topal B, 2003, J SURG RES, V112, P31, DOI 10.1016/S0022-4804(03)00140-9; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; WANG E, 1991, J BIOL CHEM, V266, P14486; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wu XZ, 2004, INT J CANCER, V110, P504, DOI 10.1002/ijc.20127; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9170	9180		10.1074/jbc.M510377200	http://dx.doi.org/10.1074/jbc.M510377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16476739	hybrid			2022-12-27	WOS:000236404700023
J	Clamp, A; Blackhall, FH; Henrioud, A; Jayson, GC; Javaherian, K; Esko, J; Gallagher, JT; Merry, CLR				Clamp, Andrew; Blackhall, Fiona H.; Henrioud, Audrey; Jayson, Gordon C.; Javaherian, Kashi; Esko, Jeff; Gallagher, John T.; Merry, Catherine L. R.			The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ANGIOGENESIS INHIBITOR ENDOSTATIN; COLLAGEN-XVIII; GLYCOSAMINOGLYCAN BIOSYNTHESIS; NC1/ENDOSTATIN DOMAIN; N-SULFOTRANSFERASE; DERMATAN SULFATE; TUMOR-GROWTH; MUTANT; BINDING	Endostatin has attracted considerable attention because of its ability to inhibit angiogenesis. This property of monomeric endostatin contrasts with that of the trimeric endostatin moiety generated from the intact C-terminal domain of collagen XVIII that induces a promigratory phenotype in endothelial cells. This activity is inhibited by monomeric endostatin. In this study we demonstrate that the effect of oligomeric endostatin can also be inhibited by exogenous glycosaminoglycans in a size-dependent manner, with heparin oligosaccharides containing more than 20 monosaccharide residues having optimal inhibitory activity. Oligomeric endostatin was also found to induce morphological changes in Chinese hamster ovary cells, an epithelial cell line. This novel observation allowed the utilization of a panel of Chinese hamster ovary cell mutants with defined glycosaminoglycan biosynthetic defects. The action of oligomeric endostatin on these cells was shown to be dependent on cell surface glycosaminoglycans, principally heparan sulfate with Nand 6-O-sulfation of glucosamine residues rather than iduronate 2-O-sulfation being important for bioactivity. The responsiveness of a cell line (pgsE-606) with globally reduced heparan sulfate sulfation and shortened S domains, however, indicates that overall heparan sulfate domain patterning is the key determinant of the bioactivity of oligomeric endostatin. Purified heparin-monomeric endostatin constructs generated by zero-length cross-linking techniques were found to be unable to inhibit the action of oligomeric endostatin. This indicates a mechanism for the perturbation of oligomeric endostatin action by its monomeric counterpart via competition for glycosaminoglycan attachment sites at the cell surface.	Canc Res UK, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Cancer Research UK; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California San Diego	Merry, CLR (corresponding author), Canc Res UK, Dept Med Oncol, Manchester M20 4BX, Lancs, England.	cmerry@picr.man.ac.uk	Jayson, Gordon C/O-8224-2015; Blackhall, Fiona/N-2186-2015	Jayson, Gordon C/0000-0002-8515-8944; merry, catherine/0000-0002-3490-2809; Blackhall, Fiona/0000-0001-8716-3395	Medical Research Council [G0601746] Funding Source: Medline; MRC [G0601746] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Javaherian K, 2002, J BIOL CHEM, V277, P45211, DOI 10.1074/jbc.M206358200; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200; Wei G, 2000, J BIOL CHEM, V275, P27733; Wei G, 2004, J BIOL CHEM, V279, P5693, DOI 10.1074/jbc.M311621200; Wen W, 1999, CANCER RES, V59, P6052; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Wilson RF, 2003, ANTICANCER RES, V23, P1289; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14813	14822		10.1074/jbc.M512400200	http://dx.doi.org/10.1074/jbc.M512400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16481316	hybrid			2022-12-27	WOS:000237671300035
J	Perrier, C; Sprenger, N; Corthesy, B				Perrier, Clementine; Sprenger, Norbert; Corthesy, Blaise			Glycans on secretory component participate in innate protection against mucosal pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; ENTEROPATHOGENIC ESCHERICHIA-COLI; CLOSTRIDIUM-DIFFICILE TOXIN; IGA MONOCLONAL-ANTIBODIES; HUMAN GASTRIC EPITHELIUM; IN-VITRO; HELICOBACTER-PYLORI; SIALIC-ACID; STREPTOCOCCUS-PNEUMONIAE; DIMERIC IGA	In mucosal secretions, secretory component (SC) is found either free or bound to polymeric IgA within the secretory IgA complex. SC displays numerous and various glycans, which are potential ligands for bacterial compounds. We first established that human SC (hSC) purified from colostrum (hSCcol) or produced in Chinese hamster ovary cells (hSCrec) exhibits the same lectin reactivity. Both forms bind to Clostridium difficile toxin A and functionally protect polarized Caco-2 cell monolayers from the cytopathic effect of the toxin. The interaction is mediated by glycans present on hSC and involves galactose and sialic acid residues. hSCcol and hSCrec were also shown to bind enteropathogenic Escherichia coli adhesin intimin and to inhibit its infectivity on HEp-2 cells in a glycan-dependent manner as well. SC remained operative in the context of the whole secretory IgA molecule and can therefore enhance its Fab-mediated neutralizing properties. On the contrary, hSC did not interact with three different strains of rotavirus (RF, RRV, and SA11). Accordingly, infection of target MA104 cells with these rotavirus strains was not reduced in the presence of either form of hSC tested. Although not a universal mechanism, these findings identify hSC as a microbial scavenger contributing to the antipathogenic arsenal that protects the body epithelial surfaces.	CHU Vaudois, R&D Lab, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; Nestle Res Ctr, Dept Nutr, CH-1000 Lausanne 26, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Nestle SA	Corthesy, B (corresponding author), CHU Vaudois, R&D Lab, Div Immunol & Allergy, Rue Bugnon,BH 19-650, CH-1011 Lausanne, Switzerland.	blaise.corthesy@chuv.ch	Perrier, Clementine/A-3925-2011					BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Brock SC, 2002, INFECT IMMUN, V70, P5091, DOI 10.1128/IAI.70.9.5091-5095.2002; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Ciarlet M, 1999, J GEN VIROL, V80, P943, DOI 10.1099/0022-1317-80-4-943; Cleary J, 2004, MICROBIOL-SGM, V150, P527, DOI 10.1099/mic.0.26740-0; CLEVELAND MG, 1991, J IMMUNOL, V147, P181; CORTHIER G, 1991, INFECT IMMUN, V59, P1192, DOI 10.1128/IAI.59.3.1192-1195.1991; Cottet S, 2002, J BIOL CHEM, V277, P33978, DOI 10.1074/jbc.M201726200; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; Delorme C, 2001, J VIROL, V75, P2276, DOI 10.1128/JVI.75.5.2276-2287.2001; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Favre LI, 2003, J CHROMATOGR B, V786, P143, DOI 10.1016/S1570-0232(02)00723-7; Frankel G, 2001, TRENDS MICROBIOL, V9, P214, DOI 10.1016/S0966-842X(01)02016-9; Giammarioli AM, 1996, VIROLOGY, V225, P97, DOI 10.1006/viro.1996.0578; GIUGLIANO LG, 1995, J MED MICROBIOL, V42, P3, DOI 10.1099/00222615-42-1-3; Gomez HF, 2003, J INFECT DIS, V187, P87, DOI 10.1086/345875; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; Hughes GJ, 1999, BBA-PROTEIN STRUCT M, V1434, P86, DOI 10.1016/S0167-4838(99)00168-5; Jepson MA, 2003, CELL MICROBIOL, V5, P773, DOI 10.1046/j.1462-5822.2003.00315.x; Jones RML, 1998, BBA-PROTEIN STRUCT M, V1429, P265, DOI 10.1016/S0167-4838(98)00239-8; Kaetzel CS, 2005, IMMUNOL REV, V206, P83, DOI 10.1111/j.0105-2896.2005.00278.x; Kaetzel CS, 2001, CURR BIOL, V11, pR35, DOI 10.1016/S0960-9822(00)00041-5; Kanamaru Y, 1999, BIOSCI BIOTECH BIOCH, V63, P246, DOI 10.1271/bbb.63.246; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kiefel MJ, 2003, METHOD ENZYMOL, V363, P395; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; Kvistgaard AS, 2004, J DAIRY SCI, V87, P4088, DOI 10.3168/jds.S0022-0302(04)73551-1; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lopez S, 2004, TRENDS MICROBIOL, V12, P271, DOI 10.1016/j.tim.2004.04.003; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Mantis NJ, 2004, J IMMUNOL, V172, P6838, DOI 10.4049/jimmunol.172.11.6838; Marchetti M, 1996, ANTIVIR RES, V29, P221, DOI 10.1016/0166-3542(95)00840-3; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Ochoa TJ, 2003, INFECT IMMUN, V71, P5149, DOI 10.1128/IAI.71.9.5149-5155.2003; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Rey J, 2004, J IMMUNOL, V172, P3026, DOI 10.4049/jimmunol.172.5.3026; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Royle L, 2003, J BIOL CHEM, V278, P20140, DOI 10.1074/jbc.M301436200; Schroten H, 1998, INFECT IMMUN, V66, P3971, DOI 10.1128/IAI.66.8.3971-3973.1998; Stubbe H, 2000, J IMMUNOL, V164, P1952, DOI 10.4049/jimmunol.164.4.1952; Superti F, 2001, BBA-GEN SUBJECTS, V1528, P107, DOI 10.1016/S0304-4165(01)00178-7; WALLACE CJA, 1987, EUR J BIOCHEM, V170, P293, DOI 10.1111/j.1432-1033.1987.tb13698.x; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	58	78	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14280	14287		10.1074/jbc.M512958200	http://dx.doi.org/10.1074/jbc.M512958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543244	hybrid			2022-12-27	WOS:000237512300053
J	Vandermoere, F; El Yazidi-Belkoura, I; Slomianny, C; Demont, Y; Bidaux, G; Adriaenssens, E; Lemoine, J; Hondermarck, H				Vandermoere, Franck; El Yazidi-Belkoura, Ikram; Slomianny, Christian; Demont, Yohann; Bidaux, Gabriel; Adriaenssens, Eric; Lemoine, Jerome; Hondermarck, Hubert			The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; NERVE GROWTH-FACTOR; MEMBRANE-FUSION; KINASE-B; SUBSTRATE; BRCA1; PHOSPHORYLATION; ACTIVATION; PROTEASOME; REVEALS	The serine/threonine kinase Akt is a key mediator of cell survival and growth, but its precise mechanism of action, and more specifically, the nature of its signaling partners largely remain to be elucidated. We show, using a proteomics-based approach, that the valosin-containing protein (VCP), a member of the AAA ( ATPases associated with a variety of cellular activities) family, is a target of Akt signaling. SDS-PAGE of Akt co-immunoprecipitated proteins obtained from MCF-7 breast cancer cells revealed the increase of a 97-kDa band under Akt activation. Mass spectrometry analysis allowed the identification of VCP, and we have shown a serine/threonine phosphorylation on an Akt consensus site upon activation by growth factors. Site-directed mutagenesis identified Ser-351, Ser-745, and Ser-747 as Akt phosphorylation sites on VCP. Confocal microscopy indicated a co-localization between Akt and VCP upon Akt stimulation. Interestingly, small interfering RNA against VCP induced an inhibition of the growth factor-induced activation of NF-kappa B and a potent pro-apoptotic effect. Together, these data identify VCP as an essential target of Akt signaling.	Univ Sci & Technol Lille, INSERM ERI 8, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, INSERM EMI 0228, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, UMR 8576, CNRS, IFR 118, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, INSERM ERI 8, Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	lemoine, jerome/C-4272-2014; Slomianny, Christian/L-8285-2018; El Yazidi-Belkoura, Ikram/AAE-8805-2022; Bidaux, Gabriel/F-1294-2016	lemoine, jerome/0000-0002-5497-6880; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509; VANDERMOERE, Franck/0000-0001-5724-7037; Bidaux, Gabriel/0000-0002-6162-3223				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; El Yazidi-Belkoura I, 2003, J BIOL CHEM, V278, P16952, DOI 10.1074/jbc.M300631200; Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Klein JB, 2005, J BIOL CHEM, V280, P31870, DOI 10.1074/jbc.M501802200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vandermoere F, 2005, ONCOGENE, V24, P5482, DOI 10.1038/sj.onc.1208713; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168	28	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14307	14313		10.1074/jbc.M510003200	http://dx.doi.org/10.1074/jbc.M510003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551632	Green Published, hybrid			2022-12-27	WOS:000237512300056
J	Caruano-Yzermans, AL; Bartnikas, TB; Gitlin, JD				Caruano-Yzermans, AL; Bartnikas, TB; Gitlin, JD			Mechanisms of the copper-dependent turnover of the copper chaperone for superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAFFICKING PROTEINS; MESSENGER-RNA; CCS; DEFICIENT; METALLOCHAPERONE; METABOLISM; ACTIVATION; TRANSPORT; INSIGHTS; DISEASE	The copper chaperone for superoxide dismutase (CCS) is an intracellular metallochaperone required for incorporation of copper into the essential antioxidant enzyme copper/zinc superoxide dismutase (SOD1). Nutritional studies have revealed that the abundance of CCS is inversely proportional to the dietary and tissue copper content. To determine the mechanisms of copper-dependent regulation of CCS, copper incorporation into SOD1 and SOD1 enzymatic activity as well as CCS abundance and half-life were determined after metabolic labeling of CCS-/- fibroblasts transfected with wild-type or mutant CCS. Wild-type CCS restored SOD1 activity in CCS-/- fibroblasts, and the abundance of this chaperone in these cells was inversely proportional to the copper content of the media, indicating that copper-dependent regulation of CCS is entirely post-translational. Although mutational studies demonstrated no role for CCS Domain I in this copper-dependent regulation, similar analysis of the CXC motif in Domain III revealed a critical role for these cysteine residues in mediating copper-dependent turnover of CCS. Further mutational studies revealed that this CXC-dependent copper-mediated turnover of CCS is independent of the mechanisms of delivery of copper to SOD1 including CCS-SOD1 interaction. Taken together these data demonstrate a mechanism determining the abundance of CCS that is competitive with the process of copper delivery to SOD1, revealing a unique post- translational component of intracellular copper homeostasis.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK061763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 61763, P30 DK056341-06, P30 DK056341-05S2, P30 DK056341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Bertinato J, 2004, J NUTR BIOCHEM, V15, P316, DOI 10.1016/j.jnutbio.2004.02.004; Bertinato J, 2003, J BIOL CHEM, V278, P35071, DOI 10.1074/jbc.M302242200; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Narayanan VS, 2001, J NUTR, V131, P1427, DOI 10.1093/jn/131.5.1427; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Prohaska JR, 2004, J NUTR, V134, P1003, DOI 10.1093/jn/134.5.1003; Prohaska JR, 2003, ARCH BIOCHEM BIOPHYS, V417, P227, DOI 10.1016/S0003-9861(03)00364-3; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Tao TY, 2003, HEPATOLOGY, V37, P1241, DOI 10.1053/jhep.2003.50281; Thiele DJ, 2003, J NUTR, V133, p1579S, DOI 10.1093/jn/133.5.1579S; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197	31	67	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13581	13587		10.1074/jbc.M601580200	http://dx.doi.org/10.1074/jbc.M601580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531609	hybrid			2022-12-27	WOS:000237336600067
J	Kim, YS; Kang, KR; Wolff, EC; Bell, JK; McPhie, P; Park, MH				Kim, YS; Kang, KR; Wolff, EC; Bell, JK; McPhie, P; Park, MH			Deoxyhypusine hydroxylase is an Fe(II)-dependent, heat-repeat enzyme - Identification of amino acid residues critical for Fe(II) binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; CELL VIABILITY; POSTTRANSLATIONAL MODIFICATION; SACCHAROMYCES-CEREVISIAE; RAT TESTIS; IN-VIVO; HYPUSINE; PROTEIN; SYNTHASE; INHIBITION	Deoxyhypusine hydroxylase ( DOHH) catalyzes the final step in the post-translational synthesis of hypusine ( N-epsilon-( 4-amino-2-hydroxybutyl) lysine) in eIF5A. DOHH is a HEAT-repeat protein with eight tandem helical hairpins in a symmetrical dyad. It contains two potential iron coordination sites ( one on each dyad) composed of two strictly conserved His-Glu motifs. The purified human recombinant DOHH was a mixture of active holoenzyme containing 2 mol of iron/mol of DOHH and inactive metal-free apoenzyme. The two species could be distinguished by their different mobilities upon native gel electrophoresis. The DOHH apoenzyme exhibited markedly reduced levels of iron and activity. DOHH activity could be restored only by the addition of Fe2+ to the apoenzyme but not by other metals including Cd2+, Co2+, Cr2+, Cu2+, Mg2+, Mn2+, Ni2+, and Zn2+. The role of the strictly conserved His-Glu residues was evaluated by site-directed mutagenesis. Substitution of any single amino acid in the four His-Glu motifs with alanine abolished the enzyme activity. Of these eight alanine substitutions, six, including H56A, H89A, E90A, H207A, H240A, and E241A, caused a severe reduction in the iron content. Our results provide strong evidence that Fe( II) is the active-site-bound metal critical for DOHH catalysis and that the strictly conserved His-Glu motifs are essential for iron binding and catalysis. Furthermore, the iron to DOHH stoichiometry and dependence of iron binding on each of the four conserved His-Glu motifs suggest a binuclear iron mediated reaction mechanism, distinct from that of other Fe( II)-dependent protein hydroxylases, such as prolyl 4-hydroxylase or lysyl hydroxylases.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Park, MH (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	mhpark@nih.gov	Bell, Jessica/I-3893-2013	Bell, Jessica/0000-0003-1455-3274	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024964, Z01DK024942] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DE999999] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; Aravind L, 2001, GENOME BIOL, V2; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; Bevec D, 1997, BIOL SIGNAL, V6, P124; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Caraglia M, 2003, J BIOCHEM, V133, P757, DOI 10.1093/jb/mvg097; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chen KY, 1997, BIOL SIGNAL, V6, P105; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Csonga R, 1996, FEBS LETT, V380, P209, DOI 10.1016/0014-5793(96)00020-8; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; Hanauske-Abel HM, 2003, CURR MED CHEM, V10, P1005, DOI 10.2174/0929867033457601; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; Hanawa-Suetsugu K, 2004, P NATL ACAD SCI USA, V101, P9595, DOI 10.1073/pnas.0308667101; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Liu YP, 1997, BIOL SIGNAL, V6, P166; Nishimura K, 2005, BIOCHEM J, V385, P779, DOI 10.1042/BJ20041477; Park JH, 2006, P NATL ACAD SCI USA, V103, P51, DOI 10.1073/pnas.0509348102; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034; PARK MH, 1984, J BIOL CHEM, V259, P2123; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; Phizicky EM, 2002, METHOD ENZYMOL, V350, P546; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Spradling AC, 1999, GENETICS, V153, P135; Sugimoto A, 2004, DIFFERENTIATION, V72, P81, DOI 10.1111/j.1432-0436.2004.07202004.x; Thompson GM, 2003, FEBS LETT, V555, P464, DOI 10.1016/S0014-5793(03)01305-X; Tshuva EY, 2004, CHEM REV, V104, P987, DOI 10.1021/cr020622y; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wei PP, 2005, J AM CHEM SOC, V127, P16098, DOI 10.1021/ja053661a; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660	44	46	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13217	13225		10.1074/jbc.M601081200	http://dx.doi.org/10.1074/jbc.M601081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533814	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000237336600027
J	Chen, YH; Beischlag, TV; Kim, JH; Perdew, GH; Stallcup, MR				Chen, YH; Beischlag, TV; Kim, JH; Perdew, GH; Stallcup, MR			Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR; AH RECEPTOR; COACTIVATOR; RECRUITMENT; PROTEIN; DIOXIN; BINDING; FAMILY; CANCER	The aryl hydrocarbon receptor (AHR), a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) gene family, binds a variety of polycyclic aromatic hydrocarbons and mediates their toxic effects. GAC63 has been shown to act as a coactivator in nuclear receptor-mediated gene transcription. In this report, we demonstrate that GAC63 interacts with AHR through its bHLH-PAS domain. Overexpression of GAC63 greatly enhanced AHR-regulated reporter gene activity in a ligand-dependent manner in transient transfection assays. Upon ligand treatment, endogenous GAC63 was recruited to the xeno-biotic response element of the mouse CYP1A1 gene, an AHR-responsive gene. Reduction of the endogenous GAC63 level by small interfering RNA inhibited transcriptional activation by AHR. These findings reveal a new function of GAC63 in AHR-mediated gene transcription.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA	University of Southern California; University of Southern California; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, MCA-51A,1333 San Pablo St, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043093, DK43093] Funding Source: Medline; NIEHS NIH HHS [ES04869, R01 ES004869] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander DL, 1998, J CELL SCI, V111, P3311; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Chen YH, 2005, MOL CELL BIOL, V25, P5965, DOI 10.1128/MCB.25.14.5965-5972.2005; Denison MS, 2002, CHEM-BIOL INTERACT, V141, P3, DOI 10.1016/S0009-2797(02)00063-7; GIERTHY JF, 1993, CANCER RES, V53, P3149; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kim JH, 2004, J BIOL CHEM, V279, P49842, DOI 10.1074/jbc.M408535200; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Rivera SP, 2005, TOXICOLOGY, V207, P401, DOI 10.1016/j.tox.2004.10.009; Saarikoski Sirkku T, 2005, Toxicol Appl Pharmacol, V207, P62, DOI 10.1016/j.taap.2004.12.027; Safe S, 1998, TOXICOL LETT, V103, P343; Sim DLC, 2002, INT J BIOCHEM CELL B, V34, P487, DOI 10.1016/S1357-2725(01)00156-X; Sim DLC, 1999, GENOMICS, V59, P224, DOI 10.1006/geno.1999.5856; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	28	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12242	12247		10.1074/jbc.M512537200	http://dx.doi.org/10.1074/jbc.M512537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513642	Green Accepted, hybrid			2022-12-27	WOS:000237134700007
J	Rahman, NS; Godderz, LJ; Stray, SJ; Capra, JD; Rodgers, KK				Rahman, NS; Godderz, LJ; Stray, SJ; Capra, JD; Rodgers, KK			DNA cleavage of a cryptic recombination signal sequence by RAG1 and RAG2 - Implications for partial V-H gene replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE REGION GENES; CODING END SEQUENCE; V(D)J RECOMBINATION; RECEPTOR REVISION; IMMUNE DIVERSIFICATION; STRUCTURE REQUIREMENTS; B-LYMPHOCYTES; PROTEIN RAG1; TRANSPOSITION; IDENTIFICATION	Antibody and T cell receptor genes are assembled from gene segments by V(D)J recombination to produce an almost infinitely diverse repertoire of antigen specificities. Recombination is initiated by cleavage of conserved recombination signal sequences (RSS) by RAG1 and RAG2 during lymphocyte development. Recent evidence demonstrates that recombination can occur at noncanonical RSS sites within Ig genes or at other loci, outside the context of normal lymphocyte receptor gene rearrangement. We have characterized the ability of the RAG proteins to bind and cleave a cryptic RSS (cRSS) located within an Ig V-H gene segment. The RAG proteins bound with sequence specificity to either the consensus RSS or the cRSS. The RAG proteins nick the cRSS on both the top and bottom strands, thereby bypassing the formation of the DNA hairpin intermediate observed in RAG cleavage of canonical RSS substrates. We propose that the RAG proteins may utilize an alternative mechanism for double-stranded DNA cleavage, depending on the substrate sequence. These results have implications for further diversification of the antigen receptor repertoire as well as the role of the RAG proteins in genomic instability.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Mol Immunogenet Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Rodgers, KK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 S L Young Blvd, Oklahoma City, OK 73190 USA.	karla-rodgers@ouhsc.edu		Rodgers, Karla/0000-0002-7338-0281	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012127, R37AI012127] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12127] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Arbuckle JL, 2001, J BIOL CHEM, V276, P37093, DOI 10.1074/jbc.M105988200; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bellan C, 2002, DIAGN MOL PATHOL, V11, P2, DOI 10.1097/00019606-200203000-00002; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Cowell LG, 2003, J EXP MED, V197, P207, DOI 10.1084/jem.20020250; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Darlow JM, 2005, IMMUNOLOGY, V114, P155, DOI 10.1111/j.1365-2567.2004.02084.x; De P, 2004, IMMUNOL REV, V200, P70, DOI 10.1111/j.0105-2896.2004.00154.x; De P, 2004, MOL CELL BIOL, V24, P6850, DOI 10.1128/mcb.24.15.6850-6860.2004; de Villartay JP, 2003, NAT REV IMMUNOL, V3, P962, DOI 10.1038/nri1247; Eastman QM, 1997, NUCLEIC ACIDS RES, V25, P4370, DOI 10.1093/nar/25.21.4370; Ezekiel UR, 1997, MOL CELL BIOL, V17, P4191, DOI 10.1128/MCB.17.7.4191; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GERSTEIN RM, 1993, GENE DEV, V7, P1459, DOI 10.1101/gad.7.7b.1459; Godderz LJ, 2003, NUCLEIC ACIDS RES, V31, P2014, DOI 10.1093/nar/gkg281; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Hillion S, 2005, ANN NY ACAD SCI, V1050, P10, DOI 10.1196/annals.1313.002; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Itoh K, 2000, J EXP MED, V192, P1151, DOI 10.1084/jem.192.8.1151; Jankovic M, 2004, ANNU REV IMMUNOL, V22, P485, DOI 10.1146/annurev.immunol.22.012703.104707; Kolar GR, 2004, SCAND J IMMUNOL, V60, P108, DOI 10.1111/j.0300-9475.2004.01467.x; Kouskoff V, 2001, LIFE SCI, V69, P1105, DOI 10.1016/S0024-3205(01)01219-X; Lee AI, 2003, PLOS BIOL, V1, P56, DOI 10.1371/journal.pbio.0000001; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lenze D, 2003, J CLIN PATHOL-MOL PA, V56, P249, DOI 10.1136/mp.56.5.249; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Montalbano A, 2003, J IMMUNOL, V171, P5296, DOI 10.4049/jimmunol.171.10.5296; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; Nemazee D, 2003, CURR OPIN IMMUNOL, V15, P182, DOI 10.1016/S0952-7915(03)00008-6; Peak MM, 2003, J BIOL CHEM, V278, P18235, DOI 10.1074/jbc.M302041200; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Santagata S, 1998, J BIOL CHEM, V273, P16325, DOI 10.1074/jbc.273.26.16325; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Shih IH, 2002, EMBO J, V21, P6625, DOI 10.1093/emboj/cdf630; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Wilson PC, 2000, J EXP MED, V191, P1881, DOI 10.1084/jem.191.11.1881; Yu KF, 1999, MOL CELL BIOL, V19, P8094; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; Zhang ZX, 2004, IMMUNOL REV, V197, P231, DOI 10.1111/j.0105-2896.2004.0107.x; Zhang ZX, 2003, IMMUNITY, V19, P21, DOI 10.1016/S1074-7613(03)00170-5	54	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12370	12380		10.1074/jbc.M507906200	http://dx.doi.org/10.1074/jbc.M507906200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531612	hybrid			2022-12-27	WOS:000237134700022
J	Sarkar, M; Leventis, PA; Silvescu, CI; Reinhold, VN; Schachter, H; Boulianne, GL				Sarkar, M; Leventis, PA; Silvescu, CI; Reinhold, VN; Schachter, H; Boulianne, GL			Null mutations in Drosophila N-acetylglucosaminyltransferase I produce defects in locomotion and a reduced life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INSECT CELLS; CAENORHABDITIS-ELEGANS; ALPHA-MANNOSIDASE; GLYCOPROTEIN-SYNTHESIS; PROTEIN GLYCOSYLATION; MUSCULAR-DYSTROPHY; GLYCANS; MELANOGASTER; COMPLEX	UDP-GlcNAc:alpha 3-D-mannoside beta 1,2-N-acetylglucosaminyltransferase I (encoded by Mgat1) controls the synthesis of hybrid, complex, and paucimannose N-glycans. Mice make hybrid and complex N-glycans but little or no paucimannose N-glycans. In contrast, Drosophila melanogaster and Caenorhabditis elegans make paucimannose N-glycans but little or no hybrid or complex N-glycans. To determine the functional requirement for beta 1,2-N-acetylglucosaminyltransferase I in Drosophila, we generated null mutations by imprecise excision of a nearby transposable element. Extracts from Mgat1(1)/Mgat1(1) null mutants showed no beta 1,2-N-acetylglucosaminyltransferase I enzyme activity. Moreover, mass spectrometric analysis of these extracts showed dramatic changes in N-glycans compatible with lack of beta 1,2-N-acetylglucosaminyltransferase I activity. Interestingly, Mgat1(1)/Mgat1(1) null mutants are viable but exhibit pronounced defects in adult locomotory activity when compared with Mgat1(1)/CyO-GFP heterozygotes or wild type flies. In addition, in null mutants males are sterile and have a severely reduced mean and maximum life span. Microscopic examination of mutant adult fly brains showed the presence of fused beta lobes. The removal of both maternal and zygotic Mgat1 also gave rise to embryos that no longer express the horseradish peroxidase antigen within the central nervous system. Taken together, the data indicate that beta 1,2-N-acetylglucosaminyltransferase I-dependent N-glycans are required for locomotory activity, life span, and brain development in Drosophila.	Hosp Sick Children, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University System Of New Hampshire; University of New Hampshire; University of Toronto; University of Toronto	Schachter, H (corresponding author), Hosp Sick Children, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	harry@sickkids.ca						ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Ashline D, 2005, ANAL CHEM, V77, P6250, DOI 10.1021/ac050724z; ATIENZASAMOLS SB, 1980, DEV BIOL, V79, P19, DOI 10.1016/0012-1606(80)90070-6; Boquet I, 2000, J NEUROBIOL, V42, P33; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Chiba A, 1997, J BIOL CHEM, V272, P2156; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DESAI CJ, 1994, J NEUROSCI, V14, P7272; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Endo T, 2003, BIOL PHARM BULL, V26, P1641, DOI 10.1248/bpb.26.1641; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Finnie JW, 2001, J COMP PATHOL, V125, P318, DOI 10.1053/jcpa.2001.0510; Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Ichimiya T, 2004, J BIOL CHEM, V279, P42638, DOI 10.1074/jbc.M404900200; Iliadi KG, 2002, BEHAV GENET, V32, P173, DOI 10.1023/A:1016017028041; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Ioffe E, 1997, GLYCOBIOLOGY, V7, P913, DOI 10.1093/glycob/7.7.913; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LAINE RA, 1994, GLYCOBIOLOGY, V4, P759, DOI 10.1093/glycob/4.6.759; LEONARD R, 2005, J BIOL CHEM, V281, P4567; Leventis PA, 2001, TRAFFIC, V2, P839; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Marek KW, 1999, GLYCOBIOLOGY, V9, P1263; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Parekh RB, 1997, CURR OPIN BIOTECH, V8, P718, DOI 10.1016/S0958-1669(97)80126-7; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Pittet M, 2006, GLYCOBIOLOGY, V16, P155, DOI 10.1093/glycob/cwj043; Rabouille C, 1999, J CELL SCI, V112, P3319; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Routtenberg A, 2005, TRENDS NEUROSCI, V28, P12, DOI 10.1016/j.tins.2004.11.006; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schachter H, 2005, GLYCOBIOLOGY, V15, P1191; Schachter H, 2005, P NATL ACAD SCI USA, V102, P15721, DOI 10.1073/pnas.0507659102; Schachter H, 2003, GLYCOCONJUGATE J, V20, P291, DOI 10.1023/B:GLYC.0000033626.65127.e4; SCHACHTER H, 2005, NEUROGLYCOBIOLOGY, P157; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STANLEY P, 2000, MOL CELLULAR GLYCOBI, V30, P169; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; SURANI MAH, 1979, CELL, V18, P217; Tan J, 1996, AM J HUM GENET, V59, P810; Tsitilou SG, 2003, BIOCHEM BIOPH RES CO, V312, P1372, DOI 10.1016/j.bbrc.2003.11.059; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zhang WL, 2003, CLIN BIOCHEM, V36, P339, DOI 10.1016/S0009-9120(03)00036-5; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	71	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12776	12785		10.1074/jbc.M512769200	http://dx.doi.org/10.1074/jbc.M512769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522637	hybrid			2022-12-27	WOS:000237134700071
J	Suhasini, AN; Sirdeshmukh, R				Suhasini, AN; Sirdeshmukh, R			Transfer RNA cleavages by onconase reveal unusual cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-II TRIAL; CYTOTOXIC RIBONUCLEASES; SELECTIVE DEGRADATION; PROTEIN; RANPIRNASE; INHIBITION; ANGIOGENIN; RESIDUES	Onconase, a protein from amphibian eggs and a homologue of pancreatic ribonuclease (RNase) superfamily, is cytotoxic, exhibits antitumor and antiviral activity, and is in phase III clinical trials. It has been shown to predominantly target cellular tRNA on its entry into mammalian cells (Saxena, S. K., Sirdeshmukh, R., Ardelt, W., Mikulski, S. M., Shogen, K., and Youle, R. J. (2002) J. Biol. Chem. 277, 15142-15146). Cleavage site mapping using natural tRNA substrates, in vitro, revealed predominant cleavage sites at UG and GG residues. Cleavages at UG or the less intense cleavages at CG sites are consistent with the known base specificity of onconase. However, predominance of cleavages at selected G-G bonds is unusual for a homologue of pancreatic RNases. Interestingly, in at least three of the four tRNA substrates studied, the predominant cleavages mapped in the triplet UGG located in the context of the variable loop or the D-arm of the tRNA. The cleavage specificity of onconase observed by us thus indicates another special feature of this enzyme, which may be relevant to its cellular actions.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Sirdeshmukh, R (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	ravi@ccmb.res.in						Ardelt B, 2003, CELL CYCLE, V2, P22, DOI 10.4161/cc.2.1.232; ARDELT W, 1991, J BIOL CHEM, V266, P245; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DLLIAO Y, 2004, PROTEIN SCI, V13, P1802; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; Liao YD, 2003, NUCLEIC ACIDS RES, V31, P5247, DOI 10.1093/nar/gkg746; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; Ogawa T, 1999, SCIENCE, V283, P2097, DOI 10.1126/science.283.5410.2097; Olsnes S, 2001, TOXICON, V39, P1723, DOI 10.1016/S0041-0101(01)00158-1; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Rosenberg HF, 1999, IMMUNOL RES, V20, P261, DOI 10.1007/BF02790409; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; Sambrook J., MOL CLONING LAB MANU; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; Saxena SK, 2002, J BIOL CHEM, V277, P15142, DOI 10.1074/jbc.M108115200; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Vogelzang NJ, 2001, INVEST NEW DRUG, V19, P255, DOI 10.1023/A:1010633004157; Wool I.G., 1997, RIBONUCLEASES STRUCT, P131; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012	33	38	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12201	12209		10.1074/jbc.M504488200	http://dx.doi.org/10.1074/jbc.M504488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497678	hybrid			2022-12-27	WOS:000237134700002
J	Chen, CL; Huang, SS; Huang, JS				Chen, CL; Huang, SS; Huang, JS			Cellular heparan sulfate negatively modulates transforming growth factor-beta(1) (TGF-beta(1)) responsiveness in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MOLECULAR-WEIGHT RECEPTOR; TGF-BETA; CARCINOMA-CELLS; GLYCOSAMINOGLYCAN CHAINS; ENDOTHELIAL-CELLS; BINDING-PROTEINS; V RECEPTOR; PROTEOGLYCAN; EXPRESSION	Cell-surface proteoglycans have been shown to modulate transforming growth factor ( TGF)-beta responsiveness in epithelial cells and other cell types. However, the proteoglycan ( heparan sulfate or chondroitin sulfate) involved in modulation of TGF-beta responsiveness and the mechanism by which it modulates TGF-beta responsiveness remain unknown. Here we demonstrate that TGF-beta(1) induces transcriptional activation of plasminogen activator inhibitor-1 ( PAI-1) and growth inhibition more potently in CHO cell mutants deficient in heparan sulfate ( CHO-677 cells) than in wild-type CHO-K1 cells. I-125-TGF-beta(1) affinity labeling analysis of cell-surface TGF-beta receptors reveals that CHO-K1 and CHO-677 cells exhibit low (<1) and high (>1) ratios of I-125-TGF-beta(1) binding to T beta R-II and T beta R-I, respectively. Receptor-bound I-125-TGF-beta(1) undergoes nystatin-inhibitable rapid degradation in CHO-K1 cells but not in CHO-677 cells. In Mv1Lu cells ( which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound I-125-TGF-beta(1)), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (< 1) to a high (>1) ratio of I-125-TGF-beta(1) binding to T beta R-II and T beta R-I and enhanced TGF-beta(1)-induced transcriptional activation of PAI-1. Sucrose density gradient analysis indicates that a significant fraction of T beta R-I and T beta R-II is localized in caveolae/lipid-raft fractions in CHO-K1 and Mv1Lu cells whereas the majority of the TGF-beta receptors are localized in non-lipid-raft fractions in CHO-677 cells. These results suggest that heparan sulfate negatively modulates TGF-beta 1 responsiveness by decreasing the ratio of TGF-beta 1 binding to T beta R-II and T beta R-I, facilitating caveolae/lipid-raft-mediated endocytosis and rapid degradation of TGF-beta 1, thus diminishing non-lipid-raft-mediated endocytosis and signaling of TGF-beta 1 in these epithelial cells.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu						Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Huang SS, 2004, FASEB J, V18, P1719, DOI 10.1096/fj.04-1872fje; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Keski-Oja J, 2004, TRENDS CELL BIOL, V14, P657, DOI 10.1016/j.tcb.2004.10.003; Kimura S, 1999, J BIOCHEM-TOKYO, V125, P406, DOI 10.1093/oxfordjournals.jbchem.a022301; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Noble Nancy A., 1992, Progress in Growth Factor Research, V4, P369, DOI 10.1016/0955-2235(92)90017-C; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Riser BL, 1999, KIDNEY INT, V56, P428, DOI 10.1046/j.1523-1755.1999.00600.x; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1993, BIOCHIM BIOPHYS ACTA, V1155, P269, DOI 10.1016/0304-419X(93)90009-2; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Taipale J, 1996, J BIOL CHEM, V271, P4342; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; WEISSMANN G, 1967, J BIOL CHEM, V242, P616; Wells RG, 2004, FEBS LETT, V559, P107, DOI 10.1016/S0014-5793(04)00037-7; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Yokoyama H, 1996, DIABETIC MED, V13, P313, DOI 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.3.CO;2-Z	48	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11506	11514		10.1074/jbc.M512821200	http://dx.doi.org/10.1074/jbc.M512821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16492675	hybrid			2022-12-27	WOS:000236988100012
J	Takahashi, Y; Dominici, M; Swift, J; Nagy, C; Ihle, JN				Takahashi, Y; Dominici, M; Swift, J; Nagy, C; Ihle, JN			Trophoblast stem cells rescue placental defect in SOCS3-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE	Stem cells have important clinical and experimental potentials. Trophoblast stem ( TS) cells possess the ability to differentiate into trophoblast subtypes in vitro and contribute to the trophoblast lineage in vivo. Suppressor of cytokine signaling 3 ( SOCS3) is a negative regulator of cytokine signaling. Targeted disruption of SOCS3 revealed embryonic lethality on E12.5; it was caused by placental defect with enhanced leukemia inhibitory factor receptor signaling. A complementation of the wild-type ( WT) placenta by using tetraploid rescue technique showed that the embryonic lethality in SOCS3-deficient embryo was due to the placental defect. Here we demonstrate that TS cells supplementation rescues placental defect in SOCS3-deficient embryos. In the rescued placenta, TS cells were integrated into the placental structure, and a substantial structural improvement was observed in the labyrinthine layer that was disrupted in the SOCS3-deficient placenta. Importantly, by supplying TS cells, living SOCS3-deficient embryos were detected at term. These results indicate a functional contribution of TS cells in the placenta and their potential application.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, Kobe, Hyogo 6500017, Japan; St Jude Childrens Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Cryopreservat Unit, Memphis, TN 38105 USA; St Jude Childrens Hosp, Transgen Core Unit, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Memphis, TN 38063 USA	Kobe University; Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Takahashi, Y (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	takahash@med.kobe-u.ac.jp	Dominici, Massimo/K-8014-2016	Dominici, Massimo/0000-0002-4007-1503				Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Ihle JN, 2000, CELL, V102, P131, DOI 10.1016/S0092-8674(00)00017-9; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072	9	17	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11444	11445		10.1074/jbc.C600015200	http://dx.doi.org/10.1074/jbc.C600015200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517610	hybrid, Green Published			2022-12-27	WOS:000236988100003
J	Dejima, K; Seko, A; Yamashita, K; Gengyo-Ando, K; Mitani, S; Izumikawa, T; Kitagawa, H; Sugahara, K; Mizuguchi, S; Nomura, K				Dejima, K; Seko, A; Yamashita, K; Gengyo-Ando, K; Mitani, S; Izumikawa, T; Kitagawa, H; Sugahara, K; Mizuguchi, S; Nomura, K			Essential roles of 3 '-phosphoadenosine 5 '-phoshosulfate synthase in embryonic and larval development of the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRACHYMORPHIC MICE; 5'-PHOSPHOSULFATE TRANSPORTER; GENETIC INTERFERENCE; PAPS SYNTHETASE; CELL-DIVISION; MAST-CELLS; SULFATE; EXPRESSION; RECEPTOR; EMBRYOGENESIS	Sulfation of biomolecules, which is widely observed from bacteria to humans, plays critical roles in many biological processes. All sulfation reactions in all organisms require activated sulfate, 3'-phosphoadenosine 5'-phosphosulfate ( PAPS), as a universal donor. In animals, PAPS is synthesized from ATP and inorganic sulfate by the bifunctional enzyme, PAPS synthase. In mammals, genetic defects in PAPS synthase 2, one of two PAPS synthase isozymes, cause dwarfism disorder, but little is known about the consequences of the complete loss of PAPS synthesis. To define the developmental role of sulfation, we cloned a Caenorhabditis elegans PAPS synthase-homologous gene, pps-1, and depleted expression of its product by isolating the deletion mutant and by RNA-mediated interference. PPS-1 protein exhibits specific activity to form PAPS in vitro, and disruption of the pps-1 gene by RNAi causes pleiotropic developmental defects in muscle patterning and epithelial cell shape changes with a decrease in glycosaminoglycan sulfation. Additionally, the pps-1 null mutant exhibits larval lethality. These data suggest that sulfation is essential for normal growth and integrity of epidermis in C. elegans. Furthermore, reporter analysis showed that pps-1 is expressed in the epidermis and several gland cells but not in neurons and muscles, indicating that PAPS in the neurons and muscles is provided by other cells.	Kyushu Univ 33, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; CREST, Kawaguchi, Saitama 3320012, Japan; Sasaki Inst, Dept Biochem, Tokyo 1010062, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tokyo Women's Medical University; Kobe Pharmaceutical University	Nomura, K (corresponding author), Kyushu Univ 33, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.	knomuscb@mbox.nc.kyushu-u.ac.jp	Gengyo-Ando, Keiko/AAC-4504-2019; Kitagawa, Hiroshi/AAJ-1344-2020; Gengyo-Ando, Keiko/B-2753-2012	Kitagawa, Hiroshi/0000-0002-9307-7079; 				Asahina M, 2000, GENES CELLS, V5, P711, DOI 10.1046/j.1365-2443.2000.00361.x; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Baugh LR, 2003, DEVELOPMENT, V130, P889, DOI 10.1242/dev.00302; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen Z, 2004, MOL CELL BIOL, V24, P7345, DOI 10.1128/MCB.24.17.7345-7358.2004; Costa M, 1997, DEV BIOL, V184, P373, DOI 10.1006/dbio.1997.8530; Edgar LG, 2001, DEV BIOL, V229, P71, DOI 10.1006/dbio.2000.9977; Entchev EV, 2005, SEMIN CELL DEV BIOL, V16, P175, DOI 10.1016/j.semcdb.2005.01.004; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Fuda H, 2002, BIOCHEM J, V365, P497, DOI 10.1042/BJ20020044; GELLER DH, 1987, J BIOL CHEM, V262, P7374; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Johnstone I.J., 1999, C ELEGANS PRACTICAL, P201; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Karabinos A, 2004, EUR J CELL BIOL, V83, P457, DOI 10.1078/0171-9335-00407; Kelly WG, 1997, GENETICS, V146, P227; Kim TH, 2005, FEBS LETT, V579, P53, DOI 10.1016/j.febslet.2004.11.044; Kinnunen T, 2005, P NATL ACAD SCI USA, V102, P1507, DOI 10.1073/pnas.0401591102; Kostrouchova M, 1998, DEVELOPMENT, V125, P1617; Kostrouchova M, 2001, P NATL ACAD SCI USA, V98, P7360, DOI 10.1073/pnas.131171898; Kuervers LM, 2003, MOL GENET GENOMICS, V270, P121, DOI 10.1007/s00438-003-0900-9; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Lee JS, 2004, NAT REV GENET, V5, P923, DOI 10.1038/nrg1490; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; Mei D, 2004, EXP CELL RES, V301, P84, DOI 10.1016/j.yexcr.2004.08.017; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; ORKIN RW, 1977, J CELL BIOL, V73, P287, DOI 10.1083/jcb.73.2.287; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Rusiniak ME, 1996, MAMM GENOME, V7, P98, DOI 10.1007/s003359900027; SCHWARTZ NB, 1983, LIMB DEV REGENERATIO, P97; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Simske JS, 2001, BIOESSAYS, V23, P12, DOI 10.1002/1521-1878(200101)23:1&lt;12::AID-BIES1003&gt;3.0.CO;2-R; Starich TA, 2003, DEV BIOL, V256, P403, DOI 10.1016/S0012-1606(02)00116-1; Stiernagle T., 1999, C ELEGANS PRACTICAL, P51; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Van Auken K, 2000, P NATL ACAD SCI USA, V97, P4499, DOI 10.1073/pnas.97.9.4499; Venkatachalam KV, 2003, IUBMB LIFE, V55, P1, DOI 10.1080/1521654031000072148; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Xu ZH, 2000, BIOCHEM BIOPH RES CO, V268, P437, DOI 10.1006/bbrc.2000.2123; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	60	23	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11431	11440		10.1074/jbc.M601509200	http://dx.doi.org/10.1074/jbc.M601509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497669	hybrid			2022-12-27	WOS:000236822200086
J	Koide, T; Nishikawa, Y; Asada, S; Yamazaki, CM; Takahara, Y; Homma, DL; Otaka, A; Ohtani, K; Wakamiya, N; Nagata, K; Kitagawa, K				Koide, T; Nishikawa, Y; Asada, S; Yamazaki, CM; Takahara, Y; Homma, DL; Otaka, A; Ohtani, K; Wakamiya, N; Nagata, K; Kitagawa, K			Specific recognition of the collagen triple helix by chaperone HSP47 II. The HSP47-binding structural motif in collagens and related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; BINDING-SPECIFICITY; PULMONARY-FIBROSIS; PEPTIDES; EXPRESSION; HEAT-SHOCK-PROTEIN-47; REQUIREMENTS; PROCOLLAGEN; STABILITY; COLLECTIN	The endoplasmic reticulum-resident chaperone heat-shock protein 47 (HSP47) plays an essential role in procollagen biosynthesis. The function of HSP47 relies on its specific interaction with correctly folded triple-helical regions comprised of Gly-Xaa-Yaa repeats, and Arg residues at Yaa positions have been shown to be important for this interaction. The amino acid at the Yaa position (Yaa(-3)) in the N-terminal-adjoining triplet containing the critical Arg ( defined as Arg(0)) was also suggested to be directly recognized by HSP47 (Koide, T., Asada, S., Takahara, Y., Nishikawa, Y., Nagata, K., and Kitagawa, K. ( 2006) J. Biol. Chem. 281, 3432 - 3438). Based on this finding, we examined the relationship between the structure of Yaa(-3) and HSP47 binding using synthetic collagenous peptides. The results obtained indicated that the structure of Yaa(-3) determined the binding affinity for HSP47. Maximal binding was observed when Yaa(-3) was Thr. Moreover, the required relative spatial arrangement of these key residues in the triple helix was analyzed by taking advantage of heterotrimeric collagen-model peptides, each of which contains one Thr(-3) and one Arg(0). The results revealed that HSP47 recognizes the Yaa(-3) and Arg(0) residues only when they are on the same peptide strand. Taken together, the data obtained led us to define the HSP47-binding structural epitope in the collagen triple helix and also define the HSP47-binding motif in the primary structure. A motif search against human protein database predicted candidate clients for this molecular chaperone. The search result indicated that not all collagen family proteins require the chaperoning by HSP47.	Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9568603, Japan; Univ Tokushima, Fac Engn, Tokushima 7708506, Japan; Univ Tokushima, Grad Sch Pharmaceut Sci, Tokushima 7708505, Japan; Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068397, Japan	Niigata University; Tokushima University; Tokushima University; Asahikawa Medical College; Kyoto University	Koide, T (corresponding author), Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9568603, Japan.	koi@niigata-pharm.ac.jp						BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Iwashita T, 2000, HUM PATHOL, V31, P1498, DOI 10.1053/hupa.2000.20378; Kakugawa T, 2004, EUR RESPIR J, V24, P57, DOI 10.1183/09031936.04.00120803; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2006, J BIOL CHEM, V281, P3432, DOI 10.1074/jbc.M509707200; Koide T, 2004, BIOORG MED CHEM LETT, V14, P125, DOI 10.1016/j.bmcl.2003.10.005; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Miyazaki M, 2003, CONTRIB NEPHROL, V139, P141; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Ottl J, 1999, J AM CHEM SOC, V121, P653, DOI 10.1021/ja983456d; PETRY F, 1991, J IMMUNOL, V147, P3988; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Razzaque MS, 2005, CONTRIB NEPHROL, V148, P57, DOI 10.1159/000086043; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tasab M, 2002, J BIOL CHEM, V277, P35007, DOI 10.1074/jbc.M202782200; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; Thomson CA, 2005, J MED CHEM, V48, P1680, DOI 10.1021/jm049148+; Thomson CA, 2003, PROTEIN SCI, V12, P1792, DOI 10.1110/ps.0236903; Yokota SI, 2003, BIOCHEM BIOPH RES CO, V303, P413, DOI 10.1016/S0006-291X(03)00352-8	33	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11177	11185		10.1074/jbc.M601369200	http://dx.doi.org/10.1074/jbc.M601369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484215	hybrid			2022-12-27	WOS:000236822200061
J	Shen, JQ; Vil, MD; Jimenez, X; Iacolina, M; Zhang, HF; Zhu, ZP				Shen, JQ; Vil, MD; Jimenez, X; Iacolina, M; Zhang, HF; Zhu, ZP			Single variable domain-IgG fusion - A novel recombinant approach to Fc domain-containing bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PHAGE DISPLAY LIBRARY; HIGH-AFFINITY BINDING; FULLY HUMAN; CRYSTAL-STRUCTURE; FACTOR RECEPTOR-2; EFFICIENT ROUTE; FRAGMENTS; CANCER; INHIBITION	Both laboratory and early clinical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially significant application in cancer therapy. The clinical development of BsAb as therapeutics has been hampered, however, by the difficulty in preparing the materials in sufficient quantity and quality by traditional methods. In recent years, a variety of recombinant methods has been developed for efficient production of BsAb, both as antibody fragments and as full-length IgG-like molecules. Here we describe a novel recombinant approach for the production of an Fc domain-containing, IgG-like tetravalent BsAb, with two antigen-binding sites to each of its target antigens, by genetically fusing a single variable domain antibody to the N terminus of the light chain of a functional IgG antibody of different specificity. A model BsAb was constructed using a single variable domain antibody to mouse platelet-derived growth factor receptor alpha and a conventional IgG antibody to mouse vascular endothelial growth factor receptor 2. The BsAb was expressed in mammalian cells and purified to homogeneity by one-step protein A affinity chromatography. Furthermore, the BsAb retains the antigen binding specificity and the receptor neutralizing activity of both of its parent antibodies. This design and expression of Fc domain-containing, IgG-like BsAb should be applicable to the construction of similar BsAb from antibodies recognizing any pair of antigens.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA	Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.	zhenping.zhu@imclone.com						Atwell S, 1997, J MOL BIOL, V270, P26, DOI 10.1006/jmbi.1997.1116; Baeuerle PA, 2003, CURR OPIN MOL THER, V5, P413; Binz HK, 2005, CURR OPIN BIOTECH, V16, P459, DOI 10.1016/j.copbio.2005.06.005; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; Cai XH, 1996, P NATL ACAD SCI USA, V93, P6280, DOI 10.1073/pnas.93.13.6280; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Chang CH, 2002, MOL CANCER THER, V1, P553; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; Corvalan J R, 1988, Int J Cancer Suppl, V2, P22; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Ferrini S, 2001, METH MOL B, V166, P177; Ford CHJ, 2001, INT J CANCER, V92, P851, DOI 10.1002/ijc.1262; Hoet RM, 2005, NAT BIOTECHNOL, V23, P344, DOI 10.1038/nbt1067; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007; Hu SZ, 1996, CANCER RES, V56, P3055; James ND, 2001, BRIT J CANCER, V85, P152, DOI 10.1054/bjoc.2001.1878; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Jespers L, 2004, J MOL BIOL, V337, P893, DOI 10.1016/j.jmb.2004.02.013; Jimenez X, 2005, MOL CANCER THER, V4, P427; Kabat EA, 1991, SEQUENCES PROTEINS I; Kipriyanov SM, 2004, CURR OPIN DRUG DISC, V7, P233; Kipriyanov SM, 2002, J IMMUNOL, V169, P137, DOI 10.4049/jimmunol.169.1.137; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Lu D, 2005, J BIOL CHEM, V280, P19665, DOI 10.1074/jbc.M500815200; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Lu D, 2002, J IMMUNOL METHODS, V267, P213, DOI 10.1016/S0022-1759(02)00148-5; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Lu D, 2001, CANCER RES, V61, P7002; Lum Lawrence G, 2005, Cancer Chemother Biol Response Modif, V22, P273; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Nuttall SD, 2004, PROTEINS, V55, P187, DOI 10.1002/prot.20005; Parker MH, 2005, PROTEIN ENG DES SEL, V18, P435, DOI 10.1093/protein/gzi050; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Ronnmark J, 2002, EUR J BIOCHEM, V269, P2647, DOI 10.1046/j.1432-1033.2002.02926.x; Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5; Stanfield RL, 2004, SCIENCE, V305, P1770, DOI 10.1126/science.1101148; Tanha J, 2001, J BIOL CHEM, V276, P24774, DOI 10.1074/jbc.M100770200; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Wu AM, 2000, Q J NUCL MED, V44, P268; Xiong DS, 2002, CANCER LETT, V177, P29, DOI 10.1016/S0304-3835(01)00758-3; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	51	43	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10706	10714		10.1074/jbc.M513415200	http://dx.doi.org/10.1074/jbc.M513415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481314	hybrid			2022-12-27	WOS:000236822200009
J	Kawano, M; Inoue, T; Tsukamoto, H; Takaya, T; Enomoto, T; Takahashi, R; Yokoyama, N; Yamamoto, N; Nakanishi, A; Imai, T; Wada, T; Kataoka, K; Handa, H				Kawano, M; Inoue, T; Tsukamoto, H; Takaya, T; Enomoto, T; Takahashi, R; Yokoyama, N; Yamamoto, N; Nakanishi, A; Imai, T; Wada, T; Kataoka, K; Handa, H			The VP2/VP3 minor capsid protein of simian virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; INSECT CELLS; POLYOMA-VIRUS; SIMIAN VIRUS-40; JC VIRUS; DNA; RESOLUTION; PURIFICATION; EXPRESSION; VIRIONS	The SV40 capsid is composed primarily of 72 pentamers of the VP1 major capsid protein. Although the capsid also contains the minor capsid protein VP2 and its amino-terminally truncated form VP3, their roles in capsid assembly remain unknown. An in vitro assembly system was used to investigate the role of VP2 in the assembly of recombinant VP1 pentamers. Under physiological salt and pH conditions, VP1 alone remained dissociated, and at pH 5.0, it assembled into tubular structures. A stoichiometric amount of VP2 allowed the assembly of VP1 pentamers into spherical particles in a pH range of 7.0 to 4.0. Electron microscopy observation, sucrose gradient sedimentation analysis, and antibody accessibility tests showed that VP2 is incorporated into VP1 particles. The functional domains of VP2 important for VP1 binding and for enhancing VP1 assembly were further explored with a series of VP2 deletion mutants. VP3 also enhanced VP1 assembly, and a region common to VP2 and VP3 (amino acids 119-272) was required to promote VP1 pentamer assembly. These results are relevant for controlling recombinant capsid formation in vitro, which is potentially useful for the in vitro development of SV40 virus vectors.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Natl Inst Longev Sci, Obu 4748522, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300192, Japan	Tokyo Institute of Technology; Nara Institute of Science & Technology	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268503, Japan.	hhanda@bio.titech.ac.jp		Imai, Takeshi/0000-0002-9503-7353; Kawano, Masaaki/0000-0001-8220-4717				ANDERER FA, 1967, VIROLOGY, V32, P511, DOI 10.1016/0042-6822(67)90302-9; BAROUCH DH, 1994, J VIROL, V68, P3982, DOI 10.1128/JVI.68.6.3982-3989.1994; BRADY JN, 1978, J VIROL, V27, P193, DOI 10.1128/JVI.27.1.193-204.1978; BRADY JN, 1977, J VIROL, V23, P717, DOI 10.1128/JVI.23.3.717-724.1977; BRADY JN, 1979, J VIROL, V32, P640, DOI 10.1128/JVI.32.2.640-647.1979; Chang DC, 1997, J GEN VIROL, V78, P1435, DOI 10.1099/0022-1317-78-6-1435; Chen XJS, 1998, EMBO J, V17, P3233, DOI 10.1093/emboj/17.12.3233; Chromy LR, 2003, P NATL ACAD SCI USA, V100, P10477, DOI 10.1073/pnas.1832245100; CLEVER J, 1993, J BIOL CHEM, V268, P20877; COLOMAR MC, 1993, J VIROL, V67, P2779, DOI 10.1128/JVI.67.5.2779-2786.1993; Finnen RL, 2003, J VIROL, V77, P4818, DOI 10.1128/JVI.77.8.4818-4826.2003; FORSTOVA J, 1993, J VIROL, V67, P1405; GARCEA RL, 1987, NATURE, V329, P86, DOI 10.1038/329086a0; Genevaux P, 2003, J VIROL, V77, P10706, DOI 10.1128/JVI.77.19.10706-10713.2003; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8; Gillock ET, 1997, J VIROL, V71, P2857, DOI 10.1128/JVI.71.4.2857-2865.1997; Goldmann C, 1999, J VIROL, V73, P4465, DOI 10.1128/JVI.73.5.4465-4469.1999; Ishizu KI, 2001, J VIROL, V75, P61, DOI 10.1128/JVI.75.1.61-72.2001; Kanesashi SN, 2003, J GEN VIROL, V84, P1899, DOI 10.1099/vir.0.19067-0; KAWANA KH, 1998, J VIROL, V67, P6929; Kimchi-Sarfaty C, 2003, HUM GENE THER, V14, P167, DOI 10.1089/104303403321070865; KOCH MA, 1967, VIROLOGY, V32, P503, DOI 10.1016/0042-6822(67)90302-9; Kosukegawa A, 1996, BBA-GEN SUBJECTS, V1290, P37; LI ML, 1995, P NATL ACAD SCI USA, V92, P5992, DOI 10.1073/pnas.92.13.5992; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Mannova P, 2002, J GEN VIROL, V83, P2309, DOI 10.1099/0022-1317-83-9-2309; Pawlita M, 1996, J VIROL, V70, P7517, DOI 10.1128/JVI.70.11.7517-7526.1996; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Sandalon Z, 1997, VIROLOGY, V237, P414, DOI 10.1006/viro.1997.8796; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; WYCHOWSKI C, 1987, J VIROL, V61, P3862, DOI 10.1128/JVI.61.12.3862-3869.1987; Yan YW, 1996, STRUCTURE, V4, P157, DOI 10.1016/S0969-2126(96)00019-6	36	27	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10164	10173		10.1074/jbc.M511261200	http://dx.doi.org/10.1074/jbc.M511261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478732	hybrid			2022-12-27	WOS:000236594300042
J	Matsumi, R; Atomi, H; Imanaka, T				Matsumi, R; Atomi, H; Imanaka, T			Identification of the amino acid residues essential for proteolytic activity in an archaeal signal peptide peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEASE-IV; METHANOCOCCUS-VOLTAE; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; LON PROTEASE; SPPA GENE; SITE; TRANSLOCATION; MEMBRANE	Signal peptide peptidases (SPPs) are enzymes involved in the initial degradation of signal peptides after they are released from the precursor proteins by signal peptidases. In contrast to the eukaryotic enzymes that are aspartate peptidases, the catalytic mechanisms of prokaryotic SPPs had not been known. In this study on the SPP from the hyperthermophilic archaeon Thermococcus koda-karaensis (SppA(Tk)), we have identified amino acid residues that are essential for the peptidase activity of the enzyme. Delta N54SppA(Tk), a truncated protein without the N-terminal 54 residues and putative transmembrane domain, exhibits high peptidase activity, and was used as the wild-type protein. Sixteen residues, highly conserved among archaeal SPP homologue sequences, were selected and replaced by alanine residues. The mutations S162A and K214A were found to abolish peptidase activity of the protein, whereas all other mutant proteins displayed activity to various extents. The results indicated the function of Ser(162) as the nucleophilic serine and that of Lys(214) as the general base, comprising a Ser/Lys catalytic dyad in SppA(Tk). Kinetic analyses indicated that Ser(184), His(191), Lys(209), Asp(215), and Arg(221) supported peptidase activity. Intriguingly, a large number of mutations led to an increase in activity levels of the enzyme. In particular, mutations in Ser(128) and Tyr(165) not only increased activity levels but also broadened the substrate specificity of SppA(Tk), suggesting that these residues may be present to prevent the enzyme from cleaving unintended peptide/protein substrates in the cell. A detailed alignment of prokaryotic SPP sequences strongly suggested that the majority of archaeal enzymes, along with the bacterial enzyme from Bacillus subtilis, adopt the same catalytic mechanism for peptide hydrolysis.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp		Atomi, Haruyuki/0000-0001-9687-6426				Albers SV, 2003, J BACTERIOL, V185, P3918, DOI 10.1128/JB.185.13.3918-3925.2003; Atomi Haruyuki, 2004, Archaea, V1, P263, DOI 10.1155/2004/204953; Bardy SL, 2005, J BACTERIOL, V187, P1188, DOI 10.1128/JB.187.3.1188-1191.2005; Bardy SL, 2003, MOL MICROBIOL, V50, P1339, DOI 10.1046/j.1365-2958.2003.03758.x; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Henke E, 2002, ANGEW CHEM INT EDIT, V41, P3211, DOI 10.1002/1521-3773(20020902)41:17<3211::AID-ANIE3211>3.0.CO;2-U; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; ICHIHARA S, 1984, J BIOL CHEM, V259, P9853; Im YJ, 2004, J BIOL CHEM, V279, P53451, DOI 10.1074/jbc.M410437200; Inagaki N, 2001, J BIOL CHEM, V276, P30099, DOI 10.1074/jbc.M102600200; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; Matsumi R, 2005, J BACTERIOL, V187, P7072, DOI 10.1128/JB.187.20.7072-7080.2005; Ng SYM, 2003, J BACTERIOL, V185, P5936, DOI 10.1128/JB.185.20.5936-5942.2003; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; PACAUD M, 1982, J BIOL CHEM, V257, P4333; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Pugsley AP, 2004, MOL MICROBIOL, V52, P3, DOI 10.1111/j.1365-2958.2003.03966.x; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; SUZUKI T, 1987, J BACTERIOL, V169, P2523, DOI 10.1128/jb.169.6.2523-2528.1987; Tanskul S, 2003, BIOCHEM BIOPH RES CO, V309, P547, DOI 10.1016/j.bbrc.2003.08.035; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Yokoyama H, 2005, J BIOL CHEM, V280, P6588, DOI 10.1074/jbc.M411748200	35	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10533	10539		10.1074/jbc.M513754200	http://dx.doi.org/10.1074/jbc.M513754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484219	hybrid			2022-12-27	WOS:000236594300083
J	Cabrera, JR; Sanchez-Pulido, L; Rojas, AM; Valencia, A; Manes, S; Naranjo, JR; Mellstrom, B				Cabrera, J. Ruben; Sanchez-Pulido, Luis; Rojas, Ana M.; Valencia, Alfonso; Manes, Santos; Naranjo, Jose R.; Mellstrom, Britt			Gas1 is related to the glial cell-derived neurotrophic factor family receptors alpha and regulates Ret signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST-SPECIFIC GENE-1; C-RET; GDNF FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-STRUCTURE; TYROSINE KINASE; LIPID RAFTS; DIFFERENTIATION; EXPRESSION; ACTIVATION	The growth arrest-specific gene 1 (Gas1) protein has been proposed to function during development as an inhibitor of growth and a mediator of cell death and is also re-expressed in adult neurons during excitotoxic insult. Here we have demonstrated that the Gas1 protein shows high structural similarity to the glial cell-derived neurotrophic factor (GDNF) family receptors alpha, which mediate GDNF responses through the receptor tyrosine kinase Ret. We found that Gas1 binds Ret in a ligand-independent manner and sequesters Ret in lipid rafts. Signaling downstream of Ret is thus modified through a mechanism that involves the adaptor protein Shc as well as ERK, eventually blocking Akt activation. Consequently, when Gas1 is induced, Ret-mediated GDNF-dependent survival effects are compromised.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Prot Design Grp, E-28049 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mellstrom, B (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Darwin 3, E-28049 Madrid, Spain.	bmellstr@cnb.uam.es	IBIS, BIOINFORMATICA/O-1882-2015; Rojas, Ana M./I-2882-2019; Rojas, Ana M/D-5777-2011; Rojas, Ana M/C-3022-2008; NARANJO, Jose R/K-1950-2014; Valencia, Alfonso/I-3127-2015; Cabrera, Jorge Rubén/H-6310-2015; Manes, Santos/E-4725-2011	Rojas, Ana M./0000-0003-0750-9099; Rojas, Ana M/0000-0003-0750-9099; NARANJO, Jose R/0000-0002-0270-3469; Valencia, Alfonso/0000-0002-8937-6789; Cabrera, Jorge Rubén/0000-0003-4481-0198; Manes, Santos/0000-0001-8023-957X; Sanchez Pulido, Luis/0000-0002-2300-8502				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; Cheung Eric C C, 2004, Sci STKE, V2004, pPE45; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Feng DF, 1996, METHOD ENZYMOL, V266, P368; Fu M, 2004, J CELL BIOL, V166, P673, DOI 10.1083/jcb.200401077; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gomez-Villafuertes R, 2005, J NEUROSCI, V25, P10822, DOI 10.1523/JNEUROSCI.3912-05.2005; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lee CS, 2001, DEV BIOL, V236, P17, DOI 10.1006/dbio.2001.0280; Lee CS, 2001, P NATL ACAD SCI USA, V98, P11347, DOI 10.1073/pnas.201418298; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Li ZH, 2005, J NEUROCHEM, V95, P361, DOI 10.1111/j.1471-4159.2005.03372.x; Liu Y, 2001, DEV BIOL, V236, P30, DOI 10.1006/dbio.2000.0146; Mellstrom B, 2002, MOL CELL NEUROSCI, V19, P417, DOI 10.1006/mcne.2001.1092; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rost B, 1996, METHOD ENZYMOL, V266, P525; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stebel M, 2000, FEBS LETT, V481, P152, DOI 10.1016/S0014-5793(00)02004-4; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200	47	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14330	14339		10.1074/jbc.M509572200	http://dx.doi.org/10.1074/jbc.M509572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551639	hybrid, Green Published			2022-12-27	WOS:000237512300059
J	Chen, ZH; Akin, BL; Stokes, DL; Jones, LR				Chen, Zhenhui; Akin, Brandy L.; Stokes, David L.; Jones, Larry R.			Cross-linking of C-terminal residues of phospholamban to the Ca2+ pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CYTOPLASMIC DOMAIN; ATPASE INTERACTION; PROTEIN-STRUCTURE; CA2+-ATPASE; THAPSIGARGIN; INHIBITION; PHOSPHORYLATION	Interactions between the transmembrane domains of phospholamban (PLB) and the cardiac Ca2+ pump (SERCA2a) have been investigated by chemical cross-linking. Specifically, C-terminal, transmembrane residues 45-52 of PLB were individually mutated to Cys, then cross-linked to V89C in the M2 helix of SERCA2a with the thiol-specific cross-linking reagents Cu2+-phenanthroline, dibromobimane, and bismaleimidohexane. V49C-, M50C-, and L52C-PLB all crosslinked strongly to V89C-SERCA2a, coupling to 70-100% of SERCA2a molecules. Residues 45-48 and 51 of PLB also cross-linked to V89C of SERCA2a, but more weakly. Evidence for the mechanism of PLB regulation of SERCA2a was provided by the conformational dependence of cross-linking. In particular, the required absence of Ca2+ for cross-linking implicated the E2 conformation of SERCA2a, and its enhancement by ATP confirmed E2(.)ATP as the conformation with the highest affinity for PLB. In contrast, E2 phosphorylated with inorganic phosphate (E2P) and E2 inhibited by thapsigargin ( E2(.)TG) both failed to cross-link to PLB. These results with transmembrane PLB residues are completely consistent with cytoplasmic PLB residues studied previously, suggesting that the dissociation of PLB from the Ca2+ pump is complete, not partial, when the pump binds Ca2+ (E1(.)Ca(2)) or adopts the E2P or E2(.)TG conformations. V49C of PLB cross-linked to 100% of SERCA2a molecules, suggesting that this residue might have functional importance for regulation. Indeed, we found that mutation of Val(49) to smaller side-chained residues V49A or V49G augmented PLB inhibition, whereas mutation to the larger hydrophobic residue, V49L, prevented PLB inhibition. A model for the interaction of PLB with SERCA2a is presented, showing that Val49 fits into a constriction at the lumenal end of the M2 helix of SERCA, possibly controlling access of PLB to its binding site on SERCA.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; New York Struct Biol Ctr, New York, NY 10027 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; New York University	Jones, LR (corresponding author), 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline; NIGMS NIH HHS [GM56960] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andronesi OC, 2005, J AM CHEM SOC, V127, P12965, DOI 10.1021/ja0530164; Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chen ZH, 2005, J BIOL CHEM, V280, P10530, DOI 10.1074/jbc.M414007200; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Haghighi K, 2004, BIOCHEM BIOPH RES CO, V322, P1214, DOI 10.1016/j.bbrc.2004.07.164; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; Hughes E, 2005, BIOCHEMISTRY-US, V44, P4055, DOI 10.1021/bi0482351; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; INESI G, 1994, J MEMBRANE BIOL, V141, P1; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kirby TL, 2004, BIOCHEMISTRY-US, V43, P5842, DOI 10.1021/bi035749b; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; Li JH, 2004, BIOCHEMISTRY-US, V43, P3870, DOI 10.1021/bi036183u; LICHTNER R, 1979, BIOCHEM J, V181, P759, DOI 10.1042/bj1810759; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Mueller B, 2004, BIOCHEMISTRY-US, V43, P8754, DOI 10.1021/bi049732k; NAPIER RM, 1987, BIOCHIM BIOPHYS ACTA, V903, P374, DOI 10.1016/0005-2736(87)90228-8; Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102; Picard M, 2006, J BIOL CHEM, V281, P3360, DOI 10.1074/jbc.M511385200; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Zamoon J, 2003, BIOPHYS J, V85, P2589, DOI 10.1016/S0006-3495(03)74681-5	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14163	14172		10.1074/jbc.M601338200	http://dx.doi.org/10.1074/jbc.M601338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554295	hybrid			2022-12-27	WOS:000237512300040
J	Suzuki, A; Ogura, T; Esumi, H				Suzuki, Atsushi; Ogura, Tsutomu; Esumi, Hiroyasu			NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; GLUCOSE STARVATION; TUMOR-SUPPRESSOR; DOCKING SITE; PHOSPHORYLATION; TOLERANCE; FAMILY; LKB1; REQUIREMENT	ARK5 is a tumor progression-associated factor that is directly phosphorylated by AKT at serine 600 in the regulatory domain, but phosphorylation at the conserved threonine residue on the active T loop has been found to be required for its full activation. In this study, we identified serine/threonine protein kinase NDR2 as a protein kinase that phosphorylates and activates ARK5 during insulin-like growth factor (IGF)-1 signaling. Upon stimulation with IGF-1, NDR2 was found to directly phosphorylate the conserved threonine 211 on the active T loop of ARK5 and to promote cell survival and invasion of colorectal cancer cell lines through ARK5. During IGF-1 signaling, phosphorylation at three residues (threonine 75, serine 282, and threonine 442) was also found to be required for NDR2 activation. Among these three residues, phosphorylation of serine 282 seemed to be the most important for NDR2 activation (the same as for the mouse homologue) because its aspartic acid-converted mutant (NDR2/S282D) induced ARK5-mediated cell survival and invasion activities even in the absence of IGF-1. As in the mouse homologue, threonine 75 in NDR2 was required for interaction with S100B, and binding was in a calcium ion- and phospholipase C-gamma-dependent manner. We also found that PDK-1 plays an important role in NDR2 activation especially in the phosphorylation of threonine 442. Based on the results of this study, we report here that NDR2 is an upstream kinase of ARK5 that plays an essential role in tumor progression through ARK5.	Natl Canc Ctr, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan; Natl Inst Physiol Sci, Dept Dev Physiol, Div Endocrinol & Metab, Okazaki, Aichi 4448585, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Bioinformat Sci, Kanazawa, Ishikawa 9201181, Japan	National Cancer Center - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Hokuriku University	Esumi, H (corresponding author), Natl Canc Ctr, Res Ctr Innovat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Chattopadhyay A, 2002, J CELL SCI, V115, P2233; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Fisher JS, 2005, AM J PHYSIOL-ENDOC M, V289, pE986, DOI 10.1152/ajpendo.00335.2004; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Stork O, 2004, J BIOL CHEM, V279, P45773, DOI 10.1074/jbc.M403552200; Suzuki A, 2005, ONCOGENE, V24, P6936, DOI 10.1038/sj.onc.1208844; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, BIOCHEM BIOPH RES CO, V311, P156, DOI 10.1016/j.bbrc.2003.09.184; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	40	24	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13915	13921		10.1074/jbc.M511354200	http://dx.doi.org/10.1074/jbc.M511354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16488889	hybrid			2022-12-27	WOS:000237512300012
J	Jia, HY; Bagherzadeh, A; Hartzoulakis, B; Jarvis, A; Loehr, M; Shaikh, S; Aqil, R; Cheng, LL; Tickner, M; Esposito, D; Harris, R; Driscoll, PC; Selwood, DL; Zachary, IC				Jia, HY; Bagherzadeh, A; Hartzoulakis, B; Jarvis, A; Loehr, M; Shaikh, S; Aqil, R; Cheng, LL; Tickner, M; Esposito, D; Harris, R; Driscoll, PC; Selwood, DL; Zachary, IC			Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor Exon 8 for NP-1 binding and role of NP-1 in KDR signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTACYCLIN PRODUCTION; CELL PROLIFERATION; CRYSTAL-STRUCTURE; VEGF RECEPTOR-1; TUMOR-CELLS; ORF VIRUS; DOMAIN; PROTEIN; ACTIVATION; SYSTEM	Neuropilin- 1 ( NP- 1) is a receptor for vascular endothelial growth factor- A(165)( VEGF- A(165)) in endothelial cells. To define the role of NP- 1 in the biological functions of VEGF, we developed a specific peptide antagonist of VEGF binding to NP- 1 based on the NP- 1 binding site located in the exon 7- and 8- encoded VEGF- A165 domain. The bicyclic peptide, EG3287, potently ( K-i 1.2 mu M) and effectively (> 95% inhibition at 100 mu M) inhibited VEGF- A(165) binding to porcine aortic endothelial cells expressing NP- 1 ( PAE/ NP- 1) and breast carcinoma cells expressing only NP- 1 receptors for VEGF- A, but had no effect on binding to PAE/ KDR or PAE/ Flt- 1. Molecular dynamics calculations, a nuclear magnetic resonance structure of EG3287, and determination of stability in media, indicated that it constitutes a stable subdomain very similar to the corresponding region of native VEGF- A(165). The C terminus encoded by exon 8 and the three- dimensional structure were both critical for EG3287 inhibition of NP- 1 binding, whereas modifications at the N terminus had little effect. Although EG3287 had no direct effect on VEGF- A(165) binding to KDR receptors, it inhibited cross- linking of VEGF- A(165) to KDR in human umbilical vein endothelial cells co- expressing NP- 1, and inhibited stimulation of KDR and PLC- gamma tyrosine phosphorylation, activation of ERKs1/ 2 and prostanoid production. These findings characterize the first specific antagonist of VEGF- A(165) binding to NP- 1 and demonstrate that NP- 1 is essential for optimum KDR activation and intracellular signaling. The results also identify a key role for the C- terminal exon 8 domain in VEGF- A(165) binding to NP-1.	UCL, BHF Labs, Dept Med, Ctr Cardiovasc Biol & Med, London WC1E 6JJ, England; UCL, Ark Therapeut Ltd, Rayne Inst, London WC1E 6JJ, England; UCL, Wolfson Inst Biomed Res, London WC1E GBT, England; NCE Discovery Ltd, Cambridge CB4 0PA, England; UCL, Dept Biochem & Mol Biol, Bloomsbury Ctr Struct Biol, London WC1E 6BT, England	University of London; University College London; University of London; King's College London; University College London; University of London; University College London; University of London; Birkbeck University London; University College London	Zachary, IC (corresponding author), UCL, BHF Labs, Dept Med, Ctr Cardiovasc Biol & Med, 5 Univ St, London WC1E 6JJ, England.	i.zachary@ucl.ac.uk	Selwood, David/C-1571-2008; Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950; Harris, Richard/0000-0001-7459-1745; Selwood, David/0000-0002-6817-5064	Medical Research Council [MC_U117533887, MC_U117574559] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Bates DO, 2002, CANCER RES, V62, P4123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cheng LL, 2004, J BIOL CHEM, V279, P30654, DOI 10.1074/jbc.M402488200; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Inai Y, 2003, BIOPOLYMERS, V70, P310, DOI 10.1002/bip.10390; Jia HY, 2004, J BIOL CHEM, V279, P36148, DOI 10.1074/jbc.M401538200; Joukov V, 1996, EMBO J, V15, P290; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PAGEL MD, 1994, PROTEINS, V18, P205, DOI 10.1002/prot.340180302; Peggion E, 2003, BIOPOLYMERS, V68, P437, DOI 10.1002/bip.10294; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SELWOOD D, 2003, Patent No. 03082918; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Song JX, 1997, BIOCHEMISTRY-US, V36, P3760, DOI 10.1021/bi962720h; Stams T, 1996, P NATL ACAD SCI USA, V93, P13589, DOI 10.1073/pnas.93.24.13589; Stauffer ME, 2002, J BIOMOL NMR, V23, P57, DOI 10.1023/A:1015346504499; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TISCHER E, 1991, J BIOL CHEM, V266, P11947; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	61	110	121	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13493	13502		10.1074/jbc.M512121200	http://dx.doi.org/10.1074/jbc.M512121200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16513643	hybrid			2022-12-27	WOS:000237336600057
J	Navarro, FJ; Machin, F; Martin, Y; Siverio, JM				Navarro, FJ; Machin, F; Martin, Y; Siverio, JM			Down-regulation of eukaryotic nitrate transporter by nitrogen-dependent ubiquitinylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HANSENULA-POLYMORPHA; PEST-LIKE SEQUENCE; AMINO-ACID PERMEASE; SACCHAROMYCES-CEREVISIAE; NICOTIANA-PLUMBAGINIFOLIA; CONSTITUTIVE EXPRESSION; NITRITE REDUCTASE; URACIL PERMEASE; ASSIMILATION; UBIQUITINATION	In the yeast Hansenula polymorpha, the YNT1 gene encodes the high affinity nitrate transporter, which is repressed by reduced nitrogen sources such as ammonium or glutamine. Ynt1 protein is degraded in response to glutamine in the growth medium. Ynt1 disappears independently of YNT1 glutamine repression as shown in strains where YNT1 repression is abolished. Ynt1-green fluorescent protein chimera and a mutant defective in vacuolar proteinase A ( Delta pep4) showed that Ynt1 is degraded in the vacuole in response to glutamine. The central hydrophilic domain of Ynt1 contains PEST-like sequences whose deletion blocked Ynt1 down-regulation. Site-directed mutagenesis showed that Lys-253 and Lys-270, located in this sequence, were involved in internalization and subsequent vacuolar degradation of Ynt1. Ynt1-ubiquitin conjugates were induced by glutamine and not nitrate. We conclude that glutamine triggers Ynt1 down-regulation via ubiquitinylation of lysines in the central hydrophilic domain, and proteolysis in the vacuole.	Univ La Laguna, Dept Bioquim & Biol Mol, Inst Univ Enfermedades Trop, E-38206 San Cristobal la Laguna, Tenerife, Spain	Universidad de la Laguna	Siverio, JM (corresponding author), Univ La Laguna, Dept Bioquim & Biol Mol, Inst Univ Enfermedades Trop, Av Astrofis Fco Sanchez S-N, E-38206 San Cristobal la Laguna, Tenerife, Spain.	jsiverio@ull.es	Machín, Félix/K-6569-2017	Machín, Félix/0000-0003-4559-7798; NAVARRO, FRANCISCO J./0000-0002-9332-0737				Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; Daniel-Vedele F, 1998, CURR OPIN PLANT BIOL, V1, P235, DOI 10.1016/S1369-5266(98)80110-6; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; Fraisier V, 2000, PLANT J, V23, P489, DOI 10.1046/j.1365-313x.2000.00813.x; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GODECKE S, 1994, GENE, V139, P35, DOI 10.1016/0378-1119(94)90520-7; GONZALEZ C, 1992, J GEN MICROBIOL, V138, P1445, DOI 10.1099/00221287-138-7-1445; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Kaiser WM, 2001, J EXP BOT, V52, P1981, DOI 10.1093/jexbot/52.363.1981; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; Liu KH, 2003, EMBO J, V22, P1005, DOI 10.1093/emboj/cdg118; Machin F, 2004, YEAST, V21, P265, DOI 10.1002/yea.1075; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Medintz I, 2000, BIOCHEMISTRY-US, V39, P4518, DOI 10.1021/bi992455a; Montanini B, 2006, BIOCHEM J, V394, P125, DOI 10.1042/BJ20051199; Navarro FJ, 2003, FEMS YEAST RES, V4, P149, DOI 10.1016/S1567-1356(03)00163-6; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Perdomo G, 2002, PLANT MOL BIOL, V50, P405, DOI 10.1023/A:1019814505677; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; Read ND, 2003, FUNGAL GENET BIOL, V39, P199, DOI 10.1016/S1087-1845(03)00045-8; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Sengupta S, 1997, FEBS LETT, V416, P51, DOI 10.1016/S0014-5793(97)01166-6; Siverio JM, 2002, FEMS MICROBIOL REV, V26, P277, DOI 10.1016/S0168-6445(02)00100-6; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Torralba S, 2002, FUNGAL GENET BIOL, V37, P221, DOI 10.1016/S1087-1845(02)00513-3; Unkles SE, 2001, EMBO J, V20, P6246, DOI 10.1093/emboj/20.22.6246; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VINCENTZ M, 1991, EMBO J, V10, P1027, DOI 10.1002/j.1460-2075.1991.tb08041.x; VOLLAND C, 1992, J BIOL CHEM, V267, P23767	41	24	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13268	13274		10.1074/jbc.M601253200	http://dx.doi.org/10.1074/jbc.M601253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543229	hybrid			2022-12-27	WOS:000237336600032
J	Tsai, HJ; Huang, WH; Li, TK; Tsai, YL; Wu, KJ; Tseng, SF; Teng, SC				Tsai, HJ; Huang, WH; Li, TK; Tsai, YL; Wu, KJ; Tseng, SF; Teng, SC			Involvement of topoisomerase III in telomere-telomere recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; SGS1 DNA HELICASE; HUMAN-CELLS; LACKING TELOMERASE; HOLLIDAY JUNCTIONS; RECQ HELICASES; YEAST; REPLICATION; MAINTENANCE; PATHWAYS	Telomere maintenance is required for chromosome stability, and telomeres are typically replicated by the action of telomerase. In both mammalian tumor and yeast cells that lack telomerase, telomeres are maintained by an alternative ( ALT) recombination mechanism. In yeast, Sgs1p and its associated type IA topoisomerase, Top3p, may work coordinately in removing Holliday junction intermediates from a crossover- producing recombination pathway. Previous studies have also indicated that Sgs1 helicase acts in a telomere recombination pathway. Here we show that topoisomerase III is involved in telomere- telomere recombination. The recovery of telomere recombination- dependent survivors in a telomerase- minus yeast strain was dependent on Top3p catalytic activity. Moreover, the RIF1 and RIF2 genes are required for the establishment of TOP3/ SGS1- dependent telomere-telomere recombination. In human Saos- 2 ALT cells, human topoisomerase III alpha( hTOP3 alpha) also contributes to telomere recombination. Strikingly, the telomerase activity is clearly enhanced in surviving si- hTOP3 alpha Saos- 2 ALT cells. Altogether, the present results suggest a potential role for hTOP3 alpha in dissociating telomeric structures in telomerase- deficient cells, providing therapeutic implications in human tumors.	Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10018, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Taiwan Univ Hosp, Inst Internal Med, Taipei 10018, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Teng, SC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Microbiol, 1,Sec 1,Jen Ai Rd, Taipei 10018, Taiwan.	scteng@ha.mc.ntu.edu.tw	Wu, Kou-Juey/P-4654-2015	LI, TSAI-KUN/0000-0003-0393-2340; Tsai, Hung-Ji/0000-0003-4192-9310; TENG, SHU-CHUN/0000-0002-6492-2560				Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bennett RJ, 2001, P NATL ACAD SCI USA, V98, P11108, DOI 10.1073/pnas.201387098; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Fourel G, 2002, BIOESSAYS, V24, P828, DOI 10.1002/bies.10139; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Le S, 1999, GENETICS, V152, P143; Levy DL, 2004, MOL CELL BIOL, V24, P10857, DOI 10.1128/MCB.24.24.10857-10867.2004; Liberi G, 2005, GENE DEV, V19, P339, DOI 10.1101/gad.322605; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liti G, 2003, MOL CELL, V11, P1373, DOI 10.1016/S1097-2765(03)00177-1; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meeker AK, 2002, CANCER RES, V62, P6405; Myung K, 2002, P NATL ACAD SCI USA, V99, P4500, DOI 10.1073/pnas.062702199; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Tsai YL, 2002, MOL CELL BIOL, V22, P5679, DOI 10.1128/MCB.22.16.5679-5687.2002; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Yeager TR, 1999, CANCER RES, V59, P4175; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	47	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13717	13723		10.1074/jbc.M600649200	http://dx.doi.org/10.1074/jbc.M600649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16546998	hybrid			2022-12-27	WOS:000237336600082
J	Yahata, Y; Shirakata, Y; Tokumaru, S; Yang, LJ; Dai, XJ; Tohyama, M; Tsuda, T; Sayama, K; Iwai, M; Horiuchi, M; Hashimoto, K				Yahata, Y; Shirakata, Y; Tokumaru, S; Yang, LJ; Dai, XJ; Tohyama, M; Tsuda, T; Sayama, K; Iwai, M; Horiuchi, M; Hashimoto, K			A novel function of angiotensin II in skin wound healing - Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated egf receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC FIBROBLASTS; CELL-PROLIFERATION; HAIR FOLLICLE; FACTOR-ALPHA; HB-EGF; MYOCYTES; METALLOPROTEINASE; MICE; HYPERTROPHY; EPIREGULIN	The role of angiotensin II ( Ang II) in the control of systemic blood pressure and volume homeostasis is well known and has been extensively studied. Recently, Ang II was suggested to also have a function in skin wound healing. In the present study, the in vivo function of Ang II in skin wound healing was investigated using Ang II type 1 receptor ( AT1R) knock-out mice. Wound healing in these mice was found to be markedly delayed. Keratinocytes and fibroblasts play important roles in wound healing, and thus the effect of Ang II on the migration of these cells was examined. Ang II stimulated keratinocyte and fibroblast migration in a dose-dependent manner. It has been reported that G protein-coupled receptor ( GPCR) activation induces epidermal growth factor ( EGF) receptor ( EGFR) transactivation through the shedding of heparin-binding EGF-like growth factor ( HB-EGF). As AT1R is a GPCR, it was hypothesized that Ang II-induced keratinocyte and fibroblast migration is mediated by EGFR transactivation. Ang II induced EGFR phosphorylation, which was inhibited by an AT1R antagonist, HB-EGF neutralizing antibody, and an HB-EGF antagonist in both keratinocytes and in fibroblasts. Moreover, Ang II-induced migration of keratinocytes and fibroblasts was also prevented by these inhibitors. Taken together, these findings clearly demonstrate, for the first time, that Ang II plays an important role in skin wound healing and that it functions by accelerating keratinocyte and fibroblast migration in a process mediated by HB-EGF shedding.	Ehime Univ, Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Ehime Univ, Sch Med, Div Med Biochem & Cardiovasc Biol, Toon, Ehime 7910295, Japan	Ehime University; Ehime University	Shirakata, Y (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Shitsukawa, Toon, Ehime 7910295, Japan.	shirakat@m.ehime-u.ac.jp						Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BOOZ GW, 1995, CARDIOVASC RES, V30, P537, DOI 10.1016/S0008-6363(96)88507-5; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; Fischer TA, 1997, AM J PHYSIOL-HEART C, V272, pH958, DOI 10.1152/ajpheart.1997.272.2.H958; HAHN AWA, 1993, J CARDIOVASC PHARM, V22, pS37, DOI 10.1097/00005344-199322005-00007; Hansen LA, 1997, AM J PATHOL, V150, P1959; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hashimoto K, 2000, J DERMATOL SCI, V24, pS46, DOI 10.1016/S0923-1811(00)00141-9; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; KIMURA B, 1992, BIOCHEM BIOPH RES CO, V187, P1083, DOI 10.1016/0006-291X(92)91308-D; KO Y, 1993, AM J HYPERTENS, V6, P496, DOI 10.1093/ajh/6.6.496; LAURENT GJ, 1987, AM J PHYSIOL, V252, pC1, DOI 10.1152/ajpcell.1987.252.1.C1; Lindblad William, 1998, Wound Repair and Regeneration, V6, P186, DOI 10.1046/j.1524-475X.1998.60304.x; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Mifune M, 2005, J BIOL CHEM, V280, P26592, DOI 10.1074/jbc.M502906200; Min LJ, 2004, ENDOCRINOLOGY, V145, P253, DOI 10.1210/en.2003-0673; Ohkubo N, 1997, CIRCULATION, V96, P3954; Okuyama N, 1999, ANN PLAS SURG, V42, P313, DOI 10.1097/00000637-199903000-00014; OWENS GK, 1985, CIRC RES, V56, P525, DOI 10.1161/01.RES.56.4.525; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Rodgers K, 2001, WOUND REPAIR REGEN, V9, P238, DOI 10.1046/j.1524-475x.2001.00238.x; Rodgers Kathleen E., 1997, Journal of Burn Care and Rehabilitation, V18, P381, DOI 10.1097/00004630-199709000-00002; SCHELLING P, 1979, J CELL PHYSIOL, V98, P503, DOI 10.1002/jcp.1040980309; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; Shirakata Y, 2005, J CELL SCI, V118, P2363, DOI 10.1242/jcs.02346; Shirakata Y, 2004, J DERMATOL SCI, V36, P41, DOI 10.1016/j.jdermsci.2004.07.002; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Shirasawa S, 2004, P NATL ACAD SCI USA, V101, P13921, DOI 10.1073/pnas.0404217101; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; SUN Y, 1994, J LAB CLIN MED, V123, P372; Takeda H, 2004, AM J PATHOL, V165, P1653, DOI 10.1016/S0002-9440(10)63422-0; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tsuzuki S, 1996, HYPERTENSION, V28, P916, DOI 10.1161/01.HYP.28.5.916; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	47	105	120	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13209	13216		10.1074/jbc.M509771200	http://dx.doi.org/10.1074/jbc.M509771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543233	hybrid			2022-12-27	WOS:000237336600026
J	Bakhrat, A; Baranes, K; Krichevsky, O; Rom, I; Schlenstedt, G; Pietrokovski, S; Raveh, D				Bakhrat, A; Baranes, K; Krichevsky, O; Rom, I; Schlenstedt, G; Pietrokovski, S; Raveh, D			Nuclear import of Ho endonuclease utilizes two nuclear localization signals and four importins of the ribosomal import system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; UBA PROTEIN DDI1; HOMING ENDONUCLEASE; CRYSTAL-STRUCTURE; EVOLUTION; SEQUENCE; INTEIN; GENE; EXPORT; DEGRADATION	Activity of Ho, the yeast mating switch endonuclease, is restricted to a narrow time window of the cell cycle. Ho is unstable and despite being a nuclear protein is exported to the cytoplasm for proteasomal degradation. We report here the molecular basis for the highly efficient nuclear import of Ho and the relation between its short half-life and passage through the nucleus. The Ho nuclear import machinery is functionally redundant, being based on two bipartite nuclear localization signals, recognized by four importins of the ribosomal import system. Ho degradation is regulated by the DNA damage response and Ho retained in the cytoplasm is stabilized, implying that Ho acquires its crucial degradation signals in the nucleus. Ho arose by domestication of a fungal VMA1 intein. A comparison of the primary sequences of Ho and fungal VMA1 inteins shows that the Ho nuclear localization signals are highly conserved in all Ho proteins, but are absent from VMA1 inteins. Thus adoption of a highly efficient import strategy occurred very early in the evolution of Ho. This may have been a crucial factor in establishment of homothallism in yeast, and a key event in the rise of the Saccharomyces sensu stricto.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Phys, IL-84105 Beer Sheva, Israel; Univ Saarland, Dept Med Biochem & Mol Biol, D-66421 Homburg, Germany; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Ben Gurion University; Ben Gurion University; Saarland University; Weizmann Institute of Science	Raveh, D (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	raveh@bgumail.bgu.ac.il	Raveh, Dina/A-7166-2012	Pietrokovski, Shmuel/0000-0001-8573-5863; Krichevsky, Oleg/0000-0002-6856-7551				Bakhrat A, 2004, GENETICS, V166, P721, DOI 10.1534/genetics.166.2.721; BUCHNIK R, 2000, THESIS B GURION U BE; Butler G, 2004, P NATL ACAD SCI USA, V101, P1632, DOI 10.1073/pnas.0304170101; Butler MI, 2005, FUNGAL GENET BIOL, V42, P452, DOI 10.1016/j.fgb.2005.01.011; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Fabre E, 2005, MOL BIOL EVOL, V22, P856, DOI 10.1093/molbev/msi070; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gimble FS, 2001, NUCLEIC ACIDS RES, V29, P4215, DOI 10.1093/nar/29.20.4215; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GU HH, 1993, J BIOL CHEM, V268, P7372; HENIKOFF S, 1995, GENE, V163, P17; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; HOOD JK, 2000, BIOCHIM BIOPHYS ACTA, V1471, P31; Ivantsiv Y, 2006, MOL CELL BIOL, V26, P1579, DOI 10.1128/MCB.26.5.1579-1588.2006; James P, 1996, GENETICS, V144, P1425; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; Kaplun L, 2005, MOL CELL BIOL, V25, P5355, DOI 10.1128/MCB.25.13.5355-5362.2005; Kaplun L, 2003, J BIOL CHEM, V278, P48727, DOI 10.1074/jbc.M308671200; Koufopanou V, 2005, MOL BIOL EVOL, V22, P1535, DOI 10.1093/molbev/msi149; Koufopanou V, 2002, MOL BIOL EVOL, V19, P239, DOI 10.1093/oxfordjournals.molbev.a004077; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Leslie DM, 2004, MOL CELL BIOL, V24, P8487, DOI 10.1128/MCB.24.19.8487-8503.2004; Leslie DM, 2002, MOL CELL BIOL, V22, P2544, DOI 10.1128/MCB.22.8.2544-2555.2002; Leung SW, 2003, J BIOL CHEM, V278, P41947, DOI 10.1074/jbc.M307162200; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Moure CM, 2002, NAT STRUCT BIOL, V9, P764, DOI 10.1038/nsb840; Nagai Y, 2003, MOL CELL BIOL, V23, P1726, DOI 10.1128/MCB.23.5.1726-1736.2003; Nahon E, 1998, NUCLEIC ACIDS RES, V26, P1233, DOI 10.1093/nar/26.5.1233; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Posey KL, 2004, NUCLEIC ACIDS RES, V32, P3947, DOI 10.1093/nar/gkh734; RAVEH D, 1989, MOL GEN GENET, V220, P33; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; Schaper S, 2005, J CELL SCI, V118, P1473, DOI 10.1242/jcs.01739; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Sydorskyy Y, 2003, MOL CELL BIOL, V23, P2042, DOI 10.1128/MCB.23.6.2042-2054.2003; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	56	13	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12218	12226		10.1074/jbc.M600238200	http://dx.doi.org/10.1074/jbc.M600238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507575	hybrid			2022-12-27	WOS:000237134700004
J	Miedel, MT; Weixel, KM; Bruns, JR; Traub, LM; Weisz, OA				Miedel, MT; Weixel, KM; Bruns, JR; Traub, LM; Weisz, OA			Posttranslational cleavage and adaptor protein complex-dependent trafficking of mucolipin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CATION CHANNEL; MUTATIONS; IV; IDENTIFICATION; TRANSPORT; TRP-ML1; SIGNALS; PH	Mucolipin-1 (ML1) is a member of the transient receptor potential ion channel superfamily that is thought to function in the biogenesis of lysosomes. Mutations in ML1 result in mucolipidosis type IV, a lysosomal storage disease characterized by the intracellular accumulation of enlarged vacuolar structures containing phospholipids, sphingolipids, and mucopolysaccharides. Little is known about how ML1 trafficking or activity is regulated. Here we have examined the processing and trafficking of ML1 in a variety of cell types. We find that a significant fraction of ML1 undergoes cell type-independent cleavage within the first extracellular loop of the protein during a late step in its biosynthetic delivery. To determine the trafficking route of ML1, we systematically examined the effect of ablating adaptor protein complexes on the localization of this protein. Whereas ML1 trafficking was not apparently affected in fibroblasts from mocha mice that lack functional adaptor protein complex (AP)-3, small interfering RNA-mediated knockdown revealed a requirement for AP-1 in Golgi export of ML1. Knockdown of functional AP-2 had no effect on ML1 localization. Interestingly, cleavage of ML1 was not compromised in AP-1-deficient cells, suggesting that proteolysis occurs in a prelysosomal compartment, possibly the trans-Golgi network. Our results suggest that posttranslational processing of ML1 is more complex than previously described and that this protein is delivered to lysosomes primarily via an AP-1-dependent route that does not involve passage via the cell surface.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, 3550 Terrace Sr, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Traub, Linton/0000-0002-1303-0298; Miedel, Mark/0000-0002-0132-6032	NIDDK NIH HHS [T32-DK61296, R01-DK54407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443; Bargal R, 2002, NEUROPEDIATRICS, V33, P199, DOI 10.1055/s-2002-34496; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cantiello HF, 2005, PFLUG ARCH EUR J PHY, V451, P304, DOI 10.1007/s00424-005-1448-9; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Di Palma F, 2002, P NATL ACAD SCI USA, V99, P14994, DOI 10.1073/pnas.222425399; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; Huang CL, 2004, J AM SOC NEPHROL, V15, P1690, DOI 10.1097/01.ASN.0000129115.69395.65; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Piper RC, 2004, TRENDS CELL BIOL, V14, P471, DOI 10.1016/j.tcb.2004.07.010; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; Vergarajauregui S, 2006, TRAFFIC, V7, P337, DOI 10.1111/j.1600-0854.2006.00387.x; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Yang W, 2000, J CELL SCI, V113, P4077	32	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12751	12759		10.1074/jbc.M511104200	http://dx.doi.org/10.1074/jbc.M511104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517607	hybrid			2022-12-27	WOS:000237134700068
J	Eltit, JM; Garcia, AA; Hidalgo, J; Liberona, JL; Chiong, M; Lavandero, S; Maldonado, E; Jaimovich, E				Eltit, JM; Garcia, AA; Hidalgo, J; Liberona, JL; Chiong, M; Lavandero, S; Maldonado, E; Jaimovich, E			Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a G beta gamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; MUSCLE DIHYDROPYRIDINE RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; ELEMENT-BINDING PROTEIN; II-III LOOP; PHOSPHOINOSITIDE 3-KINASE-GAMMA; PHOSPHOLIPASE-C; RYANODINE RECEPTOR; CALCIUM CHANNELS; IP3 RECEPTORS	Tetanic electrical stimulation of myotubes evokes a ryanodine receptor-related fast calcium signal, during the stimulation, followed by a phospholipase C/inositol 1,4,5-trisphosphate-dependent slow calcium signal few seconds after stimulus end. L-type calcium channels (Cav 1.1, dihydropyridine receptors) acting as voltage sensors activate an unknown signaling pathway involved in phospholipase C activation. We demonstrated that both G protein and phosphatidylinositol 3- kinase were activated by electrical stimulation, and both the inositol 1,4,5-trisphosphate rise and slow calcium signal induced by electrical stimulation were blocked by pertussis toxin, by a G beta gamma scavenger peptide, and by phosphatidylinositol 3- kinase inhibitors. Immunofluorescence using anti-phosphatidylinositol 3- kinase gamma antibodies showed a clear location in striations within the cytoplasm, consistent with a position near the I band region of the sarcomere. The time course of phosphatidylinositol 3- kinase activation, monitored in single living cells using a pleckstrin homology domain fused to green fluorescent protein, was compatible with sequential phospholipase C gamma 1 activation as confirmed by phosphorylation assays for the enzyme. Co-transfection of a dominant negative form of phosphatidylinositol 3- kinase gamma inhibited the phosphatidylinositol 3- kinase activity as well as the slow calcium signal. We conclude that G beta gamma/phosphatidylinositol 3- kinase gamma signaling pathway is involved in phospholipase C activation and the generation of the slow calcium signal induced by tetanic stimulation. We postulate that membrane potential fluctuations in skeletal muscle cells can activate a pertussis toxin-sensitive G protein, phosphatidylinositol 3- kinase, phospholipase C pathway toward modulation of long term, activity-dependent plastic changes.	Univ Chile, Fac Med, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Santiago 7, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Santiago 7, Chile	Universidad de Chile; Universidad de Chile	Jaimovich, E (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Independecia 1027, Santiago 7, Chile.	ejaimovi@med.uchile.cl	Chiong, M./ABH-5784-2020; Jaimovich, Enrique/AAY-7632-2020; Lavandero, Sergio/B-6001-2013; Chiong, Mario/I-1043-2013	Chiong, M./0000-0002-5174-6545; Lavandero, Sergio/0000-0003-4258-1483; Chiong, Mario/0000-0002-5174-6545	FIC NIH HHS [R03TW07053-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anis Y, 1999, J BIOL CHEM, V274, P7431, DOI 10.1074/jbc.274.11.7431; Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; Bell DC, 2001, J NEUROPHYSIOL, V85, P816, DOI 10.1152/jn.2001.85.2.816; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cardenas C, 2005, J CELL SCI, V118, P3131, DOI 10.1242/jcs.02446; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Carrasco MA, 2003, AM J PHYSIOL-CELL PH, V284, pC1438, DOI 10.1152/ajpcell.00117.2002; CARRASCO MA, 1994, ARCH BIOCHEM BIOPHYS, V310, P76, DOI 10.1006/abbi.1994.1142; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Eltit JM, 2004, BIOPHYS J, V86, P3042, DOI 10.1016/S0006-3495(04)74353-2; FOSSET M, 1983, J BIOL CHEM, V258, P6086; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Le Blanc C, 2004, CIRC RES, V95, P300, DOI 10.1161/01.RES.0000138017.76125.8b; LERCHE H, 1995, PFLUG ARCH EUR J PHY, V429, P738, DOI 10.1007/BF00373997; MILTING H, 1994, FEBS LETT, V345, P211, DOI 10.1016/0014-5793(94)00440-4; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Powell JA, 2003, J NEUROSCI, V23, P8185; Powell JA, 2001, J CELL SCI, V114, P3673; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Shah AS, 2001, CIRCULATION, V103, P1311; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TOUTANT M, 1990, EMBO J, V9, P363, DOI 10.1002/j.1460-2075.1990.tb08119.x; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vecchione C, 2005, J EXP MED, V201, P1217, DOI 10.1084/jem.20040995; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	47	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12143	12154		10.1074/jbc.M511218200	http://dx.doi.org/10.1074/jbc.M511218200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513646	hybrid			2022-12-27	WOS:000236988100084
J	Giaime, E; Sunyach, C; Herrant, M; Grosso, S; Auberger, P; McLean, PJ; Checler, F; da Costa, CA				Giaime, E; Sunyach, C; Herrant, M; Grosso, S; Auberger, P; McLean, PJ; Checler, F; da Costa, CA			Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-SYNUCLEIN AGGREGATION; PARKINSONS-DISEASE; MOLECULAR PATHWAYS; NEURONAL CELLS; LEWY BODIES; WILD-TYPE; APOPTOSIS; MUTATION; DOPAMINE	Parkinson disease is the second most frequent neurodegenerative disorder after Alzheimer disease. A subset of genetic forms of Parkinson disease has been attributed to alpha-synuclein, a synaptic protein with remarkable chaperone properties. Synphilin-1 is a cytoplasmic protein that has been identified as a partner of alpha-synuclein ( Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F., Dawson, V. L., Dawson, T. M., and Ross, C. A. ( 1999) Nat. Gen. 22, 110-114), but its function remains totally unknown. We show here for the first time that synphilin-1 displays an antiapoptotic function in the control of cell death. We have established transient and stable transfectants overexpressing wild-type synphilin-1 in human embryonic kidney 293 cells, telecephalon-specific murine 1 neurons, and SH-SY5Y neuroblastoma cells, and we show that both cell systems display lower responsiveness to staurosporine and 6-hydroxydopamine. Thus, synphilin-1 reduces procaspase-3 hydrolysis and thereby caspase-3 activity and decreases poly( ADP-ribose) polymerase cleavage, two main indicators of apoptotic cell death. Furthermore, we establish that synphilin-1 drastically reduces p53 transcriptional activity and expression and lowers p53 promoter transactivation and mRNA levels. Interestingly, we demonstrate that synphilin-1 catabolism is enhanced by staurosporine and blocked by caspase-3 inhibitors. Accordingly, we show by transcription/translation assay that recombinant caspase-3 and, to a lesser extent, caspase-6 but not caspase-7 hydrolyze synphilin-1. Furthermore, we demonstrate that mutated synphilin-1, in which a consensus caspase-3 target sequence has been disrupted, resists proteolysis by cellular and recombinant caspases and displays drastically reduced antiapoptotic phenotype. We further show that the caspase-3-derived C-terminal fragment of synphilin-1 was probably responsible for the antiapoptotic phenotype elicited by the parent wild-type protein. Altogether, our study is the first demonstration that synphilin-1 harbors a protective function that is controlled by the C-terminal fragment generated by its proteolysis by caspase-3.	Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097,Equipe Labellisee Fdn Rech Med, F-06560 Valbonne, France; INSERM, Fac Med, U526, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; Massachusetts Gen Hosp, Dept Neurol, Alzheimer Dis Res Unit, Charlestown, MA 02129 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Massachusetts General Hospital	Checler, F (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097,Equipe Labellisee Fdn Rech Med, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr; acosta@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; AUBERGER, Patrick/G-1491-2013; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; AUBERGER, Patrick/0000-0002-2481-8275; da Costa, Cristine Alves/0000-0002-7777-005X; McLean, Pamela/0000-0003-4870-5715				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Gasser T, 2005, CURR OPIN NEUROL, V18, P363, DOI 10.1097/01.wco.0000170951.08924.3d; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Kahns S, 2003, J BIOL CHEM, V278, P23376, DOI 10.1074/jbc.M300495200; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; KHAN NL, 2004, HOSP PHARM, V11, P9; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee SJ, 2003, ANTIOXID REDOX SIGN, V5, P337, DOI 10.1089/152308603322110904; Lev N, 2003, PROG NEURO-PSYCHOPH, V27, P245, DOI 10.1016/S0278-5846(03)00019-8; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Marambaud P, 1998, BIOCHEM BIOPH RES CO, V252, P134, DOI 10.1006/bbrc.1998.9619; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Maruyama Wakako, 2002, Journal of Neurology, V249, P6; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Morris HR, 2005, ANN MED, V37, P86, DOI 10.1080/07853890510007269; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; Pankratz N, 2002, AM J HUM GENET, V71, P124, DOI 10.1086/341282; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajagopalan S, 2001, MECH AGEING DEV, V122, P1499, DOI 10.1016/S0047-6374(01)00283-4; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tanaka K, 2004, BBA-MOL CELL RES, V1695, P235, DOI 10.1016/j.bbamcr.2004.09.026; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Vaux DL, 1999, CELL DEATH DIFFER, V6, P493, DOI 10.1038/sj.cdd.4400523; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	64	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11515	11522		10.1074/jbc.M508619200	http://dx.doi.org/10.1074/jbc.M508619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495229	hybrid			2022-12-27	WOS:000236988100013
J	Hsu, T; Adereth, Y; Kose, N; Dammai, V				Hsu, T; Adereth, Y; Kose, N; Dammai, V			Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RENAL-CARCINOMA CELLS; TRACHEAL DEVELOPMENT; SIGNAL-TRANSDUCTION; FIBRONECTIN MATRIX; LIGASE COMPLEX; FGF RECEPTORS; IN-VITRO; VHL GENE; DISEASE	The tumor suppressor VHL ( von Hippel-Lindau protein) serves as a negative regulator of hypoxia-inducible factor-alpha subunits. However, accumulated evidence indicates that VHL may play additional roles in other cellular functions. We report here a novel hypoxia- inducible factor- independent function of VHL in cell motility control via regulation of fibroblast growth factor receptor 1 ( FGFR1) endocytosis. In VHL null tumor cells or VHL knock-down cells, FGFR1 internalization is defective, leading to surface accumulation and abnormal activation of FGFR1. The enhanced FGFR1 activity directly correlates with increased cell migration. VHL disease mutants, in two of the mutation hot spots favoring development of renal cell carcinoma, failed to rescue the above phenotype. Interestingly, surface accumulation of the chemotactic receptor appears to be selective in VHL mutant cells, since other surface proteins such as epidermal growth factor receptor, platelet-derived growth factor receptor, IGFR1, and c-Met are not affected. We demonstrate that 1) FGFR1 endocytosis is defective in the VHL mutant and is rescued by reexpression of wild-type VHL, 2) VHL is recruited to FGFR1-containing, but not EGFR-containing, endosomal vesicles, 3) VHL exhibits a functional relationship with Rab5a and dynamin 2 in FGFR1 internalization, and 4) the endocytic function of VHL is mediated through the metastasis suppressor Nm23, a protein known to regulate dynamin-dependent endocytosis.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Dammai, V (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 86 Jonathan Lucas St,HCC321, Charleston, SC 29425 USA.	dammaiv@musc.edu		Hsu, Tien/0000-0003-2308-4297	NCI NIH HHS [R01 CA109860, P01 CA078582, R01CA109860, P01 CA078582-070005, R01 CA109860-03, P01CA78582] Funding Source: Medline; NIGMS NIH HHS [R01 GM057843-07, R01 GM057843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582, R01CA109860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adereth Y, 2005, BIOTECHNIQUES, V38, P864, DOI 10.2144/05386BM03; Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Chen HY, 2003, BIOCHEM J, V370, P1039, DOI 10.1042/BJ20021308; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Dammai V, 2003, GENE DEV, V17, P2812, DOI 10.1101/gad.1096903; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Deitcher D, 2001, TRENDS NEUROSCI, V24, P625, DOI 10.1016/S0166-2236(00)01927-5; Duclos S, 2003, J CELL SCI, V116, P907, DOI 10.1242/jcs.00259; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fuchs M, 2004, CELL MOTIL CYTOSKEL, V59, P50, DOI 10.1002/cm.20019; Gemmill RM, 2005, BRIT J CANCER, V92, P2266, DOI 10.1038/sj.bjc.6602646; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamada M, 2001, CANCER RES, V61, P4184; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Matsuno K, 2003, J MED CHEM, V46, P4910, DOI 10.1021/jm020505v; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miura Y, 2003, JPN J OPHTHALMOL, V47, P268, DOI 10.1016/S0021-5155(03)00003-0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; Reilly JF, 2004, DNA CELL BIOL, V23, P538, DOI 10.1089/1044549041939223; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Ueda H, 1998, J CLIN INVEST, V102, P804, DOI 10.1172/JCI3273; UENO H, 1992, J BIOL CHEM, V267, P1470; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wright G, 2003, J BIOL CHEM, V278, P20235, DOI 10.1074/jbc.M301391200; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zaman GJR, 1999, BIOCHEM PHARMACOL, V57, P57, DOI 10.1016/S0006-2952(98)00271-8; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	61	54	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12069	12080		10.1074/jbc.M511621200	http://dx.doi.org/10.1074/jbc.M511621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505488	Green Accepted, hybrid			2022-12-27	WOS:000236988100077
J	Schroder, HC; Boreiko, A; Korzhev, M; Tahir, MN; Tremel, W; Eckert, C; Ushijima, H; Muller, IM; Muller, WEG				Schroder, HC; Boreiko, A; Korzhev, M; Tahir, MN; Tremel, W; Eckert, C; Ushijima, H; Muller, IM; Muller, WEG			Co-expression and functional interaction of silicatein with galectin - Matrix-guided formation of siliceous spicules in the marine demosponge Suberites domuncula	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEODIA-CYDONIUM; SPONGE CELLS; EXPRESSION; BIOSILICA; PROTEIN; POLYMERIZATION; PRIMMORPHS; COLLAGENS; INDUCTION; TISSUE	Sponges ( phylum Porifera) of the class of Demospongiae are stabilized by a siliceous skeleton. It is composed of silica needles (spicules), which provide the morphogenetic scaffold of these metazoans. In the center of the spicules there is an axial filament that consists predominantly of silicatein, an enzyme that catalyzes the synthesis of biosilica. By differential display of transcripts we identified additional proteins involved in silica formation. Two genes were isolated from the marine demosponge Suberites domuncula; one codes for a galectin and the other for a fibrillar collagen. The galectin forms aggregates to which silicatein molecules bind. The extent of the silicatein-mediated silica formation strongly increased if associated with the galectin. By applying a new and mild extraction procedure that avoids hydrogen fluoride treatment, native axial filaments were extracted from spicules of S. domuncula. These filaments contained, in addition to silicatein, the galectin and a few other proteins. Immunogold electron microscopic studies underscored the role of these additional proteins, in particular that of galectin, in spiculogenesis. Galectin, in addition to silicatein, presumably forms in the axial canal as well as on the surface of the spicules an organized net-like matrix. In the extraspicular space most of these complexes are arranged concentrically around the spicules. Taken together, these additional proteins, working together with silicatein, may also be relevant for potential ( nano)biotechnological applications of silicatein in the formation of surface coatings. Finally, we propose a scheme that outlines the matrix (galectin/silicatein)-guided appositional growth of spicules through centripetal and centrifugal synthesis and deposition of biosilica.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Anorgan Chem & Analyt Chem, D-55099 Mainz, Germany; Univ Berlin, Museum Naturkunde, Inst Systemat Zool, D-10115 Berlin, Germany; Univ Tokyo, Dept Dev Med Sci, Inst Int Hlth, Grad Sch Med,Bunkyo Ku, Tokyo 1130033, Japan	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Leibniz Institut fur Evolutions und Biodiversitatsforschung; University of Tokyo	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	wmueller@uni-mainz.de	Tremel, Wolfgang/D-8125-2011; Tahir, Muhammad Nawaz/F-2900-2015; Tremel, Wolfgang/AAT-1137-2021; Müller, W. E. G./AAR-8651-2020; Tahir, Muhammad Nawaz/B-2001-2016; tahir, Muhammad Nawaz/B-7650-2011	Tremel, Wolfgang/0000-0002-4536-994X; Müller, W. E. G./0000-0002-8223-3689; Tahir, Muhammad Nawaz/0000-0002-9031-5537; Schroder, Heinz C./0000-0003-0992-6427				[Anonymous], 2004, CURRENT PROTOCOLS MO; Bergquist P.R., 1978, SPONGES; Butschli O, 1901, Z WISS ZOOL ABT A, V69, P235; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Coligan J.E., 2000, CURRENT PROTOCOLS PR; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; CONNES R, 1980, ARCH ZOOL EXP GEN, V121, P213; CROOCKEWIT JH, 1843, LIEBIGS ANN CHEM, V48, P43; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DIEHLSEIFERT B, 1985, J CELL SCI, V79, P271; DIEHLSEIFERT B, 1985, EUR J BIOCHEM, V147, P517; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; Garrone R, 1998, Prog Mol Subcell Biol, V21, P119; Garrone R., 1984, P461; Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002; GROSS J, 1956, J HISTOCHEM CYTOCHEM, V4, P227, DOI 10.1177/4.3.227; Klein SL, 2002, DEV DYNAM, V225, P384, DOI 10.1002/dvdy.10174; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Krasko A, 2002, DNA CELL BIOL, V21, P67, DOI 10.1089/10445490252810320; Krasko A, 2000, EUR J BIOCHEM, V267, P4878, DOI 10.1046/j.1432-1327.2000.01547.x; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; Kruse M, 1999, J CELL SCI, V112, P4305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minchin E. A., 1909, Ergebnisse der Zoologie Jena, V2; MULLER W, 1968, Senckenbergiana Biologica, V49, P469; Muller WEG, 2006, MICRON, V37, P107, DOI 10.1016/j.micron.2005.09.003; Muller WEG, 2005, FEBS J, V272, P3838, DOI 10.1111/j.1742-4658.2005.04795.x; Muller WEG, 2005, CELL TISSUE RES, V321, P285, DOI 10.1007/s00441-005-1141-5; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; Muller WEG, 2002, IMMUNOGENETICS, V54, P48, DOI 10.1007/s00251-002-0441-0; Muller WEG, 1997, TRENDS GLYCOSCI GLYC, V9, P123; MULLER WEG, 2004, Patent No. 1320624; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Schroder HC, 2000, FASEB J, V14, P2022, DOI 10.1096/fj.00-0043com; Schulze F. E., 1887, REPORT SCI RESULTS V, V21, P513; Schulze FE, 1889, BEZEICHNUNG SPONGIEN; Schutze J, 2001, J MOL EVOL, V53, P402, DOI 10.1007/s002390010230; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; Simpson T., 1984, CELL BIOL SPONGES; STANLEY PE, 1990, BIOLUMINESCENCE CHEM; Tahir MN, 2005, CHEM COMMUN, P5533, DOI 10.1039/b510113a; Tahir MN, 2004, CHEM COMMUN, P2848, DOI 10.1039/b410283e; Uriz MJ, 2000, CELL TISSUE RES, V301, P299, DOI 10.1007/s004410000234; Weaver JC, 2003, MICROSC RES TECHNIQ, V62, P356, DOI 10.1002/jemt.10401; Weissenfels N., 1989, BIOL MIKROSKOPISCHE; Wiens M, 2005, J BIOL CHEM, V280, P27949, DOI 10.1074/jbc.M504049200; Wiens M, 2003, J MOL EVOL, V57, pS60, DOI 10.1007/s00239-003-0008-1; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; Yoneda C, 1999, EUR J BIOCHEM, V261, P714, DOI 10.1046/j.1432-1327.1999.00313.x	51	100	107	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12001	12009		10.1074/jbc.M512677200	http://dx.doi.org/10.1074/jbc.M512677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495220	hybrid			2022-12-27	WOS:000236988100070
J	Kaus, S; Castellone, MD; Bedell, VM; Konar, M; Gutkind, JS; Ramchandran, R				Kaus, S; Castellone, MD; Bedell, VM; Konar, M; Gutkind, JS; Ramchandran, R			Robo4 signaling in endothelial cells implies attraction guidance mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGIC ROUNDABOUT; AXON GUIDANCE; RHO-GTPASES; SLIT; ZEBRAFISH; RECEPTORS; MIGRATION; PROTEINS; ANGIOGENESIS; CDC42	Roundabouts (robo) are cell-surface receptors that mediate repulsive signaling mechanisms at the central nervous system midline. However, robos may also mediate attraction mechanisms in the context of vascular development. Here, we have performed structure-function analysis of roundabout4 (Robo4), the predominant robo expressed in embryonic zebrafish vasculature and found by gain of function approaches in vitro that Robo4 activates Cdc42 and Rac1 Rho GTPases in endothelial cells. Indeed, complementary robo4 gene knockdown approaches in zebrafish embryos show lower amounts of active Cdc42 and Rac1 and angioblasts isolated from these knockdown embryos search actively for directionality and guidance cues. Furthermore, Robo4-expressing endothelial cells show morphology and phenotype, characteristic of Rho GTPase activation. Taken together, this study suggests that Robo4 mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance.	NIH, Pathol Lab, NCI, Rockville, MD 20850 USA; NIDCR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ramchandran, R (corresponding author), NIH, Pathol Lab, NCI, Key W Facil,Room 320,9610 Med Ctr Dr, Rockville, MD 20850 USA.	ramchanr@mail.nih.gov	Gutkind, J. Silvio/A-1053-2009; Xiao, Yang/B-5668-2012; Gutkind, J. Silvio/J-1201-2016; Kaur, Sukhbir/ADW-6023-2022	Gutkind, J. Silvio/0000-0002-5150-4482; Kaur, Sukhbir/0000-0003-0513-6225; Bedell, Victoria/0000-0002-8959-6431; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [K22 CA095325-02, K22 CA095325-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010651, K22CA095325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bedell VM, 2005, P NATL ACAD SCI USA, V102, P6373, DOI 10.1073/pnas.0408318102; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Challa AK, 2001, MECH DEVELOP, V101, P249, DOI 10.1016/S0925-4773(00)00570-0; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Englund C, 2002, DEVELOPMENT, V129, P4941; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ghose A, 2002, BIOESSAYS, V24, P401, DOI 10.1002/bies.10080; Gorn M, 2005, LUNG CANCER-J IASLC, V49, P71, DOI 10.1016/j.lungcan.2004.12.005; Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Hu HL, 2005, P NATL ACAD SCI USA, V102, P4613, DOI 10.1073/pnas.0409325102; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hutson LD, 2003, DEV DYNAM, V228, P358, DOI 10.1002/dvdy.10386; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lee JS, 2001, DEV DYNAM, V221, P216, DOI 10.1002/dvdy.1136; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Sang Q, 2002, MOL CELL NEUROSCI, V21, P250, DOI 10.1006/mcne.2002.1156; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Yarar D, 2002, MOL BIOL CELL, V13, P4045, DOI 10.1091/mbc.E02-05-0294; Yeo SY, 2001, DEV BIOL, V230, P1, DOI 10.1006/dbio.2000.0105	36	68	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11347	11356		10.1074/jbc.M508853200	http://dx.doi.org/10.1074/jbc.M508853200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481322	hybrid			2022-12-27	WOS:000236822200077
J	Garcia-Martin, A; Kwa, LG; Strohmann, B; Robert, B; Holzwarth, AR; Braun, P				Garcia-Martin, A; Kwa, LG; Strohmann, B; Robert, B; Holzwarth, AR; Braun, P			Structural role of (bacterio)chlorophyll ligated in the energetically unfavorable beta-position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; BACTERIOCHLOROPHYLL-BINDING-SITE; RHODOBACTER-SPHAEROIDES R-26; MEMBRANE-PROTEINS; CRYSTAL-STRUCTURE; PHOTOSYSTEM-I; DIASTEREOTOPIC LIGATION; TRANSMEMBRANE HELIX; CIRCULAR-DICHROISM; REACTION CENTERS	Chlorophyll is attached to apoprotein in diastereotopically distinct ways, by beta- and alpha-ligation. Both the beta- and alpha-ligated chlorophylls of photosystem I are shown to have ample contacts to apoprotein within their proteinaceous binding sites, in particular, at C-13 of the isocyclic ring. The H-bonding patterns for the C-13(1) oxo groups, however, are clearly distinct for the beta-ligated and alpha-ligated chlorophylls. The beta-ligated chlorophylls frequently employ their C-13(1) oxo in H-bonds to neighboring helices and subunits. In contrast, the C-13(1) oxo of alpha-ligated chlorophylls are significantly less involved in H-bonding interactions, particularly to neighboring helices. Remarkably, in the peripheral antenna, light harvesting complex (LH2) from Rhodobacter sphaeroides, a single mutation in the alpha-subunit, introduced to eliminate H-bonding to the beta-bacteriochlorophyll-B850, which is ligated in the "beta-position," results in significant thermal destabilization of the LH2 in the membrane. In addition, in comparison with wild type LH2, the expression level of the LH2 lacking this H-bond is significantly reduced. These findings show that H-bonding to the C-13(1) keto group of beta-ligated(bacterio)-chlorophyll is a key structural motif and significantly contributes to the stability of bacteriochlorophyll proteins in the native membrane. Our analysis of photosystem I and II suggests that this hitherto unrecognized motif involving H-bonding to beta-ligated chlorophylls may be equally critical for the stable assembly of the inner core antenna of these multicomponent chlorophyll proteins.	Univ Munich, Dept 1, D-80638 Munich, Germany; Ctr Etud Saclay, CEA, DBJC, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Braun, P (corresponding author), Univ Munich, Dept 1, D-80638 Munich, Germany.	paula.braun@lrz.uni-muenchen.de	Robert, Bruno/D-1264-2012; Holzwarth, Alfred R/G-2704-2013; Holzwarth, Alfred/ABE-7424-2020	Robert, Bruno/0000-0001-5999-4538; Holzwarth, Alfred/0000-0002-9562-4873; GARCIA MARTIN, ADELA MARIA/0000-0001-7054-7907				Adamian L, 2003, J MOL BIOL, V327, P251, DOI 10.1016/S0022-2836(03)00041-X; Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; Balaban TS, 2005, PHOTOSYNTH RES, V86, P251, DOI 10.1007/s11120-005-4732-9; Balaban TS, 2002, BBA-BIOENERGETICS, V1556, P197, DOI 10.1016/S0005-2728(02)00363-8; Balaban TS, 2003, FEBS LETT, V545, P97, DOI 10.1016/S0014-5793(03)00531-3; Bandilla M, 1998, BBA-BIOENERGETICS, V1364, P390, DOI 10.1016/S0005-2728(98)00086-3; Barber J, 2000, BBA-BIOENERGETICS, V1459, P239, DOI 10.1016/S0005-2728(00)00158-4; BRAUN P, 1990, BIOCHEMISTRY-US, V29, P10376, DOI 10.1021/bi00497a012; BRAUN P, 1991, BIOCHEMISTRY-US, V30, P5177, DOI 10.1021/bi00235a010; Braun P, 2003, BBA-BIOENERGETICS, V1607, P19, DOI 10.1016/j.bbabio.2003.08.004; Braun P, 2002, J MOL BIOL, V318, P1085, DOI 10.1016/S0022-2836(02)00192-4; Camara-Artigas A, 2003, PHOTOSYNTH RES, V75, P49, DOI 10.1023/A:1022406703110; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CLAYTON RK, 1981, P NATL ACAD SCI-BIOL, V78, P5583, DOI 10.1073/pnas.78.9.5583; COGDELL RJ, 1985, PHOTOCHEM PHOTOBIOL, V42, P669, DOI 10.1111/j.1751-1097.1985.tb01629.x; COLEMAN WJ, 1990, ANNU REV BIOPHYS BIO, V19, P333; DeGrado WF, 2003, PROTEIN SCI, V12, P647, DOI 10.1110/ps.0236503; Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; Encinar JA, 2005, FEBS LETT, V579, P5199, DOI 10.1016/j.febslet.2005.08.038; Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; FOWLER GJS, 1995, J BIOL CHEM, V270, P23875, DOI 10.1074/jbc.270.40.23875; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gall A, 2003, BIOCHEMISTRY-US, V42, P7252, DOI 10.1021/bi0268293; Gall A, 1997, BIOCHEMISTRY-US, V36, P16282, DOI 10.1021/bi9717237; GARCIAMARTIN A, 2005, CHLOROPHYLLS BACTERI; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Ho BK, 2002, J MOL BIOL, V317, P291, DOI 10.1006/jmbi.2001.5385; Ishimura M, 1995, THERMOCHIM ACTA, V266, P355, DOI 10.1016/0040-6031(95)02443-3; Ivancich A, 1998, BIOCHEMISTRY-US, V37, P11812, DOI 10.1021/bi9806908; Janovjak H, 2005, BIOPHYS J, V88, P1423, DOI 10.1529/biophysj.104.052746; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kashiwada A, 1999, CHEM LETT, P1301, DOI 10.1246/cl.1999.1301; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; Koolhaas MHC, 1998, BIOCHEMISTRY-US, V37, P4693, DOI 10.1021/bi973036l; Kwa LG, 2004, J BIOL CHEM, V279, P15067, DOI 10.1074/jbc.M312429200; Lapouge K, 1998, J RAMAN SPECTROSC, V29, P977, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<977::AID-JRS325>3.0.CO;2-K; Liang J, 2002, CURR OPIN CHEM BIOL, V6, P878, DOI 10.1016/S1367-5931(02)00393-9; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liebl U, 1996, PHOTOCHEM PHOTOBIOL, V64, P38, DOI 10.1111/j.1751-1097.1996.tb02419.x; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MATTIOLI TA, 1991, BIOCHEMISTRY-US, V30, P1715, DOI 10.1021/bi00220a038; MATTIOLI TA, 1995, BIOCHEMISTRY-US, V34, P6142, DOI 10.1021/bi00018a017; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MOENNELOCCOZ P, 1990, BIOCHEMISTRY-US, V29, P4740, DOI 10.1021/bi00471a031; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; MOSS GP, 1987, PURE APPL CHEM, V59, P779, DOI 10.1351/pac198759060779; Oba T, 2002, PHOTOSYNTH RES, V74, P1, DOI 10.1023/A:1020816128794; Olsen JD, 1997, BIOCHEMISTRY-US, V36, P12625, DOI 10.1021/bi9710481; Parkes-Loach PS, 2004, BIOCHEMISTRY-US, V43, P7003, DOI 10.1021/bi049798f; POLOZOVA AI, 1995, FEBS LETT, V358, P17, DOI 10.1016/0014-5793(94)01378-E; ROBERT B, 1985, BIOCHIM BIOPHYS ACTA, V807, P10, DOI 10.1016/0005-2728(85)90048-9; Scheer H., 1995, ANOXYGENIC PHOTOSYNT, P649; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; STURGIS JN, 1995, BIOCHEMISTRY-US, V34, P517, DOI 10.1021/bi00002a016; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	66	18	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10626	10634		10.1074/jbc.M510731200	http://dx.doi.org/10.1074/jbc.M510731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484226	hybrid			2022-12-27	WOS:000236594300095
J	McGarrigle, D; Shan, DD; Yang, SY; Huang, XY				McGarrigle, D; Shan, DD; Yang, SY; Huang, XY			Role of tyrosine kinase Csk in G protein-coupled receptor- and receptor tyrosine kinase-induced fibroblast cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE PTP-PEST; SRC FAMILY KINASES; FOCAL ADHESIONS; PHOSPHORYLATED PROTEINS; ACTIVATION; PAXILLIN; INTEGRIN; ASSOCIATION; SIGNALS; GROWTH	Tyrosine kinase Csk is essential for mouse embryonic development. Csk knock-out mice died at early stages of embryogenesis ( around embryonic day 10). The molecular mechanism for this defect is not completely understood. Here we report that Csk deficiency in mouse embryonic fibroblast cells blocked cell migration induced by lysophosphatidic acid through G protein-coupled receptors, by platelet-derived growth factor and epidermal growth factor through receptor tyrosine kinases, and by serum. Re-expression of Csk in these Csk-deficient cells rescued the migratory phenotype. Furthermore, deletion of Csk did not interfere with Rac activation and lamellipodia formation, but impaired the focal adhesions. Our data demonstrate a critical role for Csk in cell migration.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.	xyhuang@med.cornell.edu	Yang, Shengyu/I-9531-2012	Yang, Shengyu/0000-0002-7933-6118	NIA NIH HHS [AG 014563] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Shan DD, 2005, P NATL ACAD SCI USA, V102, P3772, DOI 10.1073/pnas.0500658102; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1995, J CELL SCI, V108, P333; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; Williams DM, 2002, J AM CHEM SOC, V124, P5956, DOI 10.1021/ja025993a; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200	40	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10583	10588		10.1074/jbc.M513002200	http://dx.doi.org/10.1074/jbc.M513002200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16501257	hybrid			2022-12-27	WOS:000236594300090
J	Wang, EX; Albritton, L; Ross, SR				Wang, EX; Albritton, L; Ross, SR			Identification of the segments of the mouse transferrin receptor 1 required for mouse mammary tumor virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; HEREDITARY HEMOCHROMATOSIS; CRYSTAL-STRUCTURE; ENVELOPE PROTEIN; BREAST-TUMORS; EXPRESSION; BINDING; GENE; HFE; SEQUENCES	Most enveloped viruses enter cells through binding of virion surface envelope proteins to receptors found on the plasma membrane of the cell. The beta retrovirus mouse mammary tumor virus (MMTV) uses transferrin receptor 1 (TfR1) to enter cells in a pH-dependent mechanism, probably co-trafficking with TfR1 to an acidic compartment where virus entry occurs. We have shown here that, although mouse and rat TfR1 function as entry receptors, cat, dog, hamster, or human TfR1s do not support MMTV infection. We also demonstrated that MMTV entry is independent of transferrin, iron, and the TfR1 cofactor hereditary hematochromatosis HFE protein. Using chimeric mouse/human hybrid TfR1 constructs, we determined the site of interaction with MMTV and found that it maps to two segments physically disparate from the TfR and HFE binding sites. Thus, MMTV has apparently evolved to enter cells independently of the iron status of the host.	Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Ctr, Philadelphia, PA 19104 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Tennessee System; University of Tennessee Health Science Center	Ross, SR (corresponding author), Univ Penn, Dept Microbiol, Rm 313BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	rosss@mail.med.upenn.edu		Ross, Susan R/0000-0002-3094-3769	NCI NIH HHS [R01 CA 73746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISEN P, 2002, INT J BIOCHEM CELL B, V36, P2137; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BREKELMANS P, 1994, CELL IMMUNOL, V159, P331, DOI 10.1006/cimm.1994.1319; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; DUDLEY JP, 1981, J VIROL, V39, P207, DOI 10.1128/JVI.39.1.207-218.1981; Dzuris JL, 1999, VIROLOGY, V263, P418, DOI 10.1006/viro.1999.9967; Etkind PR, 2004, CLIN CANCER RES, V10, P5656, DOI 10.1158/1078-0432.CCR-03-0364; Evans P, 1997, GENE, V199, P123, DOI 10.1016/S0378-1119(97)00356-9; Ford CE, 2003, CLIN CANCER RES, V9, P1118; FRITSCH EF, 1977, J VIROL, V24, P461, DOI 10.1128/JVI.24.2.461-469.1977; FUTRAN J, 1989, J IMMUNOL, V143, P787; Giannetti AM, 2004, J BIOL CHEM, V279, P25866, DOI 10.1074/jbc.M401467200; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUEX N, 1999, IMMUNOL NEWS, V6, P132; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Indik S, 2005, CANCER RES, V65, P6651, DOI 10.1158/0008-5472.CAN-04-2609; Katz RA, 2005, J CELL BIOCHEM, V94, P880, DOI 10.1002/jcb.20358; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCKENNA WR, 1988, INFECT IMMUN, V56, P785, DOI 10.1128/IAI.56.4.785-791.1988; Parkkila S, 2000, HAEMATOLOGICA, V85, P340; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; REDMOND S, 1984, VIROLOGY, V133, P393, DOI 10.1016/0042-6822(84)90405-7; Riegert P, 1998, IMMUNOGENETICS, V47, P174, DOI 10.1007/s002510050344; Ross SR, 2002, P NATL ACAD SCI USA, V99, P12386, DOI 10.1073/pnas.192360099; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHULMAN HM, 1989, BIOCHIM BIOPHYS ACTA, V1010, P1, DOI 10.1016/0167-4889(89)90176-6; SHIMOOKA T, 1986, J CELL PHYSIOL, V126, P341, DOI 10.1002/jcp.1041260304; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tailor CS, 2000, J VIROL, V74, P9797, DOI 10.1128/JVI.74.20.9797-9801.2000; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; Velin D, 1996, J VIROL, V70, P7250, DOI 10.1128/JVI.70.10.7250-7254.1996; WANG Y, 1995, CANCER RES, V55, P5173; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048; Xu GZ, 2005, MOL CELL PROTEOMICS, V4, P1959, DOI 10.1074/mcp.M500095-MCP200; Xu LZ, 2003, P NATL ACAD SCI USA, V100, P8454, DOI 10.1073/pnas.1433063100; Zhang YM, 2003, J VIROL, V77, P10468, DOI 10.1128/JVI.77.19.10468-10478.2003	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10243	10249		10.1074/jbc.M511572200	http://dx.doi.org/10.1074/jbc.M511572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481319	hybrid			2022-12-27	WOS:000236594300052
J	Popov, Y; Patsenker, E; Bauer, M; Niedobitek, E; Schulze-Krebs, A; Schuppan, D				Popov, Yury; Patsenker, Eleonora; Bauer, Michael; Niedobitek, Edith; Schulze-Krebs, Anja; Schuppan, Detlef			Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER FIBROSIS; COLLAGEN-SYNTHESIS; FIBROTIC HUMAN; 3-DIMENSIONAL COLLAGEN; SKIN FIBROBLASTS; BILIARY FIBROSIS; PROTEIN-KINASES; GENE-EXPRESSION; TISSUE-REPAIR; I SYNTHESIS	The semisynthetic plant alkaloid halofuginone (HAL) was reported to prevent and partly reverse experimental liver fibrosis. However, its mechanisms of action are poorly understood. We therefore aimed to determine the antifibrotic potential of HAL and to characterize involved signal transduction pathways in hepatic stellate cells (HSCs). Results were compared with its in vivo effects in a rat model of reversal of established liver fibrosis induced by thioacetamide. In vitro HAL inhibited HSC proliferation and migration dose dependently at submicromolar concentrations. HAL ( 200 nM) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. Procollagen alpha 1(I) and MMP-2 transcript levels were suppressed 2- to 3-fold, whereas expression of other profibrogenic mRNAs remained unaffected. p38 mitogen-activated protein kinase ( p38 MAPK) and nuclear factor kappa B (NF kappa B) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NF kappa B dose dependently inhibited MMP-13 induction. Treatment with HAL did not affect HSC viability, and observed effects were reversible after its removal. In vivo HAL up-regulated MMP-3 and -13 mRNA expression 1.5- and 2- fold, respectively, in cirrhotic rats, whereas tissue inhibitor of metalloproteinase-1 was suppressed by 50%. In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF kappa B. The remarkable induction of MMP-3 and -13 makes HAL a promising agent for antifibrotic combination therapies.	Harvard Univ, Sch Med, Beth Israel Deaconess MC, Div Gastroenterol & Hepatol, Boston, MA 02215 USA; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Erlangen Nuremberg	Schuppan, D (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess MC, Div Gastroenterol & Hepatol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	dschuppa@bidmc.harvard.edu	Popov, Yury V./A-7781-2008	Popov, Yury V./0000-0001-7973-942X				Benten D, 2005, HEPATOLOGY, V42, P1072, DOI 10.1002/hep.20889; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; Bruck R, 2001, HEPATOLOGY, V33, P379, DOI 10.1053/jhep.2001.21408; Cassiman D, 2002, J HEPATOL, V36, P200, DOI 10.1016/S0168-8278(01)00260-4; Cho JJ, 2000, GASTROENTEROLOGY, V118, P1169, DOI 10.1016/S0016-5085(00)70370-2; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Dufour JF, 1997, ANN INTERN MED, V127, P981, DOI 10.7326/0003-4819-127-11-199712010-00006; Elkin M, 1999, CLIN CANCER RES, V5, P1982; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; GRANOT I, 1991, POULTRY SCI, V70, P1559, DOI 10.3382/ps.0701559; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; GREENWEL P, 1993, LAB INVEST, V69, P210; Halevy O, 1996, BIOCHEM PHARMACOL, V52, P1057, DOI 10.1016/0006-2952(96)00427-3; Hammel P, 2001, NEW ENGL J MED, V344, P418, DOI 10.1056/NEJM200102083440604; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Iimuro Y, 2003, GASTROENTEROLOGY, V124, P445, DOI 10.1053/gast.2003.50063; Knittel T, 1999, HISTOCHEM CELL BIOL, V112, P387, DOI 10.1007/s004180050421; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Lee HS, 2003, J BIOMED SCI, V10, P757, DOI 10.1159/000073963; Lee HS, 2001, HEPATO-GASTROENTEROL, V48, P1114; McCrudden R, 2000, HISTOL HISTOPATHOL, V15, P1159, DOI 10.14670/HH-15.1159; McGaha TL, 2002, ARTHRITIS RHEUM, V46, P2748, DOI 10.1002/art.10549; MILANI S, 1994, AM J PATHOL, V144, P528; Nagler A, 1997, ARTERIOSCL THROM VAS, V17, P194, DOI 10.1161/01.ATV.17.1.194; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Pines A, 2003, BIOL BLOOD MARROW TR, V9, P417, DOI 10.1016/S1083-8791(03)00151-4; Pines M, 1998, GEN PHARMACOL, V30, P445, DOI 10.1016/S0306-3623(97)00307-8; Pinzani M, 1998, LIVER, V18, P2; Popov Y, 2005, J HEPATOL, V43, P1045, DOI 10.1016/j.jhep.2005.06.025; PURUKAWA P, 2003, HEPATOLOGY, V38, P879; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reeves HL, 2000, J HEPATOL, V32, P465, DOI 10.1016/S0168-8278(00)80398-0; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Schaefer B, 2003, AM J PATHOL, V162, P1771, DOI 10.1016/S0002-9440(10)64312-X; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Schulze-Krebs A, 2005, GASTROENTEROLOGY, V129, P246, DOI 10.1053/j.gastro.2005.03.089; Schuppan D, 2003, FALK SYMP, V132, P169; Shiffman ML, 1999, GASTROENTEROLOGY, V117, P1164, DOI 10.1016/S0016-5085(99)70402-6; Siller-Lopez F, 2004, GASTROENTEROLOGY, V126, P1122, DOI 10.1053/j.gastro.2003.12.045; Takahara T, 1997, HEPATOLOGY, V26, P1521; Varela-Rey M, 2002, FEBS LETT, V528, P133, DOI 10.1016/S0014-5793(02)03276-3; Watanabe T, 2000, J HEPATOL, V33, P224, DOI 10.1016/S0168-8278(00)80363-3; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437	53	83	86	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15090	15098		10.1074/jbc.M600030200	http://dx.doi.org/10.1074/jbc.M600030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16489207	hybrid			2022-12-27	WOS:000237922200011
J	Edlich, F; Weiwad, M; Wildemann, D; Jarczowski, F; Kilka, S; Moutty, MC; Jahreis, G; Lucke, C; Schmidt, W; Striggow, F; Fischer, G				Edlich, Frank; Weiwad, Matthias; Wildemann, Dirk; Jarczowski, Franziska; Kilka, Susann; Moutty, Marie-Christine; Jahreis, Guenther; Luecke, Christian; Schmidt, Werner; Striggow, Frank; Fischer, Gunter			The specific FKBP38 inhibitor N-(N ',N '-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; FK506 BINDING-PROTEIN; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A; CELL-DEATH; NEUROIMMUNOPHILIN LIGANDS; IMMUNOPHILIN LIGANDS; DOPAMINERGIC-NEURONS	FK506 and FK506-derived inhibitors of the FK506-binding protein ( FKBP)-type peptidylprolyl cis/trans-isomerases ( PPIase) display potent neuroprotective and neuroregenerative properties in various neurodegeneration models, showing the importance of neuroimmunophilins as targets for the treatment of acute and chronic neurodegenerative diseases. However, the PPIase activity targeted by active site-directed ligands remainsed unknown so far. Here we show that neurotrophic FKBP ligands, such as GPI1046 and N-[methyl( ethoxycarbonyl)] cycloheximide, inhibit the calmodulin/Ca2+ ( CaM/Ca2+)-regulated FKBP38 with up to 80-fold higher affinity than FKBP12. In contrast, the non-neurotrophic rapamycin inhibits FKBP38 center dot CaM/Ca2+ 500-fold less affine than other neuroimmunophillins. In the context of the high expression of FKBP38 in neuroblastoma cells, these data suggest that FKBP38 center dot CaM/Ca2+ inhibition can mediate neurotrophic properties of FKBP ligands. The FKBP38-specific cycloheximide derivative, N-( N', N'-dimethylcarboxamidomethyl) cycloheximide ( DM-CHX) was synthesized and used in a rat model of transient focal cerebral ischemia. Accordingly, DM-CHX caused neuronal protection as well as neural stem cell proliferation and neuronal differentiation at a dosage of 27.2 mu g/kg. These effects were still dominant, if DM-CHX was applied 2 - 6 h post-insult. In parallel, sustained motor behavior deficits of diseased animals were improved by drug administration, revealing a potential therapeutic relevance. Thus, our results demonstrate that FKBP38 inhibition by DM-CHX regulates neuronal cell death and proliferation, providing a promising strategy for the treatment of acute and/or chronic neurodegenerative diseases.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany; KeyNeurotek AG, D-39120 Magdeburg, Germany	Max Planck Society	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Germany.	fischer@enzyme-halle.mpg.de						Alemdar AY, 2001, EXP NEUROL, V172, P416, DOI 10.1006/exnr.2001.7801; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; Burnett AL, 2004, J UROLOGY, V171, P495, DOI 10.1097/01.ju.0000089775.88825.ec; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; COOPER TG, 1976, J BIOL CHEM, V251, P7278; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DREYER EB, 1995, NEUROREPORT, V6, P942, DOI 10.1097/00001756-199504190-00029; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FUNAUCHI M, 1994, NEUROSCI RES, V19, P269, DOI 10.1016/0168-0102(94)90039-6; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Gold BG, 1998, NEUROREPORT, V9, P553, DOI 10.1097/00001756-199802160-00031; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Gold BG, 1997, MOL NEUROBIOL, V15, P285, DOI 10.1007/BF02740664; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; Graziani F, 1999, J BIOMOL SCREEN, V4, P3, DOI 10.1177/108705719900400102; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; Hamilton GS, 1997, BIOORG MED CHEM LETT, V7, P1785, DOI 10.1016/S0960-894X(97)00304-1; Hamilton GS, 1997, CURR PHARM DESIGN, V3, P405; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hodgkiss JP, 1995, BRAIN RES, V705, P241, DOI 10.1016/0006-8993(95)01168-4; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kuzmic P, 1999, ANAL BIOCHEM, V267, P17, DOI 10.1006/abio.1998.2670; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; Metz GA, 2002, NEUROSCIENCE, V111, P325, DOI 10.1016/S0306-4522(02)00013-1; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mogi M, 2000, NEUROSCI LETT, V289, P165, DOI 10.1016/S0304-3940(00)01275-1; MORRIS I, 1966, NATURE, V211, P1190, DOI 10.1038/2111190b0; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poulter MO, 2004, NEUROSCIENCE, V128, P1, DOI 10.1016/j.neuroscience.2004.06.016; RATAN RR, 1994, J NEUROCHEM, V62, P376; SERGHINI R, 1994, NEUROREPORT, V6, P29, DOI 10.1097/00001756-199412300-00009; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Steiner JP, 1996, MOL MED, V2, P325, DOI 10.1007/BF03401630; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TASCA RJ, 1970, NATURE, V225, P1022, DOI 10.1038/2251022a0; TORTOSA A, 1994, J NEUROL SCI, V121, P10, DOI 10.1016/0022-510X(94)90149-X; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086	57	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14961	14970		10.1074/jbc.M600452200	http://dx.doi.org/10.1074/jbc.M600452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547004	hybrid			2022-12-27	WOS:000237671300049
J	De Jong, AS; Visch, HJ; De Mattia, F; van Dommelen, MM; Swarts, HG; Luyten, T; Callewaert, G; Melchers, WJ; Willems, PH; van Kuppeveld, FJ				De Jong, Arjan S.; Visch, Henk-Jan; De Mattia, Fabrizio; van Dommelen, Michiel M.; Swarts, Herman G.; Luyten, Tomas; Callewaert, Geert; Melchers, Willem J.; Willems, Peter H.; van Kuppeveld, Frank J.			The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PERMEABILIZATION; POLIOVIRUS INFECTION; CHANNEL ACTIVITY; QUALITY-CONTROL; AMPHIPATHIC HELIX; LIVING CELLS; 3A PROTEIN; CALCIUM; REPLICATION; HOMEOSTASIS	Coxsackievirus infection leads to a rapid reduction of the filling state of the endoplasmic reticulum ( ER) and Golgi Ca2+ stores. The coxsackievirus 2B protein, a small membrane protein that localizes to the Golgi and to a lesser extent to the ER, has been proposed to play an important role in this effect by forming membrane-integral pores, thereby increasing the efflux of Ca2+ from the stores. Here, evidence is presented that supports this idea and that excludes the possibility that 2B reduces the uptake of Ca2+ into the stores. Measurement of intra-organelle-free Ca2+ in permeabilized cells revealed that the ability of 2B to reduce the Ca2+ filling state of the stores was preserved at steady ATP. Biochemical analysis in a cell-free system further showed that 2B had no adverse effect on the activity of the sarco/endoplasmic reticulum calcium ATPase, the Ca2+-ATPase that transports Ca2+ from the cytosol into the stores. To investigate whether 2B specifically affects Ca2+ homeostasis or other ion gradients, we measured the lumenal Golgi pH. Expression of 2B resulted in an increased Golgi pH, indicative for the efflux of H+ from the Golgi lumen. Together, these data support a model that 2B increases the efflux of ions from the ER and Golgi by forming membrane-integral pores. We have demonstrated that a major consequence of this activity is the inhibition of protein trafficking through the Golgi complex.	Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Biochem, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Catholic Univ Louvain, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; Radboud University Nijmegen; Universite Catholique Louvain	van Kuppeveld, FJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.ru.nl	Jong, A.S./L-4416-2015; Melchers, Willem/C-8819-2015; Willems, P.H.G.M./L-4759-2015	Melchers, Willem/0000-0002-5446-2230; Willems, P.H.G.M./0000-0002-0915-1599; van Kuppeveld, Frank/0000-0001-5800-749X				Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BIENZ K, 1994, ARCH VIROL, P147; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; de Jong AS, 2004, J BIOL CHEM, V279, P19924, DOI 10.1074/jbc.M314094200; de Jong AS, 2003, J BIOL CHEM, V278, P1012, DOI 10.1074/jbc.M207745200; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Schoonderwoert VTG, 2001, J MEMBRANE BIOL, V182, P159, DOI 10.1007/s00232-001-0040-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Toomre D, 1999, J CELL SCI, V112, P21; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; Visch HJ, 2004, J BIOL CHEM, V279, P40328, DOI 10.1074/jbc.M408068200; Wessels E, 2005, J VIROL, V79, P5163, DOI 10.1128/JVI.79.8.5163-5173.2005; Zuber C, 2000, MOL BIOL CELL, V11, P4227, DOI 10.1091/mbc.11.12.4227	48	79	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14144	14150		10.1074/jbc.M511766200	http://dx.doi.org/10.1074/jbc.M511766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540472	hybrid			2022-12-27	WOS:000237512300038
J	Gui, PC; Wu, X; Ling, SZ; Stotz, SC; Winkfein, RJ; Wilson, E; Davis, GE; Braun, AP; Zamponi, GW; Davis, MJ				Gui, Peichun; Wu, Xin; Ling, Shizhang; Stotz, Stephanie C.; Winkfein, Robert J.; Wilson, Emily; Davis, George E.; Braun, Andrew P.; Zamponi, Gerald W.; Davis, Michael J.			Integrin receptor activation triggers converging regulation of Cav1.2 calcium channels by c-Src and protein kinase A pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ALPHA(1C) CA(V)1.2 SUBUNIT; GATED POTASSIUM CHANNELS; CA2+ CHANNEL; SMOOTH-MUSCLE; ALPHA(V)BETA(3) INTEGRIN; ADHESION MOLECULES; CARBOXYL-TERMINUS; ION CHANNELS; N-TERMINUS	L-type, voltage-gated Ca2+ channels (CaL) play critical roles in brain and muscle cell excitability. Here we show that currents through heterologously expressed neuronal and smooth muscle CaL channel isoforms are acutely potentiated following alpha 5 beta 1 integrin activation. Only the alpha(1C) pore-forming channel subunit is critical for this process. Truncation and site-directed mutagenesis strategies reveal that regulation of Cav1.2 by alpha 5 beta 1 integrin requires phosphorylation of alpha(1C) C-terminal residues Ser(1901) and Tyr(2122). These sites are known to be phosphorylated by protein kinase A(PKA) and c-Src, respectively, and are conserved between rat neuronal (Cav1.2c) and smooth muscle (Cav1.2b) isoforms. Kinase assays are consistent with phosphorylation of these two residues by PKA and c-Src. Following alpha 5 beta 1 integrin activation, native CaL channels in rat arteriolar smooth muscle exhibit potentiation that is completely blocked by combined PKA and Src inhibition. Our results demonstrate that integrin-ECM interactions are a common mechanism for the acute regulation of CaL channels in brain and muscle. These findings are consistent with the growing recognition of the importance of integrin-channel interactions in cellular responses to injury and the acute control of synaptic and blood vessel function.	Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA; Texas A&M Univ, Coll Med, Dept Syst Biol & Translat Med, College Stn, TX 77840 USA; Univ Calgary, Sch Med, Smooth Muscle Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Sch Med, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Missouri System; University of Missouri Columbia; Texas A&M University System; Texas A&M University College Station; University of Calgary; University of Calgary	Davis, MJ (corresponding author), 1 Hosp Dr,M451, Columbia, MO 65212 USA.	davismj@health.missouri.edu	Ling, Shizhang/J-6114-2014	Ling, Shizhang/0000-0002-6856-3577; Zamponi, Gerald W./0000-0002-0644-9066; wu, xin/0000-0002-5005-6358	NCRR NIH HHS [RR-017353] Funding Source: Medline; NHLBI NIH HHS [HL-72989] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017353] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072989] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Artym VV, 2002, J GEN PHYSIOL, V120, P29, DOI 10.1085/jgp.20028607; Bahr BA, 1997, J NEUROSCI, V17, P1320; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Bloch W, 2001, J CELL BIOL, V154, P753, DOI 10.1083/jcb.200103011; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; Dubuis E, 2006, CARDIOVASC RES, V69, P391, DOI 10.1016/j.cardiores.2005.11.006; Gall CM, 2003, NEUROSCIENCE, V118, P925, DOI 10.1016/S0306-4522(02)00990-9; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gualandris A, 1996, J NEUROSCI, V16, P2220; HELL JW, 1993, J BIOL CHEM, V268, P19451; Hernandez RV, 2001, BIOL BULL, V201, P236, DOI 10.2307/1543341; Hescheler Juergen, 2002, Basic Research in Cardiology, V97; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Kramar EA, 2002, NEUROSCIENCE, V110, P29, DOI 10.1016/S0306-4522(01)00540-1; Kramar EA, 2003, J BIOL CHEM, V278, P10722, DOI 10.1074/jbc.M210225200; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; McDonough SI, 2002, J GEN PHYSIOL, V119, P313, DOI 10.1085/jgp.20028560; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; Meiners S, 2003, MOL NEUROBIOL, V27, P177, DOI 10.1385/MN:27:2:177; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Murchison D, 1998, J NEUROPHYSIOL, V80, P350, DOI 10.1152/jn.1998.80.1.350; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Rueckschloss U, 2004, J PHYSIOL-LONDON, V560, P403, DOI 10.1113/jphysiol.2004.062604; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Sadeghi A, 2002, AM J PHYSIOL-CELL PH, V282, pC1502, DOI 10.1152/ajpcell.00435.2001; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Staubli U, 1998, J NEUROSCI, V18, P3460; Vasilyev DV, 2003, J PHYSIOL-LONDON, V547, P859, DOI 10.1113/jphysiol.2002.036889; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; Wang YG, 2000, J PHYSIOL-LONDON, V526, P57, DOI 10.1111/j.1469-7793.2000.t01-1-00057.x; Wang YG, 2000, J PHYSIOL-LONDON, V527, P3, DOI 10.1111/j.1469-7793.2000.t01-2-00003.x; WEI XY, 1994, J BIOL CHEM, V269, P1635; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; WIJETUNGE S, 1995, BRIT J PHARMACOL, V115, P534, DOI 10.1111/j.1476-5381.1995.tb16367.x; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Zhong JM, 1999, AM J PHYSIOL-CELL PH, V277, pC840	76	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14015	14025		10.1074/jbc.M600433200	http://dx.doi.org/10.1074/jbc.M600433200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554304	hybrid			2022-12-27	WOS:000237512300024
J	Shibata, M; Lu, T; Furuya, T; Degterev, A; Mizushima, N; Yoshimori, T; MacDonald, M; Yankner, B; Yuan, JY				Shibata, Mamoru; Lu, Tao; Furuya, Tsuyoshi; Degterev, Alexei; Mizushima, Noboru; Yoshimori, Tamotsu; MacDonald, Marcy; Yankner, Bruce; Yuan, Junying			Regulation of Intracellular Accumulation of Mutant Huntingtin by Beclin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Intracellular accumulation of mutant Huntingtin with expanded polyglutamine provides a context-dependent cytotoxicity critical for the pathogenesis of Huntington disease (Everett, C. M., and Wood, N. W. (2004) Brain 127, 2385-2405). Here we demonstrate that the accumulation of mutant Huntingtin is highly sensitive to the expression of beclin 1, a gene essential for autophagy. Moreover, we show that the accumulated mutant Huntingtin recruits Beclin 1 and impairs the Beclin 1-mediated long lived protein turnover. Thus, sequestration of Beclin 1 in the vulnerable neuronal population of Huntington disease patients might further reduce Beclin 1 function and autophagic degradation of mutant Huntingtin. Finally, we demonstrate that the expression of beclin 1 decreases in an age-dependent fashion in human brains. Because beclin 1 gene is haploid insufficient in regulating autophagosome function (Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003) J. Clin. Invest. 112, 1809-1820; Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 15077 15082), we propose that the age-dependent decrease of beclin 1 expression may lead to a reduction of autophagic activity during aging, which in turn promotes the accumulation of mutant Htt and the progression of the disease.	[Shibata, Mamoru; Furuya, Tsuyoshi; Degterev, Alexei; Yuan, Junying] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Shibata, Mamoru; Furuya, Tsuyoshi; Degterev, Alexei; Yuan, Junying] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Lu, Tao; Yankner, Bruce] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Lu, Tao; Yankner, Bruce] Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; [MacDonald, Marcy] Massachusetts Gen Hosp East, Ctr Human Genet Res, Charlestown, MA 02129 USA; [MacDonald, Marcy] Massachusetts Gen Hosp East, Mol Neurogenet Unit, Charlestown, MA 02129 USA; [Mizushima, Noboru] Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Bunkyo Ku, Tokyo 1138613, Japan; [Yoshimori, Tamotsu] Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Tokyo Metropolitan Institute of Medical Science; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Mizushima, Noboru/C-3635-2009; Shibata, Mamoru/L-8537-2013	Mizushima, Noboru/0000-0002-6258-6444; Shibata, Mamoru/0000-0002-2416-4259	HighQ Foundation; NIA, National Institutes of Health [R37-12859, NS32765, NS16367]; Huntington's Disease Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016367, R01NS032765, P50NS016367] Funding Source: NIH RePORTER	HighQ Foundation; NIA, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Huntington's Disease Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the HighQ Foundation, by NIA, National Institutes of Health Grant R37-12859 (to J. Y.), by National Institutes of Health Grants NS32765 and NS16367, and by the Huntington's Disease Center Without Walls (to M. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Donati A, 2001, J GERONTOL A-BIOL, V56, pB375, DOI 10.1093/gerona/56.9.B375; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MacDonald Marcy E, 2003, Sci STKE, V2003, ppe48; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	40	357	373	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14474	14485		10.1074/jbc.M600364200	http://dx.doi.org/10.1074/jbc.M600364200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16522639	Green Published, hybrid			2022-12-27	WOS:000207179300006
J	Ghosh, S; Johnson, JJ; Sen, R; Mukhopadhyay, S; Liu, YY; Zhang, F; Wei, Y; Chapman, HA; Stack, MS				Ghosh, S; Johnson, JJ; Sen, R; Mukhopadhyay, S; Liu, YY; Zhang, F; Wei, Y; Chapman, HA; Stack, MS			Functional relevance of urinary-type plasminogen activator receptor-alpha 3 beta 1 integrin association in proteinase regulatory pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; ORAL KERATINOCYTES; BASEMENT-MEMBRANE; BINDING-SITES; TUMOR-GROWTH; EXPRESSION; METASTASIS; INVASION	Squamous cell carcinoma of the oral cavity is characterized by persistent, disorganized expression of integrin alpha 3 beta 1 and enhanced production of urinary-type plasminogen activator (uPA) and its receptor ( uPAR) relative to normal oral mucosa. Because multivalent aggregation of alpha 3 beta 1 integrin up-regulates uPA and induces a dramatic co-clustering of uPAR, we explored the hypothesis that lateral ligation of alpha 3 beta 1 integrin by uPAR contributes to uPA regulation in oral mucosal cells. To investigate mechanisms by which uPAR/alpha 3 beta 1 binding enhances uPA expression, integrin-dependent signal activation was assessed. Both Src and ERK1/2 were phosphorylated in response to integrin aggregation, and blocking Src kinase activity completely abrogated ERK1/2 activation and uPA induction, whereas inhibition of epidermal growth factor receptor tyrosine kinase activity did not alter uPA expression. Proteinase up-regulation occurred at the transcriptional level and mutation of the AP1 (-1967) site in the uPA promoter blocked the uPAR/integrin-mediated transcriptional activation. Because uPAR is redistributed to clustered alpha 3 beta 1 integrins, the requirement for uPAR/alpha 3 beta 1 interaction in uPA regulation was assessed. Clustering of alpha 3 beta 1 in the presence of a peptide (alpha 325) that disrupts uPAR/alpha 3 beta 1 integrin binding prevented uPA induction. Depletion of cell surface uPAR using small interfering RNA also blocked uPA induction following integrin alpha 3 beta 1 clustering. These results were confirmed using a genetic strategy in which alpha 3 null epithelial cells reconstituted with wild type alpha 3 integrin, but not a mutant alpha 3 unable to bind uPAR, induced uPA expression upon integrin clustering, confirming the critical role of uPAR in integrin-regulated proteinase expression. Disruption of uPAR/alpha 3 beta 1 binding using peptide alpha 325 or small interfering RNA blocked filopodia formation and matrix invasion, indicating that this interaction stimulates invasive behavior. Together these data support a model wherein matrix-induced clustering of alpha 3 beta 1 integrin promotes uPAR/alpha 3 beta 1 interaction, thereby potentiating cellular signal transduction pathways culminating in activation of uPA expression and enhanced uPA-dependent invasive behavior.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of California System; University of California San Francisco	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Super St,Lurie Bldg 3-111, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA085870] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA85870] Funding Source: Medline; NHLBI NIH HHS [R01HL44712] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BECKER J, 1991, VIRCHOWS ARCH A, V419, P237, DOI 10.1007/BF01626354; Berndt A, 1997, INVAS METAST, V17, P251; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Ghosh S, 2002, CANCER-AM CANCER SOC, V95, P2524, DOI 10.1002/cncr.10997; Haas KM, 2001, J HISTOCHEM CYTOCHEM, V49, P1261; Hicks WL, 1997, HEAD NECK-J SCI SPEC, V19, P400; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jones JCR, 2000, MICROSC RES TECHNIQ, V51, P211, DOI 10.1002/1097-0029(20001101)51:3<211::AID-JEMT1>3.0.CO;2-P; Kosmehl H, 1999, BRIT J CANCER, V81, P1071, DOI 10.1038/sj.bjc.6690809; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; Myohanen H, 2004, CELL MOL LIFE SCI, V61, P2840, DOI 10.1007/s00018-004-4230-9; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Shinohara M, 1999, AM J CLIN PATHOL, V111, P75; Shiratsuchi T, 2002, J CELL PHYSIOL, V193, P340, DOI 10.1002/jcp.10181; Smith PC, 2004, J PERIODONTAL RES, V39, P380, DOI 10.1111/j.1600-0765.2004.00753.x; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Wang H, 2004, J CELL BIOL, V164, P935, DOI 10.1083/jcb.200309112; Wang ZM, 1999, J CELL SCI, V112, P2925; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	48	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13021	13029		10.1074/jbc.M508526200	http://dx.doi.org/10.1074/jbc.M508526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16510444	hybrid			2022-12-27	WOS:000237336600005
J	Leroyer, SN; Tordjman, J; Chauvet, G; Quette, J; Chapron, C; Forest, C; Antoine, B				Leroyer, SN; Tordjman, J; Chauvet, G; Quette, J; Chapron, C; Forest, C; Antoine, B			Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE ACTIVITY; INSULIN-RESISTANCE; DIABETES-MELLITUS; IN-VIVO; METABOLISM; ADIPOCYTES; TRIGLYCERIDE; OBESITY; GENE	Control of fatty acid homeostasis is crucial to prevent insulin resistance. During fasting, the plasma fatty acid level depends on triglyceride lipolysis and fatty acid re-esterification within fat cells. In rodents, Rosiglitazone (R) controls fatty acid homeostasis by stimulating two pathways in the adipocytes, glyceroneogenesis and glycerol phosphorylation, that provide the glycerol 3-phosphate necessary for fatty acid re-esterification. Here, we analyzed the functionality of both pathways for controlling fatty acid release in subcutaneous adipose tissue samples from lean and overweight women before and after Rosiglitazone (R) ex vivo treatment. In controls, pyruvate, used as a substrate of glyceroneogenesis, could contribute to the re-esterification of up to 65% of the fatty acids released after basal lipolysis, whereas glycerol phosphorylation accounted for only 14 +/- 9%. However, the efficiency of glyceroneogenesis diminished as body mass index (BMI) of women increased. After Rosiglitazone treatment, increase of either pyruvate- or glycerol-dependent fatty acid re-esterification was strictly correlated to that of phosphoenolpyruvate carboxykinase and glycerol kinase, the key enzymes of each pathway, but depended on BMI of the women. Whereas the Rosiglitazone (R) responsiveness of glyceroneogenesis was rather constant according to the BMI of the women, glycerol phosphorylation was mostly enhanced in lean women (BMI < 27). Overall, these data indicate that, whereas glyceroneogenesis is more utilized than glycerol phosphorylation for fatty acid re-esterification in human subcutaneous adipose tissue in the physiological situation, both are solicited in response to Rosiglitazone (R) but with lower efficiency when BMI is increased.	Univ Paris 06, INSERM UMR S 530 747, F-75006 Paris, France; CHU Cochin, Grp Hosp Univ Ouest, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Antoine, B (corresponding author), Ctr Univ St Antoine, INSERM, U 680, 27 Rue Chaligny, F-75012 Paris, France.	benedicte.antoine@univ-paris5.fr	Chapron, Charles/O-8567-2017	Forest, Claude/0000-0003-3401-8148				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; BLIGH EG, 1959, CAN J BIOCH PHYSL, V371, P1991; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bogacka I, 2004, DIABETES CARE, V27, P1660, DOI 10.2337/diacare.27.7.1660; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; CHAKRABARTY K, 1984, INT J OBESITY, V8, P609; CHANG HC, 1966, J BIOL CHEM, V241, P2413; Chen JL, 2005, J BIOL CHEM, V280, P25396, DOI 10.1074/jbc.M413948200; DUFF DA, 1982, BIOCHEM J, V206, P147, DOI 10.1042/bj2060147; Duplus E, 2003, BIOCHIMIE, V85, P1257, DOI 10.1016/j.biochi.2003.10.016; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; HAMMOND VA, 1987, METABOLISM, V36, P308, DOI 10.1016/0026-0495(87)90199-5; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; JENSEN MD, 1991, J CLIN INVEST, V87, P187, DOI 10.1172/JCI114969; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Miyazaki Y, 2001, DIABETOLOGIA, V44, P2210, DOI 10.1007/s001250100031; NEWSHOLME EA, 1967, BIOCHIM BIOPHYS ACTA, V132, P338, DOI 10.1016/0005-2744(67)90153-2; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; PERSICO PA, 1975, AM J PHYSIOL, V228, P1868, DOI 10.1152/ajplegacy.1975.228.6.1868; RANDLE PJ, 1963, LANCET, V1, P785; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; RESHEF L, 1969, J BIOL CHEM, V244, P1994; RESHEF L, 1969, J BIOL CHEM, V244, P5577; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Tan GD, 2005, DIABETOLOGIA, V48, P83, DOI 10.1007/s00125-004-1619-9; Tan GD, 2003, NAT MED, V9, P811, DOI 10.1038/nm0703-811; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; WATFORD M, 1980, CAN J BIOCHEM CELL B, V58, P440, DOI 10.1139/o80-058	37	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13141	13149		10.1074/jbc.M512943200	http://dx.doi.org/10.1074/jbc.M512943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524879	hybrid			2022-12-27	WOS:000237336600019
J	Matos, P; Jordan, P				Matos, P; Jordan, P			Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRCP-UBIQUITIN LIGASE; IKK-ALPHA; CYCLIN D1; INDEPENDENT PATHWAYS; DEPENDENT PATHWAY; NF-KAPPA-B2 P100; SPLICE VARIANT; NADPH OXIDASE; RHO-GTPASES	Increased NF- kappa B- mediated transcription has been extensively linked to tumorigenesis and can be stimulated by deregulated Rac1 signaling. For example, the overexpression of Rac1b, a highly activated splicing variant of Rac1 with increased expression in colorectal tumors, stimulates NF- kappa B- mediated G(1)/ S progression and cell survival, and was shown to promote cell transformation and epithelial-mesenchymal transition. Here we show evidence of further complexity between Rac1b and Rac1 signaling toward NF- kappa B in colorectal cells. Consistent with data from other cell types we demonstrate that both Rac1 and Rac1b stimulate transcriptional activation from reporter genes driven by NF- kappa B motifs or the cyclin D1 promoter in an I kappa B alpha- and reactive oxygen species- dependent manner. However, we found that in colorectal cells Rac1, but not Rac1b, induces nuclear translocation of RelB and p52, activates transcription from a RelB- specific reporter, and can be isolated in a complex with endogenous RelB and its inhibitor NF- kappa B2/ p100. In addition, Rac1 colocalizes at the plasmamembrane with RelB, p100, and cullin-1, a core subunit of the E3 ubiquitin ligase that marks p100 for proteolytic processing to p52. Interestingly, this Rac1- specific pathway is not mediated via the production of reactive oxygen species. These data provide evidence that both Rac1 and Rac1b activate the canonical RelA- I kappa B alpha pathway, whereas Rac1 further stimulates NF- kappa B by inducing the RelB- NF- kappa B2/ p100 pathway. The RelB pathway was reported to down- regulate canonical NF- kappa B activation during the inflammatory response, suggesting that increased levels of Rac1b in colorectal tumors may promote tumorigenesis by stimulating canonical NF- kappa B signaling while circumventing a negative feedback from the RelB pathway.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019; Jordan, Peter/G-9335-2012	Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696; Jordan, Peter/0000-0002-1425-9211				Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Senadheera D, 2001, INT J MOL MED, V8, P127; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	55	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13724	13732		10.1074/jbc.M513243200	http://dx.doi.org/10.1074/jbc.M513243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551621	hybrid			2022-12-27	WOS:000237336600083
J	Rosenkilde, MM; Benned-Jensen, T; Andersen, H; Holst, PJ; Kledal, TN; Luttichau, HR; Larsen, JK; Christensen, JP; Schwartz, TW				Rosenkilde, MM; Benned-Jensen, T; Andersen, H; Holst, PJ; Kledal, TN; Luttichau, HR; Larsen, JK; Christensen, JP; Schwartz, TW			Molecular pharmacological phenotyping of EBI2 - An orphan seven-transmembrane receptor with constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; GHRELIN RECEPTOR; CELL-SURVIVAL; CHEMOKINE; EXPRESSION; CLONING; LIGAND; IDENTIFICATION	Epstein-Barr virus ( EBV)-induced receptor 2 ( EBI2) is an orphan seven-transmembrane ( 7TM) receptor originally identified as the most up-regulated gene (> 200-fold) in EBV-infected cells. Here we show that EBI2 signals with constitutive activity through G alpha(i) as determined by a receptor-mediated inhibition of forskolin-induced cAMP production and an induction of the serum response element-driven transcriptional activity in a pertussis toxin-sensitive manner. G alpha(s) and G alpha(q) were not activated constitutively as determined by the lack of cAMP production, the lack of inositol phosphate turnover, and the lack of activities of the transcription factors: cAMP response element-binding protein and nuclear factor-kappa B. Immunohistochemistry and confocal microscopy of FLAG- and green fluorescent protein-tagged EBI2 revealed cell-surface expression. A putative N-terminal truncated version of EBI2, Delta 4-EBI2, showed similar expression and signaling through G alpha(i) as full-length EBI2. By using a P-32-labeled EBI2 probe we found a very high expression in lymphoid tissue ( spleen and lymph node) and peripheral blood mononuclear cells and a high expression in lung tissue. Real-time PCR of EBV-infected cells showed high expression of EBI2 during latent and lytic infection, in contrast to the EBV-encoded 7TM receptor BILF1, which was induced during lytic infection. EBI2 clustered with the orphan GPR18 by alignment analysis as well as by close proximity in the chromosomal region 13q32.3. Based on the constitutive signaling and cellular expression pattern of EBI2, it is suggested that it may function in conjunction with BILF1 in the reprogramming of the cell during EBV infection.	Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Panum Inst, Inst Med Microbiol & Immunol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Finser Ctr, Finsen Lab, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Dept Infect Dis, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Clin Res Unit, DK-2650 Hvidovre, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	rosenkilde@molpharm.dk	Christensen, Jan Pravsgaard/I-4782-2017	Christensen, Jan Pravsgaard/0000-0002-4299-9479; Rosenkilde, Mette Marie/0000-0001-9600-3254; Holst, Peter Johannes/0000-0002-1279-304X; Schwartz, Thue W./0000-0002-0261-6904; Luttichau, Hans Rudolf/0000-0002-5428-4075				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 2005, J VIROL, V79, P441, DOI 10.1128/JVI.79.1.441-449.2005; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BIRKENBACH M, 1989, J VIROL, V63, P4079, DOI 10.1128/JVI.63.9.4079-4084.1989; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Couty JP, 2005, TRENDS PHARMACOL SCI, V26, P405, DOI 10.1016/j.tips.2005.06.004; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Goltz M, 2002, VIROLOGY, V294, P383, DOI 10.1006/viro.2002.1390; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Hill Stephen J., 2001, Current Opinion in Pharmacology, V1, P526, DOI 10.1016/S1471-4892(01)00091-1; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2004, TRENDS PHARMACOL SCI, V25, P113, DOI 10.1016/j.tips.2004.01.010; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Joost P, 2002, GENOME BIOL, V3; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Lapinsh M, 2002, PROTEIN SCI, V11, P795, DOI 10.1110/ps.2500102; Lindow M, 2003, TRENDS PHARMACOL SCI, V24, P126, DOI 10.1016/S0165-6147(03)00033-6; Liu CQ, 2004, J VIROL, V78, P2460, DOI 10.1128/JVI.78.5.2460-2471.2004; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Melchjorsen J, 2002, J VIROL, V76, P2780, DOI 10.1128/JVI.76.6.2780-2788.2002; Melchjorsen J, 2003, J LEUKOCYTE BIOL, V74, P331, DOI 10.1189/jlb.1102577; Montaner S, 2001, CANCER RES, V61, P2641; Moorman NJ, 2003, VIROLOGY, V307, P179, DOI 10.1016/S0042-6822(02)00023-5; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Nakayama T, 2002, J VIROL, V76, P3072, DOI 10.1128/JVI.76.6.3072-3077.2002; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rosenkilde MM, 2006, CURR DRUG TARGETS, V7, P103, DOI 10.2174/138945006775270259; Rosenkilde MM, 2005, NEUROPHARMACOLOGY, V48, P1, DOI 10.1016/j.neuropharm.2004.09.017; Rosenkilde MM, 2004, J BIOL CHEM, V279, P32524, DOI 10.1074/jbc.M313392200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; ROSENKILDE MM, 2004, HDB CELL SIGNALING, P779; Sabroe I, 1998, J IMMUNOL, V161, P6139; SCHWARTZ TW, 2003, TXB RECEPTOR PHARM, P65; Seifert R, 2001, RECEPTOR CHANNEL, V7, P357; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	53	83	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13199	13208		10.1074/jbc.M602245200	http://dx.doi.org/10.1074/jbc.M602245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540462	hybrid			2022-12-27	WOS:000237336600025
J	Anand, AR; Ganju, RK				Anand, AR; Ganju, RK			HIV-1 gp120-mediated apoptosis of T cells is regulated by the membrane tyrosine phosphatase CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FAS-LIGAND; PHOSPHATIDYLINOSITOL 3-KINASE; CD95-MEDIATED APOPTOSIS; INHIBITS APOPTOSIS; KINASE ACTIVATION; ANTIGEN RECEPTOR; UP-REGULATION; PROTEIN; DEATH	The molecular mechanism of the human immunodeficiency virus type 1 (HIV-1) gp120-induced apoptosis of bystander T cells is not well defined. Here, we demonstrate that CD45, a key component of the T cell receptor pathway, plays a crucial role in apoptosis induced by HIV-1 gp120. We observed that HIV-1 gp120-induced apoptosis was significantly reduced in a CD45-deficient cell line and that reconstitution of CD45 in these cells restored gp120-induced apoptosis. However, expression of a chimeric protein containing only the intracellular phosphatase domain was not able to restore the apoptotic function in the CD45-negative clone, indicating an important role for the extracellular domain of CD45 in this function. The role of CD45 in gp120-induced apoptosis was further confirmed in T cell lines and peripheral blood mononuclear cells using a selective CD45 inhibitor as well as CD45-specific small interfering RNA. We also observed that gp120 treatment induced CD45 association with the HIV coreceptor CXCR4. Further elucidation of downstream signaling events revealed that CD45 modulates HIV-1 gp120-induced apoptosis by regulating Fas ligand induction and activation of the phosphoinositide 3-kinase/Akt pathway. These results suggest a novel CD45-mediated mechanism for the HIV envelope-induced apoptosis of T cells.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Ctr Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Ganju, RK (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Ctr Med, Harvard Inst Med Bldg,Rm 343,4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu			NIAID NIH HHS [AI49140] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accornero P, 1998, FEBS LETT, V436, P461, DOI 10.1016/S0014-5793(98)01127-2; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Ameisen J C, 1995, Curr Top Microbiol Immunol, V200, P195; Badley AD, 2000, BLOOD, V96, P2951, DOI 10.1182/blood.V96.9.2951.h8002951_2951_2964; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Descamps G, 2004, J IMMUNOL, V173, P4953, DOI 10.4049/jimmunol.173.8.4953; DISOMMA MM, 1995, FEBS LETT, V363, P101, DOI 10.1016/0014-5793(95)00292-H; Dockrell DH, 1999, AIDS RES HUM RETROV, V15, P1509, DOI 10.1089/088922299309793; Eischen CM, 1997, J IMMUNOL, V159, P1135; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fernandez M, 2004, J MOL ENDOCRINOL, V33, P155, DOI 10.1677/jme.0.0330155; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fortin M, 2002, J IMMUNOL, V168, P6084, DOI 10.4049/jimmunol.168.12.6084; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Giovannetti A, 2000, AIDS RES HUM RETROV, V16, P211, DOI 10.1089/088922200309304; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Guntermann C, 1998, BIOCHEM BIOPH RES CO, V252, P69, DOI 10.1006/bbrc.1998.9595; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Klaus SJ, 1996, J IMMUNOL, V156, P2743; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Kozieradzki I, 1997, J IMMUNOL, V158, P3130; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; Oliveira DM, 2003, GENESIS, V36, P203, DOI 10.1002/gene.10212; PANTALEO G, 1995, NAT MED, V1, P118, DOI 10.1038/nm0295-118; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Shenoi H, 1999, J IMMUNOL, V162, P7120; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Sloand EM, 1997, BLOOD, V89, P1357, DOI 10.1182/blood.V89.4.1357; STAQUIER J, 1996, BLOOD, V87, P4959; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Urbanek RA, 2001, J MED CHEM, V44, P1777, DOI 10.1021/jm000447i; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu MX, 1996, J IMMUNOL, V157, P707	62	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12289	12299		10.1074/jbc.M511786200	http://dx.doi.org/10.1074/jbc.M511786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524887	hybrid			2022-12-27	WOS:000237134700013
J	Bluschke, B; Volkmer-Engert, R; Schneider, E				Bluschke, B; Volkmer-Engert, R; Schneider, E			Topography of the surface of the signal-transducing protein EIIA(Glc) that interacts with the MalK subunits of the maltose ATP-binding cassette transporter (MalFGK(2)) of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; ESCHERICHIA-COLI; INDUCER EXCLUSION; GLUCOSE-TRANSPORTER; SUGAR-TRANSPORT; IIA(GLC); DOMAIN; IIA(GLUCOSE); SEQUENCE	The signal-transducing protein EIIA(Glc), a component of the phosphoenolpyruvate-glucose phosphotransferase system, plays a key role in carbon regulation in enteric bacteria, such as Escherichia coli and Salmonella typhimurium. The phosphorylation state of EIIAGlc governs transport and metabolism of a number of carbohydrates. When glucose as preferred carbon source is transported, EIIAGlc becomes predominantly unphosphorylated and allosterically inhibits several permeases, including the maltose ATP-binding cassette transport system (MalFGK2) in a process termed "inducer exclusion." We have mapped the binding surface of EIIAGlc that interacts with the MalK subunits by using synthetic cellulose-bound peptide arrays like pep scan- and substitutional analyses. Three regions constituting two binding sites were identified encompassing residues 69-79 (I), 87-91 (II), and 118-127 (III). Region III is MalK-specific, whereas residues from regions I and II partly overlap but are not identical to the binding interfaces for interaction with glycerol kinase and lactose permease. These results were fully verified by studying the inhibitory effect of purified EIIAGlc variants carrying mutations at positions representative of each of the three regions on the ATPase activity of the purified maltose transport complex reconstituted into proteoliposomes. Moreover, a synthetic peptide encompassing residues 69-91 was demonstrated to partially inhibit ATPase activity. We also show for the first time that the N-terminal domain of EIIAGlc is essential for inducer exclusion.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Charite Univ Med Berlin, Inst Med Immunol, D-10098 Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.	erwin.schneider@rz.hu-berlin.de	Müller, Bettina/H-3276-2018	Müller, Bettina/0000-0002-0030-7710; Volkmer, Rudolf/0000-0003-4710-1143				BENTRUP KHZ, 1994, MICROBIOL-UK, V140, P945, DOI 10.1099/00221287-140-4-945; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; KUHNAU S, 1991, J BACTERIOL, V173, P2180; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; LEGELER JW, 1996, HDB BIOL PHYS; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MISKO TP, 1987, J BIOL CHEM, V262, P16261; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; REINEKE U, 2003, CURR OPIN BIOTECH, V12, P59; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Samanta S, 2003, J BIOL CHEM, V278, P35265, DOI 10.1074/jbc.M301171200; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SCHNEIDER E, 2003, ABC PROTEINS BACTERI, P157; Sondej M, 2000, BIOCHEMISTRY-US, V39, P2931, DOI 10.1021/bi9919596; Stein A, 2002, EUR J BIOCHEM, V269, P4074, DOI 10.1046/j.1432-1033.2002.03099.x; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; VOLKMERENGERT R, 1994, LETT PEPT SCI, V1, P243; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wang GS, 2003, PROTEIN SCI, V12, P1087, DOI 10.1110/ps.0301503; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; Weiser AA, 2005, ANAL BIOCHEM, V342, P300, DOI 10.1016/j.ab.2005.04.033; Wenschuh H, 2000, PRACT APPROACH SER, V233, P95; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZENG GQ, 1992, RES MICROBIOL, V143, P251, DOI 10.1016/0923-2508(92)90017-I	33	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12833	12840		10.1074/jbc.M512646200	http://dx.doi.org/10.1074/jbc.M512646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527815	hybrid			2022-12-27	WOS:000237134700078
J	Raghevendran, V; Patil, KR; Olsson, L; Nielsen, J				Raghevendran, V; Patil, KR; Olsson, L; Nielsen, J			Hap4 is not essential for activation of respiration at low specific growth rates in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; CHEMOSTAT CULTURES; METABOLIC NETWORK; YEAST; OXYGEN; IDENTIFICATION; REPRESSION; NUCLEAR; COMPLEX	In Saccharomyces cerevisiae, the heme-activated protein complex Hap2/3/4/5 plays a major role in the transcription of genes involved in respiration. Thus, overexpression of HAP4 has been shown to result in a 10% increase in the respiratory capacity. Here the physiology of a HAP4-deleted S. cerevisiae strain was investigated, and we found that the hap4 Delta S. cerevisiae exhibited poor growth on ethanol, although the growth rate on glucose was indifferent from the wild type in aerobic as well as anaerobic cultures. Moreover, it exhibited a large (75%) reduction in the critical glucose uptake rate at which fermentative metabolism is onset, indicating a substantial reduction in respiratory capacity. We also performed whole genome transcription analysis for the hap4 Delta and the wild type, grown in carbon-limited chemostat cultures operated at a dilution rate of 0.05 h(-1). Although both strains exhibited respiratory metabolism, there was significant change in expression of many genes in the hap4 Delta strain. These genes are involved in several different parts of the metabolism, including oxidative stress response, peroxisomal functions, and energy generation. This study strongly indicates that Hap4 activation only occurs at intermediate specific growth rates, below which the transcription of genes responsible for respiration is dependent on the Hap2/3/5 complex and above which the Hap4 protein augments the transcription. Furthermore, statistical analysis of the transcription data and integration of the data with a genome scale metabolic network provided new insight and evidence for the role of Hap4 in transcriptional regulation of mitochondrial respiration.	Tech Univ Denmark, BioCentrum, Ctr Microbial Biotechnol, DK-2800 Lyngby, Denmark	Technical University of Denmark	Nielsen, J (corresponding author), Tech Univ Denmark, BioCentrum, Ctr Microbial Biotechnol, Bldg 223, DK-2800 Lyngby, Denmark.	jn@biocentrum.dtu.dk	Raghavendran, Vijay/G-6425-2015; Patil, Kiran R/B-9709-2009; Nielsen, Jens/Q-1347-2017	Raghavendran, Vijay/0000-0002-2021-2786; Patil, Kiran R/0000-0002-6166-8640; /0000-0002-0827-5442; Nielsen, Jens/0000-0002-9955-6003				Bakker BM, 2000, J BACTERIOL, V182, P4730, DOI 10.1128/JB.182.17.4730-4737.2000; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Berkey CD, 2004, EUKARYOT CELL, V3, P311, DOI 10.1128/EC.3.2.311-317.2004; Brons JF, 2002, YEAST, V19, P923, DOI 10.1002/yea.886; Buschlen S, 2003, COMP FUNCT GENOM, V4, P37, DOI 10.1002/cfg.254; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; dos Santos MM, 2004, METAB ENG, V6, P352, DOI 10.1016/j.ymben.2004.06.002; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Gombert AK, 2001, J BACTERIOL, V183, P1441, DOI 10.1128/JB.183.4.1441-1451.2001; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HESHEY JWB, 1996, TRANSLATIONAL CONTRO; Kaniak A, 2004, EUKARYOT CELL, V3, P221, DOI 10.1128/EC.3.1.221-231.2004; KAPPELI O, 1986, ADV MICROB PHYSIOL, V28, P181; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lascaris R, 2004, MICROBIOL-SGM, V150, P929, DOI 10.1099/mic.0.26742-0; LEI F, 2001, THESIS TU DENMARK LY; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liu WD, 2002, EUR J BIOCHEM, V269, P3560, DOI 10.1046/j.1432-1033.2002.03047.x; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Machado CR, 1997, J MOL BIOL, V273, P114, DOI 10.1006/jmbi.1997.1302; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Patil KR, 2005, P NATL ACAD SCI USA, V102, P2685, DOI 10.1073/pnas.0406811102; Pinkham JL, 1997, CURR GENET, V31, P281, DOI 10.1007/s002940050207; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Seino A, 2005, BBA-GENE STRUCT EXPR, V1681, P166, DOI 10.1016/j.bbaexp.2004.11.009; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Stebbins JL, 2004, EUKARYOT CELL, V3, P339, DOI 10.1128/EC.3.2.339-347.2004; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; van Maris AJA, 2001, FEMS YEAST RES, V1, P139, DOI 10.1016/S1567-1356(01)00022-8; VERDUYN C, 1990, J GEN MICROBIOL, V136, P405, DOI 10.1099/00221287-136-3-405; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Westergaard SL, 2004, FEMS YEAST RES, V5, P193, DOI 10.1016/j.femsyr.2004.06.013; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; ZOLLNER A, 1994, CURR GENET, V25, P291, DOI 10.1007/BF00351480	38	27	27	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12308	12314		10.1074/jbc.M512972200	http://dx.doi.org/10.1074/jbc.M512972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522629	hybrid			2022-12-27	WOS:000237134700015
J	Wada, K; Nakajima, A; Katayama, K; Kudo, C; Shibuya, A; Kubota, N; Terauchi, Y; Tachibana, M; Miyoshi, H; Kamisaki, Y; Mayumi, T; Kadowaki, T; Blumberg, RS				Wada, K; Nakajima, A; Katayama, K; Kudo, C; Shibuya, A; Kubota, N; Terauchi, Y; Tachibana, M; Miyoshi, H; Kamisaki, Y; Mayumi, T; Kadowaki, T; Blumberg, RS			Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; PROGENITOR CELLS; GROWTH-FACTOR; CYCLE CONTROL; LIGANDS; KINASE; CANCER; MICE; MECHANISMS	Peroxisome proliferator-activated receptor gamma ( PPAR gamma) plays an important role in insulin sensitivity, tissue homeostasis, and regulating cellular functions. We found high-level expression of PPAR gamma in embryo mouse brain and neural stem cells (NSCs), in contrast to extremely low levels in adult mouse brain. Here, we show that PPAR gamma mediates the proliferation and differentiation of murine NSCs via up-regulation of the epidermal growth factor receptor and activation of the ERK pathway. Cell growth rates of NSCs prepared from heterozygous PPAR gamma-deficient mouse brains, PPAR gamma-RNA-silenced NSCs, and PPAR gamma dominant-negative NSCs were significantly decreased compared with those of wild-type NSCs. Physiological concentrations of PPAR gamma agonists, rosiglitazone and pioglitazone, stimulated NSC growth, whereas antagonists caused cell death in a concentration-dependent manner via activation of the caspase cascade. The stimulation of cell growth by PPAR gamma was associated with a rapid activation of the ERK pathway by phosphorylation and up-regulation of epidermal growth factor receptor and cyclin B protein levels. In contrast, activation of PPAR gamma by agonists inhibited the differentiation of NSCs into neurons. The inhibition of differentiation was associated with an activation of STAT3. These data indicate that PPAR gamma regulates the development of the central nervous system during early embryogenesis via control of NSC proliferation.	Osaka Univ, Grad Sch Dent, Dept Pharmacol, Suita, Osaka 5650871, Japan; Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yokohama City Univ, Sch Med, Dept Internal Med 3, Yokohama, Kanagawa 2360004, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan; Univ Tokyo, Bunkyo Ku, Dept Metab Dis, Grad Sch Med, Tokyo 1130033, Japan; Tsukuba Inst, RIKEN, BioResource Ctr, Subteam Manipulat Cell Fate, Ibaraki 3050074, Japan	Osaka University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yokohama City University; Osaka University; University of Tokyo; RIKEN	Wada, K (corresponding author), Osaka Univ, Grad Sch Dent, Dept Pharmacol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kwada@dent.osaka-u.ac.jp	Mayumi, Toshihiko/AAC-7418-2019; Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015; Miyoshi, Hiroyuki/G-9808-2013	Tachibana, Masashi/0000-0002-0376-508X	NIDDK NIH HHS [DK44319, DK53056, DK51362] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044319, R01DK044319, R01DK053056, R01DK051362] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Chang TH, 2000, CANCER RES, V60, P1129; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GRANA X, 1995, ONCOGENE, V11, P211; Gritti A, 1996, J NEUROSCI, V16, P1091; Han SW, 2001, CLIN CANCER RES, V7, P98; HANAOKATAHARA S, 2002, EXP HEMATOL, V30, P11; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Katayama K, 2003, GASTROENTEROLOGY, V124, P1315, DOI 10.1016/S0016-5085(03)00262-2; Katayama K, 2004, FEBS LETT, V560, P178, DOI 10.1016/S0014-5793(04)00100-0; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; LEBRASSEUR NK, 2006, AM J PHYSL ENDOCRINO; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Reh TA, 2002, NAT NEUROSCI, V5, P392, DOI 10.1038/nn0502-392; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Saha AK, 2004, BIOCHEM BIOPH RES CO, V314, P580, DOI 10.1016/j.bbrc.2003.12.120; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torii MA, 1999, DEVELOPMENT, V126, P443; Toyota M, 2002, LIFE SCI, V70, P1565, DOI 10.1016/S0024-3205(01)01524-7; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x	38	140	149	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12673	12681		10.1074/jbc.M513786200	http://dx.doi.org/10.1074/jbc.M513786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524877	hybrid			2022-12-27	WOS:000237134700058
J	Peeters, E; Willaert, R; Maes, D; Charlier, D				Peeters, E; Willaert, R; Maes, D; Charlier, D			Ss-LrpB from Sulfolobus solfataricus condenses about 100 base pairs of its own operator DNA into globular nucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING FORCE MICROSCOPY; REGULATORY PROTEIN; TRANSCRIPTIONAL REGULATOR; ESCHERICHIA-COLI; BINDING PROTEIN; EXPRESSION; FAMILY; FORMS	Ss-LrpB from the hyperthermoacidophilic crenarchaeote Sulfolobus solfataricus P2 is a member of the Lrp-like family of Bacterial/ Archaeal transcription regulators that binds its own control region at three regularly spaced and partially conserved 15-bp-long imperfect palindromes. We have used atomic force microscopy to analyze the architecture of Ss-LrpB . DNA complexes with a different stoichiometry formed with the wild type operator and with an operator mutant. Binding of dimeric Ss-LrpB to all three target sites is accompanied by the formation of globular complexes, in which the protein induces strong DNA deformations. Furthermore, DNA contour length foreshortening of these complexes indicates DNA wrapping, with about 100 bp being condensed. The average bending angle is 260 degrees. The establishment of protein-protein contacts between Ss-LrpB dimers in these globular complexes will contribute to the cooperativity of the binding. The profound remodeling of the control region is expected to have a strong impact on gene expression and might constitute the key element in the autoregulatory process.	Vrije Univ Brussel, Erfelijkheidsleer Microbiol, B-1050 Brussels, Belgium; Vrije Univ Brussel, Lab Ultrastruct, B-1050 Brussels, Belgium; Vlaams Interuniv Inst Biotechnol, B-1050 Brussels, Belgium	Vrije Universiteit Brussel; Vrije Universiteit Brussel	Charlier, D (corresponding author), Vrije Univ Brussel, Erfelijkheidsleer Microbiol, Pleinlaan 2, B-1050 Brussels, Belgium.	dcharlie@vub.ac.be		Peeters, Eveline/0000-0001-7423-8714; Maes, Dominique/0000-0002-9179-3186; Willaert, Ronnie/0000-0002-5400-7019; Charlier, Daniel/0000-0002-6844-376X				Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Beerens N, 2005, J BIOL CHEM, V280, P4722, DOI 10.1074/jbc.M409147200; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; Dame RT, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni073; Dame RT, 2005, NUCLEIC ACIDS RES, V33, P2767, DOI 10.1093/nar/gki577; Dame RT, 2003, J MICROSC-OXFORD, V212, P244, DOI 10.1111/j.1365-2818.2003.01243.x; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; Enoru-Eta J, 2002, MOL MICROBIOL, V45, P1541, DOI 10.1046/j.1365-2958.2002.03136.x; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; Heddle JG, 2004, J MOL BIOL, V337, P597, DOI 10.1016/j.jmb.2004.01.049; Jafri S, 2002, J BACTERIOL, V184, P5293, DOI 10.1128/JB.184.19.5293-5300.2002; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; Koike H, 2004, P NATL ACAD SCI USA, V101, P2840, DOI 10.1073/pnas.0400109101; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; Ouhammouch M, 2001, EMBO J, V20, P146, DOI 10.1093/emboj/20.1.146; Peeters E, 2004, MOL MICROBIOL, V54, P321, DOI 10.1111/j.1365-2958.2004.04274.x; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0; ZILLIG W, 1980, ARCH MICROBIOL, V125, P259, DOI 10.1007/BF00446886	32	20	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11721	11728		10.1074/jbc.M600383200	http://dx.doi.org/10.1074/jbc.M600383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522627	hybrid			2022-12-27	WOS:000236988100036
J	Sastry, SK; Rajfur, Z; Liu, BP; Cote, JF; Tremblay, ML; Burridge, K				Sastry, SK; Rajfur, Z; Liu, BP; Cote, JF; Tremblay, ML; Burridge, K			PTP-PEST couples membrane protrusion and tail retraction via VAV2 and p190RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; RAC ACTIVATION; CELL-ADHESION; C-SRC; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; PROTEIN; SUBSTRATE; MIGRATION	Cell motility is regulated by a balance between forward protrusion and tail retraction. These phenomena are controlled by a spatial asymmetry in signals at the front and the back of the cell. We show here that the protein-tyrosine phosphatase, PTP-PEST, is required for the coupling of protrusion and retraction during cell migration. PTP-PEST null fibroblasts, which are blocked in migration, exhibit exaggerated protrusions at the leading edge and long, unretracted tails in the rear. This altered morphology is accompanied by changes in the activity of Rho GTPases, Rac1 and RhoA, which mediate protrusion and retraction, respectively. PTP-PEST null cells exhibit enhanced Rac1 activity and decreased RhoA activity. We further show that PTP-PEST directly targets the upstream regulators of Rac1 and RhoA, VAV2 and p190RhoGAP. Moreover, we demonstrate that the activities of VAV2 and p190RhoGAP are regulated by PTP-PEST. Finally, we present evidence indicating the VAV2 can be regulated by integrin-mediated adhesion. These data suggest that PTP-PEST couples protrusion and retraction by acting on VAV2 and p190RhoGAP to reciprocally modulate the activity of Rac1 and RhoA.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Biochem, Montreal, PQ H2W 1R7, Canada; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Texas System; University of Texas Medical Branch Galveston; Yale University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sastry, SK (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	sasastry@utmb.edu	Sastry, Sarita/A-1291-2013; Rajfur, Zenon/H-2506-2013	Rajfur, Zenon/0000-0003-1265-6480	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; HART M, 1995, METHOD ENZYMOL, V255, P129; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jamieson JS, 2005, J CELL SCI, V118, P5835, DOI 10.1242/jcs.02693; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200	66	53	56	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11627	11636		10.1074/jbc.M600897200	http://dx.doi.org/10.1074/jbc.M600897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513648	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000236988100026
J	Tomikawa, J; Fukatsu, K; Tanaka, S; Shiota, K				Tomikawa, J; Fukatsu, K; Tanaka, S; Shiota, K			DNA methylation-dependent epigenetic regulation of dimethylarginine dimethylaminohydrolase 2 gene in trophoblast cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; MOUSE EMBRYO; EXPRESSION; DEMETHYLATION; STEM; UNDERMETHYLATION; EMBRYOGENESIS; TRANSCRIPTION; LOCALIZATION	Trophoblast cell lineage is established through the first cellular differentiation in mammalian embryogenesis, and its developmental potential is restricted to the extraembryonic tissues contributing solely to the placenta. Several lines of evidence suggest a relative lack of importance of DNA methylation in gene regulation in the extraembryonic tissues when compared with embryonic ones. Here we analyzed the dynamics of epigenetic status in the upstream region of mouse Ddah2 gene, which was found to be specifically repressed in a stem cell population of trophoblast cell lineage. We found a tissue-dependent differentially methylated region in the regulatory region of the Ddah2 gene. This region was hypermethylated in trophoblast stem cells and was hypomethylated in differentiated cells both in vivo and in vitro. This change was well correlated with Ddah2 expression. In addition, in vitro methylation confined to the differentially methylated region was sufficient to repress promoter activity in the reporter assay. Furthermore, a repressive pattern of histone modifications was formed around the differentially methylated region in undifferentiated trophoblast stem cells with repressed Ddah2. Our data suggest that DNA methylation-mediated chromatin remodeling is involved in the regulation of the Ddah2 gene expression and thus is important even in trophoblast cell lineage.	Univ Tokyo, Lab Cellular Biochem Anim Resource Sci Vet Med Sc, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Tanaka, S (corresponding author), Univ Tokyo, Lab Cellular Biochem Anim Resource Sci Vet Med Sc, Bunkyo Ku, Tokyo 1138657, Japan.	asatoshi@mail.ecc.u-tokyo.ac.jp		Tanaka, Satoshi/0000-0002-4745-550X; Tomikawa, Junko/0000-0002-6149-1400				Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Gagioti S, 2000, BIOL REPROD, V62, P260, DOI 10.1095/biolreprod62.2.260; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Jones LC, 2003, BIOCHEM BIOPH RES CO, V310, P836, DOI 10.1016/j.bbrc.2003.09.097; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MacAllister RJ, 1996, BRIT J PHARMACOL, V119, P1533, DOI 10.1111/j.1476-5381.1996.tb16069.x; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200; Ohgane J, 2002, BIOCHEM BIOPH RES CO, V290, P701, DOI 10.1006/bbrc.2001.6258; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; ROSSANT J, 1986, DEV BIOL, V117, P567, DOI 10.1016/0012-1606(86)90325-8; Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tanaka M, 1999, MECH DEVELOP, V87, P129, DOI 10.1016/S0925-4773(99)00158-6; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tran CTL, 2000, GENOMICS, V68, P101, DOI 10.1006/geno.2000.6262; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400	36	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12163	12169		10.1074/jbc.M513782200	http://dx.doi.org/10.1074/jbc.M513782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520373	hybrid			2022-12-27	WOS:000236988100086
J	Fraser, ME; Hayakawa, K; Hume, MS; Ryan, DG; Brownie, ER				Fraser, ME; Hayakawa, K; Hume, MS; Ryan, DG; Brownie, ER			Interactions of GTP with the ATP-grasp domain of GTP-specific Succinyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-LACTATE LIGASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; RIBONUCLEOTIDE SYNTHETASE; STRUCTURAL CLASSIFICATION; NUCLEOTIDE SPECIFICITY; GLUTATHIONE SYNTHETASE; VANCOMYCIN RESISTANCE; CONFORMATIONAL-CHANGE	Two isoforms of succinyl-CoA synthetase exist in mammals, one specific for ATP and the other for GTP. The GTP-specific form of pig succinyl-CoA synthetase has been crystallized in the presence of GTP and the structure determined to 2.1 angstrom resolution. GTP is bound in the ATP-grasp domain, where interactions of the guanine base with a glutamine residue (Gln-20 beta) and with backbone atoms provide the specificity. The gamma-phosphate interacts with the side chain of an arginine residue (Arg-54 beta) and with backbone amide nitrogen atoms, leading to tight interactions between the gamma-phosphate and the protein. This contrasts with the structures of ATP bound to other members of the family of ATP-grasp proteins where the gamma-phosphate is exposed, free to react with the other substrate. To test if GDP would interact with GTP-specific succinyl-CoA synthetase in the same way that ADP interacts with other members of the family of ATP-grasp proteins, the structure of GDP bound to GTP-specific succinyl-CoA synthetase was also determined. A comparison of the conformations of GTP and GDP shows that the bases adopt the same position but that changes in conformation of the ribose moieties and the alpha- and beta-phosphates allow the gamma-phosphate to interact with the arginine residue and amide nitrogen atoms in GTP, while the beta-phosphate interacts with these residues in GDP. The complex of GTP with succinyl-CoA synthetase shows that the enzyme is able to protect GTP from hydrolysis when the active-site histidine residue is not in position to be phosphorylated.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H1, Canada	University of Calgary; Western University (University of Western Ontario); University of Alberta	Fraser, ME (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	frasm@ucalgary.ca		Fraser, Marie/0000-0001-8501-1494	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Fraser ME, 2002, BIOCHEMISTRY-US, V41, P537, DOI 10.1021/bi011518y; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce MA, 1999, BIOCHEMISTRY-US, V38, P7273, DOI 10.1021/bi990527s; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; KAUFMAN S, 1955, J BIOL CHEM, V216, P141; KAUFMAN S, 1953, J BIOL CHEM, V203, P869; Kuzin AP, 2000, STRUCT FOLD DES, V8, P463, DOI 10.1016/S0969-2126(00)00129-5; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO GX, 1992, J BIOL CHEM, V267, P9516; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURAKAMI K, 1972, J BIOL CHEM, V247, P6247; MURAKAMI Y, 1974, BIOCHIM BIOPHYS ACTA, V336, P252, DOI 10.1016/0005-2795(74)90402-4; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Roper DI, 2000, P NATL ACAD SCI USA, V97, P8921, DOI 10.1073/pnas.150116497; Sakai H, 2003, J MOL BIOL, V332, P729, DOI 10.1016/S0022-2836(03)00946-X; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; SMITH CM, 1974, J BIOL CHEM, V249, P1497; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 2002, J BIOL CHEM, V277, P23898, DOI 10.1074/jbc.M202251200; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	56	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11058	11065		10.1074/jbc.M511785200	http://dx.doi.org/10.1074/jbc.M511785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481318	hybrid			2022-12-27	WOS:000236822200047
J	Nemoto, S; Combs, CA; French, S; Ahn, BH; Fergusson, MM; Balaban, RS; Finkel, T				Nemoto, S; Combs, CA; French, S; Ahn, BH; Fergusson, MM; Balaban, RS; Finkel, T			The mammalian longevity-associated gene product p66(shc) regulates mitochondrial metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FLUORESCENCE RECOVERY; SYSTEMATIC RNAI SCREEN; PHOTOBLEACHING ED-FRAP; LIFE-SPAN; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; C-ELEGANS; SIGNALING PATHWAY; IN-VITRO; APOPTOSIS	Previous studies have determined that mice with a homozygous deletion in the adapter protein p66(shc) have an extended life span and that cells derived from these mice exhibit lower levels of reactive oxygen species. Here we demonstrate that a fraction of p66(shc) localizes to the mitochondria and that p66(shc-/-) fibroblasts have altered mitochondrial energetics. In particular, despite similar cytochrome content, under basal conditions, the oxygen consumption of spontaneously immortalized p66(shc-/-) mouse embryonic fibroblasts were lower than similarly maintained wild type cells. Differences in oxygen consumption were particularly evident under chemically uncoupled conditions, demonstrating that p66(shc-/-) cells have a reduction in both their resting and maximal oxidative capacity. We further demonstrate that reconstitution of p66(shc) expression in p66(shc-/-) cells increases oxygen consumption. The observed defect in oxidative capacity seen in p66(shc-/-) cells is partially offset by augmented levels of aerobic glycolysis. This metabolic switch is manifested by p66(shc-/-) cells exhibiting an increase in lactate production and a stricter requirement for extracellular glucose in order to maintain intracellular ATP levels. In addition, using an in vivo NADH photobleaching technique, we demonstrate that mitochondrial NADH metabolism is reduced in p66(shc-/-) cells. These results demonstrate that p66(shc) regulates mitochondrial oxidative capacity and suggest that p66(shc) may extend life span by repartitioning metabolic energy conversion away from oxidative and toward glycolytic pathways.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Light Microscopy Facil, Bethesda, MD 20892 USA; NHLBI, Cardiac Energet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@nih.gov	Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005012, ZIAHL004601, Z01HL004601, Z01HL005012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Combs CA, 2004, METHOD ENZYMOL, V385, P257; Combs CA, 2001, BIOPHYS J, V80, P2018, DOI 10.1016/S0006-3495(01)76172-3; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Francia P, 2004, CIRCULATION, V110, P2889, DOI 10.1161/01.CIR.0000147731.24444.4D; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Johnson TE, 2001, EXP GERONTOL, V36, P1609, DOI 10.1016/S0531-5565(01)00144-9; Joubert F, 2004, BIOPHYS J, V86, P629, DOI 10.1016/S0006-3495(04)74141-7; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; SARIBANSOHRABY S, 1983, CANCER RES, V43, P4662; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751	27	120	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10555	10560		10.1074/jbc.M511626200	http://dx.doi.org/10.1074/jbc.M511626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481327	hybrid			2022-12-27	WOS:000236594300086
J	Zimmerman, TL; Thevananther, S; Ghose, R; Burns, AR; Karpen, SJ				Zimmerman, Tracy L.; Thevananther, Sundararajah; Ghose, Romi; Burns, Alan R.; Karpen, Saul J.			Nuclear export of retinoid X receptor alpha in response to interleukin-1 beta-mediated cell signaling - Roles for JNK and Ser(260)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACUTE-PHASE RESPONSE; VITAMIN-D-RECEPTOR; ANION TRANSPORTERS; ACID RECEPTORS; BILE-ACIDS; PHOSPHORYLATION; LIVER; EXPRESSION; CYTOKINES	As the obligate heterodimer partner to class II nuclear receptors, the retinoid X receptor alpha( RXR alpha) plays a vital physiological role in the regulation of multiple hepatic functions, including bile formation, intermediary metabolism, and endobiotic/xenobiotic detoxification. Many RXR alpha-regulated genes are themselves suppressed in inflamed liver via unknown mechanisms, which constitute a substantial component of the negative hepatic acute phase response. In this study we show that RXR alpha, generally considered a stable nuclear resident protein, undergoes rapid nuclear export in response to signals initiated by the pro-inflammatory cytokine interleukin-1 beta( IL-1 beta), a central activator of the acute phase response. Within 30 min of exposure to IL-1 beta, nuclear levels of RXR alpha are markedly suppressed in human liver-derived HepG2 cells, temporally coinciding with its appearance in the cytoplasm. The nuclear residence of RXR alpha is maintained by inhibiting c-jun N-terminal kinase ( JNK, curcumin or SP600125) or CRM-1-mediated nuclear export ( Leptomycin B). Pretreatment with the proteasome inhibitor MG132 blocks IL-1 beta-mediated reductions in nuclear RXR alpha levels while increasing accumulation in the cytoplasm. Mutational studies identify one residue, serine 260, a JNK phosphoacceptor site whose phosphorylation status had an unknown role in RXR alpha function, as critical for IL-1 beta-mediated nuclear export of transfected human RXR alpha-green fluorescent fusion constructs. These findings indicate that inflammation-mediated cell signaling leads to rapid and profound reductions in nuclear RXR alpha levels, via a multistep, JNK-dependent mechanism involving Ser260, nuclear export, and proteasomal degradation. Thus, inflammation-meditated cell signaling targets RXR alpha for nuclear export and degradation; a potential mechanism that explains the broad suppression of RXR alpha-dependent gene expression in the inflamed liver.	Baylor Coll Med, TX Childrens Liver Ctr, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine	Karpen, SJ (corresponding author), Baylor Coll Med, TX Childrens Liver Ctr, Dept Pediat, 1 Baylor Pl, Houston, TX 77030 USA.	skarpen@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338, R01DK056239] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46773] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239, R01 DK056239-05, DK56239, DK56338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Bruck N, 2005, CELL SIGNAL, V17, P1229, DOI 10.1016/j.cellsig.2004.12.006; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835; Feingold KR, 1996, J LIPID RES, V37, P223; Geier A, 2003, HEPATOLOGY, V38, P345, DOI 10.1053/jhep.2003.50317; Ghose Romi, 2004, Nucl Recept, V2, P4, DOI 10.1186/1478-1336-2-4; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hartmann G, 2002, J PHARMACOL EXP THER, V303, P273, DOI 10.1124/jpet.102.039404; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; MATKOVITS T, 1995, MOL ENDOCRINOL, V9, P232, DOI 10.1210/me.9.2.232; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Moseley Richard H, 2004, Clin Liver Dis, V8, P83; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Poulos JE, 1997, AM J PHYSIOL-GASTR L, V273, pG804, DOI 10.1152/ajpgi.1997.273.4.G804; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	34	81	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15434	15440		10.1074/jbc.M508277200	http://dx.doi.org/10.1074/jbc.M508277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551633	hybrid			2022-12-27	WOS:000237922200049
J	Detmers, FJM; De Groot, BL; Muller, EM; Hinton, A; Konings, IBM; Sze, M; Flitsch, SL; Grubmuller, H; Deen, PMT				Detmers, Frank J. M.; De Groot, Bert L.; Mueller, E. Matthias; Hinton, Andrew; Konings, Irene B. M.; Sze, Mozes; Flitsch, Sabine L.; Grubmueller, Helmut; Deen, Peter M. T.			Quaternary ammonium compounds as water channel blockers - Specificity, potency, and site of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; MOLECULAR-DYNAMICS; POTASSIUM CHANNEL; AQUAPORIN CHIP; EXPRESSION; MEMBRANE; MICE; GENE; SELECTIVITY; PERMEATION	Excessive water uptake through Aquaporins (AQP) can be life-threatening and reversible AQP inhibitors are needed. Here, we determined the specificity, potency, and binding site of tetraethylammonium (TEA) to block Aquaporin water permeability. Using oocytes, externally applied TEA blocked AQP1/AQP2/AQP4 with IC50 values of 1.4, 6.2, and 9.8 mu M, respectively. Related tetraammonium compounds yielded some ( propyl) or no ( methyl, butyl, or pentyl) inhibition. TEA inhibition was lost upon a Tyr to Phe amino acid switch in the external water pore of AQP1/AQP2/AQP4, whereas the water permeability of AQP3 and AQP5, which lack a corresponding Tyr, was not blocked by TEA. Consistent with experimental data, multi-nanosecond molecular dynamics simulations showed one stable binding site for TEA, but not tetramethyl (TMA), in AQP1, resulting in a nearly 50% water permeability inhibition, which was reduced in AQP1-Y186F due to effects on the TEA inhibitory binding region. Moreover, in the simulation TEA interacted with charged residues in the C (Asp128) and E (Asp185) loop, and the A(Tyr37-Asn42-Thr44) loop of the neighboring monomer, but not directly with Tyr186. The loss of TEA inhibition in oocytes expressing properly folded AQP1-N42A or -T44A is in line with the computationally predicted binding mode. Our data reveal that the molecular interaction of TEA with AQP1 differs and is about 1000-fold more effective on AQPs than on potassium channels. Moreover, the observed experimental and simulated similarities open the way for rational design and virtual screening for AQP-specific inhibitors, with quaternary ammonium compounds in general, and TEA in particular as a lead compound.	RUNMC Nijmegen, Dept Physiol 286, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Biophys Chem, Theoret & Computat Biophys Dept, D-37077 Gottingen, Germany; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Radboud University Nijmegen; Max Planck Society; University of Edinburgh	Deen, PMT (corresponding author), RUNMC Nijmegen, Dept Physiol 286, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.deen@ncmls.ru.nl	Deen, P.M.T./H-8023-2014; Deen, Peter MT/B-9854-2013; Flitsch, Sabine/AAJ-6812-2020	Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655; Flitsch, Sabine/0000-0003-3974-646X				*ACC INC, 2000, INS MOD ENV REL 2000; BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184; BERENDSEN HJ, 2004, INTERMOLECULAR FORCE; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Blaustein RO, 2004, NATURE, V427, P499, DOI 10.1038/427499a; Brooks HL, 2000, MOL PHARMACOL, V57, P1021; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Deen PMT, 2000, EUR J CELL BIOL, V79, P523, DOI 10.1078/0171-9335-00075; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Deen PMT, 1997, PFLUG ARCH EUR J PHY, V433, P780, DOI 10.1007/s004240050345; DeLano W.L, PYMOL MOL GRAPHICS S; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; Knoers NVAM, 2001, PEDIATR NEPHROL, V16, P1146, DOI 10.1007/s004670100051; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Lee MD, 1996, J BIOL CHEM, V271, P8599, DOI 10.1074/jbc.271.15.8599; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lu MQ, 1996, P NATL ACAD SCI USA, V93, P10908, DOI 10.1073/pnas.93.20.10908; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; Marr N, 2001, PFLUG ARCH EUR J PHY, V442, P73, DOI 10.1007/s004240000498; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Mulders SM, 1998, PFLUG ARCH EUR J PHY, V436, P599, DOI 10.1007/s004240050677; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; PEARLMAN RS, 1998, CONCORD USERS MANUAL; Pedersen RS, 2003, KIDNEY INT, V63, P1417, DOI 10.1046/j.1523-1755.2003.00858.x; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Song YL, 2002, J PHYSIOL-LONDON, V541, P561, DOI 10.1113/jphysiol.2001.020180; Sougrat R, 2002, J INVEST DERMATOL, V118, P678, DOI 10.1046/j.1523-1747.2002.01710.x; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; van Balkom BWM, 2003, J BIOL CHEM, V278, P1101, DOI 10.1074/jbc.M207339200; van Os CH, 2000, PFLUG ARCH EUR J PHY, V440, P513, DOI 10.1007/s004240000317; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; VANGUNSTEREN WF, 1987, GROMOS MANUAL BIOMOS; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Widmer A., 1997, WITNOTP COMPUTER PRO; Yool Andrea J, 2002, BMC Physiol, V2, P4, DOI 10.1186/1472-6793-2-4; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	59	104	110	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14207	14214		10.1074/jbc.M513072200	http://dx.doi.org/10.1074/jbc.M513072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551622	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000237512300044
J	Seo, BB; Nakamaru-Ogiso, E; Flotte, TR; Matsuno-Yagi, A; Yagi, T				Seo, Byoung Boo; Nakamaru-Ogiso, Eiko; Flotte, Terence R.; Matsuno-Yagi, Akemi; Yagi, Takao			In vivo complementation of complex I by the yeast Ndi1 enzyme - Possible application for treatment of Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-QUINONE OXIDOREDUCTASE; ADENOASSOCIATED VIRAL VECTORS; INSENSITIVE INTERNAL NADH; SACCHAROMYCES-CEREVISIAE MITOCHONDRIA; UBIQUINONE OXIDOREDUCTASE; OXIDATIVE-PHOSPHORYLATION; RESPIRATORY-CHAIN; MAMMALIAN-CELLS; GENE-THERAPY; DEFECTS	Recent studies suggest that dysfunction of the NADH-quinone oxidoreductase (complex I) is associated with a number of human diseases, including neurodegenerative disorders such as Parkinson disease. We have shown previously that the single subunit rote-none-insensitive NADH-quinone oxidoreductase (NdI1) of Saccharomyces cerevisiae mitochondria can restore NADH oxidation in complex I-deficient mammalian cells. The Ndi1 enzyme is insensitive to complex I inhibitors such as rotenone and 1-methyl-4-phenylpyridinium ion, known as a metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). To test the possible use of the NDI1 gene as a therapeutic agent in vivo, we chose amouse model of Parkinson disease. The NDI1-recombinant adeno-associated virus particles (rAAV-NDI1) were injected unilaterally into the substantia nigra of mice. The animals were then subjected to treatment with MPTP. The degree of neurodegeneration in the nigrostriatal system was assessed immunohistochemically through the analysis of tyrosine hydroxylase and glial fibrillary acidic protein. It was evident that the substantia nigra neurons on the side used for injection of rAAV-NDI1 retained a high level of tyrosine hydroxylase-positive cells, and the ipsilateral striatum exhibited significantly less denervation than the contralateral striatum. Furthermore, striatal concentrations of dopamine and its metabolites in the hemisphere that received rAAV-NDI1 were substantially higher than those of the untreated hemisphere, reaching more than 50% of the normal levels. These results indicate that the expressed NdI1 protein elicits resistance to MPTP-induced neuronal injury. The present study is the first successful demonstration of complementation of complex I by the NdI1 enzyme in animals.	Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Florida, Genet Inst, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA	Scripps Research Institute; State University System of Florida; University of Florida	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ayagi@scripps.edu; yagi@scripps.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048441] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL59412] Funding Source: Medline; NIDDK NIH HHS [R01DK053244] Funding Source: Medline; NINDS NIH HHS [R01NS048441] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Champy P, 2004, J NEUROCHEM, V88, P63, DOI 10.1046/j.1471-4159.2003.02138.x; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; de Grey ADNJ, 2000, TRENDS BIOTECHNOL, V18, P394, DOI 10.1016/S0167-7799(00)01476-1; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; Hinchliffe P, 2005, SCIENCE, V309, P771, DOI 10.1126/science.1113988; Janssen RJRJ, 2004, EXPERT REV MOL DIAGN, V4, P143, DOI 10.1586/14737159.4.2.143; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Lau YS, 2003, METH MOLEC MED, V79, P103; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Muramatsu SI, 2002, HUM GENE THER, V13, P345, DOI 10.1089/10430340252792486; NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; SONSALLA PK, 1986, EUR J PHARMACOL, V129, P339, DOI 10.1016/0014-2999(86)90444-9; Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; WAGNER J, 1982, J NEUROCHEM, V38, P1241, DOI 10.1111/j.1471-4159.1982.tb07897.x; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7; Zullo SJ, 2001, SEMIN NEUROL, V21, P327, DOI 10.1055/s-2001-17949	37	68	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14250	14255		10.1074/jbc.M600922200	http://dx.doi.org/10.1074/jbc.M600922200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543240	hybrid			2022-12-27	WOS:000237512300049
J	Zhang, XL; Zhang, SW; Yamane, H; Wahl, R; Ali, A; Lofgren, JA; Kendall, RL				Zhang, Xiaoling; Zhang, Shiwen; Yamane, Harvey; Wahl, Robert; Ali, Arisha; Lofgren, Julie A.; Kendall, Richard L.			Kinetic mechanism of AKT/PKB enzyme family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; ADENOSINE 5'-DIPHOSPHATE PHOSPHORYLATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; 3-KINASE/AKT PATHWAY; INSULIN-RESISTANCE; AKT PROTOONCOGENE; CRYSTAL-STRUCTURE; MAMMALIAN TARGET; ACTIVATION	AKT/PKB is a phosphoinositide-dependent serine/threonine protein kinase that plays a critical role in the signal transduction of receptors. It also serves as an oncogene in the tumorigenesis of cancer cells when aberrantly activated by genetic lesions of the PTEN tumor suppressor, phosphatidylinositol 3-kinase, and receptor tyrosine kinase overexpression. Here we have characterized and compared kinetic mechanisms of the three AKT isoforms. Initial velocity studies revealed that all AKT isozymes follow the sequential kinetic mechanism by which an enzyme-substrate ternary complex forms before the product release. The empirically derived kinetic parameters are apparently different among the isoforms. AKT2 showed the highest K-m value for ATP, and AKT3 showed the highest k(cat) value. The patterns of product inhibition of AKT1, AKT2, and AKT3 by ADP were all consistent with an ordered substrate addition mechanism with ATP binding to the enzymes prior to the peptide substrate. Further analysis of steady state kinetics of AKT1 in the presence of dead-end inhibitors supported the finding and suggested that the AKT family of kinases catalyzes reactions via an Ordered Bi Bi sequential mechanism with ATP binding to the enzyme prior to peptide substrate and ADP being released after the phosphopeptide product. These results suggest that ATP is an initiating factor for the catalysis of AKT enzymes and may play a role in the regulation AKT enzyme activity in cells.	Amgen Inc, Dept Oncol Res, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Prot Sci, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mol Pharmacol, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen	Zhang, XL (corresponding author), Amgen Inc, Dept Oncol Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	xzhang@amgen.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dragoi AM, 2005, EMBO J, V24, P779, DOI 10.1038/sj.emboj.7600539; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; QAMAR R, 1993, BIOCHEMISTRY-US, V32, P6802, DOI 10.1021/bi00077a035; QAMAR R, 1992, BIOCHEMISTRY-US, V31, P9986, DOI 10.1021/bi00156a018; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Segel I.H, 1993, ENZYME KINETICS; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	55	30	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13949	13956		10.1074/jbc.M601384200	http://dx.doi.org/10.1074/jbc.M601384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540465	hybrid			2022-12-27	WOS:000237512300016
J	Dresios, J; Chan, YL; Wool, IG				Dresios, J; Chan, YL; Wool, IG			Determination of the amino acids in yeast ribosomal protein YS11 essential for the recognition of nucleotides in 18 S ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ANGSTROM-RESOLUTION; NEAMINE RESISTANCE; NEW-MODEL; MUTATION; L25; SUBUNIT; IDENTIFICATION; LOCALIZATION	The nucleotides in domain I of 18 S rRNA that are important for the binding of the essential yeast ribosomal protein YS11 are mainly in a kink- turn motif and the terminal loop of helix 11 ( H11). In the atomic structure of the Thermus thermophilus 30 S subunit, 16 amino acids in S17, the homolog of YS11, are within hydrogen bonding distance of nucleotides in 16 S rRNA. The homologous or analogous 16 amino acids in YS11 were replaced with alanine; nine of the substitutions slowed the growth of yeast cells. The most severe effects were caused by mutations R103A, N106A, K133A, T134A, and K151A. The T. thermophilus analogs of Arg(103), Asn(106), Thr(134), and Lys(151) contact nucleotides in the kink- turn motif of 16 S rRNA, whereas Lys(133) contacts nucleotides in the terminal loop of H11. These contacts are predominantly with backbone phosphate and sugar oxygens in regions that deviate from A- form geometry, suggesting that YS11 recognizes the shape of its rRNA- binding site rather than reading the sequence of nucleotides. The effect of the mutations on the binding of YS11 to a domain I fragment of 18 S rRNA accorded, in general, with their effect on growth. Mutations of seven YS11 amino acids ( Ser(77), Met(80), Arg(88), Tyr(97), Pro(130), Ser(132), and Arg(136)) whose homologs or analogs in S17 are within hydrogen bonding distance of nucleotides in 16 S rRNA did not affect binding. Apparently, proximities alone do not define either the amino acids or the nucleotides that are important for recognition.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Wool, IG (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 929 E 57th St, Chicago, IL 60637 USA.	irawool@uchicago.edu			NIGMS NIH HHS [GM33702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BOLLEN A, 1975, J MOL BIOL, V99, P795, DOI 10.1016/S0022-2836(75)80185-9; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Dresios J, 2005, J MOL BIOL, V345, P681, DOI 10.1016/j.jmb.2004.10.027; Dresios J, 2002, J MOL BIOL, V316, P475, DOI 10.1006/jmbi.2001.5374; ELBARADI TTAL, 1987, BIOCHIMIE, V69, P939, DOI 10.1016/0300-9084(87)90227-6; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; FOLLEY LS, 1994, GENETICS, V137, P369; HELD WA, 1974, J BIOL CHEM, V249, P3103; HERZOG A, 1979, MOL GEN GENET, V171, P15, DOI 10.1007/BF00274010; Jakovljevic J, 2004, MOL CELL, V14, P331, DOI 10.1016/S1097-2765(04)00215-1; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; KOOI EA, 1994, J MOL BIOL, V240, P243, DOI 10.1006/jmbi.1994.1438; Lescoute A, 2005, NUCLEIC ACIDS RES, V33, P2395, DOI 10.1093/nar/gki535; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; POWERS T, 1995, RNA, V1, P194; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RUTGERS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P74, DOI 10.1016/0167-4781(90)90144-Q; RUTGERS CA, 1991, J MOL BIOL, V218, P375, DOI 10.1016/0022-2836(91)90719-M; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; TRAUB P, 1968, J MOL BIOL, V34, P575, DOI 10.1016/0022-2836(68)90182-4; Urlaub H, 1997, J PROTEIN CHEM, V16, P375, DOI 10.1023/A:1026380504377; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; YAGUCHI M, 1976, J MOL BIOL, V104, P617, DOI 10.1016/0022-2836(76)90124-8	31	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13478	13484		10.1074/jbc.M513036200	http://dx.doi.org/10.1074/jbc.M513036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540469	hybrid			2022-12-27	WOS:000237336600055
J	Chen, YY; Sankala, M; Ojala, JRM; Sun, Y; Tuuttila, A; Isenman, DE; Tryggvason, K; Pikkarainen, T				Chen, YY; Sankala, M; Ojala, JRM; Sun, Y; Tuuttila, A; Isenman, DE; Tryggvason, K; Pikkarainen, T			A phage display screen and binding studies with acetylated low density lipoprotein provide evidence for the importance of the scavenger receptor cysteine-rich (SRCR) domain in the ligand-binding function of MARCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SPLENIC MARGINAL ZONE; LIPOTEICHOIC ACID; COLLAGENOUS STRUCTURE; CRYSTAL-STRUCTURE; HOST-DEFENSE; IN-VIVO; BACTERIA; PEPTIDE; LIPOPOLYSACCHARIDE	MARCO is a class A scavenger receptor capable of binding both Gram-negative and -positive bacteria. Using the surface plasmon resonance technique, we show here that a recombinant, soluble form of MARCO, sMARCO, binds the major Gram-negative and -positive bacterial surface components, lipopolysaccharide and lipoteichoic acid. Yet, the interaction of these two polyanions with sMARCO is of much lower affinity than that of polyinosinic acid, a polyanionic inhibitor of bacterial binding to MARCO. To further elucidate the ligand-binding functions of MARCO, we performed a phage display screen with sMARCO. The screening resulted in the enrichment of only a handful of phage clones. Contrary to expectations, no polyanionic peptides, but only those with a predominantly hydrophobic nature, were enriched. One peptide, VRWGSFAAWL, was displayed on two-thirds of the phages recovered after four rounds of screening. The VRWGSFAAWL phage-sMARCO interaction had significantly slower dissociation kinetics than that between sMARCO and lipopolysaccharide or lipoteichoic acid. Further work with this phage, and the second most enriched phage, displaying the peptide RLNWAWWLSY, demonstrated that both peptides bind to the SRCR domain of MARCO, and that they probably bind to the same site. Data base searches suggested that the VRWGSFAAWL peptide represents complement component C4, but we could not convincingly confirm this suggestion. A study with chimeric scavenger receptors indicated that even minor sequence changes in the MARCO scavenger receptor cysteine-rich (SRCR) domain can have profound effects on the binding of the prototypic scavenger receptor ligand, acetylated low density lipoprotein. As shown by differential binding of glutathione S-transferase-VRWGSFAAWL, these differences were very likely due to conformational changes. These findings led to experiments that demonstrated a crucial role of the SRCR domain for acetylated low density lipoprotein binding in MARCO. Thus, our results strengthen the notion that the SRCR domain is the major ligand-binding domain in MARCO. Furthermore, they suggest that the domain may contain multiple ligand-binding sites.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Toronto, Dept Biochem, Toronto, ON M55 1A8, Canada	Karolinska Institutet; University of Toronto	Pikkarainen, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.	timo.pikkarainen@ki.se		Ojala, Juha/0000-0003-2018-6124				Andrew CD, 2001, PROTEINS, V45, P449, DOI 10.1002/prot.1161; Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; ASHKENAS J, 1993, J LIPID RES, V34, P983; Aurell CA, 1998, BIOCHEM BIOPH RES CO, V253, P119, DOI 10.1006/bbrc.1998.9773; Bin LH, 2003, J IMMUNOL, V171, P924, DOI 10.4049/jimmunol.171.2.924; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Cardo-Vila M, 2003, MOL CELL, V11, P1151, DOI 10.1016/S1097-2765(03)00138-2; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Ito S, 1999, ARCH HISTOL CYTOL, V62, P83, DOI 10.1679/aohc.62.83; Karlsson MCI, 2003, J EXP MED, V198, P333, DOI 10.1084/jem.20030684; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; LABISCHINSKI H, 1991, EUR J BIOCHEM, V202, P1269, DOI 10.1111/j.1432-1033.1991.tb16499.x; Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200; Murai KK, 2003, MOL CELL NEUROSCI, V24, P1000, DOI 10.1016/j.mcn.2003.08.006; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; Pikkarainen T, 1999, J BIOL CHEM, V274, P10975, DOI 10.1074/jbc.274.16.10975; Pillutla RC, 2002, J BIOL CHEM, V277, P22590, DOI 10.1074/jbc.M202119200; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RISCO C, 1991, J HISTOCHEM CYTOCHEM, V39, P607, DOI 10.1177/39.5.2016511; Sankala M, 2002, J BIOL CHEM, V277, P33378, DOI 10.1074/jbc.M204494200; Santos NC, 2003, CHEMBIOCHEM, V4, P96, DOI 10.1002/cbic.200390020; Sarraj MA, 2005, DEV DYNAM, V234, P1026, DOI 10.1002/dvdy.20594; Stefanidakis M, 2003, J BIOL CHEM, V278, P34674, DOI 10.1074/jbc.M302288200; van den Elsen JMH, 2002, J MOL BIOL, V322, P1103, DOI 10.1016/S0022-2836(02)00854-9; van der Laan LJW, 1999, J IMMUNOL, V162, P939; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1; Wellinghausen N, 1996, J IMMUNOL, V157, P3139	37	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12767	12775		10.1074/jbc.M513628200	http://dx.doi.org/10.1074/jbc.M513628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524885	hybrid			2022-12-27	WOS:000237134700070
J	Niebisch, A; Kabus, A; Schultz, C; Weil, B; Bott, M				Niebisch, A; Kabus, A; Schultz, C; Weil, B; Bott, M			Corynebacterial protein kinase G controls 2-oxoglutarate dehydrogenase activity via the phosphorylation status of the OdhI protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; GLUTAMATE-PRODUCING BACTERIUM; MYCOBACTERIUM-TUBERCULOSIS; PYRUVATE-DEHYDROGENASE; MOLECULAR ANALYSIS; BREVIBACTERIUM-LACTOFERMENTUM; FHA DOMAINS; IN-VIVO; GLUTAMICUM; GROWTH	A novel regulatory mechanism for control of the ubiquitous 2-oxoglutarate dehydrogenase complex (ODH), a key enzyme of the tricarboxylic acid cycle, was discovered in the actinomycete Corynebacterium glutamicum, a close relative of important human pathogens like Corynebacterium diphtheriae and Mycobacterium tuberculosis. Based on the finding that a C. glutamicum mutant lacking serine/threonine protein kinase G (PknG) was impaired in glutamine utilization, proteome comparisons led to the identification of OdhI as a putative substrate of PknG. OdhI is a 15-kDa protein with a forkhead-associated domain and a homolog of mycobacterial GarA. By using purified proteins, PknG was shown to phosphorylate OdhI at threonine 14. The glutamine utilization defect of the Delta pknG mutant could be abolished by the additional deletion of odhI, whereas transformation of a Delta odhI mutant with a plasmid encoding OdhI-T14A caused a defect in glutamine utilization. Affinity purification of OdhI-T14A led to the specific copurification of OdhA, the E1 subunit of ODH. Because ODH is essential for glutamine utilization, we assumed that unphosphorylated OdhI inhibits ODH activity. In fact, OdhI was shown to strongly inhibit ODH activity with a K-i value of 2.4 nM. The regulatory mechanism described offers a molecular clue for the reduced ODH activity that is essential for the industrial production of 1.5 million tons/year of glutamate with C. glutamicum. Moreover, because this signaling cascade is likely to operate also in mycobacteria, our results suggest that the attenuated pathogenicity of mycobacteria lacking PknG might be caused by a disturbed tricarboxylic acid cycle.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bott, M (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany.	m.bott@fz-juelich.de	Bott, Michael/E-8004-2011	Bott, Michael/0000-0002-4701-8254				Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Belanger AE, 1999, J BACTERIOL, V181, P6670, DOI 10.1128/JB.181.21.6670-6678.1999; Cowley S, 2004, MOL MICROBIOL, V52, P1691, DOI 10.1111/j.1365-2958.2004.04085.x; CREMER J, 1990, MOL GEN GENET, V220, P478, DOI 10.1007/BF00391757; Eggeling L., 2005, HDB CORYNEBACTERIUM, DOI 10.1201/9781420039696; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kawahara Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1109, DOI 10.1271/bbb.61.1109; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI [10.2323/jgam.3.193, DOI 10.2323/JGAM.3.193]; KORNFELD S, 1977, J BIOL CHEM, V252, P2940; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; KRAMER R, 1990, EUR J BIOCHEM, V194, P929, DOI 10.1111/j.1432-1033.1990.tb19488.x; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Molle V, 2004, FEMS MICROBIOL LETT, V234, P215, DOI 10.1016/j.femsle.2004.03.033; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252; Nguyen L, 2005, J BACTERIOL, V187, P5852, DOI 10.1128/JB.187.16.5852-5856.2005; Niebisch A, 2001, ARCH MICROBIOL, V175, P282, DOI 10.1007/s002030100262; Pallen M, 2002, TRENDS MICROBIOL, V10, P556, DOI 10.1016/S0966-842X(02)02476-9; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2; Schreiner ME, 2005, J BACTERIOL, V187, P6005, DOI 10.1128/JB.187.17.6005-6018.2005; Schwinde JW, 2001, MICROBIOL-SGM, V147, P2223, DOI 10.1099/00221287-147-8-2223; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; SHIIO I, 1982, AGR BIOL CHEM TOKYO, V46, P493, DOI 10.1080/00021369.1982.10865088; SHIIO I, 1980, AGR BIOL CHEM TOKYO, V44, P1897, DOI 10.1080/00021369.1980.10864219; Shirai T, 2005, METAB ENG, V7, P59, DOI 10.1016/j.ymben.2004.10.001; SIEWE RM, 1995, ARCH MICROBIOL, V164, P98; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; Tian J, 2005, P NATL ACAD SCI USA, V102, P10670, DOI 10.1073/pnas.0501605102; Tian J, 2005, MOL MICROBIOL, V57, P859, DOI 10.1111/j.1365-2958.2005.04741.x; Usuda Y, 1996, MICROBIOL-UK, V142, P3347, DOI 10.1099/13500872-142-12-3347; Uy D, 2005, BIOPROC BIOSYST ENG, V27, P153, DOI 10.1007/s00449-004-0393-x; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102; Wittmann C, 2004, ANAL BIOCHEM, V327, P135, DOI 10.1016/j.ab.2004.01.002	41	150	173	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12300	12307		10.1074/jbc.M512515200	http://dx.doi.org/10.1074/jbc.M512515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522631	hybrid			2022-12-27	WOS:000237134700014
J	Yagasaki, Y; Numakawa, T; Kumamaru, E; Hayashi, T; Su, TP; Kunugi, H				Yagasaki, Y; Numakawa, T; Kumamaru, E; Hayashi, T; Su, TP; Kunugi, H			Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ACTIVITY; POSTMORTEM BRAIN; BINDING-SITES; MESSENGER-RNA; ELECTROCONVULSIVE SEIZURE; CA2+ OSCILLATIONS; MAP KINASE; EXPRESSION; PROTEIN; BDNF	Up-regulation of BDNF (brain-derived neurotrophic factor) has been suggested to contribute to the action of antidepressants. However, it is unclear whether chronic treatment with antidepressants may influence acute BDNF signaling in central nervous system neurons. Because BDNF has been shown by us to reinforce excitatory glutamatergic transmission in cultured cortical neurons via the phospholipase-gamma (PLC-gamma)/inositol 1,4,5-trisphosphate (IP3)/Ca2+ pathway (Numakawa, T., Yamagishi, S., Adachi, N., Matsumoto, T., Yokomaku, D., Yamada, M., and Hatanaka, H. (2002) J. Biol. Chem. 277, 6520-6529), we examined in this study the possible effects of pretreatment with antidepressants on the BDNF signaling through the PLC-gamma)/IP3/Ca2+ pathway. Furthermore, because the PLC-gamma IP3/Ca2+ pathway is regulated by sigma-1 receptors (Hayashi, T., and Su, T. P. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 491-496), we examined whether the BDNF signaling is modulated by sigma-1 receptors (Sig-1R). We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+](i)) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release. Furthermore, enhancement of the interaction between PLC-gamma and TrkB ( receptor for BDNF) after imipramine pretreatment was observed. Interestingly, BD1047, a potent Sig-1R antagonist, blocked the imipraminedependent potentiation on the BDNF-induced PLC-gamma activation and glutamate release. In contrast, overexpression of Sig-1R per se, without antidepressant pretreatment, enhances BDNF-induced PLC-gamma activation and glutamate release. These results suggest that antidepressant pretreatment selectively enhance the BDNF signaling on the PLC-gamma/IP3/Ca2+ pathway via Sig-1R, and that Sig-1R plays an important role in BDNF signaling leading to glutamate release.	NCNP, Dept Mental Disorder Res, Natl Inst Neurosci, Tokyo 1878502, Japan; DPS, Cellular Pathobiol Unit, Cellular Neurobiol Res Branch, Intramural Res Program,Dept Hlth & Human Serv,NID, Baltimore, MD 21224 USA	National Center for Neurology & Psychiatry - Japan	Numakawa, T (corresponding author), NCNP, Dept Mental Disorder Res, Natl Inst Neurosci, Tokyo 1878502, Japan.	numakawa@ncnp.go.jp	Kunugi, Hiroshi/ABC-5260-2021; Hayashi, Teruo/A-9690-2008	Kunugi, Hiroshi/0000-0002-7209-3790				Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6; Conti AC, 2002, J NEUROSCI, V22, P3262, DOI 10.1523/JNEUROSCI.22-08-03262.2002; COWBURN RF, 1994, BRAIN RES, V633, P297, DOI 10.1016/0006-8993(94)91552-0; Dijkhuizen PA, 2005, J NEUROBIOL, V62, P278, DOI 10.1002/neu.20100; Dowlatshahi D, 1999, J NEUROCHEM, V73, P1121, DOI 10.1046/j.1471-4159.1999.0731121.x; Duman RS, 2002, MOL PSYCHIATR, V7, pS29, DOI 10.1038/sj.mp.4001016; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Dwivedi Y, 2005, NEUROPSYCHOPHARMACOL, V30, P473, DOI 10.1038/sj.npp.1300605; Dwivedi Y, 2002, NEUROPHARMACOLOGY, V43, P1269, DOI 10.1016/S0028-3908(02)00253-8; Dwivedi Y, 2001, J NEUROCHEM, V77, P916, DOI 10.1046/j.1471-4159.2001.00300.x; Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804; Fitzgerald LR, 1996, J NEUROCHEM, V66, P429; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; Hayashi T, 2003, J PHARMACOL EXP THER, V306, P718, DOI 10.1124/jpet.103.051284; Hayashi T, 2003, J PHARMACOL EXP THER, V306, P726, DOI 10.1124/jpet.103.051292; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jensen JB, 2000, EUR NEUROPSYCHOPHARM, V10, P105, DOI 10.1016/S0924-977X(99)00064-4; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; KAWAMURA M, 2003, RRD NEUROCHEMISTRY, V6, P105; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Morin-Surun MP, 1999, P NATL ACAD SCI USA, V96, P8196, DOI 10.1073/pnas.96.14.8196; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Numakawa T, 2004, HUM MOL GENET, V13, P2699, DOI 10.1093/hmg/ddh280; Numakawa T, 1999, BRAIN RES, V842, P431, DOI 10.1016/S0006-8993(99)01867-3; Numakawa T, 2003, J BIOL CHEM, V278, P41259, DOI 10.1074/jbc.M304409200; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2002, J BIOL CHEM, V277, P28861, DOI 10.1074/jbc.M202927200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; Pandey GN, 1999, AM J PSYCHIAT, V156, P1895; Pilc A, 1995, NEUROREPORT, V7, P85, DOI 10.1097/00001756-199512290-00020; Reddy DS, 1998, NEUROREPORT, V9, P3069, DOI 10.1097/00001756-199809140-00028; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Saarelainen T, 2003, J NEUROSCI, V23, P349; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Shirayama Y, 1997, EUR J PHARMACOL, V331, P319, DOI 10.1016/S0014-2999(97)01051-0; Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4; Skolnick P, 1999, EUR J PHARMACOL, V375, P31, DOI 10.1016/S0014-2999(99)00330-1; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; Su TP, 2003, CURR MED CHEM, V10, P2073, DOI 10.2174/0929867033456783; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; Takebayashi M, 2004, PHARMACOPSYCHIATRY, V37, pS208, DOI 10.1055/s-2004-832679; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Urani A, 2001, J PHARMACOL EXP THER, V298, P1269; WAHL MI, 1992, J BIOL CHEM, V267, P10447; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	53	98	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12941	12949		10.1074/jbc.M508157200	http://dx.doi.org/10.1074/jbc.M508157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522641	hybrid			2022-12-27	WOS:000237134700089
J	Boughan, PK; Argent, RH; Body-Malapel, M; Park, JH; Ewings, KE; Bowie, AG; Ong, SJ; Cook, SJ; Sorensen, OE; Manzo, BA; Inohara, N; Klein, NJ; Nunez, G; Atherton, JC; Bajaj-Elliott, M				Boughan, PK; Argent, RH; Body-Malapel, M; Park, JH; Ewings, KE; Bowie, AG; Ong, SJ; Cook, SJ; Sorensen, OE; Manzo, BA; Inohara, N; Klein, NJ; Nunez, G; Atherton, JC; Bajaj-Elliott, M			Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor - Critical regulators of beta-defensins during helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASES; HUMAN BETA-DEFENSIN-2; INNATE IMMUNITY; INTERLEUKIN-8 SECRETION; ANTIMICROBIAL RESPONSE; GENE-EXPRESSION; INCREASED RISK; UP-REGULATION	Host-pathogen interactions that allow Helicobacter pylori to survive and persist in the stomach of susceptible individuals remain unclear. Human beta-defensins ( hBDs), epithelial-derived antimicrobial peptides are critical components of host-defense at mucosal surfaces. The role of H. pylori-mediated NF-kappa B and epidermal growth factor receptor ( EGFR) activation on beta-defensin expression was investigated. Transient transfection studies utilizing beta-defensin promoter constructs were conducted in gastric cells with contribution of individual signaling events evaluated by the addition of specific inhibitors, small interference nucleotide-binding oligomerization domain 1( NOD1) RNA or plasmids encoding Vaccinia virus proteins that interrupt interleukin-1 and Toll-like receptor signaling. The role of individual MAPK pathways was further delineated in HEK-293 cells expressing conditional MAPK mutants. We found hBD2 expression exclusively dependent on the presence of the bacterial cag pathogenicity island, with NOD1 a critical host sensor. Impairment of murine beta-defensin 4( an orthologue of hBD2) expression in NOD1-deficient mice 7-days post-infection further confirmed the role of this cytoplasmic pattern-recognition receptor in eliciting host innate immunity. In contrast to hBD2, hBD3 expression was NOD1-independent but EGFR and ERK pathway-dependent. Importantly, Toll-like receptor signaling was not implicated in H. pylori-mediated hBD2 and hBD3 gene expression. The divergent signaling events governing hBD2 and hBD3 expression suggest temporal functional variation, such that hBD2 may contribute to antimicrobial barrier function during the inflammatory phase with hBD3 playing a greater role during the repair, wound healing phase of infection.	Inst Child Hlth, Infect Dis & Microbiol Unit, London WC1N 1EH, England; Univ Nottingham, Queens Med Ctr, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Babraham Inst, Lab Mol Signaling, Cambridge CB2 4AT, England; Lund Univ, Biomed Ctr B14, Dept Clin Sci, Sect Clin & Expt Infect Med, SE-22184 Lund, Sweden; Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Biol, Res Ctr Gastroenterol, London E1 2AD, England	University of London; University College London; University of Nottingham; University of Nottingham; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Trinity College Dublin; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Lund University; University of London; Queen Mary University London	Bajaj-Elliott, M (corresponding author), Inst Child Hlth, Infect Dis & Microbiol Unit, 30 Guilford St, London WC1N 1EH, England.	M.Bajaj-Elliott@ich.ucl.ac.uk	Body-Malapel, Mathilde/K-9981-2018; Nuñez, Gabriel/A-7160-2014	Body-Malapel, Mathilde/0000-0003-3392-4229; /0000-0001-6180-0042; Bajaj-Elliott, Mona/0000-0002-5234-576X; Klein, Nigel/0000-0003-3925-9258; Bowie, Andrew/0000-0001-5316-4373	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199] Funding Source: Medline; NIDDK NIH HHS [R01-DK61707] Funding Source: Medline; Wellcome Trust [065883] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Atherton JC, 1998, BRIT MED BULL, V54, P105; Atherton JC, 1997, GUT, V40, P701, DOI 10.1136/gut.40.6.701; Bajaj-Elliott M, 2002, GUT, V51, P356, DOI 10.1136/gut.51.3.356; Bebb JR, 2003, INFECT IMMUN, V71, P3623, DOI 10.1128/IAI.71.6.3623-3627.2003; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 2000, J EXP MED, V191, P587, DOI 10.1084/jem.191.4.587; Crabtree JE, 1999, J CLIN PATHOL, V52, P653, DOI 10.1136/jcp.52.9.653; CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Finlay BB, 2004, NAT REV MICROBIOL, V2, P497, DOI 10.1038/nrmicro908; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; George JT, 2003, MOL IMMUNOL, V40, P451, DOI 10.1016/S0161-5890(03)00158-5; Gewirtz AT, 2004, J INFECT DIS, V189, P1914, DOI 10.1086/386289; Hamanaka Y, 2001, GUT, V49, P481, DOI 10.1136/gut.49.4.481; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; Jang BC, 2004, BIOCHEM BIOPH RES CO, V320, P1026, DOI 10.1016/j.bbrc.2004.06.049; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; Keates S, 2005, GUT, V54, P1363, DOI 10.1136/gut.2005.066977; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kim SY, 2006, CELL MICROBIOL, V8, P97, DOI 10.1111/j.1462-5822.2005.00603.x; Leahy DJ, 2004, ADV PROTEIN CHEM, V68, P1; Levenstein S, 1999, CAN J GASTROENTEROL, V13, P753, DOI 10.1155/1999/521393; Liu LD, 2003, J IMMUNOL, V170, P575, DOI 10.4049/jimmunol.170.1.575; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Naumann M, 2001, INT J MED MICROBIOL, V291, P299, DOI 10.1078/1438-4221-00133; Naumann M, 2004, TRENDS MICROBIOL, V12, P29, DOI 10.1016/j.tim.2003.11.005; Nozawa Y, 2002, BIOCHEM PHARMACOL, V64, P21, DOI 10.1016/S0006-2952(02)01030-4; O'Neil DA, 2000, INFECT IMMUN, V68, P5412, DOI 10.1128/IAI.68.9.5412-5415.2000; Ozato K, 2002, BIOTECHNIQUES, P66; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Rittig MG, 2003, CELL MICROBIOL, V5, P887, DOI 10.1046/j.1462-5822.2003.00328.x; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Semple CAM, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-32; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Torok AM, 2005, INFECT IMMUN, V73, P1523, DOI 10.1128/IAI.73.3.1523-1531.2005; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wang XR, 2003, FASEB J, V17, P1727, DOI 10.1096/fj.02-0616fje; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Zilbauer M, 2005, INFECT IMMUN, V73, P7281, DOI 10.1128/IAI.73.11.7281-7289.2005	70	141	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11637	11648		10.1074/jbc.M510275200	http://dx.doi.org/10.1074/jbc.M510275200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513653	hybrid			2022-12-27	WOS:000236988100027
J	Hakansson-McReynolds, S; Jiang, SK; Rong, LJ; Caffrey, M				Hakansson-McReynolds, S; Jiang, SK; Rong, LJ; Caffrey, M			Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURE DETERMINATION; SIMIAN IMMUNODEFICIENCY VIRUS; SARS-ASSOCIATED CORONAVIRUS; PROTEIN FUSION CORE; 44 KDA ECTODOMAIN; MEMBRANE-FUSION; SPIKE PROTEIN; CRYSTAL-STRUCTURE; INFLUENZA HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN	The envelope glycoprotein, termed the spike protein, of severe acute respiratory syndrome coronavirus (SARS-CoV) is known to mediate viral entry. Similar to other class 1 viral fusion proteins, the heptad repeat regions of SARS-CoV spike are thought to undergo conformational changes from a prefusion form to a subsequent post-fusion form that enables fusion of the viral and host membranes. Recently, the structure of a post-fusion form of SARS-CoV spike, which consists of isolated domains of heptad repeats 1 and 2 (HR1 and HR2), has been determined by x-ray crystallography. To date there is no structural information for the prefusion conformations of SARS-CoV HR1 and HR2. In this work we present the NMR structure of the HR2 domain ( residues 1141 - 1193) from SARS-CoV ( termed S2-HR2) in the presence of the co-solvent trifluoroethanol. We find that in the absence of HR1, S2-HR2 forms a coiled coil symmetric trimer with a complex molecular mass of 18 kDa. The S2-HR2 structure, which is the first example of the prefusion form of coronavirus envelope, supports the current model of viral membrane fusion and gives insight into the design of structure-based antagonists of SARS.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Caffrey, M (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.	caffrey@uic.edu						BAX A, 1994, METHOD ENZYMOL, V239, P79; Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 2001, BBA-MOL BASIS DIS, V1536, P116, DOI 10.1016/S0925-4439(01)00042-4; Caffrey M, 1997, J MOL BIOL, V271, P819, DOI 10.1006/jmbi.1997.1217; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOUGHERTY WG, 1989, VIROLOGY, V172, P302, DOI 10.1016/0042-6822(89)90132-3; Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008; Huth JR, 1997, PROTEIN SCI, V6, P2359; Hwang TL, 1998, J BIOMOL NMR, V11, P221, DOI 10.1023/A:1008276004875; Jiang SK, 2002, J BIOMOL NMR, V24, P365, DOI 10.1023/A:1021641814058; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Lamb RA, 2006, VIROLOGY, V344, P30, DOI 10.1016/j.virol.2005.09.007; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lindhout DA, 2004, BIOPOLYMERS, V75, P367, DOI 10.1002/bip.20150; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Stuart AC, 1999, J AM CHEM SOC, V121, P5346, DOI 10.1021/ja984172w; Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322; Yin HS, 2005, P NATL ACAD SCI USA, V102, P9288, DOI 10.1073/pnas.0503989102; Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141	64	39	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11965	11971		10.1074/jbc.M601174200	http://dx.doi.org/10.1074/jbc.M601174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507566	hybrid, Green Published			2022-12-27	WOS:000236988100066
J	Kay, JG; Murray, RZ; Pagan, JK; Stow, JL				Kay, JG; Murray, RZ; Pagan, JK; Stow, JL			Cytokine secretion via cholesterol-rich lipid raft-associated SNAREs at the phagocytic cup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; PLASMA-MEMBRANE; CELLULAR CHOLESTEROL; PHAGOSOME FORMATION; VESICLE FUSION; PC12 CELLS; MACROPHAGES; PROTEINS; EXOCYTOSIS	Lipopolysaccharide-activated macrophages rapidly synthesize and secrete tumor necrosis factor alpha(TNF alpha) to prime the immune system. Surface delivery of membrane carrying newly synthesized TNF alpha is controlled and limited by the level of soluble N-ethylmaleimide-sensitive factor attachment protein receptor ( SNARE) proteins syntaxin 4 and SNAP-23. Many functions in immune cells are coordinated from lipid rafts in the plasma membrane, and we investigated a possible role for lipid rafts in TNF alpha trafficking and secretion. TNF alpha surface delivery and secretion were found to be cholesterol-dependent. Upon macrophage activation, syntaxin 4 was recruited to cholesterol-dependent lipid rafts, whereas its regulatory protein, Munc18c, was excluded from the rafts. Syntaxin 4 in activated macrophages localized to discrete cholesterol-dependent puncta on the plasma membrane, particularly on filopodia. Imaging the early stages of TNF alpha surface distribution revealed these puncta to be the initial points of TNF alpha delivery. During the early stages of phagocytosis, syntaxin 4 was recruited to the phagocytic cup in a cholesterol-dependent manner. Insertion of VAMP3-positive recycling endosome membrane is required for efficient ingestion of a pathogen. Without this recruitment of syntaxin 4, it is not incorporated into the plasma membrane, and phagocytosis is greatly reduced. Thus, relocation of syntaxin 4 into lipid rafts in macrophages is a critical and rate-limiting step in initiating an effective immune response.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.stow@imb.uq.edu.au	Pagan, Julia/O-1929-2016; Stow, Jennifer L/I-4723-2013; Murray, Rachael/J-1370-2012	Pagan, Julia/0000-0002-7079-6388; Stow, Jennifer L/0000-0002-5409-9101; Murray, Rachael/0000-0002-4935-7794; Kay, Jason/0000-0001-8944-6612				Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Christian AE, 1997, J LIPID RES, V38, P2264; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cuschieri J, 2004, SURGERY, V136, P169, DOI 10.1016/j.surg.2004.04.009; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Gaus K, 2005, J LIPID RES, V46, P1526, DOI 10.1194/jlr.M500103-JLR200; Gaus K, 2003, P NATL ACAD SCI USA, V100, P15554, DOI 10.1073/pnas.2534386100; Gil C, 2005, BIOCHEM BIOPH RES CO, V329, P117, DOI 10.1016/j.bbrc.2005.01.111; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grusovin J, 2000, BIOCHEM J, V350, P741, DOI 10.1042/0264-6021:3500741; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Hailstones D, 1998, J LIPID RES, V39, P369; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Hong WJ, 2005, BBA-MOL CELL RES, V1744, P120, DOI 10.1016/j.bbamcr.2005.03.014; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47, DOI 10.1055/s-0037-1612902; Kiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105, DOI 10.1016/S0162-3109(00)00272-1; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Loike JD, 2004, ARTERIOSCL THROM VAS, V24, P2051, DOI 10.1161/01.ATV.0000143858.15909.29; Matsumoto M, 2004, J IMMUNOL, V172, P7377, DOI 10.4049/jimmunol.172.12.7377; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Murray RZ, 2005, J BIOL CHEM, V280, P10478, DOI 10.1074/jbc.M414420200; Murray RZ, 2005, SCIENCE, V310, P1492, DOI 10.1126/science.1120225; Pagan JK, 2003, CURR BIOL, V13, P156, DOI 10.1016/S0960-9822(03)00006-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Poloso NJ, 2004, J IMMUNOL, V173, P4539, DOI 10.4049/jimmunol.173.7.4539; Pombo I, 2003, FEBS LETT, V550, P144, DOI 10.1016/S0014-5793(03)00864-0; Predescu SA, 2005, J BIOL CHEM, V280, P37130, DOI 10.1074/jbc.M505659200; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Ravasi T, 2002, J IMMUNOL, V168, P44, DOI 10.4049/jimmunol.168.1.44; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Salaun C, 2005, J BIOL CHEM, V280, P19449, DOI 10.1074/jbc.M501923200; Shurety W, 2001, LAB INVEST, V81, P107, DOI 10.1038/labinvest.3780216; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; Stoddart A, 2002, IMMUNITY, V17, P451, DOI 10.1016/S1074-7613(02)00416-8; Sun DX, 2003, CELL IMMUNOL, V223, P52, DOI 10.1016/S0008-8749(03)00148-5; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	66	87	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11949	11954		10.1074/jbc.M600857200	http://dx.doi.org/10.1074/jbc.M600857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513632	hybrid			2022-12-27	WOS:000236988100064
J	San Filippo, J; Chi, P; Sehorn, MG; Etchin, J; Krejci, L; Sung, P				San Filippo, J; Chi, P; Sehorn, MG; Etchin, J; Krejci, L; Sung, P			Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; HOMOLOGOUS RECOMBINATION; COMPLEX-FORMATION; PROTEIN; BINDING; REPAIR; DEFICIENCY; YEAST; DSS1	BRCA2 likely exerts its tumor suppressor function by enhancing the efficiency of the homology-directed repair of injured chromosomes. To help define the DNA repair role of BRCA2, we expressed and purified a polypeptide, BRC3/4-DBD, that harbors its BRC3 and BRC4 repeats and DNA binding domain. BRC3/4-DBD interacted with hRad51 and bound DNA with a distinct preference for single-stranded ( ss) DNA. Importantly we demonstrated by biochemical means and electron microscopy that BRC3/4-DBD nucleates hRad51 onto ssDNA and acts as a recombination mediator in enabling hRad51 to utilize replication protein A-coated ssDNA as recombination substrate. These functions of BRC3/4-DBD required both the BRC repeats and the BRCA2 DNA binding domain. The results thus clarify the role of BRCA2 in Rad51-dependent DNA recombination and repair, and the experimental strategies described herein should be valuable for systematically deciphering this BRCA2 function.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,C130 Sterling Hall Med, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Huang, Wenchi/F-3981-2010; Chi, Peter/AAI-1580-2019; Krejci, Lumir/B-7842-2009	Huang, Wenchi/0000-0001-5556-1460; Chi, Peter/0000-0001-9229-8729; Krejci, Lumir/0000-0002-4732-1405	NATIONAL CANCER INSTITUTE [R01CA110415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA110415, R01 CA110415] Funding Source: Medline; NIEHS NIH HHS [R01 ES007061] Funding Source: Medline; Wellcome Trust [GR076476, 076476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chi P, 2006, DNA REPAIR, V5, P381, DOI 10.1016/j.dnarep.2005.11.005; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; KIM JS, 1993, PROTEIN SCI, V2, P348; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Lo T, 2003, DNA REPAIR, V2, P1015, DOI 10.1016/S1568-7864(03)00097-1; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yonetani Y, 2005, NUCLEIC ACIDS RES, V33, P4544, DOI 10.1093/nar/gki766; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; Yuan SSF, 1999, CANCER RES, V59, P3547	32	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11649	11657		10.1074/jbc.M601249200	http://dx.doi.org/10.1074/jbc.M601249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513631	hybrid, Green Accepted			2022-12-27	WOS:000236988100028
J	Wilson, SJ; Smyth, EM				Wilson, SJ; Smyth, EM			Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-INDEPENDENT INTERNALIZATION; SMOOTH-MUSCLE-CELLS; ROD PHOSPHODIESTERASE; THROMBOXANE A(2); BINDING-PROTEIN; HUMAN PLATELETS; PDE-DELTA; DESENSITIZATION; PHOSPHORYLATION; RAB13	Prostacyclin, the major cyclooxygenase-derived product of arachidonic acid formed in the vasculature, mediates its potent anti-thrombotic and anti-proliferative effects through its G protein-coupled receptor (GPCR) termed the IP. Unlike many GPCRs, agonist-induced internalization of the IP occurs in an arrestin/ GPCR kinase-independent manner. However, deletion of the IP COOH-terminal region prevented internalization suggesting that protein interactions at this region are involved in IP regulation. Using the COOH-terminal region of IP as bait we identified the delta subunit of cGMP phosphodiesterase 6 (PDE6 delta) as a novel hIP-interacting protein in two independent yeast two-hybrid screens. Interaction of IP and PDE6 delta was confirmed by co-immunoprecipitation in HEK293 cells, and in HEPG2 cells, which endogenously express neither IP nor PDE6 delta. IP isoprenylation was critical for this interaction, as PDE6 delta was unable to associate with an isoprenylation-deficient mutant IP (IPSSLC). PDE6 delta overexpression altered the temporal pattern of agonist-induced internalization of IP, but not IPSSLC, in HEPG2 cells, increasing initial internalization but facilitating the return of IP to the cell surface despite the continued presence of agonist. Depletion of PDE6 delta using short interfering RNA abolished cicaprost-induced IP internalization in human aortic smooth muscle cells. Recycling of IP, but not IPSSLC, upon agonist removal was facilitated by overexpression of PDE6 delta. Thus PDE6 delta interacts specifically with IP to modulate receptor trafficking.	Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Smyth, EM (corresponding author), Univ Penn, Inst Translat Med & Therapeut, 808 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	emer@spirit.gcrc.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL066233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Fisch A, 1997, CIRCULATION, V96, P756; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Giebing G, 2005, CIRC RES, V97, P707, DOI 10.1161/01.RES.0000184670.58688.9F; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Hamelin E, 2005, J BIOL CHEM, V280, P36195, DOI 10.1074/jbc.M503438200; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hanzal-Bayer M, 2005, J MOL BIOL, V350, P1074, DOI 10.1016/j.jmb.2005.05.036; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kothapalli D, 2005, PROSTAG OTH LIPID M, V78, P3, DOI 10.1016/j.prostaglandins.2005.04.003; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Lawler OA, 2001, J BIOL CHEM, V276, P33596, DOI 10.1074/jbc.M104434200; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Marzesco AM, 2001, METHOD ENZYMOL, V329, P197; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Miggin SM, 2002, EUR J BIOCHEM, V269, P1714, DOI 10.1046/j.1432-1327.2002.02817.x; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; Munro S, 2005, BIOCHEM SOC T, V33, P601, DOI 10.1042/BST0330601; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; Nilius SM, 2000, FEBS LETT, V484, P211, DOI 10.1016/S0014-5793(00)02156-6; Norton AW, 2005, J BIOL CHEM, V280, P1248, DOI 10.1074/jbc.M410475200; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; Sobolewski A, 2004, AM J PHYSIOL-LUNG C, V287, pL352, DOI 10.1152/ajplung.00270.2003; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Wilson SJ, 2004, J BIOL CHEM, V279, P53036, DOI 10.1074/jbc.M405002200; Wong DR, 2005, CURR OPIN PHARMACOL, V5, P204, DOI 10.1016/j.coph.2005.02.001	37	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11780	11786		10.1074/jbc.M513110200	http://dx.doi.org/10.1074/jbc.M513110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16527812	hybrid			2022-12-27	WOS:000236988100043
J	Miyamoto, A; Lau, R; Hein, PW; Shipley, JM; Weinmaster, G				Miyamoto, A; Lau, R; Hein, PW; Shipley, JM; Weinmaster, G			Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMURATI-ENGELMANN-DISEASE; FIBRILLIN-CONTAINING MICROFIBRILS; LATENCY-ASSOCIATED PEPTIDE; SIGNAL-TRANSDUCTION; CELL DIFFERENTIATION; TGF-BETA; LIGAND; GLYCOPROTEIN-2; MUTATIONS; PATHWAY	Unlike most receptors, Notch serves as both the receiver and direct transducer of signaling events. Activation can be mediated by one of five membrane-bound ligands of either the Delta-like (-1, -2, -4) or Jagged/Serrate (-1, -2) families. Alternatively, dissociation of the Notch heterodimer with consequent activation can also be mediated experimentally by calcium chelators or by mutations that destabilize the Notch1 heterodimer, such as in the human disease T cell acute lymphoblastic leukemia. Here we show that MAGP-2, a protein present on microfibrils, can also interact with the EGF-like repeats of Notch1. Co-expression of MAGP-2 with Notch1 leads to both cell surface release of the Notch1 extracellular domain and subsequent activation of Notch signaling. Moreover, we demonstrate that the C-terminal domain of MAGP-2 is required for binding and activation of Notch1. Based on the high level of homology, we predicted and further showed that MAGP-1 can also bind to Notch1, cause the release of the extracellular domain, and activate signaling. Notch1 extracellular domain release induced by MAGP-2 is dependent on formation of the Notch1 heterodimer by a furin-like cleavage, but does not require the subsequent ADAM metalloprotease cleavage necessary for production of the Notch signaling fragment. Together these results demonstrate for the first time that the microfibrillar proteins MAGP-1 and MAGP-2 can function outside of their role in elastic fibers to activate a cellular signaling pathway.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)	Weinmaster, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	gweinmaster@mednet.ucla.edu	Hein, Patrick/F-1180-2015		NINDS NIH HHS [NS 31885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031885, R37NS031885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Eiraku M, 2005, NAT NEUROSCI, V8, P873, DOI 10.1038/nn1492; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Hanssen E, 2004, J BIOL CHEM, V279, P29185, DOI 10.1074/jbc.M313672200; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Kielty CM, 2002, J CELL SCI, V115, P2817; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Ladi E, 2005, J CELL BIOL, V170, P983, DOI 10.1083/jcb.200503113; Lemaire R, 2005, ARTHRITIS RHEUM-US, V52, P1812, DOI 10.1002/art.21059; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004; Tan-Pertel HT, 2000, J IMMUNOL, V165, P4428, DOI 10.4049/jimmunol.165.8.4428; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	45	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10089	10097		10.1074/jbc.M600298200	http://dx.doi.org/10.1074/jbc.M600298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492672	hybrid			2022-12-27	WOS:000236594300034
J	Song, KH; Li, TG; Chiang, JYL				Song, KH; Li, TG; Chiang, JYL			A prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4 alpha that regulates the cholesterol 7 alpha-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; PROX1 FUNCTION; EXPRESSION; LIVER; GLUCONEOGENESIS; REPRESSION; CYP7A1	Prox1, an early specific marker for developing liver and pancreas in foregut endoderm has recently been shown to interact with alpha-fetoprotein transcription factor and repress cholesterol 7 alpha-hydroxylase (CYP7A1) gene transcription. Using a yeast two-hybrid assay, we found that Prox1 strongly and specifically interacted with hepatocyte nuclear factor (HNF)4 alpha, an important transactivator of the human CYP7A1 gene in bile acid synthesis and phosphoenolpyruvate carboxykinase (PEPCK) gene in gluconeogenesis. A real time PCR assay detected Prox1 mRNA expression in human primary hepatocytes and HepG2 cells. Reporter assay, GST pull-down, co-immunoprecipitation, and yeast two-hybrid assays identified a specific interaction between the N-terminal LXXLL motif of Prox1 and the activation function 2 domain of HNF4 alpha. Prox1 strongly inhibited HNF4 alpha and peroxisome proliferators-activated receptor gamma coactivator-1 alpha co-activation of the CYP7A1 and PEPCK genes. Knock down of the endogenous Prox1 by small interfering RNA resulted in significant increase of CYP7A1 and PEPCK mRNA expression and the rate of bile acid synthesis in HepG2 cells. These results suggest that Prox1 is a novel co-regulator of HNF4 alpha that may play a key role in the regulation of bile acid synthesis and gluconeogenesis in the liver.	Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Chiang, JYL (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, 4209 State Route 44,POB 95, Rootstown, OH 44272 USA.	jchiang@neoucom.edu	Chiang, John Y. L./G-2658-2011	Chiang, John Y. L./0000-0001-9360-7650	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058379, R01DK044442, R56DK044442, R37DK058379] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK058379, DK 58379, R01 DK058379, R56 DK044442, R01 DK044442, DK 44442] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; FELDMANN D, 1983, CLIN CHEM, V29, P1694; Glass CK, 2000, GENE DEV, V14, P121; Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li JX, 2000, GENE DEV, V14, P464; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Sladek R, 2000, ADV PHARMACOL, V47, P23; Song KH, 2006, HEPATOLOGY, V43, P117, DOI 10.1002/hep.20919; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Steffensen KR, 2004, EMBO REP, V5, P613, DOI 10.1038/sj.embor.7400147; Stroup D, 2000, J LIPID RES, V41, P1; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392	38	56	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10081	10088		10.1074/jbc.M513420200	http://dx.doi.org/10.1074/jbc.M513420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16488887	Green Accepted, hybrid			2022-12-27	WOS:000236594300033
J	Ueda, T; Postnikov, YV; Bustin, M				Ueda, T; Postnikov, YV; Bustin, M			Distinct domains in high mobility group n variants modulate specific chromatin modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS HMG-14; HISTONE H3; NUCLEOSOME CORES; GENE-REGULATION; PHOSPHORYLATION; ACETYLATION; H1; TRANSCRIPTION; MSK1	We have demonstrated that levels of specific modification in histone H3 are modulated by members of the nucleosome-binding high mobility group N (HMGN) protein family in a variant-specific manner. HMGN1(but not HMGN2) inhibits the phosphorylation of both H3S10 and H3S28, whereas HMGN2 enhances H3K14 acetylation more robustly than HMGN1. Two HMGN domains are necessary for modulating chromatin modifications, a non-modification-specific domain necessary for chromatin binding and a modification-specific domain localized in the C terminus of the HMGNs. Thus, chromatin-binding structural proteins such as HMGNs affect the levels of specific chromatin modifications and therefore may play a role in epigenetic regulation.	NCI, Prot Sect, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bustin, M (corresponding author), NCI, Prot Sect, Lab Metab, NIH, Bldg 37,Rm 3122, Bethesda, MD 20892 USA.	bustin@helix.nih.gov	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [Z01BC004496] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC004496-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BUSTIN M, 1995, SEMIN CELL BIOL, V6, P247, DOI 10.1006/scel.1995.0033; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lim JH, 2005, EMBO J, V24, P3038, DOI 10.1038/sj.emboj.7600768; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Lim JH, 2004, METHOD ENZYMOL, V375, P323; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779	23	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10182	10187		10.1074/jbc.M600821200	http://dx.doi.org/10.1074/jbc.M600821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484217	hybrid			2022-12-27	WOS:000236594300044
J	Zhang, Q; Adiseshaiah, P; Kalvakolanu, DV; Reddy, SP				Zhang, Q; Adiseshaiah, P; Kalvakolanu, DV; Reddy, SP			A phosphatidylinositol 3-kinase-regulated Akt-independent signaling promotes cigarette smoke-induced FRA-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; ALPHA-CONVERTING ENZYME; BREAST-CANCER CELLS; SERUM RESPONSE ELEMENT; PROTEIN-KINASE-B; LUNG-CANCER; C-FOS; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; IN-VITRO	The FRA-1 proto-oncogene is overexpressed in a variety of human tumors and is known to up-regulate the expression of genes involved in tumor progression and invasion. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is also known to regulate these cellular processes. More importantly, respiratory toxicants and carcinogens activate both the PI3K-Akt pathway and FRA-1 expression in human bronchial epithelial (HBE) cells. In this study we investigated a potential link between the PI3K-Akt pathway and the cigarette smoke (CS)-stimulated epidermal growth factor receptor-mediated FRA-1 induction in non-oncogenic HBE cells. Treatment of cells with LY294002, an inhibitor of the PI3K-Akt pathway, completely blocked CS-induced FRA-1 expression. Surprisingly pharmacological inhibition of Akt had no significant effect on CS-induced FRA-1 expression. Likewise the inhibition of protein kinase C zeta, which is a known downstream effector of PI3K, did not alter FRA-1 expression. We found that the PI3K through p21-activated kinase 1 regulates FRA-1 proto-oncogene induction by CS and the subsequent activation of the Elk1 and cAMP-response element-binding protein transcription factors that are bound to the promoter in HBE cells.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Rm E7610,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NCI NIH HHS [CA 105005, CA 78282] Funding Source: Medline; NIEHS NIH HHS [ES 11863] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES011863, R01ES011863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cook SJ, 1999, MOL CELL BIOL, V19, P330; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fiala ES, 2005, CARCINOGENESIS, V26, P605, DOI 10.1093/carcin/bgh341; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Karin M, 2001, IUBMB LIFE, V52, P17; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MATSUI M, 1990, ONCOGENE, V5, P249; Nelson HH, 2002, ONCOGENE, V21, P7284, DOI 10.1038/sj.onc.1205804; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, pA828; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; Shah A, 2005, CLIN CANCER RES, V11, P2930, DOI 10.1158/1078-0432.CCR-04-1385; Shao MXG, 2004, AM J PHYSIOL-LUNG C, V287, pL420, DOI 10.1152/ajplung.00019.2004; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Tiwari G, 2003, MOL CANCER RES, V1, P475; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zhang Q, 2004, AM J PHYSIOL-LUNG C, V286, pL427, DOI 10.1152/ajplung.00221.2003	56	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10174	10181		10.1074/jbc.M513008200	http://dx.doi.org/10.1074/jbc.M513008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16490785	hybrid			2022-12-27	WOS:000236594300043
J	Herbert, AP; Uhrin, D; Lyon, M; Pangburn, MK; Barlow, PN				Herbert, Andrew P.; Uhrin, Dusan; Lyon, Malcolm; Pangburn, Michael K.; Barlow, Paul N.			Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-H; GROWTH FACTOR/SCATTER FACTOR; DECAY-ACCELERATING FACTOR; HEPARIN-BINDING DOMAIN; CONTROL PROTEIN MODULE; MACULAR DEGENERATION; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; C3B INACTIVATOR	Mutations and polymorphisms in the regulator of complement activation, factor H, have been linked to atypical hemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis, and age-related macular degeneration. Many aHUS patients carry mutations in the two C-terminal modules of factor H, which normally confer upon this abundant 155-kDa plasma glycoprotein its ability to selectively bind self-surfaces and prevent them from inappropriately triggering the complement cascade via the alternative pathway. In the current study, the three-dimensional solution structure of the C-terminal module pair of factor H has been determined. A binding site for a fully sulfated heparin-derived tetrasaccharide has been delineated using chemical shift mapping and the C3d/C3b-binding site inferred from sequence comparisons and computational docking. The resultant information allows assessment of the likely consequences of aHUS-associated amino acid substitutions in this critical region of factor H. It is striking that, excepting those likely to perturb the three-dimensional structure, aHUS-associated missense mutations congregate in the polyanion-binding site delineated in this study, thus potentially disrupting a vital mechanism for control of complement on self-surfaces in the microvasculature of the kidney. It is intriguing that a single nucleotide polymorphism predisposing to age-related macular degeneration occupies another region of factor H that harbors a polyanion-binding site.	Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Texas Hlth Ctr, Tyler, TX 75708 USA; Univ Manchester, Christie Hosp NHS Trust, Canc Res UK Dept Med Oncol, Manchester M20 4BX, Lancs, England	University of Edinburgh; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Barlow, PN (corresponding author), Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Barlow, Paul N/G-2853-2011; Herbert, Andy P/F-6693-2010; Herbert, Andrew P/C-4755-2008	Herbert, Andy P/0000-0002-4549-6965; Herbert, Andrew P/0000-0002-4549-6965; Lyon, Malcolm/0000-0001-9575-6879	Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH HHS [DK 35081] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035081, R37DK035081] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877; Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FREMEAUXBACCHI V, 2005, J MED GENET, V22, P22; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Habeck Michael, 2004, Methods Mol Biol, V278, P379; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KRAULIS PJ, 1994, J MOL BIOL, V243, P696, DOI 10.1016/0022-2836(94)90042-6; KUHN S, 1995, J IMMUNOL, V155, P5663; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200; Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Neuhaus TJ, 1997, ARCH DIS CHILD, V76, P518, DOI 10.1136/adc.76.6.518; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Olie KH, 2004, PEDIATR NEPHROL, V19, P1173, DOI 10.1007/s00467-004-1565-2; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201; Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337; RENAUD C, 1995, PEDIATR NEPHROL, V9, P24, DOI 10.1007/BF00858960; Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1111/j.1523-1755.1998.00824.x; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426	62	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16512	16520		10.1074/jbc.M513611200	http://dx.doi.org/10.1074/jbc.M513611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16533809	hybrid			2022-12-27	WOS:000238165700041
J	Schafer, E; Seelert, H; Reifschneider, NH; Krause, F; Dencher, NA; Vonck, J				Schaefer, Eva; Seelert, Holger; Reifschneider, Nicole H.; Krause, Frank; Dencher, Norbert A.; Vonck, Janet			Architecture of active mammalian respiratory chain supercomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; OXIDATIVE-PHOSPHORYLATION COMPLEXES; MITOCHONDRIAL ELECTRON-TRANSPORT; BLUE NATIVE ELECTROPHORESIS; C-OXIDASE; YEAST MITOCHONDRIA; PROTEIN COMPLEXES; ANGSTROM; RESPIRASOMES; LOCALIZATION	In the inner mitochondrial membrane, the respiratory chain complexes generate an electrochemical proton gradient, which is utilized to synthesize most of the cellular ATP. According to an increasing number of biochemical studies, these complexes are assembled into supercomplexes. However, little is known about the architecture of the proposed multicomplex assemblies. Here, we report the electron microscopic characterization of the two respiratory chain supercomplexes I1III2 and I1III2IV1 in bovine heart mitochondria, which are also two major supercomplexes in human mitochondria. After purification and demonstration of enzymatic activity, their structures in projection were determined by single particle image analysis. A difference map between the supercomplexes I1III2 and I1III2IV1 closely fits the x-ray structure of monomeric complex IV and shows its location in the assembly. By comparing different views of supercomplex I1III2IV1, the location and mutual arrangement of complex I and the complex III dimer are discussed. Detailed knowledge of the architecture of the active supercomplexes is a prerequisite for a deeper understanding of energy conversion by mitochondria in mammals.	Max Planck Inst Biophys, Dept Biol Struct, D-60438 Frankfurt, Germany; Tech Univ Darmstadt, Dept Chem Phys Biochem, D-64287 Darmstadt, Germany	Max Planck Society; Technical University of Darmstadt	Vonck, J (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Max von Laue Str 3, D-60438 Frankfurt, Germany.	janet.vonck@mpibp-frankfurt.mpg.de	Dencher, Norbert/G-6640-2014	Vonck, Janet/0000-0001-5659-8863				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; ANGERMULLER S, 1981, HISTOCHEMISTRY, V71, P33, DOI 10.1007/BF00592568; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; BOSTINA M, 2004, THESIS J WOLFGANG GO; CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Gabaldon T, 2005, J MOL BIOL, V348, P857, DOI 10.1016/j.jmb.2005.02.067; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Krause F, 2005, BIOCHEM BIOPH RES CO, V329, P583, DOI 10.1016/j.bbrc.2005.02.010; Krause F, 2004, J BIOL CHEM, V279, P48369, DOI 10.1074/jbc.M406085200; Krause F, 2004, J BIOL CHEM, V279, P26453, DOI 10.1074/jbc.M402756200; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Poetsch A, 2000, BBA-BIOMEMBRANES, V1466, P339, DOI 10.1016/S0005-2736(00)00191-7; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	36	202	212	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15370	15375		10.1074/jbc.M513525200	http://dx.doi.org/10.1074/jbc.M513525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551638	hybrid			2022-12-27	WOS:000237922200042
J	Bellodi, C; Kindle, K; Bernassola, F; Dinsdale, D; Cossarizza, A; Melino, G; Heery, D; Salomoni, P				Bellodi, Cristian; Kindle, Karin; Bernassola, Francesca; Dinsdale, David; Cossarizza, Andrea; Melino, Gerry; Heery, David; Salomoni, Paolo			Cytoplasmic Function of Mutant Promyelocytic Leukemia (PML) and PML-Retinoic Acid Receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAR-ALPHA; HISTONE DEACETYLASE; FUSION PROTEINS; EXPRESSION; ISOFORMS; GENE; DEGRADATION; DISEASE; APL	The promyelocytic leukemia (PML) tumor suppressor of acute promyelocytic leukemia (APL) regulates major apoptotic and growth-suppressive pathways. In APL, PML is involved in a chromosomal translocation generating the PML-retinoic acid receptor-alpha (RAR alpha) fusion protein. Two missense mutations in the remaining PML alleles have been identified, which give rise to a truncated cytoplasmic PML protein (Mut PML). APL patients carrying these mutations display resistance to retinoic acid (RA) and very poor prognosis. Here we show that Mut PML associates with the cytoplasmic regions we refer to as PML-cytoplasmic bodies (PML-CBs). Mut PML interacts with PML-RAR alpha in PML-CB and potentiates PML-RAR alpha-mediated inhibition of RA-dependent transcription. Remarkably, Mut PML stabilizes PML-RAR alpha and inhibits differentiation induced by pharmacological doses of RA. A mutant form of PML-RAR alpha that accumulates in the cytoplasm inhibits RA-dependent transcription and differentiation, thus suggesting that cytoplasmic localization of PML-RAR alpha may contribute to transformation. Finally, we show that the bcr3 PML-RAR alpha form is predominantly cytoplasmic and accumulates in PML-CBs. Taken together, these findings reveal novel insights into the molecular mechanisms contributing to APL.	[Bellodi, Cristian; Dinsdale, David; Melino, Gerry; Salomoni, Paolo] Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England; [Kindle, Karin; Heery, David] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; [Bernassola, Francesca] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, I-00133 Rome, Italy; [Bellodi, Cristian; Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Nottingham; University of Rome Tor Vergata; Universita di Modena e Reggio Emilia	Salomoni, P (corresponding author), Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England.	ps90@le.ac.uk	Bellodi, Cristian/J-8157-2013; Bellodi, Cristian/N-2341-2015	Heery, David/0000-0002-5035-2392; Bellodi, Cristian/0000-0001-8047-5329; Garrie, Karin/0000-0003-2204-9975; Cossarizza, Andrea/0000-0002-5381-1558	Medical Research Council; MRC [MC_U132670601, MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670601, MC_U132670600] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Chen GQ, 1997, BLOOD, V89, P3345; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hofmann H, 2002, J VIROL, V76, P5769, DOI 10.1128/JVI.76.11.5769-5783.2002; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhu J, 2005, CANCER CELL, V7, P143, DOI 10.1016/j.ccr.2005.01.005; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	31	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14465	14473		10.1074/jbc.M600457200	http://dx.doi.org/10.1074/jbc.M600457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16540467	hybrid			2022-12-27	WOS:000207179300005
J	Sayan, BS; Sayan, AE; Knight, RA; Melino, G; Cohen, GM				Sayan, BS; Sayan, AE; Knight, RA; Melino, G; Cohen, GM			p53 is cleaved by caspases generating fragments localizing to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; APOPTOSIS; ACTIVATION; DEGRADATION; DISRUPTION; MUTATIONS; COMPLEX; CANCER; DEATH	The p53 tumor suppressor protein exerts most of its anti- tumorigenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis and also suggests the presence of a positive feedback loop in which activated caspases cleave p53 to augment mitochondrial membrane depolarization.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Melino, G (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd,POB 138, Leicester LE1 9HN, Leics, England.	gm89@leicester.ac.uk	SAYAN, A. EMRE/H-7330-2012; Cohen, Gerald M/A-1687-2008	SAYAN, A. EMRE/0000-0002-5291-1485; 	Medical Research Council [MC_U132670600] Funding Source: Medline; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADDISON C, 1990, ONCOGENE, V5, P423; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	24	77	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13566	13573		10.1074/jbc.M512467200	http://dx.doi.org/10.1074/jbc.M512467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531411	hybrid			2022-12-27	WOS:000237336600065
J	Shmuel, M; Santy, LC; Frank, S; Avrahami, D; Casanova, JE; Altschuler, Y				Shmuel, M; Santy, LC; Frank, S; Avrahami, D; Casanova, JE; Altschuler, Y			ARNO through its coiled-coil domain regulates endocytosis at the apical surface of polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSYLATION FACTOR 6; NUCLEOTIDE EXCHANGE FACTOR; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; RECEPTOR ENDOCYTOSIS; HOMOLOGY DOMAINS; SORTING SIGNAL; SEC7 DOMAIN; MDCK CELLS	ARNO is a guanine-nucleotide exchange protein for the ARF family of GTPases. Here we show that in polarized epithelial cells, ARNO is localized exclusively to the apical plasma membrane, where it regulates endocytosis. Expression of ARNO stimulates apical endocytosis of the polymeric immunoglobulin receptor, and coexpression of ARF6 with ARNO leads to a synergistic stimulation of apical endocytosis. Expression of a dominant negative ARF6 mutant, ARF6-T27N, antagonizes this stimulatory effect. Deletion of the N-terminal coiled-coil ( CC) domain of ARNO causes the mutant ARNO to localize to both the apical and basolateral plasma membranes. Expression of the CC domain alone abolishes ARNO-induced apical endocytosis as well as co-localization of IgA-receptor complexes with ARNO and clathrin. These results suggest that the CC domain contributes to the specificity of apical localization of ARNO through association with components of the apical plasma membrane. We conclude that ARNO acts together with ARF6 to regulate apical endocytosis.	Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	Hebrew University of Jerusalem; University of Virginia	Altschuler, Y (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yoram11@md.huji.ac.il		Santy, Lorraine/0000-0002-4795-0738				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Austin C, 2002, BIOCHEMISTRY-US, V41, P4669, DOI 10.1021/bi016064j; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Claing A, 2004, BIOCHEM CELL BIOL, V82, P610, DOI 10.1139/O04-113; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Decressac S, 2004, EMBO REP, V5, P1171, DOI 10.1038/sj.embor.7400292; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Hernandez-Deviez DJ, 2004, MOL BIOL CELL, V15, P111, DOI 10.1091/mbc.E03-06-0410; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Hyman T, 2006, MOL BIOL CELL, V17, P427, DOI 10.1091/mbc.E05-05-0420; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lecat S, 2000, J CELL SCI, V113, P2607; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Luton F, 2004, MOL BIOL CELL, V15, P1134, DOI 10.1091/mbc.E03-10-0751; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Mangravite LM, 2001, AM J PHYSIOL-RENAL, V280, pF879, DOI 10.1152/ajprenal.2001.280.5.F879; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Park JG, 2001, J BIOL CHEM, V276, P47751, DOI 10.1074/jbc.C100524200; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Reich V, 1996, J CELL SCI, V109, P2133; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Song J, 1998, J CELL SCI, V111, P2257; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vitale N, 2002, ANN NY ACAD SCI, V971, P193, DOI 10.1111/j.1749-6632.2002.tb04463.x; Yang CZ, 1999, J BIOL CHEM, V274, P25297, DOI 10.1074/jbc.274.36.25297; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13300	13308		10.1074/jbc.M513723200	http://dx.doi.org/10.1074/jbc.M513723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16484220	hybrid			2022-12-27	WOS:000237336600035
J	Squires, LN; Jakubowski, JA; Stuart, JN; Rubakhin, SS; Hatcher, NG; Kim, WS; Chen, K; Shih, JC; Seif, I; Sweedler, JV				Squires, LN; Jakubowski, JA; Stuart, JN; Rubakhin, SS; Hatcher, NG; Kim, WS; Chen, K; Shih, JC; Seif, I; Sweedler, JV			Serotonin catabolism and the formation and fate of 5-hydroxyindole thiazolidine carboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED FLUORESCENCE DETECTION; CAPILLARY-ELECTROPHORESIS; BRAIN-SEROTONIN; 5-HYDROXYTRYPTAMINE; MITOCHONDRIA; METABOLISM; BEHAVIOR; NEURONS; DRUGS; RAT	Serotonin ( 5- HT) functions as a neurotransmitter and neuromodulator in both the central and enteric nervous systems of mammals. The dynamic degradation of 5- HT metabolites in 5- HT- containing nervous system tissues is monitored by capillary electrophoresis with wavelength-resolved laser- induced native fluorescence detection in an effort to investigate known and novel 5- HT catabolic pathways. Tissue samples from wild type mice, genetically altered mice, Long Evans rats, and cultured differentiated rat pheochromocytoma PC- 12 cells, are analyzed before and after incubation with excess 5- HT. From these experiments, several new compounds are detected. One metabolite, identified as 5- hydroxyindole thiazoladine carboxylic acid ( 5- HITCA), has been selected for further study. In 5- HT-incubated central and enteric nervous system tissue samples and differentiated PC- 12 cells, 5- HITCA forms at levels equivalent to 5- hydroxyindole acetic acid, via a condensation reaction between L- cysteine and 5- hydroxyindole acetaldehyde. In the enteric nervous system, 5- HITCA is detected without the addition of 5- HT. The levels of L- cysteine and homocysteine in rat brain mitochondria are measured between 80 and 140 mu M and 1.9 and 3.4 mu M, respectively, demonstrating that 5- HITCA can be formed using available, free L- cysteine in these tissues. The lack of significant accumulation of 5- HITCA in the central and enteric nervous systems, along with data showing the degradation of 5- HITCA into 5- hydroxyindole acetaldehyde, suggests that an equilibrium coupled to the enzyme, aldehyde dehydrogenase type 2, prevents the accumulation of 5- HITCA. Even so, the formation of 5- HITCA represents a catabolic pathway of 5- HT that can affect the levels of 5- HT- derived compounds in the body.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ So Calif, Keck Sch Med, Pharmaceut Sci Ctr, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Southern California; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sweedler, JV (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave,63-5, Urbana, IL 61801 USA.	jsweedle@uiuc.edu	Sweedler, Jonathan V/A-9405-2009; Squires, Leah/B-9798-2017; Rubakhin, Stanislav S/E-6685-2017	Sweedler, Jonathan V/0000-0003-3107-9922; Squires, Leah/0000-0002-9546-0792; Rubakhin, Stanislav S/0000-0003-0437-1493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA018310] Funding Source: NIH RePORTER; NIDA NIH HHS [P30 DA018310, DA018310] Funding Source: Medline; NIDDK NIH HHS [DK70285, R33 DK070285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida A, 1997, BRAIN RES, V764, P167, DOI 10.1016/S0006-8993(97)00453-8; Buhot HC, 2000, ANN MED, V32, P210, DOI 10.3109/07853890008998828; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DHASMANA KM, 1993, LIFE SCI, V53, P1651; Fuller RR, 1998, NEURON, V20, P173, DOI 10.1016/S0896-6273(00)80446-8; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; GERSHON MD, 1966, J PHYSIOL-LONDON, V186, P451, DOI 10.1113/jphysiol.1966.sp008046; GREENE LA, 1981, ADVANCES CELLULAR NE, P373; Jin CY, 2006, TETRAHEDRON LETT, V47, P943, DOI 10.1016/j.tetlet.2005.11.153; Keung WM, 1998, P NATL ACAD SCI USA, V95, P2198, DOI 10.1073/pnas.95.5.2198; Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5; Kim WS, 2002, ANAL CHEM, V74, P5614, DOI 10.1021/ac025917q; Murphy DL, 1998, J CLIN PSYCHIAT, V59, P4; ORLICZSZCZESNA G, 1989, Z MIKROSK ANAT FORSC, V103, P504; OSBORNE NN, 1988, NEURONAL SEROTONIN; Park YN, 1999, ANAL CHEM, V71, P4997, DOI 10.1021/ac990659r; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SINGH S, 1992, J MED CHEM, V35, P2667, DOI 10.1021/jm00092a018; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Stuart JN, 2003, J NEUROCHEM, V84, P1358, DOI 10.1046/j.1471-4159.2003.01617.x; Stuart JN, 2003, ANAL BIOANAL CHEM, V375, P28, DOI 10.1007/s00216-002-1609-z; SUSILO R, 1989, J NEUROCHEM, V52, P1793, DOI 10.1111/j.1471-4159.1989.tb07259.x; SUSILO R, 1988, J NEUROCHEM, V50, P1817, DOI 10.1111/j.1471-4159.1988.tb02483.x; UNDENFRIEND S, 1956, J BIOL CHEM, V217, P335; Verge KM, 2002, J AM SOC MASS SPECTR, V13, P901, DOI 10.1016/S1044-0305(02)00386-0; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Zhang X, 2002, ANAL BIOANAL CHEM, V373, P332, DOI 10.1007/s00216-002-1288-9; Zhang X, 2001, FRESEN J ANAL CHEM, V369, P206, DOI 10.1007/s002160000654	32	24	26	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13463	13470		10.1074/jbc.M602210200	http://dx.doi.org/10.1074/jbc.M602210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537538	hybrid			2022-12-27	WOS:000237336600053
J	Delos Santos, NM; Gardner, LA; White, SW; Bahouth, SW				Delos Santos, NM; Gardner, LA; White, SW; Bahouth, SW			Characterization of the residues in helix 8 of the human beta(1)-adrenergic receptor that are involved in coupling the receptor to G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; LEUKOTRIENE B-4; RHODOPSIN; INTERNALIZATION; DESENSITIZATION; MUTATION; TAIL	Several key amino acids within amphipathic helix 8 of the human beta(1)-adrenergic receptor (beta(1)-AR) were mutagenized to characterize their role in signaling by G protein-coupled receptors. Mutagenesis of phenylalanine at position 383 in the hydrophobic interface to histidine (F383H) prevented the biosynthesis of the receptor, indicating that the orientation of helix 8 is important for receptor biosynthesis. Mutagenesis of aspartic acid at position 382 in the hydrophilic interface to leucine (D382L) reduced the binding and uncoupled the receptor from G protein activation. Mutagenesis of the basic arginine residue at position 384 to glutamine (R384Q) or to glutamic acid (R384E) increased basal and agonist-stimulated adenylyl cyclase activities. R384Q and R384E displayed features associated with constitutively active receptors because inverse agonists markedly reduced their elevated basal adenylyl cyclase activities. Isoproterenol increased the phosphorylation and promoted the desensitization of the Gly389 or Arg389 allelic variants of the wild type beta(1)-AR but failed to produce these effects in R384Q and R384E, because these receptors were maximally phosphorylated and desensitized under basal conditions. In contrast to the membranous distribution of the wild type beta(1)-AR, R384Q and R384E were localized mostly within intracellular punctate structures. Inverse agonists restored the membranous distribution of R384Q and R384E, indicating that they recycled normally when their constitutive internalization was blocked by inverse agonists. These data combined with computer modeling of the putative three-dimensional organization of helix 8 indicated that the amphipathic character of helix 8 and side chain projections of Asp(382) and Arg(384) within the hydrophilic interface might serve as a tethering site for the G protein.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Pediat Nephrol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Bahouth, SW (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	sbahouth@utmem.edu	White, Stephen W/N-8164-2018		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013725] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bahouth SW, 1996, MOL PHARMACOL, V49, P1049; BAHOUTH SW, 1995, BIOCHEM J, V307, P831, DOI 10.1042/bj3070831; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRUNTON LL, 2005, PHARMACOL BASIS THER, P237; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; Christopoulos A, 2004, BIOCHEM SOC T, V32, P873, DOI 10.1042/BST0320873; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Faussner A, 2005, FEBS J, V272, P129, DOI 10.1111/j.1432-1033.2004.04390.x; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gardner LA, 2004, J BIOL CHEM, V279, P21135, DOI 10.1074/jbc.M313652200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Guthrie CR, 2005, J PHARMACOL EXP THER, V313, P1003, DOI 10.1124/jpet.104.081919; KONG SD, 2002, MOL PHARM, V62, P281; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; May LT, 2003, CURR OPIN PHARMACOL, V3, P551, DOI 10.1016/S1471-4892(03)00107-3; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhong M, 2004, BIOCHEMISTRY-US, V43, P3490, DOI 10.1021/bi035899m	50	57	59	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12896	12907		10.1074/jbc.M508500200	http://dx.doi.org/10.1074/jbc.M508500200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16500896	hybrid			2022-12-27	WOS:000237134700085
J	Ercan, A; Panico, M; Sutton-Smith, M; Dell, A; Morris, HR; Matta, KL; Gay, DF; West, CM				Ercan, A; Panico, M; Sutton-Smith, M; Dell, A; Morris, HR; Matta, KL; Gay, DF; West, CM			Molecular characterization of a novel UDP-galactose : fucoside alpha 3-galactosyltransferase that modifies Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; DISCOIDEUM; HYDROXYPROLINE; GLYCOSYLATION; PURIFICATION; COMPLEX; GENOME; FP21	Skp1 is a nucleocytoplasmic protein that is post-translationally modified by a pentasaccharide, Ga1 alpha 1, Ga1 alpha 1, 3Fuc alpha 1, 2Gal beta 1, 3GlcNAc alpha 1O-, at a 4-hydroxylated derivative of Pro-143 in the amebazoan Dictyostelium discoideum. An enzymatic activity that catalyzes formation of the Ga1 alpha 1, 3Fuc linkage by transfer of Gal from UDP-alpha Gal to Fuc alpha 1, 2Gal beta 1, 3G1cNAc alpha 1O-benzyl, or the corresponding glycoform of Skp1, was described previously in cytosolic extracts of Dictyostelium. A protein GT78 associated with this activity has been purified to chromatographic homogeneity. In-gel tryptic digestion followed by nano-liquid chromatography-mass spectrometry on a quadrupole time-of-flight geometry instrument with data-dependent tandem mass spectrometry acquisition yielded a number of peptide fragmentation spectra, nine of which were manually de novo sequenced and found to map onto a predicted 3-exon gene of unknown function on chromosome 4. GT78 is predicted to comprise 648 amino acids with an N-terminal glycosyltransferase and a C-terminal beta-propeller domain. Overexpression of GT78 with a His(6)-tag resulted in a 120-fold increase in Ga1T-activity in cytosolic extracts, and purified His(6)-GT78 exhibited alpha 3Ga1T-activity toward a synthetic acceptor substrate. Expression of the truncated N-terminal region confirmed the predicted catalytic activity of this domain. Disruption of the GT78 gene led to a loss of enzyme activity in extracts and accumulation of the non-galactosylated isoform of Skp1 in cells. GT78 therefore represents the Skp1 alpha 3Ga1T, and its mechanism conforms to the sequential model of Skp1 glycosylation in the cytoplasm shown for earlier enzymes in the pathway. Informatics studies suggest that related catalytic domains are expressed in the Golgi or cytoplasm of plants, other protozoans, and animals.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AY, England; M SCAN Res & Training Ctr, Ascot SL5 7PZ, Berks, England; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Imperial College London; Roswell Park Cancer Institute	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 937, Oklahoma City, OK 73104 USA.	Cwest2@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NIGMS NIH HHS [R01-GM-37539] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barth C, 1998, PLASMID, V39, P141, DOI 10.1006/plas.1997.1326; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Egelund J, 2004, PLANT PHYSIOL, V136, P2609, DOI 10.1104/pp.104.042978; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Faix J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh136; Greer Fiona M, 2003, Methods Mol Biol, V211, P195; Ketcham C, 2004, J BIOL CHEM, V279, P29050, DOI 10.1074/jbc.M313858200; Kostlanova N, 2005, J BIOL CHEM, V280, P27839, DOI 10.1074/jbc.M505184200; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; Steimle PA, 2001, J BIOL CHEM, V276, P6853, DOI 10.1074/jbc.M008992200; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; van der Wel H, 2005, J BIOL CHEM, V280, P14645, DOI 10.1074/jbc.M500600200; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; West C. M., 2005, DICTYOSTELIUM GENOMI, P235; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2004, BBA-GEN SUBJECTS, V1673, P29, DOI 10.1016/j.bbagen.2004.04.007; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Xue J, 2004, RAPID COMMUN MASS SP, V18, P1947, DOI 10.1002/rcm.1573; Young WW, 2004, J MEMBRANE BIOL, V198, P1, DOI 10.1007/s00232-004-0656-5; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; Zhang YY, 1999, J CELL SCI, V112, P4367; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	26	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12713	12721		10.1074/jbc.M513664200	http://dx.doi.org/10.1074/jbc.M513664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16495217	hybrid			2022-12-27	WOS:000237134700063
J	Ignatova, Z; Gierasch, LM				Ignatova, Z; Gierasch, LM			Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; AMYLOID-LIKE FIBRILS; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISEASES; GLUTAMINE-REPEAT; RETINOIC ACID; MUTANT HUNTINGTIN; CLAM PROTEIN; INTRANUCLEAR INCLUSIONS; EXPANDED GLUTAMINE	Formation of fibrillar intranuclear inclusions and related neuropathologies of the CAG-repeat disorders are linked to the expansion of a polyglutamine tract. Despite considerable effort, the etiology of these devastating diseases remains unclear. Although polypeptides with glutamine tracts recapitulate many of the observed characteristics of the gene products with CAG repeats, such as in vitro and in vivo aggregation and toxicity in model organisms, extended polyglutamine segments have also been reported to structurally perturb proteins into which they are inserted. Additionally, the sequence context of a polyglutamine tract has recently been shown to modulate its propensity to aggregate. These findings raise the possibility that indirect influences of the repeat tract on adjacent protein domains are contributory to pathologies. Destabilization of an adjacent domain may lead to loss of function, as well as favoring non-native structures in the neighboring domain causing them to be prone to intermolecular association and consequent aggregation. To explore these phenomena, we have used chimeras of a well studied globular protein and exon 1 of huntingtin. We find that expansion of the polyglutamine segment beyond the pathological threshold (> 35 glutamines) results in structural perturbation of the neighboring protein whether the huntingtin exon is N- or C- terminal. Elongation of the polyglutamine region also substantially increases the propensity of the chimera to aggregate, both in vitro and in vivo, and in vitro aggregation kinetics of a chimera with a 53-glutamine repeat follow a nucleation polymerization mechanism with amonomeric nucleus.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, 913 Lederle Grad Res Tower B,710 N Pleasant St, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009	Ignatova, Zoya/0000-0002-9478-8825	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM027616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Armen RS, 2005, P NATL ACAD SCI USA, V102, P13433, DOI 10.1073/pnas.0502068102; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Bhattacharyya A, 2006, J MOL BIOL, V355, P524, DOI 10.1016/j.jmb.2005.10.053; Bhattacharyya AM, 2005, P NATL ACAD SCI USA, V102, P15400, DOI 10.1073/pnas.0501651102; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chow MKM, 2004, J BIOL CHEM, V279, P47643, DOI 10.1074/jbc.M405799200; Chow MKM, 2004, J MOL BIOL, V335, P333, DOI 10.1016/j.jmb.2003.08.064; Clark PL, 1996, PROTEIN SCI, V5, P1108; Clark PL, 1997, NAT STRUCT BIOL, V4, P883, DOI 10.1038/nsb1197-883; Clark PL, 1998, FOLD DES, V3, P401, DOI 10.1016/S1359-0278(98)00053-4; Clerico EM, 2000, BBA-PROTEIN STRUCT M, V1476, P203, DOI 10.1016/S0167-4838(99)00247-2; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Gunasekaran K, 2004, PROTEINS, V54, P179, DOI 10.1002/prot.10520; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Ignatova Z, 2005, BIOCHEMISTRY-US, V44, P7266, DOI 10.1021/bi047404e; Ignatova Z, 2004, P NATL ACAD SCI USA, V101, P523, DOI 10.1073/pnas.0304533101; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Khare SD, 2005, PLOS COMPUT BIOL, V1, P230, DOI 10.1371/journal.pcbi.0010030; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nozaki K, 2001, NEUROREPORT, V12, P3357, DOI 10.1097/00001756-200110290-00042; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Park Y, 2005, MOL CELLS, V19, P23; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; Radley TL, 2003, J MOL BIOL, V332, P529, DOI 10.1016/S0022-2836(03)00925-2; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Sharma D, 2005, PROTEINS, V61, P398, DOI 10.1002/prot.20602; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang WF, 2005, NEUROBIOL DIS, V20, P500, DOI 10.1016/j.nbd.2005.03.026; Wang ZL, 2005, APPL RADIAT ISOTOPES, V63, P311, DOI 10.1016/j.apradiso.2005.03.017; WETZEL R, 2006, GENETIC INSTABILITIE; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12959	12967		10.1074/jbc.M511523200	http://dx.doi.org/10.1074/jbc.M511523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524881	hybrid			2022-12-27	WOS:000237134700091
J	Taniura, H; Sanada, N; Kuramoto, N; Yoneda, Y				Taniura, H; Sanada, N; Kuramoto, N; Yoneda, Y			A metabotropic glutamate receptor family gene in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; PROTEIN; CLONING	Metabotropic glutamate receptors (mGluRs) are a class of G-protein-coupled receptors that possess a seven transmembrane region involved in the modulation of excitatory synaptic transmission in the nervous system. mGluR orthologs have been identified in Drosophila, Caenorhabditis elegans, and higher organisms. Drosophila possesses two mGluR genes, DmGluRA and DmXR. We screened the Dictyostelium genome data base using the ligand binding domain of rat mGluR1 as bait, and identified a new receptor, Ddm-GluPR, belonging to the mGluR family. Similar to Drosophila DmXR, the residues of mGluRs involved in the binding of the alpha-carboxylic and alpha-amino groups of glutamate were well conserved in DdmGluPR, but the residues interacting with the gamma-carboxylic group of glutamate were not. The phylogenetic analysis suggests that DdmGluPR diverged after the mGluR family-GABA(B) receptors split but before mGluR family divergence. DdmGluPR mRNA was expressed in vegetative cells and throughout starvation-induced development, but the level of the expression was relatively high until 4 h after starvation. DdmGluPR was localized to the plasma membrane of axenically grown Ax-2 cells expressed as a green fluorescent protein fusion protein. DdmGluPR-null cells grew faster at high cell density and reached higher densities than wild-type cells. DdmGluPR-null cells exhibited delayed aggregates formation upon starvation and impaired chemotaxis toward cAMP. Although expressions of cAR1 and aca, cAMP-signaling components, were rapidly induced and peaked at 2-4 h in wild-type cells, DdmGluPR-null cells displayed sustained and peaked at 8 h of the expressions of these genes. Our findings suggest the involvement of DdmGluPR in the early development of Dictyostelium discoideum.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Taniura, H (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.	hideo@p.kanazawa-u.ac.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X				Bogdanik L, 2004, J NEUROSCI, V24, P9105, DOI 10.1523/JNEUROSCI.2724-04.2004; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; MATSUNAMI H, 1997, CELL, V90, P773; Mitri C, 2004, J BIOL CHEM, V279, P9313, DOI 10.1074/jbc.M310878200; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Parmentier ML, 1996, J NEUROSCI, V16, P6687; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; RATHI A, 1992, MECH DEVELOP, V36, P173, DOI 10.1016/0925-4773(92)90068-U	17	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12336	12343		10.1074/jbc.M512723200	http://dx.doi.org/10.1074/jbc.M512723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527814	hybrid			2022-12-27	WOS:000237134700018
J	Yiu, GK; Toker, A				Yiu, GK; Toker, A			NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NUCLEAR FACTOR; COLON-CANCER; MATRIX METALLOPROTEINASE-2; COLORECTAL CARCINOMAS; EXPRESSION; PROSTAGLANDIN; ANGIOGENESIS	The NFAT (nuclear factor of activated T cells) family of transcription factors plays a fundamental role in the transcriptional regulation of the immune response. However, NFATs are ubiquitously expressed, and recent evidence points to their important functions in human epithelial cells and carcinomas. Specifically, NFAT has been shown to be active in human breast and colon carcinoma cells and to promote their invasion through Matrigel. The mechanisms by which NFAT promotes invasion have not been defined. To identify NFAT target genes that induce carcinoma invasion, we have established stable breast cancer cell lines that inducibly express transcriptionally active NFAT. Gene expression profiling by cDNA microarray of cells induced to express NFAT revealed up-regulation of cyclooxygenase-2 (COX-2). Increased NFAT expression and activity induced COX-2 expression as well as prostaglandin E-2 synthesis. This induction was more prominent when NFAT was activated by phorbol 12-myristate 13-acetate and calcium ionophore ionomycin and was blocked by the NFAT antagonist cyclosporin A. Breast cancer cells with elevated COX-2 expression showed increased invasion through Matrigel, and this was reduced in cells treated with COX-2 inhibitors. Conversely, loss of NFAT1 protein expression using small interfering RNA led to a reduction in COX-2 transcription and reduced invasion. Similarly, Matrigel invasion was reduced in cells in which COX-2 expression was reduced using specific siRNA. These findings demonstrate that NFAT promotes breast cancer cell invasion through the induction of COX-2 and the synthesis of prostaglandins.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Toker, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN-237, Boston, MA 02215 USA.	atoker@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA096710] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007893] Funding Source: NIH RePORTER; NCI NIH HHS [CA96710] Funding Source: Medline; NHLBI NIH HHS [T32HL007893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Fujita T, 1998, CANCER RES, V58, P4823; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Half E, 2002, CANCER RES, V62, P1676; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Jacobs EJ, 2005, JNCI-J NATL CANCER I, V97, P975, DOI 10.1093/jnci/dji173; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kawamori T, 1998, CANCER RES, V58, P409; Liu ZM, 2005, J BIOL CHEM, V280, P14700, DOI 10.1074/jbc.M500322200; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Morimoto T, 2001, J BIOL CHEM, V276, P34983, DOI 10.1074/jbc.M005498200; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy BS, 2000, CANCER RES, V60, P293; Richards JA, 2003, J CLIN ENDOCR METAB, V88, P2810, DOI 10.1210/jc.2002-021475; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Sivula A, 2005, BREAST CANCER RES TR, V89, P215, DOI 10.1007/s10549-004-0714-4; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474	57	123	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12210	12217		10.1074/jbc.M600184200	http://dx.doi.org/10.1074/jbc.M600184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505480	hybrid			2022-12-27	WOS:000237134700003
J	Jain, AK; Jaiswal, AK				Jain, AK; Jaiswal, AK			Phosphorylation of tyrosine 568 controls nuclear export of Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDOREDUCTASE-1 GENE-EXPRESSION; ELEMENT-MEDIATED EXPRESSION; CUL3-BASED E3 LIGASE; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; ANTIOXIDANT INDUCTION; ACTIVATION; KEAP1; FAMILY	Nuclear factor Nrf2, under normal conditions, is retained in the cytosol by INrf2. Antioxidants and oxidants antagonize this interaction, resulting in the release of Nrf2. Nrf2 translocates to the nucleus binds to ARE and activates a battery of chemopreventive genes. Once this is achieved, Nrf2 is exported out of the nucleus, binds with INrf2, and degrades. Nrf2 contains well defined signals that control nuclear import and export of Nrf2. The present studies demonstrate that phosphorylation of tyrosine 568 is required for Crm1-mediated nuclear export and degradation of Nrf2. Mutation of tyrosine 568 to alanine and phenylalanine resulted in the loss of interaction with Crm1 and abrogation of nuclear export of Nrf2. Nrf2Y568A is deficient in nuclear export and displays delayed degradation compared with wild-type Nrf2. In addition, Src inhibitor PP2 caused nuclear accumulation of Nrf2 in normal and hydrogen peroxide-treated cells but had no effect on localization of mutant Nrf2Y568A. Further experiments with small interfering RNA revealed that Fyn phosphorylated Nrf2Y568 leading to nuclear export and degradation of Nrf2.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Jain, Abhinav K/A-2540-2013		NIEHS NIH HHS [R01-ES012265] Funding Source: Medline; NIGMS NIH HHS [R01-GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; He ZW, 2005, J BIOL CHEM, V280, P2446, DOI 10.1074/jbc.M402053200; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3	24	146	158	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12132	12142		10.1074/jbc.M511198200	http://dx.doi.org/10.1074/jbc.M511198200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513647	hybrid			2022-12-27	WOS:000236988100083
J	Yang, TTC; Ung, PMU; Rincon, M; Chow, CW; Wing, C				Yang, TTC; Ung, PMU; Rincon, M; Chow, CW; Wing, C			Role of the CCAAT/enhancer-binding protein NFATc2 transcription factor cascade in the induction of secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED T-CELLS; ACUTE-PHASE RESPONSE; NUCLEAR-FACTOR; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; CYCLOSPORINE-A; CYCLOOXYGENASE-2 EXPRESSION; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS	Inflammatory cytokines such as interleukin-1 and tumor necrosis factor-alpha modulate a transcription factor cascade in the liver to induce and sustain an acute and systemic defense against foreign entities. The transcription factors involved include NF-kappa B, STAT, and CCAAT/enhancer-binding protein ( C/EBP). Whether the NFAT group of transcription factors ( which was first characterized as playing an important role in cytokine gene expression in the adaptive response in immune cells) participates in the acute- phase response in hepatocytes is not known. Here, we have investigated whether NFAT is part of the transcription factor cascade in hepatocytes during inflammatory stress. We report that interleukin-1 or tumor necrosis factor-alpha increases expression of and activates NFATc2. C/EBP-mediated NFATc2 induction is temporally required for expression of type IIA secretory phospholipase A(2). NFATc2 is also required for expression of phospholipase D-1 and the calcium-binding protein S100A3. Thus, a C/EBP-NFATc2 transcription factor cascade provides an additional means to modulate the acute-phase response upon stimulation with inflammatory cytokines.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT 05401 USA	Yeshiva University; Albert Einstein College of Medicine; University of Vermont	Chow, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	cchow@aecom.yu.edu	Ung, Peter Man-Un/J-1654-2019	Ung, Peter Man-Un/0000-0002-6849-5252	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI051454, R56AI051454, R01AI051454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063167] Funding Source: NIH RePORTER; NIAID NIH HHS [AI051454] Funding Source: Medline; NIDDK NIH HHS [DK063167, R01 DK063167-04, R01 DK063167-05, R01 DK063167-01A2, R01 DK063167, R01 DK063167-02, R01 DK063167-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; BAK CET, 1991, AGENTS ACTIONS, V34, P81, DOI 10.1007/BF01993244; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Bingham CO, 1999, P ASSOC AM PHYSICIAN, V111, P516, DOI 10.1046/j.1525-1381.1999.99321.x; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Burger D, 2002, ANN NY ACAD SCI, V966, P464, DOI 10.1111/j.1749-6632.2002.tb04248.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cush JJ, 1999, J RHEUMATOL, V26, P1176; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; Gilroy DW, 2004, FASEB J, V18, P489, DOI 10.1096/fj.03-0837com; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Granja AG, 2004, J BIOL CHEM, V279, P53736, DOI 10.1074/jbc.M406620200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holvoet P, 2004, ACTA CARDIOL, V59, P479, DOI 10.2143/AC.59.5.2005219; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jaross W, 2002, EUR J CLIN INVEST, V32, P383, DOI 10.1046/j.1365-2362.2002.01000.x; Jin L, 2003, NAT STRUCT BIOL, V10, P807, DOI 10.1038/nsb975; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kountouras J, 2004, J CELL MOL MED, V8, P317, DOI 10.1111/j.1582-4934.2004.tb00321.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Laye JP, 2003, DRUG DISCOV TODAY, V8, P710, DOI 10.1016/S1359-6446(03)02754-5; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin MKS, 1996, J RHEUMATOL, V23, P1162; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rao A, 2000, BRIT MED BULL, V56, P969, DOI 10.1258/0007142001903634; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Sved P, 2004, CANCER RES, V64, P6934, DOI 10.1158/0008-5472.CAN-03-3018; Svetlov SI, 2002, BBA-MOL CELL BIOL L, V1582, P251, DOI 10.1016/S1388-1981(02)00178-6; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Wendum D, 2003, MODERN PATHOL, V16, P130, DOI 10.1097/01.MP.0000052101.58988.1F; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Yang TTC, 2005, MOL CELL BIOL, V25, P907, DOI 10.1128/MCB.25.3.907-920.2005; Yang TTC, 2003, J BIOL CHEM, V278, P15874, DOI 10.1074/jbc.M211560200; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	91	11	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11541	11552		10.1074/jbc.M511214200	http://dx.doi.org/10.1074/jbc.M511214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500900	hybrid			2022-12-27	WOS:000236988100016
J	Pagler, TA; Rhode, S; Neuhofer, A; Laggner, H; Strobl, W; Hinterndorfer, C; Volf, I; Pavelka, M; Eckhardt, ERM; van der Westhuyzen, DR; Schutz, GJ; Stangl, H				Pagler, TA; Rhode, S; Neuhofer, A; Laggner, H; Strobl, W; Hinterndorfer, C; Volf, I; Pavelka, M; Eckhardt, ERM; van der Westhuyzen, DR; Schutz, GJ; Stangl, H			SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR-BI; SELECTIVE LIPID UPTAKE; CASSETTE TRANSPORTER 1; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; RETRO-ENDOCYTOSIS; HUMAN-FIBROBLASTS; SKIN FIBROBLASTS; PLASMA-MEMBRANE	The high density lipoprotein (HDL) receptor, scavenger receptor class B, type I (SR-BI), mediates selective cholesteryl ester uptake from lipoproteins into liver and steroidogenic tissues but also cholesterol efflux from macrophages to HDL. Recently, we demonstrated the uptake of HDL particles in SR-BI overexpressing Chinese hamster ovarian cells (ldlA7-SRBI) using ultrasensitive microscopy. In this study we show that this uptake of entire HDL particles is followed by resecretion. After uptake, HDL is localized in endocytic vesicles and organelles en route to the perinuclear area; many HDL-positive compartments were classified as multivesiculated and multilamellated organelles by electron microscopy. By using I-125-labeled HDL, we found that similar to 0.8% of the HDL added to the media is taken up by the ldlA7-SRBI cells within 1 h, and almost all HDL is finally resecreted. I-125-Labeled low density lipoprotein showed a very similar association, uptake, and resecretion pattern in ldlA7-SRBI cells that do not express any low density lipoprotein receptor. Moreover, we demonstrate that the process of HDL cell association, uptake, and resecretion occurs in three physiologically relevant cell systems, the liver cell line HepG2, the adrenal cell line Y1BS1, and phorbol myristate acetate-differentiated THP-1 cells as a model for macrophages. Finally, we present evidence that HDL retroendocytosis represents one of the pathways for cholesterol efflux.	Med Univ Vienna, Dept Med Chem, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Physiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Cell Biol & Ultrastruct Res, Ctr Anat & Cell Biol, A-1090 Vienna, Austria; Johannes Kepler Univ, Inst Biophys, A-4040 Linz, Austria; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Johannes Kepler University Linz; University of Kentucky; University of Kentucky	Stangl, H (corresponding author), Med Univ Vienna, Dept Med Chem, Ctr Physiol & Pathophysiol, Wahringerstr 10, A-1090 Vienna, Austria.	Herbert.Stangl@meduniwien.ac.at	Stangl, Herbert/AAT-4379-2021; Schuetz, Gerhard/B-1243-2008; Stangl, Herbert/R-9441-2019	Schuetz, Gerhard/0000-0003-1542-1089; Stangl, Herbert/0000-0002-7288-7320; Neuhofer, Angelika/0000-0002-8989-6207; Eckhardt, Erik/0000-0002-3015-5180	NHLBI NIH HHS [HL63763] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063763] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; Altilia S, 2003, J LIPID RES, V44, P254, DOI 10.1194/jlr.M200248-JLR200; Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409; AULINSKAS TH, 1981, BIOCHIM BIOPHYS ACTA, V664, P255, DOI 10.1016/0005-2760(81)90048-5; AULINSKAS TH, 1985, ARTERIOSCLEROSIS, V5, P45, DOI 10.1161/01.ATV.5.1.45; BADIMON JJ, 1992, CIRCULATION, V86, P86; Barth H, 2005, J VIROL, V79, P5774, DOI 10.1128/JVI.79.9.5774-5785.2005; Bertolini S, 2001, ATHEROSCLEROSIS, V154, P599, DOI 10.1016/S0021-9150(00)00587-6; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; Bocharov AV, 2004, J BIOL CHEM, V279, P36072, DOI 10.1074/jbc.M314264200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BURSTEIN M, 1970, J LIPID RES, V11, P583; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; FAUST JR, 1979, ARCH BIOCHEM BIOPHYS, V192, P86, DOI 10.1016/0003-9861(79)90074-2; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENSPAN P, 1984, J BIOL CHEM, V259, P1703; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; Hasty AH, 2005, J LIPID RES, V46, P1433, DOI 10.1194/jlr.M400418-JLR200; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; HO YK, 1977, J EXP MED, V145, P1531, DOI 10.1084/jem.145.6.1531; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Huang ZH, 2002, J LIPID RES, V43, P375; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Pavelka M, 1998, HISTOCHEM CELL BIOL, V109, P555, DOI 10.1007/s004180050255; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Rhode S, 2004, CELL BIOCHEM BIOPHYS, V41, P343, DOI 10.1385/CBB:41:3:343; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; RINNINGER F, 1988, J LIPID RES, V29, P1179; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	66	102	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11193	11204		10.1074/jbc.M510261200	http://dx.doi.org/10.1074/jbc.M510261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488891	hybrid			2022-12-27	WOS:000236822200063
J	Yi, AK; Yoon, H; Park, JE; Kim, BS; Kim, HJ; Martinez-Hernandez, A				Yi, Ae-Kyung; Yoon, Hyunsook; Park, Jeoung-Eun; Kim, Beom-Sue; Kim, Hae Jong; Martinez-Hernandez, Antonio			CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice - The mitochondrial apoptotic pathway-dependent death of hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; ACTIVATED PROTEIN-KINASES; CYTOCHROME-C RELEASE; BACTERIAL-DNA; TNF-ALPHA; ENDOTOXIC-SHOCK; CELL ACTIVATION; HEPATIC-INJURY; SEPTIC SHOCK	Unmethylated CpG motifs present in bacterial DNA ( CpG DNA) induce innate inflammatory responses, including rapid induction of proinflammatory cytokines. Although innate inflammatory responses induced by CpG DNA and other pathogen-associated molecular patterns are essential for the eradication of infectious microorganisms, excessive activation of innate immunity is detrimental to the host. In this study, we demonstrate that CpG DNA, but not control non-CpG DNA, induces a fulminant liver failure with subsequent shock-mediated death by promoting massive apoptotic death of hepatocytes in D-galactosamine ( D-GalN)-sensitized mice. Inhibition of mitochondrial membrane permeability transition pore opening or caspase 9 activity in vivo protects D-GalN-sensitized mice from the CpG DNA-mediated liver injury and death. CpG DNA enhanced production of proinflammatory cytokines in D-GalN-sensitized mice via a TLR9/MyD88-dependent pathway. In addition, CpG DNA failed to induce massive hepatocyte apoptosis and subsequent fulminant liver failure and death in D-GalN-sensitized mice that lack TLR9, MyD88, tumor necrosis factor (TNF)-alpha, or TNF receptor I but not interleukin-6 or -12p40. Taken together, our results provide direct evidence that CpG DNA induces a severe acute liver injury and shock-mediated death through the mitochondrial apoptotic pathway-dependent death of hepatocytes caused by an enhanced production of TNF-alpha through a TLR9/MyD88 signaling pathway in D-GalN-sensitized mice.	Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA; Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Vet Adm Med Ctr, Pathol & Lab Med Serv, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, 50 N Dunlap St,WPT Rm 315, Memphis, TN 38103 USA.	ayi@utmem.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047379] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 053137] Funding Source: Medline; NIAMS NIH HHS [AR 47379] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Bang R, 2003, J PHARMACOL EXP THER, V305, P31, DOI 10.1124/jpet.102.043539; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bohlinger I, 1996, AM J PATHOL, V149, P1381; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cowdery J, 1996, J IMMUNOL, V156, P4570; Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P1; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR1196, DOI 10.1152/ajpregu.2000.278.5.R1196; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kim WH, 2003, AM J PHYSIOL-GASTR L, V285, pG761, DOI 10.1152/ajpgi.00224.2003; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kobayashi Y, 2004, PEDIATR INT, V46, P685, DOI 10.1111/j.1442-200x.2004.01980.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1994, J IMMUNOL, V153, P1778; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Louis H, 1997, GASTROENTEROLOGY, V112, P935, DOI 10.1053/gast.1997.v112.pm9041256; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; Michie HR, 1996, WORLD J SURG, V20, P460, DOI 10.1007/s002689900072; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Nagaki M, 1999, J HEPATOL, V31, P815, DOI 10.1016/S0168-8278(99)80282-7; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Oku H, 2002, EUR J PHARMACOL, V446, P167, DOI 10.1016/S0014-2999(02)01757-0; Osawa Y, 2001, LIVER, V21, P309, DOI 10.1034/j.1600-0676.2001.210503.x; Razin A, 1981, Prog Nucleic Acid Res Mol Biol, V25, P33, DOI 10.1016/S0079-6603(08)60482-1; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takenaka K, 1998, DIGEST DIS SCI, V43, P887, DOI 10.1023/A:1018898905478; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wang XD, 2001, GENE DEV, V15, P2922; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 1996, J IMMUNOL, V156, P558; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	62	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					15001	15012		10.1074/jbc.M601337200	http://dx.doi.org/10.1074/jbc.M601337200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16554296	hybrid			2022-12-27	WOS:000237671300053
J	Spinelli, S; Campanacci, V; Blangy, S; Moineau, S; Tegoni, M; Cambillau, C				Spinelli, Silvia; Campanacci, Valerie; Blangy, Stephanie; Moineau, Sylvain; Tegoni, Mariella; Cambillau, Christian			Modular structure of the receptor binding proteins of Lactococcus lactis phages - The RBP structure of the temperate phage TP901-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENOVIRUS FIBER; ACID BACTERIA; BETA-HELIX; CELL-WALL; BACTERIOPHAGES; IDENTIFICATION; CHEESE; ATTACHMENT; EVOLUTION	Lactococcus lactis is a Gram-positive bacterium widely used by the dairy industry. Several industrial L. lactis strains are sensitive to various distinct bacteriophages. Most of them belong to the Siphoviridae family and comprise several species, among which the 936 and P335 are prominent. Members of these two phage species recognize their hosts through the interaction of their receptor-binding protein (RBP) with external cell wall saccharidices of the host, the "receptors." We report here the 1.65 angstrom resolution crystal structure of the RBP from phage TP901-1, a member of the P335 species. This RBP of 163 amino acids is a homotrimer comprising three domains: a helical N terminus, an interlaced beta-prism, and a beta-barrel, the head domain (residues 64-163), which binds a glycerol molecule. Fluorescence quenching experiments indicated that the RBP exhibits high affinity for glycerol, muramyl-dipeptide, and other saccharides in solution. The structural comparison of this RBP with that of lactococcal phage p2 RBP, a member of the 936 species (Spinelli, S., Desmyter, A., Verrips, C. T., de Haard, J.W., Moineau, S., and Cambillau, C. (2006) Nat. Struct. Mol. Biol. 13, 85-89) suggests a large extent of modularity in RBPs of lactococcal phages.	CNRS, Architectrure & Fonct Macromol Biol, UMR 6098, F-13288 Marseille 09, France; Univ Aix Marseille 1, F-13288 Marseille 09, France; Univ Aix Marseille 2, F-13288 Marseille 09, France; Univ Laval, Grp Rech Ecol Buccale, Fac Med Dent, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Felix Herelle Reference Ctr Bacterial Viruses, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Dept Biochim & Microbiol, Fac Sci & Genie, Quebec City, PQ G1K 7P4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Laval University; Laval University; Laval University	Cambillau, C (corresponding author), CNRS, Architectrure & Fonct Macromol Biol, UMR 6098, Campus Luminy,Case 932, F-13288 Marseille 09, France.	cambillau@afmb.univ-mrs.fr	Moineau, Sylvain/I-7231-2019; Moineau, Sylvain/N-3578-2013	Moineau, Sylvain/0000-0002-2832-5101; Campanacci, Valerie/0000-0001-6407-6395				Bamford DH, 2002, THEOR POPUL BIOL, V61, P461, DOI 10.1006/tpbi.2002.1591; Bissonnette F, 2000, J DAIRY SCI, V83, P620, DOI 10.3168/jds.S0022-0302(00)74921-6; Brondsted L, 2001, VIROLOGY, V283, P93, DOI 10.1006/viro.2001.0871; Burmeister WP, 2004, J VIROL, V78, P7727, DOI 10.1128/JVI.78.14.7727-7736.2004; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; De Haard HJW, 2005, J BACTERIOL, V187, P4531, DOI 10.1128/JB.187.13.4531-4541.2005; Delcour J, 1999, ANTON LEEUW INT J G, V76, P159, DOI 10.1023/A:1002089722581; Deveau H, 2002, APPL ENVIRON MICROB, V68, P4364, DOI 10.1128/AEM.68.9.4364-4369.2002; Dupont K, 2004, APPL ENVIRON MICROB, V70, P5818, DOI 10.1128/AEM.70.10.5818-5824.2004; Dupont K, 2004, APPL ENVIRON MICROB, V70, P5825, DOI 10.1128/AEM.70.10.5825-5832.2004; Geller BL, 2005, J DAIRY SCI, V88, P900, DOI 10.3168/jds.S0022-0302(05)72756-9; JOSEPHSEN J, 1988, MILCHWISSENSCHAFT, V43, P219; JOSEPHSEN J, 1998, LACTIC ACID BACTERIA, P385; LASKOWSKI R, 1993, J APPL CRYSTALLOGR, V26, P91; Ledeboer AM, 2002, J DAIRY SCI, V85, P1376, DOI 10.3168/jds.S0022-0302(02)74204-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mitraki A, 2002, J STRUCT BIOL, V137, P236, DOI 10.1006/jsbi.2002.4447; MOINEAU S, 1993, APPL ENVIRON MICROB, V59, P197, DOI 10.1128/AEM.59.1.197-202.1993; MOINEAU S, 1992, CAN J MICROBIOL, V38, P875, DOI 10.1139/m92-143; Moineau S, 1996, J DAIRY SCI, V79, P2104, DOI 10.3168/jds.S0022-0302(96)76584-0; Moineau S, 2002, ASM NEWS, V68, P388; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ROUSSEL A, 1991, TURBO FRODO GRAPHICS; Schibli DJ, 2004, MOL MEMBR BIOL, V21, P361, DOI 10.1080/09687860400017784; Smith NL, 2005, P NATL ACAD SCI USA, V102, P17652, DOI 10.1073/pnas.0504782102; Spinelli S, 2006, NAT STRUCT MOL BIOL, V13, P85, DOI 10.1038/nsmb1029; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Tremblay DM, 2006, J BACTERIOL, V188, P2400, DOI 10.1128/JB.188.7.2400-2410.2006; VALYASEVI R, 1990, APPL ENVIRON MICROB, V56, P1882, DOI 10.1128/AEM.56.6.1882-1889.1990; VALYASEVI R, 1994, J DAIRY SCI, V77, P1, DOI 10.3168/jds.S0022-0302(94)76921-6; van Raaij MJ, 2001, J MOL BIOL, V314, P1137, DOI 10.1006/jmbi.2000.5204; Vegge CS, 2006, J BACTERIOL, V188, P55, DOI 10.1128/JB.188.1.55-63.2006; Vegge CS, 2005, J BACTERIOL, V187, P4187, DOI 10.1128/JB.187.12.4187-4197.2005; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	40	98	100	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14256	14262		10.1074/jbc.M600666200	http://dx.doi.org/10.1074/jbc.M600666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16549427	hybrid			2022-12-27	WOS:000237512300050
J	Ullers, RS; Houben, ENG; Brunner, J; Oudega, B; Harms, N; Luirink, J				Ullers, Ronald S.; Houben, Edith N. G.; Brunner, Josef; Oudega, Bauke; Harms, Nellie; Luirink, Joen			Sequence-specific interactions of nascent Escherichia coli polypeptides with trigger factor and signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; PRESECRETORY PROTEINS; SEC-TRANSLOCASE; RIBOSOME; YIDC; SITE; CHAPERONE; INSERTION; PEPTIDE; BINDS	As nascent polypeptides exit the ribosomal tunnel they immediately associate with chaperones, folding catalysts, and targeting factors. These interactions are decisive for the future conformation and destination of the protein that is being synthesized. Using Escherichia coli as a model organism, we have systematically analyzed how the earliest contacts of nascent polypeptides with cytosolic factors depend on the nature and future destination of the emerging sequence using a photo cross-linking approach. Together, the data suggest that the chaperone trigger factor is adjacent to emerging sequences by default, consistent with both its placement near the nascent chain exit site and its cellular abundance. The signal recognition particle (SRP) effectively competes the contact with TF when a signal anchor (SA) sequence of a nascent inner membrane protein appears outside the ribosome. The SRP remains in contact with the SA and downstream sequences during further synthesis of similar to 30 amino acids. The contact with trigger factor is then restored unless another transmembrane segment reinitiates SRP binding. Importantly and in contrast to published data, the SRP appears perfectly capable of distinguishing SA sequences from signal sequences in secretory proteins at this early stage in biogenesis.	Free Univ Amsterdam, Inst Cell & Mol Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Vrije Universiteit Amsterdam; Swiss Federal Institutes of Technology Domain; ETH Zurich	Luirink, J (corresponding author), Free Univ Amsterdam, Inst Cell & Mol Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl	Houben, Edith N.G./B-2110-2015; Luirink, Joen/AAB-8658-2021	Houben, Edith N.G./0000-0002-8805-2002; Luirink, J./0000-0001-8431-0804				Albanese V, 2002, NAT STRUCT BIOL, V9, P716, DOI 10.1038/nsb1002-716; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; Etchells SA, 2004, NAT STRUCT MOL BIOL, V11, P391, DOI 10.1038/nsmb0504-391; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; Jong WSP, 2004, EUR J BIOCHEM, V271, P4779, DOI 10.1111/j.1432-1033.2004.04442.x; Kebir MO, 2002, BIOCHEMISTRY-US, V41, P5573, DOI 10.1021/bi015798t; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LEE JI, 1992, J BIOL CHEM, V267, P938; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; Ying BW, 2005, J BIOL CHEM, V280, P12035, DOI 10.1074/jbc.M500364200; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	47	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13999	14005		10.1074/jbc.M600638200	http://dx.doi.org/10.1074/jbc.M600638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551615	Green Published, hybrid			2022-12-27	WOS:000237512300022
J	Andrews, BJ; Lehman, JA; Turchi, JJ				Andrews, BJ; Lehman, JA; Turchi, JJ			Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; KINASE CATALYTIC SUBUNIT; INDUCED OXIDATIVE STRESS; CYSTEINE RESIDUES; MAMMALIAN-CELLS; REPAIR PROTEINS; STOPPED-FLOW; END; PK; DAMAGE	Ku is a heterodimeric protein comprising 70- and 80-kDa subunits that participate in the non- homologous end-joining (NHEJ) repair pathway for rejoining DNA double strand breaks. We have analyzed the pre- steady state binding of Ku with various DNA duplex substrates and identified a redox- sensitive Ku- DNA interaction. Pre-steady state analysis of Ku DNA binding was monitored via intrinsic Ku quenching upon binding DNA and revealed that, under fully reduced conditions, binding occurred in a single- step process. Reactions performed under limited reduction revealed a two- step binding process, whereas under fully oxidized conditions, we were unable to detect quenching of Ku fluorescence upon binding DNA. The differential quenching observed under the different redox conditions could not be attributed to two Ku molecules binding to a single substrate or Ku sliding inward on the substrate. Although only modest differences in Ku DNA binding activity were observed in the stoichiometric anisotropy and electrophoretic mobility shift assay studies, as a function of redox conditions, a dramatic difference in the rate of Ku dissociation from DNA was observed. This effect was also induced by diamide treatment of Ku and could be abrogated by dithiothreitol treatment, demonstrating a reversible redox effect on the stability of the Ku-DNA complex. The redox-dependent alteration in Ku- DNA interactions is manifested by a redox-dependent alteration in Ku structure, which was confirmed by limited proteolysis and mass spectrometry analyses. The results support a model for the interaction of Ku with DNA that is regulated by redox status and is achieved by altering the dissociation of the Ku- DNA complex.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Wright State Univ, Dept Biomed Sci, Dayton, OH 45435 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Wright State University Dayton	Turchi, JJ (corresponding author), Indiana Univ, Inst Canc Res, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	jturchi@iupui.edu	Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NCI NIH HHS [R01 CA082741, R01 CA082741-05, CA82741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 2001, MOL CELL BIOCHEM, V223, P71, DOI 10.1023/A:1017900810837; Agrawal A, 2001, MOL CELL BIOCHEM, V224, P9, DOI 10.1023/A:1011990704575; Andrews BJ, 2004, MOL CANCER THER, V3, P385; Arosio D, 2004, J BIOL CHEM, V279, P42826, DOI 10.1074/jbc.M406529200; Arosio D, 2002, J BIOL CHEM, V277, P9741, DOI 10.1074/jbc.M111916200; Ayene IS, 2002, J BIOL CHEM, V277, P9929, DOI 10.1074/jbc.M111366200; Ayene IS, 2000, INT J RADIAT BIOL, V76, P1523; Bacsi A, 2005, FREE RADICAL BIO MED, V39, P1650, DOI 10.1016/j.freeradbiomed.2005.08.013; Bianchi A, 1999, J BIOL CHEM, V274, P35284; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Boldogh I, 2003, TOXICOLOGY, V193, P137, DOI 10.1016/j.tox.2003.08.013; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; MIMORI T, 1986, J BIOL CHEM, V261, P375; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Pawelczak KS, 2005, NUCLEIC ACIDS RES, V33, P152, DOI 10.1093/nar/gki157; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Song JY, 2003, J BIOL CHEM, V278, P36676, DOI 10.1074/jbc.M303692200; Turchi JJ, 2000, NUCLEIC ACIDS RES, V28, P4634, DOI 10.1093/nar/28.23.4634; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; ZHANG WW, 1993, BIOCHEM J, V293, P769, DOI 10.1042/bj2930769	36	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13596	13603		10.1074/jbc.M512787200	http://dx.doi.org/10.1074/jbc.M512787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537541	hybrid, Green Accepted			2022-12-27	WOS:000237336600069
J	Brondijk, THC; van Boxel, GI; Mather, OC; Quirk, PG; White, SA; Jackson, JB				Brondijk, THC; van Boxel, GI; Mather, OC; Quirk, PG; White, SA; Jackson, JB			The role of invariant amino acid residues at the hydride transfer site of proton-translocating transhydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; MOBILE-LOOP REGION; RHODOSPIRILLUM-RUBRUM; DOMAIN-I; ESCHERICHIA-COLI; NAD(H)-BINDING COMPONENT; NADP(H)-BINDING DOMAINS; CONFORMATIONAL DYNAMICS; CATALYTIC-PROPERTIES; CRYSTAL-STRUCTURE	Transhydrogenase couples proton translocation across a membrane to hydride transfer between NADH and NADP(+). Previous x-ray structures of complexes of the nucleotide-binding components of transhydrogenase ("dI(2)dIII(1)" complexes) indicate that the dihydronicotinamide ring of NADH can move from a distal position relative to the nicotinamide ring of NADP(+) to a proximal position. The movement might be responsible for gating hydride transfer during proton translocation. We have mutated three invariant amino acids, Arg-127, Asp-135, and Ser-138, in the NAD( H)-binding site of Rhodospirillum rubrum transhydrogenase. In each mutant, turnover by the intact enzyme is strongly inhibited. Stopped-flow experiments using dI(2)dIII(1) complexes show that inhibition results from a block in the steps associated with hydride transfer. Mutation of Asp-135 and Ser-138 had no effect on the binding affinity of either NAD(+) or NADH, but mutation of Arg-127 led to much weaker binding of NADH and slightly weaker binding of NAD(+). X-ray structures of dI(2)dIII(1) complexes carrying the mutations showed that their effects were restricted to the locality of the bound NAD( H). The results are consistent with the suggestion that in wild-type protein movement of the Arg-127 side chain, and its hydrogen bonding to Asp-135 and Ser-138, stabilizes the dihydronicotinamide of NADH in the proximal position for hydride transfer.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	j.b.jackson@bham.ac.uk	Brondijk, Harma/AAD-6485-2019	Brondijk, Harma/0000-0002-0234-673X; White, Scott/0000-0002-0202-6154	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMBARTSOUMIAN G, 1994, MICROBIOL-UK, V140, P1737, DOI 10.1099/13500872-140-7-1737; Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 1996, J BIOL CHEM, V271, P10103, DOI 10.1074/jbc.271.17.10103; Broos J, 2003, J BIOL CHEM, V278, P47578, DOI 10.1074/jbc.M309287200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; CLAYTON RK, 1963, BIOCHIM BIOPHYS ACTA, V75, P312, DOI 10.1016/0006-3002(63)90618-8; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Diggle C, 1996, J BIOL CHEM, V271, P10109, DOI 10.1074/jbc.271.17.10109; Evans W, 1997, CHEM BRIT, V33, P22; FISHER RR, 1971, J BIOL CHEM, V246, P4679; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Grimley RL, 1997, BIOCHEMISTRY-US, V36, P14762, DOI 10.1021/bi971832l; Gupta S, 1998, BBA-BIOENERGETICS, V1409, P25, DOI 10.1016/S0005-2728(98)00146-7; Hickman JW, 2002, J BACTERIOL, V184, P400, DOI 10.1128/JB.184.2.400-409.2002; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 2005, RSC BIOMOLEC SCI, P376; Jackson JB, 2003, FEBS LETT, V545, P18, DOI 10.1016/S0014-5793(03)00388-0; Jeeves M, 1999, J BIOMOL NMR, V13, P305, DOI 10.1023/A:1008300609352; Johansson T, 2005, J MOL BIOL, V352, P299, DOI 10.1016/j.jmb.2005.07.022; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EADB, V226; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Mather OC, 2004, BIOCHEMISTRY-US, V43, P10952, DOI 10.1021/bi0497594; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Prasad GS, 2002, BIOCHEMISTRY-US, V41, P12745, DOI 10.1021/bi020251f; Quirk PG, 1999, BBA-BIOENERGETICS, V1412, P139, DOI 10.1016/S0005-2728(99)00057-2; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Singh A, 2003, J BIOL CHEM, V278, P33208, DOI 10.1074/jbc.M303061200; Sundaresan V, 2005, J MOL BIOL, V346, P617, DOI 10.1016/j.jmb.2004.11.070; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; van Boxel GI, 2003, BIOCHEMISTRY-US, V42, P1217, DOI 10.1021/bi027032e; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	54	11	14	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13345	13354		10.1074/jbc.M513230200	http://dx.doi.org/10.1074/jbc.M513230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533815	hybrid			2022-12-27	WOS:000237336600040
J	Chou, CY; Jen, WP; Hsieh, YH; Shiao, MS; Chang, GG				Chou, CY; Jen, WP; Hsieh, YH; Shiao, MS; Chang, GG			Structural and functional variations in human apolipoprotein E3 and E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; RECEPTOR-BINDING DOMAIN; ALZHEIMERS-DISEASE; LIPID INTERACTION; A-I; PROTEIN INTERACTIONS; SECONDARY STRUCTURE; NEURONAL CELLS; ASSOCIATION; MODEL	There are three major apolipoprotein E ( apoE) isoforms. Although APOE-epsilon 3 is considered a longevity gene, APOE-epsilon 4 is a dual risk factor to atherosclerosis and Alzheimer disease. We have expressed full-length and N- and C-terminal truncated apoE3 and apoE4 tailored to eliminate helix and domain interactions to unveil structural and functional disturbances. The N- terminal truncated apoE4-( 72 - 299) and C-terminal truncated apoE4-( 1 - 231) showed more complicated or aggregated species than those of the corresponding apoE3 counterparts. This isoformic structural variation did not exist in the presence of dihexanoylphosphatidylcholine. The C-terminal truncated apoE-( 1 - 191) and apoE-( 1 - 231) proteins greatly lost lipid binding ability as illustrated by the dimyristoylphosphatidylcholine turbidity clearance. The low density lipoprotein ( LDL) receptor binding ability, determined by a competition binding assay of H-3-LDL to the LDL receptor of HepG2 cells, showed that apoE4 proteins with N- terminal ( apoE4-( 72 - 299)), C-terminal ( apoE4-( 1 - 231)), or complete C-terminal truncation ( apoE4-( 1 - 191)) maintained greater receptor binding abilities than their apoE3 counterparts. The cholesterol-lowering abilities of apoE3-( 72 - 299) and apoE3-( 1 - 231) in apoE- deficient mice were decreased significantly. The structural preference of apoE4 to remain functional in solution may explain the enhanced opportunity of apoE4 isoform to display its pathophysiologic functions in atherosclerosis and Alzheimer disease.	Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, Struct Biol Program, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Chang, GG (corresponding author), Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, Struct Biol Program, 155 Li Nong St,Sec 2, Taipei 112, Taiwan.	ggchang@ym.edu.tw		Chou, Chi-Yuan/0000-0002-3400-171X				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Braman J, 1996, Methods Mol Biol, V57, P31; BURNS RA, 1980, BIOCHEMISTRY-US, V19, P3100, DOI 10.1021/bi00554a041; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chou CY, 2005, BIOPHYS J, V88, P455, DOI 10.1529/biophysj.104.046813; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; de la Torre JC, 2002, J ALZHEIMERS DIS, V4, P497, DOI 10.3233/jad-2002-4606; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; DYER CA, 1991, J BIOL CHEM, V266, P22803; Fan DP, 2004, BIOCHEMISTRY-US, V43, P5055, DOI 10.1021/bi035958w; Farkas MH, 2004, J LIPID RES, V45, P1546, DOI 10.1194/jlr.M400104-JLR200; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Greenow K, 2005, J MOL MED, V83, P329, DOI 10.1007/s00109-004-0631-3; GREGG RE, 1988, CLIN CHEM, V34, pB28; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200; Hoff J, 2000, LAB ANIMAL, V29, P47; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Kiss RS, 2003, J BIOL CHEM, V278, P21952, DOI 10.1074/jbc.M302676200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREMPLER F, 1987, J CLIN INVEST, V80, P401, DOI 10.1172/JCI113086; Lane RM, 2005, J LIPID RES, V46, P949, DOI 10.1194/jlr.M400486-JLR200; Li XP, 2003, BIOCHEMISTRY-US, V42, P10406, DOI 10.1021/bi027093c; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; LUNDBERG BB, 1985, BIOCHEM J, V228, P219, DOI 10.1042/bj2280219; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Peters-Libeu CA, 2006, J BIOL CHEM, V281, P1073, DOI 10.1074/jbc.M510851200; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Schneeweis LA, 2005, BIOCHEMISTRY-US, V44, P12525, DOI 10.1021/bi050872j; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P26; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Song SM, 2004, TRENDS MOL MED, V10, P565, DOI 10.1016/j.molmed.2004.09.005; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	63	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13333	13344		10.1074/jbc.M511077200	http://dx.doi.org/10.1074/jbc.M511077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540478	hybrid			2022-12-27	WOS:000237336600039
J	Herold, MJ; Zeitz, J; Pelzer, C; Kraus, C; Peters, A; Wohlleben, G; Berberich, I				Herold, MJ; Zeitz, J; Pelzer, C; Kraus, C; Peters, A; Wohlleben, G; Berberich, I			The stability and anti-apoptotic function of A1 are controlled by its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; NF-KAPPA-B; CELL-DEATH; BH3-ONLY PROTEINS; UBIQUITIN LIGASE; DOWN-REGULATION; BETA-TRCP; DEGRADATION; EXPRESSION; BAX	Most Bcl-2 family members can localize to intracellular membranes via hydrophobic sequences within their C-terminal portion. We found that the C terminus of the anti-apoptotic family member A1 did not function as a membrane anchor. Instead, this stretch of the protein rendered A1 highly unstable by mediating its polyubiquitination and rapid proteasomal degradation. Moreover, the domain did not only function independently of its position within the A1 protein but when transfered could even destabilize unrelated proteins like enhanced green fluorescent protein and caspase-3. A1 was, however, much more stable in the presence of the Bcl-2 homology-only protein BimEL, suggesting that direct interaction of A1 with pro-apoptotic members of the Bcl-2 family strongly reduces its rate of turnover. We further show that the C-terminal end of A1 also contributes to the anti-apoptotic capacity of the protein. In conclusion, our data demonstrate that the C terminus serves a dual function by controlling the stability of A1 and by amplifying the capacity of the protein to protect cells against apoptosis.	Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany	University of Wurzburg	Berberich, I (corresponding author), Univ Wurzburg, Inst Immunol & Virol, Versbacher Str 7, D-97078 Wurzburg, Germany.	berberich.i@uni-wuerzburg.de	Herold, Marco J/C-8039-2013	Herold, Marco J/0000-0001-7539-7581				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; BERBERICH I, 1992, EUR J IMMUNOL, V22, P525, DOI 10.1002/eji.1830220235; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI SS, 1995, ONCOGENE, V11, P1693; Chuang PI, 2002, BLOOD, V99, P3350, DOI 10.1182/blood.V99.9.3350; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Gonzalez J, 2003, BLOOD, V101, P2679, DOI 10.1182/blood-2002-04-1229; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kucharczak JF, 2005, CELL DEATH DIFFER, V12, P1225, DOI 10.1038/sj.cdd.4401684; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; LIN EY, 1993, J IMMUNOL, V151, P1979; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Schliephake DE, 1996, EUR J IMMUNOL, V26, P268, DOI 10.1002/eji.1830260142; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yang WS, 2005, J CELL BIOCHEM, V94, P1234, DOI 10.1002/jcb.20381; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13663	13671		10.1074/jbc.M600266200	http://dx.doi.org/10.1074/jbc.M600266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551634	hybrid			2022-12-27	WOS:000237336600077
J	Krut, O; Wiegmann, K; Kashkar, H; Yazdanpanah, B; Kronke, M				Krut, O; Wiegmann, K; Kashkar, H; Yazdanpanah, B; Kronke, M			Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SPHINGOMYELINASE; CERAMIDE PRODUCTION; PHOSPHOLIPASE-C; MEMBRANE; PREDICTION; APOPTOSIS; RECEPTOR; ELEGANS; DISEASE; MOUSE	Two genes encoding neutral sphingomyelinases- 1 and - 2 ( sphingomyelin phosphodiesterases- 2 and - 3) have been recently identified that hydrolyze sphingomyelin to phosphorylcholine and ceramide. Data bank searches using a peptide sequence derived from a previously purified bovine neutral sphingomyelinase ( nSMase) allowed us to identify a cDNA encoding a novel human sphingomyelinase, nSMase3, that shows only a little homology to nSMase1 and - 2. nSMase3 was biochemically characterized by overexpression in a yeast strain, JK9 - 3d Delta Isc1p, lacking endogenous SMase activity. Similar to nSMase2, nSMase3 is Mg2+- dependent and shows optimal activity at pH7, which is enhanced in the presence of phosphatidylserine and inhibited by scyphostatin. nSMase3 is ubiquitously expressed as a 4.6- kb mRNA species. nSMase3 lacks an N- terminal signal peptide, yet contains a 23- amino- acid transmembrane domain close to the C terminus, which is indicative for the family of C- tail- anchored integral membrane proteins. Cellular localization studies with hemagglutinin- tagged nSMase3 demonstrated colocal-ization with markers of the endoplasmic reticulum as well as with Golgi markers. Tumor necrosis factor stimulates rapid activation of nSMase3 in MCF7 cells with peak activity at 1.5 min, which was impaired by expression of dominant negative FAN.	Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med, D-50935 Cologne, Germany	University of Cologne	Kronke, M (corresponding author), Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med, Goldenfelsstr 19-21, D-50935 Cologne, Germany.	M.Kroenke@uni-koeln.de						Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aubin I, 2005, NAT GENET, V37, P803, DOI 10.1038/ng1603; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; CAMPADELLI G, 1993, P NATL ACAD SCI USA, V90, P2798, DOI 10.1073/pnas.90.7.2798; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jung M, 1999, AM J HUM GENET, V65, P1068, DOI 10.1086/302580; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KOOY J, 1992, J BIOL CHEM, V267, P20255; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Pajukanta P, 2000, AM J HUM GENET, V67, P1481, DOI 10.1086/316902; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Sambrook J., 2001, MOL CLONING LAB MANU; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	42	102	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13784	13793		10.1074/jbc.M511306200	http://dx.doi.org/10.1074/jbc.M511306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517606	hybrid			2022-12-27	WOS:000237336600089
J	Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK				Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK			Tax-dependent displacement of nucleosomes during transcriptional activation of human T-cell leukemia virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSACTIVATION IN-VITRO; BINDING PROTEIN CREB; RNA-POLYMERASE-II; REGULATORY SEQUENCES; COACTIVATOR CBP; GENE-EXPRESSION; CHROMATIN; PROMOTER; ELONGATION	The human T-cell leukemia virus type 1 (HTLV-1) is integrated into the host cell DNA and assembled into nucleosomes. Within the repressive chromatin environment, the virally encoded Tax protein mediates the recruitment of the coactivators CREB-binding protein/p300 to the HTLV-1 promoter, located within the long terminal repeats (LTRs) of the provirus. These proteins carry acetyltransferase activity that is essential for strong transcriptional activation of the virus in the context of chromatin. Consistent with this, the amino-terminal tails of nucleosomal histones at the viral promoter are acetylated in Tax-expressing cells. We have developed a system in which we transfect Tax into cells carrying integrated copies of the HTLV-1 LTR driving the luciferase gene to analyze changes in "activating" histone modifications at the LTR. Unexpectedly, Tax transactivation led to an apparent reduction of these modifications at the HTLV-1 promoter and downstream region that correlates with a similar reduction in histone H3 and linker histone H1. Micrococcal nuclease protection analysis showed that less LTR-luciferase DNA is nucleosomal in Tax-expressing cells. Furthermore, nucleosome depletion correlated with RNA polymerase II recruitment and loss of SWI/SNF. The M47 Tax mutant, deficient in HTLV-1 transcriptional activation, was also defective for nucleosome depletion. Although this mutant formed complexes with CREB and p300 at the HTLV-1 promoter in vivo, it was unable to mediate RNA polymerase II recruitment or SWI/SNF displacement. These results support a model in which nucleosomes are depleted from the LTR and transcribed region during Tax-mediated transcriptional activation and correlate RNA polymerase II recruitment with nucleosome depletion.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Laybourn, PJ (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Paul.Laybourn@colostate.edu	Lemasson, Isabelle/N-1355-2013	polakowski, Nicholas/0000-0003-4949-5799	NCI NIH HHS [CA55035, CA87540, R01 CA055035-13, R01 CA055035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087540, R01CA055035, R55CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Azran Inbal, 2004, Retrovirology, V1, P20; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Hager GL, 1999, METHOD ENZYMOL, V304, P626; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13075	13082		10.1074/jbc.M512193200	http://dx.doi.org/10.1074/jbc.M512193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547351	hybrid			2022-12-27	WOS:000237336600011
J	Li, HX; Kobayashi, M; Blonska, M; You, Y; Lin, X				Li, HX; Kobayashi, M; Blonska, M; You, Y; Lin, X			Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-RECEPTOR; LIPID RAFTS; KINASE RIP; TAK1; RECRUITMENT; PATHWAY; COMPLEX; MEKK3; TAB2; IKK	Stimulation of cells with tumor necrosis factor (TNF alpha) triggers a recruitment of various signaling molecules, such as RIP, to the TNF alpha receptor 1 complex, leading to activation of NF-K B. Previous studies indicate that RIP plays an essential role for TNF alpha- induced NF-KB activation, but the molecular mechanism by which RIP mediates TNF alpha signals to activate NF-KB is not fully defined. Earlier studies suggest that RIP undergoes a ligand- dependent ubiquitination. However, it remains to be determined whether the ubiquitination of RIP is required for TNF alpha-induced NF-KB activation. In this study, we have identified Lys(377) of RIP as the functional ubiquitination site, because mutating this residue to arginine completely abolished RIP-mediated NF-K B activation. The K377R mutation of RIP cannot undergo ligand-dependent ubiquitination and fails to recruit its downstream signaling components into the TNF alpha receptor 1 complex. Together, our studies provide the first genetic evidence that the ubiquitination of RIP is required for TNF alpha-induced NF-KB activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; SUNY Buffalo, Grad Program Biochem, Buffalo, NY 14214 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Lin, X (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	xllin@mdanderson.org	Blonska, Marzenna/U-7751-2019	Blonska, Marzenna/0000-0001-5237-8732	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065899, R56GM065899] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058048] Funding Source: Medline; NIGMS NIH HHS [GM065899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Morlon A, 2005, HUM MOL GENET, V14, P3751, DOI 10.1093/hmg/ddi405; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	25	209	226	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13636	13643		10.1074/jbc.M600620200	http://dx.doi.org/10.1074/jbc.M600620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543241	hybrid			2022-12-27	WOS:000237336600074
J	Sivan, SS; Tsitron, E; Wachtel, E; Roughley, PJ; Sakkee, N; van der Ham, F; DeGroot, J; Roberts, S; Maroudas, A				Sivan, SS; Tsitron, E; Wachtel, E; Roughley, PJ; Sakkee, N; van der Ham, F; DeGroot, J; Roberts, S; Maroudas, A			Aggrecan turnover in human intervertebral disc as determined by the racemization of aspartic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; AGE-RELATED ACCUMULATION; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; HYALURONATE; PRODUCTS; PROTEINS; COLLAGEN	We have used the racemization of aspartic acid as a marker for the "molecular age" of aggrecan components of the human intervertebral disc matrix (aggregating and non-aggregating proteoglycans as well as the different buoyant density fractions of aggrecan). By measuring the D/L-Asp ratio of the various aggrecan species as a function of age and using the values of the racemization constant, k(i), found earlier for aggrecan in articular cartilage, we were able to establish directly the relative residence time of these molecules in human intervertebral disc matrix. For A1 preparations taken from normal tissue, turnover rates of 0.059 +/- 0.01 and 0.063 +/- 0.01/year correspond to half-life values of 12 +/- 2.0 and 11.23 +/- 1.9 years for nucleus pulposus and annulus fibrosus, respectively; the turnover rates of 0.084 +/- 0.022 and 0.092 +/- 0.034/year for degenerate tissue correspond to half-life values of 8.77 +/- 2.2 and 8.41 +/- 2.8 years, suggesting increased rate of removal of small aggrecan fragments. For the large monomer, fraction A1D1, turnover is 0.13 +/- 0.04/year, corresponding to a half-life of 5.56 +/- 1.58 years, similar to 3.4 years in human articular cartilage. For the binding region (A1D6), turnover is 0.033 +/- 0.0012/year, corresponding to a half-life of 21.53 +/- 0.6 years, similar to 23.5 years in articular cartilage. A1 preparations from nucleus pulposus contain a lower proportion of aggregating proteoglycans as compared with annulus fibrosus, suggesting increased proteolytic modification in the nucleus pulposus. D/L-Asp values in aggregating and non-aggregating proteoglycans of a 24-year-old individual show similar results, suggesting that the non-aggregating molecules are synthesized initially as aggregating proteoglycans, which thereafter undergo cleavage and detachment from hyaluronan.	Technion Israel Inst Technol, Julius Silver Inst Biomed Sci, Fac Biomed Engn, Dept Biomed Engn, IL-32000 Haifa, Israel; Weizmann Inst Sci, Fac Chem, IL-76100 Rehovot, Israel; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; TNO, Qual Life, Business Unit Biomed Res, NL-2301 CE Leiden, Netherlands; Robert Jones & Agnes Hunt Orthopaed Hosp, Ctr Spinal Studies, Oswestry SY10 7AG, Shrops, England	Technion Israel Institute of Technology; Weizmann Institute of Science; McGill University; Netherlands Organization Applied Science Research; Keele University	Sivan, SS (corresponding author), Technion Israel Inst Technol, Julius Silver Inst Biomed Sci, Fac Biomed Engn, Dept Biomed Engn, IL-32000 Haifa, Israel.	sarit@bm.technion.ac.il	DeGroot, Jeroen/C-4585-2012	Sivan, Sarit/0000-0002-6074-8032				ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; BAYLISS MT, 1985, BIOCHEM J, V232, P111, DOI 10.1042/bj2320111; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BAYLISS MT, 1990, METHODS CARTILAGE RE, P220; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HARDINGHAM TE, 1976, BIOCHEM J, V159, P143, DOI 10.1042/bj1590143; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1975, J ANAT, V120, P113; MAROUDAS A, 1992, CONNECT TISSUE RES, V28, P161, DOI 10.3109/03008209209015033; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MELROSE J, 1994, MATRIX BIOL, V14, P61, DOI 10.1016/0945-053X(94)90030-2; Ohtani S, 1998, J FORENSIC SCI, V43, P949; PFEIFFER H, 1995, INT J LEGAL MED, V108, P19, DOI 10.1007/BF01845611; POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z; ROUGHLEY PJ, 2006, IN PRESS EUR SPINE J; Sztrolovics R, 2002, BIOCHEM J, V362, P473, DOI 10.1042/0264-6021:3620473; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2001, MATRIX BIOL, V20, P409, DOI 10.1016/S0945-053X(01)00158-5; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200	27	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13009	13014		10.1074/jbc.M600296200	http://dx.doi.org/10.1074/jbc.M600296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537531	hybrid, Green Published			2022-12-27	WOS:000237336600003
J	Moreland, JG; Davis, AP; Bailey, G; Nauseef, WM; Lamb, FS				Moreland, JG; Davis, AP; Bailey, G; Nauseef, WM; Lamb, FS			Anion channels, including ClC-3, are required for normal neutrophil oxidative function, phagocytosis, and transendothelial migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHLORIDE CHANNELS; PLASMA-MEMBRANE; OXIDASE; ACTIVATION; EXPRESSION; EFFLUX; CL; IDENTIFICATION; GRANULOCYTES; MODULATION	NADPH oxidase activity, phagocytosis, and cell migration are essential functions of polymorphonuclear leukocytes (PMNs) in host defense. The cytoskeletal reorganization necessary to perform these functions has been extensively studied, but the role of cell volume regulation, which is likely dependent upon anion channels, has not been defined. Mice lacking the anion channel ClC-3 (Clcn3((-/-))) died from presumed sepsis following intravascular catheter placement, whereas Clcn3((+/+)) littermates survived. We hypothesized that ClC-3 has a critical role in host defense and reasoned that PMN function would be compromised in these mice. Clcn3((-/-)) PMNs displayed markedly reduced NADPH oxidase activity in response to opsonized zymosan and modestly reduced activity after phorbol 12-myristate 13-acetate. Human PMNs treated with the anion channel inhibitors niflumic acid or 5-nitro-2-(3-phenylpropylamino)benzoic acid had a very similar defect. ClC-3 protein was detected in the secretory vesicles and secondary granules of resting PMNs and was up-regulated to the phagosomal membrane. Clcn3((-/-)) PMNs and human PMNs lacking normal anion channel function both exhibited reduced uptake of opsonized zymosan at 1, 5, and 10 min in a synchronized phagocytosis assay. Niflumic acid-treated PMNs also had impaired transendothelial migration in vitro, whereas migration in vivo was not altered in Clcn3((-/-)) PMNs. Selective inhibition of the swelling-activated chloride channel with tamoxifen profoundly reduced PMN migration but had no effect on NADPH oxidase activity. In summary, PMNs lacking normal anion channel function exhibited reduced NADPH oxidase activity, diminished phagocytosis, and impaired migration. ClC-3 was specifically involved in the respiratory burst and phagocytosis.	Univ Iowa, Dept Pediat, Div Pediat Crit Care, Iowa City, IA 52242 USA; Univ Iowa, Div Crit Care, Iowa City, IA 52242 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Moreland, JG (corresponding author), Univ Iowa, Dept Pediat, Div Pediat Crit Care, 200 Hawkins Dr, Iowa City, IA 52242 USA.	jessica-moreland@uiowa.edu		Nauseef, William/0000-0003-4032-757X; Lamb, Fred/0000-0003-2955-5133	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD041922] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062483, R56HL062483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034879, R01AI034879] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62483] Funding Source: Medline; NIAID NIH HHS [AI34879] Funding Source: Medline; NICHD NIH HHS [T32 HD041922, T32 HD041922-04] Funding Source: Medline; NIEHS NIH HHS [ES00378] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BLRD VA		Allen LAH, 1999, BLOOD, V93, P3521, DOI 10.1182/blood.V93.10.3521.410k21_3521_3530; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; de Tassigny AD, 2003, FUND CLIN PHARMACOL, V17, P539, DOI 10.1046/j.1472-8206.2003.00197.x; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Dickerson LW, 2002, BRAIN RES, V958, P227, DOI 10.1016/S0006-8993(02)03519-9; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Garcia-Duran M, 1999, CIRC RES, V85, P1020; Geiszt M, 1997, J BIOL CHEM, V272, P26471, DOI 10.1074/jbc.272.42.26471; HELLEBERG L, 1981, CLIN PHARMACOKINET, V6, P245, DOI 10.2165/00003088-198106040-00001; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jiang BH, 2002, LIFE SCI, V70, P1383, DOI 10.1016/S0024-3205(01)01517-X; Kobayashi T, 1998, J CELL SCI, V111, P81; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; MAKERT M, 1988, J LAB CLIN MED, V111, P57; Menegazzi R, 1996, J CELL BIOL, V135, P511, DOI 10.1083/jcb.135.2.511; Moreland JG, 2004, J IMMUNOL, V172, P426, DOI 10.4049/jimmunol.172.1.426; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Parij N, 1998, EUR J PHARMACOL, V352, P299, DOI 10.1016/S0014-2999(98)00370-7; Perez-Cornejo P, 2004, J IMMUNOL, V172, P6988, DOI 10.4049/jimmunol.172.11.6988; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Ransom CB, 2001, J NEUROSCI, V21, P7674, DOI 10.1523/JNEUROSCI.21-19-07674.2001; REENWOOD IA, 1998, AM J PHYSIOL, V275, pH1524; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; ROCHARVEILLER M, 1995, INFLAMM RES, V44, P198, DOI 10.1007/BF01782258; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SHIMIZU Y, 1993, BIOCHEM PHARMACOL, V45, P1743; SIMCHOWITZ L, 1986, J GEN PHYSIOL, V88, P167, DOI 10.1085/jgp.88.2.167; Soroceanu L, 1999, J NEUROSCI, V19, P5942, DOI 10.1523/JNEUROSCI.19-14-05942.1999; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; STODDARD JS, 1993, AM J PHYSIOL, V265, pC156, DOI 10.1152/ajpcell.1993.265.1.C156; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wang Bor-Sen, 2000, Proceedings of the National Science Council Republic of China Part B Life Sciences, V24, P178; Wheeler M, 2000, FASEB J, V14, P476, DOI 10.1096/fasebj.14.3.476; WINERBOURN CC, 2004, JPN J INFECT DIS, V57, pS31	45	121	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12277	12288		10.1074/jbc.M511030200	http://dx.doi.org/10.1074/jbc.M511030200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522634	hybrid			2022-12-27	WOS:000237134700012
J	Wang, J; Okamoto, Y; Morishita, J; Tsuboi, K; Miyatake, A; Ueda, N				Wang, J; Okamoto, Y; Morishita, J; Tsuboi, K; Miyatake, A; Ueda, N			Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; CANNABINOID-RECEPTOR-LIGAND; CRYSTAL-STRUCTURE; ACYLATED GLYCEROPHOSPHOLIPIDS; ENZYMATIC-SYNTHESIS; ACTIVE-SITE; BINDING; PHOSPHODIESTERASE; IDENTIFICATION; BIOSYNTHESIS	In animal tissues, bioactive N-acylethanolamines including the endocannabinoid anandamide are formed from their corresponding N-acylphosphatidylethanolamines (NAPEs) by the catalysis of a specific phospholipase D (NAPE-PLD) that belongs to the metallo-beta-lactamase family. Despite its potential physiological importance, NAPE-PLD has not yet been characterized with a purified enzyme preparation. In the present study we expressed a recombinant NAPE-PLD in Escherichia coli and highly purified it. The purified enzyme was remarkably activated in a dose-dependent manner by millimolar concentrations of Mg2+ as well as Ca2+ and, hence, appeared to be constitutively active. The enzyme showed extremely high specificity for NAPEs among various glycerophospholipids but did not reveal obvious selectivity for different long chain or medium chain N-acyl species of NAPEs. These results suggested the ability of NAPE-PLD to degrade different NAPEs without damaging other membrane phospholipids. Metal analysis revealed the presence of catalytically important zinc in NAPE-PLD. In addition, site-directed mutagenesis studies were addressed to several histidine and aspartic acid residues of NAPE-PLD that are highly conserved within the metallo-beta-lactamase family. Single mutations of Asp-147, His-185, His-187, Asp-189, His-190, His-253, Asp-284, and His-321 caused abolishment or remarkable reduction of the catalytic activity. Moreover, when six cysteine residues were individually mutated to serine, only C224S showed a considerably reduced activity. The activities of L207F and H380R found as single nucleotide polymorphisms were also low. Thus, NAPE-PLD appeared to function through a mechanism similar to those of the well characterized members of this family but play a unique role in the lipid metabolism of animal tissues.	Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa 7610793, Japan; Kagawa Univ, Life Sci Res Ctr, Miki, Kagawa 7610793, Japan; China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Peoples R China	Kagawa University; Kagawa University; China Medical University	Ueda, N (corresponding author), Kagawa Univ, Sch Med, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	nueda@med.kagawa-u.ac.jp	OKAMOTO, Yasuo/J-8438-2015					APPLEBUR.ML, 1970, J BIOL CHEM, V245, P4968; Aravind L, 1999, In Silico Biol, V1, P69; Bates PA, 2001, PROTEINS, P39; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; Caramelo JJ, 2003, BIOCHEM J, V374, P109, DOI 10.1042/BJ20021840; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COMFURIUS P, 1990, J LIPID RES, V31, P1719; Curtiss NP, 2005, GENOMICS, V85, P600, DOI 10.1016/j.ygeno.2005.01.013; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Garau G, 2005, J BIOL CHEM, V280, P28591, DOI 10.1074/jbc.M502744200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Guo Y, 2005, J BIOL CHEM, V280, P23429, DOI 10.1074/jbc.C500168200; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Haruta S, 2000, ANTIMICROB AGENTS CH, V44, P2304, DOI 10.1128/AAC.44.9.2304-2309.2000; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200; Kim MH, 2005, P NATL ACAD SCI USA, V102, P17606, DOI 10.1073/pnas.0504996102; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU J, 2005, 2005 S CANN INT CANN, P119; Liu Q, 2002, CHEM PHYS LIPIDS, V115, P77, DOI 10.1016/S0009-3084(02)00015-4; Maccarrone M, 2005, J CELL SCI, V118, P4393, DOI 10.1242/jcs.02536; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Martin SF, 2000, ANAL BIOCHEM, V278, P106, DOI 10.1006/abio.1999.4420; Materon IC, 2004, J MOL BIOL, V344, P653, DOI 10.1016/j.jmb.2004.09.074; Materon IC, 2001, PROTEIN SCI, V10, P2556, DOI 10.1110/ps.ps.40884; McFarland MJ, 2004, PHARMACOL THERAPEUT, V104, P117, DOI 10.1016/j.pharmthera.2004.07.008; Morishita J, 2005, J NEUROCHEM, V94, P753, DOI 10.1111/j.1471-4159.2005.03234.x; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Okamoto Y, 2005, BIOCHEM J, V389, P241, DOI 10.1042/BJ20041790; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; PIEPER U, 2004, NUCLEIC ACIDS RES, V2, P217; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Rohman M, 2000, PROTEIN EXPRES PURIF, V20, P45, DOI 10.1006/prep.2000.1271; ROZA M, 1973, BIOCHIM BIOPHYS ACTA, V327, P24, DOI 10.1016/0005-2744(73)90099-5; Sasaki T, 1997, LIFE SCI, V61, P1803, DOI 10.1016/S0024-3205(97)00804-7; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1986, CHEM PHYS LIPIDS, V41, P195, DOI 10.1016/0009-3084(86)90022-8; Spath B, 2005, J BIOL CHEM, V280, P35440, DOI 10.1074/jbc.M506418200; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302	69	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12325	12335		10.1074/jbc.M512359200	http://dx.doi.org/10.1074/jbc.M512359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527816	hybrid			2022-12-27	WOS:000237134700017
J	Chen, M; Chen, SC; Pallen, CJ				Chen, M; Chen, SC; Pallen, CJ			Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC-FAMILY KINASES; ACTIVATION LOOP PHOSPHORYLATION; PTP-ALPHA; CATALYTIC DOMAINS; AUTOPHOSPHORYLATION; FAK; BINDING; PP60(C-SRC); PP125(FAK)	Protein-tyrosine phosphatase-alpha (PTP alpha) activates Src family kinases (SFKs) to promote the integrin-stimulated early autophosphorylation of focal adhesion kinase (FAK). We report here that integrin stimulation induces tyrosine phosphorylation of PTP alpha. PTP alpha was dephosphorylated upon fibroblast detachment from the substratum and rephosphorylated when cells were plated on the integrin ligand fibronectin. PTP alpha phosphorylation occurred at Tyr(789) and required SFKs ( Src or Fyn/Yes), FAK, and an intact cytoskeleton. It also required active PTP alpha or constitutively active Src. These observations indicate that PTP alpha activates SFKs and that the subsequently activated SFK . FAK tyrosine kinase complex in turn phosphorylates PTP alpha. Reintroduction of wild-type PTP alpha or unphosphorylatable PTP alpha(Y789F) ( but not inactive PTP alpha) into PTP alpha-null fibroblasts restored defective integrin-induced SFK activation, FAK phosphorylation, and paxillin phosphorylation. PTP alpha( Y789F) and inactive PTP alpha could not rescue delayed actin stress fiber assembly and focal adhesion formation or defective cell migration. This study distinguishes two roles of PTP alpha in integrin signaling: an early role as an activator of SFKs and FAK with no requirement for PTP alpha phosphorylation and a later downstream role in cytoskeleton-associated events for which PTP alpha phosphorylation at Tyr(789) is essential.	Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Inst Mol & Cell Biol, Singapore 138673, Singapore; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Child & Family Research Institute; University of British Columbia; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of British Columbia	Pallen, CJ (corresponding author), Univ British Columbia, Dept Pediat, Rm 3102,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	cpallen@interchange.ubc.ca		Pallen, Catherine/0000-0002-3576-5295				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	37	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11972	11980		10.1074/jbc.M600561200	http://dx.doi.org/10.1074/jbc.M600561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507567	hybrid			2022-12-27	WOS:000236988100067
J	Levdikov, VM; Blagova, E; Joseph, P; Sonenshein, AL; Wilkinson, AJ				Levdikov, VM; Blagova, E; Joseph, P; Sonenshein, AL; Wilkinson, AJ			The structure of CodY, a GTP- and isoleucine-responsive regulator of stationary phase and virulence in Gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATOR; CRYSTAL-STRUCTURE; GLOBAL REGULATOR; GAF DOMAINS; PROTEIN; PROMOTER; BINDING; LIGAND; GENES	CodY is a global regulator of transcription in Gram-positive bacteria. It represses during growth genes required for adaptation to nutrient limitation, including virulence genes in some human pathogens. CodY activity is regulated by GTP and branched chain amino acids, metabolites whose intracellular concentrations drop as cells enter stationary phase. Although CodY has a highly conserved sequence, it has no significant similarity to proteins of known structure. Here we report crystal structures of two fragments of CodY from Bacillus subtilis that clearly constitute its cofactor and DNA binding domains and reveal that CodY is a chimera of previously observed folding units. The N-terminal cofactor-binding fragment adopts a fold reminiscent of the GAF domains found in cyclic nucleotide phosphodiesterases and adenylate cyclases. It is a dimer stabilized by an intermolecular six alpha-helical bundle that buries an extensive apolar surface rich in residues invariant in CodY orthologues. The branched chain amino acid ligands reside in hydrophobic pockets of each monomer distal to the dimer-forming surface. The structure of the C-terminal DNA binding domain belongs to the winged helix-turn-helix family. The implications of the structure for DNA binding by CodY and its control by cofactor binding are discussed.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	University of York - UK; Tufts University	Wilkinson, AJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	ajw@ysbl.york.ac.uk	Levdikov, Vladimir/AAA-6139-2022	Levdikov, Vladimir/0000-0003-3041-1049; Wilkinson, Anthony/0000-0003-4577-9479	Biotechnology and Biological Sciences Research Council [BBS/B/1213X] Funding Source: Medline; NIGMS NIH HHS [GM042219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042219] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; AVARIND L, 1997, TRENDS BIOCHEM SCI, V22, P458; Blagova EV, 2003, ACTA CRYSTALLOGR D, V59, P155, DOI 10.1107/S0907444902018358; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guedon E, 2001, MOL MICROBIOL, V40, P1227, DOI 10.1046/j.1365-2958.2001.02470.x; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Joseph P, 2005, J BACTERIOL, V187, P4127, DOI 10.1128/JB.187.12.4127-4139.2005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Molle V, 2003, J BACTERIOL, V185, P1911, DOI 10.1128/JB.185.6.1911-1922.2003; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Petranovic D, 2004, MOL MICROBIOL, V53, P613, DOI 10.1111/j.1365-2958.2004.04136.x; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Ratnayake-Lecamwasam M, 2001, GENE DEV, V15, P1093, DOI 10.1101/gad.874201; Serror P, 1996, MOL MICROBIOL, V20, P843, DOI 10.1111/j.1365-2958.1996.tb02522.x; Shivers RP, 2004, MOL MICROBIOL, V53, P599, DOI 10.1111/j.1365-2958.2004.04135.x; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; Sonenshein AL, 2005, CURR OPIN MICROBIOL, V8, P203, DOI 10.1016/j.mib.2005.01.001; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tani TH, 2002, P NATL ACAD SCI USA, V99, P13471, DOI 10.1073/pnas.212510999; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	35	80	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11366	11373		10.1074/jbc.M513015200	http://dx.doi.org/10.1074/jbc.M513015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488888	hybrid			2022-12-27	WOS:000236822200079
J	Li, G; Hu, YC; Huo, YY; Liu, ML; Freeman, D; Gao, J; Liu, X; Wu, DC; Wu, H				Li, G; Hu, YC; Huo, YY; Liu, ML; Freeman, D; Gao, J; Liu, X; Wu, DC; Wu, H			PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PROTEIN-TYROSINE-PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; PROSTATE-CANCER; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-SURVIVAL; BETA-CATENIN; ANGIOGENESIS; ACTIVATION	Tumor suppressor gene PTEN is highly mutated in a wide variety of human tumors. To identify unknown targets or signal transduction pathways that are regulated by PTEN, microarray analysis was performed to compare the gene expression profiles of Pten null mouse embryonic fibroblasts (MEFs) cell lines and their isogenic counterparts. Expression of a heparin binding growth factor, pleiotrophin (Ptn), was found to be up-regulated in Pten(-/-) MEFs as well as Pten null mammary tumors. Further experiments revealed that Ptn expression is regulated by the PTEN-PI3K-AKT pathway. Knocking down the expression of Ptn by small interfering RNA resulted in the reduction of Akt and GSK-3 beta phosphorylation and suppression of the growth and the tumorigenicity of Pten null MEFs. Our results suggest that PTN participates in tumorigenesis caused by PTEN loss and PTN may be a potential target for anticancer therapy, especially for those tumors with PTEN deficiencies.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Inst Radiat Med, Beijing 100850, Peoples R China	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, H (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	ligang@nic.bmi.ac.cn; hwu@mednet.ucla.edu	LI, GANG/O-1409-2016	LI, GANG/0000-0003-3203-8567; HUO, YANYING/0000-0003-4747-4951	NCI NIH HHS [R01 CA107166, UO1 CA84128-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107166, U01CA084128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aigner A, 2003, ANN ONCOL, V14, P1525, DOI 10.1093/annonc/mdg416; Bandyopadhyay S, 2004, CANCER RES, V64, P7655, DOI 10.1158/0008-5472.CAN-04-1623; Bernard-Pierrot I, 2001, J BIOL CHEM, V276, P12228, DOI 10.1074/jbc.M010913200; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; CZUBAYKO F, 1995, BREAST CANCER RES TR, V36, P157, DOI 10.1007/BF00666037; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2003, MOL CELL NEUROSCI, V24, P1051, DOI 10.1016/j.mcn.2003.08.010; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Malerczyk C, 2005, GENE THER, V12, P339, DOI 10.1038/sj.gt.3302398; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Satyamoorthy K, 2000, PIGM CELL RES, V13, P87, DOI 10.1034/j.1600-0749.13.s8.16.x; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 2003, CANCER RES, V63, P674; Ulbricht U, 2003, J NEUROPATH EXP NEUR, V62, P1265, DOI 10.1093/jnen/62.12.1265; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Weber D, 2000, CANCER RES, V60, P5284; Xiang CC, 2002, NAT BIOTECHNOL, V20, P738, DOI 10.1038/nb0702-738; Zhong H, 2000, CANCER RES, V60, P1541; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	29	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10663	10668		10.1074/jbc.M512509200	http://dx.doi.org/10.1074/jbc.M512509200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16507572	hybrid			2022-12-27	WOS:000236822200004
J	Zarini, S; Gijon, MA; Folco, G; Murphy, RC				Zarini, S; Gijon, MA; Folco, G; Murphy, RC			Effect of arachidonic acid reacylation on leukotriene biosynthesis in human neutrophils stimulated with granulocyte-macrophage colony-stimulating factor and formyl-methionyl-leucyl-phenylalanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULAR CALCIUM; PROSTANOID SYNTHESIS; REAGENT THIMEROSAL; SULFHYDRYL REAGENT; THIOL REAGENT; CA2+ SPIKES; 5-LIPOXYGENASE; CELLS	Priming of human neutrophils with granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by treatment with formyl-methionyl-leucyl-phenylalanine (fMLP) stimulates cells in a physiologically relevant manner with modest 5-lipoxygenase activation and formation of leukotrienes. However, pretreatment of neutrophils with thimerosal, an organomercury thiosalicylic acid derivative, led to a dramatic increase (>50-fold) in the production of leukotriene B-4 and 5-hydroxyeicosatetraenoic acid, significantly higher than that observed after stimulation with calcium ionophore A23187. Little or no effect was observed with thimerosal alone or in combination with either GM-CSF or fMLP. Elevation of [Ca2+](i) induced by thimerosal in neutrophils stimulated with GM-CSF/fMLP was similar but more sustained compared with samples where thimerosal was absent. However, [Ca2+](i) was significantly lower compared with calcium ionophore-treated cells, suggesting that a sustained calcium rise was necessary but not sufficient to explain the effects of this compound on the GM-CSF/fMLP-stimulated neutrophil. Thimerosal was found to directly inhibit neutrophil lysophospholipid: acyl-CoA acyltransferase activity at the doses that stimulate leukotriene production, and analysis of lysates from neutrophil preparations stimulated in the presence of thimerosal showed a marked increase in free arachidonic acid, supporting the inhibition of the reincorporation of this fatty acid into the membrane phospholipids as a mechanism of action for this compound. The dramatic increase in production of leukotrienes by neutrophils when a physiological stimulus such as GM-CSF/fMLP is employed in the presence of thimerosal suggests a critical regulatory role of arachidonate reacylation that limits leukotriene biosynthesis in concert with 5-lipoxygenase and cytosolic phospholipase A(2)alpha activation.	Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA; Hlth Sci Ctr, Aurora, CO 80045 USA; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Milan	Murphy, RC (corresponding author), Univ Colorado Denver, Dept Pharmacol, Mail Stop 8303,12801 E 17th Ave,POB 6511, Aurora, CO 80045 USA.	robert.murphy@uchsc.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Zarini, Simona/0000-0002-7460-3299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25785] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Elferink JGR, 1999, GEN PHARMACOL, V33, P1, DOI 10.1016/S0306-3623(98)00258-4; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FANTONE JC, 1982, AM J PATHOL, V107, P397; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HANSCH GM, 1985, J IMMUNOL, V135, P1320; HASLETT C, 1985, AM J PATHOL, V119, P101; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Kaever V, 1988, Eicosanoids, V1, P49; KAEVER V, 1988, PROSTAGLANDINS, V35, P885, DOI 10.1016/0090-6980(88)90114-1; Kerkhoff Claus, 2003, Methods Mol Biol, V228, P111, DOI 10.1385/1-59259-400-X:111; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; LANDS WEM, 1976, ENZYMES BIOL MEMBR, P3; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101; Meloni I, 2002, NAT GENET, V30, P436, DOI 10.1038/ng857; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Peters-Golden M, 2003, PROSTAG LEUKOTR ESS, V69, P99, DOI 10.1016/S0952-3278(03)00070-X; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; STUNING M, 1988, PROSTAG LEUKOTR ESS, V32, P1, DOI 10.1016/0952-3278(88)90086-5; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	44	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10134	10142		10.1074/jbc.M510783200	http://dx.doi.org/10.1074/jbc.M510783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16495221	hybrid			2022-12-27	WOS:000236594300039
J	Kim, YR; Kim, JS; Lee, SH; Lee, WR; Sohn, JN; Chung, YC; Shim, HK; Lee, SC; Kwon, MH; Kim, YS				Kim, Young-Rim; Kim, Jeong-Sun; Lee, Seung-Hyun; Lee, Woo-Ram; Sohn, Jong-Nam; Chung, Yu-Chul; Shim, Hye-Kyung; Lee, Suk-Chan; Kwon, Myung-Hee; Kim, Yong-Sung			Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FV; AUTOANTIBODY; RECOGNITION; FAB; MODULATION; EXPRESSION; CLEAVAGE; FRAGMENT; MOUSE; SERA	Anti-DNA antibodies (Abs) are of biomedical interest because they are associated with autoimmune diseases in human and mice. Previously we isolated an anti-DNA monoclonal Ab 3D8 from an autoimmune-prone MRL-lpr/lpr mouse. Here we have characterized DNA binding kinetics and hydrolyzing activities of the recombinant single chain variable fragment ( scFv) and the single variable domains of heavy chain (VH) and light chain (VL) using various single-stranded (ss) and double-stranded (ds) DNA substrates. All the Abs bound to both ds- and ssDNAs without significant preferential sequence specificity showing scFv higher affinities (K-D = similar to 17-74 n(M)) than VH (K-D = similar to 2.4-8.4 mu(M)) and VL (K-D = similar to 3.2-72 mu(M)), and efficiently hydrolyzed both ds- and ssDNAs without sequence specificity in a Mg2+-dependent manner, except for the poor activity of 3D8 scFv for ss-(dT)(40). Elucidated crystal structure-based His to Ala mutations on the complementarity determining regions of VH (His-H35 -> Ala) and/or VL (His-L94 -> Ala) of 3D8 scFv significantly inhibited the catalytic activities, indicating that the His residues are involved in the catalytic mechanism of 3D8 scFv. However, the DNA hydrolyzing activities of single domain VH and VL were not affected by the mutations, indicative of their different catalytic mechanisms from that of 3D8 scFv. Our results demonstrate single domain Abs with DNase activities for the first time, which might provide new insights into substrate recognition and catalytic mechanisms of anti-DNA Abs.	Chonnam Natl Univ, Dept Chem, Kwangju 500757, South Korea; Ajou Univ, Sch Med, Dept Microbiol, Suwon 443749, South Korea; Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea	Chonnam National University; Ajou University; Ajou University; Sungkyunkwan University (SKKU)	Kim, JS (corresponding author), Chonnam Natl Univ, Dept Chem, 300 Yongbong Dong, Kwangju 500757, South Korea.	jsunkim@chonnam.ac.kr; kwonmh@ajou.ac.kr; kimys@ajou.ac.kr		Kim, Yong-Sung/0000-0003-2673-1509				Ay J, 2000, J MOL BIOL, V301, P239, DOI 10.1006/jmbi.2000.3971; Baranovskii AG, 2001, IMMUNOL LETT, V76, P163, DOI 10.1016/S0165-2478(01)00185-7; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BRIGIDO MM, 1993, J IMMUNOL, V150, P469; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerutti ML, 2001, J BIOL CHEM, V276, P12769, DOI 10.1074/jbc.M100260200; Chen Y, 1999, J IMMUNOL, V162, P4663; CLARK P, 1974, BIOCHEMISTRY-US, V13, P5098, DOI 10.1021/bi00722a007; Cleary J, 2003, BIOCHEMISTRY-US, V42, P30, DOI 10.1021/bi0203942; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P6218, DOI 10.1021/bi026866u; Dubrovskaya VV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1081, DOI 10.1023/A:1026350426842; Eivazova ER, 2000, IMMUNOLOGY, V101, P371, DOI 10.1046/j.1365-2567.2000.00119.x; Gololobov GV, 1997, MOL IMMUNOL, V34, P1083, DOI 10.1016/S0161-5890(97)00129-6; GOLOLOBOV GV, 1995, P NATL ACAD SCI USA, V92, P254, DOI 10.1073/pnas.92.1.254; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jang YJ, 2003, CELL MOL LIFE SCI, V60, P309, DOI 10.1007/s000180300026; Jang YJ, 2001, MOL IMMUNOL, V38, P383, DOI 10.1016/S0161-5890(01)00066-9; Jin HL, 2004, PROTEIN SCI, V13, P3222, DOI 10.1110/ps.04921704; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNOWICZ E, 1973, BIOCHIM BIOPHYS ACTA, V312, P72, DOI 10.1016/0005-2787(73)90053-1; Kanyshkova TG, 1997, FEBS LETT, V416, P23, DOI 10.1016/S0014-5793(97)01163-0; Komissarov AA, 1999, BIOCHEMISTRY-US, V38, P14631, DOI 10.1021/bi991347l; KUBOTA T, 1986, IMMUNOL LETT, V14, P53, DOI 10.1016/0165-2478(86)90020-9; Kumar S, 2001, J MOL BIOL, V308, P527, DOI 10.1006/jmbi.2001.4534; Kwon MH, 2002, IMMUNOL INVEST, V31, P205, DOI 10.1081/IMM-120016241; Lee HW, 2005, BIOCHEM BIOPH RES CO, V330, P1205, DOI 10.1016/j.bbrc.2005.03.101; Marion TN, 1997, METHODS, V11, P3, DOI 10.1006/meth.1996.0381; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mouratou B, 2002, J IMMUNOL METHODS, V269, P147, DOI 10.1016/S0022-1759(02)00231-4; Nevinsky GA, 2002, J IMMUNOL METHODS, V269, P235, DOI 10.1016/S0022-1759(02)00234-X; Nevinsky GA, 2000, APPL BIOCHEM BIOTECH, V83, P115, DOI 10.1385/ABAB:83:1-3:115; NEVINSKY GA, 2005, NATURAL CATALYTIC AN; O'Connor KC, 2001, J MOL RECOGNIT, V14, P18, DOI 10.1002/1099-1352(200101/02)14:1<18::AID-JMR515>3.0.CO;2-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; POLYMENIS M, 1995, J IMMUNOL, V154, P2198; RADIC MZ, 1993, J IMMUNOL, V150, P4966; Schuermann JP, 2005, J MOL BIOL, V347, P965, DOI 10.1016/j.jmb.2005.02.008; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Stevens SY, 1999, BIOCHEMISTRY-US, V38, P560, DOI 10.1021/bi981899o; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0	42	86	100	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15287	15295		10.1074/jbc.M600937200	http://dx.doi.org/10.1074/jbc.M600937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551636	hybrid			2022-12-27	WOS:000237922200032
J	Canty, EG; Garrigue-Antar, L; Kadler, KE				Canty, EG; Garrigue-Antar, L; Kadler, KE			A complete domain structure of Drosophila tolloid is required for cleavage of short gastrulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; ACTIVITY GRADIENT; FAMILY-MEMBER; EMBRYO; GENE; SOG; RESIDUES; HOMOLOG; PRODUCT	Drosophila tolloid ( TLD) is a member of a family of proteinases that play important roles in development and includes mammalian tolloid ( mTLD) and bone morphogenetic protein ( BMP)-1. TLD accentuates the activity of decapentaplegic ( DPP), a transforming growth factor beta superfamily growth factor, by cleaving its antagonist Short gastrulation ( Sog). Similarly, the activity of BMP-2/4 ( vertebrate homologues of DPP) is augmented by cleavage of chordin. However, whereas TLD is an effective Sogase, mTLD is a poor chordinase and is functionally replaced by its smaller splice variant BMP-1, which lacks the most C-terminal epidermal growth factor ( EGF)-like and CUB domains of mTLD. Moreover, the minimal chordinase activity resides in the N-terminal half of BMP-1. This study showed that the proteolytic activity of TLD is considerably enhanced by Ca2+ and tested the hypothesis that the Sogase activity of TLD resides in the N-terminal half of the proteinase. Unexpectedly, it was found that TLD lacking the CUB4 and CUB5 domains and/or the EGF-like domains was unable to cleave Sog. Loss of function mutations have been reported in the tld gene that result in amino acid substitutions at E835K ( in CUB4), S915L ( in CUB5), and N760I ( in EGF2) in TLD. The CUB mutants were found to be ineffective Sogases, but the activity of the EGF2 mutant was unchanged. The results show that substrate recognition and cleavage by Drosophila tolloid and mTLD are different despite their identical domain structure and homologous functions in patterning. The result that the N760I mutant has full Sogase activity suggests that novel substrates for TLD exist.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr CellMatrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr CellMatrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	Laird, Elizabeth/AAX-7280-2020; KADLER, KARL/ABI-2403-2020	Laird, Elizabeth/0000-0001-5041-1316; KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FINELLI L, 1995, GENETICS, V141, P271; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Petropoulou V, 2005, J BIOL CHEM, V280, P22616, DOI 10.1074/jbc.M413468200; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Serpe M, 2005, DEVELOPMENT, V132, P2645, DOI 10.1242/dev.01838; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Shimmi O, 2003, DEVELOPMENT, V130, P4673, DOI 10.1242/dev.00684; Shimmi O, 2005, CELL, V120, P873, DOI 10.1016/j.cell.2005.02.009; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TAKAHARA K, 1995, GENOMICS, V29, P9, DOI 10.1006/geno.1995.1209; Yu K, 2000, DEVELOPMENT, V127, P2143	34	13	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13258	13267		10.1074/jbc.M510483200	http://dx.doi.org/10.1074/jbc.M510483200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16488892	hybrid			2022-12-27	WOS:000237336600031
J	Li, XQ; Lu, Y; Jin, WD; Liang, K; Mills, GB; Fan, Z				Li, XQ; Lu, Y; Jin, WD; Liang, K; Mills, GB; Fan, Z			Autophosphorylation of Akt at Threonine 72 and Serine 246 - A potential mechanism of regulation of Akt kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CANCER CELLS; ACTIVATION; DOMAIN; PHOSPHORYLATES; RESISTANCE; AKT/PKB; INSULIN; B/AKT	Activation of the serine/ threonine protein kinase Akt is a multistep process. We here propose that the kinase activity of Akt is regulated via autophosphorylation in trans at two putative sites ( threonine 72 and serine 246) that lie in the characteristic Akt substrate motif ( RXRXX( S/ T)). Incubation of Akt immunoprecipitated from transfected cells with a pre- activated Akt recombinant protein and gamma- P-32- labeled ATP led to marked incorporation of radioactivity in wild- type Akt but not Akt/ T72A/ S246A mutant. Western blot analysis using a phosphorylated Akt substrate- specific antibody of Akt immunoprecipitated from transfected cells confirmed the autophosphorylation of wild- type Akt but not Akt/ T72A/ S246A mutant in insulin- like growth factor- 1 ( IGF- 1)- stimulated cells. Autophosphorylation of Akt on Thr- 72 and Ser- 246 appeared to require prior phosphorylation of Akt on Thr- 308 and Ser- 473. Compared with wild- type Akt, Akt/ T72A/ S246A mutant exhibited markedly reduced basal Akt kinase activity and response to cellular stimulation by insulin-like growth factor- 1, and also conferred less cellular resistance to doxorubicin- induced apoptosis. The findings from these pilot studies suggest that Akt regulates its kinase activity through autophosphorylation. Further investigation of this potential novel regulatory mechanism by which Akt performs its cellular functions is warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 036, Houston, TX 77030 USA.	zfan@mdanderson.org						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alkan S, 2002, BLOOD, V99, P2278, DOI 10.1182/blood-2001-01-0317; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Carter Michael D, 2004, J Biomol Tech, V15, P257; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Coffer PJ, 1998, BIOCHEM J, V335, P1; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Liu B, 2000, BRIT J CANCER, V82, P1991; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Ringel MD, 2001, CANCER RES, V61, P6105; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271	30	23	23	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13837	13843		10.1074/jbc.M602060200	http://dx.doi.org/10.1074/jbc.M602060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549426	hybrid			2022-12-27	WOS:000237336600094
J	Cipriano, DJ; Wood, KS; Bi, YM; Dunn, SD				Cipriano, DJ; Wood, KS; Bi, YM; Dunn, SD			Mutations in the dimerization domain of the b subunit from the Escherichia coli ATP synthase - Deletions disrupt function but not enzyme assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; 2ND STALK; F1F0-ATPASE; PROTEINS; SECTOR; ENERGY; ALPHA; DIMER; F1	The b subunit dimer of Escherichia coli ATP synthase serves essential roles as an assembly factor for the enzyme and as a stator during rotational catalysis. To investigate the functional importance of its coiled coil dimerization domain, a series of internal deletions including each individual residue between Lys-100 and Ala-105 (b(Delta K100)-b(Delta A105)), b(Delta K100-A103), and b(Delta K100-Q106) as well as a control b(K100A) missense mutation were prepared. All of the mutants supported assembly of ATP synthase, but all single-residue deletions failed to support growth on acetate, indicating a severe defect in oxidative phosphorylation, and b(Delta K100-Q106) displayed moderately reduced growth. The membrane-bound ATPase activities of these strains showed a related reduction in sensitivity to dicyclohexylcarbodiimide, indicative of uncoupling. Analysis of dimerization of the soluble constructs of b(Delta K100) and the multiple-residue deletions by sedimentation equilibrium revealed reduced dimerization compared with wild type for all deletions, with b(Delta K100-Q106) most severely affected. In cross-linking studies it was found that F-1-ATPase can mediate the dimerization of some soluble b constructs but did not mediate dimerization of b(Delta K100) and b(Delta K100-Q106); these two forms also were defective in F-1 binding analyses. We conclude that defective dimerization of soluble b constructs severely affects F-1 binding in vitro, yet allows assembly of ATP synthase in vivo. The highly uncoupled nature of enzymes with single-residue deletions in b indicates that the b subunit serves an active function in energy coupling rather than just holding on to the F-1 sector. This function is proposed to depend on proper, specific interactions between the b subunits and F-1.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@uwo.ca	Dunn, Stanley/D-3418-2013					Bhatt D, 2005, J BIOENERG BIOMEMBR, V37, P67, DOI 10.1007/s10863-005-4129-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; Cipriano DJ, 2006, J BIOL CHEM, V281, P501, DOI 10.1074/jbc.M509986200; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; DUNCAN TM, 2003, ENZYMES, V23, P203; Dunn S. D., 2004, HDB ATPASES, P311; Dunn SD, 2001, BIOCHEMISTRY-US, V40, P187, DOI 10.1021/bi001821j; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Futai M., 2004, HDB ATPASES BIOCH CE, P237; Gruber M, 2003, TRENDS BIOCHEM SCI, V28, P679, DOI 10.1016/j.tibs.2003.10.008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	36	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12408	12413		10.1074/jbc.M513368200	http://dx.doi.org/10.1074/jbc.M513368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531410	hybrid			2022-12-27	WOS:000237134700026
J	Hekim, C; Leinonen, J; Narvanen, A; Koistinen, H; Zhu, L; Koivunen, E; Vaisanen, V; Stenman, UH				Hekim, C; Leinonen, J; Narvanen, A; Koistinen, H; Zhu, L; Koivunen, E; Vaisanen, V; Stenman, UH			Novel peptide inhibitors of human kallikrein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN-GLANDULAR-KALLIKREIN; SUBSTRATE-SPECIFICITY; BINDING PEPTIDES; MESSENGER-RNA; CELL-ADHESION; CANCER; HK2; EXPRESSION; PLASMINOGEN	Human kallikrein 2 (hK2) is a serine protease produced by the secretory epithelial cells in the prostate. Because hK2 activates several factors participating in proteolytic cascades that may mediate metastasis of prostate cancer, modulation of the activity of hK2 is a potential way of preventing tumor growth and metastasis. Furthermore, specific ligands for hK2 are potentially useful for targeting and imaging of prostate cancer and for assay development. We have used enzymatically active recombinant hK2 captured by a monoclonal antibody exposing the active site of the enzyme to screen phage display peptide libraries. Using libraries expressing 10 or 11 amino acids long linear peptides, we identified six different peptides binding to hK2. Three of these were shown to be specific and efficient inhibitors of the enzymatic activity of hK2 toward a peptide substrate. Furthermore, the peptides inhibited the activation of the proform of prostate-specific antigen by hK2. Amino acid substitution analyses revealed that motifs of six amino acids were required for the inhibitory activity. These peptides are potentially useful for treatment and targeting of prostate cancer.	Univ Helsinki, Cent Hosp, Dept Clin Chem, Biomedicum, FIN-00290 Helsinki, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Turku, Dept Biotechnol, FIN-20520 Turku, Finland	University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland; University of Helsinki; University of Turku	Stenman, UH (corresponding author), Univ Helsinki, Cent Hosp, Dept Clin Chem, POB 700, Helsinki 00029, Finland.	ulf-hakan.stenman@hus.fi	Narvanen, Ale/A-6002-2009; Koistinen, Hannu/AGU-1279-2022	Koistinen, Hannu/0000-0003-0926-3109; Koivunen, Erkki/0000-0002-6443-9595				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bangma CH, 1997, J UROLOGY, V157, P2191, DOI 10.1016/S0022-5347(01)64712-8; Boerman OC, 2000, SEMIN NUCL MED, V30, P195, DOI 10.1053/snuc.2000.7441; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Catalona WJ, 2000, UROLOGY, V55, P791, DOI 10.1016/S0090-4295(99)00602-0; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; Cloutier SM, 2004, EUR J BIOCHEM, V271, P607, DOI 10.1111/j.1432-1033.2003.03963.x; Cloutier SM, 2002, EUR J BIOCHEM, V269, P2747, DOI 10.1046/j.1432-1033.2002.02960.x; Darson MF, 1999, UROLOGY, V53, P939, DOI 10.1016/S0090-4295(98)00637-2; Darson MF, 1997, UROLOGY, V49, P857, DOI 10.1016/S0090-4295(97)00108-8; Denmeade SR, 1997, CANCER RES, V57, P4924; Denmeade SR, 1998, CANCER RES, V58, P2537; Fortier AH, 1999, J NATL CANCER I, V91, P1635, DOI 10.1093/jnci/91.19.1635; Frenette G, 1997, INT J CANCER, V71, P897, DOI 10.1002/(SICI)1097-0215(19970529)71:5<897::AID-IJC31>3.0.CO;2-2; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; Koivunen E, 1999, J NUCL MED, V40, P883; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kwiatkowski MK, 1998, UROLOGY, V52, P360, DOI 10.1016/S0090-4295(98)00245-3; Leinonen J, 2002, CLIN CHEM, V48, P2208; Lintula S, 2005, PROSTATE, V63, P324, DOI 10.1002/pros.20194; Liu S, 1999, CHEM REV, V99, P2235, DOI 10.1021/cr980436l; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; Mikolajczyk SD, 1998, PROSTATE, V34, P44; Morpurgo M, 2002, BIOCONJUGATE CHEM, V13, P1238, DOI 10.1021/bc0100511; MORRIS BJ, 1989, CLIN EXP PHARMACOL P, V16, P345, DOI 10.1111/j.1440-1681.1989.tb01570.x; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nam RK, 2000, J CLIN ONCOL, V18, P1036, DOI 10.1200/JCO.2000.18.5.1036; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Stege R, 2000, CLIN CANCER RES, V6, P160; Stenman UH, 1999, TUMOR BIOL, V20, P1, DOI 10.1159/000056523; Stenman UH, 2005, SCAND J UROL NEPHROL, V39, P64, DOI 10.1080/03008880510030941; STENMAN UH, 1991, CANCER RES, V51, P222; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WANG MC, 1979, INVEST UROL, V17, P159; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Wu P, 2004, PROSTATE, V58, P345, DOI 10.1002/pros.10337; Wu P, 2004, CLIN CHEM, V50, P125, DOI 10.1373/clinchem.2003.026146; ZHANG WM, 1995, CLIN CHEM, V41, P1567	47	39	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12555	12560		10.1074/jbc.M600014200	http://dx.doi.org/10.1074/jbc.M600014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527822	hybrid			2022-12-27	WOS:000237134700044
J	Ren, YJ; Barnwell, LF; Alexander, JC; Lubin, FD; Adelman, JP; Pfaffinger, PJ; Schrader, LA; Anderson, AE				Ren, YJ; Barnwell, LF; Alexander, JC; Lubin, FD; Adelman, JP; Pfaffinger, PJ; Schrader, LA; Anderson, AE			Regulation of surface localization of the small conductance Ca2+-activated potassium channel, Sk2, through direct phosphorylation by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; RAT SUPRAOPTIC NUCLEUS; K+-CHANNEL; SYNAPTIC PLASTICITY; PLASMA-MEMBRANE; CYCLIC-AMP; TRAFFICKING; EXPRESSION; KV4.2; BRAIN	Small conductance, Ca2+-activated voltage-independent potassium channels (SK channels) are widely expressed in diverse tissues; however, little is known about the molecular regulation of SK channel subunits. Direct alteration of ion channel subunits by kinases is a candidate mechanism for functional modulation of these channels. We find that activation of cyclic AMP-dependent protein kinase (PKA) with forskolin ( 50 mu M) causes a dramatic decrease in surface localization of the SK2 channel subunit expressed in COS7 cells due to direct phosphorylation of the SK2 channel subunit. PKA phosphorylation studies using the intracellular domains of the SK2 channel subunit expressed as glutathione S-transferase fusion protein constructs showed that both the amino-terminal and carboxyl-terminal regions are PKA substrates in vitro. Mutational analysis identified a single PKA phosphorylation site within the amino-terminal of the SK2 subunit at serine 136. Mutagenesis and mass spectrometry studies identified four PKA phosphorylation sites: Ser(465) ( minor site) and three amino acid residues Ser(568), Ser(569), and Ser(570) ( major sites) within the carboxyl-terminal region. A mutated SK2 channel subunit, with the three contiguous serines mutated to alanines to block phosphorylation at these sites, shows no decrease in surface expression after PKA stimulation. Thus, our findings suggest that PKA phosphorylation of these three sites is necessary for PKA-mediated reorganization of SK2 surface expression.	Baylor Univ, Dept Pediat, Cain Fdn Labs, Feigin Ctr 955, Houston, TX 77030 USA; Baylor Univ, Dept Neurol, Houston, TX 77030 USA; Baylor Univ, Dept Neurosci, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Baylor University; Baylor University; Baylor University; Oregon Health & Science University	Anderson, AE (corresponding author), Baylor Univ, Dept Pediat, Cain Fdn Labs, Feigin Ctr 955, 1102 Bates St,MC 3-6365, Houston, TX 77030 USA.	annea@bcm.tmc.edu	Schrader, Laura/ABH-4854-2020	Schrader, Laura/0000-0003-3355-1194				ADAMS J, 1999, SOC NEUR ABSTR, V25, P541; Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Anderson AE, 2000, J BIOL CHEM, V275, P5337, DOI 10.1074/jbc.275.8.5337; Armstrong WE, 2005, J COMP NEUROL, V491, P175, DOI 10.1002/cne.20679; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Cingolani LA, 2002, J NEUROSCI, V22, P4456, DOI 10.1523/JNEUROSCI.22-11-04456.2002; Cloues RK, 2003, J NEUROSCI, V23, P1593; Faber ESL, 2005, NAT NEUROSCI, V8, P635, DOI 10.1038/nn1450; Gallo G, 2002, J NEUROSCI, V22, P5016, DOI 10.1523/JNEUROSCI.22-12-05016.2002; Grunnet M, 2004, J NEUROSCI RES, V78, P845, DOI 10.1002/jnr.20318; Hammond RS, 2006, J NEUROSCI, V26, P1844, DOI 10.1523/JNEUROSCI.4106-05.2006; Haug T, 2000, J NEUROPHYSIOL, V83, P2071, DOI 10.1152/jn.2000.83.4.2071; Heusser K, 2005, CURR OPIN NEUROBIOL, V15, P364, DOI 10.1016/j.conb.2005.04.001; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Lee AL, 2003, J NEUROCHEM, V86, P1079, DOI 10.1046/j.1471-4159.2003.01880.x; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; Markstein R, 1999, N-S ARCH PHARMACOL, V359, P454, DOI 10.1007/PL00005375; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; O'Connell AD, 2005, P NATL ACAD SCI USA, V102, P9954, DOI 10.1073/pnas.0504332102; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Sailer CA, 2002, J NEUROSCI, V22, P9698; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P468, DOI 10.1152/jn.1988.59.2.468; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Stackman RW, 2002, J NEUROSCI, V22, P10163; Stern JE, 1997, J PHYSIOL-LONDON, V500, P497, DOI 10.1113/jphysiol.1997.sp022036; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; STORM JF, 1990, PROG BRAIN RES, V83, P161; Strassmaier T, 2005, J BIOL CHEM, V280, P21231, DOI 10.1074/jbc.M413125200; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300; Wagner EJ, 2001, J PHARMACOL EXP THER, V299, P21; YOO D, 2005, J BIOL CHEM; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou JS, 2002, CIRC RES, V91, P540, DOI 10.1161/01.RES.0000033598.00903.27	46	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11769	11779		10.1074/jbc.M513125200	http://dx.doi.org/10.1074/jbc.M513125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513649	hybrid			2022-12-27	WOS:000236988100042
J	Wei, L; Sandbulte, MR; Thomas, PG; Webby, RJ; Homayouni, R; Pfeffer, LM				Wei, L; Sandbulte, MR; Thomas, PG; Webby, RJ; Homayouni, R; Pfeffer, LM			NF kappa B negatively regulates interferon-induced gene expression and anti-influenza activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; MX PROTEINS; VIRUS; ACTIVATION; RESISTANCE; BETA	Interferons (IFNs) are antiviral cytokines that selectively regulate gene expression through several signaling pathways including nuclear factor kappa B (NF kappa B). To investigate the specific role of NF kappa B in IFN signaling, we performed gene expression profiling after IFN treatment of embryonic fibroblasts derived from normal mice or mice with targeted deletion of NF kappa B p50 and p65 genes. Interestingly, several antiviral and immunomodulatory genes were induced higher by IFN in NF kappa B knock-out cells. Chromatin immunoprecipitation experiments demonstrated that NF kappa B was basally bound to the promoters of these genes, while IFN treatment resulted in the recruitment of STAT1 and STAT2 to these promoters. However, in NF kappa B knock-out cells IFN induced STAT binding as well as the binding of the IFN regulatory factor-1 (IRF1) to the IFN-stimulated gene (ISG) promoters. IRF1 binding closely correlated with enhanced gene induction. Moreover, NF kappa B suppressed both antiviral and immunomodulatory actions of IFN against influenza virus. Our results identify a novel negative regulatory role of NF kappa B in IFN-induced gene expression and biological activities and suggest that modulating NF kappa B activity may provide a new avenue for enhancing the therapeutic effectiveness of IFN.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA; Univ Tennessee, Inst Canc, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, 930 Madison Ave,Rm 530, Memphis, TN 38163 USA.	lpfeffer@utmem.edu	Homayouni, Ramin/U-2837-2019; Thomas, Paul G./H-1063-2018; Webby, Richard J/N-5657-2018; Wei, Lai/D-1088-2014; Homayouni, Ramin/B-3547-2009	Homayouni, Ramin/0000-0003-0186-5076; Thomas, Paul G./0000-0001-7955-0256; Homayouni, Ramin/0000-0003-0186-5076; Sandbulte, Matthew/0000-0001-6693-674X; Pfeffer, Lawrence/0000-0003-2809-1234	NCI NIH HHS [R01 CA073753, CA73753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; Arduini RM, 2004, PROTEIN EXPRES PURIF, V34, P229, DOI 10.1016/j.pep.2003.11.004; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belz GT, 2000, J VIROL, V74, P3486, DOI 10.1128/JVI.74.8.3486-3493.2000; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Govorkova EA, 2004, ANTIMICROB AGENTS CH, V48, P4855, DOI 10.1128/AAC.48.12.4855-4863.2004; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Lee SH, 2002, GENOME RES, V12, P527, DOI 10.1101/gr.20102; Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; Ploegh H L, 2000, Nutr Rev, V58, pS25; PLOEGH HL, 2000, NUTR REV, V58, pS63; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270; Uger RA, 1997, J IMMUNOL, V158, P685; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Zhang Y, 2005, J BIOL CHEM, V280, P34306, DOI 10.1074/jbc.M503263200	26	88	100	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11678	11684		10.1074/jbc.M513286200	http://dx.doi.org/10.1074/jbc.M513286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517601	Green Accepted, hybrid			2022-12-27	WOS:000236988100031
J	Feng, J; Che, YS; Milse, J; Yin, YJ; Liu, L; Ruckert, C; Shen, XH; Qi, SW; Kalinowski, J; Liu, SJ				Feng, J; Che, YS; Milse, J; Yin, YJ; Liu, L; Ruckert, C; Shen, XH; Qi, SW; Kalinowski, J; Liu, SJ			The gene ncgl2918 encodes a novel maleylpyruvate isomerase that needs mycothiol as cofactor and links mycothiol biosynthesis and gentisate assimilation in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-SMEGMATIS MUTANTS; COMPLETE GENOME SEQUENCE; STRUCTURAL-ANALYSIS; OVOTHIOL-A; STRAIN U2; PATHWAY; IDENTIFICATION; THIOL; DEGRADATION; METABOLISM	Data mining of the Corynebacterium glutamicum genome identified 4 genes analogous to the mshA, mshB, mshC, and mshD genes that are involved in biosynthesis of mycothiol in Mycobacterium tuberculosis and Mycobacterium smegmatis. Individual deletion of these genes was carried out in this study. Mutants mshC(-) and mshD(-) lost the ability to produce mycothiol, but mutant mshB(-) produced mycothiol as the wild type did. The phenotypes of mutants mshC(-) and mshD(-) were the same as the wild type when grown in LB or BHIS media, but mutants mshC(-) and mshD(-) were not able to grow in mineral medium with gentisate or 3-hydroxybenzoate as carbon sources. C. glutamicum assimilated gentisate and 3-hydroxybenzoate via a glutathione-independent gentisate pathway. In this study it was found that the maleylpyruvate isomerase, which catalyzes the conversion of maleylpyruvate into fumarylpyruvate in the glutathione-independent gentisate pathway, needed mycothiol as a cofactor. This mycothiol-dependent maleylpyruvate isomerase gene (ncgl2918) was cloned, actively expressed, and purified from Escherichia coli. The purified mycothiol-dependent isomerase is a monomer of 34 kDa. The apparent K-m and V-max values for maleylpyruvate were determined to be 148.4 +/- 11.9 mu M and 1520 +/- 57.4 mu mol/min/mg, respectively (mycothiol concentration, 2.5 mu M). Previous studies had shown that mycothiol played roles in detoxification of oxidative chemicals and antibiotics in streptomycetes and mycobacteria. To our knowledge, this is the first demonstration that mycothiol is essential for growth of C. glutamicum with gentisate or 3-hydroxybenzoate as carbon sources and the first characterization of a mycothiol-dependent maleylpyruvate isomerase.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China; Univ Bielefeld, Inst Genomforsch, D-33615 Bielefeld, Germany; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Bielefeld; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Liu, SJ (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China.	liusj@sun.im.ac.cn	Che, Yongsheng/D-9840-2017; Liu, Lei/C-2725-2012	Ruckert-Reed, Christian/0000-0002-9722-4435				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; Eggeling L., 2005, HDB CORYNEBACTERIUM, DOI 10.1201/9781420039696; Fuenmayor SL, 1998, J BACTERIOL, V180, P2522, DOI 10.1128/JB.180.9.2522-2530.1998; GOETZ FE, 1992, FEMS MICROBIOL LETT, V97, P45; GRUND E, 1992, APPL ENVIRON MICROB, V58, P1874, DOI 10.1128/AEM.58.6.1874-1877.1992; HAGEDORN SR, 1985, J BACTERIOL, V163, P640, DOI 10.1128/JB.163.2.640-647.1985; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1; Itoh N, 1996, BIOSCI BIOTECH BIOCH, V60, P1826, DOI 10.1271/bbb.60.1826; Jain RK, 1996, APPL MICROBIOL BIOT, V45, P502, DOI 10.1007/BF00578462; JONES DCN, 1990, ARCH MICROBIOL, V154, P489, DOI 10.1007/BF00245233; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; MissetSmits M, 1997, FEBS LETT, V409, P221, DOI 10.1016/S0014-5793(97)00510-3; MONTICELLO DJ, 1985, APPL ENVIRON MICROB, V49, P761, DOI 10.1128/AEM.49.4.761-764.1985; Newton GL, 2005, J BACTERIOL, V187, P7309, DOI 10.1128/JB.187.21.7309-7316.2005; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; OHMOTO T, 1991, AGR BIOL CHEM TOKYO, V55, P1733, DOI 10.1080/00021369.1991.10870876; POH C L, 1980, Journal of Bacteriology, V143, P59; Rani M, 1996, BIOCHEM BIOPH RES CO, V220, P377, DOI 10.1006/bbrc.1996.0413; Rawat M, 2004, J BACTERIOL, V186, P6050, DOI 10.1128/jb.186.18.6050-6058.2004; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Robson ND, 1996, MICROBIOL-SGM, V142, P2115, DOI 10.1099/13500872-142-8-2115; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Shen X.-H., 2005, MICROB ENV, V20, P160, DOI [10.1264/jsme2.20.160, DOI 10.1264/JSME2.20.160]; Shen XH, 2005, SCI CHINA SER C, V48, P241, DOI 10.1360/062004-32; Shen XH, 2005, APPL ENVIRON MICROB, V71, P3442, DOI 10.1128/AEM.71.7.3442-3452.2005; Shen XH, 2004, BIOTECHNOL LETT, V26, P575; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; STEENKAMP DJ, 1994, EUR J BIOCHEM, V223, P43, DOI 10.1111/j.1432-1033.1994.tb18964.x; Tauch A, 2005, J BACTERIOL, V187, P4671, DOI 10.1128/JB.187.13.4671-4682.2005; Tauch A, 2002, CURR MICROBIOL, V45, P362, DOI 10.1007/s00284-002-3728-3; Werwath J, 1998, J BACTERIOL, V180, P4171, DOI 10.1128/JB.180.16.4171-4176.1998; Zhou NY, 2001, J BACTERIOL, V183, P700, DOI 10.1128/JB.183.2.700-708.2001	43	66	69	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10778	10785		10.1074/jbc.M513192200	http://dx.doi.org/10.1074/jbc.M513192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481315	hybrid			2022-12-27	WOS:000236822200017
J	Patel, HV; Vyas, KA; Mattoo, RL; Southworth, M; Perler, FB; Comb, D; Roseman, S				Patel, Himatkumar V.; Vyas, Kavita A.; Mattoo, Roshan L.; Southworth, Maurice; Perler, Francine B.; Comb, Donald; Roseman, Saul			Properties of the C-terminal domain of enzyme I of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; BACTERIAL PHOSPHOENOLPYRUVATE; SALMONELLA-TYPHIMURIUM; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; PROTEIN HPR; COMPLEX; VITRO; SITE; ULTRACENTRIFUGATION	The bacterial phosphoenolpyruvate (PEP):glycose phosphotransferase system (PTS) mediates uptake/phosphorylation of sugars. The transport of all PTS sugars requires Enzyme I (EI) and a phosphocarrier histidine protein of the PTS (HPr). The PTS is stringently regulated, and a potential mechanism is the monomer/dimer transition of EI, because only the dimer accepts the phosphoryl group from PEP. EI monomer consists of two major domains, at the N and C termini (EI-N and EI-C, respectively). EI-N accepts the phosphoryl group from phospho-HPr but not PEP. However, it is phosphorylated by PEP(Mg2+) when complemented with EI-C. Here we report that the phosphotransfer rate increases similar to 25-fold when HPr is added to a mixture of EI-N, EI-C, and PEP(Mg2+). A model to explain this effect is offered. Sedimentation equilibrium results show that the association constant for dimerization of EI-C monomers is 260-fold greater than the K-a for native EI. The ligands have no detectable effect on the secondary structure of the dimer (far UV CD) but have profound effects on the tertiary structure as determined by near UV CD spectroscopy, thermal denaturation, sedimentation equilibrium and velocity, and intrinsic fluorescence of the 2 Trp residues. The binding of PEP requires Mg2+. For example, there is no effect of PEP on the T-m, an increase of 7 degrees C in the presence of Mg2+, and similar to 14 degrees C when both are present. Interestingly, the dissociation constants for each of the ligands from EI-C are approximately the same as the kinetic (K-m) constants for the ligands in the complete PTS sugar phosphorylation assays.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; New England Biolabs Inc, Ipswich, MA 01938 USA	Johns Hopkins University; New England Biolabs	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	roseman@jhu.edu	Vyas, Kavita/GRJ-4578-2022		NIGMS NIH HHS [GM 38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; Brokx SJ, 2000, BIOCHEMISTRY-US, V39, P3624, DOI 10.1021/bi991250z; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Chauvin F, 1996, P NATL ACAD SCI USA, V93, P7028, DOI 10.1073/pnas.93.14.7028; Dam J, 2004, METHOD ENZYMOL, V384, P185; Fersht A., 1985, ENZYME STRUCTURE MEC; Fomenkov A, 1998, P NATL ACAD SCI USA, V95, P8491, DOI 10.1073/pnas.95.15.8491; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HAN MK, 1987, ANAL BIOCHEM, V161, P479, DOI 10.1016/0003-2697(87)90477-5; HAN MK, 1990, J BIOL CHEM, V265, P1985; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Herzberg O, 2002, BIOCHEMISTRY-US, V41, P780, DOI 10.1021/bi011799+; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meadow ND, 2005, BIOCHEMISTRY-US, V44, P12790, DOI 10.1021/bi0502846; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Oberholzer AE, 2005, J MOL BIOL, V346, P521, DOI 10.1016/j.jmb.2004.11.077; Patel HV, 2006, J BIOL CHEM, V281, P17570, DOI 10.1074/jbc.M508965200; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Peterkofsky A, 2001, J MOL MICROB BIOTECH, V3, P347; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; Saier MH, 2001, J MOL MICROB BIOTECH, V3, P325; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	36	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17579	17587		10.1074/jbc.M508966200	http://dx.doi.org/10.1074/jbc.M508966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16547354	hybrid			2022-12-27	WOS:000238490300007
J	Bornhovd, C; Vogel, F; Neupert, W; Reichert, AS				Bornhoevd, Carsten; Vogel, Frank; Neupert, Walter; Reichert, Andreas S.			Mitochondrial membrane potential is dependent on the oligomeric state of F1F0-ATP synthase supracomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST SACCHAROMYCES-CEREVISIAE; RED FIBERS MERRF; ATP SYNTHASE; MYOCLONUS EPILEPSY; INHIBITOR PROTEIN; HUMAN-CELLS; SUBUNIT-E; MORPHOLOGY; MUTATION	The F1F0-ATP synthase in mitochondria, in addition to its function in energy transduction, has a structural role in determining cristae morphology. This depends on its ability to form dimeric and higher oligomeric supracomplexes. Here we show that mutants of the dimer-specific subunits e and g, which destabilize dimeric and oligomeric F1F0-ATP synthase supracomplexes, have a decreased mitochondrial membrane potential Delta Psi. The degree of destabilization correlated with the reduction of the membrane potential. The enzymatic activities of F1F0-ATP synthase and cytochrome c oxidase, maximal respiration rate, coupling of oxidative phosphorylation, and tubular mitochondrial morphology were not affected or only to a minor extent. In mutants lacking one or two coiled-coil domains of subunit e, the reduction of the mitochondrial membrane potential was not due to loss of mitochondrial DNA, a reduced capacity of oxidative phosphorylation, or to altered cristae morphology. We propose a role for the supracomplexes of the F1F0-ATP synthase in organizing microdomains within the inner membrane, ensuring optimal bioenergetic competence of mitochondria.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reichert, AS (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	Andreas.Reichert@med.uni-muenchen.de	Reichert, Andreas/A-4090-2012	Reichert, Andreas/0000-0001-9340-3113				Antonicka H, 1999, BIOCHEM J, V342, P537, DOI 10.1042/0264-6021:3420537; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Boyle GM, 1999, EUR J BIOCHEM, V262, P315, DOI 10.1046/j.1432-1327.1999.00345.x; Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Everard-Gigot V, 2005, EUKARYOT CELL, V4, P346, DOI 10.1128/EC.4.2.346-355.2005; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L	27	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13990	13998		10.1074/jbc.M512334200	http://dx.doi.org/10.1074/jbc.M512334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551625	hybrid			2022-12-27	WOS:000237512300021
J	de Saro, FJL; Marinus, MG; Modrich, P; O'Donnell, M				Lopez de Saro, Francisco J.; Marinus, Martin G.; Modrich, Paul; O'Donnell, Mike			The beta sliding clamp binds to multiple sites within MutL and MutS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA MISMATCH REPAIR; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI MUTS; REPLICATION FIDELITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN MUTS; PCNA; STRAND	The MutL and MutS proteins are the central components of the DNA repair machinery that corrects mismatches generated by DNA polymerases during synthesis. We find that MutL interacts directly with the beta sliding clamp, a ring-shaped dimeric protein that confers processivity to DNA polymerases by tethering them to their substrates. Interestingly, the interaction of MutL with beta only occurs in the presence of single-stranded DNA. We find that the interaction occurs via a loop in MutL near the ATP-binding site. The binding site of MutL on beta locates to the hydrophobic pocket between domains two and three of the clamp. Site-specific replacement of two residues in MutL diminished interaction with beta without disrupting MutL function with helicase II. In vivo studies reveal that this mutant MutL is no longer functional in mismatch repair. In addition, the human MLH1 has a close match to the proliferating cell nuclear antigen clamp binding motif in the region that corresponds to the beta interaction site in Escherichia coli MutL, and a peptide corresponding to this site binds proliferating cell nuclear antigen. The current report also examines in detail the interaction of beta with MutS. We find that two distinct regions of MutS interact with beta. One is located near the C terminus and the other is close to the N terminus, within the mismatch binding domain. Complementation studies using genes encoding different MutS mutants reveal that the N-terminal beta interaction motif on MutS is essential for activity in vivo, but the C-terminal interaction site for beta is not. In light of these results, we propose roles for the beta clamp in orchestrating the sequence of events that lead to mismatch repair in the cell.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Rockefeller University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Duke University; Howard Hughes Medical Institute	de Saro, FJL (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	fjlopez@cbm.uam.es		Modrich, Paul/0000-0001-8708-9885; O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [R01 GM063790-04, GM38839, GM63790, GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R01GM063790, R37GM023719, R37GM038839, R01GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Calmann MA, 2005, J BACTERIOL, V187, P6577, DOI 10.1128/JB.187.18.6577-6579.2005; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen C, 1999, MOL CELL BIOL, V19, P7801; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Constantin N, 2005, J BIOL CHEM, V280, P39752, DOI 10.1074/jbc.M509701200; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Fijalkowska IJ, 1998, P NATL ACAD SCI USA, V95, P10020, DOI 10.1073/pnas.95.17.10020; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Indiani C, 2005, MOL CELL, V19, P805, DOI 10.1016/j.molcel.2005.08.011; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Lau PJ, 2002, MOL CELL BIOL, V22, P6669, DOI 10.1128/MCB.22.19.6669-6680.2002; Lee SD, 2006, J MOL BIOL, V355, P175, DOI 10.1016/j.jmb.2005.10.059; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang HX, 2004, EMBO J, V23, P2126, DOI 10.1038/sj.emboj.7600153; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wijffels G, 2004, BIOCHEMISTRY-US, V43, P5661, DOI 10.1021/bi036229j; Yang W, 2000, COLD SPRING HARB SYM, V65, P225, DOI 10.1101/sqb.2000.65.225	59	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14340	14349		10.1074/jbc.M601264200	http://dx.doi.org/10.1074/jbc.M601264200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16546997	hybrid			2022-12-27	WOS:000237512300060
J	Bai, SM; Ghoshal, K; Jacob, ST				Bai, SM; Ghoshal, K; Jacob, ST			RETRACTED: Identification of T-cadherin as a novel target of DNA methyltransferase 3B and its role in the suppression of nerve growth factor-mediated neurite outgrowth in PC12 cells (Retracted article. See vol. 293, pg. 3592, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							H-CADHERIN; BINDING PROTEIN; SMOOTH-MUSCLE; TRANSCRIPTIONAL REPRESSOR; PROMOTER METHYLATION; GENE-EXPRESSION; PWWP DOMAIN; CDH13 GENE; DNMT3B; PROLIFERATION	Previously we showed that DNA methyltransferase 3b (Dnmt3b) is required for nerve growth factor (NGF)- induced differentiation of PC12 cells to neuronal phenotype. The present study identified T-cadherin (T-Cad) as one of the targets of Dnmt3b by chromatin immunoprecipitation (ChIP) assay. Combined bisulfite restriction analysis and bisulfite sequencing showed that T- Cad promoter was sparsely methylated in PC12 cells. ChIP-CHOP analysis demonstrated that Dnmt3b is associated with T-Cad promoter irrespective of its methylation status. The mRNA and protein levels of T-Cad were markedly elevated in cells depleted of Dnmt3b by antisense or small interfering RNA. Suppression of T- Cad promoter activity by Dnmt3b was independent of its catalytic activity, which was consistent with the insignificant change in T-Cad promoter methylation status in Dnmt3b-depleted cells. In contrast, deletion of its N-terminal ATRX and PWWP domain abolished its repressor function. Association of histone deacetylase 2 (Hdac2) with T-Cad promoter and restoration of the promoter activity from Dnmt3b-mediated suppression upon treatment with Hdac inhibitor indicated involvement of histone deacetylation in this process. NGF-induced neurite outgrowth was inhibited in a dose dependent manner upon ectopic expression of T-Cad in PC12 cells. Immunofluorescence studies showed that T-Cad was redistributed upon NGF treatment, as evident from its concentration in axon growth cones as opposed to its localization at cell-cell contact region in undifferentiated cells. These results demonstrate a novel role of T-Cad in the NGF-mediated differentiation of PC12 cells to neuronal phenotype.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	jacob.42@osu.edu	Jacob, Samson/H-3135-2011		NATIONAL CANCER INSTITUTE [R01CA086978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA086978-02, R01 CA086978-03, R01 CA086978-01A2, R01 CA086978-04, R01 CA086978-05, R01 CA086978, R01 CA086978-06A1, CA 86978] Funding Source: Medline; NIEHS NIH HHS [R01 ES010874, R01 ES010874-02, R01 ES010874-03, ES 10874, R01 ES010874-01, R01 ES010874-04, R01 ES010874-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474; Angst BD, 2001, J CELL SCI, V114, P629; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Datta J, 2005, CANCER RES, V65, P10891, DOI 10.1158/0008-5472.CAN-05-1455; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Ghoshal K, 2002, METHOD ENZYMOL, V353, P476; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647; Hibi K, 2004, BRIT J CANCER, V91, P1139, DOI 10.1038/sj.bjc.6602095; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Marin-Vicente C, 2005, MOL BIOL CELL, V16, P2848, DOI 10.1091/mbc.E05-01-0067; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; RANSCHT B, 1991, DEVELOPMENT, V111, P15; Reddy CVG, 2004, BBA-BIOMEMBRANES, V1667, P15, DOI 10.1016/j.bbamem.2004.08.011; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Shimazu K, 2005, J CELL PHYSIOL, V203, P501, DOI 10.1002/jcp.20309; Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Takeuchi T, 2000, HISTOPATHOLOGY, V37, P193, DOI 10.1046/j.1365-2559.2000.00985-5.x; Takeuchi T, 1999, HISTOPATHOLOGY, V35, P87; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Takeuchi T, 2002, MOL CARCINOGEN, V35, P173, DOI 10.1002/mc.10088; Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1; Takeuchi T, 2001, HISTOL HISTOPATHOL, V16, P1287, DOI 10.14670/HH-16.1287; Tkachuk VA, 1998, FEBS LETT, V421, P208, DOI 10.1016/S0014-5793(97)01562-7; Weinstein LS, 2001, BIOL PSYCHIAT, V50, P927, DOI 10.1016/S0006-3223(01)01295-1; Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706	56	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13604	13611		10.1074/jbc.M513278200	http://dx.doi.org/10.1074/jbc.M513278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537533	Green Accepted, hybrid			2022-12-27	WOS:000237336600070
J	Del Borgo, MP; Hughes, RA; Bathgate, RAD; Lin, F; Kawamura, K; Wade, JD				Del Borgo, MP; Hughes, RA; Bathgate, RAD; Lin, F; Kawamura, K; Wade, JD			Analogs of insulin-like peptide 3 (INSL3) B-chain are LGR8 antagonists in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXIN FAMILY PEPTIDES; RECEPTOR-BINDING SITE; INSULIN-LIKE PEPTIDE; CIRCULAR-DICHROISM; PHAGE DISPLAY; CELL-SURVIVAL; CRYPTORCHIDISM; CONFORMATION; TESTIS; GROWTH	Insulin-like peptide 3 (INSL3) is a member of the insulin superfamily that plays an important role in mediating testes descent during fetal development. More recently, it has also been demonstrated to initiate oocyte maturation and suppress male germ cell apoptosis. These actions are mediated via a specific G-protein-coupled receptor, LGR8. Little is known regarding the structure and function relationship of INSL3, although it is believed that the principal receptor binding site resides within its B-chain. We subsequently observed that the linear B-chain alone (INSL3B-(1-31)) bound to LGR8 and was able to antagonise INSL3 stimulated cAMP accumulation in HEK-293T cells expressing LGR8. Sequentially N- and C-terminally shortened linear analogs were prepared by solid phase synthesis and subsequent assay showed that the minimum length required for binding was residues 11-27. It was also observed that increased binding affinity correlated with a corresponding increase in alpha-helical content as measured by circular dichroism spectroscopy. Molecular modeling studies suggested that judicious placement of a conformational constraint within this peptide would increase its alpha-helix content and result in increased structural similarity to the B-chain within native INSL3. Consequently, intramolecularly disulfide-linked analogs of the B-chain showed a potentiation of INSL3 antagonistic activity, as well as exhibiting increased proteolytic stability, as assessed in rat serum in vitro. Administration of one of these peptides into the testes of rats resulted in a substantial decrease in testis weight probably due to the inhibition of germ cell survival, suggesting that INSL3 antagonists may have potential as novel contraceptive agents.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Stanford University	Wade, JD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.	j.wade@hfi.unimelb.edu.au	Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X; Wade, John/0000-0002-1352-6568				Adham IM, 2002, MOL ENDOCRINOL, V16, P244, DOI 10.1210/me.16.2.244; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bathgate RA, 2005, ANN NY ACAD SCI, V1041, P61, DOI 10.1196/annals.1282.010; BATHGATE RAD, 2005, PHYSL REPROD, P679; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; Claasz AA, 2002, EUR J BIOCHEM, V269, P6287, DOI 10.1046/j.1432-1033.2002.03348.x; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Del Borgo MP, 2005, J PEPT SCI, V11, P564, DOI 10.1002/psc.652; Deshayes K, 2002, CHEM BIOL, V9, P495, DOI 10.1016/S1074-5521(02)00129-1; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Fu P, 2004, J PEPT RES, V63, P91, DOI 10.1111/j.1399-3011.2003.00118.x; Gorlov IP, 2002, HUM MOL GENET, V11, P2309, DOI 10.1093/hmg/11.19.2309; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hombach-Klonisch S, 2003, INT J ONCOL, V22, P993; Horvat S, 1999, SPECTROCHIM ACTA A, V55, P2347, DOI 10.1016/S1386-1425(99)00132-8; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Kubota Y, 2002, MOL HUM REPROD, V8, P900, DOI 10.1093/molehr/8.10.900; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lim HN, 2001, EUR J ENDOCRINOL, V144, P129, DOI 10.1530/eje.0.1440129; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Maruyama K, 1999, PEPTIDES, V20, P881, DOI 10.1016/S0196-9781(99)00076-5; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Muda M, 2005, MOL HUM REPROD, V11, P591, DOI 10.1093/molehr/gah205; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Scott DJ, 2005, ANN NY ACAD SCI, V1041, P13, DOI 10.1196/annals.1282.003; Skelton NJ, 2001, BIOCHEMISTRY-US, V40, P8487, DOI 10.1021/bi0103866; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; TAPANAINEN JS, 1993, MOL ENDOCRINOL, V7, P643, DOI 10.1210/me.7.5.643; Tugyi R, 2005, J PEPT SCI, V11, P642, DOI 10.1002/psc.669; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; Yan Y, 2005, ANN NY ACAD SCI, V1041, P35, DOI 10.1196/annals.1282.007; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	43	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13068	13074		10.1074/jbc.M600472200	http://dx.doi.org/10.1074/jbc.M600472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547350	hybrid			2022-12-27	WOS:000237336600010
J	Kizuka, Y; Matsui, T; Takematsu, H; Kozutsumi, Y; Kawasaki, T; Oka, S				Kizuka, Y; Matsui, T; Takematsu, H; Kozutsumi, Y; Kawasaki, T; Oka, S			Physical and functional association of glucuronyltransferases and sulfotransferase involved in HNK-1 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE EPITOPE HNK-1; MYELIN GLYCOPROTEIN P0; PROTEIN LINKAGE REGION; MOLECULAR-CLONING; GOLGI-APPARATUS; NERVOUS-SYSTEM; COMPLEX-FORMATION; MICE DEFICIENT; RAT-BRAIN; N-GLYCANS	HNK-1 carbohydrate expressed predominantly in the nervous system is considered to be involved in cell migration, recognition, adhesion, and synaptic plasticity. Human natural killer-1 (HNK-1) carbohydrate has a unique structure consisting of a sulfated trisaccharide (HSO(3)(-)3GlcA beta 1-3Gal-1-4GlcNAc-) and is sequentially biosynthesized by one of two glucuronyltransferases (GlcAT-P or GlcAT-S) and a sulfotransferase (HNK-1ST). Considering that almost all the HNK-1 carbohydrate structures so far determined in the nervous system are sulfated, we hypothesized that GlcAT-P or GlcAT-S functionally associates with HNK-1ST, which results in efficient sequential biosynthesis of HNK-1 carbohydrate. In this study, we demonstrated that both GlcAT-P and GlcAT-S were co-immunoprecipitated with HNK-1ST with a transient expression system in Chinese hamster ovary cells. Immunofluorescence staining revealed that these enzymes are mainly co-localized in the Golgi apparatus. To determine which domain is involved in this interaction, we prepared the C- terminal catalytic domains of GlcAT-P, GlcAT-S, and HNK-1ST, and we then performed pulldown assays with the purified enzymes. As a result, we obtained evidence that mutual catalytic domains of GlcAT-P or GlcAT-S and HNK-1ST are important and sufficient for formation of an enzyme complex. With an in vitro assay system, the activity of HNK-1ST increased about 2-fold in the presence of GlcAT- P or GlcAT-S compared with that in its absence. These results suggest that the function of this enzyme complex is relevant to the efficient sequential biosynthesis of the HNK-1 carbohydrate.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Membrane Biochem & Biophys, Kyoto 6068501, Japan; Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan	Kyoto University; Kyoto University; Ritsumeikan University	Oka, S (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan.	shogo@pharm.kyoto-u.ac.jp		Kizuka, Yasuhiko/0000-0002-3181-9743				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; Gallego RG, 2001, J BIOL CHEM, V276, P30834, DOI 10.1074/jbc.M101013200; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Kakuda S, 2005, GLYCOBIOLOGY, V15, P203, DOI 10.1093/glycob/cwi001; Kakuda S, 2004, J BIOL CHEM, V279, P22693, DOI 10.1074/jbc.M400622200; Kakuda S, 2004, PROTEIN EXPRES PURIF, V35, P111, DOI 10.1016/j.pep.2003.12.021; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Nilsson T, 1996, J CELL SCI, V109, P1975; OKA S, 1992, J BIOL CHEM, V267, P22711; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Seko A, 2005, GLYCOBIOLOGY, V15, P943, DOI 10.1093/glycob/cwi082; Senn C, 2002, MOL CELL NEUROSCI, V20, P712, DOI 10.1006/mcne.2002.1142; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; Tagawa H, 2005, J BIOL CHEM, V280, P23876, DOI 10.1074/jbc.M501728200; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Wakabayashi H, 1999, J BIOL CHEM, V274, P5436, DOI 10.1074/jbc.274.9.5436; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200; Yamamoto S, 2002, J BIOCHEM, V131, P337, DOI 10.1093/oxfordjournals.jbchem.a003108; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13644	13651		10.1074/jbc.M601453200	http://dx.doi.org/10.1074/jbc.M601453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543228	hybrid			2022-12-27	WOS:000237336600075
J	Chen, ZJ; Hague, C; Hall, RA; Minneman, KP				Chen, ZJ; Hague, C; Hall, RA; Minneman, KP			Syntrophins regulate alpha(1D)-adrenergic receptors through a PDZ domain-mediated interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NITRIC-OXIDE SYNTHASE; ALPHA(1)-ADRENOCEPTOR SUBTYPES; ALPHA(1B)-ADRENERGIC RECEPTOR; TRANSGLUTAMINASE ACTIVITY; SARCOLEMMAL LOCALIZATION; DEPENDENT EXPRESSION; DYSTROPHIN COMPLEX; SODIUM-CHANNELS; PROTEIN	To find novel cytoplasmic binding partners of the alpha(1D)-adrenergic receptor (AR), a yeast two-hybrid screen using the alpha(1D)-AR C terminus as bait was performed on a human brain cDNA library. alpha-Syntrophin, a protein containing one PDZ domain and two pleckstrin homology domains, was isolated in this screen as an alpha(1D)-AR-interacting protein. alpha-Syntrophin specifically recognized the C terminus of alpha(1D)- but not alpha(1A)- or alpha(1B)-ARs. In blot overlay assays, the PDZ domains of syntrophin isoforms alpha, beta 1, and beta 2 but not gamma 1 or gamma 2 showed strong selective interactions with the alpha(1D)-AR C-tail fusion protein. In transfected human embryonic kidney 293 cells, full-length alpha(1D)- but not alpha(1A)- or alpha(1B)-ARs co-immunoprecipitated with syntrophins, and the importance of the receptor C terminus for the alpha(1D)-AR/syntrophin interaction was confirmed using chimeric receptors. Mutation of the PDZ-interacting motif at the alpha(1D)-AR C terminus markedly decreased inositol phosphate formation stimulated by norepinephrine but not carbachol in transfected HEK293 cells. This mutation also dramatically decreased alpha(1D)-AR binding and protein expression. In addition, stable overexpression of alpha-syntrophin significantly increased alpha(1D)-AR protein expression and binding but did not affect those with a mutated PDZ-interacting motif, suggesting that syntrophin plays an important role in maintaining receptor stability by directly interacting with the receptor PDZ-interacting motif. This direct interaction may provide new information about the regulation of alpha(1D)-AR signaling and the role of syntrophins in modulating G protein-coupled receptor function.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Minneman, KP (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	kminneman@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728				Adams ME, 2004, J NEUROSCI, V24, P10302, DOI 10.1523/JNEUROSCI.3408-04.2004; Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chen ZJ, 2004, J BIOL CHEM, V279, P35326, DOI 10.1074/jbc.M403703200; Chockalingam PS, 1999, BIOCHEMISTRY-US, V38, P5596, DOI 10.1021/bi982564+; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gee SH, 1998, J NEUROSCI, V18, P128; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hogan A, 2004, J BIOL CHEM, V279, P53717, DOI 10.1074/jbc.M410654200; Iwata Y, 2005, MOL CELL BIOCHEM, V268, P59, DOI 10.1007/s11010-005-2998-z; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; Pupo AS, 2003, EUR J PHARMACOL, V462, P1, DOI 10.1016/S0014-2999(03)01292-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Tanoue A, 2002, LIFE SCI, V71, P2207, DOI 10.1016/S0024-3205(02)02012-X; Thomas GD, 2003, CIRC RES, V92, P554, DOI 10.1161/01.RES.0000061570.83105.52; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Uberti MA, 2003, MOL PHARMACOL, V64, P1379, DOI 10.1124/mol.64.6.1379; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wiedemann U, 2004, J MOL BIOL, V343, P703, DOI 10.1016/j.jmb.2004.08.064; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	40	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12414	12420		10.1074/jbc.M508651200	http://dx.doi.org/10.1074/jbc.M508651200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533813	hybrid			2022-12-27	WOS:000237134700027
J	Hu, PQ; Berkowitz, P; Madden, VJ; Rubenstein, DS				Hu, PQ; Berkowitz, P; Madden, VJ; Rubenstein, DS			Stabilization of plakoglobin and enhanced keratinocyte cell-cell adhesion by intracellular O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; TETRATRICOPEPTIDE REPEATS; ADHERENS JUNCTIONS; CYTOSOLIC PROTEINS; PEMPHIGUS-VULGARIS; NUCLEAR; PHOSPHORYLATION; DESMOSOMES; MEMBRANE	O-Glycosylation modifies and regulates a variety of intracellular proteins. Plakoglobin, which functions in both cell-cell adhesion and signal transduction, is modified by O-glycosylation; however, the significance is unknown. To investigate the functional consequence of plakoglobin O-glycosylation, we cloned and overexpressed in keratinocytes murine O-GlcNAc transferase (mOGT). Over expression of mOGT in murine keratinocytes resulted in (i) glycosylation of plakoglobin and (ii) increased levels of plakoglobin due to post-translational stabilization of plakoglobin. Additionally, overexpression of mOGT in keratinocytes correlated with increased staining for cell-cell adhesion proteins and greater cell-cell adhesion. These observations suggest that O-glycosylation functions to regulate the post-translational stability of plakoglobin and keratinocyte cell-cell adhesion.	Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rubenstein, DS (corresponding author), Univ N Carolina, Dept Dermatol, Sch Med, Suite 3100 Thurston Bowles CB 7287, Chapel Hill, NC 27599 USA.	druben@med.unc.edu	Ariel, Pablo/AGJ-4118-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049427] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49427] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hatsell S, 2003, J BIOL CHEM, V278, P37745, DOI 10.1074/jbc.M301346200; Hu PQ, 2003, J INVEST DERMATOL, V121, P242, DOI 10.1046/j.1523-1747.2003.12376.x; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lubas WA, 1997, J BIOL CHEM, V272, P9316; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	21	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12786	12791		10.1074/jbc.M511702200	http://dx.doi.org/10.1074/jbc.M511702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16510446	hybrid, Green Published			2022-12-27	WOS:000237134700072
J	Sims, JK; Houston, SI; Magazinnik, T; Rice, JC				Sims, JK; Houston, SI; Magazinnik, T; Rice, JC			A trans-tail histone code defined by monomethylated H4 Lys-20 and H3 Lys-9 demarcates distinct regions of silent chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-LYSINE; MAMMALIAN CHROMATIN; HETEROCHROMATIN; METHYLTRANSFERASE; UBIQUITINATION; TRANSCRIPTION; EXPRESSION; PR-SET7; SET8; H2B	The specific post-translational modifications of the histone proteins are associated with specific DNA-templated processes, such as transcriptional activation or repression. To investigate the biological role(s) of histone H4 lysine 20 (H4 Lys-20) methylation, we created a novel panel of antibodies that specifically detected mono-, di-, or trimethylated H4 Lys-20. We report that the different methylated forms of H4 Lys-20 are compartmentalized within visually distinct, transcriptionally silent regions in the mammalian nucleus. Interestingly, direct comparison of methylated H4 Lys-20 with the different methylated states of histone H3 lysine 9 (H3 Lys-9) revealed significant overlap and exclusion between the specific groups of methyl modifications. Trimethylated H4 Lys-20 and H3 Lys-9 were both selectively enriched within pericentric heterochromatin. Similarly, monomethylated H4 Lys-20 and H3 Lys-9 partitioned together and the dimethylated forms partitioned together within the chromosome arms; however, the mono- and dimethylated modifications were virtually exclusive. These findings strongly suggest that the combinatorial presence or absence of the different methylated states of H4 Lys-20 and H3 Lys-9 define particular types of silent chromatin. Consistent with this, detailed analysis of monomethylated H4 Lys-20 and H3 Lys-9 revealed that both were preferentially and selectively enriched within the same nucleosome particle in vivo. Collectively, these findings define a novel trans-tail histone code involving monomethylated H4 Lys-20 and H3 Lys-9 that act cooperatively to mark distinct regions of silent chromatin within the mammalian epigenome.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California	Rice, JC (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, 1501 San Pablo St,ZNI 225,MC 2821, Los Angeles, CA 90033 USA.	juddrice@usc.edu	Rice, Judd C/B-7806-2009		NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NCI NIH HHS [2 CA 014089-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Perez-Burgos L, 2004, METHOD ENZYMOL, V376, P234; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Stadler F, 2005, J NEUROCHEM, V94, P324, DOI 10.1111/j.1471-4159.2005.03190.x; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Van Holde KE, 1988, SPRINGER SERIES MOL; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905; Yin YL, 2005, J BIOL CHEM, V280, P30025, DOI 10.1074/jbc.M501691200; Zhang KL, 2003, J CHROMATOGR B, V783, P173, DOI 10.1016/S1570-0232(02)00631-1	40	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12760	12766		10.1074/jbc.M513462200	http://dx.doi.org/10.1074/jbc.M513462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517599	hybrid			2022-12-27	WOS:000237134700069
J	Wieczorek, A; McHenry, CS				Wieczorek, A; McHenry, CS			The NH2-terminal php domain of the alpha subunit of the Escherichia coli replicase binds the epsilon proofreading subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; STRUCTURAL BASIS; EXONUCLEASE ACTIVITY; ACTIVE-SITE; IDENTIFICATION; PURIFICATION; HOLOENZYME; REPAIR; ACID; GENE	The alpha subunit of the replicase of all bacteria contains a php domain, initially identified by its similarity to histidinol phosphatase but of otherwise unknown function (Aravind, L., and Koonin, E. V. ( 1998) Nucleic Acids Res. 26, 3746 - 3752). Deletion of 60 residues from the NH2 terminus of the alpha php domain destroys epsilon binding. The minimal 255-residue php domain, estimated by sequence alignment with homolog YcdX, is insufficient for is an element of binding. However, a 320-residue segment including sequences that immediately precede the polymerase domain binds is an element of with the same affinity as the 1160-residue full-length alpha subunit. A subset of mutations of a conserved acidic residue (Asp(43) in Escherichia coli alpha) present in the php domain of all bacterial replicases resulted in defects in is an element of binding. Using sequence alignments, we show that the prototypical Gram(+) Pol C, which contains the polymerase and proofreading activities within the same polypeptide chain, has an is an element of-like sequence inserted in a surface loop near the center of the homologous YcdX protein. These findings suggest that the php domain serves as a platform to enable coordination of proofreading and polymerase activities during chromosomal replication.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B-121, Denver, CO 80262 USA.	Charles.McHenry@uchsc.edu			NIGMS NIH HHS [GM060273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Bailey MF, 2004, J MOL BIOL, V336, P673, DOI 10.1016/j.jmb.2003.11.023; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; COX EC, 1982, GENETICS, V100, P7; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Jin YH, 2005, MOL CELL BIOL, V25, P461, DOI 10.1128/MCB.25.1.461-471.2005; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Lecointe F, 2004, MOL MICROBIOL, V53, P1721, DOI 10.1111/j.1365-2958.2004.04233.x; Lehtinen DA, 2004, BIOCHEM J, V384, P337, DOI 10.1042/BJ20040660; LOW RL, 1976, J BIOL CHEM, V251, P1311; Mah TF, 2000, GENE DEV, V14, P2664, DOI 10.1101/gad.822900; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Perrino FW, 1999, BIOCHEMISTRY-US, V38, P16001, DOI 10.1021/bi991429+; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; Pritchard AE, 1999, J MOL BIOL, V285, P1067, DOI 10.1006/jmbi.1998.2352; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Taft-Benz SA, 1999, J BACTERIOL, V181, P2963, DOI 10.1128/JB.181.9.2963-2965.1999; Teplyakov A, 2003, PROTEINS, V51, P315, DOI 10.1002/prot.10352; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506	46	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12561	12567		10.1074/jbc.M513844200	http://dx.doi.org/10.1074/jbc.M513844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517598	hybrid			2022-12-27	WOS:000237134700045
J	Houliston, RS; Endtz, HP; Yuki, N; Li, JJ; Jarrell, HC; Koga, M; van Belkum, A; Karwaski, MF; Wakarchuk, WW; Gilbert, M				Houliston, RS; Endtz, HP; Yuki, N; Li, JJ; Jarrell, HC; Koga, M; van Belkum, A; Karwaski, MF; Wakarchuk, WW; Gilbert, M			Identification of a sialate o-acetyltransferase from Campylobacter jejuni - Demonstration of direct transfer to the C-9 position of terminal alpha-2,8-linked sialic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; DE-ORTHO-ACETYLATION; HUMAN-MELANOMA CELLS; N-LINKED GLYCANS; NEISSERIA-MENINGITIDIS; CORE OLIGOSACCHARIDE; GANGLIOSIDE MIMICS; FORM VARIATION; SEROGROUP-Y; LIPOOLIGOSACCHARIDE	We have identified a sialate O-acetyltransferase in the lipo-oligosaccharide biosynthesis locus of Campylobacter jejuni. Strains possessing this locus are known to produce sialylated outer core structures that mimic host gangliosides, and have been implicated in triggering the onset of Guillain-Barre syndrome. The acetyltransferase, which was cloned and expressed as a fusion construct in Escherichia coli, is soluble and homologous with members of the NodL-LacA-CysE family of O-acetyltransferases. This enzyme catalyzes the transfer of O-acetyl groups onto oligosaccharide-bound sialic acid, with a high specificity for terminal alpha 2,8-linked residues. The modification is directed to C-9 and not C-7 as is believed to occur more commonly in other organisms. Despite their wide prevalence and importance in both eukaryotes and prokaryotes, this is the first report to describe the characterization of a purified sialate O-acetyltransferase.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3015 GD Rotterdam, Netherlands; Dokkyo Univ, Sch Med, Dept Neurol, Tochigi 3210293, Japan	National Research Council Canada; Erasmus University Rotterdam; Erasmus MC; Dokkyo Medical University	Gilbert, M (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	Michel.Gilbert@nrc-cnrc.gc.ca	Wakarchuk, Warren/AAO-2774-2020; Yuki, Nobuhiro/H-3187-2012; Koga, Michiaki/L-4825-2019; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Koga, Michiaki/0000-0002-1356-955X; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1029, DOI 10.1111/j.1432-1033.1993.tb17850.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; Fahr C, 2001, J INVEST DERMATOL, V116, P254, DOI 10.1046/j.1523-1747.2001.01237.x; Gilbert M, 2005, CAMPYLOBACTER: MOLECULAR AND CELLULAR BIOLOGY, P219; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 2002, J BIOL CHEM, V277, P327, DOI 10.1074/jbc.M108452200; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Godschalk PCR, 2004, J CLIN INVEST, V114, P1659, DOI 10.1172/JCI200415707; HARA O, 1992, J BACTERIOL, V174, P5141, DOI 10.1128/JB.174.15.5141-5144.1992; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Iwersen M, 2003, BIOL CHEM, V384, P1035, DOI 10.1515/BC.2003.116; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KNIEP B, 1995, J BIOL CHEM, V270, P30173; Koga M, 2006, J INFECT DIS, V193, P547, DOI 10.1086/499969; Lemercinier X, 1996, CARBOHYD RES, V296, P83, DOI 10.1016/S0008-6215(96)00253-4; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nachamkin I, 1998, CLIN MICROBIOL REV, V11, P555, DOI 10.1128/CMR.11.3.555; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Parker CT, 2005, J CLIN MICROBIOL, V43, P2771, DOI 10.1128/JCM.43.6.2771-2781.2005; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Shen YQ, 2002, BIOL CHEM, V383, P307, DOI 10.1515/BC.2002.033; Shi WX, 1998, GLYCOBIOLOGY, V8, P199, DOI 10.1093/glycob/8.2.199; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; Smits SL, 2005, J BIOL CHEM, V280, P6933, DOI 10.1074/jbc.M409683200; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Vandamme-Feldhaus V, 1998, J BIOCHEM-TOKYO, V124, P111, DOI 10.1093/oxfordjournals.jbchem.a022069; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Wakarchuk Warren W, 2003, Methods Mol Biol, V213, P263; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771	47	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11480	11486		10.1074/jbc.M512183200	http://dx.doi.org/10.1074/jbc.M512183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16481326	hybrid			2022-12-27	WOS:000236988100009
J	Kim, HY; Park, SJ; Joe, EH; Jou, I				Kim, HY; Park, SJ; Joe, EH; Jou, I			Raft-mediated Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP-2) regulation in microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING SOCS; T-CELL-RECEPTOR; TYROSINE PHOSPHATASE; LIPID RAFTS; NEURODEGENERATIVE DISEASES; JAK/STAT PATHWAY; BRAIN MICROGLIA; ACTIVATION; PHOSPHORYLATION; PROTEIN	Janus kinase-signal transducer and activator of transcription (JAK-STAT) signals play important roles in cell proliferation, apoptosis, and inflammation, and they recently have been considered as therapeutic targets for suppressing oncogenesis and inflammatory process. Phosphatases including Src homology 2 domain-containing protein-tyrosine phosphatases (SHPs), are well known as negative regulators of the JAK-STAT pathway, but their precise mechanisms are largely unknown. Based on our previous finding that in cultured rat brain microglia, gangliosides induce rapid and transient activation of the JAK-STAT pathway, we hypothesized that raft-mediated SHP-2 activation is involved in transient activation of JAK-STAT signaling by gangliosides. We first used Western blot analysis to confirm that gangliosides rapidly induce the phosphorylation of SHP-2. This was inhibited by pretreatment with the lipid raft disrupter filipin and was restored following filipin removal. Immunostaining using antibodies directed against p-SHP-2 and flotillin-1 revealed ganglioside-induced clustering and polarization of p-SHP-2 in membrane rafts. Raft-associated regulation of SHP-2 was further demonstrated in fractionation experiments using detergent and detergent-free sucrose gradient ultracentrifugation. Rapid SHP-2 recruitment to detergent-insoluble raft fractions by gangliosides was inhibited by filipin, further indicating the involvement of rafts. We also confirmed by immunoprecipitation that SHP-2 rapidly binds in a raft-dependent manner to JAK2 in response to gangliosides. Our study therefore showed that transient activation of the JAK-STAT pathway by gangliosides is accomplished by SHP-2 in a raft-dependent manner in brain microglia.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea; Ajou Univ, Sch Med, Chron Inflammatory Dis Res Ctr, Suwon 442721, South Korea	Ajou University; Ajou University	Jou, I (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea.	jouilo@ajou.ac.kr						Aldskogius H, 2001, MICROSC RES TECHNIQ, V54, P40, DOI 10.1002/jemt.1119; Arnaud M, 2004, BIOCHEM J, V382, P545, DOI 10.1042/BJ20040103; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Burkart A, 2003, J BIOL CHEM, V278, P18360, DOI 10.1074/jbc.M210701200; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; Fawcett VCJ, 2005, J IMMUNOL, V174, P2849, DOI 10.4049/jimmunol.174.5.2849; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGOOKEY DJ, 1983, J CELL BIOL, V96, P1273, DOI 10.1083/jcb.96.5.1273; Minoo P, 2003, CELL SIGNAL, V15, P319, DOI 10.1016/S0898-6568(02)00122-5; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Pyo H, 1999, J BIOL CHEM, V274, P34584, DOI 10.1074/jbc.274.49.34584; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; ROBINSON JM, 1980, J HISTOCHEM CYTOCHEM, V28, P161, DOI 10.1177/28.2.6766487; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Skwarek M, 2004, ARCH IMMUNOL THER EX, V52, P427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Su MWC, 2001, J IMMUNOL, V166, P3975, DOI 10.4049/jimmunol.166.6.3975; Wang Q, 2005, J BIOL CHEM, V280, P8397, DOI 10.1074/jbc.M410462200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	55	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11872	11878		10.1074/jbc.M511706200	http://dx.doi.org/10.1074/jbc.M511706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507579	hybrid, Green Published			2022-12-27	WOS:000236988100054
J	Wang, YM; Li, G				Wang, YM; Li, G			ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CUTANEOUS MELANOMA; DOWN-REGULATION; DNA-REPAIR; P53; EXPRESSION; INDUCTION; FAMILY; ACETYLATION; CANCER	The novel ING tumor-suppressor family proteins (ING1-5) have been discovered during the past decade and are recognized as the regulators of transcription, cell cycle checkpoints, DNA repair, apoptosis, cellular senescence, angiogenesis, and nuclear phosphoinositide signaling. ING proteins contain a few conserved domains, including plant homeodomain motif, nuclear localization signal, and potential chromatin regulatory domain, suggesting that the ING family proteins may share common biological functions. ING3 has been shown to modulate p53-mediated transcription, cell cycle control, and apoptosis, possibly by modulating the NuA4 complex histone acetyltransferase activity. Because ING1b and ING2 have been shown to be involved in cellular stress responses such as nucleotide excision repair and apoptosis after UV irradiation, we investigated whether ING3 also mediated UV-induced apoptosis. We found that ING3 expression was rapidly induced by UV irradiation at both mRNA and protein levels. Using the stable clones of melanoma cells overexpressing ING3, we showed that overexpression of ING3 significantly promoted UV-induced apoptosis. Unlike its homologues ING1b and ING2, ING3-increased apoptosis was independent of functional p53. Furthermore, ING3 did not affect the expression of mitochondrial proteins but increased the cleavage of Bid and caspases-8, -9, and -3. Moreover, ING3-mediated apoptosis was blocked by inhibition of caspase-8 or Fas activation. In addition, ING3 up-regulated Fas expression at both mRNA and protein levels. Knock down of ING3 decreased UV-induced apoptosis remarkably. These data indicate that ING3 plays an important role in cellular response to UV irradiation by enhancing UV-induced apoptosis through the activation of Fas/caspase-8 pathway.	Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver Coastal Hlth Res Inst, Vancouver, BC BCV6H 3Z6, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver Coastal Hlth Res Inst, 2660 Oak St, Vancouver, BC BCV6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011					Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Chin MY, 2005, EXP CELL RES, V304, P531, DOI 10.1016/j.yexcr.2004.11.023; Dauda M M, 2005, Niger Postgrad Med J, V12, P125; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; GICHREST BA, 1999, NEW ENGL J MED, V340, P1341; Girnita L, 2000, CANCER RES, V60, P5278; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; GONZANI O, 2003, CELL, V114, P99; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Li G, 2000, J INVEST DERMATOL, V114, P514, DOI 10.1046/j.1523-1747.2000.00867.x; Luu Y, 2003, ANTICANCER RES, V23, P99; NAFATA S, 1999, ANNU REV GENET, V33, P29; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rager EL, 2005, AM FAM PHYSICIAN, V72, P269; Sabel MS, 2003, ONCOLOGIST, V8, P451, DOI 10.1634/theoncologist.8-5-451; Scott M, 2001, J CELL SCI, V114, P3455; Shi XB, 2005, J CELL BIOCHEM, V96, P1127, DOI 10.1002/jcb.20625; Shiseki M, 2003, CANCER RES, V63, P2373; Stratton Michael R, 2004, J Drugs Dermatol, V3, P573; Takahashi M, 2004, ONCOL REP, V12, P811; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Tsang FC, 2003, FEBS LETT, V553, P277, DOI 10.1016/S0014-5793(03)01024-X; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; VANELSAS A, 1997, MELANOMA RES S, V2, pS107; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wei Jian-Bao, 2005, Ai Zheng, V24, P141; Wellbrock C, 2005, CURR BIOL, V15, P1629, DOI 10.1016/j.cub.2005.08.036; Yamashita T, 2001, J INVEST DERMATOL, V117, P914, DOI 10.1046/j.0022-202x.2001.01464.x; Yu GZ, 2004, WORLD J GASTROENTERO, V10, P3597, DOI 10.3748/wjg.v10.i24.3597; ZOLZER F, 1995, RADIOTHER ONCOL, V37, P20, DOI 10.1016/0167-8140(95)01618-Q	53	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11887	11893		10.1074/jbc.M511309200	http://dx.doi.org/10.1074/jbc.M511309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520380	hybrid			2022-12-27	WOS:000236988100056
J	Lewis, AL; Hensler, ME; Varki, A; Nizet, V				Lewis, AL; Hensler, ME; Varki, A; Nizet, V			The group B streptococcal sialic acid O-acetyltransferase is encoded by neuD, a conserved component of bacterial sialic acid biosynthetic gene clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; N-ACETYLNEURAMINIC ACID; CAPSULAR POLYSACCHARIDE; GUILLAIN-BARRE; SERUM RESISTANCE; PSEUDOMONAS-AERUGINOSA; MOLECULAR-CLONING; SOMATIC ANTIGENS; FORM VARIATION; C3 DEPOSITION	Nearly two dozen microbial pathogens have surface polysaccharides or lipo-oligosaccharides that contain sialic acid (Sia), and several Sia-dependent virulence mechanisms are known to enhance bacterial survival or result in host tissue injury. Some pathogens are also known to O-acetylate their Sias, although the role of this modification in pathogenesis remains unclear. We report that neuD, a gene located within the Group B Streptococcus (GBS) Sia biosynthetic gene cluster, encodes a Sia O-acetyltransferase that is itself required for capsular polysaccharide (CPS) sialylation. Homology modeling and site-directed mutagenesis identified Lys-123 as a critical residue for Sia O-acetyltransferase activity. Moreover, a single nucleotide polymorphism in neuD can determine whether GBS displays a "high" or "low" Sia O-acetylation phenotype. Complementation analysis revealed that Escherichia coli K1 NeuD also functions as a Sia O-acetyltransferase in GBS. In fact, NeuD homologs are commonly found within Sia biosynthetic gene clusters. A bioinformatic approach identified 18 bacterial species with a Sia biosynthetic gene cluster that included neuD. Included in this list are the sialylated human pathogens Legionella pneumophila, Vibrio parahemeolyticus, Pseudomonas aeruginosa, and Campylobacter jejuni, as well as an additional 12 bacterial species never before analyzed for Sia expression. Phylogenetic analysis shows that NeuD homologs of sialylated pathogens share a common evolutionary lineage distinct from the poly-Sia O-acetyltransferase of E. coli K1. These studies define a molecular genetic approach for the selective elimination of GBS Sia O-acetylation without concurrent loss of sialylation, a key to further studies addressing the role(s) of this modification in bacterial virulence.	Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Nizet, V (corresponding author), Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	vnizet@ucsd.edu	Nizet, Victor/AAF-3190-2019	Lewis, Amanda/0000-0001-6195-3030; Nizet, Victor/0000-0003-3847-0422	NHLBI NIH HHS [P01HL57345] Funding Source: Medline; NICHD NIH HHS [R01HD051796] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07202] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051796] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; ANNUNZIATO PW, 1995, J BACTERIOL, V177, P312, DOI 10.1128/jb.177.2.312-319.1995; Berry DS, 2002, INFECT IMMUN, V70, P3707, DOI 10.1128/IAI.70.7.3707-3713.2002; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; Chaffin DO, 2005, J BACTERIOL, V187, P4615, DOI 10.1128/JB.187.13.4615-4626.2005; Charland N, 1996, FEMS IMMUNOL MED MIC, V14, P195, DOI 10.1111/j.1574-695X.1996.tb00287.x; Chattopadhyay A, 2002, J PEDIATR SURG, V37, P108, DOI 10.1053/jpsu.2002.29439; Daines DA, 2000, FEMS MICROBIOL LETT, V189, P281, DOI 10.1111/j.1574-6968.2000.tb09244.x; Daines DA, 2000, J BACTERIOL, V182, P5267, DOI 10.1128/JB.182.18.5267-5270.2000; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; Doran KS, 2005, J CLIN INVEST, V115, P2499, DOI 10.1172/JCI23829; Edwards MS, 2006, INFECT DIS FETUS NEW, P403; Fattom AI, 1998, INFECT IMMUN, V66, P4588, DOI 10.1128/IAI.66.10.4588-4592.1998; Feng L, 2005, J BACTERIOL, V187, P758, DOI 10.1128/JB.187.2.758-764.2005; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; HAFT RF, 1994, J BACTERIOL, V176, P7372, DOI 10.1128/JB.176.23.7372-7374.1994; HIGA HH, 1988, J BIOL CHEM, V263, P8872; Hitoshi S, 1996, J NEUROIMMUNOL, V66, P95, DOI 10.1016/0165-5728(96)00024-0; Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Jurcisek J, 2005, INFECT IMMUN, V73, P3210, DOI 10.1128/IAI.73.6.3210-3218.2005; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Koga M, 2005, NEUROLOGY, V65, P1376, DOI 10.1212/01.wnl.0000176914.70893.14; Koga M, 1999, J NEUROL SCI, V164, P50, DOI 10.1016/S0022-510X(98)00331-1; Kooistra O, 2001, BIOCHEMISTRY-US, V40, P7630, DOI 10.1021/bi002946r; LEWENDON A, 1995, J BIOL CHEM, V270, P26326, DOI 10.1074/jbc.270.44.26326; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; McNeely TB, 1998, INFECT IMMUN, V66, P3705, DOI 10.1128/IAI.66.8.3705-3710.1998; MORAN AP, 1991, J BACTERIOL, V173, P618, DOI 10.1128/jb.173.2.618-626.1991; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SILVER RP, 1981, NATURE, V289, P696, DOI 10.1038/289696b0; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; Suryanti V, 2003, PROTEIN EXPRES PURIF, V27, P346, DOI 10.1016/S1046-5928(02)00633-2; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Vann WF, 2004, J BACTERIOL, V186, P706, DOI 10.1128/JB.186.3.706-712.2004; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Vogel U, 1997, INFECT IMMUN, V65, P4022, DOI 10.1128/IAI.65.10.4022-4029.1997; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; Zou CH, 1999, J BACTERIOL, V181, P4137, DOI 10.1128/JB.181.13.4137-4141.1999	51	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11186	11192		10.1074/jbc.M513772200	http://dx.doi.org/10.1074/jbc.M513772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490781	hybrid			2022-12-27	WOS:000236822200062
J	Zhao, H; Robertson, NB; Jewhurst, SA; Waite, JH				Zhao, H; Robertson, NB; Jewhurst, SA; Waite, JH			Probing the adhesive footprints of Mytilus californianus byssus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-ANALYSIS; PLAQUE PROTEIN; MUSSEL; EXPRESSION; EDULIS; DOPA; HYDROLYSIS; TRYPTOPHAN; SURFACES	California mussels Mytilus californianus owe their tenacity to a holdfast known as the byssus, a fibrous extracellular structure that ends distally in flattened adhesive plaques. The "footprints" of freshly secreted plaques deposited onto glass coverslips were shown by matrix-assisted laser desorption ionization time of flight mass spectrometry to consist chiefly of proteins ranging in mass from 5200 to 6700 Da. These proteins, variants of a family known as mcfp3 ((M.) under bar(c) under bar alifornianus (f) under bar oot (p) under bar rotein 3), were purified from acetic acid/urea extracts of plaques and foot tissue. Mcfp3 appears to sort into fast and slow electrophoretic variants. Both are rich in Gly and Asn and exhibit post-translational hydroxylation of Tyr and Arg to Dopa and 4-hydroxyarginine, respectively, with the fast variant containing more than twice as much Lys+Arg. Both the slow and fast variants were partially sequenced from the N terminus, and the complete sequences of 12 variants were deduced from cDNA using degenerate oligonucleotides, PCR, and rapid amplification of cDNA ends. Mcfp3s are highly polar molecules and contain up to 28 mol% Dopa, which remains intact and may be crucial for adhesion to metal and mineral surfaces.	Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Waite, JH (corresponding author), Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	waite@lifesci.ucsb.edu			NIDCR NIH HHS [DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson KE, 2000, J EXP BIOL, V203, P3065; Chen BN, 2002, COMB CHEM HIGH T SCR, V5, P409; Chirdon WM, 2003, J BIOMED MATER RES B, V66B, P532, DOI 10.1002/jbm.b.10041; COMYN J, 1981, DEV ADHESIVES, P279; DALSIN, 2005, MAT TODAY, V8, P53; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; Deming TJ, 1999, CURR OPIN CHEM BIOL, V3, P100, DOI 10.1016/S1367-5931(99)80018-0; Floriolli RY, 2000, MAR BIOTECHNOL, V2, P352; GARVEY KJ, 1990, VIROLOGY, V175, P391, DOI 10.1016/0042-6822(90)90424-P; Inoue K, 1996, EUR J BIOCHEM, V239, P172, DOI 10.1111/j.1432-1033.1996.0172u.x; ISRAELACHVILI J, 1985, INTERMOLECULAR SURFA, P22; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; PAZ MA, 1991, J BIOL CHEM, V266, P689; PETTIT LD, 1984, PURE APPL CHEM, V56, P247, DOI 10.1351/pac198456020247; PROUDFOOT GM, 1983, AUST J CHEM, V36, P885, DOI 10.1071/CH9830885; Schmitt L, 2000, BIOPHYS J, V78, P3275, DOI 10.1016/S0006-3495(00)76863-9; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WAITE JH, 1990, INT J BIOL MACROMOL, V12, P139, DOI 10.1016/0141-8130(90)90065-I; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; Waite JH, 2002, INTEGR COMP BIOL, V42, P1172, DOI 10.1093/icb/42.6.1172; Waite JH, 2001, BIOCHEMISTRY-US, V40, P2887, DOI 10.1021/bi002718x; WAITE JH, 1984, METHOD ENZYMOL, V107, P397; Warner SC, 1999, MAR BIOL, V134, P729, DOI 10.1007/s002270050589; WITMAN JD, 1984, MAR ECOL PROG SER, V16, P259, DOI 10.3354/meps016259	27	121	133	2	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11090	11096		10.1074/jbc.M510792200	http://dx.doi.org/10.1074/jbc.M510792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495227	hybrid			2022-12-27	WOS:000236822200051
J	Bellve, KD; Leonard, D; Standley, C; Lifshitz, LM; Tuft, RA; Hayakawa, A; Corvera, S; Fogarty, KE				Bellve, Karl D.; Leonard, Deborah; Standley, Clive; Lifshitz, Lawrence M.; Tuft, Richard A.; Hayakawa, Akira; Corvera, Silvia; Fogarty, Kevin E.			Plasma membrane domains specialized for clathrinmediated endocytosis in primary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; MEDIATED ENDOCYTOSIS; COATED PITS; POPULATION; VESICLES; BIOLOGY; INSULIN; COMPLEX; GLUT4; CARGO	Clathrin assembly at the plasma membrane is a fundamental process required for endocytosis. In cultured cells, most of the clathrin is localized to large patches that display little lateral mobility. The functional role of these regions is not clear, and it has been thought that they may represent artifacts of cell adhesion of cultured cells. Here we have analyzed clathrin organization in primary adipose cells isolated from mice, which are nonadherent and fully differentiated. The majority of clathrin on the plasma membrane of these cells (> 60%) was found in large clathrin patches that displayed virtually no lateral mobility and persisted for many minutes, and a smaller amount was found in small spots that appeared and disappeared rapidly. Direct visualization of transferrin revealed that it bound onto large arrays of clathrin, internalizing through vesicles that emerge from these domains. High resolution imaging (50 images/s) revealed fluorescence intensity fluctuations consistent with the formation and detachment of coated vesicles from within large patches. These results reveal that large clathrin assemblies are active regions of endocytosis in mammalian cells and highlight the importance of understanding the mechanistic basis for this organization.	Univ Massachusetts, Sch Med, Program Mol Med, Dept Physiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Corvera, S (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Dept Physiol, 373 Plantat St, Worcester, MA 01605 USA.	silvia.corvera@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK060564] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK60564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Beaumont V, 2003, BIOCHEM SOC T, V31, P819, DOI 10.1042/BST0310819; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lifshitz L. M., 1994, Proceedings of the IEEE Workshop on Biomedical Image Analysis (Cat. No.94TH0624-7), P166, DOI 10.1109/BIA.1994.315854; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Moskowitz HS, 2005, MOL BIOL CELL, V16, P1769, DOI 10.1091/mbc.E04-08-0739; Rappoport J, 2004, TRAFFIC, V5, P327, DOI 10.1111/j.1600-0854.2004.00187.x; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2005, TRAFFIC, V6, P539, DOI 10.1111/j.1600-0854.2005.00280.x; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001	21	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16139	16146		10.1074/jbc.M511370200	http://dx.doi.org/10.1074/jbc.M511370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16537543	hybrid			2022-12-27	WOS:000237996000067
J	Citri, A; Harari, D; Shohat, G; Ramakrishnan, P; Gan, J; Lavi, S; Eisenstein, M; Kimchi, A; Wallach, D; Pietrokovski, S; Yarden, Y				Citri, Ami; Harari, Daniel; Shohat, Galit; Ramakrishnan, Parameswaran; Gan, Judith; Lavi, Sara; Eisenstein, Miriam; Kimchi, Adi; Wallach, David; Pietrokovski, Shmuel; Yarden, Yosef			Hsp90 recognizes a common surface on client kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-AMINO ACID SEQUENCE; HIGH-AFFINITY BINDING; SHOCK-PROTEIN 90; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONES; TYROSINE KINASES; AMINO-TERMINUS; CO-CHAPERONE; DEGRADATION; DOMAIN	Hsp90 is a highly abundant chaperone whose clientele includes hundreds of cellular proteins, many of which are central players in key signal transduction pathways and the majority of which are protein kinases. In light of the variety of Hsp90 clientele, the mechanism of selectivity of the chaperone toward its client proteins is a major open question. Focusing on human kinases, we have demonstrated that the chaperone recognizes a common surface in the amino-terminal lobe of kinases from diverse families, including two newly identified clients, NF kappa B-inducing kinase and death-associated protein kinase, and the oncoprotein HER2/ErbB-2. Surface electrostatics determine the interaction with the Hsp90 chaperone complex such that introduction of a negative charge within this region disrupts recognition. Compiling information on the Hsp90 dependence of 105 protein kinases, including 16 kinases whose relationship to Hsp90 is first examined in this study, reveals that surface features, rather than a contiguous amino acid sequence, define the capacity of the Hsp90 chaperone machine to recognize client kinases. Analyzing Hsp90 regulation of two major signaling cascades, the mitogen-activated protein kinase and phosphatidylinositol 3-kinase, leads us to propose that the selectivity of the chaperone to specific kinases is functional, namely that Hsp90 controls kinases that function as hubs integrating multiple inputs. These lessons bear significance to pharmacological attempts to target the chaperone in human pathologies, such as cancer.	Weizmann Inst Sci, Dept Biol Regulat, IL-97100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-97100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-97100 Rehovot, Israel; Ben Gurion Univ Negev, Bioinformat Support Unit, IL-84105 Beer Sheva, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Ben Gurion University	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-97100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012; Ramakrishnan, Parameswaran/AAB-9083-2020	Citri, Ami/0000-0002-9914-0278; Ramakrishnan, Parameswaran/0000-0002-1314-827X; Shohat-Ophir, Galit/0000-0003-1246-1827; Pietrokovski, Shmuel/0000-0001-8573-5863	NCI NIH HHS [CA72981] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brugge J S, 1983, Prog Clin Biol Res, V119, P135; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Citri A, 2004, CELL CYCLE, V3, P51; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; HENIKOFF S, 1995, GENE, V163, P17; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; Millson SH, 2005, EUKARYOT CELL, V4, P849, DOI 10.1128/EC.4.5.849-860.2005; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P3836, DOI 10.1093/nar/24.19.3836; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prince T, 2004, J BIOL CHEM, V279, P39975, DOI 10.1074/jbc.M406882200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Scroggins BT, 2003, BIOCHEMISTRY-US, V42, P12550, DOI 10.1021/bi035001t; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith DF, 1998, BIOL CHEM, V379, P283; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yun BG, 2005, EXP CELL RES, V307, P212, DOI 10.1016/j.yexcr.2005.03.003; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zheng FF, 2000, CANCER RES, V60, P2090	53	178	185	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14361	14369		10.1074/jbc.M512613200	http://dx.doi.org/10.1074/jbc.M512613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551624	hybrid			2022-12-27	WOS:000237512300062
J	Danielsson, R; Suorsa, M; Paakkarinen, V; Albertsson, PA; Styring, S; Aro, EM; Mamedov, F				Danielsson, Ravi; Suorsa, Marjaana; Paakkarinen, Virpi; Albertsson, Per-Ake; Styring, Stenbjorn; Aro, Eva-Mari; Mamedov, Fikret			Dimeric and monomeric organization of photosystem II - Distribution of five distinct complexes in the different domains of the thylakoid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; PROTEIN COMPLEXES; PROTEOMIC APPROACH; SUPRAMOLECULAR ORGANIZATION; PHOTOSYNTHETIC OXIDATION; FUNCTIONAL-PROPERTIES; CYTOCHROME B(559); CRYSTAL-STRUCTURE; REACTION CENTERS; DIFFERENT PARTS	The supramolecular organization of photosystem II (PSII) was characterized in distinct domains of the thylakoid membrane, the grana core, the grana margins, the stroma lamellae, and the so-called Y100 fraction. PSII supercomplexes, PSII core dimers, PSII core monomers, PSII core monomers lacking the CP43 subunit, and PSII reaction centers were resolved and quantified by blue native PAGE, SDS-PAGE for the second dimension, and immunoanalysis of the D1 protein. Dimeric PSII (PSII supercomplexes and PSII core dimers) dominate in the core part of the thylakoid granum, whereas the monomeric PSII prevails in the stroma lamellae. Considerable amounts of PSII monomers lacking the CP43 protein and PSII reaction centers (D1-D2-cytochrome b(559) complex) were found in the stroma lamellae. Our quantitative picture of the supramolecular composition of PSII, which is totally different between different domains of the thylakoid membrane, is discussed with respect to the function of PSII in each fraction. Steady state electron transfer, flash-induced fluorescence decay, and EPR analysis revealed that nearly all of the dimeric forms represent oxygen-evolving PSII centers. PSII core monomers were heterogeneous, and a large fraction did not evolve oxygen. PSII monomers without the CP43 protein and PSII reaction centers showed no oxygen-evolving activity.	Uppsala Univ, Dept Photochem & Mol Sci, S-75236 Uppsala, Sweden; Lund Univ, Dept Biochem, Ctr Chem & Chem Engn, S-22100 Lund, Sweden; Univ Turku, Dept Biol, FI-20014 Turku, Finland	Uppsala University; Lund University; University of Turku	Mamedov, F (corresponding author), Uppsala Univ, Dept Photochem & Mol Sci, S-75236 Uppsala, Sweden.	fikret.mamedov@fotomol.uu.se	Aro, Eva-Mari/Q-8664-2017; Mamedov, Fikret/A-1761-2016; Styring, Stenbjörn/L-8414-2016	Aro, Eva-Mari/0000-0002-2922-1435; Mamedov, Fikret/0000-0002-6218-3039; Styring, Stenbjörn/0000-0002-2803-9244; Suorsa, Marjaana/0000-0002-3821-0607				Albertsson P-A, 2000, RECENT RES DEV BIOEN, V1, P143; ALBERTSSON PA, 1994, METHOD ENZYMOL, V228, P469; Albertsson PA, 1995, PHOTOSYNTH RES, V46, P141, DOI 10.1007/BF00020424; Albertsson PA, 2001, TRENDS PLANT SCI, V6, P349, DOI 10.1016/S1360-1385(01)02021-0; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1982, FEBS LETT, V146, P13, DOI 10.1016/0014-5793(82)80695-9; Andersson B, 2001, ADV PHOTOSYNTH, V11, P377; ANDREASSON E, 1988, BIOCHIM BIOPHYS ACTA, V936, P339, DOI 10.1016/0005-2728(88)90010-2; [Anonymous], 2002, PHOTOSYNTHETICA; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Aro EM, 2005, J EXP BOT, V56, P347, DOI 10.1093/jxb/eri041; Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; BARBER J, 1998, PHYSIOL PLANTARUM, V100, P817; BASSI R, 1995, EUR J BIOCHEM, V233, P709, DOI 10.1111/j.1432-1033.1995.709_3.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; Boekema EJ, 2000, BIOCHEMISTRY-US, V39, P12907, DOI 10.1021/bi0009183; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boussac A, 2000, BBA-BIOENERGETICS, V1457, P145, DOI 10.1016/S0005-2728(00)00073-6; Boussac A, 1996, BIOCHEMISTRY-US, V35, P6984, DOI 10.1021/bi960636w; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BRITT DR, 1996, OXYGENIC PHOTOSYNTHE, P137; CASEY JL, 1984, BIOCHIM BIOPHYS ACTA, V767, P21, DOI 10.1016/0005-2728(84)90075-6; Ciambella C, 2005, PROTEOMICS, V5, P746, DOI 10.1002/pmic.200401129; Danielsson R, 2004, BBA-BIOENERGETICS, V1608, P53, DOI 10.1016/j.bbabio.2003.10.005; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Dekker JP, 2002, PHOTOSYNTH RES, V72, P203, DOI 10.1023/A:1016188818591; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; HARRISON MA, 1992, PLANT CELL PHYSIOL, V33, P627; Heinemeyer J, 2004, PHYTOCHEMISTRY, V65, P1683, DOI 10.1016/j.phytochem.2004.04.022; HENRYSSON T, 1990, PHOTOSYNTH RES, V25, P107, DOI 10.1007/BF00035459; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Jahns P, 1997, BBA-BIOENERGETICS, V1318, P1, DOI 10.1016/S0005-2728(96)00133-8; KAMINSKAYA O, 1999, BIOCHEMISTRY-US, V38, P10578; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kettunen R, 1996, PLANT PHYSIOL, V111, P1183, DOI 10.1104/pp.111.4.1183; Kim EH, 2005, BBA-BIOENERGETICS, V1708, P187, DOI 10.1016/j.bbabio.2005.03.011; Kirchhoff H, 2004, BIOCHEMISTRY-US, V43, P9204, DOI 10.1021/bi0494626; Kruse O, 2000, J BIOL CHEM, V275, P6509, DOI 10.1074/jbc.275.9.6509; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavergne J, 1996, OXYGENIC PHOTOSYNTHE, P265; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Magnuson A, 1999, BBA-BIOENERGETICS, V1411, P180, DOI 10.1016/S0005-2728(99)00044-4; Mamedov F, 2000, BIOCHEMISTRY-US, V39, P10478, DOI 10.1021/bi992877k; Mamedov F, 2003, PHYSIOL PLANTARUM, V119, P328, DOI 10.1034/j.1399-3054.2003.00187.x; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Mustardy L, 2003, TRENDS PLANT SCI, V8, P117, DOI 10.1016/S1360-1385(03)00015-3; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NUGENT JHA, 1989, FEBS LETT, V255, P53, DOI 10.1016/0014-5793(89)81059-2; PETER GF, 1991, J BIOL CHEM, V266, P16745; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; Rova M, 1998, BIOCHEMISTRY-US, V37, P11039, DOI 10.1021/bi980381h; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x; SVENSSON P, 1991, BIOCHIM BIOPHYS ACTA, V1060, P45, DOI 10.1016/S0005-2728(05)80117-3; VANMIEGHEM FJE, 1991, BIOCHIM BIOPHYS ACTA, V1058, P379, DOI 10.1016/S0005-2728(05)80134-3; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; ZIMMERMANN JL, 1986, BIOCHEMISTRY-US, V25, P4609, DOI 10.1021/bi00364a023; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	73	108	112	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14241	14249		10.1074/jbc.M600634200	http://dx.doi.org/10.1074/jbc.M600634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16537530	hybrid			2022-12-27	WOS:000237512300048
J	Rishi, AK; Zhang, LY; Yu, YJ; Jiang, Y; Nautiyal, J; Wali, A; Fontana, JA; Levi, E; Majumdar, APN				Rishi, AK; Zhang, LY; Yu, YJ; Jiang, Y; Nautiyal, J; Wali, A; Fontana, JA; Levi, E; Majumdar, APN			Cell cycle- and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; HUMAN BREAST-CANCER; TYROSINE KINASE; TRANSDUCTION PATHWAYS; RETINOID CD437; STRESS; ACTIVATION; INHIBITORS; MEDIATORS; NETWORK	CARP-1, a novel apoptosis inducer, regulates apoptosis signaling by diverse agents, including adriamycin and growth factors. Epidermal growth factor receptor ( EGFR)-related protein ( ERRP), a pan-ErbB inhibitor, inhibits EGFR and stimulates apoptosis. Treatments of cells with ERRP or Iressa ( an EGFR tyrosine kinase inhibitor) results in elevated CARP-1 levels, whereas antisense-dependent depletion of CARP-1 causes inhibition of apoptosis by ERRP. CARP-1 is a tyrosine-phosphorylated protein, and ERRP treatments cause elevated tyrosine phosphorylation of CARP-1. CARP-1 contains multiple, nonoverlapping apoptosis-inducing subdomains; one such subdomain is present within amino acids 1 - 198. Wild-type or CARP-1-( 1 - 198) proteins that have substitution of tyrosine 192 to phenylalanine abrogate apoptosis by ERRP. In addition, apoptosis mediated by wild type or CARP-1-( 1 198), and not CARP-1-( 1 - 198(Y192F)), results in activation of caspase-9 and increased phosphorylation of p38 MAPK. However, the expression of dominant-negative forms of p38 MAPK activators MKK3 or MKK6 proteins inhibits apoptosis induced by both the full-length and truncated ( amino acids 1 - 198) proteins. Together, data demonstrate that tyrosine 192 of CARP-1 is a target of apoptosis signaling, and CARP-1, in turn, promotes apoptosis by activating p38 MAPK and caspase-9.	VA Med Ctr, Detroit, MI 48201 USA; Wayne State Univ, Dept Internal Med, Detroit, MI 48201 USA; Wayne State Univ, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Rishi, AK (corresponding author), VA Med Ctr, Rm B4334,4646 John R, Detroit, MI 48201 USA.	Rishia@Karmanos.org		Fontana, Joseph/0000-0003-3829-3358; Levi, Edi/0000-0003-1809-2866	NCI NIH HHS [R01 CA109370] Funding Source: Medline; NIA NIH HHS [R01 AG 14343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KRISCHBAUM MH, 2000, J CELL BIOCH S, V34, P52; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liang JY, 1999, PROSTATE, V38, P228; Lohrisch C, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.29713; Marciniak DJ, 2004, MOL CANCER THER, V3, P1615; Marciniak DJ, 2003, GASTROENTEROLOGY, V124, P1337, DOI 10.1016/S0016-5085(03)00264-6; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rae JM, 2004, BREAST CANCER RES TR, V83, P99, DOI 10.1023/B:BREA.0000010702.10130.29; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REED JC, 2004, SCI STKE 2004, P9; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SHAO ZM, 1995, ONCOGENE, V11, P493; Tikhomirov O, 2004, J BIOL CHEM, V279, P12988, DOI 10.1074/jbc.M311655200; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Xu H, 2005, MOL CANCER THER, V4, P435; Yu YJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1083, DOI 10.1152/ajpcell.2001.280.5.C1083	33	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13188	13198		10.1074/jbc.M512279200	http://dx.doi.org/10.1074/jbc.M512279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543231	hybrid			2022-12-27	WOS:000237336600024
J	Begg, GE; Holman, SR; Stokes, PH; Matthews, JM; Graham, RM; Iismaa, SE				Begg, GE; Holman, SR; Stokes, PH; Matthews, JM; Graham, RM; Iismaa, SE			Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; PHOSPHOLIPASE C-DELTA-1; STRUCTURAL BASIS; CORE DOMAIN; PROTEIN; RECEPTOR; CALCIUM; G(H); G(H)/TRANSGLUTAMINASE; IDENTIFICATION	Transglutaminase type 2 (TG2; also known as Gh) is a multifunctional protein involved in diverse cellular processes. It has two well characterized enzyme activities: receptor-stimulated signaling that requires GTP binding and calcium-activated transamidation or cross-linking that is inhibited by GTP. In addition to the GDP binding residues identified from the human TG2 crystal structure (Liu, S., Cerione, R. A., and Clardy, J. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2743 - 2747), we have previously implicated Ser(171) in GTP binding, as binding is lost with glutamate substitution (Iismaa, S. E., Wu, M.-J., Nanda, N., Church, W. B., and Graham, R. M. ( 2000) J. Biol. Chem. 275, 18259 - 18265). Here, we have shown that alanine substitution of homologous residues in rat TG2 ( Phe(174) in the core domain or Arg(476), Arg(478), or Arg(579) in barrel 1) does not affect TG activity but reduces or abolishes GTP binding and GTP gamma S inhibition of TG activity in vitro, indicating that these residues are important in GTP binding. Alanine substitution of Ser(171) does not impair GTP binding, indicating this residue does not interact directly with GTP. Arg(579) is particularly important for GTP binding, as isothermal titration calorimetry demonstrated a 100-fold reduction in GTP binding affinity by the R579A mutant. Unlike wild-type TG2 or its S171E or F174A mutants, which are sensitive to both trypsin and mu-calpain digestion, R579A is inherently more resistant to mu-calpain, but not trypsin, digestion, indicating reduced accessibility and/or flexibility of this mutant in the region of the calpain cleavage site(s). Basal TG activity of intact R579A stable SH-SY5Y neuroblastoma cell transfectants was slightly increased relative to wild-type transfectants and, in contrast to the TG activity of the latter, was further stimulated by muscarinic receptor-activated calcium mobilization. Thus, loss of GTP binding sensitizes TG2 to intracellular calcium concentrations. These findings are consistent with the notion that intracellularly, under physiological conditions, TG2 is maintained largely as a latent enzyme, its calcium-activated cross-linking activity being suppressed allosterically by guanine nucleotide binding.	Victor Chang Cardiac Res Inst, Mol Cardiol Program, Darlinghurst, NSW 2010, Australia; Univ Sydney, Sydney, NSW 2006, Australia	Victor Chang Cardiac Research Institute; University of Sydney	Iismaa, SE (corresponding author), Victor Chang Cardiac Res Inst, Mol Cardiol Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.iismaa@victorchang.unsw.edu.au	Matthews, Jacqueline/A-7322-2013; Iismaa, Siiri/C-9300-2013; Iismaa, Siiri/A-9924-2008	Iismaa, Siiri/0000-0003-2409-7356; Matthews, Jacqueline/0000-0001-8518-3472				Ahvazi B, 2004, J BIOL CHEM, V279, P7180, DOI 10.1074/jbc.M312310200; Akimov SS, 2001, J CELL SCI, V114, P2989; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Dupuis M, 2004, J BIOL CHEM, V279, P19257, DOI 10.1074/jbc.M314299200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 2003, P NATL ACAD SCI USA, V100, P12636, DOI 10.1073/pnas.1635052100; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IM MJ, 1990, J BIOL CHEM, V265, P18952; Jeon JH, 2002, BIOCHEM BIOPH RES CO, V294, P818, DOI 10.1016/S0006-291X(02)00582-X; Lai TS, 1997, J BIOL CHEM, V272, P16295, DOI 10.1074/jbc.272.26.16295; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; MISHRA S, 2006, J BIOL CHEM; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Murthy SNP, 2002, P NATL ACAD SCI USA, V99, P2738, DOI 10.1073/pnas.052715799; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang JW, 1998, J NEUROCHEM, V71, P240; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45	38	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12603	12609		10.1074/jbc.M600146200	http://dx.doi.org/10.1074/jbc.M600146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522628	hybrid			2022-12-27	WOS:000237134700050
J	Ratner, AJ; Hippe, KR; Aguilar, JL; Bender, MH; Nelson, AL; Weiser, JN				Ratner, AJ; Hippe, KR; Aguilar, JL; Bender, MH; Nelson, AL; Weiser, JN			Epithelial cells are sensitive detectors of bacterial pore-forming toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; STREPTOCOCCUS-PNEUMONIAE; HUMAN NEUTROPHILS; IN-VITRO; SIGNALING PATHWAYS; ANTHROLYSIN-O; MURINE MODEL; PNEUMOLYSIN; INFECTION	Epithelial cells act as an interface between human mucosal surfaces and the surrounding environment. As a result, they are responsible for the initiation of local immune responses, which may be crucial for prevention of invasive infection. Here we show that epithelial cells detect the presence of bacterial pore-forming toxins ( including pneumolysin from Streptococcus pneumoniae, alpha-hemolysin from Staphylococcus aureus, streptolysin O from Streptococcus pyogenes, and anthrolysin O from Bacillus anthracis) at nanomolar concentrations, far below those required to cause cytolysis. Phosphorylation of p38 MAPK appears to be a conserved response of epithelial cells to subcytolytic concentrations of bacterial pore-forming toxins, and this activity is inhibited by the addition of high molecular weight osmolytes to the extracellular medium. By sensing osmotic stress caused by the insertion of a sublethal number of pores into their membranes, epithelial cells may act as an early warning system to commence an immune response, while the local density of toxin-producing bacteria remains low. Osmosensing may thus represent a novel innate immune response to a common bacterial virulence strategy.	Univ Penn, Dept Microbiol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ratner, AJ (corresponding author), Univ Penn, Dept Microbiol, Sch Med, Johnson Pavil 401A, Philadelphia, PA 19104 USA.	ratner@mail.med.upenn.edu		Weiser, Jeffrey/0000-0001-7168-8090; Ratner, Adam/0000-0003-1761-794X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI065450, R21AI054647, R21AI044231, R01AI044231, R01AI038446] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI038446, R01 AI044231, AI065450, AI044231, R21 AI054647, R21 AI044231, AI054647, K08 AI065450, AI038446] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Braun JS, 2002, J CLIN INVEST, V109, P19; Burns D., 2003, BACTERIAL PROTEIN TO; Chung WO, 2004, INFECT IMMUN, V72, P352, DOI 10.1128/IAI.72.1.352-358.2004; Cockeran R, 2002, J INFECT DIS, V186, P562, DOI 10.1086/341563; Cockeran R, 2001, INFECT IMMUN, V69, P3494, DOI 10.1128/IAI.69.5.3494-3496.2001; Cockeran R, 2001, J INFECT DIS, V183, P604, DOI 10.1086/318536; Fickl H, 2005, CLIN EXP IMMUNOL, V140, P274, DOI 10.1111/j.1365-2249.2005.02757.x; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Kernodle DS, 1997, INFECT IMMUN, V65, P179, DOI 10.1128/IAI.65.1.179-184.1997; Korchev YE, 1998, BIOCHEM J, V329, P571; KORCHEV YE, 1992, J MEMBRANE BIOL, V127, P195; Limbago B, 2000, INFECT IMMUN, V68, P6384, DOI 10.1128/IAI.68.11.6384-6390.2000; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Monier RM, 2002, J INFECT DIS, V185, P921, DOI 10.1086/339483; Nonnenmacher C, 2003, INFECT IMMUN, V71, P850, DOI 10.1128/IAI.71.2.850-856.2003; Okahashi N, 2003, INFECT IMMUN, V71, P948, DOI 10.1128/IAI.71.2.948-955.2003; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215; Ratner AJ, 2005, P NATL ACAD SCI USA, V102, P3429, DOI 10.1073/pnas.0500599102; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Schmeck B, 2004, J BIOL CHEM, V279, P53241, DOI 10.1074/jbc.M313702200; Shannon JG, 2003, INFECT IMMUN, V71, P3183, DOI 10.1128/IAI.71.6.3183-3189.2003; Srivastava A, 2005, INFECT IMMUN, V73, P6479, DOI 10.1128/IAI.73.10.6479-6487.2005; Stringaris AK, 2002, NEUROBIOL DIS, V11, P355, DOI 10.1006/nbdi.2002.0561; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; van Rossum AMC, 2005, INFECT IMMUN, V73, P7718, DOI 10.1128/IAI.73.11.7718-7726.2005; Walev I, 2001, FASEB J, V15, P237, DOI 10.1096/fj.01-0572fje	32	140	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12994	12998		10.1074/jbc.M511431200	http://dx.doi.org/10.1074/jbc.M511431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520379	Green Accepted, hybrid			2022-12-27	WOS:000237134700095
J	Chen, S; Barbieri, JT				Chen, S; Barbieri, JT			Unique substrate recognition by botulinum neurotoxins serotypes A and E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM; LIGHT-CHAIN; TOXIN PRODUCTION; TETANUS; SNAP-25; INHIBITORS; BINDING; REQUIREMENTS; SPECIFICITY; PROTEOLYSIS	Botulinum neurotoxins (BoNTs) are zinc proteases that cleave SNARE proteins to elicit flaccid paralysis by inhibiting the fusion of neurotransmitter-carrying vesicles to the plasma membrane of peripheral neurons. There are seven serotypes of BoNT, termed A-G. BoNT serotype A and serotype E cleave SNAP25 at residues 197-198 and 180-181, respectively. Unlike other zinc proteases, the BoNTs recognize extended regions of SNAP25 for cleavage. The basis for this extended substrate recognition and specificity is unclear. Saturation mutagenesis and deletion mapping identified residues 156-202 of SNAP25 as the optimal cleavage domain for BoNT/A, whereas the optimal cleavage domain for BoNT/E was shorter, comprising residues 167-186 of SNAP25. Two sub-sites were resolved within each optimal cleavage domain, which included a recognition or active site (AS) domain that contained the site of cleavage and a binding (B) domain, which contributed to substrate affinity. Within the AS domains, the P1', P3, and P5 sites of SNAP25 contributed to scissile bond cleavage by LC/A, whereas the P1' and P2 sites of SNAP25 contributed to scissile bond cleavage by LC/E. These studies provide insight into the development of strategies for small molecule inhibitors of the BoNTs.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu		Chen, Sheng/0000-0003-3526-7808	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI057153] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2005, BIOCHEMISTRY-US, V44, P8291, DOI 10.1021/bi050253a; Arndt JW, 2005, J MOL BIOL, V346, P1083, DOI 10.1016/j.jmb.2004.12.039; ARNON SS, 1978, LANCET, V1, P1273; Baldwin MR, 2004, PROTEIN EXPRES PURIF, V37, P187, DOI 10.1016/j.pep.2004.05.009; Breidenbach MA, 2005, TRENDS MOL MED, V11, P377, DOI 10.1016/j.molmed.2005.06.012; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Marvaud JC, 2002, CR BIOL, V325, P863, DOI 10.1016/S1631-0691(02)01498-1; Middlebrook JL, 1995, ADV EXP MED BIOL, V383, P93; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Poulain B., 2003, Annales de Readaptation et de Medecine Physique, V46, P265, DOI 10.1016/S0168-6054(03)00114-4; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; Robinson RF, 2003, ANN PHARMACOTHER, V37, P127, DOI 10.1345/aph.1C034; Rupp B, 2001, NAT STRUCT BIOL, V8, P663, DOI 10.1038/90361; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Schmidt JJ, 2005, BIOCHEMISTRY-US, V44, P4067, DOI 10.1021/bi0477642; Schmidt JJ, 1998, FEBS LETT, V435, P61, DOI 10.1016/S0014-5793(98)01041-2; Schmidt JJ, 1997, J PROTEIN CHEM, V16, P19, DOI 10.1023/A:1026386710428; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; SIEGEL LS, 1979, APPL ENVIRON MICROB, V38, P606, DOI 10.1128/AEM.38.4.606-611.1979; Tonello F, 1996, ADV EXP MED BIOL, V389, P251; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8	32	82	90	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10906	10911		10.1074/jbc.M513032200	http://dx.doi.org/10.1074/jbc.M513032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478727	hybrid			2022-12-27	WOS:000236822200031
J	Ren, JW; Kan, A; Leong, SH; Ooi, LLPJ; Jeang, KT; Chong, SS; Kon, OL; Lee, CGL				Ren, JW; Kan, A; Leong, SH; Ooi, LLPJ; Jeang, KT; Chong, SS; Kon, OL; Lee, CGL			FAT10 plays a role in the regulation of chromosomal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; NECROSIS-FACTOR-ALPHA; MITOTIC CHECKPOINT; COLORECTAL-CANCER; MAD2; EXPRESSION; CELLS; GENE; INSTABILITY	Aneuploidy is a key process in tumorigenesis. Dysfunction of the mitotic spindle checkpoint proteins has been implicated as a cause of aneuploidy in cells. We have previously reported that FAT10, a member of the ubiquitin-like modifier family of proteins, is overexpressed in several gastrointestinal and gynecological cancers. Here we show that FAT10 interacts with MAD2, a spindle checkpoint protein, during mitosis. Notably, we show that localization of MAD2 at the kinetochore during the prometaphase stage of the cell cycle was greatly reduced in FAT10-overexpressing cells. Furthermore, compared with parental HCT116 cells, fewer mitotic cells were observed after double thymidine-synchronized FAT10-overexpressing cells were released into nocodazole for more than 4 h. Nonetheless, when these double thymidine-treated cells were released into media, a similar number of G(1) parental and FAT10-overexpressing HCT116 cells was observed throughout the 10-h time course. Additionally, more nocodazole-treated FAT10-overexpressing cells escape mitotic controls and are multinucleate compared with parental cells. Significantly, we observed a higher degree of variability in chromosome number in cells overexpressing FAT10. Hence, our data suggest that high levels of FAT10 protein in cells lead to increased mitotic nondisjunction and chromosome instability, and this effect is mediated by an abbreviated mitotic phase and the reduction in the kinetochore localization of MAD2 during the prometaphase stage of the cell cycle.	Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore; Natl Canc Ctr, Dept Surg Oncol, Singapore 169610, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 117597, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore 117597, Singapore; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019; Ooi, London Lucien/AGK-1395-2022; Jeang, Kuan-Teh/A-2424-2008; Chong, Samuel S./D-8098-2015	Lee, Caroline G/0000-0002-4323-3635; Chong, Samuel S./0000-0002-1872-5937	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI001023, ZIAAI001023, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; FitzPatrick DR, 2002, HUM MOL GENET, V11, P3249, DOI 10.1093/hmg/11.26.3249; Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAMIHIRA S, 1994, LEUKEMIA RES, V18, P79, DOI 10.1016/0145-2126(94)90122-8; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li GQ, 2003, WORLD J GASTROENTERO, V9, P1972, DOI 10.3748/wjg.v9.i9.1972; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tanaka K, 2001, JPN J CANCER RES, V92, P952, DOI 10.1111/j.1349-7006.2001.tb01186.x; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	35	69	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11413	11421		10.1074/jbc.M507218200	http://dx.doi.org/10.1074/jbc.M507218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495226	hybrid			2022-12-27	WOS:000236822200084
J	Jaschke, H; Neumann, S; Moore, S; Thomas, CJ; Colson, AO; Costanzi, S; Kleinau, G; Jiang, JK; Paschke, R; Raaka, BM; Krause, G; Gershengorn, MC				Jaschke, H; Neumann, S; Moore, S; Thomas, CJ; Colson, AO; Costanzi, S; Kleinau, G; Jiang, JK; Paschke, R; Raaka, BM; Krause, G; Gershengorn, MC			A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VIRUS TYPE-1 ENTRY; MODELS; IDENTIFICATION; ACTIVATION; RHODOPSIN; DYNAMICS; LIGAND	Many cognate low molecular weight (LMW) agonists bind to seven transmembrane-spanning receptors within their transmembrane helices (TMHs). The thienopyrimidine org41841 was identified previously as an agonist for the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and suggested to bind within its TMHs because it did not compete for LH binding to the LHCGR ectodomain. Because of its high homology with LHCGR, we predicted that thyroid-stimulating hormone receptor (TSHR) might be activated by org41841 also. We show that org41841 is a partial agonist for TSHR but with lower potency than for LHCGR. Analysis of three-dimensional molecular models of TSHR and LHCGR predicted a binding pocket for org41841 in common clefts between TMHs 3, 4, 5, 6, and 7 and extracellular loop 2 in both receptors. Evidence for this binding pocket was obtained in signaling studies with chimeric receptors that exhibited improved responses to org41841. Furthermore, a key receptor-ligand interaction between the highly conserved negatively charged E3.37 and the amino group of org41841 predicted by docking of the ligand into the three-dimensional TSHR model was experimentally confirmed. These findings provide the first evidence that, in contrast to the ectodomain binding of cognate ligands, a LMW agonist can bind to and activate glycoprotein hormone receptors via interaction with their transmembrane domain.	Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Computat Chem Core Lab, NIH, Bethesda, MD 20892 USA; Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Leipzig University	Jaschke, H (corresponding author), Leibniz Inst Mol Pharmacol, Robert Roessle Str 10, D-13125 Berlin, Germany.	marving@intra.niddk.nih.gov	Neumann, Susanne/GPK-6035-2022; Kleinau, Gunnar/GPX-6330-2022; Costanzi, Stefano/G-8990-2013	Thomas, Craig/0000-0001-9386-9001; Costanzi, Stefano/0000-0003-3183-7332	Intramural NIH HHS [Z01 DK070005-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011006, Z01DK013025, Z01DK070005, Z01DK047045, Z01DK047044] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Case DA, 2002, ACCOUNTS CHEM RES, V35, P325, DOI 10.1021/ar010020l; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; McLachlan SM, 2005, ENDOCR REV, V26, P800, DOI 10.1210/er.2004-0023; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Stenkamp RE, 2005, ARCH PHARM, V338, P209, DOI 10.1002/ardp.200400995; STRADER CD, 1989, J BIOL CHEM, V264, P13572; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; ter Laak AM, 1999, RECEPTOR CHANNEL, V6, P295; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; van Straten NCR, 2005, J MED CHEM, V48, P1697, DOI 10.1021/jm049676l; van Straten NCR, 2002, CHEMBIOCHEM, V3, P1023, DOI 10.1002/1439-7633(20021004)3:10<1023::AID-CBIC1023>3.0.CO;2-9; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Woodmansee WW, 2004, CLIN ENDOCRINOL, V61, P163, DOI 10.1111/j.1365-2265.2004.02025.x	26	73	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9841	9844		10.1074/jbc.C600014200	http://dx.doi.org/10.1074/jbc.C600014200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16488885	hybrid			2022-12-27	WOS:000236594300004
J	Molnar, F; Perakyla, M; Carlberg, C				Molnar, F; Perakyla, M; Carlberg, C			Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIDE-CHAINS; NUCLEAR RECEPTOR; CRYSTAL-STRUCTURE; 20-EPI ANALOGS; DOMAIN; COACTIVATOR; D-3; CONFORMATIONS; ACTIVATION; GEMINI	Existing crystal structure data has indicated that 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) and its analogues bind the ligand-binding pocket (LBP) of the human vitamin D receptor in a very similar fashion. Because docking of a ligand into the LBP is a more flexible process than crystallography can monitor, we analyzed 1 alpha,25(OH)(2)D-3, its 20-epi derivative MC1288, the two side-chain analogues Gemini and Ro43-83582 ( a hexafluoro-derivative) by molecular dynamics simulations in a complex with the vitamin D receptor ligand-binding domain and a co-activator peptide. Superimposition of the structures showed that the side chain of MC1288, the first side chain of the conformation II of Gemini, the second side chain of Ro43-83582 in conformation I and the first side chain of Ro43-83582 in conformation II take the same agonistic position as the side chain of 1 alpha,25(OH)(2)D-3. Compared with the LBP of the natural hormone MC1288 reduced the volume by 17%, and Gemini expanded it by 19%. The shrinking of the LBP of MC1288 and its expansion to accommodate the second side chain of Gemini or Ro43-83582 is the combined result of minor movements of more than 30 residues and major movements of a few critical amino acids. The agonist-selective recognition of anchoring OH groups by the conformational flexible residues Ala-303, Leu-309, and His-397 was confirmed by in vitro assays. In summary, variations in the volume of agonists lead to adaptations in the volume of the LBP and alternative contacts of anchoring OH-groups.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Molnár, Ferdinand/E-2290-2011; Carlberg, Carsten/C-9075-2011	Molnár, Ferdinand/0000-0001-9008-4233; Carlberg, Carsten/0000-0003-2633-0684				BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bury Y, 2001, J CELL BIOCHEM, P179; Carlberg C, 2003, EXPERT OPIN THER PAT, V13, P761; Carlberg C, 2003, J CELL BIOCHEM, V88, P274, DOI 10.1002/jcb.10337; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 2001, STEROIDS, V66, P213, DOI 10.1016/S0039-128X(00)00150-1; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Ciesielski F, 2004, J STEROID BIOCHEM, V89-90, P55, DOI 10.1016/j.jsbmb.2004.03.109; Eelen G, 2005, MOL PHARMACOL, V67, P1566, DOI 10.1124/mol.104.008730; Hansen CM, 2001, FRONT BIOSCI-LANDMRK, V6, pD820, DOI 10.2741/Hansen; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; Jimenez-Lara AM, 1999, J BIOL CHEM, V274, P13503, DOI 10.1074/jbc.274.19.13503; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kohonen T., 1995, SELF ORG MAPS, V30, DOI 10.1007/978-3-642-97610-0; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MACIASGONZALEZ M, 2003, MOL ENDOCRINOL, V17, P2028; Nayeri S, 1996, J CELL BIOCHEM, V62, P325, DOI 10.1002/(SICI)1097-4644(199609)62:3<325::AID-JCB3>3.0.CO;2-T; Norman AW, 2000, J MED CHEM, V43, P2719, DOI 10.1021/jm0000160; ONATE SA, 1995, SCIENCE, V270, P1354; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331; Tocchini-Valentini G, 2004, J MED CHEM, V47, P1956, DOI 10.1021/jm0310582; Tocchini-Valentini G, 2001, P NATL ACAD SCI USA, V98, P5491, DOI 10.1073/pnas.091018698; Vaisanen S, 2003, MOL PHARMACOL, V63, P1230, DOI 10.1124/mol.63.6.1230; Vaisanen S, 2002, MOL PHARMACOL, V62, P788, DOI 10.1124/mol.62.4.788; Vanhooke JL, 2004, BIOCHEMISTRY-US, V43, P4101, DOI 10.1021/bi036056y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weyts FA, 2004, BIOCHEM PHARMACOL, V67, P1327, DOI 10.1016/j.bcp.2003.12.006; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	38	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10516	10526		10.1074/jbc.M513609200	http://dx.doi.org/10.1074/jbc.M513609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478719	hybrid			2022-12-27	WOS:000236594300081
J	Tanner, DR; Dewey, JD; Miller, MR; Buskirk, AR				Tanner, DR; Dewey, JD; Miller, MR; Buskirk, AR			Genetic analysis of the structure and function of transfer messenger RNA pseudoknot 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TMRNA; TRANSLATION; SEQUENCE; DEGRADATION; UPSTREAM; RIBOSOME; SYSTEM	tmRNA rescues stalled ribosomes in eubacteria by forcing the ribosome to abandon its mRNA template and resume translation with tmRNA itself as a template. Pseudoknot 1 (pk1), immediately upstream of this coding region in tmRNA, is a structural element that is considered essential for tmRNA function based on the analysis of pk1 mutants in vitro. pk1 binds near the ribosomal decoding site and may make base-specific contacts with tmRNA ligands. To study pk1 structure and function in vivo, we have developed a genetic selection that ties the life of Escherichia coli cells to tmRNA activity. Mutation of pk1 at 20% per base and selection for tmRNA activity yielded sequences that retain the same pseudoknot fold. In contrast, selection of active mutants from 106 completely random sequences identified hairpin structures that functionally replace pk1. Rational design of a hairpin with increased stability using an unrelated sequence yielded a tmRNA mutant with nearly wild-type activity. We conclude that the role of pk1 in tmRNA function is purely structural and that it can be replaced with a variety of hairpin structures. Our results demonstrate that in the study of functional RNAs, the inactivity of a mutant designed to destroy a given structure should not be interpreted as proof that the structure is necessary for RNA function. Such mutations may only destabilize a global fold that could be formed equally well by an entirely different, stable structure.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Buskirk, AR (corresponding author), Brigham Young Univ, Dept Chem & Biochem, C203 BNSN, Provo, UT 84602 USA.	buskirk@chem.byu.edu						Aalberts DP, 2005, NUCLEIC ACIDS RES, V33, P2210, DOI 10.1093/nar/gki508; Burks J, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-14; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; de Novoa PG, 2004, NUCLEIC ACIDS RES, V32, pD104, DOI 10.1093/nar/gkh102; Felden B, 1997, RNA, V3, P89; Fong DH, 2002, EMBO J, V21, P2323, DOI 10.1093/emboj/21.10.2323; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; Lim VI, 2005, J MOL BIOL, V346, P395, DOI 10.1016/j.jmb.2004.11.061; Michiels PJA, 2001, J MOL BIOL, V310, P1109, DOI 10.1006/jmbi.2001.4823; Nameki N, 1999, NUCLEIC ACIDS RES, V27, P3667, DOI 10.1093/nar/27.18.3667; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nameki N, 1999, J MOL BIOL, V286, P733, DOI 10.1006/jmbi.1998.2487; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; Reeder J, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-104; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Su L, 1999, NAT STRUCT BIOL, V6, P285, DOI 10.1038/6722; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1996, RNA, V2, P1306; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	25	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10561	10566		10.1074/jbc.M600167200	http://dx.doi.org/10.1074/jbc.M600167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481313	hybrid			2022-12-27	WOS:000236594300087
J	Taurin, S; Sandbo, N; Qin, YM; Browning, D; Dulin, NO				Taurin, S; Sandbo, N; Qin, YM; Browning, D; Dulin, NO			Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; GENE-EXPRESSION; COLON-CANCER; ACTIVATION; INTERACTS; PATHWAY; CELLS; APC; UBIQUITINATION; ACETYLATION	beta-Catenin is a signaling molecule that promotes cell proliferation by the induction of gene transcription through the activation of T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors. The canonical mechanism of the regulation of beta-catenin involves its phosphorylation by casein kinase 1 at the Ser-45 site and by glycogen synthase kinase 3 (GSK3) at the Thr-41, Ser-37, and Ser-33 sites. This phosphorylation targets beta-catenin to ubiquitination and degradation by the proteasome system. Mitogenic factors promote beta-catenin signaling through the inhibition of GSK3, resulting in reduced beta-catenin phosphorylation, its stabilization, and subsequent accumulation in the nucleus, where it stimulates TCF/LEF-dependent gene transcription. In the present study, we have shown that (i) beta-catenin can be phosphorylated by protein kinase A (PKA) in vitro and in intact cells at two novel sites, Ser-552 and Ser-675; (ii) phosphorylation by PKA promotes the transcriptional activity (TCF/LEF transactivation) of beta-catenin; (iii) mutation of Ser-675 attenuates the promoting effect of PKA; (iv) phosphorylation by PKA does not affect the GSK3-dependent phosphorylation of beta-catenin, its stability, or intracellular localization; and ( v) phosphorylation at the Ser-675 site promotes the binding of beta-catenin to its transcriptional coactivator, CREB-binding protein. In conclusion, this study identifies a novel, noncanonical mechanism of modulation of beta-catenin signaling through direct phosphorylation of beta-catenin by PKA, promoting its interaction with CREB-binding protein.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University of Chicago; University System of Georgia; Augusta University	Dulin, NO (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	ndulin@medicine.bsd.uchicago.edu	高, 雨莉/HGU-8187-2022	Browning, Darren/0000-0003-0497-7620; Taurin, Sebastien/0000-0003-2167-5253	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 071755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boucher MJ, 2005, J CELL PHYSIOL, V202, P178, DOI 10.1002/jcp.20104; Davis A, 2003, CELL SIGNAL, V15, P597, DOI 10.1016/S0898-6568(02)00148-1; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hogarth DK, 2004, AM J PHYSIOL-CELL PH, V287, pC449, DOI 10.1152/ajpcell.00547.2003; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Khaled M, 2002, J BIOL CHEM, V277, P33690, DOI 10.1074/jbc.M202939200; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Niu JX, 2002, BIOCHEM J, V365, P677, DOI 10.1042/BJ20020390; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200	34	337	354	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9971	9976		10.1074/jbc.M508778200	http://dx.doi.org/10.1074/jbc.M508778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476742	hybrid			2022-12-27	WOS:000236594300019
J	Rich, A				Rich, A			Discovery of the hybrid helix and the first DNA-RNA hybridization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							DEOXYRIBONUCLEIC-ACID; ENZYMATIC-SYNTHESIS; STRAND SEPARATION; POLYADENYLIC-ACID; POLYINOSINIC ACID; POLYNUCLEOTIDES; RECOMBINATION; COMPLEX		MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	cbeckman@mit.edu						DAVIES DR, 1958, J AM CHEM SOC, V80, P1003, DOI 10.1021/ja01537a068; DOTY P, 1960, P NATL ACAD SCI USA, V46, P461, DOI 10.1073/pnas.46.4.461; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; FELSENFELD G, 1957, BIOCHIM BIOPHYS ACTA, V26, P457, DOI 10.1016/0006-3002(57)90091-4; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FURTH JJ, 1961, BIOCHEM BIOPH RES CO, V4, P362, DOI 10.1016/0006-291X(61)90219-4; GRUNBERGMANAGO M, 1955, SCIENCE, V122, P907, DOI 10.1126/science.122.3176.907; HALL BD, 1961, P NATL ACAD SCI USA, V47, P137, DOI 10.1073/pnas.47.2.137; HOOGSTEEN K, 1959, ACTA CRYSTALLOGR, V12, P822, DOI 10.1107/S0365110X59002389; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V21, P197, DOI 10.1016/0006-3002(56)90127-5; LEHMAN IR, 1958, P NATL ACAD SCI USA, V44, P1191, DOI 10.1073/pnas.44.12.1191; MARMUR J, 1960, P NATL ACAD SCI USA, V46, P453, DOI 10.1073/pnas.46.4.453; RICH A, 1954, NATURE, V173, P995, DOI 10.1038/173995a0; RICH A, 1959, ANN NY ACAD SCI, V81, P709, DOI 10.1111/j.1749-6632.1959.tb49352.x; Rich A, 1956, J AM CHEM SOC, V78, P3548, DOI 10.1021/ja01595a086; RICH A, 1960, P NATL ACAD SCI USA, V46, P1044, DOI 10.1073/pnas.46.8.1044; RICH A, 1954, P NATL ACAD SCI USA, V40, P759, DOI 10.1073/pnas.40.8.759; RICH A, 1958, NATURE, V181, P521, DOI 10.1038/181521a0; RICH A, 1957, SPEC PUB NY ACAD SCI, V5, P186; RICH A, 1957, CHEM BASIS HEREDITY, P557; RICH ALEXANDER, 1959, BROOKHAVEN SYMPOSIA IN BIOL, V12, P17; SINSHEIMER RL, 1959, J MOL BIOL, V1, P43, DOI 10.1016/S0022-2836(59)80006-1; TENER GM, 1958, J AM CHEM SOC, V80, P6223, DOI 10.1021/ja01556a017; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; WARNER RC, 1956, FED PROC, V15, P379; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	26	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7693	7696		10.1074/JBC.X600003200	http://dx.doi.org/10.1074/JBC.X600003200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16547011	hybrid			2022-12-27	WOS:000236031000001
J	Honnappa, S; Jahnke, W; Seelig, J; Steinmetz, MO				Honnappa, Srinivas; Jahnke, Wolfgang; Seelig, Joachim; Steinmetz, Michel O.			Control of intrinsically disordered stathmin by multisite phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-DESTABILIZING ACTIVITY; IN-VITRO; TUBULIN; PROTEINS; BINDING; OP18/STATHMIN; DYNAMICS; SPINDLE; PREDICTION; INCREASES	Stathmin is an intrinsically disordered protein implicated in the regulation of microtubule dynamics and in the development of cancer. The microtubule destabilizing activity of stathmin is down-regulated by phosphorylation of four serine residues, Ser(16), Ser(25), Ser(38), and Ser(63). Here we have used calorimetric and spectroscopic methods, including nuclear magnetic resonance to analyze the properties of seven stathmin phosphoisoforms to bind tubulin and inhibit microtubule formation. We found that stathmin phosphorylation results in a substantial loss in hydration entropy upon tubulin-stathmin complex formation. Remarkably, a linear correlation between the free energy change of complex formation and the microtubule inhibition activities of stathmin phosphoisoforms was observed. This finding provides a biophysical basis for understanding the mechanism by which local stathmin activity gradients important for promoting localized microtubule growth are established. We further found that phosphorylation of Ser16 and Ser63 disrupts the formation of a tubulin-interacting beta-hairpin and a helical segment, respectively, explaining the dominant role of these residues in regulating cell cycle progression. The insight into the tubulin-stathmin interaction offers a molecular basis for understanding the nature and the factors that control intrinsically disordered protein systems in general.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Novartis Pharma AG, NIBR, Discovery Technol, CH-4002 Basel, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Novartis; University of Basel	Steinmetz, MO (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	michel.steinmetz@psi.ch	Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687				Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Clement MJ, 2005, BIOCHEMISTRY-US, V44, P14616, DOI 10.1021/bi0512492; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; DI PG, 1997, FEBS LETT, V416, P149; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; Honnappa S, 2003, J BIOL CHEM, V278, P38926, DOI 10.1074/jbc.M305546200; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Iancu C, 2001, J CELL SCI, V114, P909; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; Luque I, 1998, METHOD ENZYMOL, V295, P100; Manna T, 2006, J BIOL CHEM, V281, P2071, DOI 10.1074/jbc.M510661200; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tholey A, 1999, BIOPHYS J, V76, P76, DOI 10.1016/S0006-3495(99)77179-1; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200	40	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16078	16083		10.1074/jbc.M513524200	http://dx.doi.org/10.1074/jbc.M513524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16554300	Green Published, hybrid			2022-12-27	WOS:000237996000060
J	Nakajima, H; Watanabe, N; Shibata, F; Kitamura, T; Ikeda, Y; Handa, M				Nakajima, Hideaki; Watanabe, Naohide; Shibata, Fumi; Kitamura, Toshio; Ikeda, Yasuo; Handa, Makoto			N-terminal Region of CCAAT/Enhancer-binding Protein epsilon Is Critical for Cell Cycle Arrest, Apoptosis, and Functional Maturation during Myeloid Differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; C/EBP-ALPHA; MICE LACKING; PROLIFERATION; TRANSCRIPTION; GROWTH; P21; GRANULOPOIESIS; HYPERPLASIA; DEGRADATION	CCAAT/enhancer-binding protein epsilon (C/EBP epsilon) plays a critical role in terminal myeloid differentiation. Differentiation is an integrated process of cell cycle arrest, morphological change, functional maturation, and apoptosis. However, the molecular networks underlying these events in C/EBP epsilon-induced differentiation remain poorly understood. To reveal these mechanisms, we performed a detailed molecular analysis of C/EBP epsilon-induced differentiation using an inducible form of C/EBP epsilon. The activation of C/EBP epsilon induced growth arrest, morphological differentiation, the expression of CD11b and secondary granule proteins, and apoptosis in myeloid cell lines. Unlike C/EBP alpha, C/EBP epsilon dramatically up-regulated p27 with a concomitant down-regulation of cdk4/6 and cyclin D2/A/E. Moreover, the anti-apoptotic proteins Bcl-2 and Bcl-x were down-regulated, whereas pro-apoptotic protein Bax remained unchanged. Using a variety of mutants, we revealed that these events were all regulated by the N-terminal activation domain of C/EBP epsilon. Interestingly, some of the differentiation processes such as the induction of secondary granule protein genes were clearly inhibited by c-Myc; however, inhibition of apoptosis by Bcl-x did not affect the entire differentiation processes. These data indicate the N terminus of C/EBP epsilon to be solely responsible for most aspects of myeloid differentiation, and these events were differentially affected by c-Myc.	[Nakajima, Hideaki] Univ Tokyo, Inst Med Sci, Ctr Excellence, Minato Ku, Tokyo 1088639, Japan; [Ikeda, Yasuo] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo 1608582, Japan; [Watanabe, Naohide; Handa, Makoto] Keio Univ, Sch Med, Dept Transfus & Cell Therapy, Tokyo 1608582, Japan; [Shibata, Fumi; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy, Tokyo 1088639, Japan	University of Tokyo; Keio University; Keio University; University of Tokyo	Nakajima, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Excellence, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	hnakajim@ims.u-tokyo.ac.jp	Handa, Makoto/B-1121-2014; Kitamura, Toshio/AAA-2071-2021		Ministry of Education, Science, Sports and Culture of Japan; Naito Foundation	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation)	This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture of Japan and the Naito Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dinauer Mary C., 2000, Hematology Am Soc Hematol Educ Program, P303; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; Verbeek W, 2001, LEUKEMIA, V15, P103, DOI 10.1038/sj.leu.2401995; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	34	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14494	14502		10.1074/jbc.M600575200	http://dx.doi.org/10.1074/jbc.M600575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16531405	hybrid			2022-12-27	WOS:000207179300008
J	Raduner, S; Majewska, A; Chen, JZ; Xie, XQ; Hamon, J; Faller, B; Altmann, KH; Gertsch, J				Raduner, Stefan; Majewska, Adriana; Chen, Jian-Zhong; Xie, Xiang-Qun; Hamon, Jacques; Faller, Bernard; Altmann, Karl-Heinz; Gertsch, Juerg			Alkylamides from Echinacea are a new class of cannabinomimetics - Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID CB2 RECEPTOR; GENE-EXPRESSION; ENDOCANNABINOID SYSTEM; IMMUNE MODULATION; SELECTIVE LIGANDS; PHOSPHOLIPASE-C; DOUBLE-BLIND; COMMON COLD; HL-60 CELLS; SR 144528	Alkylamides (alkamides) from Echinacea modulate tumor necrosis factor alpha mRNA expression in human monocytes/ macrophages via the cannabinoid type 2 (CB2) receptor (Gertsch, J., Schoop, R., Kuenzle, U., and Suter, A. (2004) FEBS Lett. 577, 563-569). Here we show that the alkylamides dodeca-2E,4E,8Z,10Z- tetraenoic acid isobutylamide (A1) and dodeca-2E, 4E-dienoic acid isobutylamide (A2) bind to the CB2 receptor more strongly than the endogenous cannabinoids. The K-i values of A1 and A2 (CB2 similar to 60 nM; CB1 > 1500 nM) were determined by displacement of the synthetic high affinity cannabinoid ligand [H-3] CP-55,940. Molecular modeling suggests that alkylamides bind in the solvent-accessible cavity in CB2, directed by H-bonding and pi-pi interactions. In a screen with 49 other pharmacologically relevant receptors, it could be shown that A1 and A2 specifically bind to CB2 and CB1. A1 and A2 elevated total intracellular Ca2+ in CB2-positive but not in CB2-negative promyelocytic HL60 cells, an effect that was inhibited by the CB2 antagonist SR144528. At 50 nM, A1, A2, and the endogenous cannabinoid anandamide (CB2 K-i > 200 nM) up-regulated constitutive interleukin (IL)-6 expression in human whole blood in a seemingly CB2-dependent manner. A1, A2, anandamide, the CB2 antagonist SR144528 (Ki < 10 nM), and also the non-CB2-binding alkylamide undeca-2E-ene,8,10-diynoic acid isobutylamide all significantly inhibited lipopolysaccharide-induced tumor necrosis factor alpha, IL-1 beta, and IL-12p70 expression (5-500 nM) in a CB2-independent manner. Alkylamides and anandamide also showed weak differential effects on anti-CD3- versus anti-CD28-stimulated cytokine expression in human whole blood. Overall, alkylamides, anandamide, and SR144528 potently inhibited lipopolysaccharide-induced inflammation in human whole blood and exerted modulatory effects on cytokine expression, but these effects are not exclusively related to CB2 binding.	ETH, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland; Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA; Novartis Inst BioMed Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Houston System; University of Houston; Novartis	Gertsch, J (corresponding author), ETH, Dept Chem & Appl Biosci, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	juerg.gertsch@pharma.ethz.ch		Gertsch, Jurg/0000-0003-0978-1555				Barnes J, 2005, J PHARM PHARMACOL, V57, P929, DOI 10.1211/0022357056127; BAUER R, 1988, PHYTOCHEMISTRY, V27, P2339, DOI 10.1016/0031-9422(88)80156-0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Brinkeborn RM, 1999, PHYTOMEDICINE, V6, P1; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; Chen JZ, 2005, LIFE SCI, V76, P2053, DOI 10.1016/j.lfs.2004.08.041; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Demuth DG, 2006, LIFE SCI, V78, P549, DOI 10.1016/j.lfs.2005.05.055; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Feng WK, 2003, BIOCHEM PHARMACOL, V65, P1077, DOI 10.1016/S0006-2952(03)00005-4; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gertsch J, 2004, FEBS LETT, V577, P563, DOI 10.1016/j.febslet.2004.10.064; Goel V, 2004, J CLIN PHARM THER, V29, P75, DOI 10.1111/j.1365-2710.2003.00542.x; Gouldson P, 2000, EUR J PHARMACOL, V401, P17, DOI 10.1016/S0014-2999(00)00439-8; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; Kaplan BLF, 2005, J LEUKOCYTE BIOL, V77, P966, DOI 10.1189/jlb.1104652; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; KLEIN TW, 1993, J PHARMACOL EXP THER, V267, P635; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Lograno MD, 2004, EUR J PHARMACOL, V494, P55, DOI 10.1016/j.ejphar.2004.04.039; LUNN CA, 2005, PHARM EXP THER, V316, P780; Makriyannis A, 2005, PROSTAG OTH LIPID M, V77, P210, DOI 10.1016/j.prostaglandins.2004.01.010; Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432-1033.2002.03078.x; Matthias A, 2005, LIFE SCI, V77, P2018, DOI 10.1016/j.lfs.2005.04.009; McAllister SD, 2003, J MED CHEM, V46, P5139, DOI 10.1021/jm0302647; McAllister SD, 2002, BIOCHEM PHARMACOL, V63, P2121, DOI 10.1016/S0006-2952(02)01031-6; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Oka S, 2005, J BIOL CHEM, V280, P18488, DOI 10.1074/jbc.M413260200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAROLARO D, 2002, CHEM PHYS LIPIDS, V108, P169; Percival SS, 2000, BIOCHEM PHARMACOL, V60, P155, DOI 10.1016/S0006-2952(99)00413-X; Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031; Raitio KH, 2005, CURR MED CHEM, V12, P1217, DOI 10.2174/0929867053764617; Randolph RK, 2003, EXP BIOL MED, V228, P1051, DOI 10.1177/153537020322800910; Rao GK, 2004, J LEUKOCYTE BIOL, V75, P884, DOI 10.1189/jlb.1203638; Rhee Man-Hee, 2002, J Vet Sci, V3, P179; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Sarfaraz S, 2005, CANCER RES, V65, P1635, DOI 10.1158/0008-5472.CAN-04-3410; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; Shire D, 1996, J BIOL CHEM, V271, P6941, DOI 10.1074/jbc.271.12.6941; Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Skapenko A, 2001, J IMMUNOL, V166, P4283, DOI 10.4049/jimmunol.166.7.4283; Song ZH, 1999, MOL PHARMACOL, V56, P834; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Turner RB, 2005, NEW ENGL J MED, V353, P341, DOI 10.1056/NEJMoa044441; Woelkart K, 2005, PLANTA MED, V71, P701, DOI 10.1055/s-2005-871290; Woelkart K, 2005, J CLIN PHARMACOL, V45, P683, DOI 10.1177/0091270004273493; Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511; Zoratti C, 2003, BRIT J PHARMACOL, V140, P1351, DOI 10.1038/sj.bjp.0705529	65	196	207	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14192	14206		10.1074/jbc.M601074200	http://dx.doi.org/10.1074/jbc.M601074200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547349	hybrid			2022-12-27	WOS:000237512300043
J	Lu, M; Gong, XG; Lu, YW; Guo, JJ; Wang, CH; Pan, YJ				Lu, M; Gong, XG; Lu, YW; Guo, JJ; Wang, CH; Pan, YJ			Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells - Inhibition cell proliferation through the Akt/p27(kip1) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; OXIDATIVE STRESS; ANGIOTENSIN-II; BETA-CAROTENE; BINDING; GLUTATHIONE; APOPTOSIS; DNA; OVEREXPRESSION; MITOCHONDRIA	In clinical oncology, many trials with superoxide dismutase (SOD) have failed to demonstrate antitumor ability and in many cases even caused deleterious effects because of low tumor-targeting ability. In the current research, the Nostoc commune Fe-SOD coding sequence was amplified from genomic DNA. In addition, the single chain variable fragment (ScFv) was constructed from the cDNA of an LC-1 hybridoma cell line secreting anti-lung adenocarcinoma monoclonal antibody. After modification, the SOD and ScFv were fused and co-expressed, and the resulting fusion protein produced SOD and LC-1 antibody activity. Tracing SOD-ScFv by fluorescein isothiocyanate and superoxide anions (O-2(-)) in SPC-A-1 cells showed that the fusion protein could recognize and enter SPC-A-1 cells to eliminate O-2(-). The lower oxidative stress resulting from the decrease in cellular O-2(-). delayed the cell cycle at G1 and significantly slowed SPC-A-1 cell growth in association with the dephosphorylation of the serine-threonine protein kinase Akt and expression of p27(kip1). The tumor-targeting fusion protein resulting from this research overcomes two disadvantages of SODs previously used in the clinical setting, the inability to target tumor cells or permeate the cell membrane. These findings lay the groundwork for development of an efficient antitumor drug targeted by the ScFv.	Zhejiang Univ, Inst Biochem, Hangzhou 310027, Peoples R China; Zhejiang Univ, Inst Chem Biol & Pharmaceut Chem, Hangzhou 310027, Peoples R China	Zhejiang University; Zhejiang University	Gong, XG (corresponding author), Zhejiang Univ, Inst Biochem, Hangzhou 310027, Peoples R China.	gongxg@zju.edu.cn; panyuanjiang@zju.edu.cn	lu, min/E-5407-2014					Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BRAVARD A, 1994, INT J CANCER, V59, P843, DOI 10.1002/ijc.2910590622; Delanian S, 2001, RADIOTHER ONCOL, V58, P325, DOI 10.1016/S0167-8140(00)00332-7; Deng TL, 2005, BIOCHEM BIOPH RES CO, V338, P748, DOI 10.1016/j.bbrc.2005.10.010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GE XR, 1989, ACTA BIOL EXP SINICA, V22, P359; Grunwaldt G, 2002, J PHOTOCH PHOTOBIO B, V67, P177, DOI 10.1016/S1011-1344(02)00323-8; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hruszkewycz A M, 1988, Basic Life Sci, V49, P449; JEFFREY SA, 2004, J BIOL CHEM, V48, P50420; Jubeh TT, 2005, MOL PHARMACEUT, V2, P2, DOI 10.1021/mp0499095; Kim CS, 1997, NUCLEIC ACIDS RES, V25, P1085, DOI 10.1093/nar/25.5.1085; Kim YC, 1999, GENE, V239, P129, DOI 10.1016/S0378-1119(99)00369-8; Kimura S, 2005, HYPERTENSION, V45, P438, DOI 10.1161/01.HYP.0000157169.27818.ae; KODAMA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P574, DOI 10.1016/0003-9861(87)90379-1; Lam EWN, 1997, CANCER RES, V57, P5550; Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719, DOI 10.1152/ajpgi.1999.276.3.G719; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; Lindsay MP, 2000, J CEREAL SCI, V31, P321, DOI 10.1006/jcrs.2000.0309; Lu Min, 2005, J Zhejiang Univ Sci B, V6, P832, DOI 10.1631/jzus.2005.B0832; Mahadevan B, 2001, CARCINOGENESIS, V22, P161, DOI 10.1093/carcin/22.1.161; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Mitchinson MJ, 1999, LANCET, V353, P381, DOI 10.1016/S0140-6736(05)74955-2; Nutt LK, 2005, CANCER BIOL THER, V4, P459; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; ORWAR O, 1995, ANAL CHEM, V67, P4261, DOI 10.1021/ac00119a010; OYANAGUI Y, 1991, BIOCHEM PHARMACOL, V42, P991, DOI 10.1016/0006-2952(91)90280-I; Palozza P, 2001, FREE RADICAL BIO MED, V30, P1000, DOI 10.1016/S0891-5849(01)00488-9; Paz-Miguel JE, 1999, J IMMUNOL, V163, P5399; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rengel RG, 2005, EUR J PHARM BIOPHARM, V60, P47, DOI 10.1016/j.ejpb.2004.12.002; Sawada GA, 1996, CYTOMETRY, V25, P254, DOI 10.1002/(SICI)1097-0320(19961101)25:3<254::AID-CYTO6>3.3.CO;2-3; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHWARZ M, 1984, CARCINOGENESIS, V5, P1663, DOI 10.1093/carcin/5.12.1663; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shi DY, 2003, FEBS LETT, V542, P60, DOI 10.1016/S0014-5793(03)00338-7; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; UNDARESAN M, 1995, SCIENCE, V270, P296; Venkataraman S, 2005, ONCOGENE, V24, P77, DOI 10.1038/sj.onc.1208145; WEFERS H, 1983, EUR J BIOCHEM, V137, P29, DOI 10.1111/j.1432-1033.1983.tb07791.x; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; XIE W, 1996, ACTA BIOL EXP SINICA, V29, P207; Zhang Y, 2002, CANCER RES, V62, P1205; Zimmerman MC, 2005, HYPERTENSION, V45, P717, DOI 10.1161/01.HYP.0000153463.22621.5e	55	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13620	13627		10.1074/jbc.M600523200	http://dx.doi.org/10.1074/jbc.M600523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551617	hybrid			2022-12-27	WOS:000237336600072
J	Yanofsky, SD; Shen, ES; Holden, F; Whitehorn, E; Aguilar, B; Tate, E; Holmes, CP; Scheuerman, R; MacLean, D; Wu, MM; Frail, DE; Lopez, FJ; Winneker, R; Arey, BJ; Barrett, RW				Yanofsky, SD; Shen, ES; Holden, F; Whitehorn, E; Aguilar, B; Tate, E; Holmes, CP; Scheuerman, R; MacLean, D; Wu, MM; Frail, DE; Lopez, FJ; Winneker, R; Arey, BJ; Barrett, RW			Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL ORGANIC-SYNTHESIS; EXTRACELLULAR DOMAIN CHIMERAS; LUCIFERASE REPORTER GENE; THYROTROPIN RECEPTOR; AMINO-ACIDS; IN-VIVO; BINDING; ANTAGONIST; SECRETION; DISCOVERY	The pituitary glycoprotein hormones, luteinizing hormone and follicle-stimulating hormone ( FSH), act through their cognate receptors to initiate a series of coordinated physiological events that results in germ cell maturation. Given the importance of FSH in regulating folliculogenesis and fertility, the development of FSH mimetics has been sought to treat infertility. Currently, purified and recombinant human FSH are the only FSH receptor ( FSH-R) agonists available for infertility treatment. By screening unbiased combinatorial chemistry libraries, using a cAMP-responsive luciferase reporter assay, we discovered thiazolidinone agonists ( EC50's = 20 mu M) of the human FSH-R. Subsequent analog library screening and parallel synthesis optimization resulted in the identification of a potent agonist ( EC50 = 2 nM) with full efficacy compared with FSH that was FSH-R-selective and -dependent. The compound mediated progesterone production in Y1 cells transfected with the human FSH-R ( EC50 = 980 nM) and estradiol production from primary rat ovarian granulosa cells ( EC50 = 10.5 nM). This and related compounds did not compete with FSH for binding to the FSH-R. Use of human FSH/thyroid-stimulating hormone ( TSH) receptor chimeras suggested a novel mechanism for receptor activation through a binding site independent of the natural hormone binding site. This study is the first report of a high affinity small molecule agonist that activates a glycoprotein hormone receptor through an allosteric mechanism. The small molecule FSH receptor agonists described here could lead to an oral alternative to the current parenteral FSH treatments used clinically to induce ovarian stimulation for both in vivo and in vitro fertilization therapy.	Affymax Inc, Palo Alto, CA 94304 USA; Wyeth Pharmaceut, Womens Hlth & Musculoskeletal Biol, Collegeville, PA 19426 USA	Pfizer	Yanofsky, SD (corresponding author), 3781 Nathan Way, Palo Alto, CA 94303 USA.	syanofsky@sbcglobal.net						AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; ALBANESE C, 1994, MOL CELL ENDOCRINOL, V101, P211, DOI 10.1016/0303-7207(94)90237-2; Arey BJ, 1997, MOL ENDOCRINOL, V11, P517, DOI 10.1210/me.11.5.517; Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004-1318; Arey BJ, 2002, ENDOCRINOLOGY, V143, P3822, DOI 10.1210/en.2002-220372; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Chappel S, 1998, HUM REPROD, V13, P18, DOI 10.1093/humrep/13.suppl_3.18; CHRISTOPHE S, 1993, BIOCHEM BIOPH RES CO, V196, P402, DOI 10.1006/bbrc.1993.2263; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; George SE, 1998, BIOCHEM PHARMACOL, V56, P25, DOI 10.1016/S0006-2952(98)00014-8; George SE, 1997, J NEUROCHEM, V69, P1278; GORDON EM, 1995, CURR OPIN BIOTECH, V6, P624, DOI 10.1016/0958-1669(95)80103-0; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Guo T, 2004, BIOORG MED CHEM LETT, V14, P1713, DOI 10.1016/j.bmcl.2004.01.042; Guo T, 2004, BIOORG MED CHEM LETT, V14, P1717, DOI 10.1016/j.bmcl.2004.01.043; HOLMES CP, 1995, J ORG CHEM, V60, P7328, DOI 10.1021/jo00127a044; HOLMES CP, 1995, J ORG CHEM, V60, P2318, DOI 10.1021/jo00113a004; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Koller KJ, 1997, ANAL BIOCHEM, V250, P51, DOI 10.1006/abio.1997.2190; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Maclean D, 2004, J COMB CHEM, V6, P196, DOI 10.1021/cc0300154; May LT, 2003, CURR OPIN PHARMACOL, V3, P551, DOI 10.1016/S1471-4892(03)00107-3; McDonnell J, 1998, BRIT J PHARMACOL, V125, P717, DOI 10.1038/sj.bjp.0702139; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; Ni ZJ, 1996, J MED CHEM, V39, P1601, DOI 10.1021/jm960043j; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; Stevis PE, 1999, ENDOCRINE, V10, P153, DOI 10.1385/ENDO:10:2:153; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; VASSART G, 1991, TRENDS ENDOCRIN MET, V2, P151, DOI 10.1016/1043-2760(91)90006-9; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	39	60	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13226	13233		10.1074/jbc.M600601200	http://dx.doi.org/10.1074/jbc.M600601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540466	hybrid			2022-12-27	WOS:000237336600028
J	Harada, K; Okiyoneda, T; Hashimoto, Y; Ueno, K; Nakamura, K; Yamahira, K; Sugahara, T; Shuto, T; Wada, I; Suico, MA; Kai, H				Harada, K; Okiyoneda, T; Hashimoto, Y; Ueno, K; Nakamura, K; Yamahira, K; Sugahara, T; Shuto, T; Wada, I; Suico, MA; Kai, H			Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; CFTR; DEGRADATION; DELTA-F508; PROTEASOME; CALNEXIN; CHAPERONE; GOLGI	Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl- channel at the plasma membrane, and its malfunction results in cystic fibrosis, the most common lethal genetic disease in Caucasians. Quality control of CFTR is strictly regulated by several molecular chaperones. Here we show that calreticulin (CRT), which is a lectin-like chaperone in the endoplasmic reticulum (ER), negatively regulates the cell surface CFTR. RNA interference- based CRT knockdown induced the increase of CFTR expression. Consistently, this effect was observed in vivo. CRT heterozygous (CRT+/-) mice had a higher endogenous expression of CFTR than the wild-type mice. Moreover, CRT overexpression induced cell surface expression of CRT, and it significantly decreased the cell surface expression and function of CFTR. CRT overexpression destabilized the cell surface CFTR by enhancing endocytosis, leading to proteasomal degradation. Deletion of the carboxyl domain of CRT, which results in its ER export, increased the negative effect and enhanced the interaction with CFTR. Thus, CRT in the post-ER compartments may act as a negative regulator of the cell surface CFTR.	Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Pediat, Kumamoto 8620973, Japan; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan	Kumamoto University; Kumamoto University; Fukushima Medical University	Kai, H (corresponding author), Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan.	hirokai@gpo.kumamoto-u.ac.jp		, Kimitoshi/0000-0003-4903-2428; Okiyoneda, Tsukasa/0000-0002-5175-2224; Wada, Ikuo/0000-0001-5668-6994				Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Cantin AM, 2006, AM J PHYSIOL-CELL PH, V290, pC262, DOI 10.1152/ajpcell.00070.2005; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Flores-Diaz M, 2004, J BIOL CHEM, V279, P21724, DOI 10.1074/jbc.M312791200; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Ihara Y, 2005, BIOCHEM BIOPH RES CO, V329, P1343, DOI 10.1016/j.bbrc.2005.02.112; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lukacs GL, 1997, BIOCHEM J, V328, P353; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; Okiyoneda T, 2004, J PHARMACOL SCI, V95, P471, DOI 10.1254/jphs.SC0040081; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Okiyoneda T, 2002, FEBS LETT, V526, P87, DOI 10.1016/S0014-5793(02)03134-4; PIND S, 1994, J BIOL CHEM, V269, P12784; Popescu CI, 2005, J BIOL CHEM, V280, P13833, DOI 10.1074/jbc.M413087200; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	44	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12841	12848		10.1074/jbc.M512975200	http://dx.doi.org/10.1074/jbc.M512975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527813	hybrid			2022-12-27	WOS:000237134700079
J	Li, HT; Liu, XP; Cui, HM; Chen, YR; Chen, YR; Cardounel, AJ; Zweier, JL				Li, HT; Liu, XP; Cui, HM; Chen, YR; Chen, YR; Cardounel, AJ; Zweier, JL			Characterization of the mechanism of cytochrome p450 reductase-cytochrome p450-mediated nitric oxide and nitrosothiol generation from organic nitrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERYL TRINITRATE BIOTRANSFORMATION; AORTIC GUANYLYL CYCLASE; XANTHINE-OXIDASE; DIPHENYLENEIODONIUM SULFATE; S-NITROSOTHIOLS; C REDUCTASE; GLUTATHIONE TRANSFERASE; PHARMACOLOGICAL ACTIONS; FLAVOPROTEIN INHIBITOR; BIOLOGICAL-SYSTEMS	Mammalian cytochrome P450 reductase (CPR) and cytochrome P450 (CP) play important roles in organic nitrate bioactivation; however, the mechanism by which they convert organic nitrate to NO remains unknown. Questions remain regarding the initial precursor of NO that serves to link organic nitrate to the activation of soluble guanylyl cyclase (sGC). To characterize the mechanism of CPR-CP-mediated organic nitrate bioactivation, EPR, chemiluminescence NO analyzer, NO electrode, and immunoassay studies were performed. With rat hepatic microsomes or purified CPR, the presence of NADPH triggered organic nitrate reduction to NO2-. The CPR flavin site inhibitor diphenyleneiodonium inhibited this NO2- generation, whereas the CP inhibitor clotrimazole did not. However, clotrimazole greatly inhibited NO2--dependent NO generation. Therefore, CPR catalyzes organic nitrate reduction, producing nitrite, whereas CP can mediate further nitrite reduction to NO. Nitrite-dependent NO generation contributed < 10% of the CPR-CP-mediated NO generation from organic nitrates; thus, NO2- is not the main precursor of NO. CPR-CP-mediated NO generation was largely thiol-dependent. Studies suggested that organic nitrite (R-O-NO) was produced from organic nitrate reduction by CPR. Further reaction of organic nitrite with free or microsome-associated thiols led to NO or nitrosothiol generation and thus stimulated the activation of sGC. Thus, organic nitrite is the initial product in the process of CRP-CP-mediated organic nitrate activation and is the precursor of NO and nitrosothiols, serving as the link between organic nitrate and sGC activation.	Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst 110G, Ctr Biomed EPR Spect & Imaging, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Div Cardiovasc Med, Dept Internal Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst 110G, Ctr Biomed EPR Spect & Imaging, 473 W 12th Ave, Columbus, OH 43210 USA.	jay.zweier@osumc.edu	Liu, Xiaoping/A-4516-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, P01HL065608, R01HL063744, R29HL038324, R01HL083237] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL083237, HL65608, HL63744, HL38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BENNETT BM, 1992, J PHARMACOL EXP THER, V261, P716; BENNETT BM, 1994, TRENDS PHARMACOL SCI, V15, P245, DOI 10.1016/0165-6147(94)90319-0; BORNFELDT KE, 1987, PHARMACOL TOXICOL, V60, P110, DOI 10.1111/j.1600-0773.1987.tb01507.x; BURGER IH, 1971, BIOCHEM J, V123, pP9; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; DELAFORGE M, 1993, CHEM-BIOL INTERACT, V86, P103, DOI 10.1016/0009-2797(93)90115-F; Doel JJ, 2001, BBA-GEN SUBJECTS, V1527, P81, DOI 10.1016/S0304-4165(01)00148-9; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; DUTHU GS, 1979, DRUG METAB DISPOS, V7, P263; FEELISCH M, 1992, BIOCHEM PHARMACOL, V44, P1149, DOI 10.1016/0006-2952(92)90379-W; Feelisch M, 1999, MOL PHARMACOL, V56, P243, DOI 10.1124/mol.56.2.243; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Grosser N, 2000, BIOCHEM BIOPH RES CO, V274, P255, DOI 10.1006/bbrc.2000.3121; HORECKER BL, 1950, ARCH BIOCHEM, V29, P232; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; Ji YB, 1996, BIOCHEM J, V313, P377, DOI 10.1042/bj3130377; KOWALUK EA, 1993, DRUG METAB DISPOS, V21, P967; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lee WI, 2003, NITRIC OXIDE-BIOL CH, V8, P103, DOI 10.1016/S1089-8603(02)00183-0; Li HT, 2004, J BIOL CHEM, V279, P16939, DOI 10.1074/jbc.M314336200; Li HT, 2005, J BIOL CHEM, V280, P16594, DOI 10.1074/jbc.M411905200; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; LIU ZG, 1993, J PHARMACOL EXP THER, V264, P1432; LIU ZG, 1992, EUR J PHARMACOL, V211, P129, DOI 10.1016/0014-2999(92)90275-9; MCDONALD BJ, 1994, CAN J PHYSIOL PHARM, V72, P1513, DOI 10.1139/y94-217; MCDONALD BJ, 1993, BIOCHEM PHARMACOL, V45, P268, DOI 10.1016/0006-2952(93)90403-J; MCDONALD BJ, 1990, CAN J PHYSIOL PHARM, V68, P1552, DOI 10.1139/y90-236; MCGUIRE JJ, 1994, J PHARMACOL EXP THER, V271, P708; McGuire JJ, 1998, BIOCHEM PHARMACOL, V56, P881, DOI 10.1016/S0006-2952(98)00216-0; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; MELLION BT, 1983, MOL PHARMACOL, V23, P653; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MEYER DJ, 1994, FEBS LETT, V351, P427, DOI 10.1016/0014-5793(94)00904-X; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; RAIKHMAN L M, 1971, Biofizika, V16, P1135; Ratz JD, 2000, J PHARMACOL EXP THER, V293, P569; Ratz JD, 1999, BRIT J PHARMACOL, V126, P61, DOI 10.1038/sj.bjp.0702268; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROMANIN C, 1988, J MOL CELL CARDIOL, V20, P389, DOI 10.1016/S0022-2828(88)80130-5; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; SCHNEEWEISS A, 1990, ADV NITRATE THERAPY, P155; SERVENT D, 1989, BIOCHEM BIOPH RES CO, V163, P1210, DOI 10.1016/0006-291X(89)91106-6; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Tiravanti E, 2004, J BIOL CHEM, V279, P11065, DOI 10.1074/jbc.M311908200; Vanin AF, 2000, BBA-GEN SUBJECTS, V1474, P365, DOI 10.1016/S0304-4165(00)00033-7; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wong PSY, 1999, DRUG METAB DISPOS, V27, P502; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Yuan R, 1997, J PHARMACOL EXP THER, V281, P1499; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	60	61	63	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12546	12554		10.1074/jbc.M511803200	http://dx.doi.org/10.1074/jbc.M511803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527817	hybrid			2022-12-27	WOS:000237134700043
J	Peterson, YK; Kelly, P; Weinbaum, CA; Casey, PJ				Peterson, YK; Kelly, P; Weinbaum, CA; Casey, PJ			A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-RNA REPLICATION; RHO-GTPASES; FARNESYLTRANSFERASE INHIBITORS; CANCER; CELLS; GERANYLGERANYLATION; PRENYLATION; FARNESYL; RAS; APOPTOSIS	Inhibiting protein prenylation is an attractive means to modulate cellular processes controlled by a variety of signaling proteins, including oncogenic proteins such as Ras and Rho GTPases. The largest class of prenylated proteins contain a so-called CaaX motif at their carboxyl termini and are subject to a maturation process initiated by the attachment of an isoprenoid lipid by either protein farnesyltransferase ( FTase) or protein geranylgeranyltransferase type I ( GGTase-I). Inhibitors of FTase, termed FTIs, have been the subject of intensive development in the past decade and have shown efficacy in clinical trials. Although GGTase-I inhibitors (GGTIs) have received less attention, accumulating evidence suggests GGTIs may augment therapies using FTIs and could be useful to treat a myriad of additional disease states. Here we describe the characterization of a selective, highly potent, and cell-active GGTase-I inhibitor, GGTI-DU40. Kinetic analysis revealed that inhibition by GGTI-DU40 is competitive with the protein substrate and uncompetitive with the isoprenoid substrate; the K-i for the inhibition is 0.8 nM. GGTI-DU40 is highly selective for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDAMB-231 breast cancer cells with GGTI-DU40 inhibited thrombin-induced cell rounding via a process that involves inhibition of Rho proteins without significantly effecting parallel mobilization of calcium via G beta gamma. These studies establish GGTI-DU40 as a prime tool for interrogating biologies associated with protein geranylgeranylation and define a novel structure for this emerging class of experimental therapeutics.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Baron Rudi A., 2004, BMC Biochemistry, V5, P19, DOI 10.1186/1471-2091-5-19; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; Carrico D, 2005, BIOORGAN MED CHEM, V13, P677, DOI 10.1016/j.bmc.2004.10.053; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Einav S, 2003, J ANTIMICROB CHEMOTH, V52, P883, DOI 10.1093/jac/dkg490; Fiordalisi JJ, 2003, J BIOL CHEM, V278, P41718, DOI 10.1074/jbc.M305733200; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Karp J. E., 2004, Annals of Hematology, V83, pS87; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Morgan MA, 2003, LEUKEMIA, V17, P1508, DOI 10.1038/sj.leu.2403022; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Sivakumar B, 2004, JAMA-J AM MED ASSOC, V292, P972, DOI 10.1001/jama.292.8.972; Smith V, 2002, CLIN CANCER RES, V8, P2002; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Sun JZ, 2003, CANCER RES, V63, P8922; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	50	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12445	12450		10.1074/jbc.M600168200	http://dx.doi.org/10.1074/jbc.M600168200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517596	hybrid			2022-12-27	WOS:000237134700031
J	Rosen, KM; Veereshwarayya, V; Moussa, CEH; Fu, QH; Goldberg, MS; Schlossmacher, MG; Shen, J; Querfurth, HW				Rosen, KM; Veereshwarayya, V; Moussa, CEH; Fu, QH; Goldberg, MS; Schlossmacher, MG; Shen, J; Querfurth, HW			Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOSITIS; ENDOPLASMIC-RETICULUM STRESS; PRECURSOR PROTEIN; ALPHA-SYNUCLEIN; OXIDATIVE DAMAGE; GENE; ALZHEIMERS; DISEASE; PROTEASOME; UBIQUITIN	Mutations in the ubiquitin ligase-encoding Parkin gene have been implicated in the pathogenesis of autosomal recessive Parkinson disease. Outside of the central nervous system, Parkin is prominently expressed in skeletal muscle. We have found accumulations of Parkin protein in skeletal muscle biopsies taken from patients with inclusion body myositis, a degenerative disorder in which intramyofiber accumulations of the beta-amyloid peptide are pathognomonic. In comparing primary cultures of skeletal muscle derived from parkin knock-out and wild-type mice, we have found the absence of parkin to result in greater sensitivity to mitochondrial stressors rotenone and carbonyl cyanide 3-chlorophenylhydrazone, without any alteration in sensitivity to calcium ionophore or hydrogen peroxide. Utilizing viral expression constructs coding for the Alzheimer disease and inclusion body myositis-linked beta-amyloid precursor protein and for its metabolic byproducts A beta 42 and C100, we found that parkin knock-out muscle cells are also more sensitive to the toxic effects of intracellular A beta. We also constructed a lentiviral system to overexpress wild-type Parkin and have shown that boosting the levels of parkin expression in normal skeletal muscle cultures provides substantial protection against both mitochondrial toxins and overexpressed beta-amyloid. Correspondingly, exogenous Parkin significantly lowered A beta levels. These data support the hypothesis that in myocytes parkin has dual properties in the maintenance of skeletal muscle mitochondrial homeostasis and in the regulation of A beta levels.	Tufts Univ, Dept Neurol, Caritas St Elizabeths Med Ctr, Sch Med, Boston, MA 02135 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rosen, KM (corresponding author), Tufts Univ, Dept Neurol, Caritas St Elizabeths Med Ctr, Sch Med, 736 Cambridge St, Boston, MA 02135 USA.	kenneth_rosen@cchcs.org; henry.querfurth@tufts.edu	Goldberg, Matthew/T-7827-2019	Goldberg, Matthew/0000-0002-5172-9841; Schlossmacher, Michael/0000-0002-0394-0300	NINDS NIH HHS [NS041373] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041373] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q; Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002; Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314; Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012; Askanas Valerie, 1995, Current Opinion in Rheumatology, V7, P486, DOI 10.1097/00002281-199511000-00005; Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Dachsel JC, 2005, FEBS LETT, V579, P3913, DOI 10.1016/j.febslet.2005.06.003; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X; Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2005, HUM MOL GENET, V14, P799, DOI 10.1093/hmg/ddi074; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Johnstone EM, 1996, BIOCHEM BIOPH RES CO, V220, P710, DOI 10.1006/bbrc.1996.0469; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Mattson MP, 2002, INT REV NEUROBIOL, V53, P387; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Ohyagi Y, 2000, NEUROREPORT, V11, P167, DOI 10.1097/00001756-200001170-00033; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Pramstaller PP, 2005, ANN NEUROL, V58, P411, DOI 10.1002/ana.20587; Querfurth HW, 2001, MOL CELL NEUROSCI, V17, P793, DOI 10.1006/mcne.2001.0972; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011; Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599; Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Ved R, 2005, J BIOL CHEM, V280, P42655, DOI 10.1074/jbc.M505910200; von Coelln R, 2004, CELL TISSUE RES, V318, P175, DOI 10.1007/s00441-004-0924-4; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; West AB, 2002, HUM MOL GENET, V11, P2787, DOI 10.1093/hmg/11.22.2787; Wilczynski GM, 2000, AM J PATHOL, V156, P1835, DOI 10.1016/S0002-9440(10)65056-0; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	59	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12809	12816		10.1074/jbc.M512649200	http://dx.doi.org/10.1074/jbc.M512649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517603	hybrid			2022-12-27	WOS:000237134700075
J	Totzke, G; Essmann, F; Pohlmann, S; Lindenblatt, C; Janicke, RU; Schulze-Osthoff, K				Totzke, G; Essmann, F; Pohlmann, S; Lindenblatt, C; Janicke, RU; Schulze-Osthoff, K			A novel member of the I kappa B family, human I kappa B-zeta, inhibits transactivation of p65 and its DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOPROTEIN BCL-3; GENE-EXPRESSION; INDUCED APOPTOSIS; TUMOR-CELLS; CYCLIN D1; PROTEIN; RECEPTOR; ALPHA; ACTIVATION; PHOSPHORYLATION	A novel member of the I kappa B family, human I kappa B-zeta, was identified by a differential screening approach of apoptosis-sensitive and -resistant tumor cells. The protein consists of 6 ankyrin repeats at its COOH terminus and shares about 30% identity with other I kappa B members. I kappa B-zeta associates with both the p65 and p50 subunit of NF-kappa B and inhibits the transcriptional activity as well as the DNA binding of the transcription factor. Interestingly, I kappa B-zeta is localized in the nucleus where it aggregates in matrix-associated deacetylase bodies, indicating that I kappa B-zeta regulates nuclear NF-kappa B activity rather than its nuclear translocation from the cytoplasm. I kappa B-zeta expression itself was regulated by NF-kappa B, suggesting that its activity is controlled in a negative feedback loop. Unlike classical I kappa B proteins, I kappa B-zeta was not degraded upon cell stimulation. Treatment with tumor necrosis factor-alpha, interleukin-1 beta, and lipopolysaccharide induced a strong induction of I kappa B-zeta transcripts. Expression of I kappa B-zeta was detected in different tissues including lung, liver, and in leukocytes but not in the brain. Suppression of endogenous I kappa B-zeta by RNA interference rendered cells more resistant to apoptosis, whereas overexpression of I kappa B-zeta was sufficient to induce cell death. Our results, therefore, suggest that I kappa B-zeta functions as an additional regulator of NF-kappa B activity and, hence, provides another control level for the activation of NF-kappa B-dependent target genes.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456				ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; Eto A, 2003, BIOCHEM BIOPH RES CO, V301, P495, DOI 10.1016/S0006-291X(02)03082-6; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hirotani T, 2005, J IMMUNOL, V174, P3650, DOI 10.4049/jimmunol.174.6.3650; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Motoyama M, 2005, J BIOL CHEM, V280, P7444, DOI 10.1074/jbc.M412738200; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Stier S, 2000, FEBS LETT, V467, P299, DOI 10.1016/S0014-5793(00)01177-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	56	78	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12645	12654		10.1074/jbc.M511956200	http://dx.doi.org/10.1074/jbc.M511956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513645	hybrid			2022-12-27	WOS:000237134700055
J	Jastrzebska, B; Fotiadis, D; Jang, GF; Stenkamp, RE; Engel, A; Palczewski, K				Jastrzebska, B; Fotiadis, D; Jang, GF; Stenkamp, RE; Engel, A; Palczewski, K			Functional and structural characterization of rhodopsin oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TANDEM MASS-SPECTROMETRY; DRIVEN FRAGMENTATION PROCESSES; ENERGY COLLISIONAL ACTIVATION; FATTY-ACIDS; TRANSDUCIN ACTIVATION; LITHIATED ADDUCTS; DIMERS; SOLUBILIZATION; DISSOCIATION	A major question in G protein-coupled receptor signaling concerns the quaternary structure required for signal transduction. Do these transmembrane receptors function as monomers, dimers, or larger oligomers? We have investigated the oligomeric state of the model G protein-coupled receptor rhodopsin (Rho), which absorbs light and initiates a phototransduction-signaling cascade that forms the basis of vision. In this study, different forms of Rho were isolated using gel filtration techniques in mild detergents, including n-dodecyl-beta-D-maltoside, n-tetradecyl-beta-D-maltoside, and n-hexadecyl-beta-D-maltoside. The quaternary structure of isolated Rho was determined by transmission electron microscopy, demonstrating that in micelles containing n-dodecyl-beta-D-maltoside, Rho exists as a mixture of monomers and dimers whereas in n-tetradecyl-beta-D-maltoside and n-hexadecyl-beta-D-maltoside Rho forms higher ordered structures. Especially in n-hexadecyl-beta-D-maltoside, most of the particles are present in tightly packed rows of dimers. The oligomerization of Rho seems to be important for interaction with its cognate G protein, transducin. Although the activated Rho (Meta II) monomer or dimers are capable of activating the G protein, transducin, the activation process is much faster when Rho exists as organized dimers. Our studies provide direct comparisons between signaling properties of Meta II in different quaternary complexes.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Case Sch Med, Cleveland, OH 44106 USA; Univ Basel, ME Muller Inst Microscopy, Biozentrum, CH-4056 Basel, Switzerland; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA	Case Western Reserve University; University of Basel; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, Case Sch Med, BRB Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu			NATIONAL EYE INSTITUTE [P30EY001730, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Griffiths WJ, 2003, MASS SPECTROM REV, V22, P81, DOI 10.1002/mas.10046; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Herrick-Davis K, 2005, J BIOL CHEM, V280, P40144, DOI 10.1074/jbc.M507396200; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P892, DOI 10.1016/S1044-0305(00)00159-8; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P797, DOI 10.1016/S1044-0305(00)00151-3; Hsu FF, 1999, J AM SOC MASS SPECTR, V10, P600, DOI 10.1016/S1044-0305(99)00041-0; Hsu FF, 2001, J AM SOC MASS SPECTR, V12, P61, DOI 10.1016/S1044-0305(00)00194-X; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P986, DOI 10.1016/S1044-0305(00)00172-0; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; Moritz OL, 2001, J BIOL CHEM, V276, P28242, DOI 10.1074/jbc.M101476200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Park PSH, 2005, P NATL ACAD SCI USA, V102, P8793, DOI 10.1073/pnas.0504016102; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; Pulfer MK, 2004, J AM SOC MASS SPECTR, V15, P194, DOI 10.1016/j.jasms.2003.10.011; STUBBS GW, 1978, BIOCHEMISTRY-US, V17, P215, DOI 10.1021/bi00595a003; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; WHITE DC, 1995, SIGNATURE LIPID BIOM, P255	41	120	124	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11917	11922		10.1074/jbc.M600422200	http://dx.doi.org/10.1074/jbc.M600422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495215	Green Accepted, hybrid			2022-12-27	WOS:000236988100060
J	Menant, A; Baudouin-Cornu, P; Peyraud, C; Tyers, M; Thomas, D				Menant, A; Baudouin-Cornu, P; Peyraud, C; Tyers, M; Thomas, D			Determinants of the ubiquitin-mediated degradation of the Met4 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SULFUR METABOLISM; GENE-EXPRESSION; PROTEIN; YEAST; ACTIVATION; PROTEOLYSIS; METHIONINE; BIOSYNTHESIS; ASSIMILATION	In yeast, the Met4 transcription factor and its cofactors Cbf1, Met28, Met31, and Met32 control the expression of sulfur metabolism and oxidative stress response genes. Met4 activity is tuned to nutrient and oxidative stress conditions by the SCFMet30 ubiquitin ligase. The mechanism whereby SCFMet30-dependent ubiquitylation of Met4 controls Met4 activity remains contentious. Here, we have demonstrated that intracellular cysteine levels dictate the degradation of Met4 in vivo, as shown by the ability of cysteine, but not methionine or S-adenosylmethionine ( AdoMet), to trigger Met4 degradation in an str4 Delta strain, which lacks the ability to produce cysteine from methionine or AdoMet. Met4 degradation requires its nuclear localization and activity of the 26 S proteasome. Analysis of the regulated degradation of a fully functional Met4-Cbf1 chimera, in which Met4 is fused to the DNA binding domain of Cbf1, demonstrates that elimination of Met4 in vivo can be triggered independently of both its normal protein interactions. Strains that harbor the Met4-Cbf1 fusion as the only source of Cbf1 activity needed for proper kinetochore function exhibit high rates of methionine-dependent chromosomal instability. We suggest that SCFMet30 activity or Met4 utilization as a substrate may be directly regulated by intracellular cysteine concentrations.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Cytom Syst SA, F-91190 Gif Sur Yvette, France; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Thomas, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	dthomas@cytomics.fr	Tyers, Michael/ABE-3194-2021	Baudouin-Cornu, Peggy/0000-0001-7296-099X				BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; Barbey R, 2005, EMBO J, V24, P521, DOI 10.1038/sj.emboj.7600556; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brunson LE, 2004, J BIOL CHEM, V279, P6674, DOI 10.1074/jbc.M308875200; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHEREST H, 1973, J BACTERIOL, V115, P1084, DOI 10.1128/JB.115.3.1084-1093.1973; CHEREST H, 1992, GENETICS, V130, P51; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jamieson D, 2002, NAT GENET, V31, P228, DOI 10.1038/ng0702-228; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kent NA, 2004, J BIOL CHEM, V279, P27116, DOI 10.1074/jbc.M403818200; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P419; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; Lafaye A, 2005, J BIOL CHEM, V280, P24723, DOI 10.1074/JBC.M502285200; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; MASISON DC, 1993, NUCLEIC ACIDS RES, V21, P4133, DOI 10.1093/nar/21.17.4133; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pocsi I, 2004, ADV MICROB PHYSIOL, V49, P1, DOI 10.1016/S0065-2911(04)49001-8; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Wheeler GL, 2003, J BIOL CHEM, V278, P49920, DOI 10.1074/jbc.M310156200; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Yen JL, 2005, MOL BIOL CELL, V16, P1872, DOI 10.1091/mbc.E04-12-1130	53	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11744	11754		10.1074/jbc.M600037200	http://dx.doi.org/10.1074/jbc.M600037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497670	hybrid			2022-12-27	WOS:000236988100039
J	Sutherland, CM; Moretti, PAB; Hewitt, NM; Bagley, CJ; Vadas, MA; Pitson, SM				Sutherland, CM; Moretti, PAB; Hewitt, NM; Bagley, CJ; Vadas, MA; Pitson, SM			The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; TARGET RECOGNITION; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; HUMAN MACROPHAGES; CELL-MIGRATION; ACTIVATION; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; RECEPTOR	Sphingosine kinases catalyze the formation of sphingosine 1-phosphate, a bioactive lipid involved in many aspects of cellular regulation, including the fundamental biological processes of cell growth and survival. A diverse range of cell agonists induce activation of human sphingosine kinase 1 (hSK1) and, commonly, its translocation to the plasma membrane. Although the activation of hSK1 in response to at least some agonists occurs directly via its phosphorylation at Ser(225) by ERK1/2, many aspects governing the regulation of this phosphorylation and subsequent translocation remain unknown. Here, in an attempt to understand some of these processes, we have examined the known interaction of hSK1 with calmodulin (CaM). By using a combination of limited proteolysis, peptide interaction analysis, and site-directed mutagenesis, we have identified that the CaM-binding site of hSK1 resides in the region spanned by residues 191 - 206. Specifically, Phe(197) and Leu(198) are critically involved in the interaction because a version of hSK1 incorporating mutations of both Phe(197) --> Ala and Leu(198) --> Gln failed to bind CaM. We have also shown for the first time that human sphingosine kinase 2 (hSK2) binds CaM, and does so via a CaM binding region that is conserved with hSK1 because comparable mutations in hSK2 also ablate CaM binding to this protein. By using the CaM-binding-deficient version of hSK1, we have begun to elucidate the role of CaM in hSK1 regulation by demonstrating that disruption of the CaM-binding site ablates agonist-induced translocation of hSK1 from the cytoplasm to the plasma membrane, while having no effect on hSK1 phosphorylation and catalytic activation.	Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Pitson, SM (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@imvs.sa.gov.au	Vadas, Mathew/R-1378-2019; Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740				Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; Blom T, 2005, CELL SIGNAL, V17, P827, DOI 10.1016/j.cellsig.2004.11.022; Censarek P, 2002, BIOCHEMISTRY-US, V41, P8598, DOI 10.1021/bi025681k; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Li CJ, 1999, J CELL SCI, V112, P1567; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mastrandrea LD, 2005, DIABETES, V54, P1429, DOI 10.2337/diabetes.54.5.1429; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pitson SM, 2001, FEBS LETT, V509, P169; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Thompson CR, 2005, J IMMUNOL, V174, P3551, DOI 10.4049/jimmunol.174.6.3551; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Yokota S, 2004, FEBS LETT, V578, P106, DOI 10.1016/j.febslet.2004.10.081; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	52	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11693	11701		10.1074/jbc.M601042200	http://dx.doi.org/10.1074/jbc.M601042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522638	hybrid			2022-12-27	WOS:000236988100033
J	Gesty-Palmer, D; Chen, MY; Reiter, E; Ahn, S; Nelson, CD; Wang, ST; Eckhardt, AE; Cowan, CL; Spurney, RF; Luttrell, LM; Lefkowitz, RJ				Gesty-Palmer, D; Chen, MY; Reiter, E; Ahn, S; Nelson, CD; Wang, ST; Eckhardt, AE; Cowan, CL; Spurney, RF; Luttrell, LM; Lefkowitz, RJ			Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; COUPLED RECEPTOR; INDEPENDENT FUNCTIONS; ADRENERGIC-RECEPTOR; KIDNEY-CELLS; PEPTIDE; PTH; BONE; DESENSITIZATION; INTERMITTENT	Parathyroid hormone (PTH) regulates calcium homeostasis via the type I PTH/PTH-related peptide (PTH/PTHrP) receptor (PTH1R). The purpose of the present study was to identify the contributions of distinct signaling mechanisms to PTH-stimulated activation of the mitogen-activated protein kinases (MAPK) ERK1/2. In Human embryonic kidney 293 (HEK293) cells transiently transfected with hPTH1R, PTH stimulated a robust increase in ERK activity. The time course of ERK1/2 activation was biphasic with an early peak at 10 min and a later sustained ERK1/2 activation persisting for greater than 60 min. Pretreatment of HEK293 cells with the PKA inhibitor H89 or the PKC inhibitor GF109203X, individually or in combination reduced the early component of PTH-stimulated ERK activity. However, these inhibitors of second messenger dependent kinases had little effect on the later phase of PTH-stimulated ERK1/2 phosphorylation. This later phase of ERK1/2 activation at 30-60 min was blocked by depletion of cellular beta-arrestin 2 and beta-arrestin 1 by small interfering RNA. Furthermore, stimulation of hPTH1R with PTH analogues, [Trp(1)] PTHrp-(1-36) and [D-Trp(12), Tyr(34)] PTH-(7-34), selectively activated G(s)/PKA-mediated ERK1/2 activation or G protein-independent/beta-arrestin-dependent ERK1/2 activation, respectively. It is concluded that PTH stimulates ERK1/2 through several distinct signal transduction pathways: an early G protein-dependent pathway meditated by PKA and PKC and a late pathway independent of G proteins mediated through beta-arrestins. These findings imply the existence of distinct active conformations of the hPTH1R responsible for the two pathways, which can be stimulated by unique ligands. Such ligands may have distinct and valuable therapeutic properties.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA; INRA, F-37380 Nouzilly, France; Xsira Pharmaceut, Morrisville, NC 27709 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; INRAE; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL70631, HL16037] Funding Source: Medline; NICHD NIH HHS [HD043446] Funding Source: Medline; NIDDK NIH HHS [DK64353] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043446] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070631, R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004-1282; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; Garcia-Ocana A, 1998, LIFE SCI, V62, P2267, DOI 10.1016/S0024-3205(98)00207-0; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUTKIND JS, 2000, SCI STKE, V40, P11; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Lederer ED, 2000, J AM SOC NEPHROL, V11, P222, DOI 10.1681/ASN.V112222; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Stalheim L, 2005, MOL PHARMACOL, V67, P78, DOI 10.1124/mol.104.006072; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	47	357	369	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10856	10864		10.1074/jbc.M513380200	http://dx.doi.org/10.1074/jbc.M513380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492667	hybrid, Green Submitted			2022-12-27	WOS:000236822200025
J	Tanaka, H; Katoh, H; Negishi, M				Tanaka, H; Katoh, H; Negishi, M			Pragmin, a novel effector of Rnd2 GTPase, stimulates RhoA activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; KINASE ROK-ALPHA; PC12 CELLS; NEURITE RETRACTION; FOCAL ADHESIONS; FAMILY GTPASES; REORGANIZATION; OUTGROWTH; RAC	The Rho family of small GTPases has been implicated in the reorganization of actin cytoskeleton and subsequent morphological changes in various cells. Rnd2 is a member of the Rnd subfamily, comprising Rnd1, Rnd2, and Rnd3. In contrast to Rnd1 and Rnd3, displaying an antagonistic action for RhoA signaling, signaling pathways of Rnd2 are not well known. Here we have performed a yeast two-hybrid screen using Rnd2 as bait and identified a novel Rnd2 effector protein, predominantly expressed in neurons, including cortical and hippocampal neurons. We named it Pragmin (pragma of Rnd2). In in vivo and in vitro binding assays, Pragmin specifically binds to Rnd2 among the Rho family GTPases in a GTP-dependent manner. Rnd2-bound Pragmin significantly stimulates RhoA activity and induces cell contraction through RhoA and the Rho-kinase pathway in HeLa cells. In PC12 cells, expressing Pragmin inhibits nerve growth factor-induced neurite outgrowth in response to Rnd2, and knock-down of Pragmin by Pragmin-specific small interfering RNA enhances neurite elongation. Therefore, Rnd2 regulates neurite outgrowth by functioning as the RhoA activator through Pragmin, in contrast to Rnd1 and Rnd3 inhibiting RhoA signaling.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp		Katoh, Hironori/0000-0002-8191-8117	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Decourt B, 2005, DEV BRAIN RES, V159, P36, DOI 10.1016/j.devbrainres.2005.06.013; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harada A, 2005, J BIOL CHEM, V280, P18418, DOI 10.1074/jbc.M411356200; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Leung T, 1996, MOL CELL BIOL, V16, P5313; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	38	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10355	10364		10.1074/jbc.M511314200	http://dx.doi.org/10.1074/jbc.M511314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481321	hybrid			2022-12-27	WOS:000236594300064
J	Cemazar, M; Daly, NL; Haggblad, S; Lo, KP; Yulyaningsih, E; Craik, DJ				Cemazar, M; Daly, NL; Haggblad, S; Lo, KP; Yulyaningsih, E; Craik, DJ			Knots in rings - The circular knotted protein momordica cochinchinensis trypsin inhibitor-II folds via a stable two-disulfide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTINE KNOT; THERMODYNAMIC STABILITY; EETI-II; MOTIF; PRINCIPLES; DIVERSITY; PATHWAYS; FAMILY; PLANT	The aim of this work was to elucidate the oxidative folding mechanism of the macrocyclic cystine knot protein MCoTI-II. We aimed to investigate how the six-cysteine residues distributed on the circular backbone of the reduced unfolded peptide recognize their correct partner and join up to form a complex cystine-knotted topology. To answer this question, we studied the oxidative folding of the naturally occurring peptide using a range of spectroscopic methods. For both oxidative folding and reductive unfolding, the same disulfide intermediate species was prevalent and was characterized to be a native-like two-disulfide intermediate in which the Cys(1)-Cys(18) disulfide bond was absent. Overall, the folding pathway of this head-to-tail cyclized protein was found to be similar to that of linear cystine knot proteins from the squash family of trypsin inhibitors. However, the pathway differs in an important way from that of the cyclotide kalata B1, in that the equivalent two-disulfide intermediate in that case is not a direct precursor of the native protein. The size of the embedded ring within the cystine knot motif appears to play a crucial role in the folding pathway. Larger rings contribute to the independence of disulfides and favor an on-pathway native-like intermediate that has a smaller energy barrier to cross to form the native fold. The fact that macrocyclic proteins are readily able to fold to a complex knotted structure in vitro in the absence of chaperones makes them suitable as protein engineering scaffolds that have remarkable stability.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Australian Res Council Special Res Ctr Funct & Ap, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; /A-6021-2011; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; /0000-0003-2110-2017; Daly, Norelle L/0000-0002-4697-6602				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Cemazar M, 2004, J BIOL CHEM, V279, P16697, DOI 10.1074/jbc.M312328200; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Clark RJ, 2006, BIOCHEM J, V394, P85, DOI 10.1042/BJ20051691; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; CRAIK D, 2006, IN PRESS CURR OPIN D; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2005, PROTEIN PEPTIDE LETT, V12, P147, DOI 10.2174/0929866053005863; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; Daly NL, 2003, LETT PEPT SCI, V10, P523, DOI 10.1007/BF02442584; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; Gran L, 2000, J ETHNOPHARMACOL, V70, P197, DOI 10.1016/S0378-8741(99)00175-0; Heitz A, 2001, BIOCHEMISTRY-US, V40, P7973, DOI 10.1021/bi0106639; HEITZ A, 1995, EUR J BIOCHEM, V233, P837, DOI 10.1111/j.1432-1033.1995.837_3.x; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Kratzner R, 2005, ACTA CRYSTALLOGR D, V61, P1255, DOI 10.1107/S0907444905021207; LENGUYEN D, 1993, PROTEIN SCI, V2, P165; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Thaimattam R, 2002, ACTA CRYSTALLOGR D, V58, P1448, DOI 10.1107/S0907444902011769; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P1483, DOI 10.1021/bi011893q; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	38	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8224	8232		10.1074/jbc.M513399200	http://dx.doi.org/10.1074/jbc.M513399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16547012	hybrid			2022-12-27	WOS:000236031000062
J	Bergo, VB; Ntefidou, M; Trivedi, VD; Amsden, JJ; Kralj, JM; Rothschild, KJ; Spudich, JL				Bergo, Vladislav B.; Ntefidou, Maria; Trivedi, Vishwa D.; Amsden, Jason J.; Kralj, Joel M.; Rothschild, Kenneth J.; Spudich, John L.			Conformational changes in the photocycle of Anabaena sensory rhodopsin - Absence of the Schiff base counterion protonation signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOCHEMICAL-REACTION CYCLE; TIME-RESOLVED FTIR; BACTERIORHODOPSIN MUTANTS; VIBRATIONAL SPECTROSCOPY; DIFFERENCE SPECTROSCOPY; RAMAN-SPECTROSCOPY; STRUCTURAL-CHANGES; LIGHT; CHROMOPHORE; PHARAONIS	Anabaena sensory rhodopsin (ASR) is a novel microbial rhodopsin recently discovered in the freshwater cyanobacterium Anabaena sp. PCC7120. This protein most likely functions as a photosensory receptor as do the related haloarchaeal sensory rhodopsins. However, unlike the archaeal pigments, which are tightly bound to their cognate membrane-embedded transducers, ASR interacts with a soluble cytoplasmic protein analogous to transducers of animal vertebrate rhodopsins. In this study, infrared spectroscopy was used to examine the molecular mechanism of photoactivation in ASR. Light adaptation of the pigment leads to a phototransformation of an all-trans/15-anti to 13-cis/15-syn retinylidene-containing species very similar in chromophore structural changes to those caused by dark adaptation in bacteriorhodopsin. Following 532 nm laser-pulsed excitation, the protein exhibits predominantly an all-trans retinylidene photocycle containing a deprotonated Schiff base species similar to those of other microbial rhodopsins such as bacteriorhodopsin, sensory rhodopsin II, and Neurospora rhodopsin. However, no changes are observed in the Schiff base counterion Asp-75, which remains unprotonated throughout the photocycle. This result along with other evidence indicates that the Schiff base proton release mechanism differs significantly from that of other known microbial rhodopsins, possibly because of the absence of a second carboxylate group at the ASR photoactive site. Several conformational changes are detected during the ASR photocycle including in the transmembrane helices E and G as indicated by hydrogen-bonding alterations of their native cysteine residues. In addition, similarly to animal vertebrate rhodopsin, perturbations of the polar head groups of lipid molecules are detected.	Boston Univ, Dept Phys, Lab Mol Biophys, Boston, MA 02215 USA; Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Boston University; University of Texas System	Rothschild, KJ (corresponding author), Boston Univ, Dept Phys, Lab Mol Biophys, 590 Commonwealth Ave, Boston, MA 02215 USA.	kjr@bu.edu	Rothschild, Kenneth J/P-6177-2018	Rothschild, Kenneth J/0000-0002-2847-6671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750, R01GM069969] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATON B, 1977, BIOCHEMISTRY-US, V16, P2995, DOI 10.1021/bi00632a029; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bergo V, 2000, BIOCHEMISTRY-US, V39, P2823, DOI 10.1021/bi991676d; Bergo V, 2004, BIOCHEMISTRY-US, V43, P9075, DOI 10.1021/bi0361968; Bergo V, 2003, J BIOL CHEM, V278, P36556, DOI 10.1074/jbc.M303719200; Bergo V, 2002, PHOTOCHEM PHOTOBIOL, V76, P341, DOI 10.1562/0031-8655(2002)076<0341:AFTISO>2.0.CO;2; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BOUSCHE O, 1991, BIOCHEMISTRY-US, V30, P5395, DOI 10.1021/bi00236a010; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; Brown LS, 2001, J BIOL CHEM, V276, P32495, DOI 10.1074/jbc.M102652200; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; Dioumaev AK, 2002, BIOCHEMISTRY-US, V41, P5348, DOI 10.1021/bi025563x; Dioumaev AK, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1269, DOI 10.1023/A:1013135419529; DOLLINGER G, 1986, BIOCHEMISTRY-US, V25, P6524, DOI 10.1021/bi00369a028; EISENSTEIN L, 1987, J AM CHEM SOC, V109, P6860, DOI 10.1021/ja00256a055; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P12287, DOI 10.1021/bi050841o; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2004, BIOCHEMISTRY-US, V43, P5204, DOI 10.1021/bi036316b; Gerwert K, 1999, BIOL CHEM, V380, P931, DOI 10.1515/BC.1999.115; GERWERT K, 1986, EMBO J, V5, P805, DOI 10.1002/j.1460-2075.1986.tb04285.x; Hein M, 2003, BIOPHYS J, V84, P1208, DOI 10.1016/S0006-3495(03)74935-2; Isele J, 2000, BIOPHYS J, V79, P3063, DOI 10.1016/S0006-3495(00)76541-6; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; LI HM, 1992, J AM CHEM SOC, V114, P7463, DOI 10.1021/ja00045a019; PARKER FS, 1983, APPL INFRARED RAMAN; RATH P, 1993, BIOCHEMISTRY-US, V32, P2272, DOI 10.1021/bi00060a020; RATH P, 1994, BIOCHEMISTRY-US, V33, P5600, DOI 10.1021/bi00184a032; RATH P, 1994, BIOPHYS J, V66, P2085, DOI 10.1016/S0006-3495(94)81003-3; ROEPE PD, 1988, J BIOL CHEM, V263, P5110; ROTHSCHILD KJ, 1982, P NATL ACAD SCI-BIOL, V79, P4045, DOI 10.1073/pnas.79.13.4045; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1988, BIOCHEMISTRY-US, V27, P2420, DOI 10.1021/bi00407a026; Sineshchekov OA, 2004, PHOTOCH PHOTOBIO SCI, V3, P548, DOI 10.1039/b316207a; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Sineshchevkov OA, 2005, J BIOL CHEM, V280, P14663, DOI 10.1074/jbc.m501416200; SMITH SO, 1987, J PHYS CHEM-US, V91, P804, DOI 10.1021/j100288a011; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SMITH SO, 1983, BIOCHEMISTRY-US, V22, P6141, DOI 10.1021/bi00295a016; Spudich JL, 2002, CURR OPIN STRUC BIOL, V12, P540, DOI 10.1016/S0959-440X(02)00359-7; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Vogeley L, 2004, SCIENCE, V306, P1390, DOI 10.1126/science.1103943; Waschuk SA, 2005, P NATL ACAD SCI USA, V102, P6879, DOI 10.1073/pnas.0409659102; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Zhu JY, 1997, PHOTOCHEM PHOTOBIOL, V66, P788, DOI 10.1111/j.1751-1097.1997.tb03225.x	50	40	40	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15208	15214		10.1074/jbc.M600033200	http://dx.doi.org/10.1074/jbc.M600033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16537532	hybrid			2022-12-27	WOS:000237922200024
J	Bohm, C; Seibel, NM; Henkel, B; Steiner, H; Haass, C; Hampe, W				Boehm, Christopher; Seibel, Nicole M.; Henkel, Birgit; Steiner, Harald; Haass, Christian; Hampe, Wolfgang			SorLA signaling by regulated intramembrane proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RECEPTOR-RELATED PROTEIN; HEAD-ACTIVATOR RECEPTOR; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; NEUROTENSIN RECEPTOR-3/SORTILIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; SORTING RECEPTOR; MOSAIC RECEPTOR	The single-transmembrane receptor SorLA/LR11 contains binding domains typical for lipoprotein receptors and a VPS10 domain, which binds the neuropeptide head-activator. This undecapeptide enhances proliferation of neuronal precursor cells in a SorLA-dependent manner. Using specific inhibitors we found previously that head activator activates shedding of SorLA by the metalloprotease TACE close to the transmembrane domain releasing the large extracellular part of the receptor. Here we show that the remaining COOH-terminal membrane fragment of SorLA is processed by gamma-secretase. Inhibition of gamma-secretase by specific inhibitors or overexpression of dominant negative presenilin mutants and knock out of the presenilin genes led to accumulation of the SorLA membrane fragment and also of full-length SorLA in the membrane. In an in vitro assay we observed the gamma-secretase-dependent release of the two soluble cleavage products, the SorLA cytoplasmic domain and the SorLA gamma-peptide. These processing steps are reminiscent of a novel signaling pathway that has been described for the notch receptor. Here, the notch cytoplasmic domain is released into the cytoplasm by the gamma-secretase and migrates to the nucleus where it acts as a transcriptional regulator. In parallel we found that a fusion protein of the released cytoplasmic tail of SorLA with EGFP located to the nucleus only if the nuclear localization signal of SorLA was intact. In a reporter gene assay the cytoplasmic domain of SorLA acted as a transcriptional activator indicating that SorLA might directly regulate transcription after activation by gamma-secretase.	Univ Hamburg, Med Ctr, Ctr Expt Med, Dept Biochem & Mol Biol 2 Mol Cell Biol, D-20246 Hamburg, Germany; Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Hamburg; University of Munich	Hampe, W (corresponding author), Univ Klinikum Eppendorf, Inst Biochem & Molekulabiol 2, Martinistr 52, D-20246 Hamburg, Germany.	hampe@uke.uni-hamburg.de						Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Boels K, 2001, J CELL SCI, V114, P3599; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Dicou E, 2004, J NEUROSCI RES, V78, P92, DOI 10.1002/jnr.20231; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Franke I, 1997, EUR J BIOCHEM, V244, P940, DOI 10.1111/j.1432-1033.1997.00940.x; Gliemann J, 2004, BIOCHEM J, V381, P203, DOI 10.1042/BJ20040149; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hampe W, 1999, DEVELOPMENT, V126, P4077; Hampe W, 2000, J CELL SCI, V113, P4475; Hampe W, 1996, EUR J BIOCHEM, V235, P814, DOI 10.1111/j.1432-1033.1996.t01-1-00814.x; Hampe Wolfgang, 1999, Results and Problems in Cell Differentiation, V26, P323; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Kanaki T, 1999, ARTERIOSCL THROM VAS, V19, P2687, DOI 10.1161/01.ATV.19.11.2687; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lintzel J, 2002, BIOL CHEM, V383, P1727, DOI 10.1515/BC.2002.193; Lleo A, 2005, J BIOL CHEM, V280, P27303, DOI 10.1074/jbc.M413969200; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martin S, 2002, GASTROENTEROLOGY, V123, P1135, DOI 10.1053/gast.2002.36000; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Navarro V, 2002, BIOCHEM BIOPH RES CO, V298, P760, DOI 10.1016/S0006-291X(02)02564-0; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nilsson J, 2005, PROTEINS, V60, P606, DOI 10.1002/prot.20583; Offe K, 2006, J NEUROSCI, V26, P1596, DOI 10.1523/JNEUROSCI.4946-05.2006; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scherzer CR, 2004, ARCH NEUROL-CHICAGO, V61, P1200, DOI 10.1001/archneur.61.8.1200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Spoelgen R, 2006, J NEUROSCI, V26, P418, DOI 10.1523/JNEUROSCI.3882-05.2006; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner Harald, 2004, Current Alzheimer Research, V1, P175, DOI 10.2174/1567205043332081; Taira K, 2001, ARTERIOSCL THROM VAS, V21, P1501, DOI 10.1161/hq0901.094500; Westergaard UB, 2004, J BIOL CHEM, V279, P50221, DOI 10.1074/jbc.M408873200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; Zhu YJ, 2004, CIRC RES, V94, P752, DOI 10.1161/01.RES.0000120862.79154.0F	55	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14547	14553		10.1074/jbc.M601660200	http://dx.doi.org/10.1074/jbc.M601660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16531402	hybrid			2022-12-27	WOS:000237671300005
J	Roy, A; Fung, YK; Liu, XJ; Pahan, K				Roy, Avik; Fung, Yiu K.; Liu, Xiaojuan; Pahan, Kalipada			Up-regulation of microglial CD11b expression by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MULTIPLE-SCLEROSIS; AMEBOID MICROGLIA; HUMAN ASTROGLIA; SYNTHASE; CELLS; ACTIVATION	Increased expression of CD11b, the beta-integrin marker of microglia, represents microglial activation during neurodegenerative inflammation. However, the molecular mechanism behind increased microglial CD11b expression is poorly understood. The present study was undertaken to explore the role of nitric oxide ( NO) in the expression of CD11b in microglial cells. Bacterial lipopolysaccharide ( LPS) induced the production of NO and increased the expression of CD11b in mouse BV-2 microglial cells and primary microglia. Either a scavenger of NO ( PTIO) or an inhibitor of inducible nitric-oxide synthase ( L-NIL) blocked this increase in microglial CD11b expression. Furthermore, co-microinjection of PTIO with LPS was also able to suppress LPS-mediated expression of CD11b and loss of dopaminergic neuronal fibers and neurotransmitters in striatum in vivo. Similarly, other inducers of NO production such as interferon-gamma, interleukin-1 beta, human immunodeficiency virus type-1 gp120, and double-stranded RNA( poly( IC)) also increased the expression of CD11b in microglia through NO. The role of NO in the expression of CD11b was corroborated further by the expression of microglial CD11b by GSNO, an NO donor. Because NO transduces many intracellular signals via guanylate cyclase ( GC), we investigated the role of GC, cyclic GMP ( cGMP), and cGMP-activated protein kinase ( PKG) in microglial expression of CD11b. Inhibition of LPS- and GSNO-mediated upregulation of CD11b either by NS2028 ( a specific inhibitor of GC) or by KT5823 and Rp-8-bromo-cGMP ( specific inhibitors of PKG), and increase in CD11b expression either by 8-bromo-cGMP or by MY-5445 ( a specific inhibitor of cGMP phosphodiesterase) alone suggest that NO increases microglial expression of CD11b via GC-cGMP-PKG. In addition, GSNO induced the activation of cAMP response element-binding protein ( CREB) via PKG that was involved in the up-regulation of CD11b. This study illustrates a novel biological role of NO in regulating the expression of CD11b in microglia through GC-cGMP-PKG-CREB pathway that may participate in the pathogenesis of devastating neurodegenerative disorders.	Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, 40th & Holdrege, Lincoln, NE 68583 USA.	kpahan@unmc.edu			NINDS NIH HHS [NS 48923, NS 39940, R01 NS039940, R01 NS039940-05A1, R21 NS048923, R21 NS048923-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048923, R01NS039940] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Auch CJ, 2004, FEBS LETT, V563, P223, DOI 10.1016/S0014-5793(04)00302-3; Barcia C, 2004, GLIA, V46, P402, DOI 10.1002/glia.20015; Bredt DS, 2003, MOL PHARMACOL, V63, P1206, DOI 10.1124/mol.63.6.1206; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Chan SHH, 2004, MOL PHARMACOL, V65, P319, DOI 10.1124/mol.65.2.319; Dasgupta S, 2004, J IMMUNOL, V173, P1344, DOI 10.4049/jimmunol.173.2.1344; Dasgupta S, 2003, J BIOL CHEM, V278, P22424, DOI 10.1074/jbc.M301789200; Dasgupta S, 2002, J BIOL CHEM, V277, P39327, DOI 10.1074/jbc.M111841200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jana A, 2004, J NEUROSCI, V24, P9531, DOI 10.1523/JNEUROSCI.3085-04.2004; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Jouvert P, 2004, J NEUROSCI, V24, P10716, DOI 10.1523/JNEUROSCI.1398-04.2004; Kim HS, 2004, J NEUROIMMUNOL, V151, P85, DOI 10.1016/j.jneuroim.2004.02.006; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; Monfort P, 2002, J NEUROSCI, V22, P10116; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; RADI R, 1991, J BIOL CHEM, V266, P4244; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Saha RN, 2003, J NEUROCHEM, V86, P1057, DOI 10.1046/j.1471-4159.2003.01942.x; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Schwarz M, 2002, THROMB RES, V107, P121, DOI 10.1016/S0049-3848(02)00207-4; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; Stoner NC, 2001, SURGERY, V130, P236, DOI 10.1067/msy.2001.115903; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	41	68	75	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14971	14980		10.1074/jbc.M600236200	http://dx.doi.org/10.1074/jbc.M600236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551637	Green Accepted, hybrid			2022-12-27	WOS:000237671300050
J	Guyot, B; Murai, K; Fujiwara, Y; Valverde-Garduno, V; Hammett, M; Wells, S; Dear, N; Orkin, SH; Porcher, C; Vyas, P				Guyot, B; Murai, K; Fujiwara, Y; Valverde-Garduno, V; Hammett, M; Wells, S; Dear, N; Orkin, SH; Porcher, C; Vyas, P			Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; GENE-EXPRESSION; CELL-LINE; DIFFERENTIATION; ELEMENT; GROWTH; FLI-1; PROLIFERATION; MATURATION; REGULATOR	Specification and differentiation of the megakaryocyte and erythroid lineages from a common bipotential progenitor provides a well studied model to dissect binary cell fate decisions. To understand how the distinct megakaryocyte- and erythroid- specific gene programs arise, we have examined the transcriptional regulation of the megakaryocyte erythroid transcription factor GATA1. Hemopoietic-specific mouse ( m) GATA1 expression requires the mGata1 enhancer mHS- 3.5. Within mHS- 3.5, the 3 ' 179 bp of mHS- 3.5 are required for megakaryocyte but not red cell expression. Here, we show mHS- 3.5 binds key hemopoietic transcription factors in vivo and is required to maintain histone acetylation at the mGata1 locus in primary megakaryocytes. Analysis of GATA1- LacZ reporter gene expression in transgenic mice shows that a 25- bp element within the 3 '- 179 bp in mHS- 3.5 is critical for megakaryocyte expression. In vitro three DNA binding activities A, B, and C bind to the core of the 25- bp element, and these binding sites are conserved through evolution. Activity A is the zinc finger transcription factor ZBP89 that also binds to other cis elements in the mGata1 locus. Activity B is of particular interest as it is present in primary megakaryocytes but not red cells. Furthermore, mutation analysis in transgenic mice reveals activity B is required for megakaryocyte- specific enhancer function. Bioinformatic analysis shows sequence corresponding to the binding site for activity B is a previously unrecognized motif, present in the cis elements of the Fli1 gene, another important megakaryocyte- specific transcription factor. In summary, we have identified a motif and a DNA binding activity likely to be important in directing a megakaryocyte gene expression program that is distinct from that in red cells.	John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Vyas, P (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	paresh.vyas@molecular-medicine.oxford.ac.uk	Vyas, Paresh/B-5708-2009; Porcher, Catherine/D-7026-2016	Vyas, Paresh/0000-0003-3931-0914; Guyot, Boris/0000-0002-4512-7123; Valverde-Garduno, Veronica/0000-0003-1490-2905	MRC [MC_U137961146, MC_U137961142] Funding Source: UKRI; Medical Research Council [MC_U137961142, MC_U137961146] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Boopathi E, 2004, J BIOL CHEM, V279, P35242, DOI 10.1074/jbc.M403160200; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Guyot B, 2004, BLOOD, V104, P89, DOI 10.1182/blood-2004-01-0108; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; ISHIDA Y, 1993, EXP HEMATOL, V21, P289; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Jackers P, 2004, J BIOL CHEM, V279, P52183, DOI 10.1074/jbc.M407489200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Okada Y, 2003, BLOOD, V101, P4748, DOI 10.1182/blood-2002-02-0380; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Park H, 2003, BLOOD, V101, P894, DOI 10.1182/blood-2002-03-0680; Ronchi Antonella, 1997, Genes and Function, V1, P245; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Starck J, 1999, MOL CELL BIOL, V19, P121; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Valverde-Garduno V, 2004, BLOOD, V104, P3106, DOI 10.1182/blood-2004-04-1333; Villeval JL, 1997, BLOOD, V90, P4369; Vyas P, 1999, DEVELOPMENT, V126, P2799; Vyas P, 1999, BLOOD, V93, P2867; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Woo AJ, 2005, BLOOD, V106, p244A; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamada A, 2001, J BIOL CHEM, V276, P18082, DOI 10.1074/jbc.M008387200	43	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13733	13742		10.1074/jbc.M602052200	http://dx.doi.org/10.1074/jbc.M602052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551635	hybrid			2022-12-27	WOS:000237336600084
J	Ho, DT; Bardwell, AJ; Grewal, S; Iverson, C; Bardwell, L				Ho, DT; Bardwell, AJ; Grewal, S; Iverson, C; Bardwell, L			Interacting JNK-docking sites in MKK7 promote binding and activation of JNK mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; HIGH-AFFINITY INTERACTION; MAP KINASES; SIGNAL-TRANSDUCTION; DOPAMINERGIC-NEURONS; MPTP MODEL; STRESS; SPECIFICITY; PHOSPHORYLATION; PATHWAY	D-sites are a class of MAPK-docking sites that have been found in many MAPK regulators and substrates. A single functional, high affinity D-site has been identified near the N terminus of each of the MAPK kinases ( MKKs orMEKs) MEK1, MEK2, MKK3, MKK4, and MKK6. Here we demonstrated that MKK7 recognizes its target JNK by a novel mechanism involving a partially cooperative interaction of three low affinity D-sites in the N-terminal domain of MKK7. Mutations of the conserved residues within any one of the three docking sites ( D1, D2, and D3) disrupted the ability of the N-terminal domain of MKK7 beta to bind JNK1 by about 50 - 70%. Moreover, mutation of any two of the three D-sites reduced binding by about 80 - 90%, and mutation of all three reduced binding by 95%. Full-length MKK7 containing combined D1/D2 mutations was compromised for binding to JNK1 and exhibited reduced JNK1 kinase activity when compared with wild-type MKK7. Peptide versions of the D-sites from MKK4 or the JIP-1 scaffold protein inhibited MKK7-JNK binding, suggesting that all three JNK regulators bind to the same region of JNK. Moreover, peptide versions of any of the three D-sites of MKK7 inhibited the ability of JNK1 and JNK2 to phosphorylate their transcription factor substrates c-Jun and ATF2, suggesting that D-site-containing substrates also compete with MKK7 for docking to JNK. Finally, MKK7-derived D-site peptides exhibited selective inhibition of JNK1 versus ERK2. We conclude that MKK7 contains three JNK-docking sites that interact to selectively bind JNK and contribute to JNK signal transmission and specificity.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Bardwell, L (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	bardwell@uci.edu	Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363; Grewal, Seema/0000-0001-6372-8590	NIGMS NIH HHS [GM60366, R01 GM060366-06, R01 GM060366] Funding Source: Medline; NLM NIH HHS [T15 LM007443, LM07443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060366] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bardwell AJ, 2004, BIOCHEM J, V378, P569, DOI 10.1042/BJ20031382; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Bhattacharyya RP, 2006, SCIENCE, V311, P822, DOI 10.1126/science.1120941; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Flatauer LJ, 2005, MOL CELL BIOL, V25, P1793, DOI 10.1128/MCB.25.5.1793-1803.2005; Grewal S, 2006, CELL SIGNAL, V18, P123, DOI 10.1016/j.cellsig.2005.04.001; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Komarova NL, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100031; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Seyfried J, 2005, MOL CELL BIOL, V25, P9820, DOI 10.1128/MCB.25.22.9820-9828.2005; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; Wang WY, 2004, NEUROSCI RES, V48, P195, DOI 10.1016/j.neures.2003.10.012; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yoshida H, 2004, J NEUROCHEM, V90, P352, DOI 10.1111/j.1471-4159.2004.02479.x	59	58	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13169	13179		10.1074/jbc.M601010200	http://dx.doi.org/10.1074/jbc.M601010200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533805	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000237336600022
J	Lohkamp, B; Andersen, B; Piskur, J; Dobritzsch, D				Lohkamp, B; Andersen, B; Piskur, J; Dobritzsch, D			The crystal structures of dihydropyrimidinases reaffirm the close relationship between cyclic amidohydrolases and explain their substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION ANALYSIS; D-HYDANTOINASE; ACTIVE-SITE; 5,6-DIHYDROPYRIMIDINE AMIDOHYDROLASE; MOLECULAR-STRUCTURE; BETA-ALANINE; PURIFICATION; PROTEIN; ENZYMES; MECHANISM	In eukaryotes, dihydropyrimidinase catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Here we describe the three- dimensional structures of dihydropyrimidinase from two eukaryotes, the yeast Saccharomyces kluyveri and the slime mold Dictyostelium discoideum, determined and refined to 2.4 and 2.05 angstrom, respectively. Both enzymes have a ( beta/ alpha)(8)- barrel structural core embedding the catalytic di- zinc center, which is accompanied by a smaller beta- sandwich domain. Despite loop- forming insertions in the sequence of the yeast enzyme, the overall structures and architectures of the active sites of the dihydropyrimidinases are strikingly similar to each other, as well as to those of hydantoinases, dihydroorotases, and other members of the amidohydrolase superfamily of enzymes. However, formation of the physiologically relevant tetramer shows subtle but nonetheless significant differences. The extension of one of the sheets of the beta- sandwich domain across a subunit- subunit interface in yeast dihydropyrimidinase underlines its closer evolutionary relationship to hydantoinases, whereas the slime mold enzyme shows higher similarity to the noncatalytic collapsin- response mediator proteins involved in neuron development. Catalysis is expected to follow a dihydroorotase- like mechanism but in the opposite direction and with a different substrate. Complexes with dihydrouracil and N- carbamyl- beta- alanine obtained for the yeast dihydropyrimidinase reveal the mode of substrate and product binding and allow conclusions about what determines substrate specificity, stereoselectivity, and the reaction direction among cyclic amidohydrolases.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Lund Univ, Dept Cell & Organism Biol, S-22362 Lund, Sweden	Karolinska Institutet; Lund University	Dobritzsch, D (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Tomtebodavagen 6, SE-17177 Stockholm, Sweden.	Doreen.Dobritzsch@ki.se	Dobritzsch, Doreen/H-7334-2018	Lohkamp, Bernhard/0000-0002-5646-2090; Andersen, Birgit/0000-0002-9696-1708				Abendroth J, 2002, J MOL BIOL, V320, P143, DOI 10.1016/S0022-2836(02)00422-9; Abendroth J, 2002, BIOCHEMISTRY-US, V41, P8589, DOI 10.1021/bi0157722; Altenbuchner J, 2001, CURR OPIN BIOTECH, V12, P559, DOI 10.1016/S0958-1669(01)00263-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS KP, 1983, ARCH BIOCHEM BIOPHYS, V226, P469, DOI 10.1016/0003-9861(83)90316-8; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; CECERE F, 1975, FEBS LETT, V57, P192, DOI 10.1016/0014-5793(75)80714-9; Cheon YH, 2004, BIOCHEMISTRY-US, V43, P7413, DOI 10.1021/bi036330o; Cheon YH, 2003, J MOL CATAL B-ENZYM, V26, P217, DOI 10.1016/j.molcatb.2003.06.005; Cheon YH, 2002, BIOCHEMISTRY-US, V41, P9410, DOI 10.1021/bi0201567; DeLano W.L, PYMOL MOL GRAPHICS S; Deo RC, 2004, EMBO J, V23, P9, DOI 10.1038/sj.emboj.7600021; Dobritzsch D, 2005, ACTA CRYSTALLOGR F, V61, P359, DOI 10.1107/S174430910500610X; DUDLEY KH, 1974, DRUG METAB DISPOS, V2, P103; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gojkovic Z, 2000, J MOL BIOL, V295, P1073, DOI 10.1006/jmbi.1999.3393; Gojkovic Z, 2003, NUCLEIC ACIDS RES, V31, P1683, DOI 10.1093/nar/gkg258; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HASINOFF BB, 1993, DRUG METAB DISPOS, V21, P883; HEGGIE GD, 1987, CANCER RES, V47, P2203; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JAHNKE K, 1993, BIOCHEMISTRY-US, V32, P5160, DOI 10.1021/bi00070a027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUTZ J, 1989, EUR J BIOCHEM, V181, P431, DOI 10.1111/j.1432-1033.1989.tb14743.x; KIKUGAWA M, 1994, EUR J BIOCHEM, V219, P393, DOI 10.1111/j.1432-1033.1994.tb19951.x; Kim GJ, 1998, BIOCHEM J, V330, P295, DOI 10.1042/bj3300295; Kim GJ, 1998, BIOCHEM BIOPH RES CO, V243, P96, DOI 10.1006/bbrc.1997.8037; Kishan KVR, 2005, J MOL BIOL, V347, P95, DOI 10.1016/j.jmb.2005.01.025; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lohkamp B, 2006, ACTA CRYSTALLOGR F, V62, P36, DOI 10.1107/S174430910503976X; Lohkamp B., 2005, CCP4 NEWSLETTER, V42; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Marti-Arbona R, 2005, BIOORG CHEM, V33, P448, DOI 10.1016/j.bioorg.2005.10.002; Marti-Arbona R, 2005, BIOCHEMISTRY-US, V44, P7115, DOI 10.1021/bi050008r; May O, 1998, BIOL CHEM, V379, P743; May O, 1998, J BIOTECHNOL, V61, P1, DOI 10.1016/S0168-1656(98)00005-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogawa J, 1997, J MOL CATAL B-ENZYM, V2, P163, DOI 10.1016/S1381-1177(96)00020-3; Porter TN, 2004, BIOCHEMISTRY-US, V43, P16285, DOI 10.1021/bi048308g; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; SANDBERG M, 1981, J NEUROCHEM, V37, P1353, DOI 10.1111/j.1471-4159.1981.tb04691.x; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; Sharma R, 1997, BIOCHEM BIOPH RES CO, V234, P485, DOI 10.1006/bbrc.1997.6659; Shim H, 2000, BIOCHEMISTRY-US, V39, P7357, DOI 10.1021/bi000291o; Sumi S, 1998, AM J MED GENET, V78, P336, DOI 10.1002/(SICI)1096-8628(19980724)78:4<336::AID-AJMG6>3.0.CO;2-J; Syldatk C, 1999, APPL MICROBIOL BIOT, V51, P293, DOI 10.1007/s002530051395; Takemoto T, 2000, GENE, V261, P259, DOI 10.1016/S0378-1119(00)00494-7; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TRAUT TW, 1984, BIOCHEMISTRY-US, V23, P2533, DOI 10.1021/bi00306a033; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; van Kuilenburg ABP, 2003, CLIN CANCER RES, V9, P4363; vanGennip AH, 1997, J INHERIT METAB DIS, V20, P339, DOI 10.1023/A:1005309423960; WALLACH DP, 1957, J BIOL CHEM, V226, P277; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; Xu Z, 2003, J BACTERIOL, V185, P4038, DOI 10.1128/JB.185.14.4038-4049.2003; Zameitat E, 2004, FEBS LETT, V568, P129, DOI 10.1016/j.febslet.2004.05.017	65	45	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13762	13776		10.1074/jbc.M513266200	http://dx.doi.org/10.1074/jbc.M513266200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517602	hybrid			2022-12-27	WOS:000237336600087
J	Choe, Y; Leonetti, F; Greenbaum, DC; Lecaille, F; Bogyo, M; Bromme, D; Ellman, JA; Craik, CS				Choe, Y; Leonetti, F; Greenbaum, DC; Lecaille, F; Bogyo, M; Bromme, D; Ellman, JA; Craik, CS			Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-V; (ACYLOXY)METHYL KETONES; INHIBITOR DESIGN; ACTIVE-SITE; EXPRESSION; LOCALIZATION; PAPAIN; DEGRADATION; OSTEOCLASTS; DEFINITION	The substrate specificities of papain-like cysteine proteases ( clan CA, family C1) papain, bromelain, and human cathepsins L, V, K, S, F, B, and five proteases of parasitic origin were studied using a completely diversified positional scanning synthetic combinatorial library. A bifunctional coumarin fluorophore was used that facilitated synthesis of the library and individual peptide substrates. The library has a total of 160,000 tetrapeptide substrate sequences completely randomizing each of the P1, P2, P3, and P4 positions with 20 amino acids. A microtiter plate assay format permitted a rapid determination of the specificity profile of each enzyme. Individual peptide substrates were then synthesized and tested for a quantitative determination of the specificity of the human cathepsins. Despite the conserved three-dimensional structure and similar substrate specificity of the enzymes studied, distinct amino acid preferences that differentiate each enzyme were identified. The specificities of cathepsins K and S partially match the cleavage site sequences in their physiological substrates. Capitalizing on its unique preference for proline and glycine at the P2 and P3 positions, respectively, selective substrates and a substrate-based inhibitor were developed for cathepsin K. A cluster analysis of the proteases based on the complete specificity profile provided a functional characterization distinct from standard sequence analysis. This approach provides useful information for developing selective chemical probes to study protease-related pathologies and physiologies.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; Icahn School of Medicine at Mount Sinai	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Box 2280, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu	Ellman, Jonathan A/C-7732-2013; Lecaille, Fabien/GRY-5313-2022	Lecaille, Fabien/0000-0003-1060-4222; Leonetti, Francesco/0000-0003-2043-7464; Bogyo, Matthew/0000-0003-3753-4412	NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669, R01AR046182] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NIAID NIH HHS [AI35707] Funding Source: Medline; NIAMS NIH HHS [AR46182, AR48669] Funding Source: Medline; NIGMS NIH HHS [GM54051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, P1105; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BROMME D, 1994, BIOL CHEM H-S, V375, P343, DOI 10.1515/bchm3.1994.375.5.343; Bromme D, 1996, PROTEIN SCI, V5, P789; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BUNIN BA, 1998, COMBINATORIAL INDEX, P6; Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1; Cotrin SS, 2004, ANAL BIOCHEM, V335, P244, DOI 10.1016/j.ab.2004.09.012; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o; Marnett AB, 2005, TRENDS BIOTECHNOL, V23, P59, DOI 10.1016/j.tibtech.2004.12.010; McGrath ME, 1998, PROTEIN SCI, V7, P1294, DOI 10.1002/pro.5560070604; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Puzer L, 2004, ARCH BIOCHEM BIOPHYS, V430, P274, DOI 10.1016/j.abb.2004.07.006; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rosenthal PJ, 2004, INT J PARASITOL, V34, P1489, DOI 10.1016/j.ijpara.2004.10.003; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200; SMITH SM, 1989, J BIOL CHEM, V264, P20487; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; WAGNER BM, 1994, J MED CHEM, V37, P1833, DOI 10.1021/jm00038a012; Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013	38	304	332	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12824	12832		10.1074/jbc.M513331200	http://dx.doi.org/10.1074/jbc.M513331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520377	hybrid			2022-12-27	WOS:000237134700077
J	Cobine, PA; Pierrel, F; Leary, SC; Sasarman, F; Horng, YC; Shoubridge, EA; Winge, DR				Cobine, PA; Pierrel, F; Leary, SC; Sasarman, F; Horng, YC; Shoubridge, EA; Winge, DR			The P174L mutation in human Sco1 severely compromises Cox17-dependent metallation but does not impair copper binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST; GENE; COX17; CARDIOMYOPATHY; DEFICIENCY; ONSET; SITES	Sco1 is a metallochaperone that is required for copper delivery to the Cu-A site in the CoxII subunit of cytochrome c oxidase. The only known missense mutation in human Sco1, a P174L substitution in the copper-binding domain, is associated with a fatal neonatal hepatopathy; however, the molecular basis for dysfunction of the protein is unknown. Immortalized fibroblasts from a SCO1 patient show a severe deficiency in cytochrome c oxidase activity that was partially rescued by overexpression of P174L Sco1. The mutant protein retained the ability to bind Cu(I) and Cu(II) normally when expressed in bacteria, but Cox17-mediated copper transfer was severely compromised both in vitro and in a yeast cytoplasmic assay. The corresponding P153L substitution in yeast Sco1 was impaired in suppressing the phenotype of cells harboring the weakly functional C57Y allele of Cox17; however, it was functional in sco1 Delta yeast when the wild-type COX17 gene was present. Pulse-chase labeling of mitochondrial translation products in SCO1 patient fibroblasts showed no change in the rate of CoxII translation, but there was a specific and rapid turnover of CoxII protein in the chase. These data indicate that the P174L mutation attenuates a transient interaction with Cox17 that is necessary for copper transfer. They further suggest that defective Cox17-mediated copper metallation of Sco1, as well as the subsequent failure of Cu-A site maturation, is the basis for the inefficient assembly of the cytochrome c oxidase complex in SCO1 patients.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; McGill University; McGill University	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	eric@ericpc.mni.mcgill.ca; dennis.winge@hsc.utah.edu	Cobine, Paul/AAH-6619-2020; Cobine, Paul A/G-3107-2011; Leary, Scot/B-3036-2012; Horng, Yih-Chern/I-6682-2018; Winge, Dennis/G-3611-2010; PIERREL, Fabien/M-6016-2014	Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189; PIERREL, Fabien/0000-0003-2083-3002	NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489; Barros MH, 2004, J BIOL CHEM, V279, P31943, DOI 10.1074/jbc.M405014200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Paret C, 2000, BIOCHEM BIOPH RES CO, V279, P341, DOI 10.1006/bbrc.2000.3949; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	23	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12270	12276		10.1074/jbc.M600496200	http://dx.doi.org/10.1074/jbc.M600496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520371	Green Submitted, hybrid			2022-12-27	WOS:000237134700011
J	Song, H; Lee, MY; Kinsey, SP; Weber, DJ; Blaustein, MP				Song, H; Lee, MY; Kinsey, SP; Weber, DJ; Blaustein, MP			An N-terminal sequence targets and tethers Na+ pump alpha 2 subunits to specialized plasma membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-ATPASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; NA,K-ATPASE ISOZYMES; CATALYTIC SUBUNIT; OUABAIN AFFINITY; ANKYRIN-BINDING; NA/CA EXCHANGER; SMOOTH-MUSCLE; CALCIUM-PUMP	Sodium pumps (alpha B dimers) with the alpha 1 isoform of the catalytic (alpha) subunit are expressed in all cells. Additionally, most cells express Na+ pumps with a second alpha isoform. For example, astrocytes and arterial myocytes also express Na+ pumps with the alpha 2 isoform. The alpha 2 pumps localize to plasma membrane ( PM) microdomains overlying "junctional" sarco-/endoplasmic reticulum (S/ER), but the alpha 1 pumps are more uniformly distributed. To study alpha 2 targeting, we expressed alpha 1/alpha 2 and alpha 2/alpha 1 chimeras and 1-90 and 1-120 amino acid N-terminal peptides in primary cultured mouse astrocytes. Immunocytochemistry revealed that alpha 2/alpha 1 ( but not alpha 1/alpha 2) chimeras markedly reduced native alpha 2 (i.e. were "dominant negatives"). N-terminal (1-120 and 1-90 amino acids) alpha 2 ( and alpha 3), but not alpha 1 peptides also targeted to the PM-S/ER junctions and were dominant negative for native alpha 2 in astrocytes and arterial myocytes. Thus alpha 2 and alpha 3 have the same targeting sequence. Ca2+ (fura-2) signals in astrocytes expressing the 1-90 alpha 2 peptide were comparable to signals in cells from alpha 2 null mutants (i.e. functionally dominant negative): 1 mu M ATP-evoked Ca2+ transients were augmented, and 100 nM ouabain-induced amplification was abolished. Amino acid substitutions in the 1-120 alpha 1 and alpha 2 constructs, and in full-length alpha 1, revealed that Leu-27 and Ala-35 are essential for targeting/tethering the constructs to PM-S/ER junctions.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Blaustein, MP (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	mblaustein@som.umaryland.edu	Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110	NHLBI NIH HHS [HL-45215] Funding Source: Medline; NIGMS NIH HHS [GM-58888, R01 GM058888] Funding Source: Medline; NINDS NIH HHS [NS-16106] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016106] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Dostanic I, 2005, AM J PHYSIOL-HEART C, V288, pH477, DOI 10.1152/ajpheart.00083.2004; Dunbar LA, 2000, EUR J CELL BIOL, V79, P557, DOI 10.1078/0171-9335-00079; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; Golovina VA, 1996, GLIA, V16, P296; Golovina VA, 2003, AM J PHYSIOL-CELL PH, V284, pC475, DOI 10.1152/ajpcell.00383.2002; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; HENSLEY CB, 1992, AM J PHYSIOL, V262, pC484, DOI 10.1152/ajpcell.1992.262.2.C484; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Juhaszova M, 1997, ANN NY ACAD SCI, V834, P524, DOI 10.1111/j.1749-6632.1997.tb52310.x; Juhaszova M, 1997, P NATL ACAD SCI USA, V94, P1800, DOI 10.1073/pnas.94.5.1800; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; LEE MY, 2005, J GEN PHYSIOL, V126, pA69; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Peng L, 1997, J NEUROSCI, V17, P3488; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; Staton TJ, 2005, FASEB J, V19, pA1619; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; Zhang J, 2005, J PHYSIOL-LONDON, V569, P243, DOI 10.1113/jphysiol.2005.091801; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	42	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12929	12940		10.1074/jbc.M507450200	http://dx.doi.org/10.1074/jbc.M507450200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524882	hybrid			2022-12-27	WOS:000237134700088
J	Tan, YV; Couvineau, A; Murail, S; Ceraudo, E; Neumann, JM; Lacapere, JJ; Laburthe, M				Tan, YV; Couvineau, A; Murail, S; Ceraudo, E; Neumann, JM; Lacapere, JJ; Laburthe, M			Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor - Photoaffinity, NMR, and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CRYSTAL-STRUCTURE; VIP RECEPTOR; AMINO-ACIDS; DOMAINS; RESIDUES; BINDING; FAMILY; IDENTIFICATION; PHARMACOLOGY	The neuropeptide vasoactive intestinal peptide (VIP) strongly impacts on human pathophysiology and does so through interaction with class II G protein-coupled receptors named VIP pituitary adenylate cyclase-activating peptide (PACAP) receptors (VPACs). The molecular nature of VIP binding to receptors remains elusive. In this work, we have docked VIP in the human VPAC1 receptor by the following approach. (i) VIP probes containing photolabile residues in positions 6, 22, and 24 of VIP were used to photolabel the receptor. After receptor cleavage and Edman sequencing of labeled receptor fragments, it was shown that Phe(6), Tyr(22), and Asn(24) of VIP are in contact with Asp(107), Gly(116), and Cys(122) in the N-terminal ectodomain (N-ted) of the receptor, respectively. (ii) The structure of VIP was determined by NMR showing a central alpha helix, a disordered N-terminal His(1)-Phe(6) segment and a 3(10) Ser(25)-Asn(28) helix termination. (iii) A three-dimensional model of the N-ted of hVPAC1 was constructed by using the NMR structure of the N-ted of corticotropin-releasing factor receptor 2 beta as a template. As expected, the fold is identified as a short consensus repeat with two antiparallel beta sheets and is stabilized by three disulfide bonds. (iv) Taking into account the constraints provided by photoaffinity, VIP was docked into the hVPAC1 receptor N-ted. The 6-28 fragment of VIP nicely lies in the N-ted C-terminal part, but the N terminus region of VIP is free for interacting with the receptor transmembrane region. The data provide a structural rationale to the proposed two-step activation mechanism of VPAC receptor and more generally of class II G protein-coupled receptors.	Fac Med Bichat, INSERM, U773, Ctr Rech Biomed Bichat Beaujon, F-75018 Paris, France; Univ Paris 07, F-75018 Paris, France; Ctr Etud Saclay, CNRS, Unite Rech 2096, Dept Biol Joliot Curie,CEA Dept Sci Biol, F-91191 Gif Sur Yvette, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Laburthe, M (corresponding author), Fac Med Bichat, INSERM, U773, Ctr Rech Biomed Bichat Beaujon, CRB3,16 Rue Henir Huchard, F-75018 Paris, France.	laburthe@bichat.inserm.fr	LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019; Murail, Samuel/AAC-3897-2019	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; Murail, Samuel/0000-0002-3842-5333				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Sexton PM, 2002, RECEPTOR CHANNEL, V8, P135, DOI 10.1080/10606820290005056; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Tan YV, 2004, J BIOL CHEM, V279, P38889, DOI 10.1074/jbc.M404460200; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; THERIAULT Y, 1991, BIOPOLYMERS, V31, P459, DOI 10.1002/bip.360310411; TURNER JT, 1986, PEPTIDES, V7, P849, DOI 10.1016/0196-9781(86)90105-1; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3	32	56	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12792	12798		10.1074/jbc.M513305200	http://dx.doi.org/10.1074/jbc.M513305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520374	hybrid			2022-12-27	WOS:000237134700073
J	Zhang, XD; Dou, SX; Xie, P; Hu, JS; Wang, PY; Xi, XG				Zhang, XD; Dou, SX; Xie, P; Hu, JS; Wang, PY; Xi, XG			Escherichia coli RecQ is a rapid, efficient, and monomeric helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 DDA HELICASE; TERMINATION FACTOR-RHO; C VIRUS HELICASE; CRYSTAL-STRUCTURE; PCRA HELICASE; REP HELICASE; STEP-SIZE; FLUORESCENCE POLARIZATION; HEXAMERIC HELICASES	RecQ family helicases play a key role in chromosome maintenance. Despite extensive biochemical, biophysical, and structural studies, the mechanism by which helicase unwinds double-stranded DNA remains to be elucidated. Using a wide array of biochemical and biophysical approaches, we have previously shown that the Escherichia coli RecQ helicase functions as a monomer. In this study, we have further characterized the kinetic mechanism of the RecQ-catalyzed unwinding of duplex DNA using the fluorometric stopped-flow method based on fluorescence resonance energy transfer. Our results show that RecQ helicase binds preferentially to 3'-flanking duplex DNA. Under the pre-steady-state conditions, the burst amplitude reveals a 1: 1 ratio between RecQ and DNA substrate, suggesting that an active monomeric form of RecQ helicase is involved in the catalysis. Under the single-turnover conditions, the RecQ-catalyzed unwinding is independent of the 3'-tail length, indicating that functional interactions between RecQ molecules are not implicated in the DNA unwinding. It was further determined that RecQ unwinds DNA rapidly with a step size of 4 bp and a rate of similar to 21 steps/s. These kinetic results not only further support our previous conclusion that E. coli RecQ functions as a monomer but also suggest that some of the Superfamily 2 helicases may function through an "inchworm" mechanism.	Chinese Acad Sci, Inst Phys, Beijing Natl Lab Condensed Matter Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Ctr Biomol Struct & Org, College Pk, MD 20742 USA; ENS, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France	Chinese Academy of Sciences; Institute of Physics, CAS; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Wang, PY (corresponding author), Chinese Acad Sci, Inst Phys, Beijing Natl Lab Condensed Matter Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China.	pywang@aphy.iphy.ac.cn	Xi, Xu Guang/AAK-4511-2020; zhang, xingdong/I-2892-2015; 王, 鹏业/A-9811-2012; Dou, Shi Xue/D-5179-2012	Dou, Shi Xue/0000-0003-3824-7693; Dou, Shuo-Xing/0000-0002-7201-2081; Wang, Peng-Ye/0000-0002-9765-0610				Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dou SX, 2004, J BIOL CHEM, V279, P6354, DOI 10.1074/jbc.M311272200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Levin MK, 2005, NAT STRUCT MOL BIOL, V12, P429, DOI 10.1038/nsmb920; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Liao JC, 2005, J MOL BIOL, V350, P452, DOI 10.1016/j.jmb.2005.04.051; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2004, J MOL BIOL, V339, P731, DOI 10.1016/j.jmb.2004.04.009; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Neuman KC, 2005, J PHYS-CONDENS MAT, V17, pS3811, DOI 10.1088/0953-8984/17/47/012; Norcum MT, 2005, P NATL ACAD SCI USA, V102, P3623, DOI 10.1073/pnas.0500713102; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; von Hippel PH, 2004, NAT STRUCT MOL BIOL, V11, P494, DOI 10.1038/nsmb0604-494; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Zhang XD, 2005, ACTA BIOCH BIOPH SIN, V37, P593, DOI 10.1111/j.1745-7270.2005.00084.x	66	63	69	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12655	12663		10.1074/jbc.M513089200	http://dx.doi.org/10.1074/jbc.M513089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507576	hybrid			2022-12-27	WOS:000237134700056
J	Bellais, S; Arthur, M; Dubost, L; Hugonnet, JE; Gutmann, L; van Heijenoort, J; Legrand, R; Brouard, JP; Rice, L; Mainardi, JL				Bellais, S; Arthur, M; Dubost, L; Hugonnet, JE; Gutmann, L; van Heijenoort, J; Legrand, R; Brouard, JP; Rice, L; Mainardi, JL			Asl(fm), the D-aspartate ligase responsible for the addition of D-aspartic acid onto the peptidoglycan precursor of Enterococcus faecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CELL-WALLS; CARBAMOYL-PHOSPHATE SYNTHETASE; BETA-LACTAM RESISTANCE; D-ALANINE LIGASE; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-PNEUMONIAE; PEPTIDE SYNTHETASES; CRYSTAL-STRUCTURE; VIRIDESCENS FEMX	D-Aspartate ligase has remained the last unidentified peptide bond-forming enzyme in the peptidoglycan assembly pathway of Gram-positive bacteria. Here we show that a two-gene cluster of Enterococcus faecium encodes aspartate racemase ( Rac(fm)) and ligase ( Asl(fm)) for incorporation of D-Asp into the side chain of the peptidoglycan precursor. Aslfm was identified as a new member of the ATP-grasp protein superfamily, which includes a diverse set of enzymes catalyzing ATP-dependent carboxylate-amine ligation reactions. Aslfm specifically ligated the beta-carboxylate of D-Asp to the epsilon-amino group of L-Lys in the nucleotide precursor UDP-N-acetylmuramyl-pentapeptide. D-iso-Asparagine was not a substrate of Aslfm, indicating that the presence of this amino acid in the peptidoglycan of E. faecium results from amidation of the alpha-carboxyl of D-Asp after its addition to the precursor. Heterospecific expression of the genes encoding Rac(fm) and Asl(fm) in Enterococcus faecalis led to production of stem peptides substituted by D-Asp instead of L-Ala(2), providing evidence for the in vivo specificity and function of these enzymes. Strikingly, sequencing of the cross-bridges revealed that substitution of L-Ala(2) by D-Asp is tolerated by the D,D-transpeptidase activity of the penicillin-binding proteins both in the acceptor and in the donor substrates. The Asl(fm) ligase appears as an attractive target for the development of narrow spectrum antibiotics active against multiresistant E. faecium.	Univ Paris 06, Univ Paris Descartes, Ctr Rech Biomed Cordeliers,Fac Med, LRMA,INSERM,U655, F-75270 Paris 06, France; Museum Natl Hist Nat, USM0502, CNRS,UMR8041, Plateforme Spectrometrie Masse & Proteom,Dept Rec, F-75005 Paris, France; Univ Paris 05, Fac Med, Hop Europeen Georges Pompidou, AP HP, F-75908 Paris 15, France; Univ Paris 11, Enveloppes Bacteriennes & Antibiot, CNRS, UMR 8619, F-91405 Orsay, France; Aventis Pharma France, F-93235 Romainville, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med Serv, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Mainardi, JL (corresponding author), Univ Paris 06, Univ Paris Descartes, Ctr Rech Biomed Cordeliers,Fac Med, LRMA,INSERM,U655, 15 Rue Ecole Med, F-75270 Paris 06, France.	jlmainar@bhdc.jussieu.fr	MAINARDI, Jean-Luc/E-2714-2014; HUGONNET, Jean-Emmanuel/ABC-7914-2021; HUGONNET, Jean-Emmanuel/H-3581-2014; Arthur, Michel/G-3680-2013	MAINARDI, Jean-Luc/0000-0002-4159-0129; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; ARTHUR M, 1994, ANTIMICROB AGENTS CH, V38, P1899, DOI 10.1128/AAC.38.9.1899; Ashiuchi M, 1999, BIOSCI BIOTECH BIOCH, V63, P792, DOI 10.1271/bbb.63.792; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; Biarrotte-Sorin S, 2004, STRUCTURE, V12, P257, DOI 10.1016/j.str.2004.01.006; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; Bouhss A, 1997, BIOCHEMISTRY-US, V36, P11556, DOI 10.1021/bi970797f; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; DUKTAMALEN S, 1992, GENE, V112, P53; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2002, P NATL ACAD SCI USA, V99, P1550, DOI 10.1073/pnas.032671699; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Hegde SS, 2003, J BIOL CHEM, V278, P22861, DOI 10.1074/jbc.M301565200; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; Liu LJ, 2002, J MOL BIOL, V319, P479, DOI 10.1016/S0022-2836(02)00296-6; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007; Naas T, 2005, J CLIN MICROBIOL, V43, P3642, DOI 10.1128/JCM.43.8.3642-3649.2005; PLAPP R, 1970, J BIOL CHEM, V245, P3667; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5095; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5289; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933; Yamashita T, 2004, EUR J BIOCHEM, V271, P4798, DOI 10.1111/j.1432-1033.2004.04445.x; YOHDA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P234, DOI 10.1016/0167-4781(91)90013-C; Yohda M, 1996, J BIOL CHEM, V271, P22017, DOI 10.1074/jbc.271.36.22017	37	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11586	11594		10.1074/jbc.M600114200	http://dx.doi.org/10.1074/jbc.M600114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510449	hybrid			2022-12-27	WOS:000236988100021
J	Hong, Y; Nagamune, K; Morita, YS; Nakatani, F; Ashida, H; Maeda, Y; Kinoshita, T				Hong, Y; Nagamune, K; Morita, YS; Nakatani, F; Ashida, H; Maeda, Y; Kinoshita, T			Removal or maintenance of inositol-linked acyl chain in glycosylphosphatidylinositol is critical in trypanosome life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; VARIANT SURFACE GLYCOPROTEINS; RNA INTERFERENCE; STRUCTURAL-CHARACTERIZATION; DEVELOPMENTAL VARIATION; INDUCIBLE EXPRESSION; ANCHORED PROTEINS; LEISHMANIA-MAJOR; MEMBRANE ANCHORS; GPI BIOSYNTHESIS	The protozoan parasite Trypanosoma brucei is coated by glycosylphosphatidylinositol ( GPI)-anchored proteins. During GPI biosynthesis, inositol in phosphatidylinositol becomes acylated. Inositol is deacylated prior to attachment to variant surface glycoproteins in the bloodstream form, whereas it remains acylated in procyclins in the procyclic form. We have cloned a T. brucei GPI inositol deacylase ( GPIdeAc2). In accordance with the acylation/deacylation profile, the level of GPIdeAc2 mRNA was 6-fold higher in the bloodstream form than in the procyclic form. Knockdown of GPIdeAc2 in the bloodstream form caused accumulation of an inositol-acylated GPI, a decreased VSG expression on the cell surface and slower growth, indicating that inositol-deacylation is essential for the growth of the bloodstream form. Overexpression of GPIdeAc2 in the procyclic form caused an accumulation of GPI biosynthetic intermediates lacking inositol-linked acyl chain and decreased cell surface procyclins because of release into the culture medium, indicating that overexpression of GPIdeAc2 is deleterious to the surface coat of the procyclic form. Therefore, the GPI inositol deacylase activity must be tightly regulated in trypanosome life cycle.	Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Ashida, Hisashi/HCI-0293-2022; Kinoshita, Taroh/C-7353-2009	Ashida, Hisashi/0000-0001-5844-4075; Morita, Yasu/0000-0002-4514-9242				Alibu VP, 2005, MOL BIOCHEM PARASIT, V139, P75, DOI 10.1016/j.molbiopara.2004.10.002; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Guther MLS, 2003, BIOCHEMISTRY-US, V42, P14532, DOI 10.1021/bi034869g; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Guther MLS, 2001, EMBO J, V20, P4923, DOI 10.1093/emboj/20.17.4923; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MENON AK, 1990, J BIOL CHEM, V265, P9033; Morita YS, 2000, J BIOL CHEM, V275, P14147, DOI 10.1074/jbc.275.19.14147; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Roditi I, 2002, TRENDS MICROBIOL, V10, P128, DOI 10.1016/S0966-842X(02)02309-0; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; Tanaka S, 2004, J BIOL CHEM, V279, P14256, DOI 10.1074/jbc.M313755200; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11595	11602		10.1074/jbc.M513061200	http://dx.doi.org/10.1074/jbc.M513061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510441	hybrid			2022-12-27	WOS:000236988100022
J	Liu, Y; Belkina, NV; Graham, C; Shaw, S				Liu, Y; Belkina, NV; Graham, C; Shaw, S			Independence of protein kinase C-delta activity from activation loop phosphorylation - Structural basis and altered functions in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; PKC-DELTA; PEPTIDE SPECIFICITY; CRYSTAL-STRUCTURE; CK2; DETERMINANTS; APOPTOSIS; ISOTYPES; SEGMENT; SERINE	Activation loop phosphorylation plays critical regulatory roles for many kinases. Unlike other protein kinase Cs ( PKC), PKC-delta does not require phosphorylation of its activation loop ( Thr-507) for in vitro activity. We investigated the structural basis for this unusual capacity and its relevance to PKC-delta function in intact cells. Mutational analysis demonstrated that activity without Thr- 507 phosphorylation depends on 20 residues N-terminal to the kinase domain and a pair of phenylalanines ( Phe-500/Phe-527) unique to PKC-delta in/near the activation loop. Molecular modeling demonstrated that these elements stabilize the activation loop by forming a hydrophobic chain of interactions from the C-lobe to activation loop to N- terminal ( helical) extension. In cells PKC-delta mediates both apoptosis and transcription regulation. We found that the T507A mutant of the PKC-delta kinase domain resembled the corresponding wild type in mediating apoptosis in transfected HEK293T cells. But the T507A mutant was completely defective in AP-1 and NF-kappa B reporter assays. A novel assay in which the kinase domain of PKC-delta and its substrate ( a fusion protein of PKC substrate peptide with green fluorescent protein) were co-targeted to lipid rafts revealed a major substrate-selective defect of the T507A mutant in phosphorylating the substrate in cells. In vitro analysis showed strong product inhibition on the T507A mutant with particular substrates whose characteristics suggest it contributes to the substrate selective defect of the PKC-delta T507A mutant in cells. Thus, activation loop phosphorylation of PKC-delta may regulate its function in cells in a novel way.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	sshaw@nih.gov			NATIONAL CANCER INSTITUTE [ZIABC009257, Z01BC009257] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; Breitenlechner C, 2004, BIOCHEMISTRY-US, V43, P7743, DOI 10.1021/bi0362525; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; Holmes JK, 2001, EUR J BIOCHEM, V268, P4647, DOI 10.1046/j.1432-1327.2001.02392.x; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu Y, 2002, BIOCHEM J, V361, P255, DOI 10.1042/bj3610255; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; Sarno S, 1998, FEBS LETT, V441, P29, DOI 10.1016/S0014-5793(98)01516-6; Sarno S, 2002, J BIOL CHEM, V277, P22509, DOI 10.1074/jbc.M200486200; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Sowadski JM, 1999, PHARMACOL THERAPEUT, V82, P157, DOI 10.1016/S0163-7258(98)00054-0; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; XIE HJ, 1995, J IMMUNOL, V154, P1717; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	32	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12102	12111		10.1074/jbc.M600508200	http://dx.doi.org/10.1074/jbc.M600508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505477	hybrid			2022-12-27	WOS:000236988100080
J	Silva, T; Bradley, RH; Gao, YF; Coue, M				Silva, T; Bradley, RH; Gao, YF; Coue, M			Xenopus CDC7/DRF1 complex is required for the initiation of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; MEIOTIC 2ND DIVISION; CDC7 PROTEIN-KINASE; S-PHASE; CELL-CYCLE; MESSENGER-RNAS; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REGULATORY SUBUNIT; CHROMATIN BINDING	The Cdc7 kinase is essential for the initiation of DNA replication in eukaryotes. Two regulatory subunits of the Xenopus Cdc7 kinase have been identified: XDbf4 and XDrf1. In this study we determined the expression pattern of XDbf4 and XDrf1 and examined their involvement in DNA replication. We show that XDrf1 expression is restricted to oogenesis and early embryos, whereas XDbf4 is expressed throughout development. Immunodepletion from Xenopus egg extracts indicated that both proteins are only found in complexes with XCdc7 and there is a 5-fold molar excess of the XCdc7/Drf1 over SCdc7/Dbf4 complexes. Both complexes exhibit kinase activity and are differentially phosphorylated during the cell cycle. Depletion of the XCdc7/Drf1 from egg extracts inhibited DNA replication, whereas depletion of XCdc7/Dbf4 had little effect. Chromatin binding studies indicated that XCdc7/Drf1 is required for pre-replication complex activation but not their assembly. XCdc7/Dbf4 complexes bound to the chromatin in two steps: the first step was independent of pre-replication complex assembly and the second step was dependent on pre-replication complex activation. By contrast, binding of XCdc7/Drf1 complexes was entirely dependent on pre-replication complex assembly. Finally, we present evidence that the association of the two complexes on the chromatin is not regulated by ATR checkpoint pathways that result from DNA replication blocks. These data suggest that Cdc7/Drf1 but not Cdc7/Dbf4 complexes support the initiation of DNA replication in Xenopus egg extracts and during early embryonic development.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Coue, M (corresponding author), 3601 4th St, Lubbock, TX 79430 USA.	martine.coue@ttuhsc.edu						Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Audic Y, 1997, MOL CELL BIOL, V17, P209, DOI 10.1128/MCB.17.1.209; Audic Y, 2001, MOL CELL BIOL, V21, P1662, DOI 10.1128/MCB.21.5.1662-1671.2001; Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Furukohri A, 2003, J BIOCHEM, V134, P447, DOI 10.1093/jb/mvg163; Hodson JA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng134; Jares P, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-5; Jares P, 2000, GENE DEV, V14, P1528; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Legagneux V, 1995, RNA, V1, P1001; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Lucas I, 2001, EMBO J, V20, P6509, DOI 10.1093/emboj/20.22.6509; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Menut S, 1999, ADV MOLEC BIOL, P196; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura T, 2000, GENES CELLS, V5, P463, DOI 10.1046/j.1365-2443.2000.00343.x; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1977, Current Topics Dev Biol, V11, P115, DOI 10.1016/S0070-2153(08)60744-9; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sible JC, 1998, CURR BIOL, V8, P347, DOI 10.1016/S0960-9822(98)70136-8; Takahashi TS, 2005, GENE DEV, V19, P2295, DOI 10.1101/gad.1339805; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Whitmire E, 2002, NATURE, V419, P722, DOI 10.1038/nature01032; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Zhang HJ, 2004, DEVELOPMENT, V131, P2089, DOI 10.1242/dev.01064	43	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11569	11576		10.1074/jbc.M510278200	http://dx.doi.org/10.1074/jbc.M510278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507577	hybrid			2022-12-27	WOS:000236988100019
J	Gale, SE; Frolov, A; Han, XL; Bickel, PE; Cao, L; Bowcock, A; Schaffer, JE; Ory, DS				Gale, SE; Frolov, A; Han, XL; Bickel, PE; Cao, L; Bowcock, A; Schaffer, JE; Ory, DS			A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL GENERALIZED LIPODYSTROPHY; EMBRYONIC STEM-CELLS; SHOTGUN LIPIDOMICS; ACID; IDENTIFICATION; LOCALIZATION; INHIBITION; RECEPTOR; ENZYMES; CLONING	Mutations in the 1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2) gene have been identified in individuals affected with congenital generalized lipodystrophy (CGL). AGPAT2 catalyzes acylation of lysophosphatidic acid to phosphatidic acid, a precursor for both triacylglycerol (TAG) and phospholipid synthesis. Recent studies suggest that reduced AGPAT2 enzymatic activity may underlie the CGL clinical phenotype. To gain insight into how altered AGPAT2 activity causes lipodystrophy, we examined the effect of knockdown of AGPAT2 expression in preadipocytes on TAG synthesis and storage, and on adipocyte differentiation. We show that AGPAT2 mRNA expression is induced 30-fold during adipocyte differentiation and that AGPAT2 enzymatic activity is required for TAG mass accumulation in mature adipocytes. We demonstrate that small interference RNA-mediated knockdown of AGPAT2 expression prevents appropriate early induction of C/EBP beta and PPAR gamma, key transcriptional activators of the adipogenic program, and delays expression of multiple adipocyte-related genes. The unexpected finding, that levels of several phospholipid species, including phosphatidic acid (PA), are elevated in TAG-depleted adipocytes with AGPAT2 knockdown, suggests that impaired AGPAT2 activity affects availability of PA for TAG synthesis but not overall PA synthesis nor utilization of PA for phospholipid synthesis. These findings underscore the importance of an AGPAT2-mediated metabolic pathway in adipocyte differentiation.	Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@wustl.edu	Bickel, Perry/Q-9185-2019	Bowcock, Anne/0000-0001-8691-9090	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067773, K02HL004482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK059577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67773, HL04482] Funding Source: Medline; NIDDK NIH HHS [DK059577, P30 DK056341-06, P30 DK056341-05S2, P30 DK056341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; Chakraborty TR, 1999, J BIOL CHEM, V274, P29786, DOI 10.1074/jbc.274.42.29786; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gargiulo CE, 1999, J LIPID RES, V40, P881; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Han XL, 2005, EXPERT REV PROTEOMIC, V2, P253, DOI 10.1586/14789450.2.2.253; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; Haque W, 2005, BIOCHEM BIOPH RES CO, V327, P446, DOI 10.1016/j.bbrc.2004.12.024; Kitajima K, 2003, METHOD ENZYMOL, V365, P72; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leung DW, 2001, FRONT BIOSCI, V6, pD944, DOI 10.2741/Leung; Lu B, 2005, BIOCHEM J, V385, P469, DOI 10.1042/BJ20041348; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Schaeffer PJ, 2004, J BIOL CHEM, V279, P39593, DOI 10.1074/jbc.M403649200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Umeda K, 2004, DEVELOPMENT, V131, P1869, DOI 10.1242/dev.01065; VANCE D, 2002, BIOCH LIPIDS LIPOPRO, P203; VERGNES L, 2006, IN PRESS J LIPID RES; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wolins NE, 2006, J LIPID RES, V47, P450, DOI 10.1194/jlr.D500037-JLR200; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200	35	100	105	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11082	11089		10.1074/jbc.M509612200	http://dx.doi.org/10.1074/jbc.M509612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495223	hybrid			2022-12-27	WOS:000236822200050
J	Maklashina, E; Iverson, TM; Sher, Y; Kotlyar, V; Andrell, J; Mirza, O; Hudson, JM; Armstrong, FA; Rothery, RA; Weiner, JH; Cecchini, G				Maklashina, E; Iverson, TM; Sher, Y; Kotlyar, V; Andrell, J; Mirza, O; Hudson, JM; Armstrong, FA; Rothery, RA; Weiner, JH; Cecchini, G			Fumarate reductase and succinate oxidase activity of Escherichia coli complex II homologs are perturbed differently by mutation of the flavin binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; QUINONE OXIDOREDUCTASES; FLAVOCYTOCHROME C(3); ELECTRON-TRANSPORT; CATALYTIC-ACTIVITY; DEHYDROGENASE; SITE; ENZYME; IDENTIFICATION	The Escherichia coli complex II homologues succinate: ubiquinone oxidoreductase (SQR, SdhCDAB) and menaquinol: fumarate oxidoreductase (QFR, FrdABCD) have remarkable structural homology at their dicarboxylate binding sites. Although both SQR and QFR can catalyze the interconversion of fumarate and succinate, QFR is a much better fumarate reductase, and SQR is a better succinate oxidase. An exception to the conservation of amino acids near the dicarboxylate binding sites of the two enzymes is that there is a Glu (FrdA Glu-49) near the covalently bound FAD cofactor in most QFRs, which is replaced with a Gln ( SdhA Gln-50) in SQRs. The role of the amino acid side chain in enzymes with Glu/Gln/Ala substitutions at FrdA Glu-49 and SdhA Gln-50 has been investigated in this study. The data demonstrate that the mutant enzymes with Ala substitutions in either QFR or SQR remain functionally similar to their wild type counterparts. There were, however, dramatic changes in the catalytic properties when Glu and Gln were exchanged for each other in QFR and SQR. The data show that QFR and SQR enzymes are more efficient succinate oxidases when Gln is in the target position and a better fumarate reductase when Glu is present. Overall, structural and catalytic analyses of the FrdA E49Q and SdhA Q50E mutants suggest that coulombic effects and the electronic state of the FAD are critical in dictating the preferred directionality of the succinate/fumarate interconversions catalyzed by the complex II superfamily.	Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci & Technol, Dept Biol Sci, London SW7 2AY, England; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Imperial College London; University of Oxford; University of Alberta	Cecchini, G (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, 151-S,4150 Clement St, San Francisco, CA 94121 USA.	Gary.Cecchini@ucsf.edu		Rothery, Richard/0000-0003-3265-1783; Mirza, Osman Asghar/0000-0001-9435-0690	Biotechnology and Biological Sciences Research Council [B19096] Funding Source: Medline; NIGMS NIH HHS [R01 GM061606, GM61606] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ACKRELL BAC, 1993, FEBS LETT, V326, P92, DOI 10.1016/0014-5793(93)81768-U; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; ACKRELL BAC, 1982, FLAVINS FLAVOPROTEIN, P488; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847; Horsefield R, 2003, ACTA CRYSTALLOGR D, V59, P600, DOI 10.1107/S0907444903002075; Hudson JM, 2005, J AM CHEM SOC, V127, P6977, DOI 10.1021/ja043404q; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leger C, 2001, BIOCHEMISTRY-US, V40, P11234, DOI 10.1021/bi010889b; Leys D, 1999, NAT STRUCT BIOL, V6, P1113; Luna-Chavez C, 2000, PROTEIN EXPRES PURIF, V19, P188, DOI 10.1006/prep.2000.1238; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; Pershad HR, 1999, BBA-BIOENERGETICS, V1412, P262, DOI 10.1016/S0005-2728(99)00066-3; Reid GA, 2000, BBA-BIOENERGETICS, V1459, P310, DOI 10.1016/S0005-2728(00)00166-3; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; Turner KL, 1999, BIOCHEMISTRY-US, V38, P3302, DOI 10.1021/bi9826308; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	50	39	40	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11357	11365		10.1074/jbc.M512544200	http://dx.doi.org/10.1074/jbc.M512544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484232	hybrid			2022-12-27	WOS:000236822200078
J	Yin, SM; Yu, SL; Li, CY; Wong, P; Chang, BG; Xiao, F; Kang, SC; Yan, HM; Xiao, GF; Grassi, J; Tien, P; Sy, MS				Yin, SM; Yu, SL; Li, CY; Wong, P; Chang, BG; Xiao, F; Kang, SC; Yan, HM; Xiao, GF; Grassi, J; Tien, P; Sy, MS			Prion proteins with insertion mutations have altered N-terminal conformation and increased ligand binding activity and are more susceptible to oxidative attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH; IDENTIFICATION; COPPER; GENE; MICE; PRP; REPLICATION; EXPRESSION; INFECTION; FEATURES	We compared the biochemical properties of a wild type recombinant normal human cellular prion protein, rPrP(c), with a recombinant mutant human prion protein that has three additional octapeptide repeats, rPrP(8OR). Monoclonal antibodies that are specific for the N terminus of rPrP(c) react much better with rPrP(8OR) than rPrP(c), suggesting that the N terminus of rPrP(8OR) is more exposed and hence more available for antibody binding. The N terminus of PrPc contains a glycosaminoglycan binding motif. Accordingly, rPrP(8OR) also binds more glycosaminoglycan than rPrP(c). In addition, the divalent cation copper modulates the conformations of rPrP(c) and rPrP(8OR) differently. When compared with rPrP(c), rPrP(8OR) is also more susceptible to oxidative damage. Furthermore, the abnormalities associated with rPrP(8OR) are recapitulated, but even more profoundly, in another insertion mutant, which has five extra octapeptide repeats, rPrP(10OR). Therefore, insertion mutants appear to share common features, and the degree of abnormality is proportional to the number of insertions. Any of these anomalies may contribute to the pathogenesis of inherited human prion disease.	Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44120 USA; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China; Wuhan Univ, Coll Life Sci, Modern Virol Res Ctr, Wuhan 430072, Hubei, Peoples R China; CEA Saclay, CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Case Western Reserve University; Chinese Academy of Sciences; Institute of Microbiology, CAS; Wuhan University; CEA; UDICE-French Research Universities; Universite Paris Saclay	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, Wolstein Res Bldg,Rm 5131,2103 Cornell Rd, Cleveland, OH 44106 USA.	mxs92@po.cwru.edu	chang, binggong/F-5043-2014	Yan, Huimin/0000-0002-7243-8429	NINDS NIH HHS [NS-045981-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045981] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bonomo RP, 2000, CHEM-EUR J, V6, P4195, DOI 10.1002/1521-3765(20001117)6:22<4195::AID-CHEM4195>3.0.CO;2-2; Brown LR, 2003, J NEUROCHEM, V87, P353, DOI 10.1046/j.1471-4159.2003.01996.x; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; Chevion M, 2000, FREE RADICAL RES, V33, pS99; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Croes EA, 2004, J NEUROL NEUROSUR PS, V75, P1166, DOI 10.1136/jnnp.2003.020198; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Frankenfield KN, 2005, PROTEIN SCI, V14, P2154, DOI 10.1110/ps.051434005; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Grasbon-Frodl E, 2004, NEUROGENETICS, V5, P249, DOI 10.1007/s10048-004-0196-x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Hijazi N, 2005, J BIOL CHEM, V280, P17057, DOI 10.1074/jbc.M411314200; Huang Z, 1996, CURR TOP MICROBIOL, V207, P49; Hutter G, 2003, BIOL CHEM, V384, P1279, DOI 10.1515/BC.2003.142; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; OWEN F, 1989, LANCET, V1, P51; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2005, J VIROL, V79, P934, DOI 10.1128/JVI.79.2.934-943.2005; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Wong BS, 2003, CELL MOL LIFE SCI, V60, P1224, DOI 10.1007/s00018-003-3057-0; Wong BS, 2001, J NEUROCHEM, V76, P565, DOI 10.1046/j.1471-4159.2001.00028.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yin SM, 2003, PROTEIN EXPRES PURIF, V32, P104, DOI 10.1016/S1046-5928(03)00195-5; Yu SL, 2004, EUR J HUM GENET, V12, P867, DOI 10.1038/sj.ejhg.5201245; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 2003, J MOL BIOL, V334, P477, DOI 10.1016/j.jmb.2003.09.048; Zanusso G, 2004, J BIOL CHEM, V279, P38936, DOI 10.1074/jbc.M405468200; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	46	36	37	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10698	10705		10.1074/jbc.M511819200	http://dx.doi.org/10.1074/jbc.M511819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478730	hybrid			2022-12-27	WOS:000236822200008
J	Schachman, HK				Schachman, HK			From "publish or perish" to "patent and prosper"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Schachman, HK (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	howardschachman@berkeley.edu						Allen Ernest M, 1980, NIH ALUMNI ASS NEWSL, V2, P6; ALTMAN LK, 2005, NY TIMES        1220; [Anonymous], 1982, BETRAYERS TRUTH FRAU; Barton JH, 2000, SCIENCE, V287, P1933, DOI 10.1126/science.287.5460.1933; Baum RM, 2006, CHEM ENG NEWS, V84, P3, DOI 10.1021/cen-v084n046.p003; Bok D., 2003, U MARKETPLACE COMMER; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Bush, 1945, SCI THE ENDLESS FRON, DOI DOI 10.1016/j.techsoc.2019.03.007; CHANG K, 2002, NY TIMES        1015; Cyranoski D, 2006, NATURE, V439, P122, DOI 10.1038/439122a; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; EISENBERG RS, 1997, WORKSH INT PROP RIGH; Fishbein EA, 2001, JAMA-J AM MED ASSOC, V285, P939, DOI 10.1001/jama.285.7.939; GUTERMAN L, 2006, CHRONICLE HIGHE 0127; HAMILTON DP, 1991, SCIENCE, V254, P788, DOI 10.1126/science.1948058; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HAYWOOD JR, 2001, FASEB NEWS, P18; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Jacoby M, 2002, CHEM ENG NEWS, V80, P31, DOI 10.1021/cen-v080n044.p031; JOHNSON G, 2002, NY TIMES        1015; Kassirer JP, 2000, JAMA-J AM MED ASSOC, V284, P2156, DOI 10.1001/jama.284.17.2156; KEVLES D, 2002, DAEDALUS         SPR, P78; Kohn A., 1986, FALSE PROPHETS FRAUD; Koski G, 2002, AAAS SCI TECHNOLOGY, P193; LEAF C, 2005, FORTUNE         0919, P250; Lloyd W.F., 1883, 2 LECT CHECKS POPULA; LOMASK M, 1975, MINOR MIRACLE INFORM; MANDEL R, 1996, DIVISION RES GRANTS; MARX AW, 2003, NY TIMES        0517; Normile D, 2006, SCIENCE, V311, P156, DOI 10.1126/science.311.5758.156; Rai AK, 2003, AM SCI, V91, P52, DOI 10.1511/2003.11.842; Rothman DJ, 2000, NEW ENGL J MED, V342, P1284, DOI 10.1056/NEJM200004273421711; Schachman HK, 2000, ANNU REV BIOCHEM, V69, P1, DOI 10.1146/annurev.biochem.69.1.1; SCHACHMAN HK, 1993, SCIENCE, V261, P148, DOI 10.1126/science.8305005	34	19	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6889	6903		10.1074/JBC.X600002200	http://dx.doi.org/10.1074/JBC.X600002200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16531416	hybrid			2022-12-27	WOS:000236030900001
J	Dixit, VD; Weeraratna, AT; Yang, HW; Bertak, D; Cooper-Jenkins, A; Riggins, GJ; Eberhart, CG; Taub, DD				Dixit, Vishwa Deep; Weeraratna, Ashani T.; Yang, Hyunwon; Bertak, Dorothy; Cooper-Jenkins, Anthony; Riggins, Gregory J.; Eberhart, Charles G.; Taub, Dennis D.			Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DES-ACYL GHRELIN; PROTEIN-KINASE-C; BIOLOGICAL-ACTIVITY; MESSENGER-RNA; EXPRESSION; ACTIVATION; IDENTIFICATION; CANCER; GLIOMA; CELLS	Originally thought of as a stomach-derived endocrine peptide acting via its receptors in the central nervous system to stimulate food intake and growth hormone expression, ghrelin and its receptor ( growth hormone secretagogue receptor (GHS-R)) are widely expressed in a number of organ systems, including cancer cells. However, the direct functional role of ghrelin and its receptor in tumors of central nervous system origin remains to be defined. Here, we demonstrate that the human astrocytoma cell lines U-118, U-87, CCF-STTG1, and SW1088 express 6-, 11-, 15-, and 29-fold higher levels of GHS-R compared with primary normal human astrocytes. The ligation of GHS-R by ghrelin on these cells resulted in an increase in intracellular calcium mobilization, protein kinase C activation, actin polymerization, matrix metalloproteinase-2 activity, and astrocytoma motility. In addition, ghrelin led to actin polymerization and membrane ruffling on cells, with the specific co-localization of the small GTPase Rac1 with GHS-R on the leading edge of the astrocytoma cells and imparting the tumor cells with a motile phenotype. Disruption of the endogenous ghrelin/GHS-R pathway by RNA interference resulted in diminished motility, matrix metalloproteinase activity, and Rac expression, whereas tumor cells stably overexpressing GHS-R exhibited increased cell motility. The relevance of ghrelin and GHS-R expression was verified in clinically relevant tissues from 20 patients with oligodendrogliomas and grade II-IV astrocytomas. Analysis of a central nervous system tumor tissue microarray revealed that strong GHS-R and ghrelin expression was significantly more common in high grade tumors compared with low grade ones. Together, these findings suggest a novel role for the ghrelin/ GHS-R axis in astrocytoma cell migration and invasiveness of cancers of central nervous system origin.	NIA, Clin Immunol Sect, Immunol Lab, NIH,Intramural Res Program, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins University	Taub, DD (corresponding author), NIA, Clin Immunol Sect, Immunol Lab, NIH,Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Taubd@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000758, Z01AG000766] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AG000758-10] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Albini A, 1998, Pathol Oncol Res, V4, P230; Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Baessler A, 2005, DIABETES, V54, P259, DOI 10.2337/diabetes.54.1.259; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Barlier A, 1999, J NEUROENDOCRINOL, V11, P491; Boon K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-39; Burton E C, 2000, Curr Treat Options Oncol, V1, P459, DOI 10.1007/s11864-000-0073-2; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; CARLINI VP, 1999, BIOCHEM BIOPH RES CO, V299, P739; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Cassoni P, 2004, EUR J ENDOCRINOL, V150, P173, DOI 10.1530/eje.0.1500173; Cassoni P, 2001, J CLIN ENDOCR METAB, V86, P1738, DOI 10.1210/jc.86.4.1738; Chen CY, 2005, GASTROENTEROLOGY, V129, P8, DOI 10.1053/j.gastro.2005.04.015; Corbetta S, 2003, J CLIN ENDOCR METAB, V88, P3117, DOI 10.1210/jc.2002-021842; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; De Vriese C, 2005, ENDOCRINOLOGY, V146, P1514, DOI 10.1210/en.2004-0964; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Dupont J, 2003, HORM METAB RES, V35, P740; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V309, P464, DOI 10.1016/j.bbrc.2003.08.024; Garcia JM, 2005, J CLIN ENDOCR METAB, V90, P2920, DOI 10.1210/jc.2004-1788; Gaytan F, 2005, J CLIN ENDOCR METAB, V90, P1798, DOI 10.1210/jc.2004-1532; Gaytan F, 2004, J CLIN ENDOCR METAB, V89, P400, DOI 10.1210/jc.2003-031375; Ghe C, 2002, ENDOCRINOLOGY, V143, P484, DOI 10.1210/en.143.2.484; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Granado M, 2005, AM J PHYSIOL-ENDOC M, V288, pE486, DOI 10.1152/ajpendo.00196.2004; Hirano H, 1999, Neuro Oncol, V1, P109, DOI 10.1093/neuonc/1.2.109; Hosoda H, 2003, J BIOL CHEM, V278, P64, DOI 10.1074/jbc.M205366200; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Jaffe AB, 2003, SCIENCE, V302, P1690, DOI 10.1126/science.1092874; Jeffery PL, 2003, CYTOKINE GROWTH F R, V14, P113, DOI 10.1016/S1359-6101(02)00089-8; Kanamoto N, 2001, J CLIN ENDOCR METAB, V86, P4984, DOI 10.1210/jc.86.10.4984; Kari F W, 1999, J Nutr Health Aging, V3, P92; Kiaris H, 1999, P NATL ACAD SCI USA, V96, P226, DOI 10.1073/pnas.96.1.226; Kim K, 2001, CLIN ENDOCRINOL, V54, P759, DOI 10.1046/j.1365-2265.2001.01286.x; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Nagaya N, 2004, CIRCULATION, V110, P3674, DOI 10.1161/01.CIR.0000149746.62908.BB; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Skinner MM, 1998, J CLIN ENDOCR METAB, V83, P4314, DOI 10.1210/jc.83.12.4314; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Smith RG, 1999, TRENDS ENDOCRIN MET, V10, P128, DOI 10.1016/S1043-2760(98)00132-5; Strickler R, 2000, Clin J Oncol Nurs, V4, P153; Sun YX, 2004, P NATL ACAD SCI USA, V101, P4679, DOI 10.1073/pnas.0305930101; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tsolakis AV, 2004, J CLIN ENDOCR METAB, V89, P3739, DOI 10.1210/jc.2003-032118; Ukkola O, 2001, J CLIN ENDOCR METAB, V86, P3996, DOI 10.1210/jc.86.8.3996; Volante M, 2003, AM J PATHOL, V162, P645, DOI 10.1016/S0002-9440(10)63858-8; Ware ML, 2003, HISTOL HISTOPATHOL, V18, P207, DOI 10.14670/HH-18.207; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	67	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16681	16690		10.1074/jbc.M600223200	http://dx.doi.org/10.1074/jbc.M600223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16527811	Green Accepted, hybrid			2022-12-27	WOS:000238165700062
J	Mizukami, Y; Fujiki, K; Duerr, EM; Gala, M; Jo, WS; Zhang, XB; Chung, DC				Mizukami, Yusuke; Fujiki, Kotoyo; Duerr, Eva-Maria; Gala, Manish; Jo, Won-Seok; Zhang, Xiaobo; Chung, Daniel C.			Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ANGIOGENESIS; INDUCIBLE FACTOR-1; COLORECTAL-CANCER; SIGNALING PATHWAY; FACTOR EXPRESSION; UP-REGULATION; IN-VIVO; RAS; ACTIVATION; CELLS	The induction of vascular endothelial growth factor (VEGF) is an essential feature of tumor angiogenesis. Hypoxia is a potent stimulator of VEGF expression, and hypoxia-inducible factor-1 (HIF-1) is considered to be critical for this induction. However, we have previously demonstrated that induction of VEGF by hypoxia was preserved when HIF-1 alpha was silenced. We sought to better define the molecular basis of this HIF-1-independent regulation. In colon cancer cells, hypoxia stimulated multiple K-ras effector pathways including phosphatidylinositol 3-kinase. VEGF promoter deletion studies identified a novel promoter region between -418 and -223 bp that was responsive to hypoxia in a PI3K/Rho/ROCK-dependent manner. Electrophoretic mobility shift assays identified a fragment between -300 and -251 bp that demonstrated a unique shift only in hypoxic conditions. Inhibition of PI3K or ROCK blocked the formation of this complex. A binding site for c-Myc, a target of ROCK, was identified at -271 bp. A role for c-Myc in the hypoxic induction of VEGF was demonstrated by site-directed mutagenesis of the VEGF promoter and silencing of c-Myc by small interfering RNA. Collectively, these findings suggest an alternative mechanism for the hypoxic induction of VEGF in colon cancer that does not depend upon HIF-1 alpha but instead requires the activation of PI3K/Rho/ROCK and c-Myc.			Chung, DC (corresponding author), Harvard Univ, Sch Med, GRJ-825,55 Fruit St, Boston, MA 02114 USA.	chung.daniel@mgh.harvard.edu	Mizukami, Yusuke/AAU-1767-2021; Mizukami, Yusuke/AAB-1777-2019	Mizukami, Yusuke/0000-0002-1068-7024; 	NCI NIH HHS [CA92594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr LF, 2000, CANCER RES, V60, P143; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chen EY, 2001, CANCER RES, V61, P2429; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kaluz S, 2003, CANCER RES, V63, P917; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Knies-Bamforth UE, 2004, CANCER RES, V64, P6563, DOI 10.1158/0008-5472.CAN-03-3176; KOONG AC, 1994, CANCER RES, V54, P5273; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mezquita P, 2005, ONCOGENE, V24, P889, DOI 10.1038/sj.onc.1208251; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; von Marschall Z, 2001, GUT, V48, P87, DOI 10.1136/gut.48.1.87; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Zhang XB, 2001, CANCER RES, V61, P6050	42	78	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13957	13963		10.1074/jbc.M511763200	http://dx.doi.org/10.1074/jbc.M511763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543245	hybrid			2022-12-27	WOS:000237512300017
J	Hong, JH; Moon, SJ; Byun, HM; Kim, MS; Jo, H; Bae, YS; Lee, SI; Bootman, MD; Roderick, HL; Shin, DM; Seo, JT				Hong, JH; Moon, SJ; Byun, HM; Kim, MS; Jo, H; Bae, YS; Lee, SI; Bootman, MD; Roderick, HL; Shin, DM; Seo, JT			Critical role of phospholipase C gamma 1 in the generation of H2O2-evoked [Ca2+](i) oscillations in cultured rat cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; HYDROGEN-PEROXIDE; REACTIVE-OXYGEN; INTRACELLULAR CA2+; OXIDATIVE STRESS; CALCIUM-RELEASE; EGF RECEPTOR; C-GAMMA; ACTIVATION	Reactive oxygen species, such as the superoxide anion, H2O2, and the hydroxyl radical, have been considered as cytotoxic by-products of cellular metabolism. However, recent studies have provided evidence that H2O2 serves as a signaling molecule modulating various physiological functions. Here we investigated the effect of H2O2 on the regulation of intracellular Ca2+ signaling in rat cortical astrocytes. H2O2 triggered the generation of oscillations of intracellular Ca2+ concentration ([Ca2+](i)) in a concentration-dependent manner over the range 10-100 mu M. The H2O2-induced [Ca2+](i) oscillations persisted in the absence of extracellular Ca2+ and were prevented by depletion of intracellular Ca2+ stores with thapsigargin. The H2O2-induced [Ca2+](i) oscillations were not inhibited by pretreatment with ryanodine but were prevented by 2-aminoethoxydiphenyl borate and caffeine, known antagonists of inositol 1,4,5-trisphosphate receptors. H2O2 activated phospholipase C (PLC) gamma 1 in a dose-dependent manner, and U73122, an inhibitor of PLC, completely abolished the H2O2-induced [Ca2+](i) oscillations. In addition, RNA interference against PLC gamma 1 and the expression of the inositol 1,4,5-trisphosphate-sequestering "sponge" prevented the generation of [Ca2+](i) oscillations. H2O2-induced [Ca2+](i) oscillations and PLC gamma 1 phosphorylation were inhibited by pretreatment with dithiothreitol, a sulfhydryl-reducing agent. Finally, epidermal growth factor induced H2O2 production, PLC gamma 1 activation, and [Ca2+](i) increases, which were attenuated by N-acetylcysteine and diphenyleneiodonium and by the overexpression of peroxiredoxin type II. Therefore, we conclude that low concentrations of exogenously applied H2O2 generate [Ca2+](i) oscillations by activating PLC gamma 1 through sulfhydryl oxidation-dependent mechanisms. Furthermore, we show that this mechanism underlies the modulatory effect of endogenously produced H2O2 on epidermal growth factor-induced Ca2+ signaling in rat cortical astrocytes.	Yonsei Univ, Coll Dent, Dept Oral Biol, Brain Korea Project Med Sci 21,Oral Sci Res Ctr, Seoul 120752, South Korea; Ewha Womans Univ, Ctr Cell Signalling Res, Div Mol Life Sci, Seoul 120750, South Korea; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	Yonsei University; Yonsei University Health System; Ewha Womans University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Shin, DM (corresponding author), Yonsei Univ, Coll Dent, Dept Oral Biol, Brain Korea Project Med Sci 21,Oral Sci Res Ctr, Seoul 120752, South Korea.	dmshin@yumc.yonsei.ac.kr; jeong@yumc.yonsei.ac.kr	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451; Shin, Dong Min/0000-0001-6042-0435; Moon, Seok Jun/0000-0001-7282-2888	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C116, BBS/E/B/00001116] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akaishi T, 2004, NEUROSCI LETT, V356, P25, DOI 10.1016/j.neulet.2003.11.012; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Gamaley IA, 1999, INT REV CYTOL, V188, P203; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hu QH, 2000, J BIOL CHEM, V275, P15749, DOI 10.1074/jbc.M000381200; Hu QH, 2002, J BIOL CHEM, V277, P32546, DOI 10.1074/jbc.M201550200; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lee ZW, 2000, CELL SIGNAL, V12, P91, DOI 10.1016/S0898-6568(99)00069-8; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Liu Q, 2005, CELL BIOCHEM FUNCT, V23, P93, DOI 10.1002/cbf.1171; Meissner G, 2004, CIRC RES, V94, P418, DOI 10.1161/01.RES.0000122072.43826.98; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pariente JA, 2001, J MEMBRANE BIOL, V179, P27, DOI 10.1007/s002320010034; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; Putney JW, 2001, J CELL SCI, V114, P2223; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Redondo PC, 2004, BIOCHEM PHARMACOL, V67, P491, DOI 10.1016/j.bcp.2003.09.031; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Servitja JM, 2000, J NEUROCHEM, V75, P788, DOI 10.1046/j.1471-4159.2000.0750788.x; Smith MA, 2003, J PHYSIOL-LONDON, V547, P417, DOI 10.1113/jphysiol.2002.034561; Sneyd J, 2004, P NATL ACAD SCI USA, V101, P1392, DOI 10.1073/pnas.0303472101; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200	58	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13057	13067		10.1074/jbc.M601726200	http://dx.doi.org/10.1074/jbc.M601726200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543237	Green Published, hybrid			2022-12-27	WOS:000237336600009
J	Kim, SH; Song, JH; Choi, BG; Kim, HJ; Kim, TS				Kim, SH; Song, JH; Choi, BG; Kim, HJ; Kim, TS			Chemical modification of santonin into a diacetoxy acetal form confers the ability to induce differentiation of human promyelocytic leukemia cells via the down-regulation of NF-kappa B DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RETINOIC ACID; HL-60 CELLS; TERMINAL DIFFERENTIATION; SESQUITERPENE LACTONE; D-3-INDUCED DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; IN-VITRO; ACTIVATION; PARTHENOLIDE	Many sesquiterpene lactone compounds either induce or enhance the cell differentiation of human leukemia cells. However, we reported in a previous study that santonin, a eudesmanolide sesquiterpene lactone, exerts no effects on the differentiation of leukemia cells. In this report, to evaluate the possibility of chemically modifying santonin into its derivatives with differentiation inducing activity, we synthesized a series of santonin derivatives, and determined their effects on cellular differentiation in the human promyelocytic leukemia HL-60 cell system. A diacetoxy acetal derivative of santonin (DAAS) was found to induce significant HL-60 cell differentiation in a dose-dependent manner, whereas santonin in its original form did not. The HL-60 cells were differentiated into a granulocytic lineage when exposed to DAAS. In addition, the observed induction in cell differentiation closely correlated with the levels of NF-kappa B DNA binding activity inhibited by DAAS. Both Western blot analyses and kinase inhibitor studies determined that protein kinase C, ERK, and phosphatidylinositol 3-kinase were upstream components of the DAAS-mediated inhibition of NF-kappa B binding activity in HL-60 leukemia cells. The results of this study indicate that santonin can, indeed, be chemically modified into a derivative with differentiation inducing abilities, and suggest that DAAS might prove useful in the treatment of neoplastic diseases.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Chonnam Natl Univ, Coll Pharm, Res Inst Drug Dev, Kwangju 500757, South Korea; Chonnam Natl Univ Hosp, Genome Res Ctr Hematopoiet Dis, Kwangju 500757, South Korea	Korea University; Chonnam National University; Chonnam National University; Chonnam National University Hospital	Kim, TS (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	tskim@korea.ac.kr		Kim, Seung Hyun/0000-0001-5527-6846				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALHARBI MM, 1994, JPN J PHARMACOL, V64, P135, DOI 10.1254/jjp.64.135; ANDO M, 1987, J ORG CHEM, V52, P4782; BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299; Bertagnolo V, 1999, CANCER RES, V59, P542; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Cai JY, 2004, ARCH BIOCHEM BIOPHYS, V424, P119, DOI 10.1016/j.abb.2004.02.012; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; Coligan J, 1995, CURRENT PROTOCOLS IM; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HALL IH, 1988, ANTICANCER RES, V8, P33; Hehner SP, 1999, J IMMUNOL, V163, P5617; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; Kang SN, 2002, BRIT J PHARMACOL, V135, P1235, DOI 10.1038/sj.bjp.0704573; KANSAS GS, 1990, BLOOD, V76, P2483; KATO K, 1971, TETRAHEDRON, V27, P5987, DOI 10.1016/S0040-4020(01)91763-6; Kim SH, 2005, EUR J PHARMACOL, V511, P89, DOI 10.1016/j.ejphar.2005.02.008; Kim SH, 2002, BIOCHEM PHARMACOL, V64, P1233, DOI 10.1016/S0006-2952(02)01292-3; Kim TS, 2001, BRIT J PHARMACOL, V134, P571, DOI 10.1038/sj.bjp.0704298; KOMADA F, 1991, CANCER RES, V51, P4271; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Makishima M, 1998, BLOOD, V91, P4715, DOI 10.1182/blood.V91.12.4715.412k07_4715_4726; Marcinkowska E, 1997, BIOCHEM BIOPH RES CO, V241, P419, DOI 10.1006/bbrc.1997.7832; MARTIN ML, 1988, J ETHNOPHARMACOL, V23, P285, DOI 10.1016/0378-8741(88)90007-4; Mata-Greenwood E, 2001, J NAT PROD, V64, P1509, DOI 10.1021/np010212p; Ohnishi M, 1997, JPN J CANCER RES, V88, P111, DOI 10.1111/j.1349-7006.1997.tb00355.x; PEREZSOUTO N, 1992, J CHROMATOGR, V593, P209, DOI 10.1016/0021-9673(92)80288-6; Ross JJ, 1999, PLANTA MED, V65, P126, DOI 10.1055/s-1999-13972; ROSSI C, 1986, J PHARM SCI, V75, P784, DOI 10.1002/jps.2600750812; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Sharma HW, 1996, ANTICANCER RES, V16, P589; Singh B, 2001, FOLIA MICROBIOL, V46, P137, DOI 10.1007/BF02873592; Sokoloski JA, 1998, CANCER LETT, V125, P157, DOI 10.1016/S0304-3835(97)00505-3; Szanto A, 2005, MOL PHARMACOL, V67, P1935, DOI 10.1124/mol.104.006445; TANAKA H, 1983, BIOCHEM BIOPH RES CO, V117, P86, DOI 10.1016/0006-291X(83)91544-9; Tsiftsoglou AS, 2003, PHARMACOL THERAPEUT, V100, P257, DOI 10.1016/j.pharmthera.2003.09.002; VANDERSCHOOT CE, 1989, ACTA HAEMATOL, V78, P32; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WU XZ, 1989, LEUKEMIA RES, V13, P869, DOI 10.1016/0145-2126(89)90039-8; Yen A, 2004, MOL PHARMACOL, V66, P1727, DOI 10.1124/mol.104.003475; ZAKARIA H, 1999, J EXP MED, V190, P1583	45	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13117	13125		10.1074/jbc.M510944200	http://dx.doi.org/10.1074/jbc.M510944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554308	hybrid			2022-12-27	WOS:000237336600016
J	Korkhov, VM; Holy, M; Freissmuth, M; Sitte, HH				Korkhov, VM; Holy, M; Freissmuth, M; Sitte, HH			The conserved glutamate (Glu(136)) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; AMINOBUTYRIC-ACID TRANSPORTER-1; ENERGY-TRANSFER MICROSCOPY; RAT GABA TRANSPORTER-1; OLIGOMER FORMATION; NEUROTRANSMITTER TRANSPORTERS; PLATELET 5-HYDROXYTRYPTAMINE; SURFACE EXPRESSION; ESCHERICHIA-COLI; COCAINE BINDING	The alternate access model provides the theoretical framework for understanding how transporters translocate hydrophilic substrates across the lipid bilayer. The model postulates at least two conformations of a transporter, an outward and an inward facing conformation, which seal the translocation pathway to the interior and exterior of the cell, respectively. It is not clear how the conformational switch is triggered in neurotransmitter/ sodium symporters, but Na+ is likely to play an essential role. Here, we focused on Glu(136) of the serotonin transporter ( SERT); this residue is conserved in transmembrane domain 2 of neurotransmitter/ sodium symporters and related proteins. Three substitutions were introduced, resulting in SERT- E136D, SERT- E136Q, and SERT- E136A, which were all correctly inserted into the plasma membrane. SERT-E136Q and SERT- E136A failed to support substrate influx into cells, whereas SERT- E136D did so at a reduced rate. Binding experiments with the inhibitor 2 beta- [H-3] carbomethoxy- 3 beta- ( 4- iodophenyl) tropane (beta- [H-3] CIT) supported the conjecture that the mutant transporters preferentially adopted the inward facing conformation: beta- [H-3] CIT interacted with SERT in a manner consistent with binding to the outward facing state. Accordingly, the Na+- induced acceleration of beta- [H-3] CIT association was most pronounced in wildtype SERT, followed bySERT- E136D > SERT- E136Q > SERT- E136A. Similarly, SERT- E136Q supported substrate efflux in a manner indistinguishable from wild- type SERT, whereas SERT- E136A was inactive. Thus, in the absence of Glu136, the conformational equilibrium of SERT is shifted progressively ( SERT- E136D > SERT- E136Q > SERT- E136A) to the inward facing conformation.	Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Sitte, Harald/O-7025-2019; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Freissmuth, Michael/0000-0001-9398-1765; Korkhov, Volodymyr/0000-0002-0962-9433				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Adams SV, 2003, BIOPHYS J, V85, P1548, DOI 10.1016/S0006-3495(03)74587-1; Adams SV, 2002, BIOPHYS J, V83, P3268, DOI 10.1016/S0006-3495(02)75328-9; ANDROUTSELLISTH, 2003, J BIOL CHEM, V278, P12073; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Farhan H, 2004, J BIOL CHEM, V279, P28553, DOI 10.1074/jbc.M307325200; Galli A, 1997, J NEUROSCI, V17, P3401; Hahn MK, 2003, J NEUROSCI, V23, P4470; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; NELSON PJ, 1979, J BIOL CHEM, V254, P84; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Rudnick Gary, 2002, P25; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Scholze P, 2000, J PHARMACOL EXP THER, V293, P870; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; Sitte HH, 2004, MOL INTERV, V4, P38, DOI 10.1124/mi.4.1.38; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Sur C, 1998, J NEUROCHEM, V70, P2545; TALVENHEIMO J, 1979, J BIOL CHEM, V254, P4631; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; WALL SC, 1993, MOL PHARMACOL, V43, P264; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	43	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13439	13448		10.1074/jbc.M511382200	http://dx.doi.org/10.1074/jbc.M511382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527819	hybrid			2022-12-27	WOS:000237336600051
J	Lansky, IB; Lukat-Rodgers, GS; Block, D; Rodgers, KR; Ratliff, M; Wilks, A				Lansky, IB; Lukat-Rodgers, GS; Block, D; Rodgers, KR; Ratliff, M; Wilks, A			The cytoplasmic heme-binding protein (PhuS) from the heme uptake system of Pseudomonas aeruginosa is an intracellular heme-trafficking protein to the delta-regioselective heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; AXIAL LIGAND MUTANTS; SHIGELLA-DYSENTERIAE; RESONANCE RAMAN; CORYNEBACTERIUM-DIPHTHERIAE; HORSERADISH-PEROXIDASE; SIGNAL-TRANSDUCTION; DEPENDENT SYSTEMS; COUPLED OXIDATION; TRANSPORT-SYSTEM	The uptake and utilization of heme as an iron source is a receptor-mediated process in bacterial pathogens and involves a number of proteins required for internalization and degradation of heme. In the following report we provide the first in-depth spectroscopic and functional characterization of a cytoplasmic heme-binding protein PhuS from the opportunistic pathogen Pseudomonas aeruginosa. Spectroscopic characterization of the heme-PhuS complex at neutral pH indicates that the heme is predominantly six-coordinate low spin. However, the resonance Raman spectra and global fit analysis of the UV-visible spectra show that at all pH values between 6 and 10 three distinct species are present to varying degrees. The distribution of the heme across multiple spin states and coordination number highlights the flexibility of the heme environment. We provide further evidence that the cytoplasmic heme- binding proteins, contrary to previous reports, are not heme oxygenases. The degradation of the heme-PhuS complex in the presence of a reducing agent is a result of H2O2 formed by direct reduction of molecular oxygen and does not yield biliverdin. In contrast, the heme-PhuS complex is an intracellular heme trafficking protein that specifically transfers heme to the previously characterized iron- regulated heme oxygenase pa-HO. Surface plasmon resonance experiments confirm that the transfer of heme is driven by a specific protein- protein interaction. This data taken together with the spectroscopic characterization is consistent with a protein that functions to shuttle heme within the cell.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA	University System of Maryland; University of Maryland Baltimore; North Dakota State University Fargo	Wilks, A (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	awilks@rx.umaryland.edu			NCRR NIH HHS [P20 RR015566, P20 RR15556] Funding Source: Medline; NIAID NIH HHS [AI-48551] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048551] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ANTONINI E, 1971, FRONTIERS BIOL HEMOG, V21; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; Avila L, 2003, J AM CHEM SOC, V125, P4103, DOI 10.1021/ja029311v; Avila L, 2000, J AM CHEM SOC, V122, P7618, DOI 10.1021/ja001137s; Boffi A, 1999, BIOPHYS J, V77, P1143, DOI 10.1016/S0006-3495(99)76965-1; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; Das TK, 1999, J BIOL CHEM, V274, P2916, DOI 10.1074/jbc.274.5.2916; Das TK, 1999, INORG CHEM, V38, P1952, DOI 10.1021/ic990049+; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Eakanunkul S, 2005, BIOCHEMISTRY-US, V44, P13179, DOI 10.1021/bi050422r; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FUHROP JH, 1975, PROPHYRINS METALLOPO; HENDERSON DP, 1993, MOL MICROBIOL, V7, P461, DOI 10.1111/j.1365-2958.1993.tb01137.x; Hornung JM, 1996, MOL MICROBIOL, V20, P725, DOI 10.1111/j.1365-2958.1996.tb02512.x; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; LETOFFE S, 1994, J BACTERIOL, V176, P5372; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Mey AR, 2001, MOL MICROBIOL, V42, P835, DOI 10.1046/j.1365-2958.2001.02683.x; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; O'Malley SM, 1999, J BACTERIOL, V181, P3594; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Palma M, 2003, ARCH MICROBIOL, V180, P374, DOI 10.1007/s00203-003-0602-z; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; Sigman JA, 2001, J AM CHEM SOC, V123, P6945, DOI 10.1021/ja015776u; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Suits MDL, 2005, P NATL ACAD SCI USA, V102, P16955, DOI 10.1073/pnas.0504289102; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Wegele R, 2004, J BIOL CHEM, V279, P45791, DOI 10.1074/jbc.M408303200; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Wilks A, 2002, ANTIOXID REDOX SIGN, V4, P603, DOI 10.1089/15230860260220102; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; Wyckoff EE, 1998, MOL MICROBIOL, V28, P1139, DOI 10.1046/j.1365-2958.1998.00873.x; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	51	79	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13652	13662		10.1074/jbc.M600824200	http://dx.doi.org/10.1074/jbc.M600824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533806	hybrid			2022-12-27	WOS:000237336600076
J	O'Brien, DP; Israel, DA; Krishna, U; Romero-Gallo, J; Nedrud, J; Medof, ME; Lin, F; Redline, R; Lublin, DM; Nowicki, BJ; Franco, AT; Ogden, S; Williams, AD; Polk, DB; Peek, RM				O'Brien, DP; Israel, DA; Krishna, U; Romero-Gallo, J; Nedrud, J; Medof, ME; Lin, F; Redline, R; Lublin, DM; Nowicki, BJ; Franco, AT; Ogden, S; Williams, AD; Polk, DB; Peek, RM			The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERING ESCHERICHIA-COLI; EPITHELIAL-CELLS; CAGA PROTEIN; IV SECRETION; FACTOR CD55; TRANSEPITHELIAL MIGRATION; TYROSINE PHOSPHORYLATION; GASTROINTESTINAL-TRACT; AFA/DR ADHESINS; IN-VITRO	Persistent gastritis induced by Helicobacter pylori is the strongest known risk factor for peptic ulcer disease and distal gastric adenocarcinoma, a process for which adherence of H. pylori to gastric epithelial cells is critical. Decay-accelerating factor ( DAF), a protein that protects epithelial cells from complement-mediated lysis, also functions as a receptor for several microbial pathogens. In this study, we investigated whether H. pylori utilizes DAF as a receptor and the role of DAF within H. pylori-infected gastric mucosa. In vitro studies showed that H. pylori adhered avidly to Chinese hamster ovary cells expressing human DAF but not to vector controls. In H. pylori, disruption of the virulence factors vacA, cagA, and cagE did not alter adherence, but deletion of DAF complement control protein ( CCP) domains 1 - 4 or the heavily O-glycosylated serinethreonine-rich COOH-terminal domain reduced binding. In cultured gastric epithelial cells, H. pylori induced transcriptional upregulation of DAF, and genetic deficiency of DAF attenuated the development of inflammation among H. pylori-infected mice. These results indicate that DAF may regulate H. pylori-epithelial cell interactions relevant to pathogenesis.	Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Canc Biol, Nashville, TN 37232 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Meharry Med Coll, Dept Obstet & Gynecol, Nashville, TN 37208 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA; Meharry Med Coll, Div Microbial Pathogenesis & Immune Response, Nashville, TN 37208 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Case Western Reserve University; Washington University (WUSTL); Meharry Medical College; Meharry Medical College; Meharry Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, 2215 Garland Ave,1030C MRB 4, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu		Franco, Aime/0000-0002-1677-5228	NATIONAL CANCER INSTITUTE [R01CA077955, R29CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052471] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77955] Funding Source: Medline; NIDDK NIH HHS [DK-58587] Funding Source: Medline; NINDS NIH HHS [R01 NS052471-04, R01 NS052471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aras RA, 2003, J EXP MED, V198, P1349, DOI 10.1084/jem.20030381; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; Berstad AE, 1998, GUT, V42, P522, DOI 10.1136/gut.42.4.522; Betis F, 2003, INFECT IMMUN, V71, P1774, DOI 10.1128/IAI.71.4.1774-1783.2003; Betis F, 2003, INFECT IMMUN, V71, P1068, DOI 10.1128/IAI.71.3.1068-1074.2003; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Camorlinga-Ponce M, 2004, J CLIN PATHOL, V57, P822, DOI 10.1136/jcp.2004.017087; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; Cover TL, 2003, CANCER RES, V63, P951; COYNE KE, 1992, J IMMUNOL, V149, P2906; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Garhart CA, 2002, INFECT IMMUN, V70, P3529, DOI 10.1128/IAI.70.7.3529-3538.2002; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Guignot J, 2000, INFECT IMMUN, V68, P3554, DOI 10.1128/IAI.68.6.3554-3563.2000; Gupta RA, 2001, J BIOL CHEM, V276, P31059, DOI 10.1074/jbc.M104141200; Hasan RJ, 2002, INFECT IMMUN, V70, P4485, DOI 10.1128/IAI.70.8.4485-4493.2002; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Karnauchow TM, 1998, J VIROL, V72, P9380, DOI 10.1128/JVI.72.11.9380-9383.1998; Kiso T, 2002, HISTOPATHOLOGY, V40, P339, DOI 10.1046/j.1365-2559.2002.01350.x; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lin F, 2001, IMMUNOLOGY, V104, P215, DOI 10.1046/j.1365-2567.2001.01287.x; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; Moss SF, 2003, CURR OPIN INFECT DIS, V16, P445, DOI 10.1097/00001432-200310000-00011; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oh JD, 2005, P NATL ACAD SCI USA, V102, P5186, DOI 10.1073/pnas.0407657102; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 1998, P ASSOC AM PHYSICIAN, V110, P531; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Rautemaa R, 2001, GASTROENTEROLOGY, V120, P470, DOI 10.1053/gast.2001.21197; Sasaki M, 1998, HISTOPATHOLOGY, V33, P554; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Selvarangan R, 2000, INFECT IMMUN, V68, P1391, DOI 10.1128/IAI.68.3.1391-1399.2000; Servin AL, 2005, CLIN MICROBIOL REV, V18, P264, DOI 10.1128/CMR.18.2.264-292.2005; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; Shafren DR, 1998, J IMMUNOL, V160, P2318; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; YOUSEF GE, 1988, LANCET, V1, P146	53	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13317	13323		10.1074/jbc.M601805200	http://dx.doi.org/10.1074/jbc.M601805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543227	hybrid			2022-12-27	WOS:000237336600037
J	Scott, PG; Dodd, CM; Bergmann, EM; Sheehan, JK; Bishop, PN				Scott, PG; Dodd, CM; Bergmann, EM; Sheehan, JK; Bishop, PN			Crystal structure of the biglycan dimer and evidence that dimerization is essential for folding and stability of class I small leucine-rich repeat proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; DERMATAN SULFATE PROTEOGLYCANS; SKIN PROTEODERMATAN SULFATE; GROWTH-FACTOR-BETA; TARGETED DISRUPTION; CORE PROTEIN; DECORIN; COLLAGEN; BONE; FIBROMODULIN	Biglycan and decorin are two closely related proteoglycans whose protein cores contain leucine-rich repeats flanked by disulfides. We have previously shown that decorin is dimeric both in solution and in crystal structures. In this study we determined whether biglycan dimerizes and investigated the role of dimerization in the folding and stability of these proteoglycans. We used light scattering to show that biglycan is dimeric in solution and solved the crystal structure of the glycoprotein core of biglycan at 3.40-A resolution. This structure reveals that biglycan dimerizes in the same way as decorin, i.e. by apposition of the concave inner surfaces of the leucine-rich repeat domains. We demonstrate that low concentrations of guanidinium chloride denature biglycan and decorin but that the denaturation is completely reversible following removal of the guanidinium chloride, as assessed by circular dichroism spectroscopy. Furthermore, the rate of refolding is dependent on protein concentration, demonstrating that it is not a unimolecular process. Upon heating, decorin shows a single structural transition at a T-m of 45 - 46 degrees C but refolds completely upon cooling to 25 degrees C. This property of decorin enabled us to show both by calorimetry and light scattering that dimer to monomer transition coincided with unfolding and monomer to dimer transition coincided with refolding; thus these processes are inextricably linked. We further conclude that folded monomeric biglycan or decorin cannot exist in solution. This implies novel interrelated functions for the parallel beta sheet faces of these leucine-rich repeat proteoglycans, including dimerization and stabilization of protein folding.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Alberta Synchrotron Inst, Res Transit Facil, Edmonton, AB T6G 2H7, Canada; Univ Manchester, Wellcome Trust Ctr CellMatrix Res, Fac Life Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Med, Acad Unit Eye & Vis Sci, Manchester M13 9PL, Lancs, England	University of Alberta; University of Alberta; University of Manchester; University of Manchester	Scott, PG (corresponding author), Univ Alberta, Dept Biochem, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	Paul.Scott@ualberta.ca		Bishop, Paul/0000-0001-7937-7932	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Le Goff MM, 2003, J BIOL CHEM, V278, P45280, DOI 10.1074/jbc.M303117200; LIU J, 1994, J BIOL CHEM, V269, P28366; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; MCEWAN PA, 2006, IN PRESS J STRUCT BI; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; Pace C N, 1986, Methods Enzymol, V131, P266; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Scott PG, 1997, BBA-GEN SUBJECTS, V1336, P254, DOI 10.1016/S0304-4165(97)00040-8; SCOTT PG, 1993, DERMATAN SULPHATE PR, P81; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZANGRANDO D, 1989, BIOPOLYMERS, V28, P1295, DOI 10.1002/bip.360280710; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	44	66	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13324	13332		10.1074/jbc.M513470200	http://dx.doi.org/10.1074/jbc.M513470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547006	hybrid			2022-12-27	WOS:000237336600038
J	Wang, YQ; Tian, GL; Cowan, NJ; Cabral, F				Wang, YQ; Tian, GL; Cowan, NJ; Cabral, F			Mutations affecting beta-tubulin folding and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ALPHA/BETA-TUBULIN; COFACTOR-A; RESISTANCE; MICROTUBULES; PROTEINS; CHAPERONIN; PREFOLDIN; ISOTYPES; ACTIN	Revertants of a colcemid-resistant Chinese hamster ovary cell line with an altered (D45Y) beta-tubulin have allowed the identification of four cis-acting mutations (L187R, Y398C, a 12-amino acid in-frame deletion, and a C-terminal truncation) that act by destabilizing the mutant tubulin and preventing it from incorporating into microtubules. These unstable beta-tubulins fail to form heterodimers and are predominantly found in association with the chaperonin CCT, suggesting that they cannot undergo productive folding. In agreement with these in vivo observations, we show that the defective beta-tubulins do not stably interact with cofactors involved in the tubulin folding pathway and, hence, fail to exchange with beta-tubulin in purified alpha beta heterodimers. Treatment of cells with MG132 causes an accumulation of the aberrant tubulins, indicating that improperly folded beta-tubulin is degraded by the proteasome. Rapid degradation of the mutant tubulin does not elicit compensatory changes in wild-type tubulin synthesis or assembly. Instead, loss of beta-tubulin from the mutant allele causes a 30-40% decrease in cellular tubulin content with no obvious effect on cell growth or survival.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; NYU, Ctr Med, Dept Biochem, New York, NY 10016 USA	University of Texas System; New York University	Cabral, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	fcabral@uth.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA085935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047234] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085935-07, CA85935, R01 CA085935-06A1, R01 CA085935] Funding Source: Medline; NIDDK NIH HHS [DK47234, R01 DK047234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; Barlow SB, 2002, J CELL SCI, V115, P3469; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; BOGGS BA, 1988, J BIOL CHEM, V263, P14566; CABRAL F, 1982, MOL CELL BIOL, V2, P720, DOI 10.1128/MCB.2.6.720; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; Cabral F, 1979, Methods Enzymol, V56, P602; Cabral F., 2000, DRUG RESIST UPDATE, V3, P1; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; DeLano W.L, PYMOL MOL GRAPHICS S; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Guasch A, 2002, J MOL BIOL, V318, P1139, DOI 10.1016/S0022-2836(02)00185-7; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hari M, 2003, MOL CANCER THER, V2, P597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nolasco S, 2005, FEBS LETT, V579, P3515, DOI 10.1016/j.febslet.2005.05.022; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Ren Y, 2003, J NEUROSCI, V23, P3316; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; Wang YQ, 2004, BIOCHEMISTRY-US, V43, P8965, DOI 10.1021/bi049637b	38	22	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13628	13635		10.1074/jbc.M513730200	http://dx.doi.org/10.1074/jbc.M513730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554299	Green Accepted, hybrid			2022-12-27	WOS:000237336600073
J	Killoran, MP; Keck, JL				Killoran, MP; Keck, JL			Three HRDC domains differentially modulate Deinococcus radiodurans RecQ DNA helicase biochemical activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; PILIN ANTIGENIC VARIATION; CRYSTAL-STRUCTURE; GENETIC-RECOMBINATION; STRAND EXCHANGE; BINDING PROTEIN; REPAIR; PATHWAY; GENOME; WERNER	RecQ helicases are key genome maintenance enzymes that function in DNA replication, recombination, and repair. In contrast to nearly every other identified RecQ family member, the RecQ helicase from the radioresistant bacterium Deinococcus radiodurans encodes three "Helicase and RNaseDC-terminal" (HRDC) domains at its C terminus. HRDC domains have been implicated in structure-specific nucleic acid binding with roles in targeting RecQ proteins to particular DNA structures; however, only RecQ proteins with single HRDC domains have been examined to date. We demonstrate that the HRDC domains can be proteolytically removed from the D. radiodurans RecQ (DrRecQ) C terminus, consistent with each forming a structural domain. Using this observation as a guide, we produced a panel of recombinant DrRecQ variants lacking combinations of its HRDC domains to investigate their biochemical functions. The N-terminal-most HRDC domain is shown to be critical for high affinity DNA binding and for efficient unwinding of DNA in some contexts. In contrast, the more C-terminal HRDC domains attenuate the DNA binding affinity and DNA-dependent ATP hydrolysis rate of the enzyme and play more complex roles in structure-specific DNA unwinding. Our results indicate that the multiple DrRecQ HRDC domains have evolved to encode DNA binding and regulatory functions in the enzyme.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Med Sci Ctr 550, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keck, JL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Med Sci Ctr 550, 1300 Univ Ave, Madison, WI 53706 USA.	jlkeck@wisc.edu		Keck, James/0000-0002-5961-0220	NIGMS NIH HHS [GM067085, R01 GM067085, GM068061] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067085, R01GM068061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bernstein DA, 2004, P NATL ACAD SCI USA, V101, P8575, DOI 10.1073/pnas.0401331101; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Earl AM, 2002, J BACTERIOL, V184, P6216, DOI 10.1128/JB.184.22.6216-6224.2002; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hegde SP, 1996, P NATL ACAD SCI USA, V93, P14468, DOI 10.1073/pnas.93.25.14468; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Ivancic-Bace I, 2005, J BACTERIOL, V187, P1350, DOI 10.1128/JB.187.4.1350-1356.2005; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Kim JI, 2002, P NATL ACAD SCI USA, V99, P7917, DOI 10.1073/pnas.122218499; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitayama S, 2000, MUTAT RES-DNA REPAIR, V461, P179, DOI 10.1016/S0921-8777(00)00044-6; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lee BI, 2004, EMBO J, V23, P2029, DOI 10.1038/sj.emboj.7600222; Leiros I, 2005, EMBO J, V24, P906, DOI 10.1038/sj.emboj.7600582; Liu JL, 2004, J BIOL CHEM, V279, P42794, DOI 10.1074/jbc.M405008200; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Makharashvili N, 2004, STRUCTURE, V12, P1881, DOI 10.1016/j.str.2004.08.006; Mehr IJ, 1998, MOL MICROBIOL, V30, P697, DOI 10.1046/j.1365-2958.1998.01089.x; Misra HS, 2006, MOL MICROBIOL, V59, P1308, DOI 10.1111/j.1365-2958.2005.05005.x; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mullen JR, 2001, GENETICS, V157, P103; Mullen JR, 2000, GENETICS, V154, P1101; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Putnam CD, 2005, DNA REPAIR, V4, P1410, DOI 10.1016/j.dnarep.2005.08.007; Rajan R, 2004, J MOL BIOL, V344, P951, DOI 10.1016/j.jmb.2004.09.087; Sambrook J., 2001, MOL CLONING LAB MANU; Serkin CD, 1998, J BACTERIOL, V180, P1955, DOI 10.1128/JB.180.7.1955-1958.1998; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	30	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12849	12857		10.1074/jbc.M600097200	http://dx.doi.org/10.1074/jbc.M600097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531400	hybrid			2022-12-27	WOS:000237134700080
J	Klein, S; Franco, M; Chardin, P; Luton, F				Klein, S; Franco, M; Chardin, P; Luton, F			Role of the Arf6 GDP/GTP cycle and Arf6 GTPase-activating proteins in actin remodeling and intracellular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR-1; TRANSITION-STATE ANALOG; EFFECTOR DOMAIN MUTANT; PLASMA-MEMBRANE; NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-D; CYTOSKELETON ORGANIZATION; CHOLERA-TOXIN; GAP; COMPLEX	We have analyzed both biochemically and functionally a series of Arf6 mutants, providing new insights into the molecular mode of action of the small G protein Arf6. First, by comparing a fast-cycling mutant (Arf6(T157N)) and a GTPase-deficient mutant (Arf6(Q67L)), we established the necessity for completion of the Arf6 GDP/GTP cycle for recycling of major histocompatibility complex molecules to the plasma membrane. Second, we found that aluminum fluoride (AlFx), known for inducing membrane protrusion in cells expressing exogenous wild-type Arf6, stabilized a functional wild-type Arf6 center dot AlFx center dot GTPase-activating protein (GAP) complex in vitro and in vivo. We also found that the tandem mutation Q37E/S38I prevented the binding of two Arf GAPs, but not the effector ARHGAP10, and blocked the formation of membrane protrusion and actin reorganization. Together, our results with AlFx and Arf6(Q37E/S38I) demonstrate the critical role of the Arf6 GAPs as effectors for Arf6-regulated actin cytoskeleton remodeling. Finally, competition experiments conducted in vivo suggest the existence of a membrane receptor for GDP-bound Arf6.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Luton, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660,Route Lucioles, F-06560 Valbonne, France.	luton@ipmc.cnrs.fr	Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021; Luton, Frederic/N-7673-2017	Franco, Michel/0000-0003-1853-8661; 				Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Hashimoto S, 2004, J BIOL CHEM, V279, P37677, DOI 10.1074/jbc.M404196200; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Honda A, 2005, J CELL BIOL, V168, P1039, DOI 10.1083/jcb.200409138; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; Jovanovic OA, 2006, MOL BIOL CELL, V17, P327, DOI 10.1091/mbc.E05-06-0523; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klein S, 2005, FEBS LETT, V579, P5741, DOI 10.1016/j.febslet.2005.09.055; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Liang JO, 1997, J BIOL CHEM, V272, P33001, DOI 10.1074/jbc.272.52.33001; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Marshansky V, 1997, ELECTROPHORESIS, V18, P538, DOI 10.1002/elps.1150180334; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Santy LC, 2002, J BIOL CHEM, V277, P40185, DOI 10.1074/jbc.C200481200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Venkateswarlu K, 2004, J BIOL CHEM, V279, P6205, DOI 10.1074/jbc.C300482200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	59	46	48	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12352	12361		10.1074/jbc.M601021200	http://dx.doi.org/10.1074/jbc.M601021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527809	hybrid			2022-12-27	WOS:000237134700020
J	Michael, IP; Pampalakis, G; Mikolajczyk, SD; Malm, J; Sotiropoulou, G; Diamandis, EP				Michael, IP; Pampalakis, G; Mikolajczyk, SD; Malm, J; Sotiropoulou, G; Diamandis, EP			Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLANDULAR KALLIKREIN; SERINE-PROTEASE; OVARIAN-CANCER; SEMENOGELIN-I; GENE FAMILY; SUBSTRATE-SPECIFICITY; BLOOD-COAGULATION; STRATUM-CORNEUM; PRO-PSA; PREDOMINANT PROTEIN	Human tissue kallikreins (hKs) are a family of fifteen serine proteases. Several lines of evidence suggest that hKs participate in proteolytic cascade pathways. Human kallikrein 5 (hK5) has trypsin-like activity, is able to self-activate, and is co-expressed in various tissues with other hKs. In this study, we examined the ability of hK5 to activate other hKs. By using synthetic heptapeptides that encompass the activation site of each kallikrein and recombinant pro-hKs, we demonstrated that hK5 is able to activate pro-hK2 and pro-hK3. We then showed that, following their activation, hK5 can internally cleave and deactivate hK2 and hK3. Given the predominant expression of hK2 and hK3 in the prostate, we examined the pathophysiological role of hK5 in this tissue. We studied the regulation of hK5 activity by cations (Zn2+, Ca2+, Mg2+, Na+, and K+) and citrate and showed that Zn2+ can efficiently inhibit hK5 activity at levels well below its normal concentration in the prostate. We also show that hK5 can degrade semenogelins I and II, the major components of the seminal clot. Semenogelins can reverse the inhibition of hK5 by Zn2+, providing a novel regulatory mechanism of its serine protease activity. hK5 is also able to internally cleave insulin-like growth factor-binding proteins 1, 2, 3, 4, and 5, but not 6, suggesting that it might be involved in prostate cancer progression through growth factor regulation. Our results uncover a kallikrein proteolytic cascade pathway in the prostate that participates in seminal clot liquefaction and probably in prostate cancer progression.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Beckman Coulter Inc, San Diego, CA 92121 USA; Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26500, Greece; Malmo Univ Hosp, Dept Lab Med, Univ Lund, Sect Clin Chem, SE-20502 Malmo, Sweden	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Beckman Coulter Inc.; University of Patras; Lund University; Skane University Hospital	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016	Michael, Iacovos P/0000-0001-7674-1233; Diamandis, Eleftherios/0000-0002-1589-820X				Bangma CH, 1997, J UROLOGY, V157, P544, DOI 10.1016/S0022-5347(01)65197-8; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BOOTH BA, 1996, AM J PHYSIOL, V271, P465; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Borgono CA, 2004, MOL CANCER RES, V2, P257; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen ZX, 1997, J UROLOGY, V157, P2166, DOI 10.1016/S0022-5347(01)64704-9; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Costello LC, 2004, PROSTATE CANCER P D, V7, P111, DOI 10.1038/sj.pcan.4500712; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1986, COLD SPRING HARB SYM, V51, P509, DOI 10.1101/SQB.1986.051.01.062; Denmeade SR, 2001, PROSTATE, V48, P122, DOI 10.1002/pros.1088; Diamandis EP, 2003, TUMOR BIOL, V24, P299, DOI 10.1159/000076462; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CLIN CHEM, V48, P1198; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Henricks WH, 1998, AM J CLIN PATHOL, V109, P533, DOI 10.1093/ajcp/109.5.533; Hsieh MC, 2000, BBA-PROTEIN STRUCT M, V1481, P75, DOI 10.1016/S0167-4838(00)00116-3; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Jonsson M, 2005, BIOCHEM J, V387, P447, DOI 10.1042/BJ20041424; KAVANAGH JP, 1985, J REPROD FERTIL, V75, P35; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim H, 2001, BRIT J CANCER, V84, P643, DOI 10.1054/bjoc.2000.1649; Kumar A, 1997, CANCER RES, V57, P3111; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; LILJA H, 1985, SCAND J CLIN LAB INV, V45, P635, DOI 10.3109/00365518509155271; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Lovgren J, 1999, EUR J BIOCHEM, V262, P781, DOI 10.1046/j.1432-1327.1999.00433.x; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; Malm J, 1996, EUR J BIOCHEM, V238, P48, DOI 10.1111/j.1432-1033.1996.0048q.x; Malm J, 2000, PROSTATE, V45, P132, DOI 10.1002/1097-0045(20001001)45:2<132::AID-PROS7>3.0.CO;2-3; Matsumura M, 2005, PROSTATE, V62, P1, DOI 10.1002/pros.20101; Meyer A, 1997, INT J CANCER, V74, P630, DOI 10.1002/(SICI)1097-0215(19971219)74:6<630::AID-IJC13>3.0.CO;2-9; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Mikolajczyk SD, 1997, EUR J BIOCHEM, V246, P440, DOI 10.1111/j.1432-1033.1997.00440.x; NAITO K, 1991, J BIOL CHEM, V266, P7353; Obiezu CV, 2005, CANCER LETT, V224, P1, DOI 10.1016/j.canlet.2004.09.024; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; Rishi I, 2003, APPL IMMUNOHISTO M M, V11, P253; Robert M, 1997, BIOCHEMISTRY-US, V36, P3811, DOI 10.1021/bi9626158; Robert M, 1999, CELL MOL LIFE SCI, V55, P944, DOI 10.1007/s000180050346; Rosenzweig SA, 2004, GROWTH HORM IGF RES, V14, P329, DOI 10.1016/j.ghir.2004.02.003; SENSABAUGH GF, 1990, J UROLOGY, V144, P1523, DOI 10.1016/S0022-5347(17)39790-2; Sotiropoulou G, 2003, ONCOL RES, V13, P381; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P15341, DOI 10.1021/bi015775e; Takayama TK, 1997, J BIOL CHEM, V272, P21582, DOI 10.1074/jbc.272.34.21582; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P1679, DOI 10.1021/bi002129r; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; Yousef GM, 2002, BIOL CHEM, V383, P1045, DOI 10.1515/BC.2002.113; Yousef GM, 2003, CANCER RES, V63, P3958; Yousef GM, 2003, CANCER RES, V63, P2223; Yousef GM, 2002, UROLOGY, V60, P714, DOI 10.1016/S0090-4295(02)01811-3; Yousef GM, 2002, PROSTATE, V51, P126, DOI 10.1002/pros.10067; Yousef GM, 2002, CLIN CHEM, V48, P1241; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202; Zaichick V. Ye, 1996, International Urology and Nephrology, V28, P687, DOI 10.1007/BF02552165; Zheng B, 1998, ENDOCRINOLOGY, V139, P1708, DOI 10.1210/endo.139.4.5945	69	99	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12743	12750		10.1074/jbc.M600326200	http://dx.doi.org/10.1074/jbc.M600326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517595	hybrid			2022-12-27	WOS:000237134700067
J	Row, PE; Prior, IA; McCullough, J; Clague, MJ; Urbe, S				Row, PE; Prior, IA; McCullough, J; Clague, MJ; Urbe, S			The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MEDIATES UBIQUITINATION; DEUBIQUITINATING ENZYME; BINDS UBIQUITIN; PROTEIN; HRS; COMPLEX; DOMAIN; MET; PATHWAY	UBPY is a ubiquitin-specific protease that can deubiquitinate monoubiquitinated receptor tyrosine kinases, as well as process Lys-48- and Lys-63-linked polyubiquitin to lower denomination forms in vitro. Catalytically inactive UBPY localizes to endosomes, which accumulate ubiquitinated proteins. We have explored the sequelae of short interfering RNA-mediated knockdown of UBPY. Global levels of ubiquitinated protein increase and ubiquitin accumulates on endosomes, although free ubiquitin levels are unchanged. UBPY-depleted cells have more and larger multivesicular endosomal structures that are frequently associated through extended contact areas, characterized by regularly spaced, electron-dense, bridging profiles. Degradation of acutely stimulated receptor tyrosine kinases, epidermal growth factor receptor and Met, is strongly inhibited in UBPY knockdown cells suggesting that UBPY function is essential for growth factor receptor down-regulation. In contrast, stability of the UBPY binding partner STAM is dramatically compromised in UBPY knockdown cells. The cellular functions of UBPY are complex but clearly distinct from those of the Lys-63-ubiquitin- specific protease, AMSH, with which it shares a binding site on the SH3 domain of STAM.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Urbe, S (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	urbe@liv.ac.uk	Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; McCullough, John/0000-0001-6836-4394; Prior, Ian/0000-0002-4055-5161; Urbe, Sylvie/0000-0003-4735-9814	Wellcome Trust [074766] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katzmann DJ, 2004, MOL BIOL CELL, V15, P468, DOI 10.1091/mbc.E03-07-0473; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Row PE, 2005, BIOCHEM J, V389, P629, DOI 10.1042/BJ20050067; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759	39	188	191	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12618	12624		10.1074/jbc.M512615200	http://dx.doi.org/10.1074/jbc.M512615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520378	hybrid			2022-12-27	WOS:000237134700052
J	Garcia, AD; Otero, J; Lebowitz, J; Schuck, P; Moss, B				Garcia, AD; Otero, J; Lebowitz, J; Schuck, P; Moss, B			Quaternary structure and cleavage specificity of a poxvirus Holliday junction resolvase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS-DNA; SIZE-DISTRIBUTION ANALYSIS; ESCHERICHIA-COLI; IN-VITRO; LINEAR MINICHROMOSOMES; CONCATEMER JUNCTIONS; RUVC PROTEIN; ANALYTICAL ULTRACENTRIFUGATION; SACCHAROMYCES-CEREVISIAE; HAIRPIN TERMINI	Recently, poxviruses were found to encode a protein with signature motifs present in the RuvC family of Holliday junction ( HJ) resolvases, which have a key role in homologous recombination in bacteria. The vaccinia virus homolog A22 specifically cleaved synthetic HJ DNA in vitro and was required for the in vivo resolution of viral DNA concatemers into unit-length genomes with hairpin telomeres. It was of interest to further characterize a poxvirus resolvase in view of the low sequence similarity with RuvC, the absence of virus-encoded RuvA and RuvB to interact with, and the different functions of the viral and bacterial resolvases. Because purified A22 aggregated severely, studies were carried out with maltose-binding protein fused to A22 as well as to RuvC. Using gel filtration, chemical cross-linking, analytical ultracentrifugation, and light scattering, we demonstrated that A22 and RuvC are homodimers in solution. Furthermore, the dimeric form of the resolvase associated with HJ DNA, presumably facilitating the symmetrical cleavage of such structures. Like RuvC, A22 symmetrically cleaved fixed HJ junctions as well as junctions allowing strand mobility. Unlike RuvC and other members of the family, however, the poxvirus enzyme exhibited little cleavage sequence specificity. Structural and enzymatic similarities of poxvirus, bacterial, and fungal mitochondrial HJ resolvases are consistent with their predicted evolutionary relationship based on sequence analysis. The absence of a homologous resolvase in mammalian cells makes these microbial enzymes excellent potential therapeutic targets.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.	bmoss@nih.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000307, ZIAAI000307] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485, Z01OD011081] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAROUDY BM, 1982, COLD SPRING HARB SYM, V47, P723, DOI 10.1101/SQB.1983.047.01.083; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; COLINAS RJ, 1990, VIROLOGY, V179, P267, DOI 10.1016/0042-6822(90)90295-3; Da Fonseca F, 2003, P NATL ACAD SCI USA, V100, P11291, DOI 10.1073/pnas.1534874100; DELANGE AM, 1987, J VIROL, V61, P1957, DOI 10.1128/JVI.61.6.1957-1963.1987; DELANGE AM, 1989, J VIROL, V63, P2437, DOI 10.1128/JVI.63.6.2437-2444.1989; DELANGE AM, 1986, J VIROL, V59, P249, DOI 10.1128/JVI.59.2.249-259.1986; DICKIE P, 1987, J MOL BIOL, V196, P541, DOI 10.1016/0022-2836(87)90031-3; Eggleston AK, 2000, J BIOL CHEM, V275, P26467, DOI 10.1074/jbc.M001496200; Garcia AD, 2000, P NATL ACAD SCI USA, V97, P8926, DOI 10.1073/pnas.150238697; Garcia AD, 2001, J VIROL, V75, P6460, DOI 10.1128/JVI.75.14.6460-6471.2001; GARON CF, 1978, P NATL ACAD SCI USA, V75, P4863, DOI 10.1073/pnas.75.10.4863; GESHELIN P, 1974, J MOL BIOL, V88, P785, DOI 10.1016/0022-2836(74)90399-4; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; HU FQ, 1991, VIROLOGY, V181, P716, DOI 10.1016/0042-6822(91)90905-Q; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KERR SM, 1991, VIROLOGY, V180, P625, DOI 10.1016/0042-6822(91)90076-N; KERR SM, 1989, NUCLEIC ACIDS RES, V17, P9039, DOI 10.1093/nar/17.22.9039; KERR SM, 1991, EMBO J, V10, P4343, DOI 10.1002/j.1460-2075.1991.tb05012.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCHLINSKY M, 1989, J VIROL, V63, P1595, DOI 10.1128/JVI.63.4.1595-1603.1989; MERCHLINSKY M, 1988, J MOL BIOL, V199, P399, DOI 10.1016/0022-2836(88)90613-4; MERCHLINSKY M, 1990, J VIROL, V64, P3437, DOI 10.1128/JVI.64.7.3437-3446.1990; MERCHLINSKY M, 1989, J VIROL, V63, P4354, DOI 10.1128/JVI.63.10.4354-4361.1989; MERCHLINSKY M, 1986, CELL, V45, P879, DOI 10.1016/0092-8674(86)90562-3; MERCHLINSKY M, 1990, J VIROL, V64, P5029, DOI 10.1128/JVI.64.10.5029-5035.1990; MOSS B, 1996, POXVIRIDAE VIRUSES T, P2637; MOYER RW, 1981, CELL, V27, P391, DOI 10.1016/0092-8674(81)90422-0; Palaniyar N, 1999, J MOL BIOL, V287, P9, DOI 10.1006/jmbi.1999.2586; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUART D, 1992, J VIROL, V66, P1551, DOI 10.1128/JVI.66.3.1551-1563.1992; STUART D, 1991, J VIROL, V65, P61, DOI 10.1128/JVI.65.1.61-70.1991; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, MOL CELL BIOL, V17, P6465, DOI 10.1128/MCB.17.11.6465	50	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11618	11626		10.1074/jbc.M600182200	http://dx.doi.org/10.1074/jbc.M600182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513635	hybrid			2022-12-27	WOS:000236988100025
J	Kiss, RS; Ma, Z; Nakada-Tsukui, K; Brugnera, E; Vassiliou, G; McBride, HM; Ravichandran, KS; Marcel, YL				Kiss, RS; Ma, Z; Nakada-Tsukui, K; Brugnera, E; Vassiliou, G; McBride, HM; Ravichandran, KS; Marcel, YL			The lipoprotein receptor-related protein-1 (LRP) adapter protein GULP mediates trafficking of the LRP ligand prosaposin, leading to sphingolipid and free cholesterol accumulation in late endosomes and impaired efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; NIEMANN-PICK-DISEASE; APOPTOTIC CELLS; TANGIER-DISEASE; SUBCELLULAR-LOCALIZATION; PSEUDOMONAS EXOTOXIN; LYSOSOMAL-ENZYMES; HUMAN FIBROBLASTS; STORAGE DISEASE; SAP PRECURSOR	One of the conserved functional pathways linked to engulfment of apoptotic corpses involves two membrane proteins low density lipoprotein receptor-related protein-1 ( LRP) and ABCA1 and the LRP adapter protein GULP. Because LRP and ABCA1 play roles in cellular lipid trafficking and efflux, here we addressed whether the third member, the LRP adapter protein GULP, also affects cellular lipid transport. Several lines of evidence show that overexpression of GULP causes glycosphingolipid and free cholesterol accumulation in the late endosome/lysosome compartment that is accompanied by down-regulation of ABCA1 and decreased efflux. Conversely, knockdown of endogenous GULP expression promoted cholesterol flux through the late endosomes and up-regulation of ABCA1, even in the context of a disease state such as Niemann-Pick Type C disease. Mechanistically, we were able to show that trafficking of the LRP ligands alpha(2)-macroglobulin and prosaposin, a protein cofactor necessary for glycosphingolipid degradation, are impaired in cells expressing full-length GULP protein, resulting in glycosphingolipid and free cholesterol accumulation in the late endosome/lysosome compartment. On the other hand, knockdown of endogenous GULP results in enhanced targeting of prosaposin and enhanced clearance of glycosphingolipids and cholesterol from the late endosomes. Taken together, these data reveal that GULP/LRP/ABCA1 represents a triad of molecules involved in engulfment and cellular lipid homeostasis.	Univ Virginia, Carter Immunol Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada	University of Virginia; University of Virginia; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Marcel, YL (corresponding author), Univ Virginia, Carter Immunol Ctr, MR4-Rm 4072D,Box 801386,Lane Rd, Charlottesville, VA 22908 USA.	ylmarcel@ottawaheart.ca	McBride, Heidi M./ABD-5774-2021; McBride, Heidi M/C-1162-2008	McBride, Heidi M./0000-0003-4666-2280; McBride, Heidi M/0000-0003-4666-2280	NIAID NIH HHS [T32 AI055432] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI055432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOFF CE, 1990, BIOCHEM BIOPH RES CO, V171, P38, DOI 10.1016/0006-291X(90)91353-T; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; DAHL NK, 1992, J BIOL CHEM, V267, P4889; Duclos S, 2003, J CELL SCI, V116, P907, DOI 10.1242/jcs.00259; Elleder M, 2005, NEUROPEDIATRICS, V36, P171, DOI 10.1055/s-2005-865608; Fadok VA, 2003, CURR BIOL, V13, pR655, DOI 10.1016/S0960-9822(03)00575-X; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; Glaros EN, 2005, J BIOL CHEM, V280, P24515, DOI 10.1074/jbc.M413862200; Gopalakrishnan MM, 2004, BIOCHEM J, V383, P507, DOI 10.1042/BJ20040175; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grimsley C, 2003, TRENDS CELL BIOL, V13, P648, DOI 10.1016/j.tcb.2003.10.004; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HASILIK A, 1980, J BIOL CHEM, V255, P4946; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Hulkova H, 2005, VIRCHOWS ARCH, V447, P31, DOI 10.1007/s00428-005-1246-y; Hulkova H, 2001, HUM MOL GENET, V10, P927, DOI 10.1093/hmg/10.9.927; Kang SJ, 2004, NAT IMMUNOL, V5, P175, DOI 10.1038/ni1034; Kiss RS, 2005, J LIPID RES, V46, P1877, DOI 10.1194/jlr.M400482-JLR200; Klein A, 2006, HEPATOLOGY, V43, P126, DOI 10.1002/hep.20985; Ko KWS, 2001, BIOCHEMISTRY-US, V40, P752, DOI 10.1021/bi001797+; Kotani Y, 1996, J NEUROCHEM, V66, P2197; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Ranganathan S, 2004, J BIOL CHEM, V279, P40536, DOI 10.1074/jbc.M407592200; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Salvioli R, 2005, BIOCHEM J, V390, P95, DOI 10.1042/BJ20050325; Salvioli R, 2004, J BIOL CHEM, V279, P17674, DOI 10.1074/jbc.M313517200; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Sun Y, 2005, J LIPID RES, V46, P2102, DOI 10.1194/jlr.M500202-JLR200; TEVRUCHTE D, 2004, J BIOL CHEM, V279, P26167; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vassiliou G, 2001, J BIOL CHEM, V276, P48823, DOI 10.1074/jbc.M103954200; Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003; Vielhaber G, 1996, J BIOL CHEM, V271, P32438, DOI 10.1074/jbc.271.50.32438; Willenborg M, 2005, J LIPID RES, V46, P2559, DOI 10.1194/jlr.M500131-JLR200; WILLNOW TE, 1994, J CELL SCI, V107, P719; Winau F, 2004, NAT IMMUNOL, V5, P169, DOI 10.1038/ni1035; YANAGIHARA K, 1995, JPN J CANCER RES, V86, P347, DOI 10.1111/j.1349-7006.1995.tb03063.x; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	68	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12081	12092		10.1074/jbc.M600621200	http://dx.doi.org/10.1074/jbc.M600621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497666	hybrid			2022-12-27	WOS:000236988100078
J	Pfister, Y; Gautschi, I; Takeda, AN; van Bemmelen, M; Kellenberger, S; Schild, L				Pfister, Y; Gautschi, I; Takeda, AN; van Bemmelen, M; Kellenberger, S; Schild, L			A gating mutation in the internal pore of ASIC1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; NA+ CHANNEL; ION PERMEATION; SELECTIVITY FILTER; AMILORIDE BLOCK; ALPHA-SUBUNIT; ENAC; IDENTIFICATION; FAMILY	Using a substituted cysteine accessibility scan, we have investigated the structures that form the internal pore of the acid-sensing ion channel 1a. We have identified the amino acid residues Ala-22, Ile-33, and Phe-34 in the amino terminus and Arg-43 in the first transmembrane helix, which when mutated into cysteine, were modified by intracellular application of MTSET, resulting in channel inhibition. The inhibition of the R43C mutant by internal MTSET requires opening of the channel. In addition, binding of Cd2+ ions to R43C slows the channel inactivation. This indicates that the first transmembrane helix undergoes conformational changes during channel inactivation. The effect of Cd2+ on R43C can be obtained with Cd2+ applied at either the extracellular or the intracellular side, indicating that R43C is located in the channel pore. The block of the A22C, I33C, and F34C mutants by MTSET suggests that these residues in the amino terminus of the channel also participate to the internal pore.	Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Schild, L (corresponding author), Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	laurent.Schild@unil.ch	van Bemmelen, Miguel/B-5971-2009; TAKEDA, Armelle-Natsuo/B-6031-2009; van Bemmelen, Miguel Xavier/A-8660-2014	van Bemmelen, Miguel Xavier/0000-0003-2762-6153; Kellenberger, Stephan/0000-0003-1755-6198				Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Kellenberger S, 2005, J BIOL CHEM, V280, P7739, DOI 10.1074/jbc.M409955200; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; Poet M, 2001, EMBO J, V20, P5595, DOI 10.1093/emboj/20.20.5595; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781	24	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11787	11791		10.1074/jbc.M513692200	http://dx.doi.org/10.1074/jbc.M513692200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497675	hybrid			2022-12-27	WOS:000236988100044
J	Tenchov, B; Vescio, EM; Sprott, GD; Zeidel, ML; Mathai, JC				Tenchov, B; Vescio, EM; Sprott, GD; Zeidel, ML; Mathai, JC			Salt tolerance of archaeal extremely halophilic lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; PHASE-BEHAVIOR; PHOSPHATIDYLETHANOLAMINE DISPERSIONS; HALOBACTERIUM-CUTIRUBRUM; POLAR LIPIDS; MICROORGANISMS; EUBACTERIUM; MECHANISMS; STABILITY; LIPOSOMES	The membranes of extremely halophilic Archaea are characterized by the abundance of a diacidic phospholipid, archaetidylglycerol methylphosphate (PGP-Me), which accounts for 50 - 80 mol% of the polar lipids, and by the absence of phospholipids with choline, ethanolamine, inositol, and serine head groups. These membranes are stable in concentrated 3 - 5 M NaCl solutions, whereas membranes of non-halophilic Archaea, which do not contain PGP-Me, are unstable and leaky under such conditions. By x-ray diffraction and vesicle permeability measurements, we demonstrate that PGP-Me contributes in an essential way to membrane stability in hypersaline environments. Large unilamellar vesicles (LUV) prepared from the polar lipids of extreme halophiles, Halobacterium halobium and Halobacterium salinarum, retain entrapped carboxyfluorescein and resist aggregation in the whole range 0 - 4 M NaCl, similarly to LUV prepared from purified PGP-Me. By contrast, LUV made of polar lipid extracts from moderately halophilic and non-halophilic Archaea ( Methanococcus jannaschii, Methanosarcina mazei, Methanobrevibacter smithii) are leaky and aggregate at high salt concentrations. However, adding PGP-Me to M. mazei lipids results in gradual enhancement of LUV stability, correlating with the PGP-Me content. The LUV data are substantiated by the x-ray results, which show that H. halobium and M. mazei lipids have dissimilar phase behavior and form different structures at high NaCl concentrations. H. halobium lipids maintain an expanded lamellar structure with spacing of 8.5 - 9 nm, which is stable up to at least 100 degrees C in 2 M NaCl and up to similar to 60 degrees C in 4 M NaCl. However, M. mazei lipids form non-lamellar structures, represented by the Pn3m cubic phase and the inverted hexagonal H-II phase. From these data, the forces preventing membrane aggregation in halophilic Archaea appear to be steric repulsion, because of the large head group of PGP-Me, or possibly out-of-plane bilayer undulations, rather than electrostatic repulsion attributed to the doubly charged PGP-Me head group.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; National Research Council Canada	Mathai, JC (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A1222 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	mathaij@dom.pitt.edu	Tenchov, Boris/W-5547-2019		NCRR NIH HHS [RR 08630] Funding Source: Medline; NIDDK NIH HHS [DK 43955] Funding Source: Medline; NIGMS NIH HHS [GM 57305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057305] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYSZEWSKA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P485, DOI 10.1016/0005-2736(88)90381-1; CHOQUET CG, 1994, APPL MICROBIOL BIOT, V42, P375, DOI 10.1007/s002530050266; DEROSA M, 1991, ARCHAEABACTERIA LIPI, P61; FREDRICKSON HL, 1989, BIOMED ENVIRON MASS, V18, P96, DOI 10.1002/bms.1200180203; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Kamekura M, 1999, BIOSCI BIOTECH BIOCH, V63, P969, DOI 10.1271/bbb.63.969; KATES M, 1993, EXPERIENTIA, V49, P1027, DOI 10.1007/BF01929909; KATES M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P46, DOI 10.1016/0005-2760(93)90080-S; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; Koynova R, 1999, COLLOID SURFACE A, V149, P571, DOI 10.1016/S0927-7757(98)00294-5; Koynova R, 1997, EUR BIOPHYS J BIOPHY, V25, P261, DOI 10.1007/s002490050038; Krishnan L, 2000, INFECT IMMUN, V68, P54, DOI 10.1128/IAI.68.1.54-63.2000; LAI MC, 1992, J BACTERIOL, V174, P7474, DOI 10.1128/jb.174.22.7474-7477.1992; Madigan MT, 1997, SCI AM, V276, P82, DOI 10.1038/scientificamerican0497-82; Margesin R, 2001, EXTREMOPHILES, V5, P73, DOI 10.1007/s007920100184; Mathai JC, 2001, J BIOL CHEM, V276, P27266, DOI 10.1074/jbc.M103265200; Oren A, 1999, MICROBIOL MOL BIOL R, V63, P334, DOI 10.1128/MMBR.63.2.334-348.1999; QUINN PJ, 1986, BIOCHIM BIOPHYS ACTA, V863, P213, DOI 10.1016/0005-2736(86)90261-0; SANDERSON PW, 1991, BIOCHIM BIOPHYS ACTA, V1067, P43, DOI 10.1016/0005-2736(91)90024-3; Sprott G. D., 1996, Cells and Materials, V6, P143; Sprott G. Dennis, 2003, Archaea, V1, P151, DOI 10.1155/2003/569283; SPROTT GD, 1991, J BACTERIOL, V173, P3907, DOI 10.1128/JB.173.12.3907-3910.1991; Sprott GD, 1997, CAN J MICROBIOL, V43, P467, DOI 10.1139/m97-066; Sprott GD, 2003, BBA-MOL CELL BIOL L, V1633, P179, DOI 10.1016/j.bbalip.2003.08.001; SPROTT GD, 1994, CAN J MICROBIOL, V40, P837, DOI 10.1139/m94-133; SPROTT GD, 1992, J BIOENERG BIOMEMBR, V24, P555, DOI 10.1007/BF00762348; SUTTON GC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P235, DOI 10.1016/0005-2736(91)90289-K; Tenchov B, 1998, BIOPHYS J, V75, P853, DOI 10.1016/S0006-3495(98)77574-5; TSUJIMOTO K, 1989, J CHEM SOC CHEM COMM, V10, P688; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; van de Vossenberg JLCM, 1999, EXTREMOPHILES, V3, P253, DOI 10.1007/s007920050124; VREELAND RH, 1987, CRIT REV MICROBIOL, V14, P311, DOI 10.3109/10408418709104443; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1110, P171, DOI 10.1016/0005-2736(92)90355-P	34	45	47	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10016	10023		10.1074/jbc.M600369200	http://dx.doi.org/10.1074/jbc.M600369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484230	hybrid			2022-12-27	WOS:000236594300025
J	Shao, BH; Oda, MN; Bergt, C; Fu, XY; Green, PS; Brot, N; Oram, JF; Heinecke, JW				Shao, BH; Oda, MN; Bergt, C; Fu, XY; Green, PS; Brot, N; Oram, JF; Heinecke, JW			Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL; HYPOCHLOROUS ACID; HUMAN NEUTROPHILS; LIPID HYDROPEROXIDES; SULFOXIDE REDUCTASE; HYDROGEN-PEROXIDE; RESIDUES; MECHANISM; SUPEROXIDE	High density lipoprotein (HDL) isolated from human atherosclerotic lesions and the blood of patients with established coronary artery disease contains elevated levels of 3-chlorotyrosine. Myeloperoxidase (MPO) is the only known source of 3-chlorotyrosine in vivo, indicating that MPO oxidizes HDL in humans. We previously reported that Tyr-192 is the major site that is chlorinated in apolipoprotein A-I (apoA-I), the chief protein in HDL, and that chlorinated apoA-I loses its ability to promote cholesterol efflux from cells by the ATP-binding cassette transporter A1 (ABCA1) pathway. However, the pathways that promote the chlorination of specific Tyr residues in apoA-I are controversial, and the mechanism for MPO-mediated loss of ABCA1-dependent cholesterol efflux of apoA-I is unclear. Using site-directed mutagenesis, we now demonstrate that lysine residues direct tyrosine chlorination in apoA-I. Importantly, methionine residues inhibit chlorination, indicating that they can act as local, protein-bound antioxidants. Moreover, we observed near normal cholesterol efflux activity when Tyr-192 of apoA-I was mutated to Phe and the oxidized protein was incubated with methionine sulfoxide reductase. Thus, a combination of Tyr-192 chlorination and methionine oxidation is necessary for depriving apoA-I of its ABCA1-dependent cholesterol transport activity. Our observations suggest that biologically significant oxidative damage of apoA-I involves modification of a limited number of specific amino acids, raising the feasibility of producing oxidation-resistant forms of apoA-I that have enhanced anti-atherogenic activity in vivo.	Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Washington; University of Washington Seattle; Cornell University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	应, 宁宁/G-9472-2011	Shao, Baohai/0000-0001-8832-2845	NHLBI NIH HHS [HL075381, HL030086] Funding Source: Medline; NIDDK NIH HHS [P30DK017047, DK02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075381, P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROT N, 1984, METHOD ENZYMOL, V107, P352; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Pankhurst G, 2003, J LIPID RES, V44, P349, DOI 10.1194/jlr.M200256-JLR200; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Peng DQ, 2005, J BIOL CHEM, V280, P33775, DOI 10.1074/jbc.M504092200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; SEGREST JP, 1992, J LIPID RES, V33, P141; Shao BH, 2005, J BIOL CHEM, V280, P36386, DOI 10.1074/jbc.M508169200; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	34	168	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9001	9004		10.1074/jbc.C600011200	http://dx.doi.org/10.1074/jbc.C600011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16497665	hybrid			2022-12-27	WOS:000236404700003
